0001104659-22-041054.txt : 20220331 0001104659-22-041054.hdr.sgml : 20220331 20220331161803 ACCESSION NUMBER: 0001104659-22-041054 CONFORMED SUBMISSION TYPE: 20-F PUBLIC DOCUMENT COUNT: 185 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220331 DATE AS OF CHANGE: 20220331 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Evaxion Biotech A/S CENTRAL INDEX KEY: 0001828253 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: G7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 20-F SEC ACT: 1934 Act SEC FILE NUMBER: 001-39950 FILM NUMBER: 22792804 BUSINESS ADDRESS: STREET 1: BREDGADE 34E CITY: COPENHAGEN K STATE: G7 ZIP: 1260 BUSINESS PHONE: 4531262615 MAIL ADDRESS: STREET 1: BREDGADE 34E CITY: COPENHAGEN K STATE: G7 ZIP: 1260 20-F 1 evax-20211231x20f.htm FORM 20-F
P0YP0YP0Y0001828253--12-312021FYfalse1.120.970.817000000001.0001919866819198668191986681919866823141524231415240000000P0YP0Y231415240001828253evax:WarrantsMember2018-01-012018-12-310001828253evax:WarrantsMembersrt:ManagementMember2021-12-310001828253evax:WarrantsMembersrt:ManagementMember2021-06-300001828253evax:WarrantsEntitlements2020Member2020-12-310001828253evax:WarrantsEntitlements2019Member2020-12-310001828253evax:WarrantsMembersrt:ManagementMember2019-10-310001828253evax:WarrantsMemberevax:EmployeesMember2019-09-300001828253evax:WarrantsMemberevax:EmployeesMember2019-02-280001828253evax:WarrantsMembersrt:ManagementMember2019-01-310001828253evax:IfrsWarrantMember2019-01-012019-12-310001828253ifrs-full:OtherPropertyPlantAndEquipmentMemberifrs-full:TopOfRangeMember2021-01-012021-12-310001828253ifrs-full:OtherPropertyPlantAndEquipmentMemberifrs-full:BottomOfRangeMember2021-01-012021-12-310001828253ifrs-full:LeaseholdImprovementsMember2021-01-012021-12-310001828253evax:IfrsEmergingGrowthCompanyMember2021-01-012021-12-310001828253ifrs-full:GrossCarryingAmountMemberifrs-full:OtherPropertyPlantAndEquipmentMember2021-12-310001828253ifrs-full:GrossCarryingAmountMemberifrs-full:LeaseholdImprovementsMember2021-12-310001828253ifrs-full:GrossCarryingAmountMemberevax:AllPropertyExceptForOtherEquipmentMember2021-12-310001828253ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:RightofuseAssetsMember2021-12-310001828253ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:OtherPropertyPlantAndEquipmentMember2021-12-310001828253ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:LeaseholdImprovementsMember2021-12-310001828253ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberevax:AllPropertyExceptForOtherEquipmentMember2021-12-310001828253ifrs-full:RightofuseAssetsMember2021-12-310001828253ifrs-full:OtherPropertyPlantAndEquipmentMember2021-12-310001828253ifrs-full:LeaseholdImprovementsMember2021-12-310001828253ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-12-310001828253evax:AllPropertyExceptForOtherEquipmentMember2021-12-310001828253ifrs-full:GrossCarryingAmountMemberifrs-full:OtherPropertyPlantAndEquipmentMember2020-12-310001828253ifrs-full:GrossCarryingAmountMemberevax:AllPropertyExceptForOtherEquipmentMember2020-12-310001828253ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:RightofuseAssetsMember2020-12-310001828253ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:OtherPropertyPlantAndEquipmentMember2020-12-310001828253ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberevax:AllPropertyExceptForOtherEquipmentMember2020-12-310001828253ifrs-full:RightofuseAssetsMember2020-12-310001828253ifrs-full:OtherPropertyPlantAndEquipmentMember2020-12-310001828253ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2020-12-310001828253evax:AllPropertyExceptForOtherEquipmentMember2020-12-310001828253ifrs-full:GrossCarryingAmountMemberifrs-full:OtherPropertyPlantAndEquipmentMember2019-12-310001828253ifrs-full:GrossCarryingAmountMemberevax:AllPropertyExceptForOtherEquipmentMember2019-12-310001828253ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:RightofuseAssetsMember2019-12-310001828253ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:OtherPropertyPlantAndEquipmentMember2019-12-310001828253ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberevax:AllPropertyExceptForOtherEquipmentMember2019-12-310001828253ifrs-full:GrossCarryingAmountMember2019-12-310001828253ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2019-12-310001828253evax:AmericanDepositarySharesMember2021-11-092021-11-090001828253evax:ConvertibleDebtsMemberifrs-full:KeyManagementPersonnelOfEntityOrParentMember2018-01-012018-12-310001828253evax:ConvertibleDebtsMember2018-01-012018-12-310001828253ifrs-full:OrdinarySharesMember2020-07-012020-09-300001828253evax:IfrsIpoMemberevax:AmericanDepositarySharesMember2021-02-050001828253ifrs-full:OrdinarySharesMember2020-08-100001828253ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2020-01-012020-12-310001828253ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2019-01-012019-12-310001828253srt:ManagementMember2021-12-310001828253srt:DirectorMember2021-12-310001828253ifrs-full:OrdinarySharesMember2021-12-310001828253evax:StevenProjanMember2021-12-310001828253evax:RobertoPregoMember2021-12-310001828253evax:NielsIversenMllerMember2021-12-310001828253evax:MarianneSogaardMember2021-12-310001828253evax:LarsAageStaalWegnerMember2021-12-310001828253evax:AndreasHolmMattssonMember2021-12-310001828253evax:IfrsIpoMemberevax:AmericanDepositarySharesMember2021-11-300001828253evax:AmericanDepositarySharesMemberevax:InitialPublicOfferingMember2021-11-090001828253srt:ManagementMember2020-12-310001828253srt:DirectorMember2020-12-310001828253ifrs-full:OrdinarySharesMember2020-12-310001828253evax:ThomasWilliamWylonisMember2020-12-310001828253evax:StevenProjanMember2020-12-310001828253evax:RobertoPregoMember2020-12-310001828253evax:NielsIversenMllerMember2020-12-310001828253evax:MarianneSogaardMember2020-12-310001828253evax:LarsAageStaalWegnerMember2020-12-310001828253evax:AndreasHolmMattssonMember2020-12-310001828253srt:ManagementMember2019-12-310001828253srt:DirectorMember2019-12-310001828253ifrs-full:OrdinarySharesMember2019-12-310001828253evax:ThomasWilliamWylonisMember2019-12-310001828253evax:StevenProjanMember2019-12-310001828253evax:RobertoPregoMember2019-12-310001828253evax:NielsIversenMllerMember2019-12-310001828253evax:LarsAageStaalWegnerMember2019-12-310001828253evax:AndreasHolmMattssonMember2019-12-310001828253ifrs-full:OrdinarySharesMember2018-12-310001828253evax:IfrsIpoMember2021-02-050001828253evax:WarrantsMember2021-12-012021-12-310001828253evax:WarrantsMembersrt:ManagementMember2021-10-012021-10-310001828253evax:WarrantsMembersrt:ManagementMember2021-06-012021-06-300001828253evax:StevenProjanMemberevax:IfrsWarrantMember2021-01-012021-12-310001828253evax:RobertoPregoMemberevax:IfrsWarrantMember2021-01-012021-12-310001828253evax:MarianneSogaardMemberevax:IfrsWarrantMember2021-01-012021-12-310001828253evax:LarsHoltugMemberevax:IfrsWarrantMember2021-01-012021-12-310001828253evax:LarsAageStaalWegnerMemberevax:IfrsWarrantMember2021-01-012021-12-310001828253evax:ErikHeegaardMemberevax:IfrsWarrantMember2021-01-012021-12-310001828253evax:WarrantsMember2020-12-012020-12-310001828253srt:DirectorMember2020-11-252020-11-250001828253srt:DirectorMember2020-06-012020-06-300001828253evax:StevenProjanMemberevax:IfrsWarrantMember2020-01-012020-12-310001828253evax:RobertoPregoMemberevax:IfrsWarrantMember2020-01-012020-12-310001828253evax:LarsAageStaalWegnerMemberevax:IfrsWarrantMember2020-01-012020-12-310001828253evax:JoannSuzichMemberevax:IfrsWarrantMember2020-01-012020-12-310001828253evax:HelenBoudreauMemberevax:IfrsWarrantMember2020-01-012020-12-310001828253srt:ManagementMemberevax:IfrsWarrantMember2019-01-012019-12-310001828253evax:WarrantsMembersrt:ChiefFinancialOfficerMember2019-01-012019-12-310001828253evax:ThomasBogenriederMemberevax:IfrsWarrantMember2019-01-012019-12-310001828253evax:GlennS.VraniakMemberevax:IfrsWarrantMember2019-01-012019-12-310001828253evax:WarrantsMember2020-04-302020-04-300001828253srt:DirectorMemberevax:IfrsWarrantMember2021-01-012021-12-310001828253evax:HelenBoudreauMemberevax:IfrsWarrantMember2021-01-012021-12-310001828253srt:ManagementMemberevax:IfrsWarrantMember2021-12-310001828253srt:DirectorMemberevax:IfrsWarrantMember2021-12-310001828253evax:ThomasWilliamWylonisMemberevax:IfrsWarrantMember2021-12-310001828253evax:ThomasBogenriederMemberevax:IfrsWarrantMember2021-12-310001828253evax:StevenProjanMemberevax:IfrsWarrantMember2021-12-310001828253evax:RobertoPregoMemberevax:IfrsWarrantMember2021-12-310001828253evax:MarianneSogaardMemberevax:IfrsWarrantMember2021-12-310001828253evax:LarsHoltugMemberevax:IfrsWarrantMember2021-12-310001828253evax:LarsAageStaalWegnerMemberevax:IfrsWarrantMember2021-12-310001828253evax:JoannSuzichMemberevax:IfrsWarrantMember2021-12-310001828253evax:GrantSeptember2019Memberevax:IfrsWarrantMember2021-12-310001828253evax:GrantSeptember2017Memberevax:IfrsWarrantMember2021-12-310001828253evax:GrantOctober2019Memberevax:IfrsWarrantMember2021-12-310001828253evax:GrantJune2021Memberevax:IfrsWarrantMember2021-12-310001828253evax:GrantFebruary2019Memberevax:IfrsWarrantMember2021-12-310001828253evax:GrantedDuring2018Memberevax:IfrsWarrantMember2021-12-310001828253evax:GrantDecember2021Memberevax:IfrsWarrantMember2021-12-310001828253evax:GrantDecember2020Memberevax:IfrsWarrantMember2021-12-310001828253evax:GrantDecember2017Memberevax:IfrsWarrantMember2021-12-310001828253evax:GrantDecember2016Memberevax:IfrsWarrantMember2021-12-310001828253evax:GrantApril2021Memberevax:IfrsWarrantMember2021-12-310001828253evax:GlennS.VraniakMemberevax:IfrsWarrantMember2021-12-310001828253evax:ErikHeegaardMemberevax:IfrsWarrantMember2021-12-310001828253evax:BirgitteRnMemberevax:IfrsWarrantMember2021-12-310001828253evax:WarrantsMember2021-12-310001828253evax:IfrsWarrantMember2021-12-310001828253srt:ManagementMemberevax:IfrsWarrantMember2020-12-310001828253srt:DirectorMemberevax:IfrsWarrantMember2020-12-310001828253evax:ThomasWilliamWylonisMemberevax:IfrsWarrantMember2020-12-310001828253evax:ThomasBogenriederMemberevax:IfrsWarrantMember2020-12-310001828253evax:StevenProjanMemberevax:IfrsWarrantMember2020-12-310001828253evax:RobertoPregoMemberevax:IfrsWarrantMember2020-12-310001828253evax:MarianneSogaardMemberevax:IfrsWarrantMember2020-12-310001828253evax:LarsAageStaalWegnerMemberevax:IfrsWarrantMember2020-12-310001828253evax:JoannSuzichMemberevax:IfrsWarrantMember2020-12-310001828253evax:HelenBoudreauMemberevax:IfrsWarrantMember2020-12-310001828253evax:GrantSeptember2019Memberevax:IfrsWarrantMember2020-12-310001828253evax:GrantSeptember2017Memberevax:IfrsWarrantMember2020-12-310001828253evax:GrantOctober2019Memberevax:IfrsWarrantMember2020-12-310001828253evax:GrantFebruary2019Memberevax:IfrsWarrantMember2020-12-310001828253evax:GrantedDuring2018Memberevax:IfrsWarrantMember2020-12-310001828253evax:GrantDecember2020Memberevax:IfrsWarrantMember2020-12-310001828253evax:GrantDecember2017Memberevax:IfrsWarrantMember2020-12-310001828253evax:GrantDecember2016Memberevax:IfrsWarrantMember2020-12-310001828253evax:GrantApril2017Memberevax:IfrsWarrantMember2020-12-310001828253evax:GlennS.VraniakMemberevax:IfrsWarrantMember2020-12-310001828253evax:WarrantsMember2020-12-310001828253evax:IfrsWarrantMember2020-12-310001828253srt:ManagementMemberevax:IfrsWarrantMember2019-12-310001828253srt:DirectorMemberevax:IfrsWarrantMember2019-12-310001828253evax:ThomasWilliamWylonisMemberevax:IfrsWarrantMember2019-12-310001828253evax:ThomasBogenriederMemberevax:IfrsWarrantMember2019-12-310001828253evax:StevenProjanMemberevax:IfrsWarrantMember2019-12-310001828253evax:RobertoPregoMemberevax:IfrsWarrantMember2019-12-310001828253evax:LarsAageStaalWegnerMemberevax:IfrsWarrantMember2019-12-310001828253evax:GrantSeptember2019Memberevax:IfrsWarrantMember2019-12-310001828253evax:GrantSeptember2017Memberevax:IfrsWarrantMember2019-12-310001828253evax:GrantOctober2019Memberevax:IfrsWarrantMember2019-12-310001828253evax:GrantJanuary2019Memberevax:IfrsWarrantMember2019-12-310001828253evax:GrantFebruary2019Memberevax:IfrsWarrantMember2019-12-310001828253evax:GrantedDuring2018Memberevax:IfrsWarrantMember2019-12-310001828253evax:GrantDecember2017Memberevax:IfrsWarrantMember2019-12-310001828253evax:GrantDecember2016Memberevax:IfrsWarrantMember2019-12-310001828253evax:GrantApril2017Memberevax:IfrsWarrantMember2019-12-310001828253evax:GlennS.VraniakMemberevax:IfrsWarrantMember2019-12-310001828253evax:WarrantsMember2019-12-310001828253evax:IfrsWarrantMember2019-12-310001828253evax:EmployeesMember2019-12-310001828253srt:ManagementMemberevax:IfrsWarrantMember2018-12-310001828253srt:DirectorMemberevax:IfrsWarrantMember2018-12-310001828253evax:ThomasWilliamWylonisMemberevax:IfrsWarrantMember2018-12-310001828253evax:ThomasBogenriederMemberevax:IfrsWarrantMember2018-12-310001828253evax:StevenProjanMemberevax:IfrsWarrantMember2018-12-310001828253evax:RobertoPregoMemberevax:IfrsWarrantMember2018-12-310001828253evax:LarsAageStaalWegnerMemberevax:IfrsWarrantMember2018-12-310001828253evax:WarrantsMember2018-12-310001828253evax:EmployeesMember2018-12-310001828253evax:ResearchAndDevelopmentExpensesMemberifrs-full:KeyManagementPersonnelOfEntityOrParentMember2021-12-310001828253evax:GeneralAndAdministrativeExpensesMemberifrs-full:KeyManagementPersonnelOfEntityOrParentMember2021-12-310001828253evax:ResearchAndDevelopmentExpensesMemberifrs-full:KeyManagementPersonnelOfEntityOrParentMember2020-12-310001828253evax:GeneralAndAdministrativeExpensesMemberifrs-full:KeyManagementPersonnelOfEntityOrParentMember2020-12-310001828253evax:ResearchAndDevelopmentExpensesMemberifrs-full:KeyManagementPersonnelOfEntityOrParentMember2019-12-310001828253evax:GeneralAndAdministrativeExpensesMemberifrs-full:KeyManagementPersonnelOfEntityOrParentMember2019-12-310001828253evax:EibLoanAgreementMemberevax:TrancheOneMember2022-02-170001828253evax:EibLoanAgreementMemberevax:TrancheOneMember2021-12-310001828253evax:EibLoanAgreementMember2021-12-310001828253evax:EibLoanAgreementMemberevax:TrancheOneMember2020-12-170001828253evax:EibLoanAgreementMemberevax:TrancheTwoMember2020-08-310001828253evax:EibLoanAgreementMemberevax:TrancheThreeMember2020-08-310001828253evax:EibLoanAgreementMemberevax:TrancheOneMember2020-08-310001828253evax:EibLoanAgreementMember2020-08-310001828253evax:ConvertibleDebt2Membercurrency:USD2018-12-310001828253evax:ConvertibleDebt2Membercurrency:DKK2018-12-310001828253evax:ConvertibleDebt1Membercurrency:USD2018-12-310001828253evax:ConvertibleDebt1Membercurrency:DKK2018-12-310001828253ifrs-full:LeaseLiabilitiesMemberifrs-full:NotLaterThanOneYearMember2021-12-310001828253ifrs-full:LeaseLiabilitiesMemberifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember2021-12-310001828253ifrs-full:LeaseLiabilitiesMemberifrs-full:LaterThanFiveYearsMember2021-12-310001828253evax:TradePayablesMemberifrs-full:NotLaterThanOneYearMember2021-12-310001828253evax:ProvisionMemberifrs-full:LaterThanFiveYearsMember2021-12-310001828253evax:OtherPayablesMemberifrs-full:NotLaterThanOneYearMember2021-12-310001828253evax:LoanFromLessorMemberifrs-full:NotLaterThanOneYearMember2021-12-310001828253evax:LoanFromLessorMemberifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember2021-12-310001828253evax:LoanFromLessorMemberifrs-full:LaterThanFiveYearsMember2021-12-310001828253ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember2021-12-310001828253ifrs-full:LaterThanFiveYearsMember2021-12-310001828253ifrs-full:LeaseLiabilitiesMemberifrs-full:NotLaterThanOneYearMember2020-12-310001828253evax:TradePayablesMemberifrs-full:NotLaterThanOneYearMember2020-12-310001828253evax:OtherPayablesMemberifrs-full:NotLaterThanOneYearMember2020-12-310001828253ifrs-full:LeaseLiabilitiesMember2021-12-310001828253evax:ProvisionMember2021-12-310001828253evax:LoanFromLessorMember2021-12-310001828253ifrs-full:LeaseLiabilitiesMember2020-12-310001828253ifrs-full:LeaseLiabilitiesMember2019-12-310001828253evax:Ifrs16Member2018-01-010001828253srt:ManagementMember2021-01-012021-12-310001828253srt:DirectorMember2021-01-012021-12-310001828253ifrs-full:KeyManagementPersonnelOfEntityOrParentMember2021-01-012021-12-310001828253srt:ManagementMember2020-01-012020-12-310001828253srt:DirectorMember2020-01-012020-12-310001828253ifrs-full:KeyManagementPersonnelOfEntityOrParentMember2020-01-012020-12-310001828253srt:ManagementMember2019-01-012019-12-310001828253srt:DirectorMember2019-01-012019-12-310001828253ifrs-full:KeyManagementPersonnelOfEntityOrParentMember2019-01-012019-12-310001828253ifrs-full:IssuedCapitalMember2021-11-092021-11-090001828253ifrs-full:IssuedCapitalMember2021-11-012021-11-300001828253ifrs-full:IssuedCapitalMember2021-02-092021-02-090001828253ifrs-full:SharePremiumMember2021-01-012021-12-310001828253ifrs-full:IssuedCapitalMember2021-01-012021-12-310001828253ifrs-full:IssuedCapitalMember2020-10-152020-10-150001828253ifrs-full:IssuedCapitalMember2020-09-172020-09-170001828253ifrs-full:SharePremiumMember2020-01-012020-12-310001828253ifrs-full:IssuedCapitalMember2020-01-012020-12-310001828253ifrs-full:IssuedCapitalMember2019-12-192019-12-190001828253ifrs-full:IssuedCapitalMember2019-07-172019-07-170001828253evax:FollowOnPublicOfferingMember2021-11-090001828253evax:IfrsIpoMemberevax:AmericanDepositarySharesMember2021-02-280001828253ifrs-full:GrossCarryingAmountMember2021-12-310001828253ifrs-full:GrossCarryingAmountMember2020-12-310001828253ifrs-full:AccumulatedDepreciationAndAmortisationMember2020-12-310001828253ifrs-full:RetainedEarningsMember2021-01-012021-12-310001828253ifrs-full:RetainedEarningsMember2020-01-012020-12-310001828253ifrs-full:RetainedEarningsMember2019-01-012019-12-310001828253evax:ProvisionMember2021-01-012021-12-310001828253evax:ConvertibleDebt2Memberifrs-full:IssuedCapitalMember2019-07-172019-07-170001828253evax:ConvertibleDebt1Memberifrs-full:IssuedCapitalMember2019-07-172019-07-170001828253ifrs-full:SharePremiumMember2019-01-012019-12-310001828253ifrs-full:IssuedCapitalMember2019-01-012019-12-310001828253evax:FollowOnPublicOfferingMemberevax:AmericanDepositarySharesMember2021-11-092021-11-090001828253evax:AmericanDepositarySharesMemberevax:InitialPublicOfferingMember2021-11-092021-11-090001828253evax:UnderwritersMemberevax:AmericanDepositarySharesMember2021-11-052021-11-050001828253evax:IfrsIpoMemberevax:AmericanDepositarySharesMember2021-02-052021-02-050001828253evax:AmericanDepositarySharesMemberevax:InitialPublicOfferingMember2021-02-052021-02-050001828253evax:IfrsIpoMemberevax:AmericanDepositarySharesMember2021-02-012021-02-280001828253ifrs-full:OrdinarySharesMember2020-10-012020-10-310001828253ifrs-full:OrdinarySharesMember2020-09-012020-09-300001828253ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2021-01-012021-12-310001828253ifrs-full:LeaseLiabilitiesMember2021-12-310001828253evax:TradePayablesMember2021-12-310001828253evax:ProvisionMember2021-12-310001828253evax:OtherPayablesMember2021-12-310001828253evax:LoanFromLessorMember2021-12-310001828253ifrs-full:LeaseLiabilitiesMember2020-12-310001828253evax:TradePayablesMember2020-12-310001828253evax:OtherPayablesMember2020-12-310001828253ifrs-full:SharePremiumMember2021-12-310001828253ifrs-full:RetainedEarningsMember2021-12-310001828253ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2021-12-310001828253ifrs-full:IssuedCapitalMember2021-12-310001828253evax:FollowOnPublicOfferingMemberevax:AmericanDepositarySharesMember2021-11-300001828253ifrs-full:SharePremiumMember2020-12-310001828253ifrs-full:RetainedEarningsMember2020-12-310001828253ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2020-12-310001828253ifrs-full:IssuedCapitalMember2020-12-310001828253ifrs-full:SharePremiumMember2019-12-310001828253ifrs-full:RetainedEarningsMember2019-12-310001828253ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2019-12-310001828253ifrs-full:IssuedCapitalMember2019-12-310001828253ifrs-full:SharePremiumMember2018-12-310001828253ifrs-full:RetainedEarningsMember2018-12-310001828253ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2018-12-310001828253ifrs-full:IssuedCapitalMember2018-12-310001828253evax:ConvertibleDebtsMember2021-01-012021-12-310001828253ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:OtherPropertyPlantAndEquipmentMember2021-01-012021-12-310001828253ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:LeaseholdImprovementsMember2021-01-012021-12-310001828253evax:ResearchAndDevelopmentExpensesMember2021-01-012021-12-310001828253evax:OperatingExpensesMember2021-01-012021-12-310001828253evax:GeneralAndAdministrativeExpensesMember2021-01-012021-12-310001828253ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:OtherPropertyPlantAndEquipmentMember2020-01-012020-12-310001828253ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberevax:AllPropertyExceptForOtherEquipmentMember2020-01-012020-12-310001828253ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2020-01-012020-12-310001828253evax:ResearchAndDevelopmentExpensesMember2020-01-012020-12-310001828253evax:OperatingExpensesMember2020-01-012020-12-310001828253evax:GeneralAndAdministrativeExpensesMember2020-01-012020-12-310001828253evax:ResearchAndDevelopmentExpensesMember2019-01-012019-12-310001828253evax:OperatingExpensesMember2019-01-012019-12-310001828253evax:GeneralAndAdministrativeExpensesMember2019-01-012019-12-310001828253evax:IfrsGrossCarryingAmountMemberifrs-full:UnusedTaxLossesMember2021-12-310001828253evax:IfrsGrossCarryingAmountMemberifrs-full:OtherTemporaryDifferencesMember2021-12-310001828253evax:IfrsGrossCarryingAmountMemberevax:IfrsWarrantMember2021-12-310001828253ifrs-full:AccumulatedImpairmentMember2021-12-310001828253evax:IfrsGrossCarryingAmountMemberifrs-full:UnusedTaxLossesMember2020-12-310001828253evax:IfrsGrossCarryingAmountMemberifrs-full:OtherTemporaryDifferencesMember2020-12-310001828253evax:IfrsGrossCarryingAmountMemberevax:ResearchAndDevelopmentExpendituresMember2020-12-310001828253evax:IfrsGrossCarryingAmountMemberevax:IfrsWarrantMember2020-12-310001828253ifrs-full:AccumulatedImpairmentMember2020-12-310001828253evax:IfrsGrossCarryingAmountMemberifrs-full:UnusedTaxLossesMember2019-12-310001828253evax:IfrsGrossCarryingAmountMemberifrs-full:OtherTemporaryDifferencesMember2019-12-310001828253evax:IfrsGrossCarryingAmountMemberevax:IfrsWarrantMember2019-12-310001828253ifrs-full:AccumulatedImpairmentMember2019-12-310001828253evax:PurchaseObligationsMemberifrs-full:NotLaterThanOneYearMember2021-12-310001828253evax:PurchaseObligationsMemberevax:SystemProviderMember2021-12-310001828253ifrs-full:NotLaterThanOneYearMember2021-12-310001828253evax:PurchaseObligationsMember2021-12-310001828253evax:PurchaseObligationsMemberifrs-full:NotLaterThanOneYearMember2020-12-310001828253evax:PurchaseObligationsMemberevax:UniversityFuturePartnersMember2020-12-310001828253evax:PurchaseObligationsMemberevax:ContractResearchOrganizationsMember2020-12-310001828253ifrs-full:NotLaterThanOneYearMember2020-12-310001828253evax:PurchaseObligationsMember2020-12-310001828253evax:ConvertibleDebtsMember2021-12-310001828253evax:TrancheOneMember2022-02-170001828253evax:EibLoanAgreementMemberevax:TrancheOneMember2022-02-140001828253evax:ConvertibleDebtsMember2020-12-310001828253evax:IfrsEmergingGrowthCompanyMember2021-12-310001828253ifrs-full:AccumulatedDepreciationAndAmortisationMember2021-01-012021-12-310001828253ifrs-full:GrossCarryingAmountMemberifrs-full:OtherPropertyPlantAndEquipmentMember2021-01-012021-12-310001828253ifrs-full:GrossCarryingAmountMemberifrs-full:LeaseholdImprovementsMember2021-01-012021-12-310001828253ifrs-full:GrossCarryingAmountMemberevax:AllPropertyExceptForOtherEquipmentMember2021-01-012021-12-310001828253ifrs-full:GrossCarryingAmountMemberifrs-full:OtherPropertyPlantAndEquipmentMember2020-01-012020-12-310001828253ifrs-full:GrossCarryingAmountMemberevax:AllPropertyExceptForOtherEquipmentMember2020-01-012020-12-310001828253ifrs-full:GrossCarryingAmountMember2021-01-012021-12-310001828253ifrs-full:TechnologybasedIntangibleAssetsMemberevax:SSIMember2020-01-012020-12-310001828253ifrs-full:TechnologybasedIntangibleAssetsMember2020-01-012020-12-310001828253ifrs-full:GrossCarryingAmountMember2020-01-012020-12-310001828253evax:GrantSeptember2019Memberevax:IfrsWarrantMember2021-01-012021-12-310001828253evax:GrantSeptember2017Memberevax:IfrsWarrantMember2021-01-012021-12-310001828253evax:GrantOctober2019Memberevax:IfrsWarrantMember2021-01-012021-12-310001828253evax:GrantJune2021Memberevax:IfrsWarrantMember2021-01-012021-12-310001828253evax:GrantFebruary2019Memberevax:IfrsWarrantMember2021-01-012021-12-310001828253evax:GrantedDuring2018Memberevax:IfrsWarrantMember2021-01-012021-12-310001828253evax:GrantDecember2021Memberevax:IfrsWarrantMember2021-01-012021-12-310001828253evax:GrantDecember2020Memberevax:IfrsWarrantMember2021-01-012021-12-310001828253evax:GrantDecember2017Memberevax:IfrsWarrantMember2021-01-012021-12-310001828253evax:GrantDecember2016Memberevax:IfrsWarrantMember2021-01-012021-12-310001828253evax:GrantApril2021Memberevax:IfrsWarrantMember2021-01-012021-12-310001828253evax:GrantSeptember2019Memberevax:IfrsWarrantMember2020-01-012020-12-310001828253evax:GrantSeptember2017Memberevax:IfrsWarrantMember2020-01-012020-12-310001828253evax:GrantOctober2019Memberevax:IfrsWarrantMember2020-01-012020-12-310001828253evax:GrantFebruary2019Memberevax:IfrsWarrantMember2020-01-012020-12-310001828253evax:GrantedDuring2018Memberevax:IfrsWarrantMember2020-01-012020-12-310001828253evax:GrantDecember2020Memberevax:IfrsWarrantMember2020-01-012020-12-310001828253evax:GrantDecember2017Memberevax:IfrsWarrantMember2020-01-012020-12-310001828253evax:GrantDecember2016Memberevax:IfrsWarrantMember2020-01-012020-12-310001828253evax:GrantApril2017Memberevax:IfrsWarrantMember2020-01-012020-12-310001828253evax:GrantSeptember2019Memberevax:IfrsWarrantMember2019-01-012019-12-310001828253evax:GrantSeptember2017Memberevax:IfrsWarrantMember2019-01-012019-12-310001828253evax:GrantOctober2019Memberevax:IfrsWarrantMember2019-01-012019-12-310001828253evax:GrantJanuary2019Memberevax:IfrsWarrantMember2019-01-012019-12-310001828253evax:GrantFebruary2019Memberevax:IfrsWarrantMember2019-01-012019-12-310001828253evax:GrantedDuring2018Memberevax:IfrsWarrantMember2019-01-012019-12-310001828253evax:GrantDecember2017Memberevax:IfrsWarrantMember2019-01-012019-12-310001828253evax:GrantDecember2016Memberevax:IfrsWarrantMember2019-01-012019-12-310001828253evax:GrantApril2017Memberevax:IfrsWarrantMember2019-01-012019-12-310001828253evax:WarrantsMemberevax:EmployeesMember2019-02-012019-02-280001828253evax:WarrantsMembersrt:ManagementMember2019-01-012019-01-310001828253evax:WarrantsMemberevax:EmployeesMember2019-09-012019-09-3000018282532018-01-012018-12-3100018282532021-01-042021-01-040001828253evax:WarrantsMember2021-04-012021-06-300001828253evax:WarrantsMembersrt:ManagementMember2021-01-012021-12-310001828253evax:WarrantsEntitlements2020Member2020-12-012020-12-310001828253evax:WarrantsEntitlements2019Member2020-12-012020-12-310001828253evax:WarrantsMembersrt:ManagementMember2019-10-012019-10-310001828253ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberevax:AllPropertyExceptForOtherEquipmentMember2021-01-012021-12-310001828253ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2021-01-012021-12-310001828253evax:WarrantsMember2021-01-012021-12-310001828253evax:WarrantsMember2020-01-012020-12-310001828253evax:WarrantsMember2019-01-012019-12-310001828253ifrs-full:OrdinarySharesMemberevax:InitialPublicOfferingMember2021-11-090001828253ifrs-full:OrdinarySharesMemberevax:InitialPublicOfferingMember2021-02-050001828253evax:ConvertibleDebt2Member2018-01-012018-12-310001828253ifrs-full:OrdinarySharesMemberevax:StockSplitMember2021-01-040001828253srt:ManagementMemberevax:IfrsWarrantMember2021-01-012021-12-310001828253evax:BirgitteRnMemberevax:IfrsWarrantMember2021-01-012021-12-310001828253srt:ManagementMemberevax:IfrsWarrantMember2020-01-012020-12-310001828253srt:DirectorMemberevax:IfrsWarrantMember2020-01-012020-12-310001828253evax:ThomasWilliamWylonisMemberevax:IfrsWarrantMember2020-01-012020-12-310001828253evax:ThomasBogenriederMemberevax:IfrsWarrantMember2020-01-012020-12-310001828253evax:MarianneSogaardMemberevax:IfrsWarrantMember2020-01-012020-12-310001828253evax:KimBjornstrupMemberevax:IfrsWarrantMember2020-01-012020-12-3100018282532019-10-012019-10-3100018282532019-01-012019-01-310001828253evax:CopenhagenDenmarkMember2021-12-310001828253ifrs-full:CountryOfDomicileMember2021-12-310001828253ifrs-full:CountryOfDomicileMember2020-12-310001828253ifrs-full:CountryOfDomicileMember2019-12-3100018282532019-12-3100018282532018-12-310001828253evax:EibLoanAgreementMember2021-08-310001828253ifrs-full:TechnologybasedIntangibleAssetsMember2020-12-310001828253evax:HrsholmDenmarkMember2020-10-012020-10-310001828253country:US2020-10-012020-10-310001828253evax:LaboratorySpaceMemberevax:HrsholmDenmarkMember2020-10-310001828253evax:HrsholmDenmarkMember2020-10-310001828253evax:LaboratorySpaceMemberifrs-full:TopOfRangeMemberevax:HrsholmDenmarkMember2020-10-310001828253evax:LaboratorySpaceMemberifrs-full:BottomOfRangeMemberevax:HrsholmDenmarkMember2020-10-310001828253ifrs-full:TopOfRangeMemberevax:HrsholmDenmarkMember2020-10-310001828253ifrs-full:BottomOfRangeMemberevax:HrsholmDenmarkMember2020-10-310001828253evax:OfficeSpaceMemberevax:HrsholmDenmarkMember2020-10-310001828253evax:IfrsWarrantMember2020-12-012020-12-310001828253ifrs-full:OrdinarySharesMember2020-08-102020-08-100001828253evax:IfrsWarrantMember2021-01-012021-12-310001828253ifrs-full:LeaseLiabilitiesMember2021-01-012021-12-310001828253evax:LoanFromLessorMember2021-01-012021-12-310001828253ifrs-full:LeaseLiabilitiesMember2020-01-012020-12-310001828253ifrs-full:OrdinarySharesMember2021-11-092021-11-090001828253ifrs-full:OrdinarySharesMember2021-11-012021-11-300001828253ifrs-full:OrdinarySharesMember2021-02-092021-02-090001828253ifrs-full:OrdinarySharesMember2020-10-152020-10-150001828253ifrs-full:OrdinarySharesMember2020-09-172020-09-170001828253ifrs-full:OrdinarySharesMember2019-12-192019-12-190001828253ifrs-full:OrdinarySharesMember2019-07-172019-07-170001828253ifrs-full:OrdinarySharesMemberevax:StockSplitMemberevax:WarrantsMember2021-01-042021-01-040001828253evax:FollowOnPublicOfferingMemberevax:AmericanDepositarySharesMember2021-11-052021-11-050001828253evax:FollowOnPublicOfferingMemberevax:AmericanDepositarySharesMember2021-11-012021-11-300001828253evax:ConvertibleDebt2Memberifrs-full:OrdinarySharesMember2019-07-172019-07-170001828253evax:ConvertibleDebt1Memberifrs-full:OrdinarySharesMember2019-07-172019-07-170001828253evax:WarrantsMember2021-06-012021-06-300001828253evax:IfrsWarrantMember2020-01-012020-12-310001828253evax:EibLoanAgreementMember2020-08-012020-08-310001828253evax:ConvertibleDebtsMember2019-12-310001828253evax:ResearchAndDevelopmentExpensesMember2021-01-012021-12-310001828253evax:GeneralAndAdministrativeExpensesMember2021-01-012021-12-310001828253evax:ResearchAndDevelopmentExpensesMember2020-01-012020-12-310001828253evax:GeneralAndAdministrativeExpensesMember2020-01-012020-12-310001828253evax:ResearchAndDevelopmentExpensesMember2019-01-012019-12-310001828253evax:GeneralAndAdministrativeExpensesMember2019-01-012019-12-310001828253evax:ConvertibleDebt2Memberevax:QualifiedCapitalIncreaseOccursInYearOfLoanIssuanceMember2018-12-310001828253evax:ConvertibleDebt2Memberevax:QualifiedCapitalIncreaseOccursInYearFollowingLoanIssuanceMember2018-12-310001828253evax:ConvertibleDebt2Memberevax:QualifiedCapitalIncreaseOccursInTwoYearsFollowingLoanIssuanceMember2018-12-310001828253evax:ConvertibleDebt1Member2018-01-012018-12-310001828253evax:SouthernDenmarkUniversityCollaborationAgreementMember2020-01-012020-12-310001828253evax:SouthernDenmarkUniversityCollaborationAgreementMember2019-01-012019-12-3100018282532020-08-012020-08-310001828253evax:ConvertibleDebt2Member2018-12-310001828253evax:ConvertibleDebt1Member2018-12-3100018282532019-01-012019-12-310001828253ifrs-full:FixedInterestRateMember2020-10-012020-10-310001828253ifrs-full:OrdinarySharesMemberevax:StockSplitMember2021-01-042021-01-040001828253evax:WarrantsMember2021-01-012021-12-310001828253evax:WarrantsMember2020-01-012020-12-310001828253evax:WarrantsMember2019-01-012019-12-310001828253evax:IfrsIpoMember2021-02-052021-02-050001828253ifrs-full:TechnologybasedIntangibleAssetsMember2020-06-012020-06-3000018282532020-01-012020-12-3100018282532020-12-3100018282532021-12-310001828253dei:BusinessContactMember2021-01-012021-12-3100018282532021-01-012021-12-31evax:segmentiso4217:DKKxbrli:sharesevax:instrumentiso4217:EURevax:Yxbrli:sharesiso4217:USDxbrli:pureiso4217:DKKiso4217:USDxbrli:sharesutr:sqmevax:loanevax:employeeevax:lease

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 20-F

(Mark One)

REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE

ACT OF 1934

OR

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2021

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________ to _________

OR

SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE

ACT OF 1934

Date of event requiring this shell company report

Commission file number: 001-39950

Evaxion Biotech A/S

(Exact name of Registrant as specified in its charter)

Not Applicable

The Kingdom of Denmark

(Translation of Registrant’s name into English)

(Jurisdiction of incorporation or organization)

Dr. Neergaards Vej 5f DK-2970 Hoersholm, Denmark

(Address of principal executive offices)

Lars Staal Wegner, MD

Chief Executive Officer

Evaxion Biotech A/S

Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark

Tel: +45 53 53 18 50

E-mail: lsw@evaxion-biotech.com

(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)

Securities registered or to be registered pursuant to Section 12(b) of the Act:

Title of each class

    

Trading Symbol

    

Name of each exchange on which registered

American Depositary Shares, each representing
one ordinary share, nominal value DKK 1 per share

EVAX

The Nasdaq Stock Market LLC

Ordinary Shares, nominal value of DKK 1 per share*

The Nasdaq Stock Market LLC*

*Not for trading, but only in connection with the registration of American Depositary Shares on the Nasdaq Stock Market LLC representing such Ordinary shares pursuant to requirements of the U.S. Securities and Exchange Commission.

Securities registered or to be registered pursuant to Section 12(g) of the Act:

None

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:

None

Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report. The number of outstanding shares as of December 31, 2021 was:

Title of each class

    

Number of Shares Outstanding at December 31, 2021

Ordinary share, nominal value DKK1 per share

(including shares underlying American Depository Shares)

23,203,808

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or an emerging growth company (as defined in Rule 12b-2 of the Act).

Large Accelerated Filer

Accelerated Filer

Non-accelerated Filer

Emerging growth company

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 13(a) of the Exchange Act.

† The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

U.S. GAAP

International Financial Reporting Standards as issued
by the International Accounting Standards Board

Other

If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow. Item 17 Item 18

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

Auditor Firm ID

1757

Auditor Name

EY Godkendt Revisionspartnerselskab

Auditor Location

Copenhagen, Denmark

TABLE OF CONTENTS

Page

PART I

Item 1.

Identity of Directors, Senior Management and Advisers

6

Item 2.

Offer Statistics and Expected Timetable

6

Item 3.

Key Information

6

Item 4.

Information on the Company

90

Item 4A.

Unresolved Staff Comments

167

Item 5.

Operating And Financial Review and Prospects

167

Item 6.

Directors, Senior Management and Employees

180

Item 7.

Major Shareholders and Related Party Transactions

194

Item 8.

Financial Information

196

Item 9.

The Offer and Listing

197

Item 10.

Additional Information

198

Item 11.

Quantitative and Qualitative Disclosures About Market Risk

216

Item 12.

Description of Securities other than Equity Securities

216

PART II

Item 13.

Defaults, Dividend Arrearages and Delinquencies

218

Item 14.

Material Modifications to the Rights of Security Holders and Use of Proceeds

218

Item 15.

Controls and Procedures

218

Item 16A.

Audit Committee Financial Expert

219

Item 16B.

Code of Ethics

219

Item 16C.

Principal Accountant Fees and Services

220

Item 16D.

Exemptions from the Listing Standards for Audit Committees

220

Item 16E.

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

220

Item 16F.

Change in Registrant’s Certifying Accountant

220

Item 16G.

Corporate Governance

220

Item 16H.

Mine Safety Disclosure

225

Item 16I.

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

225

PART III

Item 17.

Financial Statements

227

Item 18.

Financial Statements

227

Item 19.

Exhibits

II-1

Signatures

II-3

Report of the Independent Registered Public Accounting Firm

F-2

CERTAIN DEFINITIONS

Unless otherwise indicated and except where the context otherwise requires, references in this annual report on Form 20-F to:

“ADSs” are to our American Depositary Shares, each of which represents one ordinary share of Evaxion Biotech A/S;
“ADRs” are to the American depositary receipts that evidence our ADSs;
“Exchange Act” are to the United States Securities Exchange Act of 1934, as amended;
“FDA” are to the United States Food and Drug Administration;
“Evaxion,” the “Company,” “we,” “us” and “our” refer to Evaxion Biotech A/S and our wholly owned subsidiaries;
“Group” are to the consolidated entities of Evaxion Biotech A/S, Evaxion Biotech Australia Pty Ltd and Evaxion Biotech, Inc.;
“IND” are to Investigational New Drug Application;
“ordinary shares” are to our ordinary shares, each of DKK 1 nominal value;
“SEC” are to the United States Securities and Exchange Commission;
“Securities Act” are to the Securities Act of 1933, as amended;
“$,” “USD,” “US$” and “U.S. dollar” are to the United States dollar; and
“DKK,” “Krone,” and “Kroner” are to the Danish Krone

1

PRESENTATION OF FINANCIAL INFORMATION

This annual report contains our audited consolidated financial statements as of December 31, 2021 and 2020 and for the years ended December 31, 2021, 2020 and 2019 (our “audited consolidated financial statements”), prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”).

Our financial information is presented in our presentation currency, U.S. Dollar, or USD. Our parent Company’s functional currency is the Danish Krone, or DKK. Certain Danish Krone amounts in this annual report have been translated solely for convenience into USD at an assumed exchange rate of DKK 6.5612 per $1.00, which was the official exchange rate of such currencies as of December 31, 2021 rounded to four decimal places.

Foreign currency transactions are translated into our functional currency, DKK, using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized as financial income or financial expenses in the statements of comprehensive loss. Non-monetary items in foreign currency, which are measured at cost at the statements of financial position date are translated into our functional currency, DKK, using the exchange rates at the date of the transaction. Such DKK translated amounts are not necessarily indicative of the amounts of DKK that could have actually been purchased with the underlying currency being exchanged into DKK at the dates indicated.

Assets and liabilities in our functional currency are translated to our presentation currency, USD, at the exchange rate applicable on December 31, 2021. Income and expenses in our functional currency are translated to USD at the average exchange rate, which corresponds to an approximation of the exchange rates prevailing on each individual transaction date. Translation differences arising in the translation to presentation currency are recognized in other comprehensive income. Such USD amounts are not necessarily indicative of the amounts of USD that could actually have been purchased upon exchange of DKK at the dates indicated.

We have made rounding adjustments to some of the figures contained in this annual report. Accordingly, numerical figures shown as totals in some tables may not be exact arithmetic aggregations of the figures that preceded them.

TRADEMARKS, SERVICE MARKS AND TRADENAMES

This annual report includes trademarks, tradenames and service marks, certain of which belong to us and others that are the property of other organizations. Solely for convenience, trademarks and tradenames referred to in this annual report appear without the and ™ symbols, but the absence of those references is not intended to indicate, in any way, that we will not assert our rights or that the applicable owner will not assert its rights to these trademarks and tradenames to the fullest extent under applicable law. We do not intend our use or display of other parties’ trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This annual report contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Many of the forward-looking statements contained in this annual report can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and other similar expressions that are predictions of or indicate future events and future trends, although not all forward-looking statements contain these identifying words.

2

Forward-looking statements appear in a number of places in this annual report and include, but are not limited to, statements regarding intent, belief or current expectations. Forward-looking statements are based on the current beliefs and assumptions of the management of Evaxion and on information currently available to such management. While the management of Evaxion believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments will be as anticipated. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to of various factors, including, but not limited to, those identified under the section “Item 3. Key Information—D. Risk Factors” in this annual report. These risks and uncertainties include factors relating to:

the initiation, timing, progress, results, and cost of our research and development programs and our current and future pre-clinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs;
the timing of and our ability to obtain and maintain regulatory approval for our product candidates;
our ability to identify research opportunities and discover and develop investigational medicines;
the ability and willingness of our third-party collaborators to continue research and development activities relating to our development candidates and investigational medicines;
our expectations regarding the size of the patient populations for our product candidates, if approved for commercial use;
our estimates of our expenses, ongoing losses, future revenue and capital requirements and our needs for or ability to obtain additional financing;
our ability to identify, recruit and retain key personnel;
our and our collaborators’ ability to protect and enforce our intellectual property protection for our proprietary and collaborative product candidates, and the scope of such protection;
the development of and projections relating to our competitors or our industry;
our ability to commercialize our product candidates, if approved;
the pricing and reimbursement of our investigational medicines, if approved;
the rate and degree of market acceptance of our investigational medicines;
the amount of and our ability to use our net operating losses, or NOLs, and research and development credits to offset future taxable income;
our ability to manage our development and expansion;
regulatory developments in the United States and foreign countries;
adverse effects on our business condition and results for operation from the global COVID-19 pandemic, including the pace of global economic recovery from the pandemic;
our ability to manufacture our product candidates with advantages in turnaround times or manufacturing cost;
our ability to implement, maintain and improve effective internal controls;

3

our expectations regarding the time during which we will be an emerging growth company under the JOBS Act and a foreign private issuer;
adverse effects on our business condition and results for operation from general economic and market conditions and overall fluctuations in the United States and international equity markets, including deteriorating market conditions due to investor concerns regarding inflation and hostilities between Russia and Ukraine; and
other risk factors discussed under “Item 3. Key Information—D. Risk Factors”.

Our actual results or performance could differ materially from those expressed in, or implied by, any forward-looking statements relating to those matters. Accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on our results of operations, cash flows or financial condition. Except as required by law, we are under no obligation, and expressly disclaim any obligation, to update, alter or otherwise revise any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future events or otherwise.

Summary of Material Risks Associated with Our Business

The principal risks and uncertainties affecting our business include the following:

We are a clinical stage AI-immunology company with only two product candidates currently in clinical trials.
We have a limited operating history and no immunotherapy drug has been approved using our technology, and none may ever be approved.
We have incurred significant losses since our inception, and we anticipate that we will continue to incur significant losses for the foreseeable future.
We will require substantial additional financing to achieve our goals.
We will need to develop and expand our company, and we may encounter difficulties in managing this development and expansion, which could disrupt our operations.
Pharmaceutical product development is inherently uncertain, and there is no guarantee that any of our product candidates will receive marketing approval.
The global pandemic caused by COVID-19 and variants such as Delta and Omicron, as well as the pace of global economic recovery from the pandemic, has affected our business and if the pandemic continues it could materially adversely impact our business, including delays in our clinical trials, supply chain operation, regulatory timelines and commercial activities.
The effects of the recent invasion of Ukraine by Russia, the resulting conflict and retaliatory measures by the global community have created global security concerns, including the possibility of expanded regional or global conflict, which have had, are likely to continue to have, short-term and likely longer-term adverse impacts on Ukraine and Europe and around the globe, which could adversely affect our business and results of operations.
Our product candidates may not work as intended, may cause undesirable side effects or may have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following marketing approval, if any.
Our future partners, if any, may not be able to obtain regulatory approval for products, if any, derived from our product candidates under applicable United States, European and other international regulatory requirements.
We face significant competition in an environment of rapid technological and scientific change, and our failure to effectively compete would prevent us from achieving our goals.

4

Even if products derived from our product candidates receive regulatory approval, such products may not gain market acceptance and our future partners, if any, may not be able to effectively commercialize them.
If we are not successful in developing our product candidates and our future partners, if any, are not successful in commercializing any products derived from our product candidates, our ability to expand our business and achieve our strategic objectives will be impaired.
We rely on third parties in the conduct of significant aspects of our pre-clinical studies and clinical trials, and we intend to rely on third parties in the conduct of future clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements and/or fail to meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates.
Our future partners, if any, may encounter difficulties in manufacturing, product release, shelf life, testing, storage, supply chain management and/or shipping.
Certain of our product candidates may be uniquely manufactured for each patient and we and/or our future partners may encounter difficulties in production, particularly with respect to the scaling of manufacturing capabilities.
If our efforts to obtain, maintain, protect, defend and/or enforce the intellectual property related to our product candidates and technologies are not adequate, we may not be able to compete effectively in our market.
We may be involved in lawsuits to protect or enforce our intellectual property or the intellectual property of our licensors, or to defend against third-party claims that we infringe, misappropriate or otherwise violate such third party’s intellectual property.

The summary risk factors described above should be read together with the text of the full risk factors below in the section entitled “Risk Factors” and the other information set forth in this Annual Report on Form 20-F, including our consolidated financial statements and the related notes, as well as in other documents that we file with the United States Securities and Exchange Commission. The risks summarized above or described in full below are not the only risks that we face. Additional risks and uncertainties not precisely known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, results of operations, and future growth prospects.

5

PART I

Item 1.Identity of Directors, Senior Management and Advisers

Not applicable.

Item 2.Offer Statistics and Expected Timetable

Not applicable.

Item 3.Key Information

3.A. Reserved

3.B. Capitalization and Indebtedness

Not applicable.

3.C. Reasons For the Offer and Use of Proceeds

Not applicable.

3.D. Risk Factors

We are a clinical-stage biotechnology company with no pharmaceutical products approved for commercial sale. Our business faces significant risks. You should carefully consider all of the information set forth in this annual report and in our other filings with the SEC, including the following risk factors which we face and which are faced by our industry. Our business, financial condition or results of operations could be materially adversely affected by any of these risks. This annual report also contains forward-looking statements that involve risks and uncertainties. Our results could materially differ from those anticipated in these forward-looking statements, as a result of certain factors including the risks described below and elsewhere in this report and our other SEC filings. See “Special Note Regarding Forward-Looking Statements” above.

Risks Related to our Financial Condition and Capital Requirements

We have incurred significant losses since our inception and we anticipate that we will continue to incur significant losses for the foreseeable future, which makes it difficult to assess our future viability. We have not generated significant revenue and may never be profitable.

We have incurred net losses in each year since our inception in 2008, including net losses of $24.5 million, $15.0 million, and $11.2 million for the years ended December 31, 2021, 2020, and 2019, respectively. As of December 31, 2021, we had accumulated deficit of $50.4 million.

We have devoted most of our financial resources to research and development, including our pre-clinical and clinical development activities and the development of our AI platform technologies, PIONEER, EDEN and RAVEN. To date, we have financed our operations primarily through the sale of equity securities, issuance of convertible debt instruments and through private and governmental grants. The amount of our future net losses will depend, in part, on the rate of our future expenditures and our ability to obtain funding through equity or debt financings, sales of assets, collaborations and grants. We believe that the cost and expense of late stage clinical testing, regulatory and marketing approval and commercialization of products for such disease indications are beyond the resources of all but the large biopharmaceutical and pharmaceutical companies. Therefore, we intend to develop our product candidates through Phase 2b clinical trials and then enter into partnership arrangements with these large biopharmaceutical and pharmaceutical companies to conduct late stage clinical trials, regulatory and marketing approval and commercialization of our product candidates. We have not yet entered into any such partnership agreements and may be unable to do so on economically viable terms, if at all. As a result, late stage clinical trials as well as pivotal clinical trials for our product candidates have not been commenced and even if such trials are commenced in the near future, it will be several years, if ever, before we have a product candidate ready for commercialization by one of our partners. Even if our future partners obtain regulatory approval to market a

6

product candidate, our future revenues will depend upon the size of any markets in which our product candidates receive such approval, upfront, milestone and any other payments we receive from our future partners, and our future partners’ ability to achieve sufficient market acceptance, reimbursement from third-party payors, and adequate market share in those markets. We may never achieve profitability.

Our ability to generate revenue and achieve profitability depends on our ability to successfully complete the development of, and our partners’ ability to obtain the regulatory approvals necessary to commercialize, our product candidates. We do not anticipate generating substantial revenues in the near term from any of our commercialization partnerships we may establish.

We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. We anticipate that our expenses will increase substantially as we:

continue or expand our research or development of our programs in pre-clinical development;
continue or expand the scope of our clinical trials for our product candidates;
initiate additional pre-clinical studies or clinical trials for our product candidates and seek to identify and validate additional product candidates;
continue to invest in our AI platforms to identify novel therapies;
change or add to internal and external manufacturing capacity or capability;
change or add more suppliers;
add more infrastructure to our quality control, quality assurance, legal, accounting, compliance and other groups to support our operations;
attract and retain skilled personnel;
create additional infrastructure to support our operations as a public company;
create additional infrastructure to support our product development, including expansion of sites in Denmark and new sites in the United States;
acquire or in-license other technologies;
make milestone or other payments under any in-license agreements;
maintain, protect, defend, enforce and expand our intellectual property portfolio; and
experience any delays or encounter issues with any of the above.

Our ability to generate future revenues from our potential commercialization partnerships depends heavily on our success in:

completing research and pre-clinical development, and successfully progressing our product candidates through clinical development, including through Phase 2b clinical trials for both immuno-oncology and infectious disease product candidates to validate our AI platforms;
seeking, negotiating and obtaining agreements with future partners, if any, on favorable terms for the completion of clinical trials, and United States and non- United States marketing approvals and commercialization of our product candidates;

7

further development of the manufacturing capabilities of, and our relationships with, third-party manufacturers in order to provide adequate (in amount and quality) products and services to support clinical development of our product candidates;
our future partners obtaining market acceptance of our product candidates as treatment options;
our future partners launching and commercializing our product candidates for which marketing approval and reimbursement have been obtained;
addressing any competing technological and market developments;
implementing additional internal systems and infrastructure;
maintaining, defending, protecting, enforcing and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how; and attracting, hiring and retaining qualified personnel.

Our operating results may fluctuate significantly, which makes our future operating results difficult to predict. If our operating results fall below expectations, the market price of the ADSs could decline.

Our financial condition and operating results have varied in the past and will continue to fluctuate from one financial period to the next due to a variety of factors, many of which are beyond our control. Factors relating to our business that may contribute to these fluctuations include the following, as well as other factors described elsewhere in this Form 20-F:

delays or failures in advancement of existing or future product candidates into clinical trials;
failures in further development of our AI platforms;
the ability of our future partners to manufacture and commercialize our product candidates;
our ability to manage our growth;
the outcomes of research programs, pre-clinical studies and clinical trials, and other product development or approval processes conducted by us and/or our future partners;
the ability of our future partners to develop and successfully commercialize products developed from our suite of therapeutic classes;
our relationships, and any associated exclusivity terms, with partners;
our contractual or other obligations to provide resources to fund our product candidates;
our operations in a net loss position for the foreseeable future;
risks associated with the international aspects of our business outside of Denmark, including the conduct of clinical trials in multiple locations;
our and our partners’ consistent ability to have our products and product candidates manufactured by third parties;
our ability to develop programs to fit into a clinical work-flow and treatment regimen;
our ability to accurately report our financial results in a timely manner;
our dependence on, and the need to attract and retain, key management and other personnel;

8

our and our partners’ ability to obtain, protect, maintain, defend and enforce our intellectual property rights;
our and our partners’ ability to prevent the theft or infringement, misappropriation or other violation of our intellectual property, trade secrets, know-how or technologies;
potential advantages that our competitors and potential competitors may have in securing funding, obtaining the rights to critical intellectual property or developing competing technologies or products;
our ability to obtain additional capital that may be necessary to expand our business;
our future partners’ ability to obtain additional capital that may be necessary to develop and commercialize products under our collaboration agreements;
business interruptions such as power outages, strikes, acts of terrorism, pandemics or natural disasters; and
our ability to use our net operating loss, or NOL, carryforwards to offset future taxable income.

Due to the various factors mentioned above, and others, the projected financial information included in this Form 20-F should not be relied upon as indications of our future operating performance.

The net losses we incur may fluctuate significantly from one reporting period to the next, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance.

In any particular period, our operating results could be below the expectations of securities analysts or investors, which could cause the market price of the ADSs to decline. While as a general matter we intend to periodically report on the status of our product candidate pipeline, including articulating anticipated next steps in the form of development plans or potential data readouts, we may not always be able to provide forward-looking guidance on the timing of those next steps. In addition, we do not control the timing of disclosures of any milestones related to any of our product candidates that are managed by our partners. Any disclosure by a partner of data that are perceived as negative, whether or not such data are related to other data that we or others release, may have a material adverse impact on the market price of the ADSs or overall valuation. The market price of the ADSs may decline as a result of unexpected clinical trial results in one or more of our programs, including adverse safety events reported for any of our programs.

Our expenses could increase beyond our expectations if we are required by the FDA, the European Medicines Agency, or the EMA, the Australian Therapeutic Goods Administration, or the TGA, or other regulatory agencies to perform clinical and other trials or make changes to our manufacturing or quality systems in addition to those that we currently anticipate. Even if we are able to generate revenues from our agreements with future partners, if any, we may not become profitable and may need to obtain additional funding to continue operations.

The amount of NOLs and research and development credits and our ability to use the same to offset future taxable income may be subject to certain limitations and uncertainty.

In Denmark, we have unused tax loss carryforwards for corporate taxes, though we have not recognized deferred tax assets related to such loss carryforwards for IFRS reporting purposes. In general, NOL carryforwards in Denmark do not expire. They are, however, subject to review and possible adjustment by the Danish tax authorities. Furthermore, under current Danish tax laws, certain substantial changes in our ownership structure and business may further limit the amount of NOL carryforwards that can be used annually to offset future taxable income. In addition, we may in the future have United States federal and state NOL carryforwards in the United States, and other jurisdictions where we maintain a subsidiary.

We may not be able to utilize a material portion of our NOLs or credits in either Denmark, the United States, or other jurisdictions where we maintain a subsidiary or otherwise engage in business. In addition, the rules regarding the timing of revenue and expense recognition for tax purposes in connection with various transactions are complex and uncertain in many respects, and our recognition could be subject to challenge by taxing authorities. In the event any such challenge is sustained, our NOLs could be materially reduced or we could be determined to be a material cash taxpayer for one or more years. Furthermore, our ability to use our NOLs or credits is conditioned upon our attaining profitability and generating taxable income. As described above, we have incurred significant net

9

losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future. We do not know whether or when we will generate the taxable income necessary to utilize our NOL or credit carryforwards.

We will need substantial additional financing to achieve our goals, and a failure to obtain this capital on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations.

As of December 31, 2021 we had $32.2 million in cash and cash equivalents. The net proceeds from our IPO completed in February 2021 was $25.3 million, based on the initial public offering price of $10.00 per ADS, after deducting underwriting discounts and commissions and offering expenses payable by us. The net proceeds from our follow-on offering completed in November 2021 was $24.9 million, based on the public offering price of $7.00 per ADS after deducting underwriting discounts and commissions and offering expenses payable by us.

In August 2020, we executed a loan agreement, or the EIB Loan Agreement, with the European Investment Bank, or EIB, for a principal amount of €20.0 million, divided into three tranches of tranche 1 in the amount of €7.0 million, tranche 2 in the amount of €6.0 million and tranche 3 in the amount of €7.0 million, or the EIB Loan. Under the EIB Loan Agreement, the EIB Loan tranche balances are due six years from their respective disbursement dates. In connection with disbursement of each tranche, EIB is entitled to receive certain warrants, or the EIB Warrants. In November 2020, we initiated the process to receive the funds from the disbursement of tranche 1 of the EIB Loan in the aggregate amount of €7.0 million but due to the timing of the IPO we did not finalize a disbursement offer. In connection therewith, EIB received 351,036 EIB Warrants, which vested immediately, pursuant to the terms of a separate warrant agreement, or the EIB Warrant Agreement. As of December 31, 2021, we initiated the draw down of the first tranche of the EIB loan Agreement amounting to €7.0 million. We received the proceeds from the draw down of the first tranche of the EIB loan of €7.0 million on February 17, 2022. We expect that the net proceeds from our IPO, our follow-on offering, the proceeds from draws on amounts available under the EIB Loan and our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements through at least 12 months from the date of this Form 20-F. However, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings, government or other third-party funding, sales of assets, other collaborations and licensing arrangements, or a combination of these approaches. In any event, we will require additional capital to achieve our goals. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific strategic considerations. Our spending will vary based on new and ongoing development and corporate activities. Due to high uncertainty of the length of time and activities associated with discovery and development of our product candidates, we are unable to estimate the actual funds we will require for our development activities.

Our future funding requirements, both near and long term, will depend on many factors, including, without limitation:

the initiation, progress, timing, costs, and results of pre-clinical or nonclinical studies and clinical trials for our product candidates;
the results of research and our other platform activities;
the clinical development plans we establish for our product candidates;
the terms of any agreements with our future commercial partners, if any;
the number and characteristics of any technology that we develop or may in-license;
the outcome, timing and cost of meeting regulatory requirements established by the FDA, the EMA, the TGA and other comparable regulatory authorities;
the cost of filing, prosecuting, obtaining, maintaining, protecting, defending and enforcing our patent claims and other intellectual property rights, including actions for patent and other intellectual property infringement,
misappropriation and other violations brought by third parties against us regarding our product candidates or actions by us challenging the patent or intellectual property rights of others;

10

the effect of competing technological and market developments, including other products that may compete with one or more of our product candidates; and
the cost and timing of completion and further expansion of clinical scale manufacturing activities by third parties sufficient to support all of our current and future programs.

To date, we have financed our operations primarily through the sale of equity securities, issuance of convertible debt instruments and from private and governmental grants and we cannot be certain that additional funding will be available on favorable terms, or at all. Until we can generate sufficient upfront fees, milestone payments and royalty revenues from our agreements with future partners, if any, to finance our operations, which we may never do, we expect to finance our future cash needs through a combination of public or private equity offerings, debt financings, sales of assets, licensing arrangements, and other product development arrangements. Any fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts, at the right time, on favorable terms, or at all. Negative clinical trial data or setbacks, or perceived setbacks, in our programs or with respect to our technology could impair our ability to raise additional financing on favorable terms, or at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our shareholders, and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of the ADSs to decline. If we raise additional funds through public or private equity offerings, the terms of these securities may include liquidation or other preferences that may adversely affect our securityholders’ rights.

Further, to the extent that we raise additional capital through the sale of ADSs, ordinary shares or securities convertible or exchangeable into ordinary shares, our shareholders’ ownership interest will be diluted. In addition, we may enter into credit facilities from time to time, which may be secured, to fund certain of our operations. If we raise additional capital through debt financing, we would be subject to fixed payment obligations and may be subject to security interests in our assets and covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional capital through sales of assets or other collaborations, or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs. We also could be required to seek future partners for one or more of our current or future product candidates at an earlier stage than otherwise would be desirable or relinquish our rights to product candidates or intellectual property that we otherwise would seek to develop ourselves. If we are unable to raise additional capital in sufficient amounts, at the right time, on favorable terms, or at all, we may have to significantly delay, scale back or discontinue the development of one or more of our product candidates, or one or more of our other research and development initiatives. Any of the above events could significantly harm our business, prospects, financial condition and results of operations, cause the market price of the ADSs to decline, and negatively impact our ability to fund operations

Any additional financing that we could seek may not be available on favorable terms or at all. For example, while the potential impact and duration of the COVID-19 pandemic on the global economy and our business in particular may be difficult to assess or predict, the pandemic has resulted in, and may continue to result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. If we are unable to obtain adequate financing or financing on terms satisfactory to us when we require it, our future plans and our ability to execute our strategy could be adversely affected, which in turn could have a material adverse effect on our business, results of operations, cash flows, financial condition and/or prospects.

We will need to develop and expand our company, and we may encounter difficulties in managing this development and expansion, which could disrupt our operations.

As of December 31, 2021, we had 61 full-time equivalent employees and, in connection with the growth and advancement of our pipeline and becoming a public company, we expect to increase the number of employees and the scope of our operations. To manage our anticipated development and expansion, we must continue to implement and improve our managerial, operational, legal, compliance and financial systems, expand our facilities, and continue to recruit and train additional qualified personnel. Also, our management may need to divert a disproportionate amount of its attention away from its day-to-day activities and devote a substantial amount of time to managing these development activities.

11

As a growing biotechnology company, we are actively pursuing drug classes, platforms and product candidates in many therapeutic areas and across a wide range of diseases. Successfully developing product candidates for and fully understanding the regulatory and manufacturing pathways to all of these therapeutic areas and disease states requires a significant depth of talent, resources and corporate processes in order to allow simultaneous execution across multiple areas. Due to our limited resources, we may not be able to effectively manage this simultaneous execution and the expansion of our operations or recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure, give rise to operational mistakes, legal or regulatory compliance failures, loss of business opportunities, loss of employees and reduced productivity among remaining employees. The physical expansion of our operations may lead to significant costs and may divert financial resources from other projects, such as the development of our product candidates. If our management is unable to effectively manage our expected development and expansion, our expenses may increase more than expected, our ability to generate or increase our revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to compete effectively and develop our product candidate will depend in part on our ability to effectively manage the future development and expansion of our company.

Risk factors

We have identified material weaknesses in our internal control over financial reporting. If we are unable to remediate these material weaknesses, or if we experience additional material weaknesses in the future, we may not be able to accurately or timely report our financial condition or results of operations and investors may lose confidence in our financial reports and the market price of the ADSs could be adversely affected.

As a public company, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal control. Section 404 of the Sarbanes-Oxley Act requires that we evaluate and determine the effectiveness of our internal control over financial reporting and provide a management report on internal control over financial reporting. The Sarbanes-Oxley Act also requires that our management report on internal control over financial reporting be attested to by our independent registered public accounting firm, to the extent we are no longer an “emerging growth company,” as defined by the JOBS Act. We do not expect to have our independent registered public accounting firm attest to our management report on internal control over financial reporting for so long as we are an emerging growth company.

As defined in the standards established by the U.S. Public Company Accounting Oversight Board, a “material weakness” is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our company’s annual consolidated financial statements will not be prevented or detected on a timely basis.

In connection with the preparation of our financial statements for the year ended December 31, 2021, we continued to be in the process of designing and implementing controls to monitor and provide oversight over the design and operating effectiveness of internal control over financial reporting in order to comply with the requirements of Section 404 of the Sarbanes-Oxley Act. We determined that management failed to implement certain components of the COSO framework, including elements of the control environment, information and communication, control activities and monitoring activities. Therefore, we have assessed that we lacked sufficient internal controls to support effective financial reporting as of December 31, 2021, which constitutes a material weakness.

To remediate this material weakness, we will continue to make further progress on the design and operating effectiveness of our internal controls over financial reporting, including the monitoring, oversight and evaluation of our internal controls. We will allocate more internal resources to internal controls and intend to engage external advisors to provide training and to reassess and redesign processes and develop new controls as appropriate including assisting with the evaluation and documentation of the risk assessment, design and operating effectiveness of our internal controls over financial reporting and assist with the remediation of any deficiencies.

Additionally, in the years ended December 31, 2020 and 2019, we had identified a material weakness in our internal control over financial reporting, which remained unremediated as of December 31, 2021. The unremediated material weakness identified relates to the lack of accounting and supervisory personnel that possess an appropriate level of technical accounting experience and training, and their lack of supervision over third party service providers in areas such as books and records, financial controlling, and financial statements preparation.

12

To remediate this previously identified material weakness, we retained an advisory firm to provide additional depth and breadth to our technical accounting and financial reporting capabilities and are taking steps such as the hiring of additional finance staff. Also, during 2021, we hired four additional accounting personnel with financial statement closing experience and technical IFRS knowledge for the purposes of timely and reliable financial reporting in accordance with IFRS and the requirements set forth by the SEC. In addition, we recently announced that we have hired a new Chief Financial Officer who has considerable public company experience.

While we intend to implement our plans to remediate these material weaknesses, we cannot predict the success of such plans or if they will result in remediation of these material weaknesses or that additional material weaknesses will not be identified in the future. If we are unable to remediate these material weaknesses or if we experience additional material weaknesses in the future or otherwise continue to fail in maintaining an effective system of internal controls, we may not be able to accurately or timely report our financial condition or results of operations. Our investors may lose confidence in the accuracy and completeness of our financial reports, the market price of the ADSs could be adversely affected, and we could become subject to investigations by the stock exchange on which our securities are listed, the SEC, or other regulatory authorities, which could require additional financial and management resources.

Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities.

We do not carry insurance for all categories of risk that our business may encounter, and insurance coverage is becoming increasingly expensive. We do not know if we will be able to maintain existing insurance with adequate levels of coverage, and any liability insurance coverage we acquire in the future may not be sufficient to reimburse us for any expenses or losses we may suffer. If our future partners obtain marketing approval for any product candidates that we or our future partners may develop, we intend to acquire insurance coverage to include the sale of commercial products, but we may be unable to obtain such insurance on commercially reasonable terms or in adequate amounts, if at all. If our losses exceed our insurance coverage, our financial condition would be adversely affected. In the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources. Clinical trials or regulatory approvals for any of our product candidates could be suspended, which could adversely affect our results of operations and business, including by preventing or limiting the development and commercialization of any product candidates that we or our future partners may develop. We also expect that operating as a public company will make it more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our Board, our board committees or our management team.

Risks Related to our Business and Industry

Our AI approach to the discovery and development of product candidates is novel and unproven, and we do not know whether we or our partners, if any, will be able to develop any products of commercial value.

We are leveraging our PIONEER, EDEN and RAVEN AI platform technologies to create a pipeline of cancer immunotherapies and bacterial and viral infectious disease product candidates for patients whose diseases have not been adequately addressed to date by other approaches, and to design and conduct efficient clinical trials with a potentially greater likelihood of success. While we believe that applying our AI platform technologies to create medicines for defined patient populations may potentially enable drug research and clinical development that is more efficient than conventional drug research and development, our approach is both novel and unproven and, therefore, the cost and time needed to develop our product candidates is difficult to predict. Our efforts may not result in the discovery and development of commercially viable medicines. We may also be incorrect about the effects of our product candidates on the diseases of our targeted patient populations, which may limit the utility of our approach or the perception of the utility of our approach. Furthermore, our defined patient populations available for study and treatment may be lower than expected, which could adversely affect our ability to conduct clinical trials and may also adversely affect the size of any market for medicines we may successfully commercialize. Our approach may not result in clinical effect, time savings, higher success rates or reduced costs as we expect and, if not, we may not attract future partners or develop new drug candidates as quickly or cost effectively as expected and therefore our future partners may not be able to commercialize our approach as originally expected.

Our AI approach may fail to help us discover and develop additional product candidates.

Any drug discovery that we are conducting using our AI platform technologies may not be successful in identifying compounds that have commercial value or therapeutic utility. Our AI platform technologies may initially show promise in identifying potential product

13

candidates, yet fail to yield viable product candidates for clinical development or commercialization for a number of reasons, including:

we may not be successful in our efforts to identify new product candidates. If we are unable to identify suitable additional compounds for pre-clinical and clinical development, our ability to develop product candidates and generate revenue in future periods could be compromised, which could result in significant harm to our financial position and adversely impact the market price of the ADSs;
compounds found through our AI platform technologies may not demonstrate efficacy, safety or tolerability;
potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to receive marketing approval and achieve market acceptance;
competitors may develop alternative therapies that render our potential product candidates non-competitive or less attractive;
a product candidate may not be capable of being manufactured at an acceptable cost and speed; or
we may not be able to scale up manufacturing of patient-specific therapies to a commercial scale.

We may experience challenges with the acquisition, development, enhancement or deployment of technology necessary for our AI platform technologies.

Our business requires sophisticated computer systems and software. Some of the technologies are changing rapidly and we must continue to adapt to these changes in a timely and effective manner at an acceptable cost. There can be no guarantee that we will be able to develop, acquire, enhance, deploy or integrate new technologies, that these new technologies will meet our needs or achieve our expected goals, or that we will be able to do so as quickly or cost-effectively as our competitors. Significant technological change could render our AI platform technologies obsolete. Our continued success will depend on our ability to adapt to changing technologies, manage and process ever-increasing amounts of data and information and improve the performance features of our AI platform technologies in response to an ever-changing patient population. We may experience difficulties that could delay or prevent the successful design, development, testing, and introduction of advanced versions of our AI platform technologies, limiting our ability to identify new product candidates. Any of these failures could have a material adverse effect on our operating results and financial condition.

Our product candidates may not work as intended, may cause undesirable side effects or may have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.

As with most biological and vaccine products, use of our product candidates could be associated with side effects or adverse events which can vary in severity from minor reactions to death and in frequency from infrequent to prevalent. The potential for adverse events is especially acute in the oncology setting, where patients may have advanced disease, have compromised immune and other systems and be receiving numerous other therapies. Undesirable side effects or unacceptable toxicities caused by our product candidates could cause us, our future partners or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, the EMA, the TGA or comparable regulatory authorities. Results of clinical trials of our product candidates could reveal a high and unacceptable severity and prevalence of side effects.

If unacceptable side effects arise in the development of our product candidates, we, our future partners, the FDA, the EMA, the TGA, competent authorities of the European Union member states, ethics committees, the institutional review boards, or IRBs, at the institutions in which clinical trials of our product candidates are conducted, or a Data Safety Monitoring Board, or DSMB, could suspend or terminate our clinical trials. The FDA, the EMA, the TGA or comparable regulatory authorities could also order us or our future partners to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete any of our or our partners’ clinical trials or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect that we or our future partners may have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate

14

training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly.

Monitoring the safety of patients receiving our product candidates is challenging, which could adversely affect our and our partners’ ability to obtain regulatory approval and commercialize our product candidates.

In our ongoing and planned clinical trials, we have contracted with and are expected to continue to contract with academic medical centers and hospitals experienced in the assessment and management of toxicities arising during clinical trials. Nonetheless, these centers and hospitals may have difficulty observing patients and treating toxicities, which may be more challenging due to personnel changes, inexperience, shift changes, house staff coverage or related issues. This could lead to more severe or prolonged toxicities or even patient deaths, which could result in us, our future partners or the FDA, EMA or other comparable regulatory authority delaying, suspending or terminating one or more of our clinical trials, and which could jeopardize regulatory approval. We also expect the centers using our product candidates, if approved, on a commercial basis could have similar difficulty in managing adverse events. Medicines used at centers to help manage adverse side effects of our product candidates may not adequately control the side effects and may have a detrimental impact on the treatment. Use of these medicines may increase with new physicians and centers administering our product candidates.

In addition, even if our future partners successfully advance one or more of our product candidates into and through late stage clinical trials, such trials will likely only include a limited number of subjects and limited duration of exposure to our product candidates. As a result, we cannot be assured that adverse effects of our product candidates will not be discovered when a significantly larger number of patients are exposed to the product candidate. Further, any clinical trials may not be sufficient to determine the effect and safety consequences of taking our product candidates over a multi-year period.

If any of our product candidates receives marketing approval and we, our future partners or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:

regulatory authorities may withdraw their approval of products derived from one or more of our product candidates;
our future partners may be required to recall products derived from one or more of our product candidates or change the way such products are administered to patients;
additional restrictions may be imposed on the marketing of the products derived from one or more of our product candidates or the manufacturing processes for such products or any component thereof;
regulatory authorities may require the addition of labeling statements, such as a “black box” warning or a contraindication;
our future partners may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a Medication Guide outlining the risks of such side effects for distribution to patients;
we or our future partners could be sued and held liable for harm caused to patients;
the products derived from one or more of our product candidates may become less competitive; and
our reputation may suffer.

Any of the foregoing events could prevent our future partners from achieving or maintaining market acceptance of the particular product candidate, even if approved, and result in the loss of significant revenues to us, which would materially and adversely affect our results of operations and business. In addition, if one or more of our product candidates generally prove to be unsafe, our AI platform technologies and product pipeline could be affected, which would have a material adverse effect on our business, financial condition, results of operations and prospects.

15

Pre-clinical development, including the timeline from target identification to clinical development, is uncertain. Our pre-clinical programs may experience delays or may never advance to clinical trials, which would adversely affect our partners’ ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all and would have an adverse effect on our business.

A portion of our product pipeline is in pre-clinical development and these programs could be delayed or not advance into the clinic. Before we can initiate clinical trials for product candidates, we must complete extensive pre-clinical studies, including IND-enabling Good Laboratory Practice toxicology testing that supports our planned INDs in the United States or similar applications in the EMA, the TGA and other jurisdictions. We must also complete extensive work on CMC activities (including collecting yield, purity and stability data) to be included in the IND filing or other equivalent regulatory filing. CMC activities for a new category of medicines require extensive manufacturing processes and analytical development, which are uncertain and lengthy. For instance, issues have occurred as we scale up our manufacturing and may occur in the future. In addition, we may have difficulty identifying appropriate buffers and storage conditions to enable sufficient shelf life of batches of our pre-clinical or clinical product candidates. If we are required to produce new batches of our product candidates due to insufficient shelf life, it may delay the commencement or completion of pre-clinical studies or clinical trials of such product candidates. For example, we cannot be certain of the timely completion or outcome of our pre-clinical testing and studies and cannot predict if the FDA, the EMA, the TGA or other regulatory authorities will accept the results of our pre-clinical testing or our proposed clinical programs or if the outcome of our pre-clinical testing, studies and CMC activities will ultimately support the further development of our programs. As a result, we cannot be sure that we will be able to submit INDs or similar applications for our pre-clinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications will result in the FDA or other regulatory authorities allowing clinical trials to begin. Additionally, while we have demonstrated our ability to move from target identification to clinical development within as little as 18 months with our EVX-02 product candidate, which is now in Phase 1/2a trial, no assurance can be given that we will be able to do the same with other product candidates in various phases of clinical development and trials in the future.

Clinical development involves a lengthy and expensive process with an uncertain outcome, and delays can occur for a variety of reasons outside of our or our future partners control. Clinical trials of our product candidates may be delayed, and certain programs may never advance in the clinic or may be more costly to conduct than we anticipate, any of which can affect our ability to fund our company and would have a material adverse impact on our business.

Clinical testing is expensive and complex and can take many years to complete. Its outcome is inherently uncertain. We and our future partners may not be able to initiate, may experience delays in, or may have to discontinue clinical trials for our product candidates. We and our future partners also may experience numerous unforeseen events during, or as a result of, any clinical trials that we or our future partners conduct that could delay or prevent us or our future partners from successfully developing our product candidates, including:

the FDA, EMA, other regulators, IRBs DSMBs, or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site for any number of reasons, including concerns regarding safety and aspects of the clinical trial design;
we or our future partners may experience delays in reaching, or fail to reach, agreement on favorable terms with prospective trial sites and prospective contract research organizations, or CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;
we have optimized in the past and may in the future optimize our manufacturing processes, including through changes to the scale and site of manufacturing, which may lead to additional studies;
or potentially significant changes in our clinical trial designs, requiring additional cost and time, and, as a consequence, lead to a delay in plans for progressing one or more product candidates;
the outcome of our pre-clinical studies and our early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results;
we and our future partners may be unable to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful;

16

in an effort to optimize product features, we or our future partners may continue to make changes to our product candidates after we or our future partners commence clinical trials of a product candidate which may require us or our future partners to repeat earlier stages of clinical testing or delay later-stage testing of the product candidate;
clinical trials of any of our product candidates may fail to show safety or efficacy, or may produce negative or inconclusive results, and we or our future partners may decide, or regulators may require us or our future partners, to conduct additional nonclinical studies or clinical trials, or we or our future partners may decide to abandon product development programs;
differences in trial design between early-stage clinical trials and later-stage clinical trials may make it difficult to extrapolate the results of earlier clinical trials to later clinical trials;
pre-clinical and clinical data are often susceptible to varying interpretations and analyses, and many product candidates believed to have performed satisfactorily in pre-clinical studies and clinical trials have nonetheless failed to obtain marketing approval;
our product candidates may have undesirable side effects or other unexpected characteristics. One or more of such effects or events could cause regulators to impose a clinical hold on the applicable trial, or cause us, our investigators, our future partners, IRBs or ethics committees to suspend or terminate the trial of that product candidate or any other of our product candidates for which a clinical trial may be ongoing;
the number of trial participants required for clinical trials of any product candidates may be larger than we or our future partners may anticipate, identification of trial participants for such trials may be limited, enrollment in these clinical trials may be slower than we or our future partners anticipate due to perceived adverse effects, limited patient populations, competitive trials or other reasons, or participants may withdraw from clinical trials or fail to return for post-treatment follow-up at a higher rate than we or our future partners anticipate;
our third-party contractors and our future partners may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or withdraw from the trial, which may require that we add new clinical trial sites;
regulators may elect to impose a clinical hold, or we, our investigators, our future partners, IRBs or ethics committees may elect to suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to an unacceptable benefit-risk ratio;
the cost of pre-clinical or nonclinical testing and studies and clinical trials of any product candidates may be greater than we or our future partners anticipate;
the supply or quality of our product candidates or other materials necessary to conduct clinical trials may be insufficient or inadequate;
safety or efficacy concerns regarding our product candidates may result from any concerns arising from nonclinical or clinical testing of other therapies targeting a similar disease state or other therapies that are perceived as similar to ours; and
the FDA, the EMA, the TGA or other regulatory authorities may require us or our future partners to submit additional data, such as long-term toxicology studies, or impose other requirements before permitting us to initiate a clinical trial.

In addition, the regulatory agencies may conduct inspections of clinical trial sites. Any findings by regulatory agencies and failure to comply with requirements may lead to delay in development, approval and failure to commercialize the potential product candidate.

17

We could also encounter delays if a clinical trial is suspended or terminated by us, our future partners, the FDA, the EMA, the TGA or other regulatory authorities, ethics committees, or the IRBs of the institutions in which such trials are being conducted, or if such trial is recommended for suspension or termination by the DSMB. We may in the future be delayed in gaining clearance from the FDA, the EMA, the TGA or other regulators to initiate clinical trials through, among other things, the imposition of a clinical hold in order to address comments from such regulators on our or our partners’ clinical trial design or other elements of our or our partners’ clinical trials. A suspension or termination may be imposed due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols; inspection of the clinical trial operations or trial site by the FDA, the EMA, the TGA or other regulatory authorities resulting in the imposition of a clinical hold; unforeseen safety issues or adverse side effects; failure to demonstrate a benefit, or adequate benefit-risk ratio, from using a product candidate; failure to establish or achieve clinically meaningful trial endpoints; changes in governmental regulations or administrative actions; or lack of adequate funding to continue the clinical trial. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. We or future partners could also experience delays if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. We and our future partners must also complete extensive work on CMC activities that require extensive manufacturing processes and analytical development, which are uncertain and lengthy.

We expect the novel nature of our product candidates to create further challenges in obtaining regulatory approval. For example, the FDA, the EMA, the TGA and regulatory authorities in other jurisdictions have limited experience with commercial development of product candidates developed using our PIONEER AI technology platform. The FDA may require an Advisory Committee to deliberate on the adequacy of the safety and efficacy data to support licensure. The opinion of the Advisory Committee, although not binding, may have a significant impact on our or our partners’ ability to obtain licensure of the product candidates based on the completed clinical trials, as the FDA often adheres to the Advisory Committee’s recommendations. Accordingly, the regulatory approval pathway for our product candidates may be uncertain, complex, expensive and lengthy, and approval may not be certain.

Significant pre-clinical or nonclinical testing and studies or clinical trial delays for our product candidates also could allow our competitors to bring products to market before our future partners do, potentially impairing our future partners ‘ability to successfully commercialize our product candidates and harming our business and results of operations. Any delays in the development of our product candidates may harm our business, financial condition and prospects significantly.

If we or our future partners encounter difficulties enrolling participants in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.

We and our future partners depend on enrollment of participants in the clinical trials for our product candidates. In the past, we and our future partners have found, and we or our future partners may in the future find, it difficult to enroll participants in clinical trials, which could delay or prevent clinical trials of our product candidates. Identifying and qualifying participants to participate in clinical trials of our product candidates is critical to our and our future partners’ success. The timing of our and our future partners clinical trials depends on the speed at which we and our future partners can recruit trial participants to participate in testing our product candidates. Delays in enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our and our partners’ ability to advance the development of our product candidates. If trial participants are unwilling to participate in our or our partners’ studies because of negative publicity from adverse events in the clinical trials or other clinical trials of similar product candidates, or those related to a specific therapeutic area, or for other reasons, including competitive clinical trials for similar patient populations, the timeline for recruiting trial participants, conducting studies, and obtaining regulatory approval of potential products may be delayed. These delays could result in increased costs, delays in advancing our product development, delays in testing the effectiveness of our product candidates, or termination of the clinical studies altogether.

We and our future partners may not be able to identify, recruit and enroll a sufficient number of trial participants, or those with required or desired characteristics to achieve diversity in a study, to complete clinical trials of our product candidates in a timely manner. Patient and subject enrollment is affected by factors including:

severity of the disease under investigation;
complexity and design of the study protocol;

18

size of the patient population;
eligibility criteria for the study in question;
proximity and availability of clinical trial sites for prospective trial participants;
availability of competing therapies and clinical trials, including between our own clinical trials;
efforts to facilitate timely enrollment in clinical trials;
patient referral practices of physicians;
ability to monitor trial participants adequately during and after treatment;
ability to recruit clinical trial investigators with the appropriate competencies and experience;
clinicians’ and trial participants’ perceptions of the potential advantages and side effects of the product candidate being studied in relation to other available therapies, including any new drugs or treatments that may be approved for the indications we are investigating;
our and our partners’ ability to obtain and maintain participant informed consent; and
the risk that participants enrolled in clinical trials will not complete a clinical trial.

In addition, our and our partners’ clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of trial participants available to us and our future partners because some trial participants who might have opted to enroll in our or our partners’ clinical trials may instead opt to enroll in a trial being conducted by a third party. Since the number of qualified clinical investigators is limited, we and our future partners will likely conduct some of our or our partners’ clinical trials at the same clinical trial sites that some of our and our partners’ competitors use, which will reduce the number of trial participants who are available for our clinical trials at such clinical trial sites. Moreover, because in some cases our product candidates represent a departure from more traditional methods for disease treatment and prevention, potential trial participants and their doctors may be inclined to use conventional therapies or other new therapies rather than enroll trial participants in any future clinical trial involving patient-specific product candidates. Additionally, if new product candidates, such as gene editing therapies, show encouraging results, potential trial participants and their doctors may be inclined to enroll trial participants in clinical trials using those product candidates. If such new product candidates show discouraging results or other adverse safety indications, potential trial participants and their doctors may be less inclined to enroll trial participants in our or our future partners’ clinical trials.

A variety of risks associated with conducting research and clinical trials in the United States and other countries outside of Denmark and marketing our product candidates, if approved, by our future partners internationally could materially adversely affect our business.

While clinical trials of EVX-01, our lead product candidate are currently being conducted only in Denmark and Australia, we expect that clinical trials or commercialization of our product candidates, if approved, may take place globally. Accordingly, we expect that we and our future partners will be subject to additional risks related to operating in multiple countries, including:

differing regulatory requirements in such countries;
unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;
increased difficulties in managing the logistics and transportation of storing and shipping product candidates produced in a particular country and shipping the product candidate to the patient in other countries;
import and export requirements and restrictions;

19

economic weakness, including inflation, or political instability in particular economies and markets;
compliance with tax, employment, immigration and labor laws for employees living or traveling in other countries;
taxes, including withholding of payroll taxes;
currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;
difficulties staffing and managing operations outside of Denmark;
workforce uncertainty in countries where labor unrest is more common;
differing payor reimbursement regimes, governmental payors or patient self-pay systems, and price controls;
potential liability under the U.S. Foreign Corrupt Practices Act of 1977 or comparable regulations in Denmark, Australia and other jurisdictions;
challenges enforcing our contractual and intellectual property rights, especially in those countries that do not respect and protect intellectual property rights to the same extent as do Denmark and the United States;
production shortages resulting from any events affecting raw material supply or manufacturing capabilities in other countries; and
business interruptions resulting from geopolitical actions, including war and terrorism, such as the recent invation of Ukraine by Russia and the resulting armed conflict as well as for natural disasters and pandemics such as those caused by COVID-19 and variants such as Delta and Omicron.

These and other risks associated with our international operations and our collaborations with our future partners may materially adversely affect our ability to attain or maintain profitable operations.

Interim top-line and preliminary data from studies or trials that we and/or our future partners announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.

From time to time, we and/or our future partners may publish interim top-line or preliminary data from pre-clinical studies or clinical trials. Interim data are subject to the risk that one or more of the outcomes may materially change as more data become available. We and/or our future partners may also make assumptions, estimations, calculations and conclusions as part of the analyses of data, and we and/or our future partners may not have received or had the opportunity to fully evaluate all data. As a result, the top-line results that we and/or our future partners report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Preliminary or top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Additionally, interim data from clinical trials that we and/or our future partners may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.

20

Further, others, including the FDA, the EMA, the TGA and other regulatory agencies, may not accept or agree with our and/or our partners’ assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we and/or our future partners choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure. Any information we and/or our future partners determine not to disclose may ultimately be deemed significant by you or others with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the top-line data that we and/or our future partners report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, product candidates may be harmed, which could significantly harm our business prospects.

Results of pre-clinical studies and clinical trials of our product candidates may not be predictive of future trial results.

Success in pre-clinical studies and early clinical trials does not ensure that later clinical trials will be successful. A number of companies in the biotechnology and pharmaceutical industries have suffered significant setbacks in clinical trials, even after positive results in earlier pre-clinical studies or clinical trials. These setbacks have been caused by, among other things, pre-clinical findings made while clinical trials were underway and safety or efficacy observations made in clinical trials, including previously unreported adverse events. Notwithstanding any potential promising results in earlier studies and trials, we and/or our future partners cannot be certain that we and/or our future partners will not face similar setbacks. Even if our or our partners’ clinical trials are completed, the results may not be sufficient to obtain regulatory approval for our product candidates. In addition, the results of our pre-clinical studies may not be predictive of the results of outcomes in human clinical trials. For example, our EVX-01 cancer immunotherapy product candidate and any future product candidates may demonstrate different chemical, biological and pharmacological properties in patients than they do in pre-clinical mouse studies or may interact with human biological systems in unforeseen or harmful ways. Product candidates in later stages of clinical trials may fail to show the desired pharmacological properties or safety and efficacy traits despite having progressed through pre-clinical studies and initial clinical trials. Even if we and/or our future partners are able to initiate and complete clinical trials, the results may not be sufficient to obtain regulatory approval for our product candidates.

Our planned clinical trials or those of our future partners may reveal significant adverse events not seen in our pre-clinical or nonclinical studies and may result in a safety profile that could delay or terminate clinical trials, or delay or prevent regulatory approval or market acceptance of any of our product candidates.

There is typically an extremely high rate of attrition for product candidates across categories of medicines proceeding through clinical trials. These product candidates may fail to show the desired safety and efficacy profile in later stages of clinical trials despite having progressed through nonclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in later-stage clinical trials due to lack of efficacy or unacceptable safety profiles, notwithstanding promising results in earlier trials. Most product candidates that commence clinical trials are never approved as products and there can be no assurance that any of our current or future clinical trials will ultimately be successful or support further clinical development of any of our product candidates.

Some of our product candidates may need to be co-administered with other developmental therapies or approved medicines. Such combinations may have additional side effects, which may be difficult to predict in future clinical trials.

If significant adverse events or other side effects are observed in any of our and/or our future partners’ current or future clinical trials, we and/or our future partners may have difficulty recruiting trial participants to any of our and/or our partners’ clinical trials, trial participants may withdraw from trials, or we and/or our future partners may be required to abandon the trials or our development efforts of one or more product candidates altogether. We, and/or our future partners, the FDA, the EMA, the TGA or other applicable regulatory authorities, ethics committees or an IRB may impose a clinical hold on, or suspend or terminate, clinical trials of a product candidate at any time for various reasons, including a belief that participants in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the drug from obtaining or maintaining marketing approval, an unfavorable benefit-risk ratio may inhibit market acceptance of the approved product due to its tolerability versus other therapies. Any of these developments could materially harm our business, financial condition and prospects.

21

We and/or our future partners may not be able to develop or obtain approval for companion diagnostics required for commercialization of some of our product candidates.

Some of our product candidates may require the use of companion diagnostic tools. If safe and effective use of a biologic product depends on an in vitro companion diagnostic, then the FDA generally requires approval or clearance of the diagnostic, known as a companion diagnostic, concurrently with approval of the therapeutic product. To date, the FDA has generally required in vitro companion diagnostics intended to select the patients who will respond to cancer treatment to obtain a pre-market approval, or PMA, for that diagnostic, which can take up to several years, simultaneously with approval of the biologic product. Similarly, in the European Union, an in vitro companion diagnostic may be placed on the market only if it conforms to certain “essential requirements” and bears the Conformité Européenne Mark, or CE Mark, and the conformity assessment process to obtain the CE Mark can be lengthy.

For our patient-specific immunotherapy candidates, the FDA and similar regulatory authorities outside of the United States such as the EMA or the TGA, may require the development and regulatory approval of a companion diagnostic assay as a condition to approval. The FDA may require PMA supplemental approvals for use of that same companion diagnostic as a condition of approval of additional individualized therapeutic candidates. We do not have experience or capabilities in developing or commercializing companion diagnostics and plan to rely in large part on third parties to perform these functions. Companion diagnostic assays are subject to regulation by the FDA and other comparable regulatory authorities in other jurisdictions as medical devices and require separate regulatory approval prior to the use of such diagnostic assays with our therapeutic candidates. If we, or any third parties that we engage to assist us, are unable to successfully develop companion diagnostic assays for use with our therapeutic candidates, or are unable to obtain regulatory approval or experience delays in either development or obtaining regulatory approval, we and/or our future partners may be unable to identify patients with the specific profile targeted by our product candidates for enrollment in our clinical trials. Accordingly, further investment may be required to further develop or obtain the required regulatory approval for the relevant companion diagnostic assay, which would delay or substantially impact our ability to conduct additional clinical trials or obtain regulatory approval.

The FDA, EMA, TGA or other regulatory authorities may not consider the endpoints of our clinical trials to provide clinically meaningful results.

There may not be pharmacologic therapies approved to treat the underlying causes of many diseases that we and/or our future partners may address in the future. For instance, we and/or our future partners may apply our technology to develop therapeutics in indications such as certain rare diseases, including some for which no or few clinical trials have been attempted. As a result, any future design and conduct of clinical trials of product candidates for the treatment of certain rare diseases may take longer, be more costly, or be less effective as part of the novelty of development in these diseases. Even if we decide to conduct clinical trials and the FDA does find our success criteria to be sufficiently validated and clinically meaningful, we may not achieve the pre-specified endpoint to a degree of statistical significance in any pivotal or other clinical trials we and/or our future partners may conduct for our programs. Further, even if we and/or our future partners do achieve the pre-specified criteria, our and/or our partners’ trials may produce results that are unpredictable or inconsistent with the results of the more traditional efficacy endpoints in the trial. The FDA also could give overriding weight to other efficacy endpoints over a primary endpoint, even if we and/or our future partners achieve statistically significant results on that endpoint, if we and/or our future partners do not do so on the secondary efficacy endpoints. The FDA also weighs the benefits of a product against its risks and the FDA may view the efficacy results in the context of safety as not being supportive of licensure. Other regulatory authorities in Europe and other countries may make similar findings with respect to these endpoints.

22

The FDA, EMA, TGA or other comparable regulatory authorities may disagree with our and/or our future partners’ regulatory plan and we and/or our future partners may fail to obtain regulatory approval of our product candidates.

If the results of our and/or our future partners’ clinical trials are sufficiently compelling, we and/or our future partners intend to discuss with the FDA, the EMA, the TGA or other regulatory authorities, submission of a BLA, EMAA, AMAA or other comparable submissions or to obtain regulatory approval in the United States or elsewhere, an European Union marketing authorization, an Australian marketing authorization or other regulatory authorization for our product candidates. However, we and/or our future partners do not have any agreement or guidance from the FDA that our and/or our partners’ regulatory development plans will be sufficient for submission of a BLA, EMAA, AMAA or other comparable submissions or to obtain regulatory approval in the United States or elsewhere for any of our product candidates. The FDA, EMA, TGA or other regulatory agencies may grant accelerated approval for our product candidates and, as a condition for accelerated approval, the FDA, EMA, TGA or other regulatory agencies may require a sponsor of a drug or biologic receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug or biologic may be subject to withdrawal procedures by the FDA, EMA, TGA or other regulatory agencies that are more accelerated than those available for regular approvals. In addition, the standard of care may change with the approval of new products in the same indications that we are studying. This may result in the FDA, EMA, TGA or other regulatory agencies requesting additional studies to show that our product candidate is superior to the new products.

Our and/or our future partners’ clinical trial results may also not support approval. In addition, our product candidates could fail to receive regulatory approval for many reasons, including the following:

the FDA, the EMA, the TGA or comparable regulatory authorities may disagree with the design or implementation of our clinical trials;
we and/or our future partners may be unable to demonstrate to the satisfaction of the FDA, the EMA, the TGA or comparable regulatory authorities that our product candidates are safe and effective for any of their proposed indications;
the results of clinical trials may not meet the level of statistical significance required by the FDA, the EMA, the TGA or comparable regulatory authorities for approval, including due to the heterogeneity of patient populations;
we and/or our future partners may be unable to demonstrate that our product candidates’ clinical and other benefits outweigh their safety risks;
the FDA, the EMA, the TGA or comparable regulatory authorities may disagree with our and/or our future partners’ interpretation of data from pre-clinical studies or clinical trials;
the data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of the FDA, the EMA, the TGA or comparable regulatory authorities to support the submission of a BLA, EMAA, AMAA or other comparable submissions or to obtain regulatory approval in the United States or elsewhere;
the FDA, the EMA, the TGA or comparable regulatory authorities will inspect our and/or our future partners manufacturing facilities and may not approve our and/or our partners’ facilities; and
the approval policies or regulations of the FDA, the EMA, the TGA or comparable regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.

23

We and/or our future partners may not be able to file INDs with the FDA, clinical trial applications with the competent authorities of European Union member states, clinical trial applications with the competent authorities in Australia or similar applications with other comparable regulatory authorities to commence additional clinical trials on the timelines we and/or our future partners expect, and even if we and/or our future partners are able to, one or more of these regulatory authorities may not permit us to proceed.

The timing of filing on our product candidates is dependent on further pre-clinical, clinical and manufacturing success. We and/or our future partners cannot be sure that filing of an IND or IND amendment with the FDA, a clinical trial application with the competent authorities of European Union member states, a clinical trial application with the competent authorities in Australia or similar application with other comparable regulatory authorities will result in the FDA, the competent authorities of European Union member states, the competent authorities in Australia or any comparable regulatory authority allowing testing and clinical trials to begin, or that, once begun, issues will not arise that result in the suspension or termination of such clinical trials. Additionally, even if such regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND, clinical trial application or similar applications, no assurance can be given that such regulatory authorities will not change their requirements in the future.

We and/or our future partners may seek orphan drug designation for some or all of our product candidates across various indications, but we and/or our future partners may be unable to obtain such designations or to maintain the benefits associated with orphan drug designation, including market exclusivity, which may cause our revenue, if any, to be reduced.

We and/or our future partners may seek for orphan drug designation in the United States and other jurisdictions, such as the European Union, where a similar designation may be available for our product candidates. In the United States, under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug or biologic intended to treat a rare disease or condition, which is defined as one occurring in a patient population of fewer than 200,000 in the United States, or a patient population of 200,000 or greater in the United States where there is no reasonable expectation that the cost of developing the drug or biologic will be recovered from sales in the United States. In the United States, orphan drug designation entitles a party to financial incentives, such as opportunities for grant funding toward clinical trial costs, tax advantages, and user-fee waivers. In addition, if a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including a full new drug application, or NDA, or a BLA, to market the same drug or biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the original manufacturer is unable to assure sufficient product quantity. Similar rules apply in the European Union and Australia with respect to drugs or biologics designated as orphan medicinal products.

In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective. Further, even if we and/or our future partners obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties may receive and be approved for the same condition, and only the first applicant to receive approval will receive the benefits of marketing exclusivity. Even after an orphan-designated product is approved, the FDA can subsequently approve a later drug with the same active moiety for the same condition if the FDA concludes that the later drug is clinically superior if it is shown to be safer, more effective, or makes a major contribution to patient care. Similar considerations apply in the European Union and Australia with respect to drugs or biologics designated as orphan medicinal products. Orphan drug designation neither shortens the development time or regulatory review time of a drug, nor gives the drug any advantage in the regulatory review or approval process. In addition, while we and/or our future partners may seek orphan drug designation for our product candidates, we may never receive such designations.

24

We and/or our future partners may seek breakthrough therapy or fast-track designation for one or more of our product candidates, but we and/or our future partners may not receive such designations. Even if we and/or our future partners do receive such designations, it may not lead to a faster development or regulatory review or approval process, and it may not increase the likelihood that such product candidates will receive marketing approval.

We and/or our future partners may seek a breakthrough therapy designation in the United States and other jurisdictions, such as the European Union, where a similar designation may be available, for one or more of our product candidates. In the United States, a breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA are also eligible for priority review if supported by clinical data at the time of the submission of the BLA.

Designation as a breakthrough therapy is at the discretion of the FDA. Accordingly, even if we and/or our future partners believe that one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a drug may not result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and it would not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product candidate no longer meets the conditions for qualification, or it may decide that the time period for FDA review or approval will not be shortened.

We and/or our future partners may also seek Fast Track Designation in the United States and/or a Conditional Market Authorization, or CMA, in the European Union for some of our product candidates. If a therapy is intended for the treatment of a serious or life-threatening condition and the therapy demonstrates the potential to address significant unmet medical needs for this condition, the drug sponsor may apply for Fast Track Designation. The FDA has broad discretion whether or not to grant this designation, and even if we and/or our future partners believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive Fast Track Designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development program. Fast Track Designation alone does not guarantee qualification for the FDA’s priority review procedures.

We expect some of the product candidates we develop will be regulated as biologics in the United States and elsewhere and therefore they may be subject to competition from biosimilars approved through an abbreviated regulatory pathway.

The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or the ACA, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or the BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-approved reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first approved by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first approved. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a BLA for the competing product containing the sponsor’s own pre-clinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of the other company’s product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation and meaning are subject to uncertainty.

We believe that any of our product candidates approved as a biological product under a BLA should qualify for a 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.

25

We and/or our future partners may be unable to obtain regulatory approval for our product candidates under applicable international regulatory requirements. The denial or delay of such approval would delay commercialization of our product candidates and adversely impact our potential to generate revenue, our business and our results of operations.

Approval by the FDA in the United States, if obtained, does not ensure approval by regulatory authorities in other countries or jurisdictions. In order to eventually market any of our product candidates in any other jurisdiction, we and/or our future partners must establish and comply with numerous and varying regulatory requirements on a jurisdiction-by-jurisdiction basis regarding safety and efficacy. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods.

Seeking regulatory approval in other jurisdictions could result in difficulties and costs for us and require additional pre-clinical studies or clinical trials which could be costly and time-consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. The European Union, Australia and other jurisdictions’ regulatory approval processes involve all of the risks associated with FDA approval. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we and/or our future partners fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of our products will be unrealized.

Even if we and/or our future partners receive regulatory approval of our product candidates, we and/or our future partners will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. We may be subject to penalties if we and/or our future partners fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.

Even if we and/or our future partners obtain regulatory approval in a jurisdiction, the applicable regulatory authority may still impose significant restrictions on the indicated uses or marketing of our product or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. For example, the holder of an approved BLA is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the BLA. The holder of an approved BLA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws.

If we and/or our future partners fail to comply with applicable regulatory requirements following approval of any of our product candidates, a regulatory agency may:

issue a warning letter asserting that we are in violation of the law;
seek an injunction or impose civil or criminal penalties or monetary fines;
suspend or withdraw regulatory approval or revoke a license;
suspend any ongoing clinical trials;
refuse to approve a pending BLA or supplements to a BLA submitted by us;
seize product; or
refuse to allow us to enter into supply contracts, including government contracts.

Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our and/or our partners’ ability to commercialize any approved products and generate revenues.

26

If any of our product candidates cause undesirable side effects, it could delay or prevent their regulatory approval, limit the commercial potential, or result in significant negative consequences following any potential marketing approval. Product candidates we and/or our future partners may develop may be associated with an adverse immune response or other serious adverse events, undesirable side effects or unexpected characteristics. In addition to serious adverse events or side effects caused by any of our product candidates, the administration process or related procedures also can cause undesirable side effects. If any such events occur, the clinical trials of any of our product candidates could be suspended or terminated.

If in the future, we and/or our future partners are unable to demonstrate that such adverse events were caused by factors other than our product candidates, the FDA, the EMA, the TGA or other regulatory authorities could order us to cease further development of, or deny approval of, any of our product candidates for any or all targeted indications. Even if we and/or our future partners are able to demonstrate that all future serious adverse events are not product-related, such occurrences could affect patient recruitment or the ability of enrolled trial participants to complete the trial. Moreover, if we and/or our future partners elect, or are required, to delay, suspend or terminate any clinical trial of any of our product candidates, the commercial prospects of such product candidates may be harmed and our ability to generate product sale revenues from any of these product candidates may be delayed or eliminated. Any of these occurrences may harm our and/or our partners’ ability to identify and develop product candidates, and may harm our business, financial condition, result of operations and prospects significantly.

Additionally, if we and/or our future partners successfully obtain regulatory approval for a product candidate, the FDA, the EMA, the TGA or other regulatory authority could require us to adopt a REMS or a risk management plan, or RMP, to ensure that the benefits of treatment with such product candidate outweigh the risks for each potential patient, which may include, among other things, a medication guide outlining the risks of the product for distribution to patients, a communication plan to health care practitioners, extensive patient monitoring, or distribution systems and processes that are highly controlled, restrictive, and more costly than what is typical for the industry. Furthermore, if we, our future partners or others later identify undesirable side effects caused by any product that we and/or our future partners develop based on one or more of our product candidates, several potentially significant negative consequences could result, including:

regulatory authorities may suspend or withdraw approvals or revoke licenses of such product;
regulatory authorities may require additional warnings on the label;
we and/or our future partners may be required to change the way a product is administered or conduct additional clinical trials;
we could be sued and held liable for harm caused to patients and their children; and
our reputation may suffer.

Any of these events could prevent us from achieving or maintaining market acceptance of any products we and/or our future partners may identify and develop based on one or more of our product candidates and could have a material adverse impact on our business, financial condition, results of operations and prospects.

If we and/or our future partners are successful in gaining approval for any of our product candidates, we and/or our future partners will continue to face significant regulatory oversight of the manufacturing and distribution of our products. Product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA, the EMA, the TGA and other regulatory authorities for compliance with Current Good Manufacturing Practices, or cGMP, and adherence to commitments made in the BLA. If we, our future partners or a regulatory agency discovers previously unknown problems with a product such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions relative to that product or the manufacturing facility, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.

27

If we and/or our future partners, as applicable, are not successful in discovering, developing and commercializing additional product candidates beyond our current portfolio, our ability to expand our business and achieve our strategic objectives would be impaired.

A key element of our strategy is to discover, develop and, through our future partners, potentially commercialize additional product candidates beyond our current portfolio to treat various conditions and in a variety of therapeutic areas. We intend to do so by investing in our own AI technology platforms to engage in drug and target discovery efforts, exploring potential collaborations for the development of new product candidates, and in-licensing delivery technologies. Identifying new product candidates requires substantial technical, financial and human resources, whether or not any product candidates are ultimately identified. Even if we identify product candidates that initially show promise, we and/or our future partners may fail to successfully develop and commercialize such product candidates for many reasons, including the following:

our AI technology platforms may not successfully identify potential product candidates;
competitors may develop alternatives that render our product candidates obsolete;
product candidates we develop may nevertheless be covered by third parties’ patents or other exclusive rights;
a product candidate may, on further study, be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;
a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and
an approved product may not be accepted as safe and effective by trial participants, the medical community or third-party payors.

If we are unsuccessful in identifying, developing and, through our future partners, commercializing additional products, our potential for growth may be impaired.

Changes in funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new or existing product candidates from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.

The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency has fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.

Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including beginning on December 22, 2018, the United States government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, has had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process its regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.

28

Since March 2020, when foreign and domestic inspections of facilities were largely placed on hold, the FDA has been working to resume routine surveillance, bioresearch monitoring and pre-approval inspections on a prioritized basis. The FDA has developed a rating system to assist in determining when and where it is safest to conduct prioritized domestic inspections. As of May 2021, certain inspections, such as foreign preapproval, surveillance, and for-cause inspections that are not deemed mission-critical, remain temporarily postponed. In April 2021, the FDA issued guidance for industry formally announcing plans to employ remote interactive evaluations, using risk management methods, to meet user fee commitments and goal dates and in May 2021 announced plans to continue progress toward resuming standard operational levels. Should FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, and the FDA does not determine a remote interactive evaluation to be adequate, the agency has stated that it generally intends to issue a complete response letter or defer action on the application until an inspection can be completed. In 2020 and 2021, a number of companies announced receipt of complete response letters due to the FDA’s inability to complete required inspections for their applications. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the ongoing COVID-19 pandemic and may experience delays in their regulatory activities.

Additionally, as of May 26, 2021, the FDA noted it is continuing to ensure timely reviews of applications for medical products during the ongoing COVID-19 pandemic in line with its user fee performance goals and conducting mission critical domestic and foreign inspections to ensure compliance of manufacturing facilities with FDA quality standards. However, the FDA may not be able to continue its current pace and approval timelines could be extended, including where a pre-approval inspection or an inspection of clinical sites is required and due to the ongoing COVID-19 pandemic and travel restrictions FDA is unable to complete such required inspections during the review period. In 2020 and 2021, a number of companies announced receipt of complete response letters due to the FDA's inability to complete required inspections for their applications.

If the FDA becomes unable to continue its current level of performance, we and/or our future partners could experience delays and setbacks for our product candidates and for any approvals we and/or our future partners may seek which could adversely affect our business.

Our business, operations and clinical development plans and timelines have been affected by the COVID-19 pandemic and if the pandemic continues our business operations could be adversely affected by the COVID-19 pandemic and other health epidemics or pandemics, on the manufacturing, clinical trial and other business activities performed by us or by third parties with whom we conduct business, including our CMOs, CROs, shippers and others.

Our business has been and could be further adversely affected by health epidemics wherever we have clinical trial sites or other business operations. In addition, health epidemics could cause significant disruption in the operations of third-party CMOs, CROs and other third parties upon whom we rely. For example, in December 2019, a novel strain of coronavirus, SARS-CoV-2, causing a disease referred to as COVID-19, was reported to have surfaced in Wuhan, China. Since then COVID-19 has spread worldwide. In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic, and the United States government ordered the closure of all non-essential businesses, imposed social distancing measures, “shelter-in-place” orders and restrictions on travel between the United States, Europe, Australia and other countries. The global pandemic and government measures taken in response have also had a significant impact on businesses and commerce worldwide, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended across a variety of industries; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen.

We may be required to develop and implement additional clinical trial policies and procedures designed to help protect subjects from the COVID-19 virus. For example, in March 2020, the FDA issued a guidance on conducting clinical trials during the pandemic, which was updated in July 2020, January 2021 and August 2021. The guidance describes a number of considerations for sponsors of clinical trials impacted by the pandemic, including the requirement to include in the clinical trial report (or as a separate document) contingency measures implemented to manage the trial and any disruption of the trial as a result of the COVID-19 pandemic; a list of all subjects affected by the COVID-19 pandemic-related trial disruptions by unique subject identifier and by investigational site and a description of how the individual's participation was altered; and analyses and corresponding discussions that address the impact of implemented contingency measures (e.g., participant discontinuation from investigational product and/or trial, alternative procedures used to collect critical safety and/or efficacy data) on the safety and efficacy results reported for the trial. In its most recent update to this guidance, the FDA addressed questions received from clinical practitioners who are adapting their operations in a pandemic environment. These questions focused on, among other things, when to suspend, continue or initiate a trial and how to submit changes to protocols for INDs and handle remote site monitoring visits. There is no assurance that this guidance governing clinical trials during the pandemic will remain in effect or, even if it does, that it will help address the risks and challenges enumerated above.

29

Other potential impacts of the COVID-19 pandemic on our ongoing clinical trial include patient dosing and trial monitoring, which may be paused or delayed due to changes in policies at various clinical sites, federal, state, local or foreign laws, rules and regulations, including quarantines or other travel restrictions, prioritization of healthcare resources toward pandemic efforts, including diminished attention of physicians serving as our clinical trial investigators and reduced availability of site staff supporting the conduct of our clinical trial, interruption or delays in the operations of the FDA, the EMA, the TGA and other similar regulatory agencies, or other reasons related to the COVID-19 pandemic.

If the COVID-19 pandemic continues, other aspects of our ongoing clinical trial and future planned clinical trials may be adversely affected, delayed or interrupted, including, for example, site initiation, patient recruitment and enrollment, availability of clinical trial materials, clinical trial site data monitoring and efficacy, safety and translational data collection, and data analysis. Some patients and clinical investigators may not be able to comply with clinical trial protocols and patients may choose to withdraw from our trials or we may have to pause enrollment or we may choose to or be required to pause enrollment and/or patient dosing in our ongoing or planned clinical trials in order to preserve health resources and protect trial participants. It is unknown how long these pauses or disruptions could continue. Patients may need to withdraw due to COVID-19 infections or experience increased adverse events and deaths in our clinical trials due to COVID-19 related infections.

In addition, we depend on a global supply chain, including timely shipment of patient specimens and ingredients, to manufacture product candidates used in our pre-clinical studies and clinical trials. Quarantines, “shelter-in-place” and similar government orders, or the expectation that such orders, shutdowns or other restrictions could occur, whether related to COVID-19 or other epidemics, could impact personnel at third-party manufacturing facilities in the United States, Europe and other countries, or the availability or cost of materials, any of which factors, either individually or collectively, could disrupt our supply chain.

Additionally, it has been widely reported that there has been a global shortage of microchips that has been affecting almost every industry, which has impacted the production of machinery and final products. This shortage could adversely impact our suppliers ability to meet their contractual obligations to provide us with necessary products and materials. If our relationships with our suppliers or other vendors are terminated or scaled back as a result of the COVID-19 pandemic or other epidemics, we may not be able to enter into arrangements with alternative suppliers or vendors or do so on commercially reasonable terms or in a timely manner. Replacing or adding additional suppliers or vendors involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new supplier or vendor commences work. As a result, delays may occur, which could adversely impact our ability to meet our desired clinical development and any future commercialization timelines. Although we carefully manage our relationships with our suppliers and vendors, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not harm our business.

In addition, our business, including our pre-clinical studies and clinical trials have been and may continue to be affected by the COVID-19 pandemic. Clinical site initiation, patient enrollment and activities that require visits to clinical sites, including data monitoring, have been and may continue to be delayed due to prioritization of hospital resources toward the COVID-19 pandemic or concerns among patients about participating in clinical trials during a pandemic. Some patients may have difficulty following certain aspects of clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. For example, some patients, may not be able to attend follow-ups and comply with trial protocols. These challenges have and, in the future, may continue to also increase the costs of completing our clinical trials. Similarly, if we are unable to successfully recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 or experience additional restrictions by their institutions, city or state, our clinical trial operations could be adversely impacted.

While we have not closed our offices, many of our employees, including members of our executive management, have periodically worked remotely during the COVID-19 pandemic and a number of our employees have contracted COVID-19 requiring them to miss a number of days of work while recovering, which, if either of these situations continue, may adversely affect our business operations.

In the event that government authorities were to enhance current restrictions, our employees who currently are not working from home may no longer be able to access our facilities, including our laboratories and our operations may be further limited or curtailed. An increase in the number of personnel working from home may negatively impact productivity, or disrupt, delay, or otherwise adversely impact our business. Further, any such enhanced restrictions may also impact the availability or cost of materials, which would disrupt our supply chain and manufacturing efforts and could affect our ability to conduct ongoing and planned clinical trials and preparatory activities. We may also face difficulties in obtaining access to manufacturing slots for our product candidates. For example, three vaccines for COVID-19 were granted Emergency Use Authorization by the FDA in late 2020 and early 2021, and resultant demand for vaccines and potential for manufacturing facilities and materials to be commandeered under the Defense Production Act of 1950,

30

or equivalent foreign legislation, may make it more difficult to obtain materials or manufacturing slots for the products needed for our clinical trials, which could lead to delays in these trials.

In addition, personnel working from home could increase our cyber security risk, create data accessibility concerns, and make us more susceptible to communication disruptions, any of which could adversely impact our business operations or delay necessary interactions with local and federal regulators, ethics committees, manufacturing sites, research or clinical trial sites and other important agencies and contractors. Further, we and our third-party service providers, including our CROs, the clinical trial sites, our manufacturers and suppliers, may experience staffing shortages as a result of personnel contracting COVID-19 and its variants such as Delta and Omicron.

The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, a widespread pandemic has resulted in significant disruption of global financial markets, resulting in an economic downturn that could continue to significantly impact our business and operations and may reduce our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of the ordinary shares and ADSs.

Further, we may experience additional disruptions that could severely impact our business and clinical trials, including:

diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;
interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines;
limitations on employee resources that would otherwise be focused on the conduct of our pre-clinical studies and clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;
risk that participants enrolled in our clinical trials will acquire COVID-19 while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events;
refusal of the FDA or other regulatory authorities to accept data from clinical trials in these affected geographies; and
shipment of patient specimens / biological material across county boarders and nationally.

These and similar, and perhaps more severe, disruptions in our operations could have a material adverse effect on our business, results of operations, cash flows, financial condition and/or prospects.

The global pandemic of COVID-19 continues to evolve rapidly. The ultimate impact of the COVID-19 pandemic or a similar health epidemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, healthcare systems or the global economy as a whole. However, these effects could have a material impact on our operations, and we continue to monitor the COVID-19 situation closely. Finally, initially, the outbreak of COVID-19 led to steep declines in the Dow Industrial Average and other domestic and international stock indices at the end of February and during March and April 2020. While the markets have rebounded since then, recent concerns over the “Delta variant” and the “Omicron variant” and the impact they may have on the United States and global economies, have led to “risk-off” sessions in the global markets.

The trading prices for our ADS and the shares of other biopharmaceutical and biotechnology companies have been highly volatile as a result of the COVID-19 pandemic and the trading prices for our ADSs could continue to experience high volatility. As a result, we may face difficulties raising additional capital through sales of our ADSs or any such sales may be on unfavorable terms. In addition, a recession, depression or other sustained adverse market event resulting from the spread of the COVID-19 could materially and adversely affect our business and the value of our ADSs.

31

To the extent the COVID-19 pandemic adversely affects our business, results of operations, cash flows, financial condition and/or prospects, it may also have the effect of heightening many of the other risks described in this “Risk Factors” section.

Russia’s invasion of Ukraine and ancillary developments may have an adverse effect on our business.

The recent invasion of Ukraine by Russia, the resulting conflict and retaliatory measures by the global community have created global security concerns, including the possibility of expanded regional or global conflict, which have had, are likely to continue to have, short-term and likely longer-term adverse impacts on Ukraine and Europe and around the globe. Potential ramifications include disruption of the supply chain including research activities and complications with the conduct of ongoing and future clinical trials of our product candidates, including patient enrollment. We and our collaborators rely on global networks of contract research organizations and clinical trial sites to enroll patients. Delays in research activities or in the conduct of our clinical trials could increase associated costs and, depending upon the duration of any delays, require us to find alternative suppliers at additional expense. In addition, the conflict between Russia and the Ukraine has had significant ramifications on global financial markets, which may adversely impact our ability to raise capital on favorable terms or at all.

Risks Related to the Manufacturing of our Product Candidates and Future Pipeline

We and/or our future partners may encounter difficulties in manufacturing, product release, shelf life, testing, storage, supply chain management or shipping. If we, and/or our future partners or any of the third-party manufacturers we and/or our future partners work with encounter such difficulties, our and/or our future partners’ ability to supply materials for clinical trials or any approved product could be delayed or stopped.

The manufacturing processes for our product candidates are novel and complex. Specifically, due to the nature of our patient-specific immunotherapies and novel delivery technologies, we and/or our future partners may encounter difficulties in manufacturing, product release, shelf life, testing, storage and supply chain management, or shipping. These difficulties could be due to any number of reasons including, but not limited to, complexities of producing batches at larger scale, equipment failure, choice and quality of raw materials and excipients, analytical testing technology, and product instability. In an effort to optimize product features, we have in the past and we and/or our future partners may in the future make changes to our product candidates in their manufacturing and stability formulation and conditions. This may in the future result in our and/or our future partners’ having to resupply batches for pre-clinical or clinical activities when there is insufficient product stability during storage and insufficient supply. Insufficient stability or shelf life of our product candidates could materially delay our and/or our future partners’ ability to continue the clinical trial for that product candidate or require us and/or our future partners to begin a new clinical trial with a newly formulated drug product, due to the need to manufacture additional pre-clinical or clinical supply.

For patient-specific therapies, we and/or our future partners may encounter issues with our and/or our future partners’ ability to timely and efficiently manufacture product given the on-demand requirements of such therapies, thereby potentially impacting clinical and commercial supply.

As we and/or our future partners continue developing new manufacturing processes for our drug substances and drug products for infectious diseases, the changes we and/or our future partners implement to manufacturing process may in turn impact specification and stability of our drug products. Changes in our manufacturing processes may lead to failure of lots and this could lead to substantial delays in our clinical trials. Our product candidates for infectious diseases may prove to have a stability profile that leads to a lower than desired shelf life of the final approved immunotherapy. This poses risk in supply requirements, wasted stock and higher cost of goods.

We and/or our future partners may be dependent on a number of equipment providers who are also implementing novel technology. Further, we and/or our future partners may develop custom manufacturing equipment for certain of our product candidates. If such equipment malfunctions or we and/or our future partners encounter unexpected performance issues, we and/or our future partners could encounter delays or interruptions to clinical and commercial supply.

Due to the number of different programs, we and/or our future partners may have cross contamination of products inside of our factories, CROs, suppliers, or in the clinic that affect the integrity of our product candidates. Additionally, for some programs the manufacturing scale is extremely small compared to the standard volumes of supply, such that we and/or our future partners run the risk of contaminating the process each time we and/or our future partners reopen a container to use remaining supplies.

32

As we and/or our future partners scale the manufacturing output for particular programs, we plan to continuously improve yield, purity, and the pharmaceutical properties of our product candidates from clinical stage studies through commercial launch, including shelf life stability, and solubility properties of drug product and drug substance. Due to continuous improvement in manufacturing processes, we and/or our future partners may switch processes for a particular program during development. However, after the change in process, more time is required for pharmaceutical property testing, such as six- or 12-month stability testing. That may require resupplying clinical material or making additional cGMP batches to keep up with clinical trial demand before such pharmaceutical property testing is completed.

We and/or our future partners may utilize a number of raw materials and excipients that are either new to the pharmaceutical industry or are being employed in a novel manner. Some of these raw materials and excipients have not been scaled to a level to support commercial supply and could experience unexpected manufacturing or testing failures, or supply shortages. Such issues with raw materials and excipients could cause delays or interruptions to clinical and commercial supply of our product candidates. Further, one or more of our programs may have a single source of supply for raw materials and excipients. Additionally, we and our manufacturers may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable political environments, such as recent events in Ukraine and Russia, or other geopolitical uncertainty. If we and/or our our future partners and manufacturers were to encounter any of these difficulties, or otherwise fail to comply with their contractual obligations, our ability to manufacture our products, or to make our product candidates available for clinical trials could be jeopardized. Any such delay or interruption in the supply of clinical trial supplies could delay the completion of clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to commence new clinical trials at additional expense or terminate clinical trials completely.

We and/or our future partners may learn that any or all of our product candidates are less stable than desired. We and/or our future partners may also find that transportation conditions negatively impact product quality. This may require changes to the formulation or manufacturing process for one or more of our product candidates and result in delays or interruptions to clinical or commercial supply. In addition, the cost associated with such transportation services and the limited pool of vendors may also add additional risks of supply disruptions.

The occurrence of any of these factors could have a material adverse effect on our business, results of operations, financial condition and prospects.

Certain of our product candidates are uniquely manufactured for each patient and we and/or our future partners may encounter difficulties in production, particularly with respect to scaling our manufacturing capabilities. If we, and/or our future partners or any of the third-party manufacturers with whom we and/or our future partners contract encounter these types of difficulties, our and/or our future partners’ ability to provide our product candidates for clinical trials or our products for patients, if approved, could be delayed or stopped, or we and/or our future partners may be unable to maintain a commercially viable cost structure.

Using our PIONEER AI platform technology, we identify and custom design product candidates that are unique and tailored specifically for each patient. Manufacturing unique lots of these product candidates is susceptible to product loss or failure due to issues with:

logistics associated with the collection of a patient’s tumor, blood or other tissue sample;
shipping such samples to a facility for genetic sequencing;
next-generation sequencing of the tumor;
biopsy of a sufficient quantity of cancerous tissue to allow for proper sequencing and identification of tumor-specific mutations;
identification of appropriate tumor-specific mutations;
the use of a software program, including proprietary and open source components, which is hosted in the cloud, to assist with the design of the patient-specific product candidate, which software must be maintained and secured;

33

effective design of the patient-specific product candidate;
batch-specific manufacturing failures or issues that arise due to the uniqueness of each patient-specific batch that may not have been foreseen;
quality control testing failures;
unexpected failures of batches placed on stability;
shortages or quality control issues with single-use assemblies, consumables or critical parts sourced from third-party vendors that must be changed out for each patient-specific batch;
significant costs associated with individualized manufacturing that may adversely affect our ability to continue development;
successful and timely manufacture and release of the patient-specific batch;
shipment issues encountered during transport of the batch to the site of patient care;
the ability to define a consistent safety profile at a given dose when each participant receives a unique treatment; and
our reliance on single-source suppliers.

One or more of our future partners may continue to evolve their manufacturing equipment. This equipment may not function as designed, which may lead to deviations in the drug products being produced. This can lead to increased batch failure and the inability to supply patients enrolled in the clinical trial. If our clinical development plans are expanded, due to the custom nature of the equipment and single-use assemblies, we may not be able to supply this expanded need reliably without significant investments. In addition, there will be considerable time to scale up the manufacturing facilities or build new facilities before our future partners can begin to meet any commercial demand if one or more of our product candidates are approved. This expansion or addition of new facilities could also lead to product comparability issues, which can further delay introduction of new capacity.

As certain of our product candidates may be manufactured for each individual patient, we and/or our future partners will be required to maintain a chain of identity with respect to each patient’s tissue sample, sequence data derived from such tissue sample, analyze results of such patient’s genomic analysis, and the custom manufactured product for each patient. Maintaining such a chain of identity is difficult and complex, and failure to do so could result in product mix-up, adverse patient outcomes, loss of product, or regulatory action, including withdrawal of any approved products from the market. Production of our patient-specific product candidates developed using our PIONEER AI platform technology involves a novel micro-batch production process based on a one patient per batch level, which necessarily increases the need for vigilant systems to be employed in order to avoid any such mix-ups We have in the past experienced one case of a product mix-up, which did not result in any adverse effects on the patient. Further, as our product candidates are developed through early-stage clinical studies to later-stage clinical trials towards approval and commercialization, we expect that multiple aspects of the complicated collection, analysis, manufacture and delivery processes will be modified in an effort to optimize processes and results. These changes may not achieve the intended objectives, and any of these changes could cause our product candidates to perform differently than we expect, potentially affecting the results of clinical trials.

Our or our future partners’ inability to manufacture or have manufactured sufficient quantities of our product candidates, or our or our future partners’ failure to comply with applicable regulatory requirements, would materially and adversely affect our business.

Manufacturing is a vital component of our patient-specific immunotherapy approach as well as our bacterial vaccines. All manufacturing must be performed in compliance with cGMP regulations. We expect to rely on external CMOs for the manufacture of our product candidates and at this time, we have limited redundancy among our manufacturing capabilities. For our patient-specific immunotherapies, we and/or our future partners do not maintain product reserves due to the patient-specific nature of our product candidates. If any of our manufacturing facilities or the facilities of our CMOs experiences difficulties, including related to manufacturing, product release, shelf life, testing, storage and supply chain management or shipping, our and/or our future partners’

34

clinical development programs may be delayed or suspended until we and/or our future partners can resume operations. We may also be required to incur significant expenditures to resolve such difficulties.

Our CMOs’ facilities are subject to various regulatory requirements and will be subject to inspection by the FDA, EMA or other regulatory authorities. If our CMOs cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, EMA or comparable regulatory authorities in other jurisdictions, we and or our future partners may not be able to rely on our CMOs’ manufacturing facilities for the manufacture of our product candidates. If the FDA, EMA or another comparable regulatory authority finds our facilities inadequate for the manufacture of our product candidates or if such facilities are subject to enforcement action in the future or are otherwise inadequate, we and /or our future partners may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates. Additionally, we and/or our future partners may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable political environments. If we and/or our future partners were to encounter any of these difficulties, our and/or our future partners’ ability to provide our product candidate to patients in clinical trials, or to provide product for the treatment of patients once approved, would be jeopardized.

We are, and our future partners shall be subject to regulatory and operational risks associated with the physical and digital infrastructure at both our future partners’ internal manufacturing facilities and at those of external service providers.

We may engage CMOs that have facilities with a high level of digitization for clinical manufacturing relative to industry standards. While this is meant to improve operational efficiency, this may pose additional risk of process equipment malfunction and even overall manufacturing system failure or shutdown due to internal or external factors including, but not limited to, design issues, system compatibility or potential cybersecurity breaches. This may lead to delay in supply or shutdown of our CMOs or our future partners facilities. Any disruption in our CMOs or our future partners’ manufacturing capabilities could cause delays in production capacity for drug substances or drug products, impose additional costs, or may require us to identify, qualify and establish relationships with additional CMOs with alternative manufacturing sites, the occurrence of which could have a material adverse effect on our business, financial condition, results of operations and prospects.

As the development and commercial capacity for our or our future partners’ product candidates and products expand, we and/or our future partners may need to establish additional manufacturing capabilities and expand to other locations or geographies, which may lead to regulatory delays or prove costly. If we or our future partners fail to select the correct location, complete the construction in an efficient manner, recruit the required personnel, and generally manage our growth effectively, the development and production of our product candidates could be delayed or curtailed. Additional investments may be needed if changes in our manufacturing process lead to required changes in our infrastructure.

Certain of our product candidates rely on the availability of specialty raw materials, which may not be available to us on acceptable terms or at all.

Certain of our product candidates require specialty raw materials, some of which are manufactured by small companies with limited resources and experience to support a commercial product, and the suppliers may not be able to deliver raw materials to our specifications. These suppliers may be ill-equipped to support our needs, especially in non-routine circumstances like an FDA inspection or medical crisis, such as widespread contamination. We also do not have contracts with many of these suppliers, and we may not be able to contract with them on acceptable terms or at all. Accordingly, we may in the future experience delays in receiving key raw materials to support clinical or commercial manufacturing.

In addition, some raw materials are currently available from a single supplier, or a small number of suppliers. We cannot be sure that these suppliers will remain in business or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce these materials for our intended purpose. In addition, the lead time needed to establish a relationship with a new supplier can be lengthy, and we may experience delays in meeting demand in the event we must switch to a new supplier. The time and effort to qualify a new supplier could result in additional costs, diversion of resources or reduced manufacturing yields, any of which would negatively impact our operating results. Further, we may be unable to enter into agreements with a new supplier on commercially reasonable terms, which could have a material adverse impact on our business.

35

Our product candidates are inherently sensitive to shipping and storage conditions and could be subject to risk of loss or damage.

Our product candidates are sensitive to temperature, storage and handling conditions. Loss in product candidates could occur if the product or product intermediates are not stored or handled properly. Shelf life for our product candidates may vary by product and is not fully quantified and is expected to be variable, and it is possible that our product candidates could be lost due to expiration prior to use. This has in the past led and could in the future lead to additional manufacturing costs and delays in our ability to supply required quantities for clinical trials or otherwise.

We are subject to significant regulatory oversight with respect to identification and manufacturing our product candidates. We do not have our own manufacturing facilities and relay on third party manufacturers to manufacturer our product candidates. The manufacturing facilities of our third-party manufacturers or suppliers may not meet regulatory requirements. Failure to meet cGMP requirements set forth in regulations promulgated by the FDA, the EMA, the TGA and other comparable regulatory authorities could result in significant delays in and costs of our products.

The manufacturing of immunotherapies for clinical trials or commercial sale is subject to extensive regulation. cGMP requirements govern manufacturing processes and procedures, including record-keeping, and the implementation and operation of quality systems to control and assure the quality of products and materials used in clinical trials. We do not have our own manufacturing facilities and rely on third party CMOs to manufacturer our product candidates. The manufacturing facilities of our third-party CMOs or suppliers may not meet regulatory requirements. Failure to meet cGMP requirements set forth in regulations promulgated by the FDA, the EMA, the TGA and other comparable regulatory authorities could result in significant delays in and costs of our product candidates.

Poor control of the cGMP production processes can lead to product quality failures that can impact our ability to supply product, resulting in cost overruns and delays to clinical timelines, which could be extensive. Such production process issues include but are not limited to:

critical deviations in the manufacturing process;
facility and equipment failures;
contamination of the product due to an ineffective quality control strategy;
facility contamination as assessed by the facility and utility environmental monitoring program;
ineffective process, equipment or analytical change management, resulting in failed lot release criteria;
raw material failures due to ineffective supplier qualification or regulatory compliance issues at critical suppliers;
ineffective product stability;
failed lot release or facility and utility quality control testing;
ineffective corrective actions or preventative actions taken to correct or avoid critical deviations due to our developing understanding of the manufacturing process as we scale; and
failed or defective components or consumables.

All necessary documentation in support of clinical trials as well as a BLA or other marketing authorization application must be provided on a timely basis and must adhere to the FDA’s, the EMA’s, the TGA’s and other countries’ cGMP or other quality assurance requirements which are enforced, in the case of the FDA, in part through its facility inspection program.

Regulatory authorities typically require representative manufacturing site inspections to assess adequate compliance with cGMPs and manufacturing controls as described in the filing. If one of our third-party manufacturing sites fails to provide sufficient quality assurance or control, approval to initiate clinical trials or to commercialize our product candidates may not be granted. Inspections by

36

regulatory authorities may occur at any time during the development or commercialization phase of products. The inspections may be product-specific or facility-specific for broader cGMP inspections or as a follow up to development or market issues that the regulatory agency may identify. Deficient inspection outcomes may negatively affect the ability of our third-party CMOs or suppliers to fulfill their supply obligations, impacting or delaying supply or delaying the development of one or more of our product candidates.

The manufacturing process for any products that we may develop is subject to the FDA’s, the EMA’s, the TGA’s and other regulatory authorities’ approval processes, and we may need to contract with manufacturers who we believe can meet applicable regulatory authority requirements on an ongoing basis. If our third-party CMOs are not able to reliably produce product candidates to specifications acceptable to the FDA, the EMA, the TGA’s or other regulatory authorities, we or our future partners may not obtain or maintain the approvals we or they need for our clinical trials or to commercialize such product candidates. Even if our future partners obtain regulatory approval for any of our immunotherapies, there is no assurance that either our CMOs or our future partners will be able to manufacture our product candidates to specifications acceptable to the FDA, EMA, TGA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential future demand. Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates, impair commercialization efforts or increase our cost of goods. The occurrence of any of the foregoing could have an adverse effect on our business, financial condition, results of operations and growth prospects.

In addition, we may not have direct control over the ability of our CMOs or our future partners to maintain adequate quality control, quality assurance and qualified personnel. Furthermore, our CMOs may be engaged with other companies to supply or manufacture materials or products for such companies, which exposes our CMOs to regulatory risks for the production of such materials and products. As a result, failure to meet the regulatory requirements for the production of those materials and products may generally affect the regulatory status of our CMOs’ facilities. Our future partners’ failure, or the failure of our third-party CMOs, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect supplies of our products and product candidates (including those of our future partners) and our overall business operations. Our future dependence upon others for the manufacture of our product candidates and raw materials may adversely affect our future profit margins and our ability to conduct our clinical trials and the ability of our future partners to commercialize any products that receive regulatory approval on a timely and competitive basis.

The FDA, EMA, TGA and other regulatory authorities may require our future partners to submit product samples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA, the TGA or other regulatory authorities may require that our future partners do not distribute a lot or lots until the relevant agency authorizes such release. Deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. Our third-party CMOs may have, in the past, experienced lot failures and some may have experienced product recalls. Lot failures or product recalls with respect to product produced by either our future partners’ own facilities or those of our third-party CMOs could cause us and our future partners to delay clinical trials or product launches, which could be costly to us and otherwise harm our business, financial condition, results of operations and prospects.

Our future partners and our third-party CMOs also may encounter problems hiring and retaining the experienced scientific, quality-control and manufacturing personnel needed to operate our manufacturing processes and operations, which could result in delays in production or difficulties in maintaining compliance with applicable regulatory requirements. While we will train and qualify all personnel around the appropriate handling of our product candidates and materials, we may not be able to control for or ultimately detect intentional sabotage or negligence by any of our employees, the employees of our future partners or any contractor.

37

Risks Related to the Commercialization of our Pipeline

We will rely on our future partners to further develop our product candidates in late-stage clinical trials and to commercialize our product candidates if regulatory approval is obtained. The successful commercialization of our product candidates by our future partners will depend in part on the extent to which governmental authorities, private health insurers and other third-party payors provide coverage and adequate reimbursement levels and implement pricing policies favorable for our product candidates. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our partners’ ability to market those products and thereby decrease our ability to generate revenue.

We will rely on our future partners to develop our product candidates in late-stage clinical trials and to commercialize our product candidates if regulatory approval is obtained. The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford expensive treatments such as the medicines that we and our future partners hope to develop and sell. In addition, because several of our product candidates represent new approaches to the treatment of cancer, we and/or our future partners cannot accurately estimate how these products would be priced, whether reimbursement could be obtained, or any potential revenue. Sales of our product candidates will depend substantially, both domestically and in other countries, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit, and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If reimbursement is not available, or is available only to limited levels, our future partners may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow our future partners to establish or maintain pricing sufficient to realize a sufficient return on our investment in any of our products.

There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products, including genetic medicines. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare & Medicaid Services, or CMS, an agency within the United States Department of Health and Human Services, or HHS, as CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare. Private payors tend to follow CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for novel products such as ours. Reimbursement agencies in Europe may be more conservative than CMS. For example, a number of cancer drugs have been approved for reimbursement in the United States but have not been approved for reimbursement in certain European countries.

Outside the United States, certain countries, including a number of member states of the European Union and Australia, set prices and reimbursement for pharmaceutical products, with limited participation from the marketing authorization holders. We cannot be sure that such prices and reimbursement will be acceptable to us or our partners. If the regulatory authorities in these jurisdictions set prices or reimbursement levels that are not commercially attractive for our future partners, our revenues from sales by our future partners, and the potential profitability of our drug products, in those countries would be negatively affected. An increasing number of countries are taking initiatives to attempt to reduce large budget deficits by focusing cost-cutting efforts on pharmaceuticals for their state-run health care systems. These international price control efforts have impacted all regions of the world but have been most drastic in the European Union. In the European Union, changes to pricing and reimbursement are almost exclusively a matter for national, and not European Union, law and policy. Additionally, some countries require approval of the sale price of a product before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. As a result, our future partners might obtain marketing approval for a product in a particular country, but then may experience delays in the reimbursement approval of such product or be subject to price regulations that would delay our partners’ commercial launch of the product, possibly for lengthy time periods, which could negatively impact the revenues we are able to generate from the sale of the product in that particular country.

Moreover, increasing efforts by governmental and third-party payors, in the United States and in other countries, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. For example, the United States government recently released a “blueprint,” which is a plan to reduce the cost of drugs. The blueprint contains certain measures that the HHS is already working to implement. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.

38

We expect that our future partners will experience pricing pressures in connection with the sale of any of our product candidates, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products in the marketplace.

We face significant competition in an environment of rapid technological and scientific change, and our failure to effectively compete would prevent us from achieving our goals. Most of our competitors have significantly greater resources than we do, and we may not be able to compete successfully.

The pharmaceutical market is intensely competitive and rapidly changing. Many large pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and other public and private research organizations are pursuing the development of novel drugs for the same diseases that we are targeting or expect to target. Many of our competitors have:

greater financial, technical and human resources than we have at every stage of the discovery, development, manufacture and commercialization of products;
more extensive experience in pre-clinical testing, conducting clinical trials, obtaining regulatory approvals, and in manufacturing, marketing and selling drug products;
product candidates that are based on previously tested or accepted technologies;
products that have been approved or are in late stages of development; and
collaborative arrangements in our target markets with leading companies and research institutions.

Our product candidates may face intense competition from drugs that have already been approved and accepted by the medical community for the treatment of the conditions for which drugs developed from our product candidates are designed to be address. We also expect that our product candidates will face competition from new drugs that enter the market. There are a number of drugs currently under development, which may become commercially available in the future, for the treatment of conditions for which we and our future partners are trying, or may in the future try, to develop drugs. These drugs may be more effective, safer, less expensive, or marketed and sold more effectively, than any products developed using our technologies.

We anticipate competing with the largest pharmaceutical companies in the world, many of which are all currently conducting research in the fields of immuno-oncology and infectious diseases. These companies have significantly greater financial and human resources than we currently have. In addition to these large pharmaceutical companies, we may directly compete with fully integrated biopharmaceutical companies and other immunotherapy-focused oncology companies, as well as a number of companies focused on immunotherapies, some of which have entered into collaboration and funding agreements with larger pharmaceutical or biotechnology companies.

If we successfully develop product candidates, and our future partners obtain approval for them, we and our future partners will face competition based on many different factors, including:

the safety and effectiveness of our products relative to alternative therapies, if any;
the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration;
the timing and scope of regulatory approvals for these products;
the availability and cost of manufacturing, marketing and sales capabilities;
the price of any approved immunotherapy;

39

reimbursement coverage; and
intellectual property position.

Our and our partners’ competitors may develop or commercialize products with significant advantages over any products we or our future partners develop based on any of the factors listed above or on other factors. In addition, our competitors may develop collaborations with or receive funding from larger pharmaceutical or biotechnology companies, providing them with an advantage over us. Our competitors may therefore be more successful in commercializing their products than our future partners are, which could adversely affect our competitive position and business. Competitive products may make any products our future partners develop using our technologies obsolete or noncompetitive before we and our future partners can recover the expenses of developing and commercializing our products, if approved.

The market opportunities for certain of our product candidates may be limited due to the rarity of the disease or limited to those patients who are ineligible for or have failed prior treatments, and may be small. As the target patient populations for some of our programs are small, we must be able to successfully identify trial participants and achieve a significant market share to maintain profitability and growth.

The FDA often approves new cancer immunotherapies initially only for use by patients with relapsed or refractory advanced cancer, or new bacterial vaccines initially only for use by patients with certain advanced diseases. We expect our future partners will initially seek approval of certain of our product candidates in this context. Subsequently, for those product candidates that prove to be sufficiently beneficial, if any, we would expect our future partners to seek approval in earlier lines of treatment and potentially as a first-line therapy but there is no guarantee that our product candidates, even if approved, would be approved for earlier lines of therapy, and, prior to any such approvals, we and/or our future partners may have to conduct additional clinical trials. In the future, we may also develop product candidates for the treatment of rare diseases.

Our projections of the number of people who have or will have the diseases we may be targeting may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of trial participants may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. Even if for our product candidate, if approved, obtain significant market share, because the potential target populations are small, we may never achieve profitability without obtaining regulatory approval for additional indications.

We do not intend to establish marketing and sales organization and as a company, we have no experience in marketing pharmaceutical products. We will rely on the marketing and sales capabilities of our future partners and other third parties, which may not be able to market and sell our product candidates effectively in the United States and other jurisdictions, if approved, or generate product sales revenue.

Given our stage of development, we have no sales, distribution or marketing capabilities, and we have not designed our pre-clinical studies and clinical trials with specific commercialization or marketing considerations in mind. We do not intend to establish marketing and sales organization and as a company, we have no experience in marketing pharmaceutical products. We will rely on the marketing and sales capabilities of our future partners and other third parties to commercialize any products that may result from our development programs in the United States, Europe and other regions. We intend to enter into collaborations with other entities to utilize their mature marketing and distribution capabilities, but we may be unable to enter into such collaboration agreements on favorable terms, if at all. If our future partners do not commit sufficient resources to commercialize products developed using our technologies, if any, product sales revenue may not be generated in amounts sufficient to sustain our business. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.

40

Our future profitability, if any, depends in part on our partners’ ability to penetrate global markets, where they may be subject to additional regulatory burdens and other risks and uncertainties associated with international operations that could materially adversely affect our business.

Our future profitability, if any, will depend in part on the ability of our future partners to commercialize any products that our future partners may develop in markets throughout the world. Commercialization of products in various markets could subject us to risks and uncertainties, including:

obtaining, on a country-by-country basis, the applicable marketing authorization from the competent regulatory authority;
the burden of complying with complex and changing regulatory, tax, accounting, labor and other legal requirements in each jurisdiction that we or our future partners pursue;
reduced protection for intellectual property rights;
differing medical practices and customs affecting acceptance in the marketplace;
import or export licensing requirements;
governmental controls, trade restrictions or changes in tariffs;
economic weakness, including inflation, or political instability in particular non-United States economies and markets;
production shortages resulting from any events affecting raw material supply or manufacturing capabilities in other countries;
longer accounts receivable collection times;
longer lead times for shipping;
language barriers;
foreign currency exchange rate fluctuations;
reimbursement, pricing and insurance regimes; and
the interpretation of contractual provisions governed by local laws in the event of a contract dispute.

Our future partners may have limited experience in these areas. Failure to successfully navigate these risks and uncertainties may limit or prevent market penetration for any products that our future partners may develop using our technologies, which would limit their commercial potential and our revenues.

41

Even if our future partners obtain regulatory approval for our product candidates, the products may not gain the market acceptance among physicians, patients, hospitals, cancer treatment centers and others in the medical community necessary for commercial success.

Even with the requisite approvals, the commercial success of products using our technologies will depend in part on the medical community, patients, and third-party or governmental payors accepting immunotherapies in general, and such products in particular, as medically useful, cost-effective and safe. Any product developed using our technologies that our future partners bring to the market may not gain market acceptance by physicians, trial participants, third-party payors, and others in the medical community. Additionally, ethical, social and legal concerns about genetic research could result in additional regulations restricting or prohibiting the products and processes we may use. If these products do not achieve an adequate level of acceptance, our future partners may not generate significant product sales revenue and may not become profitable, which could adversely affect our business operations and financial condition. The degree of market acceptance of products derived from our product candidates, if approved for commercial sale, will depend on a number of factors, including:

the potential efficacy and potential advantages over alternative treatments;
the ability to offer such products, if approved, at competitive prices;
the prevalence and severity of any side effects, including any limitations or warnings contained in a product’s approved labeling;
the prevalence and severity of any side effects resulting from checkpoint inhibitors or other drugs or therapies with which our products are administered;
relative convenience and ease of administration;
any restrictions on the use of our products, if approved, together with other medications;
the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;
the strength of marketing and distribution support and timing of market introduction of competitive products;
publicity concerning our products or competing products and treatments; and
sufficient third-party insurance coverage or reimbursement, and patients’ willingness to pay out-of-pocket in the absence of third-party coverage or adequate reimbursement.

Even if a potential product displays a favorable efficacy and safety profile in pre-clinical studies and clinical trials, market acceptance of the product will not be known until after it is launched. Our and our partners’ efforts to educate the medical community and third-party payors on the benefits of the products may require significant resources and may never be successful. Our and our partners’ efforts to educate the marketplace may require more resources than are required by the conventional technologies marketed by our competitors due to the complexity and uniqueness of our programs.

Commercial success of any approved products will also depend in large part on the availability of coverage and adequate reimbursement from third-party payors, including government payors such as the Medicare and Medicaid programs and entry into managed care organizations, which may be affected by existing and future healthcare reform measures designed to reduce the cost of healthcare. Third-party payors could require us to conduct additional studies, including post-marketing studies related to the cost effectiveness of a product, to qualify for reimbursement, which could be costly and divert our resources. If government and other healthcare payors do not provide adequate coverage and reimbursement levels for any of products derived from our product candidates once approved, whether due to healthcare reform legislation or otherwise, market acceptance and commercial success would be reduced.

42

In addition, if any of products derived from our product candidates are approved for marketing, we and/or our future partners will be subject to significant regulatory obligations regarding the submission of safety and other post-marketing information and reports for such product, and will need to continue to comply (or ensure that our third-party providers comply) with cGMP and current good clinical practices, or GCP, for any clinical trials that we or our future partners conduct post-approval. In addition, there is always the risk that we or a partner or regulatory authority might identify previously unknown problems with a product post-approval, such as adverse events of unanticipated severity or frequency. Compliance with these requirements is costly, and any such failure to comply or other issues with products derived from our product candidates identified post-approval could have a material adverse impact on our business, financial condition and results of operations.

Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for our future partners to sell products derived from our product candidates, if approved, profitably.

Successful sales of our product candidates, if approved, depend on the availability of coverage and adequate reimbursement from third-party payors including governmental healthcare programs, such as Medicare and Medicaid, managed care organizations and commercial payors, among others. Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which regulatory approval is obtained. In addition, because our product candidates represent new approaches to the treatment of cancer and prevention of infectious diseases, we cannot accurately estimate the potential revenue from our product candidates.

Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Obtaining coverage and adequate reimbursement from third-party payors is critical to new product acceptance.

Third-party payors decide which drugs and treatments they will cover and the amount of reimbursement. Reimbursement by a third-party payor may depend upon a number of factors, including, but not limited to, the third-party payor’s determination that use of a product is:

a covered benefit under its health plan;
safe, effective and medically necessary;
appropriate for the specific patient;
cost-effective; and
neither experimental nor investigational.

Obtaining coverage and reimbursement of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to the payor supporting scientific, clinical and cost-effectiveness data for the use of products derived from our product candidates. Even if coverage for a given product is obtained, if the resulting reimbursement rates are insufficient, hospitals may not approve the product for use in their facility or third-party payors may require co-payments that patients find unacceptably high. Patients are unlikely to use products derived from our product candidates unless coverage is provided, and reimbursement is adequate to cover a significant portion of the cost of such products. Separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or procedure in which the product is used. Further, from time to time, CMS revises the reimbursement systems used to reimburse health care providers, including the Medicare Physician Fee Schedule and Outpatient Prospective Payment System, which may result in reduced Medicare payments. In some cases, private third-party payors rely on all or portions of Medicare payment systems to determine payment rates. Changes to government healthcare programs that reduce payments under these programs may negatively impact payments from private third-party payors and reduce the willingness of physicians to use our product candidates.

In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. Further, one payor’s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.

43

We expect that our future partners will seek approval to market products derived from our product candidates in the United States, the European Union, Australia and other selected jurisdictions. If approval for a product in any particular jurisdiction, our future partners will be subject to rules and regulations in that jurisdiction. In some countries, particularly those in Europe and Australia, the pricing of biologics is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. Some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines but monitor and control company profits. The downward pressure on health care costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new products into the marketplace. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.

The marketability of any product derived from our product candidates which receives regulatory approval for commercial sale may suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing to continue. Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products which receives regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.

Enacted and future legislation may increase the difficulty and cost for us or our future partners to obtain marketing approval of and commercialize any products derived from our product candidates and affect the prices we may charge for such products.

The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product for which we obtain marketing approval.

In March 2010, the ACA was enacted, which substantially changes the way health care is financed by both governmental and private insurers, and significantly impacts the United States pharmaceutical industry. The ACA, among other things, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs, and promoted a new Medicare Part D coverage gap discount program. Considerable uncertainty remains regarding the implementation and impact of the ACA.

Since its enactment, there have been and there remain executive, judicial and congressional challenges to certain aspects of the ACA. As a result, there have been delays in the implementation of, and action taken to repeal or replace, certain aspects of the ACA. Since January 2017, former President Trump has signed two Executive Orders designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. On January 20, 2017, former President Trump signed the first Executive Order, directing federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. On October 13, 2017, former President Trump signed the second Executive Order terminating the cost-sharing subsidies (CSRs), that reimburse insurers under the ACA. On August 14, 2020, the United States Court of Appeals for the Federal Circuit ruled in two separate cases that the federal government is liable for the full amount of unpaid CSRs for the years preceding and including 2017. For CSR claims made by health insurance companies for years 2018 and later, further litigation will be required to determine the amounts due, if any. Payments are expected to increase premiums on certain policies issued by qualified health plans under the ACA. Further, on June 14, 2018, the United States Court of Appeals for the Federal Circuit ruled that the federal government was not required to pay to third-party payors more than $12 billion in ACA risk corridor payments that they argued were owed to them. This decision was appealed to the United States Supreme Court, which on April 27, 2020, reversed the decision, concluding the government has an obligation to pay these risk corridor payments under the relevant formula. It is not clear what effect this result will have on our business, but we will continue to monitor any developments. While Congress has not passed comprehensive repeal legislation to date, it has enacted laws that modify certain provisions of the ACA such as the Tax Cuts and Jobs Act of 2017 (TCJA), which decreased the “individual mandate” to $0. On December 14, 2018, a Texas United States District Court Judge ruled that the ACA is unconstitutional in its entirety because the “individual mandate” was repealed. On June 17, 2021, the United States Supreme Court dismissed this case. It is unclear how the Supreme Court’s decision will impact the ACA and our business. There is significant uncertainty regarding the future of the ACA and its impact on our business and operations. We continue to evaluate the effect that the ACA and its possible repeal and replacement has on our business.

44

In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, in August 2011, the Budget Control Act of 2011 was signed into law, which, among other things, included aggregate reductions to Medicare payments to providers of, on average, 2% per fiscal year through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2021, unless Congress takes additional action. Proposed legislation, if passed, would extend this suspension until the end of the COVID-19 pandemic.

Recently, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent United States congressional inquiries and legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. At the federal level, the United States Presidential administration’s budget proposal for the fiscal year 2021 includes a $135 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. On March 10, 2020, the Trump administration sent “principles” for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary out-of-pocket pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly out-of-pocket expenses, and place limits on pharmaceutical price increases. Further, the Trump administration previously released a “Blueprint” to lower drug prices and reduce out of pocket costs of drugs that contained proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. HHS has solicited feedback on some of these measures and has implemented others under its existing authority. For example, in May 2019, CMS issued a final rule that amends the Medicare Advantage and Medicare Part D prescription drug benefit regulations to reduce out of pocket costs for plan enrollees and allow Medicare plans to negotiate lower rates for certain drugs. Among other things, the final rule now allows Medicare Advantage plans the option to use step therapy, a type of pre-authorization, for Part B drugs beginning January 1, 2020. This final rule codified CMS’s policy change that was effective January 1, 2019. In addition, there have been several changes to the 340B drug pricing program, which imposes ceilings on prices that drug manufacturers can charge for medications sold to certain healthcare facilities. Some of these changes are undergoing legal challenges, and their status is currently in question. It is unclear how these developments could affect covered hospitals who might purchase our future products and affect the rates we may charge such facilities for our approved products in the future, if any.

Additionally, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that attempt to implement several of the administration’s proposals. As a result, the FDA released a final rule on September 24, 2020, effective November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. On November 20, 2020, CMS issued an interim final rule implementing Former President Trump’s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. On December 28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against the implementation of the interim final rule. Although a number of these executive orders and other proposed measures will require authorization through additional legislation to become effective, and the Biden administration may reverse or otherwise change these measures, we expect that Congress will continue to seek new legislative measures to control drug costs. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payers. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control costs of pharmaceutical and biological products. Moreover, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs.

In the United States and in some other jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the health care system that could prevent or delay marketing approval of our drug or biologic candidates, restrict or regulate post-approval activities, or affect our ability to profitably sell any drug or biologic candidates for which we obtain marketing approval, if any. Further, increased scrutiny by the United States Congress of the FDA’s approval process for drugs and biological products may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements. There also are a number of state and local legislative and regulatory efforts related to drug or biologic pricing, including drug or biologic price transparency laws that apply to pharmaceutical manufacturers, that may have an impact on our business.

45

In addition, the Drug Supply Chain Security Act enacted in 2013 imposes new obligations on manufacturers of pharmaceutical products related to product tracking and tracing, and that law is expected to be fully implemented over a ten-year period. Most recently, on December 20, 2019, former President Trump signed the Further Consolidated Appropriations Act for 2020 into law (P.L. 116-94) that includes a piece of bipartisan legislation called the Creating and Restoring Equal Access to Equivalent Samples Act of 2019 or the “CREATES Act.” The CREATES Act aims to address the concern articulated by both the FDA and others in the industry that some brand manufacturers have improperly restricted the distribution of their products, including by invoking the existence of a REMS for certain products, to deny generic and biosimilar product developers access to samples of brand products. The CREATES Act establishes a private cause of action that permits a generic or biosimilar product developer to sue the brand manufacturer to compel it to furnish the necessary samples on “commercially reasonable, market-based terms.” Whether and how generic and biosimilar product developments will use this new pathway, as well as the likely outcome of any legal challenges to provisions of the CREATES Act, remain highly uncertain and its potential effects on our future commercial products are unknown. Other legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical or biological products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals, if any, of our drug or biologic candidates, may be or whether such changes will have any other impacts on our business. In addition, increased scrutiny by the United States Congress of the FDA’s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing conditions and other requirements.

We expect that the healthcare reform measures that have been adopted, and that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product and could seriously harm our future revenues. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products. Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic.

In the European Union, similar political, economic and regulatory developments may affect our ability to profitably commercialize products derived from our product candidates. In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union member state level may result in significant additional requirements or obstacles that may increase our operating costs.

The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than European Union, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most European Union member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing European Union and national regulatory burdens on those wishing to develop and market products derived from our product candidates, this could prevent or delay marketing approval of products derived from our product candidates, restrict or regulate post-approval activities, and affect our or our future partners’ ability to commercialize any products derived from our product candidates for which we or they obtain marketing approval.

We expect that additional healthcare reform measures or proposals will be adopted in the future, any of which could limit the amounts that governments will pay for healthcare products and services, which could result in reduced demand for products derived from our product candidates or additional pricing pressures. In the event that the pricing structures for healthcare products, such as the product candidates we are developing, change materially and limit payments for such product candidates, our business will be adversely impacted as any products derived from our product candidates may no longer be commercially viable based on their expected net present value; we may have invested significant resources in product candidates that cannot be commercially developed; or we may determine that assets that have reached an early phase of development cannot or will not be taken into further development, notwithstanding their clinical viability. In addition, development assets or clinical programs that are part of our collaborations may no longer be deemed commercially viable to pursue based on our partners’ assessments of the impact of any proposed, announced, or legislated pricing reforms

46

We cannot predict what healthcare reform initiatives may be adopted in the future. Our product candidates from PIONEER may be issued with PD-1 or PD-L1 inhibitors and as a result become too expensive for government, or commercial payors coverage and as a result may reduce our potential market. Further legislative and regulatory developments are likely, and we expect ongoing initiatives to increase pressure on drug pricing. Such reforms could have an adverse effect on anticipated revenues from products derived from our product candidates that we may successfully develop and for which we or our future partners may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates.

European Union drug marketing and reimbursement regulations may materially affect our partners’ ability to market and receive coverage for products derived from our product candidates in the European Union member states.

We expect that our future partners will have to seek approval to market products derived from our product candidates in the United States and in other selected jurisdictions. If our future partners obtain approval for products derived from our product candidates in a particular jurisdiction, they will be subject to rules and regulations in that jurisdiction. In some countries, particularly those in the European Union, the pricing of biologics is subject to governmental control and other market regulations that could put pressure on the pricing and usage of products derived from our product candidates. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. In addition, market acceptance and sales of products derived from our product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for any such product and may be affected by existing and future healthcare reform measures.

In addition, in most countries outside the United States, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. A member state may approve a specific price for the medicinal product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. In some countries, we and/or our future partners may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of any of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United States and, generally, prices tend to be significantly lower in the European Union. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our products is unavailable or limited in scope or amount, our revenues from sales by us or our future partners and the potential profitability of any of our product candidates in those countries would be negatively affected.

Risks Related to our Reliance on Third Parties

We will rely on third parties in the conduct of significant aspects of our pre-clinical studies and clinical trials and intend to rely on third parties in the conduct of future clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or fail to meet expected deadlines, regulatory approval for our product candidates may not be obtained.

We currently rely and expect to continue to rely on third parties, such as CROs, clinical data management organizations, future partners, medical institutions and clinical investigators, to conduct various and significant elements of our clinical trials. We currently rely and expect to continue to rely on third parties to conduct certain research and pre-clinical testing activities. In some cases, these third parties may terminate their engagements with us. If we need to enter into alternative arrangements, it would delay our discovery or product development activities.

Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our regulatory or contractual responsibilities. We will be responsible for ensuring that each of our pre-clinical studies and clinical trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial.

47

Moreover, the FDA requires us to comply with Good Clinical Practice, or GCP, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity, and civil and criminal sanctions. For any violations of laws and regulations during the conduct of our pre-clinical studies and clinical trials, we could be subject to warning letters or enforcement action that may include civil penalties up to and including criminal prosecution.

We and our CROs will be required to comply with regulations, including GCP, for conducting, monitoring, recording and reporting the results of pre-clinical studies and clinical trials to ensure that the data and results are scientifically credible and accurate and that the trial participants are adequately informed, among other things, of the potential risks of participating in clinical trials. We also are responsible for ensuring that the rights of our clinical trial participants are protected. These regulations are enforced by the FDA, the competent authorities of the member states, and comparable regulatory authorities of other jurisdictions for any product candidates in clinical development. The FDA enforces GCP regulations through periodic inspections of clinical trial sponsors, principal investigators and trial sites. If we or our CROs fail to comply with applicable GCP, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable regulatory authorities of other jurisdictions may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, the FDA will determine that any of our future clinical trials will comply with GCP. In addition, our clinical trials must be conducted with product candidates produced in accordance with the requirements of cGMP regulations. Our failure or the failure of our CROs or CMOs to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process and could also subject us to enforcement action.

Although we intend to design the clinical trials for certain of our product candidates, our future partners may design the clinical trials that they are managing (in some cases, with our input) and in the case of clinical trials controlled by us, we expect that CROs will conduct all of the clinical trials. As a result, many important aspects of our development programs, including their conduct and timing, will be outside of our direct control. Our reliance on third parties to conduct future pre-clinical studies and clinical trials will also result in less direct control over the management of data developed through pre-clinical studies and clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also potentially lead to mistakes as well as difficulties in coordinating activities. Outside parties may:

have staffing difficulties;
fail to comply with contractual obligations;
experience regulatory compliance issues;
undergo changes in priorities or become financially distressed;
form relationships with other entities, some of which may be our competitors;
have human errors; or
be subject to cyberattacks.

These factors may materially adversely affect the willingness or ability of third parties to conduct our pre-clinical studies and clinical trials and may subject us to unexpected cost increases that are beyond our control. If the CROs do not perform pre-clinical studies and clinical trials in a satisfactory manner, breach their obligations to us or fail to comply with regulatory requirements, the development, regulatory approval and commercialization of our product candidates may be delayed, our future partners may not be able to obtain regulatory approval and commercialize products derived from our product candidates, or our development programs may be materially and irreversibly harmed. If we are unable to rely on pre-clinical and clinical data collected by our CROs, we could be required to repeat, extend the duration of, or increase the size of any clinical trials we conduct and this could significantly delay the development of our product candidates and/or commercialization of any products derived from our product candidates and could require significantly greater expenditures.

48

We also expect to rely on other third parties to transport, store and distribute the required materials for our clinical trials. In the past certain of our third-party vendors have mishandled our materials, resulting in loss of full or partial lots of material. Any further performance failure on the part of these third parties could result in damaged products and could delay clinical development or marketing approval of any product candidates we may develop or commercialization of our medicines, if approved, producing additional losses and depriving us of potential product sales revenue, causing us to default on our contractual commitments, result in losses that are not covered by insurance, and damage our reputation and overall perception of our products in the marketplace.

Our existing collaboration, or any future collaboration arrangements or agreements with future partners, if any, that we may enter into, may not be successful, which could significantly limit the likelihood of receiving the potential economic benefits of the collaboration and adversely affect our ability to develop our product candidates and the commercialization of any products derived from our product candidates.

We have entered into a collaboration under which our collaborator may in the future provide funding and other resources for developing our product candidates and potentially commercializing any products derived from our product candidates. We intend to enter into additional collaborations and agreements with future partners, if any, to access additional funding, capabilities and expertise in the future. Our existing collaboration, and any future collaborations or agreements with future partners, if any, we enter into, may pose a number of risks, including the following:

future partners may not perform or prioritize their obligations as expected;
the clinical trials conducted as part of such collaborations may not be successful;
future partners may not pursue development and commercialization of any products derived from our product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization of programs based on clinical trial results, changes in the partners’ focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;
future partners may delay clinical trials, provide insufficient funding for clinical trials, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing;
future partners could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the future partners believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;
product candidates developed in collaborations with us may be viewed by our future partners as competitive with their own product candidates or products, which may cause future partners to cease to devote resources to the development or commercialization of products derived from our product candidates;
a partner with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of any such product;
disagreements with future partners, including disagreements over proprietary rights, contract interpretation, or the preferred course of development of any product candidates, may cause delays or termination of the research, development of such product candidates or commercialization of products derived from our product candidates, may lead to additional responsibilities for us with respect to such product candidates, or may result in litigation or arbitration, any of which would be time-consuming and expensive;
future partners may not properly maintain, protect, defend or enforce our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;
disputes may arise with respect to the ownership of intellectual property developed pursuant to our collaborations;

49

future partners may infringe, misappropriate or otherwise violate the intellectual property rights of third parties, which may expose us to litigation and potential liability;
collaborations may be terminated for the convenience of the partner and, if terminated, the development of our product candidates may be delayed, and we could be required to raise additional capital to pursue further development of the applicable product candidates or commercialization of products derived from such product candidates;
future relationships may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing shareholders, or disrupt our management and business;
we could face significant competition in seeking appropriate future partners, and the negotiation process is time-consuming and complex; and
our international operations through any future collaborations, acquisitions or joint ventures may expose us to certain operating, legal and other risks not encountered in the United States.

If our collaborations do not result in the successful development of our product candidates or commercialization of products derived from such product candidates, or if one or more of our future partners terminates its agreement with us, we may not receive any future research funding or milestone, earn-out, royalty, or other contingent payments under the collaborations. If we do not receive the funding we expect under these agreements, our development of product candidates could be delayed, and we may need additional resources to develop our product candidates. In addition, in general our future partners have the right to terminate their agreements with us for convenience. If one or more of our future partners terminates its agreement with us, we may find it more difficult to attract new future partners and the perception of us in the business and financial communities could be adversely affected. All of the risks relating to product development, regulatory approval and commercialization described in this Form 20-F apply to the activities of our partners.

Our business is dependent on the successful development, regulatory approval and commercialization of product candidates based on our AI platform technologies. If our future partners, if any, are unable to obtain approval for, and effectively commercialize, our product candidates for the treatment of patients in their intended indications, our business would be significantly harmed.

We believe that the cost and expense of late-stage clinical testing, regulatory approval and commercialization of products for disease indications targeted by our product candidates are beyond the resources of all but the large biopharmaceutical and pharmaceutical companies. Therefore, we intend to develop our product candidates through Phase 2b clinical trials and then enter into partnership arrangements with these large biopharmaceutical and pharmaceutical companies to conduct late-stage clinical trials, regulatory and marketing approval and commercialization of our product candidates. We have not yet entered into any such partnerships and may be unable to do so on economically viable terms, if at all. As a result, late-stage clinical trials as well as pivotal clinical trials for our product candidates have not been commenced and even if such processes are commenced in the near future, it will be several years, if ever, before we or our future partners have a product candidate ready for commercialization. Even if we complete the necessary pre-clinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain, and our future partners may not be able to obtain approvals for the commercialization of any product candidates we may develop. Any immunotherapy we may develop, and the activities associated with its development and commercialization, including design, testing, manufacture, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA, the EMA, the TGA and by comparable global health authorities. To obtain the requisite regulatory approvals to commercialize any of our product candidates, we and our future partners must demonstrate through extensive pre-clinical studies and clinical trials that our products are safe and effective, including in the target populations. Successful completion of clinical trials is a prerequisite to submitting a biologics license application, or BLA, or a NDA to the FDA, a Marketing Authorization Application, or EMAA, to the EMA, a Marketing Authorization Application to the TGA, or AMAA and similar marketing applications to comparable global regulatory authorities, for each product candidate and, consequently, the ultimate approval and commercial marketing of any product candidates.

50

Failure to obtain marketing approval for a product candidate will prevent our future partners from commercializing the product candidate in a given jurisdiction. Neither we nor our future partners have received approval to market any of our product candidates from regulatory authorities in any jurisdiction, and it is possible that none of our product candidates, or any product candidates we may seek to develop in the future, will ever obtain regulatory approval. We have limited experience in filing and supporting the applications necessary to gain marketing approvals and intend to rely on our future partners to conduct this process. To our knowledge, there is no current precedent for an immunotherapy such as the type we are developing being approved for sale by the FDA, the EMA, the TGA or any other regulatory agency elsewhere in the world. Securing regulatory approval requires the submission of extensive pre-clinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the product candidate’s safety and efficacy. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Any product candidates we or our future partners develop may not be effective, may be only moderately effective, or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use.

The process of obtaining marketing approvals in the United States, the European Union, Australia and elsewhere, is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application may cause delays in the approval or rejection of an application. The FDA, the EMA, the TGA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that the data are insufficient for approval and require additional pre-clinical, clinical or other trials. In addition, varying interpretations of the data obtained from pre-clinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we, or our future partners, ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable. Additional delays, or non-approval if an FDA panel of experts, referred to as an Advisory Committee, or the EMA, the TGA or other regulatory authority recommends non-approval or restrictions on approval. In addition, we and our future partners may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory agency policy during the period of product development, clinical trials, and the review process.

Regulatory agencies also may approve an immunotherapy for fewer or more limited indications than requested or may grant approval subject to the performance of post-marketing studies. In addition, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates.

The FDA, the EMA, the TGA and other regulatory agencies review the Chemistry, Manufacturing and Controls, or CMC, section of regulatory filings. Any aspects found unsatisfactory by regulatory agencies may result in delays in clinical trials and commercialization.

In addition, the regulatory agencies typically conduct pre-approval inspections at the time of a BLA, NDA, EMAA, AMAA or comparable filing. Any findings by regulatory agencies and failure to comply with requirements may lead to delay in approval and failure to commercialize the potential product candidate.

If our future partners experience delays in obtaining, or if they fail to obtain, approval of any product candidates we may develop, the commercial prospects for those product candidates will be harmed, and our ability to generate revenues from our collaboration agreements will be materially impaired. Additionally, even if our future partners are successful in obtaining marketing approval for product candidates, because our pre-clinical studies and clinical trials have not been designed with specific commercialization considerations, the commercial prospects for those product candidates could be harmed, and our ability to generate revenues could be materially impaired.

51

If we are not able to establish collaborations on commercially reasonable terms, we may have to alter our research and development plans.

Our research and product development programs and the potential commercialization of any product candidates we develop alone or with future partners will require substantial additional cash to fund expenses, and we expect that we will continue to seek collaborative arrangements with others in connection with the development and potential commercialization of current and future product candidates or the development of ancillary technologies. We face significant competition in establishing relationships with appropriate partners. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future partners. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the partner’s resources and expertise, the terms and conditions of the proposed collaboration and the proposed partner’s evaluation of a number of factors. Those factors may include, among other things and as applicable for the type of potential product or technology, an assessment of the opportunities and risks of our technology, the design or results of studies or trials, the likelihood of approval, if necessary, of the FDA, the EMA, the TGA or similar regulatory authorities outside the United States, Europe and Australia, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products and technologies and industry and market conditions generally.

Current or future partners may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us. Additionally, we may be restricted under existing collaboration agreements from entering into future agreements on certain terms or for certain development activities with potential partners. Similarly, our collaboration agreements may contain non-competition provisions that could limit our ability to enter into collaborations with future partners.

Collaborations are complex and time-consuming to negotiate and document. We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we do enter into additional collaboration agreements, the negotiated terms may force us to relinquish rights that diminish our potential profitability from development and commercialization of the subject product candidates or others. If we are unable to enter into additional collaboration agreements, we may have to curtail the research and development of the product candidate or technology for which we are seeking to collaborate, reduce or delay research and development programs, delay potential commercialization timelines, reduce the scope of any sales or marketing activities or undertake research, development or commercialization activities at our own expense. If we elect to increase our expenditures to fund research, development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all.

We have entered into in-licensing arrangements and may form or seek to enter into additional licensing arrangements in the future, and we may not realize the benefits of such licensing arrangements.

We may obtain licenses that give us rights to third-party intellectual property, including patents and patent applications that are necessary or useful for our business. In particular, we have entered into license agreements with Statens Serum Institut, or SSI, and PharmaJet, Inc. or PharmaJet to obtain licenses for intellectual property useful in pharmaceutical formulations and delivery devices. We may enter into additional licenses to third-party intellectual property in the future.

The success of products developed based on in-licensed technology will depend in part on the ability of our current and future licensors to prosecute, obtain, maintain, protect, enforce and defend patent protection for our in-licensed intellectual property. Our current and future licensors may not successfully prosecute any patent applications we may license. Even if patents were issued in respect of these patent applications, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents, or may pursue such litigation less aggressively than we would. Without protection for the intellectual property we license, other companies might be able to offer substantially identical products for sale, which could adversely affect our competitive business position and harm our business prospects. In addition, we may sublicense our rights under various third-party licenses to our partners. Any impairment of these sublicensed rights could result in reduced revenues under our collaboration agreements or result in termination of an agreement by one or more of our partners.

Disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including:

the scope of rights granted under the license agreement and other interpretation-related issues;

52

whether and the extent to which our technology and processes infringe, misappropriate or otherwise violate the intellectual property of the licensor that is not subject to the licensing agreement;
our right to sublicense patent and other intellectual property rights to third parties under collaborative relationships;
our diligence obligations with respect to the use of the licensed intellectual property and technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations;
the ownership of inventions, trade secrets, know-how and other intellectual property resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and
the priority of invention of patented technology.

If disputes over intellectual property that we have in-licensed or other related contractual rights prevent or impair our ability to maintain our current licensing arrangements on favorable terms, we may be unable to successfully develop our product candidates and the commercialization of any products derived from such product candidates may be adversely affected.

We are generally also subject to all of the same risks with respect to protection of intellectual property that we license, as we are for intellectual property that we own, which are described below. If we, our co-owners or our licensors fail to adequately protect, defend, maintain or enforce this intellectual property, our ability to commercialize products could suffer.

We rely on third parties to manufacture certain of our clinical product supplies, and we will rely on third parties to produce and process our product candidates, if approved.

We rely on outside vendors to manufacture supplies and process our product candidates. None of our product candidates have been manufactured or processed on a late-stage clinical trial or commercial scale and our third party CMOs and our future partners may not be able to achieve late-stage clinical trial or commercial-scale manufacturing and processing and may be unable to create an inventory of mass-produced product to satisfy demands for our product candidates.

We do not yet have sufficient information to reliably estimate the cost of the commercial manufacturing and processing of our product candidates, and the actual cost to manufacture and process our product candidates could materially and adversely affect the availability of our product candidates in sufficient quantities to conduct our clinical trials or the commercial viability of any products derived from our product candidates. As a result, we and/or our future partners may never be able to develop a commercially viable product.

In addition, our reliance on a limited number of third-party manufacturers exposes us to the following risks:

we may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and the FDA, the EMA, the TGA or other regulatory authorities may have questions regarding any replacement contractor. This may require new testing and regulatory interactions. In addition, a new manufacturer would have to be educated in, or develop substantially equivalent processes for, production of our product candidates or any products derived from our product candidates after receipt of regulatory authority questions, if any;
our third-party CMOs might not be able to timely formulate and manufacture our product candidates or any products derived from our product candidates or produce the quantity and quality required to meet our and our partners’ clinical and commercial needs, if any;
CMOs may not be able to execute our manufacturing procedures appropriately;
our future CMOs may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our product candidates or any products derived from our product candidates;

53

manufacturers are subject to ongoing periodic unannounced inspection by the FDA, the United States Drug Enforcement Administration, or the DEA, and corresponding state agencies and by regulatory authorities in other jurisdictions to ensure strict compliance with GMP and other government regulations and corresponding standards in other jurisdictions. We do not have control over third-party CMOs or our future partners compliance with these regulations and standards;
we may not own, or may have to share, the intellectual property rights to any improvements made by our third-party CMOs in the manufacturing process for our products;
our third-party CMOs could breach or terminate their agreement with us; and
our third-party CMOs would also be subject to the same risks we face in developing our own manufacturing capabilities, as described above.

Each of these risks could delay our clinical trials, the approval, if any, of our product candidates or any products derived from our product candidates by the FDA, the EMA, the TGA or regulatory authorities in other jurisdictions or the commercialization of our product candidates, or result in higher costs or deprive us of potential product sales revenue. In addition, we will rely on third parties to perform release tests on our product candidates or any products derived from our product candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable, patients could be put at risk of serious harm.

We and/or our future partners may, in the future, be dependent on single-source suppliers for some of the components and materials used in, and the processes required to develop, our product candidates.

We and/or our future partners may, in the future, be dependent on single-source suppliers for some of the components and materials used in, and manufacturing processes required to develop, our product candidates. We cannot ensure that these suppliers or service providers will remain in business, or have sufficient capacity or supply to meet our needs, or that they will not be purchased by one of our competitors or another company that is not interested in continuing to work with us. Our or our future partners use of single-source suppliers of raw materials, components, key processes and finished goods exposes us to several risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. These vendors may be unable or unwilling to meet our future demands for our clinical trials or our future partners commercial sale of any products derived from our product candidates. Establishing additional or replacement suppliers for these components, materials and processes could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. Any disruption in supply from any single-source supplier or service provider could lead to supply delays or interruptions which would damage our business, financial condition, results of operations and prospects.

If we have to switch to a replacement supplier, the manufacture and delivery of our product candidates could be interrupted for an extended period, which could adversely affect our business. Establishing additional or replacement suppliers for any of the components or processes used in our product candidates, if required, may not be accomplished quickly. If we are able to find a replacement supplier, the replacement supplier would need to be qualified and may require additional regulatory authority approval, which could result in further delay. While we intend to maintain adequate inventory of the single source components and materials used in our product candidates, any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand for our product candidates.

In addition, as part of the FDA’s approval of our product candidates, FDA review of the individual components of our process, which include the manufacturing processes and facilities of our single-source suppliers will also be required.

Our reliance on these suppliers, service providers and manufacturers may subject us to a number of risks that could harm our reputation, business and financial condition, including, among other things:

delays to the development timelines for our product candidates;
interruption of supply resulting from modifications to or discontinuation of a supplier’s operations;
delays in product shipments resulting from uncorrected defects, reliability issues, or a supplier’s variation in a component;

54

a lack of long-term supply arrangements for key components with our suppliers;
inability to obtain adequate supply in a timely manner, or to obtain adequate supply on commercially reasonable terms;
difficulty and cost associated with locating and qualifying alternative suppliers for our components in a timely manner;
production delays related to the evaluation and testing of components from alternative suppliers, and corresponding regulatory qualifications;
delay in delivery due to our suppliers’ prioritizing other customer orders over ours;
damage to our reputation caused by defective components produced by our suppliers; and
fluctuation in delivery by our suppliers due to changes in demand from us or their other customers.

If any of these risks materialize, costs could significantly increase and our and/or our partners’ ability to meet demand for our product candidates or any products derived from our product candidates could be adversely affected.

Risks Related to Our Intellectual Property

If our efforts to obtain, maintain, protect, defend and/or enforce the intellectual property related to our product candidates and technologies are not adequate, we may not be able to compete effectively in our market.

Our commercial success depends in part on our ability to obtain, maintain, protect, defend and enforce patent and other intellectual property, including trade secret and know-how, protection for our product candidates, proprietary technologies and their uses, as well as our and our partners’ ability to operate, develop, manufacture and commercialize our product candidates without infringing, misappropriating or otherwise violating the intellectual property or other proprietary rights of our competitors or any other third parties, including any non-practicing entities or patent assertion entities. We generally seek to protect our intellectual property position by filing and/or licensing patent applications in the United States, and Europe as well as in other countries related to our product candidates, proprietary technologies (including methods of manufacture) and their uses that are important to our business. While in some jurisdictions patent applications can be enforced through the issuance of a preliminary injunction, in general, our patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent that the issued claims cover third parties’ activities in the countries in which they are performed. We cannot be certain that the claims in any of our patent applications will be considered patentable by the United States Patent and Trademark Office, or the USPTO, courts in the United States or the patent offices and courts in Europe and in other jurisdictions, nor can we be certain that the claims in our issued patents will not be found invalid or unenforceable if challenged. Accordingly, there can be no assurance that our patent applications or those of our licensors will result in additional patents being issued or that issued patents will adequately cover our product candidates or otherwise afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents issued will not be infringed, designed around, invalidated or held unenforceable. Furthermore, we may not be able to obtain patents on certain aspects of our current or future product candidates, proprietary technologies and their uses in a timely fashion, at a reasonable cost, in all jurisdictions, or at all, and any potential patent protection we obtain may not be sufficient to prevent substantial competition.

Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings before various patent offices or in courts in the United States, Europe or other jurisdictions. The degree of future protection for our intellectual property and other proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our technologies or permit us to gain or keep any competitive advantage. If we do not adequately obtain, maintain, protect, defend and enforce our intellectual property and proprietary technology, competitors may be able to use our product candidates and proprietary technologies and erode or negate any competitive advantage we may have, which could have a material adverse effect on our financial condition and results of operations.

55

The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our current or future licensors or future partners will be successful in prosecuting, obtaining, protecting, maintaining, enforcing or defending patents and patent applications necessary or useful to protect our product candidates, proprietary technologies (including methods of manufacture) and their uses. These risks and uncertainties include, from time to time, the following:

the USPTO and various other governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application or a finding that a patent is unenforceable, and partial or complete loss of patent rights in the relevant jurisdiction;
patent applications may not result in any patents being issued;
issued patents that we own (solely or jointly) or have in-licensed may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage;
our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or eliminate our ability to make, use, sell, import or otherwise exploit our product candidates or other technologies;
other parties may have designed around our patent claims or developed technologies that may be related or competitive to our product candidates or other technologies, may have filed or may file patent applications and may have received or may receive patents that overlap or conflict with our patent filings, either by claiming the same or overlapping methods, products, reagents or devices or by claiming subject matter that could dominate one or more of our patent claims;
any successful opposition to any patents owned by or in-licensed to us could deprive us of rights necessary for the economically feasible development and exploitation of our product candidates and other technologies or the economically successful commercialization of any product candidates and other technologies that we may develop;
because patent applications in the United States, Europe and most other jurisdictions are confidential for a period of time after filing, we cannot be certain that we, our co-owners or our licensors were the first to file any patent application related to our product candidates, proprietary technologies and their uses;
a court or patent office proceeding, such as a derivative action or interference, can be provoked or instituted by a third party or a patent office, and might determine that one or more of the inventions described in our patent filings, or in those we licensed, was first invented by someone else, so that we may lose rights to such invention(s);
a court or other patent proceeding, such as an inter partes review, post grant review or opposition, can be instituted by a third party to challenge the inventorship, scope, validity and/or enforceability of our patent claims and might result in invalidation or revision of one or more of our patent claims, or in a determination that such claims are unenforceable;
there may be significant pressure on the United States government, European government and other international governmental bodies to limit the scope of patent protection both inside and outside the United States and Europe for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and
United States government, European government and other international governments, may receive compulsory licensing wherein patents are required to be made available to third parties at reduce rates; and
countries other than the United States may have patent laws less favorable to patentees than those upheld by United States courts, allowing competitors a better opportunity to create, develop and market competing product candidates.

56

The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. The standards that the USPTO and its counterparts use to grant patents are not always applied predictably or uniformly and can change. Similarly, the ultimate degree of protection that will be afforded to biotechnology inventions, including ours, in the United States and other countries, remains uncertain and is dependent upon the scope of the protection decided upon by patent offices, courts and lawmakers. Moreover, there are periodic changes in patent law, as well as discussions in the Congress of the United States and in international jurisdictions about modifying various aspects of patent law. There is no uniform, worldwide policy regarding the subject matter and scope of claims granted or allowable in pharmaceutical or biotechnology patents. In certain countries, for example, methods for the medical treatment of humans are not patentable. More generally, the laws of some countries do not protect intellectual property rights to the same extent as United States laws, and those countries may lack adequate rules and procedures for granting, maintaining, protecting, defending and enforcing our intellectual property rights. However, while certain incentives such as natural occurring products are not patentable in the United States, such inventions may be patentable in other jurisdictions, including Europe.

Furthermore, the patent prosecution process is also expensive and time-consuming, and we may not be able to file, prosecute, maintain, protect, defend, enforce or license all necessary or desirable patents or patent applications, as applicable, at a reasonable cost or in a timely manner. It is possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate future partners, outside scientific future partners, CROs, CMOs, consultants, advisors and other third parties, any of these parties may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. We also rely to a certain extent on trade secrets, know-how, and technology, which are not protected by patents, to maintain our competitive position. If any trade secret, know-how or other technology not protected by a patent were to be disclosed to or independently developed by a competitor, our business and financial condition could be materially adversely affected.

The issuance of a patent is not conclusive as to its inventorship, priority date, scope, term, validity or enforceability so that any patents that may issue or that we may license may be challenged in the courts or patent offices in the United States, Europe and other jurisdictions. Once granted, patents may remain open to a variety of challenges, including opposition, interference, re-examination, post-grant review, inter partes review, nullification or derivation action in court or before patent offices or similar proceedings, and furthermore, may be challenged as a defense in any enforcement action that we might bring. Such challenges may result in loss of exclusivity or in patent claims being narrowed, terminated, disclaimed, invalidated, assigned to others or held unenforceable, any or all of which could limit our ability to stop others from using or commercializing similar or identical products, or limit the scope and/or term of patent protection of our products and product candidates and/or eliminate it altogether, thus hindering or removing our ability to limit third parties from making, using or selling products or technologies that are similar or identical to ours, and/or reduce or eliminate royalty payments to us from our licensees. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Furthermore, our pending and future patent applications may not result in patents being issued which protect our technology or product candidates or which effectively prevent others from commercializing competitive technologies and product candidates. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.

Our ability to enforce our owned and in-licensed patent and other intellectual property rights depends on our ability to detect infringement, misappropriation and other violation of such patents and other intellectual property. It may be difficult to detect infringers, misappropriators and other violators who do not advertise the components or methods that are used in connection with their products and services. Moreover, it may be difficult or impossible to obtain evidence of infringement, misappropriation or other violation in a competitor’s or potential competitor’s product or service, and in some cases, we may not be able to introduce obtained evidence into a proceeding or otherwise utilize it to successfully demonstrate infringement. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded if we were to prevail may not be commercially meaningful.

57

In addition, proceedings to enforce or defend our owned or in-licensed patents could put our patents at risk of being invalidated, held unenforceable or interpreted narrowly. Such proceedings could also provoke third parties to assert claims against us, including that some or all of the claims in one or more of our patents are invalid or otherwise unenforceable. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. If any of our owned or in-licensed patents covering our product candidates or other technologies are narrowed, invalidated or found unenforceable, or if a court found that valid, enforceable patents held by third parties covered one or more of our product candidates or other technologies, our competitive position could be harmed or we could be required to incur significant expenses to protect, enforce or defend our rights. If we initiate lawsuits to protect, defend or enforce our patents, or litigate against third-party claims, such proceedings would be expensive and would divert the attention of our management and technical personnel, even if the eventual outcome is favorable to us. Furthermore, because of the potentially substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during the course of litigation.

The degree of future protection for our intellectual property and other proprietary rights is uncertain, and we cannot ensure that:

any of our patents, or any of our pending patent applications, if issued, or those of our licensors, will include claims having a scope sufficient to protect our product candidates and other technologies;
any of our pending patent applications or those of our licensors may issue as patents;
others will not or may not be able to make, use, offer to sell or sell products that are the same as or similar to our own product candidates or any products derived from our product candidates, but that are not covered by the claims of the patents that we own or license;
our future partners will be able to successfully commercialize products derived from our product candidates on a substantial scale, if approved, before the relevant patents that we own, or license expire;
we were the first to make the inventions covered by each of the patents and pending patent applications that we own or license;
we, our co-owners or our licensors were the first to file patent applications for these inventions;
others will not develop similar or alternative products or technologies that do not infringe the patents we own or license;
any of the patents we own, or license will be found to ultimately be valid and enforceable;
any patents issued to us or our licensors will provide a basis for an exclusive market for our commercially viable product candidates and other technologies or will provide us with any competitive advantages;
a third party may not challenge the patents we own, or license and, if challenged, a court would hold that such patents are valid, enforceable and infringed;
we may develop or in-license additional proprietary technologies that are patentable;
the patents of others will not have an adverse effect on our business;
our competitors do not conduct research and development activities in countries where we do not have enforceable patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;
we will develop additional proprietary technologies or product candidates that are separately patentable; or

58

our development and commercialization activities of our future partners, including manufacturing processes, or products derived from our product candidates will not infringe upon the patents of our competitors or any other third parties, including any non-practicing entities or patent assertion entities.

Other companies or organizations may challenge our intellectual property rights or may assert intellectual property rights that prevent us from developing our product candidates and other technologies, and may prevent our future partners from commercializing any products derived from our product candidates.

Our business involves new and evolving scientific fields, the continued development and potential use of which has resulted in many different patents and patent applications from organizations and individuals seeking to obtain intellectual property protection in the fields. We own and in-license patent applications and issued patents that describe and/or claim certain technologies, including products, reagents, formulations and methods including uses and manufacturing methods, or features or aspects of any of these. These issued patents and pending patent applications claim certain compositions of matter and methods relating to the discovery, development, manufacture and commercialization of therapeutic modalities and our delivery technologies, including LNPs. If we, our co-owners, our licensors, including our future partners, are unable to obtain, maintain, protect, defend or enforce patent protection with respect to our product candidates and other technology and any product candidates and technology we develop, our business, financial condition, results of operations and prospects could be materially harmed.

As the scientific fields mature, our known competitors and other third parties have filed, and will continue to file, patent applications claiming inventions in the field in the United States and in other countries. There is uncertainty about which patents will issue, and, if they do, as to when, to whom and with what claims. With respect to both in-licensed and owned intellectual property, we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors.

We, our co-owners or our licensors, including our future partners, may in the future become a party to patent proceedings or priority disputes in the United States, Europe or other jurisdictions. The Leahy-Smith America Invents Act, or the America Invents Act, enacted in September 2011, included a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent through USPTO-administered post-grant proceedings, including post-grant review, inter partes review and derivation proceedings. We expect that our competitors and other third parties may institute litigation and other proceedings, such as interference, reexamination and opposition proceedings, as well as inter partes and post-grant review proceedings against us and the patents and patent applications that we own and in-license. We expect that we may be subject to similar proceedings or priority disputes, including oppositions, in Europe or other foreign jurisdictions relating to patents and patent applications in our portfolio.

If we, our co-owners or our licensors, including our future partners, are unsuccessful in any interference proceedings or other priority or validity disputes, including any derivations, post-grant review, inter partes review or oppositions, to which we or they are subject, we may lose valuable intellectual property rights through the narrowing or loss of one or more patents owned or in-licensed, or our owned or in-licensed patent claims may be narrowed, invalidated or held unenforceable. In many cases, the possibility of appeal exists for either us or our opponents, and it may be years before final, unappealable rulings are made with respect to these patents in certain jurisdictions. The timing and outcome of these and other proceedings is uncertain and may adversely affect our business if we are not successful in defending the patentability and scope of our pending and issued patent claims. In addition, third parties may attempt to invalidate our intellectual property rights. Even if our rights are not directly challenged, disputes could lead to the weakening of our intellectual property rights. Our defense against any attempt by third parties to circumvent or invalidate our intellectual property rights could be costly to us, could require significant time and attention of our management and could have a material adverse impact on our business and our ability to successfully compete against our current and future competitors.

59

There are many issued and pending patent filings that claim aspects of technologies that we or our future partners may need for our product candidates or any products derived from our product candidates, including patent filings that relate to relevant delivery technologies. There are also many issued patents that claim targeting genes or portions of genes that may be relevant for immunotherapies we wish to develop. In addition, there may be issued and pending patent applications that may be asserted against us in a court proceeding or otherwise based upon the asserting party’s belief that we or our future partners may need such patents for the development, manufacturing and commercialization of our product candidates or any products derived from our product candidates. Thus, it is possible that one or more organizations, ranging from our competitors to non-practicing entities or patent assertion entities, has or will hold patent rights to which we may need a license, or hold patent rights which could be asserted against us. Such licenses may not be available on commercially reasonable terms or at all, or may be non-exclusive. If those organizations refuse to grant us a license to such patent rights on reasonable terms or a court rules that we need such patent rights that have been asserted against us and we are not able to obtain a license on reasonable terms or at all, we may be unable to perform research and development or other activities or market products covered by such patents, and we or our future partners may need to cease the development, manufacture and commercialization of one or more of the product candidates or any products derived from our product candidates we or our future partners may develop. Any of the foregoing could result in a material adverse effect on our business, financial condition, results of operations or prospects.

We may not be successful in obtaining, maintaining, protecting or defending the necessary intellectual property rights to allow us to identify and develop product candidates, product components and manufacturing processes for our development pipeline.

We currently have rights to certain intellectual property, through our owned and in-licensed patents and other intellectual property rights, relating to identification and development of our product candidates or other technologies. As our pipeline may involve additional product candidates that could require the use of intellectual property and other proprietary rights held by third parties, the growth of our business could depend in part on our ability to acquire, in-license or use such intellectual property and proprietary rights. In addition, our product candidates may require specific formulations to work effectively and efficiently and these intellectual property and other proprietary rights may be held by others. We may be unable to secure such licenses or otherwise acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary, on reasonable terms, or at all, for product candidates and other technologies that we may develop. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities.

For example, we have in the past and may continue to collaborate with academic institutions in certain aspects of our pre-clinical research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution’s rights in technology resulting from the collaboration. However, these institutions may not honor our option and right of first negotiation for intellectual property rights or we may otherwise be unable to negotiate a license within the specified time frame or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program or otherwise continue to develop certain product candidates or other technologies.

Moreover, some of our owned patents and patent applications are, and may in the future be, co-owned with third parties. If we are unable to obtain, or continue to maintain, exclusive rights to any such third-party co-owners’ interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technologies. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.

In addition, third parties that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain, protect, defend or enforce the existing intellectual property rights we have, we may have to abandon the development of the relevant program or product candidate and our future partners may have to abandon the commercialization of any products derived from our product candidates, which could have a material adverse effect on our business, financial condition, results of operations and prospects.

60

The lifespans of our patents may not be sufficient to effectively protect our product candidates, technologies and business.

Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after its first effective non-provisional filing date, assuming maintenance fees are timely paid after the patent has issued. Most foreign jurisdictions also provide a 20-year nominal patent term, though many require payment of regular, often annual, annuities to maintain pendency of an application or viability of an issued patent. In some jurisdictions, one or more options for extension of a patent term may be available, but even with such extensions, the lifespan of a patent, and the protection it affords, is limited. Even if patents covering our product candidates, proprietary technologies and their uses are obtained, once the patent term has expired, we may be subject to competition from third parties that can then use the inventions included in such patents to create competing products and technologies. In addition, although upon issuance in the United States a patient’s life can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such candidates are commercialized. If any patents that we own or in-license expire, we would not be able to stop others from using or commercializing similar or identical technology and products, and our competitors could market competing products and technology. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.

If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed.

Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our United States patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984, or Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations and prospects could be materially harmed.

If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.

We may be reliant upon licenses to certain intellectual property and other proprietary rights from third parties that are important or necessary to the development and commercialization of our technology and product candidates, and we expect to enter into similar license agreements in the future. Licensing of intellectual property is important to our business and involves complex legal, business and scientific issues and is complicated by the rapid pace of scientific discovery in our industry. Our licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products in the future. As a result, we may not be able to prevent competitors from developing and commercializing competitive products in territories included in any or all of our licenses.

61

Where we obtain licenses from, or collaborate with, third parties, in some circumstances we may not have the right to control the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications covering the technology that we license from third parties, or such activities, if controlled by us, may require the input of such third parties. In some cases, patent prosecution of our in-licensed intellectual property is controlled solely by the licensor. We may also require the cooperation of our licensors and future partners to enforce or defend any in-licensed patent rights, and such cooperation may not be provided. Therefore, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, protected, enforced or defended in a manner consistent with the best interests of our business. Any patents or patent applications that we in-license may be challenged, narrowed, circumvented, invalidated or held unenforceable, or our licensors may not properly maintain such patents or patent applications and they may expire. If our licensors fail to obtain, maintain, defend, protect or enforce the intellectual property we license from them, we could lose our rights to the intellectual property and our competitors could market competing products using the inventions in such intellectual property. In certain cases, we control the prosecution of patents included from in-licensed technology. In the event we breach any of our obligations related to such prosecution, we may incur significant liability to our partners. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.

Moreover, any failure to satisfy obligations or any material breach under any of our licenses to third-party intellectual property could give the licensor the right to terminate the license. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone and royalty payment, exclusivity and other obligations on us. If we fail to comply with our obligations under these agreements, or we are subject to a bankruptcy, the licensor may have the right to terminate the license agreement, in which event we would not be able to develop, market and commercialize product candidates covered by the license agreement. In spite of our best efforts and even if we disagree, our licensors might still conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize the product candidates covered by these license agreements. In the event that any of our license agreements were to be terminated by the licensor, we may need to negotiate new or reinstated agreements, which may not be available to us on equally favorable terms, or at all. If these license agreements are terminated, or if the underlying patents or other intellectual property fail to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market and commercialize, products similar or identical to ours. In addition, we may seek to obtain additional licenses from our licensors and, in connection with obtaining such licenses, we may agree to amend our existing license agreements in a manner that may be more favorable to the licensors, including by agreeing to terms that could enable third parties (potentially including our competitors) to receive licenses to a portion of the intellectual property that is subject to our existing licenses.

We are generally also subject to all of the same risks with respect to protection of intellectual property that we license, as we are for intellectual property that we own, which are described in this section. If we, our co-owners or our licensors, including our future partners, fail to adequately protect this intellectual property, our and our future partners ability to develop our product candidates, as well as the economic feasibility and our partners’ ability to develop, market and commercialize any products derived from our product candidates, could suffer. Moreover, if disputes over intellectual property that we have in-licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop our product candidates, and our future partners may not be able to successfully market and commercialize any products derived from our product candidates, which could have a material adverse effect on our business, financial condition, results of operations and prospects.

Our current proprietary position for certain product candidates depends upon our owned or in-licensed patent filings covering components of such product candidates, manufacturing-related methods, formulations and/or methods of use, which may not adequately prevent a competitor or other third party from using the same product candidate for the same or a different use.

Composition of matter patent protection is generally considered to be desirable because it provides protection without regard to any particular method of use or manufacture or formulation. While we have obtained patent protection covering components of certain product candidates, manufacturing-related methods, formulations and/or methods of use and claims issued that are directed to a vaccine formulation containing a broadly defined protein antigen, we do not currently have any claims in our owned or in-licensed issued United States or European patents that cover the overall construct used in our product candidates, and we cannot be certain that claims in any future patents issuing from our pending owned or in-licensed patent applications or our future owned or in-licensed patent applications will cover the composition of matter of our current or future product candidates.

62

Method of use patents protect the use of a product for the specified method and formulation patents cover formulations to deliver therapeutics. These types of patents do not prevent a competitor or other third party from developing, marketing or commercializing a similar or identical product for an indication that is outside the scope of the patented method or from developing a different formulation that is outside the scope of the patented formulation. Moreover, with respect to method of use patents, even if competitors or other third parties do not actively promote their product for our targeted indications or uses for which we may obtain patents, physicians may recommend that patients use these products off-label, or patients may do so themselves. Although off-label use may infringe or contribute to the infringement of method of use patents, the practice is common and this type of infringement is difficult to prevent or enforce. Consequently, we may not be able to prevent third parties from practicing our inventions in the United States or other countries.

Moreover, competitors or other third parties may in their commercial activities rely on secret know-how, including reliance on secret technologies. Such secret technologies may include manufacturing processes, intermediary products, manufacturing tools etc., the existence and utility of which is by nature not known to the public and for which we at a later stage may therefore seek patent protection and obtain valid patents. Such competitors and third parties could, if they can document their prior secret use of the patented technologies, have acquired prior user rights under applicable national laws, including in the United States the defense to patent infringement defined in 35 U.S.C. §273, that protect such competitors and third parties from claims of patent infringement raised by us. Under such circumstances, we might not be able to adequately prevent such a competitor or third party from commercially exploiting our patented technology in the United States or in other countries.

Intellectual property rights of third parties could adversely affect our partners’ ability to commercialize any products derive from our product candidates, and we and/or our future partners might be required to litigate or obtain licenses from third parties in order to develop or market our product candidates.

Because our product candidates are still in early developmental stages, and one or more features of the product candidates or related technologies such as their manufacture, formulation or use, may still change, we cannot be confident that we are aware of all third-party intellectual property that might be relevant to products that we eventually hope to commercialize. Various third-party competitors practice in relevant spaces, and may have issued patents, or patent applications that will issue as patents in the future, that will impede or preclude our ability to commercialize products. Furthermore, while United States patent laws provide a “safe harbor” to our clinical product candidates under 35 U.S.C. § 271(e)(1), which exempts from patent infringement activities related to pursuing FDA approval for a drug product, that exemption expires when a BLA or NDA is submitted. Given the uncertainty of clinical trials, we cannot be certain of the timing of their completion and it is possible that we might want to submit a BLA or NDA at a time when one or more relevant third-party patents is in force. Thus, it is possible that at the time that we commercialize our product candidates, one or more third parties may have issued patent claims that cover our products or critical features of their production or use. We may not be able to commercialize our products if patents issued to third parties or other third-party intellectual property rights cover, or may be alleged to cover, our products or elements thereof, or their methods of manufacture or use at the time that we seek to commercialize them. In such cases, we may not be in a position to develop or commercialize product candidates unless we successfully pursue litigation to nullify or invalidate the third-party intellectual property right concerned, successfully design around their claims, or enter into a license agreement with the intellectual property right holder(s). Such litigation or licenses could be costly or not available on commercially reasonable terms or at all, and design-around could be prohibitively expensive or impossible.

It is also possible that we have failed to identify relevant third-party patents that cover, or applications that will mature into patents that cover, one or more aspects of our platforms or product candidates. Given that, in most jurisdictions, a patent application is confidential when initially filed, and typically remains so until it is published about 18 months after the initial filing, it may not be possible for us to identify certain relevant filings in time to avoid using the technology that they claim. Additionally, the claims of pending patent applications and divisional continuation applications filed at a late stage can, subject to certain limitations, be amended over time, so that even patent applications whose claims did not cover our products or activities when published could be amended to cover one or more aspects of our platforms or product candidates over time, and we might not be aware that such amendment had been made.

63

We may be involved in lawsuits to protect or enforce our intellectual property or the intellectual property of our licensors, or to defend against third-party claims that we infringe, misappropriate or otherwise violate such third party’s intellectual property, each of which could be expensive, time consuming and unsuccessful.

There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, ex parte reexaminations, post-grant review, and inter partes review proceedings before the USPTO and corresponding European and other non-United States patent offices. Competitors and other third parties may infringe, misappropriate or otherwise violate our intellectual property rights or those of our licensors. To prevent infringement, misappropriation or other unauthorized use, we may be required to file claims, which can be expensive and time-consuming. In certain instances, we may institute inter partes review proceedings against issued United States patents and opposition proceedings against European patents owned by third parties in the field of immunotherapy. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.

In addition, in a patent infringement proceeding, our owned, or in-licensed patents may be challenged and a court may decide that a patent we own, or in-license is not valid, is unenforceable and/or is not infringed. If we or any of our potential future partners were to initiate legal proceedings against a third party to enforce a patent directed at one of our product candidates, the defendant could counterclaim that our patent is invalid and/or unenforceable in whole or in part. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may also raise similar claims before the USPTO, even outside the context of litigation. Similar mechanisms for challenging the validity and enforceability of a patent exist in ex-United States patent offices and may result in the revocation, cancellation or amendment of any ex-United States patents we hold in the future. The outcome following legal assertions of invalidity and unenforceability is unpredictable, and prior art could render our patents or those of our licensors invalid. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such product candidate. Such a loss of patent protection would have a material adverse impact on our competitive position, business, financial conditions, results of operations and prospects.

Third parties, ranging from our competitors to non-practicing entities or patent assertion entities, may assert that we are employing their intellectual property and other proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use, development, manufacture or commercialization of our product candidates. As patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that our technologies infringe upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may obtain injunctive or other equitable relief, which could effectively block our ability to develop and commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms, or at all, or may be non-exclusive.

Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same intellectual property and technology. Our defense of litigation, interference, derivation or similar proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development or manufacturing collaborations that would help us bring our product candidates to market.

64

Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.

In the event of a successful claim of infringement, misappropriation or other violation against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, pay royalties, redesign our infringing products, or obtain one or more licenses from third parties, which may not be made available on commercially favorable terms, if at all, or may require substantial time and expense.

Such licenses are likely to be non-exclusive and, therefore, our competitors may have access to the same intellectual property and technology licensed to us. If we fail to obtain a required license and are unable to design around a patent, we may be unable to effectively market some of our technology and product candidates, which could limit our ability to generate revenues or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations. Moreover, certain of our collaborations provide, and we expect additional collaborations to provide, that royalties payable to us for licenses to our intellectual property may be offset by amounts paid by our future partners to third parties for licenses to such third parties’ intellectual property in the relevant fields, which could result in significant reductions in our revenues from products developed through collaborations.

In addition, in connection with certain license and collaboration agreements, we have agreed, and may in the future agree, to indemnify certain third parties for certain costs incurred in connection with litigation relating to intellectual property rights or the subject matter of the agreements. The cost to us of any litigation or other proceeding relating to intellectual property rights, even if resolved in our favor, could be substantial.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation in the United States, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments in any litigation or other intellectual property proceedings. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of the ADSs.

Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.

Periodic maintenance fees, renewal fees, annuity fees, and various other governmental fees on patents and applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents or applications. We have systems in place to remind us to pay these fees and we may employ outside firms and rely on our outside counsel to pay these fees due to non-United States patent agencies; however, we cannot guarantee that we will successfully pay these fees. The USPTO and various non-United States governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. We are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our in-licensed intellectual property, and we cannot guarantee that they will do so. In such an event, our competitors might be able to enter the market with similar or identical products or technology, and this would have a material adverse impact on our business, financial condition, results of operations and prospects.

65

Changes in patent law in the United States or in other countries could diminish the value of patents in general, thereby impairing our ability to protect our products.

As is the case with other biotechnology companies, our success is dependent on our intellectual property rights, particularly patents that we own and in-license. Obtaining and enforcing patents in the biotechnology industry involve both technological and legal complexity, and therefore obtaining and enforcing biotechnology patents is costly, time-consuming and inherently uncertain. Moreover, there are periodic changes in patent law. For example, after March 2013, under the America Invents Act, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. The America Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. The America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.

In addition, recent United States Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the United States Congress, the federal courts and the USPTO, and their equivalents in other jurisdictions, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to obtain, maintain, protect, defend or enforce our intellectual property in the future.

If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.

In addition to seeking patent protection for some of our technology and product candidates, we also seek to rely on trade secret protection and confidentiality agreements to maintain our competitive position and protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our product discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets and know-how may be difficult to protect.

We seek to protect these trade secrets, know-how and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate future partners, outside scientific future partners, CROs, CMOs, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants and require all of our employees and key consultants who have access to our trade secrets, proprietary know-how, information or technology to enter into confidentiality agreements. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. Despite our best efforts, any of these parties may breach the agreements and we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. We may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret or know-how is difficult, expensive and time consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets and know-how. If any of our trade secrets or know-how were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results, financial condition and prospects.

66

We may be subject to claims that we have wrongfully hired an employee from a competitor, or that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.

We have received confidential and proprietary information from third parties in the course of our research and other collaborations with others in the industry, academic institutions and other third parties. In addition, many of our employees, consultants and advisors are currently or were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants, independent contractors and advisors do not use the confidential or proprietary information, trade secrets or know-how of others in their work for us, we may be subject to claims that we have inadvertently or otherwise used or disclosed confidential or proprietary information, trade secrets or know-how of these third parties, or that our employees, consultants, independent contractors or advisors have inadvertently or otherwise used or disclosed confidential information, trade secrets or know-how of such individual’s current or former employer. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees. Claims that we, our employees, consultants or advisors have misappropriated the confidential or proprietary information, trade secrets or know-how of third parties could have a material adverse effect on our business, financial condition, results of operations and prospects.

We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.

We may, in the future, be subject to claims that current or former employees, consultants, independent contractors, future partners or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. While it is our policy to require our employees, consultants, independent contractors, future partners and other third parties who may be involved in the conception, development or reduction to practice of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives, develops or reduces to practice such intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached. For example, we may have inventorship disputes arise from conflicting obligations of employees, consultants, independent contractors, future partners or other third parties who are involved in developing and commercializing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business, operating results and financial condition. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.

Furthermore, the laws of some countries do not protect intellectual property and other proprietary rights or establish ownership of inventions to the same extent or in the same manner as the laws of the United States. A majority of our employees work in Denmark and are subject to Danish employment law. Employees’ inventions that are either patentable or registrable as Danish utility models are subject to the provisions of the Danish Act on Employee Inventions, which regulates the ownership of, and compensation for, inventions made by employees. We face the risk that disputes can occur between us and our employees or former employees pertaining to alleged non-adherence to the provisions of this act. Such disputes may be costly to defend and may take up our management’s time and efforts regardless of whether we prevail or fail in any such dispute. There is a risk that the compensation we provided to employees who have assigned the rights to inventions to us may be deemed to be insufficient and we may under Danish law be required to increase the compensation due to such employees for the assignment of rights to such inventions. In those cases where rights to employees’ inventions have not been assigned to us, we may need to agree with the respective employees on the assignment of such inventions, including i.e. by paying a suitable compensation for the use of those patents. If we are required to pay additional compensation or face other disputes under the Danish Act on Employee Inventions, our business, results of operations and financial condition could be adversely affected.

67

We will not seek to protect our intellectual property rights in all jurisdictions throughout the world, and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection.

Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some countries do not protect intellectual property rights to the same extent as laws in Denmark and the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and to the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own product candidates and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement, misappropriation or other violation of our patents and other intellectual property or development, marketing and commercialization of competing products in violation of our intellectual property and other proprietary rights generally. Proceedings to enforce our intellectual property rights in such jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or in-license.

Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.

If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.

Our unregistered trademarks or trade names, as well as any trademarks or service marks that we may register, may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential future partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and trade names by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, trade secrets, know-how, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and prospects.

68

Intellectual property rights do not necessarily address all potential threats to our competitive advantage.

The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example:

others may be able to make patient-specific cancer immunotherapies and infectious disease products or product candidates that are similar to any product candidates we may develop and commercialize or utilize similar technologies that are not covered by the claims of the patents that we now or may in the future own or have exclusively in-licensed;
we, our co-owners or our licensors or future partners might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or have exclusively in-licensed;
we, our co-owners or our licensors or future partners might not have been the first to file patent applications covering certain of our or their inventions;
others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or in-licensed intellectual property rights;
it is possible that our pending patent applications or those that we may own or in-license in the future will not lead to issued patents;
issued patents that we own or have exclusively in-licensed may be held invalid or unenforceable, including as a result of legal challenges by our competitors;
our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;
we may not develop additional proprietary technologies that are patentable;
the patents of others may have an adverse effect on our business; and
we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.

Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.

69

We and our future partners or other contractors or consultants depend on information technology systems, and any failure of these systems could harm our business. Security breaches, loss of data and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business, results of operations and financial condition.

Our internal computer systems and those of our current and any future partners, vendors, and other contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, pandemics, terrorism, cybersecurity threats, war, and telecommunication and electrical failures. If any such material system failure, accident or security breach were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of pre-clinical data and/or clinical trial data from one or more ongoing or completed pre-clinical projects or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition, because of our approach to running multiple projects in parallel, any breach of our computer systems may result in a loss of data or compromised data integrity across many of our programs in many stages of development. Any such breach, loss or compromise of clinical trial participant personal data may also subject us to civil fines and penalties, including under the GDPR and relevant member state law in the European Union, and the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, and other relevant state and federal privacy laws in the United States. To the extent that any disruption or security breach were to result in a loss of, or damage to, data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of our product candidates could be delayed.

While we have not experienced any material system failures, accidents or security breaches to date, however, we cannot guarantee that third parties will not be able to gain unauthorized access to or otherwise breach our systems in the future. Any such unauthorized access or breach could adversely affect our business, results of operations and financial condition.

Risks Related to Government Regulation

Even if our future partners obtain regulatory approval for a product derived from one of our product candidates, such products will remain subject to regulatory scrutiny.

If a product derived from one of our product candidates is approved, it will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy, and other post- market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities.

BLA and NDA holders, as well as manufacturers of drug and biologics facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any approved marketing application. Accordingly, we, our partner and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality control.

Our future partners will have to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription drugs and biologics are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product’s approved label. As such, our future partners may not promote our products “off-label” for indications or uses for which they do not have approval. The holder of an approved application must submit new or supplemental applications and obtain approval for certain changes to the approved product, product labeling, or manufacturing process. Our future partners could also be asked to conduct post-marketing clinical studies to verify the safety and efficacy of our products in general or in specific patient subsets. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval.

70

If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things:

issue warning letters;
impose civil or criminal penalties;
suspend or withdraw regulatory approval;
suspend any of our clinical studies;
refuse to approve pending applications or supplements to approved applications submitted by us;
impose restrictions on our operations, including closing our contract manufacturers’ facilities; or
seize or detain products, or require a product recall.

Any government investigation of alleged violations of law could require us and/or our future partners to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our partners’ ability to commercialize and generate revenue from any products derived from our product candidates. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected.

Moreover, the policies of the FDA, the EMA and of other regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of any products derived from our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States, Europe or other countries. For example, certain policies of the current United States administration may impact our business and industry. Namely, the current United States administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA’s ability to engage in routine oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict how these orders will be implemented, and the extent to which they will impact the FDA’s ability to exercise its regulatory authority. If these executive actions impose restrictions on FDA’s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. In addition, if we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.

71

We and our future partners may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and other healthcare laws. If we and/or our future partners are unable to comply, or have not fully complied, with such laws, we and/or our future partners could face substantial penalties.

We and/or our future partners may be subject to additional healthcare regulation and enforcement by the United States federal government and by authorities in the United States, the European Union and other jurisdictions in which we conduct our business. If our future partners obtain FDA approval for any products derived from our product candidates and begin commercializing those products in the United States, our operations may be indirectly through our future partners and their prescribers, customers and purchasers, subject to various federal and state fraud and abuse laws and regulations, including, without limitation, the federal Health Care Program Anti-Kickback Statute, the federal civil and criminal False Claims Act, and the Physician Payments Sunshine Act and regulations. Many states and other jurisdictions have similar laws and regulations, some of which may be broader in scope. These laws will impact, among other things, our proposed sales, marketing and educational programs. In addition, we may be subject to patient privacy laws enacted by both the federal government and the states in which we conduct our business. The laws that will affect our operations include, but are not limited to the following:

The federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, in return for the purchase, recommendation, leasing or furnishing of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand, and prescribers, purchasers, and formulary managers on the other. The ACA amends the intent requirement of the federal Anti-Kickback Statute to provide that a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it;
The federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, false or fraudulent claims for payment or approval from Medicare, Medicaid or other government payors. The ACA provides, and recent government cases against pharmaceutical and medical device manufacturers support, the view that federal Anti-Kickback Statute violations and certain marketing practices, including off-label promotion, may implicate the False Claims Act;
HIPAA, which created new federal criminal statutes that prohibit a person from knowingly and willfully executing a scheme or making false or fraudulent statements to defraud any healthcare benefit program, regardless of the payor (e.g., public or private);
HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and their implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization by entities subject to the rule, such as health plans, health care clearinghouses and health care providers;
The United States Federal Food, Drug, and Cosmetic Act, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices;
The United States Public Health Service Act, which prohibits, among other things, the introduction into interstate commerce of a biological product unless a biologics license is in effect for that product;
Federal transparency laws, including the federal Physician Payment Sunshine Act, which require disclosure of payments and other transfers of value provided to physicians and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations;
State law equivalents of each of the above federal laws, state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare professionals or marketing expenditures, and state laws governing the privacy and security of health information in certain circumstances which are also applicable to us, and many of them differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts in certain circumstances;

72

The U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other things, United States companies and their employees and agents, as well as non-United States companies registered with the SEC from authorizing, promising, offering or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office, and foreign political parties or officials thereof; and
Similar healthcare laws and regulations in the European Union and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers.

Due to the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the laws described above or any other government regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.

The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the European Union. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of European Union member states, such as the U.K. Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment.

Payments made to physicians in certain European Union member states must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician’s employer, his or her competent professional organization or the regulatory authorities of the individual European Union member states. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the European Union member states. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.

We are subject to certain anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations.

Among other matters, anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, which are collectively referred to as “trade laws”, prohibit companies and their employees, agents, CROs, CMOs, legal counsel, accountants, consultants, contractors and other future partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of trade laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We plan to engage third parties for clinical trials and/or to obtain necessary permits, licenses, intellectual property (including patents) and other regulatory approvals, and we can be held liable for the corrupt or other illegal activities of our personnel, agents or future partners, even if we do not explicitly authorize or have prior knowledge of such activities.

We are subject to stringent privacy laws, information security policies and contractual obligations governing the use, processing, and cross-border transfer of personal information and our data privacy and security practices.

We receive, generate and store significant and increasing volumes of sensitive information, such as employee, personal and patient data. We are subject to a variety of local, state, national and international laws, directives and regulations that apply to the collection, use, storage, retention, protection, disclosure, transfer and other processing of personal data, collectively referred to as “data processing”, in the different jurisdictions in which we operate, including comprehensive regulatory systems in the United States and Europe. Legal requirements relating to data processing continue to evolve and may result in ever-increasing public scrutiny and escalating levels of enforcement, sanctions and increased costs of compliance.

73

Compliance with United States and international data protection laws and regulations could cause us to incur substantial costs or require us to change our business practices and compliance procedures in a manner adverse to our business. Moreover, complying with these various laws could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with United States, European and other international data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business. Claims that we have violated individuals’ privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend, could result in adverse publicity and could have a material adverse effect on our business, financial condition and results of operations.

Various states in the United States, such as California and Massachusetts, have implemented similar privacy laws and regulations, such as the California Confidentiality of Medical Information Act, that impose restrictive requirements regulating the use and disclosure of patient health information and other personal information. In addition to fines and penalties imposed upon violators, some of these state laws also afford private rights of action to individuals who believe their personal information has been misused. California’s patient privacy laws, for example, provide for penalties of up to $250,000 and permit injured parties to sue for damages. In addition to the California Confidentiality of Medical Information Act, California also recently enacted the California Consumer Privacy Act of 2018, or CCPA, which became effective on January 1, 2020. The CCPA has been characterized as the first “GDPR-like” privacy statute to be enacted in the United States because it mirrors a number of the key provisions of the European Union General Data Protection Regulation (described below). The CCPA establishes a new privacy framework for covered businesses in the State of California, by creating an expanded definition of personal information, establishing new data privacy rights for consumers imposing special rules on the collection of consumer data from minors, and creating a new and potentially severe statutory damages framework for violations of the CCPA and for businesses that fail to implement reasonable security procedures and practices to prevent data breaches. An initiative called the California Privacy Rights Act, or CCPA 2.0, passed in November 2020 and builds upon and amends the original CCPA aligning it more closely with the GDPR. CCPA 2.0 expands the privacy rights of California residents and could impact our operations or that of our partners. Other states have been considering legislation similar to the CCPA, and several federal privacy proposals are under consideration in the current session of Congress.

The collection and use of personal health data in the European Union had previously been governed by the provisions of the Data Protection Directive, which has been replaced by the European Union General Data Protection Regulation, or GDPR. While the Data Protection Directive did not apply to organizations based outside the European Union, the GDPR has expanded its reach to include any business, regardless of its location, that provides goods or services to residents in the European Union. The GDPR imposes strict requirements on controllers and processors of personal data, including special protections for “sensitive information” which includes health and genetic information of data subjects. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the United States and other third countries. In addition, the GDPR provides that European Union member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data. The GDPR is a complex law and the regulatory guidance is still evolving, including with respect to how the GDPR should be applied in the context of clinical studies. Furthermore, some of the countries within the European Union are still in the process of drafting supplementary data protection legislation in key fields where the GDPR allows for national variation, including the fields of clinical study and other health-related information. These variations in the law may raise our costs of compliance and result in greater legal risks. Additionally, on July 16, 2020, the Court of Justice of the European Union, or the CJEU, issued a landmark opinion in the case Maximilian Schrems vs. Facebook (Case C-311/18), called Schrems II. This decision calls into question certain data transfer mechanisms as between the European Union member states and the United States. The CJEU is the highest court in Europe and the Schrems II decision heightens the burden on the data exporters (transferring the data out of the European Union) as well as the data importers (the recipient of the data in the United States) to assess United States national security laws on their business and future actions of European Union data protection authorities are difficult to predict at the early date. Consequently, there is some risk of any such data transfers from the European Union being halted. Any contractual arrangements requiring the transfer of personal data from the European Union to us in the United States will require greater scrutiny and assessments as required under Schrems II and may have an adverse impact on cross-border transfers of personal data, or increase costs of compliance.

Since we are located in the European Union, we are subject to the GDPR. GDPR regulations have imposed additional responsibility and liability in relation to the personal data that we process and we may be required to put in place additional mechanisms to ensure compliance with the new data protection rules. This may be onerous and may interrupt or delay our development activities, and adversely affect our business, financial condition, results of operations and prospects.

74

Other jurisdictions outside the European Union are similarly introducing or enhancing privacy and data security laws, rules and regulations, which could increase our compliance costs and the risks associated with non-compliance. We cannot guarantee that we are, or will be, in compliance with all applicable international regulations as they are enforced now or as they evolve. For example, depending on the jurisdiction, our privacy policies may be insufficient to protect any personal information we collect, or may not comply with applicable laws, in which case we may be subject to regulatory enforcement actions, lawsuits or reputational damage, all of which may adversely affect our business. There is significant uncertainty related to the manner in which data protection authorities will seek to enforce compliance with the GDPR, especially with regard to clinical trial conduct. For example, it is not clear if the authorities will conduct random audits of companies doing business in the European Union, or if the authorities will wait for complaints to be filed by individuals who claim their rights have been violated. Enforcement uncertainty and the costs associated with ensuring GDPR compliance may be onerous and adversely affect our business, financial condition, results of operations and prospects. If we fail to comply with the GDPR and the applicable national data protection laws of the European Union member states, or if regulators assert we have failed to comply with these laws, it may lead to regulatory enforcement actions, which in a worst-case scenario can result in monetary penalties of up to $20,000,000 or up to 4% of the total worldwide annual revenue of the preceding financial year, whichever is higher, and other administrative penalties. If any of these events were to occur, our business and financial results could be significantly disrupted and adversely affected.

Although we take measures to protect sensitive data from unauthorized access, use or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers or viruses or breached due to employee error, malfeasance or other malicious or inadvertent disruptions. Any such breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties, manipulated, publicly disclosed, lost or stolen. Any such access, breach or other loss of information could result in legal claims or proceedings, and liability under federal or state laws that protect the privacy of personal information, as well as regulatory penalties. In the United States, notice of breaches must be made to affected individuals and the United States Secretary of HHS, and for extensive breaches, notice may need to be made to the media or state Attorneys General. Such a notice could harm our reputation and our ability to compete. HHS has the discretion to impose penalties without attempting to resolve violations through informal means. In addition, state Attorneys General are authorized to bring civil actions seeking either injunctions or damages in response to violations that threaten the privacy of state residents. Although we have implemented security measures to prevent unauthorized access to patient data, such data is currently accessible through multiple channels, and there is no guarantee we can protect our data from breach. Unauthorized access, loss or dissemination could also damage our reputation or disrupt our operations, including our ability to conduct our analyses, deliver test results, process claims and appeals, provide customer assistance, conduct research and development activities, collect, process and prepare company financial information, provide information about our tests and other patient and physician education and outreach efforts through our website, and manage the administrative aspects of our business.

If we, our future partners or our third-party suppliers fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.

We and our future partners will become subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations and the operations of our future partners will involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations and the operations of our future partners also may produce hazardous waste products. We generally anticipate contracting with third parties for the disposal of these materials and wastes. We will not be able to eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from any use by us of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.

Although we maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities.

In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.

75

Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.

Our business operations and the operations of our future partners and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved.

Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations.

If any of the physicians or other providers or entities with whom we expect to do business were found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly and time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.

General Risks Related to our Business

Our future success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified executive management and scientific personnel.

Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel with capabilities and expertise in immuno-oncology and infectious diseases. We are highly dependent upon members of our management and scientific teams. We may not be able to retain these persons due to the competitive environment in the biotechnology industry. The loss of any of these persons’ services may adversely impact the achievement of our research, development, financing and commercialization objectives. We currently do not have “key person” insurance on any of our employees.

In addition, we rely on consultants, contractors and advisors, including scientific and clinical advisors, to assist us in formulating our research and development, regulatory approval and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. The loss of the services of one or more of our current employees or advisors might impede the achievement of our research, development, regulatory approval and commercialization objectives. In addition, we have flexibly grown our workforce through the use of contractors and part-time workers. We may not be able to retain the services of such personnel, which might result in delays in the operation of our business.

Recruiting and retaining other qualified employees, consultants and advisors for our business, including scientific and technical personnel, also will be critical to our success. Competition for skilled personnel, clinical operations, regulatory affairs, therapeutic area management and manufacturing, is intense and the turnover rate can be high. We may not be able to attract and retain personnel on favorable terms given the competition among numerous pharmaceutical and biotechnology companies and academic institutions for individuals with similar skill sets. In addition, adverse publicity, failure to succeed in pre-clinical studies or clinical trials or applications for marketing approval may make it more challenging to recruit and retain qualified personnel. The inability to recruit, or loss of services of certain executives, key employees, consultants or advisors, may impede the progress of our research, development and commercialization objectives and have a material adverse impact on our business, financial condition, results of operations and prospects.

76

Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of our current or future product candidates.

We face an inherent risk of product liability exposure related to the testing of any of our current or future product candidates in clinical trials, and we may face an even greater risk if any products derived from our product candidates are commercialized. If we cannot successfully defend ourselves against claims that our product candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:

decreased demand for any product candidate that we may develop;
loss of revenue;
substantial monetary awards to patients, healthy volunteers or their children;
significant time and costs to defend the related litigation;
withdrawal of clinical trial participants;
the inability to commercialize any product candidates that we may develop; and
injury to our reputation and significant negative media attention.

We carry clinical trial insurance, including product liability insurance, which we believe to be sufficient in light of the status of our current clinical programs; however, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If and when any products derived from our product candidates obtain regulatory approval, we intend to expand our insurance coverage; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action lawsuits based on drugs or medical treatments that had unanticipated adverse effects. A successful product liability claim or series of claims brought against us could cause the price of the ADSs to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business.

If our products become subject to a product recall it could harm our reputation, business and financial results.

The FDA, the EMA and similar governmental authorities in other jurisdictions have the authority to require the recall of certain commercialized products. In the case of the FDA, the authority to require a recall of a biologic product must be based on an FDA finding that a batch, lot of other quantity of the biologic product presents an imminent or substantial hazard to the public health. For products developed using our AI platform technologies, a product recall may prevent other products derived from one or more of our product candidates using our AI platform technologies that target the same disease indication until we can demonstrate that the reason for any such product recall did not involve our technology. In addition, some governmental bodies outside the United States have the authority to require the recall of any product derived from one or more of our product candidates in the event of material deficiencies or defects in design or manufacture. Manufacturers may, under their own initiative, recall a product if any material deficiency in a product is found. A government-mandated or voluntary recall by us could occur as a result of manufacturing errors, design or labeling defects or other deficiencies and issues. Recalls of any of our product candidates would divert managerial and financial resources and have an adverse effect on our financial condition and results of operations. A recall announcement could harm our reputation with customers and negatively affect our sales, if any.

77

If we engage in future acquisitions, joint ventures, partnerships or collaborations, this may increase our capital requirements, dilute our shareholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks. We may not realize the benefits of these acquisitions, joint ventures or collaborations.

We may evaluate various acquisitions and collaborations, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any potential acquisition, joint venture, partnerships or collaboration may entail numerous risks, including:

increased operating expenses and cash requirements;
the assumption of additional indebtedness or contingent liabilities;
assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel;
the diversion of our management’s attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition;
retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships;
risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals; and
our inability to generate revenue from acquired technology or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.

In addition, if we undertake acquisitions, we may utilize our cash, issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense.

Moreover, we may not be able to locate suitable acquisition or collaboration opportunities and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business.

We may be adversely affected by global climate change or by legal, regulatory or market responses to such change.

Increasing stakeholder environmental, social and governance, or ESG, expectations, physical and transition risks associated with climate change, and emerging ESG regulation and policy requirements may pose risk to our market outlook, brand and reputation, financial outlook, cost of capital, global supply chain and production continuity, which may impact our ability to achieve our business objectives. Changes in environmental and climate change laws or regulations could lead to additional operational restrictions and compliance requirements upon us or our third -party providers or otherwise could negatively impact our business Physical impacts of climate change may drive increased costs to us and our suppliers and impact our continuity and data facilities.

Risks Related to Ownership of the ADSs

The price of the ADSs has been and may continue to be highly volatile and fluctuate substantially, which could result in substantial losses for purchasers of the ADSs who may not be able to resell the ADSs at or above the price they paid.

Since the closing of our IPO in February 2021 and our follow-on offering in November 2021, the market price of the ADSs has been and may continue to be highly volatile. The stock market in general, and the market for biopharmaceutical companies in particular, have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, ADS holders may not be able to resell the ADSs at or above the price they paid for our ADSs. The market price for the ADSs may be influenced by many factors, including, but not limited to:

results of our pre-clinical development and clinical trials of our product candidates or those of our competitors;

78

the success of existing competitive products or technologies or new competitive products or technologies that may emerge;
announcements by us or our competitors of commencement or termination of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments;
regulatory or legal developments in the United States and other countries;
developments or disputes concerning patent applications, issued patents, or other intellectual property or proprietary rights;
the recruitment or departure of key personnel;
issuances or sales of our ordinary shares or ADSs by us, our insiders or our other shareholders or holders of the ADSs;
the level of expenses related to any of our product candidates or clinical development programs;
the results of our efforts to discover, develop, acquire or in-license additional product candidates;
actual or anticipated changes in estimates as to financial condition, operating results, development timelines or issuance of new or updated research, reports or recommendations by securities analysts;
variations in our financial results or those of companies that are perceived to be similar to us;
announcement or expectation of additional debt or equity financing efforts;
currency fluctuations;
changes in the structure of healthcare payment systems;
market conditions in the pharmaceutical and biotechnology sectors;
general economic, industry and market conditions, including the disruption in the financial markets caused by the COVID-19 pandemic; and
the numerous programs in our pipeline, the development of which could each generate news or significant adverse events that could impact financial results or recommendations by securities analysts.

If our quarterly or annual results fall below the expectations of investors or securities analysts, the price of the ADSs could decline substantially. Furthermore, any such fluctuations in our results may, in turn, cause the price of the ADSs to fluctuate substantially. We believe that period-to-period comparisons of our results are not necessarily meaningful and should not be relied upon as an indication of our future performance. In the past, following periods of volatility in the market price of a company’s securities, securities class action litigation often has been instituted against that company. Such litigation, if instituted against us, could cause us to incur substantial costs to defend such claims and divert management’s attention and resources, which could seriously harm our business, financial condition, results of operations and prospects.

An active and liquid market for the ADSs and our ordinary shares may not be sustained, which could harm the market price of the ADSs.

Although the ADSs are listed on the Nasdaq Capital Market, an active trading market for the ADSs may not be sustained. In the absence of an active trading market for the ADSs, investors may not be able to sell their ADSs at the desired price or at the time that they would like to sell. In addition, the market price of the ADSs in our follow-on offering was based on the closing price of the ADSs at the time of such follow-on offering, there is no guarantee that such price will be free from challenge by our existing shareholders based on allegations that it does not reflect the “market price” at which we are required by our articles of association and Danish law to sell our ordinary shares. Any such shareholder challenge could be time consuming and costly and, if decided in a manner unfavorable to us, could result in liability to us and our directors, and could prevent any such offering from closing.

79

We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management has been and will continue to be required to devote substantial time to compliance initiatives. We are subject to financial reporting and other requirements for which our accounting and other management systems and resources may not be adequately prepared. We may fail to comply with the rules that apply to public companies, including Section 404 of the Sarbanes-Oxley Act, which could result in sanctions or other penalties that would harm the business.

As a public company, and particularly after we are no longer an “emerging growth company” as defined in the JOBS Act, we have incurred and will continue to incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, since becoming a public company as a result of our IPO in February 2021, the federal securities laws, including the Sarbanes-Oxley Act, and rules subsequently implemented by the SEC and The Nasdaq Stock Market LLC, or Nasdaq, have imposed various requirements on our company, including requirements to file annual and event-driven reports with respect to our business and financial condition, and to establish and maintain effective disclosure and financial controls and corporate governance practices. Our management and other personnel have devoted and will continue to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have increased and will continue to increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, these rules and regulations have made it more difficult and more expensive for us to obtain director and officer liability insurance. We may not be able to produce reliable financial statements or file these financial statements as part of a periodic report in a timely manner with the SEC or comply with Nasdaq listing requirements. In addition, we could make errors in our financial statements that could require us to restate our financial statements.

Pursuant to Section 404 of the Sarbanes-Oxley Act, or Section 404, we are required to furnish a report in connection with issuing our annual financial statements as of and for the year ending December 31, 2021 by our management on our internal control over financial reporting, and may be required to provide the attestation report on internal control over financial reporting issued by our independent registered public accounting firm. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm in our annual filings with the SEC. To achieve compliance with Section 404 within the prescribed period, we have been and will continue to be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants, and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented, and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section 404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.

In July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act. Recent legislation permits emerging growth companies to implement many of these requirements over a longer period and up to five years from the last day of the fiscal year following the fifth anniversary of the closing of our IPO in February 2021 (December 31, 2026). We intend to take advantage of this new legislation but cannot guarantee that we will not be required to implement these requirements sooner than budgeted or planned and thereby incur unexpected expenses. Shareholder activism, the current political environment, and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. Our management and other personnel have devoted and will continue to devote a substantial amount of time to these compliance initiatives.

We are an “emerging growth company” and the reduced disclosure requirements applicable to emerging growth companies may make our ordinary shares and the ADSs less attractive to investors.

We are an “emerging growth company” under the JOBS Act, and we will remain an emerging growth company until the earlier of:

the last day of the first fiscal year in which our annual gross revenues exceed $1.07 billion;
the date on which we have issued more than $1 billion in nonconvertible debt securities during the previous three years;

80

the date on which we are deemed to be a large accelerated filer under the rules of the SEC, which means the first day of the year following the first year in which, as of the last business day of our most recently completed second fiscal quarter, the market value of our common equity held by non-affiliates exceeds $700 million; and
the last day of the fiscal year following the fifth anniversary of the closing of our IPO (December 31, 2026).
For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to public companies that are not emerging growth companies. These exemptions include:
not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act;
not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements;
reduced disclosure obligations regarding executive compensation; and
exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.

We may choose to take advantage of some, but not all, of the available exemptions. We have taken advantage of reduced reporting burdens in this Form 20-F. In particular, we have not included all of the executive compensation information that would be required if we were not an emerging growth company. We cannot predict whether investors will find the ADSs less attractive if we rely on certain or all of these exemptions. If some investors find the ADSs less attractive as a result, there may be a less active trading market for the ADSs and the price per ADS may be more volatile.

In addition, the JOBS Act provides that an emerging growth company may take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. Such provisions are only applicable under U.S. GAAP. As a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required or permitted by the IASB.

81

As a “foreign private issuer,” we are exempt from a number of rules under the United States securities laws, as well as Nasdaq rules, and we are permitted to file less information with the SEC than are domestic United States issuers. This may limit the information available to holders of the ADSs and may make our ordinary shares and the ADSs less attractive to investors.

We qualify as a foreign private issuer. As a result, in accordance with the listing requirements of The Nasdaq Capital Market, we rely on home country governance requirements and certain exemptions thereunder rather than relying on the corporate governance requirements of The Nasdaq Capital Market. For instance, the Listing Rules for The Nasdaq Stock Market, or The Nasdaq Listing Rules, for domestic United States issuers require listed companies to have, among other things, a majority of their board members be independent, and to have independent director oversight of executive compensation, nomination of board members and corporate governance matters. As a foreign private issuer, however, while we intend to comply with these requirements, we are permitted to follow home country practice in lieu of the above requirements. Danish law does not require that a majority of our board consist of independent directors or the implementation of a remuneration committee or nominating and corporate governance committee, and our board may thus in the future not include, or include fewer, independent directors than would be required if we were subject to The Nasdaq Listing Rules, or they may decide that it is in our interest not to have a remuneration committee or nominating and corporate governance committee, or have such committees governed by practices that would not comply with Nasdaq Listing Rules. Since a majority of our board of directors may not consist of independent directors if we decide to rely on the foreign private issuer exemption to The Nasdaq Listing Rules, our board’s approach may, therefore, be different from that of a board with a majority of independent directors, and as a result, the management oversight of our company could, in the future, be more limited than if we were subject to the Nasdaq Listing Rules. We intend to follow home country practice with regard to, among other things, quorum requirements generally applicable to general meetings of shareholders.

Furthermore, Danish law does not have a regulatory regime for the solicitation of proxies and the solicitation of proxies is not a generally accepted business practice in Denmark, thus our practice varies from the requirement of Nasdaq Listing Rule 5620(b).

Due to the above exemptions for foreign private issuers, our shareholders will not be afforded the same protections or information generally available to investors holding shares in public companies organized in the United States, some investors may find the ADSs less attractive as a result, and there may be a less active trading market for the ADSs.

We qualify as a foreign private issuer and, as a result, we will not be subject to United States proxy rules and will be subject to Exchange Act reporting obligations that, to some extent, are more lenient and less frequent than those of a United States domestic public company.

We report under the Exchange Act, as a non-United States company with foreign private issuer status. Because we qualify as a foreign private issuer under the Exchange Act and although we are subject to Danish laws and regulations with regard to such matters and intend to furnish quarterly financial information to the SEC, we are exempt from certain provisions of the Exchange Act that are applicable to United States domestic public companies, including (i) the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act; (ii) the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and liability for insiders who profit from trades made in a short period of time; and (iii) the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q containing unaudited financial and other specified information, or current reports on Form 8-K, upon the occurrence of specified significant events. In addition, foreign private issuers are not required to file their annual report on Form 20-F until four months after the end of each fiscal year, while United States domestic issuers depending on their size are required to file their annual report on Form 10-K within 60 or 90 days after the end of each fiscal year. Foreign private issuers are also exempt from the Regulation Fair Disclosure, aimed at preventing issuers from making selective disclosures of material information. As a result of the above, our shareholders and the holders of the ADSs may not have the same protections afforded to shareholders of companies that are not foreign private issuers.

82

Our status as a “foreign private issuer” allows us to adopt IFRS accounting principles, which are different than accounting principles under U.S. GAAP.

We have adopted and presented our financial statements in accordance with IFRS as issued by the IASB. IFRS is an internationally recognized body of accounting principles that are used by many companies outside of the United States to prepare their financial statements; and the SEC recently permitted foreign private issuers such as our company to prepare and file their financial statements in accordance with IFRS rather than U.S. GAAP. IFRS accounting principles are different from those of U.S. GAAP, and SEC rules do not require us to provide a reconciliation of IFRS accounting principles to those of U.S. GAAP. Persons who are not familiar with IFRS may misunderstand certain information presented in our financial statements. Accordingly, we suggest that readers of our financial statements familiarize themselves with the provisions of IFRS accounting principles in order to better understand the differences between these two sets of principles.

We may lose our foreign private issuer status, which would then require us to comply with the Exchange Act’s domestic reporting regime and cause us to incur significant legal, accounting and other expenses.

We qualify as a foreign private issuer and therefore we are not required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable to United States domestic issuers. If we cease to be a foreign private issuer, which is measured as of the end of our second fiscal quarter in each fiscal year after the completion of our IPO, we will be required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable to United States domestic issuers as of January 1 of the following year. In order to maintain our current status as a foreign private issuer, either (a) a majority of our ordinary shares or ADSs must be either directly or indirectly owned of record by non-residents of the United States or (b)(i) a majority of our executive management or directors may not be United States citizens or residents, (ii) more than 50% of our assets cannot be located in the United States and (iii) our business must not be administered principally inside the United States. If we lost this status, we would be required to comply with the Exchange Act reporting and other requirements applicable to United States domestic issuers, which are more detailed and extensive than the requirements for foreign private issuers. We may also be required to make changes in our corporate governance practices in accordance with various SEC and Nasdaq rules. The regulatory and compliance costs to us under United States securities laws if we are required to comply with the reporting requirements applicable to a United States domestic issuer may be significantly higher than the cost we would incur as a foreign private issuer. As a result, we expect that a loss of foreign private issuer status would increase our legal and financial compliance costs and would make some activities highly time consuming and costly. We also expect that if we were required to comply with the rules and regulations applicable to United States domestic issuers, it would make it more difficult and expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These rules and regulations could also make it more difficult for us to attract and retain qualified members of our board of directors.

Holders of the ADSs may be subject to certain limitations on the transfer of the ADSs and the withdrawal of the underlying ordinary shares.

Our ADSs, which may be evidenced by American Depositary Receipts, or ADRs, are transferable on the books of the depositary. However, the depositary may close its books at any time or from time to time when it deems expedient in connection with the performance of its duties. The depositary may refuse to deliver, transfer or register transfers of the ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary think it is advisable to do so because of any requirement of law, government or governmental body, or under any provision of the deposit agreement, or for any other reason subject to a holder’s right to cancel the ADSs and withdraw the underlying ordinary shares. Temporary delays in the cancellation of the ADSs and withdrawal of the underlying ordinary shares may arise because the depositary has closed its transfer books or we have closed our transfer books, the transfer of ordinary shares is blocked to permit voting at a shareholders’ meeting or we are paying a dividend on our ordinary shares. In addition, holders of ADSs may not be able to cancel the ADSs and withdraw the underlying ordinary shares when such holder owes money for fees, taxes and similar charges and when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of ordinary shares or other deposited securities. See “Item 12D. Description of Securities Other than Equity Securities.”

83

A significant portion of our total outstanding ordinary shares may be sold in the near future. The large number of shares eligible for sale or subject to rights requiring us to register them for sale could cause the market price of the ADSs to drop significantly, even if our business is performing well.

Sales of a substantial number of ordinary shares or the ADSs could occur at any time. These sales, or the perception in the market that holders of a large number of shares intend to sell shares, could reduce the market price of the ADSs. We had 23,203,828 ordinary shares outstanding as of December 31, 2021.

On April 6, 2021, we filed a registration statement on Form S-8 under the Securities Act of 1933, as amended, or the Securities Act, to register a total of 4,808,076 ordinary shares, representing all ordinary shares issued or issuable under our equity incentive scheme pursuant to the Appendices to our Articles of Association. Such Form S-8 registration statement automatically became effective upon filing. Accordingly, shares registered under such registration statement are available for sale in the open market following the expiration of the applicable lock-up period.

As of December 31 2021, there were 2,732,618 warrants outstanding. If these warrants are exercised then an additional 2,732,618 ordinary shares will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules and Rule 144 and Rule 701 under the Securities Act. If these additional ordinary shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of the ADSs could decline. Any sales of securities by these security holders could have a negative effect on the trading price of our ordinary shares and ADSs. In addition, as of December 31, 2021, there were 351,036 warrants issued to EIB under the loan agreement with EIB, which are expected to be cash settled. For a more detailed description of the EIB warrants see the section herein entitled “Our EIB warrants.”

Additionally, on November 28, 2021, we entered into a Share Sale and Restriction Agreement with, Dr. Lars Staal Wegner, our Chief Executive Officer, Dr. Niels Iversen Møller our Co-Founder, Chief Business Officer and interim Chief Financial Officer and Andreas Mattsson, our Co-Founder and Chief Innovation Officer, pursuant to which Dr. Wegner agreed to exercise 211,849 warrants in each of the two week exercise windows established under our Articles of Association that are expected to open two trading days following publication of our annual report and interim quarterly financial reports in March 2022, May 2022, August 2022 and November 2022, respectively.

Under the terms of this agreement, Dr. Wegner, Dr. Møller and Mr. Mattson further agreed with us that in the corresponding open trading window related to each such exercise consisting of the four-week period commencing on the third full trading day after the date of publication of our annual report or interim financial reports in March 2022, May 2022, August 2022 and November 2022, each a Trading Window, Dr. Wegner would sell such Ordinary Shares and Dr. Møller and Mr. Mattson will purchase such ordinary shares, with each of Dr. Møller and Mr. Mattson purchasing fifty per cent (50%) of such shares, at a purchase price per share equal to the Volume Weighted Average Price, or VWAP, of our ADSs at the close of the market on the date of exercise as reported on Nasdaq.

Under the terms of the agreement, Dr. Møller and Mr. Mattson agreed that during each Trading Window each of them will sell 328,731 ADSs representing Ordinary Shares at a price equal to the prevailing market price thereof on the date of such sale as reported on Nasdaq. Furthermore, pursuant the terms of the agreement, Dr. Møller and Mr. Mattson are required to sell such shares and are prohibited from exercising any subsequent influence over how, when, or whether to effect the trade(s).

Sales of ADSs or our ordinary shares as restrictions end or pursuant to the above described agreement or pursuant to registration rights may make it more difficult for us to finance our operations through the sale of equity securities in the future at a time and at a price that we deem appropriate. These sales also could cause the trading price of the ADSs to fall and make it more difficult for holders of ADSs to sell the ADSs.

Holders of the ADSs are not treated as shareholders of our company and will not have the same voting rights as our shareholders, which may affect the value of the ADSs.

Holders of ADSs are not treated as our shareholders unless they withdraw the ordinary shares underlying the ADSs from the depositary, which is the holder of the ordinary shares underlying the ADSs. Holders of ADSs, therefore, do not have any rights as shareholders of our company, other than the rights that they have pursuant to the deposit agreement. As such, holders of ADSs will not be able to directly vote underlying ordinary shares. Holders of ADSs may instruct the depositary how to vote the ordinary shares underlying their ADSs. If we ask it to, the depositary will send out information about shareholder meetings and solicit voting instructions and will try to carry out voting instructions it receives. However, we are not required to instruct the depositary to take

84

action with respect to shareholder meetings. If we do not do so, holders of the ADSs can still send voting instructions to the depositary and the depositary may try to carry out those instructions, but it is not required to do so. Holders of the ADSs may not become aware of shareholder meetings if the depositary does not send out information. Even if the depositary does solicit voting instructions, holders of ADSs may not receive the information in time. As a result of these factors, holders of ADSs may not be able to effectively exercise voting rights that they would have if they held our ordinary shares directly.

If we issue new ordinary shares or sell ADSs in future financings, holders of ADSs may experience immediate dilution and, as a result, the price of the ADSs may decline.

We may from time-to-time issue additional ordinary shares or sell ADSs at a discount from the current trading price of our ordinary shares or ADSs. As a result, holders of ADSs could experience further immediate dilution upon the issuance of any ordinary shares or ADSs sold at such discount. In addition, as opportunities present themselves, we may enter into financing or similar arrangements in the future, including the issuance of debt securities, ordinary shares or ADSs. If we issue ordinary shares or securities convertible or exchangeable into ordinary shares, such as ADSs, holders of the ADSs could experience additional dilution and, as a result, the price of the ADSs may decline.

Raising additional capital may cause dilution to our existing shareholders, restrict our operations, or require us to relinquish rights to our technologies or product candidates.

We may seek additional capital through a combination of public and private equity offerings, debt financings, collaborations and licensing arrangements. To the extent that we raise additional capital through the sale of equity or debt securities, our existing shareholders’ ownership interest will be diluted and the terms may include liquidation or other preferences that adversely affect our existing shareholders’ rights as a holder of ADSs. The incurrence of indebtedness would result in increased fixed payment obligations and could involve restrictive covenants, such as imitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through collaborations and licensing arrangements with third parties or through asset sales, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms unfavorable to us.

Investors should be aware that the rights provided to our shareholders under Danish corporate law and our articles of association differ in certain respects from the rights that you would typically enjoy as a shareholder of a United States company under applicable United States federal and state laws.

Under Danish corporate law, except in certain limited circumstances (which require as a minimum that a proposal for inspection has been supported by a minimum of 25% of the shareholders voting and being present at a general meeting), our shareholders may not ask for an inspection of our corporate records, while under Delaware corporate law any shareholder, irrespective of the size of such shareholder’s shareholdings, may do so. Shareholders of a Danish limited liability company are also unable to initiate a derivative action, a remedy typically available to shareholders of United States companies, in order to enforce a right of our company, in case we fail to enforce such right ourselves, other than in certain cases of director/management liability under limited circumstances. In addition, a majority of our shareholders may release a director or manager from any claim of liability we may have, including if such director or manager has acted in bad faith, negligently or fraudulently. However, a shareholder may bring a derivative action on behalf of our company against, among other persons, a director or manager, provided that the circumstances of the act or omission giving rise to the claim of liability was not known to the shareholder at the time of such shareholder resolution, or if shareholders representing at least 10% of the share capital represented at the relevant general meeting have opposed such shareholder resolution. In contrast, most United States federal and state laws prohibit a company or its shareholders from releasing a director from liability altogether if such director has acted in bad faith or has breached such director’s duty of loyalty to our company. Additionally, distribution of dividends from Danish companies to foreign companies and individuals can be eligible for non-refundable withholding tax, and not all receiving countries allow for deduction. Also, the rights as a creditor may not be as strong under Danish insolvency law, as under United States law or other insolvency law, and consequently creditors may recover less in the event our company is subject to insolvency compared to a similar case including a United States debtor. In addition, the use of the tax asset consisting of the accumulated tax deficit requires that we are able to generate positive taxable income and can be restricted by future amendments to Danish tax law. Finally, Danish corporate law may not provide appraisal rights in the case of a business combination equivalent to those generally afforded a shareholder of a United States company under applicable United States laws. As a result of these differences between Danish corporate law and our articles of association, on the one hand, and United States federal and state laws, on the other hand, in certain instances, holders of the ADSs could receive less protection as an shareholder of our company than such holders would as a shareholder of a United States company.

85

Holders of our ordinary shares or ADSs may not be able to exercise their pre-emptive subscription rights and may suffer dilution of their shareholding in the event of future issuances of our ordinary shares.

Under the Danish Companies Act, our shareholders benefit from a pre-emptive subscription right on the issuance of ordinary shares for cash consideration only and not in the event of issuance of shares against non-cash contribution or debt conversion. Even the shareholders’ pre-emptive subscription rights in the event of issuances of shares against cash payment may be disapplied by a resolution of the shareholders at a general meeting of our shareholders and/or the shares or ADSs may be issued on the basis of an authorization granted to the board of directors pursuant to which the board may disapply the shareholders’ pre-emptive subscription rights. Such shares or ADSs may be issued at market value as well as by way of incorporation of available reserves (including premium). In addition, a shareholder may not be able to exercise the shareholder’s pre-emptive right on a timely basis or at all, unless the shareholder complies with the Danish Companies Act and applicable laws in the jurisdiction in which the shareholder is resident. Furthermore, the use of pre-emptive subscription rights in relation to future capital increases in our company can be restricted for United States residents according to United States securities law. As a result, the ownership interest of shareholders or ADS holders may be materially diluted in the event shares or ADSs are issued in the future. Shares or ADSs may be issued at a discount to market price in rights offerings provided that the resolution is approved by two-thirds of the votes cast and the share capital represented at the general meeting and in these cases a restriction on the ability to exercise pre-emptive rights may materially dilute the value of the ordinary shares or ADSs held by the shareholder or ADS holder in question.

Our shareholders have authorized our board of directors to issue securities, including in connection with (i) issues of new ordinary shares with preemptive rights for our existing shareholders at market price or at a discount price against cash payment, (ii) issues of new ordinary shares without preemptive rights for our existing shareholders at market price or at a discount price against cash payment, (iii) issues of warrants without preemptive rights for our existing shareholders at market price or at a discount price against cash payment, and (iv) issues of convertible bonds without preemptive rights for our existing shareholders at market price against cash payment. The absence of pre-emptive rights for existing shareholders may cause dilution to such holders.

However, holders of the ADSs in the United States will not be entitled to exercise or sell pre-emptive subscription rights related to their ordinary shares, unless we register the pre-emptive subscription rights and the securities to which the pre-emptive subscription rights relate under the Securities Act or an exemption from the registration requirements is available. In addition, the deposit agreement provides that the depositary will not make rights available to ADS holders unless both the rights and any related securities are either registered under the Securities Act or exempted from registration under the Securities Act.

Holders of ADSs may not receive distributions on our ordinary shares represented by the ADSs or any value for them.

If we offer holders of our ordinary shares the option to receive dividends in either cash or shares, under the deposit agreement the depositary may require satisfactory assurances from us that extending the offer to holders of ADSs does not require registration of any securities under the Securities Act before making the option available to holders of ADSs. We are under no obligation to file a registration statement with respect to any such rights or securities or to endeavor to cause such a registration statement to be declared effective. Moreover, we may not be able to establish an exemption from registration under the Securities Act. Accordingly, ADS holders may be unable to participate in our rights offerings or to elect to receive dividends in shares and may experience dilution in their holdings. In addition, if the depositary is unable to sell rights that are not exercised or not distributed or if the sale is not lawful or reasonably practicable, it will allow the rights to lapse, in which case ADS holders will receive no value for these rights.

86

United States holders of ADSs may suffer adverse tax consequences if we are characterized as a passive foreign investment company.

A non-United States corporation will be classified as a passive foreign investment company, or PFIC, for United States federal income tax purposes for any taxable year, if either (i) 75% or more of its gross income for such year consists of certain types of “passive” income or (ii) 50% or more of the value of its assets (determined on the basis of a quarterly average) during such year produce or are held for the production of passive income. Passive income generally includes dividends, interest, royalties, rents, annuities, net gains from the sale or exchange of property producing such income and net foreign currency gains. In addition, a non-United States corporation will be treated as owning its proportionate share of the assets and earning its proportionate share of the income of any other corporation in which it owns, directly or indirectly, more than 25% (by value) of the stock. We do not believe we were a PFIC for United States federal income tax purposes for the taxable year ended December 31, 2021. PFIC status is based on our income, assets and activities for the entire taxable year, which we expect may vary substantially over time, and therefore, it is not possible to determine whether we will be characterized as a PFIC for any taxable year until after the close of the applicable taxable year. Moreover, we must determine our PFIC status annually based on tests that are factual in nature, and our status for the taxable year ending December 31, 2022 and in future years will depend on our income, assets and activities in each of those years. There can be no assurance that we will not be considered a PFIC for any taxable year. If we were to be or become a PFIC for any taxable year during which a United States holder (defined below in “Taxation – Certain Material United States Federal Income Tax Considerations”) holds ADSs, certain adverse United States federal income tax consequences could apply to such United States holder. See “Taxation – Certain Material United States Federal Income Tax Considerations – Passive Foreign Investment Company Considerations.”

The Danish tax treatment of ADSs by the Danish tax authorities is uncertain.

The specific treatment of ADSs under Danish tax law is highly uncertain and not codified in law. The interpretation by the Danish tax authorities may have adverse effects on the taxation of investors. In the tax description contained herein we are assuming that the ADSs are to be treated as ordinary unlisted shares for Danish tax purposes. However, recent communications from the Danish tax authorities indicate that a holder of ADSs may not be treated as holding unlisted shares in the company for Danish tax purposes. In the event that the holders of ADSs are not treated as holding unlisted shares in the company, it is likely that they will be treated as either holding listed shares or financial instruments for Danish tax purposes, which will impact the Danish tax treatment of the ADS holders, including in respect of the taxation of dividends paid to ADS holders. Furthermore, the communications from the Danish tax authorities indicate if the holders of ADS are not treated as holders of shares in the Danish company, then the depository bank may be considered the holder of the ordinary shares in the company for Danish tax purposes.

Claims of United States civil liabilities may not be enforceable against us.

We are incorporated under the laws of Denmark. Substantially all of our assets are located outside the United States. A number of our directors and the majority of our officers and employees reside outside the United States. As a result, it may not be possible for investors to effect service of process within the United States upon such persons or to enforce against them or us in United States courts, including judgments predicated upon the civil liability provisions of the securities laws of the United States.

The United States and Denmark currently do not have a treaty providing for the reciprocal recognition and enforcement of judgments, other than arbitration awards, in civil and commercial matters. Consequently, a final judgment for payment given by a court in the United States, whether or not predicated solely upon United States securities laws, would not automatically be recognized or enforceable in Denmark. In order to obtain a judgment which is enforceable in Denmark, the party in whose favor a final and conclusive judgment of the United States court has been rendered will be required to file its claim with a court of competent jurisdiction in Denmark. Such party may submit to the Danish court the final judgment rendered by the United States court. If and to the extent that the Danish court finds that the jurisdiction of the United States court has been based on grounds which are internationally acceptable and that proper legal procedures have been observed, the Danish court should, in principle, give binding effect to the judgment of the United States court, unless such judgment contravenes principles of public policy of Denmark. Danish courts are likely to deny the recognition and enforcement of punitive damages or other awards. Moreover, a Danish court may reduce the amount of damages granted by a United States court and recognize damages only to the extent that they are necessary to compensate actual losses or damages. Enforcement and recognition of judgments of United States courts in Denmark are solely governed by the provisions of the Danish Administration of Justice Act.

87

Based on the lack of a treaty as described above, United States investors may not be able to enforce against us or members of our board of directors, our executive board, our executive management or certain experts named herein who are residents of Denmark or countries other than the United States any judgments obtained in United States courts in civil and commercial matters, including judgments under the United States federal securities laws.

We may fail to meet our publicly announced guidance or other expectations about our business, which could cause the market value of our ADSs to decline significantly.

We may provide from time to time guidance regarding our expected financial and business performance. Correctly identifying key factors affecting business conditions and predicting future events is inherently an uncertain process, and our guidance may not ultimately be accurate in all respects. Our guidance is based on certain assumptions, such as those relating to anticipated production and sales volumes, average sales prices, supplier and commodity costs, and planned cost reductions. If our guidance varies from actual results, the market value of the ADSs could decline significantly.

If securities analysts do not publish research or reports about our business or if they publish negative evaluations of the ADSs, the market price of the ADSs and their trading volume could decline.

The trading market for the ADSs will rely, in part, on the research and reports that securities or industry analysts publish about us or our business. If no or only limited securities or industry analysts cover our company, the trading price for the ADSs would be negatively impacted. If any of the analysts who cover us downgrades our equity securities or issues an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our clinical trials and operating results fail to meet the expectations of analysts, the market price of the ADSs would likely decline. If one or more of these analysts cease to cover the ADSs, or downgrades our securities, we could lose visibility in the market for the ADSs, which in turn could cause the market price of the ADSs to decline or their trading volume to decline.

Our principal shareholders and executive management own a significant percentage of our ordinary shares and will be able to exert significant control over matters subject to shareholder approval.

As of December 31, 2021, our executive management, directors, holders of 5% or more of our ordinary shares and their respective affiliates beneficially own 42% of our outstanding voting securities. As a result, these security holders will have the ability either alone or voting together as a group to determine and/or significantly influence the outcome of matters submitted to our shareholders for approval, including the election and removal of directors, payment of dividends, amendments to our articles of association, including changes to our share capital or any mergers, demergers, liquidations and similar transactions. This may prevent or discourage unsolicited acquisition proposals or offers for our ordinary shares or ADSs that holders of ADSs may feel are in their best interest as a holder of ADSs. In addition, this group of shareholders may have the ability to control our management and affairs. Such control and concentration of ownership may affect the market price of the ADSs and may discourage certain types of transactions, including those involving actual or potential change of control of us (whether through merger, consolidation, take-over or other business combination), which might otherwise have a positive effect on the market price of the ADSs.

We have broad discretion in the use of our cash, cash equivalents and investments, including the funds raised from our follow-on offering and our IPO, and we may not use them effectively.

Our management will have broad discretion in the application of our cash, cash equivalents and investments, including the funds raised from our follow-on offering and our IPO, and could spend these funds in ways that do not improve our results of operations or enhance the value of our ordinary shares. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse impact on our business, cause the market price of the ADSs to decline, and delay the development of our product candidates. Pending their use, we may invest our cash, cash equivalents and investments, including the funds raised from our follow-on offering and our IPO, in a manner that does not produce income or that loses value.

88

We may not have sufficient funds available to pay amounts due and owing European Investment Bank upon the exercise of certain warrants and may be required to use a portion of the proceeds from funds raised from the follow-on offering or our IPO to make such payments.

In August 2020, we executed a loan agreement, or the EIB Loan Agreement, with the European Investment Bank, or EIB, for a principal amount of €20.0 million, divided into three tranches of tranche 1 in the amount of €7.0 million, tranche 2 in the amount of €6.0 million and tranche 3 in the amount of €7.0 million, or the EIB Loan. Under the EIB Loan Agreement, the EIB Loan tranche balances are due six years from their respective disbursement dates. In connection with disbursement of each tranche, EIB is entitled to receive certain warrants, or the EIB Warrants. In November 2020, we initiated the process to receive the funds from the disbursement of tranche 1 of the EIB Loan in the aggregate amount of €7.0 million but due to the timing of the IPO we did not finalize a disbursement offer. In connection therewith, EIB received 351,036 EIB Warrants, which vested immediately, pursuant to the terms of a separate warrant agreement, or the EIB Warrant Agreement. As of December 31, 2021, we initiated the draw down of the first tranche of the EIB Loan Agreement amounting to €7.0 million. The Company received the first tranche of €7.0 million on February 17, 2022.

Under Article 18, Paragraph 2 of the Statute of the European Investment Bank, or the EIB Statute, establishing EIB, a direct equity investment by EIB requires a separate authorization from the EIB Board of Governors pursuant to which the EIB Board of Directors, acting by qualified majority, has to establish the terms and conditions of such direct equity investment. Under the EIB Statute, in the absence of a separate authorization from the EIB Board of Governors, commercial shareholdings financed from EIB’s own resources are not allowed. Since the EIB Loan is being made from EIB’s own resources, the EIB Statute does not allow EIB to acquire any of our ordinary shares, therefore, we fully expect that if and when EIB exercises the EIB Warrants, it will do so on either a net cash settlement basis at a price equal to the market price on the date of exercise thereof, or by means of exercising its right to cause us to purchase the EIB Warrants at a purchase price equal to the volume weighted average price per ordinary share, or VWAP, for a period of six months following the exercise of such Put Right. In the first six months following the completion of our IPO that occurred in February 2021, the VWAP price to be paid by us is calculated for the entire period from the completion of our IPO until the exercise of the Put Right. Since we fully expect the EIB Warrants to be cash settled, we do not expect them to affect our share capital at any time. However, since the amount of cash that we will need in order to meet our obligations to pay the amounts due and payable to EIB upon the exercise of the EIB Warrants is based on valuations to be determined in the future and, therefore, cannot be determined as of the date of this Form 20-F, we may not have sufficient funds on hand to pay such amounts in which case we may be required to use a portion of the funds raised from our follow-on offering and/or our IPO for such payments. For a more detailed discussion of the terms of the EIB Warrants see the section herein entitled “Description of Share Capital  –  Our EIB Warrants.”

Because we do not currently pay cash dividends on our ordinary shares and do not anticipate doing so in the foreseeable future, capital appreciation, if any, will be the sole source of gain on investments in the ADSs.

Currently, we do not have any plans to declare or pay cash dividends on our ordinary shares. Our intention is to retain all future earnings, if any, to finance the growth and development of the business. Additionally, the terms of any future debt agreements may preclude dividend payments. As a result, capital appreciation, if any, on the ADSs will be the sole source of gain for the foreseeable future.

You may be subject to limitations on surrenders of the ADSs and the withdrawal of the underlying shares.

Temporary delays in the cancellation of the ADSs and withdrawal of the underlying shares may arise because the depositary has closed its books or we have closed our transfer books, the transfer of shares is blocked to permit voting at a shareholders’ meeting or we are paying a dividend on our shares. In addition, you may not be able to cancel the ADSs and withdraw the underlying shares when you owe money for fees, taxes and similar charges and when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of shares or other deposited securities. See “Description of American Depositary Shares.”

We could be subject to securities class action litigation.

In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biopharmaceutical companies have experienced significant price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management’s attention and resources, which could harm our business.

89

ADS holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement or relating to our ordinary shares or the ADSs, which could result in less favorable outcomes to the plaintiffs in an action of that kind.

The deposit agreement governing the ADSs representing our ordinary shares provides that, to the fullest extent permitted by law, ADS holders waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our ordinary shares, the ADSs or the deposit agreement, including any claim under United States federal securities laws.

If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable based on the facts and circumstances of that case in accordance with the applicable state and federal law. To our knowledge, the enforceability of a contractual pre-dispute jury trial waiver in connection with claims arising under the federal securities laws has not been finally adjudicated by the United States Supreme Court. However, we believe that a contractual pre-dispute jury trial waiver provision is generally enforceable, including under the laws of the State of New York, which govern the deposit agreement, by a federal or state court in the City of New York, which has non-exclusive jurisdiction over matters arising under the deposit agreement. In determining whether to enforce a contractual pre-dispute jury trial waiver provision, courts will generally consider whether a party knowingly, intelligently and voluntarily waived the right to a jury trial. We believe that this is the case with respect to the deposit agreement and the ADSs. It is advisable that holders of ADSs consult legal counsel regarding the jury waiver provision before entering into the deposit agreement.

If you or any other ADS holders bring a claim against us or the depositary in connection with matters arising under the deposit agreement or relating to the ADSs, including claims under federal securities laws, you may not be entitled to a jury trial with respect to such claims, which may have the effect of limiting and discouraging lawsuits against us or the depositary. If a lawsuit is brought against us or the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court, which would be conducted according to different civil procedures and may result in different outcomes than a trial by jury would have had, including results that could be less favorable to the plaintiffs in that action.

Nevertheless, if this jury trial waiver provision is not permitted by applicable law, an action could proceed under the terms of the deposit agreement with a jury trial.

No condition, stipulation or provision of the deposit agreement or the ADSs serves as a waiver by any ADS holder or by us or the depositary of compliance with any substantive provision of the United States federal securities laws and the rules and regulations promulgated thereunder.

Item 4.Information on the Company

4.A. Business Overview

General

We are a clinical-stage AI-immunology™ platform company using our proprietary artificial intelligence, or AI, technology, engineering expertise and drug development know-how to simulate the human immune system and generate predictive models to identify and develop novel immunotherapies for the treatment of various cancers, bacterial diseases and viral infections. Drug discovery and clinical development using historically prevailing techniques is a long, costly process with a high attrition rate. We believe our proprietary AI-immunology platforms, trained to translate vast amounts of data into a deep understanding of biological processes in the human body, can be harnessed to rapidly and cost effectively design and develop unique immunotherapies, thereby potentially revolutionizing the process of drug discovery and development. In an effort to validate the predictive power and scalability of our AI platforms, we have identified and are developing a pipeline of clinical product candidates initially focused in the areas of immuno-oncology and infectious disease. We are currently in the clinic with our two lead product candidates, EVX-01 and EVX-02, for the treatment of various cancers.

90

Our AI Platforms

Our four proprietary AI platforms include (i) PIONEER™, our immuno-oncology platform, (ii) EDEN™, our bacterial disease platform, (iii) RAVEN™, our viral disease platform, and (iv) AI-DeeP™, our newly developed immuno-oncology platform for prediction of drug response. Currently, we are focused on using PIONEER for the development of patient-specific immunotherapies for various cancers and using EDEN to develop vaccines against bacterial diseases. We plan to use our RAVEN platform to discover and develop vaccines against future coronaviruses as well as other viral infections. We intend to use AI-DeeP to determine which patients may benefit from cancer immunotherapies. We may, in the future, develop additional platforms to address other conditions known to have a large immunological component, examples of which could include autoimmune diseases, microbiome dysbiosis, allergies and parasites.

Graphic

Figure 1. Present (orange) and potential future (blue) AI platforms based on Evaxion’s AI-Immunology core.

Using the powerful AI technology of our PIONEER and EDEN platforms, we are currently developing four product candidates: EVX-01, for the treatment of advanced or metastatic unresectable melanoma; EVX-02, for adjuvant treatment of resectable melanoma; EVX-03, for multiple cancer indications; and EVX-B1, a vaccine for the prevention of S. aureus (including methicillin-resistant S. aureus, or MRSA, induced skin and soft tissue infections, or SSTI. Upon completion of successful Phase 2b, proof-of-concept, or PoC, trials, we plan to monetize our product candidates via out-licensing arrangements with pharmaceutical partners. We believe this scalable strategy will allow us to capture value from both the predictive power of our proprietary AI technology platforms and their ability to accelerate drug development.

The immune system is generally considered nature’s strongest weapon to fight disease. When the immune system is engaged, people are often able to entirely eliminate a disease or infection from the body. Using our deep understanding of the human immune system and our proprietary AI technology, we are able to mimic the human immune system in silico and predict whether the body will have an immune response to certain stimuli. Our predictive power relies on our ability to process and interpret vast amounts of data, a process known as computational immunology. Using our in silico AI models, we are able to transform such data into advanced algorithms that we believe can accurately predict cellular interactions within the immune system and identify the right targets that will stimulate a relevant response. To translate the identified targets into product candidates, we test multiple delivery modalities and move the most promising forward. We believe this process allows us to discover new product candidates and move them into the clinic without expending time and resources on clinical development of product candidates that may ultimately fail to produce a therapeutic or prophylactic response.

91

Our Proprietary Platforms and Product Pipeline

In order to validate the predictive ability of our platforms, combined with our multiple delivery modality approach, we are developing the following pipeline of drug candidates:

Timeline

Description automatically generated

Figure 2: Our current product development pipeline.

Our first lead product candidate developed using our PIONEER platform, EVX-01, is a novel liposomal, peptide-based cancer immunotherapy designed to engage a patient’s own immune system to fight various cancers by mounting a targeted response against tumors. EVX-01 is administered in combination with PD1/ PD-L1 checkpoint inhibitor, or CPI. In July 2021, we announced initial data readout from our Phase 1/2a clinical trial of EVX-01 in advanced or metastatic unresectable melanoma demonstrating an overall response rate, or ORR, of 67% across all nine patients compared with a historical ORR of 40% with anti-PD-1 treatment alone. The study also demonstrated a complete response, or CR, of 22%, compared with a historical CR of 7% with anti-PD-1 treatment alone. Among the four patients on the highest two doses, there was an ORR of 75%. Three patients with stable disease, or SD, for 10, eight and nine months on anti-PD-1 treatment alone, achieved CR, CR and partial response, or PR, respectively, following EVX-01 administration. In addition, the data showed induction of neoepitope-specific T cells in 100% of patients. 76.2% of the administered neoepitopes induced reactive T cells in patients, of which 83.3% were de novo responses.

The results also demonstrated that our recently introduced, novel proprietary AI-Immunogenetic Drug Response Platform, or AI-DeeP, which seeks to infer which patients benefit from our cancer immunotherapies based on immunogenetic expression signatures in the tumor microenvironment, is able to identify patients responding to therapy with high precision.

Based on our Phase 1/2a clinical trial initial data readout,on October 21, 2021, we entered into Clinical Trial Collaboration and Supply Agreement, or the Merck CTCSA, with MSD International GmbH and MSD International Business GmbH, subsidiaries of Merck & Co., Inc., (known collectively as MSD outside the United States and Canada), or MSD, to evaluate in a new Phase 2b clinical trial, the combination of our patient-specific neoepitope cancer immunotherapy compound, EVX- 01,with MSD’s anti-PD-1 therapy KEYTRUDA ® (pembrolizumab) compound, a humanized anti-human PD-1 monoclonal antibody.

We will act as the sponsor of the clinical trial under our own IND with the right of reference to the IND of MSD’s compound. The planned multi-center Phase 2b clinical trial will enroll patients with Stage III and IV advanced or metastatic unresectable melanoma and will investigate EVX-01 in combination with KEYTRUDA®. Under terms of the Merck CTCSA, we will be responsible for the conduct of the study. MSD will be responsible for the supply of all of the necessary KEYTRUDA® and we will continue to collaborate with MSD as the data mature.

92

We will own all data (including raw data) and results generated from the clinical trial other than data related to Sample Testing Results, Joint Clinical Data or MSD Clinical Data, as those terms are defined in the Merck CTCSA, a copy of which is filed as Exhibit 99.2 to Form 6-K filed with the SEC on October 25, 2021.

Under the terms of the Merck CTCSA, MSD may terminate the agreement in the event it believes that its compound is being used unsafely. Either we or MSD may terminate the agreement if either of us determines (i) that there has been a material breach thereof by the other party, (ii) that the clinical trial may adversely affect patient safety or (iii) to withdraw the development of its compound for medical, scientific or legal reasons. In addition, either we or MSD may terminate the agreement if any regulatory authority takes any action or raises any objection that prevents the terminating party from supplying its compound.

In January 2022, we received regulatory clearance from the Australia Therapeutic Goods Administration, or the TGA, to initiate a Phase 2b clinical trial of our lead product candidate EVX-01 in combination with KEYTRUDA® for the treatment of melanoma. We expect to initiate our Phase 2b clinical trial in the first half of 2022.

Our second lead product candidate developed using our PIONEER platform, EVX-02, is a novel, DNA-based cancer immunotherapy designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma, administered in combination with PD-1 CPI.

In July 2021, we announced preliminary data readout from our Phase 1/2a adjuvant clinical trial of EVX-02 in resectable melanoma demonstrating activation of neoepitope-specific T cells with tumor killing potential. In addition, EVX-02 appeared to be well-tolerated. As of December 31, 2021, 16 patients were recruited to the trial. In March 2022, we reported completion of recruitment of Part 1 of the EVX-02 Phase 1/2a clinical trial.

We believe that the preliminary clinical immune and safety data from the Phase 1/2a clinical trial together with pre-clinical data from both our DNA-based patient-specific cancer immunotherapies, EVX-02 and EVX-03, support moving this candidate into a combined EVX-02/EVX-03 Phase 2b clinical trial. We intend to submit a regulatory filing in the first half of 2022.

Our third lead product candidate developed using our PIONEER platform, EVX-03, is a novel, DNA-based cancer immunotherapy with an antigen presenting cell, or APC, targeting, proprietary unit intended for the treatment of multiple cancers. EVX-03 is in late pre-clinical development. Data from ongoing pre-clinical studies has shown high levels of neoepitope-reactive T cells. We intend to submit a regulatory filing for initiation of a combined Phase 2b clinical trial of our DNA-based cancer immunotherapies, EVX-02 and EVX-03, in the first half of 2022.

For each cancer immunotherapy derived from our PIONEER platform, we have selected the optimal delivery modality to maximize its potential antitumor effect. We are screening and testing a variety of modalities including but not limited to peptides, DNA and mRNA for their ability to elicit an active antitumor effect and T-cell response. Data readouts from our standardized pre-clinical models allow us to select those modalities which we believe will exert the most active antitumor effect in patients. In addition, we also screen and ultimately select different modalities for their speed and cost of manufacturing ensuring they allow for rapid development and large-scale production of our cancer immunotherapies. We believe utilizing this strategy, will provide an advantage as our success with patient-specific cancer immunotherapies does not depend on one single modality.

Additionally, using our EDEN platform, we are developing EVX-B1, a prophylactic multi-component subunit vaccine initially in development for the prevention of S. aureus induced SSTI in patients undergoing elective abdominal hernia surgery. EVX-B1 includes two proprietary and highly protective antigens identified by EDEN in combination with our proprietary chimeric toxin, formulated with a potent adjuvant system. We believe that the predictive power of EDEN and our unique approach to vaccine design may lead to a more effective and highly protective vaccine. EVX-B1 is in late pre-clinical development and we intend to submit a regulatory filing for initiation of our clinical trial in the second half of 2022. We also plan to select our second bacterial product candidate in the first half of 2022.

93

Graphic

Figure 3: Anticipated key milestones 2022-2025.

Our Strengths

Our fully AI-based approach enables us to discover and develop immunotherapies with unique targets, which we believe may translate into a higher likelihood of clinical success.
Our fully AI-based approach enables us to discover and develop immunotherapies more rapidly when compared to other standard approaches.
Our unique ability to generate and leverage biologically relevant data that enables the continuous development of our AI-immunology platforms with enhanced predictive power, which we believe may translate into a higher likelihood of clinical success.
Our model for iterative training provides continuous improvement of our AI platforms as data is generated throughout the development stages.
Our model for screening and testing different delivery modalities that we believe will allow us to potentially develop a broad portfolio of product candidates.
Our ability to rapidly move from target identification to clinical development. We expect that we will be able to speed up the time from target identification to clinical development. For our EVX-02 program, we demonstrated our ability to do so in just 18 months. However, there is no guarantee that we will be able to identify potential product candidates in this time frame in the future.
Our portfolio of product candidates that target large patient populations.
Our AI-immunology technology that enables a high level of scalability, offering the potential to expand our portfolio of product candidates as well as our proprietary AI-immunology platforms.

Our Strategy

Validate the predictive ability of our four proprietary AI-immunology platforms by developing our current pipeline of product candidates through successful Phase 2b PoC. To demonstrate that our AI platform derived product

94

candidates translate into clinical effect, we plan to take at least one product candidate from each platform through clinical PoC. Upon receipt of platform validation, we plan to expand our product portfolio within each platform.
Rapidly advance our three lead product candidates, EVX-01, EVX-02 and EVX-03, derived from our PIONEER platform through completion of Phase 2b PoC trials. In July 2021, we announced data from our EVX-01 Phase 1/2a clinical trial and interim data from our EVX-02 Phase 1/2a clinical trial. We intend to initiate a Phase 2b clinical trial for EVX-01 in the first half of 2022 and a Phase 2b clinical trial for EVX-02 in combination with EVX-03 in the first half of 2022. We believe a positive readout in these planned Phase 2b trials will provide us with validation of our lead product candidates as well as our PIONEER platform technology and overall AI-immunology platform approaches.
Leverage our clinical collaboration with MSD to advance our EVX-01 lead product candidate into Phase 2b clinical trials in combination with KEYTRUDA. We recently entered into the Merck CTCSA and are planning to conduct a multicenter Phase 2b clinical trial in patients with Stage III and IV advanced or metastatic unresectable melanoma to investigate EVX-01 in combination with KEYTRUDA, MSD’s anti-PD-1 therapy in the first half of 2022. Under terms of the Merck CTCSA, we will be responsible for the conduct of the study, and MSD will supply all of the necessary KEYTRUDA® and will continue to collaborate as the data mature.
Pursue out-licensing arrangements for late-stage clinical development with pharmaceutical partners for our lead product candidates to advance them toward regulatory approvals and allow us to monetize the development of our product candidates. We plan to out-license on a non-exclusive basis the PIONEER platform, while specific delivery modalities will carry exclusivity for one or more cancer indications. The PIONEER platform will remain in our full control. We also plan to out-license our EDEN derived product candidates. We retain all rights to our core AI-immunology technology and platforms for future product candidate development and platform enhancements.
Progress additional pipeline candidates developed with our PIONEER, EDEN and RAVEN platforms into the clinic and through Phase 2b trials, and then pursue out-licensing arrangements. After progressing our lead product candidates through Phase 2b, we plan to move EVX-B1 from our EDEN platform, into the clinic and through Phase 2b PoC trials. We will then focus our attention on our earlier stage programs, including selection of our next bacterial and viral targets.

Become a world leader in AI-immunology, translating our platforms into products.
oWith our PIONEER platform, we plan to develop our pipeline with the use of new delivery modalities. To create our patient-specific cancer immunotherapies, we develop or in-license delivery modalities we believe have the ability to induce antitumor effect of PIONEER predicted neoepitopes. We progress the most promising modality candidates tested in the pre-clinical setting into our clinical pipeline. In addition, this enables us to mitigate the uncertainty of the antitumor effect of different delivery modalities.
oWith our EDEN platform, we plan to progress additional bacterial product candidates through pre-clinical and clinical development. We have already demonstrated in vivo protection and filed patent applications for vaccine antigens identified by EDEN for seven different bacterial pathogens, of which the majority have been classified as public health threats by the United States Centers for Disease Control and Prevention, or CDC. We believe EDEN can be applied for the development of multiple bacterial product candidates in the future.
oWith our RAVEN platform, we plan to develop vaccine product candidates for the use against future coronaviruses as well as other viruses. Initially, we intend to develop our RAVEN platform as a response platform with the ability to rapidly develop and produce a vaccine candidate against the next coronavirus. We also plan to expand the platform to target other viruses such as human respiratory syncytial virus, cytomegalovirus and influenza.
Continue to invest in our PIONEER, EDEN, RAVEN and AI-DeeP platforms.
oFurther refine and strengthen the predictive performance of our existing AI platforms. Through machine learning and new immunological data generation, we are continuously working to improve the predictive power of

95

our in silico AI models incorporated in our AI-immunology technology. With each major iteration of our PIONEER platform, we have demonstrated significant improvement in its predictive power which has led to stronger antitumor effect in pre-clinical models. We believe this speed with which we are able to train and improve our platforms provides us with a clear advantage over our competition.
oGenerate and utilize new data to improve our platform performance. We generate new, proprietary data to support the continuous development and increase the performance of our platforms. We also develop new methodologies for data generation such as unique mass spectrometry methodologies. Furthermore, we are utilizing and will continue to use our clinical data from our ongoing trials to improve our platforms.
oDevelop new AI platforms to allow us to target indications beyond cancer, bacterial disease and viral infections. We are continuously exploring new frontiers in AI-immunology, including evaluating new therapeutic areas where our know-how and technologies can make a difference such as autoimmune diseases, allergies, microbiome dysbiosis and parasites. We are continuously monitoring the technologies and medical development in such therapeutic areas for timely launch of new AI platforms applicable to such areas.
Continue to grow and develop the best talent within AI-immunology. By bringing together leading experts within AI and immunology, our goal is to invest in our team to realize their full potential and maximize their expertise. We intend to further strengthen our leadership position by collaborating closely with leading academic institutions and advisors to share and develop new capabilities that are critical to our ability to develop and maintain proprietary AI platforms.
Secure and maintain a strong IP portfolio. We have developed a strong IP portfolio, pursuing different strategies for our immuno-oncology and infectious diseases products, to ensure the exclusive rights to all our lead product candidates and protect our proprietary AI technology as well as to support best the possible commercialization outcomes. We intend to keep all IP rights with respect to a product candidate until end of Phase 2b and out-licensing of the product candidate. We will retain all IP rights to our AI platforms. We currently have 14 issued patents, one allowed and 45 pending patent applications.

Our Management Team

We believe that our fully AI-driven approach and our portfolio of AI platforms places us at the forefront of effectively translating the immune system into novel drug candidates that trigger the immune system to treat a variety of diseases. To deliver on our objectives, we have built an experienced and broadly skilled management team. Our Chief Executive Officer, Lars Staal Wegner, M.D., joined us in August 2017. He served as part of the Senior Management team, leading all commercial and medical affairs efforts at Bavarian Nordic A/S, a NASDAQ Copenhagen listed biotech company, for 10 years prior to joining our company. Prior to that, Dr. Wegner worked in oncology at Pfizer Inc. and served as a clinician at public institutions. On October 15, 2021, our then Chief Financial Officer, Glenn S. Vraniak, informed us that he would be leaving to pursue opportunities outside the biopharmaceutical industry effective on November 1, 2021. Prior to joining us, Mr. Vraniak had served as Chief Financial Officer of electroCore, Inc., a US publicly traded company, from August 2016 until April 2019. As of November 1, 2021, our Co-Founder and Chief Business Officer, Niels Iversen Møller, M.D., replaced Mr. Vraniak, and since that time has acted as our Interim Chief Financial Officer. Prior to founding our company, from our inception in 2008 until August 2017, Dr. Møller was our Chief Executive Officer. Dr. Møller received his M.D. from the University of Copenhagen and his BA in Economics from Copenhagen Business School. Dr. Møller has also held positions as Medical Director at Medical Prognosis, a bioinformatic company, and as Medical Advisor on new oncology product development at AstraZeneca PLC. Erik Deichmann Heegaard, Ph.D., DMSc, joined us in April 2021 as our Chief Medical Officer. Dr. Heegaard has more than 25 years of experience within oncology and infectious diseases. Prior to joining us, Dr. Heegaard served as Head of Medical at Novartis Oncology, Nordics, and as Chief Medical Officer of the oral GLP-1 project at Novo Nordisk where he successfully completed Phase 1 and 2 clinical trials for the project and served as chief architect of the global Phase 3 clinical development program for the project. Prior to that, Dr. Heegaard held numerous research and clinical positions in companies such as Sandia National Laboratories, Bavarian Nordic and Statens Serum Institut. Our other Co-Founder and Chief Innovation Officer, Andreas Holm Mattsson, is a pioneer within in silico development, having already initiated the framework of our proprietary AI platforms while enrolled in academic studies, and eventually inventing the EDEN platform. Our Chief Scientific Officer, Birgitte Rønø, Ph.D., joined us in September 2017. Dr Rønø has more than 15 years’ experience in biopharmaceutical drug discovery from academia and industry. Prior to joining Evaxion, Dr. Rønø served as a specialist, team leader and project manager at Novo Nordisk, from 2013-2017, where she was leading early drug discovery projects, evaluating in-licensing opportunities, and supporting drug development projects with pre-clinical and biomarker expertise.

96

Jesper Nyegaard Nissen, MSc joined us in March 2022 as our Chief Operating Officer pursuant to the terms of his Service Agreement entered into on January 16, 2022. Mr. Nissen has more than 25 years of experience in the pharmaceutical industry across finance, investments, research and development. Mr. Nissen began his career in Novo Nordisk Corporate Finance being responsible for development of controlling and performance management processes followed by the role as finance responsible for different corporate business areas. In 2020, Mr. Nissen moved into senior leadership roles as Vice President / and later as Corporate Vice President within for Global Research Operations with the focus on research and development and strategic and operational development, which included the responsibilities for clinical sourcing, development IT strategies, establishment of development shared service center in India, application of real world evidence, orRWE and health economics related to clinical trials, development of research strategies, research portfolio governance, operation of global research sites, design and operation of external research engagement models among others. Since January 2021 until joining us, Mr. Nissen has worked for Fujifilm Diosynth Biotechnologies in the program management team for large scale capital projects driving Fujifilm Diosynth Biotechnologies mission to become a global leader within contract development and manufacturing orgsanizations, or CDMOs. Mr. Nissen received his MSc Business Economics (Cand. Oecon.) from the University of Aarhus, Denmark.

On March 14, 2022, we announced that Bo Karmark would join us as our Chief Financial Officer. Mr. Karmark is an experienced financial executive with a career spanning more than 25 years working for several multinational listed companies, primarily in the biotech, pharma, and bioscience industries. Before joining us, he served as the Chief Financial Officer for Aquaporin A/S, a water technology company, for the past seven years. Aquaporin is listed on the Nasdaq Copenhagen stock exchange. Before that, Mr. Karmark held numerous financial management positions at various companies including Chr Hansen Holding A/S, H. Lundbeck A/S, and NsGene A/S. Mr. Karmark received his M.Sc. in Business Administration and Auditing form the Copenhagen Business School, Denmark.

Background on Cancer Immunotherapy and the Role of Neoepitopes

The immune system is our body’s natural defense system that protects us against infection and diseases. It keeps track of all of the substances normally found in the body and raises an alarm if an unfamiliar substance is found, launching an attack against it. However, cancer cells can present a more challenging target for the immune system. Cancer cells are altered normal cells and therefore the immune system doesn’t always recognize them as foreign. In fact, cancer cells possess several mechanisms through which they escape immune surveillance as they:

Harbor genetic changes that make them less visible to the immune system
Express proteins on their cell surface that inhibit immune cell effector functions
Induce changes in the normal cells around the tumor thus interfering with how the immune system responds to the cancer cells

To overcome this, immunotherapies use different ways to seek the power of the patient’s own immune system to fight cancerous cells. The regulatory approval of immune CPIs has been a major breakthrough in treatment of patients suffering from advanced solid tumor cancers by demonstrating beneficial clinical responses, durable disease control and improved survival in subsets of patients. Detailed mapping of the underlying mechanisms has revealed that the CPI-induced antitumor effect is associated with the patient’s ability to mount a tumor-specific T-cell response. To further improve clinical efficacy, different co-targeting strategies are currently being explored, including the combination of CPI and T-cell immunotherapies capable of directing and improving the patients’ immune response specifically towards essential functions in the cancer cells.

The Role of T Cells in Cancer Immunotherapy

T cells are a type of white blood cell that play a central role in the immune system. T cells are involved in both detecting and killing infected or abnormal cells, such as cancer cells, as well as coordinating immune responses. T cells can be classified into two major subsets, CD4+ T cells and CD8+ T cells, each possessing different functionalities. CD8+ T cells are considered the main effectors in T-cell mediated tumor killing, however, several reports have highlighted the importance of inducing both CD4+ and CD8+ T cells as T helper 1, or Th1, CD4+ T cells support CD8+ T cells priming as well as promote the desired effects via secretion of effector cytokines.

97

T cells recognize cancer cells using T-cell receptors, or TCRs, that interact with specific immune targets, or epitopes, presented by a molecular structure on the surface of cells known as the major histocompatibility complex, or MHC. The MHC molecules bind to peptides from protein degradation inside the cell before being transported to the cell surface to present the peptide to TCRs. If a peptide bound to the MHC molecule is recognized by T cells, it is called an epitope. There are two classes of MHC molecules, class I and class II, that activate CD8+ and CD4+ T cells, respectively. In humans, MHC is encoded by the genes of the HLA locus. HLA genes show high allelic variation, resulting in MHC molecules that have different peptide binding preferences. Each person expresses a unique combination of molecularly distinct class I and class II MHC molecules that bind a specific set of peptides and epitopes.

Mutated genes in cancer cells lead to expression of altered proteins which are, like all proteins, processed by the cellular machinery into protein fragments known as peptides. When these mutated peptides are presented on MHC molecules, by either tumor cells or antigen presenting cells, and recognized by T cells, they are known as neoepitopes.

The immune system refrains from targeting the body’s own healthy cells principally through processes known as central and peripheral tolerance, by which T cells are educated not to respond to MHCs displaying peptides from normal proteins and therefore avoid targeting normal cells for destruction. The TCR-peptide-MHC interaction is a vital immune mechanism that allows the body both to respond against threats, including cancer, as well as to avoid targeting the body’s own healthy cells. Understanding the interactions between TCRs, peptides and specific MHC alleles is critical to directing and activating an immune response to cancer.

Neoepitope-Based Cancer Immunotherapies

The common feature of cancer is accumulation of mutations in the genes, which manifests as tumors with uncontrolled growth. Cancer is a complex, extremely heterogeneous condition. Despite this complexity and variability, patients with the same type and stage of cancer have historically been administered the same treatment. This approach has been altered in recent years with the introduction of precision medicine cancer immunotherapies, a tailored approach for selecting therapy at the individual patient level based on the genetic makeup of a patient’s cancer. Discovery of molecular cancer biomarkers (i.e. cancer oncogenes) has paved the way for the first generation of personalized therapies. Genomic screening approaches have been commonly employed to identify tumor-specific, overexpressed proteins or genetic mutations that may confer targets for an effective cancer immunotherapy.

We believe a truly personalized, or patient-specific approach, incorporating the entirety of the tumor ecosystem, while taking a more unbiased approach to drug design, is required to advert the inherent complexities of the tumor microenvironment and heterogeneous cellular landscape, and to improve the clinical outcome of cancer immunotherapies. We believe such approach can be achieved by directing immunotherapies towards cancer-exclusive peptide sequences, so called neoepitopes, displayed on the surface of tumor cell originating from patient-specific mutations. Neoepitope-targeting immunotherapies have shown great promise in pre-clinical animal models as well as in early clinical trials.

Neoepitopes provide an avenue for tumor-specific immune cell recognition, a prerequisite for a beneficial clinical response of a neoepitope-based immunotherapy. Antigen presenting cells, or APCs, educate the immune system by presenting neoepitopes to T cells. Tumor cells can also present neoepitopes on their cell surface, providing accessible targets for T cells. T cells recognize and kill neoepitope-presenting cancer cells and effect a positive feedback loop to heighten and broaden the cancer specific immune response as more epitopes will be available for APC uptake upon T-cell mediated tumor cell lysis.

Once patient-specific neoepitopes are administered to the patient, APCs will process the neoepitopes by the MHC epitope presentation machinery, migrate to the lymph node and present neoepitopes to T cells. TCRs on circulating CD4+ and CD8+ T cells bind to the presented neoepitopes triggering initial T-cell activation. Once activated, the T cells will enter the circulation to reach distant organs, including the tumor. In the tumor, reactive T cells will encounter tumor cell surface displayed neoepitopes, resulting in T cell mediated tumor cell killing.

Cancer patients normally do not have a meaningful numbers of T cells that recognize their tumor. We believe a neoepitope-targeting approach will generate a strong, de novo tumor-specific T-cell response which will lead to killing of tumor cells and thereby an improved clinical response. Further, we believe such approach has great therapeutic potential because neoepitopes represent foreign elements to the immune system and are unique to each person’s tumor cells which means neither self-tolerance nor adverse side effects are likely to limit the clinical application of a neoepitope-based immunotherapy.

98

We believe our truly patient-specific approach targeting neoepitopes will allow us to harness the natural power of a patient’s own immune system to elicit a strong, cancer-specific immune response, potentially holding the key to long-lasting tumor control or even universal cure for many cancer patients.

PIONEER – Our AI Platform for the Discovery of Novel, Patient-Specific Immuno-Oncology Therapies

Overview

PIONEER is our proprietary AI platform for the rapid discovery and design of patient-specific neoepitopes used to derive immuno-oncology therapies. Our proprietary in silico AI models within PIONEER, for the prediction of T-cell activation, allow us to efficiently identify and select those neoepitopes that we believe are most likely to generate a strong, de novo T-cell response leading to significant antitumor effect in each patient. The goal of our PIONEER derived immunotherapies is to deliver therapeutic neoepitopes to patients in a way that trains the patients’ own immune system to target and kill tumor cells with no or very limited adverse effects on healthy non-cancer cells. As shown in Figure 4 below, PIONEER simulates the key biological steps in presenting each neoepitope to the patient’s immune system with our high-performance, AI-based in silico models.

Graphic

Figure 4: Illustration of mechanisms within the tumor cell that are required for a neoepitope to have a clinical effect in patients.

Key biological steps simulated by PIONEER Include:

Step 1 – Mutation: PIONEER identifies cancer-specific mutations by comparing DNA sequencing data from the tumor sample(s) and normal tissue sample using our proprietary AI-based somatic variant caller.

Step 2 – Expression: Only a subset of the cancer-specific mutations is found in genes that are expressed in the tumor cells. The expression levels of each gene are determined by analyzing tumor RNA sequencing data. In addition, PIONEER calculates the mutation-specific expression levels using an in-house developed computational model.

Step 3 – Translation: Not all cancer-specific mutations result in altered protein sequences. Some mutations may be found in regions that do not code for protein sequences or they may simply be synonymous mutations (where the DNA sequence is altered, but the encoded amino acid is the same). PIONEER determines the effects of each cancer-specific mutation. The coding regions around non-synonymous mutations are then translated into amino acid sequences, generating cancer-specific neopeptide sequences.

Step 4 – Presentation on MHC Class I and Class II: To induce an immune response, neopeptides must contain subsequences that are bound by MHC molecules and presented on the cell surface. The identified neopeptides are given as input to our proprietary AI-based tool suite, EvaxMHC, along with the patient’s HLA type to identify neopeptides containing MHC ligands bound by the patient’s MHC molecules specifically.

Step 5 – T-Cell Response: Neoepitopes presented by MHC class I and class II are recognized by T cells, triggering an immune response and tumor cell death. However, while being presented as MHC ligands is a prerequisite for generating an immune response, not all MHC ligands are recognized by T cells. PIONEER includes a tool that predicts the likelihood of a given mutated MHC ligand eliciting a T-cells response.

Step 6 – Clonal Neoepitopes: Tumors are extremely heterogeneous, meaning that not all tumor cells necessarily encode and express the same neoepitopes. Targeting clonal neoepitopes, defined as neoepitopes arising from clonal mutations that are present in all cancer cells, allows for systemic eradication of the whole tumor, as well as potential metastases in the patient. Multiple reports suggest that targeting clonal neoepitopes results in a more effective treatment. PIONEER determines the clonal status of a neoepitope by analyzing

99

the DNA sequencing data using in silico AI models. For patients where DNA sequencing data from multiple tumor biopsies is available, PIONEER seamlessly integrates the information from each biopsy to improve the clonality estimate.

Identifying those neoepitopes that will induce a strong antitumor immune response capable of eradicating all tumor cells in the patient requires sophisticated AI-based in silico models. Such models must be capable of accurately identifying tumor specific mutations along with all steps involved in neoepitope processing, presentation and TCR recognition. State-of-the-art, publicly available tools for neoepitope prediction return a vast number of candidates, of which only a handful are ever found to trigger bona fide antitumor responses in patients. We have benchmarked our proprietary tools from PIONEER against state-of-the-art public tools (Mutect2, MixMHCpred-v2.1/MixMHC2pred-v1.2, RSEM-v1.2.0 quantified expression) and we believe our platform produces superior results.

Graphic

Figure 5: Benchmark study of PIONEER against state-of-the-art, public tools for number of hits identified in the top 10 best-ranked neoepitopes.

To compare PIONEER to a pipeline of state-of-the-art public tools, we designed a simulation study with 3,000 patients. Each patient was assigned 500 potential neoepitopes in a 1:5 positive to negative ratio. Both pipelines were tasked with selecting a set of 10 neoepitopes for each patient and the average number of positive neoepitopes was assessed. Results are depicted in Figure 5 above.

Our benchmark study demonstrates that the best publicly available tools are only capable of identifying 2.6 correct neoepitopes in the top 10, which, we believe, in a neoepitope-based cancer immunotherapy is not sufficient to reach a strong antitumor effect. In comparison, PIONEER was able to identify 8.7 correct neoepitopes in the top 10, which we anticipate is optimal to drive an enhanced antitumor immune response. PIONEER include several in silico tools, some of which are AI-based, corresponding to each biological step in neoepitope presentation to the immune system. We believe that our multi-parameter improvements incorporated across our in silico AI models will translate into better antitumor effect. In pre-clinical studies,we have already demonstrated that enhanced neoepitope prediction directly links to improved antitumor effect in mice (see Figure 6 below).

Improved Neoepitope Prediction Directly Translate into Better Antitumor Effect

Our proprietary in silico AI models within PIONEER have been trained on our proprietary data as well as other data, including, but not limited to, next generation sequencing data from tumor samples, mass spectrometry immunopeptidomics, peptide-MHC-binding affinity data, T-cell immunogenicity data, peptide-MHC-binding stability data. We have demonstrated that development and iterative training of our AI platform directly translates into improved antitumor effect in pre-clinical studies. In a pre-clinical tumor study, the efficacy of three versions of PIONEER, each with increasing number of new features were directly compared (see Figure 6 below). Mice treated with neoepitopes predicted by PIONEER 2.0 demonstrated statistically significant better antitumor effect than the groups

100

treated with neoepitopes predicted by earlier versions of PIONEER, thereby demonstrating that improved neoepitope prediction directly translates into improved antitumor effect.

Graphic

Figure 6: To explore the biological impact of different improvements, three versions of PIONEER were evaluated in the CT26 mouse tumor model. For each version, the top 10 ranked neoepitopes were encoded in separate DNA constructs, designated PIONEER 0.1, PIONEER 1.0, and PIONEER 2.0. Mice were intramuscularly treated twice with the various DNA constructs prior to CT26 cells inoculation. A “mock” plasmid without neoepitopes was included as control.

We believe we are uniquely positioned to develop a neoepitope-based immunotherapy and address the shortcomings from competing approaches through our proprietary algorithms and in silico AI models contained in PIONEER.

Key Advantages of Our PIONEER Platform

Identification of Therapeutic Neoepitopes: PIONEER is able to identify therapeutic neoepitopes that drive a T-cell response with higher accuracy compared to predictions done by state-of-the-art public tools. These neoepitopes have been shown to have an antitumor effect in mice. Clinical data from our ongoing EVX-01 clinical trial demonstrate that our immunotherapies induce specific and active T cells in 100% of all patients and 76.2% of the administered neoepitopes induced reactive T cells in patients, of which 83.3% were de novo responses.
Identification of Therapeutic Patient-Specific Neoepitopes: PIONEER is able to identify truly patient-specific neoepitopes that are unique to a patient’s cancer based on their HLA subtype.
Identification of Multiple Neoepitopes: PIONEER identifies multiple neoepitopes that can be incorporated in the immunotherapy to increase therapeutic effect and overcome issues related to cancer clonal heterogenicity and tumor immune escape.
Speed: PIONEER rapidly identifies neoepitopes in as little as 24 hours from receipt of patient biopsy sequencing data.
World Wide Clinical Applicability: PIONEER is clinically applicable, automated and deployable anywhere in the world and has been through a process of validation according to the International Society for Pharmacoepidemiology, ISPE’s, latest revised guide for Good Manufacturing Practice, or GAMP5, to ensure compliance with legislature and good practice regulations to maintain a high standard of quality in the system.
Potential for Repeat Use of PIONEER Over the Lifetime of a Patient’s Cancer Treatment: Multiple PIONEER designed therapies targeting different sets of neoepitopes can be applied. We believe that with this approach, even relapsing patients will benefit from additional, newly designed PIONEER immunotherapies that target emerging cancer clones specifically.
Safety Profile: PIONEER has been configured to deselect potentially harmful neoepitopes, limiting off target effects.
Continuous Improvement: PIONEER was developed in 2016 and has been updated and improved numerous times by incorporating additional unique data generated in-house and through strategic partnerships, and other available data sets. We

101

will continue this ongoing data incorporation as we generate more pre-clinical and clinical data from our ongoing trials to ensure that our in silico AI models remain state-of-the-art. In addition, we continue to include new features in the platform to increase its predictive power.

Example of Continuous Improvement: Proprietary, In-House MS Methodology Moves Prediction from 60% to 90% Accuracy

We take a unique approach to data generation to further improve the predictive power of PIONEER. One such example includes our novel mass spectrometry, or MS, -based assay for proprietary data generation of in vivo MHC ligand stability data, which we believe overcomes limitations of current stability assays that only explore the feature in vitro. The unique data generated from our assay was used to create an MHC ligand stability prediction tool. Figure 7 below shows data from our PoC study in which predictions were benchmarked on confirmed cancer neoepitopes demonstrating superior performance of our tool in predicting the top 10 neoepitopes compared to predictors created using traditional MS data. We have filed patent applications on both the experimental assay and the algorithmic approach for data interpretation. Our article describing these findings have been published in Nature Communication.

Graphic

Figure 7: EvaxMHCIstab demonstrates improved performance when compared to the current state-of-the-art prediction tools (EvaxMHCI and NetMHCpan-4.0).

As shown in Figure 7 above, the AI model was trained using proprietary thermostability data from a mass spectrometry-based immunopeptidomics workflow and used to predict 26 immunogenic cancer neoepitopes and 20 confirmed negative cancer peptides curated from the Immune Epitope Database. Of the 10 peptides predicted to be the most stable by EvaxMHCIstab, nine were confirmed neoepitopes. In comparison, only six to eight of the neoepitopes were ranked as part of the top 10 predicted peptides by the other prediction tools.

102

Using PIONEER to Derive Our Immuno-Oncology Product Candidates

Graphic

Figure 8: Our process for delivering a patient-specific cancer immunotherapy.

As shown in Figure 8 above, the following steps describe our process for delivering patient-specific cancer immunotherapy:

Step 1 – Tissue Biopsy: Tumor tissue sample(s) and a blood sample are collected from the patient;

Step 2 – DNA and RNA sequencing: We then apply deep-sequencing to the patient’s tumor biopsy specimen and blood to derive high-quality DNA and RNA sequence information;

Step 3 – Identify Critical Neoepitopes: PIONEER uses this sequence information to identify tumor mutations. Next, PIONEER identifies potential neoepitopes from the tumor mutations and ranks such neoepitopes according to their likelihood of being (a) truly cancer-specific (b) present in all cancer cells (c) presented by MHC molecules on tumor cells and (d) able to interact with a TCR and (e) generating an immune response. PIONEER selects the top 10-20 neoepitope candidates and designs the final cancer immunotherapy; and

Step 4 – Administer Neoepitopes to Patient: The selected neoepitopes are manufactured and administered to the patient.

Initially, our patient-specific immunotherapies are intended for the use as a combination therapy with CPIs. Evidence suggests that in patients responding well to CPI treatment, the response is partly mediated by neoepitope-reactive T cells. Induction of de novo neoepitope-specific T cells in combination with CPIs represent a synergistic strategy to expand the number of patients responding to treatment as well as improving the clinical outcome. We intend to evaluate our patient-specific immunotherapies as monotherapies in the future.

103

Our PIONEER Derived Immuno-Oncology Programs

We are currently advancing a unique pipeline of patient-specific cancer immunotherapies derived from our PIONEER platform.

For each cancer immunotherapy derived from our PIONEER platform, we have selected the optimal delivery modality to maximize its potential antitumor effect. We are screening and testing a variety of modalities including peptides, mRNA and DNA for their ability to elicit a strong antitumor and T-cell response. Data readouts from our standardized pre-clinical models allow us to select those modalities which we believe will exert the strongest antitumor effect in patients and rapidly move them into the clinic.

Graphic

Figure 9: Our immuno-oncology product development pipeline derived from PIONEER.

Our Lead Product Candidate EVX-01

Overview

Our lead product candidate EVX-01, is a novel cancer immunotherapy designed to engage the patient’s own immune system by mounting a targeted response against tumors. EVX-01, in combination with PD-1/-L1 CPIs, is intended for the first-line treatment of a variety of metastatic and unresectable cancers amenable to PD-1/-L1 inhibition. In July 2021, we announced initial data readout from our Phase 1/2a clinical trial of EVX-01. Based on the data readout, we entered into a collaboration with MSD and plan to advance EVX-01 into a Phase 2b clinical trial in combination with MSD’s KEYTRUDA. We expect to initiate our Phase 2b clinical trial in the first half of 2022.

EVX-01 consists of five to 10 PIONEER-identified neoepitopes formulated as peptides (neopeptides) together with a strong CD8+ and CD4+ T-cell inducing adjuvant, CAF09, in-licensed from SSI. When administered to the patient, we believe EVX-01 will induce neoepitope -specific T cells that will migrate to the tumor site and induce tumor killing or target circulating tumor cells to eliminate these before becoming metastatic.

We have selected CAF09, a cationic liposomal adjuvant formulation, for its potent ability to induce neoepitope-specific T-cells and for its ability to induce significantly higher T cells compared to well-characterized adjuvants or similar liposomal systems in pre-clinical studies performed by SSI.

To investigate the ability of CAF09 to induce a tumor specific immune response and prevent tumor growth, we performed a pre-clinical study in mice engrafted with the mice cancer melanoma cell line B16F10. A mouse EVX-01, or mEVX-01, immunotherapy comprising three B16F10 tumor specific epitopes was produced and mixed with CAF09. In mice treated with mEVX-01 a reduced tumor burden was observed compared to untreated or CAF09 only treated mice (p-value <0.05, unpaired t test with Welch’s correction, Figure 10A). In whole blood from the mEVX-01 group, high frequent epitope-specific CD8+ T cells were detected (p-value <0.05, unpaired t test with Welch’s correction, Figure 10B). Collectively, these pre-clinical data underline the ability of EVX-01 to promote functional T cells with tumor killing potential.

104

Graphic

Figure 10: CAF09 was co-formulated with three well-described B16F10 specific CD8+ T cell epitopes, referred to as mEVX-01 in the graph. Mice were treated prophylactically with mEVX-01 starting two weeks prior to B16F10 tumor cell inoculation at day 0. P-values were calculated using unpaired t test with Welch’s correction. 10A: P<0.05; 10B: P<0.05.

EVX-01 was developed in collaboration with a consortium consisting of Center for Cancer Immune Therapy at Herlev Hospital, Department of Health Technology at Danish Technical University, Center for Genomic Medicine at University Hospital Copenhagen and the Center for Vaccine Research at SSI. The development and Phase 1/2a clinical trial of EVX-01 was partly funded through a $3 million grant from the Innovation Fund Denmark. Evaxion retains all of the commercial development rights to EVX-01.

Addressable Market for EVX-01

We are currently developing EVX-01 for the treatment of advanced or metastatic unresectable melanoma with the potential to expand into other solid tumor types such as non-small cell lung cancer, or NSCLC, and bladder cancer. All indications we believe are large market opportunities with unmet medical need globally. According to the American Cancer Society, in 2021 there will be in the U.S.:

106,110 new melanoma cases and 7,180 deaths from melanoma;
235,760 new lung cancer cases and 131,880 deaths from lung cancer. NSCLC makes up on average 84% of all lung cancer cases; and
83,730 new cases of bladder cancer and 17,200 deaths from bladder cancer.

The treatment paradigm for metastatic and unresectable melanoma, NSCLC and bladder cancer has been revolutionized over the last few years with the approval of PD-1/PD-L1 CPIs across treatment lines, including first-line for metastatic and unresectable melanoma and in NSCLC as monotherapy or in combination with chemotherapy/other CPIs depending on a patient’s status. In bladder cancer, PD-1/PD-L1 CPIs are approved in the first-line setting for cisplatin ineligible patients as well as later line treatments. Only a minority of patients in these three indications have durable responses to PD-1/PD-L1 CPIs with a majority of patients ultimately showing progressive disease. We believe that our therapeutic neoepitopes could change the treatment paradigm in combination with PD-1/PD-L1 CPIs across these three indications by expanding the patient population responding to PD-1/PD-L1 inhibitor treatment (CPI-resistant patients) and potentially increasing the effect in patients already responding to PD-1/PD-L1inhibitor treatment.

Our EVX-01 Phase 1/2a Clinical Trial

Our EVX-01 Phase 1/2a clinical trial was a first-in-human clinical trial of EVX-01 in combination with anti-PD-1 or anti-PD-L1 (NCT03715985). The trial commenced in January 2019 and was an open-label, single-arm trial. The objectives of the trial were to evaluate the safety/tolerability (primary endpoint) and immunogenicity and feasibility of manufacturing (secondary endpoint) and

105

establish a recommended Phase 2b dose, or RP2D. The trial was initially intended as a basket trial for three indications: metastatic melanoma, NSCLC and bladder cancer. The indications were subsequently changed to advanced or metastatic unresectable melanoma.

Graphic

Figure 11: Clinical design of the first-in-human Phase 1/2a clinical trial in the EVX-01 program.

Initial Data Readout from Our EVX-01 Phase 1/2a Clinical Trial and MSD Collaboration

In July 2021, we announced initial data readout from our Phase 1/2a clinical trial of EVX-01 in advanced or metastatic unresectable melanoma demonstrating an ORR of 67% across all nine patients compared with a historical ORR of 40% with anti-PD-1 treatment alone. The study also demonstrated a CR of 22%, compared with a historical CR of 7% with anti-PD-1 treatment alone. Among the four patients on the highest two doses, there was an ORR of 75%. Three patients with stable disease, or SD, for 10, eight and nine months on anti-PD-1 treatment alone, achieved CR, CR and PR, respectively, following EVX-01 administration. In addition, the data showed induction of neoepitope-specific T cells in 100% of patients. 76.2% of the administered neoepitopes induced reactive T cells in patients, of which 83.3% were de novo responses. Data from the trial also showed that EVX-01 appeared to be well-tolerated with only Grade 1 and 2 adverse events such as fatigue and fever.

Based on our Phase 1/2a clinical trial initial data readout,on October 21,2021, we entered into the Merck CTCSA to evaluate in a new Phase 2b clinical trial, the combination of our patient-specific neoepitope cancer immunotherapy compound, EVX- 01, with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) compound, a humanized anti-human PD-1 monoclonal antibody.

In January 2022, we received regulatory clearance from the Australia Therapeutic Goods Administration, or the TGA, to initiate a Phase 2b clinical trial of our lead product candidate EVX-01 in combination with KEYTRUDA® for the treatment of melanoma. We expect to initiate our Phase 2b clinical trial in the first half of 2022.

106

Our EVX-01 Phase 1/2a Clinical Trial Data

As of December 31, 2021, 13 Stage IV (M1a-c) metastatic and unresectable melanoma patients were treated with EVX-01; five at dose level 1, three at dose level 2 and five at dose level 3.

Graphic

Figure 12: Results on nine patients with metastatic melanoma treated with EVX-01 in the EVX-01 Phase 1/2a clinical trial.

Graphic

Figure 13: % change in target lesion size for nine patients treated with EVX-01. Disease development determined according to RECIST criteria.

107

As shown in Figure 13 above, a benefit of the combination therapy was observed for six patients. Of these, two patients had a CR, four patients had a partial response, or PR, one patient had stable disease, or SD, and two patients had progressive disease, or PD as best outcome.

Graphic

Figure 14: Overview of RECIST disease assessment of EVX-01 compared to KEYTRUDA label (Keynote-006 study) and KEYNOTE-006 (Robert et al. 2015. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 372: 2521–32, Keynote 006 responses after 2 months corresponding to time from biopsy to first dose of EVX-01). High dose level refers to dose level 1 and 2.

As shown in Figure 14 above, ORR, CR and PR Achieved by EVX-01 in combination with anti-PD-1 compares favorably to anti-PD-1 treatment alone.

Immunogenicity Data From our EVX-01 Phase 1/2a

Immune monitoring data from the nine patients treated with EVX-01 demonstrated that 100% of patients had reactive T cells and 76.2% of the administered neoepitopes induced reactive T cells in patients, of which 83.3% were de novo responses (see Figure 15).

Graphic Graphic

Figure 15: Immune readout for the nine patients treated with EVX-01 in combination with PD-1 inhibitor treatment.

108

Neoepitope and Clinical Response Correlations

As shown in Figure 16 below, we observe a correlation between broadness of immune response and clinical benefit when investigated if responding patients had a higher frequency of neoepitopes resulting in a tumor specific immune response as measured in blood by ELISpot. As seen in Figure 16, responding patients in general had a higher frequency of immunogenic neoepitopes after three EVX-01 doses. Furthermore, de novo induced neoepitopes were also more frequently induced in responding patients. We also observed a correlation between PIONEER predictions and clinical benefit when investigating the PIONEER score and the number of identified, high quality neoepitopes against clinical outcome in the nine patients. As seen in Figure 17 below, responding patients generally harbor more high scoring neoepitopes and more high quality neoepitopes.

Graphic

Figure 16: Frequency of immunogenic neoepitopes (left)and frequency of neoepitopes inducing a de novo immune response (right). Clinical response as defined by RECIST, immunogenic neoepitopes are defined as neoepitopes where the T-cell response (SFU) after three EVX-01 treatments is at least double the response induced by irrelevant peptides at the same timepoint, frequency of immunogenic neoepitopes is calculated per patient and de novo immunogenic neoepitopes are defined as neoepitopes where the T-cell response (SFU) is less than or equal to twice the response induced by irrelevant peptides at timepoints before EVX-01 treatment and at least double the response induced by irrelevant peptides after 3 EVX01 treatments.

Graphic

Figure 17: Average PIONEER neoepitope score (left) and frequency of high-quality PIONEER neoepitopes (right). Clinical response as defined by RECIST, mean PIONEER score is the mean PIONEER score of the 5-10 neoepitopes included in the treatment of individual patients, high quality neoepitopes are defined as neoepitopes with a PIONEER score above the median value of all neoepitopes included in the treatments in EVX-01 (5-10 neoepitopes per patient, 63 neoepitopes in total).

109

Patient Cases From our EVX-01 Phase 1/2a Trial

Patient D02_A is a 64-year-old female diagnosed with Stage IV (M1a) metastatic melanoma with a PD-L1 tumor expression of <1%. Lesion A (right arm sc, target lesion) and lesion B (abdominal sc) were identified at baseline. This patient had SD on CPI for 10 months prior to EVX-01 treatment (Cohort B) and achieved a complete response after treatment with EVX-01. The patient had a T-cell response to 100% of EVX-01 neoepitopes and the neoepitope-specific T-cell responses were observed to migrate to the neoepitope target. CT scan and PET-CT show complete elimination of the tumor following EVX-01 treatment.

Graphic

Figure 18: The change in lesion size measured for Patient D02_A. The % change in lesion size is plotted at each evaluation time point. The time point for each EVX-01 dose is indicated in the plots with black arrows. The strength of the neoepitope-specific immune response in patient PMBCs, as measured by IFNy ELISPOT, are also included in the spider plots, visualized with blue bars.

110

Graphic

Figure 19: CT scan and PET-CT for Patient D02_A at enrollment (top) and following EVX-01 treatment (bottom).

Graphic Graphic

Figure 20 (left): EVX-01 induction of neoepitope-specific T cells in patient D02_A. T cells staining double positive for IFNg/TNFa/CD107a/CD137 upon stimulation with EVX-01 neopeptide pool. Figure 20 (right): EVX-01 induction of neoepitope-specific T cells that migrates to the neoepitope target, measured as Skin Infiltrating Lymphocytes (SKIL’s) after 2 injections of EVX-01 for patient D02_A.

111

Patient D01_B is an 81-year-old male diagnosed with Stage IV (M1b) metastatic melanoma. Lesion A (left lung) and lesion B (left thorax wall) were identified at baseline. This patient was treatment näive upon enrollment (Cohort A) and achieved a partial response lasting more than 24.5 months after treatment with EVX-01. The patient had a T-cell response to 100% of EVX-01 neoepitopes, sustained EVX-01 specific T-cell levels and increased immune activation in the tumor microenvironment following EVX-01 treatment was observed. CT scan and PET-CT show clear reduction in tumor size following EVX-01 treatment.

tm2119736d4-lc_neop4c.jpg

Figure 21: The change in lesion size measured for Patient D01_B. The % change in lesion size is plotted at each evaluation time point. The time point for each EVX-01 dose is indicated in the plots with black arrows. The strength of the neoepitope-specific immune response in patient PMBCs, as measured by IFNy ELISPOT, are also included in the spider plots, visualized with blue bars.

112

tm2119736d4-ph_fig224c.jpg

Figure 22: CT scan and PET-CT for Patient D01_B at enrollment (top) and following EVX-01 treatment (bottom).

Graphic

Figure 23: Sustained circulating CD4+ T-cell activation for patient D01_B. T cells staining double positive for IFNg/TNFa/CD107a/CD137 upon stimulation with EVX-01 neopeptide pool.

113

Graphic

Figure 24: Genomic biomarker expression profiling of baseline and follow-up tumor biopsies of patient D01_B indicating that CD8+ T cells and NK cells are activated and infiltrating the tumor microenvironment. Induction is observed after CPI treatment and further induction is observed after EVX-01 treatment.

Our EVX-01 Phase 1/2a Clinical Trial Dose Escalation and Safety Reporting

Data from our clinical trial suggest that patients treated with higher dose levels of EVX-01 (dose level two and three) seem to have a better T-cell response. When investigating the effect of peptide dose on T-cell response in general, we find that higher dose levels increase ORR and T-cell activation, see Figure 25 below.

114

Graphic

Figure 25: ELISpot count of each peptide plotted as a function of dose. * Dose levels 2 and 3.

Increasing the dose level of EVX-01 does not affect the safety profile. Only grade 1 and 2 treatment related adverse events, or TRAEs, were observed across the three dose levels. Most frequently observed TRAEs include fatigue, stomach pain and fever.

Graphic

Figure 26: Summary of safety data observed for the nine patients treated with EVX-01.

115

Our Phase 2b Clinical Trial Plans

Based on our Phase 1/2a clinical trial initial data readout,on October 21,2021, we entered into the Merck CTCSA to evaluate in a new Phase 2b clinical trial, the combination of our patient-specific neoepitope cancer immunotherapy compound, EVX- 01, with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) compound, a humanized anti-human PD-1 monoclonal antibody. We expect to initiate our Phase 2b clinical trial in the first half of 2022.

The proposed Phase 2b clinical trial will be an open-label, multi-center, single arm trial evaluating the efficacy (best objective response, overall response rate, progression free survival and overall survival) and safety of EVX-01 in adults with advanced or metastatic unresectable melanoma on pembrolizumab (anti-PD-1 antibody) treatment. The trial will be powered to show an improvement in the best overall response of patients with SD or PR after 12 weeks on pembrolizumab treatment. The trial design is guided by recently published KEYNOTE-001 and 006 data from MSD which demonstrates that advanced melanoma patients with SD at week 12 and subsequent progression had poor survival outcomes. We believe EVX-01 in combination with pembrolizumab has the potential to significantly improve patient outcomes. The trial design is developed in collaboration with world leading KOLs; Georgina Long (Melanoma Institute Australia, AU), Patrick Ott (Dana-Faber Cancer Institute, USA) and Inge-Marie Svane (Center for Cancer Immune Therapy, Denmark), and will be conducted in partnership with MSD.

Graphic

Figure 27: EVX-01 Phase 2b clinical trial design.

The trial design allows for fast readout, and we anticipate interim readout in the second half of 2023, 1-year readout in 2024 and 2-year readout in 2025. Each readout will serve as a decision point for out-licensing the program. First-patient-first-visit is planned for the first half of 2022.

Manufacturing of Our EVX-01 Drug Product

The peptide-based format used to deliver PIONEER-identified neoepitopes in EVX-01 is able to specifically stimulate neoepitope-specific T cells and has a turnaround time of approximately seven weeks from collection of patient-specific biopsies to administration of the therapy. We believe that this seven-week turnaround time is significantly shorter as compared to other current patient-specific, peptide-based, immunotherapies, which have been shown to have turnaround times of 20 or more weeks. Using the peptide-based format, we believe that we have successfully addressed a major bottleneck in the production of patient-specific immunotherapies and can significantly accelerate the manufacturing process for the treatment of patients with advanced cancer.

Our Second Lead Product Candidate EVX-02

Overview

Our second lead product candidate, EVX-02, for adjuvant treatment of resectable melanoma, was also developed using our PIONEER AI platform. EVX-02 is a novel, neoepitope-based immunotherapy administered using a DNA plasmid modality. We have chosen a DNA-based format due to its strong pre-clinical data, its self-adjuvating effects and because of its potential for delivery of a large number of neoepitopes simultaneously.

116

The goal of the cancer immunotherapy is to promote T-cell priming and expansion of effector T cells for direct and specific tumor killing. It is well-established that DNA vaccination harbors self-adjuvating effects via the innate DNA sensing machinery in mammalian cells. This directs the immune response towards Th1-like immunity which is generally considered to be preferable in cancer therapies. Further, the DNA plasmid allows for a large number of neoepitopes to be delivered simultaneously in one single drug molecule thus making it possible to include all top ranked PIONEER predicted neoepitopes in the therapy. When administered to the patient, we expect that EVX-02 DNA plasmid will be taken up by APCs and neoepitopes will be expressed, processed into smaller components and loaded onto the MHC molecules on the cell surface eliciting a neoepitope-specific immune response.

Addressable Market for EVX-02

Despite the recent significant advances with the use of CPIs for melanoma, there continues to be a significant unmet medical need for patients with Stage IIIB/IIIC/IIID and Stage IV melanoma that are completely surgically excised. With current standard of care, approximately 30.0% of patients relapse within one year and more than 40.0% within three years and eventually succumb to their disease. Thus, we believe well-tolerated and effective treatments are still needed in the adjuvant setting of melanomas to improve clinical outcomes.

Our EVX-02 Pre-Clinical Data

The pharmacological effect of EVX-02 mouse specific compounds was addressed in the well-established CT26 syngeneic tumor mouse model. As the EVX-02 immunotherapy is truly patient-specific and the plasmid design is based on each patient’s individual tumor mutational profile, pre-clinical efficacy testing of patient-specific EVX-02 molecules is not feasible. Instead, mouse surrogate compounds were designed by PIONEER directed identification of CT26 tumor-specific neoepitopes.

In several in vivo pharmacology studies, treatment with a mouse specific EVX-02 immunotherapy, or mEVX-02, induced robust, dose-dependent antitumor immunity in the CT26 tumor model (see Figure 28A and Figure 29 below). Moreover, we have demonstrated enhanced antitumor effects by including both MHC class I and II epitopes in the mEVX-02 neoepitope-targeting immunotherapy (Figure 30) and by combining mEVX-02 immunizations with anti-mouse PD1 treatment (Figure 31). Further, detailed complementary ex vivo analyses, unravelling the mEVX-02 induced T-cell response, demonstrated neoepitope-recognizing circulating CD8+ T cells (see Figure 28B below) and neoepitope-reactive T cells in the spleens of EVX-02 treated mice as evidenced by cytokine positive CD4+ and CD8+ T cells (Figure 28C-D).

117

Graphic

Figure 28: In vivo pharmacology study testing the antitumor effect of a mouse EVX-02 surrogate compound. P-values were calculated using unpaired t test with Welch’s correction. 30A: P<0.001 (tumor volume AUC of Empty plasmid vs mEVX-02 - 5 neoepitopes) and P<0.001 (tumor volume AUC of Empty plasmid vs mEVX-02 - 13 neoepitopes); 29B: P<0.05 Empty plasmid vs mEVX-02 - 13 neoepitopes, 30C: P<0.05 Empty plasmid vs mEVX-02 - 13 neoepitopes, 28D: P<0.05 Empty plasmid vs mEVX-02 - 13 neoepitopes.

As shown in Figure 28 above, groups of BALB/c mice were intramuscular, or IM, administered with 100 μg empty plasmid or plasmids encoding either 5 or 13 top ranked PIONEER identified CT26 neoepitopes, co-formulated with poloxamer 188, designated Empty plasmid, mEVX-02 - 5 neoepitopes and mEVX-02 - 13 neoepitopes, respectively. Figure 28A shows that the mEVX-02 compound containing 13 neoepitopes completely prevented tumor establishment (n=13-14 in all groups). Whole blood neoepitope-MHC I tetramer staining revealed presence of circulating neoepitope-specific CD8+ T cells in the mEVX-02 groups as illustrated in Figure 28B. Complementary ex vivo analysis revealed intermediate and high levels of neoepitope-reactive CD4+ and CD8+ T cells, respectively, in the mEVX-02 -13 neoepitope group depicted in Figure 28C and 30D.

118

Graphic

Figure 29: mEVX-02 dose-dependently inhibited the growth of subcutaneous CT26 tumors. In mice immunized with PIONEER-predicted neoepitopes encoded in a plasmid DNA at doses as low as 5 μg DNA, the growth of CT26 tumors was prevented.

As shown in Figure 29 above, in BALB/c mice IM administered with either 0.25, 2 or 5 ug of clinically grade mEVX-02 plasmid encoding 13 PIONEER identified CT26 neoepitopes, co-formulated with poloxamer 188, a clear dose-response effect was obtained (n=13-14 in all groups).

In further in vivo studies, we have demonstrated that the antitumor effect is enhanced by including both MHC class I and II neoepitopes in the mEVX-02 drug construct compared to either a mono MHC class I or II neoepitope-targeting immunotherapy (see Figure 30).

Graphic

119

Figure 30: In vivo tumor study investigating the interplay of MHC class I and II neoepitopes in mEVX-02-mediated antitumor immunity. P-values were calculated using unpaired t test with Welch’s correction. Not significant (tumor volume AUC of Empty plasmid vs MHC I neoepitopes), P<0.001 (tumor volume AUC of Empty plasmid vs MHC II neoepitopes) and P<0.001 (tumor volume AUC of Empty plasmid vs MHC I+II neoepitopes).

As depicted in Figure 30 the mean tumor volume observed in CT26 bearing BALB/c mice IM administered with 50 μg mEVX-02 containing two MHC class I and three class II neoepitopes was reduced compared to the tumor volumes in mice treated with either 50 μg mEVX-02 consisting of the two MHC class I or the three MHC class II PIONEER predicted neoepitopes. (n=13-14 in all groups.).

In an additional in vivo pharmacology study, co-treatment with a suboptimal mEVX-02 dose and an anti-mouse PD-1, or mPD-1, antibody led to a combinatorial antitumor effect in a syngeneic tumor model illustrated by an increase in time to reach humane endpoints in mEVX-02 + anti-mPD-1 administered mice compared to single compound treatment groups (see Figure 31 below).

Graphic

Figure 31: In vivo tumor study investigating the combinatorial effect of mEVX-02 and anti-mPD-1 antibody. P-values were calculated using log-rank (Mantel-Cox) test P<0.01.

In Figure 31, the time to reach humane endpoint, defined by tumor ulceration or a tumor diameter of more than 12 mm, was increased in CT26 tumor bearing BALB/c mice receiving IM injections of a sub-optimal mEVX-02 dose and intraperitoneal, or IP, injections of 200 μg anti-mPD-1 antibody compared to mEVX-02 and anti-PD-1 monotherapy. The anti-PD-1 antibody treatment was initiated when the tumors reached a mean volume 80-100 mm3 in the groups receiving mEVX-02 treatment. As control for unspecific antibody mediated antitumor effect, parallel isotype control antibody groups were included (n=12-13 in all groups.).

The comprehensive in vivo pharmacology data package provides clear evidence of complete EVX-02 induced antitumor responses accompanied by induction of reactive CD4+ and CD8+ T cells and an effect of combining the EVX-02 therapy with standard of care, for example, CPI treatment. The pre-clinical data holds great promise for an efficient patient-specific neoepitope immunotherapy to the benefit of patients suffering from resectable melanoma.

120

Our EVX-02 Phase 1/2a Clinical Trial

The EVX-02-001 clinical trial is a first-in-human, open label, safety and pharmacodynamic multi-center trial in resectable Stage III/IV melanoma patients (NCT04455503), initiated in the third quarter of 2020. Each patient will, upon tumor resection, receive a unique EVX-02 immunotherapy designed based on their tumor genomic fingerprint in combination with PD-1 CPI. Each patient will receive eight doses of EVX-02 at a two-week interval. Antibodies targeting PD-1 will be administered before, during and after administration of EVX-02 to unleash the potential of the induced EVX-02-specific T cells as well as direct and specific tumor killing. Our goal for the clinical development of EVX-02 is to take it through completion of Phase 2b clinical trials.

Graphic

Figure 32: Clinical design of the first-in-human Phase 1/2a clinical trial of EVX-02.

As shown in Figure 32 above, the EVX-02-001 clinical trial was intended to consist of two parts. In the first part, two different methodologies for DNA plasmid delivery are being evaluated. The second part was intended to consist of an expansion cohort of the most effective DNA delivery modality, determined by assessment of safety and induced immune response. We believe data from the ongoing EVX-02-001 clinical trial supports progressing the development of EVX-02 from Part 1 into a subsequent Phase 2b trial. As of December 31, 2021, 16 patients were recruited in the EVX-02-001 trial. In March 2022, we reported completion of recruitment of Part 1 of the EVX-02 Phase 1/2a clinical trial.

Preliminary Data Readout from Our EVX-02 Phase 1/2a Clinical Trial

In July 2021 we announced preliminary data readout from our Phase 1/2a adjuvant clinical trial of EVX-02 in resectable melanoma demonstrating activation of neoepitope-specific T cells with tumor killing potential. In addition, EVX-02 appeared to be well- tolerated.

Graphic

Figure 33: Preliminary clinical data from first two patients treated with EVX-02.

Our EVX-02/EVX-03 Phase 2b Clinical Trial Plans

We believe preliminary clinical immune and safety data from the Phase 1/2a clinical trial of EVX-02 together with pre-clinical data from both our DNA-based patient-specific cancer immunotherapies, EVX-02 and EVX-03, support moving into a combined Phase clinical 2b trial for which we intend to submit a regulatory filing in the first half of 2022. The proposed combined Phase 2b clinical trial will be a randomized, multi-center, three-arm adjuvant trial in 225 patients with Stage IIIB/IIIC/IIID and Stage IV resectable melanoma, studying our DNA-based patient-specific cancer immunotherapies, EVX-02 and EVX-03 in combination with anti-PD1 against anti-PD1 monotherapy. The objectives of the trial are to evaluate recurrence-free survival (primary) and the induction of relevant immunologic response (secondary). First-patient-first-visit is planned for the second half of 2022.

121

Manufacturing Our EVX-02 Drug Product

To produce patient-specific therapies, DNA plasmids are designed to encode 13 PIONEER identified neoepitopes. EVX-02 is manufactured in two investigational drug products: EVX-02A is patient-specific DNA plasmid formulated with Poloxamer 188 delivered by a standard syringe IM and EVX-02B is patient-specific DNA plasmid delivered via the PharmaJet Stratis® needle-free injection system for IM administration. We have established a manufacturing process with a number of different contract development and manufacturing organizations, or CDMOs, and the entire process from the time of patient biopsy to the time of treatment for these two drug products takes approximately 10 to 12 weeks.

Graphic

Figure 34: Illustration of our EVX-02 DNA plasmid containing a backbone vector with immune stimulating inserts and PIONEER-identified neoepitopes.

Our Third Lead Product Candidate EVX-03

Overview

Our third lead product candidate based on our PIONEER AI-platform, is a next generation neoepitope-based immunotherapy using a DNA modality with a proprietary APC targeting unit for the treatment of a variety of cancers. EVX-03 is in late pre-clinical development. Data from our pre-clinical studies demonstrates high levels of neoepitope-reactive T cells as well as antitumor effect as shown in Figures 37-39. We intend to submit a regulatory filing for a combined EVX-03 and EVX-02 Phase 2b clinical trial in the first half of 2022.

122

Directing neoepitopes to APCs is known to be an effective way to initiate an immune response by mediating maturation of the APCs. APC-targeting can be accomplished by introducing modules that selectively engage receptors on specific APC populations.

GraphicGraphic

Figure 35: Design and protein structure of our proprietary APC targeting EVX-03 compound.

Figure 35A above shows that the EVX-03 plasmid contains a cassette encoding a fusion protein with an APC targeting unit, a dimerization domain and a multi-neoepitope unit. Figure 35B above shows that the translated protein product from the DNA cassette will form a homo-dimeric structure through the dimerization domain, which improves stability of the protein and APC internalization.

Graphic

Figure 36: Illustration of our EVX-03 DNA plasmid containing a backbone plasmid with immune stimulating inserts, PIONEER-identified neoepitopes and an APC-targeting unit.

Our EVX-03 Pre-Clinical Data

The pharmacological effect of EVX-03 mouse specific compounds was addressed in the well-established CT26 syngeneic mouse tumor model. As the EVX-03 immunotherapy is truly patient-specific and the plasmid design is based on each patient’s individual tumor mutational profile, pre-clinical efficacy testing of patient-specific EVX-03 molecules is not feasible. Instead, mouse surrogate compounds were designed by PIONEER directed identification of CT26 tumor-specific neoepitopes.

Figure 37A and 37B below show that the majority of mice treated with mouse EVX-03, or mEVX-03, had complete tumor eradication compared to mice treated without an APC targeting unit. Figure 37C below shows that two weeks after tumor inoculation, whole blood neoepitope-MHC I tetramer staining revealed higher levels of neoepitope-specific CD8+ T cells in the group treated with mEVX-03 compared to mEVX-03 without a targeting unit. Figure 37D below shows that complementary ex vivo analysis revealed higher levels of neoepitope-reactive T cells in the mEVX-03 group as compared to mEVX-03 without a targeted unit.

123

Figure 38 below shows that EVX-03 induces both a CD4+ and CD8+ neoepitope-specific T-cell response cells detected by intracellular cytokine staining.

Graphic

Figure 37: In vivo pre-clinical data for EVX-03. AUC = Area under the curve. Statistical analysis was performed using non-parametric Kruskal-Wallis with Dunn’s multiple comparison corrections (*p<0.05, ****p<0.0001).

124

Graphic

Figure 38: In vivo pre-clinical data for EVX-03 showing mEVX-03 induces neoepitope-reactive CD4+ and CD8+ T cells detected by intracellular cytokine staining.

In Figure 39 below, BALB/c mice were prophylactically treated once a week starting two weeks prior to CT26 tumor cell inoculation. mEVX-03 DNA doses ranging from 5-0.25 μg plasmid encoding the thirteen top ranked PIONEER identified CT26 neoepitopes, co-formulated with poloxamer 188, were IM administered to the mice. mEVX-03 doses as low as 0.25 μg elicited a significant antitumor effect.

Graphic

Figure 39: In vivo pre-clinical data for EVX-03. Establishment of subcutaneous CT26 tumors is prevented in mice immunized with PIONEER-predicted neoepitopes encoded in a plasmid DNA. Antitumor efficacy at DNA doses as low as 0.25 μg is observed.

Our EVX-03 Clinical Development Plans

Our EVX-03 product candidate is currently in pre-clinical development. We believe preliminary clinical immune and safety data from the Phase 1/2a clinical trial of EVX-02 together with pre-clinical data from both our DNA-based patient-specific cancer immunotherapies, EVX-02 and EVX-03, support moving into a combined Phase 2b clinical trial for which we intend to submit a regulatory filing in the first half of 2022.

125

The proposed combined Phase 2b clinical trial will be a randomized, multi-center, three-arm adjuvant trial in 225 patients with Stage IIIB/IIIC/IIID and Stage IV resectable melanoma , studying our DNA-based patient-specific cancer immunotherapies, EVX-02 and EVX-03 in combination with anti-PD1 against anti-PD1 monotherapy. The objectives of the trial are to evaluate recurrence-free survival (primary) and the induction of relevant immunologic response (secondary). First-patient-first-visit is planned for the first half of 2022.

AI-DeeP, Our Proprietary Immuno-Oncology Platform for Prediction of Drug Response

We recently developed AI-DeeP, an AI-immunogenetic drug response prediction platform, that is based on immunogenetic expression signatures in the tumor microenvironment and seeks to identify patients who may benefit from cancer immunotherapies.

As shown in Figure 40 below, AI-DeeP identifies patients responding to therapy with high precision. When applied to EVX-01, we see an increase in ORR to 100% versus 67% without the predictions of AI-DeeP. We believe this platform may decrease clinical development risk and increase patient and payer benefit through patient stratification based on predicted likelihood of response to immunotherapy. We continue to generate data to further validate and increase sensitivity and precision of AI-DeeP.

Graphic

Figure 40: Prediction of patient response to immunotherapy from immunogenetic expression profiles in baseline tumor biopsy. At enrollment to the EVX-01clinical trials, tumor biopsies were collected from malignant melanoma patients. Immunogenetic profiling was performed on the tumor biopsies using RNA sequencing. Leave-one-patient- out analysis demonstrate that patient outcomes can be successfully predicted on the 9 patients in the EVX-01 clinical trial. The prediction of patient outcome was found statistically significant (p=0.01) using the permutation test.

Bacterial Diseases

Drug-resistant bacteria pose a major medical and societal issue as bacteria are rapidly becoming resistant to many of the antibiotics that are currently used as standard of care. According to the World Health Organization, or the WHO, antibiotic resistance is one of the biggest threats to global health and it is rising to dangerously high levels in all parts of the world. New resistance mechanisms are emerging and spreading globally, threatening our ability to treat common bacterial diseases. A misuse of antibiotics is accelerating this process.

We believe the development of prophylactic vaccines is the sustainable solution to address and counteract drug-resistant bacterial infections for several reasons, including:

Vaccines can be used for decades without generating significant resistance

126

Vaccines reduce antimicrobial use to further diminish pressure toward resistance
Vaccines are cost-effective

The market for combatting drug-resistant bacteria is projected to increase significantly. According to The World Bank, drug-resistant infections could by 2050 cause global economic damage on par with the 2008 financial crisis. The Global Bacterial Vaccines Market was valued at $16.27 billion in 2018 and is projected to reach $29.85 billion by 2026, growing at a CAGR of 7.9% from 2019 to 2026.

Bacterial Vaccinology

Vaccines work by training the immune system to recognize and combat pathogens, either bacteria or viruses. To do this, certain molecules, called antigens, from the pathogen must be introduced into the body to trigger a protective immune response. By injecting vaccines containing antigens, the immune system will safely recognize them and trigger an immune response that leads to protective immunity. If the antigen-harboring bacteria or virus appears in the body during an early infection, the immune system will recognize the antigens displayed and immediately attack the pathogen before it can invade and establish a persistent infection and cause disease. The antigens can be secreted toxins or specific virulence factors and by targeting them, the pathogen can more easily be neutralized.

The adaptive immune response following vaccination protects the body from infections by mounting a specific antibody-mediated immune response (B-cell response) and/or a T-cell response. Antibodies can have different functions, but in general they either lead to neutralization of the pathogen (blocking function of important surface molecules or toxins), opsonization (antibodies bind to pathogen surface and flag them for phagocytosis and killing by immune cells), or complement activation (bound antibodies trigger a cascade of proteins that bind to the pathogen and form a pore that eventually lyses the bacteria or enhances opsonization further). On the other hand, the cellular immune response involves cell-mediated cytotoxicity (killing of infected cells), release of cytokines and chemokines as well as phagocytosis (pathogens are taken up and neutralized by macrophages).

In order to provoke the correct type of immunity as well as receive long-lasting and high protection, many vaccines include adjuvants as part of the formulation. Different adjuvants systems trigger different parts of the immune system. Even though adjuvants are critical components of the vaccines, they typically do not have protective properties by themselves in the absence of the specific antigens. The use of correct adjuvants in combination with the selected vaccine antigen(s) is important for the vaccine design.

A typical bacterial pathogen consists of thousands of unique proteins. Only few of them elicit a protective immune response in a vaccine setting. Modern sequencing technology has enabled detailed insight into the entire genome of several clinical isolates of the same pathogen. This in turn has paved the way for computational antigen selection tools that can select a limited number of vaccine antigen candidates from whole bacterial genomes as a starting point for vaccine development. A challenge in computational, or bioinformatic, predictions, however, is to correctly identify posttranslational modifications and other molecular mechanisms that can change the structure and potential antigenic properties of bacterial antigens and optimize antigens in terms of stability, epitope presentation, ease of production and safety.

EDEN – Our AI Platform for the Discovery and Design of Novel Prophylactic Vaccines for Bacterial Diseases

Overview

EDEN is our second AI-driven platform that rapidly identifies novel, highly protective antigens for the use in pathogen-specific prophylactic vaccines against drug-resistant bacteria. Within EDEN, our proprietary algorithms allow us to predict and identify those antigens that we believe will trigger a robust, protective immune response against almost any bacterial infectious disease. EDEN has also been constructed to redesign vaccine antigens, i.e. engineer such antigens into soluble vaccine constructs for large scale production which potentially allow us to move antigen candidates into the clinic far faster than traditional vaccine discovery and development approaches.

127

The core of our EDEN technology is a proprietary machine learning ensemble of AI models used to interpret immunological-relevant information in relation to bacterial antigens that incur protection in a vaccine setting. EDEN has been trained on our own curated data set derived by trawling through publicly available patents and publications reported to identify truly protective and non-protective antigens tested in clinical and pre-clinical settings. The input to the AI models is a feature transformation of the protein data set, in which several global and sequence-resolved properties are extracted. These structural and functional features have been selected for their relevance in protein chemistry, immunology and protein structure and ability to guide the network in discriminating protective versus non-protective antigens.

Graphic

Figure 41: EDEN is a self-taught AI model that provides important insight into what makes antigens elicit a protective immune response. EDEN identifies novel protective proteins by recognizing abstract features shared with known highly protective proteins.

We believe our approach can be used to target almost any bacterial infection and rapidly enables the discovery and development of vaccine product candidates. We have applied EDEN in seven pathogens to test its predictive power. For each pathogen, EDEN identified novel vaccine antigens which were subsequently expressed as proteins and tested in pre-clinical, mouse infection models, demonstrating protection against all seven pathogens. We intend to develop a pipeline of vaccine product candidates using this platform. We are currently focused on the development of EVX-B1, our novel vaccine product candidate for the prevention of S. aureus, specifically MRSA, infections. We expect to submit a regulatory filing for a clinical Phase 1 trial in the second half of 2022.

Graphic

Figure 42: Evaxion’s approach to bacterial vaccine discovery and design.

Key Steps in the EDEN AI Platform Include:

Step 1 – Isolation and Sequencing of the Target Pathogen: To identify novel, broadly protective vaccine antigens for a bacterial infection, EDEN utilizes proteomes from clinically relevant bacterial strains as input;

Step 2 – Prepare Pathogen Proteome: The protein coding regions of such strains are translated into amino acid sequences;

128

Step 3 – Discriminate Protective from Non-Protective Antigens: EDEN identifies unique feature combinations. 23 features are built into EDEN, one such example is an abstract MHC epitope feature along with antibody recognition features that attribute to protective antigens. EDEN predicts previously untested proteins, scoring each of them from 0 to 1 for their probability of eliciting a protective immune response.

Step 4 – Select and Design Antigen: Using EDEN, only a few dozen candidate antigens identified from a whole bacterial proteome are left to be tested experientially. AI-based antigen optimization strategies incorporated in EDEN are used to optimize the design of identified vaccine antigens in term of antigenic and structural properties as well as ease of production; and

Step 5 – Process Antigen Through Pre-Clinical Development Pipeline: Once designed, the antigen candidates are produced in high quality and processed through a pre-clinical development pipeline for in vivo confirmation. As part of each vaccine product candidate project, we evaluate different adjuvants and delivery modalities to optimize the immune response and the potency of our developed vaccines. We believe that the correct composition of antigens and adjuvants generates highly potent vaccines.

We have demonstrated that within as little as 48 hours, EDEN is able to identify novel and highly protective vaccine antigens, although there is no guarantee that we will be able to identify product candidates within this time frame in the future. Following discovery of such antigens, within a matter of weeks, new product candidates can be produced to be tested in pre-clinical studies. We believe that if such performance is reproducible, it will accelerate the speed of antigen identification and design, resulting in reduced costs associated with drug discovery and pre-clinical development.

Graphic

Figure 43: To demonstrate the power of EDEN, Evaxion has performed a retrospective validation on Group A Streptococcus M1 strain comparing reverse vaccinology (RV) with the EDEN platform. EDEN was able to identify the same six vaccine product candidates as identified using RV within only 48 hours at a cost of approximately $5,000 compared to five years and more than $10 million spent applying the RV approach. In addition, EDEN identified 24 vaccine product candidates not identified by the RV approach.

129

Key Advantages of our EDEN Platform

We believe that our AI-based vaccine discovery and design approach has several advantages over more traditional approaches, including:

Ability to Predict Protective Vaccine Antigens: The ability of EDEN to predict protective vaccine antigens has been shown in pre-clinical models. Once clinically validated, we believe our approach may have the ability to improve on the attrition rates for new vaccine product candidates.
Identification of Novel and Unbiased Targets: EDEN has been trained to identify the underlying feature patterns (e.g. structural or immunological elements) that are important for protection to enable discovery of novel and unbiased targets that are not necessarily homologous to existing products. Traditional reverse vaccinology, or RV, relies heavily on sequence homology (proteins identical to previously tested antigens) in antigen identification.
Data Driven Precision: With carefully curated data, EDEN has learned to filter away irrelevant proteins, narrowing the field of candidates substantially from thousands to a few dozen proteins, reducing the burden on pre-clinical development.
Extraordinary Sensitivity: EDEN has been retrospectively benchmarked against marketed vaccines and shows extraordinary sensitivity in finding antigens included in the vaccines as well as novel, protective antigens.
Ability to Provide Broad Protection: The rapid “evolution” of the genome that can occur in some bacterial pathogens makes it difficult to capture all pathogen strains by a single vaccine. EDEN is capable of leveraging genomic sequencing data to find important targets or domains that are present in the majority of clinical strains. By combining the correct antigens, most, if not all, relevant strains can be covered.
Speed: Traditionally, developing and verifying the safety and efficacy of a novel vaccine takes between 10 to 15 years, often resulting in a new vaccine arriving too late on the market to influence the spread of infections to the general population. We believe that EDEN is capable of identifying vaccine product candidates in a matter of weeks instead of years thus potentially lowering the overall development time.
Scalability: EDEN is highly scalable due to its ability to rapidly produce a broad range of antigens, or vaccine candidates, against almost any bacteria, including drug-resistant bacteria, such as MRSA.

The EDEN platform is continuously improved to ensure it remains state-of-the-art and incorporates multiple aspects of vaccine development from discovery to clinical testing. We explore among other improvements, incorporation of new translational features and data into EDEN, novel machine learning architectures such as deep learning and probabilistic programming to enhance protein structure and function prediction, generation of novel high-throughput data to be incorporated into our AI technology for assessment of solubility and CMC-readiness and methods for determining broadness of protection across strains. By continuous improvement in all aspects of vaccine development, we believe the EDEN platform will continue to produce potent vaccine product candidates with minimal testing before entering clinical development.

130

EDEN in Vivo PoC

To obtain initial in vivo PoC, EDEN was applied to seven pathogens reported to exhibit resistance to standard antibiotics, identifying both novel and known antigens. For each pathogen, EDEN-identified vaccine antigens were expressed as proteins and their protective ability tested in pre-clinical infection models. Intellectual property, or IP, rights have been filed for all identified targets conferring significant protection.

Bacterial species

    

In vivo
PoC

    

In vivo model (mouse challenge models)

    

IP
filed

Staphylococcus aureus

Lethal peritonitis and skin abscess model

Pseudomonas aeruginosa

Lethal peritonitis and lethal acute pneumonia model

Non-typeable Haemophilus influenzae

Lung colonization model

Moraxella catarrhalis

Lethal peritonitis and lung colonization model

Neisseria gonorrhoeae

Vaginal colonization model

Acinetobacter baumannii

Lethal acute pneumonia model

Klebsiella pneumoniae

Lethal peritonitis and lethal acute pneumonia model

In Vivo PoC Data Example

For Pseudomonas aeruginosa, or PA, we employed EDEN and identified 35 vaccine antigens which were expressed as recombinant protein constructs. These antigens were tested for induction of protective immunity in mouse models. 16 antigens confirmed protection in peritonitis and acute pneumonia models. These lead antigens are involved in numerous different biological functionalities including; adhesion, iron uptake, secretion of toxins and thus targeting different virulence factors.

Data from four of the 16 candidates are shown in the figure below, demonstrating protection in two different lethal challenge mouse models.

Graphic

Figure 44: Pseudomonas aeruginosa antigens identified by EDEN show high level of protection in two challenge models.

131

The data demonstrate that our EDEN platform is capable of identifying highly protective antigens based on the bacterium proteome. A finding that holds true for multiple bacteria with diverse pathogenicity, emphasizing the broad usability of the platform.

Our EVX-B1 Product Candidate

Overview

Our EVX-B1 product candidate is a multi-component subunit prophylactic vaccine, initially being developed for the prevention of SSTI in patients undergoing elective hernia surgery. EVX-B1 includes two proprietary and highly protective antigens identified by EDEN in combination with two known toxins that play a key role in S. aureus pathogenesis formulated together with a potent adjuvant, CAF01. EVX-B1 is intended to be administered prior to surgery. Upon administration to the patient, we believe that EVX-B1 will significantly reduce S. aureus related SSTI.

EVX-B1 is currently in pre-clinical development. We intend to assess the final formulation of EVX-B1 for safety in a repeat dose toxicity trial for a regulatory filing in the second half of 2022.

Previous attempts to design vaccines to combat S. aureus have not been successful. We believe EVX-B1 is a highly competitive vaccine capable of out-performing other programs in clinical development as it has been designed to:

Include novel antigens with high protection abilities. Our proprietary AI platform EDEN has identified several novel vaccine antigens and of these, two have been selected based on protection levels observed in different pre-clinical animal models such as sepsis and skin abscess, and when using multiple challenge strains.
Induce broad and effective protection: By including antigens widely present and highly conserved among multiple clinically relevant strains, the vaccine will have a broad coverage and effectively address the medical need.
Include multiple antigens: By including multiple antigens with conserved B- and T-cell epitopes, the infecting bacteria is attacked from several angles and critical functions needed for bacterial pathogenicity, persistence and growth are targeted.
Target critical toxins: To increase protection even further, EVX-B1 includes a proprietary designed toxoid fusion protein targeting two critical toxins released by the bacteria during infection.
Include a potent adjuvant: By including the liposomal adjuvant CAF01, driving a balanced Th1 and Th17 type of immune response, we believe the vaccine induces the most optimal response needed to combat the pathogen.

Addressable Market for EVX-B1

S. aureus is responsible for significant morbidity and mortality worldwide and antibiotic-resistant S. aureus, and in particular MRSA infections, are, according to the CDC, of critical concern and remain a prevention priority. In the United States, S. aureus is estimated to cause 20,000 deaths and amount to a total bill of $15 billion on the health service annually. The global MRSA drugs market is expected to reach over US$ 3.9 billion by 2025.

We are initially developing EVX-B1 for the prevention of S. aureus induced SSTI in patients undergoing hernia surgery. To date, no prophylactic vaccine for the prevention of S. aureus infections has received marketing authorization. With the development of EVX-B1, we are addressing this unmet medical need and believe our candidate has the potential to be the first vaccine to receive approval for the prevention of S. aureus infections.

Upon successful completion of a Phase 2b clinical trial, we intend to expand development of EVX-B1 for the prevention of S. aureus in surgical infections beyond abdominal hernia surgery, such as orthopedic surgical infections, and may explore other indications such as recurrent skin infection indications including, acne, diabetic foot ulcers and impetigo.

132

Our EVX-B1 Pre-Clinical Data

EVX-B1 is a multicomponent vaccine, consisting of three components to derive a strong vaccine product candidate:

Novel, EDEN-identified vaccine antigens evaluated in pre-clinical protection and challenge studies and with critical functions.
Uniquely designed toxins selected from a long list of relevant toxins and pre-clinically evaluated as single proteins and fusion protein constructs.
Adjuvant selected based on pre-clinical tests and optimal profile for clinical indication.

Each component has been carefully tested and evaluated pre-clinically as outlined in Figure 45 below.

Graphic

Figure 45: Multicomponent approach to the development of EVX-B1.

133

Evaluation and Selection of Vaccine Antigens

We applied EDEN to the proteome of S. aureus to predict the antigens most likely to induce protective immunity. Forty-four (44) novel vaccine antigens were identified, expressed as recombinant proteins and assessed for protection in a S. aureus mouse sepsis model. Of these, 13 antigens demonstrated consistent high and significant protection in this model. The protection data is summarized in the table below.

No. of

No. of

%

  

%

Difference in

 

Protein

No. of

Test

Control

Survival of

Survival of

% Survival

 

#

    

ID

    

Experiments

    

Mice

    

Mice

    

Test Mice

    

Control Mice

    

(Test vs. Control)

 

1

 

EDEN-1

 

4

 

59

 

60

 

76

%  

28

%  

48

%

2

 

EDEN-2

 

2

 

24

 

24

 

58

%  

13

%  

46

%

3

 

EDEN-3

 

3

 

43

 

44

 

77

%  

32

%  

45

%

4

 

EDEN-4

 

2

 

28

 

28

 

68

%  

25

%  

43

%

5

 

EDEN-5

 

2

 

28

 

28

 

68

%  

25

%  

43

%

6

 

EDEN-6

 

2

 

27

 

28

 

85

%  

43

%  

42

%

7

 

EDEN-7

 

3

 

36

 

36

 

61

%  

19

%  

42

%

8

 

EDEN-8

 

5

 

61

 

64

 

51

%  

9

%  

41

%

9

 

EDEN-9

 

3

 

43

 

44

 

63

%  

30

%  

33

%

10

 

EDEN-10

 

3

 

36

 

36

 

69

%  

36

%  

33

%

11

 

EDEN-11

 

3

 

32

 

35

 

53

%  

20

%  

33

%

12

 

EDEN-12

 

3

 

42

 

42

 

62

%  

31

%  

31

%

13

 

EDEN-13

 

3

 

36

 

36

 

47

%  

28

%  

19

%

The 13 antigens were further subject to extensive bioinformatic analyses to determine their function. Also, early production and formulation characteristics were addressed. Two antigens were selected based on the following parameters:

Level of protection in different challenge models and against different S. aureus challenge strains as single antigens and as part of a fusion protein construct.
Virulence functions critical for S. aureus pathogenicity and infection, including evasion of innate and adaptive immunity, secretion of virulence factors and toxins and replication , verified by functional assays.
Attractive CMC profile of the individual constructs

The two lead antigens were designed and expressed as one fusion protein, EDEN-Fusion-1.

Evaluation and Selection of Toxins

We have evaluated multiple S. aureus toxins and selected the two most promising candidates for our proprietary toxoid fusion protein, which has demonstrated protection in sepsis models and skin abscess models of infection using two different challenge strains. Our toxoid fusion protein, Hla-LukE, includes inactivated forms of α-hemolysin (Hla) and Leukotoxin E (LukE), two toxoids having demonstrated high levels of protection when assessed in animal models amongst publicly described S. aureus toxins.

Evaluation and Selection of Adjuvant

The vaccine antigens and toxin constructs will be formulated with the potent adjuvant CAF01. CAF01 is a cationic liposomal formulation. The hallmark for CAF01 is its ability to induce CD4+ T-cell responses, especially Th1 cells and Th17 cells after parenteral vaccination with strong antibody response. CAF01 has been used in other vaccine programs undergoing clinical testing (in tuberculosis and chlamydia) and has an attractive safety and immunogenicity profile.

134

Our EVX-B1 Product Candidate

EVX-B1 will include two EDEN-predicted antigens as one fusion protein (EDEN-Fusion-1), two toxins as one toxoid fusion protein (Hla-LukE). EVX-B1 will therefore comprise a total of four antigens expressed as two fusion protein constructs and formulated with CAF01. All protein constructs are engineered to be proprietary to Evaxion.

Pre-clinical data testing our EVX-B1 product demonstrates highly significant levels of protection in two different challenge models (Figure 46-47) and high IgG titers (Figure 48), suggesting good overall immunogenicity.

Graphic

Figure 46: Assessing protection of EVX-B1 in a mouse sepsis model. Survival proportions of mice having received EVX-B1 product or PBS was followed for 7 days post infection (p.i.). Statistical analysis was performed using Log-rank Mantel-Cox test (p-value <0.0001****).

Figure 46 above shows that EVX-B1 is inducing 79% protection compared to control (PBS) in a mouse sepsis model using S. aureus USA300 for challenge.

Graphic

Figure 47: Assessing protection of EVX-B1 in a mouse skin infection model. Abscess sizes are presented as area under the curve (AUC) for individual mice and mean with standard deviation. Statistical significance was calculated with Mann-Whitney test (p-value <0.0001****).

135

Figure 47 above shows that EVX-B1 is inducing highly significant protection compared to control (PBS) in an abscess mouse model of infection using S. aureus USA300 for challenge.

tm2119736d4-lc_halfmax4c.jpg

Figure 48: IgG titers. Mice were immunized with EVX-B1. IgG titers are shown as half-max titers for individual mice, groups median values and 95% confidence interwall are shown.

In order to study the immune response following immunization, IgG titers were investigated. Figure 48 above shows that the EVX-B1 product induce high IgG titers specific for both of the two fusion protein constructs, EDEN-Fusion-1 and Hla-LukE, and holds promise for continued development.

Our EVX-B1 Clinical Development Plan

EVX-B1 is currently in pre-clinical development. We intend to assess the final formulation of EVX-B1 in a non-clinical, repeat dose toxicity study for a regulatory filing in the second half of 2022.

The initial clinical development of EVX-B1, Phase 1 clinical trial, will include 20-30 subjects to evaluate the safety and immunogenicity of the vaccine. We plan to conduct the Phase 2 clinical trial in collaboration with Walter Reed Army Institute of Research, or WRAIR, utilizing their prior experience from S. aureus vaccine development, resources and know-how. Collaboration with WRAIR and the United States military has several advantages including high enrollment rate of eligible trial subjects, relatively high and defined attack rate in the control arm over a short period of time, enrollment of subjects with healthy immune systems, relative ease of data capture given the close monitoring of enrolled subjects that is feasible in such a situation. The high attack rate of S. aureus infections among army recruits will allow the trial to be relatively small and more cost-effective than any large-scale population-based development program, provided fast and clear clinical PoC, before initiation of a larger pivotal trial in hernia mesh elective surgery.

Our EVX-B2 Product Candidate

We intend to select our second bacterial product candidate, EVX-B2, in the first half of 2022.

136

Viral disease Background

So far in the 21st century, seven known coronavirus strains have made the transition from animals to humans causing significant morbidity/mortality around the world. Four of these strains (HCoV-229E, -OC43 -NL63 and -HKU1) cause approximately 30 % of common colds in developed countries, and, therefore, contribute to significant loss of productivity and quality of life. The remaining three strains emerging in 2003 (SARS-CoV-1), 2013 (MERS-CoV) and most recently COVID-19 in 2019 (SARS-CoV-2), have been more virulent with significant human mortality and economic burden. In addition, efforts by the United States Agency for International Development, through the Emerging Pandemic Threats program, have revealed several novel coronavirus strains in animals across the globe that are poised to become the next potential pandemic threat. These observations, combined with the ability of most coronaviruses to re-infect humans after first exposure, clearly underline the need for an effective vaccination strategy against both current coronavirus strains and any future pandemic strains. Research conducted to date on coronaviruses points to the fact that an effective coronavirus vaccine needs to provide a potent B-cell response that facilitates the generation of neutralizing antibodies that blocks viral cell entry. This mechanism needs further support from T cells that can actively locate infected cells and eliminate them before the virus spreads uncontrollably in the human body.

RAVEN – Our AI Platform for the Discovery and Design of Novel Prophylactic Vaccines for Viral Diseases

Overview

We are developing our third, proprietary AI platform, RAVEN, to apply our unique AI technology approach to vaccine design and development against viral diseases.

We believe our RAVEN platform will address the public health threat posed by emerging viral diseases in two key areas:

1.

The need for a viral platform that can address unmet medical needs in viral diseases such as future coronaviruses, respiratory syncytial virus, or RSV, cytomegalovirus, or CMV and human immunodeficiency virus, or HIV, etc.

2.

The need to act fast when the next pandemic virus emerges. RAVEN will allow for highly, broadly effective vaccines for human use in, initially, less than 11 weeks. We believe we will be able to significantly reduce this timeline in the coming years.

Initially, we plan to apply RAVEN for the development of a pan-beta-coronavirus vaccine that will protect against current and future beta corona strains. The development is funded through non-dilutive sources and will serve as a PoC for our RAVEN platform. Once PoC is achieved, we plan to apply RAVEN for commercial, viral targets such as RSV, CMV, HIV, etc.

RAVEN combines the essential AI tools from our PIONEER platform with structural in silico AI tools from EDEN to arrive at a novel potent B- and T-cell vaccine design concept (see Figure 49 below). Our goal with RAVEN is to identify minimal constructs from viral fusion proteins for the generation of neutralizing antibodies (B-cell driven) and to incorporate potent T-cell epitopes with high population coverage from the entire viral genome to ensure elimination of infected cells in any stage of the viral replication cycle.

Key Advantages of our RAVEN Platform

We believe, the combination of the B- and T-cell design approach results in a number of unique features of vaccine design by the RAVEN platform:

Promiscuous T-cell epitopes: The AI components of our RAVEN platform enable the identification and combination of T-cell epitopes that cover the entire immunological diversity of the human populations (HLA type).
Multiple hits on target: By combining multiple potent epitopes in one vaccine, different T cells will be able to target the same infected cell and curtail spread of the infection more effectively.
Coverage of entire viral cycle: By selecting epitopes from all proteins in the viral genome, vaccine generated T cells will be able to kill infected cells at any stage of the viral replication cycle.
Mutation proof: Combining multiple epitopes ensures that any given variant of a strain is covered by more than five conserved T-cell epitopes, hence new mutations are likely to have little effect on the vaccine efficacy.

137

Neutralizing focused: Design of minimal constructs from viral fusion proteins for the generation of neutralizing antibodies.
Cross-reactive antibodies: The RAVEN viral fusion protein antigen is designed using information from all available variants of the target strain to ensure that the generated antibodies offer cross-reactive neutralization.
Broadly applicable: While being specialized in tackling the corona issue, the RAVEN platform can be applied to any known virus.

Early Pre-Clinical PoC for AICoV and RAVEN

To address the threats against human health posed by current and future coronavirus strains, with the support of the Danish government in the form of a grant, we have launched the Adaptive and Intelligent Vaccine for a Rapid Response against Corona Viruses, or AICoV. This program aims to improve our vaccine design and pandemic preparedness capabilities, not only for coronaviruses but also for other emerging viruses that pose a threat to human health. The backbone of AICoV is our RAVEN platform. We combine RAVEN with our proprietary APC targeting, DNA-based delivery technology to further improve the immunogenicity of the vaccine.

tm2119736d1-fc_bussec234c.jpg

Figure 49: Current workflow for the design of an integrated B- and T-cell corona vaccine using our proprietary RAVEN platform.

Using a precursor to our RAVEN platform, we have demonstrated that an optimized B- and T-cell vaccine designed against influenza induces 10 to 20 times higher level of neutralizing antibodies against hemagglutinin, when compared to a strategy utilizing the protein alone. Hemagglutinin is a viral fusion protein located on the surface of the influenza virus where it facilitates cellular entry, serving the same purpose as the spike protein in coronaviruses and its neutralization is therefore key in the development of an effective vaccine.

To evaluate the applicability of our APC targeting DNA vaccine technology in coronavirus, a PoC pre-clinical study in mice was conducted utilizing the receptor-binding domain (RBD) from the spike protein inserted into our APC-targeting DNA technology to arrive at a SARS-COV-2 vaccine (EVX-APC-RBD). The ability of EVX-APC-RBD to induce both T-cell and a functional antibody response was then assessed using IFNγ ELISpot and a live virus neutralization assay, respectively. In Figure 50A, mice immunized with EVX-APC-RBD show induction of a strong T-cell response against peptide epitopes covering the entire RBD fragment. Figure 50B shows the ability of sera from vaccinated mice to neutralize live SARS-CoV-2 in a cytopathic effect microneutralization assay. The obtained neutralization titers are comparable to that of human convalescent sera derived from previously infected individuals.

138

tm2119736d1-bc_30figure4c.jpg

Figure 50: C57BL/6 mice were IM immunized once a week for five weeks with either 25 ug EVX-APC-RBD or empty plasmid (DNA mock). Splenic material and sera were collected one week post last immunization. A) The EVX-APC-RBD plasmid induced antigen reactive T cells across the RBD fragment as measured by IFNγ ELISpot upon stimulation of spleenocytes from vaccinated mice with three groups of RBD derived 20 mer peptides. Concanavalin A (ConA) is a lectin that activates IFN-γ release and functions as a positive control for the highest possible level of stimulation. B) A micro-neutralization assay using a cytopathic effect (CPE) read-out with live SARS-CoV-2 2019 nCOV ITALY/INMI1 was performed with sera derived from either DNA mock or EVX-APC-RBD vaccinated mice and found to be comparable to data from convalescent patients (PMC7781313, bioRxiv preprint).

A second mice immunogenicity study was performed to evaluate the ability of the RAVEN platform to identify immunogenic epitopes both within and outside the spike protein. Figure 51 shows a specific T-cell response for 15 of the 16 RAVEN predicted epitopes designed specifically for C57BL/6 mice as reported by IFN-y ELISpot, with the majority of the epitopes located outside the spike protein.

tm2119736d1-bc_31figure4c.jpg

Figure 51: C57BL/6 mice were IM immunized once a week for five weeks with 25 ug APC targeting plasmid containing RAVEN predicted epitopes as “epitopes on a string”. Splenic material was collected one week post last immunization. Epitopes were predicted as “hotspots” with a high density of MHCI/II ligands across the SARS-CoV-2 genome specific for the C57Bl/6 MHC haplotype. 15 out of the 16 RAVEN predicted SARS-COV-2 T cell epitopes gave high IFN-γ response in an ELISpot upon

139

restimulation with the corresponding peptides. Cut-off for a positive response was defined as the average value for irrelevant peptide stimulation + 3 standard deviations (- - -).

Our Adaptive Vaccine Approach and RAVEN Process

To shorten vaccine development timelines for pandemic viruses (including coronaviruses) in the future, we aim to rely on an adaptive vaccine approach, similar to that applied for pandemic Influenza (H1N1 2009), where a pre-developed vaccine design (Pandemic Preparedness Vaccine framework, EMA) against an already circulating strain is adapted to an emerging strain. As a PoC for this strategy, we believe that targeting SARS-CoV-2 or one of the strains causing the common cold would serve as a suitable basis for the Pandemic Preparedness Vaccine concept for coronavirus. We believe that our AI-CoV program in this setting will allow for a vaccine that can be rapidly developed in approximately 11 weeks from available genomic information to first human dose. Such a rapid vaccine response would allow for a targeted immunization strategy in the endemic area, thereby significantly reducing the effect on the global economy and human suffering.

Graphic

Figure 52: Overview of the planned response cycle for our AICoV program.

We anticipate that we, with our planned response cycle for our AICoV program and the RAVEN platform, will be able to effectively and rapidly address future corona outbreaks. From the time of a zoonosis event to first in human dose in a Phase 1 trial, we believe less than 11 weeks will be required using our approach as outlined in Figure 52 above.

Once we achieve PoC on our RAVEN platform, we plan to further utilize the built-in, adaptive nature of the platform to identity our first commercial, viral candidate in the second half of 2022 and subsequently apply RAVEN to target other viruses that display seasonal reoccurring and/or pandemic potential or general medical need. In addition, the patient-specific manufacturing pipeline and methodologies from our immuno-oncology portfolio have the potential to be combined with our RAVEN platform to generate truly patient-specific vaccines against persistent viruses such as RSV, CMV, HIV, etc.

Our EVX-V1 Product Candidate

We intend to select our first viral product candidate, EVX-V1, in the second half of 2022.

Third-Party Collaborations

We are collaborating with MSD on the Phase 2b clinical trial which will combine our patient-specific neoepitope cancer immunotherapy compound, EVX-01, with MSD’s anti-PD-1 therapy KEYTRUDA compound, a humanized anti-human PD-1 monoclonal antibody.

140

The planned multi-center Phase 2b clinical trial will enroll patients with Stage III and IV advanced or metastatic unresectable melanoma and will investigate EVX-01 in combination with KEYTRUDA. We expect to initiate the trial during the first half of 2022. We will act as the sponsor of the clinical trial and MSD will supply all the necessary KEYTRUDA. We will continue to collaborate with MSD as the data mature.

We are also collaborating with the National Center for Cancer Immune Therapy (CCIT-DK) at Herlev Hospital, Department of Health Technology at Danish Technical University, Center for Genomic Medicine at University Hospital Copenhagen and the Center for Vaccine Research at SSI on the development and Phase 1/2a clinical trial of our EVX-01 product candidate.

We retain the commercial rights to EVX-01 and our other clinical stage programs. We plan to continue to identify potential collaborators who can contribute meaningful resources and insights to our programs and allow us to more rapidly expand our impact to broader patient populations.

Government Regulation

Government authorities in the United States, at the federal, state and local levels, and in the European Union and other countries and jurisdictions, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, record-keeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting and import and export of pharmaceutical products, including biological products. In addition, some jurisdictions regulate the pricing of pharmaceutical products. The processes for obtaining marketing approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other requirements of regulatory authorities, require the expenditure of substantial time and financial resources.

Regulation and Procedures Governing Approval of Drug and Biological Products in the United States

In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or the FDCA, and the FDCA’s implementing regulations and regulates biologics under both the FDCA, the Public Health Service Act, or the PHSA, and their implementing regulations. Both drugs and biologics also are subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state and local statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable United States requirements at any time during the product development process, approval process or following approval may subject a sponsor to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA’s refusal to approve pending applications, withdrawal of an approval, license revocation, clinical hold, untitled or warning letters, voluntary or mandatory product recalls, market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.

A sponsor seeking approval to market and distribute a new drug or biological product in the United States generally must satisfactorily complete each of the following steps:

pre-clinical laboratory tests, animal studies and formulation studies all performed in accordance with applicable regulations, including the FDA’s good laboratory practice, or GLP, regulations;
submission to the FDA of an IND for human clinical testing, which must become effective before human clinical trials may begin;
approval by the institutional review board, or IRB, or ethics committee representing each clinical site before each clinical trial may be initiated;
performance of adequate and well-controlled human clinical trials to establish the safety, potency and purity of the product candidate for each proposed indication, in accordance applicable regulations, including with good clinical practice, or GCP, regulations;
preparation and submission to the FDA of a NDA for a drug product, or a biologics license application, or BLA, for a biological product requesting marketing approval for one or more proposed indications, including submission of detailed

141

information on the manufacture and composition of the product in clinical development, evidence of safety, efficacy, purity and potency from pre-clinical testing and clinical trials, and proposed labeling;
review of the product by an FDA advisory committee, if applicable;
satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities, including those of third parties, at which the product, or components thereof, are produced to assess compliance with current good manufacturing practice, or cGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the product’s identity, strength, quality and purity;
satisfactory completion of any FDA audits of the clinical trial sites to assure compliance with GCPs, and the integrity of clinical data in support of the NDA or BLA;
payment of user fees and securing FDA approval of the NDA or BLA;
compliance with any post-approval requirements, including the potential requirement to implement a REMS and to conduct any post-approval studies required by the FDA.

The pre-clinical and clinical testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for our investigational medicines and any future investigational medicines will be granted on a timely basis, or at all.

Pre-Clinical Studies and IND Application

Before testing any drug or biological product candidate in humans, the product candidate must undergo pre-clinical testing. Pre-clinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as animal studies to evaluate the potential for activity and toxicity. The conduct of the pre-clinical tests and formulation of the compounds for testing must comply with federal regulations and requirements. The results of the pre-clinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, are submitted to the FDA as part of an IND. The IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions about the product or conduct of the proposed clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks, and places the trial on a clinical hold. In that case, the IND sponsor and the FDA must resolve any outstanding FDA concerns before the clinical trial can begin.

As a result, submission of the IND may result in the FDA not allowing the trial to commence or not be conducted on the terms originally specified by the sponsor in the IND. If the FDA raises concerns or questions either during this initial 30-day period, or at any time during the IND process, it may choose to impose a partial or complete clinical hold. If the FDA imposes a clinical hold, trials being conducted under the IND may not recommence without FDA authorization and then only under terms authorized by the FDA. A clinical hold issued by the FDA may therefore delay either a proposed clinical trial or cause suspension of an ongoing trial, until all outstanding concerns have been adequately addressed and the FDA has notified the company that investigation may proceed. This could cause significant difficulties in completing planned clinical trials in a timely manner.

The FDA may impose clinical holds on a biological product candidate at any time before or during clinical trials due to safety concerns or non-compliance.

Human Clinical Trials in Support of an NDA or a BLA

Clinical trials involve the administration of the investigational product candidate to healthy volunteers or patients with the disease to be treated under the supervision of qualified principal investigators, generally physicians not employed by or under the trial sponsor’s control, in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent for their participation. Clinical trials are conducted under trial protocols detailing, among other things, the objectives of the trial, inclusion and exclusion criteria, the parameters to be used in monitoring safety, dosing procedures and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of an IND.

142

A sponsor who wishes to conduct a clinical trial outside the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of the NDA or BLA so long as the clinical trial is well-designed and well-conducted in accordance with GCP, including review and approval by an independent ethics committee, and the FDA is able to validate the trial data through an onsite inspection, if necessary.

Further, each clinical trial must be reviewed and approved by an IRB either centrally or individually at each institution at which the clinical trial will be conducted. The IRB will consider, among other things, clinical trial design, patient informed consent, ethical factors and the safety of human subjects. An IRB must operate in compliance with FDA regulations. The FDA, IRB, or the clinical trial sponsor may suspend or discontinue a clinical trial at any time for various reasons, including a finding that the clinical trial is not being conducted in accordance with FDA requirements or that the subjects or patients are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive GCP rules and the requirements for informed consent. The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee, or DSMB. This group may recommend continuation of the trial as planned, changes in trial conduct, or cessation of the trial at designated check points based on access to certain data from the trial.

Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Additional studies may be required after approval.

Phase 1 clinical trials (or Phase 1) are initially conducted in a limited population to test the product candidate for safety, including adverse effects, dose tolerance, absorption, metabolism, distribution, excretion and pharmacodynamics in healthy humans or, on occasion, in patients, such as in the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers.
Phase 2 clinical trials (or Phase 2) are generally conducted in a limited patient population to identify possible adverse effects and safety risks, preliminarily evaluate the efficacy of the product candidate for specific targeted indications and determine dose tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger Phase 3 clinical trials. When a drug is intended to treat life-threatening or severely debilitating illnesses, the FDA may accept well-controlled Phase 2 clinical trials as adequate to provide sufficient data on the drug’s safety and effectiveness to support a decision on its approvability for marketing, in which case Phase 3 clinical trials would not be required.
Phase 3 clinical trials (or Phase 3) proceed if the Phase 2 clinical trials demonstrate that a certain dose or dose range of the product candidate is potentially effective and has an acceptable safety profile. Phase 3 clinical trials are undertaken within an expanded patient population, often at geographically dispersed clinical trial sites, to gather additional information about safety and effectiveness necessary to evaluate the overall benefit-risk relationship of the product and to provide an adequate basis for product labeling.

In some cases, the FDA may approve an NDA or a BLA for a product candidate but require the sponsor to conduct additional clinical trials to further assess the product candidate’s safety and effectiveness after approval. Such post-approval trials are typically referred to as Phase 4 clinical trials (or Phase 4). These studies may be used to gain additional experience from the treatment of patients in the intended therapeutic indication and to document a clinical benefit in the case of biologics approved under accelerated approval regulations. If the FDA approves a product while a company has ongoing clinical trials that were not necessary for approval, a company may be able to use the data from these clinical trials to meet all or part of any Phase 4 clinical trial requirement or to request a change in the product labeling. Failure to exhibit due diligence with regard to conducting required Phase 4 clinical trials could result in withdrawal of approval for products.

143

During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA and the investigators for serious and unexpected adverse events, any findings from other trials, tests in laboratory animals or in vitro testing that suggest a significant risk for human subjects, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor’s initial receipt of the information. The FDA or the sponsor or its DSMB may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB’s requirements or if the new drug candidate or biological product candidate has been associated with unexpected serious harm to patients.

There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Sponsors of clinical trials of FDA-regulated products, including biologics, are required to register and disclose certain clinical trial information, which is publicly available at www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, trial sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed until the new product or new indication being studied has been approved.

Compliance with cGMP Requirements

Before approving an NDA or a BLA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in full compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final drug or biological product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the drug or biological product does not undergo unacceptable deterioration over its shelf life. In particular, the PHSA emphasizes the importance of manufacturing control for products like biologics whose attributes cannot be precisely defined.

Sponsors of BLAs and NDAs must report changes in CMC including manufacturing sites to FDA. Such changes may result in delays in approval of pending BLAs and NDAs or delays in manufacturing approved producers.

Manufacturers and others involved in the manufacture and distribution of approved drugs and biological products must also register their establishments with the FDA and certain state agencies. Both domestic and foreign manufacturing establishments must register and provide additional information to the FDA upon their initial participation in the manufacturing process.

The manufacturing facilities may be subject to periodic unannounced inspections by government authorities to ensure compliance with cGMPs and other laws. Manufacturers may have to provide, on request, electronic or physical records regarding their establishments. Delaying, denying, limiting or refusing inspection by the FDA may lead to a product being deemed to be adulterated.

Review and Approval of an NDA or a BLA

The results of product candidate development, pre-clinical testing and clinical trials, including negative or ambiguous results as well as positive findings, are submitted to the FDA as part of an NDA or a BLA requesting a license to market the product. These applications must contain extensive manufacturing information and detailed information on the composition of the product and proposed labeling. The FDA charges drug and biologic product manufacturers user fees, which are adjusted on an annual basis in accordance with the Prescription Drug User Fee Act, or PDUFA. The fee for the submission of an NDA or BLA for which clinical data is substantial (for example, for FY2021 this application fee exceeds $2.8 million), and the sponsor of an approved NDA or BLA is also subject to an annual program fee, currently more than $300,000 per program. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs or BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.

144

The FDA has 60 days after submission of the application to conduct an initial review to determine whether the NDA or BLA is sufficient to accept for filing based on the agency’s threshold determination that it is substantially complete so as to permit substantive review. Once the submission has been accepted for filing, the FDA begins an in-depth review of the application. Under the goals and policies agreed to by the FDA under PDUFA, the FDA aims to complete its initial review of a standard application and respond to the sponsor within ten months of the 60-day filing date, and for a priority review application within six months. The FDA does not always meet its PDUFA goal dates for standard and priority NDA or BLA applications, and its review goals are subject to change from time to time. The review process may often be significantly extended by FDA requests for additional information or clarification. The review process and the PDUFA goal date may also be extended by three months if the FDA requests or if the sponsor otherwise provides additional information or clarification regarding information already provided in the submission within the last three months before the PDUFA goal date.

Under the Pediatric Research Equity Act, or PREA, as amended, a BLA or supplement to a BLA must contain data that are adequate to assess the safety and efficacy of the product candidate for the claimed indications in all relevant pediatric populations and to support dosing and administration for each pediatric population for which the product is safe and effective. The FDA may grant deferrals for submission of pediatric data or full or partial waivers. The Food and Drug Administration Safety and Innovation Act, or the FDASIA, enacted in 2012, made permanent PREA to require a sponsor who is planning to submit a marketing application for a product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration to submit an initial Pediatric Study Plan, or PSP, within sixty days of an end-of-Phase 2 meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or Phase 2/3 clinical trial. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including trial objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an agreed upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from pre-clinical studies, early phase clinical trials or other clinical development programs.

The FDA reviews NDA and BLA applications to determine, among other things, whether the proposed product is safe and potent, or effective, for its intended use, and has an acceptable purity profile, and whether the product is being manufactured in accordance with GMP requirements to assure and preserve the product’s identity, safety, strength, quality, potency and purity. On the basis of the FDA’s evaluation of the application and accompanying information, including the results of the inspection of the manufacturing facilities and any FDA audits of clinical trial sites to assure compliance with GCPs, the FDA may issue an approval letter, denial letter or complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. Under the FDCA, the FDA may approve an NDA if it determines that the product is safe and effective for its intended use, the benefits of the drug outweigh any risks, and the methods used in manufacturing the drug and the controls used to maintain the drug’s quality are adequate to preserve the drug’s identity, strength, quality and purity. Under the PHSA, the FDA may approve a BLA if it determines that the product is safe, pure and potent and the facility where the product will be manufactured meets standards designed to ensure that it continues to be safe, pure and potent. If the application is not approved, the FDA will issue a complete response letter, or CRL, which describes the conditions that must be met in order to secure final approval of the application, and when possible will outline recommended actions the sponsor might take to obtain approval of the application. If a CRL is issued, the sponsor may either resubmit the NDA or BLA, addressing all of the deficiencies identified in the letter, or withdraw the application.

Sponsors that receive a CRL who elect to address the deficiencies may submit to the FDA information that represents a complete response to the issues identified by the FDA in the response letter. Such resubmissions are classified under PDUFA as either Class 1 or Class 2, based on the information submitted by a sponsor in response to an action letter. Under the goals and policies agreed to by the FDA under PDUFA, the FDA aims to review and act on a Class 1 resubmission with two months of receipt and, with respect to a Class 2 resubmission, within six months of receipt. The FDA will not approve an application until issues identified in the CRL have been addressed.

The FDA may also refer the application to an Advisory Committee for review, evaluation and recommendation as to whether the application should be approved and under what conditions. In particular, the FDA may refer applications for novel drug or biological products or drug or biological products that present difficult questions of safety or efficacy to an advisory committee. Typically, an Advisory Committee is a panel of independent experts, including clinicians and other scientific experts. The FDA is not bound by the recommendations of an Advisory Committee, but it considers such recommendations carefully when making decisions.

145

If the FDA approves a new product, it may limit the approved indications for use of the product, or limit the approval to specific dosages. It may also require that certain contraindications, warnings or precautions be included in the product labeling. In addition, the FDA may call for post-approval studies, including Phase 4 clinical trials, to further assess the product’s safety after approval. The agency may also require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including risk evaluation and mitigation strategies, or REMS, to help ensure that the benefits of the product outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring and the use of patent registries. If the FDA concludes a REMS is needed, the sponsor of the NDA or BLA must submit a proposed REMS; the FDA will not approve the NDA or BLA without a REMS, if required. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.

Fast Track, Breakthrough Therapy and Priority Review Designations

The FDA may designate certain products for expedited review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs include fast track designation, breakthrough therapy designation and priority review designation.

The FDA may designate a product for fast track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new drug or biologic may request that the FDA designate the drug or biologic as a fast track product at any time during the clinical development of the product. For fast track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a fast track product’s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a fast track product may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. However, the FDA’s time period goal for reviewing a fast track application does not begin until the last section of the application is submitted. Fast track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process.

In 2012, Congress enacted the FDASIA. This law established a new regulatory scheme allowing for expedited review of products designated as “breakthrough therapies.” A product may be designated as a breakthrough therapy if it is intended, either alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The FDA may take certain actions with respect to breakthrough therapies, including holding meetings with the sponsor throughout the development process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review process; assigning a cross-disciplinary project lead for the review team; and taking other steps to facilitate the design of clinical trials in an efficient manner.

The FDA may designate a product for priority review if it is a product that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines, on a case-by-case basis, whether the proposed product represents a significant improvement when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes and evidence of safety and effectiveness in a new subpopulation. A priority designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA’s goal for taking action on a marketing application to six months (compared to 10 months under standard review).

Fast track designation, priority review and breakthrough therapy designation may expedite the development or approval process, but do not change the standards for approval.

146

Accelerated Approval Pathway and Regenerative Medicine Advanced Therapy Designation

The FDA may grant accelerated approval to a product for a serious or life-threatening condition that provides meaningful therapeutic advantage to patients over existing treatments based upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant accelerated approval for such a condition when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, or IMM, and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. Products granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval.

For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a product, such as an effect on IMM. The FDA has stated that although it has limited experience with accelerated approvals based on intermediate clinical endpoints, such endpoints generally may support accelerated approval where the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate clinical benefit of a product.

The accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a product. Thus, accelerated approval has been used extensively in the development and approval of products for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large trials to demonstrate a clinical or survival benefit.

The accelerated approval pathway is usually contingent on a sponsor’s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the product’s clinical benefit. As a result, a product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or to confirm a clinical benefit during post-marketing studies, may lead the FDA to withdraw the product from the market. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by the FDA.

Accelerated approval pathways are available for regenerative medicine therapies that meet certain conditions. Regenerative medicine therapies include cell therapies (both allogenic and autologous), therapeutic tissue engineering products, human cell and tissue products, and combination products using any such therapies or products, except those regulated under section 361 of the PHSA. Human gene therapies, including genetically modified cells, that lead to a sustained effect on cells or tissues, may also meet the definition of a regenerative medicine therapy, as may xenogeneic cell products.

Regenerative medicine therapies designed to treat, modify, reverse or cure serious conditions are eligible for FDA’s expedited programs, including fast track designation, breakthrough therapy designation, priority review and accelerated approval, if they meet the criteria for such programs. They may also be eligible for Regenerative Medicine Advanced Therapy Designation, or RMAT designation.

An investigational drug is eligible for RMAT designation if it meets the definition of regenerative medicine therapy, it is intended to treat, modify, reverse or cure a serious condition, and preliminary clinical evidence indicates that the regenerative medicine therapy has the potential to address unmet medical needs for such condition. An unmet medical need is a condition whose treatment or diagnosis is not addressed adequately by available therapy.

RMAT designation confers all the benefits of the fast track and breakthrough therapy designation programs, including early actions with the FDA. The FDA reviews each application on a case-by-case basis to determine whether the clinical evidence is sufficient to support RMAT designation, considering factors such as the rigor of data collection, the consistency and persuasiveness of the outcomes, the number of patients or subjects, and the severity, rarity or prevalence of the condition, among other factors. The FDA may decline to grant RMAT designation if it finds the clinical evidence insufficient.

RMAT designation may expedite the development or approval process, but it does not change the standards for approval.

147

Patent Term Restoration

Depending upon the timing, duration and specifics of FDA approval of our drugs, some of our US patents may be eligible for limited patent term extension. These patent term extensions permit a patent restoration term of up to five years as compensation for any patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product’s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND, and the submission date of an NDA or BLA, plus the time between the submission date of an NDA or BLA and the approval of that application. Only one patent applicable to an approved drug is eligible for the extension, and the extension must be applied for prior to expiration of the patent. The United States Patent and Trademark Office, or the USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration.

Pediatric Exclusivity

Pediatric exclusivity is a type of non-patent marketing exclusivity available in the United States and, if granted, it provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity or listed patents. This six-month exclusivity may be granted if an NDA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA’s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve another application. The issuance of a Written Request does not require the sponsor to undertake the described studies.

Post-Approval Regulation

If regulatory approval for marketing of a new drug or biologic product or for a new indication for an existing product is obtained, the sponsor will be required to comply with rigorous and extensive post-approval regulatory requirements as well as any post-approval requirements that the FDA has imposed on the particular product as part of the approval process. The sponsor will be required, among other things, to report certain adverse reactions and production problems to the FDA, provide updated safety and efficacy information and comply with requirements concerning advertising and promotional labeling. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMP regulations, which impose certain procedural and documentation requirements upon manufacturers. Accordingly, the BLA holder and its third-party manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMP regulations and other regulatory requirements. In addition, changes to the manufacturing process or facility generally require prior FDA approval before being implemented, and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.

Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market study requirements or clinical trial requirements to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:

restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;
fines, untitled letters or warning letters or holds on post-approval clinical trials;
adverse publicity;
refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals;

148

product seizure or detention, or refusal to permit the import or export of products; or
injunctions, fines, debarment, disgorgement of profits or the imposition of civil or criminal penalties.

The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Pharmaceutical products may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.

In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. Most recently, the Drug Supply Chain Security Act, or DSCSA, was enacted with the aim of building an electronic system to identify and trace certain prescription drugs distributed in the United States, including most biological products. The DSCSA mandates phased-in and resource-intensive obligations for pharmaceutical manufacturers, wholesale distributors, and dispensers over a 10-year period that is expected to culminate in November 2023. From time to time, new legislation and regulations may be implemented that could significantly change the statutory provisions governing the approval, manufacturing and marketing of products regulated by the FDA. It is impossible to predict whether further legislative or regulatory changes will be enacted, or FDA regulations, guidance or interpretations changed or what the impact of such changes, if any, may be.

Biosimilars and Reference Product Exclusivity

The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, signed into law in 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or the BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. A federal district court ruling in Texas struck down the Affordable Care Act in its entirety based on constitutionality, and in December 2019 the Fifth Circuit Court of Appeals upheld lower court’s finding that the individual mandate in the law is unconstitutional. On June 17, 2021, the Supreme Court reversed the District Court decision on the basis that the Plaintiffs lacked standing.

The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars. Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity and potency, can be shown through analytical studies, animal studies, and a clinical trial or trials. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA.

149

A reference biological product is granted 12 years of data exclusivity from the time of first licensure of the product, and the first approved interchangeable biologic product will be granted an exclusivity period of up to one year after it is first commercially marketed. If pediatric studies are performed and accepted by the FDA as responsive to a Written Request, the 12-year exclusivity period will be extended for an additional six months. In addition, the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product. “First licensure” typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a supplement for the reference product for a subsequent application filed by the same sponsor or manufacturer of the reference product (or licensor, predecessor in interest or other related entity) for a change (not including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength or for a modification to the structure of the biological product that does not result in a change in safety, purity or potency. Therefore, one must determine whether a new product includes a modification to the structure of a previously licensed product that results in a change in safety, purity or potency to assess whether the licensure of the new product is a first licensure that triggers its own period of exclusivity. Whether a subsequent application, if approved, warrants exclusivity as the “first licensure” of a biological product is determined on a case-by-case basis with data submitted by the sponsor.

The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, recent government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate implementation and impact of the BPCIA is subject to significant uncertainty.

Regulation of Combination Products in the United States

Certain products may be comprised of components that would normally be regulated under different types of regulatory authorities and frequently by different centers at the FDA. These products are known as combination products. Specifically, under regulations issued by the FDA, a combination product may be:

A product comprised of two or more regulated components that are physically, chemically or otherwise combined or mixed and produced as a single entity;
Two or more separate products packaged together in a single package or as a unit and comprised of drug and device products, device and biological products, or biological and drug products;
A drug, or device or biological product packaged separately that according to its investigational plan or proposed labeling is intended for use only with an approved individually specified drug, device or biological product where both are required to achieve the intended use, indication or effect and where upon approval of the proposed product the labeling of the approved product would need to be changed, e.g., to reflect a change in intended use, dosage form, strength, route of administration or significant change in dose; or
Any investigational drug, device or biological product packaged separately that according to its proposed labeling is for use only with another individually specified investigational drug, device or biological product where both are required to achieve the intended use, indication or effect.

Under the FDCA, the FDA is charged with assigning a center with primary jurisdiction, or a lead center, for review of a combination product. That determination is based on the “primary mode of action” of the combination product. Thus, if the primary mode of action of a device-biologic combination product is attributable to the biological product, the FDA center responsible for premarket review of the biological product would have primary jurisdiction for the combination product. The FDA has also established an Office of Combination Products to address issues surrounding combination products and provide more certainty to the regulatory review process. That office serves as a focal point for combination product issues for agency reviewers and industry. It is also responsible for developing guidance and regulations to clarify the regulation of combination products, and for assignment of the FDA center that has primary jurisdiction for review of combination products where the jurisdiction is unclear or in dispute.

150

In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of products. Whether or not it obtains FDA approval for a product, an applicant will need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can initiate clinical trials or market and sell the product in those countries or jurisdictions.

Regulation Outside of the United States

In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our products outside of the United States. Whether or not we obtain FDA approval for a product candidate, we must obtain approval by the comparable regulatory authorities of foreign countries or economic areas, such as the 28-member European Union, before we may commence clinical trials or market products in those countries or areas. It is not yet clear how the United Kingdom’s withdrawal from the European Union, will affect the approval of medicinal products in the United Kingdom. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly between countries and jurisdictions and can involve additional testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.

Regulation and Procedures Governing Approval of Medicinal Products in the European Union

The process governing approval of medicinal products, including biological medicinal products and advanced therapy medicinal products, or ATMPs, which comprise gene therapy products, somatic cell therapy products and tissue-engineered products, in the European Union generally follows the same lines as in the United States. It entails satisfactory completion of pharmaceutical development, nonclinical and clinical studies to establish the safety and efficacy of the medicinal product for each proposed indication. Moreover, an applicant must also demonstrate the ability to manufacture the product to a suitable quality.

Clinical Trial Approval

Pursuant to the currently applicable Clinical Trials Directive 2001/20/EC and the Directive 2005/28/EC on GCP, a system for the approval of clinical trials in the European Union has been implemented through national legislation of the member states.

Clinical trials must be conducted in accordance with European Union and national regulations and the International Conference on Harmonization, or ICH, guidelines on GCP. Additional GCP guidelines from the European Commission, focusing in particular on traceability, apply to clinical trials of advanced therapy medicinal products. If the sponsor of the clinical trial is not established within the European Union, it must appoint an entity within the European Union to act as its legal representative.

Under this system, a sponsor must obtain approval from the competent national authority of a European Union member state in which the clinical trial is to be conducted or in multiple member states if the clinical trial is to be conducted in a number of member states. Furthermore, the sponsor may only start a clinical trial at a specific trial site after the independent ethics committee has issued a favorable opinion. The clinical trial application must be accompanied by a copy of the trial protocol and an investigational medicinal product dossier with supporting information prescribed by Directive 2001/20/EC and Directive 2005/28/EC and corresponding national laws of the member states and further detailed in applicable guidance documents. Moreover, the sponsor must take out a clinical trial insurance policy, and in most European Union countries the sponsor is liable to provide ‘no fault’ compensation to any trial subject injured in the clinical trial.

In April 2014, the new Clinical Trials Regulation, (EU) No 536/2014 (Clinical Trials Regulation) was adopted, but it is not yet applicable in the European Union. The Clinical Trials Regulation will be directly applicable in all the European Union Member States, repealing the current Clinical Trials Directive 2001/20/EC. Conduct of all clinical trials performed in the European Union will continue to be bound by currently applicable provisions until the new Clinical Trials Regulation becomes applicable. The extent to which ongoing clinical trials will be governed by the Clinical Trials Regulation will depend on when the Clinical Trials Regulation becomes applicable and on the duration of the individual clinical trial. If a clinical trial continues for more than three years from the day on which the Clinical Trials Regulation becomes applicable the Clinical Trials Regulation will at that time begin to apply to the clinical trial.

151

The new Clinical Trials Regulation aims to simplify and streamline the approval of clinical trials in the European Union. The main characteristics of the regulation include: a streamlined application procedure via a single entry point, the “EU portal”; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts. Part I is assessed by the competent authorities of all European Union Member States in which an application for authorization of a clinical trial has been submitted (Member States concerned). Part II is assessed separately by each Member State concerned. Strict deadlines have been established for the assessment of clinical trial applications. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the concerned European Union Member State. However, overall related timelines will be defined by the Clinical Trials Regulation. The sponsor of a clinical trial must register the clinical trial in advance, and information related to the product, patient population, phase of investigation, trial sites and investigators, and other aspects of the clinical trial will be made public as part of the registration. The results of the clinical trial must be submitted to the competent authorities and, with the exception of non-pediatric Phase 1 trials, will be made public at the latest within 12 months after the end of the trial.

During the development of a medicinal product, the EMA and national medicines regulators within the European Union provide the opportunity for dialogue and guidance on the development program. At the EMA level, this is usually done in the form of scientific advice, which is given by the Scientific Advice Working Party of the Committee for Medicinal Products for Human Use, or CHMP. A fee is incurred with each scientific advice procedure. Advice from the EMA is typically provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and clinical studies, and pharmacovigilance plans and risk-management programs. Advice is not legally binding with regard to any future marketing authorization application of the product concerned.

Marketing Authorization

To obtain a marketing authorization for a product under the European Union regulatory system, a sponsor must submit a marketing authorization application, or MAA, either under a centralized procedure administered by the EMA or one of the procedures administered by competent authorities in European Union member states (decentralized procedure, national procedure or mutual recognition procedure).

All application procedures require an application in the common technical document, or CTD, format, which includes the submission of detailed information about the manufacturing and quality of the product, and nonclinical and clinical trial information. There is an increasing trend in the European Union toward greater transparency and, while the manufacturing or quality information is currently generally protected as confidential information, the EMA and national regulatory authorities are now liable to disclose much of the nonclinical and clinical information in marketing authorization dossiers, including the full clinical trial reports, in response to freedom of information requests after the marketing authorization has been granted. In October 2014, the EMA adopted a policy under which clinical trial reports would be posted on the agency’s website following the grant, denial or withdrawal of a MAA, subject to procedures for limited redactions and protection against unfair commercial use. A similar requirement is contained in the new Clinical Trials Regulation that is currently expected to take effect at earliest in 2020.

A marketing authorization may be granted only to a sponsor established in the European Union. Regulation (EC) No. 1901/2006 on medicinal products for pediatric use provides that prior to obtaining a marketing authorization in the European Union in the centralized procedure, a sponsor must demonstrate compliance with all measures included in an EMA-approved Pediatric Investigation Plan covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, class waiver or deferral for one or more of the measures included in the Pediatric Investigation Plan.

The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid for all European Union member states. Pursuant to Regulation (EC) No. 726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products and products with a new active substance indicated for the treatment of certain diseases, including products for the treatment of cancer. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of patients, the centralized procedure may be optional.

Under the centralized procedure, the CHMP established at the EMA is responsible for conducting the assessment of a product to define its risk/benefit profile. Under the centralized procedure, the maximum timeframe for the evaluation of an MAA is 210 days, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response to

152

questions from the CHMP. Accelerated evaluation may be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health determined by three cumulative criteria: (i) the seriousness of the disease (e.g., heavy disabling or life-threatening diseases) to be treated, (ii) the absence or insufficiency of an appropriate alternative therapeutic approach, and (iii) anticipation of high therapeutic benefit.

If the CHMP accepts such a request, the time limit of 210 days will be reduced to 150 days, but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that it is no longer appropriate to conduct an accelerated assessment.

The Committee for Advanced Therapies, or CAT, is responsible in conjunction with the CHMP for the evaluation of ATMPs. The CAT is primarily responsible for the scientific evaluation of ATMPs and prepares a draft opinion on the quality, safety and efficacy of each ATMP for which a MAA is submitted. The CAT’s opinion is then taken into account by the CHMP when giving its final recommendation regarding the authorization of a product in view of the balance of benefits and risks identified. Although the CAT’s draft opinion is submitted to the CHMP for final approval, the CHMP may depart from the draft opinion if it provides detailed scientific justification. The CHMP and CAT are also responsible for providing guidelines on ATMPs and have published numerous guidelines, including specific guidelines on gene therapies and cell therapies. These guidelines, which are not legally binding, provide additional guidance on the factors that the EMA will consider in relation to the development and evaluation of ATMPs and include, inter alia, the pre-clinical studies required to characterize ATMPs, the manufacturing and control information that should be submitted in a MAA; and post-approval measures required to monitor patients and evaluate the long term efficacy and potential adverse reactions of ATMPs.

The European Commission may grant a so-called “marketing authorization under exceptional circumstances.” Such authorization is intended for products for which the applicant can demonstrate that it is unable to provide comprehensive data on the efficacy and safety under normal conditions of use, because the indications for which the product in question is intended are encountered so rarely that the applicant cannot reasonably be expected to provide comprehensive evidence, or in the present state of scientific knowledge, comprehensive information cannot be provided, or it would be contrary to generally accepted principles of medical ethics to collect such information. Consequently, marketing authorization under exceptional circumstances may be granted subject to certain specific obligations, which may include the following:

the applicant must complete an identified program of studies within a time period specified by the competent authority, the results of which form the basis of a reassessment of the benefit/risk profile;
the medicinal product in question may be supplied on medical prescription only and may in certain cases be administered only under strict medical supervision, possibly in a hospital, and in the case of a radio-pharmaceutical, by an authorized person; and
the package leaflet and any medical information must draw the attention of the medical practitioner to the fact that the particulars available concerning the medicinal product in question are as yet inadequate in certain specified respects.

A marketing authorization under exceptional circumstances is subject to annual review to reassess the risk-benefit balance in an annual re-assessment procedure. Continuation of the authorization is linked to the annual reassessment and a negative assessment could potentially result in the marketing authorization being suspended or revoked. The renewal of the marketing authorization of a medicinal product under exceptional circumstances follows the same rules as a “normal” marketing authorization. After five years, the marketing authorization will then be renewed under exceptional circumstances for an unlimited period, unless the EMA decides, on justified grounds, to proceed with one additional five-year renewal.

The European Commission may also grant a so-called “conditional marketing authorization” prior to obtaining the comprehensive clinical data required for an application for a full marketing authorization. Such conditional marketing authorizations may be granted for product candidates (including medicines designated as orphan medicinal products) if the CHMP finds that all the following requirements are met:

the benefit-risk balance of the product is positive;
it is likely that the applicant will be able to provide comprehensive data;

153

unmet medical needs will be fulfilled; and
the benefit to public health of the medicinal product’s immediate availability on the market outweighs the risks due to need for further data.

A conditional marketing authorization may contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with respect to the completion of ongoing or new studies, and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations are valid for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need for additional or modified conditions and/or specific obligations. The timelines for the centralized procedure described above also apply with respect to the review by the CHMP of applications for a conditional marketing authorization. Once comprehensive data on the medicinal product have been obtained, the marketing authorization may be converted into a standard marketing authorization which is no longer subject to specific obligations. Initially, this is valid for five years, but can be renewed for unlimited validity.

The European Union medicines rules expressly permit the member states to adopt national legislation prohibiting or restricting the sale, supply or use of any medicinal products containing, consisting of or derived from a specific type of human or animal cell, such as embryonic stem cells.

Conditional Approval

In specific circumstances, European Union legislation (Article 14(7) Regulation (EC) No 726/2004 and Regulation (EC) No 507/2006 on Conditional Marketing Authorizations for Medicinal Products for Human Use) enables applicants to obtain a conditional marketing authorization prior to obtaining the comprehensive clinical data required for an application for a full marketing authorization. Such conditional approvals may be granted for product candidates (including medicines designated as orphan medicinal products) if (1) the risk-benefit balance of the product candidate is positive, (2) it is likely that the applicant will be in a position to provide the required comprehensive clinical trial data, (3) the product fulfills unmet medical needs and (4) the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. A conditional marketing authorization may contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with respect to the completion of ongoing or new studies, and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations are valid for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need for additional or modified conditions or specific obligations. The timelines for the centralized procedure described above also apply with respect to the review by the CHMP of applications for a conditional marketing authorization.

Pediatric Studies

Prior to obtaining a marketing authorization in the European Union, applicants have to demonstrate compliance with all measures included in an EMA-approved Pediatric Investigation Plan, or PIP, covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, a class waiver, or a deferral for one or more of the measures included in the PIP. The respective requirements for all marketing authorization procedures are set forth in Regulation (EC) No 1901/2006, which is referred to as the Pediatric Regulation. This requirement also applies when a company wants to add a new indication, pharmaceutical form or route of administration for a medicine that is already authorized. The Pediatric Committee of the EMA, or PDCO, may grant deferrals for some medicines, allowing a company to delay development of the medicine in children until there is enough information to demonstrate its effectiveness and safety in adults. The PDCO may also grant waivers when development of a medicine in children is not needed or is not appropriate, such as for diseases that only affect the elderly population.

Before a marketing authorization application can be filed, or an existing marketing authorization can be amended, the EMA determines that companies actually comply with the agreed studies and measures listed in each relevant PIP.

154

European Union Regulatory Exclusivity

In the European Union, new products authorized for marketing (i.e., reference products) qualify for eight years of data exclusivity and an additional two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar applicants from relying on the pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the European Union during a period of eight years from the date on which the reference product was first authorized in the European Union. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the European Union until ten years have elapsed from the initial authorization of the reference product in the European Union. The ten-year market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.

European Union Orphan Designation and Exclusivity

The criteria for designating an orphan medicinal product in the European Union, are similar in principle to those in the United States. Under Article 3 of Regulation (EC) 141/2000, a medicinal product may be designated as orphan if (1) it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (2) either (a) such condition affects no more than five in 10,000 persons in the European Union when the application is made, or (b) the product, without the benefits derived from orphan status, would not generate sufficient return in the European Union to justify investment; and (3) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the European Union, or if such a method exists, the product will be of significant benefit to those affected by the condition, as defined in Regulation (EC) 847/2000. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and are, upon grant of a marketing authorization, entitled to ten years of market exclusivity for the approved therapeutic indication. The application for orphan designation must be submitted before the application for marketing authorization. The applicant will receive a fee reduction for the marketing authorization application if the orphan designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.

The ten-year market exclusivity in the European Union may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, marketing authorization may be granted to a similar product for the same indication at any time if:

the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior;
the applicant consents to a second orphan medicinal product application; or
the applicant cannot supply enough orphan medicinal product.

PRIME Designation

The EMA grants access to the Priority Medicines, or PRIME, program to investigational medicines for which it determines there to be preliminary data available showing the potential to address an unmet medical need and bring a major therapeutic advantage to patients. As part of the program, EMA provides early and enhanced dialogue and support to optimize the development of eligible medicines and speed up their evaluation, aiming to bring promising treatments to patients sooner.

Periods of Authorization and Renewals

A marketing authorization is valid for five years, in principle, and it may be renewed after five years on the basis of a reevaluation of the risk benefit balance by the EMA or by the competent authority of the authorizing Member State. To that end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least six months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the European Commission or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one

155

additional five-year renewal period. Any authorization that is not followed by the placement of the product on the European Union market (in the case of the centralized procedure) or on the market of the authorizing Member State within three years after authorization ceases to be valid.

Regulatory Requirements after Marketing Authorization

Following approval, the holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of the medicinal product. These include compliance with the European Union’s stringent pharmacovigilance or safety reporting rules, pursuant to which post-authorization studies and additional monitoring obligations can be imposed. The holder of a marketing authorization must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety update reports, or PSURs. All new MAAs must include a risk management plan, or RMP, describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the marketing authorization. Such risk-minimization measures or post-authorization obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety studies. RMPs and PSURs are routinely available to third parties requesting access, subject to limited redactions.

In addition, the manufacturing of authorized products, for which a separate manufacturer’s license is mandatory, must also be conducted in strict compliance with the EMA’s GMP requirements and comparable requirements of other regulatory bodies in the European Union, which mandate the methods, facilities and controls used in the manufacturing, processing and packing of products to assure their safety and identity. Specifically, medicinal products may only be manufactured in the European Union, or imported into the European Union from another country, by the holder of a manufacturing/import authorization from the competent national authority. The manufacturer or importer must have a qualified person who is responsible for certifying that each batch of product has been manufactured in accordance with European Union standards of good manufacturing practice, or GMP, before releasing the product for commercial distribution in the European Union or for use in a clinical trial. Manufacturing facilities are subject to periodic inspections by the competent authorities for compliance with GMP.

Finally, the marketing and promotion of authorized products, including industry-sponsored continuing medical education and advertising directed toward the prescribers of products and/or the general public, are strictly regulated in the European Union. In principle, all advertising and promotional activities for the product must be consistent with the approved summary of product characteristics, and therefore all off-label promotion is prohibited. Direct-to-consumer advertising of prescription medicines is also prohibited in the European Union. Although general requirements for advertising and promotion of medicinal products are established under Directive 2001/83/EC, as amended, the details are governed by regulations in each member state and can differ from one country to another.

Human Cells and Tissues

Human cells and tissues that are intended for human applications but that do not fall within the scope of rules governing medicinal products or medical devices are not subject to premarket review and approval, nor do they require extensive pre-clinical and clinical testing. However, there are European Union rules governing the donation, procurement, testing and storage of human cells and tissues intended for human application, whether or not they are ATMPs. These rules also cover the processing, preservation and distribution of human cell and tissues that are not ATMPs. Establishments that conduct such activities must be licensed and are subject to inspection by regulatory authorities. Such establishments must implement appropriate quality systems and maintain appropriate records to ensure that cells and tissues can be traced from the donor to the recipient and vice versa. There are also requirements to report serious adverse events and reactions linked to the quality and safety of cells and tissues. More detailed rules may exist at the national level.

Named Patient Supplies

The European Union medicines rules allow individual member states to permit the supply of a medicinal product without a marketing authorization to fulfill special needs, where the product is supplied in response to a bona fide unsolicited order, formulated in accordance with the specifications of a healthcare professional and for use by an individual patient under his direct personal responsibility. This may in certain countries also apply to products manufactured in a country outside the European Union and imported to treat specific patients or small groups of patients.

156

Rest of the World Regulation

For other countries outside of the European Union and the United States, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from jurisdiction to jurisdiction. Additionally, the clinical trials must be conducted in accordance with cGCP requirements and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.

If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.

European Data Collection and Data Protection Laws

We are required to comply with strict data protection and privacy legislation in the jurisdictions in which we operate, including the General Data Protection Regulation (EU) 2016/679, or GDPR. The GDPR governs our collection and use of personal data in the European Union relating to individuals (e.g., patients). The GDPR imposes several requirements on organizations that process such data, including: to observe core data processing principles; to comply with various accountability measures; to provide more detailed information to individuals about data processing activities; to establish a legal basis to process personal data (including enhanced consent requirements); to maintain the integrity, security and confidentiality of personal data; and to report personal data breaches. The GDPR also restricts the transfer of personal data outside of the European Economic Area (e.g., to the United States and other countries that are not deemed to provide adequate protection under their domestic laws). The GDPR may impose additional responsibility and liability in relation to personal data that we process and require us to put in place additional mechanisms ensuring compliance with the new data protection rules. This may be onerous and adversely affect our business, financial condition, results of operations and prospects. Failure to comply with the requirements of the GDPR and related national data protection laws of European Union member states may result in a variety of enforcement measures, including significant fines and other administrative measures. The GDPR has introduced substantial fines for breaches of the data protection rules, increased powers for regulators, enhanced rights for individuals, and new rules on judicial remedies and collective redress. We may be subject to claims by third parties, such as patients or regulatory bodies, that we or our employees or independent contractors inadvertently or otherwise breached GDPR and related data protection rules.

Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and if we do not prevail, we could be required to pay substantial fines and/or damages and could suffer significant reputational harm. Even if we are successful, litigation could result in substantial cost and be a distraction to management and other employees.

Coverage, Pricing and Reimbursement

Sales of pharmaceutical products approved by the FDA will depend in significant part on the availability of third-party coverage and reimbursement for the products. Third-party payors include government healthcare programs in the United States such as Medicare and Medicaid, managed care providers, private health insurers and other organizations. These third-party payors are increasingly challenging the price and examining the cost-effectiveness of medical products and services. In addition, significant uncertainty exists as to the reimbursement status of newly approved healthcare products. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the approved products for a particular indication. We may need to conduct expensive pharmacoeconomic studies to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Moreover, a payor’s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Third-party reimbursement may not be sufficient to maintain price levels high enough to realize an appropriate return on investment in product development. Our product candidates may not be considered cost-effective. It is time consuming and expensive to seek reimbursement from third-party payors. Reimbursement may not be available or sufficient to allow us to sell our products on a competitive and profitable basis.

In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. Some countries provide that drug products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of our product candidate to currently available therapies (so called health technology assessment, or HTA) in order to obtain reimbursement or pricing approval. For example, the European Union provides options for its member states

157

to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Other member states allow companies to fix their own prices for drug products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United States and generally tend to by significantly lower.

The downward pressure on health care costs in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states and parallel distribution (arbitrage between low-priced and high-priced member states) can further reduce prices. Any country that has price controls or reimbursement limitations for drug products may not allow favorable reimbursement and pricing arrangements.

Other United States Healthcare Laws and Regulations

Healthcare providers and third-party payors play a primary role in the recommendation and prescription of pharmaceutical products that are granted marketing approval. Our current and future arrangements with providers, researchers, consultants, third-party payors and customers are subject to broadly applicable federal and state fraud and abuse, anti-kickback, false claims, transparency and patient privacy laws and regulations and other healthcare laws and regulations that may constrain our business and/or financial arrangements. Restrictions under applicable federal and state healthcare laws and regulations include, without limitation, the following:

the United States federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in-cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or a specific intent to violate it in order to have committed a violation. Moreover, the government may assert that a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;
the federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false, fictitious, or fraudulent or knowingly making, using, or causing to be made or used a false record or statement to avoid, decrease, or conceal an obligation to pay money to the federal government;
HIPAA, which created additional federal criminal laws that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or a specific intent to violate it in order to have committed a violation;
HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their respective implementing regulations, including the Final Omnibus Rule published in January 2013, which impose obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without the appropriate authorization by entities subject to the law, such as healthcare providers, health plans and healthcare clearinghouses and their respective business associates;
the federal transparency requirements known as the federal Physician Payments Sunshine Act, under the ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare & Medicaid Services, or CMS, within the United States Department of Health and Human Services, information related to payments and other transfers of value made by that entity to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;

158

federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;
federal government price reporting laws, which require us to calculate and report complex pricing metrics to government programs and which may be used in the calculation of reimbursement and/or discounts on marketed products;
the Foreign Corrupt Practices Act, a United States law which regulates certain financial relationships with foreign government officials (which could include, for example, certain medical professionals);
the national anti-bribery laws and laws governing interactions with healthcare professionals of European Union Member States;
the U.K. Bribery Act 2010; and
analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to healthcare items or services that are reimbursed by non-governmental third-party payors, including private insurers.

Some state laws require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring pharmaceutical manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures and pricing information. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.

The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry.

Violations of these laws can subject us to criminal, civil and administrative sanctions including monetary penalties, damages, fines, disgorgement, individual imprisonment and exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, reputational harm, and we may be required to curtail or restructure our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to similar actions, penalties, and sanctions. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company’s attention from the business. Moreover, we expect that there will continue to be federal and state laws and regulations, proposed and implemented, that could impact our future operations and business.

Current and Future Healthcare Reform Legislation

The FDA’s and other regulatory authorities’ policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. For example, in December 2016, the 21st Century Cures Act, or Cures Act, was signed into law. The Cures Act, among other things, is intended to modernize the regulation of drugs and devices and to spur innovation, but its ultimate implementation is uncertain. In addition, in August 2017, the FDA Reauthorization Act was signed into law, which reauthorized the FDA’s user fee programs and included additional drug and device provisions that build on the Cures Act. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we otherwise may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations.

As previously mentioned, a primary trend in the United States health care industry and elsewhere is cost containment. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products and services, implementing reductions in Medicare and other health care funding and applying new payment methodologies. For example, in March 2010, the Affordable Care Act was enacted, which, among other things, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; introduced a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused,

159

instilled, implanted or injected; extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care plans; imposed mandatory discounts for certain Medicare Part D beneficiaries as a condition for manufacturers’ outpatient drugs coverage under Medicare Part D; and established a Center for Medicare Innovation at the United States Centers for Medicare and Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending.

Since its enactment, there have been judicial and Congressional challenges to certain aspects of the Affordable Care Act, and we expect there will be additional challenges and amendments to the Affordable Care Act in the future. The current Presidential administration and members of the United States Congress have indicated that they may continue to seek to modify, repeal or otherwise invalidate all, or certain provisions of, the Affordable Care Act. For example, the Tax Cuts and Jobs Acts was enacted in 2017, which, among other things, removed penalties for not complying with the individual mandate to carry health insurance. As noted above, a 2018 federal district court ruling struck down the Affordable Care Act in its entirety although the Fifth Circuit Court of Appeals recently limited it to the individual mandate and remanded the case to the district court to determine if other reforms not specifically related to the individual mandate or health insurance could be severed from the rest of the Affordable Care Act. On June 17, 2021, the Supreme Court reversed the district court decision on the basis that the plaintiffs lacked standing.

In addition, other legislative changes have been proposed and adopted in the United States since the Affordable Care Act that affect health care expenditures. There has been heightened governmental scrutiny in recent years over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for pharmaceutical and biologic products. Notably, on December 20, 2019, President Trump signed the Further Consolidated Appropriations Act for 2020 into law (P.L. 116-94) that includes a piece of bipartisan legislation called the Creating and Restoring Equal Access to Equivalent Samples Act of 2019 or the CREATES Act. The CREATES Act aims to address the concern articulated by both the FDA and others in the industry that some brand manufacturers have improperly restricted the distribution of their products, including by invoking the existence of a REMS for certain products, to deny generic and biosimilar product developers access to samples of brand products. Because generic and biosimilar product developers need samples to conduct certain comparative testing required by the FDA, some have attributed the inability to timely obtain samples as a cause of delay in the entry of generic and biosimilar products. To remedy this concern, the CREATES Act establishes a private cause of action that permits a generic or biosimilar product developer to sue the brand manufacturer to compel it to furnish the necessary samples on “commercially reasonable, market-based terms.” Whether and how generic and biosimilar product developments will use this new pathway, as well as the likely outcome of any legal challenges to provisions of the CREATES Act, remain highly uncertain and its potential effects on our future commercial products are unknown.

We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. We expect that additional state and federal health care reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for health care products and services.

Packaging and Distribution in the United States

If our products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities also are potentially subject to federal and state consumer protection and unfair competition laws.

The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products.

The failure to comply with any of these laws or regulatory requirements subjects’ firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, exclusion from federal healthcare programs, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals, or refusal to allow a firm to enter into supply contracts, including government contracts. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business. Prohibitions or restrictions on sales or withdrawal of future products marketed by us could materially affect our business in an adverse way.

160

Changes in regulations, statutes, or the interpretation of existing regulations could impact our business in the future by requiring, for example, (i) changes to our manufacturing arrangements, (ii) additions or modifications to product labeling, (iii) the recall or discontinuation of our products or (iv) additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.

Other United States Environmental, Health and Safety Laws and Regulations

We may be subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.

We maintain workers’ compensation employers’ liability insurance to cover us for costs and expenses we may incur due to injuries to our employees, but this insurance may not provide adequate coverage against potential liabilities.

In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and regulations may impair our research, development or production efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions.

Intellectual Property

Introduction

We actively seek to protect the intellectual property and proprietary technology that we believe is important to our business. Further, we seek to protect our proprietary position by, amongst other methods, filing patent applications in Europe, the United States and potentially other relevant jurisdictions relating to our inventions, improvements and product candidates that are important to our business. We also pursue IP protection for assets that may be used in future development programs and/or that may be of interest to our collaborators, or otherwise may prove valuable in the field. We pursue a patent strategy which seeks to protect marketed products and methods of their production, as well as therapy methods enabled by our proprietary AI technologies without disclosure to the public of the core elements in each technology. Furthermore, we have filed patent protection of aspects of our PIONEER platform, however, we do not believe that the value of obtaining patent protection for all component of our platform technologies outweighs the risks of disclosing such information. We rely on trade secrets and know-how relating to our proprietary technologies to develop, maintain and strengthen our proprietary position in AI-based drug discovery and development.

Patent applications that relate to the PIONEER technology cannot meaningfully be directed to single antigens and their various uses; neoepitopes identified by PIONEER are by nature unique for each patient, therefore, the precise nature of each neoepitope has no relevance as an object for intellectual property rights. We are therefore establishing a patent protection which protects generally applicable aspects of the PIONEER enabled patient-specific immunotherapy, i.e. protection of additional features and elements which characterize the PIONEER-enabled therapy compositions, and which could be applied to other anti-cancer therapies that are based on immunization against neoepitopes. The focus on the patent protection in the PIONEER setting is therefore aiming at securing patent protection for 1) specific essential elements/ features needed to identify neoepitopes not specific to the PIONEER system, 2) specific features characterizing the composition of the designed therapy, and 3) specific features related to patient safety of the administered composition.

For the EDEN technology, we file patents to protect vaccine antigens identified, vaccine compositions, antibodies, and antibody compositions as well as methods for prophylactic treatment of infectious diseases where the vaccine antigens and antibodies constitute the active ingredient. We draft applications relating to several vaccine targets for each infectious agent causing the diseases and prosecute those antigens that have shown greatest promise as protective antigens in animal models. Our patent strategy for the EDEN technology also entails identification of optimal combinations of vaccine antigens as well as identification of specific vaccine formulations and modes of immunization that can be made the subject of 2nd and later generation patent applications that protect the final marketed product.

161

Most of our IP assets were developed and are owned solely by us. In the few cases where our IP assets are jointly owned or in-licensed from third parties, we retain full rights to the commercial exploitation of such assets. We expect that we will continue to make additional patent application filings and will continue to pursue opportunities to acquire and license additional IP assets.

Regardless, given the early stage of development of our product candidates, we cannot be certain that any of the patent filings or other IP rights that we have pursued or obtained will provide protection for any product candidates that may ultimately be commercialized. Our most advanced product candidates are currently in clinical testing, with no certainty that they will be successful, or that significant modification or adjustment may not be required for successful commercialization.

Our success will depend on our ability to obtain and maintain patent and other proprietary protection for commercially important technologies, inventions, and know-how related to our business, defend and enforce our patents, preserve the confidentiality of our trade secrets and operate without infringing the valid and enforceable patents and proprietary rights of third parties. For more information, please see “Risk Factors – Risk Related to Our Intellectual Property”.

An issued patent provides its owner (or possibly its licensee) with a right to exclude others from making, using or selling that which is claimed in the patent, for a specified period of time (the “term” of the patent), in the jurisdiction in which the patent is issued. In the United States, and in many other countries, patents have a presumptive term of 20 years from their accorded filing date (which is the earliest filing date to which the patent claims lineage, excluding filing dates claimed as priorities under the Paris Convention Priorities and/or priorities claimed from provisional patent applications). We believe that due to the patient-specific nature of our PIONEER-based immunotherapies, in which our PIONEER platform is an inherent part, and the platform predicted neoepitopes cannot, we believe, be copied, such therapies will not be subject to competition from generic products even when the patent protection expires.

Patent Portfolio

As of December 31, 2021, we owned a total of 26 patent families, of which 13 are currently in their priority year or international phase and we own several granted patents in the United States (8), Germany (2), France (2) and Great Britain (2) two patents allowed in Europe and have 30 pending national/regional applications.

So far none of our granted patents has been subject to opposition, administrative reexamination, inter partes review, invalidity actions, or similar actions aiming at revoking or restricting the scope of a granted patent.

The patent portfolio related to our most advanced product candidates and technologies as of December 31, 2021 are summarized below.

EVX-01

EVX-01 is protected by trade secrets and the proprietary nature of the PIONEER technologies which cannot be copied. Our patent portfolio related to EVX-01 currently includes one patent family. The first patent family is directed to a method of treating cancer in a patient using EVX-01 and has entered national phase in CA, CN, US, EP, JP and AU. We expect the patent family to lapse in January 2040.

EVX-02

EVX-02 is protected by trade secrets and the proprietary nature of the PIONEER technologies which cannot be copied. Our patent portfolio related to EVX-02 currently includes two patent families. The first patent family, also related to EVX-03, is a method patent directed at inducing an anti-cancer immune response in patients by administrating EVX-02 immunotherapy concept comprising DNA plasmid and polaxomer 188, a novel adjuvant. The second patent family is directed at a method of inducing and anti-cancer immune response in patients by administrating the EVX-02 plasmid alone. As of December 31, 2021, the first patent family is in national phase in CA, CN, US, JP and AU and the second in the international phase. The first patent family is expected to lapse in March 2040 and the second in December 2040.

EVX-03

EVX-03 is protected by trade secrets and the proprietary nature of the PIONEER technologies which cannot be copied. Our patent portfolio related to EVX-03 currently includes two patent families. The first patent family is a composition of matter family directed

162

to the EVX-03 product concept. As of December 31, 2021, the patent family was in its international phase and is expected to lapse upon entering international and/or national phase in April 2041. The second patent family, also related to EVX-02, is a method patent directed at inducing an anti-cancer immune response in patients by administrating EVX-03 immunotherapy comprising DNA plasmid and polaxomer 188, a novel adjuvant.

EVX-B1

Our patent portfolio related to EVX-B1 currently includes five patent families. The patent families are composition of matter patents directed against compositions comprising one or more S. aureus antigens. As of December 31, 2021, the first patent family comprised five issued patents in the US, one in DE, one in FR and one in GB as well as one pending application in US and one pending in EP. The patent family is expected to expire in April 2032. The second patent family comprises one US and one EP pending application. We expect the patent family to lapse in December 2034. The third patent family currently comprises one US registered patent and one EP application which has been allowed by the EPO and is entering validation in EP countries. We expect the family to lapse in February 2037. Our fourth EVX-B1 related patent family has pending applications in EP and US jurisdictions. We expect this patent family to lapse in July 2037. The fifth family is in international phase and upon national phases, we expect this patent family to lapse in November 2041.

PIONEER

The PIONEER system is mainly protected as a trade secret as computational methods are complicated to patent and protect from infringement. However, our current patent portfolio comprises of two patent families related to PIONEER. Including a new patent family born in December 2021 with the filing of a European priority founding patent application. The first patent family is directed against a method for selecting a set of neoepitopes for treatment of cancer comprising the SLICE model used in PIONEER for epitope prioritization. As of December 31, 2021, the patent family is in its international phase and upon entry into national stages, we expect the family to lapse in July 2041. The technology covered by the new European patent family supplements the identification of neoepitopes with a system for identifying and utilising highly immunogenic hERVs (human endogenous retroviral sequences) and other, normally non-expressed DNA sequences found in the human genome.

AICoV

Our AICoV program is protected by trade secrets and the proprietary nature of the RAVEN platform. Our patent portfolio related to AICoV currently includes two patent families. The first patent family is a composition of matter family directed to the vaccine delivery concept in AICoV. This patent family entered international phase in July 2021 and will upon entering national phase lapse in July 2041. The second patent family is aimed at the design of vaccines using the RAVEN platform. As of December 31, 2021, this patent family was in its priority year and is expected to lapse upon entry into international and national phase, in 2042.

In-Licensing

We have pursued a strategy of identifying and in-licensing third-party patents that we believe are complementary to or otherwise interact synergistically with our own intellectual property portfolio. On November 30, 2020 we entered into a CAF®09b Supply, Patent Know How Trademark License Agreement with Statens Serum Institut, or SSI, which will grant us a non-exclusive, royalty-bearing sub-licensable license to SSI’s adjuvant technology CAF®09b. Pursuant to the terms of the agreement, we or our affiliates may import, have imported, export, have exported, formulate or have formulated, commercialize, market, use, offer for sale, sell, have sold, supply, or have supplied PIONEER derived immunotherapies administered together or in combination with licensed adjuvant, but not, on a stand-alone basis, the licensed adjuvant. The license specifically excludes any manufacturing rights to the licensed adjuvant, unless the license is extended and the license further excludes any research and development in relation to the licensed adjuvant other than where such research and development is in connection with and for the purpose of research and development in respect of PIONEER derived immunotherapies administered together or in combination with licensed adjuvant.

Pursuant to the SSI agreement, we have rights to three issued United States patents and other patents and patent applications in jurisdictions outside the United States.

The SSI license requires us to pay to SSI an upfront licensing fee equal to €50,000. In addition, in the event we commercialize any PIONEER derived immunotherapies administered together or in combination with licensed adjuvant on our own, we are required to pay SSI a royalty on net sales in the low teens. The royalty term extends for a fixed period of 10 years commencing on the first

163

calendar day of the calendar month following the first commercial sale of a PIONEER derived immunotherapy administered together or in combination with the licensed adjuvant. Upon expiration thereof, the SSI license shall be deemed to be fully paid up, royalty-free, irrevocable and perpetual with respect to such immunotherapy. However, if any PIONEER derived immunotherapies administered together or in combination with licensed adjuvant are commercialized by one of our partners, if any, we are required to pay SSI a percentage of any out-licensing revenue (milestones and royalties) earned by us and our affiliates. The size of the income share due to SSI shall be determined and reflect the extent to which we have invested in carrying out the Phase 2 and Phase 3 clinical trials in respect of the PIONEER derived immunotherapies administered together or in combination with licensed adjuvant prior to entering into a sub-license agreement. If we enter into a sublicense agreement with a partner on our EVX-01 product candidate subsequent to the initiation of a Phase 2b clinical trial, we are required to pay to SSI a percentage of any sublicensing income in an amount in the lower double-digit range. If we enter into a sublicense agreement with a partner on our EVX-01 product candidate subsequent to the initiation of a Phase 3 trial, we are required to pay to SSI a percentage of any sublicensing income in the lower double-digit range. If we enter into a sublicense agreement with a partner on our EVX-01 product candidate without initiating Phase 2b trial, we are required to pay to SSI a percentage of any sublicensing income in the mid double-digit range. Prior to any out-licensing or commercialization of EVX-01, we are not required to make any additional payments to SSI outside of the €50.000 upfront fee mentioned above.

The SSI license will terminate on the earlier of (i) a fixed period of 10 years commencing on the first calendar day of the calendar month following the first commercial sale of a PIONEER derived immunotherapy administered together or in combination with licensed adjuvant and (ii) the effective date of termination. In this connection, we or SSI may terminate the license upon prior written notice in the event of (a) a material breach which is not capable of remedy, or if capable of being remedied, such remedy does not occur within a specified time after notification or (b) an order is made or a resolution passed for the winding up of either SSI or us. In addition, we may terminate the SSI License upon prior written notice if we are not able to reach a supply agreement with SSI’s designated commercial supplier of the licensed adjuvant. Apart from such causes, SSI may not terminate the license agreement and we may only terminate the SSI license on (c) the grounds of lack of efficacy of a PIONEER derived immunotherapy administered together or in combination with licensed adjuvant, as a result of which we determine not to progress with the development and commercialization of such product or (d) due to safety concerns, market and/or competitive situation that would prevent commercialization of a PIONEER derived immunotherapy administered together or in combination with licensed adjuvant.

On June 29, 2020, we entered into a license agreement with PharmaJet or the PharmaJet License Agreement, which grants us non-exclusive, sub-licensable license to certain intellectual property of PharmaJet and supply of the Stratis® device and disposable needle-free syringes and filling adapter items for use with any products derived from one or more of our product candidates in the field of prophylaxis, diagnosis prediction, and/or treatment of cancer in humans and/or animals. Subject to meeting certain development milestones, additional consideration of up to $320,000 is to be transferred to the seller. Further, $250,000 is to be transferred to the seller upon each regulatory approval of an Evaxion product utilizing the in-licensed technology. Also, we will owe PharmaJet customary royalties in the low single digits based on net commercial sales of any products derived from our product candidates for so long as we continue to use in our product candidates the intellectual property and products licensed from PharmaJet pursuant to the PharmaJet License Agreement. The PharmaJet License Agreement will remain in effect for an initial period until successful completion of the first Phase 1/2a clinical study of our product candidate in combination with the PharmaJet product with the option to extend the term for additional 10 years, after which the term will automatically extend for successive periods of 24 months if not terminated prior to the beginning of each such subsequent extension. Either party may terminate the agreement upon six months prior notice with effect immediately prior to a subsequent extension term. Either party may terminate the agreement with immediate effect upon written notice to the other party due to a material breach by the other party. Moreover, we may terminate the agreement in the event of i) change of control or divestment, ii) regulatory action taken by the FDA or EMA, iii) termination of development of our product in combination with PharmaJet product or iv) if PharmaJet undergoes a change of control to a third party who does not agree to continue to supply us PharmaJet product.

Trade secret protection

Certain of our technologies, including in particular certain proprietary manufacturing processes or technologies and/or AI-based prediction technologies, are protected as trade secrets.

In addition to patent protection, we rely upon unpatented trade secrets and confidential know-how and continuing technological innovation to develop and maintain our competitive position. We protect certain of our technologies, including but not limited to algorithms and software, from becoming public knowledge. However, trade secrets and confidential know-how are difficult to protect. We seek to protect our proprietary information, in part, by using confidentiality agreements with any future collaborators, scientific

164

advisors, employees and consultants, and invention assignment agreements with our employees. These agreements may not provide meaningful protection. These agreements may also be breached, and we may not have an adequate remedy for any such breach. In addition, our trade secrets and/or confidential know-how may become known or be independently developed by a third party or misused by any collaborator to whom we disclose such information. Despite any measures taken to protect our intellectual property, unauthorized parties may attempt to copy aspects of our products or to obtain or use information that we regard as proprietary. Although we take steps to protect our proprietary information, third parties may independently develop the same or similar proprietary information or may otherwise gain access to our proprietary information. As a result, we may be unable to meaningfully protect our trade secrets and proprietary information. See “Risk Factors – Risks Related to our Intellectual Property” for a more comprehensive description of risks related to our intellectual property.

Competition

We compete in an industry characterized by rapidly advancing technologies, intense competition and a complex intellectual property landscape. We face substantial competition from many different sources, including large and specialty pharmaceutical and biotechnology companies, academic research institutions and governmental agencies and public and private research institutions.

AI platforms

We face competition from several companies developing AI platforms and software including Schrodinger, BenevolentAI, Atomwise, AI Therapeutics, Insilico Medicine, Recursion Pharmaceuticals, Lantern Pharma, Adaptive Biotechnologies, Immatics, BIOVIA, and Citrine, among others. However, because most of these companies are not focused on developing therapeutic drug candidates centered around neoepitopes or bacteria-identified antigens, we do not consider the majority of them to be our direct competitors. Below is a description of the companies we consider to be our main competitors for each of our three platforms and their respective indications.

PIONEER – Immuno-Oncology

The immuno-oncology therapeutics landscape in general is highly competitive and includes large and specialty pharmaceutical and biotechnology companies, academic research institutions and governmental agencies and public and private research institutions. It includes both competition from marketed therapies as well as potential new therapeutics in development. We may compete with products with different mechanisms of action as well as against established standards of care. Well-established companies such as AstraZeneca, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceuticals, Merck & Co., Novartis, Pfizer, Roche and Sanofi are developing diversified immuno-oncology programs and have substantial resources. Smaller companies are also developing immuno-oncology drugs, such as Jounce Therapeutics, Arcus Biosciences, ALX Oncology, iTeos Therapeutics and Five Prime Therapeutics, among others. We expect our immunotherapy candidates for the treatment of solid tumors to face direct competition from companies such as Moderna in collaboration with Merck & Co., CureVac in collaboration with Eli Lilly, and BioNTech SE.

We also expect to face competition from smaller specialized oncology companies active in the neopepitope/personalized anti-cancer therapy space including Agenus, Gritstone Bio, Advaxis Immunotherapies, Achilles Therapeutics, NousCom, ISA Pharmaceuticals, Genocea Biosciences, Vaccibody, PACT Pharma, PersImmune, Geneos Therapeutics and ZIOPHARM Oncology.

EDEN – Bacterial Diseases

Our main competitors taking a prophylactic approach to bacterial diseases are GlaxoSmithKline and Sanofi Pasteur. Additional competitors within the bacterial disease space include well-established pharmaceutical companies including AbbVie, Bayer, Gilead, Janssen Pharmaceuticals, Merck & Co. and Novartis. In addition, Seqirus UK, Biomedical Corp. of Quebec and AstraZeneca produce vaccines.

RAVEN – Viral Diseases

As we intend to use our RAVEN platform to develop drug candidates for the current and future coronavirus pandemics, we face competition from all of the biotechnology and large pharmaceutical companies developing potential treatments for coronavirus including: Moderna, Pfizer/BioNTech, CureVac, AstraZeneca, Merck & Co., Novavax, Sanofi, Johnson & Johnson and the multitude of other companies currently developing COVID-19 vaccine candidates. Our plans to leverage our RAVEN platform to develop

165

vaccines for future coronaviruses and other viral diseases beyond coronavirus, will put us in competition with several other companies focused on viral vaccines including GSK, Merck & Co. and AstraZeneca.

Many of our competitors and potential competitors, either alone or with their collaborators, have greater scientific, research and product development capabilities as well as greater financial, marketing, sales and human resources and experience than we do. In addition, smaller or early-stage companies, including immunotherapy-focused therapeutics companies, may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Some of our collaborators may also be competitors within the same market or other markets. Accordingly, our competitors may be more successful than us in developing and potentially commercializing technologies and achieving widespread market acceptance. In addition, our competitors may design technologies that are more efficacious, safer or more effectively marketed than ours or have fewer side effects or may obtain regulatory approvals more quickly than we are able to, which could eliminate or reduce our commercial potential. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.

We anticipate that the key competitive factors affecting our technologies will be efficacy, safety, cost, speed and convenience. The availability of reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our products. The timing of market introduction of our products and competitive products will also affect competition among products. We expect the relative speed with which we can develop our products, complete the clinical trials and approval processes, and supply commercial quantities of the products to the market to be important competitive factors. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.

Employees

As of December 31, 2021, we had 61 full-time equivalent employees, of which 25 hold a doctoral degree or higher. The following tables provide breakdowns of our full-time equivalent employees as of December 31, 2021 by function and by region:

Function

    

Number

Clinical Research & Development

 

8

Scientific Research & Development

 

38

Supporting Functions

 

11

Commercial & Business Development

 

4

TOTAL

 

61

Region

    

Number

Capital Region, Denmark

 

60

New York, United States

 

1

TOTAL

 

61

Since 2020, our workforce has grown by 74%, and we have plans to increase the size of our team over the next several years.

None of our employees have engaged in any labor strikes. We have no collective bargaining agreements with our employees. We consider our relationship with our employees to be positive and have not experienced any major labor disputes.

4.B. Organizational Structure

Evaxion was formed as a private limited liability company organized under Danish law on August 11, 2008 and re-registered as a public limited liability company on March 29, 2019. Certain of our operations are conducted through our wholly-owned subsidiaries, Evaxion Biotech Australia PTY LTD (Australia) and Evaxion Biotech, Inc., in Australia and the United States, respectively, both of which are listed in Exhibit 8.1 to this annual report.

166

4.C. Property and Equipment

In October 2020, the Company entered into a lease for approximately 1,356 square meters, which is allocated on 839 square meters of office space, and 518 square meters of laboratory space in Hørsholm, Denmark. The commencement date for the lease of the 839 square meters of office space was February 1, 2021 and the lease continues for a term of 10 years from that date. The commencement date for the lease of the laboratory space is August 13, 2021 and the lease continues for a term of 10 years. Both leases have a subsequent 12-month cancellation notice period. The lease agreement contains an early termination provision which would trigger a termination fee of $2.7 million. The initial monthly payment is expected to be between $28,000 and $30,000, which consists of $12,000 for the office space, and is expected to be between $16,000 and $18,000 for the laboratory space. Through-out the term, the lease is subject to annual increases ranging from two to four percent on the annual lease payment amount.

Item 4A.Unresolved Staff Comments

None.

Item 5.Operating And Financial Review And Prospects

5.A. Operating Results

You should read the following discussion of our financial condition and results of operations in conjunction with our audited financial statements and the related notes thereto included elsewhere in this annual report as well as the discussion in the Business section of this annual report. Our financial information is presented in our presentation currency, United States Dollar, or USD. Our functional currency is the Danish Krone, or DKK. Some Danish Krone amounts in this discussion and analysis have been translated solely for convenience into USD at an assumed exchange rate of DKK 6.5612 per $1.00, which was the official exchange rate of such currencies as of December 31, 2021 rounded to four decimal places. In addition to historical information, the following discussion and analysis contains forward-looking statements that involve risks and uncertainties. The forward-looking statements are not historical facts, but rather reflect our plans, estimates, assumptions and projections about our industry, business and future financial results. Our actual results and the timing of events could differ materially from those anticipated in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this annual report, particularly in sections titled “Risk Factors” and “Special Note Regarding Forward-Looking Statements.” The financial statements as of December 31, 2021 and 2020 and for the years ended December 31, 2021, 2020 and 2019 were prepared in accordance with IFRS, as issued by the IASB.

Overview

We are a clinical-stage AI-immunology™ platform company using our proprietary artificial intelligence, or AI, technology, engineering expertise and drug development know-how to simulate the human immune system and generate predictive models to identify and develop novel immunotherapies for the treatment of various cancers, bacterial diseases and viral infections. Drug discovery and clinical development using historically prevailing techniques is a long, costly process with a high attrition rate. We believe our proprietary AI-immunology platforms, trained to translate vast amounts of data into a deep understanding of biological processes in the human body, can be harnessed to rapidly and cost effectively design and develop unique immunotherapies, thereby potentially revolutionizing the process of drug discovery and development. In an effort to validate the predictive power and scalability of our AI platforms, we have identified and are developing a pipeline of clinical product candidates initially focused in the areas of immuno-oncology and infectious disease. We are currently in the clinic with our two lead product candidates, EVX-01 and EVX-02, for the treatment of various cancers.

Our three proprietary platforms include (i) PIONEER, our immuno-oncology platform, (ii) EDEN, our bacterial disease platform, and (iii) RAVEN, our viral disease platform. Currently, we are focused on using PIONEER for the development of patient-specific immunotherapies for various cancers and using EDEN to develop immunotherapies for bacterial diseases. We plan to use our RAVEN platform to discover and develop vaccines against future coronaviruses as well as other viral infections. We may, in the future, develop additional platforms to address other conditions known to have a large immunological component, examples of which could include autoimmune diseases, microbiome dysbiosis, allergies and parasites.

167

Key Factors and Trends Affecting our Business

We believe that our performance and future success depend on several factors that present significant opportunities for us but also pose risks and challenges, including those discussed below and in the section of this annual report titled “Risk Factors.”

COVID-19

In December 2019, a novel strain of coronavirus was reported in Wuhan, China and on March 11, 2020 the World Health Organization, or the WHO, declared COVID-19 a pandemic. To date, COVID-19 has surfaced in nearly all regions around the world and resulted in travel restrictions and business slowdowns and/or shutdowns in affected areas. Denmark, all states in the United States, and many local jurisdictions and countries around the world have, at times during the pandemic, issued “shelter-in-place” orders, quarantines, executive orders and similar government orders, restrictions, and recommendations for their residents to control the spread of COVID-19. Such orders, restrictions and/or recommendations, and/or the perception that additional orders, restrictions or recommendations could occur, have, at times during the pandemic, resulted in widespread closures of businesses, including healthcare systems, work stoppages, slowdowns and/or delays, work-from-home policies and travel restrictions, among other effects.

The full extent to which the COVID-19 outbreak will impact our business, results of operations, financial condition and cash flows will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19 and the actions to contain it or treat its impact and the economic impact on local, regional, national and international markets. As the COVID-19 pandemic continues, our results of operations, financial condition, and cash flows may be adversely affected, and may differ from current projections.

These uncertainties include, among others, the ultimate severity and duration of the pandemic; the emergence and prevalence of COVID-19 variants, such as the recent emergence of the Omicron variant; governmental, business or other actions that have been, are being or will be, taken in response to the pandemic, including restrictions on travel and mobility, business closures and operating restrictions, and imposition of social distancing measures; impacts of the pandemic on our employees, the vendors or distribution channels in our supply chain and on the our ability to continue to manufacture its products; impacts of the pandemic on the conduct of our clinical trials, including with respect to enrollment rates, availability of investigators and clinical trial sites, and monitoring of data; impacts of the pandemic on healthcare systems, impacts of the pandemic on the regulatory agencies with which we interact in the development, review, approval and commercialization of products derived from our product candidates, if any; impacts of the pandemic on reimbursement for products derived from our product candidates, if any, and for services related to the use of products derived from our product candidates, if any; and impacts of the pandemic on the Danish, United States and global economies more broadly.

In addition, we rely upon third parties for many aspects of our business, including the provision of goods and services related to the manufacture of our clinical products and the conduct of our clinical trials. Any prolonged material disruption to the third parties on which we rely could negatively impact our ability to conduct business in the manner and on the timelines presently planned, which could have a material adverse impact on our business, results of operations and financial condition.

COVID-19 or other public health epidemics, pandemics or outbreaks, and the resulting business or economic disruptions resulting therefrom, may adversely impact our business as well as our ability to raise capital. While we continue to conduct research and development, or R&D, activities, including our ongoing clinical trials, the COVID-19 pandemic has, at times, impacted the timelines of certain of our early-stage discovery efforts and clinical trials, and may continue to impact such timelines while the pandemic persists. We work closely with our internal teams, our clinical investigators, R&D vendors and critical supply chain vendors to continually assess, and mitigate, any potential adverse impacts of COVID-19 on our R&D activities. We are closely monitoring the potential impact of COVID-19 on our business and operations, financial results and cash flows. Our top priority remains the health and safety of our staff and the patients in our studies.

168

Russia’s Invasion of Ukraine

On February 24, 2022, Russia invaded Ukraine creating a global conflict. The resulting conflict and retaliatory measures by the global community have created global security concerns, including the possibility of expanded regional or global conflict, which have had, and are likely to continue to have, short-term and more likely longer-term adverse impacts on Ukraine and Europe and around the globe. Potential ramifications include disruption of the supply chain including research activities and complications with the conduct of ongoing and future clinical trials of our product candidates, including patient enrollment. We rely on global networks of contract research organizations and clinical trial sites to enroll patients, Delays in research activities or in the conduct of our clinical trials could increase associated costs and, depending upon the duration of any delays, require us to find alternative suppliers at additional expense. In addition, the conflict between Russia and the Ukraine has had significant ramifications on global financial markets, which may adversely impact our ability to raise capital on favorable terms or at all.

Selected Financial Data

The selected historical consolidated financial information for the years ended December 31, 2021, 2020 and 2019 and the selected statements of financial position data as of December 31, 2021, 2020 and 2019 have been derived from, and should be read in conjunction with, the audited consolidated financial statements and notes thereto appearing elsewhere in this annual report.

The information presented below is qualified by the more detailed historical consolidated financial statements set forth in this annual report and should be read in conjunction with those consolidated financial statements, the notes thereto and the discussion included below.

Consolidated Statements of Comprehensive Loss Data

    

Years Ended December 31,

    

2021

    

2020

    

2019

(USD in thousands, except per share data)

Consolidated Statement of Comprehensive Loss Data:

Research and development expenses

$

19,583

$

10,902

$

8,216

General and administrative expenses

 

6,251

 

5,666

 

2,647

Operating loss

 

(25,834)

 

(16,568)

 

(10,863)

Finance income

 

2,039

 

216

 

65

Finance expenses

 

(915)

 

(223)

 

(1,222)

Net loss before tax

 

(24,710)

 

(16,575)

 

(12,020)

Income taxes

 

178

 

1,557

 

825

Net loss for the period

$

(24,532)

$

(15,018)

$

(11,195)

Net loss attributable to equity holders of Evaxion Biotech A/S

$

(24,532)

$

(15,018)

$

(11,195)

Loss per share – basic and diluted

$

(1.26)

$

(0.97)

$

(0.81)

Number of shares used for calculation (basic and diluted)

 

19,493,143

 

15,434,758

 

13,892,314

Consolidated Statements of Financial Position Data

    

December 31, 

    

2021

    

2020

    

2019

(USD in thousands)

Consolidated Statements of Financial Position Data:

Cash and cash equivalents

$

32,166

$

5,834

$

9,559

Total assets

 

40,163

 

11,965

 

11,084

Total liabilities

 

7,726

 

4,927

 

1,722

Share capital

 

3,755

 

2,648

 

2,481

Other reserves

 

79,144

 

31,669

 

22,693

Accumulated deficit

 

(50,432)

 

(27,279)

 

(15,812)

Total equity

 

32,437

 

7,038

 

9,362

Total liabilities and equity

$

40,163

$

11,965

$

11,084

169

Key Components of Our Results of Operations

Operating Expenses

Research and development

Research and development expenses are primarily internal and external costs incurred in the development of our product candidates, including personnel costs, share-based compensation, external research and development expenses, maintenance of our patents, overhead allocation and enhancements and maintenance of our technology platform.

The research activities are comprised of activities performed before filing an Investigational New Drug, or IND, or equivalent and necessary pre-clinical activities for such product candidates. All research expenses are recognized in the period in which they are incurred and payments made prior to the receipt of goods or services to be used in research and development are deferred until the goods or services are received. We record accruals for estimated research and development costs, including payments for work performed by third-party contractors and others. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid expense or accrued expense.

For the year ended December 31, 2021, substantially all of our third-party expenses were related to the development of product candidates in conjunction with our AI platforms. We deploy our personnel and facilities across all of our research and development activities. Costs incurred directly for individual programs consist primarily of trial and product production-related costs. Other costs such as share-based compensation, personnel and facilities expenses, which are not directly attributable to individual programs, are allocated between research and development and other functions and recorded as incurred.

We will continue to increase our research and development expenses as we continue the development of our product candidates, our AI platforms, and our research activities for our pre-clinical and clinical-stage programs. We may receive government grants or tax credits in the future that may result in a reduction of our research and development expenses.

As part of the process of preparing our financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and communicating with our personnel to identify services that have been performed on our behalf by third-party service providers and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. Payments for these services are based on the terms of individual agreements and payment timing may differ significantly from the period in which the services were performed. We make estimates of our accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known to us at that time. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the amount of prepaid expenses accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period.

We cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future pre-clinical and nonclinical studies, and clinical trials of our product candidates due to the inherently unpredictable nature of pre-clinical and clinical development.

General and Administrative

General and administrative expenses consist primarily of fees paid to external consultants and personnel costs, including share-based compensation for our executive, finance, corporate and business development functions. In addition, general and administrative expenses also include depreciation and lease expenses for corporate headquarters as well as other allocated overhead.

As a result of the completion of our follow-on offering and initial public offering, we expect to incur additional general and administrative expenses as a result of expanding our corporate functions and operating as a public company.

170

Finance Income

Finance income consist primarily of foreign currency gains.

Finance Expenses

Finance expenses consist primarily of interest on lease liabilities, fair value adjustments of liability classified warrants being measured at fair value and interest on loan from lessor.

Income Taxes

We are subject to corporate taxation in Denmark and Australia and may be subject to taxation in other jurisdictions where we maintain subsidiaries or otherwise engage in business. Due to the nature of our business, we have generated losses since inception and have therefore not paid Danish taxes to date. Tax payable in Australia has been offset against tax receivable and receivable tax credits classified as government grants receivable. Tax on the profit or loss for the year comprises current tax. Tax is recognized in the statement of comprehensive loss, except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity. Current tax is the expected tax payable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the balance sheet date, and any adjustment to tax payable in respect of previous years.

Deferred tax is recognized on temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The amount of deferred tax is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the balance sheet date. A deferred tax asset is recognized only to the extent that it is probable that future taxable profits will be available against which the asset can be utilized. No deferred tax assets are recognized on our losses carried forward because there is currently no indication that we will make sufficient profits to utilize these tax losses.

Research and development tax credits are available to the Group under the tax laws of Denmark and Australia respectively, based on qualifying research and development expenses as defined under those tax laws. Tax credits not exceeding the corporate tax rate are recognized as a reduction of income tax expense. Tax credits in excess of the corporate tax rate are classified as government grants. Tax credits are accrued for the year based on calculations that conform to Danish research and development programs. As part of the recovery of the Danish economy after COVID-19, the current tax credits in relation to research and development are increased from 103% (2020) and 105% (2021), respectively, to 130% (both years).

Results of Operations

Comparison of the years ended December 31, 2021, 2020 and 2019:

    

Years Ended December 31,

    

Change

    

2021

    

2020

    

2019

    

2021 vs 2020

    

2020 vs 2019

(USD in thousands)

Operating expenses:

  

 

  

 

  

  

 

  

Research and development

$

19,583

$

10,902

$

8,216

$

8,681

$

2,686

General and administrative

 

6,251

 

5,666

 

2,647

 

585

 

3,019

Total operating expenses

 

25,834

 

16,568

 

10,863

 

9,266

 

5,705

Operating loss

 

(25,834)

 

(16,568)

 

(10,863)

 

(9,266)

 

(5,705)

Finance income

 

2,039

 

216

 

65

 

1,823

 

151

Finance expenses

 

(915)

 

(223)

 

(1,222)

 

(692)

 

999

Net loss before tax

 

(24,710)

 

(16,575)

 

(12,020)

 

(8,135)

 

(4,555)

Income taxes

 

178

 

1,557

 

825

 

(1,379)

 

732

Net loss for the year

$

(24,532)

$

(15,018)

$

(11,195)

$

(9,514)

$

(3,823)

Research and Development

Research and development expenses were $19.6 million for the year ended December 31, 2021 compared to $10.9 million for the year ended December 31, 2020. The increase in research and development expenses was primarily due to increased spending of $5.7

171

million, net of grant income of $0.3 million in 2021, for ongoing development on our platform, pre-clinical product candidates, and clinical trials. In addition, employee-related costs increased by $3.0 million due to higher headcount.

Research and development expenses were $10.9 million for the year ended December 31, 2020 compared to $8.2 million for the year ended December 31, 2019. The increase in research and development expenses was primarily due to increased spending of $1.5 million, net of grant income of $0.8 million in 2020, for ongoing development on our platform, pre-clinical product candidates, and clinical trials. In addition, employee-related costs increased by $1.2 million due to higher headcount.

General and Administrative

General and administrative expenses were $6.3 million for the year ended December 31, 2021, as compared to $5.7 million for the year ended December 31, 2020. The increase in general and administrative expenses was primarily due to a $1.4 million increase in professional fees related to the expansion of our corporate function for our IPO, partially offset by a decrease of $0.9 million in employee-related costs.

General and administrative expenses were $5.7 million for the year ended December 31, 2020, as compared to $2.6 million for the year ended December 31, 2019. The increase in general and administrative expenses was primarily due to a $1.2 million increase in employee-related costs due to increased headcount and a $1.9 million increase in professional fees related to the expansion of our corporate function for our IPO.

Finance Income

Finance income primarily related to foreign exchange gains recognized were $2.0 million and $0.2 million for the years ended December 31, 2021 and 2020, respectively. Finance income for the year ended December 31, 2019 was immaterial.

Finance Expenses

Finance expenses for the year ended December 31, 2021 were $0.9 million, compared to $0.2 million for the year ended December 31, 2020. The increase in finance expenses were primarily related to an increase of $0.6 million in foreign exchange losses recognized.

Finance expenses for the year ended December 31, 2020 were $0.2 million, compared to $1.2 million for the year ended December 31, 2019. This decrease in finance expenses is primarily related to the conversion of our convertible debt instruments to equity in 2019, resulting in no related fair value changes in 2020.

Income Taxes

The benefits from income tax were $0.2 million for the year ended December 31, 2021, compared to $1.6 million for the year ended December 31, 2020. Our effective tax rates for the year ended December 31, 2021 and 2020 were different from the Danish effective statutory tax rate of 22% since we only recognize deferred tax assets on temporary differences to the extent the requirements for capitalization are met. Taxable income is mainly related to expected tax receivable from R&D Tax Schemes in Denmark and Australia based on tax losses incurred in the current financial year. In connection with our IPO, we incurred non-deductible expenses which resulted in differences in our effective tax rates. In December 2021, as a result of a tax ruling from the Australian tax authorities, we were forced to reevaluate our Australian tax benefit and reverse approximately $1.0 million of tax benefit previously reported in prior years.

The income tax benefit was $1.6 million for the year ended December 31, 2020, compared to $0.8 million for the year ended December 31, 2019. Our effective tax rates for the year ended December 31, 2020 and 2019 were different from the Danish statutory tax rate of 22% since we do not meet the requirement for capitalization of deferred tax assets, and we incurred non-deductible expenses which resulted in differences in our effective tax rates.

Tax losses carried forward for which deferred tax assets have not been recognized in the statement of financial position were $9.5 million for the year ended December 31, 2021 as compared to $3.8 million for the year ended December 31, 2020. Deferred tax assets will be recognized for unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Currently no deferred tax assets from tax losses carried forward are recognized.

172

Tax losses carried forward for which deferred tax assets have not been recognized in the statement of financial position were $3.8 million for the year ended December 31, 2020 as compared to $1.3 million for the year ended December 31, 2019. Deferred tax assets will be recognized for unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Currently no deferred tax assets from tax losses carried forward are recognized.

5.B. Liquidity and Capital Resources

Liquidity and Capital Resources

Overview

We are a clinical development stage AI-immunology company that has not generated revenues for the years ended December 31, 2021, 2020 or 2019. We are exposed to a variety of financial risks including liquidity risks. We have incurred significant losses and negative cash flows from operations since our inception. As of December 31, 2021, we had an accumulated deficit of $50.4 million and expect to continue to incur significant losses for the foreseeable future.

As of December 31, 2021 and December 31, 2020, our available liquidity, comprised of cash and cash equivalents, was $32.2 million and $5.8 million, respectively and our total equity was $32.4 million and $7.0 million, respectively. We have not generated any revenues during the periods ended December 31, 2021 and December 31, 2020 and we do not anticipate generating significant revenues unless and until we successfully complete Phase 2b development and obtain an out-licensing partnership of any current or future product candidates.

In August 2020, we executed a loan agreement, or the EIB Loan Agreement, with the European Investment Bank, or EIB, for a principal amount of €20.0 million, divided into three tranches of €7.0 million, €6.0 million and €7.0 million on the EIB Loan. Under the EIB Loan Agreement, the EIB Loan tranche balances are due six years from their respective disbursement dates. For all tranches, EIB is entitled to an aggregate of 1,003,032 cash settled warrants with an exercise price of 1 DKK per warrant. The 351,036 warrants attributable to the first tranche of €7.0 million were incorporated in the articles of association on December 17, 2020. As of December 31, 2021, we initiated the draw down of the first tranche of the EIB Loan Agreement amounting to €7.0 million. The Company received the first tranche of €7.0 million on February 17, 2022.

In September 2020, we received $6.6 million of additional funding from the issuance of 745,380 of our ordinary shares as part 1 of our “bridging round” with outside investors. On October 15, 2020, we successfully completed part 2 of our “bridging round” of capital with outside investors in the amount of $2.4 million from the issuance of 269,136 of our ordinary shares and received the proceeds in November 2020.

In October 2020, we entered into a lease for approximately 1,356 square meters, which is allocated on 839 square meters of office space, and 518 square meters of laboratory space in Hørsholm, Denmark. The commencement date for the lease of the 839 square meters of office space was February 1, 2021 and the lease continues for a term of 10 years from that date. In October 2020, we entered into a lease for approximately 518 square meters, which was allocated for additional laboratory space, in Hørsholm, Denmark. The commencement date for the lease is August 13, 2021 and the lease continues for a term of 10 years with a subsequent 12-month cancellation notice period. The lease agreement contains an early termination provision which would trigger a termination fee of $2.7 million. The initial monthly payment is expected to be between $28,000 and $30,000, which consists of $12,000 for the office space, and is expected to be between $16,000 and $18,000 for the laboratory space. Through-out the term, the lease is subject to annual increases ranging from two to four percent on the annual lease payment amount.

In addition to the ordinary lease payments, we obtained financing from DTU Science Park A/S (“DTU”) for rebuilding the laboratory facility and engineering building to match ours needs. We will repay the $1.3 million financing at a fixed interest rate of 6% over 8 years. If the lease is terminated due to default by us before the outstanding balance, including interest accrued, has been repaid, the remaining balance is due immediately. As of December 31, 2021, the Company is still in discussions with DTU on the final settlement terms. Consequently, no payments have been made to date and we continue to accrue interests on the outstanding balance.

On February 5, 2021, we completed our IPO through which we issued and sold 3,000,000 ADSs, each of which represents one ordinary share, at a price to the public of $10.00 per ADS. We received aggregate net proceeds of $25.3 million from the IPO, after deducting the underwriting discounts and commissions and offering expenses. Upon the completion of the IPO, our registered, issued, and outstanding share capital was nominal DKK 19,198,668.

173

On November 9, 2021, we completed a follow-on public offering through which we issued and sold 3,942,856 ADSs, each of which represents one ordinary share, at a price to the public of $7.00 per ADS. The shares issued were inclusive of the 514,285 ADSs issued to the underwriters pursuant to the full exercise of their option to purchase additional shares on November 5, 2021. We received aggregate net proceeds of $24.9 million from the follow-on public offering, which includes the funds received for the additional shares issued to the underwriters, after deducting the underwriting discounts and commissions and offering expenses. Upon the completion of the follow-on public offering, our registered, issued, and outstanding share capital was nominal DKK 23,141,524.

As of December 31, 2021, due to warrant exercise, our outstanding share capital was nominal DKK 23,203,808.

Financing Requirements

We anticipate incurring additional losses until such time, if ever, we can complete our research and development activities and obtain an out-licensing partnership for our product candidates and generate revenues from such product candidates. Substantial additional financing will be needed by us to fund our operations and to continue development of our product candidates.

Based on our current operating plans, we expect that our existing cash and cash equivalents, will be sufficient to fund our operating expenses and capital expenditure requirements through at least 12 months from the date of this annual report. However, our operating plans may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings, government or other third -party funding, sales of assets, other collaborations and licensing arrangements, or a combination of these approaches. In any event, we will require additional capital to achieve our goals. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific strategic considerations. Our spending will vary based on new and on going development and corporate activities. Due to high uncertainty of the length of time and activities associated with discovery and development of our product candidates, we are unable to estimate the actual amount of funds we will require for our developmental activities.

Future financing requirements will depend on many factors, including, but not limited to:

the scope, progress, results and costs of researching and developing our AI platforms;
the timing of, and the costs involved in providing support to our future partners, if any, in connection with their efforts in seeking regulatory approvals in the United States and elsewhere for any future products derived from our product candidates if clinical trials are successful;
the cost of providing support to our future partners, if any, in connection with their commercialization activities for products derived from our product candidates, if approved for sale, including marketing, sales and distribution costs;
the cost of manufacturing any future product candidates for clinical trials and scaling up manufacturing in preparation for late stage clinical trials;
the number and characteristics of additional product candidates that we pursue;
our ability to establish and maintain collaboration, partnerships, licensing or other arrangements with third parties, including the timing of receipt of any potential milestone payments, licensing fees or royalty payments under these agreements;
the impact of the COVID-19 pandemic on the initiation or completion of pre-clinical studies or clinical trials and the supply of our product candidates;
the effects of the recent invasion of Ukraine by Russia, the resulting conflict and retaliatory measures by the global community have created global security concerns, including the possibility of expanded regional or global conflict, which have had, are likely to continue to have, short-term and likely longer-term adverse impacts on Ukraine and Europe and around the globe;

174

our ability to maintain, expand, and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make in connection with the licensing, filing, defense, and enforcement of any patents or other intellectual property rights;
the timing, receipt, and amount of sales of, or royalties on, any products developed by our future partners, if any, derived from our product candidates;
our need and ability to hire additional management, scientific, technical and business personnel; and
the extent to which we acquire or invest in businesses, products, or technologies (although we currently have no commitments or agreements relating to any of these types of transactions).

We expect to finance cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements.

We may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of current shareholders could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of the current shareholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, licenses and other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable and/or may reduce the value of our ordinary shares. Failure to raise capital or enter into such other arrangements when needed could have a negative impact on financial conditions and our ability to pursue our business plans and strategies. If we are unable to raise additional capital when needed, we could be forced to delay, limit, reduce or terminate product candidate development or grant rights to develop and market product candidates.

Cash Flows

The following table summarizes our cash flows for the periods indicated (in thousands):

    

Years Ended December 31, 

    

2021

    

2020

    

2019

(USD in thousands)

Cash Flow Data:

  

 

  

 

  

Net cash used in operating activities

$

(21,933)

$

(12,438)

$

(7,019)

Net cash used in investing activities

 

(1,330)

 

(393)

 

(68)

Net cash provided by financing activities

 

49,805

 

8,817

 

9,508

Net (decrease)/increase in cash and cash equivalents

$

26,542

$

(4,014)

$

2,421

Operating Activities

Net cash used in operating activities was $21.9 million for the year ended December 31, 2021. The largest components of our cash used in operating activities during this period was a net loss for the year of $24.5 million offset by non-cash adjustments of $0.5 million, $0.8 million of income taxes received, and net cash change in our working capital during the period of $1.2 million. The non-cash charges primarily consisted of share-based compensation expense of $1.4 million. This non-cash charge was offset by a change in income tax benefit of $0.2 million and various other immaterial changes of $0.7 million. The positive net cash attributable to changes in our current operating assets (excluding cash) and our current operating liabilities during the period was primarily comprised of an increase of $1.9 million increase of receivables due to timing of prepayments in our research and development activities, offset by a decrease of $0.6 million in trade payables and a decrease of $0.1 million in other payables, both due to the timing of invoices received.

Net cash used in operating activities was $12.4 million for the year ended December 31, 2020. The largest component of our cash used in operating activities during this period was a net loss for the year of $15.0 million offset by non-cash charges of $1.6 million, $0.8 million of income taxes received related changes, and net cash change in our working capital during the period of $0.2 million. The

175

non-cash charges primarily consisted of share-based compensation expense of $3.4 million and various other immaterial changes of $0.3 million. These increases in non-cash charges were offset by a change in income tax benefit of $1.6 million and a change in tax credit schemes accounted for as grants of $0.5 million. The positive net cash attributable to changes in our current operating assets (excluding cash) and our current operating liabilities during the period was primarily comprised of an increase of $2.0 million in trade payables and an increase of $1.1 million in other payables, both due to the timing of invoices received, offset by a $2.7 million increase of receivables due to timing of prepayments in our research and development activities and other immaterial changes of $0.2 million.

Net cash used in operating activities was $7.0 million for the year ended December 31, 2019. The largest component of our cash used in operating activities during this period was a net loss for the year of $11.2 million, offset by non-cash charges of $3.0 million, $0.7 million of income taxes received related changes, and net cash change in our working capital during the period of $0.6 million. The non-cash charges primarily consisted of share-based compensation expense of $2.4 million, changes in fair value of convertible debt facilities of $1.2 million and various other immaterial changes of $0.2 million. These increases in non-cash charges were offset by a change in income tax benefit of $0.8 million. The positive net cash attributable to changes in our current operating assets (excluding cash) and our current operating liabilities (excluding convertible debt) during the period was primarily comprised of an increase of $0.5 million in trade payables and an increase of $0.4 million in other payables, both due to the timing of invoices received, offset by an increase of receivables due to timing of prepayments in our research and development activities.

Investing Activities

Net cash used in investing activities was primarily driven by the purchase of property and equipment in the amounts of $1.3 million, $0.1 million, and $0.1 million, and changes in leasehold deposits which were nominal, $0.2 million, and nominal, for the years ended December 31, 2021, 2020 and 2019, respectively. Net cash used in investing activities for the purchase of intangible assets was $0.1 million for the year ended December 31, 2021, and nominal for the year ended December 31, 2020. No intangible asset purchases were made in 2019.

Financing Activities

Net cash provided by financing activities was $49.8 million for the year ended December 31, 2021, which was primarily due to net proceeds from the issuance of shares of $53.9 million, partially offset by transaction costs of $3.8 million related to the issuance of shares and $0.3 million related to repayment of lease liabilities.

Net cash provided by financing activities was $8.8 million for the year ended December 31, 2020, which was primarily due to net proceeds from the issuance of shares of $9.0 million, partially offset by transaction costs of $0.1 million related to the issuance of shares and $0.1 million related to repayment of lease liabilities.

Net cash provided by financing activities was $9.5 million for the year ended December 31, 2019, which was primarily due to net proceeds from the issuance of shares of $9.4 million.

Off-balance Sheet Arrangements

As of December 31, 2021, we did not have any material off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on our financial condition, results of operations, liquidity, capital expenditures or capital resources. We did not have any other off-balance sheet arrangements, as defined in the rules and regulations of the SEC, as of or during the periods presented.

176

The following summarizes our contractual obligations, which include research and development and other service contract commitments, as of December 31, 2021.

Tabular Disclosure of Contractual Obligations

    

Payments Due by Period

    

Within 1 Year

    

1 – 2 Years

    

2 – 5 Years

    

Over 5 Years

    

Total

(USD in thousands)

Leases(1)

$

326

$

332

$

891

$

2,149

$

3,698

Loan from lessor(5)

192

192

577

497

1,458

Purchase obligations(2)

 

72

 

 

 

 

72

Total(3)(4)

$

590

$

524

$

1,468

$

2,646

$

5,228

(1)In September 2020, we entered into a 10-year lease for office and laboratory space. The office space commenced in February 2021 and the laboratory space commenced in August 2021. The initial monthly payment was $28,800 and the lease is subject to two to four percent increases in annual lease payment throughout the term.
(2)We enter into contracts in the normal course of business with Clinical Research Organizations, or CROs, and other third parties for clinical trials and pre-clinical research studies and testing. Purchase obligations in the preceding table include agreements that are enforceable and legally binding on us and that specify all significant terms, including fixed or minimum quantities to be purchased, fixed, minimum or variable price provisions, and the approximate timing of the transaction. For obligations with cancellation provisions, the amounts included in the preceding table are limited to the non-cancelable portion of the agreement terms or the minimum cancellation fee.
(3)In June 2020, we entered into a license agreement for the rights to certain intellectual properties which triggered a milestone payment of $35,000 upon execution. Throughout the term, the agreement may require additional future milestone payments between $70,000 to $250,000.
(4)In November 2020, we entered into a license agreement with SSI for the rights to three issued United States patents and other patents which triggered an upfront payment of $60,000. In addition, in the event we commercialize any PIONEER derived immunotherapies administered together or in combination with licensed adjuvant on our own, we are required to pay SSI a royalty on net sales in the low teens. However, if any PIONEER derived immunotherapies administered together or in combination with licensed adjuvant are commercialized by one of our partners, if any, we are required to pay SSI a percentage of any out-licensing revenue (milestones and royalties) earned by us and our affiliates. The size of the income share depends on the stage of the development of any such immunotherapy when the out-licensing arrangement is entered into and ranges from the lower to mid double digits. For more information on the terms of the SSI license agreement see the section herein entitled “Business Overview  —  In-Licensing.”
(5)The loan amount as of December 31, 2021 is still subject to possible minor adjustment. Further information is provided in Note 17 to our financial statements appearing at the end of this annual report.

Quantitative and Qualitative Disclosures About Market Risk

Market risk is the risk that the fair value of, or future cash flows from, a financial instrument will vary due to changes in market prices. The type of market risk that primarily impacts us is foreign currency risk.

Foreign Currency Risk

Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The primary exposure derives from our expenditures in foreign currencies, mainly USD, AUD and GBP. This exposure is known as transaction exposure. We are exposed to foreign currency risk as a result of operating transactions and the translation of foreign currency bank accounts and short-term deposits. For the year ended December 31, 2021, our net foreign exchange gain was $1.3 million. For the years ended, 2020 and 2019, our foreign exchange loss was immaterial. We believe a 10% change in foreign exchange rate would not have a material impact on our operating results.

Interest Rate Risk

We manage interest rate risk by monitoring short- and medium-term interest rates and placing cash on deposit for periods that optimize the amount of interest earned while maintaining access to sufficient funds to meet day-to-day cash requirements. We do not currently have any loans or holdings that have variable interest rate. Accordingly, we are not exposed to material interest rate risk.

Recently Adopted Accounting Pronouncements and Accounting Pronouncements Not Yet Adopted

A description of recently adopted accounting pronouncements and accounting pronouncements not yet adopted that may potentially impact our financial position and results of operations is disclosed in Note 2 to our financial statements appearing at the end of this annual report.

177

5.C. Research and development, patents and licenses, etc.

For a description of the Company’s research and development policies for the last three years see “Item 5. Operating and Financial Review and Prospects—A. Operating Results—Results of Operations—Research and Development.” For a description of Evaxion’s intellectual property, see “Item 4. Information On the Company—B. Business Overview—Intellectual Property Introduction.”

5.D. Trend Information

We are currently in the development stage and we expect to remain in that stage for the upcoming year, and therefore trends relating to production, sales, inventory, backlog and selling prices are not applicable. See “Item 5. Operating and Financial Review and Prospects—A. Operating Results.”

5.E. Critical Accounting Estimates

Our Management’s Discussion and Analysis of Financial Condition and Results of Operations is based on our financial statements, which have been prepared in accordance with IFRS, issued by the IASB. The preparation of our financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates.

While our significant accounting policies are described in greater detail in Note 2 to our consolidated financial statements included in this annual report, the following discussion describes the judgments and estimates used in the preparation of our financial statements.

Share-Based Compensation

Accounting for share-based compensation requires us to make a number of judgments, estimates and assumptions. If any of our estimates prove to be inaccurate, our net loss and operating results could be adversely affected. Since our warrants issued before December 2021 are exercisable for nominal consideration, we estimate the fair value of warrant grants by using the fair value of the underlying ordinary share on the grant date. Prior to our initial public offering, we were required to estimate the fair value of our ordinary shares, as discussed in “Ordinary Share Valuation” below.

Prior to IPO, the fair value of each warrant grant is estimated on the date of grant using the interpolated ordinary share value. Warrants granted during 2021 were valued using black-scholes option pricing model, using the below-mentioned assumptions.

178

The table below summarizes the fair value by grant:

    

Per warrant

    

Per warrant

grant date

grant date

fair value

fair value

(DKK)

(USD)

Outstanding program

Grant (December 2016)

 

20.91

 

3.13

Grant (April 2017)

 

24.05

 

3.60

Grant (September 2017)

 

28.71

 

4.30

Grant (December 2017)

 

28.71

 

4.30

Granted (during 2018)

 

37.05

 

5.55

Granted (January 2019)

 

37.05

 

5.55

Granted (February 2019)

 

42.57

 

6.38

Granted (September 2019)

 

56.35

 

8.44

Granted (October 2019)

 

56.97

 

8.53

Granted (December 2019)

 

57.48

 

8.60

Granted (December 2020)

 

56.75

 

9.35

Granted (June 2021)

40.86

6.56

Granted (December 2021)

19.22

2.93

Leasehold Improvements and Loan from Lessor

Our lease contract comprises funding for the customization of the premises to our specific needs. The payment is determined based on the actual costs incurred for the customization, a repayment period of 8 years and an interest rate of 6% per annum. We have assessed whether this is a lease component, or a leasehold improvement funded by the lessor. We have considered the following factors:

1. Which party designed the customization

2. Which party had the right to direct changes to the work

3. Who is taking on the economic risk of the cost price of the work

A third party has designed the project according to our instructions, and we had the right to direct changes to the work during the construction period. Further, we have the full economic risk of the work due to 1:1 linkage between construction costs and payments to the lessor. Consequently, we have assessed that the customization is a leasehold improvement funded by the lessor and accordingly presented a leasehold improvement and a corresponding liability for the loan from the lessor.

Refer to Note 2 and Note 4 to our consolidated financial statements included in this annual report for additional detail on our accounting policy, judgements and assumptions used in accounting for share-based compensation.

Fair Value of Convertible Debt with Embedded Derivatives

Our convertible debt instruments contain embedded conversion features which allow for settlement in a variable number of shares. The embedded features were determined to be embedded derivatives. We elected not to bifurcate the embedded derivatives and to recognize the entire instrument at fair value. Accordingly, the entire instrument is recognized at fair value at inception and subsequently carried at fair value through the statement of comprehensive loss. The debt instrument was extinguished in July 2019 when the facilities were converted into our ordinary shares.

The convertible debt instruments were valued using the present value of a probability weighting of the mutually exclusive settlement alternatives. We contemplated a variety of inputs including the: USD to DKK exchange rate, the discount rate of the debt instrument, the probability of a qualifying financing event and the price of our ordinary shares. The key assumption used to determine the fair value of these debt instruments was the ordinary share valuation. See “Ordinary Share Valuation” in this annual report.

Refer to Note 2 to our consolidated financial statements included in this annual report for additional detail on our accounting policy, judgements and assumptions used in accounting for convertible debt instruments.

179

Ordinary Share Valuation

Prior to our initial public offering the fair value of our ordinary shares underlying our warrants has historically been determined by our board of directors with input from management, as there has been no public market for the ordinary shares. We believe that our board of directors has the relevant experience and expertise to determine the fair value of our ordinary shares. Given the absence of a public trading market of our ordinary shares, our board of directors exercised reasonable judgement and considered numerous objective and subjective factors to determine the best estimate of the fair value of our ordinary shares at each grant date. These factors include important developments in our operations and development, financing transactions with unrelated parties, actual operating results and financial performance, the conditions in the biotechnology industry and the economy in general, the stock price, and the lack of liquidity of our ordinary shares. Following our IPO, the fair value of each ordinary share is determined based on the ADSs closing sale price reported on the Nasdaq Capital Market.

Item 6. Directors, Senior Management and Employees

6.A. Directors and Senior Management

We have a two-tier governance structure consisting of a board of directors and an executive management team.

Our Executive Management

The following table sets forth certain information relating to our executive management as of the date of this annual report.

Name

    

Age

    

Position(s)

Executive Management:

 

  

 

  

Lars Staal Wegner, M.D

 

47

 

Chief Executive Officer

Niels Iversen Møller, M.D.

 

42

 

Interim Chief Financial Officer and Chief Business Officer

Erik Deichmann Heegaard, PhD, DMSc

 

54

 

Chief Medical Officer

Birgitte Rønø, Ph.D.

 

45

 

Chief Scientific Officer

Andreas Holm Mattsson

46

Chief Innovation Officer

Jesper Nyegaard Nissen, MSc(1)

52

Chief Operating Officer

Bo Karmark, M.Sc(2)

56

Incoming Chief Financial Officer

Glenn S. Vraniak(3)

59

Former Chief Financial Officer

(1)Mr. Nissen entered into agreement to join us on January 16, 2022, and joined us in March 14, 2022.
(2)Mr. Karmark entered into agreement to join us on January 14, 2022, and is expected to join us by August 2022.
(3)Mr. Vraniak resigned effective November 1, 2021.

The following is a brief summary of the prior business experience of the members of our executive management:

Lars Staal Wegner, M.D. joined us in August 2017 as our Chief Executive Officer. Dr. Wegner is one of our founding investors and has previously been involved in multiple startups and early ventures. Dr. Wegner began his career as a medical doctor and worked for several years as a clinician. Since then, Dr. Wegner has gained extensive experience within the vaccine industry, first at Pfizer from 2006 to 2007 and then for ten years from 2007 to 2017 as member of senior management to Bavarian Nordic, a Nasdaq listed immuno-oncology and vaccine company. Dr. Wegner received his M.D. from the University of Southern Denmark.

180

Erik Deichmann Heegaard, Ph.D., DMSc joined us as our Chief Medical Officer pursuant to the terms of his Service Agreement entered into in November 2020. Dr. Heegaard has more than 25 years of experience within oncology and infectious diseases. Prior to joining us, Dr. Heegaard served as Nordic Medical Director at Novartis Oncology from 2015 and he was the Chief Medical Officer of the oral GLP-1 project at Novo Nordisk, from 2011 to 2014, where he successfully completed Phase 1 and 2 clinical trials for the project and served as chief architect of the global Phase 3 clinical development program for the project. Prior to that, Dr. Heegaard held numerous research and clinical positions in companies such as Sandia National Laboratories, Bavarian Nordic and SSI. Dr. Heegaard received his BA from the University of Copenhagen, Denmark (Cand. med), and both his Ph.D. and his DMSc from the Health Faculty, University of Copenhagen, Denmark.

Birgitte Rønø, Ph.D., joined us as Senior Director, Immuno-Oncology in September 2017. Dr. Rønø has successfully developed and led our pre-clinical and early clinical oncology pipeline. In September 2021, Dr. Rønø was appointed Chief Scientific Officer. Dr Rønø has more than 15 years’ experience in biopharmaceutical drug discovery from academia and industry. Prior to joining Evaxion, Dr. Rønø served as a specialist, team leader and project manager at Novo Nordisk, from 2013-2017, where she was leading early drug discovery projects, evaluating in-licensing opportunities, and supporting drug development projects with pre-clinical and biomarker expertise. Dr. Rønø holds a bachelor’s degree in medicine and a master’s degree in human biology, both from the University of Copenhagen, Denmark. Dr. Rønø received her Ph.D.in experimental oncology and immunology from National Institutes of Health, Bethesda, USA and Copenhagen University Hospital, Denmark.

Niels Iversen Møller, M.D. is one of our co-founders. From our inception in 2008 until August 2017, Dr. Møller was our Chief Executive Officer and in 2016, he was awarded “CEO of the Year” in the vaccine industry by European CEO. Since August 2017, Dr. Møller has served as our Chief Business Officer. As of November 1, 2021, Dr. Møller replaced Mr. Vraniak as our Interim Chief Financial Officer. From 2009 to 2011 he was a Medical Director within the area of Companion Diagnostics for Medical Prognosis A/S and from 2008 to 2009 he was a Medical Advisor within the area of cancer and biopharmaceuticals for AstraZeneca. Dr. Møller began this career at Servier Pharmaceuticals as Marketing Manager. Dr. Møller received his M.D. from the University of Copenhagen and his BA in Economics from Copenhagen Business School.

Andreas Holm Mattsson is one of our Founders and has served as our Chief Innovation Officer since our inception. Mr. Mattsson is an experienced bioinformatician from the Technical University of Denmark. Prior to joining us Mr. Mattsson was at Novo Nordisk from 2004 to 2011 developing in silico platforms. Since founding of Evaxion in 2008, Andreas has worked on developing Evaxion’s AI platforms including EDEN and PIONEER, as well as other in silico models enabling vaccine discovery and development in the areas of immuno-oncology and infectious disease.

Jesper Nyegaard Nissen, MSc joined us on March 14, 2022 as our Chief Operating Officer pursuant to the terms of his Service Agreement entered into on January 16, 2022. Mr. Nissen has more than 25 years of experience in the pharmaceutical industry across finance, investments, research and development. Mr. Nissen began his career in Novo Nordisk Corporate Finance being responsible for development of controlling and performance management processes followed by the role as finance responsible for different corporate business areas. In 2010, Mr. Nissen moved into senior leadership roles as Vice President and later as Corporate Vice President for Global Research Operations. with the focus on research and development and strategic and operational development which included responsibilities for clinical sourcing, development IT strategies, establishment of development shared service center in India, application of real world evidence, or RWE and health economics related to clinical trials, development of research strategies, research portfolio governance, operation of global research sites, design and operation of external research engagement models among others. Since January 2021 until joining us, Mr. Nissen has worked for Fujifilm Diosynth Biotechnologies in the program management team for large scale capital projects driving Fujifilm Diosynth Biotechnologies mission to become a global leader within CDMOs. Mr. Nissen received his MSc Business Economics (Cand. Oecon.) from the University of Aarhus, Denmark.

Glenn S. Vraniak joined us in October 2019 as our Chief Financial Officer. Prior to joining our company, Mr. Vraniak served as Chief Financial Officer of electroCore, Inc. from August 2016 until April of 2019 and was a key member of the management team that carried the company through a successful IPO in June of 2018. Prior to that, from February 2014 to January 2016, Mr. Vraniak served as Chief Financial Officer at G&W Laboratories, Inc., a specialty pharmaceutical company, where he executed the growth strategy by acquiring two companies and over 35 products. Prior to that, from October 2011 through July 2013, he was President of Aprecia Pharmaceuticals, Inc., a 3D printing technology enabled pharmaceutical company. From 2003 through 2011, Mr. Vraniak was the CFO and Head of Strategic Planning for Prasco Laboratories, a generic pharmaceutical company. From January 2000 to January 2002, he served as Executive VP for GE Capital, and subsequently founded Preceptus, a boutique consulting firm focused on helping small and mid-market companies achieve efficient and scalable growth in the healthcare and technology sectors. Mr. Vraniak received an Electronic Engineering Technology degree and a Managerial M.B.A. in Finance from the Rutgers University.

181

Executive Management Joining Us Subsequent to the Date of this Annual Report

Bo Karmark, M.Sc. will join us by August 2022 as our Chief Financial Officer pursuant to the terms of his Service Agreement entered into on January 14, 2022. Mr. Karmark is an experienced financial executive with a career spanning more than 25 years working for several multinational listed companies, primarily in the biotech, pharma, and bioscience industries. Before joining us, Mr. Karmark served as the Chief Financial Officer for Aquaporin A/S, a water technology company for the past seven years Aquaporin is listed on the Nasdaq Copenhagen stock exchange. Before that, Mr. Karmark held numerous financial management positions at various companies including Chr. Hansen Holding A/S, H. Lundbeck A/S, and NsGene A/S. Mr. Karmark received his M.Sc. in Business Administration and Auditing form the Copenhagen Business School, Denmark.

Family Relationships

There are no family relationships among any of our directors and/or executive management.

6.B. Compensation

Compensation of Executive Management and Directors

Our executive management consists of our Chief Executive Officer, Chief Business Officer, Chief Innovation Officer, Chief Medical Officer, Chief Scientific Officer and Chief Financial Officer. The members of our executive management are eligible to receive an annual performance-based cash bonus subject to certain predefined corporate and individual goals as determined by our board of directors on an annual basis. The members of our executive management are also eligible to receive an extraordinary bonus at the discretion of our board of directors.

182

The following table presents compensation received by our executive management, for the years ended December 31, 2021, 2020, and 2019.

Years Ended December 31, 

    

2021

    

2020

    

2019

(USD in thousands)

Lars Staal Wegner (CEO)

Salary

    

378

321

    

238

Bonus

 

105

 

Other employee benefits

 

127

621

 

650

Total

 

610

942

 

888

Niels Iversen Møller (CBO) (3)

 

  

 

  

Salary

 

245

202

 

175

Bonus

 

23

11

 

Other employee benefits

 

0

 

Total

 

268

213

 

175

Andreas Holm Mattson (CIO)

 

  

 

  

Salary

 

245

202

 

175

Bonus

 

45

11

 

Other employee benefits

 

0

 

Total

290

213

175

Erik Deichmann Heegaard, Ph.D., DMSc (CMO)(4)

Salary

214

Bonus

52

Other employee benefits

266

Total

532

Birgitte Rønø, Ph.D. (CSO) (5)

 

  

 

  

Salary

 

110

 

Bonus

 

33

 

Other employee benefits

 

56

 

Total

 

199

 

Glenn S. Vraniak (CFO) (1)

 

  

 

  

Salary

 

310

350

 

88

Bonus

 

73

43

 

Other employee benefits(2)

 

65

1,045

 

204

Total

 

448

1,438

 

292

(1)Mr. Vraniak resigned as the Chief Financial Officer of the Company effective November 1, 2021.
(2)As noted in Note 8 to our consolidated financial statements included in this annual report, in 2019, the CFO was issued 150,660 warrants. The terms of the warrants issued to the Company’s CFO were amended, resulting in an acceleration of stock-based compensation expense in 2020. Mr. Vraniak resigned as our CFO effective November 1, 2021.
(3)Effective November 1, 2021, Mr. Møller became our Interim Chief Financial Officer.
(4)Dr. Heegaard joined our company in April 2021 as CMO and did not receive any compensation from us in 2019 and 2020.

(5)

Dr. Rønø was appointed Chief Scientific Officer in September 2021. Prior to September 2021, Dr. Rønø was a non-executive employee. The salary above is for the period July 1, 2021 to December 31, 2021, as she took the responsibility on July 1, 2021.

183

The following table lists compensation to our board of directors for the years ended December 31, 2021, 2020, and 2019:

Years Ended December 31,

    

2021

    

2020

    

2019

(USD in thousands)

Marianne Søgaard (Chairman of the Board of Directors) (1)

Board and committee fees

    

121

    

Travel allowance

 

 

Share-based compensation

 

45

12

 

Total

 

166

12

 

Roberto Prego

 

  

 

  

Board and committee fees

 

55

 

Travel allowance

 

 

Share-based compensation

 

14

62

 

61

Total

 

69

62

 

61

Steven Projan

  

    

  

Board and committee fees

59

 

Travel allowance

 

Share-based compensation

14

98

 

62

Total

73

98

 

62

Lars Holtug(5)

Board and committee fees

36

 

Travel allowance

 

Share-based compensation

14

 

Total

50

 

Helen M. Boudreau(3)

 

  

 

  

Board and committee fees

 

24

 

Travel allowance

 

 

Share-based compensation

 

48

 

Total

 

24

48

 

Jo Ann Suzich(4)

 

  

 

  

Board and committee fees

 

18

 

Travel allowance

 

 

Share-based compensation

 

26

 

63

Total

 

18

26

 

63

Thomas William Wylonis

 

  

 

  

Board and committee fees

 

 

Travel allowance

 

 

Share-based compensation

 

60

 

166

Total

 

60

 

166

Kim Bjoernstrup (2)

Board and committee fees

 

Travel allowance

 

Share-based compensation

52

 

Total

52

 

(1)Ms. Søgaard was appointed as Chairman of the Board on November 25, 2020.
(2)Mr. Bjoernstrup stepped down from his position as Chairman of the Board effective November 4, 2020.
(3)Ms. Boudreau elected not to stand for re-election to the Board in 2021.
(4)Ms. Suzich elected not to stand for re-election to the Board in 2021.
(5)Mr. Holtug was elected as a member of the Board at the 2021 Annual General Meeting held on May 25, 2021.

184

No member of the board of directors is entitled to any kind of compensation upon retirement from his or her position as a member of the board of directors. We have not allocated funds for any pension benefits, severance schemes or similar measures, or undertaken any other obligations to do so on behalf of the board of directors, and we have no obligation to do so.

The following table lists aggregate compensation to our employees, excluding executive management and board of directors, and subsequently aggregate executive management compensation and Board of Directors compensation for the years ended December 31, 2021, 2020 and 2019:

Years Ended December 31, 

    

2021

    

2020

    

2019

 

(USD in thousands)

Employee costs, excluding Executive Management and Board of Directors

Salaries

    

5,094

2,717

    

1,919

Cash bonus

 

337

 

Share-based compensation

 

778

1,484

 

1,055

Pensions

 

649

206

 

96

Other social security contributions

 

28

17

 

12

Other staff costs

 

364

196

 

176

Total employee costs, excluding Executive Management and Board of Directors

 

7,250

4,620

 

3,258

Executive Management compensation

 

  

 

  

Salaries

 

1,502

1,234

 

900

Cash bonus

 

331

65

 

Share-based compensation

 

514

1,565

 

956

Pensions

 

 

Other social security contributions

 

 

Other staff costs

 

 

Total Executive Management compensation

 

2,347

2,864

 

1,856

Board of Directors compensation

 

  

 

  

Board and committee fees

 

313

 

Travel allowance

 

 

Share-based compensation

 

87

359

 

351

Total board of directors compensation

 

400

359

 

351

Total employee costs

 

9,997

7,843

 

5,465

Recognized as follows in the Statement of Comprehensive Loss:

 

  

 

  

Research and development expenses

 

7,845

4,833

 

3,607

General and administrative expenses

 

2,152

3,007

 

1,858

Total employee costs

 

9,997

7,840

 

5,465

Average number of full-time employees

 

53

33

 

25

Number of full-time employees

 

61

35

 

31

Executive Management Agreements

Lars Staal Wegner, M.D.

In September 2020, we entered into an executive service contract with Dr. Wegner. The service contract confirms Dr. Wegner’s employment by the Company since July 2017 and his title, his base salary, his eligibility for an annual bonus, and his eligibility for benefits and also provides for certain benefits upon termination of his employment under specified conditions. Dr. Wegner’s employment under the executive service contract continues until terminated by us or Dr. Wegner. We may terminate Dr. Wegner’s employment for any reason with 12 months’ notice and Dr. Wegner may terminate his employment with three months’ notice.

185

Niels Iversen Møller, M.D.

In September 2020, we entered into an executive service contract with Dr. Møller. The executive service contract confirms Dr. Møller’s title, his base salary, his eligibility for an annual bonus, and his eligibility for benefits and also provides for certain benefits upon termination of his employment under specified conditions. Dr. Møller’s employment under the executive service contract continues until terminated by us or Dr. Møller. We may terminate Dr. Møller’s employment for any reason with 12 months’ notice and Dr. Møller may terminate his employment with three months’ notice.

Erik Deichmann Heegaard, Ph.D., DMSc

In November 2020, we entered into an executive service contract with Dr. Heegaard. Dr. Heegaard’s executive service contract also confirms his title, base salary, his eligibility for an annual bonus, and his eligibility for benefits and provides for certain benefits upon termination of his employment under specified conditions. Dr. Heegaard’s employment under the executive service contract continues until terminated by us or Dr. Heegaard. We may terminate Dr. Heegaard’s employment for any reason with 12 months’ notice and Dr. Heegaard may terminate his employment with three months’ notice.

Birgitte Rønø, Ph.D.

In September 2021, we entered into an executive service contract with Dr. Rønø. The contract confirms Dr. Rønø’s employment by the Company since September 2017. Dr. Rønø’s executive service contract also confirms her title, base salary, her eligibility for an annual bonus, and her eligibility for benefits and provides for certain benefits upon termination of her employment under specified conditions. Dr. Rønø’s employment under the executive service contract continues until terminated by us or Dr. Rønø. We may terminate Dr. Rønø’s employment for any reason with 12 months’ notice and Dr. Rønø may terminate her employment with three months’ notice.

Andreas Holm Mattsson

In September 2020, we entered into an executive service contract with Mr. Mattsson. The executive service contract confirms Mr. Mattsson’s title, his base salary, his eligibility for an annual bonus, and his eligibility for benefits and also provides for certain benefits upon termination of his employment under specified conditions. Mr. Mattsson’s employment under the executive service contract continues until terminated by us or Mr. Mattsson. We may terminate Mr. Mattsson’s employment for any reason with 12 months’ notice and Mr. Mattsson may terminate his employment with three months’ notice.

Jesper Nyegaard Nissen, MSc

In January 2022, we entered into an executive service contract with Mr. Nissen, with start in March 2022. Mr. Nissen’s executive service contract also confirms his title, base salary, his eligibility for an annual bonus, and his eligibility for benefits and provides for certain benefits upon termination of his employment under specified conditions. Mr. Nissen’s employment under the executive service contract continues until terminated by us or Mr. Nissen. We may terminate Mr. Nissen’s employment for any reason with 12 months’ notice and Mr. Nissen may terminate his employment with three months’ notice.

Glenn S. Vraniak

In October 2019, we entered into an executive employment contract with Mr. Vraniak. The executive employment contract confirms Mr. Vraniak’s title, his base salary, his eligibility for a bonus contingent upon our obtaining certain equity based financing, his eligibility for a bonus based on certain new targets, and his eligibility for benefits and also provides for certain benefits upon termination of his employment under specified conditions. Mr. Vraniak’s employment under the executive employment contract continues until terminated by us or Mr. Vraniak. We may terminate Mr. Vraniak’s employment with six months’ notice, however, we may terminate Mr. Vraniak’s employment with one months’ notice if, within a period of 12 consecutive months, Mr. Vraniak has been paid salary during an illness for a total of 120 days. Mr. Vraniak may terminate his employment voluntarily upon one month’s notice.

On October 15, 2021, Glenn S. Vraniak, our Chief Financial Officer, informed us that effective November 1, 2021, he would be leaving to pursue other opportunities outside the biopharmaceutical industry. In his place, as of November 1, 2021, we appointed Niels Iversen Møller, as Interim Chief Financial Officer. Mr. Møller was one of our co-founders and is currently also our Chief Business

186

Officer, a position he will retain. As noted herein, in addition to his medical degree, Mr. Moller has a BA in Economics from Copenhagen Business School.

Mr. Vraniak had agreed to continue to act as our Chief Financial Officer on a full time basis until the effective date of his resignation in order to ensure an orderly transition. In addition, Mr. Vraniak has agreed to provide additional transition services beyond the effective date, as needed, including providing assistance in preparing our third quarter financial statements and earnings call. In exchange for these services, we agreed to continue to pay Mr. Vraniak his then current base salary until the effective date of his resignation and to waive Mr. Vraniak’s one month’s notice of voluntary termination requirement.

Incoming Executive Management Agreement

Bo Karmark, M.Sc.

In January 2022, we entered into an executive service contract with Mr. Karmark, with start in August 2022. Mr. Karmark’s executive service contract also confirms his title, base salary, his eligibility for an annual bonus, and his eligibility for benefits and provides for certain benefits upon termination of his employment under specified conditions. Mr. Karmark’s employment under the executive service contract continues until terminated by us or Mr. Karmark. We may terminate Mr. Karmark’s employment for any reason with 12 months’ notice and Mr. Karmark may terminate his employment with three months’ notice.

Board of Directors

Descriptions and summaries of the prior business experience of the members of our board of directors is described in “Item 6.C. Board practices” below.

Warrant Incentive Plan

Our directors, executive management, employees, consultants, and advisors are eligible to participate in our warrant incentive program. Warrants have been issued by the board of directors pursuant to valid authorizations in our articles of association or by the shareholders acting in general meeting.

The terms and conditions of the warrants have, in accordance with applicable Danish laws and regulations, been incorporated into our articles of association as appendices 1-3 and 5.

Warrants granted during 2021

In June 2021 62,147 warrants were granted to the Chief Medical Officer with an exercise price of DKK 1 per warrant. The warrants vest over 36 months.

In December 2021 523,599 warrants were granted to employees, the board of directors and executive management with an exercise price of USD 5.38 per warrant. The warrants vest over 36 months for employees and executive management. For the board of directors warrants vested immediately.

Warrants granted up until year-end 2020

On December 17, 2020 our board of directors approved the issuance and allocation of 581,796 warrants. Said warrants were granted in the years 2018, 2019 and the first quarter of 2020, but were only formally issued on December 17, 2020. Our board of directors additionally issued and approved the issuance and allocation of 175,824 warrants on December 17, 2020, which were granted during the second, third and fourth quarter of 2020. The terms and conditions of warrants granted for the years 2016 - 2018 are set out in appendices 1-3 of our articles of association and the terms and conditions of warrants granted for years 2019 and 2020 are set out in appendix 5 of our articles of association.

Each warrant grants the holder the right to subscribe for one ordinary share of nominal DKK 1 against cash payment of the exercise price of DKK 1.

187

General matters related to warrants

As of December 31, 2021, our board of directors is authorized to issue an additional 1,437,853 warrants during the period ending January 3, 2026.

The grant of warrants to any participant is at the discretion of our board of director and based on the recommendation of our Compensation Committee. The board of directors may determine the terms and conditions of the warrants issued, including exercise periods, subscription price and adjustments caused by changes to our company’s share capital.

Warrants granted for the years 2016 – 2018 vest upon certain exit or liquidation events, which include an event such as the closing of our IPO in February 2021. Warrants granted for the years 2019 - 2021 generally vest with 1/36th per month. However, in relation to all warrants granted and issued prior to the closing of our IPO, our board of directors established four annual exercise windows in which warrants may be exercised following the completion of our IPO. The first such exercise window began in November 2021.

Warrants granted before or during the second quarter of 2021 has an exercise price of DKK 1 per warrant.

Warrants granted before or during 2019 expires December 31, 2036. Warrants granted thereafter expires 10 years after grant date.

The table below provides an overview of the warrants granted to our board of directors and executive management as of December 31, 2021.

Number of

Ordinary

Shares

Underlying

Name

    

Grant Date

    

Warrants

Marianne Søgaard (Chairman)

2018-2021

103,487

Lars Holtug (Director).

2021

4,583

Roberto Prego (Director)

2017-2021

38,747

Steven Projan (Director)

2018-2021

46,631

Lars Staal Wegner (CEO)

2016-2021

916,251

Niels Iverson Møller (CBO)

Andreas Holm Mattson (CIO)

Erik Deichmann Heegaard (CMO)

2021

97,564

Birgitte Rønø (CSO)

2017-2021

74,376

Insurance and Indemnification

According to the Danish Companies Act, the general meeting is permitted to discharge our directors and members of our executive management from liability for any particular financial year based on a resolution relating to the period covered by the financial statements for the previous financial year. This discharge means that the general meeting will relieve such directors and members of our executive management from liability to us. However, the general meeting cannot discharge any claims by individual shareholders or other third parties. In addition, the discharge can be set aside in case the general meeting prior to its decision to discharge was not presented with all reasonable information necessary for the general meeting to assess the matter at hand.

Additionally, we have agreed to indemnify our directors and members of our executive management and employees, in relation to certain claims. We will not, however, indemnify our directors, executive management and employees, in respect of: (i) claims against a person pursuant to Danish law raised before the Danish Courts, except claims arising from the offer, sale and listing of our securities in the United States and/or our subsequent status as a listed company in the United States, including in respect of our reports filed with or furnished to the SEC; (ii) claims against a person for damages and legal costs related to criminal and/or grossly negligent or willful acts or omissions committed by the indemnified person; (iii) claims against an indemnified person, which is attributable to the gaining or purported gaining of any profit or advantage to which the indemnified person or any related natural or legal person was not legally entitled; (iv) claims covered by insurance; (v) claims brought against the indemnified person by the Company or any subsidiary of the

188

Company; and (vi) any sum payable to a regulatory authority by way of a penalty in respect of the indemnified person’s personal non-compliance with any requirement of a regulatory nature howsoever arising. The indemnification will be limited to a maximum amount per claim per person equivalent to the gross proceeds obtained by us in connection with the offering of ADSs in the United States. The indemnification shall remain in force for a period of five years after the resignation of the indemnified person from the company or its subsidiaries, if the claims made within such period are related to such person’s services to us.

There is a risk that such indemnification will be deemed void under Danish law, either because the indemnification is deemed contrary to the rules on discharge of liability in the Danish Companies Act (Selskabsloven) as set forth above, because the indemnification is deemed contrary to sections 19 and 23 of the Danish Liability and Compensation Act (Erstatningansvarsloven), which contain mandatory provisions on recourse claims between an employee (including members of our executive management) and the company, or because the indemnification is deemed contrary to the general provisions of the Danish Contracts Act (Aftaleloven).

In addition, we provide our directors and executive management with directors’ and officers’ liability insurance.

6.C. Board practices

Members of Our Board of Directors

Our Board of Directors

The following table sets forth certain information relating to our board of directors as of the date of this annual report. The terms of office of all of our directors expire at the next annual general meeting to be held in 2022. All directors are eligible for re-election.

 

Year of first

    

Expiration

Name

    

Position

    

Age

    

Independent

    

appointment

    

of current term

Marianne Søgaard(1) (3)

 

Chairman

 

53

 

No

 

2020

 

2022

Steven Projan(1)(2)(3)

 

Member

 

69

 

Independent

 

2018

 

2022

Roberto Prego(1)(2)

 

Member

 

50

 

Independent

 

2018

 

2022

Lars Holtug(2)(3)

 

Member

 

62

 

Independent

 

2021

 

2022

(1)Member of Nomination and Corporate Governance Committee
(2)Member of Audit Committee
(3)Member of Compensation Committee

The following is a brief summary of the prior business experience of the members of our board of directors:

Marianne Søgaard joined us in 2018 as an executive and legal advisor and in November 2020 she was elected and became the Chairman of our board of directors. In 1996, Ms. Søgaard joined Kammeradvokaten/Law Firm Poul Schmith where she worked for more than 20 years as a lawyer, primarily working with technology and processes to acquire technology solutions. For more than 17 years, Ms. Søgaard was a partner at Kammeradvokaten/Law Firm Poul Schmith and from January 2014 to March 2017 she served on the board of directors of the law firm. Ms. Søgaard serves as a member of the board of directors at various privately held companies, including as the chairperson of the board at Garbanzo ApS, a small startup food company, Homemate ApS, a ready to cook food company, and Altapay A/S, a payment solution company. Ms. Søgaard received her Master of Law degree from Aarhus Universitet in 1993.

In preparation of becoming a publicly traded company in the United States and in order to ensure compliance with the requirements of a company listed on the Nasdaq Capital Market, we underwent a restructuring of our Board. In connection therewith, on November 4, 2020, we asked our Chairman, Kim Bjoernstrup, to step down from the Board, and Mr. Bjoernstrup submitted his resignation. In his place, the Board nominated Marianne Søgaard for the position of Chairman of the Board, subject to the approval of our shareholders. At a Special General Meeting of Shareholders held on November 25, 2020, Ms. Søgaard was elected as a member of our board of directors to serve until the next annual general meeting of Shareholders to be held in 2021.

189

Roberto Prego joined us in 2018. Mr. Prego has over 20 years of pharmaceutical experience and was one of our first outside investors. Mr. Prego was with Teva Venezuela as its General Manager from 1998 to 2012 and with Teva Latin American Region as its Head of Region from 2011 to 2015. Since 2015, he has served as the General Manager of Viax Dental Technologies, a research and development venture firm in the dental field. Mr. Prego has a B.S. in Economics from Universidad Católica Andrés Bello in Caracas, Venezuela and an M.B.A. from Fuqua School of Business at Duke University.

Steven Projan joined us in 2018. From 2010 until he retired in April 2018, Mr. Projan was a Sr V.P. R&D and Head of Infectious Disease & Vaccines at Medimmune. From 2008 until 2010, Mr. Projan served as V.P., Global and Head of Infectious Disease at Novartis. Mr. Projan was at Wyeth-Ayerst Research in various positions since 1993, with the most recent position from 2008 until 2010 being V.P. and Head of Biological. Mr. Projan is an expert in infectious diseases, having worked many years with both basic and applied research. He successfully led four programs resulting in the approval of novel anti-infective drugs as well as other drugs in various stages of development, and produced more than 110 peer-reviewed publications. Mr. Projan received his S.B. in Life Sciences (Nutrition & Food Sciences) from Massachusetts Institute of Technology, and his M.A., M. Phil.and Ph.D. from Columbia University.

Lars Holtug joined us in 2021. Mr. Holtug was a partner at PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab, or PwC from 1993 to 2015. Mr. Holtug also currently serves as a board member of Ascendis Pharma and as chairman of Gaming Investment A/S, a gaming solutions provider, and its 11 subsidiaries, and of MTI Caretag ApS, a company investing in healthcare technology. Mr. Holtug also currently serves as a board member of Frida Forsikring Agentur A/S and Domus Forsikring A/S, as well as the Audit Committee Chair of the board of Domus Forsikring A/S. Previously, he was Chairman of PwC in Denmark from 2005 to 2009. From 2004 to 2015, Mr. Holtug was a member of the Danish Commercial Appeals Board (Erhvervsankenaevnet) and a board member of the Danish Company law association (Dansk Forening for Selskabsret). He was also a member of the Accounting Standards Board of the Federation of State Authorized Accountants in Denmark (Foreningen af Statsautoriserede Revisorer) from 1998 to 2002, and a member of the Auditing Standards Board from 1993 to 1998. Mr. Holtug holds an M.Sc. from Copenhagen Business School and is educated as a state authorized public accountant in Denmark.

Director Compensation Policy

Our board of directors and shareholders have approved and adopted a policy with respect to the compensation payable to our directors, which became effective as of January 1, 2021. Under this policy, each director will be eligible to receive compensation for his or her service on the board of directors and for service on each committee on which the director is a member, which will consist of annual cash retainers. Our directors have received the following annual cash payments for their service in 2021:

Board Member

    

Position

    

Committees

    

Retainer

 

Marianne Søgaard

Chairman

Nomination and Governance

$

120,667

Roberto Prego 

Director

Audit Committee, Nomination and Governance

$

54,875

Steven Projan

Director

Audit Committee, Nomination and Governance, Compensation

$

58,542

Lars Holtug

Director

Audit Committee, Compensation

$

35,562

Directors may also receive equity awards.

Directors will be reimbursed for travel, food, lodging and other expenses directly related to their service as directors. Directors are also entitled to the protection provided by their indemnification agreements and the indemnification provisions in our current certificate of incorporation and bylaws, as well as our amended and restated certificate of incorporation and amended and restated bylaws that will become effective upon the completion.

Committees of our Board of Directors

Our board of directors has three standing committees: an audit committee, a compensation committee and a nomination and corporate governance committee.

Audit Committee

The audit committee consists of Lars Holtug, Steven Projan and Roberto Prego, and assists the board of directors in over, seeing our accounting and financial reporting processes. Mr. Holtug serves as chairperson of the audit committee. The audit committee consists exclusively of members of our board of directors who are financially literate, and Mr. Holtug is considered an “audit committee financial expert” as defined by applicable SEC rules and has the requisite financial sophistication as defined under the applicable

190

Nasdaq rules and regulations. Our board of directors has determined that all of the members of the audit committee satisfy the “independence” requirements set forth in Rule 10A-3 under the Exchange Act and the Nasdaq rules. The audit committee will be governed by a charter that complies with Nasdaq rules.

The audit committee’s responsibilities include, among other things:

recommending and supervising our external auditors;
pre-approve all non-audit services to be provided by any external auditors exceeding a cap determined by our board of directors;
providing our board of directors with advice regarding the proposed external auditors from time to time as well as evaluate the quality of work being performed by the external auditors;
ensuring that appropriate policies with regard to hiring employees from our external auditors are in place;
reviewing and monitoring the independence and quality of work being performed by our external auditors, especially the appropriateness of the provision of non-audit services;
evaluating the information contained in our external financial reporting;
reviewing our annual and quarterly financial statements prior to publication and/or filing (or submission, as the case may be) with the SEC;
informing our board of directors of the result of the statutory audit, including the financial reporting process;
monitoring the financial reporting process and submit recommendations or proposals to ensure its integrity and monitoring of remediation of the material weakness in internal controls over financial reporting;
evaluating the “going-concern” principle, including any special assumptions, qualifications and/or uncertainties related thereto;
evaluating the main accounting policies and principles applied including to make recommendations to our board of directors regarding whether these should be amended;
evaluating significant accounting estimates and judgments made and changes hereto;
reviewing and evaluating transactions with related parties;
evaluating relevant risks and uncertainties for the relevant year, e.g. in relation to the outlook in the financial reporting;
evaluating the overall presentation of our financial reporting in order to ensure that it provides a true and fair view of the financial position as well as our development and performance;
evaluating our compliance with relevant audit and accounting related laws and regulations;
supervising our internal audit program;
such other matters that are specifically delegated to our audit committee by our board of directors from time to time; and
meeting separately, periodically, with management, internal auditors and the independent auditor.

191

Compensation Committee

The compensation committee consists of Steven Projan, Lars Holtug and Marianne Søgaard. Mr. Projan serves as chairperson of the compensation committee. Under SEC and Nasdaq rules, there are heightened independence standards for members of the compensation committee, including a prohibition against the receipt of any compensation from us other than standard director fees. Although foreign private issuers are not required to meet this heightened standard, all of our compensation committee members are expected to meet this heightened standard. Ms. Søgaard is not deemed to be independent under Nasdaq Rule 5605(a)(2)(A), since as noted herein, she was an executive and legal adviser of our company during the past three (3) years. However, due to the fact that our Board of Directors, or the Board, consists of only four (4) members, three (3) of which are independent, and these three (3) independent directors serve on either our Audit Committee or our Nomination and Corporate Governance Committee or both, the Board believes that it would be unduly burdensome to have all of these same three (3) Board members also serve on the Compensation Committee. Based on these circumstances, and the fact that each of the independent members of the Board considers Ms. Søgaard to be highly qualified to serve on the Compensation Committee, the Board has determined that Ms. Søgaard’s membership on the Compensation Committee is required by the best interests of our company and our shareholders and, therefore, is relying on the Exceptional and Limited Circumstance exception for non-independent nominations committee members provided by Nasdaq Rule 5605(d)(2)(B). The Board recognizes that Ms. Søgaard may only serve on the Compensation Committee for two (2) years under the exception provided by Rule 5605(d)(2)(B), unless she meets Nasdaq’s independence requirements for serving on the Nomination and Corporate Governance Committee at the end of such two-year term.

The compensation committee’s responsibilities include, among other things:

continuously ensuring that the compensation of the members of our board of directors and our executive management is in accordance with our compensation policy and is consistent with the performance of the relevant member;
annually reviewing and, if relevant, making recommendations for amendment of the compensation policy for the members of our board of directors and our executive management;
annually reviewing the compensation level of our executive management and comparing it to the market level of management compensation among comparable companies;
ensuring that agreements with the members of our executive management entitle us under special circumstances to reclaim in full or in part variable compensation that is paid on the basis of information, which subsequently proves to be manifestly misstated (“claw-back”) and that termination/severance payments shall not exceed the aggregate compensation for the last two years;
reviewing any proposals and make recommendations to our board of directors regarding any change to the compensation or contract terms of our executive management;
reviewing any proposals and make recommendations to our board of directors regarding any severance payment to our executive management;
making recommendations to our board of directors regarding the compensation of the members of our board of directors, including components and levels thereof.
monitoring that the information in the annual report regarding the compensation of our board of directors and our executive management is correct, sufficient, and gives a true and fair view;
ensuring that key compensation terms are disclosed accurately in connection with our annual reporting;
making recommendations regarding the criteria for assessing the annual incentive and performance pay for our executive management;
making recommendations to our board of directors at the start of each financial year regarding the criteria for determining the size of our incentive and performance pay for all employees for the present year and at the conclusion of each financial year,

192

review and make recommendations to our board of directors regarding the size and allocation of the incentive and performance pay; and
such other matters that are specifically delegated to the compensation committee by our board of directors from time to time.

Nomination and Corporate Governance Committee

The Nomination and Corporate Governance Committee consists of Roberto Prego, Steven Projan and Marianne Søgaard. Mr. Prego serves as chairperson of the nomination and corporate governance committee. Both Mrs. Prego and Mr. Projan meet Nasdaq’s independence requirements for membership on the Nomination and Corporate Governance Committee. Ms. Søgaard is not deemed to be independent under Nasdaq Rule 5605(a)(2)(A), since as noted herein, she was an executive and legal adviser of our company during the past three (3) years. However, due to the fact that our Board of Directors, or the Board, consists of only four (4) members, three (3) of which are independent, and these three (3) independent directors serve on either our Audit Committee or our Compensation Committee or both, the Board believes that it would be unduly burdensome to have all of these same three (3) Board members also serve on the Nomination and Corporate Governance Committee. Based on these circumstances, and the fact that each of the independent members of the Board considers Ms. Søgaard to be highly qualified to serve on the Nomination and Corporate Governance Committee, the Board has determined that Ms. Søgaard’s membership on the Nomination and Corporate Governance Committee is required by the best interests of our company and our shareholders and, therefore, is relying on the Exceptional and Limited Circumstance exception for non-independent nominations committee members provided by Nasdaq Rule 5605(e)(3). The Board recognizes that Ms. Søgaard may only serve on the Nomination and Corporate Governance Committee for two (2) years under the exception provided by Rule 5605 (e)(3), unless she meets Nasdaq’s independence requirements for serving on the Nomination and Corporate Governance Committee at the end of such two-year term.

The Nomination and Corporate Governance Committee’s responsibilities include, among other things:

assisting the chairman of our board of directors with the annual evaluation of the effectiveness, achievements and competencies of our board of directors and executive management;
annually reviewing developments in respect of independence criteria for our board of directors and executive management and review the composition of our board of directors and executive management in relation to independence;
ensuring a formal, thorough and transparent process for selection and nomination of candidates to our board of directors taking into consideration the need for diversity as well as recommending that the majority of the members of our board of directors elected by the general meeting be independent;
reviewing and recommending to our board of directors the target figures and policy for the gender composition of our board of directors and other managerial positions;
considering proposals for candidates to our board of directors and executive management submitted by relevant persons, including shareholders and members of our board of directors and executive management;
recommending to our board of directors candidates and any changes to our board of directors and executive management, which shall include a review and assessment of potential candidates for our board of directors and executive management, including their qualifications, experience and other competences as well as any possible conflicts of interests such candidates may have;
ensuring that recommendations for the nomination and/or replacement of members of our board of directors and executive management shall be prepared on the basis of the qualifications and competences deemed to be required by the Nomination Committee;
ensuring that recommendations for the nomination and/or replacement of members of our board of directors and executive management shall be prepared in accordance with the target figures and policy for the gender composition of our board of directors and other managerial positions as set out by our board of directors;

193

prepare descriptions of nominated candidates’ qualifications, including information on other executive functions (e.g. memberships of management boards, boards of directors, supervisory boards, board committees etc.) in Danish and foreign companies as well as any demanding positions and tasks in organizations;
annually make suggestions for appointment of members to the committees established by our board of directors; and
such other matters that are specifically delegated to the nominating committee by our board of directors from time to time.

6.D. Employees

As of December 31, 2021, 2020 and 2019, Evaxion had 61, 35 and 31 employees, respectively. All of our employees are engaged in either general and administrative or research and development functions. None of our employees are represented by a labor union or covered under a collective bargaining agreement. For a further description of our employees, see the section entitled “Business - Employees” in this annual report.

6.E. Share Ownership

See “Item 7.A. Major Shareholders and Related Party Transactions – Major Shareholders.” Our employees are eligible to own shares of the company through a warrant incentive plan. For information on the plan, see “Item 6.B. Compensation—Warrant Incentive Plan.”

Item 7.Major Shareholders and Related Party Transactions

7.A. Major Shareholders

The following table presents information, as of December 31, 2021, regarding the beneficial ownership of our ordinary shares by:

each person, or group of affiliated persons, known by us to own beneficially 5% or more of our outstanding ordinary shares;
each of our directors and members of our executive management individually; and
each of our directors and members of our executive management as a group.

The number of ordinary shares beneficially owned by each entity, person, and member of our board of directors or members of our executive management is determined in accordance with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any ordinary shares over which the individual has sole or shared voting power or investment power as well as any ordinary shares that the individual has the right to acquire within 60 days of December 31, 2021 through the exercise of any option, warrant or other right. Except as otherwise indicated, and subject to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all ordinary shares held by that person.

The percentage of outstanding ordinary shares is computed on the basis of 23,203,808 ordinary shares, DKK 1 nominal value per share, each outstanding as of December 31, 2021. Ordinary shares that a person has the right to acquire within 60 days of December 31, 2021 are deemed outstanding for purposes of computing the percentage ownership of the person holding such rights, but are not deemed outstanding for purposes of computing the percentage ownership of any other person, except with respect to the percentage ownership of all members of our board of directors or executive management as a group. None of our shareholders has different voting rights from other shareholders. We are not aware of any arrangement that may, at a subsequent date, result in a change of

194

control of our company. Unless otherwise indicated, the business address for each beneficial owner is Dr. Neergaards Vej 5f, DK-2970 Hoersholm, Denmark.

 Shares Beneficially Owned

Name of Beneficial Owner

    

Number

    

Percent

5% or Greater Shareholders

 

NIMedical Holding ApS(1)

    

4,292,604

    

18.50

Mattsson Holding af 2008 ApS(2)

 

4,163,832

 

17.94

Executive Management

 

  

 

Lars Staal Wegner

 

1,039,076

 

4.32

Niels Iverson Møller(1)

 

4,292,604

 

18.50

Andreas Holm Mattson(2)

 

4,163,832

 

17.94

Glenn S. Vraniak(3)

 

 

Birgitte Rønø

27,953

*

Erik Deichmann Heegaard

27,358

*

Directors

 

  

 

  

Roberto Prego

 

348,995

 

1.50

Steven Projan

 

73,919

 

*

Lars Holtug

4,583

*

Marianne Søgaard

 

144,642

 

*

All current directors and executive management, as a group (9 persons)

 

10,122,962

 

41.64

*

Represents beneficial ownership of less than 1%

(1)Consists of 4,292,604 ordinary shares held by NIMedical Holding ApS, which is a personal investment company wholly-owned by Dr. Møller.
(2)Consists of 4,163,832 ordinary shares held by Mattsson Holding af 2008 ApS, which is a personal investment company wholly-owned by Mr. Mattsson.
(3)Mr. Vraniak resigned as our Chief Financial Officer effective November 1, 2021.

Holdings by United States Shareholders

As of December 31, 2021, approximately 8% of our issued and outstanding ordinary shares were held by eight United States record holders. The number of individual holders of record is based exclusively upon our share register and does not address whether a share or shares may be held by the holder of record on behalf of more than one person or institution who may be deemed to be the beneficial owner of a share or shares in our company.

Significant Changes in Percentage Ownership

We are not aware of any arrangement that may, at a subsequent date, result in a change of control of our company. To Evaxion’s knowledge, and other than changes in percentage ownership as a result of the shares issued in connection with Evaxion’s initial public offering in the United States, there has been no significant change in the percentage ownership held by the major shareholders listed above in the last three years, except as discussed in “Item 7.B. Related Party Transactions.”

7.B. Related Party Transactions

Below is a summary of our grants, agreements, and transactions since January 1, 2017 in which the amount involved exceeded or will exceed $120,000, and in which any of our then directors, executive management or holders of more than 10% of any class of our voting securities at the time of such transaction, or any members of their immediate family, had or will have a direct or indirect material interest.

Share-based Awards to Directors and Executive Management

We have granted share-based awards to certain of our directors and executive management. For more information regarding the warrants granted to our executive management and directors see the section herein entitled “Warrant Incentive Plan”.

195

Employment Agreements and Indemnification Agreements

We have entered employment agreements with each member of our executive management and intend to enter into indemnification agreements with each member of our executive management and each of our directors. For more information see the sections herein entitled “Compensation of Executive Officers and Directors” and “Insurance and indemnification.”

Policies and Procedures for Related Person Transactions

Prior to our IPO, we have not had a formal policy regarding approval of transactions with related parties. We have adopted a related person transaction policy setting forth the policies and procedures for the identification, review and approval or ratification of related person transactions. This policy covers, with certain exceptions set forth in Item 404 of Regulation S-K under the Securities Act, any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we and a related person were or will be participants and the amount involved exceeds $120,000, including purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness and guarantees of indebtedness. In reviewing and approving any such transactions, our audit committee will consider all relevant facts and circumstances as appropriate, such as the purpose of the transaction, the availability of other sources of comparable products or services, whether the transaction is on terms comparable to those that could be obtained in an arm’s length transaction, management’s recommendation with respect to the proposed related person transaction, and the extent of the related person’s interest in the transaction.

7.C. Interests of Experts and Counsel

Not applicable.

Item 8.Financial Information

8.A. Consolidated Statements and Other Financial Information

See “Item 18. Financial Statements.”

Legal Proceedings

There are no governmental, legal or arbitration proceedings (including any such proceedings which are pending or threatened of which Evaxion is aware) that may have, or have had in the recent past (covering the 12 months immediately preceding the date of this annual report), significant effects on Evaxion’s financial position or profitability.

Dividend Policy

Evaxion does not expect to pay dividends in the foreseeable future. If we pay any dividends on our ordinary shares, we will pay those dividends, which shall be payable in respect of the ordinary shares underlying the ADS to the depositary, as the registered holder of such ordinary shares, and the depositary then will pay such amounts to the ADS holders in proportion to the ordinary shares underlying the ADSs held by such ADS holders, subject to the terms of the deposit agreement, including the fees and expenses payable thereunder. Cash dividends on our ordinary shares, if any, will be paid in USD.

Legal and Regulatory Requirements

In accordance with the Danish Companies Act, dividends, if any, are declared with respect to a financial year at the annual general meeting of shareholders in the following year, where the statutory annual report (which includes the audited financial statements) for that financial year is approved. Any resolution to distribute interim dividends within six months of the date of the statement of financial position as set out in our latest adopted annual report must be accompanied by the statement of financial position from our latest annual report or an interim statement of financial position which must be reviewed by our auditor. If the decision to distribute interim dividends is passed more than six months after the date of the statement of financial position as set out in our latest adopted annual report, an interim statement of financial position must be prepared and reviewed by our auditor. The statement of financial position or the interim statement of financial position, as applicable, must show that sufficient funds are available for distribution. Dividends may not exceed the amount recommended by the board of directors for approval by the general meeting of shareholders. Moreover, dividends and interim dividends may only be made out of distributable reserves and may not exceed what is considered

196

sound and adequate with regard to our financial condition or be to the detriment of our creditors and such other factors as the board of directors may deem relevant.

In accordance with the Danish Companies Act, share buybacks, if any, may only be carried out by the board of directors using funds that could have been distributed as dividends at the latest annual general meeting of shareholders. Any share buyback must be conducted in accordance with an authorization obtained at a general meeting of our shareholders. The authorization must be granted for a defined period of time not exceeding five years. In addition, the authorization must specify the maximum permitted value of treasury shares as well as the minimum and maximum amount that we may pay as consideration for such shares. A decision by our board of directors to engage in share buybacks, if any, will be made in accordance with the factors applicable to dividend payments set forth above.

See “Item 10.E. Taxation — Danish Tax Considerations” for a description of Danish withholding taxes and certain other Danish considerations relevant to the purchase or holding of ordinary shares and ADSs and “Item 10.E. Taxation — Certain Material United States Federal Income Tax Considerations” for a description of United States federal income tax considerations relevant to the purchase or holding of shares and ADSs.

8.B. Significant changes

See Note 23 to the audited consolidated financial statements included elsewhere in this annual report.

Item 9.The Offer And Listing

9.A. Offer and Listing Details

ADSs/Ordinary shares

Our ADSs, each representing one ordinary shares of ours, with a DKK 1 nominal value per share, have been listed on The Nasdaq Capital Market since February 5, 2021. Our ADSs trade under the symbol “EVAX.” Prior to that date, there was no public trading market for our ADSs.

9.B. Plan of Distribution

Not applicable.

9.C. Markets

For a description of our publicly-traded ADSs, see “Item 9.A. Offer and Listing Details—ADSs/Ordinary Shares.”

9.D. Selling Shareholders

Not applicable.

9.E. Dilution

Not applicable.

9.F. Expenses of the Issue

Not applicable.

197

Item 10.Additional Information

10.A.Share Capital

Development of the Share Capital

As of December 31, 2021, our registered, issued and outstanding share capital was nominal DKK 23,203,808 divided into 23,203,808 ordinary shares of DKK 1. The development of our share capital since December 31, 2016 to December 31, 2021 is set forth in the table below. The below Price Per share (DKK) is based on the registrations with the Danish Business Authority.

Share Capital

Price Per

 

After

Share

 

Date

    

Transaction

    

Transaction

    

(DKK)

 

August 2008

    

Formation (Nominal DKK 1)

    

250,000

    

1.00

March 2014

 

Cash contribution (Nominal DKK 1)

 

268,148

 

120.00

December 2014

 

Cash contribution (Nominal DKK 1)

 

316,751

 

178.22

December 2015

 

Cash contribution (Nominal DKK 1)

 

336,549

 

435.76

March 2016

 

Cash contribution (Nominal DKK 1)

 

342,880

 

432.12

September 2017

 

Cash contribution (Nominal DKK 1)

 

358,806

 

1,034.75

March 2019

 

Transfer of reserves (Nominal DKK 1)

 

717,612

 

1.00

July 2019

 

Cash contribution and debt conversion (Nominal DKK 2)

 

836,994

 

914.71

(avg)

December 2019

 

Cash contribution (Nominal DKK 1)

 

843,564

 

1,037.50

September 2020

 

Cash contribution (Nominal DKK 1)

 

884,974

 

1,002.90

October 2020

 

Cash contribution (Nominal DKK 1)

 

899,926

 

1,008.45

January 2021

 

Share split 2-for-1 (Nominal DKK 1)

 

899,926

 

January 2021

Bonus share issuance 17-for-1 (Nominal DKK 1)

16,198,668

February 2021

Initial public offering (3,000,000 ADSs / 3,000,000 new share issue)

19,198,668

61.99

November 2021

Follow-on public offering (3,942,856 ADSs / 3,942,856 new share issue)

23,141,524

45.00

November 2021

 

Cash contribution (Nominal DKK 1)

 

23,203,808

 

1.00

10.B.Memorandum and Articles of Association

The following describes our issued share capital, summarizes the material provisions of our articles of association and highlights certain differences in corporate law in the Kingdom of Denmark and Delaware corporate law, the law under which many publicly listed companies in the United States are incorporated. Please note that this summary is not intended to be exhaustive. For further information, please refer to the full version of our articles of association, which are included as an exhibit to the registration statement of which this annual report is a part.

Introduction

Set forth below is a summary of certain information concerning our share capital as well as a description of certain provisions of our articles of association and relevant provisions of the Danish Companies Act. The summary includes certain references to and descriptions of material provisions of our articles of association to be effective in connection with the consummation of the offering and Danish law in force as of the date of this annual report. The summary below contains only material information concerning our share capital and corporate status and does not purport to be complete and is qualified in its entirety by reference to our articles of association. Further, please note that as an ADS holder you will not be treated as one of our shareholders and will not have any shareholder rights.

General

We were incorporated under the laws of the Kingdom of Denmark on August 11, 2008, as a private limited liability company (in Danish: Anpartsselskab, or ApS) under Danish law and are registered with the Danish Business Authority (in Danish: Erhvervsstyrelsen) in Copenhagen, Denmark under registration number 31762863. On March 29, 2019, our company was converted into a public limited liability company (in Danish: Aktieselskab, or A/S). Our principal executive offices are located at Dr. Neergaards Vej 5f, DK-2970 Hoersholm, Denmark and our telephone number is +45 53 53 18 50. Our website address is

198

www.evaxionbiotech.com. The information on, or that can be accessed through, our website is not part of and is not incorporated by reference into this annual report. We have included our website address as an inactive textual reference only.

Authorizations to the Board of Directors

Our board of directors is authorized to increase the share capital as follows:

Our board of directors is authorized to increase our share capital (i) by up to nominal DKK 5,500,000 without pre-emptive subscription rights for existing shareholders in connection with cash contributions, debt conversion and contributions in kind; provided, however, that the capital increases are carried out at market value and (ii) by up to nominal DKK 5,500,000, with preemptive subscription rights for existing shareholders in connection with cash contributions.
Our board of directors is authorized to issue warrants and to increase our share capital by up to nominal DKK 1,500,000 without pre-emptive subscription rights for existing shareholders in connection with the exercise, if any, of said warrants and to determine the terms and conditions thereof.
Our board of directors is, without pre-emptive rights for the existing shareholders, authorized to obtain loans against issuance of convertible bonds which confer the right to subscribe up to nominal DKK 1,000,000. The convertible bonds shall be offered at a subscription price and a conversion price that corresponds in aggregate to at least the market price of the shares at the time of the decision of our board of directors. The loans shall be paid in cash and our board of directors shall determine the terms and conditions for the convertible bonds.

The above authorizations are valid until January 3, 2026.

The ADSs

Our ADSs are listed on The Nasdaq Capital Market under the symbol “EVAX.”

Our ADSs issued are settled through The Depository Trust Company, or DTC, in accordance with its customary settlement procedures for equity securities. Each person owning ADSs held through DTC must rely on the procedures thereof and on institutions that have accounts therewith to exercise any rights of a holder of the ADSs.

Our Warrants

We have established warrant programs for members of our board of directors, our executive management, other employees, consultants and advisors. Under the terms of our warrant plans, warrants are issued to our directors, executive management and employees, on a discretionary basis following consultation with and recommendation from our Compensation Committee. All warrants have been issued by the general meeting or by our board of directors pursuant to valid authorizations in our articles of association and the terms and conditions have, in accordance with the Danish Companies Act, been incorporated in our articles of association.

199

The description below merely contains a summary of the applicable terms and conditions and does not purport to be complete. As of January 1, 2022, we have issued and outstanding 2,732,618 warrants (excluding the EIB warrants) that each confer the right to subscribe to nominal DKK 1 shares. Our warrants have previously been granted, on the dates, and with exercise prices as set forth below:

    

    

Number of

Grant Date

    

Vesting Period

    

Expiration Date

    

Exercise Price

    

 Warrants

December 19, 2016

 

Upon IPO Event

December 31, 2036

 

DKK 1.0

 

758,448

December 10, 2017

 

Upon IPO Event

December 31, 2036

 

DKK 1.0

 

632,700

December 19, 2017

 

Upon IPO Event

December 31, 2036

 

DKK 1.0

 

141,804

December 17, 2020

 

See vesting principles below

December 31, 2031

 

DKK 1.0

 

757,620

June 2021

See vesting principles below

December 31, 2032

DKK 1.0

62,147

December 2021

See vesting principles below

December 31, 2032

USD 5.38

523,599

Exercised

(62,284)

Lapsed or annulled without exercise

 

  

  

 

  

 

(81,416)

 

2,732,618

On December 17, 2020, our board of directors issued 757,620 warrants related to 2018 – 2020. In addition, we have issued 351,036 to EIB on December 17, 2020, which are expected to be cash settled. For a more detailed description of the EIB Warrants see the section below entitled “Our EIB Warrants.”

Vesting Principles Generally

Warrants granted for the years 2016 – 2018 vested upon the closing of our initial public offering. Warrants granted for the years 2019 and 2020 generally vest at a rate of 1/36th per month. Vested warrants may be exercised in four annual exercise windows of two weeks each that each commence two trading days following publication of our annual report, the six-month report and the interim quarterly reports. However, our board of directors determined that the first such exercise window began November 2021.

For the 331,632 warrants granted in 2019 (issued in 2020), 117,612 warrants were fully vested on the date of grant and 214,020 warrants vest with 1/36 per month from date of grant. For the 236,196 warrants granted and issued in 2020, 120,888 warrants were fully vested on the date of issuance, 6,084 vest with 1/36 per month starting on January 1, 2020, 19,008 warrants vest three years from the date of joining us, 90,216 warrants vest with 1/36 per month starting on January 1, 2021.

There are certain restrictions on exercise in the event that warrant holders terminate their employment or are dismissed for prior to exercise.

Adjustments

Warrant holders are entitled to an adjustment of the number of warrants issued and/or the exercise price applicable in the event of certain changes to our share capital at a price other than the market price. Events giving rise to an adjustment include, among other things, increases or decreases to our share capital at a price below or above market value, respectively, and issuance of bonus shares. For the purpose of implementing the capital increases necessary in connection with the exercise of warrants, our board of directors has been authorized to increase our share capital by one or more issuances of shares with a total nominal value corresponding to the number of warrants issued upon cash payment of the exercise price without any preemptive subscription rights to existing shareholders.

Our EIB Warrants

In connection with the EIB Loan Agreement, we agreed to issue the EIB Warrants to EIB in the event we make draws on the EIB Loan. Under the terms of the EIB Warrant Agreement, we are obligated to issue up to an aggregate of 1,047,744 EIB Warrants in three separate tranches with each tranche of EIB Warrants to be issued upon a draw down of a tranche of the EIB Loan in accordance with the following schedule: (i) 351,036 EIB Warrants upon a draw down of the first tranche of the EIB Loan in the amount of €7.0 million; (ii) 345,672 EIB Warrants upon a draw down of the second tranche of the EIB Loan in the amount of €6.0 million, upon shareholders approval and (iii) 351,036 EIB Warrants upon a draw down of the third and final tranche of the EIB Loan in the amount of €7.0 million, upon shareholders approval. In November 2020, we initiated the process of making a draw down on the first tranche of the EIB Loan in the amount of €7.0 million and, in connection therewith, on December 17, 2020 and through the date of the annual report, our board of directors approved the issuance of 351,036 EIB Warrants to EIB.

200

Under the terms of the EIB Warrant Agreement, each EIB Warrant entitles EIB to subscribe for one ordinary share, nominal DKK 1, at an exercise price of DKK 1 per ordinary share. In addition, EIB has the right to cause us to net settle the exercise of the EIB Warrants in cash based on the value of our ordinary shares on the date of exercise thereof. Finally, upon the occurrence of certain events, including the completion of our initial public offering, the prepayment of the EIB Loan, the sale of all or substantially all of our issued share capital or assets, a change in control transaction, or Messrs. Mattson and Moller cease to own and control directly or indirectly 25% or more of the voting rights or economic interest of our company, EIB has the right, but not the obligation, to cause us to purchase any EIB Warrant, or the Put Right. If EIB exercise its Put Right, we are required to pay EIB an amount equal to the volume weighted average price per ordinary share, or VWAP, for a period of six months following the exercise of such Put Right. In the first six months following the completion of our initial public offering, the VWAP price to be paid by us is calculated for the entire period from the completion of our initial public offering until the exercise of the Put Right.

Under Article 18, Paragraph 2 of the Statute of the European Investment Bank, or the EIB Statute, establishing EIB, a direct equity investment by EIB requires a separate authorization from the EIB Board of Governors pursuant to which the EIB Board of Directors, acting by qualified majority, has to establish the terms and conditions of such direct equity investment. As of the date of this annual report, the EIB Board of Governors has not granted any such special authorization to the EIB Board of Directors. Under the EIB Statute, in the absence of a separate authorization from the EIB Board of Governors, commercial shareholdings financed from EIB’s own resources are not allowed. Since the EIB Loan is being made from EIB’s own resources, the EIB Statute does not allow EIB to acquire any of our ordinary shares, therefore, we fully expect that if and when EIB exercises the EIB Warrants it will do so on either a net cash settlement basis or by means of exercising its Put Right. In either case, we may not have sufficient funds on hand to pay such amounts in which case we may be required to use a portion of the proceeds from our initial public offering in order to meet our obligations to pay the amounts due and payable to EIB upon the exercise of the EIB Warrants.

Under the terms of the EIB Warrant Agreement, EIB may not exercise the EIB Warrants and cause us to settle the exercise of the EIB Warrants on a net cash basis or pursuant to its Put Right, for a period of 180 days from the date of the completion of our initial public offering, provided that such lock-up arrangement shall cease to be effective in the event there is a material adverse event relating to our company as determined in accordance with ordinary principles of Danish law.

The number of our ordinary shares that may be subject to either net cash settlement or EIB’s Put Right upon the exercise of the EIB Warrants are subject to adjustment in the event of changes to our capital structure which are not carried out at the then current market price, provided that there shall be no such adjustment as a result of the issuance of additional shares or warrants to employees as well as for any future exercise of such warrants. In addition, the EIB Warrants are not subject to any adjustment in the event of any capital increases in directed issuances or our ordinary shares following the completion of our initial public offering with customary discounts of up to 10% of the market price.

Shareholders’ Register

We are obligated to maintain an owners’ register (DK: ejerbog). The owners’ register is maintained by Computershare A/S (company registration number (CVR) no. 27088899), Lottenborgvej 26 D, 1., DK-2800 Kgs. Lyngby, Denmark, our Danish share registrar and transfer agent. It is mandatory that the owners’ register is maintained within the European Union and that it is available to public authorities. As of December 15, 2019, the Danish Companies Act includes a provision whereby public and private limited liability companies are required to register with the Danish Business Authority information regarding shareholders who own at least 5% of the share capital or the voting rights. Pursuant to this provision, we will file registrations with the Public Owners’ Register of the Danish Business Authority. Shareholders that exceed or fall below the ownership threshold must notify us and we will subsequently file the information with the Danish Business Authority. Reporting is further required upon passing or falling below thresholds of 10, 15, 20, 25, 50, 90, and 100%.

Articles of Association and Danish Corporate Law

At the extraordinary general meeting of shareholders on January 4, 2021 our shareholders resolved to amend our articles of association. The following resolutions came into effect:

Adoption of the authorizations set out above in the section entitled “Authorizations to the Board of Directors”;
A stock split of 2-for-1 ordinary share, changing the nominal denomination of our shares from DKK 2 to DKK 1; and

201

A bonus share issuance of 17-for-1 ordinary share.

Objects Clause

Our corporate object, as set out in article 1.2 of our articles of association, is to create advanced software that enables the development of novel immune therapies and vaccines.

Summary of Provisions Regarding the Board of Directors

Pursuant to our articles of association, our Board shall be elected by our shareholders at the general meeting and shall be composed of not less than three and no more than seven members. With respect to the duration of the term which our directors severally hold office, the board of directors is elected to serve for a term of one year subject to re-election at the next annual general meeting of shareholders or until their successors have been duly elected and qualified, subject to their earlier removal, retirement or death.

Currently, the board of directors consists of five members who are elected by the shareholders.

The board of directors shall appoint and employ an executive management consisting of one to seven members to attend to our day-to-day management, and the board of directors shall determine the terms and conditions of their employment.

Voting Rights

Each shareholder is entitled to one vote for each share owned at the time of any general meeting. As compared with Danish citizens, there are no limitations under the articles of association or under Danish law on the rights of foreigners or non-Danish citizens to hold or vote our ordinary shares.

Dividend Rights

Our shareholders may at general meetings authorize the distribution of ordinary and extraordinary dividends. Our shareholders may not distribute dividends in excess of the recommendation from our board of directors and may only pay out dividends from our distributable reserves, which are defined as results from operations carried forward and reserves that are not bound by law after deduction of loss carried forward.

Our shareholders are eligible to receive any dividends declared and paid out. However, we have not to date declared or paid any dividends and we currently intend to retain all available financial resources and any earnings generated by our operations for use in the business and we do not anticipate paying any dividends in the foreseeable future. The payment of any dividends in the future will depend on a number of factors, including our future earnings, capital requirements, financial condition and future prospects, applicable restrictions on the payment of dividends under Danish law and other factors that our board of directors may consider relevant.

See “Item 10.E. Taxation” for a summary of certain tax consequences in respect of dividends or distributions to holders of our ordinary shares or ADSs.

Pre-emptive Subscription Rights

Under Danish law, all shareholders have pre-emptive subscription rights in connection with capital increases that are carried out as cash contributions. An increase in share capital can be resolved by the shareholders at a general meeting or by the board of directors pursuant to an authorization given by the shareholders. In connection with an increase of a company’s share capital, the shareholders may, by resolution at a general meeting, approve deviations from the general Danish pre-emptive rights of the shareholders. Under the Danish Companies Act, such resolution must be adopted by the affirmative vote of shareholders holding at least a two-thirds majority of the votes cast and the share capital represented at the general meeting, and requires that such capital increases will be carried out as a cash contribution at market price.

The board of directors may resolve to increase our share capital without pre-emptive subscription rights for existing shareholders pursuant to the authorizations set forth above under the caption “Development of the Share Capital”.

202

Unless future issuances of new shares and/or pre-emptive rights are registered under the Securities Act or with any authority outside Denmark, United States shareholders and shareholders in jurisdictions outside Denmark may be unable to exercise their pre-emptive subscription rights.

Rights on Liquidation

Upon a liquidation or winding-up of the Company, shareholders will be entitled to participate, in proportion to their respective shareholdings, in any surplus assets remaining after payment of our creditors.

Limitations on Holding of Shares

There are no limitations on the right to hold shares under the articles of association or Danish law.

Disclosure Requirements

Pursuant to Section 55 of the Danish Companies Act, a shareholder is required to notify us when such shareholder’s stake represents 5% or more of the voting rights in our company or the nominal value accounts for 5% or more of the share capital, and when a change of a holding already notified entails that the limits of 5, 10, 15, 20, 25, 50, 90 or 100% and the limits of one-third and two-thirds of the share capital’s voting rights or nominal value are reached or are no longer reached. The notification shall be given within two weeks following the date when the limits are reached or are no longer reached. This also applies to beneficial holders of our ordinary shares, such as holders of the ADSs.

The notification shall provide information about the full name, address or, in the case of undertakings, registered office, the number of shares and their nominal value and share classes as well as information about the basis on which the calculation of the holdings has been made. In the event that the shareholder is a non-resident company or citizen of Denmark, the notification shall include documentation, which clearly identifies the owner. The company shall cause the notification to be entered in the owners’ register.

General Meetings

The general meeting of shareholders is the highest authority in all matters, subject to the limitations provided by Danish law and the articles of association. The annual general meeting shall be held in the Greater Copenhagen area not later than the end of May in each year.

At the annual general meeting, the audited annual report is submitted for approval, together with the proposed appropriations of profit/treatment of loss, the election of the board of directors and election of our auditors. In addition, the board of directors reports on our activities during the past year.

General meetings are convened by the board of directors with a minimum of two weeks’ notice and a maximum of four weeks’ notice. A convening notice will also be forwarded to shareholders recorded in our owners’ register, who have requested such notification and by publication in the Danish Business Authority’s computerized information system and on the company’s website.

At the latest, two weeks before a general meeting (inclusive of the day of the general meeting), we shall make the following information and documents available at our offices.

the convening notice,
the documents that shall be presented at the general meeting, and
the agenda and the complete proposals.

Shareholders are entitled to attend general meetings, either in person or by proxy.

203

Any shareholder is entitled to submit proposals to be discussed at the general meetings. However, proposals by the shareholders to be considered at the annual general meeting must be submitted in writing to the board of directors not later than six weeks prior the general meeting.

Extraordinary general meetings must be held upon resolution of a general meeting to hold such a meeting or upon request of, the board of directors, our auditors or shareholders representing at least 1/20 of the registered share capital or such lower percentage as our articles of association may provide. Our articles of association do not state such lower percentage.

Holders of ADSs are not entitled to directly receive notices or other materials and may not attend or vote at general meetings.

Resolutions in General Meetings

Resolutions made by the general meeting generally may be adopted by a simple majority of the votes cast, subject only to the mandatory provisions of the Danish Companies Act and our articles of association. Resolutions concerning all amendments to the articles of association must be passed by two-thirds of the votes cast as well as two-thirds of the share capital represented at the general meeting. Certain resolutions, which limit a shareholder’s ownership or voting rights, are subject to approval by a nine-tenth majority of the votes cast and the share capital represented at the general meeting. Decisions to impose or increase any obligations of the shareholders towards the company require unanimity.

Quorum Requirements

There are no quorum requirements generally applicable to general meetings of shareholders. To this extent, our practice varies from the requirement of Nasdaq Listing Rule 5620(c), which requires an issuer to provide in its bylaws for a generally applicable quorum, and that such quorum may not be less than one-third of the outstanding voting shares.

Squeeze out

According to Section 73 of the Danish Companies Act, a minority shareholder may require a majority shareholder that holds more than 90% of the company’s registered share capital and the corresponding voting rights to redeem his or her shares. Similarly, a majority shareholder holding more than 90% of the company’s share capital and the corresponding voting rights may, according to Section 70 of the same act, redeem the minority shareholder’s shares. In the event that the parties cannot agree to the terms of redemption and the valuation basis of the redemption price, this shall be determined by an independent evaluator appointed by the court for the district in which the registered office of the company is situated (i.e. currently the Copenhagen City Court).

Comparison of Danish Corporate Law and our Articles of Association and Delaware Corporate Law

The following comparison between Danish corporate law, which applies to us, and Delaware corporate law, the law under which many publicly listed companies in the United States are incorporated, discusses additional matters not otherwise described in this annual report. This summary is subject to Danish law, including the Danish Companies Act, and Delaware corporation law, including the Delaware General Corporation Law. Further, please note that as an ADS holder you will not be treated as one of our shareholders and will not have any shareholder rights.

Duties of Directors

Denmark. Public limited liability companies in Denmark are usually subject to a two-tier governance structure with the board of directors having the ultimate responsibility for the overall supervision and strategic management of the company in question and with an executive board/management being responsible for the day-to-day operations. Each Director and member of the executive board/management is under a fiduciary duty to act in the interest of the company, but shall also take into account the interests of the creditors and the shareholders. Under Danish law, the members of the board of directors and executive management of a limited liability company are liable for losses caused by negligence whether shareholders, creditors or the company itself suffers such losses. They may also be liable for wrongful information given in the annual financial statements or any other public announcements from the company. An investor suing for damages is required to prove its claim with regard to the incurred loss, negligence and causation. Danish courts, when assessing negligence, have been reluctant to impose liability unless the directors and officers neglected clear and specific duties. This is also the case when it comes to liability with regard to public offerings or liability with regard to any other public information issued by the company.

204

Delaware. The board of directors bears the ultimate responsibility for managing the business and affairs of a corporation. In discharging this function, directors of a Delaware corporation owe fiduciary duties of care and loyalty to the corporation and to its stockholders. Delaware courts have decided that the directors of a Delaware corporation are required to exercise informed business judgment in the performance of their duties. Informed business judgment means that the directors have informed themselves of all material information reasonably available to them. Delaware courts have also imposed a heightened standard of conduct upon directors of a Delaware corporation who take any action designed to defeat a threatened change in control of the corporation. In addition, under Delaware law, when the board of directors of a Delaware corporation approves the sale or break-up of a corporation, the board of directors may, in certain circumstances, have a duty to obtain the highest value reasonably available to the shareholders.

Terms of the Members of our Board of Directors

Denmark. Under Danish law, the members of the board of directors of a limited liability company are generally appointed for an individual term of one year (terms may have a maximum period of 4 years). There is no limit in the number of consecutive terms the directors may serve. Pursuant to our articles of association, our directors are appointed by the general meeting of shareholders for a term of one year and are divided into two classes. Election of directors is, according to our articles of association, an item that shall be included on the agenda for the annual general meeting.

At the general meeting, shareholders are entitled at all times to dismiss a director elected by the general meeting by a simple majority vote.

Pursuant to the Danish Companies Act, in a limited liability company that employed an average of at least 35 employees in the preceding three years, the employees are entitled to elect a minimum of two representatives and alternate members to the company’s board of directors and up to one half the number of the shareholder elected directors. If the number of representatives to be elected by the employees is not a whole number, such number must be rounded up. However, our company currently employees less than an average of 35 employees and consequently our employees are not entitled to demand representation on our board of directors.

Delaware. The Delaware General Corporation Law generally provides for a one-year term for directors, but permits directorships to be divided into up to three classes, of relatively equal size, with up to three-year terms, with the years for each class expiring in different years, if permitted by the certificate of incorporation, an initial bylaw or a bylaw adopted by the stockholders. A director elected to serve a term on a “classified” board may not be removed by stockholders without cause. There is no limit in the number of terms a director may serve.

Director Vacancies

Denmark. Under Danish law, new directors are elected by the shareholders in a general meeting also in the event of vacancies. A general meeting will thus have to be convened in order to fill a vacancy on the board of directors. However, the board of directors may choose to wait to fill vacancies until the next annual general meeting of the company, provided that the number of remaining directors is more than two, and provided that the remaining directors can still constitute a quorum. It is only a statutory requirement to convene a general meeting to fill vacancies if the number of remaining members on the board is less than three.

Delaware. The Delaware General Corporation Law provides that vacancies and newly created directorships may be filled by a majority of the directors then in office (even though less than a quorum) unless

(1) otherwise provided in the certificate of incorporation or bylaws of the corporation or (2) the certificate of incorporation directs that a particular class of stock is to elect such director, in which case any other directors elected by such class, or a sole remaining director elected by such class, will fill such vacancy.

Conflict-of-interest Transactions

Denmark. Under Danish law, directors may not take part in any matter or decision-making that involves a subject or transaction in relation to which the director has a conflict of interest with us.

205

Delaware. The Delaware General Corporation Law generally permits transactions involving a Delaware corporation and an interested director of that corporation if:

the material facts as to the director’s relationship or interest are disclosed and a majority of disinterested directors consent;
the material facts are disclosed as to the director’s relationship or interest and a majority of shares entitled to vote thereon consent; or
the transaction is fair to the corporation at the time it is authorized by the board of directors, a committee of the board of directors or the stockholders.

Proxy Voting by Directors

Denmark. In the event that a director in a Danish limited liability company is unable to participate in a board meeting, the elected alternate, if any, shall be given access to participate in the board meeting. Unless the board of directors has decided otherwise, or as otherwise is set out in the articles of association, the director in question may grant a power of attorney to another director, provided that this is considered safe considering the agenda in question.

Delaware. A director of a Delaware corporation may not issue a proxy representing the director’s voting rights as a director.

10.C. Material Contracts

Except as otherwise disclosed in this annual report (including the Exhibits), we are not currently party to any material contract, other than contracts entered into in the ordinary course of business.

10.D. Exchange Controls

There are no governmental laws, decrees, regulations, or other legislation in Denmark that may affect the import or export of capital, including the availability of cash and cash equivalents for use by Evaxion, or that may affect the remittance of dividends, interest, or other payments by Evaxion to non-resident holders of our ordinary shares or ADSs, other than withholding tax requirements. There is no limitation imposed by Danish law or in the Articles on the right of non-residents to hold or vote shares.

10.E. Taxation

Danish Tax Considerations

The following discussion describes the material Danish tax consequences under present law of an investment in the ADSs. To the extent that the discussion below relates to matters of Danish tax law, it represents the opinion of KPMG Acor Tax P/S. The summary is for general information only and does not purport to constitute exhaustive tax or legal advice. It is specifically noted that the summary does not address all possible tax consequences relating to an investment in the ADSs. The summary is based solely on the tax laws of Denmark in effect on the date of this annual report. Danish tax laws may be subject to change, possibly with retroactive effect.

The summary does not cover investors to whom special tax rules apply, and, therefore, may not be relevant, for example, to investors subject to the Danish Tax on Pension Yields Act (i.e., pension savings), professional investors, certain institutional investors, insurance companies, pension companies, banks, stockbrokers and investors with tax liability on return on pension investments. The summary does not cover taxation of individuals and companies who carry on a business of purchasing and selling shares. The summary only sets out the tax position of the direct owners of the ADSs and further assumes that the direct investors are the beneficial owners of the ADSs and any dividends thereon. Sales are assumed to be sales to a third party.

Potential investors in the ADSs are advised to consult their tax advisors regarding the applicable tax consequences of acquiring, holding and disposing of the ADSs based on their particular circumstances.

Investors who may be affected by the tax laws of other jurisdictions should consult their tax advisors with respect to the tax consequences applicable to their particular circumstances as such consequences may differ significantly from those described herein.

206

Taxation of Danish Tax Resident Holders of the ADSs

It is currently not clear under the current Danish tax legislation or case law how the listed ADSs are to be treated for tax purposes, and therefore no level of assurance can be given on this matter. For the purpose of the below comments, it is assumed that Danish tax resident holders of the ADSs should be treated as holders of unlisted shares in the company for Danish tax purposes, as the company’s ordinary shares are not admitted to trading on a regulated market. However, recent communications from the Danish Tax authorities indicate that based on an individual analysis based on the actual facts and circumstances and terms and conditions of the depositary agreement, a holder of ADSs may not be treated as holding unlisted shares in the company for Danish tax purposes, which has hitherto been assumed when the underlying asset consists of an unlisted share. Furthermore, the communications from the Danish Tax authorities indicate if the holders of ADSs are not treated as holders of shares in the Danish company, then the depository bank may be considered the holder of the ordinary shares in the company for Danish tax purposes.

However, the tax position and treatment of ADSs under Danish law are still unclear. In the event that the holders of ADSs are not treated as holding unlisted shares in the company, it is likely that they will be treated as either holding listed shares or financial instruments for tax purposes.

As described above, the below summary assumes that the holders of ADSs listed in the United States should be treated as holding unlisted ordinary shares in the company for Danish tax purposes, but if this is not the case, then this will impact the Danish tax treatment of the holders of ADSs, including in respect of the taxation of dividends paid to holders of ADSs.

Sale of the ADSs (Individuals) assuming treatment as unlisted shares under Danish tax law

For individual investor in 2022, gains from the sale of shares are include in the computation of the annual share income subject to 27% tax on the first DKK 57,200 (for cohabiting spouses, a total of DKK 114,400) and at a rate of 42% on share income exceeding DKK 57,200 (for cohabiting spouses over DKK 114,400). Such amounts are subject to annual adjustments and include all share income (i.e., all capital gains and dividends derived by the individual or cohabiting spouses, respectively).

Gains and losses on the sale of shares are calculated as the difference between the purchase price and the sales price. The purchase price is generally determined using the average method (in Danish “gennemsnitsmetoden”) as a proportionate part of the aggregate purchase price for all the shareholder’s shares in the company.

As the ADSs, for the purpose of this tax description, are considered unlisted shares for Danish tax purposes, losses may be offset against other share income, (i.e., received dividends and capital gains on the sale of shares). Unused losses will automatically be offset against a cohabiting spouse’s share income. In case the share income becomes negative, a negative tax on the share income will be calculated and offset against the individual’s other final taxes. Unused negative tax on share income will be offset against a cohabiting spouse’s final taxes. If the negative tax on share income cannot be offset against a cohabiting spouse’s final taxes, the negative tax can be carried forward indefinitely and offset against future year’s taxes. The tax treatment follows from the realization principle.

Sale of the ADSs (Companies) assuming treatment as unlisted shares under Danish tax law

For the purpose of taxation of sales of shares made by shareholders (companies), a distinction is made between Subsidiary Shares, Group Shares, Tax-Exempt Portfolio Shares and Taxable Portfolio Shares (note that the ownership threshold described below are applied on the basis of the number of all shares issued by the company, and not on the basis of the number of the ADSs issued):

Subsidiary Shares” are generally defined as shares owned by a shareholder holding at least 10% of the nominal share capital of the issuing company.

Group Shares” are generally defined as shares in a company in which the shareholder of the company and the issuing company are subject to Danish joint taxation or fulfill the requirements for international joint taxation under Danish law (i.e., the company is controlled by the shareholder).

Tax-Exempt Portfolio Shares” are defined as shares not admitted to trading on a regulated market or multilateral trading facility owned by a shareholder holding less than 10% of the nominal share capital of the issuing company.

207

Gains or losses on disposal of Subsidiary Shares and Group Shares and Tax-Exempt Portfolio Shares are not included in the taxable income of the shareholder.

Special rules apply with respect to Subsidiary Shares and Group Shares to prevent certain holding company structures just as other anti-avoidance rules may apply. These rules will not be described in further detail.

Dividends (Individuals)

As described above, it is uncertain if holders of ADSs for Danish tax purposes are treated as holders of the ordinary shares in the company. Therefore, it is highly uncertain if the actual distribution of dividends on ADSs to Danish investors are considered dividends for Danish tax purposes. However, if such distributions to Danish tax resident individual investors are treated as dividends, taxation as share income, as described above, will take place. All share income must be included when calculating whether the amounts described above are exceeded. Dividends paid to individuals are generally subject to 27% withholding tax.

Dividends (Companies)

For corporate investors, dividends paid (subject to the same uncertainty as described immediately above) on Subsidiary Shares and Group Shares are tax-exempt irrespective of ownership period.

Dividends paid on Tax-Exempt Portfolio Shares are partly taxable as 70% of the dividends received are included in the taxable income, which is equivalent to an effective taxation of 15.4% (70% of 22%) irrespective of ownership period.

The actual withholding tax rate is as a starting point 27%, while it can be reduced (0%, 15.4%, 22%) if certain requirements are met. A claim for repayment can be made within two months or the excess tax will offset the corporation income tax for the year. The statute of limitation is three years. However, in recent unpublished case law this has been extended to five years. This case law is still pending with the courts.

Taxation of Shareholders Residing Outside Denmark

It is currently not clear under the Danish tax legislation or case law how listed ADSs are treated for tax purposes, and therefore no level of assurance can be given on this matter. For the purpose of this summary, it is assumed that a holder of ADSs listed in the United States should be treated as holding non-listed shares in the company, as the company’s ordinary shares are not admitted to trading on a regulated market. However, recent communications from the Danish Tax authorities indicate that based on an individual analysis based on the actual facts and circumstances and terms and conditions of the depositary agreement, a holder of ADSs may not be treated as holding unlisted shares in the company for Danish tax purposes, which has hitherto been assumed when the underlying asset consists of an unlisted share. Furthermore, the communications from the Danish Tax authorities indicate if the holders of ADSs are not treated as holders of shares in the Danish company, then the depository bank may be considered the holder of the ordinary shares in the company for Danish tax purposes.

However, the tax position and treatment of ADSs under Danish law are still unclear. In the event that the holders of ADSs are not treated as holding unlisted shares in the company, it is likely that they will be treated as either holding listed shares or financial instruments for tax purposes.

As described above, the below summary assumes that the holders of ADSs listed in the United States should be treated as holding unlisted ordinary shares in the company for Danish tax purposes, but if this is not the case, then this will impact the Danish tax treatment of the holders of ADSs, including in respect of the taxation of dividends paid to holders of ADSs.

Sale of the ADSs (Individuals and Companies)

Holders of the ADSs not resident in Denmark are normally not subject to Danish taxation on any gains realized on the sale of ADSs, irrespective of the ownership period, subject to certain anti-avoidance rules seeking to prevent that taxable dividend payments are converted to tax exempt capital gains.

No Danish share transfer tax or stamp duties are payable on transfer of ADSs.

208

If an investor holds the ADSs in connection with a trade or business conducted from a permanent establishment in Denmark, gains on shares may be included in the taxable income of such activities pursuant to the rules applying to Danish tax residents as described above.

Dividends (Individuals)

As described above, it is uncertain if holders of ADSs for Danish tax purposes are treated as holders of the ordinary shares in the company. Therefore, it is highly uncertain if the holders of ADSs are entitled to apply for a refund of Danish withholding tax on dividends paid by the company. If the holders of ADSs are not entitled to apply for a refund of Danish withholding tax on dividends paid by the company, then the depository bank may according to the recent communications from the Danish Tax authorities in certain circumstances be entitled to apply for a refund of Danish withholding tax.

However, if the holders of ADS for Danish purposes are treated as holders of the ordinary shares in the company and are entitled to apply for a refund of Danish withholding tax on dividends paid by the company, then the below should apply;

Dividends paid to individuals are generally subject to 27% withholding tax. The withholding tax is 44% for dividends paid to beneficial owners in “Blacklisted Jurisdictions” which encompasses American Samoa, Fiji, Guam, Palau, Panama, Samoa, Trinidad and Tobago, US Virgin Islands, Vanuatu. The 44% rate only applies to “Main Shareholders” which generally encompass individual shareholders holding more than 25% of the shares or 50% of the votes.

Non-residents of Denmark are not subject to additional Danish income tax in respect to dividends received on shares.

If the holders of the ADSs are considered beneficial owners of the dividends according to the applicable double tax treaty between Denmark and the tax residence country of the ADS holder, the withholding tax rate under such double tax treaty may apply to the extent the tax residency of the ADS holder can be documented.

For holders of ADSs (as the beneficial owners of the dividends on the ordinary shares), if the withholding tax rate applied is higher than the applicable final tax rate (as reduced according to domestic law or an applicable double tax treaty) for the holder of ADSs, a request for a refund of Danish tax in excess hereof can be made in the following situations:

Reduction According to Tax Treaty

In the event that the ADS holder is a resident of a state with which Denmark has entered into a tax treaty, the holder may generally, through certain certification procedures, seek a refund from the Danish tax authorities of the tax withheld in excess of the applicable treaty rate, which is typically 15%. Denmark has entered into tax treaties with approximately 80 countries, including the United States, Switzerland and almost all members of the European Union. The tax treaty between Denmark and the United States generally provides for a 15% tax rate.

Reduction According to Danish Tax Law

If the ADS holder holds less than 10% of the nominal share capital (in the form of ordinary shares in the company and not on the basis of the number of the ADSs issued) of the company and the ADS holder is tax resident in a state which has a double tax treaty or an international agreement, convention or other administrative agreement on assistance in tax matters according to which the competent authority in the state of the ADS holder is obligated to exchange information with Denmark, dividends are subject to tax at a rate of 15%. If the ADS holder is tax resident outside the European Union, it is an additional requirement for eligibility for the 15% tax rate that the ADS holder together with related ADS holders holds less than 10% of the nominal share capital of the company.

Note that the reduced tax rate does not affect the withholding rate, which is why the holder must claim a refund as described above in order to benefit from the reduced rate.

Where a non-resident of Denmark holds shares which can be attributed to a permanent establishment in Denmark, dividends are taxable pursuant to the rules applying to Danish tax residents described above.

209

Dividends (Companies)

As described above, it is uncertain if holders of ADSs for Danish tax purposes are treated as holders of the ordinary shares in the company. Therefore, it is highly uncertain if the holders of ADSs are entitled to apply for a refund of Danish withholding tax on dividends paid by the company. If the holders of ADSs are not entitled to apply for a refund of Danish withholding tax on dividends paid by the company, then the depository bank may according to the recent communications from the Danish Tax authorities in certain circumstances be entitled to apply for a refund of Danish withholding tax.

However, if the holders of ADS for Danish purposes are treated as holders of the ordinary shares in the company and are entitled to apply for a refund of Danish withholding tax on dividends paid by the company, then the below should apply;

Dividends paid to companies are generally subject to 27% withholding tax. The withholding tax is 44% for dividends paid on Group Shares and Subsidiary Shares held by beneficial owners in Blacklisted Jurisdictions.

Non-residents of Denmark are not subject to additional Danish income tax in respect to dividends received on shares.

If the investors of the ADSs are considered beneficial owners of the dividends according to the applicable double tax treaty between Denmark and the tax residence country of the ADS holder, the withholding tax rate under such double tax treaty may apply to the extent the tax residency of the ADS holder can be documented.

For investors (as beneficial owners of the dividends on the ordinary shares), if the withholding tax rate applied is higher than the applicable final tax rate (as reduced according to domestic law or an applicable double tax treaty) for the investor, a request for a refund of Danish tax in excess hereof can be made.

Dividends from Subsidiary Shares are tax exempt provided the taxation of the dividends is to be waived or reduced in accordance with the Parent-Subsidiary Directive (2011/96/EEC) or in accordance with a tax treaty with the jurisdiction in which the company investor is resident. If Denmark is to reduce taxation of dividends to a foreign company under a tax treaty, Denmark will not – as a matter of domestic law – exercise such right and will in general not impose any tax at all. Further, dividends from Group Shares – not also being Subsidiary Shares – are exempt from Danish tax provided the company investor is a resident of the European Union or the EEA and provided the taxation of dividends should have been waived or reduced in accordance with the Parent-Subsidiary Directive (2011/96/EEC) or in accordance with a tax treaty with the country in which the company investor is resident had the shares been Subsidiary Shares.

Dividend payments on both Tax-Exempt and Taxable Portfolio Shares will generally be subject to withholding tax at a rate of 27% irrespective of ownership period. While the actual withholding tax rate is as a starting point 27%, it can be reduced if certain requirements are met. If the withholding tax rate applied is higher than the applicable final tax rate for the shareholder, a request for a refund of Danish tax in excess hereof can be made by the shareholder in the following situations:

Reduction According to Tax Treaty

In the event that the shareholder is a resident of a state with which Denmark has entered into a double taxation treaty, the shareholder may generally, through certain certification procedures, seek a refund from the Danish tax authorities of the tax withheld in excess of the applicable treaty rate, which is typically 15%. Denmark has entered into tax treaties with a large number countries, including the United States and almost all members of the European Union. The tax treaty between Denmark and the United States generally provides for a 15% rate.

Reduction According to Danish Tax law

If the shareholder holds less than 10% of the nominal share capital (in the form of ordinary shares in the company and not on the basis of the number of the ADSs issued) in the company and the shareholder is resident in a jurisdiction which has a tax treaty or an international agreement, convention or other administrative agreement on assistance in tax according to which the competent authority in the state of the shareholder is obligated to exchange information with Denmark, dividends are generally subject to a tax rate of 15%. If the shareholder is tax resident outside the European Union, it is an additional requirement for eligibility for the 15% tax rate that the shareholder together with related shareholders holds less than 10% of the nominal share capital of the company. Note that the reduced tax rate does not affect the withholding rate, hence, in this situation the shareholder must also in this situation claim a refund as

210

described above in order to benefit from the reduced rate. Where a non-resident company of Denmark holds shares which can be attributed to a permanent establishment in Denmark, dividends are taxable pursuant to the rules applying to Danish tax residents described above.

If a reclaim is not possible in accordance with above or an applicable Tax Treaty to a rate which is lower than 22% then a reclaim can always be made to 22% unless the beneficial owner holds Group Shares or Subsidiary Shares and is tax resident in a Blacklisted Jurisdiction.

Share Transfer Tax and Stamp Duties

No Danish share transfer tax or stamp duties are payable on transfer of the shares.

Certain Material United States Federal Income Tax Considerations

The following discussion describes certain material United States federal income tax considerations relating to the acquisition, ownership and disposition of ADSs by a United States Holder (as defined below) that acquires the ADSs and holds them as a capital asset (generally property held for investment) under the Internal Revenue Code of 1986, as amended from time to time, or the “Code”. This discussion is based upon existing United States tax law (including the Code, its legislative history, existing, temporary and proposed United States Department of the Treasury Regulations promulgated thereunder, or the “Treasury Regulations”, administrative and judicial interpretations thereof, and other published rulings, guidance, and court decisions) in effect on the date hereof. These tax laws are subject to change, possibly with retroactive effect, and subject to differing interpretations that could affect the tax consequences described herein. No ruling has been sought from the Internal Revenue Service, or the “IRS”, or any other taxing authority, with respect to any United States federal income tax consequences described below. In addition, because the authorities upon which this summary is based are subject to various interpretations, the IRS, other taxing authorities, and the United States courts could disagree with one or more of the positions taken in this summary. This summary is not binding on the IRS or any other taxing authority or court, none of which are precluded from taking a position that is different from or contrary to, any position taken in this summary and there can be no assurance that the IRS, other taxing authority, or a court will not take a contrary position. No opinion from United States legal counsel has been requested, or will be obtained, regarding the United States federal income tax consequences of the acquisition, ownership and disposition of the ADSs.

This discussion does not address all aspects of United States federal income taxation that may be applicable to U.S. Holders in light of their particular circumstances or status including investors subject to special tax rules (such as, bank thrifts, and other financial institutions, insurance companies, broker-dealers in stocks, securities, currencies, or notional principal contracts, traders that have elected to mark securities to market, regulated investment companies, real estate investment trusts, partnerships or other pass-through entities, tax-exempt organizations including private foundations and charitable remainder trusts, pension plans, persons that hold our ADSs or ordinary shares as part of a straddle, hedge, conversion, constructive sale, or other integrated investment or transaction as determined for U.S. federal income tax purposes, persons subject to alternative minimum tax or whose “functional currency” is not the USD, U.S. expatriates or former long-term residents of the United States, persons that directly, indirectly or constructively own 10% or more (by vote or value) of the Company, persons who acquired interests in the Company pursuant to the exercise of any employee share option or otherwise as compensation, or persons holding interests in the Company through partnerships or other pass-through entities).

This section does not address the treatment of a non-U.S. holder, nor does it address the tax treatment under the laws of any U.S. state or local state or non-U.S. taxing jurisdiction or any U.S. estate or alternative minimum tax consequences.

This summary is for general information purposes only and does not purport to be a complete analysis or listing of all potential U.S. federal income tax considerations that may apply to a U.S. Holder as a result of the acquisition, ownership and disposition of the ADSs. In addition, this summary does not take into account the individual facts and circumstances of any particular U.S. Holder that may affect the U.S. federal income tax consequences to such U.S. Holder. Accordingly, this summary is not intended to be, and should not be construed as, legal or U.S. federal income tax advice with respect to any particular U.S. Holder. Except as specifically set forth below, this summary does not discuss applicable tax reporting requirements.

211

For purposes of this discussion, a “U.S. Holder” is a beneficial owner of the ADSs that, for United States federal income tax purposes, is:

an individual who is a citizen or resident of the United States;
a corporation (or other entity taxable as a corporation for United States federal income tax purposes) created or organized in or under the laws of the United States or of any State thereof or the District of Columbia;
an estate the income of which is subject to United States federal income taxation regardless of its source; or
a trust if (i) a court within the United States is able to exercise primary supervision over the trust’s administration and one or more United States persons have the authority to control all substantial decisions of the trust or (ii) a valid election under the Treasury regulations is in effect for the trust to be treated as a United States person.

If a partnership or other pass-through entity (including any entity or arrangement treated as a partnership or other pass-through entity for United States federal income tax purposes) holds the ADSs, the tax treatment of a person treated as a partner or other owner in the partnership or other pass-through entity for United States federal income tax purposes generally will depend on the status of the partner or other owner and the activities of the partnership or other pass-through entity. Partnerships (and other entities or arrangements so treated for United States federal income tax purposes) and their future partners should consult their own tax advisors.

In general, and taking into account the earlier assumptions, for United States federal income tax purposes, a holder of ADSs will be treated as the owner of the shares represented by those ADSs. Exchanges of shares for ADSs, and ADSs for shares, generally will not be subject to United States federal income tax.

This discussion addresses only U.S. Holders and does not discuss any tax considerations other than United States federal income tax considerations. Prospective investors are urged to consult their own tax advisors regarding the United States federal, state and local, and non-United States tax consequences of the purchase, ownership, and disposition of ADSs.

Dividends

Under the United States federal income tax laws, and subject to the PFIC rules discussed below under “– Passive Foreign Investment Company Considerations, any distributions of cash or other property with respect to the ADSs (including any amounts withheld in respect thereof), generally will, to the extent made out of our current and accumulated earnings and profits as determined for United States federal income tax purposes, constitute dividends for United States federal income tax purposes. Generally, the gross amount of any dividend we pay out of our current or accumulated earnings and profits (as determined for United States federal income tax purposes) is includible in income for a U.S. Holder and subject to United States federal income taxation. Dividends paid to a non-corporate U.S. Holder that constitute dividend income from a “qualified foreign corporation” will be taxable at a preferential tax rate applicable to long-term capital gains, provided that the U.S. Holder holds the ADSs for more than 60 days during the 121-day period beginning 60 days before the ex-dividend date and meets other holding period requirements. A non-United States corporation (other than a corporation that is classified as a PFIC for the taxable year in which the dividend is paid or the preceding taxable year) generally will be considered to be a qualified foreign corporation (i) if it is eligible for the benefits of a comprehensive tax treaty with the United States which the Secretary of Treasury of the United States determines is satisfactory for purposes of this provision and which includes an exchange of information program, or (ii) with respect to any dividend it pays on stock (or ADSs in respect of such stock) which is readily tradable on an established securities market in the United States. The ADSs are listed on The Nasdaq Capital Market, which is an established securities market in the United States. We therefore expect that dividends we pay with respect to the ADSs generally will constitute qualified dividend income. There can be no assurance, however, that our ADSs will be considered readily tradeable on an established securities market in later years.

A U.S. Holder must include any Danish tax withheld from the dividend payment, as described above under “– Danish Tax Considerations – Taxation of Shareholders Residing Outside Denmark,” in the gross amount of dividend paid even though the holder does not in fact receive it. The dividend is taxable to the holder when the depositary receives the dividend, actually or constructively. Because we are not a United States corporation and do not expect to meet the dividends-received deduction eligibility criteria for non-United States corporations, the dividend is not expected to be eligible for the dividends-received deduction generally allowed to United States corporations in respect of dividends received from other United States corporations. The amount of the dividend distribution includible in a U.S. Holder’s income will be the USD value of the Danish Krone payments made, determined at the spot

212

Danish Krone/USD rate on the date the dividend distribution is includible in income, regardless of whether the payment is in fact converted into USD. Generally, any gain or loss resulting from currency exchange fluctuations during the period from the date the dividend payment is included in income to the date the payment is converted into USD will be treated as ordinary income or loss to the U.S. Holder and will not be eligible for the special tax rate applicable to qualified dividend income. The currency gain or loss generally will be income or loss from sources within the United States for foreign tax credit limitation purposes.

To the extent a distribution with respect to ADSs exceeds our current or accumulated earnings and profits, as determined under United States federal income tax principles, the distribution will be treated, first, as a tax-free return of the U.S. Holder’s capital invested in the Company, up to the holder’s adjusted tax basis in its ADSs, and, thereafter, as capital gain, which is subject to the tax treatment described below in “– Gain on Sale, Exchange or Other Taxable Disposition.”

Because we do not intend to determine our earnings and profits on the basis of United States federal income tax principles, all distributions paid will generally be treated as “dividends” for United States federal income tax purposes.

Dividends paid by the Company generally will be treated as income from foreign sources for United States foreign tax credit purposes and generally will constitute passive category income. A U.S. Holder may be eligible, subject to a number of complex limitations, to claim a foreign tax credit in respect of any foreign withholding taxes imposed on dividends received on our ADSs, including the Danish tax withheld in accordance with the Treaty and paid over to the Danish taxing authority, which may, subject to such limitations, be creditable against a U.S. Holder’s United States federal income tax liability. A U.S. Holder who does not elect to claim a foreign tax credit for foreign tax withheld, may instead claim a deduction, for United States federal income tax purposes, in respect of such withholdings, but only for a year in which such U.S. Holder elects to do so for all creditable foreign income taxes. To the extent a refund of the tax withheld is available to a U.S. Holder under Danish law or under the Treaty, the amount of tax withheld that is refundable will not be eligible for credit against a U.S. Holder’s United States federal income tax liability. See “– Danish Taxation – Withholding Tax Refund for United States Treaty Beneficiaries” above for the procedures for obtaining a tax refund. Investors are urged to consult their own tax advisors about the availability of any foreign tax credits or deductions in respect to their specific tax situations.

Gain on Sale, Exchange or Other Taxable Disposition

Subject to the PFIC rules described below under “– Passive Foreign Investment Company Considerations”, a U.S. Holder that sells, exchanges or otherwise disposes of ADSs in a taxable disposition generally will recognize capital gain or loss for United States federal income tax purposes equal to the difference between the United States dollar value of the amount realized and the holder’s adjusted tax basis, determined in United States dollars, in the ADSs. Gain or loss recognized on such a sale, exchange or other disposition of ADSs generally will be long-term capital gain if the U.S. Holder’s holding period in the ADSs exceeds one year. Long-term capital gains of non-corporate U.S. Holders are generally taxed at preferential rates. The gain or loss generally will be income or loss from sources within the United States for foreign tax credit limitation purposes. A U.S. Holder’s ability to deduct capital losses is subject to limitations.

Passive Foreign Investment Company Considerations

We have not made a determination as to whether the Company will or will not be treated as a PFIC in the current taxable year and subsequent taxable years. The determination of PFIC status is inherently factual, is subject to a number of uncertainties, and can be determined only annually after the close of the tax year in question. Additionally, the analysis depends, in part, on the application of complex United States federal income tax rules, which are subject to differing interpretations. There can be no assurance that the Company will or will not be determined to be a PFIC for the current tax year or any prior or future tax year, and no opinion of legal counsel or ruling from the IRS concerning the status of the Company as a PFIC has been obtained or will be requested. U.S. Holders should consult their own United States tax advisors regarding our PFIC status.

If we were classified as a “passive foreign investment company”, or a “PFIC”, for United States federal income tax purposes in any taxable year, a U.S. Holder would be subject to special rules with respect to distributions on and sales, exchanges and other dispositions of the ADSs. A non-United States corporation, such as the Company, will be classified as a PFIC for United States federal income tax purposes for any taxable year, if either (i) 75% or more of its gross income for such year consists of certain types of “passive” income (the “income test”) or (ii) 50% or more of the value of its assets (generally determined on the basis of a quarterly average) during such year is attributable to assets that produce or are held for the production of passive income (the “asset test”). For this purpose, cash and assets readily convertible into cash are categorized as passive assets and the company’s goodwill and other

213

unbooked intangibles are taken into account. Passive income generally includes, among other things, dividends, interest, rents, royalties, and gains from the disposition of passive assets. However, certain rents and royalties received from unrelated parties in connection with the active conduct of a trade or business are not considered passive income for purposes of the PFIC test. For purposes of the PFIC test, we will be treated as owning a proportionate share of the assets and earning a proportionate share of the income of any other corporation in which we own, directly or indirectly, at least 25% (by value) of the stock.

If we were a PFIC with respect to a U.S. Holder, then unless such U.S. Holder makes one of the elections described below, a special tax regime would apply to the U.S. Holder with respect to (i) any “excess distribution” (generally, aggregate distributions in any year that are greater than 125% of the average annual distribution received by the holder in the shorter of the three preceding years or the holder’s holding period for the ADSs) and (ii) any gain realized on the sale or other disposition of the ADSs. Under this regime, any excess distribution and realized gain will be treated as ordinary income and will be subject to tax as if (a) the excess distribution or gain had been realized ratably over the U.S. Holder’s holding period, (b) the amount deemed realized in each year had been subject to tax in each year of that holding period at the highest marginal rate for such year (other than income allocated to the current period or any taxable period before we became a PFIC, which would be subject to tax at the U.S. Holder’s regular ordinary income rate for the current year and would not be subject to the interest charge discussed below), and (c) the interest charge generally applicable to underpayments of tax had been imposed on the taxes deemed to have been payable in those years. If we were determined to be a PFIC, this tax treatment for U.S. Holders would apply also to indirect distributions and gains deemed realized by U.S. Holders in respect of stock of any of our subsidiaries determined to be PFICs. In addition, dividend distributions would not qualify for the lower rates of taxation applicable to long-term capital gains discussed above under “– Taxation of Dividends.”

A U.S. Holder that holds the ADSs at any time during a taxable year in which we are classified as a PFIC generally will continue to treat such ADSs as ADSs in a PFIC, even if we no longer satisfy the PFIC income and asset tests described above, unless the U.S. Holder elects to recognize gain, which will be taxed under the excess distribution rules as if such ADSs had been sold on the last day of the last taxable year for which we were a PFIC.

Certain elections by a U.S. Holder would alleviate some of the adverse consequences of PFIC status and would result in an alternative treatment of the ADSs, as described below. These elections include a “qualified electing fund” or “QEF” election and a “mark-to-market” election, which is described in more detail below. We do not expect that a U.S. Holder would be able to make a QEF election with respect to the ADSs because we do not intend to provide to U.S. Holders the required information to make a valid QEF election.

In the event we are determined to be a PFIC, the rules applicable to PFICs described above would not apply to a U.S. Holder that makes a “mark-to-market” election with respect to the ADSs, but this election will be available with respect to the ADSs only if they meet certain minimum trading requirements to be considered “marketable stock” for purposes of the PFIC rules. Generally, shares of ADSs will be treated as marketable stock if they are “regularly traded” on a “qualified exchange” within the meaning of applicable Treasury Regulations. ADSs generally will be considered regularly traded during any calendar year during which they are traded, other than in de minimis quantities, on at least 15 days during each calendar quarter. Any trades that have as their principal purpose meeting this requirement will be disregarded. Our ADSs will be considered marketable stock as long as they remain listed on The Nasdaq Capital Market and are regularly traded. We anticipate that our ADSs should qualify as being regularly traded, but no assurances may be given in this regard.

A U.S. Holder that makes a valid mark-to-market election for the first tax year in which the holder holds (or is deemed to hold) ADSs and for which we are a PFIC will be required to include each year an amount equal to the excess, if any, of the fair market value of such ADSs the holder owns as of the close of the taxable year over the holder’s adjusted tax basis in such ADSs. The U.S. Holder will be entitled to a deduction for the excess, if any, of the holder’s adjusted tax basis in the ADSs over the fair market value of such ADSs as of the close of the taxable year, but only to the extent of any net mark-to-market gains with respect to such ADSs included by the U.S. Holder under the election for prior taxable years and may be subject to certain other limitations. The U.S. Holder’s adjusted tax basis in such ADSs will be adjusted to reflect the amounts included or deducted pursuant to the election. Amounts included in income pursuant to a mark-to-market election, as well as gain on the sale, exchange or other taxable disposition of such ADSs, will be treated as ordinary income. The deductible portion of any mark-to-market loss, as well as loss on a sale, exchange or other disposition of ADSs to the extent that the amount of such loss does not exceed net mark-to-market gains previously included in income, will be treated as ordinary loss.

Because a mark-to-market election cannot be made for any lower-tier PFICs that we may own, a U.S. Holder may continue to be subject to the PFIC rules with respect to such U.S. Holder’s indirect interest in any investments held by us that are treated as an equity interest in a PFIC for United States federal income tax purposes.

214

The mark-to-market election applies to the taxable year for which the election is made and all subsequent taxable years, unless the shares cease to be treated as marketable stock for purposes of the PFIC rules or the IRS consents to its revocation. The excess distribution rules described above generally will not apply to a U.S. Holder for tax years for which a mark-to-market election is in effect. However, if we were a PFIC for any year in which the U.S. Holder owns the ADSs but before a mark-to-market election is made, the interest charge rules described above would apply to any mark-to-market gain recognized in the year the election is made.

A U.S. Holder of PFIC shares must generally file an annual information return on IRS Form 8621 (Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund).

The failure to file IRS Form 8621 could result in the imposition of penalties and the extension of the statute of limitations with respect to United States federal income tax.

U.S. Holders are urged to consult their tax advisors as to our status as a PFIC, and the tax consequences to them if we were a PFIC, including the reporting requirements and the desirability of making, and the availability of a mark-to-market election with respect to the ADSs.

Net Investment Income Tax

Non-corporate U.S. Holders that are individuals, estates or trusts and whose income exceeds certain thresholds generally are subject to a 3.8% tax on all or a portion of their net investment income, which may include their gross dividend income and net gains from the disposition of ADSs. A United States person that is an individual, estate or trust is encouraged to consult its tax advisors regarding the applicability of this net investment income tax to its income and gains in respect of any investment in ADSs.

Information Reporting with Respect to Foreign Financial Assets

Individual U.S. Holders may be subject to certain reporting obligations on IRS Form 8938 (Statement of Specified Foreign Financial Assets) with respect to the ADSs for any taxable year during which the U.S. Holder’s aggregate value of these and certain other “specified foreign financial assets” exceed a threshold amount that varies with the filing status of the individual. This reporting obligation also applies to domestic entities formed or availed of to hold, directly or indirectly, specified foreign financial assets, including the ADSs. Significant penalties can apply if U.S. Holders are required to make this disclosure and fail to do so.

U.S. Holders who acquire ADSs for cash may be required to file IRS Form 926 (Return by a U.S. Transferor of Property to a Foreign Corporation) with the IRS and to supply certain additional information to the IRS if (i) immediately after the transfer, the U.S. Holder owns directly or indirectly (or by attribution) at least 10% of our total voting power or value or (ii) the amount of cash transferred to us in exchange for ADSs, when aggregated with all related transfers under applicable regulations, exceeds $100,000. Substantial penalties may be imposed on a U.S. Holder that fails to comply with this reporting requirement.

Information Reporting and Backup Withholding

Dividend payments with respect to the ADSs and proceeds from the sale, exchange or redemption of our ADSs may be subject to information reporting to the IRS and possible United States backup withholding (currently at a 24% rate). In general, information reporting, including IRS Form 1099 reporting, will apply to dividends in respect of ADSs and the proceeds from the sale, exchange or redemption of ADSs that are paid to a holder of ADSs within the United States (and in certain cases, outside the United States), unless such holder is an exempt recipient such as a corporation. Backup withholding will not apply, however, to a U.S. Holder who furnishes a correct taxpayer identification number and makes other required certifications, or who is otherwise exempt from backup withholding. U.S. Holders that are required to establish their exempt status generally must provide such certification on IRS Form W-9. Backup withholding is not an additional tax. A U.S. Holder generally may obtain a refund of any amounts withheld under the backup withholding rules that exceed the U.S. Holder’s income tax liability by filing a refund claim with the IRS. U.S. Holders are urged to consult their tax advisors regarding the application of the United States information reporting and backup withholding rules.

10.F. Dividends and Paying Agents

Not applicable.

215

10.G. Statement by Experts

Not applicable.

10.H. Documents on Display

We are subject to certain of the information reporting requirements of the Exchange Act. As a foreign private issuer, we are exempt under the Exchange Act from, among other things, the rules prescribing the furnishing and content of proxy statements, and our directors, executive management and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we will not be required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as United States companies whose securities are registered under the Exchange Act. However, we are required to file with the SEC, within four months after the end of each fiscal year, an annual report on Form 20-F containing financial statements audited by an independent accounting firm. We publish unaudited interim financial information after the end of each quarter. We furnish this quarterly financial information to the SEC under cover of a Form 6-K.

The SEC maintains a website that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC. The address of this website is http://www.sec.gov. The company’s website is www.evaxion-biotech.com.

10.I. Subsidiary Information

Not applicable.

Item 11. Quantitative and Qualitative Disclosures About Market Risk

See “Item 5. Operating and Financial Review and Prospects—Quantitative and Qualitative Disclosures about Market Risk.”

Item 12.Description of Securities Other Than Equity Securities

12.A. Debt Securities

Not applicable.

12.B. Warrants and Rights

Not applicable.

12.C. Other Securities

Not applicable.

216

12.D. American Depositary Shares Fees and Charges

Pursuant to the terms of the deposit agreement, the holders of ADSs will be required to pay the following fees:

·

Persons depositing or withdrawing shares or ADS holders must pay:

·

For:

·

$5.00 (or less) per 100 ADSs (or portion of 100

·

ADSs)

·

Issuance of ADSs, including issuances resulting from a distribution of shares or rights or other property

·

Cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement terminates

·

$.05 (or less) per ADS

·

Any cash distribution to ADS holders

·

A fee equivalent to the fee that would be payable if securities distributed to you had been shares and the shares had been deposited for issuance of ADSs

·

Distribution of securities distributed to holders of deposited securities (including rights) that are distributed by the depositary to ADS holders

·

$.05 (or less) per ADS per calendar year

·

Depositary services

·

Registration or transfer fees

·

Transfer and registration of shares on our share register to or from the name of the depositary or its agent when you deposit or withdraw shares

·

Expenses of the depositary

·

Cable and facsimile transmissions (when expressly provided in the deposit agreement)

·

Converting foreign currency to United States dollars

·

Taxes and other governmental charges the depositary or the custodian has to pay on any ADSs or shares underlying ADSs, such as stock transfer taxes, stamp duty or withholding taxes

·

As necessary

·

Any charges incurred by the depositary or its agents

·

As necessary

The depositary collects its fees for delivery and surrender of ADSs directly from investors depositing shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary services by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants acting for them. The depositary may collect any of its fees by deduction from any cash distribution payable (or by selling a portion of securities or other property distributable) to ADS holders that are obligated to pay those fees. The depositary may generally refuse to provide fee-attracting services until its fees for those services are paid.

From time to time, the depositary may make payments to us to reimburse us for costs and expenses generally arising out of establishment and maintenance of the ADS program, waive fees and expenses for services provided to us by the depositary or share revenue from the fees collected from ADS holders. In performing its duties under the deposit agreement, the depositary may use brokers, dealers, foreign currency dealers or other service providers that are owned by or affiliated with the depositary and that may earn or share fees, spreads or commissions.

The depositary may convert currency itself or through any of its affiliates and, in those cases, acts as principal for its own account and not as agent, advisor, broker or fiduciary on behalf of any other person and earns revenue, including, without limitation, transaction spreads, that it will retain for its own account. The revenue is based on, among other things, the difference between the exchange rate assigned to the currency conversion made under the deposit agreement and the rate that the depositary or its affiliate receives when buying or selling foreign currency for its own account. The depositary makes no representation that the exchange rate used or obtained in any currency conversion under the deposit agreement will be the most favorable rate that could be obtained at the time or that the method by which that rate will be determined will be the most favorable to ADS holders, subject to the depositary’s obligations under the deposit agreement.

The methodology used to determine exchange rates used in currency conversions is available upon request. Where the custodian converts currency, the custodian has no obligation to obtain the most favorable rate that could be obtained at the time or to ensure that the method by which that rate will be determined will be the most favorable to ADS holders, and the depositary makes no representation that the rate is the most favorable rate and will not be liable for any direct or indirect losses associated with the rate. In

217

certain instances, the depositary may receive dividends or other distributions from the us in USD that represent the proceeds of a conversion of foreign currency or translation from foreign currency at a rate that was obtained or determined by us and, in such cases, the depositary will not engage in, or be responsible for, any foreign currency transactions and neither it nor we make any representation that the rate obtained or determined by us is the most favorable rate and neither it nor we will be liable for any direct or indirect losses associated with the rate.

PART II

Item 13.Defaults, Dividend Arrearages And Delinquencies

None.

Item 14. Material Modifications To The Rights Of Security Holders And Use Of Proceeds

A.-D. Material Modifications to the Rights of Security Holders

Not applicable.

E. Use of Proceeds

Not applicable.

Item 15. Controls And Procedures

(a)Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act and regulations promulgated thereunder) as of December 31, 2021, or the Evaluation Date. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the Evaluation Date, our disclosure controls and procedures were ineffective due to the material weaknesses as of December 31, 2021 which are detailed in the accompanying Item 15(b), Management’s Annual Report on Internal Control over Financial Reporting.

(b)Management’s Annual Report on Internal Control over Financial Reporting

Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2021. In making this assessment, it used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO 2013) in the Internal Control-Integrated Framework. Based on its assessment and those criteria, our management identified the following weaknesses in our internal control over financial reporting and therefore determined that our internal control over financing reporting were not effective at the reasonable assurance level as of December 31, 2021.

As defined in the standards established by the U.S. Public Company Accounting Oversight Board, a “material weakness” is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our company’s annual or interim consolidated financial statements will not be prevented or detected on a timely basis.

Material weaknesses related to the lack of sufficiently designed internal controls

During 2021 we identified this material weakness which arose because we did not design or operate sufficient internal controls to support mitigate risks of material errors in our financial statement. Additionally, we did not appropriately implement certain components of the COSO framework, including elements of the control environment, information and communication, risk assessment, control activities and monitoring activities. Therefore, we have assessed that we lacked sufficient internal controls to support effective financial reporting as of December 31, 2021, which constitutes a material weakness.

218

Material weaknesses relating to establishing an effective control environment over financial reporting

In connection with the preparation of our financial statements for the years ended December 31, 2020 and 2019, we had identified material weakness in our internal control over financial reporting, which remained unremediated as of December 31, 2021.

The material weaknesses identified related to the lack of accounting and supervisory personnel that possessed an appropriate level of technical accounting experience and training, and their lack of supervision over third party service providers in areas such as bookkeeping, financial controlling, and financial statements preparation.

Remediation plans

To remediate our identified material weaknesses, we will allocate more internal resources to internal controls and engage external advisors to provide training and to assist with reassessing and redesigning processes and developing new controls as appropriate, including assisting with the evaluation and documentation of the risk assessment, design, and operating effectiveness of our internal controls over financial reporting and assist with the remediation of any deficiencies. Furthermore, we retained accounting advisors to provide additional depth and breadth to our technical accounting and financial reporting capabilities and are taking steps such as the hiring of additional finance staff. We also plan to hire additional accounting personnel with financial statement closing experience and technical IFRS knowledge for the purposes of timely and reliable financial reporting in accordance with IFRS and the requirements set forth by the SEC, to perform specific functions, design and implement improved processes and internal controls, build our financial management and reporting infrastructure, and further develop and document our accounting policies and financial reporting procedures, including ongoing senior management review and audit committee oversight. In addition, we recently announced that we have hired a new Chief Financial Officer who has considerable public company experience.

While we intend to implement this plan to remediate these material weaknesses, we cannot predict the success of such plan or the outcome of our assessment of these plans at this time. We can give no assurance that this implementation will remediate these material weaknesses in our internal control or that other material weaknesses or significant deficiencies in our internal control over financial reporting will not be identified in the future.

(c)Attestation Report of the Registered Public Accounting Firm

This annual report does not include an attestation report of the Company's registered public accounting firm because as an emerging growth company, we are exempt from this requirement.

(d)Changes in Internal Control over Financial Reporting

Except as described above in Management’s Annual Report on Internal Control over Financial Reporting, there were no changes in our internal control over financial reporting as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act that occurred during the period covered by this annual report that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.

Item 16A. Audit Committee Financial Expert

Our board has determined that Mr. Lars Holtug qualifies to serve as an “audit committee financial expert” as defined under the SEC rules, and has the requisite financial sophistication as defined under the applicable Nasdaq rules and regulations. Mr. Lars Holtug also qualifies as an independent director under the corporate governance standards of the Nasdaq listing requirements and the audit committee independence requirements of Rule 10A-3 of the Exchange Act. For more information see “Item 6. Directors, Senior Management and Employees—C. Board Practices— Committees of the Evaxion Board—Audit and Risk Committee.”

Item 16B. Code of Ethics

Code of Business Conduct

We have adopted a code of business conduct and ethics, or code of conduct, which outlines the principles of legal and ethical business conduct under which we do business. The code of conduct applies to all of our directors and employees, including our executive

219

management. The full text of the code of conduct will be made available on our website at www.evaxion-biotech.com . The information on, or that can be accessed through, our website is not part of and is not incorporated by reference into this Form 20-F. We have included our website address as an inactive textual reference only. Any amendments to the provisions of the code of conduct will be made only after approval by our board of directors or committees thereof and will be disclosed on our website promptly following the date of such amendment or waiver. Any waivers from the provisions of the code of conduct for the benefit of a director or a member of executive management will be made only after approval by our board of directors or committee thereof and will be disclosed in accordance with applicable securities laws and any waiver from the provisions of the code of conduct for other employees may be made by our compliance officer or by our board of directors or committee thereof.

Item 16C. Principal Accountant Fees and Services

The following table provides information regarding fees paid by us to EY Godkendt Revisionspartnerselskab for all services, for the years ended December 31, 2021 and 2020 (in thousands):

Years Ended December 31, 

    

2021

    

2020

Audit fees

    

$

613

    

$

333

Audit related fees

 

 

Other fees

 

 

Total fees

$

613

$

333

In 2021, audit fees relate to audit of the annual consolidated financial statements and for review services, and fees related to the prospectus for our initial public offering, our follow-on public offering, and related filing comfort services provided to us by EY Godkendt Revisionspartnerselskab.

Audit Committee

Pre-Approval Policies and Procedures

Our audit committee’s specific responsibilities in carrying out its oversight of the quality and integrity of the accounting, auditing and reporting practices of Evaxion include the approval of audit and non-audit services to be provided by the independent auditor before the auditor is engaged to render such services. The audit committee approves in advance the particular services or categories of services to be provided to Evaxion during the following yearly period and also sets forth a specific budget for such audit and non-audit services. Additional non-audit services may be pre-approved by the audit committee.

Item 16D. Exemptions From The Listing Standards For Audit Committees

None.

Item 16E. Purchases of Equity Securities By The Issuer And Affiliated Purchasers

Not applicable.

Item 16F. Change in Registrant’s Certifying Accountant

None.

Item 16G. Corporate Governance

Foreign Private Issuer Exemption

As a “foreign private issuer,” as defined by the SEC, although we are permitted to follow certain corporate governance practices of the Kingdom of Denmark instead of those otherwise required under the Nasdaq Rules applicable to domestic issuers, we intend to follow

220

the Nasdaq corporate governance rules applicable to foreign private issuers. While we shall voluntarily follow most Nasdaq corporate governance rules that are applicable to Evaxion, we intend to take advantage of the following limited exemptions:

·

exemption from filing quarterly reports on Form 10-Q and providing current reports on Form 8-K disclosing significant events within four days of their occurrence (however, we intend to furnish quarterly financial information under cover of Form 6-K);

·

exemption from Section 16 rules regarding sales of ordinary shares by insiders, which will provide less data in this regard than the data provided to shareholders of United States companies that are subject to the Exchange Act; and

·

exemption from the Nasdaq rules applicable to domestic issuers requiring disclosure within four business days of any determination to grant a waiver of the code of business conduct and ethics to directors and officers. Although we will require board of directors approval of any such waiver, we may choose not to disclose the waiver in the manner set forth in the Nasdaq rules, as permitted by the foreign private issuer exemption.

Except as stated above, we intend to substantially comply with the rules applicable to United States companies listed on The Nasdaq Stock Market. Furthermore, Nasdaq Rule 5615(a)(3) provides that a foreign private issuer may rely on home country corporate governance practices in lieu of certain of the rules in the Nasdaq Rule 5600 Series and Rule 5250(d), provided that we nevertheless comply with Nasdaq’s Notification of Noncompliance requirement (Rule 5625) and the Voting Rights requirement (Rule 5640) and that we have an audit committee that satisfies Rule 5605(c)(3), consisting of committee members that meet the independence requirements of Rule 5605(c)(2)(A)(ii). Although we are permitted to follow certain corporate governance rules that conform to Danish requirements in lieu of many of the Nasdaq corporate governance rules, we intend to comply with the Nasdaq corporate governance rules applicable to foreign private issuers. We may utilize these exemptions for as long as we continue to qualify as a foreign private issuer.

Accordingly, our shareholders and holders of ADSs will not have the same protections afforded to shareholders of companies that are subject to all of the corporate governance requirements of Nasdaq and the domestic reporting requirements of the SEC. We may utilize these exemptions for as long as we continue to qualify as a foreign private issuer. For an overview of our corporate governance principles, see the section titled “Description of Share Capital – Comparison of Danish Corporate Law and our Articles of Association and Delaware Corporate Law.”

Evaxion Shareholder Rights Under Danish Law

Notice of Meeting

Denmark. According to the Danish Companies Act, general meetings in limited liability companies shall be convened by the board of directors with a minimum of two weeks’ notice and a maximum of four weeks’ notice as set forth in the articles of association. A convening notice shall also be forwarded to shareholders recorded in our owners’ register, who have requested such notification. There are specific requirements as to the information and documentation required to be disclosed in connection with the convening notice.

Delaware. Under Delaware law, unless otherwise provided in the certificate of incorporation or bylaws, written notice of any meeting of the stockholders must be given to each stockholder entitled to vote at the meeting not less than ten nor more than 60 days before the date of the meeting and shall specify the place, date, hour, and purpose or purposes of the meeting.

Voting Rights

Denmark. Each ordinary share confers the right to cast one vote at the general meeting of shareholders, unless the articles of association provide otherwise. Each holder of ordinary shares may cast as many votes as it holds shares. Shares that are held by us or our direct or indirect subsidiaries do not confer the right to vote.

Delaware. Under the Delaware General Corporation Law, each stockholder is entitled to one vote per share of stock, unless the certificate of incorporation provides otherwise. In addition, the certificate of incorporation

221

According to Section 73 of the Danish Companies Act, a minority shareholder may require a majority shareholder that holds more than 90% of the company’s registered share capital to redeem his or her shares. Similarly, a majority shareholder holding may provide for cumulative voting at all elections of directors of the corporation, or at elections held under specified circumstances. Either the certificate of incorporation or the bylaws may specify the number of shares and/or the amount of other securities that must be represented at a meeting in order to constitute a quorum, but in no event can a quorum consist of less than one third of the shares entitled to vote at a meeting.

Stockholders as of the record date for the meeting are entitled to vote at the meeting, and the board of directors may fix a record date that is no more than 60 nor less than ten days before the date of the meeting, and if no record date is set then the record date is the close of business on the day next preceding the day on which notice is given, or if notice is waived then the record date is the close of business on the day next preceding the day on which the meeting is held. The determination of the stockholders of record entitled to notice or to vote at a meeting of stockholders shall apply to any adjournment of the meeting, but the board of directors may fix a new record date for the adjourned meeting.

Shareholder Proposals

Denmark. According to the Danish Companies Act, extraordinary general meetings of shareholders will be held whenever our board of directors or our appointed auditor requires. In addition, one or more shareholders representing at least 1/20th of the registered share capital of the company may, in writing, require that a general meeting be convened. If such a demand is forwarded, the board of directors shall convene the general meeting within two weeks thereafter.

All shareholders have the right to present proposals for adoption at the annual general meeting, provided that the proposals are forwarded at the latest six weeks prior thereto. In the event that the proposal is received at a later date, the board of directors will decide whether the proposal has been forwarded in due time to be included on the agenda. Any business not included on the agenda may be transacted by the general meeting only if all shareholders’ consent.

Delaware. Delaware law does not specifically grant stockholders the right to bring business before an annual or special meeting of stockholders. However, if a Delaware corporation is subject to the SEC’s proxy rules, a stockholder who owns at least $2,000 in market value, or 1% of the corporation’s securities entitled to vote, may propose a matter for a vote at an annual or special meeting in accordance with those rules.

Action by Written Consent

Denmark. Under Danish law, it is permissible for shareholders to take action and pass resolutions by written consent in the event of unanimity; however, this will normally not be the case in listed companies and for a listed company, this method of adopting resolutions is generally not feasible.

Delaware. Although permitted by Delaware law, publicly listed companies do not typically permit stockholders of a corporation to take action by written consent.

Appraisal Rights

Denmark. The concept of appraisal rights does not exist under Danish law, except in connection with statutory redemptions rights according to the Danish Companies Act, more than 90% of the company’s share capital may, according to Section 70 of the same act, squeeze out the minority shareholders. In the event that the parties cannot agree to the redemption squeeze out price, this shall be determined by an independent evaluator appointed by the court. Additionally, there are specific regulations in Sections 249, 267, 285 and 305 of the Danish Companies Act that require compensation in the event of national or cross-border mergers and demergers. Moreover, shareholders who vote against a cross-border merger or demerger are, according to Sections 286 and 306 of the Danish Companies Act, entitled to have their shares redeemed.

Delaware. The Delaware General Corporation Law provides for stockholder appraisal rights, or the right to demand payment in cash of the judicially determined fair value of the stockholder’s shares, in connection with certain mergers and consolidations.

222

Shareholder Suits

Denmark. Under Danish law, only a company itself can bring a civil action against a third party; an individual shareholder does not have the right to bring an action on behalf of a company. An individual shareholder may, in its own name, have an individual right to take action against such third party in the event that the cause for the liability of that third party also constitutes a negligent act directly against such individual shareholder.

Delaware. Under the Delaware General Corporation Law, a stockholder may bring a derivative action on behalf of the corporation to enforce the rights of the corporation. An individual also may commence a class action suit on behalf of himself and other similarly situated stockholders where the requirements for maintaining a class action under Delaware law have been met. A person may institute and maintain such a suit only if that person was a stockholder at the time of the transaction which is the subject of the suit. In addition, under Delaware case law, the plaintiff normally must be a stockholder at the time of the transaction that is the subject of the suit and throughout the duration of the derivative suit. Delaware law also requires that the derivative plaintiff make a demand on the directors of the corporation to assert the corporate claim before the suit may be prosecuted by the derivative plaintiff in court, unless such a demand would be futile.

Repurchase of Shares

Denmark. Danish limited liability companies may not subscribe for newly issued shares in their own capital. Such company may, however, according to the Danish Companies Act Sections 196-201, acquire fully paid shares of its own capital provided that the board of directors has been authorized thereto by the shareholders acting in a general meeting. Such authorization can only be given for a maximum period of five years and the authorization shall fix (i) the maximum value of the shares and (ii) the minimum and the highest amount that the company may pay for the shares. Shares may generally only be acquired using distributable reserves.

Delaware. Under the Delaware General Corporation Law, a corporation may purchase or redeem its own shares unless the capital of the corporation is impaired or the purchase or redemption would cause an impairment of the capital of the corporation. A Delaware corporation may, however, purchase or redeem out of capital any of its preferred shares or, if no preferred shares are outstanding, any of its own shares if such shares will be retired upon acquisition and the capital of the corporation will be reduced in accordance with specified limitations.

Anti-takeover Provisions

Denmark. Under Danish law, it is possible to implement limited protective anti-takeover measures. Such provisions may include, among other things, (i) different share classes with different voting rights, (ii) specific requirements to register the shares on name in the company’s owners register and

(iii) notification requirements concerning participation in general meetings. We have currently not adopted any such provisions.

Delaware. In addition to other aspects of Delaware law governing fiduciary duties of directors during a potential takeover, the Delaware General Corporation Law also contains a business combination statute that protects Delaware companies from hostile takeovers and from actions following the takeover by prohibiting some transactions once an acquirer has gained a significant holding in the corporation.

Section 203 of the Delaware General Corporation Law prohibits “business combinations,” including mergers, sales and leases of assets, issuances of securities and similar transactions by a corporation or a subsidiary with an interested stockholder that beneficially owns 15% or more of a corporation’s voting stock, within three years after the person becomes an interested stockholder, unless:

·

the transaction that will cause the person to become an interested stockholder is approved by the board of directors of the target prior to the transaction;

·

after the completion of the transaction in which the person becomes an interested stockholder, the interested stockholder holds at least 85% of the voting stock of the corporation not including shares owned by persons who are directors and officers of interested stockholders and shares owned by specified employee benefit plans; or

223

·

after the person becomes an interested stockholder, the business combination is approved by the board of directors of the corporation and holders of at least 66.67% of the outstanding voting stock, excluding shares held by the interested stockholder.

A Delaware corporation may elect not to be governed by Section 203 by a provision contained in the original certificate of incorporation of the corporation or an amendment to the original certificate of incorporation or to the bylaws of the company, which amendment must be approved by a majority of the shares entitled to vote and may not be further amended by the board of directors of the corporation. Such an amendment is not effective until 12 months following its adoption.

Inspection of Books and Records

Denmark. According to Section 150 of the Danish Companies Act, a shareholder may request an inspection of the company’s books regarding specific issues concerning the management of the company or specific annual reports. If approved by shareholders with simple majority, one or more investigators are elected. If the proposal is not approved by simple majority but 25% of the share capital votes in favor, then a shareholder can request the court to appoint an investigator.

Delaware. Under the Delaware General Corporation Law, any stockholder may inspect certain of the corporation’s books and records, for any proper purpose, during the corporation’s usual hours of business.

Pre-emptive Rights

Denmark. Under Danish law, all shareholders have pre-emptive subscription rights in connection with capital increases that are carried out as cash contributions. In connection with an increase of a company’s share capital, the shareholders may, by resolution at a general meeting, approve deviations from the general Danish pre-emptive rights of the shareholders. Under the Danish Companies Act, such resolution must be adopted by the affirmative vote of shareholders holding at least a two-thirds majority of the votes cast and the share capital represented at the general meeting and requires that such capital increases will be carried out as a cash contribution at market price.

The board of directors may resolve to increase our share capital without pre-emptive subscription rights for existing shareholders pursuant to the authorizations described above under the caption “Development of the Share Capital.”

Unless future issuances of new shares are registered under the Securities Act or with any authority outside Denmark, United States shareholders and shareholders in jurisdictions outside Denmark may be unable to exercise their pre-emptive subscription rights under United States securities law.

Delaware. Under the Delaware General Corporation Law, stockholders have no pre-emptive rights to subscribe for additional issues of stock or to any security convertible into such stock unless, and to the extent that, such rights are expressly provided for in the certificate of incorporation.

Dividends

Denmark. Under Danish law, the distribution of ordinary and extraordinary dividends requires the approval of a company’s shareholders at a company’s general meeting. The shareholders may not distribute dividends in excess of the recommendation from the board of directors and may only pay out dividends from our distributable reserves, which are defined as amounts stated as retained earnings in the Company’s latest approved financial statements, and reserves not being non-distributable under a statute or the Company’s articles of association, less retained earnings. It is possible under Danish law to pay out interim dividends. The decision to pay out interim dividends shall be accompanied by a balance sheet, and the board of directors determine whether it will be sufficient to use the balance sheet from the annual report or if an interim balance sheet for the period from the annual report period until the interim dividend payment shall be prepared. If interim dividends are paid out later than six months following the financial year for the latest annual report, an interim balance sheet showing that there are sufficient funds shall always be prepared. Furthermore, it is possible under Danish law to distribute assets other than cash as dividends. If assets other than cash are distributed as dividends, a valuation report must be prepared. The valuation report must be prepared by one or more impartial valuation experts.

Delaware. Under the Delaware General Corporation Law, a Delaware corporation may pay dividends out of its surplus (the excess of net assets over capital), or in case there is no surplus, out of its net profits for the fiscal year in which the dividend is declared and/or

224

the preceding fiscal year (provided that the amount of the capital of the corporation is not less than the aggregate amount of the capital represented by the issued and outstanding stock of all classes having a preference upon the distribution of assets). In determining the amount of surplus of a Delaware corporation, the assets of the corporation, including stock of subsidiaries owned by the corporation, must be valued at their fair market value as determined by the board of directors, without regard to their historical book value. Dividends may be paid in the form of shares, property or cash.

Shareholder Vote on Certain Reorganizations

Denmark. Under Danish law, all amendments to the articles of association shall be approved by the general meeting of shareholders with a minimum of two-thirds of the votes cast and two-thirds of the represented share capital. The same applies to solvent liquidations, mergers with the company as the discontinuing entity, mergers with the company as the continuing entity if shares are issued in connection therewith and demergers. Under Danish law, it is debatable whether the shareholders must approve a decision to sell all or virtually all of the company’s business/assets.

Delaware. Under the Delaware General Corporation Law, the vote of a majority of the outstanding shares of capital stock entitled to vote thereon generally is necessary to approve a merger or consolidation or the sale of all or substantially all of the assets of a corporation. The Delaware General Corporation Law permits a corporation to include in its certificate of incorporation a provision requiring for any corporate action the vote of a larger portion of the stock or of any class or series of stock than would otherwise be required.

Under the Delaware General Corporation Law, no vote of the stockholders of a surviving corporation to a merger is needed, however, unless required by the certificate of incorporation, if (1) the agreement of merger does not amend in any respect the certificate of incorporation of the surviving corporation, (2) the shares of stock of the surviving corporation are not changed in the merger and (3) the number of shares of common stock of the surviving corporation into which any other shares, securities or obligations to be issued in the merger may be converted does not exceed 20% of the surviving corporation’s common stock outstanding immediately prior to the effective date of the merger. In addition, stockholders may not be entitled to vote in certain mergers with other corporations that own 90% or more of the outstanding shares of each class of stock of such corporation, but the stockholders will be entitled to appraisal rights.

Amendments to Governing Documents

Denmark. All resolutions made by the general meeting may be adopted by a simple majority of the votes, subject only to the mandatory provisions of the Danish Companies Act and the articles of association. Resolutions concerning all amendments to the articles of association must be passed by two-thirds of the votes cast as well as two-thirds of the share capital represented at the general meeting. Certain resolutions, which limit a shareholder’s ownership or voting rights, are subject to approval by a nine-tenth majority of the votes cast and the share capital represented at the general meeting. Decisions to impose any or increase any obligations of the shareholders towards the company require unanimity.

Delaware. Under the Delaware General Corporation Law, a corporation’s certificate of incorporation may be amended only if adopted and declared advisable by the board of directors and approved by a majority of the outstanding shares entitled to vote, and the bylaws may be amended with the approval of a majority of the outstanding shares entitled to vote and may, if so provided in the certificate of incorporation, also be amended by the board of directors.

Transfer Agent and Registrar

The transfer agent and registrar for our ordinary shares is Computershare A/S, Lottenborgvej 26 D, 1., DK- 2800 Kgs. Lyngby, Denmark. Since the closing of our public offering, The Bank of New York Mellon has served as the depositary, registrar and transfer agent for the ADSs.

Item 16H. Mine Safety Disclosure

Not applicable.

Item 16I. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

225

Not applicable.

226

PART III

Item 17.Financial Statements

We have elected to provide financial statements pursuant to Item 18.

Item 18.Financial Statements

Our audited consolidated financial statements are included in this annual report beginning at Page F-1.

227

Report of Independent Registered Public Accounting Firm

To the Shareholders and the Board of Directors of Evaxion Biotech A/S

Opinion on the Financial Statements

We have audited the accompanying consolidated statements of financial position of Evaxion Biotech A/S (the Company) as of December 31, 2021 and 2020, the related consolidated statements of comprehensive loss, changes in equity and cash flows for each of the three years in the period ended December 31, 2021, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the United States federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ EY Godkendt Revisionspartnerselskab

We have served as the Company’s auditor since 2019.

Copenhagen, Denmark

March 31, 2022

F-2

EVAXION BIOTECH A/S

Statements of Comprehensive Loss

Years Ended December 31, 

Note

2021

2020

2019

(USD in thousands, except per share amounts)

Operating expenses:

    

    

    

Research and development

 

6,7

$

19,583

$

10,902

$

8,216

General and administrative

 

6,7

6,251

5,666

 

2,647

Total operating expenses

 

25,834

16,568

 

10,863

Operating loss

 

(25,834)

(16,568)

 

(10,863)

Finance income

 

9

2,039

216

 

65

Finance expenses

 

9

(915)

(223)

 

(1,222)

Net loss before tax

 

(24,710)

(16,575)

 

(12,020)

Income tax benefit

 

10

178

1,557

 

825

Net loss for the year

$

(24,532)

$

(15,018)

$

(11,195)

Net loss attributable to shareholders of Evaxion Biotech A/S

$

(24,532)

$

(15,018)

$

(11,195)

Other comprehensive income that may be reclassified to profit or loss in subsequent periods (net of tax):

Exchange differences on translation of foreign operations

(83)

(18)

Exchange rate adjustments of investments in subsidiaries

93

Tax on other comprehensive income, income/(expense)

(5)

Other comprehensive income that will not be reclassified to profit or loss in subsequent periods (net of tax):

Exchange differences on currency translation to presentation currency

(1,547)

412

 

2

Other comprehensive loss for the year, net of tax

$

(1,542)

$

394

$

2

Total comprehensive loss

$

(26,074)

$

(14,624)

$

(11,193)

Total comprehensive loss attributable to shareholders of Evaxion Biotech A/S

$

(26,074)

$

(14,624)

$

(11,193)

Loss per share – basic and diluted

11

$

(1.26)

$

(0.97)

$

(0.81)

The accompanying notes are an integral part of these financial statements.

F-3

EVAXION BIOTECH A/S

Statements of Financial Position

December 31, 

    

Note

    

2021

2020

(USD in thousands)

ASSETS

Non-current assets

Intangible assets

12

$

93

$

100

Deferred tax assets

10

262

Property and equipment, net

13

 

5,174

 

221

Government grants receivables

194

Leasehold deposits

17

191

238

Total non-current assets

 

5,458

 

1,015

Current assets

 

 

Prepayments and other receivables

14

 

1,138

 

1,553

Deferred offering costs

2

 

 

1,729

Government grants receivable

563

418

Tax receivables

 

838

 

1,416

Cash and cash equivalents

16

 

32,166

 

5,834

Total current assets

34,705

10,950

TOTAL ASSETS

$

40,163

$

11,965

EQUITY AND LIABILITIES

 

Share capital

 

19

$

3,755

$

2,648

Other reserves

 

19

 

79,114

 

31,669

Accumulated deficit

 

19

(50,432)

(27,279)

Total equity

 

32,437

 

7,038

Non-current liabilities

 

 

Lease liabilities, non-current

 

17

 

2,206

 

Loan from lessor, non-current

17

1,044

Provisions

23

153

Total non-current liabilities

3,403

Lease liabilities

 

17

314

20

Loan from lessor, current

17

126

Trade payables

 

 

2,848

 

3,673

Other payables

15

 

1,035

 

1,234

Total current liabilities

 

4,323

 

4,927

Total liabilities

 

7,726

 

4,927

TOTAL EQUITY AND LIABILITIES

$

40,163

$

11,965

The accompanying notes are an integral part of these financial statements.

F-4

EVAXION BIOTECH A/S

Statements of Changes in Equity

    

    

    

    

Other reserves

    

    

    

    

Foreign

 currency

Share

 translation

Accumulated

    

Note

Share capital

 premium

    

 reserve

 deficit

Total equity

(USD in thousands)

Equity at December 31, 2018

$

2,113

$

4,106

$

(171)

$

(6,979)

$

(931)

Net loss for the year

 

 

 

 

(11,195)

 

(11,195)

Other comprehensive income

 

 

 

2

 

 

2

Share-based compensation

8

 

 

 

 

2,362

 

2,362

Issuance of shares for cash

19

 

181

 

9,261

 

 

 

9,442

Transaction costs

19

 

 

(13)

 

 

 

(13)

Settlement of convertible debt instruments

20

 

187

 

9,508

 

 

 

9,695

Equity at December 31, 2019

$

2,481

$

22,862

$

(169)

$

(15,812)

$

9,362

Net loss for the year

(15,018)

(15,018)

Other comprehensive income

395

395

Share-based compensation

8

3,551

3,551

Issuance of shares for cash

19

167

8,853

9,020

Transaction costs

19

(272)

(272)

Equity at December 31, 2020

$

2,648

$

31,443

$

226

$

(27,279)

$

7,038

Net loss for the year

(24,532)

(24,532)

Other comprehensive income

(1,537)

(1,537)

Tax effect on OCI items

(5)

(5)

Share-based compensation

8

1,379

1,379

Issuance of shares for cash

19

1,107

56,502

57,609

Transaction costs

19

(7,515)

(7,515)

Equity at December 31, 2021

$

3,755

$

80,430

$

(1,316)

$

(50,432)

$

32,437

The accompanying notes are an integral part of these financial statements.

F-5

EVAXION BIOTECH A/S

Statements of Cash Flows

    

Years Ended December 31, 

   

Note

   

2021

   

2020

   

2019

(USD in thousands)

Operating activities:

Net loss for the year

$

(24,532)

$

(15,018)

$

(11,195)

Adjustments for non-cash items

 

16

541

1,583

 

2,945

Interest received

 

9

Interest paid

(25)

(30)

 

(39)

Income taxes received

846

812

 

688

Cash flow from operating activities before changes in working capital

(23,170)

(12,653)

 

(7,592)

Cash flow from changes in working capital:

Changes in net working capital

 

16

1,237

215

 

573

Net cash used in operating activities

(21,933)

(12,438)

 

(7,019)

Investing activities:

Investment in intangible assets

12

(60)

(35)

Purchase of property and equipment

 

13

(1,300)

(149)

 

(61)

Payment of non-current financial assets – leasehold deposits

30

(209)

(7)

Net (cash used in)/ provided by investing activities

(1,330)

(393)

(68)

Financing activities:

 

 

Proceeds from issuance of shares and exercise of warrants, less underwriter discounts

19

53,854

9,019

 

9,442

Transaction costs related to issuance of shares

 

(3,760)

(128)

 

(13)

Proceeds from issuance of convertible debt instruments

 

20

 

152

Repayment of loan from lessor

(63)

Leasing installments

16,17

(226)

(74)

(73)

Net cash provided by financing activities

49,805

8,817

 

9,508

Net (decrease)/increase in cash and cash equivalents

 

26,542

(4,014)

 

2,421

Cash and cash equivalents at January 1

16

5,834

9,559

 

7,433

Exchange rate adjustments on cash and cash equivalents

 

(210)

288

(295)

Cash and cash equivalents at December 31

16

$

32,166

$

5,834

$

9,559

Supplemental disclosure of cash flow information

Non-cash investing and financing activities

Capitalized intangible assets included in trade payables

12

60

Acquisition of property and equipment included in trade payables

90

The accompanying notes are an integral part of these financial statements.

F-6

Table of Contents

EVAXION BIOTECH A/S

Notes to Financial Statements

Note 1. General Company Information

Evaxion Biotech A/S (the “Company” or “Evaxion”) is an artificial intelligence (“AI”)-immunology platform company that uses its proprietary AI technology, engineering expertise and drug development know-how to simulate the human immune system and generate predictive models to identify and develop efficacious immunotherapies for patients in the global market. Unless the context otherwise requires, references to the “Company,” “we,” “us,” and “our”, refer to Evaxion Biotech A/S and its subsidiaries.

Evaxion is a public limited liability company incorporated and domiciled in Denmark with its registered office located at Dr. Neergaards Vej 5f, DK-2970 Hoersholm, Denmark.

On February 5, 2021, the Company completed an initial public offering (“IPO”), which resulted in the listing of American Depository Shares (“ADS”) representing the company’s ordinary shares, under the symbol “EVAX” in the United States on the NASDAQ Capital Market. Through the IPO, the Company sold 3,000,000 ADSs, each of which represents one ordinary share, at a price to the public of $10.00 per ADS. The Company received net proceeds of $25.3 million from the IPO, after deducting the underwriting discounts and commissions and offering expenses. Upon the completion of the IPO, authorized share capital consists of 3,000,000 shares of ordinary shares, par value DKK 1 per share.

On November 9, 2021, the Company completed a follow-on public offering through which we issued and sold 3,942,856 ADSs, each of which represents one ordinary share, at a price to the public of $7.00 per ADS. The shares issued were inclusive of the 514,285 ADSs issued to the underwriters pursuant to the full exercise of their option to purchase additional shares on November 5, 2021. The Company received aggregate net proceeds of $24.9 million from the follow-on public offering, which includes the funds received for the additional shares issued to the underwriters, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. Upon the completion of the follow-on public offering, the Company’s registered, issued, and outstanding share capital was nominal DKK 23,141,524.

At year end, due to warrant exercise, the outstanding share capital was nominal DKK 23,203,808.

The consolidated financial statements of Evaxion Biotech and its subsidiaries (collectively, the “Group”) for the year ended December 31, 2021, were approved, and authorized for issuance, by the Board of Directors on March 31, 2022.

Basis of Going Concern

The Company’s Board of Directors has, at the time of approving the consolidated financial statements, a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. Based on the Company’s net proceeds secured through its recent IPO and follow-on public offering, together with access to its EIB loan, of which the Company has already received the proceeds from tranche no. 1 of €7 million on February 17, 2022, and the current cash on hand will allow the Company to meet its liabilities as they fall due for at least 12 months from the issuance of this Form 20-F. Thus, these consolidated financial statements are prepared on a going concern basis of accounting.

Emerging Growth Company Status

Evaxion is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”).

The Company has elected to take advantage of specified reduced reporting and regulatory requirements in contrast to those otherwise applicable generally to public companies. This provision includes the exemption from the auditor attestation requirement in the assessment of the Company’s internal control over financial reporting pursuant to Section 404 the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act.

Evaxion will remain an emerging growth company until the earliest of (i) the last day of the first fiscal year (a) following the fifth anniversary of the completion of the global offering, (b) in which its annual gross revenue totals at least $1.07 billion or (c) when the Company is deemed to be a large accelerated filer, which means the market value of the Company’s ordinary shares that is held by

F-7

Table of Contents

EVAXION BIOTECH A/S

Notes to Financial Statements

non-affiliates exceeds $700.0 million as of the prior June 30th and (ii) the date on which the Company has issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.

COVID 19

In December 2019, a novel strain of coronavirus (“COVID-19”) was reported in Wuhan, China and on March 11, 2020 the World Health Organization declared COVID-19 a pandemic. The COVID-19 pandemic has resulted in a widespread health crisis and numerous disease control measures being taken to limit its spread. As the pandemic unfolds throughout the world, the healthcare systems of the countries in which the Company is conducting its studies have experienced great disruption. Governments have instituted quarantining and mandated business and school closures. Travel has been severely restricted.

The Company has closely been monitoring the impact of COVID-19. The Company’s top priority remained the health and safety of its staff and the patients in the studies. The Company maintains compliance with government and health authorities.

The Company has worked closely with laboratories and investigators to ensure safe continuation and working requirements of our ongoing research activities and human clinical trials. The Company has not experienced a materially negative impact from COVID 19. As of December 31, 2021, the impact of the COVID-19 pandemic continues to unfold. As events continue to evolve and additional information becomes available, our estimates may change materially in the future.

While business travel has been limited, the Company has remained active and effective in the process of raising capital with institutional investors by conducting key meetings on a virtual basis.

Note 2. Summary of Significant Accounting Policies

Basis of preparation

The financial statements have been prepared in accordance with IFRS as issued by the IASB. The Company adopted IFRS in 2019 and applied it from the beginning of the period preceding adoption, starting on January 1, 2018.

Management has assessed the impact of new or amended and revised accounting standards and interpretations (IFRSs) issued by the IASB and IFRSs endorsed by the European Union effective on or after January 1, 2021. It is assessed that application of amendments effective from January 1, 2021 has not had a material impact on the consolidated financial statements for 2021. Furthermore, Management does not anticipate any significant impact on future periods from the adoption of these amendments.

The financial statements are presented in the Company’s presentation currency, U.S. dollar (“USD”) which is not the functional currency of the parent company. The Group’s financial statements are presented in USD as the result of the Company’s publicly listing the ADSs in the United States. The company’s functional currency is DKK for Denmark, AUD for Australia, and USD for the United States. The financial statements have been prepared on a going concern basis using a historical cost basis. All financial assets and liabilities are measured at amortized cost unless otherwise stated.

Reclassifications of prior period presentation

Certain items in prior year consolidated financial statements have been reclassified to conform to the current period’s presentation.

Basis of consolidation

The audited consolidated financial statements of the Company comprise the Statement of Financial Position as of December 31, 2021 and 2020, and the Statement of Comprehensive Loss for the twelve months ended December 31, 2021, 2020 and 2019. Subsidiaries are entities controlled by the Company. The Company controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and can affect those returns through its power over the entity. The financial statements of subsidiaries are included in the audited consolidated financial statements from the date that control commences until the date that control ceases. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Company. Control is reassessed whenever facts and circumstances indicate that there are changes of the control.

F-8

Table of Contents

EVAXION BIOTECH A/S

Notes to Financial Statements

All intra-Group assets and liabilities, equity, income, expenses, and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

Retrospective effect of share split and bonus share issuance

All share and per share data, including that related to warrants, in the consolidated financial statements give retroactive effect to a 2:1 share split and a bonus issue of shares in the ratio of 17:1 of the Company’s authorized, issued and outstanding ordinary shares, which was effective on January 4, 2021, with the corresponding impacts on both share capital and share premium also retroactively recognized.

Currency translation of transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized as financial income or financial expenses in the statements of comprehensive loss. Non-monetary items in foreign currency which are measured at cost at the statements of financial position date are translated using the exchange rates at the date of the transaction.

Translation of foreign operations

Assets and liabilities in the Company’s functional currency, DKK and AUD, for Denmark and Australia, respectively, are translated to the Company’s presentation currency at the exchange rate applicable on December 31 for the respective year. Income and expenses in the Company’s functional currency are translated to USD at the average exchange rate which corresponds to an approximation of the exchange rates prevailing on each individual transaction date. Translation differences arising in the translation to presentation currency are recognized in other comprehensive income.

Research and development expenses

Research and development expenses are primarily internal and external costs incurred in the development of the Company’s product candidates, including personnel costs, share-based compensation, external research and development expenses, maintenance of the Company’s patents, overhead allocation and enhancements and maintenance of the Company’s technology platforms.

The research activities are comprised of activities performed before filing an IND or equivalent and necessary pre-clinical activities for such product candidates. All research expenses are recognized in the period in which they are incurred and payments made prior to the receipt of goods or services to be used in research and development are deferred until the goods or services are received. The Company records accruals for estimated research and development costs, comprising payments for work performed by third-party contractors and others. Payments for these activities are based on the terms of the individual agreements, which may differ from the timing of the expense recognition of these costs, in which case, they are reflected in the financial statements as either prepaid- or accrued expenses.

The development activities are comprised of the activities performed following the filing of an IND or equivalent clinical-enabling activities for such product candidates, including but not limited to, research and clinical development activities. In line with industry practice, internal and subcontracted development costs are expensed as incurred. Due to regulatory uncertainties and other uncertainties inherent in the development of new products, development expenses do not qualify for capitalization as intangible assets until marketing approval by a regulatory authority is obtained or considered highly probable. To date, the Company has not incurred any development costs which qualified for capitalization.

Contract Research Organizations expenses and related prepayments and accruals

Substantial portions of the Company’s clinical studies are performed by third-party laboratories, medical centers, contract research organizations and other vendors (collectively, the “CROs”). The CROs generally bill monthly or quarterly for services performed. For studies, the Company accrues expenses based upon estimated percentage of work completed.

F-9

Table of Contents

EVAXION BIOTECH A/S

Notes to Financial Statements

The Company’s estimates depend on the timeliness and accuracy of the data provided by the CROs regarding the status of each program and total program spending. The Company evaluates the estimates to determine if adjustments are necessary or appropriate based on information received.

CROs invoice the Company upon the occurrence of predetermined contractual or activity-based milestones; however, the timing of these invoices and the Company’s related payments often do not correspond directly to the level of performance of contracted activities. To the extent payments are made by the Company in advance of the related activities performed by the CROs, they are included in prepayments to clinical research organizations and expensed when the activities performed by the CROs. To the extent the payments are made by the Company following the performance of the related activities, the expense is accrued for as a payable to clinical research organizations.

Intellectual property

The Company actively seeks to create, maintain and protect intellectual property and proprietary information and technology that is considered important to the Company’s business, which includes seeking and maintaining patents covering proprietary technology, product candidates, proprietary processes and any other inventions that are commercially and / or strategically important to the Company’s business development. These expenses are expensed as incurred and not capitalized as intangible assets until marketing approval by a regulatory authority is obtained or considered highly probable. The Company has not incurred any costs that qualify for capitalization.

Income from government grants

The Company receives grants for certain research and development activities. The grant income is recognized as a reduction of research and development expenses in the period in which the underlying expenditures were incurred and when there is reasonable assurance that the Company will comply with all conditions to receive the grant income. Government grants comprise direct grants and tax credits related to qualifying research and development costs in excess of the corporate tax rate. Tax credits in an amount up to the corporate tax rate are classified as income tax benefits.

General and administrative expenses

General and administrative expenses consist primarily of fees paid to external consultants and personnel costs, including share-based compensation for the Company’s executive, finance, corporate and business development functions. In addition, general and administrative expenses also include depreciation and other expenses for the Company’s corporate headquarters as well as other allocated overhead.

Share-based payments

The Company issues warrants as an incentive to employees and non-employees. The fair value of the warrants granted is recognized as an expense with a corresponding credit to accumulated deficit. The fair value is expensed over the requisite service period of the awards. The expense recognition is based on an estimate of the number of warrants expected to vest. The estimate is reassessed regularly, and on a cumulative basis, the expense is equal to the fair value of the number of warrants which actually vest.

For employees and consultants providing services similar to employees of the Company, the fair value of the equity instruments is determined at the date of grant resulting in a fixed fair value at grant date that is not adjusted for future changes in the fair value of the equity awards that may occur over the service period. The grant date is defined as the date at which the parties agree to the contractual terms.

For consultants providing other services that are not similar to employees of the Company, the transactions are measured at the fair value of the services received unless this is not reliably measurable. In such cases, the transactions are measured at fair value of the equity instruments granted at the dates when the services are provided.

Modification of warrants which are beneficial are accounted for with their incremental value or over the shorter vesting period. Non-beneficial modifications such as an extension of the vesting period are not accounted for. Consequently, the original terms are deemed

F-10

Table of Contents

EVAXION BIOTECH A/S

Notes to Financial Statements

to continue to exist. The Company estimates the fair value of warrants using the underlying value of the Company's ordinary shares. Since the warrants granted before December 2020 are exercisable for nominal consideration, the warrants are valued using the fair value of the Company's ordinary shares on grant date less the exercise consideration. Warrants granted during 2021 are valued using a black-scholes share option pricing model. The assumptions used in calculating the fair value of share-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. The key assumption in this estimate is the fair value of the Company's ordinary share on the warrant grant date.

Post-employment benefit costs

The Company contributes to a defined contribution plan covering eligible employees. The contribution amount is based upon a fixed percentage of employee compensation and such contributions are expensed as incurred.

Accounting for joint operations – Southern Denmark University

The Company enters into agreements from time to time that may be subject to the requirements of IFRS 11, Joint Arrangements. The Company evaluates these agreements on execution and applies the requirements of the guidance. The collaboration agreement with Southern Denmark University (“SDU”) is considered a joint operation as defined in IFRS 11, with the principal place of business being Denmark. In September 2020, the Company terminated its existing agreement with SDU. For the years ended December 31, 2020, and 2019, the Company recorded $0.3 million and $0.3 million, respectively, in compensation cost for SDU employees which was reported in research and development costs in the statement of comprehensive loss.

Accounting for joint operations - MSD International GmbH and MSD International Business GmbH

The Company has entered into a collaboration agreement with MSD International GmbH and MSD International Business GmbH (jointly ‘MSD’). Under the arrangement, the Company will share its clinical trial in which the Company’s compound and MSD’s compound is dosed in combination.

In determining the accounting treatment for these types of arrangements, the Company carefully evaluates the relationship between the two parties in order to determine whether the arrangement is, in substance, a collaboration arrangement between the two parties (to be accounted for in accordance with IFRS 11, Joint Arrangements), or rather, a vendor-customer contract (to be accounted for in accordance with IFRS 15, Revenue from Contracts with Customers).

Management has determined that MSD does not meet the definition of a customer under IFRS 15. Consequently, the arrangement is classified as a collaboration arrangement and is accounted for as a joint operation in accordance with IFRS 11 resulting in the recognition of the Company’s own income and expense and assets and liabilities, respectively.

Finance Income

Finance income is comprised primarily of foreign currency gains.

Finance Expense

Finance expense is comprised primarily of changes in fair value of the Company’s convertible debt instruments and interest on the Company’s lease liability.

Income tax

The income tax for the period comprises current and deferred tax, including prior-year adjustments and changes in provisions for uncertain tax positions. Tax is recognized in the statement of comprehensive loss, except to the extent that it relates to items recognized in equity.

F-11

Table of Contents

EVAXION BIOTECH A/S

Notes to Financial Statements

Research and development tax credits are available to the Group under the tax laws of Denmark and Australia respectively, based on qualifying research and development spend as defined under those tax laws. Tax credits not exceeding the corporate tax rate are recognized as an income tax benefit. Tax credits in excess of the corporate tax rate are classified as government grants.

Accruals for uncertain tax positions and/or valuation of government grant receivables require management to make judgments of potential exposures. Accruals for uncertain tax positions and/or valuation of government grant receivables are measured using either the most likely amount or the expected value amount, depending on which method the entity expects to better predict the resolution of the uncertainty. Tax benefits are not recognized unless the tax positions will probably be accepted by the tax authorities. This is based upon management’s interpretation of applicable laws and regulations and the expectation of how the tax authority will resolve the matter. Once considered probable of not being accepted, management reviews each material tax benefit and reflects the effect of the uncertainty in determining the related taxable amounts.

Deferred taxes

Deferred tax is measured according to the liability method on all temporary differences between the carrying amount and the tax base of assets and liabilities. Where the tax value can be determined according to alternative tax rules, deferred tax is measured on the basis of the planned use of the asset or the settlement of the obligation.

Deferred tax assets are measured at the value at which they are expected to be utilized, either through elimination against tax on future earnings or through a set-off against deferred tax liabilities. Deferred tax assets are set off within the same legal tax entity and jurisdiction.

Uncertainties exist with respect to the interpretation of complex tax regulations and the amount and timing of future taxable income. Given the complexity of existing contractual agreements, differences arising between the actual results and the assumptions made, or future changes to such assumptions could necessitate future adjustments to tax income and expenses already recorded. As at December 31, 2021 and 2020, the Company has not recognized any provisions for uncertain tax positions resulting in a risk that the deferred tax asset related to warrants is lower than disclosed.

The Company recognizes deferred income tax assets if it is probable that sufficient taxable income will be available in the future against which the temporary differences and unused tax losses can be utilized. Management has considered future taxable income in assessing whether deferred income tax assets should be recognized and has concluded that the deferred income tax assets do not meet the criteria for recognition as assets in the statements of financial position.

Tax receivables

Current tax assets for the current and prior periods are measured at the amount expected to be recovered from the taxation authorities, using the tax rates and tax laws that have been enacted or substantively enacted by the end of the reporting period.

Deferred offering costs

Offering costs, consisting of legal, accounting, printer and filing fees directly attributable to the issuance of new shares relating to the Company’s initial public offering (“IPO”) in February 2021, were deferred and were offset against proceeds from the IPO upon the effectiveness of the offering. Deferred offering costs recorded as of December 31, 2020 were $1.7 million.

Leases

The Company assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

The Company applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Company recognizes lease liabilities for future remaining lease payments and right-of-use assets representing the right to use the underlying assets.

F-12

Table of Contents

EVAXION BIOTECH A/S

Notes to Financial Statements

Leasehold improvements and Loan from lessor

The Company’s lease contract comprises funding for the customization of the premises to the Company’s specific needs. The payment is determined based on the actual costs incurred for the customization, a repayment period of 8 years and an interest rate of 6% per annum.

The Company has assessed whether this is a lease component, or a leasehold improvement funded by the lessor. We have considered the following factors:

1.Which party designed the customization
2.Which party had the right to direct changes to the work
3.Who is taking on the economic risk of the cost price of the work

A third party has designed the project according to the Company’s instructions, and the Company had the right to direct changes to the work during the construction period. Further, the Company has the full economic risk of the work due to 1:1 linkage between construction costs and payments to the lessor. Consequently, the Company has assessed that the customization is a leasehold improvement funded by the lessor and accordingly presented a leasehold improvement and a corresponding liability for the loan from the lessor.

Right-of-use assets

The Company recognizes a right-of-use asset at the lease commencement date (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost less any accumulated depreciation and impairment losses and adjusted for certain remeasurements of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, lease payments made at or before the commencement date less any lease incentives received, initial direct costs incurred, and restoration costs.

Right-of-use assets are depreciated over the shorter of the lease term and the useful life of the right-of-use asset using the straight-line method. In addition, right-of-use assets are reduced by impairment losses, if any, and adjusted for certain remeasurements.

The Company’s right-of-use assets are presented within property and equipment, net.

Lease liabilities

At the commencement date of the lease, the Company recognizes lease liabilities measured at the present value of the following payments, when applicable:

fixed payments (including in-substance fixed payments), less any lease incentives receivable;
variable lease payments (linked to an index or interest rate);
expected payments under residual value guarantees;
the exercise price of purchase options, where exercise is reasonably certain;
lease payments in optional renewal periods, where exercise of extension options is reasonably certain;
and penalty payments for the termination of a lease, if the lease term reflects the exercise of the respective termination option.

F-13

Table of Contents

EVAXION BIOTECH A/S

Notes to Financial Statements

The lease payments are discounted using the interest rate implicit in the lease if this rate can be readily determined. Otherwise, the Company’s incremental borrowing rate is used, being the rate that the Company would have to pay to borrow the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment with similar terms, security and conditions. Generally, the Company uses its incremental borrowing rate as the discount rate.

Lease liabilities are subsequently measured at amortized cost using the effective interest method. In addition, the carrying amount of the lease liabilities are remeasured if there is a modification, a change in the lease term, or a change in the lease payments (e.g., changes to future payments resulting from a change in an index or rate used to determine such lease payments).

Intangible assets

The Company recognized intangible assets for licenses. Licenses are measured at cost less cumulative amortization and impairment. Cost is measured at fair value of the consideration transferred with addition of transactions costs. If additional consideration is transferred to the seller due to meeting certain milestones, these payments are added to the cost price once the conditions for making the payments are met.

The capitalized assets are amortized over their useful lives, which are determined on the basis of the expected pattern of consumption of the expected future economic benefits embodied in the license or similar development agreement. Amortization commences only once the necessary regulatory and marketing approval has been received for the product candidates to which they relate. To date, the Company has not received any regulatory and marketing approval for any of its product candidates. Consequently, the Company did not recognize any amortization expense for its intangible assets.

Property and equipment

Property and equipment are stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. Depreciation is recognized on a straight-line basis over the estimated useful lives of the assets, as follows:

Assets

    

Useful life

Properties

Shorter of lease term and useful life of the asset

Leasehold improvements

11 years

Other equipment

5 – 10 years

Impairment of non-financial assets

Assets are tested for impairment annually, or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash-generating units). Non-financial assets other than goodwill that suffered impairment are reviewed for possible reversal of the impairment at the end of each reporting period. The Company has not recognized any impairment losses to date.

Provisions

Provisions are recognized when we have an existing legal or constructive obligation as a result of events occurring prior to or on the balance sheet date, and it is probable that the utilization of economic resources will be required to settle the obligation. Provisions are measured as the best estimate of the expense necessary to settle the obligation at the balance sheet date. Provisions that are estimated to mature after more than one year after the balance sheet date are measured at their present values, using a discount rate based on the Company’s risk adjusted incremental borrowing rate.

F-14

Table of Contents

EVAXION BIOTECH A/S

Notes to Financial Statements

Financial instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. Financial instruments are classified at initial recognition, including on the basis of the purpose for which the instrument was acquired and managed. This classification determines the valuation of the instruments.

(i) Non-derivative financial assets

Non-derivative financial assets are recognized initially on the date they are originated. The Company derecognizes non-derivative financial assets when the contractual rights to cash flows expire or it transfers the right to receive cash flows in a transaction which transfers substantially all the risks and rewards of ownership of the asset. The Company’s financial assets are initially recognized at fair value and subsequently measured at amortized cost less accumulated impairment losses.

The Company holds the following categories of non-derivative financial assets:

Receivables

Receivables (including lease deposits, receivables and receivables from unpaid capital) represent the Company’s right to an amount of consideration that is unconditional (i.e., only the passage of time is required before payment of the consideration is due). They are measured at amortized cost less impairment.

Prepayments include expenditures related to future financial periods and are measured at amortized cost

Cash and cash equivalents

Cash is comprised of cash on hand and in bank deposit accounts. Cash equivalents are instruments with original maturities of 90 days or less. The Company does not have any cash equivalents for the years ended December 31, 2021 and 2020.

(ii) Non-derivative financial liabilities

Non-derivative financial liabilities comprise other payables which are measured initially at fair value and subsequently at amortized cost.

Trade Payables

Trade payables and accruals relate to the Group’s purchase of products and services from various vendors in the normal course of business.

Other Payables

Other payables are comprised of payables to clinical research organizations, employee liabilities and other liabilities. The contract liabilities consist of CROs and vendor accruals. Employee cost liabilities are comprised of provision for holiday allowance, provision for salaries and other employee related provisions. Other liabilities consist of commitments and liabilities related to government grants received in advance.

Debt

Debt is comprised of debt agreements that are carried at amortized cost using the effective interest method.

F-15

Table of Contents

EVAXION BIOTECH A/S

Notes to Financial Statements

(iii) Derivative financial liabilities

Convertible debt instruments

During 2018, the Company issued two convertible debt instruments which are determined to be financial instruments. As required by IAS 32 and IFRS 9, these instruments were separated into their components: debt, and embedded derivatives related to the conversion features, early settlement mechanism and change of control prepayment provision. The Company elected the fair value option and accounts for both the debt and the embedded derivatives as a single instrument that is measured at fair value. Details of the significant inputs and assumptions into the fair values of these instruments are provided in Note 20.

Segment Information

An operating segment is a part of the Company that conducts business activities from which it can generate revenue and incur costs, and for which independent financial information is available. Identification of segments is based on internal reporting to the chief operating decision maker (“CODM”). The CODM for the Company is the Chief Executive Officer. The Company does not divide its operations into different segments and the CODM operates and manages the Company’s entire operations as one segment, which is consistent with the Company’s internal organization and reporting system. The Company does not have any revenue and there are no material non-current assets attributable to countries other than Denmark.

Shareholders’ Equity

The share capital comprises the nominal amount of the company’s ordinary shares, each at a nominal value of DKK 1.

Other Reserves includes the share premium comprising the amount received, attributable to shareholders’ equity, in excess of the nominal amount of the shares issued at the company’s capital increases, reduced by any expenses directly attributable to the capital increases as well as translation reserves. Translation reserves include exchange rate adjustments of equity and intragroup receivables forming part of the net investments in our group enterprises.

Accumulated Deficit include the accumulated profit or loss as well as well as the reserve for share-based payment representing the corresponding entries to the share-based payment recognized in the profit or loss, arising from our warrant programs.

Loss Per Share

The calculation of basic loss per share is based on the Company’s net loss for the year attributable to shareholders of Evaxion Biotech A/S and on the weighted average number of ordinary shares outstanding during the year. The number of shares outstanding take in effect the 2 for 1 stock split and the 17 for 1 bonus share issuance on January 4, 2021. In calculating diluted loss per share, earnings and the average number of shares are adjusted for the dilutive effects of potential ordinary shares. Loss per share is not adjusted for any dilution that results in a loss per share that is lower than loss per ordinary share before dilution.

Standards issued but not yet effective

There were a number of standards and interpretations which were issued but were not yet effective at December 31, 2021 and have not been adopted for these financial statements:

Amendment to IAS 37 Provisions, contingent liabilities and contingent assets, Onerous Contracts— Cost of Fulfilling a Contract (January 1, 2022)
Amendments to IAS 16 Property, Plant and Equipment, proceeds before intended use (January 1, 2022)
Annual Improvements 2018-2020 (January 1, 2022)
Amendment to IAS 1 Presentation of Financial Statements: Disclosure of Accounting Policies (January 1, 2023)

F-16

Table of Contents

EVAXION BIOTECH A/S

Notes to Financial Statements

Amendment to IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors: Definition of Accounting Estimates (January 1, 2023)
Amendments to IFRS 16 Leases: COVID-19-Related Rent Concessions beyond June 30, 2021 (April 1, 2021)

The Company expects to adopt these standards, updates and interpretations when they become mandatory. These standards are not expected to have a significant impact on disclosures or amounts reported in the Company’s financial statements in the period of initial application and future reporting periods.

Note 3. First-Time Adoption of IFRS

IFRS 1 – First-time adoption of IFRS

Impact of initial application of IFRS 1 – first-time adoption of International Financial Reporting Standards

The Company adopted IFRS as issued by IASB in the accompanying financial statements. The figures for 2019 in the statements of comprehensive loss have been prepared in accordance with IFRS as issued by the IASB.

The disclosures required by IFRS 1, First-Time Adoption of IFRS, concerning the transition from Danish Financial Statement Act (“Local GAAP”) to IFRS were presented in the prior year financials. The financial statements for the year ended December 31, 2019 are the first the Company has prepared in accordance with IFRS. For periods up to and including the year ended December 31, 2018, the Company prepared its financial statements in accordance with the Danish Financial Statements Act. Accordingly, the Company has prepared financial statements that comply with IFRS applicable as at December 31, 2021, together with the comparative period data for the years ended December 31, 2020 and 2019.

Note 4. Significant Accounting Judgements, Estimates, and Assumptions

The preparation of the consolidated financial statements in conformity with IFRS as issued by the IASB requires management to make judgements, estimates and assumptions that affect the application of policies and amounts reported in the financial statements and accompanying notes. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods.

The critical accounting policies which involve significant estimates, assumptions or judgements, the actual outcome of which could have a material impact on the Company’s results and financial position outlined below, are as follows:

Share-based compensation

Management determines costs for share-based payments using market-based valuation techniques. The fair value of the share awards is determined at the date of grant using generally accepted valuation techniques or valuation based on the Company’s fundraising events. Assumptions are made and judgments are used in applying valuation techniques. Prior to the Company’s IPO completed in February 2021, these assumptions and judgments include estimating the fair value for the underlying Ordinary share on the warrant grant date, as well as the likelihood of liquidity events such as IPOs. Such judgments and assumptions are inherently uncertain. Changes in these assumptions affect the fair value estimates as well as the term applied to the expense recognition.

Subsequent to the Company’s IPO completed in February 2021, determining the initial fair value and subsequent accounting for equity awards require significant judgment regarding expected life and volatility of an equity award; however, as a public listed company there is objective evidence of the fair value of an ordinary share on the date an equity award is granted. Refer to Note 8 for further detail surrounding share-based compensation.

F-17

Table of Contents

EVAXION BIOTECH A/S

Notes to Financial Statements

Leasehold Improvements and Loan from Lessor

A significant judgment was made in respect of determining whether customization of leased premises forms part of the lease or is a leasehold improvement funded by the lessor. See the section “Leasehold improvements and Loan from lessor” in Note 2.

There have been no other changes to the application of critical accounting judgments, or estimation uncertainties regarding accounting estimates.We refer to note 2 for a summary of significant accounting policies for further discussion.

Note 5. Financial Instruments and Risk Management

Financial risk management and risk management framework

In terms of financial risks, the Company has exposure to liquidity risk and market risk comprising foreign exchange risk. This note presents information about the Company’s exposure to each of the above risks together with the Company’s objectives, policies and processes for measuring and managing risks. The Company’s Board of Directors monitors each of these risks on a regular basis and implements policies as and when they are required. Details of the current risk management policies are provided below.

Liquidity risk

The exposure to liquidity risk primarily relates to the risk of failure to meet the Company’s obligations when they become due, which could happen if current assets are not enough to cover the amount of short-term liabilities. The Company has been dependent on its shareholders to fund its operations. The Company’s ability to continue as a going concern is dependent on its ability to raise financing to enable it to complete its product development and clinical trials. Management has determined that there is not substantial doubt about the Company’s ability to continue as a going concern for one year from the latest balance sheet date.

As of December 31, 2021 and December 31, 2020, our available liquidity, comprised of cash and cash equivalents, was $32.2 million and $5.8 million, respectively and our total equity was $32.4 million and $7.0 million, respectively.

On February 5, 2021, the Company completed our initial public offering through which we issued and sold 3,000,000 ADSs, each of which represents one ordinary share, at a price to the public of $10.00 per ADS. We received aggregate net proceeds of $25.3 million from the initial public offering, after deducting the underwriting discounts and commissions and offering expenses payable by us. Upon the completion of the initial public offering, our registered, issued, and outstanding share capital was nominal DKK 19,198,668 divided into 19,198,668 ordinary shares of DKK 1 each.

On November 9, 2021, we completed a follow-on public offering through which we issued and sold 3,942,856 ADSs, each of which represents one ordinary share, at a price to the public of $7.00 per ADS. The shares issued were inclusive of the 514,285 ADSs issued to the underwriters pursuant to the full exercise of their option to purchase additional shares on November 5, 2021. We received aggregate net proceeds of $24.9 million from the follow-on public offering, which includes the funds received for the additional shares issued to the underwriters, after deducting the underwriting discounts and commissions and offering expenses payable by us. Upon the completion of the follow-on public offering, the Company’s registered, issued, and outstanding share capital was nominal DKK 23,141,524.

At year end, due to warrant exercise, the outstanding share capital was nominal DKK 23,203,808.

We expect that the net proceeds from our initial public offering, our cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements through at least 12 months subsequent to the issuance of this annual report.

The Company’s approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to their reputation.

F-18

Table of Contents

EVAXION BIOTECH A/S

Notes to Financial Statements

The following are the contractual undiscounted outflows associated with the Company’s financial liabilities in the current and prior year:

    

December 31, 2021

(USD in thousands)

Carrying

Contractual 

 amount

cash flows

<1 year

1 – 5 years

>5 years

Total

Loan from lessor (1)

$

1,170

$

1,458

$

192

$

769

$

497

$

1,458

Lease liabilities

 

2,520

 

3,698

 

326

 

1,223

 

2,149

 

3,698

Trade payables

2,848

 

2,848

 

2,848

 

 

 

2,848

Provisions

153

153

153

153

Other payables

 

46

46

46

46

Total

$

6,737

$

8,203

$

3,412

$

1,992

$

2,799

$

8,203

(1)The loan amount as of December 31, 2021 is still subject to possible minor adjustment. Further information is provided in Note 17.

    

December 31, 2020

(USD in thousands)

Carrying

Contractual 

 amount

cash flows

<1 year

1 – 5 years

>5 years

Total

Lease liabilities

$

20

$

20

$

20

$

$

$

20

Trade payables

3,673

3,673

3,673

3,673

Other payables

 

180

 

180

 

180

 

 

 

180

Total

$

3,873

$

3,873

$

3,873

$

$

$

3,873

The financial liabilities include estimated or contractual interest rate payments.

Market risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. The type of market risk that impacts the Company is currency risk. The Company does not currently have any loans or holdings that have variable interest rate. Accordingly, the Company is not exposed to material interest rate risk.

Foreign currency risk

Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The primary exposure derives from the Company’s operating expenses paid in foreign currencies, mainly USD and Australian dollars. This exposure is known as transaction exposure. Any reasonable or likely movements in foreign exchange rates would not have a material impact on the Company’s operating results. The Company’s policy for managing foreign currency risks is to convert cash received from financing activities to currencies consistent with the Company’s expected cash outflows.

Credit risk

Credit risk is the risk that a counterparty will not meet its obligations under a financial instrument, leading to a financial loss for the Company. The Company’s exposure to credit risk is limited to deposits with banks with high credit ratings. Accordingly, the Company does not have material credit risk and no provision for credit risk is recognized.

Capital management

The Company’s objectives when managing capital are to safeguard the Company’s ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders and to maintain an optimal capital structure to reduce the cost of capital.

F-19

Table of Contents

EVAXION BIOTECH A/S

Notes to Financial Statements

The Company raises capital from the issue of equity, grants or convertible loan notes. On a regular basis, management receives financial and operational performance reports that enable management to assess the adequacy of resources on hand and the Company’s liquidity position to determine future financing needs.

Fair values

Financial instruments measured at fair value in the statements of financial position are grouped into three levels of fair value hierarchy. This grouping is determined based on the lowest level of significant inputs used in fair value measurement, as follows:

1.Level I – quoted prices in active markets for identical assets or liabilities.
2.Level II – inputs other than quoted prices included within Level I that are observable for the instrument, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
3.Level III – inputs for instrument that are not based on observable market data (unobservable inputs).

There were no financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of December 31, 2021 and 2020.

Convertible debt instruments

The Company’s convertible debt instruments are Level III financial instruments and are carried at fair value through profit and loss. The convertible debt instruments were valued based on the present value of a probability weighting of the mutually exclusive settlement alternatives. Key inputs for this valuation were: (i) the exchange rate between USD and DKK, (ii) the discount rate on the issuance, (iii) the probability of a qualifying financing event and (iv) the Company’s share price. The most significant assumptions used in the valuation were the: Company’s share price, the probability of a qualifying financing event, the discount rate and the USD to DKK exchange rate. An increase or decrease in the key input ranging from 10 percent, depending on the input analyzed, would not result in a material change in the fair value of the convertible debt instruments. There were no transfers into or out of any classification of financial instruments in any period

See Note 20 for the change in fair value of convertible debt during the year ended December 31, 2019.

Note 6. Operating Activities

Research and Development Expenses

    

Years Ended December 31, 

    

2021

    

2020

    

2019

(USD in thousands)

Employee salary and benefit expenses, excluding share-based compensation

$

(6,794)

$

(3,337)

$

(2,586)

Share-based compensation expenses

 

(1,051)

(1,496)

(1,021)

Depreciation

 

(273)

(92)

(65)

External expenses

 

(11,465)

(5,977)

(4,544)

Total research and development expenses

$

(19,583)

$

(10,902)

$

(8,216)

During the years ended December 31, 2021, 2020 and 2019, the Company recognized $0.3 million, $0.8 million and $0.5 million, respectively, related to government grants as a reduction of research and development expenses.

F-20

Table of Contents

EVAXION BIOTECH A/S

Notes to Financial Statements

General and Administrative Expenses

    

Years Ended December 31, 

    

2021

    

2020

    

2019

(USD in thousands)

Employee salary and benefit expenses, excluding share-based compensation

$

(1,824)

$

(1,098)

$

(517)

Share-based compensation expenses

(328)

(1,912)

(1,341)

Professional and other fees

(4,028)

(2,644)

(773)

Depreciation

(71)

(12)

(16)

Total general and administrative expenses

$

(6,251)

$

(5,666)

$

(2,647)

Note 7. Employees and Employee-Related Costs

The number of employees, including executive and non-executive directors, during the year was as follows:

    

Years Ended December 31, 

    

2021

    

2020

    

2019

Average number of full-time employees

 

53

33

25

Number of employees at end of period:

 

  

Denmark and United States

 

61

35

31

Total employees, at end of period

 

61

35

31

Employee Costs:

    

Years Ended December 31, 

    

2021

    

2020

    

2019

(USD in thousands)

Wages and salaries

$

6,909

$

4,016

$

2,819

Cash bonus

668

Share-based compensation expenses

1,379

3,408

 

2,362

Defined contribution plans

649

206

 

96

Other social security expenses

28

17

 

12

Other staff expenses

364

196

 

176

Total

$

9,997

$

7,843

$

5,465

    

Years Ended December 31,

    

2021

    

2020

    

2019

(USD in thousands)

Total Employee costs classified as:

 

  

Research and development expenses

$

7,845

$

4,833

$

3,607

General and administrative expenses

2,152

3,010

 

1,858

Total

$

9,997

$

7,843

$

5,465

    

Years Ended December 31, 

    

2021

    

2020

    

2019

(USD in thousands)

Non-management employee benefit expenses classified as:

 

  

Research and development expenses

$

6,414

$

4,009

$

2,590

General and administrative expenses

836

611

 

668

Total

$

7,250

$

4,620

$

3,258

F-21

Table of Contents

EVAXION BIOTECH A/S

Notes to Financial Statements

Remuneration to the Board of Directors and Executive Management

    

Year Ended December 31, 

2021

2020

2019

(USD in thousands)

Remuneration to the Executive Management:

 

  

 

  

Wages and salaries

$

1,833

$

1,298

$

900

Share-based compensation expenses

514

1,566

 

956

Total

2,347

2,864

 

1,856

Remuneration to the Board of Directors:

 

  

Wages and salaries

313

Share-based compensation expenses

87

359

 

351

Total

400

359

 

351

Remuneration to the Board of Directors and Executive Management classified as:

 

  

Research and development expenses

1,431

824

 

1,017

General and administrative expenses

1,316

2,399

 

1,190

Total

$

2,747

$

3,223

$

2,207

The Executive Management was comprised of four members in January 2019 and expanded again to five members in October 2019, of which one member resigned in 2020 and one other member resigned in 2021. It was expanded to 5 members again in 2021.

Note 8. Share-Based Payments

Warrant Program and Amendments

The Company’s Articles of Association allow for the granting of equity compensation, in the form of equity settled warrants, to employees, consultants and Scientific Advisory Board members who provide services similar to employees, members of executive management, and the board of directors. The warrants granted in 2018 or before become exercisable upon an exit event, which triggers an immediate vesting, or at any time as determined by the board of directors in accordance with the terms of the plan. The warrants granted in 2021 vest gradually over 36 months after grant date or in the case of warrants to the Board of Directors vest immediately. The warrants granted in 2020 vest either gradually over 36 months or vest immediately. Vested warrants granted in 2020 are exercisable in certain exercise windows beginning in the second half of the year of 2021. Warrants granted up until 2019 expire on December 31, 2036. Warrants granted in 2021 and 2020 expire on December 31, 2032 and 2031, respectively. For the years ended December 31, 2021, 2020 and 2019, the number of warrants outstanding as a percentage of outstanding ordinary shares was 11.8%, 13.8% and 13.5%, respectively.

In the second quarter of 2021, the Company granted 62,147 warrants to its Chief Medical Officer (“CMO”) which vest over 36 months.

In 2019, the Company granted 150,660 warrants to its Chief Financial Officer (“CFO”) which were exercisable upon an exit event. In December 2020, the terms of the warrants issued to the Company’s CFO were amended to no longer comprise exercisability upon an exit event. Consequently, these warrants did not vest upon the IPO in February 2021 and will vest in accordance with the vesting schedule for warrants granted in 2020.

On January 4, 2021, the Company’s board of directors and shareholders approved (i) a 2-for-1 stock split of its issued and outstanding ordinary shares and (ii) a bonus share issuance in the ratio of 17-for-1 of its issued and outstanding ordinary shares. The stock split also resulted in a reduction of the nominal value of the Company’s ordinary shares from DKK 2 to DKK 1. In accordance with the anti-dilution provisions of the warrant agreements, the number of warrants was increased by a ratio of 36 and the exercise price was decreased from DKK 2 to 1 DKK. Accordingly, information related to the Company’s warrants, have been retroactively adjusted to reflect the stock split and the bonus shares for all periods presented.

F-22

Table of Contents

EVAXION BIOTECH A/S

Notes to Financial Statements

The following schedule specifies the granted warrants:

Weighted

Weighted

 Average

 Average

Remaining

Number of

 Exercise

Contractual

    

 warrants

    

Price/Share

    

Life (years)

Warrants granted as at December 31, 2018

1,674,324

DKK 1

18

Warrants granted(1)

257,832

DKK 1

17

Warrants granted as at December 31, 2019

 

1,932,156

 

DKK 1

 

17

Warrants granted

363,168

 

DKK 1

 

11

Warrants forfeited

(45,216)

DKK 1

16

Warrants cancelled

(22,032)

DKK 1

16

Warrants granted as at December 31, 2020

2,228,076

DKK 1

15

Warrants granted during 2021(2)

63,802

 

DKK 1

 

10

Warrants granted December 2021

523,599

USD 5.38

10

Warrants exercised

(62,284)

(3)

DKK 1

Warrants forfeited

(10,178)

1

Warrants cancelled

(10,397)

1

Warrants granted as at December 31, 2021

2,732,618

DKK 7.53

(4)

13

Warrants exercisable as at December 31, 2019

Warrants exercisable as at December 31, 2020

Warrants exercisable as at December 31, 2021

 

2,072,122

 

 

(1)The warrants are not incorporated in the articles of association. Rectification conducted in October 2020.

(2)

Of which 62,147 warrants were legally granted in June 2021 and the remaining 1,655 warrants were legally granted in December 2020.

(3)

The share price at the exercise date was USD 5.59.

(4)

December 31, 2021 USD-end rate used.

During 2019 employees, external consultants, executive management and board members became contractually entitled to warrants that was rectified on December 17, 2020:

In January 2019, 45,216 warrants granted to a member of executive management. They vest from December 2020 – December 2022. Fair value at grant date amounted to $0.3 million.
In February 2019, 7,956 warrants granted to an employee. They vest from December 2020 – December 2022. Fair value at grant date amounted to $0.1 million.
In September 2019, 54,000 warrants granted to an employee. The warrants vested immediately. Fair value at grant date amount to $0.5 million.
In October 2019, 150,660 warrants granted to a member of executive management. The warrants vest annually over 3 years. Fair value at grant date amounted to $1.3 million.
In December 2020, an aggregate of 126,972 warrants attributable to 2019 entitlements were granted to employees, members of our board of directors and consultants who provide similar services as employees. 63,612 warrants vested immediately and 63,360 warrants vest monthly over three years from January 2020 – December 2022. Fair value at grant date amounted to $1.2 million.

F-23

Table of Contents

EVAXION BIOTECH A/S

Notes to Financial Statements

In December 2020, an aggregate of 236,196 warrants attributable to 2020 entitlements were granted to employees, members of our board of directors and consultants who provide similar services as employees. Of the warrants granted, 120,888 warrants vested immediately and 115,308 warrants vest monthly over three years from January 2020 – December 2022. Fair value at grant date amounted to $2.3 million.
In June 2021, 62,147 were granted to a member of Executive Management. Fair value at grant date amounted to $0.4 million.
During 2021, an aggregate of 523,599 warrants attributable to 2021 entitlements were granted to employees, member of our board of directors and executive management. Of the warrants 22,916 were granted to our board of directors vested immediately. The warrants granted to employees and executive management vest over 36 months. Fair value at grant date amounted to $1.5 million.
For the year ended December 31, 2019 the Company had 22,032 outstanding warrants to SDU employees and recognized an immaterial amount of expense for these warrants as research and development expenses in the statement of comprehensive loss. In September 2020, the Company terminated its existing agreement with SDU for business reasons. Under the terms of the SDU agreement, the Company did not incur a termination penalty and has no further obligations under this agreement.
A member of the executive board terminated his employment contract as of April 30, 2020 and forfeited his right to 45,216 unvested warrants.
A member of the executive board terminated his employment contract as of October, 2021 but no granted warrants remained unvested as of that date.

Share-based compensation expenses included in the statements of comprehensive loss:

    

Years Ended

December 31, 

    

2021

    

2020

    

2019

(USD in thousands)

Research and development expenses

$

1,051

$

1,496

$

1,021

General and administrative expenses

328

1,912

 

1,341

Total

$

1,379

$

3,408

$

2,362

In 2020 an amount of $0.1 million related to warrants issued as compensation for arranging investors to subscribe for shares has been recognized in equity as a share-based compensation expense related to the capital increase.

Determination of Fair Value of Warrants

The warrants issued under the share-based payment arrangement until December 2021 are exercisable for nominal consideration compared to the fair value of the shares resulting in virtually no time value. The Company values these warrants based on the intrinsic value of the shares measured as the difference between the fair value of the Company’s Ordinary shares and the warrant exercise price. Due to the highly specialized nature of services provided by consultants who provide services similar to those provided by employees of the Company, transactions with those consultants are measured at fair value of the equity instruments granted.

Under the share-based payment arrangement, there is no protection against capital increases at a discount and dividend distribution. However, dividends are not likely to be distributed and there is generally no reason to raise new capital at below the current share price. On this basis, the Company has assessed that it is generally appropriate to assume that no such transactions will take place during the holding period. When issuing warrants in 2018, convertible bonds with a potential dilutive effect were outstanding, and fair value was adjusted to reflect this potential dilution.

The stock split and bonus share issuance executed on January 4, 2021 resulted in a dilution of the warrant holders due to the increase of the exercise price compared to the pre stock split and bonus share issue. For warrants granted on December 17, 2020, the fair value was adjusted to reflect this dilution. For other grants, no such adjustment has been made.

F-24

Table of Contents

EVAXION BIOTECH A/S

Notes to Financial Statements

The fair values of the warrants are measured with reference to the share price of the underlying share. Up until December 2020, this share value was determined using the value established in different financing transactions with unrelated parties. In each of these transactions, the relative ownership of the Company was changed, and a share value was established using these fund-raising transactions. The fair values of warrants are estimated using a linear interpolation in USD of the share value on grant date based on the value established on capital event dates before and after the grant date.

For warrants granted in December 2020, the Probability-Weighted Expected Return Method (“PWERM”) was applied, based on the weighted value of the share in a stay private scenario and an IPO scenario. 40% weight was put to the stay private scenario applying a share price equal to the share price of USD 8.89 at the November 2020 capital increase and 60% weight was put to the IPO scenario applying the mid-price of the indicative IPO price range of USD 11.00 available on the balance sheet. A 10% lack of marketability discount (DLOM) was applied to the IPO price.

Warrants granted prior to December 2020 are exercisable only upon an exit event or upon the Board of Director’s decisions, which is a post vesting restriction. Since the warrants granted prior to 2020 do not expire until December 31, 2036, Management considers it highly unlikely that the warrants will not become exercisable and no downward adjustment to reflect the risk of the warrant not becoming exercisable is made to the fair value of the warrants.

During 2020, the Company revised the estimated date of an IPO exit event to occur in February 2021. As of December 31, 2019, the estimated IPO exit event was December 2021. As a result of this change in estimate, the Company recognized an acceleration of expense of $0.8 million for the year ended December 31, 2020.

Subsequent to the Company’s initial public offering completed in February 2021, determining the initial fair value and subsequent accounting for equity awards require significant judgment regarding expected life and volatility of an equity award; however, as a public listed company there is objective evidence of the fair value of an ordinary share on the date an equity award is granted. Due to the fact that as of 2021, warrants was granted at the share price on the date of grant, fair value comprises a time value which is significantly affected by the expected life and estimated volatility. The expected life of a warrant is based on the assumption that the holder will not exercise until after the equity award is fully vested. Actual exercise patterns may differ from the assumption used herein. The estimated volatility is based on peer group data and reflects the assumption that the historical volatility over a period similar to the life of the warrant is indicative of future trends, which may not necessarily be the actual outcome. The peer group consists of listed companies that management believes are similar to the Company in respect to industry and stage of development. Even with objective evidence of the fair value of an ordinary share, small changes in any other individual assumption or in combination with other assumptions could have resulted in significantly different valuations.

The following assumptions have been applied for the warrants issued in December 2021:

Expected term (in years)

    

6.5

Risk-free interest rate

 

1.34

Expected volatility

 

85.0

%

Share price

$

4.20

The exercise price of the warrants issued in June 2021 was DKK 1 and consequently, the warrants have virtually no time value. Therefore, fair value of the warrants has been determined as the intrinsic value based on a share price of $6.24.

Amendments to Warrants

As discussed above, the terms of the warrant granted to the company’s CFO were amended to no longer comprise an accelerated vesting upon an exit clause. This is considered a non-beneficial change, and consequently the accelerated vesting upon an exit event clause is deemed to continue to exist.

For warrants to which the employees became entitled in 2019 but were not granted until December 2020, the Company recognized stock-based compensation expenses during the year ended December 31, 2019 and the interim period ended September 30, 2020, based on the terms expected to apply for these awards. Management expected the terms to be similar to the terms applicable to warrants granted up until 2018, including the accelerated vesting upon an exit clause. However, these warrants were granted subjected

F-25

Table of Contents

EVAXION BIOTECH A/S

Notes to Financial Statements

to a vesting schedule up to three years and did not allow for immediate vesting upon an exit event. Because the warrants were not granted until December 2020, the Company recognized the difference in expenses as a change in accounting estimate and not a modification of existing awards. As a result of this change in the accounting estimate, the share-based payment expense for 2020 was reduced by $0.4 million.

The following schedule specifies the outstanding warrants as at December 31, 2021:

Per

warrant

Average

Remaining

grant

Number of

exercise price

term to

    

date fair value

    

warrants

    

per warrant

    

maturity

Outstanding program

(DKK)

outstanding

(DKK)

(years)

Grant (December 2016)

 

20.91

 

701,356

 

1

 

15

Grant (September 2017)

 

28.71

 

617,184

 

1

 

15

Grant (December 2017)

 

28.71

 

122,040

 

1

 

15

Grant (during 2018)

 

37.05

 

174,564

 

1

 

15

Grant (February 2019)

 

42.57

 

7,956

 

1

 

15

Grant (September 2019)

 

56.35

 

54,000

 

1

 

15

Grant (October 2019)

 

56.97

 

150,660

 

1

 

15

Grant (December 2020)

 

56.75

 

317,457

 

1

 

9

Grant (April 2021)

 

45.31

 

1,655

 

1

 

10

Grant (June 2021)

 

40.86

 

62,147

 

1

 

10

Grant (December 2021)

19.22

523,599

USD 5.38

10

Granted at December 31, 2021

 

  

 

2,732,618

 

  

 

  

Warrants exercisable at December 31, 2021

 

The following schedule specifies the outstanding warrants as at December 31, 2020:

Per 

warrant

Average

Remaining

grant

Number of

 exercise price

 term to 

date fair value

 warrants 

per warrant

maturity

Outstanding program

    

(DKK)

    

outstanding

    

(DKK)

    

(years)

Grant (December 2016)

20.91

712,332

1

16

Grant (April 2017)

24.05

13,896

1

16

Grant (September 2017)

 

28.71

 

617,184

 

1

 

16

Grant (December 2017)

 

28.71

 

127,044

 

1

 

16

Grant (during 2018)

 

37.05

 

181,836

 

1

 

16

Grant (February 2019)

 

42.57

 

7,956

 

1

 

16

Grant (September 2019)

56.35

54,000

1

16

Grant (October 2019)

56.97

150,660

1

16

Grant (December 2020)

56.75

363,168

1

11

Granted at December 31, 2020

2,228,076

1

15

Warrants exercisable at December 31, 2020

 

 

 

 

F-26

Table of Contents

EVAXION BIOTECH A/S

Notes to Financial Statements

The following schedule specifies the outstanding warrants as at December 31, 2019:

Per 

warrant

Average

Remaining

grant

Number of

 exercise price

 term to 

date fair value

 warrants 

per warrant

maturity

Outstanding program

    

(DKK)

    

outstanding

    

(DKK)

    

(years)

Grant (December 2016)

20.91

712,332

1

17

Grant (April 2017)

24.05

13,896

1

17

Grant (September 2017)

28.71

617,184

1

17

Grant (December 2017)

28.71

138,384

1

17

Grant (during 2018)(1)**

37.05

192,528

1

17

Grant (January 2019)(1)**

 

37.05

 

45,216

 

1

 

17

Grant (February 2019)**

 

42.57

 

7,956

 

1

 

17

Grant (September 2019)**

 

56.35

 

54,000

 

1

 

17

Grant (October 2019)**

 

56.97

 

150,660

 

1

 

17

Granted at December 31, 2019

 

 

1,932,156

 

1

 

17

Warrants exercisable at December 31, 2019

 

 

 

 

(1)Awards valued on December 31, 2018 and January 1, 2019, respectively.

**

The warrants are not incorporated in the articles of association. Rectification was conducted in December 2020.

F-27

Table of Contents

EVAXION BIOTECH A/S

Notes to Financial Statements

The Board of Directors and Executive Management holding of share awards for the years ended December 31, 2019, 2020 and 2021 is shown below:

Warrants held when

Warrants held when

becoming or leaving

becoming or leaving

December 31, 

December 31, 

as a member

December 31, 

as a member

December 31, 

Number of warrants held

    

2018

    

Granted

    

2019

    

of management

    

Granted

    

Forfeited

    

2020

    

of management

    

Granted

    

Exercised

    

Forfeited

    

2021

Thomas William Wylonis(former)1

342,612

342,612

(369,252)

26,640

369,252

369,252

Steven Projan

23,436

23,436

18,612

42,048

4,583

46,631

Roberto Prego

 

19,800

 

 

19,800

 

 

14,364

34,164

4,583

38,747

Joann Suzich(former)7

 

 

 

 

 

10,260

10,260

10,260

Marianne Søgaard2

65,952

28,368

94,320

9,167

103,487

Helen Boudreau (former)3

 

5,436

5,436

(5,436)

Kim Bjørnstrup (former)4

 

(5,868)

5,868

Lars Holtug

4,583

4,583

Board of Directors in total

 

385,848

 

 

385,848

 

(309,168)

 

109,548

555,480

22,916

(5,436)

572,960

Lars Aage Staal Wegner

 

844,416

 

 

844,416

 

 

7,668

852,084

64,167

916,251

Birgitte Rønø

29,376

45,000

74,376

Thomas Bogenrieder (former)5

 

4,356

 

45,216

 

49,572

 

(4,356)

 

(45,216)

4,356

4,356

Erik Heegaard

97,564

97,564

Glenn S. Vraniak (former)6

 

150,660

 

150,660

 

 

150,660

150,660

Executive Management in total

848,772

 

195,876

 

1,044,648

 

(4,356)

 

7,668

(45,216)

1,007,100

29,376

206,731

1,243,207

(1)Board member until June 30, 2020, 252 warrants were granted for services provided after retirement from the Board of Director position.
(2)As of November 25, 2020, 26,964 warrants were granted for services provided before taking on the Board of Directors position.
(3)Board member from June 30, 2020 to May 25, 2021.
(4)Board member from June 30, 2020 to November 4, 2020.
(5)Part of Executive Management until March 31, 2020.
(6)Mr. Vraniak resigned as the Chief Financial Officer of the Company effective November 1, 2021.
(7)Board member until May 25, 2021.

F-28

Table of Contents

EVAXION BIOTECH A/S

Notes to Financial Statements

Note 9. Financial Income and Expenses

    

Year Ended 

December 31, 

    

2021

    

2020

    

2019

(USD in thousands)

Financial income:

Interest income, bank

$

$

$

8

Interest income, other

 

1

Foreign exchange gains

2,039

216

 

56

Total financial income

2,039

216

 

65

Financial expenses:

Interest expenses

(5)

(29)

 

(36)

Changes in fair value of convertible debt instruments

 

(1,183)

Interest expenses, lease liabilities

(123)

 

(3)

Interest, loan from lessor

(31)

Foreign exchange losses

(756)

(194)

 

Total financial expenses

(915)

(223)

 

(1,222)

Net financial items

$

1,124

$

(7)

$

(1,157)

Note 10. Income Taxes

(a)   Analysis of charge/(credit) for the year:

    

Year Ended

December 31, 

    

2021

    

2020

    

2019

(USD in thousands)

Income tax expense/(benefit)

$

(178)

$

(1,557)

$

(825)

Total income taxes for the year

$

(178)

$

(1,557)

$

(825)

On December 31, 2021, the Company had tax loss carry-forwards in Denmark of $9.5 million (2020: $3.8 million in Denmark; 2019: $1.3 million in Denmark) for income tax purposes, all of which can be carried forward infinitely according to Danish Corporate Income Tax Act. As of December 31, 2021, the Company did not have any tax loss carry-forwards in any other tax jurisdictions.

The benefit from income taxes for each year includes a tax credit for research and development expenditures at the applicable tax rate under the Danish Tax Assessment Act and Australian tax legislation, respectively.

(b) Reconciliation of effective tax rate to Danish statutory tax rate

    

Year Ended December 31, 

    

2021

    

2020

    

2019

Statutory corporate income tax rate in Denmark

 

22

%  

22

%  

22

%  

Difference in corporate income tax rate in subsidiaries

%

Non-deductible income / (expenses)

 

%  

(1)

%  

(5)

%  

Non-taxable income / (expenses)

%

1

%

Additional tax deduction R&D expenses

6

%

3

%

Tax credit research and development expenditures

 

(4)

%  

9

%  

7

%  

Change in deferred tax asset not capitalized

 

(23)

%  

(25)

%  

(17)

%  

Total effective tax rate

 

1

%  

9

%  

7

%  

F-29

Table of Contents

EVAXION BIOTECH A/S

Notes to Financial Statements

(c) Deferred tax in the statements of financial position

    

Year Ended

December 31, 

    

2021

    

2020

    

2019

(USD in thousands)

Deferred Tax Positions:

 

Warrants

$

2,118

$

4,289

$

3,034

Loss carry forward

9,530

3,759

 

1,270

Research and development expenditures

262

Other items

(98)

(6)

(34)

Valuation allowance on deferred tax assets

(11,550)

(8,042)

 

(4,270)

Total capitalized

$

$

262

$

Deferred tax attributable to research and development expenditures relates to development costs recognized as an expense in the consolidated financial statements in 2020 and are tax deductible in 2021.

Under Danish tax legislation, the value of warrants to employees is income tax exempt subject to meeting certain conditions. The value of income tax exempt warrants is not tax deductible for the issuer. There is currently uncertainty in respect of the extent to which the conditions for being tax exempt are met and consequently the extent to which a tax deduction will be available for the company. Consequently, the deferred tax asset disclosed above is subject to uncertainty and there is a risk that the amount disclosed above is not tax deductible in full.

Note 11. Basic and Diluted Loss Per Share

Basic loss per share is calculated by dividing the net loss attributable for the year to shareholders of Evaxion Biotech A/S by the weighted average number of ordinary shares outstanding during the year. As net losses from continuing operations were recorded in the years 2021, 2020 and 2019, the dilutive potential shares are anti-dilutive for the earnings per share calculation.

    

Year Ended December 31, 

    

2021

    

2020

    

2019

(USD in thousands, except share amounts and per share amounts)

Loss per share before and after dilution

 

  

 

  

Net loss attributable to shareholders of Evaxion Biotech A/S

$

(24,532)

$

(15,018)

$

(11,195)

Weighted-average number of ordinary shares outstanding

19,493,143

15,434,758

 

13,892,314

Loss per share before and after dilution

$

(1.26)

$

(0.97)

$

(0.81)

The following potential shares are anti-dilutive and are therefore excluded from the weighted average number of shares for the purpose of diluted loss per share:

    

December 31, 

    

2021

    

2020

    

2019

Warrants

 

2,732,618

2,228,076

2,059,128

Note 12. Intangible Assets

In June 2020, the Company entered into a license agreement for the rights to certain intellectual properties. Upon execution of the license agreement, the Company was obligated to make a milestone payment of $35,000. The agreement remains in effect until the Company completes a Phase I/IIa clinical study, after that the Company has an option to extend the agreement for an additional 10-year term. Over the initial term of the agreement, the Company is obligated to make various additional milestone payments based on the progress of developed drug candidates. The Company determined that the milestone payments meet the definition of intangible assets and will be capitalized.

F-30

Table of Contents

EVAXION BIOTECH A/S

Notes to Financial Statements

During the twelve months ended December 31, 2020, the Company capitalized $35,000 as intangible assets for the acquisition of a non-exclusive technology license. Subject to meeting certain development milestones, additional consideration of up to $320,000 is to be transferred to the seller. Further, $250,000 is to be transferred to the seller upon each regulatory approval of an Evaxion product utilizing the in-licensed technology. As of December 31, 2020, the Company accrued for an additional $60,000 related to the license. The Company did not recognize any amortization expense for the years ended December 31, 2021 and 2020 as the asset has not been put in use. No intangible assets were recognized in earlier periods as the Company’s expenditures did not qualify for capitalization.

During the twelve months ended December 31, 2020, the Company capitalized $60,000 as intangible assets for the acquisition of a non-exclusive technology license from SSI. Subject to successful commercialization of any Evaxion product utilizing the in-licensed technology, Evaxion is required to pay to the seller a royalty on net sales in the low teens. In the event any Evaxion product utilizing the in-licensed technology are commercialized by one of the Company’s partners, Evaxion is required to pay to the seller a percentage of any out-licensing revenue earned by the Company or its affiliates. If Evaxion enters into a sublicense agreement with a partner subsequent to the initiation of a Phase 2b clinical trial, Evaxion is required to pay to the seller a percentage of any sublicensing income in an amount in the lower double-digit range. If Evaxion enters into a sublicense agreement with a partner subsequent to the initiation of a Phase 3 trial, Evaxion is required to pay to the seller a percentage of any sublicensing income in the lower double-digit range. If Evaxion enters into a sublicense agreement with a partner without initiating a Phase 2b trial, Evaxion is required to pay to SSI a percentage of any sublicensing income in the mid double-digit range.

The Company did not recognize any amortization expense for the years ended December 31, 2021, and 2020 as the asset has not been put in use.

    

Intangible

    

    

Assets

Total

(USD in thousands)

Cost at December 31, 2020

$

100

$

100

Additions during the year

 

 

Exchange rate adjustments

 

(7)

 

(7)

Cost at December 31, 2021

 

93

 

93

Amortization at December 31, 2020

 

 

Amortization for the year

 

 

Exchange rate adjustment

 

 

Amortization at December 31, 2021

 

 

Carrying amount at December 31, 2021

$

93

$

93

Intangible 

 

    

Assets

    

Total

(USD in thousands)

Cost at December 31, 2019

 

$

 

$

Additions during the year

95

95

Exchange rate adjustments

5

5

Cost at December 31, 2020

100

100

Amortization at December 31, 2019

Amortization for the year

Exchange rate adjustment

Amortization at December 31, 2020

Carrying amount at December 31, 2020

 

$

100

 

$

100

F-31

Table of Contents

EVAXION BIOTECH A/S

Notes to Financial Statements

Note 13. Property and Equipment, Net

    

    

Other

Leasehold

Property

    

Equipment

    

Improvements

    

Total

(USD in thousands)

Cost at December 31, 2020

$

257

$

263

$

$

520

Additions during the year

 

2,891

 

1,025

 

1,634

 

5,550

Disposals during the year

(244)

(244)

Exchange rate adjustments

 

(148)

 

(63)

 

(67)

 

(278)

Cost at December 31, 2021

 

2,756

 

1,225

 

1,567

 

5,548

Depreciation at December 31, 2020

$

(237)

$

(62)

$

$

(299)

Depreciation for the year

 

(179)

 

(105)

 

(59)

 

(343)

Depreciation reversed on disposals during the year

244

244

Exchange rate adjustment

 

17

 

6

 

1

 

24

Depreciation at December 31, 2021

 

(155)

 

(161)

 

(58)

 

(374)

Carrying amount at December 31, 2021

$

2,601

$

1,064

$

1,509

$

5,174

Carrying amount of right-of-use assets at December 31, 2021

$

2,601

$

$

$

2,601

Other 

    

Property

    

Equipment

    

Total

(USD in thousands)

Cost at December 31, 2019

$

179

$

93

$

272

Additions during the year

 

55

 

149

 

204

Exchange rate adjustments

 

23

 

21

 

44

Cost at December 31, 2020

 

257

 

263

 

520

Depreciation at December 31, 2019

 

(144)

 

(27)

 

(171)

Depreciation for the year

 

(71)

 

(34)

 

(105)

Exchange rate adjustment

 

(22)

 

(1)

 

(23)

Depreciation at December 31, 2020

 

(237)

 

(62)

 

(299)

Carrying amount at December 31, 2020

$

20

$

201

$

221

Carrying amount of right-of-use assets at December 31, 2020

$

20

$

$

20

Depreciation included in the statement of comprehensive loss:

    

Year Ended

December 31, 

    

2021

    

2020

    

2019

(USD in thousands)

Research and development

$

270

$

90

$

64

General and administrative

73

15

 

16

Total depreciation included in the statement of comprehensive loss

$

343

$

105

$

80

Total accumulated depreciation of right-of-use assets at December 31, 

$

557

$

236

$

145

Note 14. Prepayments and other receivables

    

December 31, 

    

2021

    

2020

(USD in thousands)

VAT receivables

$

387

$

376

Prepayments

 

638

 

1,175

Other receivables

 

113

 

2

Total prepayments and other receivables

$

1,138

$

1,553

F-32

Table of Contents

EVAXION BIOTECH A/S

Notes to Financial Statements

Note 15. Other Payables

    

December 31, 

    

2021

    

2020

(USD in thousands)

Employee cost liabilities

$

989

$

1,054

Other liabilities

 

46

 

180

Total other payables

$

1,035

$

1,234

Note 16. Cash and Cash Equivalents

    

December 31, 

    

2021

    

2020

(USD in thousands)

Cash and cash equivalents

$

32,166

$

5,834

Total cash and cash equivalents

$

32,166

$

5,834

Cash and cash equivalents consist mainly of cash on deposit with banks.

Changes in Net Working Capital

    

December 31, 

    

2021

    

2020

    

2019

(USD in thousands)

Changes in receivables and tax receivables

$

1,863

$

(2,501)

$

(337)

Changes in trade payables

(647)

1,798

 

507

Changes in other payables

21

918

 

403

Changes in net working capital

$

1,237

$

215

$

573

Working capital is defined as current assets (excluding cash) less current liabilities (excluding convertible debt) and measures the net liquid assets the Company has available for the business.

Adjustments for non-cash items

Adjustments of non-cash items in the statements of comprehensive loss:

    

Year Ended

December 31, 

    

2021

    

2020

    

2019

(USD in thousands)

Income taxes

$

(178)

$

(1,557)

$

(825)

Tax credit schemes accounted for as grants

(12)

(510)

Depreciation

344

105

 

81

Interest income

 

(9)

Interest expense

159

30

 

39

Share-based compensation expenses

1,379

3,408

 

2,362

Acquisition of property, plant and equipment

(90)

Change in fair value of convertible debt instruments

 

1,183

Other adjustments: Other adjustments, primarily exchange rate adjustments

(1,061)

107

 

114

Total adjustments for non-cash items

$

541

$

1,583

$

2,945

F-33

Table of Contents

EVAXION BIOTECH A/S

Notes to Financial Statements

Reconciliation of Liabilities from Financing Activities

December 31, 

Accumulated

Exchange rate

December 31, 

(USD in thousands)

    

2020

    

Cash flows

    

 interest

    

Additions

    

 adjustment

    

2021

Lease liabilities

$

20

$

(226)

$

123

$

2,731

$

(128)

$

2,520

Loan from lessor

31

1,269

(130)

1,170

Provisions

161

(8)

153

Total liabilities from financing activities

$

20

$

(226)

$

154

$

4,161

$

(266)

$

3,843

December 31, 

Accumulated

Exchange rate

December 31, 

(USD in thousands)

    

2019

    

Cash flows

    

 interest

    

Additions

    

 adjustment

    

2020

Lease liabilities

$

36

$

(74)

$

1

$

54

$

3

$

20

Total liabilities from financing activities

$

36

$

(74)

$

1

$

54

$

3

$

20

Note 17. Leases

As a result of the lease accounting of IFRS 16, the Company has capitalized the only right-of-use asset being the domicile lease. Upon implementation on January 1, 2018, the Company has recognized a liability to make lease payments (i.e. the lease liabilities) of $0.2 million and an asset representing the right to use the underlying asset during the lease term (i.e. the right-to-use asset) of $0.2 million. The liability was measured at the present value of the remaining lease payments, discounted using the lessee’s incremental borrowing rate as of the standard adoption date of January 1, 2018. The Company applied an incremental borrowing rate of 3.8%. For the years ended December 31, 2019,2020 and 2021, the expense related to variable lease payments not included in the lease liabilities was immaterial and was recognized in operating expense.

In October 2020, the Company entered into a lease for approximately 1,356 square meters, which is allocated on 839 square meters of office space, and 518 square meters of laboratory space in Hørsholm, Denmark. The commencement date for the lease of the 839 square meters of office space was February 1, 2021 and the lease continues for a term of 10 years from that date. The commencement date for the additional laboratory space was August 13, 2021 and the lease continues for a term of 10 years with a subsequent 12-month cancellation notice period. The lease agreement contains an early termination provision which would trigger a termination fee of $2.7 million. The initial monthly payment is expected to be between $28,000 and $30,000, which consists of $12,000 for the office space, and is expected to be between $16,000 and $18,000 for the laboratory space. Through-out the term, the lease is subject to annual increases ranging from two to four percent on the annual lease payment amount.

The Company had one operating lease in Copenhagen, Denmark as of December 31, 2020.

We also occupied an office space in New York, New York, United States. The terms of the lease agreement included a 13 month occupancy period from January 2, 2020 through January 31, 2021. A termination notice was provided in November 2020 and the lease and occupancy terminated on January 31, 2021.

For the years ended December 31, 2021, 2020 and 2019, the expense related to variable lease payments not included in the lease liabilities was immaterial and was recognized in operating expense.

F-34

Table of Contents

EVAXION BIOTECH A/S

Notes to Financial Statements

Set out below are the carrying amounts of the Company’s right-of-use assets and lease liabilities and the movements during the period:

    

Right-of-Use Asset

    

Lease liabilities

(USD in thousands)

At December 31, 2020

$

20

$

20

Additions

 

2,891

 

2,731

Depreciation

 

(179)

 

Interest Expense

 

 

123

Payments

 

 

(226)

Translation

 

(131)

 

(128)

At December 31, 2021

$

2,601

$

2,520

    

Right-of-Use Asset

    

Lease liabilities

(USD in thousands)

At December 31, 2019

$

35

$

36

Additions

 

54

54

Depreciation

 

(73)

Interest Expense

 

Payments

 

4

(74)

Translation

 

4

At December 31, 2020

 

$

20

$

20

The total cash outflow for leases was $0.2 million in 2021, and $0.2 million in 2020.

Loan from Lessor

In addition to the ordinary lease payments, the Company obtained financing from DTU Science Park A/S (“DTU”) for rebuilding the laboratory facility and engineering building to match the Company’s needs. The Company will repay the $1.3 million financing at a fixed interest rate of 6% over 8 years. If the lease is terminated due to default by the Company before the outstanding balance, including interest accrued, has been repaid, the remaining balance is due immediately. The finance liability is recorded at costs, which approximates fair value at the time of issuance. As of December 31, 2021, the Company is still in discussions with DTU on the actual costs incurred.

As a result of the finance structure this amount is not included as Purchase of property and equipment within the consolidated statements of cash flows. The leasehold improvements recognized will be subject for adjustment when the actual costs incurred are made available from DTU.

The following table sets forth the finance liability (in thousands):

    

December 31,

2021

Loan from lessor

$

1,170

Total Loan from lessor

 

1,170

Less: Loan from lessor, current portion

 

(126)

Total Loan from lessor, net of current portion

$

1,044

Note 18. Debt

In August 2020, we executed a loan agreement, or the EIB Loan Agreement, with the European Investment Bank, or EIB, for a principal amount of 20.0 million, divided into three tranches of 7.0 million, 6.0 million and 7.0 million on the EIB Loan. Under the EIB Loan Agreement, the EIB Loan tranche balances are due six years from their respective disbursement dates. For all tranches, EIB is entitled to an aggregate of 1,047,744 cash settled warrants with an exercise price of 1 DKK per warrant. The 351,036 warrants attributable to the first tranche of 7.0 million were incorporated in the articles of association on December 17, 2020. As of December

F-35

Table of Contents

EVAXION BIOTECH A/S

Notes to Financial Statements

31, 2021, the Company initiated the draw down of the first tranche of the EIB Loan Agreement amounting to 7.0 million. The Company received the first tranche of 7.0 million on February 17, 2022.

Note 19. Capital Structure and Financial Matters

Share Capital – Ordinary Shares

Loss of subscribed share capital

On December 31, 2018, the Company had lost more than 50% of its subscribed share capital. At the annual general meeting of the shareholders held on March 29, 2019, the Board of Directors gave, in accordance with section 119 of the Danish Companies Act, an account of the Company’s financial position. As part of the account, the Board of Directors stated that in its view, special actions were not required. The share capital of the Company was subsequently re-established through the conversion of the convertible debt instruments and issue of new shares during 2019.

Capital transactions

In September 2020, the Company issued 745,380 shares of ordinary shares to existing investors in the Company. The purchase price was $8.89 per share for aggregate proceeds of $6.6 million. The Company incurred immaterial issuance costs. The proceeds were received by the Company on September 17, 2020. On August 10, 2020, the Company’s articles of association were amended in connection with the execution of this transaction. The revised articles increased the authorized number of shares the Company can issue by: (i) the 745,380 shares issued in this transaction, as well as (ii) an additional 1,800,000 shares of Common ordinary share at a nominal price of DKK 1, to be issued any time prior to June 1, 2025. The amended articles also allow the Company to issue an additional 1,298,196 of compensatory ordinary share warrants to employees and consultants any time prior to June 1, 2025.

In October 2020, we successfully completed part 2 of our “bridging round” of capital with outside investors in the amount of $2.4 million with a purchase price of $8.89 per share from the issuance of 269,136 of our ordinary shares and received the proceeds in November 2020. Transaction costs directly attributable to the third quarter of 2020 “bridging round” of capital with outside investors have a total amount of $144,022.

In February 2021, we completed our IPO through which we issued and sold 3,000,000 American Depositary Shares, or ADSs, each of which represents one ordinary share, at a price to the public of $10.00 per ADS. We received aggregate net proceeds of $25.3 million from the IPO, after deducting the underwriting discounts and commissions and offering expenses. Upon the completion of the IPO, our registered, issued, and outstanding share capital was nominal DKK 19,198,668.

In November 2021, we completed a follow-on public offering through which we issued and sold 3,942,856 ADSs, each of which represents one ordinary share, at a price to the public of $7.00 per ADS. The shares issued were inclusive of the 514,285 ADSs issued to the underwriters pursuant to the full exercise of their option to purchase additional shares on November 5, 2021. The Company received aggregate net proceeds of $24.9 million from the follow-on public offering, which includes the funds received for the additional shares issued to the underwriters, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. Upon the completion of the follow-on public offering, the Company’s registered, issued, and outstanding share capital was nominal DKK 23,141,524.

At year end, due to warrant exercise, the outstanding share capital was nominal DKK 23,203,808.

F-36

Table of Contents

EVAXION BIOTECH A/S

Notes to Financial Statements

The following are changes in the Company’s share capital for the years ended December 31, 2019, 2020 and 2021:

Number of

Share Capital

    

 Ordinary Shares

    

 (DKK in thousands)

Share capital, December 31, 2018

12,917,016

12,917

Capital increase at July 17, 2019 (issuance of shares for cash)

 

997,668

 

998

Capital increase at July 17, 2019 (conversion of Convertible Debt 1)

 

302,976

 

303

Capital increase at July 17, 2019 (conversion of Convertible Debt 2)

848,232

848

Capital increase at December 19, 2019 (issuance of shares for cash)

118,260

118

Share capital, December 31, 2019

 

15,184,152

 

15,184

Capital increase at September 17, 2020 (issuance of shares for cash)

 

745,380

 

745

Capital increase at October 15, 2020 (issuance of shares for cash)

269,136

269

Share capital, December 31, 2020

16,198,668

16,198

Capital increase at February 9, 2021 (for initial public offering)

3,000,000

3,000

Capital increase at November 9, 2021 (for follow-on offering)

 

3,942,856

 

3,943

Capital increase November 2021 (exercised warrants)

62,284

63

Share capital, December 31, 2021

 

23,203,808

 

23,204

The Company’s share capital consists of the following ordinary shares:

    

December 31, 

    

2021

2020

(USD in thousands)

Authorized, issued and fully paid

23,203,808 (2020: 16,198,668) ordinary shares of DKK 1 each (2020: ordinary shares of DKK 1 each)

$

3,755

$

2,648

$

3,755

$

2,648

The Company’s ordinary shares shall confer on the holders thereof the right to receive notice of, attend and vote at general meetings of the Company.

Executive Management’s and Board of Director’s holding of shares

At December 31, the board of directors and executive management held the following shareholdings in the Company:

Number of ordinary shares owned

    

2021

    

2020

    

2019

Niels Iversen Møller

4,292,604

4,292,604

4,292,604

Andreas Holm Mattsson

 

4,163,832

4,163,832

4,163,832

Lars Aage Staal Wegner

 

182,124

182,124

182,124

Executive Management in total

 

8,638,560

8,638,560

8,638,560

Number of ordinary shares owned

    

2021

    

2020

    

2019

Roberto Prego

 

310,248

310,248

310,248

Thomas William Wylonis (former)

 

485,676

481,860

Marianne Søgaard

41,652

41,652

Steven Projan

 

27,288

27,288

11,736

Board of Directors in total

 

379,188

864,864

803,844

Note 20. Convertible Debt Instruments

During 2018, the Company issued two types of convertible debt instruments, (“Convertible Debt 1”) and one (“Convertible Debt 2”) for total proceeds of $8.0 million, of which $0.1 million was received from related parties, including members of the Board of Directors and Executive Management. The Company originally recorded both debt instruments at fair value as a financial liability and

F-37

Table of Contents

EVAXION BIOTECH A/S

Notes to Financial Statements

subsequently remeasured the instruments with the change being presented on the statement of comprehensive income for the reporting period. In July 2019, both instruments were converted into ordinary shares as a result of a qualified capital increase triggering a conversion based on the terms of the agreements.

The following table summarizes the changes in the convertible debt instruments during the year ended December 31, 2019:

    

 Convertible loans

(USD in thousands)

Carrying amount at December 31, 2018

$

8,569

Amount received in 2019

 

152

Fair value adjustment included in finance expenses

 

1,183

Currency adjustment

 

(209)

Converted to equity during 2019

 

(9,695)

Carrying amount at December 31, 2019

$

The main terms of Convertible Debt 1 were:

Term: 12 months from issuance;
Interest coupon 7.5 percent p.a. accruing over the term of the loan;
Loan currencies: $0.9 million is USD denominated and $1.0 million is denominated in DKK (DKK 7.1 million);
Lender conversion option if a capital increase in excess of DKK 9.8 million (or a qualified capital increase event) takes place before maturity. The conversion price is the share price obtained at the qualified capital increase event less a 20 percent discount;
Repayment in cash of principal + accrued interest at a premium of 50 percent if all shares of the Company are sold; and
Lender conversion option to a fixed number of shares if the loan has not been repaid or converted under the other settlement terms of the agreement.

The main terms of Convertible Debt 2 were:

Term: Expires on December 31, 2020;
Interest coupon 7.5 percent p.a. accruing over the term of the loan;
Loan currencies: $5.4 million is USD denominated and $0.7 million is denominated in DKK (DKK 5.0 million);
Mandatory conversion if a capital increase in excess of $10.0 million (qualified capital increase) takes place before maturity. The conversion price is the share price obtained less a 5 percent discount if the capital increase take place in 2018, 10 percent if it takes place in 2019 and 20 percent if it takes place in 2020;
Repayment in cash of principal + accrued interest at a premium of 50% if all shares of the Company are sold; and
Mandatory conversion at maturity with a conversion price of $160.41. 10 days before conversion, USD denominated loans will convert into DKK whereas the conversion price remains denominated in USD.

Convertible debt instruments were classified as financial liabilities until such time that the Company had an unconditional right to avoid settlement in cash and had no obligation to settle in a variable number of shares.

F-38

Table of Contents

EVAXION BIOTECH A/S

Notes to Financial Statements

For Convertible Debt 1, the Company did not have an unconditional right to avoid settlement in cash. In addition, Convertible Debt 2 comprised an obligation to settle in a variable number of shares at maturity. Therefore, both convertible debt instruments comprised a debt host instrument.

Conversion features comprising a fixed number of the entity’s shares in exchange for a fixed principal in the entity’s functional currency were equity instruments and separated from the debt host contract as the residual between fair value of the contract and fair value of a similar debt instrument without the conversion feature. All other equity conversion features were embedded derivatives.

Both convertible debt instruments included a conversion feature resulting in settlement in a variable number of shares. Consequently, none of the instruments comprised an equity component. They included the following non-closely related embedded derivatives:

At maturity conversion options for Convertible Debt Instrument 1;
At maturity conversion provisions for Convertible Debt Instrument 2;
Early settlement mechanism on both issuances through delivery of a variable number of shares at a discounted price; and
Change of control prepayment provision.

Note 21. Related Party Transactions

    

December 31, 

    

2021

    

2020

    

2019

(USD in thousands)

The Company’s transactions with other related parties:

 

  

 

  

Transactions with related parties (expenses):

 

  

 

  

Accrued interest on convertible debt instruments issued to members of executive management and board of directors

$

$

$

(4)

Balances with related parties at year-end (asset):

Prepaid rent and deposit for a leased property from a related party

$

$

7

$

Balances with related parties at year-end (liabilities):

 

  

Convertible debt instruments issued to members of executive management and board of directors (nominal value plus accrued interest of 7.5%)

$

$

$

The Company’s related parties are comprised of significant shareholders of the Company, the executive management group, the board of directors and the close members of the family of these persons.

The Company has not granted any loans, guarantees, or other commitments to or on behalf of any of the members in the board of directors or executive management. Other than the remuneration and other transactions relating to the board of directors or executive management and capital increases on the same terms as other investors, no other significant transactions have taken place with the board of directors or executive management for the years ended December 31, 2021, 2020 and 2019.

Note 22. Contractual Obligations

Litigations and investigations

The Company is not involved in any pending litigations, claims and investigations that individually and in the aggregate that is expected to have a material impact on the financial position, operating profit or cash flow.

The contractual obligations are similarly individually and, in the aggregate, not material to the future financial position, operating profit or cash flow.

F-39

Table of Contents

EVAXION BIOTECH A/S

Notes to Financial Statements

Contractual obligations

At December 31, 2021, the Company had the following contractual commitments which fall due as follows:

    

December 31, 2021

(USD in thousands)

Contractual

cash flows

<1 year

1 – 2 years

2 – 5 years

>5 years

Total

Purchase obligations

$

72

$

72

$

$

$

$

72

Total

$

72

$

72

$

$

$

$

72

The Company has purchase obligations of $72 thousand due to CRO’s and a nominal amount due system provider as of December 31, 2021.

At December 31, 2020, the Company had the following contractual commitments which fall due as follows:

    

December 31, 2020

(USD in thousands)

Contractual

    

 cash flows

    

<1 year

    

1 – 2 years

    

2 – 5 years

    

>5 years

    

Total

Purchase obligations

$

712

$

712

$

$

$

$

712

Total

$

712

$

712

$

$

$

$

712

The Company has purchase obligations of $0.6 million due to CRO’s and $0.1 million due to university future partners as of December 31, 2020.

Note 23. Provisions

The Company is required to restore the lease premises of its office and laboratory space in Hørsholm, Denmark to its original condition at the end of the lease term. A provision is recognized for the present value using a discount rate based on the Company’s risk adjusted incremental borrowing rate of the estimated expenditure required to remove any leasehold improvements. These costs have been capitalized as part of the cost of leasehold improvements and are amortized over the lease term.

Changes in the provision balance during the year ended December 31, 2021 are as follows:

    

Provisions

(USD in

thousands)

Carrying amount at January 1, 2021

$

Provision recognized

 

161

Additions

 

Utilization of provision

 

Change in the provision

 

Currency adjustment

 

(8)

Carrying amount at December 31, 2021

$

153

F-40

Table of Contents

EVAXION BIOTECH A/S

Notes to Financial Statements

Note 24. Fees to auditors

The following table presents the fees to our independent registered public accounting firm, EY Godkendt Revisionspartnerselskab, recognized in general and administrative expenses in the Statement of Profit or Loss for the years ended December 31, 2021 and 2020. This note was prepared in accordance with the requirements of the Danish Financial Statements Act:

December 31, 

2021

2020

 

(USD in thousands)

Audit fees

    

$

177

    

$

308

Audit related fees

 

108

 

119

Other fees

 

328

 

253

Total fees

$

613

$

680

Audit fees

Audit fees consist of fees billed for professional services rendered by EY for the audit of our annual consolidated financial statements or services that are normally provided by the accountant in connection with statutory and regulatory filings or engagements for those fiscal years.

Audit-Related fees

Audit-related fees consist of assurance and related services performed by EY that are reasonably related to the performance of the audit or review of our consolidated financial statements and are not reported under “Audit-Related fees.”

Other fees

Other fees consist of services provided by EY for other permitted services, including fees for work performed by EY in connection with the initial public offering.

Note 25. Events After the Reporting Period

EIB Loan Drawdown

As of December 31, 2021, the Company initiated the draw down of the first tranche of the EIB Loan Agreement amounting to 7.0 million. The Company received the first tranche of 7.0 million on February 17, 2022.

Executive Management Agreements

The Company entered into agreements to hire executives in its Chief Operating Officer and Chief Financial Officer roles subsequent to the date of this annual report. The Chief Operating Officer joined the Company on March 14, 2022 and the Chief Financial Officer is expected to join the Company in August 2022.

Russia’s Invasion of Ukraine

On February 24, 2022, Russia invaded Ukraine creating a global conflict. The resulting conflict and retaliatory measures by the global community have created global security concerns, including the possibility of expanded regional or global conflict, which have had, and are likely to continue to have, short-term and more likely longer-term adverse impacts on Ukraine and Europe and around the globe. Potential ramifications include disruption of the supply chain including research activities and complications with the conduct of ongoing and future clinical trials of our product candidates, including patient enrollment. The Company relies on global networks of contract research organizations and clinical trial sites to enroll patients, Delays in research activities or in the conduct of our clinical trials could increase associated costs and, depending upon the duration of any delays, require us to find alternative suppliers at additional expense. In addition, the conflict between Russia and the Ukraine has had significant ramifications on global financial markets, which may adversely impact our ability to raise capital on favorable terms or at all.

F-41

Item 19.Exhibits

EXHIBIT INDEX

Exhibit Number

    

Exhibit Description

    

Form

    

Date

    

Incorporated by Reference Number

    

File
Number

    

Provided Herewith

1.1

Articles of Association currenty in effect (including English translation)

6-K

3/23/2022

1.1

001-39950

2.1

Form of Deposit Agreement among the Registrant, the depositary and holders and beneficial owners of the American Depositary Shares

F-6

01/12/2021

1

333-252038

2.2

Form of Specimen American Depositary Receipt (included in Exhibit 2.1)

4.1

CAF®09b Supply, Patent Know How & Trademark License Agreement dated November 30, 2020, between Statens Serum Institut and Evaxion Biotech A/S

F-1

01/08/2021

10.1

333-251982

4.2

Finance Contract between European Investment Bank and Evaxion Biotech A/S dated August 6, 2020

F-1

01/08/2021

10.2

333-251982

4.3

Lease Agreement dated October 2, 2020 between Evaxion Biotech A/S and DTU Science Park A/S.

F-1

01/08/2021

10.3

333-251982

4.4

Clinical Trial Collaboration and Supply Agreement by and among Evaxion Biotech A/S, MSD International GmbH and MSD International Business GmbH, subsidiaries of Merck & Co., Inc., (known collectively as MSD outside the United States and Canada) (Incorporate by Reference to Exhibit 99.2 to Form 6-K filed with the Commission on October 25, 2021)

6-K

10/25/2021

99.2

001-39950

8.1

List of Subsidiaries of the Registrant

F-1/A

11/03/2021

21.1

333-260493

12.1

Certification by Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

X

12.2

Certification by Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

X

13.1

Certification by Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

X

13.2

Certification by Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

X

15.1

Consent of EY Godkendt Revisionspartnerselskab

X

101.INS

Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

101.SCH

Inline XBRL Taxonomy Extension Schema

101.CAL

Inline XBRL Taxonomy Extension Schema Calculation Linkbase

II-1

101.DEF

Inline XBRL Taxonomy Extension Schema Definition Linkbase

101.LAB

Inline XBRL Taxonomy Extension Schema Label Linkbase

101.PRE

Inline XBRL Taxonomy Extension Schema Presentation Linkbase

104

Cover Page Interactive Date File (formatted as Inline XBRL and contained in Exhibit 101)

II-2

SIGNATURES

Evaxion Biotech A/S hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.

EVAXION BIOTECH A/S

/s/ Lars Staal Wegner

Name:

Lars Staal Wegner

Title:

Chief Executive Officer

Date:

March 31, 2022

/s/ Niels Iversen Møller

Name:

Niels Iversen Møller

Title:

Interim Chief Financial Officer

Date:

March 31, 2022

II-3

EX-12.1 2 evax-20211231xex12d1.htm EXHIBIT 12.1

Exhibit 12.1

CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Lars Staal Wegner, certify that:

1. I have reviewed this annual report on Form 20-F of Evaxion Biotech A/S (the “Company”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;

4. The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a 15(f) and 15d 15(f)) for the Company and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and

5. The Company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

Date: March 31, 2022

By:

/s/ Lars Staal Wegner, M.D.

Name:

Lars Staal Wegner

Title:

Chief Executive Officer


EX-12.2 3 evax-20211231xex12d2.htm EXHIBIT 12.2

Exhibit 12.2

CERTIFICATION BY THE PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Niels Iversen Møller, certify that:

1. I have reviewed this annual report on Form 20-F of Evaxion Biotech A/S (the “Company”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;

4. The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a 15(f) and 15d 15(f)) for the Company and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and

5. The Company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

Date: March 31, 2022

By:

/s/ Niels Iversen Møller

Name:

Niels Iversen Møller

Title:

Interim Chief Financial Officer


EX-13.1 4 evax-20211231xex13d1.htm EXHIBIT 13.1

Exhibit 13.1

CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C.

SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002*

In connection with the Annual Report on Form 20-F of Evaxion Biotech A/S (the “Company”) for the year ended December 31, 2021, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Lars Staal Wegner, as Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 31, 2022

By:

/s/ Lars Staal Wegner

Name:

Lars Staal Wegner

Title:

Chief Executive Officer


EX-13.2 5 evax-20211231xex13d2.htm EXHIBIT 13.2

Exhibit 13.2

CERTIFICATION BY THE PRINCIPAL FINANCIAL OFFICER

PURSUANT

TO 18 U.S.C.

SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002*

In connection with the Annual Report on Form 20-F of Evaxion Biotech A/S (the “Company”) for the year ended December 31, 2021, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Niels Iversen Møller, as Interim Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 31, 2022

By:

/s/ Niels Iversen Møller

Name:

Niels Iversen Møller

Title:

Interim Chief Financial Officer


EX-15.1 6 evax-20211231xex15d1.htm EXHIBIT 15.1

Exhibit 15.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statement (No. 333-255064) on Form S-8 of our report dated March 31, 2022, with respect to the consolidated financial statements of Evaxion Biotech A/S included in this Annual Report (Form 20-F) for the year ended December 31, 2021.

/s/ EY Godkendt Revisionspartnerselskab

Copenhagen, Denmark

March 31, 2022


EX-101.SCH 7 evax-20211231.xsd XBRL TAXONOMY EXTENSION SCHEMA 00100 - Statement - Unaudited Condensed Consolidated Interim Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Unaudited Condensed Consolidated Interim Statements of Financial Position link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Unaudited Condensed Consolidated Interim Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Operating Activities (Details) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - Employees and Employee-Related Costs - Employee Costs (Details) link:presentationLink link:calculationLink link:definitionLink 40703 - Disclosure - Employees and Employee-Related Costs - Board of Directors and Executive Management (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Financial Income and Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 41002 - Disclosure - Income Taxes - Reconciliation of effective tax rate (Details) link:presentationLink link:calculationLink link:definitionLink 41401 - Disclosure - Prepayments and other receivables (Details) link:presentationLink link:calculationLink link:definitionLink 41501 - Disclosure - Other Payables (Details) link:presentationLink link:calculationLink link:definitionLink 41601 - Disclosure - Cash and Cash Equivalents (Details) link:presentationLink link:calculationLink link:definitionLink 41602 - Disclosure - Cash and Cash Equivalents - Changes in Net Working Capital (Details) link:presentationLink link:calculationLink link:definitionLink 41603 - Disclosure - Cash and Cash Equivalents - Adjustments for non-cash items (Details) link:presentationLink link:calculationLink link:definitionLink 42401 - Disclosure - Fees to auditors (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Unaudited Condensed Consolidated Interim Statements of Changes in Equity link:presentationLink link:calculationLink link:definitionLink 32003 - Disclosure - Convertible Debt Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - General Company Information (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Summary of Significant Accounting Policies - Retrospective effect of share split and bonus share issuance (Details) link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - Summary of Significant Accounting Policies - Accounting for joint operation (Details) link:presentationLink link:calculationLink link:definitionLink 40205 - Disclosure - Summary of Significant Accounting Policies - Estimated useful lives of assets (Details) link:presentationLink link:calculationLink link:definitionLink 40210 - Disclosure - Summary of Significant Accounting Policies - Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - Financial Instruments and Risk Management - IPO (Details) link:presentationLink link:calculationLink link:definitionLink 40503 - Disclosure - Financial Instruments and Risk Management - Contractual undiscounted outflows (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Employees and Employee-Related Costs - Number of employees (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Share-Based Payments - Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - Share-Based Payments - Schedule of Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 40803 - Disclosure - Share-Based Payments - Warrants Rectified (Details) link:presentationLink link:calculationLink link:definitionLink 40804 - Disclosure - Share-Based Payments - Compensation expense (Details) link:presentationLink link:calculationLink link:definitionLink 40805 - Disclosure - Share-Based Payments - Fair value of warrants (Details) link:presentationLink link:calculationLink link:definitionLink 40806 - Disclosure - Share-Based Payments - Assumptions of Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 40807 - Disclosure - Share-Based Payments - Amendments to Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 40808 - Disclosure - Share-Based Payments - Outstanding warrants (Details) link:presentationLink link:calculationLink link:definitionLink 40809 - Disclosure - Share-Based Payments - Key Management Holdings (Details) link:presentationLink link:calculationLink link:definitionLink 41003 - Disclosure - Income Taxes - Deferred tax (Details) link:presentationLink link:calculationLink link:definitionLink 41102 - Disclosure - Basic and Diluted Loss Per Share - Anti-dilutive shares (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - Intangible assets - Paragraph (Details) link:presentationLink link:calculationLink link:definitionLink 41202 - Disclosure - Intangible assets - Table (Details) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 41302 - Disclosure - Property, Plant and Equipment - Depreciation (Details) link:presentationLink link:calculationLink link:definitionLink 41604 - Disclosure - Cash and Cash Equivalents - Reconciliation of Liabilities from Financing Activities (Details) link:presentationLink link:calculationLink link:definitionLink 41701 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 41801 - Disclosure - Debt (Details) link:presentationLink link:calculationLink link:definitionLink 41901 - Disclosure - Capital Structure and Financial Matters - Loss of subscribed share capital (Details) link:presentationLink link:calculationLink link:definitionLink 41902 - Disclosure - Capital Structure and Financial Matters - Capital transactions (Details) link:presentationLink link:calculationLink link:definitionLink 41903 - Disclosure - Capital Structure and Financial Matters - Changes in Share Capital (Details) link:presentationLink link:calculationLink link:definitionLink 41904 - Disclosure - Capital Structure and Financial Matters - Share Capital (Details) link:presentationLink link:calculationLink link:definitionLink 41905 - Disclosure - Capital Structure and Financial Matters - Shareholdings by Directors and Executive Management (Details) link:presentationLink link:calculationLink link:definitionLink 42001 - Disclosure - Convertible Debt Instruments - Issuance (Details) link:presentationLink link:calculationLink link:definitionLink 42002 - Disclosure - Convertible Debt Instruments - Summary of changes in the convertible debt instruments (Details) link:presentationLink link:calculationLink link:definitionLink 42003 - Disclosure - Convertible Debt Instruments - Terms of Convertible Debt (Details) link:presentationLink link:calculationLink link:definitionLink 42101 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 42201 - Disclosure - Contractual Obligations - Contractual Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 42501 - Disclosure - Events After the Reporting Period (Details) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - General Company Information link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - First-Time Adoption of IFRS link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Significant Accounting Judgements, Estimates, and Assumptions link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Financial Instruments and Risk Management link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Operating Activities link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Employees and Employee-Related Costs link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Share-Based Payments link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Financial Income and Expenses link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Basic and Diluted Loss Per Share link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Intangible assets link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - Property, Plant and Equipment link:presentationLink link:calculationLink link:definitionLink 11401 - Disclosure - Prepayments and other receivables link:presentationLink link:calculationLink link:definitionLink 11501 - Disclosure - Other Payables link:presentationLink link:calculationLink link:definitionLink 11601 - Disclosure - Cash and Cash Equivalents link:presentationLink link:calculationLink link:definitionLink 11701 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 11801 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 11901 - Disclosure - Capital Structure and Financial Matters link:presentationLink link:calculationLink link:definitionLink 12001 - Disclosure - Convertible Debt Instruments link:presentationLink link:calculationLink link:definitionLink 12101 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 12201 - Disclosure - Contractual Obligations link:presentationLink link:calculationLink link:definitionLink 12301 - Disclosure - Provisions link:presentationLink link:calculationLink link:definitionLink 12401 - Disclosure - Fees to auditors link:presentationLink link:calculationLink link:definitionLink 12501 - Disclosure - Events After the Reporting Period link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Financial Instruments and Risk Management (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Operating Activities (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Employees and Employee-Related Costs (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Share-Based Payments (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Financial Income and Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 31103 - Disclosure - Basic and Diluted Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 31203 - Disclosure - Intangible assets (Tables) link:presentationLink link:calculationLink link:definitionLink 31303 - Disclosure - Property, Plant and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 31403 - Disclosure - Prepayments and other receivables (Tables) link:presentationLink link:calculationLink link:definitionLink 31503 - Disclosure - Other Payables (Tables) link:presentationLink link:calculationLink link:definitionLink 31603 - Disclosure - Cash and Cash Equivalents (Tables) link:presentationLink link:calculationLink link:definitionLink 31703 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 31903 - Disclosure - Capital Structure and Financial Matters (Tables) link:presentationLink link:calculationLink link:definitionLink 32103 - Disclosure - Related Party Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 32203 - Disclosure - Contractual Obligations (Tables) link:presentationLink link:calculationLink link:definitionLink 32303 - Disclosure - Provisions (Tables) link:presentationLink link:calculationLink link:definitionLink 32403 - Disclosure - Fees to auditors (Tables) link:presentationLink link:calculationLink link:definitionLink 40203 - Disclosure - Summary of Significant Accounting Policies - Deferred Offering Costs (Details) link:presentationLink link:calculationLink link:definitionLink 40204 - Disclosure - Summary of Significant Accounting Policies - Leasehold improvements and Loan from lessor (Details) link:presentationLink link:calculationLink link:definitionLink 40206 - Disclosure - Summary of Significant Accounting Policies - Impairment of non-financial assets (Details) link:presentationLink link:calculationLink link:definitionLink 40207 - Disclosure - Summary of Significant Accounting Policies - Cash and cash equivalents (Details) link:presentationLink link:calculationLink link:definitionLink 40208 - Disclosure - Summary of Significant Accounting Policies - Convertible debt instruments (Details) link:presentationLink link:calculationLink link:definitionLink 40209 - Disclosure - Summary of Significant Accounting Policies - Segment (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Financial Instruments and Risk Management - Liquidity risk (Details) link:presentationLink link:calculationLink link:definitionLink 40504 - Disclosure - Financial Instruments and Risk Management - Convertible debt instruments (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Income Taxes - Analysis of charge(credit) (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Basic and Diluted Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 41702 - Disclosure - Leases - Movements in Right-of-use Assets and Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 41703 - Disclosure - Leases - Summary of finance liability (Details) link:presentationLink link:calculationLink link:definitionLink 42301 - Disclosure - Provisions (Details) link:presentationLink link:calculationLink link:definitionLink 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 evax-20211231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 evax-20211231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 evax-20211231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 11 evax-20211231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 12 evax-20211231x20f005.jpg GRAPHIC begin 644 evax-20211231x20f005.jpg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end GRAPHIC 13 evax-20211231x20f006.jpg GRAPHIC begin 644 evax-20211231x20f006.jpg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evax-20211231x20f007.jpg GRAPHIC begin 644 evax-20211231x20f007.jpg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evax-20211231x20f008.jpg GRAPHIC begin 644 evax-20211231x20f008.jpg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end GRAPHIC 16 evax-20211231x20f009.jpg GRAPHIC begin 644 evax-20211231x20f009.jpg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evax-20211231x20f010.jpg GRAPHIC begin 644 evax-20211231x20f010.jpg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
  •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end GRAPHIC 18 evax-20211231x20f011.jpg GRAPHIC begin 644 evax-20211231x20f011.jpg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end GRAPHIC 19 evax-20211231x20f012.jpg GRAPHIC begin 644 evax-20211231x20f012.jpg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end GRAPHIC 20 evax-20211231x20f013.jpg GRAPHIC begin 644 evax-20211231x20f013.jpg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evax-20211231x20f014.jpg GRAPHIC begin 644 evax-20211231x20f014.jpg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�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end GRAPHIC 22 evax-20211231x20f015.jpg GRAPHIC begin 644 evax-20211231x20f015.jpg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evax-20211231x20f016.jpg GRAPHIC begin 644 evax-20211231x20f016.jpg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evax-20211231x20f017.jpg GRAPHIC begin 644 evax-20211231x20f017.jpg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end GRAPHIC 25 evax-20211231x20f018.jpg GRAPHIC begin 644 evax-20211231x20f018.jpg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evax-20211231x20f019.jpg GRAPHIC begin 644 evax-20211231x20f019.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BJVH3S6 MNFW5Q;6YN9XH7>. '!D8 D+^)XKEM$\5>(+K6WL=;T"TTR&*T^USS)J'FF)2 M<*&&P8SAN_\ ": .RHK \->(SXGBDOK:W6+3&_X]GDD_>S#.-Y3'R*<'&3DC MG J'Q-K^KZ/YS6&CQW-O;64EY-<3W!B3"'F,$*?G(R><#B@#I:*\_P!0^)H@ ML+.[M=.&R;1CK+"ZF\K,8('E)P=TG/TZ>M=/I&O?VW=R_9;5Q911@/<.<9F. M"8U'?:.&.>#QU!P ;-%9VJ:]I6B"/^TKZ&V,N?+5V^9L#)( Y( ZGM7,^*?' M\&EW6@V>EW-A(^L.QCNIF+PI&%SN^0Y;)P!@T =O17-Z[XPL_"6D:;<>("$N M;N2.!DMAN42-C<1G'R ]^N*RI/B%!8^-;G3M2N;"#1ETR._@O"S!FW/M .>/ M4\"@#N:*R;WQ/H>GVEM=W6J6L<%TN^W?S ?-7&C\_PGUZ5S MD/Q!@NO'4&E6EQ8SZ1)82W;7:%LKL(!Y^Z5ZG(S0!W-%<_#XZ\*W!40Z_8.6 MB:9<3#E%SDCUQBJ^I>,;5;+1KS2+[2[F#4;U(%DGN=@="<-Y> =S@X&V@#J* M*P+CQOX7M)YH+C7;&*6&802JTH!1SV/I37\1B/QA/I4EQIJVD%A]JE9KG$Z' M<,EDQ@)M(.[- '0T5R>J?$?PSIF@W6K_ &\74%L45H[8;G)?[F <<$9(/3 - M:-QXO\/6EI;W5QJUM%#*-"OK&[OK;5K22ULV*W$HE 6(C^\3THM_%&A76 MGW-_#JMJ;6U_U\C2!1%QD;L],@C&>N: -:BLJU\3:)>V=U=P:I;-!:..?:@#K:*R&\4:$FJ#3&U6U%X9/*\HR#_ %F,[,]-W^SU]JKR M>./"\-PUO)KUBDJ3?9V5I0-LG]T^E &_165=^)M$L-273KK5+6&[8J/*>0 @ MM]W/IGMGKVH'B713J_\ 9(U*W-]O\OR0V3OQNV^F['..N* -6BBB@ KB+7PQ MJFH:#XOAU-EMK_7)ITB=7W^7#L$<0X] ,D>YKMZ* /*O"_@K7-*UG2-1&F6M M@^E:0UG,LBY .6Y!/3BM3Q.GC'6](TZQ;PW!+;SQB35+>/4EB MWD'_ %(?!.PX!8CJ.,]:]!HH Y-M-UG5/#ND65]9V=M=D#[9-$%/V11VA'9B M,*&'W>O4 5D^%=!\3Z3K-C%.\D5A;_:ENO\ 2 T,R%A]G$4>24*CJ<#OG=G- M>A44 <3K6AZM!\1;+Q58V@U&!-.>QDM1,L;(2VX.N[@@]#SGZUS&D>!/$.A# MP2@M4NAI5S=7-WY4ZJL?G9 1-V"=N>.-4UI]'7R+GP^;"-3<1L1,26Q].<9]O2 MNVT?51K%F]R+*\L]LKQ>7>1>6YVG&X#T/8UH4 >,0> ?$EK!X6NS9R2R:?IT MFFW=I!?+%)@DG>C\J00<$<'%>@#0KG3?AT^B:';PP7*6;16\-T_G(K$'Y6)' MS#DCD8_"K=AXGM[_ ,5:GX?6UN(KG3XHY7D?;L=7S@K@D]N^*W* /&H? GBO M4)-2-[ +=[_PZ--\V6\1_+F#$XP@ "'T' !_"M/2= \41>(/#^HW.B10Q:=H MCZ=)&EXC$N ,$=L':,#MGFO4J.M 'D/A_P $>(-.M_ ,=QI46[1)[M[PK/&? M]9G:5YYZ@_A4OS8Q[5[%10!Y- MK'@[7[^#X@I'I2;]=:#[&S3Q\A %.[GCIG_Z]7+KPWKEUXI?4)=#CGM'\,G3 M&AGNE >8G=M;!SM/W43^! M_%%UX$\2:&B$03I;+IEO>W"23H$8,T;2KP4&,)DY'M5SQ!X4U_5/%-KXA.FS M/#=:6VG7MA#J"QR1 L3G?C:RD'D#FO0+C6HH;O2X8[2\N8]1)V7%O%OBB 7< M#(W\((Z>M:= 'G-CX/NK'X@Z1=IHZ'1;'15TY3).DAC?=NR,\D ?+G&?;%9V MB_#[4+'7YK;4[*:\T]=:;5K:[CU 1QJY.07BQN+CIZ'/:O5ZYGQ#XZTKPS=S M6]]#?.8+9;N9X+TC3;73;-;EH=2@NI5:14 2,Y(^;J3TK6T#Q58 M^(I[J&U@O(9;9(I'6YA,9*R E"/4$ UN=\4 >1Z_X"U[79_'44=O';1ZN]I- M9R/,I60P8RK@U*Y33Y;/6[FXM9YDO=1$XNO(SA"RC"C M!P#[#.*]6FD,<,CK&TC(I(1,9;V&2!GZUQME\2M.OM/\/WL>GWRPZW>-9PE@ MG[MU9E^?YO\ 9)XS0!S/B/X?Z[XMD\4WYCCTR34K2V@MK628.7:)PY,A7(&< M;1R?4^E9_C'19-.^&/BG5=1T^>QU*^CM8IC77GA36M9N/$FM0V$<']H:"-*LK47"$R$C M_6,RG: .,@IU 'D$G@#Q"V@7?A<01&&?7/[175?/'$18,25^]YG&.F/ M>LV;3+WQ3?\ Q%\/Z7:P2O?ZE KW;S(%@50I+$9W'&#C Z^E>XU!#96MO(\D M%M#$[_>9(PI;ZD=: /++GX=ZA_PDVLQ75I/J>BZM);RF2/4!!L,8 Q(N,M@@ M$%?2M.U\-:]:_$%M2L;(6-C-?237JMCT4 %% M%% !1110 4444 %%%% !39=GE/YG*;3N^G>G44 ?/Z6DTG@72K=K341-%XIW MD"&8.EJ7)+=,A=NWG^M6]4M-7LK#Q]IF@6VHQV@O;:2&&!) 6AP!/Y1/7GK@ M],U[K10!X?.4T+1KR*UO-#@-B!:21"1T!/RY ^;..#R2.]2VK:C=^ M(K6XT6SU*&=_"#VT4TMO)&OVM3&TNQ#BR.G MRVL5NZKM.T2$DD\;L<9KO:* /)])T87OQ"\:RK#=I/%)%/I1?S4A\X1,K..B MMAV[Y')K&\%Z=J$-DM],-2_MBQL+N.^TT64T4EZ[9(WSL2K-G&TKSZ5[C10! MX1X>36O[59]'L;NQDNO"TL<2K:S1H+P,=HD=_O2#G]X<9-3#0K#5/A5J7V?2 M=4_X2&+2%AO(9[>52\RMN+?,,.Y.X@C)Q7N-% 'D,D=F-3^',FFV%W#;1M(M MT!:2H%#1[?G!' +D\G^56M!\+7EGXGO/#TEFYTK3[YM7L[J0$J^]-L<6>^QM MQ/LJUZI10!XO\.](U-]9TV;5;N]M-&##)X;TV:.,JYM( MHW+1E'RJXP00#P<]:\[T"RDF\1:Q%KMKJ \2QZK-I-::_)-<(;63,2>9(=S?+P,.O/O]:]ZHH \D\,6TUK\ M2V*6EW?03W%Y*UU+ M+&U)2W!N9!_=X4?C_A51BY;(3DEN;]-9U1=SL%'J3BN!N_%&IW.0DBP)Z1#G M\S63+-+.VZ:5Y#ZNQ-;QPSZLR=9=#TF76-.A.'O8 ?9P?Y5$NOZ4Q8+>(=JL MYP#T R3T]!7G%6+/[\__ %[3_P#HMJOZO%+RS*3^6:^>U^Z/I00#V%;/!1Z,Q6+EU1])]:*^>[+6=4TX@ MV>H7,('\*R';^1XKJ],^)^IVQ5-1MXKN/NZ?(_\ @?TK">#FOAU-8XJ+WT/6 M:*PM%\7Z/KF$MKD1W!_Y83?*_P"'K^%;M\2BW+VEBP,PX>7J$]A[_ ,JXUF9V+,Q9F.22Q[_0_G7'45,X1FK2149RB[H^A=,U6RUBS6ZL9UEB M/7'53Z$=C5VOGS2-9OM#O1=6,Q1^C*>5<>C#O7L_AKQ/9^)++S(?W=S&!YT! M/*GU'J/>O,KX=T]5L>A1KJ>CW-RBBBN8W"BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH *YGQ+KQM@UC:/B8C]XX_@'H/>M+7=5&E6)9<&>3Y8E/K MZ_05YVS,[L[L69CDD]2:Z*%*_O,RJ3MHA****[#G"BGQ*C28DP[,HU8L_OS_ /7M/_Z+:J]6+/[\ M_P#U[3_^BVH>PD>>K]T?2EI%^Z/I2UUG&%%%% !1110 5:T[4;K2K^*]LY3' M-&>#V([@CN#56BAJ^C&G;4]Z\-^(+?Q%I:W4.$E7Y9HL\HW^'H:V*\#\.:]/ MX>U>.\CRT1^6>,?QI_B.HKW>VN8;RUBN;=P\,JAT8=P:\G$4?9RTV9Z-"KSK M79I";LKG):SJ)U/4I)@3Y2_+$/11W_'K6?117I) M)*R.-N[N%%%% $MO.;:=)E1&9>0'&1FIQJ,B2O+'%"DC @,J\J",''/IZU3H MH:3"[+T.J3VZXB2% #N7"?=.W;G\1ZTRWU*XMDV1[ N -O0C//UY-5**7*A MW8=*L6?WY_\ KVG_ /1;57JQ9_?G_P"O:?\ ]%M0]A(\]7[H^E+2+]T?2EKK M.,**** "BBB@ HHHH *])^&.O']YH<[] 9;;/_CR_P!?SKS:K%A>RZ;J%O?0 M']Y!(''OCJ/Q&16=6G[2#B:4Y\DDSZ*HJ&SNH[VS@NH3F.9 ZGV(S4U>*>J% M%%% !1110 4444 %%%% !1110 4444 %<%XKNOM&L&('*P*%_$\G^E=Z3@9/ M2O++N8W-[/.>LDC-^M=&&C>39E6>EB&BBBNPYPHHHH **** "BBB@ JQ9_?G M_P"O:?\ ]%M5>K%G]^?_ *]I_P#T6U)[ CSU?NCZ4M(OW1]*6NLXPHHHH ** M** "BBB@ HHHH ]?^&FH_:_#;6C-E[.4H/\ =/(_J/PKLZ\F^%UX8=?NK0GY M9X-P'NI_P)KUFO(Q,>6HSTZ$N:F@HHHK V"BBB@ HHHH **** "BBB@ HHHH M @O"PL;@H"S^6VT#J3BO-3IU\B_-9W _[9&NY\6$KX3U4@X/V9_Y5X9'>W<7 M^KN[A,?W96']:[L+!N+:.7$346DSM&BD3[\;K]5(IF0.]7KJ4C_P#71$;^8KI]G(P]K$Z#(HK#'B[5?XQ9R?[]HG] *D7Q M=<_\M--TU_I$R_R:ER2[#]I$V**RU\61'_6:);_]LYY%_F34B^*--;[^DW"_ M]<[L'^:T/1?Y U8AO-,A2>0:Q9/_ M */*H4,P8DH0 0.YJ7>VQ2:[G +]T?2EI%^Z/I2UUG&%%%% !1110 4444 M%%%% '0^!I_(\9Z>?[[-&?Q4U[C7@GA0D>+=*Q_S\K7O=>;C5[Z]#OPGPL** M**XSJ"BBB@ HHHH **** "BBB@ HHHH RO$T1F\+ZH@[VLG_ *":\"'(KZ,N MH10_EM'\Z]GKS,:_?2\CT,*O<;"BBBN0Z0HHHH **** M "BBB@ HHHH **** "O!_%MB=.\5:A!C"M*94_W6^;^IKWBO-/BGI9#V>K(O M!_<2D?FI_F*ZL)/EJ6[G/B8WA?L><4445ZAYP4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !110>E 'I7PJL2%U#4&'4K A^G)_F*](K$\):4='\ M,V=JRXE*^9+_ +S?/4;/5I1Y8)!11161H%%%% !1110 4444 M %%%% !1110 5G:[I4>M:+=6$F!YJ?*Q_A8O M3TJ.=]BN3S.:(()!!!'!!'2DKH=8N;&^TT3QWG[]=H\D+CS"/DR<\_= ()/? M'7-<]51=T*2LPHHHJB0KHO!.B'6O$<(=56=@JJ69 MC@*!DD^E>X^#O#X\/Z(D4@'VN;]Y.1_>[+^ X_.N?$U>2&F[-J%/GEY(Z"BB MBO)/3"BBB@ HHHH **** "BBB@ HHHH **** "BBB@"*YMH;RVEMKB,20RJ5 M=6Z$&O#?%'AR?PYJA@;<]K)EK>4_Q+Z'W'_UZ]WJAK.CVFN:=)97B91N58?> M1NS#WK>A6=.7D8UJ7M%YGSY16KK^@7GAZ_-M=+N1LF*8#Y9!_0^HK*KUDU)7 M1YK33LPHHHIB"BBB@ HHHH **** "BBB@ HHHH ***[;P5X)?5G34M2C*V"G M,<9X,Y_^)_G43G&"YI%0@YNR-#X>>%"SIKE]'A1S:QL.O^V?Z?GZ5Z92*H50 MJ@!0, #H*6O(JU'4ES,]2G34(V04445F6%%%% !1110 4444 %%%% !1110 M4444 %%%% !1110!3U/2[/6+%[.^A66)O7JI]0>QKR#Q-X)O] 9YX@UU8=1* MH^9!Z./Z]/I7M=(0""" 0>H-;4J\J;TV,JE&-3?<^;J*]=U_XIP3HSAN9 M-%&<]**V,@HHHH **** "BBA068*H+,>B@9)_"@ IT:/+(L<:,\CG"HHR2?0 M"NIT7X?ZQJI62X3[#;'^.8?.1[+U_/%>F:#X4TOP^F;6'?<$8:XDY<_X#V%< M]7$PAHM6;T\/*>^B.2\*_#O:R7VN("1\R6F<@>[_ .'YUZ. % ' [4M% M>;4JRJ.\COA3C!604445F6%%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !2$ @@@$'J#2T4 <]J7@G0-3)>2Q6&4]9+<^6?TX_2N8O M/A2IR;'5&'HL\>?U&/Y5Z116L:]2.S,Y482W1X_/\,]>B/[I[28?[,A7^8JH MWP^\2K_RXQM])T_QKVNBMEC*GD9/"P/%D^'?B5NMI"G^].O],U?M_A=J\F#/ M=VD([X+.?Y"O6J*3QE1C6%@<%9?"W38B&O;VXN#_ '4 C7^I_6NLTW0-*T@? MZ#8PPM_?"Y8_\"/-:-%8SJSG\3-8TX1V04445F6%%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% &(GBBQD\3MH 2;[6HR6VC9]W=USZ M>U._X2&&$W'VF)U\J:5!Y:E_E0 ECZ<&M$6-H+LW8M8!)B=S,3YC#)+!CW_ +P!Q[5(Q@URT+NA$RL&V*"F-[;]F%]?FXII\0Z> MNS+OAADG8<)][KZ?<;\JF.CV3')C;.20=[<$OOR.>N[FJC^'HC>"1)62':$, M0R05YW*>>=VXY)YH D_X2.QV!QYS#YB=L9.T#;DGVPZFI8=7BEG:$*[2B1DV MQJ3M"MMR?;-.;1[-XEC=9'58VC&Z5B=K8R,Y_P!D?E3DTJTBN!.B,LNYF+!V M&=QR0>>1GG% %VJNH7\6FVC7,P8HI (49/)JU3)8HYD*2QI(AZJPR*:M?4&9 MEUK7E:;:W\%NTL4SCM=.M MK(CR$*X01C+$_*"2.ONQ_.H4T6QCV[8F&TJ1\[=58N._]YB:0$7_ D%F3$% M2X8R*C+MB/\ 'NVCZ_*13TURR=5*F0[MN/D/\49D'_CH/XT]-&L8RA6-@8]F MW]XW&S=M[]MS?G35T.P4H1$P**%7]XW92H[\G:Q&: (U\063P^8!-[(8SN(V M!\X]-I!I6\0Z>KL-[E0,A]ORGE1@'ZNH_&GG0[ H%\IL #]XV0 NS&<]-HP M?6J\?A^,7,SO.[0RDDQ*2!U!7OQMP,8Q0!-%KUG-+'&@E/F;<-Y9P"VX $_5 M"*?8ZK%?"(1J[,R*SE5.U"5W $GV_F*>=+M3*)2KF0;#N,C$G9G;W_VC^=+: MZ9:V3AK=&3"!,!S@@# R,\G'&: +E%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 6444 %%%% !1110 4444 %%%% '__V0$! end GRAPHIC 27 evax-20211231x20f020.jpg GRAPHIC begin 644 evax-20211231x20f020.jpg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end GRAPHIC 28 evax-20211231x20f021.jpg GRAPHIC begin 644 evax-20211231x20f021.jpg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end GRAPHIC 29 evax-20211231x20f022.jpg GRAPHIC begin 644 evax-20211231x20f022.jpg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end GRAPHIC 30 evax-20211231x20f023.jpg GRAPHIC begin 644 evax-20211231x20f023.jpg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end GRAPHIC 31 evax-20211231x20f024.jpg GRAPHIC begin 644 evax-20211231x20f024.jpg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end GRAPHIC 32 evax-20211231x20f025.jpg GRAPHIC begin 644 evax-20211231x20f025.jpg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end GRAPHIC 33 evax-20211231x20f026.jpg GRAPHIC begin 644 evax-20211231x20f026.jpg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evax-20211231x20f027.jpg GRAPHIC begin 644 evax-20211231x20f027.jpg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end GRAPHIC 35 evax-20211231x20f028.jpg GRAPHIC begin 644 evax-20211231x20f028.jpg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end GRAPHIC 36 evax-20211231x20f029.jpg GRAPHIC begin 644 evax-20211231x20f029.jpg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end GRAPHIC 37 evax-20211231x20f030.jpg GRAPHIC begin 644 evax-20211231x20f030.jpg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�!HZO_ ,AG0?\ KZD_]$R5L5CZAX>AU&^C MNY+[4(GB.Z-8;@JJ':5) ^A/YTW_ (1P?]!C5_\ P+/^% 'B?B7_ )&C5?\ MKZD_G677LT_PO\/W5Q)//)J+RR,6=S=MEB>IJ/\ X51X:]=0_P# MJ]&.,@D ME9GERP,VV[H\=HKV+_A5'AKUU#_P+:C_ (51X:]=0_\ MJKZ[#LQ?4*G='& M)]Q?H*6N[/PYT55R;G4@ /\ G[;BH;GX=Z4UM*EM>WZW+1MY1:[) ;'!/MFO MC7E-5OXE^)]BLTI)?"SBJ;)_JG_W37=0_#K2?*19;K4&F"CS-MVV,XYI_P#P MKG16'_'QJ1!_Z>VH64U;_$OQ"6:4VFN5GCU%>M?\*K\.?WM0_P# MJ/^%6>' M/[VH?^!;5Z7U:7<^-_L^IW1Y+6IX9_Y&C2_^OE/YUZ-_PJSPY_>U#_P+:I(/ MAGH5K<1SP2ZC'+&P9'%VV01WIK#R3O&5[Q>^#[74;1[6[U+59 MH'QN1KLX.#GTK)_X51X:];__ ,"VKLP^(C2CRM'%B<+*K/F3/':*]B_X51X: M]=0_\"VH_P"%4>&O74/_ +:M_KL.S.?ZA4[H\MT;_C^_P" &N@KM8OA=X>@ M??$^H*V,9%VU3'X=Z*" ;K4LGH/M;$EBZ_M8.RLEJ?0Y7B8X2A[*:N M[MZ'"45V4GPZTU[NW>"]O?LJA_/'VMB2<#;@^QS5C_A7NA_+_I>H_-]W_3#S M7G_V35_F7XGH_P!JTOY7^!YKJW^IC_WOZ5DUZ_+\,]"F $DVHL!R,W;5%_PJ MSPY_>U#_ ,"VKMH8*=.'*VCYO,J3Q>(=6&B=M_0\EHKUK_A5GAS^]J'_ (%M M1_PJSPY_>U#_ ,"VK7ZM+N<']GU.Z*'PH_X]M5_ZZ1_R-=;XK_Y%'5_^O.7_ M -!-4-.\"Z=I*R+87VJ6XD(+A+L\XZ=:LS^%8;JWD@GU35I(9%*NC71PP/4' MBNJG'EBDST:%-TZ:BS=7[H^E+1T%%6:C9)$AB>65U2- 69F. H'4DU7@U.QN M;%KV&\@DM4!+3*X*KCKD]L5#KMA)JFAWEC$X22:,JI;IGT/L>AK!;0]4N-/U MB)X;>%]3E,^P2Y$158U53QSNV')[9[T =/:7MKJ%N+BSN(YX22 \;!AD=16; MX7_Y G_;U=?^CY*BTG2+E;;53>.UK+J%T9]MM+S"-JJ &QU.W)X[TEOX4@M8 MO*@U75D3K$L3T[DDT >=_%/_D:H?\ KU7_ -":N(KVW4/AWH^JW N+ M^YU*>4+M#O=MG'IQ]:J?\*H\->NH?^!;5WT\7&$%%H\VK@YSFY)K4\=K6T+_ M %L_^Z/YUZ9_PJCPUZZA_P"!;5)%\,/#]ON:.74$R.2+MJY\?56)P\J,=&_\ MTSHP%"6&Q$:TM4O\CB:*[L_#O1%!)NM1 '7-VW%5K'X=:RT^T,_FR1+*F/(1 M?ND_W@1FJ4VAZY!K+-90SB&]U.>=G+_+;LJ.LC44 <".-^X^8#\QSCMUYKL*** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@#!\2VLL[Z;*;:2[LH;@ME>@T4 >:QZ9KUOJVJS MVMG.+B=;J.-F0*J-)(NQ_,SF08RV"/E P*ZKPE8W>DZ=-I5S"4BM92+9@Y=3 M$PR &/)()(.17044 %%%% !1110 4444 %%%% !1110 5R$EDR:OJOVO2;BZ MN;B4-:7:*&5$\L!1G/R;2&SZYSSFNOHH \QET;4)M*C6PTFZM533H8+M"H4R MRB2,[@F?G*A7)SC=G&>:J7FA:T]M#ML;DD6UPL86W7YF,X9!C=^XR/3[H_*O M6:* &IN,:EAAL#(SG!^M.HHH **** "BBB@ HHHH **** "BBB@ HHHH *Q_ M%5E)J/A?4+.*)Y7GB*;$."P)Y /TS6Q10!YU!I>JPZLQU33KB\L+6Y6/"$/] MH18MLU''EHI*\_WE;^==)110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% % M.[NHK6.:>YN1;P1 %G. !GU)K-_X2C0O^@];_P#?:_X5+K^ER:UH^H:=%(L; MSJJAV&0.0?Z5P'_"I=0_Z"EK_P!^VK>E"E)>_*QSUIU8NT(W1W:>)=$ED6-- M=@9W(55#KDD]!TK1O9X]/LIKRYNG2"%"[MM!P!UX KSFS^%=_;7UO<-J5LPB ME60@1MS@@UZ%KFGOJVA7VGI((VN86C#G.!D=>*FK&G&W([E495)7]HK%>WUJ MPN;>25+]P8F*O%(FR0,!DKL8 YP1^=7%GA9BOVX!U02,A90RJ>Y'85B7'@VT M-U++;)$N^RG@#2[I'\R3;\Y9B2>%QUS5!_!%Q(]TC3VIBE67$IC/FL9$"E&/ M=!C@>P]*R-CI9M0LK86QFU.-%N9/+A8LN)&P3@'\#5B-TE,@CO0YC.UPI4[3 MZ'TJAJNB_:ETS[)%:K]AN1,L4D?R%=K*0,=#\V1[BJ/AWPS-H]_)<32VY46X MMT$"%3* Q;?)GJ_./S]: +UKKFF7KP+;:JD@G0O$ZE=K#., XZY/3K5TSPJT MBM?J#%CS 67Y,],^E M;Y(91/+O$LCNS.IF64JR_=_AQ^72@#K4N;>0L$U%&*KO8*Z'"^I]O>E2:&5= MT=^KJ03E64C Z_E7'ZKX/OY;W4[Z.6"17MKB.&)%(8J\6U8\<+@$=>_M27?A M>^$4,2101S7=V!/]CCVPQ6QC"2CDY!8*/^!8],T =LJ,RAEN&((R",<_I2^4 M_P#SW?\ (?X5(B+&BHBA548 X I: (O*?\ Y[O^0_PH\I_^>[_D/\*EHH B M\I_^>[_D/\*/*?\ Y[O^0_PJ6B@"+RG_ .>[_D/\*/*?_GN_Y#_"I:* (O*? M_GN_Y#_"CRG_ .>[_D/\*EHH B\I_P#GN_Y#_"CRG_Y[O^0_PJ6B@"+RG_Y[ MO^0_PH\I_P#GN_Y#_"I:* (X68A@QR58C/K4E10=9?\ ?-2T %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110!F:M?2:=I][=Q*K/&%(#=#VKD MO^$\U#_GUMO_ ![_ !KMY88;@7$5PBO$V RMT-4_["T7_GRMOR%<6)I8BXFMV03)$B-@(3E2?,P>>,9QS6UK/B62R MTN&2TM&DNKBRENT1F"B-40,2<]3EE&._M5J32?#[6%O;R6]D;5'+PAB,;NY! M[Y[^O>K>I:7INJ6ZIJ%K#/%'EAY@X48P?PQUKJ.8PH_&2JJQM;-<2"V,A:$_ M>D6-79,8P#@GC)Z=JL?\)?;R/ \$!>RFF,2WC/MB."HZX/)+$#.,[3S5\:#I MJ3-=V=M#!=LFU+E$!*_+MR,\=,?7%,M_#6DP65C:FTCD2R&(=XZ'.:T:NR,28_,;:A(QC!/J1[9KG]-\8:E#8W%[JUK&T"P M^?F%\LNZ5HT0#'/*CGZ_2NLNM&TV]O8KRYLXI;B+;LD9>1M.1^1Y'I4*Z/HM MQC9:VT@B1X,+@@*3EE(^I/!H IV/B2:^U&WL1I4\4CI(\C2ML"*C!7D$=G)=-$\G 94"JD:.>>_WN/?VK8L])L+ H;6V2-D4HK#D M@$@D9/N!1_9^GS33/Y$+R,664]3\R@$'ZJ%_(4 8)\3W#W#"VA$EL4FD:1R% M:,)'&XVC^+_6=ZBO?&WV6W=(;<33_8WEB=F(4R+$)"K8&!P>Q/X5N/I&CR*" MUK;D0,6STV':%.?^ @ ^P% \/Z*9_M8L+8R,FWS-N" M\DM7LFENV*[8%D4*N(O,;YSUX]1U/IS4^G>+(]2NXEALI5M)I5ACN&<T.:!K0V-NZ*5+(>2"!A<]^G'TJXFFV4;ATMHU82>:"%QA] MNS/UV\?2@#"U3Q:UF;Y8+(N(&D@29G 5IUA,NTKUVX'7U_.AM5U2/3]!M?,A M&H:EP]Q(F4CPAM_$2Z;&(;HPQ0/*([8A7#NX9BV[ MY,*H..%=[D 811A5&.PR?SH T**** (H.LO^^:EJ*#K+_OFI: "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH P?%%G7?\(7XG_Y\)O\ OZO^->U,K+(65@-W4$9I-TO]Y?\ OG_Z]93I*;NS MFK8:-67,V>/6'@_Q)%J5K))8S!$F1F)E' ##/>O4_$=K/>^'-1M;6(2SRP,B M(7V[B1ZU>W2_WE_[Y_\ KT9E_O+_ -\__7ITZ:AL71H1I7Y7N<3;>'KR;P_/ MI\ED,7>H F66-%=8"%WML'RH2%*@#U![UI^,;34[NU$%BER]L]K/&T=JX1C* M5 CW9_@^]GZC-='NE_O+_P!\_P#UZ,R_WE_[Y_\ KUH;'$K;^(UO'5I);"T6 MU>(R&0&./;&NR3);KN!R /7)-2VDGB"]M]*U1TN3)<2&9[)'VQHC%<9<'LH) MP00'-8TG3V_L];V._DLE1&:?A[I?[R_]\_\ UZ,R_P!Y?^^?_KT WTEI%#(P$G[O+E MQM5QN).%SU/UJ/4+#79[Z_\ )ENH8=T[PF&0+N;RH_+S[;@_7\>*ZK=+_>7_ M +Y_^O1F7^\O_?/_ ->@#C)],UB6Z^US179GVW"Q>5( H9HHMNY0<$;E?KGM M534=.\47[SV@CN%MYK&2"1!( I;R1L8'=P2^1P!CN>:[[,O]Y?\ OG_Z]&9? M[R_]\_\ UZ .+FM-=5F^SIJ0L2RX5)0)SB$!=Y#?2NDS+_ 'E_[Y_^O1F7^\O_ 'S_ /7H X[6 M;#Q!>7.IP(;IHYEF1=LH$)@,)"J!G(D\SOZ=\5-K6C7 TKP[!;0S%+.4&79& MDS(/)=?NMP>2!75[I?[R_P#?/_UZ,R_WE_[Y_P#KT 5 M>7)8*I26)7_ +Y_^O0!PEIH%[#:7R76FM)_H$T$X^5_ MM> K"U:"[CN(4MO,B1]DO[MEW $'KA3CGFND MW2_WE_[Y_P#KT;I?[R_]\_\ UZ .(&D^(K.&_DTIKB.:YFNF199 5 .#&V#T M8X//J>:O6-CK@6%I+F^F2))Y%CD;RBS_ ";$8[F)&=W)/>NIS+_>7_OG_P"O M1F7^\O\ WS_]>@#SQ'\10RVMO?MJ?DSW;%$@<+*R_9V8KDL3@2#N?TXK9TA] M=.O6UA>W/F+';1W=VRL#LE*;#%QV+ O^%=5F0D' GRAPHIC 38 evax-20211231x20f031.jpg GRAPHIC begin 644 evax-20211231x20f031.jpg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n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end GRAPHIC 39 evax-20211231x20f032.jpg GRAPHIC begin 644 evax-20211231x20f032.jpg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evax-20211231x20f033.jpg GRAPHIC begin 644 evax-20211231x20f033.jpg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

    +]<32[=Y8XA)Y(:> M-X7\V)AQLY(#NW7MWQGBK@\2:]#8P3"U3RBT,+>9$[.FZ(.TK'/(4Y!'ZT#/^1-TK_KW6M/4_ M^05>?]<'_P#0369X,_Y$W2O^O=:R?\1>G^1UK_=)?XE^3-S(]11D'H17!S^& M-5_M"9E0&T:X-LH\T#_0Y&\R1OJ&. /04EGH.M?:;9H[.&VL[;4FGCMY),$* MSD[AM)!^4X /3FKYGV.0ZV?0],N;N6ZFM$>:9/+D))PXV[<$9P>#BE32=+A0 M;;6!%3R\$#&W9PF/3':N:UW1=<;6;F[TM T:!;N &4*&N=OEE2/39SGUK,E\ M,ZA#+-;VNG2&T0QL&4Q,)W6(IO*L2/O$$Y&<>]*_D!V=UX;T:\>=[BQB=IR& MDY(W$QA>7;CI[U%J/AC3;ZYM[B11$(65F" M #?MQM!.,X&T5#H>D3)X9NM.O(C"L[S!5X!".3C(7Y5//1>!7-KH?B ".XOM M.BO2Z_:)K9YE*M.@\J->>""N'/N/6A^@'HH92< @G&>O:EKAO#/A^]TW5('> MSDC"22R/SZ:F8T83VI\T#=)*HBD!' MHJY<>YIW=@.XW+_>'7'7O7*^*_\ D/>%_P#K^/\ Z#6"WAZ<2/ GAR6*(E;= M9(S&3'&A/[U?FYE;^]QM&.N*WO%7&N^%O^OX]?\ =K;#N\_O_(SJ_#]WYG5, MH="K#((P16/!X7TR 6@VSR"S??;>;.[^4=NW"Y/3';V![5LT5G8T,E?#NCQQ MR1"U3;)#Y#@L?F7)Z_[7)YZ\U!#X>T>WN?.$LIDC1UDWW3'<'^\7!/).!R?0 M>E4/$>A7]]JPN+)%,1A$C$R;2+B$EH?P)8@GM@5BR>&M2>\TJX?2DF-KF2^C M+Q;;EF!) /5B&;H_'R\/S M-$G@S1IH6AEBGDB; ='N'(91PJGGH.P[5I:-;366C6=M<-F6.)5;G.#Z9]NG MX5>JK(#%7PWI=M(;EO-^5EET2ZOFN&=AMJ>%+FWE@E7='(A1AZ@C!K@X_!^IQFU:\U.WA4_\?$@ M)RSI^[AQG'6,D'OGI2>G0$KFU;^'_#%S.$@DBG=86C2-;HMLC88; ![]S4UU MX4MKC68=0CE:$"9+B9$S^^=/NY.<8&!VK.\-^'=2TR]MEOH+/[/9I(MN]LVW M&\Y)9<>F !G %=C0E?H 44450!7,>$_^0CXC_P"PD_\ Z"*Z>N8\)_\ (1\1 M_P#82?\ ]!%:P^"7R_,SE\43IZ***R-#-GT'3;F[GN9KZDFDEL_FF. M7VR.N3D'C!&,D G'7 S2W'AK2+J=II[3?(V"6,C?> #=>& &[K[UK4460& M./"VC*FQ^$]$A51#9>6%8L-DCC!/7H>^!GU[UK MF6,2B(R()&&0A/)'KBGT606,RZ\/:5>PPPW%HKQ0KL1-S ;<@X.#R,@'!]*K MOX1T.2,QO9;XVQN1I7(;'0$9Y [#MVK;HHL@,74O#-A?VHCCC6"569DE )9" MQRQ'/!-:5A91:=I]O909\JWC6-,GG &*L446 ****8'*^-?O:%_V$XOZUU5< MKXU^]H7_ &$XOZUU5:S_ (%88(TCB085$7 ]A4E%% !1110!R_@;_D%ZA_V$KC_T*NHKE_ W M_(+U#_L)7'_H5=16M?\ B,SH_ @HHHK(T"BBB@ HHHH *Y;X@_\ (K_]O,/_ M *$*ZFN6^(/_ "*__;S#_P"A"M:'\2/J9UOX;.H'04M(.@I:R- HHHH **** M *NI_P#(*O/^N#_^@FLSP9_R)NE?]>ZUIZG_ ,@J\_ZX/_Z":S/!G_(FZ5_U M[K63_B+T_P CK7^Z2_Q+\F)XU./!NJX./W!Z?45K:?\ \@VU_P"N*?R%9/C7 M_D3-5_ZX'^8K5T__ )!MK_UQ3^0H7\5^G^82_P!TC_B?Y1)IO]3)_NG^5<_X M%)/@ZQR2?O\ 7_?:N@F_U,G^Z?Y5S_@3_D3K'_@?_H;4/^*O1_H$/]UG_BC^ M4CHZYC0\_P#"9^)>3]Z#_P! KIZYC0_^1S\2_P"]!_Z!14^*/K^C##_PZO\ MA_\ ;HG3US'C,D+HN"?^0G#_ %KIZYCQG]W1?^PI#_6BM\## _[Q'^NAT]5[ M\D:?.P#HMKG_G_M__ $.NGKF/'7_(%M?^ MO^W_ /0ZRK?PV=> _P!YAZG3T445J<@4444 %OZ([,5\-+_#^K"BBBM3C"BB MB@ HHHH Y7QK][0O^PG%_6NJKE?&OWM"_P"PG%_6NJK6?\./S,X_'+Y!1116 M1H%%%% !1110 5R^N_\ (Y^&?]Z?_P! KJ*Y?7?^1S\,_P"]/_Z!65;X?FOS M1UX+^*_\,O\ TEG44445J<@4444 %%%% !1110!R_@;_ )!>H?\ 82N/_0JZ MBN7\#?\ (+U#_L)7'_H5=16M?^(S.C\""BBBLC0**** "BBB@ KD?B)<0Q^' M5A>5%E>>-E0GE@&&2/I775A^*?#L?B334MF<1R1R!TDQG _B'XC/Z5K1:C43 MEL9U4W!I&O;SQ7-NDT$BR1.,JZ'((]C4M5[<6UI;QV\3QI'$H15W#@ 8J3SX M?^>J?]]"LVM="T^Y)14?GP_\]4_[Z%'GP_\ /5/^^A19A=$E%1^?#_SU3_OH M4>?#_P ]4_[Z%%F%T5-:N(;;1KMYY4B0Q,H9S@9(.!6;X'N(9O".G)%*CO%" MJR*IR4/H?0UI:G;6>JZ;<6-Q)&8YD*GYAQZ'\#S57P[I=KH&BPV"31,Z_-)( M"!O<]363C/VB?2QUJI2^JN#?O:)';#12$@[&'0U8BG)7+L1GTK>O([2^LYK2X>-XID*,"PZ&LSPS MH]IX=TA;-)XWD+%Y),@;R?\ ZV!0XS]HG;2S"%2DL+*#?O-I_--?$5U"YF,/E;7!WX3G'KBNL\^'_ )ZI_P!]"N?TGPYI^E>(-0U2 M*2+-SCRT!'[O/+8^IHJ1DY1LNH8>I2C3JJ;U:T^]/]#I*Y'QO>6T+:/')<1H MZZA%*RLP!"#.6^GO75>?#_SU3_OH5@^)/#UAXC-D9IHU:WE#,M5M3ECBTRY:1U13$PRQP M,X-3++ BA5DC"@8 ## %5-5M;/5M+N+&>2,QS(5SN'!['\#S5R4N736-_!VFHCJS)%A@#DJI]!6A MX6TBW\/:+'9^=$\Q)>:12/F8_P!.U4O$GABTU[5M-O#-$H@?%P"1^\C'('Y\ M?0FKP?N\O/II^@9A*,ZLW2=TW?\ $ZH$, 000>012U&)H0 !)& .VX4>?#_S MU3_OH4K,SNA994AB:65PD:#+,QP /6N5\#WEM-'JL4=Q&\AOYI0JL"2A(PWT M]ZZAY()$9'DC96&""PP16%X:\/V/AQ;SRIHV:XF+!LC*I_"OX5E*,W.+6VIU MTJE)8>I&3]YVL=%14?GP_P#/5/\ OH4>?#_SU3_OH5K9G)=$E:=4E:[BE"GNJM\Q_"NL\^'_GJG_?0K(\0Z+8>(K2&"YF1?*E60,",X!Y'X MCBLJT92@U'M2U$DEO&BHCQJJ MC 88 I?/A_YZI_WT*T2?4YFXWT)**C\^'_GJG_?0H\^'_GJG_?0IV8KH>S* MBEF("@9))X%J?]]"CSX?^>J?]]"BS"Z)**C\^'_GJG_?0 MH\^'_GJG_?0HLPNCC=2U:PC^)6G![E 8K:2!QSP[$;5^IKMJP;C0M/N/%%MK MC2Q^;#&4*Y&&/\+?4 FMKSX?^>J?]]"LJ<))ROW.O%5:4XTU3Z1L_6[)**C\ M^'_GJG_?0H\^'_GJG_?0K6S.2Z)**C\^'_GJG_?0H\^'_GJG_?0HLPNB2BH_ M/A_YZI_WT*//A_YZI_WT*+,+HYCQJ1OT+D?\A.+^M=6#D9%(9M/E MBGC1XI LS;P,Q'K^(_K741O;PQ)'&\:H@"J PX K6=O9Q2WU,XM\\KDU%1^? M#_SU3_OH4>?#_P ]4_[Z%969I=$E%1^?#_SU3_OH4>?#_P ]4_[Z%%F%T245 M'Y\/_/5/^^A1Y\/_ #U3_OH46871)7">*-0O8/'6A116 E*%C"=^!)O&UL\< M;>M=OY\/_/5/^^A44BV?#_ M ,]4_P"^A19A=$E%1^?#_P ]4_[Z%'GP_P#/5/\ OH46871)37=(T+NRJ@Y+ M,< 4WSX?^>J?]]"F3FUN8)()FC>.12K*6&"#UHL%T&H?#T-V!*DLTTIPRG.(P?E'Y=?K735I7:=1N.Q%)-029 MR.E>-X[V-9KF&&,3?ZJT@E,UVK<_+)$%RI !)[#%75\::0\>]/M;Y=D4"UDR MS+G< ,$'FUFWUB35YSJ-JC1P3"&,85L;@P"_-G Z].U22^$+:6T MM(S<,\]M++*LLL2."9"2X*D8ZG\,5AJ:#3X]\._NF%Z[1S.(X9$A=EF;\^4*;>#\A_SBJEMX T^UDM_*EQ%! M\;74UIX7N7@D,;L50LIP<$\UT-!JI7.5P/2C ]*ZNW\,V6(5N[B:.600*RJR? M(\A8'/L-HI;/PQ87V,]:'B((2P55V\SD\#T MHP/2NGN-%L_[#2<%DEA@E9IE(V.RRE0&'7)'3%8NE6T%YJ4,%S.(8W< D@G/ M/3CI]:N-5--]C*="49*+ZE+ ]*,#TK5TVTM9/$MK:/(MQ:M.%9L%0P].>:V# MH]E=:C<:=Y"6LK(DL,A'E\!OG&"Q_AYZ]J4JT8NS]2J>&E-77>QR6!Z48'I7 M616>E7=I>7,5K$DBO*+"$R$>>H'4CVZCIGI5/1]-M)9KI=T&H3)$C11@E5;+ M -UP<@4O;*S=MA_597236O\ 7]?+NCG\#THP/2NFNM*MO[,UB2TMU=+:Z M[ M@/DLF3N[\@<=JYJKA-3V,ZM)TVD^O_#"8'I1@>E+15F0F!Z48'I2T4 )@>E& M!Z4M% "8'I1@>E+10 F!Z48'I2T4 )@>E&!Z4M% "8'I1@>E+10 F!Z48'I2 MT4 )@>E&!Z4M% "8'I1@>E+10 F!Z48'I2T4 )@>E&!Z4M% %_1+J:RUJSFM MY"C>]%GT>1M\DUZ!1117F' MNA1110 4444 %%Y'J*,CU%>Z?V+I?_0.M/^_*_P"%']BZ7_T#K3_O MRO\ A1_:4?Y0_L.I_.ON/"\CU%&1ZBO=/[%TO_H'6G_?E?\ "C^Q=+_Z!UI_ MWY7_ H_M*/\H?V'4_G7W'A>1ZBC(]17NG]BZ7_T#K3_ +\K_A1_8NE_] ZT M_P"_*_X4?VE'^4/[#J?SK[CPO(]11D>HKW3^Q=+_ .@=:?\ ?E?\*/[%TO\ MZ!UI_P!^5_PH_M*/\H?V'4_G7W'A>1ZBC(]17NG]BZ7_ - ZT_[\K_A1_8NE M_P#0.M/^_*_X4?VE'^4/[#J?SK[CPO(]11D>HKW3^Q=+_P"@=:?]^5_PH_L7 M2_\ H'6G_?E?\*/[2C_*']AU/YU]QX7D>HHR/45[I_8NE_\ 0.M/^_*_X4?V M+I?_ $#K3_ORO^%']I1_E#^PZG\Z^X\+R/449'J*]T_L72_^@=:?]^5_PH_L M72_^@=:?]^5_PH_M*/\ *']AU/YU]QX7D>HHR/45[I_8NE_] ZT_[\K_ (4? MV+I?_0.M/^_*_P"%']I1_E#^PZG\Z^X\+R/449'J*]T_L72_^@=:?]^5_P * M/[%TO_H'6G_?E?\ "C^TH_RA_8=3^=?<>%Y'J*,CU%>Z?V+I?_0.M/\ ORO^ M%']BZ7_T#K3_ +\K_A1_:4?Y0_L.I_.ON/"\CU%&1ZU[I_8NE_\ 0.M/^_*_ MX4?V+I?_ $#K3_ORO^%']I1_E#^PZG\Z^X\+R/449'K7NG]BZ7_T#K3_ +\K M_A1_8NE_] ZT_P"_*_X4?VE'^4/[#J?SK[CPO(]:,CUKW3^Q=+_Z!UI_WY7_ M H_L72_^@=:?]^5_P */[2C_*']AU/YU]QX7D>HHR/45[I_8NE_] ZT_P"_ M*_X4?V+I?_0.M/\ ORO^%']I1_E#^PZG\Z^X\+R/6C(]17NG]BZ7_P! ZT_[ M\K_A1_8NE_\ 0.M/^_*_X4?VE'^4/[#J?SK[CPO(]:,CUKW3^Q=+_P"@=:?] M^5_PH_L72_\ H'6G_?E?\*/[2C_*']AU/YU]QX7D>M&1ZU[I_8NE_P#0.M/^ M_*_X4?V+I?\ T#K3_ORO^%']I1_E#^PZG\Z^X\+R/449'J*]T_L72_\ H'6G M_?E?\*/[%TO_ *!UI_WY7_"C^TH_RA_8=3^=?<>%Y'J*,CU%>Z?V+I?_ $#K M3_ORO^%']BZ7_P! ZT_[\K_A1_:4?Y0_L.I_.ON/"\CU%&1ZBO=/[%TO_H'6 MG_?E?\*/[%TO_H'6G_?E?\*/[2C_ "A_8=3^=?<>%Y'J*,CU%>Z?V+I?_0.M M/^_*_P"%']BZ7_T#K3_ORO\ A1_:4?Y0_L.I_.ON/"\CU%&1ZBO=/[%TO_H' M6G_?E?\ "C^Q=+_Z!UI_WY7_ H_M*/\H?V'4_G7W'A>1ZBC(]17NG]BZ7_T M#K3_ +\K_A1_8NE_] ZT_P"_*_X4?VE'^4/[#J?SK[CPO(]11D>HKW3^Q=+_ M .@=:?\ ?E?\*/[%TO\ Z!UI_P!^5_PH_M*/\H?V'4_G7W'A>1ZBC(]17NG] MBZ7_ - ZT_[\K_A1_8NE_P#0.M/^_*_X4?VE'^4/[#J?SK[CPO(]11D>HKW3 M^Q=+_P"@=:?]^5_PH_L72_\ H'6G_?E?\*/[2C_*']AU/YU]QX7D>HHR/45[ MI_8NE_\ 0.M/^_*_X4?V+I?_ $#K3_ORO^%']I1_E#^PZG\Z^X\+R/449'J* M]T_L72_^@=:?]^5_PH_L72_^@=:?]^5_PH_M*/\ *']AU/YU]QX7D>HHR/45 M[I_8NE_] ZT_[\K_ (4?V+I?_0.M/^_*_P"%']I1_E#^PZG\Z^X\+R/449'J M*]T_L72_^@=:?]^5_P */[%TO_H'6G_?E?\ "C^TH_RA_8=3^=?<>,:1#)<__ 'Y;_"C[;'_SSG_[\M_A5FBC0-2M]MC_ .><_P#W MY;_"C[;'_P \Y_\ ORW^%6:*- U*WVV/_GG/_P!^6_PH^VQ_\\Y_^_+?X59H MHT#4K?;8_P#GG/\ ]^6_PH^VQ_\ /.?_ +\M_A5FBC0-2M]MC_YYS_\ ?EO\ M*/ML?_/.?_ORW^%6:*- U*WVV/\ YYS_ /?EO\*/ML?_ #SG_P"_+?X59HHT M#4K?;8_^><__ 'Y;_"C[;'_SSG_[\M_A5FBC0-2M]MC_ .><_P#WY;_"C[;' M_P \Y_\ ORW^%6:*- U*WVV/_GG/_P!^6_PH^VQ_\\Y_^_+?X59HHT#4K?;8 M_P#GG/\ ]^6_PH^VQ_\ /.?_ +\M_A5FBC0-2M]MC_YYS_\ ?EO\*/ML?_/. M?_ORW^%6:*- U*WVV/\ YYS_ /?EO\*/ML?_ #SG_P"_+?X59HHT#4K?;8_^ M><__ 'Y;_"C[;'_SSG_[\M_A5FBC0-2M]MC_ .><_P#WY;_"C[;'_P \Y_\ MORW^%6:*- U*WVZ/_GG/_P!^6_PH^WP';MWN6&<+&20,XYXXYS5FJ%C$4N[] MNS3#'_?(/\R::L&I-]MC_P"><_\ WY;_ H^VQ_\\Y_^_+?X59HI:!J5OML? M_/.?_ORW^%'VV/\ YYS_ /?EO\*LT4:!J5OML?\ SSG_ ._+?X4?;8_^><__ M 'Y;_"K-%&@:E;[;'_SSG_[\M_A1]MC_ .><_P#WY;_"K-%&@:E;[;'_ ,\Y M_P#ORW^%'VV/_GG/_P!^6_PJS11H&I6^VQ_\\Y_^_+?X4?;8_P#GG/\ ]^6_ MPJS11H&I6^VQ_P#/.?\ [\M_A1]MC_YYS_\ ?EO\*LT4:!J5OML?_/.?_ORW M^%'VV/\ YYS_ /?EO\*LT4:!J5OML?\ SSG_ ._+?X4?;8_^><__ 'Y;_"K- M%&@:E;[;'_SSG_[\M_A1]MC_ .><_P#WY;_"K-%&@:E;[;'_ ,\Y_P#ORW^% M'VV/_GG/_P!^6_PJS11H&I6^VQ_\\Y_^_+?X4?;8_P#GG/\ ]^6_PJS11H&I M6^VQ_P#/.?\ [\M_A1]MC_YYS_\ ?EO\*LT4:!J5OML?_/.?_ORW^%'VV/\ MYYS_ /?EO\*LT4:!J5OML?\ SSG_ ._+?X4?;8_^><__ 'Y;_"K-%&@:E;[; M'_SSG_[\M_A1]MC_ .><_P#WY;_"K-%&@:E&>;[4$ACBE^9U+%HRH"@Y/)^E M7J**&P"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **X6[\0WUOHVJ2BZ_P!)@UL6T:$#/E^8F$Q[J3^!S4O_ M D^JS:/>/\ Z$ER=,6_MY(272,'/RMGJ?0]^?2IY@.UHKCX?%&HK?QQSQV3 MP"_33I/*+"1G9 V]03C;R..N 3FLYO%^MZ>MTLL=I>237MS:62*"A\Y7Q'&W ML5W<]?EHYD!Z#17 GQ]=W,=U=65O9_9+:V-WNFD(,R*=K*O^T&#C//0#'-7] M?\93Z))/%]A$LS0I<6:9.98P"9<^A0#_ ,>6GS(#KZ*X*7QIK,,RM]RVO MVU3L8*\7\0R6&,7O#^FWGIUQSFKFL>( MM3TC3(I'6SDOC!+=/"B.5\M "<,2,8R 2?7I3YD!UE%<9J'B[48R\]C:6K6T M5O:SLLSL';SV*@ C@8X.:I2^.-4MKVZM98K O:7J64[@,J*T@!1MQ/ ^89&# MT/(I:AJ-_&;6T@C,\D5LD4TK?(69@SLH['&5]5(/>KEOXTU5 M=6T&VO;6Q6#5+FXM2T;ME&A#9;GC#%>!V]Z.9 =U3514+$#ECD_7I_2N#LO& MNKZC&]Q;6NG^0M['9C<[$L7;:&R.,#@X[\]*D?QKJ2B[C%O8B;3HII;HN[*L MHCD*8C]"<9YS@D#O3YD!W5%.:::8QO%P851F 4!L@=/ M\FN=N_$FKM9:?D1M9SO(/,V,QMU0D99009"< M=%P1[U/=^,[H1O<62V4UK;V]M-(S%@T_G' ,8[ >_)/'%/F0':T5Q&E:OJ]K MX5TNYFN+>YOM2O?+,D[,(T#;N@]MO"C%4)/B%JYM-4GMM)AF_LIFBN%!;$K# M.71LX"<9YR3SZ4N9 >C45YKXH\8>(-.\.ZW,4L8GL8X"TL+L&Q-@*5ST*D\D M]?:M"3Q?K,&MW>E-;Z=(]G9M>S31L^&0!2%4?WN3U/H?:CF0'=45YKJ_B[58 MIK:*5H5;R?M)-E(0KH\3D(2*-2?Q%;VK+82Z9+-M8U2,3V]IIX@:^6Q0F1B267(?CL/3O MZBL[6?'FJQ:7/@6T;+=O8F6+*!)HVY^9CRI .>. >M',@/4**Q]$U2YOKC4; M2\6#S[*98S);D^6X9 XQGD$ X(_QK8J@"BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@"A/HNFW%VUY)8VYNRA3[1Y8\P#&.&QG M.*33]#TW3+-K:ULX4C= DN(QF4 8^;CGC^9HHI6 (-#TJVN8[F#3;2*>)=B2 M)$H*KZ XXJ4:98"X:X%E;^$&%<1DG)(XXR>?K2/I<$VLKJ4KR2211&**-B-D8;&X@8SDX .3VHHH A M'AC05((T:QX;70]*G6!9=.M76W.8@8AA,G/'ISS1119 .ET?39[ MQKN:PMI+ED,;2O$"Q7&,9^G%.O-+T_41$+VRM[@1'*"6,-M[<9HHH >;"T*E M3:PE2JJ1L&"%.5'X=O2JL_A_1KJYDN;C2K*6:3[\CP*2WU..>E%%%@+']F6! MN?M/V*W\_P"7]YY8W?+]WGVR<>E1W&CZ9=PK#)2%).21Z$FBB MBP#X=,L+>,1PV5O&@8.%2( ;AT./44R?1M+NG1I]/M96CD,J%XE.')R6Z=2: M**+ 326%G-:/:R6L+V\A)>)D!5B3DY'0\\U4'AS1%\C;I-D/LYS#B!?D.<\< M<<\T446 9J?A[3M2\Z1X5BN)T\J2YB51*4/!7<0>"./I4TFAZ5+)!))IUJ[P M((XF:($HHZ >PHHHL!'/X;T.YFDFGTFRDED.YW:%26/KG'6K$FD:=+/;3R6% MLTML (',0S&!T"^F***+ 17VAZ?J%K;VL]NAMH)1*L(4;"0",$8Z?,:23P]H MTIA\S2K-O)3RX]T*G:OH..E%%%@+$^FV-S%+'/9V\LM%%%D!9ATRPMT"0V5O&BN) J1@ ,. >. M_O5=_#VBO<23OI-DTLIS([0*2Q]3QR:**+("W9V-IIT'D65M%;Q;BVR) HR> MIX[U8HHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9 end GRAPHIC 41 evax-20211231x20f034.jpg GRAPHIC begin 644 evax-20211231x20f034.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^O+?'GC" M^L/$XBT_44MX=(B2XNH"X4W19A^[ [X7FO4JY^'P9HJR:A+,9=)T2_P 6[W)TW4DTT//,6>4$J-[''7FF7'C[58KB5HM$ MAEM(]3;3 _VG#O)G"D#' ]:U+SX?Z3>W=U.]Q?HES<+=20)/B,R@@[L8Z\5; M/@[3&B:,M<;6U+^TS\__ "VSGT^[[5%I@8:>/;YKF_6>.7:\4Q&,H<<#';FEM?!&E6DEI*K7+SV]TUX9I)=SS2E=I9SCGCMQ M1:?<"AXQOM4TK2M'UW>\)M+F,ZA;PN2C1O\ *X/J 2,&L6+Q7J MK=W7]GZ9;--L@_=KNEE)Y]J]#U+3[?5M,N=/NTW6]Q&8W .#@^GO6&/ FD)H MEAID!N8!8.9+:XBEVS(YSD[L++W4M:T.%EDL;F#4IK6_MH MY=R.5B+#G^)>AK1M_',L^F>'KLV* ZMYVY?,/[O8K'CCG.VM&T\$Z59O92(; MAIK6X>Z,LDFYII77:S.>_'TJM:?#[2;.:U=+F_=+1I#;0O/E(0X(8*,=.:+3 M Q[/Q]KU\=.6'0+4-J=J\]KNN\ ;/O%_EX'IBH)_BJ?LEB]M80>?+:?:IDGG M* 8)78A .YC@XKK+/PAIMB^E-"T^=,MWMX-SY^5Q@[N.35$?#S28K>VBM;G4 M+5H8&MC+!/M>2(L6*L<<\GKP:5JG<#H]-ODU/3+6^C1D2XB60*XP5R,X-6JB MMX$M;:*WCW;(U"+N8L< 8Y)Y-2UL@"BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "L7Q!XJTGPPD+:G/(AFW%$BB:1MJC+MA02% M4' MY-9ATJ.^WSS!"CK&QBRR;U4OC:&*C(&>E2Z!XNT7Q-)/'I=RTK0A7(>)DW(V M=KKN W*<'!'I7"V?PUU:QU"WTY9K=]'\^WNY+K>1*KQ6YBV!,<@G!SG@5H># M/!&L:<\_]L31V_E:9#I5N]A,=[)&S'SXTKXA3Z M8-4U&[M&TI;C9>3F7:_FEH_8+>] M\RY\QH]JQ/C] $M%%0SW M<%J81/*J&:011Y_B<@D ?D: )J*** "BH5NH7EGB#_/!CS!@_+D9'Z46MU!? M6D-U;2K+!,@>-UZ,I&010!-1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%<)\2O$^K^'H-/CT=@)[C MSW8+;^?(1'&6&$R/ES@,W8&ANP'=T5Y3;_$+6IM5AO?,LWTI+BVLY;:&,L9' MEM_-,BOGH#@ 8Z5=\&>.-4NVG;7WBEADTN'5HC:6[;HDD9AY>T9+XP,'J>:5 MP-]?^2KR?]@1?_1[5U5<+HVM6>N?$^XGLA2$Y\XG@. 3]:[JA M8FL:%>:G<"6W\0:CIR[-OEVWE[2?[WS*3G\:X#P1\*?$'AR?4Y+OQ?=H+EP5 M%F0=^"?G?S%/S<]OSKTR\UK3-.E\J\O[:"3;NVR2!3CUQ6/IOC[P[J;S+'?K M"8CC_2/W>X>JYZBEH0ZD$[-ZF_:0/:V<4$EQ)Z%$SAGN]JB1MXM)"I6-MLC [>54]33=BSESX1U+3HWNH([E'@^R.C&\ M9MN$(N#@MR3W]>U4=+\.WVHZ;HMW_95W]@5+*:>&:[#--(,[YER_]UAW!/IQ M736_C2[OM7N[&U;1=\5Q+!';R7;">39G!V[<AJTOBVXO;+3O['TY+B\N MK)[M[>239Y03 *$XZER5'T-39 4/"D=Y)I.K7UQ>-<0P1/8V,PD+"2&+=^]] MR2<9_P!BL'2-&UNXTO3+[3M.N(XQ:V\K17-WDSW C?,H;<2N=RC/!.>G%=UX M:\1)XBAENK2T\G2EQ'%))\K/(,AUV]@I^7W(/:LVW\7ZE,CK19 ISSBN]\+V=QI MWA32;*ZC\NX@M(XY$W!MK!0",CK3+GQ)96%E837#-,]XF^);.-I@^%W,5VCD M8YS5=/&_A^26-4OLQN%_?^6PB!9=ZJ7(P"5YQ35D!T-%V4TSPSP3APD/EM!$[B=Y QVH,9. A/X'TJY'XXT*698TN)B/W>]_ ML[A(B[%5#MC"DL",'H>M%T!T5%-Q^F2!4E% %'3=274X#,EM<0IG ,P4;N2#C!/I5ZLSP__P @2#_> M?_T-JTZ$ 4444 %%%% !1110 4444 %%%% !61KOAG2?$B0KJ=NTAAW>6Z2M M&RAAAAN4@X(X([UKU3OM6T[2_+_M"_M;3S,[/M$RQ[L=<9/- &7%X(\.P:M; MZG#IJ1W$"*L85V"#:NQ3LSM)"D@$C.*FT+PGHOAIYWTFR%NT^ YWLV%&<*,D M[5&3@#CFKL>KZ;-=0VT>H6KW$T?FQ1+,I9T_O 9R1[U)::C97YE%G>07'DOL MD\F0/L;T..AI: <\O_)5Y/\ L"+_ .CS755RJ_\ )5Y/^P(O_H]JZJA 0S6= MM<-NFMX9#C&70'C\:R]-\)Z%I+S-9Z="AF.6+#?^ SG J_82V?F!3_%^[VGTY'-.Q2H*2YM-/0WT18T"(H50, 8 KG M'\&6CVIMS=3A3:W5KGC.V=]['Z@]*Z*)G:)6D38Y'*@YP?K7FUQXK\3K#)=) M+&;9B0MO+L"9W<[@>3V[4G8DZG3O#-WI=XSVVMSBT>X:=K9K>(@ M[CDC=C=C\:1?!UO%_;!M[ZZ@?4V&YT(W01Y)9(SCY02SG/7+'VKE]'D74?$% MX+J6$F34)D5FUJ1)47. %A'''8?C4=M?37T%Q8ZQJMS;6WAZREAU"ZCD*,TY M.V-LCJVQ0X]2XJ;H#K+?P1HMM-(J6R&P8HZV+J#%'*HQYBCJ&(P#ZXSUJE<> M EFMI8(]:O8$$;PVOEA0;:)W#.H.,G. N3R!Q5#P;J^JR1W*.: MS!6,00%>.VLY[GQ%>1&ZMY7U-8Y-[0N)D541?^ M6;$EHQT]>V:- /0K3PY;)H"Z-J'EW]HN J20(BA1C:NU0!@8I^I:++*Z2:2*(D8C:0 MM@D6EY/821RP-(J!2S R*"A/..O)%/H!?A\-V=M'I4 M5NTD<6F0M#"N2WV*LL;Q(6D8)LSOQN4$8R >H MJ&;4S'XWLQ;:K-*M9L=8O9$%M+8 M6M^EF+98CYLNZ$29W9X.> ,4: 6)_AW;WB1->:G/.F*B@\!2+J$\#7TB:2]O;QR0QH@^TE'=VW8'R#)'W>H)%95AXXUJ M\-K;RW6G0?;?)87A"E;;>KL4*ASD_( I8C.3D4B>/]9DN41$LML B#$X5;W? M*R;HRS@@87(P&Y..E*Z Z"/P&EM-!/9:M=6\T$<:QL$1L,@=0Q!'.5D8$?0U M4MO /]]>F5\$J0W! M7.. >5.<470&_;_#:PM;>>""[*HR".(&UA(5-V[:^5_>= /F[#UYKIM#TF/0 M]'M].BE>5(00&?KR2>!V'/ [# KSO_A8&LQ6EH_VC3KM[^-6S"F!8$RJG[S+ MX(.[N5^8>E6&\=:Q$UNTTU@D,3LL[H%D:4"78#L5\J"/[F_#>U%T@/3****L M HHHH **** "BBB@ HHJCK.JVVAZ->:I>%A;6D32R;%R< =AZT 1>'_^0)!_ MO/\ ^AM6G7$_#'QGI_C'P[))913PM:RM'*DH&1N)8$$<'@UVU) %%%%, HHH MH **** "BBB@ JEJNI)I5@]T\$\^T@"*!=SL3V X_7@"KM8GB'PSIOB(VCZE M"]Q'9NTBP9^60E<8(_E_]%-1ALY2-MQ#-#< ]"51B<> MXS3?'VC'7M'M=/2P2X:YNXH)9C$KM;P,Q:2XA!66Z1G+2[01 MO&"/FSSFO6**+ <)HMOJUM\3KA=7U""]F.C*4>&V\D*OG'@C<<\]Z[NN57_D MJ\G_ &!%_P#1[5U5- %%%%, J(VMN1M,$6,%<;!T/)'T-2T4 5/[*T[[2+G[ M!:^>&W>;Y*[L^N<9S4S6MNX<-!$PD8,X* [B.A/J>!^52T4 ,\J,3&;RU\TK MMWX^;'IGTJNVEZ>WG[K&U/GD--F%?WA'0MQR?K5NB@"&VM+:SB\JUMXH(\YV M1(%&?7 J22-)4*2(KJ>JL,BG44 5Q8V@O#>"U@%T5VF?RQO(]-W7%2&WA+%C M%'DL')VC.X< _7WJ2B@"G_96G>1+!_9]KY,K;I(_)7:[>I&,$T\Z?9,\$AM( M"\ Q"WEC,8_V3CC\*LT4 9NEZ#INCV26MG:1*B!?F* LQ7H6..2/6K TVQ6: M.9;*W$L>=CB)=R9ZX..,YJU118#,T[P_I>EZ=]@M[*'R"@1PR F0#^^%[%L7.JY6X<<^3:C_6O]2"$'NWM727=U!8V,X4$X&>N. M* /,/A=9W$&HVK0V\SZ9]F;R+J30XK;S%XVGS0Q8Y]QSWKL?&_C>+P='8IY$ M4US>,XC$TXAC 1=S%FP<=@..I[5YY\/KK1]!U6T\R;0KFX>-HA-IM_/=7$K, M1R8L;1GJ3@8]J]-\4^$T\2_8YDOIK&\M#((KB)%?"R(4=2K @Y4_A4K8#%'Q M(7^VTMGTPKIPEBMI[P7"MY<\D7FJH4?>7'&X'J:L^%?'Z>())UOK$:8HM([^ M!Y)U97MG)"LQXVGCD>_6H+/X7Z98ZA;207MU_9T)BD:P;:4DECC,:N6QG[IZ M=":M^&OA_8^'S<>==2ZDDELEG&EVBE8[9"2L> ,-U/)Z\4:@,LKZSO\ XIS2 M6=W!2 *[.F M@"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1534XR^G3[998F1&8-&VTY -9!U>+0/!::M>RSW!%NDF&;<\LC !47 MW9B ![TK@4O$./$OB"V\+HVZS@"WFJXZ,F?W<)_WV&2/[J^]=<2J+DD*H]> M*PO">CS:7I;37V&U6_D-U?/U_>-_"#_=484>PK;FABN(6AGB26)AAD=0RGZ@ MT(#-\.R(^BP['5L,^<'/\;5JU7M;"SL0PM+2"W#?>\F,)GZX%6*: **** "B MBB@ HHHH **** "FNXCC9R"0H)P!DTZF3,4@D8'!"D@XSCCTH \]\&?$.S\1 MZZ+.+2;:V>X$CJT$R.X50K#S "I.['L1BO1:\G^&%O=RZA'J\\.LB2^@:2> M>2UMXK:8DY!!0;_< _C6I\69VBT_3 =6BT^(2RR.)GFC6B45X78ZUJ5SXFLY4>^M=8>>T6TTV6=V"V;6I9\J>&&[JQYR!S6I M\,]4U*:2]:PFN=4<:5;S745U<-@:@6?>FYL[#@#('3 XHY@.V7_DJ\G_ &!% M_P#1[5U5<)HMUJMU\3[A]6TR*PE&C*$2.Y$P9?./.0!CGM7=TT 4444P"BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH KW_.G M7/\ UR;^1KBM'QXHU?3H]N_2M!AB)/\ #+>E!@>XC4Y_WF]J?\4YKZX\+G0] M&N9(M8U%ML*Q-M/EK\TA9OX5"\$^X'>K'PMT*^\.^ +"RU&=)IVW3Y3D*'.X M#/<\]:74#LJ***8!1110 4444 %%%% !1110 4444 %-D_U3_P"Z>U.JCK&G MQ:II MT"D#;<(W 8YZ]CD5Z=XB\0Z=X6T2?5]4E,=K#C.T99B3@!1W)J8[ :?EH9!( M47>!@-CD#TS0L:)NV(J[CDX&,GUKFAX\T7^VX]*)N1(Y13.83Y*2/'YBQL_9 MBHSBIO#GC/2?%,LT6G_:5>.-9@)X3'YD3$A9$SU4X/-.Z K+_P E7D_[ B_^ MCVKJJY5?^2KR?]@1?_1YKJJ$ 4444P"BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ JCK&KV>A:5/J-](4@A&3M&68G@*H[L20 .Y- M720 22 !U)KCM.#>,M=369DSH6GR'^S4;I<3#@W!']TF06UV\+O"BQAH00" !U[\4 7J***8!1110 444 M4 %%%% !1110 4444 %8?B];9O#5RMW!J4\9*833"PN"VX;=FT@YSCVQUK<^ =&\4Z?K]U=WEJEOHUPA(%\(GOW?MO>(#(_P!XDUK_ M ! \$2^,]/6.'5)K2:"*41)@&)W==N7!!/3(R.1DUB_#SQOJNL:BFAZC/IMR M]O"VZ[BF??<;3C0RJ-.BTNW^Q,\;&&,L0[-P0YR.G3'6O0 M**=D!PVD:/;:-\4)X;5[EE?1E8FXN'F.?.(X+DD#VKN:Y5?^2KR?]@1?_1[5 MU5" ****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M6!XGUNXTVWAL=,C6?6K]C%9Q-]U3CYI']$0@#/UZ>3Q-JS>%;"9TM8 MP'UBXC.-L9Z0 ]F?OZ+GU%=7!!%:V\=O!&L<,2A$1!@*H& /2L_0-$@T#2D MM(G:65F,MQ5N6=OLV6A/<:)J(MKJ".2;R$CC>2 MXVKG"[SC:.K8R<#BN%^&5J-,\4VUE-I,-M-]FDV7$FC2VT\H!&29'8ANHSQS M7JFM>'-'\1PQ1:OI\-VD1+1^8.5)&#@CGD<$=ZE; >;6_CS6KG5X=1COXI=/ M6YM;,V44(VS^;;&5I0Q^8'=T'H*O^!O&&LW+SMJT\FII+I,&JHEK;#?$9&8& M)57[W08SSUKM5\)Z!'J\.JII5LM] @CCF5,%5"[0 .G ) ]JDT?PUHWA]KAM M)TZ"T-PP:4Q+C=C./PY/'3FBS YG1=776/B?<3+87]GLT95V7MN86/[XG(!Z MBN[KE5_Y*O)_V!%_]'FNJIH HHHI@%%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4'.#CK13)IHK>%YII$CBC4L[NI)8 #N:7PQI%UY\_B'65QJ]\N!$3D6D&Z>ADN/M-O$ M(P!EP\JJ5&> 2"0#VKI*:\:2KMD177(.&&1D=* //O">DRQ>)8[J[\/>(()( MXG$5UJ>J+6%K;:1HK7LTQ>*:[C$9DM(6&'\L.0-[#Y?:EL!T@\1:,=6ATH:I:&_F MC\V.W$H+NF,@@=QCGZ4_3-=TG6C<#3-1MKPV[^7,() VQO0XKR^#P9JR:W': MVFD2VEG)>6MY#=O*A-M%';&(Q-@D[\\<9'/6KW@/PKKUB\YGMVT62'2(-,28 M>7(9)8V8F55Y!'(QNZY-*[ ZA?\ DJ\G_8$7_P!'FNJKA-%L=0L?B?<)J.K2 M:E(VC*5D>!(MH\X\87@UW=- %%%%, HHHH **** "BBB@ HHHH **** "BBB M@ HHHH ***CN+B&UMY+BXE2*&)2[R.V%51U)/84 $\\5M!)//(D4,:EW=VPJ M@=23V%<;'%-X^G6YNXGB\+1G?!;N"&U%@>'<=HNX4_>X)XP*(8)_'MPEU>Q- M%X7C(>WM7!#:@P/$D@[1]U4_>X)XP*[4 *H4 8 ':EN!A:-<2MJVH!M.O+ M>*9U:)I8PJX5%7'!..0:WJ**$ 4444P"BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH ***YGQSXGN?"?A]M1M=->]<.JGG;'&"P!9SU[\ =30!TU% M<)?>/[BR\63636$1TBVNX[">X\P^;YSQ&0%5QC:!@'G/-'A3X@OJYN&UJVMM M-A^PQZG#*)\J+>0D#>2!AACGMS2N!HK_ ,E7D_[ B_\ H]JZJN'TK6=,UKXH M3S:7?VU[$FC*C/;R!PI\XG!([UW%" ****8!1110 4444 %%%% !1110 444 M4 %%%% !116)KGB:UT>:&RCBDOM5N ?L]A;X,C_[3=D0=V/% %K7M1M])T*] MOKF;RHH86+)4O+D'=!81D_9K/_ '>[N/[Y_ "M[3]' ML-+,GV* Q>82S#>Q!).2<$]<]Z6X%T * .@%+113 **** "BBB@ HHHH M***BN+>.Z@>&8$QN,, Q4_F.: ):*Q?#%M!%I*2Q%V:1FW,TK/G#$#J36U0@ M"BBB@ HHHH **** "BBB@ HHHH *S/$&AVWB/0[C2;MY$@N-NYHCAAA@PQGW M%:=% '+W'@33+GQ.=;DFNOGD6>6SWCR9)E0HLA&,Y"G'7%+X:\#:9X9>X:"6 MYNO-B2W073AQ% I)6)>/NC)ZY-=/12L@.2@@A@^*LJPQ)&IT120B@9_?GTKK M:Y5?^2KR?]@1?_1[5U5" ****8!1110 4444 %%%% !117/'QUX675KO2WUV MRCO+0$SQR2;-F.HR< D>@- '0T5RO_"P=$GD\O2UOM7?/_,/M'E7_OO 7'XT MKZMXMO<#3_#EO9HW274KP9'U2,-_.E<#J:I:OJUEH>E7.IZC,(;2W0O(Y&<# MZ=S6#_PC_B;4.=4\5O AZPZ7;+#C_@;[F_E27'P^\-7%I*NJP3:@&0AYK^Z> M4@8Z@L<+]1B@#.L?'$WCJV\OP6K)%NVW.I7D6$MO]E4/+R8YQ]T<9/:NFT/P MY8Z#'(T(>>\GP;F]G.Z:<^K-_(#@=A4'A'P_H/AS1!:>'4C%F[F0NLGF%VZ$ MEN_0#\*WJ "BH9KJWMT9YIXXU4$L68# K(T[QEH&J1RR6^IP*(FVMYS>6?J- MV,BBZ)B.'UFRSZ"8$_I4+>,]!Y"7K2'MY=O(_\EHNA>TA MW1OT5YUX>^(=[JFM75I)8//'&"8A:P'>P!QEMS86NH;4]>F'^C: L>>ANKM5 M_1=U)23)C6A)7B[_ 'F[16!]G\57/^LO]-LU]((&E8?BQ _2A?#MU*R+7B.\BL-#N+J:^DLEC&1+'C.[L,$'.3CM6-HWB_ M2%T:V:75Y;ZZD0,\8CWRALOYT[6O"6BG29Q)8W=W*RX5A(\LH;L1 MDG'-7O"&GVVF^'K>W@LYK9@H\T3)M=G(!8^_-+6Y/[URZ)??_D']MZE=+G3] M N2".'O'6 ?ERWZ56O-*\2:Q93V]UJEK8QRH5*6D19N1T+L?Y"NGJ*X262!U M@E$4I'RN4W!?P[T[%.G?XF>]%RH)*'R0A7))/0G/6M&A*RL5""A%1CL@HHHIE!1110 4444 %% M%% !1110 4444 07GG?8;C[/_K_+;R_][''ZUY+\,3J2RWS:9#,TBZ5 +M+X MR(C:CN?S-Q()SC&2!Z5[#12: \K@N/&!^)S&2TLQ>?8]K1ASY(M\D@AL9^_G MG&<\=*[3S_%G_/CI/_@1)_\ $UC0>++:7X@&W_L8*KS/I*:EYHW-)&GG%"F. M%Y/.>M=S22\S&-)J_O,YXS^+NUEI'_@1)_\ $U0NM<\46NKV&FO8:49KU96C M83OM'E@$YX]Q785QGB'Q"^E>*]+^T>'C-;^>EK!?F=0^^;@B./JP W'C H9 M7LW_ #,MW,_C7[++Y5GI'F;#MVS.3G'&,C'YUC^%Y_'[64OVVWMG/F?*;]BC M^^ HZ?6O0**+>9+HMR4N9G':CK7BS3'LEFL]()O+E;:/;+(<,P)!/'3Y35TO MXT(XAT,?\#E_PJKXZ\3:=X?32Q6/,W,^#C! QQUQ M1RV1,*2BK7;^9B?\('XED&+O66O/7S[R<@_@K 5@:1\--5LO%DUU'ING1F,N MZ3RQ"2,ENZALG/UZ5[#IUY_:&F6MYL$?GQ+)L#A\9&<;AP?J*M4 06D#S.L-N@.U5)(&1Z"BVT[Q;?6D%T-M?QSK<&A>&)I[FSCNH)W6UD2:7RX@LAVDR-@[5YY.*M^%-5CUOPM MI^HPVOV6*:(;(=VX* =HP>XXR#W&*+:E\L>WXO\ S,'^P/$I.7U:Z;V%YM_D ME5]0\*ZS>Z;<6TUU<.LB$'=?,_\ X[@ _0UWU:5:?V=<7)U"[C MMC*HQ%$';;EF]?1>_--I XP>CBCE/"GA65="BEM\7=O.?-1S=R0J0?15..W? MFMX>%BW^LT>P?_?N96_F:AT+Q; OB%/#MMH_V73%FN+*SG64'=) 9%V8^4< MG!R,>GZC>)']J6=0TD\P+LRQ]6 .=QXQZ4:#4:?\ (K^AO1V]]",16&G) M_NDC^E2[M7 P+>S ]I&_PK2K+\0ZS_8.BW&H?8KF\:)25@MDW,QQ^@]2>@JB MN9=D9K'_/" MS_[^-_A6>FMZA)K\VC"VM_M$5LERS;SMVLQ4#IURIK8O[P:?837;0SSB)=WE M6\>^1_95[FO.KOXC65EINE^(?[&ACU35DFBV7%T(@D4+ME6<@C.>@QU)YP*& M["YO([6^EUL6@IC]HK6LC"FUC48-9M-+:VMO/N M8I)48.=H"%0<\=?F%6II-:$#E(+7=M.-KDG\,BN+G^(5LVF7/B%]!,-S8ZB= M+B-[*(3$KA27E.#Y8/RY'/.*[;P[K U_P]8ZL+=K<740D\ICDK^/<=P>XI)B MY_)&+%<>,1$OV6SL9ER&3'@O+!/M*N^YI/)3> ,1EM_')XS MZ4,4I-;?Q(NO7$36ZA(K4P(Z(G&\+NZ%N[#G!KKJ M* "BBB@#D_%GP^T?Q;(+BZ\^&\ C3[1%*P.Q'#[< XP3GZ9SU%=5&@CC6-<[ M5 RB@#D]/\#06'BM]:&H7$L0FGN8+-E79# M+, )&#=3G'0],FNLHHH R_$FB1^(_#M]H\LSPQW(UU^X4P(L4=JT".B1C&Y5)Y4MCDCGFNOHI6 *KWUJ+ZPN;1F*K/$T18= M0&!&?UJQ13 X;4OA9HFIZ=IT$TEPMS90VT NDD96>.$@A2H..<'GJ,Y%=PBA M$51G &!DYI:*+ %<-=?#:&;1M.LK;5KBVGL?M*IV*[ MFBE8"KIMA#I>F6FGV^[R;6%(8]QR=J@ 9_*K5%%,#C+WX?0W,-WY6ISPW$VK M?VM%+Y:N(I=NW:5/#+C/6N@\/:)#X=T&UTJ"629(%/[R3&6))8G X')/ Z5I MT4K !Z5Y]#\+_P#1]9@O/$%U=+JC"61V@C$BS*P9'WXR=N,!3QBO0:*+ 8WA MKP^GAS39;?[5)=W%Q<275S<2*%,LKG+' X';@>E;-%%, HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@#E/%VIZS;:KH&EZ+GK6 OQ2.D:.SZ]9>;=6UU/:W,EHZJC&)PI9%9MQSD' SCGFNS MUSPUIWB$VC7PN!):.SP26\[Q.A(VG#*0>AQ61I=P(+CXEZ;;F>/[#>R7-N;GSK>) SHL(!+8ST;Z?@S6]#X6TJ"SU:S6&0VVJO))=1-*Q4EQA]HS\N2 M1NNI"&:'_5LPS\Q XR>U&H&.WQ:M%MS<'0=3\@6IO=^8_P#4"3RV?&[LW;J: MOS_$FPM[F;?IU]]ACN);1;W"^7).B%R@&=W12 2,9%:#> O#SV9M39OY)LFL M<>:W^I+[RO7^]SGK22> ?#TM]-=O:2%IB[M%Y[^6'==C2!,X#E21NQGFC4") M?'$"^#X/$4^EWL,=T\:6MLVPRS&0@1XP<#)8=3Q6?JOQ0L=$E@M]2TJ_MKIH MVFF@?9NCC#[-P^;Y\GD!9%NW3?:I/,F#-N82-G+ L,\T]0,K0?&&I:GXP739# ;1 MIM04%4(8K"\8CYSZ._H*Z M:S\+:18:H-2M[=EN@\[[MY(S,5:3CIR5'TJ'_A#-#^T7$_V5O,N!)((9K[:HCADF4,BD9W'[RY(&!FI(OB+# M)8P7[Z)J45C=30QVMPP3;,)9/+4\-D=> 6L_ER;=@^TR?N K[U$7/R -SQ1J!FS_ !#( MU]XX;9C8VL5\+B-MH=Y()(URK%@ IWGK5"7XJ27K6XTS3)!$RWBW$KLC^4\, M>\%<-AAR#[]*Z%OAQX9DM9+>2RDD202AB\[EB9&5G.\=V_B'4H+1--O+47,$MQ;RS;-LJQR>6_0DCDCKU%2Q_# M_P .17UO=)9,&@\IA'YS^6SQC;&[)G#,H P2.U7M.\+:3I4UG-:6[(]G#)!" M3(3M21P[#D\Y8 T]0-FBBBF 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M17GWCVZO%\3Z!9P2:H89TG,D&FR[)), $8SQQ_+-3*7*K@>@T5Q7P]O[NXCU M>TO+F[9[:[Q';WQS<0QE05#GOGDBNUIQ=U< HHIDWF>1)Y6/,VG9GUQQ3 ?1 M7D.EW.CKI*/(]Z_BG[)=&]4%R=X1MWG@\;>F/PQ5BU\1>(8]$O+N&]CAM;%+ M2%8Q:A@BR)'ND)ZD+DG'YUE[5 >K45YE/XVO+!&/]LQ7=L;&[:WN_LFP33H1 ML [,>>W!K-'B34;)-1ECO6M[J[N$P!)Z"AU4!Z_17CEG MKVH7U_\ :+R^$DMQ/ILJVK)\JAA\S+Z '(^IYJZ_B[Q1:Z=#>"X2Z:[LIYEC M%J!Y!CE"[ACEL*22#Z4>U0'JU%NNK2+NK@%%%%, HKDO'%]>1G1=+L[J2S.IWRV\ES$<.B8)(4]B<8JUH6D3 M:-K%W /$$]];-&K)9W4GF2PGNV[.<'Z5/-K8#HZ***H HHKROQIJFIVWB/6? M)N-2%M:V,+K]ENO+6W9BP\QEP2RYQG'85,IFWVQDC)J"U^)&J7#_9C;6*S3R0"WG8NL2K+N^9@>2/ MEXZ9SVJ?:1 ]-HKRK6O%>M+=7!:^LC;IIRR%;*$+(W7/'3L,UJ7OQ"O M+)M1@:PB>ZTM)I+Q06"A0P$14_[6X$^P-'M$!Z#17.^$=?O-2RMHHF5C M;,^[AA*(PK (]?FUN6(7%O-(=3EBMHDE8+Q!N53C[R'C\3 MXD7US;QSV%A%Y,TT=HDD@8[9]A:0$#J%X4>^:[7P_JN^%;+7[NTNKBXO;>>T#"*2UF\MANQGD M?2MRBDTGN!D:%X,U-Q;P0^']1DNYX'F>#8B.BHVT@[B,\],9S49^(.D;K M,0VMS)#=1QR,X15V!W\M05)RQW<$ '%1-X8\31ZC9ZG%K%E-?QVTD$TEQ"VW MYWW?* 1P. ,U0?X;7*/9)!J,+)%%$C331GS8660R,T)!PI8D@UE>8';VVH:? M=WMS8PNC36942)C[NX9&/P]*QX/$[S^(CHIT"[29,2.[-'M6,DJ)/O=./K4^ ME^$-)TC6KO5+6W19I\;0%QY7&#M^O4U-%HLL?C&YUHS(8I;-+81X.X%6+9SZ M#5(]-EO+1+YQE(&=0Y';BLG5=>\/WFFM;B6*_AEN$LY$MI!E& M!ZYZCM63IOPWN[)8 M!)>6Q:WDMPCJ'):.-BW.3@$YZ#@5+C54+VL MT 44458&=K>AV/B"P^QWZ,4#"1'C8J\;CHRL.A%5-"\*Z?H%Q<74+W-S>7 " MRW5W*9)&4=%R>WM6Y12Y5>X!1113 YZX\:Z-:ZL=/DEF++,L$DRPL88Y6Z(S MXP#TJM;^*?#E[J[V_D.D]R[69GFM"J3,I(\O>1AN_%4[?2_%.EW]Y9V$.G/8 MW>HF\^V3.2T<;$%T,>.6XP#FLY/"WB2XMXM)DBM+6TBU5[\7HFWOC>S* F.# MDCJ:CW@.DM)/"\VLW=K;VEE]KTJ)5ED$"@0J0<*&QV&>.U.N;/PW9:*]Y'H] MM<6ACP_H-OIXGDF>- '=W9@6P =N3\J\<#M0D^J SM$G\-^)H% M>TT93!;IY<37%CL7:2?E0DH6G@+^QI9D@OC!-&)(VR$9BVT@^V17'OX)UR33;2-=(TRV%L\7G0PSY-X M50J7;..=IK?CFB ME+".1'*G#;6!P?0UYFG@774O;"3,#1PK:!]\Y)'EF0L,X!.-P -:G@7PSJ^@ M:E>-=Q6\5F\2JJAQ)(7#$YW!02N/[W-"YNJ [NBBBK *Y*X^'>CW5W>327.I M".]E,UQ;I=%8I">N5'45UM%)Q3W CAACMX(X(45(HU"HBC 4#@ 5)113 1F" MJ68@*!DD]JYJ#QYH=P\H22X5$ADFCE>W94G1!EC&Q&&P!VK?O;87EC<6I8J) MHVC+#J,C&?UKBH-)\5OH)T*:UTV*U@T^6U$RREFN&V;4(&!L'QLWLM--G"HG,GG,=@;)V_*, M+QUP34MOX O+[0I+:\D:P8WXN88(KIY!''E20S#&]OE.">F14>]V WO$'_", M^']/BDU#18FM%Z-8$O-);^5$9Y223Q]YCDGZU'XGT:^U3PQ!96HBDFB MDAD>"1RJ3JA!:,GT.*JSOL!I/I^C262VCVEBUK,Y=8BB['<\Y Z$^]5=.\1: M-)_\ VMWDL$L=A96T31E%M;>YPMH3)NW MJS*>2.NS'(]*ENO NLSK=*T<$JR-=D#[04+"1T9>0#S\ISQCUI7ET0'IL@KI:M;:@%%%% M,#E=;\>:;H7B&VT6>"YDN9S'S&HVJKL5#')R0#@''J*ZJO'/$;2:?\3H!=7H M(DN(I5Q-,?+1I %7&[')&< 8KV.@ HKA]4\;W%K\1K'P]!:N;(EU34;BPDTZ]L;F"))62Z5!N5B0""K'NIH VJ*** M "BBB@ HHHH **** "BBB@ HHKF+?QSIEUXN;PY%#TF<*LRA67&3QP6!Y]*Y?5/!VLW?@31]#>Q^T M76EQHD4J7JH&D$.T2893E58XP>HY]J /3D=7171@RL,@@Y!%+7!W]GK>AOH5 MU)XANY6GO[:VN+4)&(,-PP4!00...:[R@ HHHH **** "BBB@ HHHH **** M"BL[6= M0?:@"U17F6KZ5X@E^+D%_:6]R+4*BI,*Z/2+W7 MX/%CZ/K%Y974;6/VI'M[9HBI$@7!RS9'- '54444 %%%% !1110 4444 %%% M% !1110!P_B'PYJFJ>+;74;-+"6*$P!+B4CS+0I(6DP-IW;E..HQ7<5QEIX7 MM[;Q%<&3Q%J4=WU<]:?\E&U/_L&VW_HR6NDKF[3_ )*-J?\ V#;;_P!&2T =)1110 4444 % M%%% !1110 4444 (P)4@=:\>\*F2U^*+6EU<":>.21'D^T2OO?RSQANN ,9/ MIQ7L5<19>&]17QXVN%-/:W>623[8A'FR0M&%6+&WL0#NW?SH [>BL_6-;T[0 M+ WNJ7*V]ON";BI8ECT !)/T%-O-?TK3]#_ +:NKZ&/3=BR"X)RI5L;2,=< MY% &5XT_U>@_]AJU_P#0C73UR_C)@T.@,IR#K-J1_P!]&NHH **** "BBB@ MHHIKR)$NZ1U1>F6.!0 ZB@'-% !1110!YW\58YVL;*229%T]9!N1RGS2Y^3 M9&).,].VE3ZOHUO!%I[7T:7223 MPQN$E,8# ^6Q( ;)'<<9K2\,6=SI_AC3K2\BCBN(H561(^@/^/K[YH UJYH_ M\E.3_L#-_P"CA72US1_Y*XCD%M'<%7+21DJ"^1P"%RV[H "O6O6:\>U" MQF.NWFHA=-$"^((XSJC6TIN8CO7Y _0)TCSTR<5[#0!2.L::-6&E&^MQJ!3S M!;>8/,V^NWK61:?\E&U/_L&VW_HR6J^J>&+[4O&-IJ1EM8;&W5_GBWK<'?&4 M(_N]P0W48QWJ'0-+CTGQ[JL$=S>7 ;3[=MUU.TK??DZ$]J .RHHHH **** " MBBB@ HHHH **** &N-R,OJ,5QWA'PO;Z))#:KXAU&[N]/B5)[4W),"[E./W> M.!CD#/:NR.<<=:\O\)M>K\4]42;0=-LYI(6DNYX9VD)P<*4.,#=G)4\\?F = MCXLT6^UBSLFTR6W2\LKI;F,7.[RVPK*0=O/1B?PKEM6^&VI:IX*L_#O]KQ0Q MZ= L5L5CW+,1&%W2@C@@[L;>F?6O2:* //\ Q%X<@T^?P_>M=WT]T=7M0YDN MI#&QS@D1YVCZ <5Z!7,>-/\ 5Z#_ -AJU_\ 0C73T %%%% !1110 5RGBF+5 MY;!G,=CY4+:B)$"H878L2/7(K0ID4JS1)*ARC@,#[>$O?4****!'+>(- M'U6ZU^UU"S\0'2;:.V:!R$5][LZ[1M<;>W7KDXKH;*&>WLH8;FZ:ZF10'G9 MI<^N!P/PK@OBI>0_9M/TZXTZ[GCDE6<3PRR(D91U/S% 3CN>X )'-=IH%Z=1 MT"QNS;R6_FPJWE2$DK^)Y/KD\^M &7<>-=.@\8#PWY]M;WXF![2YAG5='8$Q2!@#YPZXI]_X#TS4?%::]-++NRCRV MV%,S3[&VM$?1R66WB6,,?.')P.: .PHH MHH **** "BBHY[>&Z@:&XB26)QAD<9!^HH SSK(&MC3OL[_]=,]\9Z>E:EWAM8%AMXDBB7[J(N /PH*DT[61)11 M102%%%% ' :Q%X5L/%;R7<5Z9UFMYY85N&%NTLK[$M=_7C M>IBYE^)TO9* "N;M/^2C:G_V#;;_T M9+725S=I_P E&U/_ +!MM_Z,EH Z2BBB@ HHHH *Q=9OM4TZ*2XB^Q&$$"-9 M ^XGW(X]:VJYW5]5@N[+4[)8W\R",G M2>#-.>UU?PO=LNGK!06#QSW?R-_K7+')8?.,CG;VKUQONG R<=/6O- M?"%UH'=4TW5(/,VP7-QOBM@1\Q1-Y"ALXRJXY]Z .WU[7K3P]8I=7 M:3R^9*(HXK>,R22.##>K<8..N* +GB^:.:#P\\;AE;6+1A]"375UP7B/PU MI6F2^'[N"SC-\-7M$>[89EDYP2Q[DXYKO: "BBB@ HHHH *R/$J*VC,Q4$B6 M+!(Z9D4']"16O63XD_Y C_\ 7:'_ -&I0--K5&JJA%"J % P .U+110(**** M .!\<6DE]XAL(?+M+Z);*>4Z?<3S)RI7,H$:G) ^49_O<5T7@YG?P?I3272W M3&W4^>.:P/'D^GVNIZ=+=1>(8)G1XDO]'4G:IY,;X!X. 1 MQVXKJM BM(-!LH["&:&U6(>7'.K+(!_M!N<]SF@#1KFC_P E.3_L#-_Z.%=+ M7-'_ )* MK#:[A_X2]$WJ5Y+X_GDB\>Z>\%];+=K]G6T6:69?(8N MQ;A%*[7 VDMTXKU:$RF",SA%FVC>$)*ALZK,;"]L\:?;KLNXPC'YY> M0 3Q73G2M/.H#4#86WVT?\O'E+YG3'WL9Z<5C6G_ "4;4_\ L&VW_HR6@#I* M*** "BBB@ K*UZ*-=#OY%10[1' Z3>J#$>28__BJ .C'045F#5+G_ * ][^F5[C["85RLCQX+>9MW% M=H^[G -=PY(1B!D@<5YSX1\0'6_$8;4+'5;2\**PC,,JVS2^7B1L$8!'W1SS M0!Z/16/XBU[^P;2WD2SDO+BYG$$$$;A2S$%NIX PIK-U#QM%:^$+3Q):Z=<7 M5E/;_:6.](_*CV[LL6/7L .IXH ?XT_U>@_]AJU_]"-=/7">)?$6D:D_AZVM M]0MFO#J]H[6GFKYR?2N[H **** "BBB@#.O-72TO1:+9W=Q+Y8E M/D("%4D@9R1Z&L'6/$4=YI,R16-VY6:'[B@X'FKUY&*VD_Y&N;_KQ3_T-Z9X M@BCBT64I&J[IH2VT8S^]2@I.-G=:C_[:D_Z ^I_]^T_^*JWI]_'J-L9XXY8\ M.T;)*N&5E."#^54[:RU"/6Y[F6YW6S9VIN)^@QVQ2Z#_ ,>UY_U^S_\ HPT! M))/1W-6BBB@DYKQQIL.I:'&)]0M+-(;E)=UZF^WD/("2+D94EO7J!6AX:M8K M+PW86T%W]KCCB"K/C ?W'H/3VQ7->/O$1TNXM=/EMKDP3A9!<6\+2-&PE4'@ M*RD!2S8(YQ75Z(;9M%M&LY))+I! Q],"@#C=<\0>((?B9I&GV] MA>)I8\Q,A/W=W(8BP)?G:JG';U/:KNFSZG/\22=3L8;1QHY"+%<>:&'G#DG: M,5VF*YH_\E.3_L#-_P"CA0!TM%%% !1110 445D0ZZ]PADM]*OI8MS*KC8 V M"03RV>HH 1HH_P#A+4.Q<_8V;..^\#/Y<5L5S!U.X_X2A&_LB]S]B8;?W>?O MC_:J_-KKVT1EGTF^CB4C;>+]5T6U^)&AQ7 M=CYETH4,VQ"9@[8C4 \MM8;N.F*])KR7Q]]K/CZTELWB:6!+;9<2F8)8LTI MW%!M E^YSFO5H/.-O']H"";:/,$9)4-CG&><9H DKF[3_DHVI_\ 8-MO_1DM M;[7,"7*6S31B>12R1%AN8#J0.I R/SK M/\ DHVI_P#8-MO_ $9+0!TE%%% M!1110!GWW_(4TO\ ZZ2?^BS3?$'_ " +W_KD:=??\A32_P#KI)_Z+-1>(V<: M'W_7Q-_Z,:K=J\KVL33H$E*@NH[&JFB?\ M@]O^OB;_ -&-0)JQHT444 -M>S/@(V[[N.?I7G_AGQUX>O\ 6+'0_#^ER+:A6B^T%-BP MLJLP3N22JYZ].M '6>(- M_$-C';S3W%L\,HFBGMG"R1N 1D$@CH2.G>L:^^ M'FGWNF6>FKJ6IV]G9/&]O#%*NV,H@5>"IR!C=SGDYKKZ* ./\66%M;)X?=8D M:<:Q:AIR@WORFZ7]OTO3]\+RR7%[=/;N4#*"D;@%03GJ03CI7<^'$AB\.:?' T+1+"H1H+ M@SH1ZB0\M]37/^,M>\,:!JEK/J]FUWJ4D#QVL2P^89 6'R 'CV^RQ31AE@( ,?^R<<9'2@#2KFC_R4Y/^P,W_ *.%7IO%&CV^OQZ' M+>JNH28VQ%&QD@D+NQ@$@$@9S@51/_)3D_[ S?\ HX4 =+1110 4444 %97A MS_D!P_[\G_HQJU:RO#G_ " X?]^3_P!&-0 -_P C8G_7BW_H:TOB/_D 77T7 M_P!"%(W_ "-B?]>+?^AK2^(_^0!=?1?_ $(4 :E%%% !1110!Y#XG-[)\4+) M+M8$22:$6FZ*'S=J/DGF4;@3G!*DCL :]>KR/Q_"9OB%8V:IJ/=5A-]>WF=/MVWW<@=A\\O .!Q795 MS=I_R4;4_P#L&VW_ *,EH Z2BBB@ HHHH SK[_D*:7_UTD_]%FJ7B'4[5=,O M;3=*T_ED;%A=LGZ@8J[??\A32_\ KH__ *+-:- %.SU.TOG9+=W9E&3NB9>/ MQ J+1/\ D'M_U\3?^C&K1K.T3_D'M_U\3?\ HQJ -&BBB@ / R>E<'IVL>'K MKQA*NDVFB7-U&NR":WGC29LC+@#^+'.2/<5W3G;&Q] 37D/PWDTR_P#%IS(&>">"'SB&0DI&RG*A.X 'O0!Z#XKUN\T:SLUTZW@FO;RZ6VB%PY M6,$JS$L0,]%/YUEW_C>YB\ Z;XFLM+\[[8D#NCR + LA4$D]3C=@8KI-8T73 M]>L?L>I6XG@WAP-Q4JPZ$$$$'KT]:@/AG1SI\MA]B3[)+Y>Z'<=O[O&P 9XQ MM'3TH YGQ7XCTR[U71M)AEE-Y%K=N'0V\BJ-K'/S%=I_ UWE*?^AO5#Q#K%D^G36R/*TRS1958) M#]V12>B^@-7T_P"1KF_Z\4_]#>M6@"E9ZK9W\C1VTCLRC)W1,O'X@57T'_CV MN_\ K]G_ /1AK5K*T'_CVN_^OV?_ -&&@#5HHHH Y;QK=Z);6$:ZI!IMS/(0 MD4-XZJS*2 VUCRO;GH.]:^A20OI4(M;2.VM$4+ L4J.A3'!4J2,5Y_\ %=K* MYU+2].U#5([&V=0[+)#&ZS9E1,,6(.T;MQ /0'->A:%%%#H5E%!/;3Q)$%26 MUC5(F'JJJ2 /I0!@:GX9U74_&EOJ5Q!^%>LUY3 MJ6C^(;WXF07AL-932[:Y#).D\$@?D?=#$&./U R3STKU:@ KF[3_ )*-J?\ MV#;;_P!&2U0NO&=U;>-WTC[)$]C&XA MZFVAZ_\ 9IK*&%#_ &;)GH0^'M$P?%GQV;FVUVZ\)7*>&UMB\ZQ0$[^#\ZN>@SCVQ7>>&_B;:^(=#@U)=!UN, M2$C;%9O,G!QPZC!% '57W_(4TO\ ZZ2?^BS3]4M)[VR,-O/Y+D@[LGIZ<5SE MUXKBEO;*5=$U_;"[%O\ B62="I'IZFIKKQ[86-K)=76E:[#!$NYY'TV0!1ZD MXH'%N+NCI+6*2"UBBED,CHH#.>YJIHG_ "#V_P"OB;_T8U9?_"9V_P#T!=?_ M /!9+_A533?%<=K:-')HFOAC+*__ "#).C.Q';T(H$W?4["BLS2=;CU=I0EC MJ%MY>,_;+5H=V?3=UK3H 1L;3GICFO.]&M_"VG>,K"/3;C5+NZN(WDCE^T&6 M!#P>W'&<9KT0C((R1GN*YGP]X,@T.5[F:^N+R]:9I3--7OM*L+%-.N(+:>\O%M_M$Z;TB&UF)QD9^[CKWKF=7\>: MI_PAFA:G9/:6MW?6=ZYKVI:Q:Z,UOX6UF3R+VVO)'2./8RCYCM)?)Z\9 K;_P"$QNO^A0\1?]^8 MO_CE '4T5YCXD\5^.KK2+V'0?"M_;7;G;;RRQH2JY^\?G(SC/K7.V?BCXI0Z M9!I=]I\JZI-#*(W-FK.VW'S9#@9&X=NXH ]PHKQ7P)J7Q'\/:3=0:UHNJ:E, M\N^'SL.5&.1NW]">W:O0%\8W94;O!_B$-CD"&+K_ -_* -5/^1KF_P"O%/\ MT-ZT+BZ@M(_,N)5C4G&6/>N.7Q+?#7)+S_A$?$'E-;+$!Y,6*P90RD$$9!'>LO0?^/: M[_Z_9_\ T8:R(O%EQ!$D2>$/$05%"C]S%T'_ &TJKIGB:^LXIUD\(^(,R7,L MHQ#$>&8D?\M/>@D[:BL/2_$,^I7OV>3P_J]BNTMYUW&BIQVRKDY_"MR@#C?' M-AH%VJ3ZQ>WD4EM \D<-K*%>1&'M)/#.GM8?:/LOD@1_:/]9C M_:]ZJ:_X67Q!J>G7%Q>RK:VC%GM-N4F/OZ'W_+%;5G:QV5I';1-(T<8VJ9'+ MMCTR>30!/7-'_DIR?]@9O_1PK$U3QIJ=C\01I<<<,EBDT5LULJ9GE,D,DN]3 MG'&P+CISUI#KFI'QDNK_ /"(Z]]G&GFVQY46[?Y@;IYG3 H ]!HKEO\ A,+K M_H4/$/\ WYB_^.5RWC#XK:OX>ETY;7P;J1%S+L;[6@7=T^5-A;YCGO\ K0!Z ME17E?BGXLZGIND3SZ3X1U,W%O<+!<&\C'EPDJ&P=C$DX*^W/7M71:?XWU"YT MVVGG\&Z^DLD2NZI%&5!(R<9<''U - '95BZ)#]H\-I#YDD>YI!OB;:P_>-T- M4?\ A,+K_H4/$/\ WYB_^.51TGQ+?6.FQV\OA'Q 75G)VQ1$3=*H<8[X4D M8_&@DNT444 >;7USKFO^+)K*V?4([32KQ9&:%1"[J3]WD[748[X.#T->DT44 M 4SI6GMJBZF;* WZIL%QY8WA?3/6KE%% 0""",@U0U6[L+.R":A.+>WN&%L M'/ W/P!GH,] 3WQ5B\O+?3[.6[NYEAMX5+.[= *\RENK[QU?1V]FN=/=OM*) M?QB2/8RLH8J"!)&>P!#HX&?8 ]+L;&&PTVWL(LM!!"L*!SDE5&!GUX%3QQI% M&L<:*B+P%48 _"JFCZ<-(T>TT\7$UP+>(1^;.VYWQW)J[0 5CZXVD:C&?#NH M7L<5:/::]X MIE'^DNMP3#<_VP]H-H\MR-L38"R(P=F3C*\AL\4 >P#@45'!%Y-O'$9'D**% MWR'+-@=2?6I* "BBB@ HHHH K7^GV>J6K6M_:PW5NQ!,YDU.)#=.;0Y>W5AZYJ;^%;F68FV4)OQC=@!MO7%3>(M6A&B:[!::K# M8WME;;I)Y.%MRRDJ3]<=LUP^A:+JWB;;;W+ZKI]I;SQW?VF>/;<.6C9'A\WC MS!@C$HYVG'7H >L44U$$:*BYVJ !DYXIU !1110 4444 5&TRP?44U%K.W:] M1-BW!C'F*OH&ZXJW110 57OK@6=C/=&,R>3&TFP$ M@9P"2 #]34TDB0QM)( MZI&@+,S' ]2:\JUW6I?&%Y/::1:2R6KDV,H9V43J5W8=<9ASDM'+@@E<'@T M =QX3N-'U.QN-;T>9I(]3F\^8,W*2!50J1_"1M (K?K"\-^&X]!%U.]S)=7U MXROMV@ J.>:.V@DGF<)%&I=V/15 R33V8(A8] , MGBO/?&6H2:O%H.X0QD1MB16VGLPP0?2NCKC_"WANX6^7Q)JCS1:A 6LT! M'EAB=S-*<;E;;@QLA&& SUH H7NKZEX[UO\ LZPC9=-!C$UO.IBEA7=N^T @ M]>!M()PRD%>M>DZ7IL.E60@BP6)WRR;0IED/WG(' )/)QWJ+1M%M=%M#% -\ MLAW3SL 'F?NS8[GKQQDFM*@ K&UCQ%!I4JVT=O/?7Q3S?LEL 9/+R 6Y('?@ M$Y)X&:NZMJEIHNE7&I7TGEVUNF]V_P ^_%>96^GZKXK\5RZI:PC29E?9<;OG M\LJ,+YD9.!.JMN1QN0AO44 &CZ4GC+4QJ$&HZE;ZAIU]-!>3AW@=HG0E"(W! M56^XI&/X37JL$0@MXX0Q81J%W-C)P,DN;)4>,2B*ZN/+\X6D9^ M_(T8Y< =1[YZ"N<\&>$8-0M;/5=0"2VB[I+.U 81)EOO*">8FVHZHP.T]* + M7@[PSMJRD#S5P%N,'YDD(R&' ;@D#I7?444 %<=XL\7V] ME87UI:7,D-PJ-%_:"PF6WM9\ JDI&=N6/ KB?!&CZZEZZQ-+!81R&-I+LAI84#9>W*8VN[-@F?GVMGY/VFXBA\Z011>8 MP7>YZ*,]2<'BI7=8T9W8*JC)8G KSCXD:E?216EK'%#+I%ZBB!_+66.ZG8C M;$S<>4".5D!Z]^,$ J>(O%NIZ]JG]EZ!"ZO$'!M;J'*WH/RYQD!D&3N5BI 8 M'!Z5W'AOP[!H=C$-NZY$8C+L=QC3J(E;&2BDG:#G I/#_AFVT0-<.S7.HRKB M:[EY=P.F>V< D ;L9-;M !4%Y>6VG64UY>3)!;0H7DDO-?'>NVN MLN=!LH;BXFMV^TF>W;#))&0?W*D;9W3.6CST]Z (_%'BJTN=5TBVUC3[ZVTV M:Z$+1SQE8[A9,>7,DB'AE;&5)! 8\<5T'@;PA+X7L2D][=R,&D186N6DA6/S M"4(4_=.W&<4_P;HNJ6-@#JTL.TJ!':Q9==V=QF=G&XR.>?\ 9Z5U= !1110 M4444 %%%% !45SDE<*J]N2>!5;6=0?2M&N[^.SFO'MXS( M+> 9>3'85YPUW?>.Y-*$6HP-&R/*L<2X0E6XG,;??BSF/:^">6'L %W>W7C/ MQ:D5H)$@B61)+*6Z=!A'VEY @W0R?-N0\AEKO?#&C2>']"BTM[@SQP.XA9CD MK$6)12>Y (&:-'\,Z7HD@FLK;RYO*\EG#L:LT4 %%%% M!1110 4444 %%%-=UC1G=@J*,LS' ]30 ZN'\;>+)["2'3M&G#7QE5)T\HD M;6!Q&LGW4F/5 W4_6CQ#XV+:'$^ALB27LC00WEU\D4>WMU9ZQ?32HPGCED@O%/FSHO*K2-AE)!U&,B@"YX(L]8M-:OWN? MM%QI>I0)="2ZM?L\J3 ["LB="S* 20!T!QS7;VEI;V-K';6D,<$$8PD<:X51 M[#M4U% !1110!B:SX8LM9OK6]D)CGA!B=@H83P-]^%P>"C?H0"*U[>"*UMXK M>! D42!$4=%4# 'Y5)10 4444 %%%% !1110 4C,$4LQ 4#))[5G:WK=KH-A M]JN0[L[B*"",9DGE;[J(.Y/_ -?H*X;Q)K6I^(-1LM.L%ECL77S1]EN=DEVZ MY$B13 [0T1^;:>'QUQ0!!JGB74M?UU(](.JMI,D(>-;18TDEP^WSXF8E9(LD M!D;!P0<8KJ_"&C7MCX;?1]:2*YBMKAX[=G1<20ALH2O(&.@'8 4SPQX,3P[J M$]^;H33W$(295B"IOSDN@_@W<%E'!/-=50 4444 %8MOX6TNUUB?4H8<-,XF M:$@&-9AD>:JX^5R#@D=>];5% !1110 4444 %%%% !1110 53L=)T_39+F2R MLX;=[F3S9FC0 R-ZFBB@"Y1110 4444 %%%% !1110 4444 %%%% !4-W:07 MUG-:742RV\R&.2-QD,I&"#110!QGA_P#+HVH3Q2WZW&CK(7A@9"99>,*L[G. M]8QPHZ=">17(=*FT M[48?-@D'8X9#V93U##L16=X8\+CP_!FXO9+^[V+$)G4($B7A$5!PH ZXZDDF BBB@#H:*** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$! end GRAPHIC 42 evax-20211231x20f035.jpg GRAPHIC begin 644 evax-20211231x20f035.jpg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evax-20211231x20f036.jpg GRAPHIC begin 644 evax-20211231x20f036.jpg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end GRAPHIC 44 evax-20211231x20f037.jpg GRAPHIC begin 644 evax-20211231x20f037.jpg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evax-20211231x20f038.jpg GRAPHIC begin 644 evax-20211231x20f038.jpg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evax-20211231x20f039.jpg GRAPHIC begin 644 evax-20211231x20f039.jpg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end GRAPHIC 47 evax-20211231x20f040.jpg GRAPHIC begin 644 evax-20211231x20f040.jpg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evax-20211231x20f041.jpg GRAPHIC begin 644 evax-20211231x20f041.jpg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end GRAPHIC 49 evax-20211231x20f042.jpg GRAPHIC begin 644 evax-20211231x20f042.jpg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end GRAPHIC 50 evax-20211231x20f043.jpg GRAPHIC begin 644 evax-20211231x20f043.jpg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�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evax-20211231x20f044.jpg GRAPHIC begin 644 evax-20211231x20f044.jpg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end GRAPHIC 52 evax-20211231x20f045.jpg GRAPHIC begin 644 evax-20211231x20f045.jpg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end GRAPHIC 53 evax-20211231x20f046.jpg GRAPHIC begin 644 evax-20211231x20f046.jpg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end GRAPHIC 54 evax-20211231x20f047.jpg GRAPHIC begin 644 evax-20211231x20f047.jpg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evax-20211231x20f048.jpg GRAPHIC begin 644 evax-20211231x20f048.jpg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end GRAPHIC 56 evax-20211231x20f049.jpg GRAPHIC begin 644 evax-20211231x20f049.jpg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

    \?MN/\ M:IBF ??,4>@_$"&P;9?EIGC M>(QR:@QQ(T.TS!MO3S!N"=NV.E 'H+V.F1E ]K:*7;:@:-1N.,X'J< _E3_[ M,L/^?&V_[]+_ (5Y79Z'XF\0ZA.+Y]6@:WOFF2669HE10LZ+Y9[-\T>2O&W' M..H/T .Y_LRP_Y M\;;_ +]+_A436NDI,(7@LEE.,(40, MY\S%R2Q8L"/F0Y4 8XV\8SFJ9\(>*I9+:[5UCO([5(GDGO3,YD7SB6#E>!N= M2!V_2@#T4V&F"01FTM!(P+!?+7) ZG'XBDDL=,A4-+:VB*2%!:-0,DX _.N! MD\*^,(Y-T6HO.L:8!DO#YSJQMS(BR;JCI'_(/'_767_T8U7J "N2\6^(=1T' M5=,,'D_8)8;EIPT+NS.B!D5=O<\\=\&NMHH \Q3XD:TVG2WC:5;+%;VLLTKM MO D83&) G;GY6QGZ=QMDMK6&.&%!A8XU"@=^E '!7 MWC_4;&;08([:TNY+^SBN)/+$@:4M(B,L8P<'#%OF_NFLR?X@:_?0%K:&*V@\ M^: S>1)N<&W9X\ YVMN&.>^ 0.E>H?9;:>#3+ M)E^U>3&#*1L7#D%_0,5"JW )SP<8/J=4['2M/TSS?L%E;VWFG+^5&%W?7'U/ MYT <]X<\3ZKJVNSV=[IL=O;%)GA="Y8>7-Y>&R,<\$8[5UM%% !574_^03>? M]<'_ /035JJNI_\ ()O/^N#_ /H)H F@_P"/>/\ W!_*JFE_\OO_ %]/_2K< M'_'O'_N#^55-+_Y??^OI_P"E %^BBB@ HHHH **** "BBB@ HHHH **** $; M[I^E5-)_Y ]E_P!<$_\ 015MONGZ54TG_D#V7_7!/_010!SGBB;4XK#4!I,W MD7,M]:0F0*251VC5B, X.#U[#-9#>/->@33VET>#_2W/\ M6$%GYXP/J1W%G_R$=1_ZZ)_Z *O4 >?Z3XU\0WFJ6,=WI-JEIBR M"7'48R##S_OC\67OCO6[.\NXVTJW6V$\D4-P?,(B5)UB,DN!]W#;N/3TY'H= M% 'G^E^.=>OKVT$N@ 03;8S&A82ES"TH*[P%"G;CYB/O"JUW\1-836-0L+32 M;>5[>0Q*A+EHFW0@-(5!7!\TCY2>5KTFHH+6"V,I@B2,RN9)-JXWL0 6/J>! M^5 'F^J^._$,,U_:V]E:126D@621HY6$*++&I=QC[KJ[,N.0%/7M*WQ#U;S[ MQ&TNVMXHKP6_GS,Y$"[G&Z15&[#!%*G@?./J?2** /,4\;:]:7$\]Y;K<1V< MMU]IBMXG79"D\2@X(R7".6&#R.V>FOH'C'6-3\2+I=_I$5HHMUED_>'>"45P M5!^\N6*]."IY[5V]% 'F$?Q(URYM+F6TT>&0PO*P9TE0/&D/FXQ@D/D%<'OV M'2HKGQ[KFGR7$UU%'(8;FYA2%(V4*OF0B+>"/F.V0D8(S_+U2J]Y8VNHVS6U MY;QSPL02DB[AD'(/U!H \Y7XD:V5EVZ19RF.Q2X!BF++(S*&RA&=R DH<#@@ M_2MC1?&&J7OB6WTB_L8(=WVA'>$.V7B=ESSC:A"@@G.2<9'&>QM[>&TMX[>V MB2&&,;4CC4*JCT %2T 4=(_Y!R_]=)/_ $-J6#_D,7O_ %SB_P#9J32/^0K M] !1110 5SOC+Q%-X;TNUN81;;I[I+3^= 'ER_$C6H)$\S2PDUT1(EK<[]_\ J[<^5&%7J3*V M"WISZ!-0\<^(;VVEEALI+/[/-.ICA.Z0[89B$<$':040@XYST]?4FMH&NDNF MA0SQHR)(5^95)!(!]#@?D*EH \UN?B#KMI%,[Z-"4+%89/GQ&JSF(M+D 8. M1@CK7?Z5=2WVDV=W/$L,TT*2/&K;@I(!(![CWJW10 4444 %%%% %*T_X^;_ M /Z[C_T6E%%I_P ?-_\ ]=Q_Z+2B@!-(_P"0>/\ KK+_ .C&J]5'2/\ D'C_ M *ZR_P#HQJO4 %%%% !1110 4444 %%%% !1110 55U/_D$WG_7!_P#T$U:J MKJ?_ "";S_K@_P#Z": )H/\ CWC_ -P?RJII?_+[_P!?3_TJW!_Q[Q_[@_E5 M32_^7W_KZ?\ I0!?HHHH ***\^\5?$ZUTN=]/T:);^_!VLW_ "RC/ID?>/L/ MSII-[!<] ) !)X JA/KVCVK;9]5LHV]'G4'^=>$ZA?Z_KSE]6U68H?\ EA&= MJ#VP./YU2_LBS1<[&8^I:M%2?4AS/H*#7]'N6VP:K92-Z+.I/\ZT 01D'(KY MO;1[)A_JRI]FJW87FN:$X?2-6G11SY,C;D/X'C^5#I/H"FCZ&HKSSPO\3[?4 M)TT[78EL+UB%67_EE(?Q^Z?T]Z]#K-IK)=$LKE[>ZU6SAF3[T;S %?J* -2BL3_A,/#8_YC=A_W_6H MI?'7A2 @2^(=.0GINN%&: .@HKFO^%A>#O\ H9=+_P# E?\ &C_A87@__H9= M+_\ E?\: .EHKFO^%A>#_\ H9=+_P# E?\ &C_A87@[_H9M+_\ E?\: .E MHKFO^%A^#O\ H9M+_P# E?\ &C_A8?@[_H9M+_\ E?\: .EHKFO^%A^#O\ MH9M+_P# E?\ &C_A8?@[_H9M+_\ E?\: .EHK'TOQ9X>UJZ-KIFLV-WUB96#* M4&"#D'BI:0PHHHH **** "J&E_\ +[_U]/\ TJ_5#2_^7W_KZ?\ I0 ?\Q\? M]>O_ +/5^J'_ #'Q_P!>O_L]7Z "BBB@ K"\3>+]'\)6L4VJSLIF)6**-"[N M1UP!Z5NUXK\9H)9/%>B.L;LAMG4$#(SN_P#U4T#.^TWXC>'=37=':UK,%W Y M,9 KZ%L?^0?;?]/\ KK+_ .C&K,\4^)4\.61N'0N ,X%:>D?\@\?] M=9?_ $8U>=?&>]-;Z@RI)\;+-,8A;ID@]149^.5B$W&)@/<5 MX]IW@_4]1QJNV."!_F42OC(]?I5^/P5J1OH(;@1R6S2!Y)$<$JGICWK=4)/H M9\Z/;;'XF+=6L-S-%]GBF($6_J^>F*E@^)=C>_>J5_<1:1HUQ;AE&H704SHJ@B-L8+ YXS6C MHQ6Z)YVSW2/XE6$SD13P.,C&''^-67^(%F@X.XYP<#I7RQ;M#/(KQ\2.-@50 M!M]Z]$\,6TSP"2Y#^3$,1EO^6A'4D>@I4Z<).U@E)H]FB\:V>'IV(]I([ M^3XLZ5&[J6DRA 8>7T/YUJ6?CNWO+]K6..4NA4-\G )&1W]/YU\XWR?\3.>> MQ#R0L_P , M@EB5QW%0:G_R";S_ *X/_P"@FDTT8TZ ?[(HU/\ Y!-Y_P!<'_\ 037*]S8G M@_X]X_\ <'\JJ:7_ ,OO_7T_]*LVKI+9P21L&1HU964Y!!'456TO_E]_Z^G_ M *4@+]%%8WBK6U\/>&[S4>#)&FV)3WD/"C\S0!P_Q&\:3_:'\-Z-*5F(Q=SJ M>5!_@![<=3^%<+:6<5G'M098]6[FHM.BF*+6SENG(3A1]YCT%:<=E90 MG+N'(X)<\9JM6+0SQ>R@\A6'TQ5B*[CDX)V'T;_&K,D%A*K"/R@XXRIZ'\*R M;FW:"0*P^4C*GL:-4&A&]9D+./EM)G/ M)_V">_'0_AZ5PEG,0PB8Y!^Z?3VIFJ1'RTN8G*3PD,K*>1@YS^!YJ914D-.S M/I.BL/PCKH\1>&;/4#CSF79,!VD7AO\ '\:W*Y341ONGZ54TG_D#V7_7!/\ MT$5;;[I^E4M&D271+%XV#*T"$$'(/RB@ L_^0CJ/_71/_0!7SQXN8CQAK '' M^FR_SKZ'L_\ D(ZC_P!=$_\ 0!7SCXLDSXVUL>E[+_Z$:J.XI;%.- _WAFH] M0T>*_LG1$ F7YHS[^GXU+"21D G'7 J[&3Z'\JULC*[/.#$H)!3!!P0>U)Y: M?W171>)=.,=R+R)#LEX< =&]?QK!V-_=;\JJR[$MON,\M/[HH\M/[HIU.,;@ MD%&!'!!4T6G M]T5( 3T!/T%!!4X((^HHY5V#F9VGP<4+\5]*P,?NY_\ T4U?55?*WP=&?BOI M7_7.;_T4U?5-<\MSHCL4=(_Y!R_]=)/_ $-J6#_D,7O_ %SB_P#9JBT.>*;3 MV$4BN8YY8WP?NL'.0?>I8/\ D+WO_7.+_P!FI#+M%%% 'FWC7XJW'@?5Q9WW MAF>6"0;K>Z2Y 24=_P"'@CN*YG_AHRT_Z%FX_P# M?\ XFM3XG^#_''C>]2T MLQI\&C6S;XD><[Y7QC>WR\=2 *\^_P"%#>,_[VF?^!#?_$UM%0MJ9MROH=8W M[1EMM.WPS/NQQF[7&?\ OFO&->\0ZIXFU274-5NWGF,_[VF?^!#?_$TI*%]03E;0 MZ[_AHRT_Z%FX_P# M?\ XFM;PW\=]'UO6X=.OM.ETQ)SM2XEF#IO[!L 8!]: M\[_X4-XS_O:9_P"!!_\ B:UO#GP"U=]:A/B*>U73$^:5+:4L\O\ L=!@'N:A MQIV*3D?0XYHID,,=O!'#$H2.-0B*.P P!3ZP- JAI?\ R^_]?3_TJ_69I$T4 MCZBB.K/%>.KJ#RI(!P?P(/XT 2?\Q\?]>O\ [/5^J'_,?'_7K_[/5^@ HHHH M *YKQ[IUOJ'@S4Q-'EXX&>.0<,A'/![=*Z6O%OB;\1VENKKPUI)9$C)CNY\< MLW=%]O4TTKL3=CS31X8;R]^SW&NZA"3G:HD;)_6M2YTHPR.(M5U-U7H3=-_C M5?04U!6/DVT*DG_6-'DG\37H4FCZN=#Q:5JUOJ\$LENZL(I#&Q4Y!([@^AK*:U+@]"_1114%A1110!2M/^ M/F__ .NX_P#1:446G_'S?_\ 7/^NLO_HQJX7XI:8=72RLR MF8FD#2'T4]7"W,K[ M"E>VAY+?7=W>ZM]GM80\ B\VW!7 DC^Z\?IGOS4?B!HM#\/O!'*!>2IY4!)_ M>1Q'G!/M6!;^-M:U.1;.QC+7+'""&(?F?3ZUK?\ "$23(9M7U)FD=M\C(N0I M[#>3_3%=W/SI\FISVMN<1!?7\EH\'VJ8Y]9#Q[=:C3?)%YRF:)_9CNKJ^PA9/DZ M ]/SIEII$\FFRZ==VTZ)*"H[_ )YK.O\ 4]/\-V2:;9E'NCPQ902!_$2?[Q].U5_"WG:KXCB6 MU0+%$0S2'HJ^E0VE[O4JW4^H-/\ ^/&'_=%)J?\ R"KS_K@__H)I; 8L8AG/ MRCFDU/\ Y!5Y_P!<'_\ 037!]HWZ'EOP@\8^9 GAJ_D^=%W63L>J]3'^'4>V M?2O3=+_Y??\ KZ?^E?*MI/-;2V\]L[)/$RO$Z?>##IC\:^GO"\MY/I)EU"%8 M+QY"TT2G(5\#(KJQ=)1ES+J<^&J.4>5]#;KR_P",EXQM-)TQ6P)YFD<>NT # M_P!"->H5Y'\70P\1:$Q^YL<#Z[E_^M7-#XCH>QRIS$AP054=#QP*RLDY8]3S M6I.";>3_ '368A&Y2>@(KI9DCH846WMXT1>>!CW/K7+ZEKB:?>M&TL6\RLQ1 MP1LX/(/X?F:Z+4%'E288@N."/X6QP:\[U^*82&.XMMA*@#.&&/4$=3S1-V6@ MTB_I.NW-S?R-)<2Q*,,%"A0>1R?PR#7:U0B%2 !M88 M/O67(09)".FX_P ZTK<8MX_]T5:$SL_@U>,J:QIC'B*195'URI_]!%>J5X_\ M) 3XIUHC[ODC/UW_ /ZZ]@KEG\1JM@/2O'?A/XP\B\D\-7TG[N21VLF8_=;) M)C_'J/Q'I7L7:OD@R/#=&6-V21)2R.IY4@Y!'O73AJ:J1E%^1SUYN#BT?5-G M_P A'4?^NB?^@"OF3Q3+_P 5]X@7TOI?_0C7T3X4N+^ZL#<:I"(;Z1(FF0=F M\L?EZX[=*^:O%4F/B'XC'I?S?^AFN>*M*QO)WCM5-:L8Y4AED9E:-=S*H!)!YQUX/\ *F@9AS1L4=I,"16P/7@X(SZ=Q_\ M6J7*SS3/),\D@)Y,A42'/J>2:;<3 QR,5422?*H()PN<\=AC&!]34K0R&65@ M-I93@'!*Y(SP>23SDTQ$!D9-P_AV-PLW#<8].:E3[1!^\C#R,8ER%^;Y2O(Q M] <$.QX MEH?B_P#X1KXF:Q;74F-,O;UUESTB?.%?^A]OI7K]N$?\\XO_ &:OFOQ< M,^,-9!_Y^Y/YU[+\*KS4KWP\7U%3E$CCMY&^])$-P4G]1GN!77B*2Y(S7D84 M:CYW!G>T445QG2%%%(S*BEF(50,DDX % "UY3\:_#VD2^'8M6;3X/[0-[;PF MY5<.R,V""1UX]:IZW\3M=\3:U+H'PYLA*WU)8^3:7#$;QZ!7)4_F*ZCP%\3XO$ MMX^AZU:'2_$,&0]NX*K*1UVYY!_V3]1FDX]4[@F>B4445!04444 %>*R^+6\ M*?%_5WF8_P!G7,R1W2_W1L7#_4?RS7M5?-7Q$_Y*!K/_ %V7_P! 6NG"Q4I. M+['/B).,4UW/H1'637$=&#(UIE6!R"-W45HUYG\)+O4KK2U6]0_9X8C':2L> M70-R/HIX!_#M7IE83CR2<3:$N:*84445)05Y+_PB6E7OB;5)9;&Z9GN6)D20 M\G/T->M5\O>([?7$\;:_+!%K A:[E,3VWF;<[N.G;&:TIJ[(F>U6_P /M%88 M*WZCWE_^M5R+X>Z'&P8?:R?>;_ZU>+Q:C>0L1_;'BJ!4 MV94].N[@BO6OA>EZEEJ/VLZBRF1#&^H!A(PV\]?>IJ1:6K*A*.R6YWU%%%8F M@4444 4K3_CYO_\ KN/_ $6E%%I_Q\W_ /UW'_HM** $TC_D'C_KK+_Z,:O+ M_CL<>'E)Z5ZAI'_(/'_767_T8U<-\4-,75XK2T?'E&0-(?\ 9!Y_/I^-.*N[ M(3=D>-:);Q>#_"+ZG<0&2]NBN0."N>40GL.Y_*N>\274^OZ;:ZIYK\#R;F$, M=L<@Y!"]@PY^H-;'B37K>\U74=+EN=MGY#1QD*2!.AW @#N3E?I7':;?R>8] ME)'6=+B:5B=0A"Q'Y>9TYPQ M/JO0^U.TZ 7,":#=3 "9RUG*%RT4N.F>R-WQWYJ*T>XT35G9FVW5O*5)(X9? M<>A'\Z[+3]!T^TEDUB)G$8JO'Q$#U R>O8?6E&+D_S!NQ3O3=VJ6&E6EQ M*)XANDD!P<8P,GW.X_E5H:EJ-C&3)>1/$!AG:$$@^E0+*DMW)=Y >3@?(.#7 M.ZSP/E6Q13P#(T:M=7\GF 9Q%#G^9KM?#>AKIKVME#* MV5<.TNW#.WO[5B1ZW#IIR:[;*Y2-'EX54 M' SZU5ZE_P#+[_U]/_2M*M1U)79%*FH1 ML7Z\U^,5B[Z1IVIHN?LLY1SZ!AQ^JC\Z]*K/US28MQN9]*O4V75JY0J?;T_G M]"*L31+-'M/!'(/I77NC'8LVKPWENA9%+H-I!&<5FZCHGR[K-3'@%0%;&T'J M>?KVJ"&9[>;?&1N''L:O#5GYW1K@]L473W I:7X>>VN2TRI@1[,[0<^N!V'_ M ->MAUATZS?RE"ISM0=,FJI!-4I)9KA_F9G;KCL/\ "C1;!N,B MB:601@]>I/85JLRQ1ECPJ#/X"H[> 0IZL>IJ.Z$US)#IUHADN[MA'&@]_P#/ M\Z-D!W_P;L6&G:GJ;K_Q\3"-2?11D_JWZ5Z=69X?T>+0-!L],B.1!'AF_O,> M6/XDFM.N1N[N:H#TKPGX8>#_ .V];DUB]CS864Q\M6'$LH.0/HO4^^/>O=6^ MZ?I6;X=LK>P\/6%O:Q".)85.!W)&2?J22:TA5<(M+J1.FI23?0EL_P#D(ZC_ M -=$_P#0!7R?XN?'Q$\2?]A";_T,U]86?_(1U'_KHG_H KY*\9MM^(?B,DX_ MXF$W_H9J(?$5+8KQSLH.&(SUP>M3"Y;^^WYUEB4?WA^=/$R_WA^=;F!J+=R* M'YT: 0RILD('0\B@S2DDF60D] M3N/-+(ZL.H_.HLCU'YT[A9CQ)( 0)'&>OS&E$TH.1*_3;]X],8Q],<5'D>H_ M.C(]1^=%T%F/5W0$*[*&QD XSCIFD9BW+$DXQR VWA63Q9\4 M-5M6#"RANWDNI!V3=]T'U;I^9[5[;90QV^HW,,**D4<,*(BC 4#< !5?P[IM MK8VMS-!'B6\NI9YG[LVXC\@ *N0?\A>]_ZYQ?\ LU:5:KG9=$3"FHW?"=%8C4-;<+*P.-L.<8SV!.<^RGUKU6O(-)3^U_VDM8N M)N1I=B%B![$J@_\ 9V_.KAO?L*1Z'X2\*Z=X/T&'2]/C&%&992/FF?NS?YX' M%;E%>,^([_4O'_C#7O"VF^(Y-'DTN,"SMHF*&]E RY=QSM' P/7-0W<9KZGX MYN-%^+\]KJ3W$?A^&TAMVD7'DQ32DLLDG< [2H;H._6G?%KP6-7TG_A)]'S# MKNE@3QS0\-*B\X]R.H_+O7G>EV5Y?>*[;2[#5KB+4-1M9K'5=.UU?M?E-$ X M0G@F-@258<^]>M^ ?"6O^&K$VNM^(?[3MUB$,%JL6(XE!S]X_,W!QSVXIIV= MQ-7-'P#XH7QAX.L=7.T3NOEW"KT65>&_ ]1[$5TM>0_!,'3]1\8Z&"?)LM1_ M=KV )9?Y(*]>IR5F"=T%%%%2,*\&UCPW/XJ^+^IZ=%N6'SE>XE'_ "SC"+D_ M4]![FO>:QM$T^VM[W5[R.,"XNKLF5^YVJ%4?0 ?J:UI5/9MM&=2GSV3'V=G; MZ?J<%I:Q+%!#9!(T7H &K6JA_P Q\?\ 7K_[-5^LC0**** "N%L+B-=X.:J-NI,CT*U9B MN"Q/U-4KG6XK2\N8I.?),*!!]YVE8@8_+]#6"-!UJXAC/VZ%+K=Y\L_S?/(G MRQ+@$?* ,GL23Q6=JEI>ZQK]CJGV:-(YDEL8H\D[F\IR)2>F VY5..A)[U<8 MI[LER?0] >X@258GFC61QE4+ %OH*CM)%D:0JX;)!R#G(/2L'^QKP&:W:V@D M,\J2?;2_S1 8^7&,Y&,#''/;G-WP]I9TJ*6$2ADVH @Z(0#NQ[$\XJ&E8N[- MJBBBI&%%%% %*T_X^;__ *[C_P!%I11:?\?-_P#]=Q_Z+2B@!-(_Y!X_ZZR_ M^C&K \9H!#$W.YW"+@9Y[?X_A6_I'_(/'_767_T8U6)[6*Y $J!L>HJH2Y9) MBDKJQ\;7]M<66L-=V\$OGQ732 [>OS$]/>K&L^#+ZYUJX>SM9WCN#YZ$#Y5# M+W)L^A\X6GAUOL5M+J= MK&UU!&%=RNY7 ^Z23U(]/YUG:I=7%_&J1VLT4>2%;R\%C_>([5]-R>&]+E.7 MMD..G'2F?\(KI&[/V2/_ +YJW7TLD)0[GR_;^#-5NT2YNKG^SXV.%79EN>A/ MIFMW1O"KZ9>AKZ'?PYIDA)>V0Y&.G:B7PWID\0CD MMD*#MBB-6,=; X-]3P*TT22WEEN=0N$D^8Y<')8 Y1OJ.EMG'_WS1*O=62!4[.Y\A16!^XUI)N/? M;TJ_I=A=IK]G_H[A%D'.WK7U;_PAVB_\^4?_ 'S4B>%-(C=66TC!7D';67-H M78N:."-)MP1@[!4FI_\ ()O/^N#_ /H)JPB+&@11@#I5?4_^03>?]<'_ /03 M4#)H/^/>/_<'\JJ:7_R^_P#7T_\ 2K<'_'O'_N#^55-+_P"7W_KZ?^E %^BB MB@#@OB#X(?6U75]* 758%Y4<>>H[?[P[?E7EMM>>=(T$R&&X0E9(W&#D=1@_ MRKZ/KEO%/@/2?$^9I%-M? 86ZA')_P!X?Q?S]ZTA4Y=&3*-SR"6WCFY=>?4= M:A%BH;ER5].AK7U;X?\ B[2WW0 W\*?=>V;+$>ZGG^=<_+-K-HVRYL)D8=I+ M=E-;*4619HM_88L]7(],T]W@M(\L5C7^?^-48Y]8NFV6UA,['C$=N[&MS3?A MYXKUJ57NH19Q?W[H@%?H@Y_E0YI!9F*FJ Y2."1F8A84 RSD^PKU;X?^")-) M)UK5U!U29<)&?^7=3V_WC^G3UK4\+^ =*\,D7"@W=_CFYF'(_P!T?P_S]ZZN ML9U+Z%J-@HHHK,H1ONGZ54TG_D#V7_7!/_015MONGZ54TG_D#V7_ %P3_P!! M% #;/_D(ZC_UT3_T 5X;XG^'D=WXLU6ZDT[4&,]T\NY-Q5MQSD8%>Y6?_(1U M'_KHG_H J]0!\WI\,;0]=-U/_P >_P *G3X6Z>>NG:E^;?X5]$T4P/GY/A3I M;'G3]2_[Z;_"G3?"W0+:,/FV_44JVOAY_NR[OH*>@CEH?A)XVD&R-B IX/)ST_&MBD,\0_X4[H'_/CJ7_?Y MO\*4?!W0/^?'4O\ O\W^%>W44 >8>#OAKI'A_P 36^J6EK>I-"K@-+*2HW*1 MT(]Z]/HHI 4=(_Y!R_\ 723_ -#:E@_Y#%[_ -_P#7.+_V:@"[1110 5X_9O\ V#^TG?1S?+'K-B#$QX!8*IQ^<;"O M8*\S^+_A>]U#3K+Q-H@8:QHC^69KC&3N(3@$*,'U.?:O,6AUZ_U?488+*#6KR]2/7-/U31 MYA \#?ZO>JOU!*@.F?\ ZWLG@/QSIWCC0TNK=TCO8U NK7/S1MZCU4]C_6LO MPYX!&@_$S5]C2RI!$\LK!(T4LS'H .2 M:?7DOQ6\:R7&/ WALFZUK46$,_E'/DH>JD]B1U]%SFB*N[";L,^!ZO?OXK\0 M%2(M0U$^6?4 LQ_]#%>NUA>#_#<'A+PK8Z-"0Q@3][(!]^0\LWYD_ABMVG)W M=P2L@HHHJ1A5#2_^7W_KZ?\ I5^J&E_\OO\ U]/_ $H /^8^/^O7_P!GJ_5# M_F/C_KU_]GJ_0 4444 %<18?\AK4/^OJ3^==O7F4'B;1[+Q'J5M=WBV\JW4F M?,! //8U443(]!A3S(&3.-RD9':K,<21QHBJ $&%XZ5BV'B/1)U'E:O9/["8 M5?.L:8.3J-I_W^7_ !I-,=T7JJ6O_'S/_P !_K5:;Q'HT"[I-3M@/7S ?Y5' MHFJV6K/?\ 7!__ $$T M 30?\>\?^X/Y54TO_E]_Z^G_ *5;@_X]X_\ <'\JJ:7_ ,OO_7T_]* +]%%% M !1110 4444 %%%% !1110 4444 (WW3]*J:3_R![+_K@G_H(JVWW3]*J:3_ M ,@>R_ZX)_Z"* &V?_(1U'_KHG_H J]5&S_Y".H_]=$_] %7J "BBB@ IGDQ M?\\T_P"^13Z* (S!$>L2?]\B@01#I$G_ 'R*DHH 9Y4><^6N?H*?110 4444 M %%%% %'2/\ D'+_ -=)/_0VI8/^0Q>_]_]+?C!HJ_9[_PE#J;+P)X5SN_[X;'Z"O9Z*OG[ZD\IXK//\8O&2FU6 MRM_#MG)\KRYV.!]"Q?"'Q6C?ZS3\>HE/\ A3Y/A-XM*C;)I['WE(_I7N]%7[61/LXG MA]M\)O%!DJ[N6]>PKU?PUX1^K'^@K9HJ93E M+<:BEL%%%%24%%%% %*T_P"/F_\ ^NX_]%I11:?\?-__ -=Q_P"BTHH 32/^ M0>/^NLO_ *,:KU4=(_Y!X_ZZR_\ HQJO4 %%%% !1110 450U+6]+T9 VI:A M;6H;H)9 I/T'4U'IGB+1M98KINIVMRXZI'("WY=:?*[7L*ZO8TZ***0PHHHH M *JZG_R";S_K@_\ Z":M55U/_D$WG_7!_P#T$T 30?\ 'O'_ +@_E532_P#E M]_Z^G_I5N#_CWC_W!_*JFE_\OO\ U]/_ $H OT444 %%%% !115:]U&STVW, M]]=0VT0_CF<*/UH LT5C6'BWP]JH **** "BBB@ HJO>7UII]N9[VY MAMX1U>5PH_,UF67B_P .ZC<""TUJREF)P$$H!/TSUIJ+:ND*Z6AMT444AA11 M10 4444 4=(_Y!R_]=)/_0VI8/\ D,7O_7.+_P!FI-(_Y!R_]=)/_0VI8/\ MD,7O_7.+_P!FH NT444 %%%% !114%W>VMA;FXO+F*WA'625PJ_F: )Z*P[/ MQCXM;E-IK<2:>P4444AA1110 50TO\ Y??^OI_Z M5?JAI?\ R^_]?3_TH /^8^/^O7_V>K]4/^8^/^O7_P!GJ_0 4444 %%%% !1 M3)IHK>)I9I$CC099W8* /< /SZ4U%O9";2W-ZB MD5E=0RL&4C((.012TAA1110 4444 4K3_CYO_P#KN/\ T6E%%I_Q\W__ %W' M_HM** $TC_D'C_KK+_Z,:KU4=(_Y!X_ZZR_^C&J]0 4444 %2XN93EI'.23_GL*8CSV=RLD;2P7$395AE'0_P Q5W0O M[0&N6ATM'>]W_NPB!F'J0#W SSVK5^(-M/;^.M5>:)D6>;S8BP^^F -P]L@_ ME7K72ER'FVO'F/8_AQXLD\4Z WVL@W]HPCG(&-X(^5\>_.?<&NRKQ?X(I*=5 MUB0 ^2(8U8]MVXX_3->T5Y6(@HU&D>C1DY0384445B:A574_^03>?]<'_P#0 M35JJNI_\@F\_ZX/_ .@F@":#_CWC_P!P?RJII?\ R^_]?3_TJW!_Q[Q_[@_E M532_^7W_ *^G_I0!?HHHH **** *.L:I!HNCW>I7.?)MHS(P'4XZ >Y/'XU\ MRZ]KU_XDU1[_ %&4N[']W'GY(E[*H_SFO=?BHDC_ ]U#R\X5HV?']T.N:^? MK);E]0MDL\_:FE40X(!WY&WKQUQ7H8.*Y7+J<6*D^91(Y8986"S0R1L1N =" MI^HS7L_PG\97.J++H6I3-+/!'YEO,YRS(#@J3W(R.?3Z5Q_Q 35;;3]'T[4E MNKE[3?YFHS\B:5^2B$\E5'&3UJ#X5I(WQ"L3'G"QRE_]W81_,BM:MJE%MF=. M].HDCZ(HHHKRCT0HHHH 1ONGZ54TG_D#V7_7!/\ T$5;;[I^E5-)_P"0/9?] M<$_]!% #;/\ Y".H_P#71/\ T 5>JC9_\A'4?^NB?^@"KU !1110 55U*_@T MO3+F_N6Q#;QM(Y]@,U:KE/B4DC_#W5Q'G(C4G']T.I/Z54%>23)D[1;/!?$? MB._\4:H]]?R$@G]S#GY(5[ #^9[UF2P2PE1-#)&6&Y1(A7(]1FEMQ*UU"(,^ M<9%\O!P=V>/UKNO&ZW/_ BFC?;#?13IY;(R7##_ )9\8 P*]AM0 M:BCS$G).3.F^$WC.YO9&\/:E,TSI&7M)7.6*CJA/?'4>V?2O5Z^ZP(LY$0)Q_=# G],U\Y6\<6Q[#FO0P< M%9RZG%BI.ZB,:)MBNT;!&^ZQ4X/T/>O7/A-XSN9[K_A'=1F:8%"UG(YRPQU0 MGN,E8GC5[2X\&::UE?V4MG;W\L-I'!NXB"* .5'S#&YO=N,U@_#Y)7\ M?Z,(L[A.6./[H4Y_2MIVJTFVC*%Z=1)'TO1117DGI!1110 50TO_ )??^OI_ MZ5?JAI?_ "^_]?3_ -* #_F/C_KU_P#9ZOU0_P"8^/\ KU_]GJ_0 4444 %( M2 "2< =2:6J>KK))HU\D6?,:WD"8]=IQ0@9\]^._&-SXJU>5$E9=+A.*]$UA;R_\"&>^75--2SMK M6."&6X4VU[C RB==V/FSS7LZ4THK8\K6HVV)\,?&=SI&LV^C7 M/)M&!13_ +4G0?AD^U-)O83=CT2O,?BAXS\'+HESHM_?&XO6(*168$CPR#HS M-^*OBOXH\4[X7N_L%BW'V:S)7(_P!I_O-^@]JX@ #I6\*33NS. M4TU8[(Q-Y2S1L)8&^[-%RI_'L?8X-"0RR*SXQ&OWI9#A%'NQX% M>6%CU,;E<_E2W%W=7>/M-S--CIYDA;'YUV^W=MCD]BK[GT'\*?&?@VQTXZ2N MH_9]1EE+227:^6L[=!L8\8QC .#[5Z^"" 0<@U\+D C!&176^%OB3XF\)%([ M*^,]FO\ RYW69(\>@[K^!KCJ4W)\USJA-)6/KRBO,/"OQO\ #FN>7;ZKG1[P M\?OFS"Q]I.W_ ("O3(Y8YHUDB=7C895E.01Z@USM-;FJ:>P^JNI_P#()O/^ MN#_^@FK55=3_ .03>?\ 7!__ $$TADT'_'O'_N#^55-+_P"7W_KZ?^E6X/\ MCWC_ -P?RJII?_+[_P!?3_TH OT444 %%)->WP::1H]FW&(6W3,/=^W_ 0/K5QIRD2Y)'N7C7Q?X5T/ M3+BRU^^C/VB)D:SB^>9P1CA1T^IP*^=%6*Y1I]/=Y[8'@D?O(QV#J.A]^A[& MN.=VDD:21V>1SEG8Y+'U)/6ECDDAD$D4CQR#HR,5(_$5UT;TMCGJI5-SL(XI MIVVQI)(?;)Q_A7<_#'Q9X1\.:I=1ZG?^7J$P$:W)7-NJ]2H<=\]2>.!@UXY/ MJ%[=)Y=Q>7$J?W7E8C\B:KUI5FYQY=B*=-0=]S[E@GAN8$G@E26)QE)(V#*P M]01UJ2OC+PYXQU_PG-YFC:C+ A.6@;YXG^J'C\1@U[5X5^/FF7NRV\26ITZ8 M\?:8T^:WUZ^B FC*&T7YY9%(P0$'/?J<#WKPSQ3\36L:3W9G* MHNAV.+:[\R;2VDFM QP''[V-<\!U'0X[C@^M-2*:=\(DDCX[ DXKD(Y'BD$D M3M&XZ,C$$?B*GFU&^N8S'/>W,J'JKRL0?PS7>JS2U1QNBF]&>N_#3Q3X3\-: MY/XL@9/3WZU[];7,%Y;I<6TT/M5N"\1]ROWE_6O7=/U*QU:S2[T^[ANK=_NRPN&4_B* MYW%QW-DT]BU1114C*.D?\@Y?^NDG_H;4L'_(8O?^N<7_ +-2:1_R#E_ZZ2?^ MAM2P?\AB]_ZYQ?\ LU %VBBB@ HKE/%/Q%\->$0R:A?J]V!Q:6_[R4_4#[OX MXKQ+Q3\'M/EAU MZ^A59HRIM1\\DBD8("#G\>E?-V+6\,LVDM+-:!CM5Q^]C7/ =1GMW'!_2N.E MEDGF>::1Y97.7DD8LS'U)/)I$=XI!)&[(Z]&4D$?B*ZZ-Z6QSU4JFYU\<4LK M!(XW=O[J@FNP^'/B;PIX9\0ROK5Z4O63RXIE3?!#G[P+#^+@<]!Z]:\GFU&^ MN(S'->W,B'JKRL0?PS5:M*E1SCR[&=.FH.^Y]QVMW;7ULES:3Q3P.,I)$X96 M'L14U?%N@>*=<\+W/GZ-J,UJ2K]4/^8^/^O7_ -GJ M_0 445A>(_&6@>%+?S=8U&*!B,I"#NE?Z(.3_*BUP-VLO7/$>C^&[3[5K&H0 M6D7\/F-\S>RJ.2?H*\+\5?'O4[[?;>&[06$!X^U3@/,1ZA?NK^M>37U_>:G> M/=W]U-=7+_>EFIR2I)NZ/0O"6L>'_ WXKM+KQ%+*#%EHXX4\SRG[-)CD8YP!D]R! M7T?I>KZ=K=DMYIE[!=V[=)(7##Z'T/L:^(^E7M)UG4]"O1>:3?3V=P.KPOC= M[$="/8USUHNH[LWIM05D?;=%>">%?C_-'LMO%%CYJ]/MEFN&^K1]/^^3^%>S M:'XDT?Q):?:M'U&"[C_B\MOF7V93R#]17+*#CN;J2>QJT445(RE:?\?-_P#] M=Q_Z+2BBT_X^;_\ Z[C_ -%I10!'ILL<&E-+-(L<:22EG?^*OC MCX>T7?;Z0#J]X,C,3;85/N_?_@(/UKP_QQXEUK5?$&HZ=>ZC/+96US((K<'; M&/F/\(P"?)O%S,E_?F*S)XL[;,<6/?NWXDUR@& M!@445LDEL9MM[A1113$%%%% !1110 5T/AKQQXB\)2 Z3J+I!G+6LOSPM_P$ M]/J,&N>HH:3W&G8^C?"WQYT74MEOX@@;2[D\>]>F75W;WV@7 M-S:3Q3P/;N4DB<,K#:>A%?$U:V@^)-9\/W:II6HSVT1:,0S#_:DZG\,"N! M& ,"BNF-.,3%S;#N3W/)/K1115D!1110 4444 %%%% &IH?B/6/#5W]IT;49 M[20G+!&RC_[RGAOQ%>R^%?C_ R>7;>*++R6Z?;+12R?5DZC\,_2O!J*F4%+ M6[#[\+AL>Q]#[&GZ3_ ,@>R_ZX)_Z"*^+-/UC4 MM!NOMNE7L]GW0<5SSA MRFT95 M?&OQ-K5IXON-&MM2G@T^6-'DAB.S>=HZDV<5Y& , 8JH4KJ[)E.VB/0_ M%7QC\3^(_,@MIO[)L6X\JU8^8P_VI.OY8KST\DDDDDY)/4FBBMU%+8R;;W"B MBBF(**** "BBB@ K1T77]6\.WGVK1]0GLY?XO+;Y7_WE/#?B*SJ*!GNOA7X_ MCY+;Q38[>WVRS7(^K1]?R)^E>R:/KNE:_9B[TF_@O(#_ !1/G'L1U!]C7Q-5 MFQU74-%NA?:9>3VERG22%RI/L?4>QK*5%/8M5'U/M+2/^0"PEMT,D4)V;^#U(Y(YZ9Q6$8MNQJW97/4_%7Q6\+^%=\,EW]NOEX M^RVA#L#_ +3=%_$Y]J\1\5?&7Q/XBWP6DHTFQ;CR[5CYC#_:DZ_EBO/ !@# M%%=$:<48N;8$DL6))9CDDG))]Z***T("BBB@ HHHH **** +^D:WJF@7@N]( MOY[.?NT38#>S#HP^HKV/PK^T R[+;Q38[AT^V6:_JT?_ ,2?PKPVBIE!2W*4 MFC[6T7Q#I'B*S%UI&H07D/ZUX'M]0U";SKJ:5S))M"[CGT KGG3Y=3:, MN8Z7_F/C_KU_]GK&\4?$+PWX14KJ6H*;D#(M(/WDI_X".GU.*\\^.WB36-"G MT^'2M0EM%NH628PX#,-W3=U'X$5X$Q+.SL2S,8"'G8?[W1?P&?>O+III;F=Y[B62:9SEY)&+,Q]R>33* M*Z%%+8Q)+0:A ./M, "3 >Z_=;]*]J\.>,] \5P>9I&HQ3N!EX2=LJ? M5#S^/2OC2GPS2VTZW%O+)#-& GRAPHIC 57 evax-20211231x20f050.jpg GRAPHIC begin 644 evax-20211231x20f050.jpg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³VO@">.Y>/4[B,1B%92 M;:3)3(+8((Y^53@C@]B:K7?@>ZBNY(DO+&'8#(T5QG M'-.Z"QRM%;\'A*\FU*\LFO;"'[*L3F>64B.02D"/:0,G=N7J!UYJ_!\.-;N% M(CELC*L:O)")&+QLV=J-A< G:W.<<\<45G+D,0F0#NX(...:+ MA8Y"BNJC\ ZA,V:+@8M%=-=^$S/XAU*PT699K>RN4MF>9 M_FYR"YPH^4%3GTXZ]:=)X#U*&V@NIKS3XK.2,NUR\C".(#;U.WG.]0"N1R>> M*+@QN(T4;9HI&9'?XJG10!]5^!/'%EXTTCSH]L-_" +JVSRA_O#U4]C^%=77QUH>N M7_AW5X-3TV;R[B(]_NNO=6'<&OJ7P?XML?&.AIJ%F=DB_)<0$_-"_H?;T/<5 MG*-BT[G&_%?XQ(.(V/_+0#T/?T//>G%]!-'D%%%%62%(0&&" 1[TM% B%K M:,] 1]#49M/[K_F*M457,PLBD;60=-I_&FF"4?P'\*OT4^=BY49QC<=4;\J[ M'P/K^EZ)IVMPZC)/%)=(@B:*,LPPL@.TX(#?,!SQ@GFN?HH<[JP*-CIK;XD2 MP32W+Z/-<[L3^ZOY4;$_N+^5/F78+,Z_2_B,H:U@U"*X2%+J6:62*8$NCL[A3\N[ M<&? 8-@=<<56;X@6\T:PS:3*78G]Q?RHO'L&IT]U\0XM0OWO+S29O,N(3!Z5-YEW;^1HHYV'*BH+1N[ ?2GK:(.K$_I5BBES M,.5#%C1/NJ!3Z**D84444#"NF\#^#KKQGKRV<>Z.SBP]W./X$]!_M'H/S[5B MZ3I5YKFJVVF6$7FW5P^U%[#U)] !R37U9X0\*V?A#0(=-M0&?[\\V,&60]6/ M\@.PJ9.PTKFKI^GVNE:?!864*PVT"!(XUZ "GW5U!96LMU=3)#!$I>21S@*H MZDFI'=8T9W8*JC)9C@ >IKYN^*?Q'?Q3>-I&E2E=%@?YG''VIQW/^P.P[]?2 ME"+DQRDHHH_$GXCW'C.^-G9L\.B0/F./H9V'\;_T';ZUP5+BC%=:22LCF;N[ ML2BEQ1BF(2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ1 MB@#1A_U$?^Z/Y44L(_<1_P"Z/Y45)9I:S?3:9X\U2^MR@F@U&=T+KD [V&<5 M2N_$%[?1".::+;YL7-\ ;:/4YRY*;POS, M Q7O@X./:NILO$WAN'3IHK_4XKVX=@9I!8&-9I 8R'"A>1A6^9B#[[$EJK M&2%L_+*>Z#S.!VR/2NCL/&6DM/'=S7T=K>AF,\PL<^="'FVQ#:ORG#1G/'3K MQ1!XI\.B&2,7RV]HZ(D]LMCN:9]\3>9G&,!49<'TZ'-(9RNG^*KVU_MC5)+: M&ZFO#"GFRPJT,3JP=?EZ%!$ZP-M=P4WG&TL-V&/09SSC-,#&@\:Z]-Y=O:FW-P/F+PVX\V5@J_. MQ_B8+&O/H*)_&6MVF:YWQMJVEZN=,DT^57DCA99A'"8T0<;0,@'/7(R0.QYI@8\/B' M4K>]U.[AF5)M3BEBN2J\,LARV!V]O2M23Q]K.=;4A@UGYV 'F^RKOD .5#$=0O0#TJ.U\::S9P&"-[=H^ M2JR0!@K%G;>/]H&1L>Q]JY^BBP7"BBB@ HHHH *W?"/BJ^\(:Y'J-F2Z'Y;B M G"S)W!]_0]C6%10!]C:)K5CXATBWU/3I1);3KD'NI[J1V(/!%7)X8KF"2": M-9(I%*.C#(8'@@U\R?#;QW)X.UGRKEV;2+I@+A.OEGH)!]._J/H*^G(I8YX4 MFB=7C=0R.IR&!Y!!K)JQ:=SY=^(O@F3P9KQ2%6;2[HE[20_P^L9/J/U&*XZO MKSQ7X:L_%GA^XTN[&-XW12 Q'(^M7%W):L4Z***H04444 %%%% !1110 4444 %%%% A%)* GKCFEI%SL M&[KCFEH ****!A1110 4444 %%%% !1110 445ZC\'O _P#;6I_V_J$6=/LW M_<(PXFF'?Z+_ #^E#=@2.^^$_@0>&M)_M34(@-6O4!(8CT M5YG\5_'Y\/6!T;3)<:K=)\[J>;>,]_\ >/;\_2LTG)V+;44//*D3PKJ-U>.0HZD,K*<%2.A%#@V-32/M*O+?C'X)_MG2?[?L M(LW]BG[Y5',L(Y/U*]?IFMSX:^-5\7:$$N74:K: )_HXM86&DWC%X& XC<\F/^9'M]*X6M M?,@**** "BBB@ HHHH **** "BBB@0BYV#=UQS2TB@A #UQS2T %%%% PHHH MH **** "BBB@ HHIR(\CJB*S,Q 4 %4=364G=FB5C#\:>*[;PA MX?DOY0)+AODMH2?]9)V_ =37RY?WESJ=_/?7LIFN9W+R.>Y/]/:N@\;>*I_& M'B"2];I]SU/X#M7.;:Z:<.5&$Y79#MHVU-MHVUH00[:-M3;: M-M $.VM[PY_PBBI<_P#"2Q:F[97R/L+ #!W;L_A6/MHVTFK@CM-WPM_Y]_$ MO_?Q?\:-WPM_Y]_$O_?Q?\:XO;1MI1VF[X6_\ /OXE_P"_B_XT;OA; M_P ^_B7_ +^+_C7%;:7;1R^81VF[X6_\^_B7_OXO^-&[X6_\^_B7_OXO^-<7MHVT]'.@Y6<9175ZUX,;P_ MHMU=W5P)Y (C$41HP,NRN"K#)Z#!J6T^'E]=7:0&_@02',+")W\Q/DQ( !PI M,@&3TP:.9!RLX^BNE/@\Q%DN=9LH)883<7<91V-O%V;@?/GC@M',@Y6O9,6=X^;=F/$'KK2K MG $JYC?',;CE6'T/]:^3[ZQN--O[BQO(S'<6\ACD4]B/Z5]D5XK\;?"FUH?$ M]K'P<07@ _[X?_V4_A6=&5G9E5(W5SQ@HI[4AC]#3Z*Z'%,RYF1>6?:DVMZ5 M-14^S0^=D&#Z45/1@>E+V8^<@HJ;:/04FQ?2E[-CYT145+L7THV+1[-ASHA4 M$( >H'-+3TB"HH/) QFG;%]*/9L.=$5%2[%]*7:OH*/9L.=$-%38'H*6G[,7 M.0[3Z&EV-Z5+13]FA<[(_+/K3A&.^33J*?*AY]AU/TKZR\/:); M>'=!M-*M!^[MXPI;'+MU9C[DY-15ERJR+IQN[LTZ\4^,'C W5Q_PC5C+^YB( M:\93]Y^H3Z#J??'I7HGCOQ2GA7P[)61Y) M'9Y'8LS,236=&%_>95270@VBC:*EVT;:Z3$BVBC:*EVT;: (MHHVBI=M M&V@"+:*])^$&A:5K=]JR:I807:Q1Q&,3)NVDELX_(5YWMKU;X'#&HZU_URB_ MFU14^%E0^(]%_P"$!\)?]"_8?]^17/>.O!OAS3O!&KW=GHMG!<10%HY$C 93 MD<@UC?%S7]9T?6].BTS4[FTCDMF9UB; 8[NIKS:[\5^(K^TEM;O6KR>WE7:\ M;OE6'H:RA"3L[FDI16ECV;P9X,\-7_@S2+J[T2RFN);96DD>($L?4UJWGPV\ M(7D#1-HEO%DQ6B2.%\<>#I?!^MBU\QIK.=3);3,.2.ZGW']17K_ M (/\%^&K[P=I%U=:)92SRVJ-)(\0)8DT'V9#G^0K ML/ W_(BZ)_UYQ_RJI2;@F3&*4FAG_" ^$O\ H7K#_OR*X;7/"^A6_P 5_#FG M0Z5:I97%O*TT C^5R V"1WZ"N"O?&GBE-0ND37[\*LSA0).@#' Z5I^!=6U+ M6/B3HLVI7LUW)'YBHTK9*C8QQ5*$EJV+FB]+':?$OP-HUIX,N+[2=+MK6XM7 M25FA3:63.&'ZY_"N?^#_ (?TC6X]8_M33K>[,31>69DW; MEW5C* 8[B)HFSZ$8KR_X)V\EI)XAMY1B6*6*-Q[KO!_E4*3Y&4XKF1R'Q8T? M3M&\56]MIMG#:0M:*Y2)=H+;FY_05PNT5Z5\:!GQE;?]>2_^AM7G6VMZ?PHR ME\3(MHHVBI=M&VK)+<2_N4_W114L2_N4_P!T45)1!K=W/8>.-3N[64Q7$.HS M/&Z]0=YHE\5:[+%=1M=%4G 1PD"J(QMV[4P/W?RC&%QD5W*L8 M8=2G9MBAF7YF 8 ]2"0?PKI;+QOHEKI\D%Q?:E?2DCS)I[?F=@8R'P& 'W"/ MF#-TYZTF_(%ZG+V&O:UJ'BO2KN5#>WEM(&AA"+&&/)). !DGDL>M.?6_$[_V MC']H7;' 'G\N./;#'M"_NR!A/E< [<'DUT-GX]LV>.:\OK^*Y5F:69(0[7$> M^7;"QR/EQ(A]!MQV%.B\;Z,(RK7&H10;41[2*!=LQ#Q-YI.;/(&B582BNWR9=CN.0=IX;+9(YY-"?D#]3#O]5\1ZW' M+9W,J2QB#[7(D4<:KL'[PL2H'/)8]\YJO:^*M=LC$8;MCY-ND$:R0JX2-&WI MPP/0\@]:Z>S\::5!IL<)DNT$=IY,MJD ,=XWE1K\YSP%*-C(/#?6KM]\1=/: M^66TDN5#3Q&5U@*EH1*S-$&8?C]*ZU M?'EC'#%MNK\N8XUD'EXVA1""N<\C]VY_X%[U)/X\T>:R@MX?M%JP1D26.W): MS;8Z^:GS8))8'"@'KDD@4:]@T[G%Z]?ZO)M1AU;Q)>W]O)+)%,RE7E7:[X1021V)()K)JUL0]PHHHIB"BBB@ MHHHH **** "BBB@ I59E8,K%64@A@<$$="*2B@#Z@^'/BT>+?#$OF7X?>*F\)^*H+J1R+ M&XQ#=KVV$\-_P$\_3-?4BLKJ&4AE(R"#D$5R5(\LM#IA+F1\@:WI%QH&MWFE M70_>VTA3./O#^%A[$8-4*]L^.'AGS+>V\26\?S18M[K ZJ3\C'Z'C\17B==, M)EVH_?7,@0''W1W8^P&3^% SUKX(>% MN)_$UU'R1V_CVC M$:#V Z_7O7"_%CQ,=-T==&MI,75\/WA!Y2+O_P!]'CZ9KC=YR.A6C$\P\<^) M7\4^(Y;E&/V*',5JO^R#RWU8\_3%,"O-/%/P\U'PGID=]>7E MI-')*(@L.[.2"<\CVKV+Q5X[L/"=Y;VUW:W,S3QF13"%P #CG)%><>//'VG^ M*]$AL;2TNH9([@2EI0N, $=B?6LJ;GIV+FHZ]ST_P'_R(FB_]>JUY+\/A_Q= MHG_II=_^S5ZWX%_Y$;1O^O5:\H\ #'Q7/_72Z_\ 9J4?M _LG8?&D9\*6?\ MU^K_ .@-74^!^/ ^B?\ 7I'_ "KF/C,,^%;/_K]7_P! :NH\$_\ (D:+_P!> MD?\ *I?\-%+XF>97/P9UN:[GF74M/ DE9P"'X!)/I6;X3T6?P]\7++2[B6.6 M6!FW/'G:KPZ_\ &:VU2WCD MCBG8[5DQN&(2.XUR7AS2_[+\;>*2JXCNS;W*?\"#AO_'@ M:O\ B;5/[(_LBX+;8WU"."3TVN&7^9!_"ML1H)3+M&\J%+=\#H/U-8;+U-=S MPSXRC/C&V_Z\E_\ 0VKSS;7H_P 8AGQA;?\ 7DO_ *$U>>[:ZZ?PHYY_$R+; M1MJ7;1MJR2W$O[E/]T45)$O[I/\ =%%(9D^)O^1LUG_K^G_]#-9==%XDLD;Q M3K#;VYO9C_X^:S/L"?WV_2A;">Y0HJ_]@3^^WZ4?8$_OM^E,"A15_P"P)_?; M]*/L"?WV_2@"A15_[ G]]OTH^P)_?;]* *%%7_L"?WV_2C[ G]]OTH H45?^ MP)_?;]*/L"?WV_2@"A15_P"P)_?;]*/L"?WV_2@"A15_[ G]]OTH^P)_?;]* M *%%7_L"?WV_2C[ G]]OTH H45?^P)_?;]*/L"?WV_2@"A15_P"P)_?;]*/L M"?WV_2@"A15_[ G]]OTH^P)_?;]* *'6OHCX/>*CK7AHZ7Q'7ZCK7R1JNFSZ-JUWIET,36LK1-[XZ'\1@_C M7V!%*DT*2Q,'C=0RL.A!Y!KQGXT^$2;B'Q+:X&_;!&L)=^)+A.6S;6N1V_C8?C M@?@:\GTS1KS5M1MK&W7$UQ((TW=B3U_#K7UAHFE0:'HMGI=L,0VT0C!]<=3] M28/ /U/\J\@VT48V5QU'K8BVT;: MDVT;:V,B/;1MJ3;1MH CVT;:DVT;: (]M&VI-M&V@"/;7I_P8&-0UC_KE%_- MJ\UVUZ;\&AB_U?\ ZY1?S:HJ_ RX?$BK\9L?V]IG_7LW_H5>;<5]5O!%*09( MD!]79(8U80'!" 'J*RA5LE&Q7XI321J66)[EG(Z*"2!G\37J?@@8\$Z/_ ->RUKK#9V*22I'!;J?FD<*$ M!]R:CFLVNY7+>QP'QD=?^$:L8R?F:[! ^B-74^"O^1)T;_KT3^5>5?$GQ/!X MAU6&VL9/,LK,,!(.DCGJ1[ #'YUZMX,&/!>CC_IT3^5.2:@KBB[R9\Z7V/[1 MN_\ KO)_Z$:Z'X%&.S5:J\RM8GDL[B_%[/_"&Q%3AA>1D'T.&KK/#VI#6/#UAJ .3/"K-_ MO8PWZYKE?BV,^#H_^OR/^35!\(M2^T>'KG3V.6M)LJ/]A^1^H:HM^[N7?W[' M)_%\9\76W_7FO_H35P&VO0OBZN?%MM_UYK_Z$U<#MKHI_"C&?Q,CVT;:DVTN MVJ)+,2_ND_W114L2_ND_W112*&:O'!+XSU&.YG\B!K^422A=Q4;SR!W-;$W@ M?RDO2L]S))$4$4(CC#_-&')<;N@W $KN[FLC5KIK+QGJ-RL<4ACOYCLF7>/[V>234Z] TZA?^&_+U"RM- M-N3=-=326P,JB/$L;;6[GY3D$'\Z;_PB>JD,R_9&3&8W%RI$XV[CY9_BP 2< M=,5)#XG>?Q#IE]<6L*Q6LYE\BV7'F.QRYP3R6./Z42>*[V(-;?8;*'R 8[=/ M+;-F=I1MF3U()SNSSS1[P:$UQX&U=+F5+807,2S>4DBR@;_F"[L=E#, 3V-- M7P==):2SS7-N2N2B02J_F#RV;<#G!&5(/X^E//CS4]J[8+1=LGF+@/@?,&(Q MNQRPSGKR0,"JEMXLO;6T6V6&T81H$1G0DKPXSUP/&-GE^6(7#J^YBK#(Z$$5AUT>I>)]5\20/9?8XF#88B!79OOY[D\;FQZ#( M KGC%((VD*,$1MC-CA6]"?7@U2OU$[=!M%*05578$*V=K$<'UP>])D9IB"M+ M3["RGL;F\OKN>"*&2.("" 2%BP8]V&!\OZUG*K.P55+,3@ #)-:4!SX6O_\ MK\M__09:3&A_V?P[_P!!34__ 3_P".4?9_#O\ T%-3_P# !/\ XY6UI5IH M=QH>F6M]$/M-VTK;X4VR@(Y))D/ &T;0I!ZYJ>W\-Z.=.:Z%M>2M+:&2V5KE M,2L8R_R8&BVCRPB:ZDB$:R.[!5+@!SF-B.C8'3(]S7':O:P66J306Q

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end GRAPHIC 58 evax-20211231x20f051.jpg GRAPHIC begin 644 evax-20211231x20f051.jpg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evax-20211231x20f052.jpg GRAPHIC begin 644 evax-20211231x20f052.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#8# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#G/&WB_5=? M\1WV^]G2SBG>."W20JBJIQG ZDXSDUS/VFX_Y^)O^_AJ75/^0Q?_ /7S+_Z& M:JUZT8I*R.1MW)?M-Q_S\3?]_#1]IN/^?B;_ +^&K-CH][J-C?WEK&KQ6$8E MN/G 94)QD#O[TC:3>)H<>L,BBRDN#;(Q<;F<#)PO7&.].Z%J5_M-Q_S\3?\ M?PT?:;C_ )^)O^_AJ+-&:+ 2_:;C_GXF_P"_AH^TW'_/Q-_W\-3SZ<\&EVFH M&XM72Y9U6))09$V]W7^$'M5/(HT E^TW'_/Q-_W\-'VFX_Y^)O\ OX:BHSU] MNM%@)?M-Q_S\3?\ ?PT?:;C_ )^)O^_AJ+-6?L%V-/CU P,+.28P+.<;3(!D MK^7-&@$?VFX_Y^)O^_AH^TW'_/Q-_P!_#4VIV#Z7J,ME)/;3O'C,EM()(VR M>&'7K5/(H5F!-]IN/^?B;_OX:/M-Q_S\3?\ ?PU%D49HL!+]IN/^?B;_ +^& MGQ7][!*LL-YBBP'TM\*_$MYXE\(^9J#F6[M9C \IZR $ M$^^#@_2NWKRWX%?\BIJ'_7Z?_0%KU*O,JI*;2.J'PH*^;?B7XOU35/%E_8+> M3PV%G*8(X(W*JQ7@LV.I)SUKZ2KY-\9?\COKO_7]+_Z$:UPJ3D[D57H9/VFX M_P"?B;_OX:/M-Q_S\3?]_#45%=UC E^TW'_/Q-_W\-'VFX_Y^)O^_AJ*BBP$ MOVFX_P"?B;_OX:/M-Q_S\3?]_#45;6@^%=3\2EUTW[*SHP79+<+&S$C/R@G) M_"AM)78:LROM-Q_S\3?]_#1]IN/^?B;_ +^&KFLZ)=Z#=I:WK6S2LN[$$ZR@ M#..2IX/'2L[(H5GL!+]IN/\ GXF_[^&C[3*+_P 0:%=VVI3/<3V,BJL[G+.C D GN1@\ M_2OGFO:O@)_Q[:[_ -=(?Y-6.(2]FV:4W[Q['1117G'0?.OQ8\4ZCJ'BV\TE M;F6+3[(B,0HQ"NV 2S8Z]<<^E>>9/K73?$3_ )*)KO\ U\_^RK7,UZM-)05C MDD[MAD^M&3ZT459(9/K1D^M%3V=I/?WL%G:QF2XGD6.-!_$Q. *!D&3ZT9/K M6CKFAW_AS4WT[4XA%]19J@#)]: M,GUHS^E&10(,GUHR?6K'V"[_ +,&I?9W^Q&;R//_ (?,QG;]<H:1?W$ERMJB2P22-N95)(*Y/)' M Q16)\!_^1@UC_KU3_T,T5YM=)5'8Z:?PGF6J?\ (8O_ /KYE_\ 0S56K>J? M\AB__P"OF7_T,U4KT5LHPV?BR.TNR!9:G$]C<9Z8<8!/_ L5V,5C M)::[IWABPU+RY=$TJ260V\<E\/%K5KHQ%FN@Q&6V_(9,?UK,TV'Q&=-UHP_8SXT$UOYN/) M\P6^WM_#G/WOUKR7%'?/>I]EYCYSV7P^D7G>#OMJV37'VS4_M.T)L+8;TXQG MIV]*I:1J%EKUCX4O_$7V-RFL36Y8QI&HC"$HI &T-MZUY/11[+S_K7_ ##G M/1_B.]P-)M(;[3KQ+E;R0QWEVT&YHR/N*(NJ=""16U\-;&1-)TF62\>?3[N: M9;BVCC@$,?48G9OG8GC 'M7CWU)-%-T_=Y;BYM;GKFB:E_9>E^"K>U^RHEYJ M=S;W6Z)&9H?-QM)(R!S^@JMJ$]_)\.]1L].DB-G8ZY/#/$NS]W:Y^4<\XR>H MYKRRBCV6MQ\Y[N+5!XB\37-BZP.FH6B[[582[QB($Q_O"%VL?0YSVJII<\T\ M>M7<>GW<.N_VOFXL[;R!.EN%'EH?,&#'CKMZUY;I/BF_TC3WL(X;*ZM&F%P( M;RV$JI*!C>N>AQ6?J6I7>KZE/J%],9;J=MTDG3/Y=![5"HOJ/G1Z2VKG1]"U MB^TRUM["Y/B18UC9(Y&@1D&Y5/( X(R.,$UO06H'BWQ-8:=;M96\]VC?VK9F M$_9CY08K(C_\LR23QW)KPZCU]^M4Z7F+G))U"7,J"19 KL Z]&P>H]CUJ.BB MMB#WOX%?\BIJ'_7Z?_0%KU*O+?@5_P BIJ'_ %^G_P! 6O4J\RM_$9U0^%!7 MR;XR_P"1WUW_ *_I?_0C7UE7R;XR_P"1WUW_ *_I?_0C6N%^)D5=C$HHHKN, M HHHH *ZCXBE)730)V=SU+P]'J)T*X?PJ+;^UCK M_@]<>]=+9?V&VK:DC?V=]ADU7_ (DFX#;]K$1\P\?\L]_X M9_"O"**R=*_4M3L>P>'8U$O@U=12W:Z^UZF+L.%Y?!SN]LU4L-4GU71_#&JW M&GVFI:A!JT\26X6.+=$$)"#H..JY[@5Y511[+^OO_P PYSL?B1:R6^O6SRWT MUS)/;"0Q7*QB:VR3B.39P2/SKCJ**TBK*Q#=W<****H HHHH *]J^ G_ ![: M[_UTA_DU>*U[5\!/^/;7?^ND/\FK'$?PV73^(]CHHHKS3I/ECXB?\E$UW_KY M_P#95KF:Z;XB]UZ_E\ MJVTJU:0/MWD2O\B87N1DG'M7&T5,E=6!.SN>PVRZ)K-UX-U=[_[?!97#:==3 M7<8C9WVEHBZDGC/&:M7)U/IGG&*\4J_H MVL7.A:I'J-HD#W$6=GGQB10?7![CL>U9.EV9:F>ERZ2=8L;V&R6U\RQ\62SW M/F.D?E09^\<_P\'BKPM-.\2>(M>T2Y>VB33M9CU!&; #08 E4'\/UKQNXGEN M[F:YGL?:G>PU'49O.M((H!#" MF<*)V?YCD8P!69H^I'1])\+0V7V6,7.N7%M.6B1F,)EQMR>0I&/R%>344>Q# MG/5M5N+Y_A_XAT_2I(OL]CK5PDL*[/W=H03QGG&3U'->4T45<(\I+=PHHHJQ M!1110!ZO\!_^1@UC_KU3_P!#-%'P'_Y#^L?]>J?^AFBO.Q'\1G33^$T/&'P: MOK_7+G4=#NK98KES*]O.2I1SR=I .03S^-<]_P *3\5?\]=._P"_S?\ Q-?0 M]%"Q$TK Z<6?/'_"D_%7_/73O^_S?_$T?\*3\5?\]=._[_-_\37T/13^LS%[ M*)\\?\*3\5?\]=._[_-_\31_PI/Q5_SUT[_O\W_Q-?0]%'UF8>RB?/'_ I/ MQ5_SUT[_ +_-_P#$T?\ "D_%7_/73O\ O\W_ ,37T/11]9F'LHGSQ_PI/Q5_ MSUT[_O\ -_\ $T?\*3\5?\]=._[_ #?_ !-?0]%'UF8>RB?/'_"D_%7_ #UT M[_O\W_Q-'_"D_%7_ #UT[_O\W_Q-?0]%'UF8>RB?/'_"D_%7_/73O^_S?_$T M?\*3\5?\]=._[_-_\37T/11]9F'LHGSQ_P *3\5?\]=._P"_S?\ Q-'_ I/ MQ5_SUT[_ +_-_P#$U]#T4?69A[*)\\?\*3\5?\]=._[_ #?_ !-/C^"/BAY% M5[C38U/5O-8X_#;7T)11]9F'LHF#X0\+V_A'P]#ID#F5@3)-*1CS'/4X[#H M/05O445@VV[LT2L%>2^._A'X->M454) MN#NA2BI*S/GC_A2?BK_GKIW_ '^;_P")H_X4GXJ_YZZ=_P!_F_\ B:^AZ*U^ MLS(]E$^>/^%)^*O^>NG?]_F_^)H_X4GXJ_YZZ=_W^;_XFOH>BCZS,/91/GC_ M (4GXJ_YZZ=_W^;_ .)H_P"%)^*O^>NG?]_F_P#B:^AZ*/K,P]E$^>/^%)^* MO^>NG?\ ?YO_ (FC_A2?BK_GKIW_ '^;_P")KZ'HH^LS#V43YX_X4GXJ_P"> MNG?]_F_^)H_X4GXJ_P">NG?]_F_^)KZ'HH^LS#V43YX_X4GXJ_YZZ=_W^;_X MFC_A2?BK_GKIW_?YO_B:^AZ*/K,P]E$^>/\ A2?BK_GKIW_?YO\ XFC_ (4G MXJ_YZZ=_W^;_ .)KZ'HH^LS#V43YX_X4GXJ_YZZ=_P!_F_\ B:/^%)^*O^>N MG?\ ?YO_ (FOH>BCZS,/91/GI?@EXI+ &;35!ZGSF./_ !VO7? G@V'P9H;6 M@E$]U,_F7$P& S8P !Z 5U%%1.M.:LQQ@EJ@HHHK(L\Q\?\ PI;Q/JO]K:5= M0VUW(H6>.8'9)@8# CH<<=.:XW_A1OB7_G^TS_OM_P#XFOH"BMHUYQ5D0Z<6 M[GS_ /\ "C?$O_/]IG_?;_\ Q-'_ HWQ+_S_:9_WV__ ,37T!13^LU!>RB? M/_\ PHWQ+_S_ &F?]]O_ /$T?\*-\2_\_P!IG_?;_P#Q-?0%%'UFH'LHGS__ M ,*-\2_\_P!IG_?;_P#Q-'_"C?$O_/\ :9_WV_\ \37T!11]9J![*)\__P#" MC?$O_/\ :9_WV_\ \31_PHWQ+_S_ &F?]]O_ /$U] 44?6:@>RB?/_\ PHWQ M+_S_ &F?]]O_ /$T?\*-\2_\_P!IG_?;_P#Q-?0%%'UFH'LHGS__ ,*-\2_\ M_P!IG_?;_P#Q-'_"C?$O_/\ :9_WV_\ \37T!11]9J![*)\__P#"C?$O_/\ M:9_WV_\ \31_PHWQ+_S_ &F?]]O_ /$U] 44?6:@>RB?/_\ PHWQ+_S_ &F? M]]O_ /$T?\*-\29_X_\ 3/\ OM__ (FOH"BCZS4#V43C_A_X$A\%:=,'G%S? MW)!FE5<* .BK[#)^N:*["BL92D_M/5?^@!-_P"!,7^--\)@?\(CI+_Q26LF2RQPQ/+*ZQQH"S.QP% M [DTKKL!E_VGJO\ T )O_ F+_&C^T]5_Z $W_@3%_C5V;4]/M_(\^^MHOM&/ M)WRJOF9Z;F%SDT778"G_:>J_] ";_ ,"8O\:/[3U7_H 3?^!,7^-: M"7MK(B.ES"R2.8T99 0S#.5'J>#Q[&IZ+KL!D?VGJO\ T )O_ F+_&C^T]5_ MZ $W_@3%_C6O40N8#<_9Q-&9]GF>7N&[;G&['7&>,T778#-_M/5?^@!-_P"! M,7^-']IZK_T )O\ P)B_QK7HHNNP&1_:>J_] ";_ ,"8O\:/[3U7_H 3?^!, M7^-:]%%UV R/[3U7_H 3?^!,7^-(VJZG&I=_#]T5')\N>)F_ ;AFMBBBZ[ 5 MK"_M]2M%N;9RR$D$,"&5@<%6!Y!!X(-6:Q-+ C\3Z[&HPA\B4@=-Q0@G\0H_ M*MNAJS&@K+N];2&\:RM;2YOKE #(D &(\]-S,0H)],Y]JU*Q/"F&T(3D?O)Y MYI)&[LQD89_( ?A0MK@/_M;4O^A=O?\ O]!_\71_:VI?]"[>_P#?Z#_XNMBF MR2)%&TDCJB*"S,QP !U)-%UV R?[6U+_ *%V]_[_ $'_ ,71_:VI?]"[>_\ M?Z#_ .+J[-JMA;I$\UY"B3(TD;%QAU5=S,#W '.?2K,_]_H/_BZOVNH6 M=\ ;6ZAFS&LH"."=C9VMCT.#@^U/2Z@DNI;5)D:>)5>2,'E0V<$CWP?RHNNP M&;_:VI?]"[>_]_H/_BZ/[6U+_H7;W_O]!_\ %UL5%'_]_H/_BZV**+KL!C_ -K: ME_T+M[_W^@_^+H_M;4O^A=O?^_T'_P 75Y=2L7NEMDNX6G9G01JX)W* 6&/4 M9&1[BK5%UV Q_P"UM2_Z%V]_[_0?_%T?VMJ7_0NWO_?Z#_XNM*2ZMXKF&WDF M19I]WE(3R^T9.!WP*FHNNP&.=8U!1N;P[?[1UVRPD_EOJ[I^HV^IVYFMRWRL M4='4J\;#JK*>0:MUB0@1>-+Q4&T36,4CX_B8.Z@_7''X"GHQ&W1114C,R[UE M8+W[%:VD][=A0SQP[0(@>A=F( SV'7VJ/^T]5_Z $W_@3%_C3/#0!MM0E(_> M2:A<[V[G;(5'Y*H'X5M53LM!&1_:>J_] ";_ ,"8O\:/[3U7_H 3?^!,7^-: M]%*Z[ 9']IZK_P! ";_P)B_QH_M/5?\ H 3?^!,7^-:]%%UV R/[3U7_ * $ MW_@3%_C1_:>J_P#0 F_\"8O\:UZ*+KL!D?VGJO\ T )O_ F+_&C^T]5_Z $W M_@3%_C6O11==@,C^T]5_Z $W_@3%_C1_:>J_] ";_P "8O\ &M>BBZ[ 9']I MZK_T )O_ )B_P :/[3U7_H 3?\ @3%_C6O11==@,C^T]5_Z $W_ ($Q?XT? MVGJO_0 F_P# F+_&M>BBZ[ 9']IZK_T )O\ P)B_QH_M/5>^@3_A1D="#V()!HJG/^[\8VKKPTFGS!SZ[ M9(]OY;F_,T4- .\)_P#(G:+_ ->,/_H K8K'\)_\B=HO_7C#_P"@"MBB6[&@ MK$\7I:/X5U%;V'SHC"P6/RC)N?'R_* <\X[5MT4@/+=<:WU#X>:7:1B073:> MD7DMIDDCSE0H,(?;F,EAC/X]LUO>.4D>#P_,VZW6.^WRO]E-R(2! MGWKM** /--0.FOJ>IK=Z;-J"7NCVT=H(]/<^@[U*^HVT>JQ::SG[5+"\R+M."BE03GZL* /*M&T?4M,E\+1I9W!L;O M4?MZA M:-#T1(1'(8MO''S*N&[YQ6:-1OK#1;%K-]1,/]F6D)W(RRF4W 62,$J6W;<@ M XZ@=Z]8JM?:?::G:M:WMND\+$$HX[@Y!'H1ZT >8RZEJYL[9(=5N5@87*M M.S3LT%SY@V1/MC+$HA'# !CGKQ6XYUQ=7:[-W?MY>JVUN(57$+0M%'YC;<=- MS,$O\ D6[?_KI-_P"C6K;K M$\)?\BW;_P#72;_T:U'V0ZFW7.>,TNKO28=*M+8SO?SI#*N2J^2/FD#-@[05 M4K_P*NCJKJ&HVFEV;7=[,L,"D L03DDX '))) '-2,\QEM-2%C!I*MW=Y=:3<:GK]HU_):VEM8SNT\9#W, M"M,)%.X#+!6W=CP/6O2JIZFEA+9^1J0A:VF=(]DOW78L-H]\G'% &#/)K=O\ M.Y+A9)Y-6> S,47=(F]MS!1CDJI( _V17)M/>VTNH7.FSZD^FSW\ EN[E94< MQ" XPP3?MW@#=C\<5ZM44MQ'"\2/NS*^Q,*3S@GG'3@'DT <#%?ZU;W^BH]Y M<:C+-;!?+C26(!LN1*V4"NN-H8-M(P"!SBH[&?4+_0].BCU+75OYKJWCU,R1 MLAA8A_,5"5PHR,?+P!MQUR?1Z* /+;];B/78)=0EU6"SM[Z^C^TVL+%Q&8X@ MF2JDX)!^;N1UHM;[Q9)J&FPZE=S64[0V;1[XY-LA/^N#*B%2QZ$,1MR",=:] M2HH \VT=KV\\:Z1-=OJXXR02._;J>PKE=1\ M%:O-IUGIUK>P"U2W43*TC)F?S/,>3 7YPQS@$@#KS6F_A68H=CVZNVMC4F8 M@E V<9Q]['X4@-I-?T>1[I$U2S9K0%K@"=3Y0'4MSQBI+K6-,L5E:[O[: 1% M1)YDH7:6^[GZX./I7%#P'J5SIJZ==36,,5KIUS8VTT 8M-YN 'D! QC:"0"< MDDYJ:Z\*Z]??VA>7 T]-0N)()(#!E:%IINI;NWD=HO-@@690TZ\:7I\%I>Q":%E^U$DP^>-A!PR@E/F(/ Y QD9KEV\ :Q%HQTZ&;3)?M M&FV]G-+.'S$T3,08^.0=W?&",\T =U;:M;3S2PN\<4J321*AE1B^P L0 3C& M1D'D=Q3H]7TV6!IX[^V:)612ZRJ0"^-HSGON&/7(KBK'0]7N;J75K"**&5=2 MO6CCOU>,/%*JKOP!D8*9 (&1W'!J:Q\!W=K=:.QN[?R+:TA6[C"D^;<0J5BD M'L-Q)!_N+0!U<6OZ/-!-/%JMD\,#!)9!.NU">@)SQFJW_"6:$;S3[5-3MI'U M .;8I("K[2 0#GKDX^H-#-783OJ=U;3RRFR#DR-('\B8NQP5 4,#PH&! M6A#X9OK/78=1MS9N@OKB5XW++B*54&1@'Y@4SCH<]: .CNM3L;&6&*ZO(()) MCB))) I<^P/6HI=;TJ"W2XEU&T2&2/S4=IE 9.!N!SR,D?F*R]=T2^OM:T^^ MT\P6\L!"O.&[$.F+-(]N885< MR[D=02")'(!Q@A!VH Z^'Q5HM2O MXBT6.Q2]?5K)+5\A)FG4*Q'4 YZBN8O?"&LWEM=0RWEK+)=6=JLMP2T;&>!] MW11]QNA(((]#5FP\(S17-I>!Q0!T*Z]I M#QW,B:I9LEK@SLLZD19Z;N>,U;M[B&[MX[BWE26&1=R2(V58>H-<2O@>YAL; M>%4LY?*TJ&S,8D>',B2!]X=1E<8R#CK76:);7UGHUK;ZE=+=7D:8EF5F64@J3[XS[U' M_P (_-_T']7_ ._D?_Q%#LW<#:KG_%]ESM[9[5X7#JTD:"3,J.QD^7"G[J@[@>O&!&_A/6X;=9]/BD M@U*X34HYYC<HM<:?HMQI=J]U8.(I)U+ 1^;YA(#'C++QGGK M5.S\-ZU;(9X_#[F]32Y+:[>XN RWD[21EF&'R00'89*YX4XKOO\ A'YO^@_J M_P#W\C_^(H_X1^;_ *#^K_\ ?R/_ .(HLNX'#V'A;4HY]+N;G29)$MM2N6A0 M[%:WBDC78P0,0JAP25!)'I1IGA;4H]&OX[^/5A=/;1Q7 A2$K<2B0,9!F3]X M>#G=MRI(]AW'_"/S?]!_5_\ OY'_ /$5QGAKQ-;>)_$=UHMOJ7B&&:W5V:22 M6':=K!3C"9[U2A=-H+V.Y\.QW4/AZQCO;6*UN%C >&'[J>@ R<<8XR<=,FM2 ML7_A'YO^@_J__?R/_P"(H_X1^;_H/ZO_ -_(_P#XBILNXS:HK%_X1^;_ *#^ MK_\ ?R/_ .(H_P"$?F_Z#^K_ /?R/_XBBR[B-JBL7_A'YO\ H/ZO_P!_(_\ MXBC_ (1^;_H/ZO\ ]_(__B*++N!M45B_\(_-_P!!_5_^_D?_ ,12'PZ[C;)K MNKNAZKYZKG\54$?@:++N FDD3>(]BDL/PW ?7-;E06EI;V% MK';6L2Q0QC"JO^>3[U/0W=C"L3PH0NABW)_>V]Q-%(O=6$C''Y$'Z$5MUEWF MAQ7-XUY!=75E=. LDELX'F =-RD%3CUQGWH6U@-2L+Q7 +K2UMVTV^O0TBNK M6,B)+ ZGON,4_\ L.[_ .ABU3_R#_\ &Z/[#N_^ABU3_P @_P#Q MNBR[B'^'I-6_LV&WUF%OML,,?FW *[)7(^;&.XXSP!D\<5P4?AWQ#/++=-IL MT6I):7QFNWN1_I5P_P L2J WW I.,@8P.G-=U_8=W_T,6J?^0?\ XW1_8=W_ M -#%JG_D'_XW19=P.2&@:SJTHCN;.YM=/DELK;RWN )!;0JSN6VL<%G(4@'. M*=:>&]2C\17MPUO^!M+M9]'@EGM9K:XFL;9OE&UP9%CW$#IN !/ MXUM?V'=_]#%JG_D'_P"-UD:S>:?X?DBCU;QG?6CS F,2>5\P'7'[OWIJ-]$% MS&&@:D=4,C:/6>BK;BTO$6?2;9;L6\BR.]TC@DL';#<9 M#<\KD>E=QX=CNXO#UC'?6L-I1 M;(0I8LS.Q9G8]69CR2?4T]$!:HHHJ1F)X;8+'J-L3B:'4)RZ]P'DACU;QCJ-HTP)C$DL?S M=?\ EG[UJKH4KHKKX@UH7M\L5M&6!EBP3>!CNQ@_=& M<9[]AZUZ)_PC2_\ 08UC_P #&H_X1I?^@QK'_@8U7&?*FD]R6KNYMT5B?\(T MO_08UC_P,:C_ (1I?^@QK'_@8U19=RC;HK$_X1I?^@QK'_@8U'_"-+_T&-8_ M\#&HLNX&W16)_P (TO\ T&-8_P# QJ/^$:7_ *#&L?\ @8U%EW VZ*Q/^$:7 M_H,:Q_X&-1_PCC+S%K6KH_9C<[P#]&!!HLNX&W167H][<3/=V5[M-W9N$=T& M!*I&5<#MD=1Z@UJ4-6 ***Y^%;OQ"\UQ]NN+/3TE>*%+8A7EVG:79L$@9!P! MC@9/7@2 Z"BL3_A&E_Z"^L?^!C4?\(TO_08UC_P,:BR[@;=%8G_"-+_T&-8_ M\#&H_P"$:7_H,:Q_X&-19=P-NBL3_A&E_P"@QK'_ (&-1_PC2_\ 08UC_P # M&HLNX&W7BGQETC7M2UO2VAT_S[0Y@MWM\LQ=B#M<=NG!Z?E7J'_"-+_T&-8_ M\#&H_P"$;7_H+ZQ_X&-6E.2A+F)DN96+VDB]&E6PU%(8[L1CS$A)**?0$]?K M5VL3_A&E_P"@QK'_ (&-1_PC2_\ 08UC_P #&J-"C;HK$_X1I?\ H,:Q_P"! MC4?\(TO_ $&-8_\ QJ5EW VZ*Q/^$:7_H,:Q_X&-1_PC2_]!C6/_ QJ++N! MMT5B?\(TO_08UC_P,:C_ (1I?^@QK'_@8U%EW VZ*Q/^$; Y76=85NQ^UDX_ M @BI=+N[I+VYTN_D$L\"K)'.%"^=&V0"0. P*D'''0\9Q1;L!K4444@"BL ? M;->N[H)>366GVTI@7[/@23NO#$L0=J@Y Y.#STJ3_A&E_Z#&L?^!C55EU V MZ*Q/^$:7_H,:Q_X&-1_PC2_]!C6/_ QJ5EW VZ*Q/^$:7_H,:Q_X&-1_PC2_ M]!C6/_ QJ++N!MT5B?\ "-+_ -!C6/\ P,:C_A&E_P"@QK'_ (&-19=P/,/C M/I&O:CK.EM#8?:+0DP6[VX)8NQ'RN.W3@]*]M4O\ A&U_Z"^L?^!C4?\ "-+_ -!C6/\ P,:M)33BH]B5&S;-NBL3_A&E M_P"@QK'_ (&-1_PC2_\ 08UC_P #&K.R[E&W16)_PC2_]!C6/_ QJ/\ A&E_ MZ#&L?^!C467<#;HK$_X1I?\ H,:Q_P"!C4?\(TO_ $&-8_\ QJ++N!MT5B? M\(TO_08UC_P,:C_A&U'36-8!_P"OPG^E%EW VZ*Q]/N+NTU1]*OIS,/_ M * *V*);L$%9NNM#'I$TMSJ,UA;Q#?)/"P#!1V!(/7IP,]A6E5+5-)L-:M!: MZC;)<0!UD"-GAAR#QW%(#FKB\UFP^%5Y>W4T\>J1V=-$TQ58&8 ,N0%RH/K74)HFFIH\FDBU4V$BL MCPL2P8-U!R<\YJFW@_0'LDM&TY&@24S(I=R53?WEJTMDT4QAE@NT59XW&1(% "YSUP /RH H:OKEQI>C6$D+6SW=PH"I/YA,A";C MM6-6)/'I@#FL:3Q[>&U2_@TR$V265I>W&^61D9#( > V M&/..<\UF:5X#T^Q@N(+HI%B?:0H*Y^8@Z7' M#Y*V:%/(:V.XEB8V.64DG)!/)J_'&D,21QJ%1 %51V Z"@!U%%% !1110!B: M=_R->N?]<[;_ -!>MNL33O\ D:]<_P"N=M_Z"];=5+<2"L3PE_R+=O\ ]=)O M_1K5MUB>$O\ D6[?_KI-_P"C6H^R'4VZ***D845S?CVYN+3P9?3VLC1SJT.P MJY0Y,J#&1TSG'XUS5]?:K/XAO(M1C6U*7.D[((;DRH UPX)SA<$XP>.PH ]) MHKD/#WBJ?5O$LM@7CFM'MGN8)EA,7"R;,#+$L.>I"].E4+_QQ=6NNW%M;M!< M6P2[5282FR2",N1N+9?D8/R@>AH [ZBO/SXNUJWA2&Y;3_M%TE@\4RQLL<'V MAF4[@6^;;LX.1DD#BI=&NKAO!/BJX:[22=+F_P 3V[$+D X*\G'3UX- '=T5 MQUMXG%K;^&X3=6[Q75B[SS229(=(D8< MBM"[\1:JG@_2]82S6&:XCCENUV&0P1E"S,J;E+8..,Y R<'% '5T5P=OXEU& M#4-7G>^M;FS%]910J4*B.*98LMG/3#D\]_RI;GQ=?7=U-8VDVG0 2WJ_:9LL MFR 1_+PP^8F0Y.> IXH [NBO,-/\3W>FZ78QV\7FSW$&FP"4LTN#) [%MI8 MGY<#!&21G-;<'B?6([K21JEM!96]R?*ED">9F4R%$4@/^[W @G<,G!Z4 =I M1110 4444 8MW_R-UE_UX7'_ *,AHHN_^1NLO^O"X_\ 1D-%4^@AWA/_ )$[ M1?\ KQA_] %;%'["/2M4WV_V0"&&=HR8YHQPI##C.,9!YSGM5S_A+ M-"_Z",7Y-_A0TVP1LUA>*M3N-,L+3[-/%:FZNX[9KJ50RP*V?F(/'8*,\985 M)_PEFA?]!*+\F_PIDOB?P[/$T4U]!)&PPR.A(/U!%+E?8=SFM0\77=EJVG6U MMJT-[MEM8KDK!&L1^5=3_ &_X7W1M]HM-T:[4/EO;O1ROL%SA;;49O^$EN))-2M-7=KO3$\Z%-J\B8X 5L9]/8C(J*V\47# MZE;:W>ZQ;O(^B33>7;P!C:,\T2A"N[YL$@?,1@@D\5WD7B#PQ"H6*YM(U!R MD6 #^7N:0:_X77S-MQ:#S,[\1??SUSQSFCE?8+G(6OB36+W5-)\W5A D.HW= MI( D>+G9&KJK;6*[CDK\I//(YJQI7BCQ+J6CSWBS6 ,UK'-&'EA5H9#( T8& M\Y^4D#?CYA@]>.G&O^%Q&D8N+01HP=5$7"L.A QP:0ZYX5(E!FLB)N9?W/W_ M />XY_&CE?8+E_P_J"ZKH%G>K*\HECR7DC",2#@Y ) Y'8D>E:=8B>*?#\:* MB7\*HHP%52 !^5._X2S0O^@E%^3?X4$OE=NRHC,Q^@ R:.5]@N-T[_ )&O7/\ KG;? M^@O6W6/HD$\EQ?:ISMI)3*]O"TA*DNR D[3E>?8G(]*S/\ A+-"_P"@E%^3?X4?\)9H7_02 MB_)O\*.5]@N7K;2]/LIY)[6QMH)923))%$JLQ)R%XIK*WDC>,1.CQ*0R#HI&.@[#M3X;&TMK8VT%K!% VG:J'_ EFA?\ 02B_)O\ "C_A+-"_ MZ"47Y-_A1ROL%R[::3IMA/)-9Z?:6TLGWWAA5&;G/) YYJY6-_PEFA?]!*+\ MF_PH_P"$LT+_ *"47Y-_A1ROL%S9HK&_X2S0O^@E%^3?X4?\)9H7_02B_)O\ M*.5]@N;-%8W_ EFA?\ 02B_)O\ "C_A+-"_Z"47Y-_A1ROL%S9K%3_D=YO^ MP='_ .C'I?\ A+-#/ U!">P"L2?PQ2:4DU[JMUJ\L$D$[7P]=7EO?JZ6< ML[W$%T$+)\YW,C8'RD,3C/!!'<&K/_"6:%_T$HOR;_"J:;=T(V:*QO\ A+-" M_P"@E%^3?X4?\)9H7_02B_)O\*7*^P[FS4 L[59?-%O$)-YDWA!G>1M+9]<< M9]*S?^$LT+_H)1?DW^%'_"6:%_T$HOR;_"CE?8+FD;*T-DUD;:$VK*4,&P;" MIZC;TQ2&PLV!!M("#%Y!S&.8_P"Y_N^W2L[_ (2S0O\ H)1?DW^%'_"6:%_T M$HOR;_"CE?8+ERYT;3+R.WCN=.M9DML>0LD*L(L=-H(XZ#IZ4^^TVQU.%8;^ MS@NHU;<$FC#@'UP:H?\ "6:%_P!!*+\F_P */^$LT+_H)1?DW^%'*^P7+DNC MZ9.\SS:?:R-/$(92T2DN@Z*>.1[5&V@:.]M';-I5D8(W\Q(C NU6QC(&,9]Z MK_\ "6:%_P!!*+\F_P */^$LT+_H)1?DW^%'*^P7+LFD:;-;R6\MA:O#(JH\ M;1*58+]T$8[=O2F)H>DQ2VTL>F6:R6PVP,L"@Q#KA3CCJ?S-5?\ A+-"_P"@ ME%^3?X4?\)9H7_02B_)O\*.5]@N;-%8W_"6:%_T$HOR;_"C_ (2S0O\ H)1? MDW^%'*^P7-FBL;_A+-"_Z"47Y-_A1_PEFA?]!&+\F_PHY7V"XEW_ ,C=9?\ M7A:A1I2S*S/@\A?E4#/7GVHIL1N45GWNM MZ;ITZP75VB3,-PB&6?'KM&3BJ_\ PE&D?\_,G_@/)_\ $TN5CN;%%8__ E& MD?\ /S)_X#R?_$T?\)1I'_/S)_X#R?\ Q-'*^P7-BBL?_A*-(_Y^9/\ P'D_ M^)H_X2C2/^?F3_P'D_\ B:.5]@N;%%8__"4:1_S\R?\ @/)_\31_PE&D?\_, MG_@/)_\ $T:AXU&H_;[:V@^R^7L M\C=SNW9SDGTK;U?4O#FN:9/I]_)));S+A@()01Z$';P17(^!_#?AOPA=W%[) MJ,MY=LQ6&1K:11''VXV_>/<_E6D8KD=UJ2[W5CU.BL?_ (2C2/\ GYD_\!Y/ M_B:/^$HTC_GYD_\ >3_ .)K/E?8JYL45C_\)1I'_/S)_P" \G_Q-'_"4:1_ MS\R?^ \G_P 31ROL%S8HK'_X2C2/^?F3_P !Y/\ XFC_ (2C2/\ GYD_\!Y/ M_B:.5]@N;%%8_P#PE&D?\_,G_@/)_P#$T'Q5HJC+WGEKW:2)U4?4D8%'*^P7 M-BBFI(DL:R1NKHP!5E.00>X-.I %%%4;W6=/TZ9(;FY"S.-RQ*I=R/7:H)Q[ MXHM<"]163_PDFF_WKK_P"F_^(H_X233?[UU_X!3?_$4^5]@-:BLG_A)--_O7 M7_@%-_\ $4?\))IO]ZZ_\ IO_B*.5]@-:BLG_A)--_O77_@%-_\ $4?\))IO M]ZZ_\ IO_B*.5]@-:O*_BKXXUGPQJ.G0:+>01B6-S,K1K(001CKTZUWW_"2: M;_>NO_ *;_XBN-\6^&_"GBZ_MKZX>^MKB-@)GALI09XQ_"WR=?0]16E))2O) M:$RNUH>@VNO_ *;_XBH<7V*-:BLG_A)--_O77_ (!3?_$4?\))IO\ >NO_ M "F_P#B*7*^P&M163_PDFF_WKK_ , IO_B*/^$DTW^]=?\ @%-_\11ROL!K M45D_\))IO]ZZ_P# *;_XBC_A)--_O77_ (!3?_$43>.O#W MA[Q;JEK?VVOBUD#!;A75V4IW9!C ;]#WKMM*UOPUH^F06%MJ1:*%=H:4N[-[ MDD].;Q3IGVJWM[=I[M[B!+A#:0/*OEL2%8E00 2#^5 &U16*GBS17%Z5O M 397:V5PNQLI*S!5&,="2!GIU]*LZKK5IHXMQZO=Z7;SE[NT M56F780%!) Y(P>0>E:- !1110 4$ @@C(-%% &'HB+9ZMJ^FPC;:PO'-#&.D M?F EE'H,@G';-;E8FG?\C7KG_7.V_P#07K;JI;B05A^%T6:PEU)QFYO)Y&D< M]<*[*J_0* /KZUN5B>$O^1;M_\ KI-_Z-:A;,.IMUA6?B[2[W5FTY/M,+.]5<\$C!_(UNUPL7@F8Z?K4T[RR7\TE^UE$T_[J+SBX5@!T8A ML$G.,FI&=H;RV&W-Q#\S;%^<*\]OO!MW#; M16UGHME=12Z2EBJLZH+.;G=*,CG.021\V4'X,M]#OKKQ-=JFGQ.8-4MI7U9W M D"Q0Q;E"XR=V".#CYCGIR =^VH0B\AMD#2M(6!:/#+'@9^8]L]J9P)'+,L"/O!!D)P%R.]<0/ U['HVE6MI#;VMREK>1W,J-@^;+&55B1RW) MZ]JAC\'WW]D&3^QLW4=W:3&TGGA9)%A/S;-B!5)!(R>3@9H ]%6Y@9W19HRR M#+J&&5'OZ4+7Y58D C:>_7'UKSEO!VLPV=V1D,"<'L3CF@#IE\26!\ M,/X@;S$LDC>0A@ V%)&,9ZDCCFKUG>K=6<5P\9MRX!,4C*63/0$J2/R-@]:F%Q S2*)HRT?WP&&5 M^OI7!6_AC5Q(8DM$M[2/5;>ZC$DB-( KNTAWJ 67Y@5#9;J*SQX*UF72I+/^ MSK6VGATRYLY+E)P3J,DF,,W&0,@L2W.3QZT >GQRQS*6BD1P"5)4YP1U%8UD MBV?BN_M8!M@GMX[ID'02%F5B![@#/N,U%H.A-H^MZM)%;PV]C;_L'1_^C'JEU$S:HHHJ1F%H4275UJ&J3 /:A))/#;6B>9,T]M)&0I&00&4%L] ML9H V:*R+OQ-IEI#82F2:87ZE[9;>!Y6D4*&) 4$XP12'Q/I*ZFFGM<.L[.L M7S1.$61EW+&6Q@.1SM)S0!L45GZ9KFG:R]TNGW(G^RR>5*0I #8!X)'/!ZCB MM"@ HHHH **** "BBB@#"CB33O%ACME$<-[:O/+&HPID1D7?CU(?!]<"BGW? M_(W67_7AEE"#]0@K8I2 MW8T%8'B[3;G4](ABM(7F>.[@F9(YO*M*OB_1#=ZG;/>"-].95N"ZD#) QCU MY8#US67>>$K\IY=C=VJK/I::7<^=$3M1=PWQ@'K\[<'CI4>H>"[NX-S';WD0 MMVEMKF$2;PXDA14VLRD':57J,$$T ;A\2Z;MCG%W;_87MY)S<&4 *$95.0>> M"V">QX-6]-U:PUB!YM/NH[B-',;%#]UAV/Y@_C7,2>"))=/,"O;6[26T\4BQ MAW4O+*CELN2Q^YSGJ3716.F-9ZQJMZ9%9;UXV5 ,%=J!>?7I0!G6/BR&ZN+" M.6#RTOWN?L\F\8V0L%R<]VSD 5'9^-+2ZN4WQ>1:F&YE:>1Q\ODS"(\#J"3D M50TGPE]HBT9-3MHGCT@W<'DW$0<3!G&QQGC[J@_C38_ U[9VOEZ?J<=K(D%S M%$T497:);@3 #!X&T%>.>S#@@CJ"/0U3TKQ M#::GH]CJ+?Z,EZ_EQ)*1DMD@+QW^4UG:!X27387-]*99S>O>)Y,\JJI8+P25KHO\ *K)*L13'KN./J,5!#XFN[V;4DL]*W+9O-$'>Y4>9)'VVC) ) MXS6./ %V9+&[;481?V+SSPNL1V>;)/YO*D\K@E?7G(((J]9Z)J&A7FK7\=MI MUR)GGN5:.$BZ8MR(]W0C( _*@#I--OH]3TNTOX@1'5X.XU" MZR/3]\QK:IRW!!1112 **** ,?Q3IEQK'AJ\LK0I]H<*\8D.%9E8,%)[ [)+>SM5T_^RXUNHYIGN728$1Y8+L5N07"]QT-==10!YYI_A+6DN-) ML[R:1+;39[L)=VDHB9H9 ICP,DC!++C_ &15J?0=5DOY; 6N;236HM3^VF5< M"--C%2/O;]R8Z8P'X=0C\0Z]<7>FRVT%Y-')"[R(V0L:I@A6) M'*D_2NEHHH **** "BBB@ HHHH Q;O\ Y&ZR_P"O"X_]&0T477/B^R Y(L)_ M_1D5%4^@AHTW5=-DD72)[5[21RXMKI6'E$G)V,O8DDX(X[''%+N\4?\ /+1_ M^_DO_P 36W12YAV,3=XH_P">6C_]_)?_ (FC=XH_YY:/_P!_)?\ XFMNBB_D M!B;O%'_/+1_^_DO_ ,31N\4?\\M'_P"_DO\ \36W11?R Q-WBC_GEH__ '\E M_P#B:-WBC_GEH_\ W\E_^)K;HHOY 8A?Q.H),>C@#DDRR\?^.U#!?:_=;OL[ MZ%-MZ^7<2-C\A5SQ)<3VOAZ^EM[*6]?RF'DPD;R",$C/7'I7D7P(EG@O=5@C ML)GAE$?F7(P(XBN[Y3GDDYZ#\:TC&\'+L2W9I'J^[Q1_SRT?_OY+_P#$T;O% M'_/+1_\ OY+_ /$UMT5G?R*,3=XH_P">6C_]_)?_ (FC=XH_YY:/_P!_)?\ MXFMNBB_D!B;O%'_/+1_^_DO_ ,31N\4?\\M'_P"_DO\ \36W11?R Q-WBC_G MEH__ '\E_P#B:#_PE#?+C2(\_P 8,CX]\8&?S%;=%%P*.EZ:NFP.#*T]Q,YE MGG<8,CD 9QV& .@ J]112>H!6--I-Y;7V^:WGB\R-G_OC!!4 MGOS@^F>:V:*:=@,7RO$W_/YI/_@+)_\ '*/*\3?\_FD_^ LG_P K: M]H=H\P)C$EK+\P'7H_O78UXC\9]-US4-=TPQZ:9K7F&VEM\L7=B#L8=CQQV/ MX5I22G*S)D[*Z/4U3Q*Z!EO=)*L,@_99.G_?RE\KQ-_S^:3_ . LG_QRKND? M;?[)M?[1BBAN_+'F1Q,65#Z9/6KM0V48OE>)O^?S2?\ P%D_^.4>5XF_Y_-) M_P# 63_XY6U12N!B^5XF_P"?S2?_ %D_P#CE'E>)O\ G\TG_P !9/\ XY6U M11<#%\KQ-_S^:3_X"R?_ !RCRO$W_/YI/_@+)_\ '*VJ*+@8OD^)CP;[2E![ MBTD)'_D2K>F:8NGK*[S/<74[!I[AP 7(&!P. . !_/)J_11< HHHI 8T^F7 MUK>S7FCSP(;@AI[:X4F-VP!O!'*M@ 'J#CIGFF[O%'_/+1_^_DO_ ,36W13N M!B;O%'_/+1_^_DO_ ,31N\4?\\M'_P"_DO\ \36W11?R Q-WBC_GEH__ '\E M_P#B:-WBC_GEH_\ W\E_^)K;HHOY 8F[Q1_SRT?_ +^2_P#Q-&[Q1_SRT?\ M[^2__$UMT47\@.7OM:U73&1;^[\.VK."4$]TZ;L>F15T/XG90PCT<@\@B67G M_P =KR;XX1WUSKFE(=.D$*JT<$Z_.)F8CY0 .&XZ=Z]ET:6YGT:TDO+-K.[Q1_P \M'_[^2__ !-&[Q1_SRT?_OY+_P#$ MUMT5G?R*,3=XH_YY:/\ ]_)?_B:-WBC_ )Y:/_W\E_\ B:VZ*+^0&)N\4?\ M/+1_^_DO_P 31N\4?\\M'_[^2_\ Q-;=%%_(#$W>*/\ GEH__?R7_P")HW>* M/^>6C_\ ?R7_ .)K;HHOY 9FFZ9+;W$M]?7"W-],H1G5-J1H.0B#G R2P((R2,^G>EV^*/^>NC_ M /?J7_XJG^$_^1/T8^ME"3]=@K8JF[.PC$V^*/\ GKH__?J7_P"*HV^*/^>N MC_\ ?J7_ .*K;HI7&8FWQ1_SUT?_ +]2_P#Q5&WQ1_SUT?\ []2__%5MT47 MQ-OBC_GKH_\ WZE_^*HV^*/^>NC_ /?J7_XJMNBBX&)M\4?\]='_ ._4O_Q5 M0VUEK]FKK;+H<*NYD<1P2*&8]2<-U/K70T4^8#$V^*/^>NC_ /?J7_XJC;XH M_P">NC_]^I?_ (JMNBE<#$V^*/\ GKH__?J7_P"*HV^*/^>NC_\ ?J7_ .*K M;HHN!B;?%'_/71_^_4O_ ,51M\4?\]='_P"_4O\ \56W11<#$V^*/^>NC_\ M?J7_ .*HV^*/^>NC_P#?J7_XJMNBBX&)M\4?\]='_P"_4O\ \51M\4?\]='_ M ._4O_Q5;=%%P,3;XH_YZZ/_ -^I?_BJ-OBC_GKH_P#WZE_^*K;HHN!B;?%' M_/71_P#OU+_\51M\4?\ /71_^_4O_P 56W11<#$V^*/^>NC_ /?J7_XJC;XH M_P">NC_]^I?_ (JMNBBX&)M\4?\ /71_^_4O_P 51M\4?\]='_[]2_\ Q5;= M%%P,3;XH_P">NC_]^I?_ (JC9XG_ .>NC_\ ?J7_ .*K;HHN!B;?%'_/71_^ M_4O_ ,51M\4?\]='_P"_4O\ \56W11<#$V^*/^>NC_\ ?J7_ .*HV^*/^>NC M_P#?J7_XJMNBBX&)M\4?\]='_P"_4O\ \51M\4?\]='_ ._4O_Q5;=%%P,3; MXH_YZZ/_ -^I?_BJ-OBC_GKH_P#WZE_^*K;HHN!B;?%'_/71_P#OU+_\51M\ M4?\ /71_^_4O_P 56W11<#$V^*/^>NC_ /?J7_XJC;XH_P">NC_]^I?_ (JM MNBBX&)M\4?\ /71_^_4O_P 51M\4?\]='_[]2_\ Q5;=%%P,3;XH_P">NC_] M^I?_ (JC;XH_YZZ/_P!^I?\ XJMNBBX&)M\4?\]='_[]2_\ Q5&WQ1_SUT?_ M +]2_P#Q5;=%%P,3;XH_YZZ/_P!^I?\ XJC;XH_YZZ/_ -^I?_BJVZ*+@8,E MOXCEV^8=%?8P==T,AVL.A'S=:?M\4?\ /71_^_4O_P 56W11S 8FWQ1_SUT? M_OU+_P#%4;?%'_/71_\ OU+_ /%5MT47 Q-OBC_GKH__ 'ZE_P#BJ-OBC_GK MH_\ WZE_^*K;HHN!B;?%'_/71_\ OU+_ /%4;?%'_/71_P#OU+_\56W11<#$ MV^*/^>NC_P#?J7_XJC;XH'_+31S[>7*/ZUMT47 S=-U.6YN);*]MQ;7T*AV1 M7WHZ'(#H<#(R".0"#^%%5[KCQ?9$<$V$^3_VTBHH:$.\)_\ (G:+_P!>,/\ MZ *V*Q_"?_(G:+_UXP_^@"MBB6[&@HHHI %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110!P&B^-O$&OZ]J-K9:/IJV%AJ3V,L MLU\5E(0C+!-G/!SUI(/B45\ ZWK]]8)#?:3<2VDMF)"09E8*HSC/)9>U8/A[ MPGJVB^-=2O[OP3;7S7.L2W,&JF]C5X(7/!"G).!DX]ZLZQX#UF[^)+M;Q1_\ M(QJ%U;:A?DR#/G0AOE"]<,=F: +FH_%"?P]#7;^ZU.TU)[7;+IB7 MN;59-A4C:.#R>'UU#0[>&UUWS!:R6MWYKQE.OF(5&!Q MU!K:TCQO>:E\0KOPU/HLMC##:&YBFGD'F2@/LSM&< \XR<\>]>?>%/AUXBLK MKPR!X>MM%NM,G\R^U9+U7>[CRVLO%G_"WG\0R>& FGR6HTXO] MOC)5!)N\['4\?P]: /3:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@#%N_P#D;K+_ *\+C_T9#11=_P#( MW67_ %X7'_HR&BJ?00GA25%T"UL"P%S81K:SQYY1T&W\CC(]016W7*>,[2V: M&WN#;Q&8MM,A0;B,=,]<5Q_DQ?\ /-/^^15\G-J*]M#UNBO)/)B_YYI_WR*/ M)B_YYI_WR*?LO,.8];HKR3R8O^>:?]\BCR8O^>:?]\BCV7F',>MT5Y)Y,7_/ M-/\ OD4>3%_SS3_OD4>R\PYCUNBO)/)B_P">:?\ ?(H\F+_GFG_?(H]EYAS' MK=%>2>3%_P \T_[Y%'DQ?\\T_P"^11[+S#F/6Z*\D\F+_GFG_?(H\F+_ )YI M_P!\BCV7F',>MT5Y)Y,7_/-/^^11Y,7_ #S3_OD4>R\PYCUNBO)/)B_YYI_W MR*/)B_YYI_WR*/9>8:?]\BCR8O^>:?]\BCV7F',>MT5Y)Y,7_/-/\ OD4>3%_SS3_OD4>R\PYC MUNBO)/)B_P">:?\ ?(H\F+_GFG_?(H]EYAS'K=%>2>3%_P \T_[Y%'DQ?\\T M_P"^11[+S#F/6Z*\D\F+_GFG_?(H\F+_ )YI_P!\BCV7F',>MT5Y)Y,7_/-/ M^^11Y,7_ #S3_OD4>R\PYCUNBO)/)B_YYI_WR*/)B_YYI_WR*/9>8:?]\BCR8O^>:?]\BCV7F' M,>MT5Y)Y,7_/-/\ OD4>3%_SS3_OD4>R\PYCUNBO)/)B_P">:?\ ?(H\F+_G MFG_?(H]EYAS'K=%>2>3%_P \T_[Y%'DQ?\\T_P"^11[+S#F/6Z*\D\F+_GFG M_?(H\F+_ )YI_P!\BCV7F',>MT5Y)Y,7_/-/^^11Y,7_ #S3_OD4>R\PYCUN MBO)/)B_YYI_WR*/)B_YYI_WR*/9>8:?]\BCR8O^>:?]\BCV7F',>MT5Y)Y,7_/-/\ OD4>3%_S MS3_OD4>R\PYCUNBO)/)B_P">:?\ ?(H\F+_GFG_?(H]EYAS'K=%>2>3%_P \ MT_[Y%*(8B1^[3_OD4>R\PYCOED2^\7;H&#QV5H\4SJ<@2.Z$+]0$R?3(]:*T :]/MX+6PABMX8X8]@.V-0HR1SP**S>]AG_]D! end GRAPHIC 60 evax-20211231x20f053.jpg GRAPHIC begin 644 evax-20211231x20f053.jpg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evax-20211231x20f054.jpg GRAPHIC begin 644 evax-20211231x20f054.jpg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

  •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end GRAPHIC 62 evax-20211231x20f055.jpg GRAPHIC begin 644 evax-20211231x20f055.jpg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end GRAPHIC 63 evax-20211231x20f056.jpg GRAPHIC begin 644 evax-20211231x20f056.jpg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end GRAPHIC 64 evax-20211231x20f057.jpg GRAPHIC begin 644 evax-20211231x20f057.jpg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end GRAPHIC 65 evax-20211231x20f058.jpg GRAPHIC begin 644 evax-20211231x20f058.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ KB=32>XUZ^']H7T2(R!4AN710- MH/0&NVKB;^>&/7]1$DL:G>G#,!_ *UHI.6ISXJ3C"\2O]DE_Z"FJ?^!LG^-' MV27_ *"FJ?\ @;)_C4GVNV_Y^(O^^Q1]KMO^?B+_ +[%=?)#L>=[6IW8NG"X MMO$&GJ-0OI$E+ATFN6=3\N>A-=S7"V<\,OB/2Q'*CG<_"L#_ UW5G4# KK M;3XJ:;+<6GVS2=6T^QO7$=M?74&V&0GISG(SVS7#ZSI5S=7_ ,2[.QMWF=8K M$K"BY,BIR0!WX!K2\:>*='\6> (= T)C=ZM>M#'%:1QGS+6!Y5.)@(P#M..3GL*Y?2)=,N? 5Q M+K5GJ,%K+X@E?[9;YCET]CTD/&0.QX[T >HZ)X[L]4O+RRO+"]TB\M(/M,D- M^@3]UW<$$@@=ZRT^+&EL([M]*U:/1I)/+357M\0$YQGKD+GOBN'3^UM1;6_# M^B>(Y?%%A/I,A%U)&#) ^?EC\T?>+#/%9B'1)/ EO97/BOQ+-=M$EL_A^)U\ MP., QB,IP 1P3Z4 ?0-[>?9-.FO%@EN/+C+B*%=SOQT4=S7B^H?$:Z6_\7ZF MNC:W&B64=G!NCPMK)M;)D^;"DLZ].:]=^S7$7AD6UK=-:W"6H2.>51(8V"_> M8=&(KP6/2O$FI>&;+/B!6B\3ZU^\@-BN7PQ)E)SG $8.WI0!Z/8:CXH@^'VA MV>AZ//\ VA)!Y,T^IG;]G*@ R,.K9.2!WK1^$EW@#NZ*** "BBB@ HHHH *\W\3W=\?%5W#'J-[#%'#$52&=D4$[LG ^@K MTBO,/$\L??_ /07U/\ \"W_ ,:A^TP?\]H_^^Q1]I@_Y[1_]]BO3]E3_E1Y7M:O\S+N MG7FH1:YI@_M2_D22Z1'22X9U93U!!->J5Y'8S1/KVDJLB,?MD? 8&O7*\W%Q MC&I:*Z'IX.4I4[R?4X_XHW%Q:?#K5YK6>2"98QMDB8JRG(Z$5G_"S6+F3PC- M9:IZ8Y6625BS,C#>K$GV/Z5=^*X)^&NL #)\L<#_ 'A7G_B,ZCX>U*U& MFPRLOB;2X;0[!]V8!1N/OM/Z5S'43?#[Q)J%]\2-9U+5+^8:;/8/>0Q22'RX MHA)M4[2<#A<_C76I\6M*(2Z?2M7CT>23RTU1[;$!.<9ZYQGOBN/UOP_*?&>O M:+I<9RGA=((548W8;&/QQ5R_\8Z)>_";^P+8-)K,MF+)=,$3>4'8SI]Y=W3(K,L[W3-2TKQK>: MCI^H2Z=/JD+[H%,HZ1>/$9HDOH@ MHE0=2"">E9\OQ4TU7EGBTC5I]*AD,*9_$]A=VDPD:X3S)+/Y?E_>]1GT./I6/I":58^"?[/U7Q?X@L[^!6@FT.)P M&+9/RHA3D'UZ0WGQ#N!XEUC4SH.N MI!::?Y/EM%@0NW.YQNP.!UKTCP_8R67@JQLX&N+9TM0$-T \D7'&X# )'I7B M<]CXGNO#^IW9\1)(-8U063Q?85!N"#MW9SP,9X% '7Z!IOB;Q-X7\/V7VG4M M+TT(S7\_F>7F+:"=Q>2^:]L^>F_ MT/I6?XI\6:GX'TJQ\.3:U!/JEU\O]H-:^6EK",#.Q2YD@A:18(_O2$#(4>YZ5YCX$\5>*-7^).M6? MB!/LD<-BLT>GJ05ARRXR>I;!Y^M 'K%%?/[^/?%TNC7/CF'5E73H=5^QKI9@ M7RS%QR6ZY^85U7BR;QLXU774UV+1-#L[03V2Q*CFX;;G#YY&3QCZ4 >K45YH M_P 0[^T^%NF:Q<6JR:[J2B*UMD7'FRDD!L>F!NJS\(-=U/7/!DMWK=ZUQ=K> MR1EWP, !>!CMR: /0J*R]:OY;2RC:TDA$TEQ%""XW !W"DX!&>#ZTOV;6O\ MH)V?_@$W_P 2%6)_ M$BH/LVM?]!.S_P# )O\ XY1]FUK_ *"=G_X!-_\ '* '_P!@:-_T";#_ ,!D M_P *3^P-&_Z!-A_X#)_A3?LVM?\ 03L__ )O_CE'V;6O^@G9_P#@$W_QR@"> M#2=-M91+;:?:PR#@/'"JG\P*N5F?9M:_Z"=G_P" 3?\ QRC[-K7_ $$[/_P" M;_XY0!HNBN,.H8>A&:#&A8,5&X=#CI6=]FUK_H)V?_@$W_QRC[-K7_03L_\ MP";_ ..4 :(C4,6"@,>IQUIB6T$PIL7:W48?] MFUK_ *"=G_X!-_\ '*/LVM?]!.S_ / )O_CE %Z*WAMUVPQ)&OHB@#]*!;0" M;SO)C\W^_M&[\ZH_9M:_Z"=G_P" 3?\ QRC[-K7_ $$[/_P";_XY0!I$ C!Y M!J,6L"B,+#&!'_JP$'R?3TJC]FUK_H)V?_@$W_QRC[-K7_03L_\ P";_ ..4 M :6.,4B(L:[44*!T &!6=]FUK_H)V?\ X!-_\K,^S:U M_P!!.S_\ F_^.4?9M:_Z"=G_ . 3?_'* -%D5U*L 0>Q%(8T.W*J=O3CI6?] MFUK_ *"=G_X!-_\ '*/LVM?]!.S_ / )O_CE &CY:[]^T;L8SCFF"V@$WG"& M,2GJX49_.J/V;6O^@G9_^ 3?_'*/LVM?]!.S_P# )O\ XY0!?EMX9P!+$DF# MD;U!Q^=+Y2#/R+\W7CK6?]FUK_H)V?\ X!-_\>NQ0,_E2&UMVE$K01F0='*#(_&J7V;6O^@G9_^ 3?_'*/LVM? M]!.S_P# )O\ XY0!I$9(M;<*JB&,*IW*-@X/J/>J7V;6O^@G9_P#@$W_Q MRC[-K7_03L__ ";_P".4 7V@B-&/JR@T+!$ARD2*?4*!5#[-K7_03L__ M ";_P".4?9M:_Z"=G_X!-_\&ZE>-@EN49<1LX(.\]U]* -6ZN8[.UF MN9CMBA1I'/H ,FO*]1^-30Q:8]AXI7T,-S87$%R0()(F20DXPI&#^E?,^G#PW''XAA3Q)JD@%K%:+J#6@")9">. M-E7YLMD$#.!P#0!],6-Y%J&GV][ 28;B-94)_NL,C^=6*J:7#;6^DV<%FP:U MCA186!SE HP<_2K= !7GFCZ%J<'QE\1:M-9R)I]S8)%%<'&UV&S('Y&O0Z* M/GF3P5XNATJX\ Q:([6,VK?:UU3S!Y0AXZ^_RCCK[5?\:V?C+5?%T$#>%K[4 M?#6F%5@LTF$:7)4#YW/.1GMCH.V37NAEC!P9%!]":'ECB3?(ZHOJQP* /+]0 M\#:QXS_LO7WOKGPS>VMNT4=A'&)?)Y(X.0!D8Z"F_"3P1?Z3H5ZGB.$R"2Z8 MQ6=W$K!/^F@Z\M_2O4GECC0O(ZJHZLQP!2JZNH9&#*>00<@T C:7:V]I M-;Z;9PRK?6V'C@56'[U>X%=+61XB_P"/&V_Z_K;_ -&K6O0 4444 %%%% !1 M110 4444 %%%% !1110 4444 %4]4L;/4-.FM[VUAN82I)CFC#KD#C@UAL) M0N,XW9QC;D=>E '344@.:6@ HHHH **YS4_'?AK1]3;3K_4UANUQF(Q2$\@' MJ%([BNB4A@".AH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **:X8H0K;6(X.,X-<3H<_B23QIJ&GW MNN13VEDL;E%LU0R;\\9!XQB@#N**** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH *P_$VO77A^P^V0:1-J$*Y,IBF1/+'&/O$9Z]JW*P?&G_(G MZE_US'_H0H T-)O+J_T^.XO-/DL)6S^XDD5R!V.5)'-7JBMO^/6+_<'\JEH M**** "BBB@ HHHH **** "BBB@ K'U;_ )#6@_\ 7U)_Z(DK8K'U;_D-:#_U M]2?^B)* +&M-:?V3=Q7MPL$,L+HSEL$*5.2/?%?/:Z7XECTDW,.H:&WA\:0V MG#4,G?\ 8R^XOY7WO,QQT_7FO@RVE_:&X:(-) %YMI[*-1'&;:0.B@# &0?2K] !2'@ M$TM(1E2/6@#YCU72_)US6/$/BSPIJKZ?+J;#[6ER8?+0MA?DQEATYZ5UWQ=M M=9NM&MM2_M.(>'EFMOL=I$IW2[L?/(3Z=A6MJ/PP\5:C]HT>?Q;Y_ANXNA<, MEPK27(&0=@8YXX'?\*ZGQIX,?Q)X2MM#L)X[9;>6%D:0$C:F../84 4O'WAK M2-8M++4?$>J20:)IRF2>U!VI,<<9(.<^@'K6%\(+H:9X;U&Y:.^CT:YOW.F1 M-$\K+'Z\ G'3\0:T_B/X!USQJVG0V6K6MK96GSM#-&7$DG8D=" .Q]370^#- M(\1Z/936_B#5K74""HMQ;VZPK$H'3 'I0 S6-=LKR&S@B6Z#M?6V-]I*@_U MJ]RH%=361XB_X\;7_K^MO_1JUKT %%%% !1110 4444 %%%% !1110 4444 M%%%% !7(Z]_R,\/_ %Z'_P!"KKJY'7O^1GA_Z]#_ .A5I1^-&&)_A,J'_D)Z M7_U]I_6NYKAC_P A/2_^OM/ZUW-57^,C!_PPHHHK$Z@HHHH **** "BBB@ H MHHH **** ,?Q4 ?"VI C(,!!%&'6[@*JEUN(D&!\J]>:[ M.*6*>,20R)(AZ,A!!_&O.-,TRP;2[5FL;8L8E))B7)X^E=3X-C2+194C141; MRX 51@#]XU:SIF7SZC81W,EGFLZIK$-]<7LD"W2H(1=RK& $C8?*& Z\_6MKPPCPZM=P_:KN:/R$;%Q< MO+@[F'&XG'X5HZ34>8Q5>+GR=3JZ***S-@HHHH **** "BBB@ HHHH **** M"BBHKJX6UM99V21UC4L5B0NQQZ*.2?:@"6BN=T+QEI_B&]FM;.UU.-X%%%([JB%G8*H&22< 4 )YB9Q MO7/IFG5YO-9>&7^)J3,FGLALS,6+K@R[_O=>M>C1R)+&LD;JZ,,AE.0: '44 M44 %%%% !1110 4444 %%%% !1110 5P_B34=3U0:IHUM!:)"I6+S9)&W= V M< 8_6NXKAI/^0_J__7=?_0%K2E%2E9F&(G*$+Q-/0];O[C4AIU[;6R 0;U>& M1FZ''.0*Z:N.T;_D;%_Z]&_]"%=C2J149-(JC)S@I,****@U,_6=:L]!L?ME M\9A#NVYBA>4@X)Z*"<<=:BT+Q%IWB2S-WIKS/ #C=) \>>,Y&X#(]Q6-XAOM M2DUB?3+:ZB@MS9JS;H=[$N74\Y&.%%4O#T^I:1=:/HQO(Y[(1F$ P;6 1.#G M/MZ5?LY*O'/BO4M9T\WWV7RK=3';J^3SMX.SOD '':O>[^T6_T^YL MW8JL\31%AU 88S^M>$&3Q?'IQ^&BW'A?[,5-F+DW*^=Y9/\ DV=@CEUM MH4A#'J0J@9_2KE !112, 5(/0T IW[,9!;MW&\Y.[CIGV]<7O$GA+5W\8:OKMAJ6AS)8:>D:6UV@N'VHH.& M0\*20>?>@#TF[\<^&['P]!KUSJD4>FSG$,Q5OWAYX"XW$\'MVJYH'B32?%&G M?;]&O$NK?<4+*""K#L00"#S7A-YK>H>+=2^'TUC9Z=:22B;RX98C]F24-@L$ M![=0/6N[^'NIW\4_B'34T33CJ=I?8NY+1S!'-D$A\'=SUXXZT =SXB_X\;;_ M *_K;_T:M:]KVVBNJH **** "BBB@ HH MHH **** "BBB@ HHHH **** "N1U[_D9X?\ KT/_ *%775R.O?\ (SP_]>A_ M]"K2C\:,,3_"93/_ "$]+_Z^T_K7 M;*TBMS/"LDOEKC>V.I]ZZBL3J"BBB@ HHHH **** "BBB@ HHHH R/%/_(KZ MC_UQ-<_%_J$_W1_*N@\4_P#(KZC_ -<37/Q?ZA/]T?RKJPW4X,;]DV_!_P#R M*FG?]YW+8*AN_^/.?_ *YM_*IJAN_^/.?_ *YM M_*D,X72O^03:?]@%%%% !1110 4444 <+_S&M:_Z_?_ &E' M6EX>_P"0Y=?]>R?^A-6;_P QK6O^OW_VE'6EX>_Y#EU_U[)_Z$U= M:-[7U._K+UG57TM(/+MQ,\\FQ5,FP#@GDX/IZ5J5SGBO[^E_]?!_] :B*O)( M51N,6T8.FZI?>'O[6N[FQ@DBN;HW'[NY)900HQ@H,GBO0:\ZUW_D#7/^[_6O M1:TK04'9&.&JRJ1;D%%%%8G28'C'_D G_KM'_P"A5A7W_'ALC M0O$>J:MJUY93Z-':I9R>7-*+P/AL9&!M&:I:_>7=GX+TIK.ZEMI)# A>+&[: M0,CD&N0B:^T^6XNK?5K]99W$DIWJ=[=.?E]*SIT)5(N2.FIB(4Y*,CV.LGQ, M ?#6H C(,1K2@8M!&S')*@D_A6=XF_Y%N_\ ^N1K%&S.2ATRP^S1_P"@VWW! M_P L5]/I72^#@%\)Z>% ", !V^8UB0?\>T?^X/Y5M^$?^13LLC=HKD+7Q-X@G\3OI$GAZ"..,"22<7X;$9. VW;R?;-=>.EC?^A"NQKCM&_Y&Q?^O1O_ $(5V-*M\;*PW\)! M11161N<;J_\ R-]Q_P!>,/\ Z'+4$'_(SZ/_ +\G_H!J?5_^1ON/^O&'_P!# MEJ"#_D9]'_WY/_0#76OX)Y\O]Y_KL=S16;K&OZ5X?@2?5KV.TB<[5>3."?PJ M32M9T_7+/[7IMTES!N*[TSC([US_Z%#75UROB? M_D8-)_Z]KG_T*&M*7QHQK_PV9=W_ ,?&G?\ 7]!_Z&*[ZN!N_P#CXT[_ *_H M/_0Q7?5>(^(SP?\ #^85CZM_R&M!_P"OJ3_T1)6Q6/JW_(:T'_KZD_\ 1$E8 M'47M36X?2[M+1MMRT+B(^CX./UKYK6;P4O@=])FT34/^$ZY3F&3SS=;N&W>F M>WZ9YKZ5U"6:#3KF6W0/.D3-&IZ,P!P/SKP_1;+Q7XBL(=:D^)MA97-P"SP> M6FZ YY0YP01TQ0![5HJ746AV$=\Q:[6WC$Y)R2^T;OUS5^JVGI)'IULDMP+B M18E#S#I(<#+?CUJS0 4V1-\;)N*[AC(ZBG4'@4 >9Q? _P -P2R21:EKJ/(V M]REZ!O/J<+S6GK/PIT#6M0-\T^I6<\D(AN&L[GR_M* 8DX.[@#/3-2W7Q+T M6'QQ9>%;8F\O+ABLDD+@I W/#'UXZ=JIZ]\5;+2-;OM+M-%U+5'TZ,2WTEJB ME(%QGDD\X% &IJWPY\/:KH=AI7D2V<6GD-:2V^>_-7_"WA+3/ M"-C+;:?Y\C3R&6>XN)-\LK>K-WK"U#XH:9!INC7.G6%[J<^L FUM;=0'('WM MV3@8Z=_RK8\(>+[7Q?I]Q_Y&>'_KT/\ Z%6E'XT88G^$RF?^0GI? M_7VG]:I^- 9O$HA=G,7V4?)O(4Y//%73_P A/2_^OM/ZU3\8?\C6/^O4?^A5 MU12==)G(FUAFUW*?AE!:^)].A@+QQ;9!Y:N=N .!C.*]1KS#0/\ D;--^DG\ MJ]/K+%I*I9'1A&W2U"BBBN8Z@HHHH **** "BBB@ HHHH R/%/\ R*^H_P#7 M$US\7^H3_='\JZ#Q3_R*^H_]<37/Q?ZA/]T?RKJPW4X,;]DV_!__ "*FG?\ M7(5-#XI\/W%VMI!KNF2W+-M$*7<;.3Z;0N5 M#=_\><__ %S;^51Z=:=;W+*%,L:N5'09%27?_ !YS_P#7-OY5D:G"Z5_R M";3_ *Y+_*NA\(?\@B;_ *_+C_T8U<]I7_()M/\ KDO\JZ'PA_R")O\ K\N/ M_1C5U5_A1Y^$_B2-^BBBN4] **** "BBB@ HHHH X7_F-:U_U^_^THZTO#W_ M "'+K_KV3_T)JS?^8UK7_7[_ .THZTO#W_(B-"07GM)(E)!((!8 $@@@XZ56\0ZKJ%IJ=K96+6R"6"25VFC+_ M '2H &&']ZL'0Y]5\/Q66G_:+2>VDNR&_<,K_O)"QP=Y'!8]JM4Y-G_ +-5/0?^ M1NTG_?E_]%-7?'_=?Z[G!+_>_P"NQZA7.>*_OZ7_ -?!_P#0&KHZYSQ7]_2_ M^O@_^@-7GP^)'?5^!^ASVN?\@:Y_W?ZUZ)7G>N?\@:Y_W?ZUZ)6V(^)'/@_A M84445SG88'C'_D G_KM'_P"A5A7W_'AD]CG(/^/:/_<'\J!/-;?"U);>:2&0 M(9R_ZE_P#=->D^&/\ MD6=/_P"N(J\9",;%%%% !1110 45RGB[5_$.D363 M:7%IDD%S.EO_ *49 P=L\_+QCBNDL_M/V2+[8(A<[?WGDYV9]L\XH GHHHH M*X:3_D/ZO_UW7_T!:[FN&D_Y#^K_ /7=?_0%K:A\9S8O^&6-&_Y&Q?\ KT;_ M -"%3^*?&@\-/'MTR2^1F5&:*ZA38[-M"E68'N.<8J#1O^1L7_KT;_T(5R-] M:V\NN:JTD$;M]LDY9 3UK3V7M:KCKOJPJ0Y).)U4Y\\5+N<;J_P#R M-]Q_UXP_^ARU!!_R,VC_ ._)_P"@&I]7_P"1ON/^O&'_ -#EJ"#_ )&;1_\ M?D_] -="_@G%+_>?Z[!X[UZ*72=7T&&QNI[M[B5ROB?_D8-)_Z]KG_ -"AKJJY7Q/_ ,C!I/\ U[7/ M_H4-84OC1M7_ (;,N[_X^-._Z_H/_0Q78ZI=7=G8//96#7TZD8@658RP[_,W M'%<==_\ 'QIW_7]!_P"ABMS7O%"Z/?16(LWGDEA,N0X4 9Q6E:+E.R,<+)1I M-ON.\)>(KKQ/I2ZC+I$EA;S(KVY>=)#*ISSA>F/?UJQJW_(:T'_KZD_]$25R MW@?77TS2M#\.W-F?-""W\Y) 5W!6;., XPIKJ=6_Y#6@_P#7U)_Z(DK&47%V MDCJC.,U>++VHFW&FW1N_^/80OYO^Y@Y_3-?,]OI_AB9[ZZ/@"X73XK'^T+8? MVA+YLUN)E0N1NP!M+-^'IS7O/C+QEH'A:WBM]=,WE7R.@6.%I-P 8''3[U? M/Q_X1;^T=L?CG75TGRC;?9O[/D\P6Q;=Y._=C;^&/:I*/IS1GM9-$L'L01:- M;QF 'J$VC;G\,5>JGI/V7^Q[+[$I6T\A/)4C!";1M_3%7* "@C(Q110!XWXC MT33=$^,7@R/3;..W$\L\TI0^N+&WEN[?/DSO$"\>>NTGD?A6==>"_"][ M=27-UX=TJ>>5MTDLMHC,Q]22.: /)?$=IH\%WX%T+2M72QTZ-96BUV.3Y@0. M55L[?F/7/M6]\(//:QU^PLKR.1;;4W/]HE#(;O/\1RW7@=..?QKT&X\*^'[K M3(M-GT:PDL8CF.W:W78A]5&..O:KFFZ7I^CV@M--LK>TMP'_ '8/_1J5SLG^J?\ W3717'_))X?]V#_T:E<[)_JG_P!TUT8+ M:1EC=X^AZ=H?_(!L/^N"?RJU=_\ 'G/_ -?_K\N/_1C5S^E?\@FT_ZY+_*K MUF2/ 6MD'!!O>1_O/777^%'GX3^)(IZAX5T6?XDV4DENY,UI/=28N) #*LD6 MUL!L<9/'3FN]&,#'2O%X].LBB.;.W+[<;C$N?Y5Z)X#&/"<"C@+-. /0"5\" MHK8=TDFV;T<2JK:2.EHHKC?&EQK]E>Z2VE:S%:0WMY'9M&UFLNTL';?DG_9 MQ7.=)V5%0VD=4 DE"; [8Y.WMGTJ:@ HHHH X7_F-:U_U^_P#M M*.M+P_\ \ARZ_P"O9/\ T)JS?^8UK7_7[_[2CK2\/?\ (M!H,,;^3+Y4PN+0N"0V&*L)5Z#/&.<=:Z3PQXB77() M(9%D%Y;*AG)A\M6W;L%1N;CY3WKA[S_D+:C_ -?\!?\AC6?\ KC;? MSEHJ8>,:2FM]#6GB)2K.F]M3NJQ_$LNI6VBW%UI=S;P30(TK>? 9 P )Q@,N M/K6Q7)^)-9NY&U#1;2PCD)M@#+)<; "X8#@*>:XC64&"$Q!0R@XP6;/UK7KD_#NM7<;:;HUW81QD6XC$L=QOR449 MX*CKBNLH::=F*,E)704444BCDO$?_(S:?_UYS?\ H<=4+C_C[T[_ *_8?_0A M5_Q'_P C-I__ %YS?^AQU0N/^/O3O^OV'_T(5UP_A,\ZK_O"^17\8_\ (UQ_ M]>G_ +-5/0?^1NTG_?E_]%-5SQC_ ,C7'_UZ?^S53T'_ )&[2?\ ?E_]%-6\ M?]U_KN3+_>_Z['J%?#XD=]7 MX'Z'/:Y_R!KG_=_K7HE>=:[_ ,@6Y_W?ZUWM[]K^Q2_8?(^U;?W?GYV9]\, M?^0"?^NT?_H585]_QX7'_7-OY5N^,?\ D G_ *[1_P#H585]_P >%Q_US;^5 M=5#X6>?B_CB/\3_\B5HW_72W_D*YBX_U#?A_.NG\3_\ (E:-_P!=+?\ D*YB MX_U#?A_.NC"?PI$8S^+$]T7^X/Y M5G>)O^1;O_\ KD:\U'I/8YR#_CVC_P!P?RJ.;_DE"_[G_M0U)!_Q[1_[@_E4 M57NM4N$6WN MS+$D4<0"LI('5"3U[FNH\-75Y<&^CN[I[DPRJ$9T52 5!Q\H ZFN=TW_ %$O M_7>3_P!"-;WA?_7ZI_UV3_T 5TU(15--(XJ-2;K.+>FIT5%%% MZ_Y#.J_]?DO_ *%74:-_R-B_]>C?^A"N7NO^0SJO_7Y+_P"A5U4/X[]#EJ_[ MM'U_S-[P'_R%]5_ZYP_^S5W=<)X#_P"0OJO_ %SA_P#9J[NN7$?Q6=F&_A1. M-U?_ )&^X_Z\8?\ T.6H(/\ D9M'_P!^3_T U/J__(WW'_7C#_Z'+4$'_(S: M/_OR?^@&M5_!.:7^\_UV,SQ%_P C9J7UC_\ 1:U8\(?\C6O_ %YR?^A)5?Q% M_P C9J7UC_\ 1:U8\(?\C6O_ %YR?^A)6\O]U_KN1'_>_P"NQZ)7*^)_^1@T MG_KVN?\ T*&NJKE?$_\ R,&D_P#7M<_^A0UPTOC1VU_X;,N[_P"/C3O^OZ#_ M -#%1^-O^1IM/^O)O_0Q4EW_ ,?&G?\ 7]!_Z&*C\;?\C3:?]>3?^ABNI?[Q M$XX_[M+^NQG:5_R,VB_]?9_]$R5W>K?\AK0?^OJ3_P!$25PFE?\ (S:+_P!? M9_\ 1,E=WJW_ "&M!_Z^I/\ T1)6>,_B&^"_A?,NZBQBL+B>.W$\T43/'&1G M+V\*-XX/CBR1P#/\ V7Y:^6,'_4X_O=L8SGOWKWC4O(_LRZ^U M$K;^2_FD=0N#G]*^9=1T_P"']O%IDMGX2H;LJT-NKL/,/!SD*6] M,=ZY3K/I71[XW^DVD\BI'/)"CRP@Y\MBH)'X'BK]<=X$\$>'/#%LVH>'UN!' MJ$4;DRRELKC*_3K78T %%%% !7D_BCXBZW_PENH:)X>ET>U73(U:>?5)=@GD M(!$:<@9.>_OTQ7K%?/'B_1[/0?B-XDN]>T*XU&UU6T;^SY8X/,"S%0/P;(// M4<4 >L:KXSD\/>!(];UNS$%^\85;.*0/YDQZ*I!((/7Z57^%GBC4O%WA234M M66);E;N2';$FT +QC\37!:=X&\=W&@^%[I9K '3+=G2TU'>=CDMM8J!U"XQ MD\5J?!?1M2F\,7T6K>9#:"]=H4AEFMY=_&XDJ1E>F/QH ])\1?\ 'C:_]?UM M_P"C5K7KE]9T2TM(+.:.6_+K?6V!+?SR+_K5ZJSD'\JZB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH *Y'7O^1GA_Z]#_Z%775R.O?\C/#_ ->A_P#0 MJTH_&C#$_P )E0_\A/2_^OM/ZU3\8?\ (UC_ *]1_P"A5$<:_W9^I5T#_D;--^DG\J]/KS#0/^1LTWZ2?RKT^L M\9_%.G!_PCE_%O\ Q_:/_P!=)/\ T$5BZQ_R#F_ZZ1_^ABMKQ;_Q_:/_ -=) M/_016+K'_(.;_KI'_P"ABG2_ALQQ'\:/R/0$^XOT%.IJ?<7Z"G5R'H!1110 M4444 %%%% &1XI_Y%?4?^N)KGXO]0G^Z/Y5T'BG_ )%?4?\ KB:Y^+_4)_NC M^5=6&ZG!C?LD5Q_R2>'_ '8/_1J5SLG^J?\ W3717'_))X?]V#_T:E<[)_JG M_P!TUT8+:1EC=X^AZ=H?_(!L/^N"?RJU=_\ 'G/_ -J.E?\ ()M/ M^N2_RJ]9_P#(@ZW];W_T)ZZZ_P *//PGQR.2B_U*?[HKN_ G_(J0_P#7>X_] M'/7"1?ZE/]T5W?@3_D5(?^N]Q_Z.>M\;\"(P/QLZ2O-ITO\ 7O)GNM5G7[+? M// D<48",C.J_P .3P3UKTFO/M*_X])/^OB;_P!&-7'0BI2U.K%3E&*<6;_A M>\O;E]2AO;IKDP3JJ.R*IP8U;'R@#J3715S'A/\ X_-:_P"OB/\ ]%)73UG- M6DTC6DVX)L****DT.%_YC6M?]?O_ +2CK2\/?\ARZ_Z]D_\ 0FK-_P"8UK7_ M %^_^THZTO#W_( O^0QK/_7&V_G+6];_=E\B: M'^\OYG=5Q6H?\C;J/_7"#_V>NUKBM0_Y&W4?^N$'_L]<5#XT=>*_A,+'_D:M M,_W9?_0:[6N*L?\ D:M,_P!V7_T&MOQ%XEM/#-H+N]M[V2#!+/;0&0(!U+8Z M"BO\8L+_ D;5%4=)U2/6+!+R*WN8$<\)G?]?L/_H0J_P"(_P#D9M/_ .O.;_T..J%Q_P ?>G?]?L/_ M *$*ZX?PF>=5_P!X7R*_C'_D:X_^O3_V:J>@_P#(W:3_ +\O_HIJN>,?^1KC M_P"O3_V:J>@_\C=I/^_+_P"BFK>/^Z_UW)E_O?\ 78]0KG/%?W]+_P"O@_\ MH#5T= M26OG.P=D522 I/\ $#63KG_(&N?]W^M7O'O_ !\Z3_OO_P"@FNN23JQ3.*BV MJ,FCF='N-1T>YMH;;5+DP3WH:6-UC(8NWS?PYKURO(E_X_K#_K[B_P#0J]=J M,7",9I15C;!SE.#QSD'_'M'_N#^51S M?\DH7_<_]J&I(/\ CVC_ -P?RJ.;_DE"_P"Y_P"U#776WB>?A=I'.2_ZE_\ M=->D^&/^19T__KB*\VE_U+_[IKTGPQ_R+.G_ /7$5MCMHBP&\C6HHHKSCT@H MHHH **** //]-_U$O_7>3_T(UO>%_P#7ZI_UV3_T 5@Z;_J)?^N\G_H1K>\+ M_P"OU3_KLG_H KKJ_P )'G4/X[^9T5%%%C?^A"N7NO\ D,ZK_P!?DO\ MZ%74:-_R-B_]>C?^A"N7NO\ D,ZK_P!?DO\ Z%750_COT.6K_NT?7_,WO ?_ M "%]5_ZYP_\ LU=W7"> _P#D+ZK_ -B5ROB?_D8-)_Z] MKG_T*&NJKE?$_P#R,&D_]>US_P"A0UPTOC1VU_X;,N[_ ./C3O\ K^@_]#%1 M^-O^1IM/^O)O_0Q4EW_Q\:=_U_0?^ABH_&W_ "--I_UY-_Z&*ZE_O$3CC_NT MOZ[&=I7_ ",VB_\ 7V?_ $3)7=ZM_P AK0?^OJ3_ -$25PFE?\C-HO\ U]G_ M -$R5W>K?\AK0?\ KZD_]$25GC/XAO@OX7S-&\M8[ZRGM9<^7-&T;X]",&O) M;3X,ZC;6FIJWB5I;FYMH].MYC!CR;0,-R=>24&WC'?GFN>U+XAZ['J3:5K6O M7FB3+<7#S^1IV]X\$"*-?[R$ G=WS^->R>"[W4M1\':7=ZQ&R7\L.9 R;&/) MVL5[$K@D=LURG6:NGV46FZ=;6,.?*MXEB3/7"@ ?RJS110 4444 %(0#UQ2U MXU\58M6TF:\UV\\4WMG;;1'I-GIY9O.*A^%/B5O[$U0ZKK@GTZ&_>"PO;Z8 M*TR#W8\]C^- '=^(O^/&V_Z_K;_T:M:]06D%KJUC/,U];;8XKA&8 M_O5Z &NGH **** "BBB@ HHHH **** "BBB@ HHHH **** "N1U[_D9X?^O0 M_P#H5==7(Z]_R,\/_7H?_0JTH_&C#$_PF5#_ ,A/2_\ K[3^M4_&'_(UC_KU M'_H57#_R$]+_ .OM/ZU3\8?\C6/^O4?^A5U0_P!X1QK_ '9^I5T#_D;--^DG M\J]/KS#0/^1LTWZ2?RKT^L\9_%.G!_PCE_%O_']H_P#UTD_]!%8NL?\ (.;_ M *Z1_P#H8K:\6_\ ']H__723_P!!%8NL?\@YO^ND?_H8ITOX;,<1_&C\CMKZ M6[@TUY;&V2YN54%(9)?+5C[M@X_*L;PCXAU3Q%:R75[I$-C "5C9+OSBQ!P< MC:,5/KGB--$-K";62=[A6(V, !US]:YGPAX@;2K2TTFYL9-\URP$B2*5&X MDCWKG5.;CS):':ZD%+E;U/1*:Y98V95W, 2%!QD^E.K/UG4)=-T\SPPI-)N" MJCN5&3ZD _RJ%J4W979AZ/XMU/4_$5QI,WAJ>T^S8\^9KN)PF1E> @;'ID54HN.Y,* MD9_"R6BBBI+,CQ3_ ,BOJ/\ UQ-<_%_J$_W1_*N@\4_\BOJ/_7$US\7^H3_= M'\JZL-U.#&_9(KC_ ))/#_NP?^C4KG9/]4_^Z:Z*X_Y)/#_NP?\ HU*YV3_5 M/_NFNC!;2,L;O'T/3M#_ .0#8?\ 7!/Y5:N_^/.?_KFW\JJZ'_R ;#_K@G\J MM7?_ !YS_P#7-OY5YIZB.%TK_D$VG_7)?Y5>L_\ D0=;^M[_ .A/5'2O^03: M?]_\ H3UUU_A1Y^$^.1R47^I3_=%=WX$_Y%2'_KO O^0QK/_7&V_G+6#>?\A;4?^ON7_P!"-;W@+_D, M:S_UQMOYRUO6_P!V7R)H?[R_F=U7%:A_R-NH_P#7"#_V>NUKBM0_Y&W4?^N$ M'_L]<5#XT=>*_A,+'_D:M,_W9?\ T&JOCK7GN;#5_#MM822326YC\XR*J@LO M'O5JQ_Y&K3/]V7_T&L;Q!_R-NI?]L_\ T&MU352MRR.>-1T\/S1.F\-^)QJE MRNFO82V\D=OOW,ZL& P#T^M=17GG@[_D:V_Z\W_]#2O0ZPKP4)N*.JA-SIJ3 M.2\1_P#(S:?_ ->H5SGBO[ M^E_]?!_] :NCKG/%?W]+_P"O@_\ H#5Y\/B1WU?@?H<]KG_(&N?]W^M7O'O_ M !\Z3_OO_P"@FJ.N?\@:Y_W?ZU>\>_\ 'SI/^^__ *":ZW_&B<-+^!,YA?\ MC^L/^ON+_P!"KUVO(E_X_K#_ *^XO_0J]=I8WXUZ&N!_AOU,#QC_ ,@$_P#7 M:/\ ]"K"OO\ CPN/^N;?RK=\8_\ (!/_ %VC_P#0JPK[_CPN/^N;?RJ:'PLC M%_'$?XG_ .1*T;_KI;_R%N6_\ Q[1?[@_E6=XF_P"1;O\ _KD:T;?_ (]HO]P?RK.\3?\ M(MW_ /UR->:CTGL<>(/%$&I:GHL]K87SQ65X99&V(,KM(X^;GFNVT37+?7;>2:WCFC\M]C+, MH!!QGL37,X22NT=ZG%NR9J5PTG_(?U?_ *[K_P"@+7C?^A"N7NO^0SJO_7Y+_Z%74:-_P C8O\ UZ-_ MZ$*Y>Z_Y#.J_]?DO_H5=5#^._0Y:O^[1]?\ ,WO ?_(7U7_KG#_[-7=UPG@/ M_D+ZK_USA_\ 9J[NN7$?Q6=F&_A1.-U?_D;[C_KQA_\ 0Y:@@_Y&;1_]^3_T M U/J_P#R-]Q_UXP_^ARU!!_R,VC_ ._)_P"@&M5_!.:7^\_UV,SQ%_R-FI?6 M/_T6M6/"'_(UK_UYR?\ H257\1?\C9J7UC_]%K5CPA_R-:_]>_Z['HE,_B&^"_A?, MXKXMZ_?Z1)H=G;ZB-(L[Z9TNM4$.]H0 " /3.3[\5PVI:E%X?L)-3TGXNWFH M7T0WQ6/ MI7#V?B72[:6.[L_@M?*_#I*E@#CN"#L_45RG6>S:15<30)))' MC&UBH)'YU=J"RG:ZL8+AX7A:6-7,3CYD)&=I]QTJ>@ HHHH *\S\7V/Q#EO] M5LM-BT_5-%U*#R8EG*QM:9&#Z;NI/?\ Q],JM>7]GIT'GWMU!;19"^9-($7) MZ#)H \<\1^ ?&B^"=#\)Z0(;JRMTWWS&X$?FMNSLYYVC)_2N^\"6>MVNCFQU MS1-,TR*WVI:PV3;UV\Y)R3SG\\UTMW?V>GVQN;V[@MH!UEFD"*/Q/%+97]GJ M5N+BQNH+J G D@D#J?Q'% &;X@AB6RM2L: _;K;D*/\ GJM;59'B+_CQMO\ MK^MO_1JUKT %%%% !1110 4444 %%%% !1110 4444 %%%% !7(Z]_R,\/\ MUZ'_ -"KKJY'7O\ D9X?^O0_^A5I1^-&&)_A,J'_ )">E_\ 7VG]:I^,/^1K M'_7J/_0JN'_D)Z7_ -?:?UJGXP_Y&L?]>H_]"KJA_O".-?[L_4JZ!_R-FF_2 M3^5>GUYAH'_(V:;])/Y5Z?6>,_BG3@_X1R_BW_C^T?\ ZZ2?^@BL76/^0<_\ MUS;^5>:>HCA=*_Y!-I_UR7^57K/_ )$'6_K>_P#H3U1TK_D$VG_7)?Y5>L_^ M1!UOZWO_ *$]==?X4>?A/CD?:5_QZ2?]?$W_ *,:O0:\^TK_ (]) M/^OB;_T8UIM>$_P#C\UK_ *^(_P#T4E>;7\$WB:>UU:]E59V5 M7=8FE17&T@*0) ,#.>,'('O7I/A/_C\UK_KXC_\ 125Y_I?_ ""K3_KBG\A6 MU"G&=22DC.M4E"E!Q=CT3P;J5UJ.EW NS&6MI_(0QJ1\H12,Y)YY]:Z.N2\ M?\@[4O\ K]/_ *+2NMKDJ)*;2.RDW*";['"_\QK6O^OW_P!I1UI>'O\ D.77 M_7LG_H35F_\ ,:UK_K]_]I1UI>'O^0Y=?]>R?^A-71+^"<5/_>7\SC[S_D+: MC_U]R_\ H1K>\!?\AC6?^N-M_.6L&\_Y"VH_]?\!?\AC6?^N-M_.6 MMZW^[+Y$T/\ >7\SNJXK4/\ D;=1_P"N$'_L]=K7%:A_R-NH_P#7"#_V>N*A M\:.O%?PF%C_R-6F?[LO_ *#6-X@_Y&W4O^V?_H-;-C_R-6F?[LO_ *#6-X@_ MY&W4O^V?_H-=5+_>/DAUYYX._Y&MO\ KS?_ M -#2O0ZPQ7\5G7A/X*.2\1_\C-I__7G-_P"AQU0N/^/O3O\ K]A_]"%7_$?_ M ",VG_\ 7G-_Z''5"X_X^]._Z_8?_0A5P_A,YJO^\+Y%?QC_ ,C7'_UZ?^S5 M3T'_ )&[2?\ ?E_]%-5SQC_R-_Z['J%N6_P#Q[1?[@_E6=XF_Y%N__P"N1K1M_P#C MVB_W!_*L[Q-_R+=__P!T?^X/Y5'-_R2A?]S_VH:D@_X]H_ M]P?RJ.;_ ))0O^Y_[4-==;>)Y^%VD?VO_'NOU/\ .NS\ _\ 'IJ/_7S_ .RBN,M?^/=?J?YUV?@'_CTU M'_KY_P#916^)_@Q^7Y$X7^/+Y_F=?7#2?\A_5_\ KNO_ * M=S7#2?\ (?U? M_KNO_H"UQT/C.K%_PRQHW_(V+_UZ-_Z$*Y>Z_P"0SJO_ %^2_P#H5=1HW_(V M+_UZ-_Z$*Y>Z_P"0SJO_ %^2_P#H5=5#^._0Y:O^[1]?\S>\!_\ (7U7_KG# M_P"S5W=<)X#_ .0OJO\ USA_]FKNZY<1_%9V8;^%$XW5_P#D;[C_ *\8?_0Y M:@@_Y&;1_P#?D_\ 0#4^K_\ (WW'_7C#_P"ARU!!_P C-H_^_)_Z :U7\$YI M?[S_ %V,SQ%_R-FI?6/_ -%K5CPA_P C6O\ UYR?^A)5?Q%_R-FI?6/_ -%K M5CPA_P C6O\ UYR?^A)6\O\ =?Z[D1_WO^NQZ)7*^)_^1@TG_KVN?_0H:ZJN M5\3_ /(P:3_U[7/_ *%#7#2^-';7_ALR[O\ X^-._P"OZ#_T,5'XV_Y&FT_Z M\F_]#%27?_'QIW_7]!_Z&*C\;?\ (TVG_7DW_H8KJ7^\1../^[2_KL9VE?\ M(S:+_P!?9_\ 1,E=WJW_ "&M!_Z^I/\ T1)7":5_R,VB_P#7V?\ T3)7=ZM_ MR&M!_P"OJ3_T1)6>,_B&^"_A?,S/&UCK^HV7V/3;#2]0T^:-DN[6]E>-WSC& MQ@,#OU]JP[/QO/X7TZVL-6\%Z[8VUK&L2RVX%W$B*,#+J,O![^*S9 M[-?U+2?L^[/V*79YF^F/UKS_Q/X%U/P;X>N_$%CX^UMKBQ42I'=7!9)"" M/E(SSGICFN4ZSV2RNX;^Q@O+L_0KV34M T^^E4))< M6TN* M]KKG/&GA1/&.B+IKW;6P6=)MZIN^ZNHPR;Y19R M2;(Y7 &X^@YS[9K5^&NH6>EVVM6%IX>O;>^@OB+NRMI5ECC8CADW%<*<=/I M72^+_ Z^)SIUU;:C-INJ:<^^VNXE#$>H(/4<"I?!O@Y?"D5]+-?RZAJ%_-YU MU=2J%+MV Z 4 ,U?6);F*SB;1]1MPU];?O)EC"C]ZO7#D_I75UD>(O^/&U_ MZ_K;_P!&K6O0 4444 %%%% !1110 4444 %%%% !1110 4444 %H_]"JX?^0GI?_7VG]:I^,/^1K'_ %ZC_P!"KJA_O".-?[L_4JZ!_P C9IOT MD_E7I]>8:!_R-FF_23^5>GUGC/XITX/^$.?\ D(Z3_P!?#XD>A4^! M^AS6J?\ ((O?^O>3_P!!-=MI_.FVW_7)?Y5Q.J?\@B]_Z]Y/_036AXDU&^T[ MP_I1L+IK:25T1G5%8XV$_P 0([>E=->+E))''A)*,9-C_!J@7_B7 '_(5E_I M765X_:WNK:0\\]MJ]QFYN5FF5XH2'9F /\'''IBO7D)**3U(%85*4J;M(ZJ5 M6-17B97BG_D5]1_ZXFN?B_U"?[H_E70>*?\ D5]1_P"N)KGXO]0G^Z/Y5MAN MIRXW[)%'_=@_P#1J5SLG^J?_=-= M&"VD98W>/H>G:'_R ;#_ *X)_*K5W_QYS_\ 7-OY55T/_D V'_7!/Y5:N_\ MCSG_ .N;?RKS3U$<+I7_ "";3_KDO\JO6?\ R(.M_6]_]">J.E?\@FT_ZY+_ M "J]9_\ (@ZW];W_ -">NNO\*//PGQR.2B_U*?[HKN_ G_(J0_\ 7>X_]'/7 M"1?ZE/\ =%=WX$_Y%2'_ *[W'_HYZWQOP(C _&SI*\^TK_CTD_Z^)O\ T8U> M@UY]I7_'I)_U\3?^C&KEP_Q,WQGP+U-KPG_Q^:U_U\1_^BDKS_2_^05:?]<4 M_D*] \)_\?FM?]?$?_HI*\_TO_D%6G_7%/Y"NG"_Q9&&)_@P.Z\ ?\@[4O\ MK]/_ *+2NMKDO '_ "#M2_Z_3_Z+2NMKBK?Q)>IW4?X?\ (6U'_K[E_P#0C6]X"_Y#&L_]<;;^ O^0QK/_7&V_G+6];_ '9?(FA_O+^9W5<5J'_(VZC_ -<(/_9Z[6N*U#_D M;=1_ZX0?^SUQ4/C1UXK^$PL?^1JTS_=E_P#0:QO$'_(VZE_VS_\ 0:V;'_D: MM,_W9?\ T&L;Q!_R-NI?]L__ $&NJE_O'R.27^Z_,M^#O^1K;_KS?_T-*]#K MSSP=_P C6W_7F_\ Z&E>AUABOXK.O"?P4G M?]?L/_H0J_XC_P"1FT__ *\YO_0XZH7'_'WIW_7[#_Z$*N'\)G-5_P!X7R*_ MC'_D:X_^O3_V:J>@_P#(W:3_ +\O_HIJN>,?^1KC_P"O3_V:J>@_\C=I/^_+ M_P"BFK>/^Z_UW)E_O?\ 78]0KG/%?W]+_P"O@_\ H#5T=NTL;\:]#7 _PWZF!XQ_Y )_Z[1_^A5A7W_'AT7^X/Y5G>)O^1;O_\ KD:\U'I/8YR#_CVC_P!P?RJ.;_DE"_[G M_M0U)!_Q[1_[@_E4 M?Z;_ *B7_KO)_P"A&M[PO_K]4_Z[)_Z *P=-_P!1+_UWD_\ 0C6]X7_U^J?] M=D_] %==7^$CSJ'\=_,\_M?^/=?J?YUV?@'_ (]-1_Z^?_917&6O_'NOU/\ M.NS\ _\ 'IJ/_7S_ .RBM\5_!C\OR)PO\>7S_,Z^N&D_Y#^K_P#7=?\ T!:[ MFN&D_P"0_J__ %W7_P! 6N.A\9U8O^&6-&_Y&Q?^O1O_ $(5R]U_R&=5_P"O MR7_T*NHT;_D;%_Z]&_\ 0A7+W7_(9U7_ *_)?_0JZJ'\=^ARU?\ =H^O^9O> M _\ D+ZK_P!(O^1LU+ZQ_P#HM:L>$/\ D:U_Z\Y/_0DJOXB_Y&S4 MOK'_ .BUJQX0_P"1K7_KSD_]"2MY?[K_ %W(C_O?]=CT2N5\3_\ (P:3_P!> MUS_Z%#755ROB?_D8-)_Z]KG_ -"AKAI?&CMK_P -F7=_\?&G?]?T'_H8J/QM M_P C3:?]>3?^ABI+O_CXT[_K^@_]#%1^-O\ D:;3_KR;_P!#%=2_WB)QQ_W: M7]=C.TK_ )&;1?\ K[/_ *)DKN]6_P"0UH/_ %]2?^B)*X32O^1FT7_K[/\ MZ)DKN]6_Y#6@_P#7U)_Z(DK/&?Q#?!?POF7 \LR(>1PH)'XUN? M$O0?$%[K/A_7-!:P672FE=FO9=B L% ^O>N-TF'XB>$]6OX([KPM%>ZQ=M>- M!/=@.SO_ '%R#CTKE.L]VCC2&)8XU"HH"JJC '0"GU!9?:#8P?:P@N?+7S@ MGW=^/FQ[9S4] !1110 4444 <]XI\::1X1BMSJ33O+^%%6/# M7BC2_%FF&_TJ5VC5S'(DB%'C<=58'H:X#XFBYO/'?A.PT>:.SUK=+)#>S\QH MFWE2N#DG_/6F_"B348+3Q#8Q):W&J0:HYO;F25ECE8]UVJ<<@\8H ]#\1?\ M'C;?]?UM_P"C5K7KEM9?6C#9B[@L$A^W6VXQ3NS?ZU>@* ?K74T %%%% !11 M10 4444 %%%% !1110 4444 %%%% !7(Z]_R,\/_ %Z'_P!"KKJY'7O^1GA_ MZ]#_ .A5I1^-&&)_A,J'_D)Z7_U]I_6J?C#_ )&L?]>H_P#0JN'_ )">E_\ M7VG]:I^,/^1K'_7J/_0JZH?[PCC7^[/U*N@?\C9IOTD_E7I]>8:!_P C9IOT MD_E7I]9XS^*=.#_A'+^+?^/[1_\ KI)_Z"*Q=8_Y!S?]=(__ $,5M>+?^/[1 M_P#KI)_Z"*Q=8_Y!S?\ 72/_ -#%.E_#9CB/XT?D3^.?^0CI/_7.3^0K!M/^ M0UI7_7VO\C6]XY_Y".D_]LUB^ M)_\ D%+_ -=DK:K%\3_\@I?^NR5Y\/B1Z%3X'Z'-:I_R"+W_ *]Y/_034_C# M_D :)_UV3_T U!JG_((O?^O>3_T$U/XP_P"0!HG_ %V3_P! -=<_XD3SZ'\* M9REW_J5_ZZQ_^ABO88_]4G^Z*\>N_P#4K_UUC_\ 0Q7L,?\ JD_W11COB1K@ M/@9E>*?^17U'_KB:Y^+_ %"?[H_E70>*?^17U'_KB:Y^+_4)_NC^51ANHL;] MDBN/^23P_P"[!_Z-2N=D_P!4_P#NFNBN/^23P_[L'_HU*YV3_5/_ +IKHP6T MC+&[Q]#T[0_^0#8?]<$_E5J[_P"/.?\ ZYM_*JNA_P#(!L/^N"?RJU=_\><_ M_7-OY5YIZB.%TK_D$VG_ %R7^57K/_D0=;^M[_Z$]4=*_P"03:?] /^0=J7_7Z?\ T6E=;7%6_B2]3NH_PX^APO\ S&M:_P"OW_VE M'6EX>_Y#EU_U[)_Z$U9O_,:UK_K]_P#:4=:7A[_D.77_ %[)_P"A-6\OX)QT M_P#>7\SC[S_D+:C_ -?\!?\AC6?\ KC;?SEK!O/\ D+:C_P!?;_\ MH:5Z'7GG@[_D:V_Z\W_]#2O0ZPQ7\5G7A/X*.2\1_P#(S:?_ ->G_ +-5/0?^ M1NTG_?E_]%-6\?\ =?Z[DR_WO^NQZA7.>*_OZ7_U\'_T!JZ.N<\5_?TO_KX/ M_H#5Y\/B1WU?@?H<]KG_ "!KG_=_K5[Q[_Q\Z3_OO_Z":HZY_P @:Y_W?ZU> M\>_\?.D_[[_^@FNM_P :)PTOX$SF%_X_K#_K[B_]"KUVO(E_X_K#_K[B_P#0 MJ]=I8WXUZ&N!_AOU,#QC_P @$_\ 7:/_ -"K"OO^/"X_ZYM_*MWQC_R 3_UV MC_\ 0JPK[_CPN/\ KFW\JFA\+(Q?QQ'^)_\ D2M&_P"NEO\ R%T7^X/Y5G>)O^ M1;O_ /KD:T;?_CVB_P!P?RK.\3?\BW?_ /7(UYJ/2>QSD'_'M'_N#^51S?\ M)*%_W/\ VH:D@_X]H_\ <'\JCF_Y)0O^Y_[4-==;>)Y^%VD3_P!"-;WA?_7ZI_UV3_T 5@Z;_J)?^N\G_H1K>\+_ .OU3_KL MG_H KKJ_PD>=0_COYGG]K_Q[K]3_ #KL_ /_ !Z:C_U\_P#LHKC+7_CW7ZG^ M==GX!_X]-1_Z^?\ V45OBOX,?E^1.%_CR^?YG7UPTG_(?U?_ *[K_P"@+7C?^A"N7NO\ D,ZK_P!?DO\ MZ%74:-_R-B_]>C?^A"N7NO\ D,ZK_P!?DO\ Z%750_COT.6K_NT?7_,WO ?_ M "%]5_ZYP_\ LU=W7"> _P#D+ZK_ -B5ROB?_D8-)_Z] MKG_T*&NJKE?$_P#R,&D_]>US_P"A0UPTOC1VU_X;,N[_ ./C3O\ K^@_]#%1 M^-O^1IM/^O)O_0Q4EW_Q\:=_U_0?^ABH_&W_ "--I_UY-_Z&*ZE_O$3CC_NT MOZ[&=I7_ ",VB_\ 7V?_ $3)7=ZM_P AK0?^OJ3_ -$25PFE?\C-HO\ U]G_ M -$R5W>K?\AK0?\ KZD_]$25GC/XAO@OX7S/.OC(UH^O>$[?7+B:#PZ\\K73 MQD@;P!MSC_/)KSJ[M-%U;PMXF\9ZY+,NH:A>NFAY=@Y"$;=H[@ A3GH%KZ5U M6STZ]L)$U6UM[BT0%W6XC#J .33 M_$6OV7AG0[G5;^0)! N<9Y=NRCU)/%8WPY\83^-_#3ZM<6D=JXN'A$:,6X ! MZGOS0!K^(O\ CQMO^OZV_P#1JUKUD>(O^/&U_P"OZV_]&K6O0 4444 %%%% M!1110 4444 %%%% !1110 4444 %_P"1GA_Z M]#_Z%6E'XT88G^$RH?\ D)Z7_P!?:?UJGXP_Y&L?]>H_]"JX?^0GI?\ U]I_ M6J?C#_D:Q_UZC_T*NJ'^\(XU_NS]2KH'_(V:;])/Y5Z?7F&@?\C9IOTD_E7I M]9XS^*=.#_A'+^+?^/[1_P#KI)_Z"*Q=8_Y!S?\ 72/_ -#%;7BW_C^T?_KI M)_Z"*Q=8_P"03_T$U/XP M_P"0!HG_ %V3_P! -0:I_P @B]_Z]Y/_ $$U/XP_Y &B?]=D_P#0#77/^)$\ M^A_"FN_]2O_ %UC_P#0Q7L,?^J3_=%& M.^)&N ^!F5XI_P"17U'_ *XFN?B_U"?[H_E70>*?^17U'_KB:Y^+_4)_NC^5 M1ANHL;]DBN/^23P_[L'_ *-2N=D_U3_[IKHKC_DD\/\ NP?^C4KG9/\ 5/\ M[IKHP6TC+&[Q]#T[0_\ D V'_7!/Y5:N_P#CSG_ZYM_*JNA_\@&P_P"N"?RJ MU=_\><__ %S;^5>:>HCA=*_Y!-I_UR7^57K/_D0=;^M[_P"A/5'2O^03:?\ M7)?Y5>L_^1!UOZWO_H3UUU_A1Y^$^.1R47^I3_=%=WX$_P"14A_Z[W'_ *.> MN$B_U*?[HKN_ G_(J0_]=[C_ -'/6^-^!$8'XV=)7GVE?\>DG_7Q-_Z,:O0: M\^TK_CTD_P"OB;_T8UIM>$_\ C\UK_KXC_P#125Y_I?\ R"K3 M_KBG\A7H'A/_ (_-:_Z^(_\ T4E>?Z7_ ,@JT_ZXI_(5TX7^+(PQ/\&!W7@# M_D':E_U^G_T6E=;7)> /^0=J7_7Z?_1:5UM<5;^)+U.ZC_#CZ'"_\QK6O^OW M_P!I1UI>'O\ D.77_7LG_H35F_\ ,:UK_K]_]I1UI>'O^0Y=?]>R?^A-6\OX M)QT_]Y?S./O/^0MJ/_7W+_Z$:WO 7_(8UG_KC;?SEK!O/^0MJ/\ U]R_^A&M M[P%_R&-9_P"N-M_.6MZW^[+Y$T/]Y?S.ZKBM0_Y&W4?^N$'_ +/7:UQ6H?\ M(VZC_P!<(/\ V>N*A\:.O%?PF%C_ ,C5IG^[+_Z#6-X@_P"1MU+_ +9_^@UL MV/\ R-6F?[LO_H-8WB#_ )&W4O\ MG_Z#752_P!X^1R2_P!U^9;\'?\ (UM_ MUYO_ .AI7H=>>>#O^1K;_KS?_P!#2O0ZPQ7\5G7A/X*.2\1_\C-I_P#UYS?^ MAQU0N/\ C[T[_K]A_P#0A5_Q'_R,VG_]>G_ +-5/0?^1NTG_?E_]%-5SQC_ ,C7'_UZ?^S5 M3T'_ )&[2?\ ?E_]%-6\?]U_KN3+_>_Z['J%?#XD=]7X'Z'/:Y_R!KG_=_K5[Q[_P ?.D_[[_\ H)JCKG_( M&N?]W^M7O'O_ !\Z3_OO_P"@FNM_QHG#2_@3.87_ (_K#_K[B_\ 0J]=KR)? M^/ZP_P"ON+_T*O7:6-^->AK@?X;]3 \8_P#(!/\ UVC_ /0JPK[_ (\+C_KF MW\JW?&/_ " 3_P!=H_\ T*L*^_X\+C_KFW\JFA\+(Q?QQ'^)_P#D2M&_ZZ6_ M\A7,7'^H;\/YUT_B?_D2M&_ZZ6_\A7,7'^H;\/YUT83^%(C&?Q8GKEO_ ,>T M7^X/Y5G>)O\ D6[_ /ZY&M&W_P"/:+_<'\JSO$W_ "+=_P#]T?^X/Y5'-_R2A?]S_VH:D@_P"/:/\ W!_*HYO^24+_ +G_ +4-==;>)Y^% MVD+(+KQ=I>K1:=?FV@MI4LG_H)KRZV_X]8?]Q?Y5U8:C&K>YRXFO*E;EZGJ6CZM M!K6GI>VZ2)&Q*[9!A@0<&K]*9Y_IO M^HE_Z[R?^A&M[PO_ *_5/^NR?^@"L'3?]1+_ -=Y/_0C6]X7_P!?JG_79/\ MT 5U5?X2."A_'?S//[7_ (]U^I_G79^ ?^/34?\ KY_]E%<9:_\ 'NOU/\Z[ M/P#_ ,>FH_\ 7S_[**WQ7\&/R_(G"_QY?/\ ,Z^N&D_Y#^K_ /7=?_0%KN:X M:3_D/ZO_ -=U_P#0%KCH?&=6+_AEC1O^1L7_ *]&_P#0A7+W7_(9U7_K\E_] M"KJ-&_Y&Q?\ KT;_ -"% _P#D M+ZK_ -?Z[&9XB_Y&S4OK'_Z+6K'A#_D:U_Z\Y/_ $)*K^(O^1LU+ZQ_^BUJQX0_ MY&M?^O.3_P!"2MY?[K_7M17?@[PW M)X3R?,%U<7C0LZ^HB'('T&*]R\0^+]!\+?9_[:U".T^T;O*WJ3NQC/0>XKS1 M_%G@UOBI'XN'BJS^SK8?9/(\J3?NR3G.,8YKE.LZGP#<>+[75]4T+Q0_VU+1 M(WM]16(JLN[JN2!DBN^J*VGBN[:*YA* ..\3P7FDVEC M<-?:KJ*G4+8&%4B(_P!8O)PH/Z]<5M/X@F75=0LAHVH,MI;B=9Q&-DY_N(<\ MM4GB+_CQMO\ K^MO_1JUK]* .;B\5SRVVC2GP]JJ'4GVNC1#-K[R<\"E/BB< M6^LR_P#"/ZIG36VHGE#-UQG,?/-=%BEQ0!C)KTS:E86G]CZ@JW&[50;Q?<+HT^H?\(WJY>*[-L+81#S'&0/, S]WG.:Z?%+B@##;Q!,-8 MN;#^Q=1*PVHN!7(?[BG/WO:JT?BN>2PTJZ/AW5E:_F\IHC$-]L.?FD&> M%XKI,4N* ,&7Q'-&=7 T/4F_L\ H5C'^E9&?W?//I1_PD>1M'!T M'5%_M$$N6B'^B_\ 73GBF?\ "5W']GZG=?\ "/:KNL9O*6'RAON!_>09Y%=' MBEQ0!CKKDK:M!8_V1?A9;8SFX*#RT/\ <)S][VKECJ\FM:Q'PA>/R MKM-KD!\;L>A[5Z#BN1U[_D9X?^O0_P#H5:4?C1AB?X3,R^N6M);*Y6"2=HKA M6$40RSX!X'O6;K&H/JNK6UZ]E<633688V]RNV1/FZ$5M-_R$]+_Z^T_K5/QA M_P C6/\ KU'_ *%75#_>$<:_W9F1;Z@^E:O:WL=E<7K0I(PM[==TC\#@"O0? M^$@F_M2PLO[&U#;=P&9I_+'EPG^XYSPU<7H'_(V:;])/Y"O3ZSQ?\4Z<'_". M"U#6)-9ETV:33+RP,=S-&$ND"LX 'S#V-5M=D,6D2R!&%'K74^./^0CI/_7.3^0K M!M/^0UI7_7VO\C6U'_=G\R*W^\KY'=Q^))I+S2K32KZQ\J]$(%T@4N ?OCG[M=?BL;Q/_R"E_Z[)7!#XD>A4^!^ MAS6J\:1>_P#7O)_Z":I:MJ\FK^$M N9--O+(O<;?+N4"LNU2,GV/45=U3_D$ M7O\ U[R?^@FI_&'_ " -$_Z[)_Z :ZY_Q('!0_A3./U28VVG23B)Y3&5<1H, MLV&!P/P1 M_P"J3Z"C'?$C3 ? SD=>UZ:Z\+Z[NT;4(?LTAMQYD8'FC('F+SRO/6H8O]0G M^Z/Y5O\ BD?\4OJ/_7$U@1?ZA/\ ='\JC#=18W[)B3ZS*?A5:K_9=Z ]S%;; MM@PH$H_>'G[AQP?<53D_U3_0UT-P/^+3P_[L'_HU*YZ3_5/_ +IKHP6TC+&[ MQ.STGQ!-#HWAQ!HVH/\ ;D",PC&+?"YS)SP#3[WQ1.NG:\__ C^J'^SLHBB M(9NLCK'SR.:V-#'_ !(K#_K@G\JM77_'G/\ ]NNO\*//PGQR.3B_U*?[HKI?#>M2Z7XX_]'/6^-^!$8'XV.E\43Q_VYC0 M-4;^R\;,1#_2\C/[KGG'^?2N9\/7#7>CI<-!) 99)7,4HPZ9D8X(]17H^*\_ MTO\ X])/^OB;_P!&M7+A_B9OC/@7J3V.K2:)::]?1:==Z@R74(^SVB!I&S&@ MR![5R6EG.DV9Q_RQ3^0KT#PG_P ?FM?]?$?_ **2O/\ 2_\ D%6G_7%/Y5TX M7^)(PQ/\&!TOAO69-'TZ3R],O;[[5JXMV^RH&\D-&GSOSPH]:Z9O$,RWFLV_ M]BZBPTV)9$D6,;;LE=VV+GDCI]:S? '_ "#M2_Z_3_Z+CKKL5Q5OXDO4[J/\ M./H>=Z;>-J$VH7CVTUJT]PLA@G7#QYAC.UAV(JVFJR:*^I:A'I]UJ#Q6L9%M M:KND?+D<#VSG\*3_ )C6M?\ 7[_[2CK2\/\ _(7\$XZ?^\OY MG&2R&6_O9"C1E[F1BCCE@%9^K3FY\0WD[0R0F2.%S%(,,F4S@^XK?L?\ D:M,_P!V7_T&L;Q!_P C M;J7_ &S_ /0:ZJ7^\')+_=?F5M,U>31-9-W%IMWJ#?9RGDVB;GYD09QZ"N]? M7IDURZTT:/J#)!:_:!=*@\J0Y^XISRWM7*^#O^1K;_KS?_T-*]$K#%?Q6=6$ M_@HX*?5'UF_TF^DL+JP:6RG)M[I=LB8DC'(JKK5XVGP6UXEK/=-#QZ==W[)(X\BU7=(@ MZUO>,?\ D:X_^O3_ -FJGH/_ "-VD_[\O_HIJWC_ +K_ %W)E_O?]=CMO[?E M_MLZ=_8VH!!:_:/M/ECR\_W,Y^][5A7^KR:SIVBWDFFWE@TMRX,%T@5TPK?#XD=]7X'Z',^))3!X=OI1&TA2/=L09+8[# MWIWBG4Y-27P_.^GW=H9UDD*3H T9VD;6YX-.UW_D#7/^[_6K_CW_ (^=)_WY M/_0376_XT3AI?P)G'7]VU@MO=+;2W+17$;"&$9=_F' 'K7IPUV4ZO;V']D7X M6:V,YN"@\M#_ '&.?O>U>=K_ ,?UA_U]1?\ H5>NTL;\:]#7 _PWZG#Z]KTN MH>%XIWT?4+4R7RPF.:,!D ;[YY^Z:BOSC3[DXSB-N!]*WO&'_(!/_7:/_P!" MK"OO^/"X_P"N;?RJ:'PLC%_'$S=>UB2X\(>&D.F7L0N9(LM(@ BVC^+GC/:L MJ\;9:2N%+%1G:O4^PKJ?$_\ R)>C?]=+?^0KF+C_ %#?A_.NC"?PI$8S^+$] M#AUV5;[3;#^R+\KQSL'_'M'_N#^59.HZM M):_#&QB&FWDPN)#$7C0%8AO/S-SPM:T'_'M'_N#^51S?\DI7_<_]J&NRMO$\ M_"_:.M#^W M)?[8-A_9%_M%M]H^T;!Y>?[F<_>]JU\4M><>D<7K?BNX;P8]Y_PCVK!KI9(6 M@\H;X1@C>XSPML/^XO\J]1UT?\4_J/_7M)_P"@FO+K;_CUA_W%_E7? M@?M'G8_[/S.F\):S)96&F:>NEWMPEW--NN84!CAP?XSGBMB3Q3.EAJ5S_P ( M_JK-93^4L2Q#?<#/WD&>13/ 8_XI>/\ Z[2?^A5TV*XI_$SNI_ CSS2',MFT MA1D+2N=K#D<]#5RSUB31OMDL>F7E^9KR*$I:H&* H/F/L*JZ;_J)?^N\G_H1 MK>\+_P"OU3_KLG_H KIJ?PD<-#^._F>?VAS;(<8Z_P ZZ+PGJTFGN;9-.O+I M;N]*-+ @*080'+G/ KGK7_CW7\?YUV?@'_CTU'_KY_\ 916^)_@Q^7Y$X7^/ M+Y_F79O%$\5GK%P- U1SITFQ(UB&ZZZ?-'SR.?TK"@G-UJ>HSM#)"9)$8Q2# M#)F->#[UWV*X>3_D/ZO_ -=U_P#0%KCH?&=6+_AE.35Y-%UZ*YCTV[OV:(1> M5:)N8!G^\1Z#O65L2:5KTT::9>7@NVAA9[= PA'S?,_H*ZZ7Q M1/'_ &UC0-4;^S,;,1#_ $O(_P"67/-8W@/_ )"^J_\ 7.'_ -FKN\5RXC^* MSLPW\*)PMQ=->^(#=/;RV[2Z=;N89AATRTG##UJAJFIR:1J>EWD=A=7[)*P\ MBU4-(V5QD GMG-:^K_\ (WW'_7E#_P"ARU!!_P C-H_^_)_Z :U7\$YI?[R9 M?B [O%6H'!&?*X/;]VM4]*UB32/%=B8],O+[[2C0'[*@;R@63YVYX4>M7?$7 M_(V:E]8__1:U8\(?\C8O_7G)_P"A)6\O]U_KN1'_ 'O^NQTK^))DN-:B_L/4 MB--B\Q'$8Q=_*3MBYY/&*Q]4OGU'4?#]T]G<6IGL;B4Q3J \9)A^5AV(KML5 MROB;_D8-)_Z]KG_T*&N&E\:.VO\ PV<_XAOWTNQ@ODM)[QH+N%Q;VZ[I)/G' M"CN:7Q;*[0-;S1?\2X/F0 ?>?[O7J,<_45TO4)H+GF\N+1,D1 M]-@/8FK_ ( TNQN/#8TNY\'SZ7;V; HE^H9IF(Y?IUXH Z?Q"Z&RM0&4G[=; M=_\ IJM3Z[:W5WI4J6>HS:?,HW":%$9N.<88$K717?_'G/_P!<^"(E@\4RI'N"FR8D;B1G>GK7HU*I!TY.+'2J*I%204445!H% M%%% '.>-X[T>&;JZL=3N;":V0RA[<(=V!T.X'BK/A:VNH-!MGO-2N;^6:-93 M)T?_H(H T**** "N1U[_D9X M?^O0_P#H5==7(Z]_R,\/_7H?_0JTH_&C#$_PF5#_ ,A/2_\ K[3^M4_&'_(U MC_KU'_H57#_R$]+_ .OM/ZU3\8?\C6/^O4?^A5U0_P!X1QK_ '9^I5T#_D;- M-^DG\J]/KS#0/^1LTWZ2?RKT^L\9_%.G!_PCE_%O_']H_P#UTD_]!%8NL?\ M(.;_ *Z1_P#H8K:\6_\ ']H__723_P!!%8NL?\@YO^ND?_H8ITOX;,<1_&C\ MB?QS_P A'2?^N\<_\ (1TG_KG)_(5@VG_(:TK_ M *^U_D:WH_[L_F16_P!Y7R/6:Q?$_P#R"E_Z[)6U6+XG_P"04O\ UV2O/A\2 M/0J? _0YK5/^01>_]>\G_H)J?QA_R -$_P"NR?\ H!J#5/\ D$7O_7O)_P"@ MFI_&'_( T3_KLG_H!KKG_$B>?0_A3.4N_P#4K_UUC_\ 0Q7L,?\ JD_W17CU MW_J5_P"NL?\ Z&*]AC_U2?[HHQWQ(UP'P,RO%/\ R*^H_P#7$US\7^H3_='\ MJZ#Q3_R*^H_]<37/Q?ZA/]T?RJ,-U%C?LD5Q_P DGA_W8/\ T:E<[)_JG_W3 M717'_))X?]V#_P!&I7.R?ZI_]TUT8+:1EC=X^AZ=H?\ R ;#_K@G\JM7?_'G M/_US;^55=#_Y -A_UP3^56KO_CSG_P"N;?RKS3U$<+I7_()M/^N2_P JO6?_ M "(.M_6]_P#0GJCI7_()M/\ KDO\JO6?_(@ZW];W_P!">NNO\*//PGQR.2B_ MU*?[HKN_ G_(J0_]=[C_ -'/7"1?ZE/]T5W?@3_D5(?^N]Q_Z.>M\;\"(P/Q MLZ2O/M*_X])/^OB;_P!&-7H->?:5_P >DG_7Q-_Z,:N7#_$S?&? O4VO"?\ MQ^:U_P!?$?\ Z*2O/]+_ .05:?\ 7%/Y"O0/"?\ Q^:U_P!?$?\ Z*2O/]+_ M .05:?\ 7%/Y"NG"_P 61AB?X,#NO '_ "#M2_Z_3_Z+2NMKDO '_(.U+_K] M/_HM*ZVN*M_$EZG=1_AQ]#A?^8UK7_7[_P"THZTO#W_( O^0QK/_7&V_G+6#>?\A;4?^ON7_T(UO> O^0QK/\ UQMOYRUO6_W9?(FA M_O+^9W5<5J'_ "-NH_\ 7"#_ -GKM:XK4/\ D;=1_P"N$'_L]<5#XT=>*_A, M+'_D:M,_W9?_ $&L;Q!_R-NI?]L__0:V;'_D:M,_W9?_ $&L;Q!_R-NI?]L_ M_0:ZJ7^\?(Y)?[K\RWX._P"1K;_KS?\ ]#2O0Z\\\'?\C6W_ %YO_P"AI7H= M88K^*SKPG\%')>(_^1FT_P#Z\YO_ $..J%Q_Q]Z=_P!?L/\ Z$*O^(_^1FT_ M_KSF_P#0XZH7'_'WIW_7[#_Z$*N'\)G-5_WA?(K^,?\ D:X_^O3_ -FJGH/_ M "-VD_[\O_HIJN>,?^1KC_Z]/_9JIZ#_ ,C=I/\ OR_^BFK>/^Z_UW)E_O?] M=CU"N<\5_?TO_KX/_H#5T=NUY$O_']8?]?<7_H5>NTL;\:]#7 _PWZF!XQ_ MY )_Z[1_^A5A7W_'A;2_ZE_]TUZ3 MX8_Y%G3_ /KB*VQVT18#>1K4445YQZ1GZ[_R+^H_]>LG_H)KRZV_X]8?]Q?Y M5ZCKO_(OZC_UZR?^@FO+K;_CUA_W%_E7?@?M'G8_[)W?@/\ Y%>/_KM)_P"A M5TU?Z;_J)?\ KO)_Z$:WO"_^OU3_ M *[)_P"@"L'3?]1+_P!=Y/\ T(UO>%_]?JG_ %V3_P! %=-7^$CAH?QW\SS^ MU_X]U^I_G79^ ?\ CTU'_KY_]E%<9:_\>Z_4_P Z[/P#_P >FH_]?/\ [**W MQ7\&/R_(G"_QY?/\SKZX:3_D/ZO_ -=U_P#0%KN:X:3_ )#^K_\ 7=?_ $!: MXZ'QG5B_X98T;_D;%_Z]&_\ 0A7+W7_(9U7_ *_)?_0JZC1O^1L7_KT;_P!" M%,/_H?Z[&9XB_ MY&S4OK'_ .BUJQX0_P"1K7_KSD_]"2J_B+_D;-2^L?\ Z+6K'A#_ )&M?^O. M3_T)*WE_NO\ 7(G''_=I?UV,[2O\ D9M%_P"OL_\ MHF2N[U;_ )#6@_\ 7U)_Z(DKA-*_Y&;1?^OL_P#HF2N[U;_D-:#_ -?4G_HB M2L\9_$-\%_"^9Y]\:(?#LCZ,VNP:W(5\WR3I87Y?NYW;A],?C7E*VWP]4G;9 M^-QDY.!%R?RKZN*ANH!^M)L3^ZOY5RG64M%$0T+3Q )1#]FCV>;]_;M&-WOC MK5^CI10 4444 %%%% "=.:!BN&^*"^)9/#5PFA7,-I;+!+)>7#9\P(JYVI[G MGGMZBF?"_4X;;X6:%->W# NCC>^6)/F-0!TWB+_CQMO^OZV_]&K6C=_\><__ M %S;^5<_KFM:?/9VZQ3EV6\MW(6-CA1*I)Z=@":O7.OZ6UK,JW0)*$ ;&]/I M0!3\ ?\ (AZ/_P!-@0;Q'I**6 M:\55 R258 ?I0!J5YIXA_P"1FO\ ZI_*NW'B+264,MXI!&00C<_I7 ZW=13Z M_>31"5XWV[66)B#Q]*Z<(TJFIRXQ-TM"_P"#?^1LD_Z\7_\ 0TKT.O-/"M[# M:>)7GN/,BB-FR;VB8#=O4XZ>QKN/^$ATK_G['_?#?X5.):=5M%85-4DF:=%9 MG_"0Z5_S]C_OAO\ "C_A(=*_Y^Q_WPW^%8'0:=%99\1:4H)-XH ZDHW^%(GB M/2'0.EZK*PR"%8@C\J (/&/_ ")VK?\ 7LW\JN:%_P B_IW_ %[1_P#H(K$\ M4ZS87?A;4K>WG,DTD#*B+&Q+'T'%6]'UW38=$L8I+G9(ENBLI1@00HR.E '0 M45F?\)#I7_/V/^^&_P */^$ATK_G['_?#?X4 :=(6Q4N(VQG=TZ5I2=IHQQ";INP'_D M)Z7_ -?:?UJGXP_Y&L?]>H_]"H&IVDE[ITJ2,T:W*LS+&Q SSTJOXHO(;OQ M&)[?S)(OLX7>L3$9STZ5TQDO;IW.11E]6:L-T#_D;--^DG\J]/KRK1;J.#Q+ M83RK*D2!]SF%\#(X[5Z%_P )#I7_ #]C_OAO\*SQ;3J71O@TU2U,KQ;_ ,?V MC_\ 723_ -!%8NL?\@YO^ND?_H8J[XEU6SNKS2V@D:18WZ;)9R-.D:2!VCC9@IXX.!61;3*FK:=(R3!([E6=O)?"C! MY/%;4I)8=J_\G_H)J?QA_P @#1/^ MNR?^@&J&HWT$NF7<:&1G:%PH$39)*GCI4GB?4[2\T;2H;9VEEAE0RHD;$I\A MZ\<5U3DO:1U."C&2I3NCG[O_ %*_]=8__0Q7L,?^J3_=%>-W+[H@%BG)\Q#Q M"_9@3VKU%/$&EB-0;L9P/X&_PHQDDY*QI@8M0=T-\4_\BOJ/_7$US\7^H3_= M'\JT/$6M:?<^'KZ&"L_P#D0=;^M[_Z$]9.G7T$6FVR.9%=8E!4Q-D''TJS;:K9 M1^#]5L7E*W4_VPQ0F-MS@LV"!CG[P_,5U5FG%6.#"Q:F[HY^+_4I_NBN[\"? M\BI#_P!=[C_T<]<#'+B) 8Y@<#_EB_\ A78^#M6LK+PY%!?Z7_P @JT_ZXI_(5V/AW6+"RN]3-U/Y(GN$\K>C#?B)>G'/0_D:XS3V,>FV MR/%.KK$H(,+Y!Q]*Z,-)*I)MF&(C)TH)([SP!_R#M2_Z_3_Z+2NMKAO!>IVE MC8WZ74C0L]V74/&PR-B#/3U!_*NF_P"$ATK_ )^Q_P!\-_A7)5UJ/U.ZBK4X M^AS'_,:UK_K]_P#:4=:7A[_D.77_ %[)_P"A-6(+^W_M759-S[);O>C>4V&' MEH,CCU!_*KNCZS86>JW$]S/Y430QH'=& +;CQG'7D?G6TFO96.2$7]8;MW.= MO/\ D+:C_P!? M(+&YED9((DE\R1HV"KE>YQQ67K5U%<>);^XA$KPR"/8ZQ,0V%['%=-*25>]S MDE&7U:UNII>#O^1K;_KS?_T-*]#KS3PM>PVGB0SW'F1Q?977>T3 9W+QT]C7 M(+*:&1GB2UE1G6-B 2T9 Z>Q_*J,]_;FYL6#/M2ZB= MCY3?*H8$D\5<&O9-&%2+^L)V[#O&/_(UQ_\ 7I_[-5/0?^1NTG_?E_\ 134[ MQ-J%M?\ B&.ZM&>> VNT21QLRD[O7%5]&N8X/$VF3RK*D4;2%W,3X7,; 9X] M2*VC)?5K7(E%_6KV/5JYSQ7]_2_^O@_^@-6A_P )#I7_ #]C_OAO\*P?$FK6 M5TVG^1*TFR*ZG) M>VB[G#3B_835C$7_ (_K#_K[B_\ 0J]=KQY90+RS;RYMJ7,;,?)?@ \GI7IW M_"0Z5_S]C_OAO\*6,:8RR>:AVK&Q. >>U8]Y?V[VGTJCK^MZ?<:#>PPW!DD>,A56-B2?RKST M>DS,@_X]H_\ <'\JCF_Y)0O^Y_[4-0PZA;+;Q@LX(4 CRF]/I44FIVC?#L:< M)&-Z$R8/+;>/G)Z8KKJM-Q//PT6N:Z,>7_4O_NFO2?#'_(LZ?_UQ%>9R2 Q. M!'-D@_\ +%_\*[WP_K6GVV@64,T_ER)$ RM&P(/Y5IC9)VLPP,6G*Z.EHK,_ MX2'2O^?L?]\-_A1_PD.E?\_8_P"^&_PK@/0'Z[_R+^H_]>LG_H)KRZV_X]8? M]Q?Y5W^M>(-+ET>]MTNPTTMO(L<85MS':>@QS7GMO)MMX@8Y@0@!!A?T^E=V M"DE>[.#'1;Y;([[P'_R*\?\ UVD_]"KIJXSP;JUE9>'DANI6AE$KG:\; X)X M[5T'_"0Z5_S]C_OAO\*XY_$SMA\*.2TW_42_]=Y/_0C6]X7_ -?JG_79/_0! M7,6%[!'#(',BDRN0#$W0GZ5KZ!K6GV<]]]IN/*\Z9/+WHPW_ "#IQST/Y5T5 M&O9HXJ,6JS;7>/)?U M^E=7X,U.TL;:^6Z=H6>?-AD;1STK;$R3HI)]B,-%JM)M=SNJX:3_D/ZO_ M -=U_P#0%KIO^$ATK_G['_?#?X5R#ZA;'6M3E#/Y".*Z:,DJ[=^AS58R^KQ5NI MT?@/_D+ZK_USA_\ 9J[NO._!M_;V6IZC)I6LOB>>XC=VA-I$@<1-@L'D)'3W'YU FIVD.NZ;UUB8AL(HXX]:G\,7L-IXE6>?S(XOLLB[VB8#)9,#I[&MI27U:U M_P"KD1C+ZU>W]6/3*Y7Q/_R,&D_]>US_ .A0UK_\)#I7_/V/^^&_PKF_$&J6 M=SK>F2PR-)''!<*[+&Q"DF+ /'?!_*N*G\:.VNFZ;L07?_'QIW_7]!_Z&*C\ M;?\ (TVG_7DW_H8J*YOH&GL2ID(2\A=L1-PH89/2HO%6H6VH>(+2YLV>> 69 M7S(XV9<[\XSCTKJ4E[>+.2,7]6DK?UH0:5_R,VB_]?9_]$R5W>K?\AK0?^OJ M3_T1)7GVFW"1>(-)F=95CBN2SL87PH\J09/'J0/QKMKO5+.^U[0H[:82,MS( MQ&TCCR)/45&+:=30VP::I:G1T445RG4%%%% !1110 4444 9GB'3Y=6\.:EI MT#(LUU;20HSDA064@9QVYK/\":!=>&/!>G:->R127%LC*[0DE3ER>,@'OZ5T M=% !1110 51UG_D"WO\ UQ;^56+JZ@LK:2YN9DA@C4L\CMA5 [DUY3J7Q&\1 M74M_J^A:?IVI>%=/F$-QM)::5< LZ\XP,^E 'J>G?\@RT_ZXI_(59K+\/:[I MOB+1H-1TN99+:1> ."A_ND=B*U* "BBB@ HHJ.::.V@>:9PD<:EF9N@ [T 1 MWW_(/N?^N3?R-5M _P"1?T__ *]T_E7G-[X^\4ZT^HW_ (/L-,U#0[ [9#,6 M,EQQEMH! QBNY\'^(;3Q1X9M-3LHO)C==K0XQY;#@K^% &]1110 4444 %1/ M)&PD0.I=5Y7/(^M/D=(HV>1E5%&69C@ 5X[KMU#%XFN?%7@/6K?4;Y%QJ6E+ M-O$Z#J5'J/:@#U#P[_R ;7Z-_P"A&M2L+PEXDTSQ/H<-[I954QMDA P87[J1 MVYK=H **** "DR*AN+A8E*JZ>>5)CC9L%CBO"-0M_$=EH:^.[[4]5MM974?+ M:SD?; 8=^ GIB@#V?PY_P @U_\ KO)_Z%6O67INK:;<2FQM[BW^V)&LLUO& M1N3<,Y(K4H ***8TL:R+&SJ'8$JI/)QUP* 'UFZ?C^T=3_ZZK_Z *\CF77O$ MGCK7[(>*+_2=6+ME?XL]S7<_#WQ5=:_;7EEJ]JEIKMA)Y=Y& MJX#GLX^HH [6BBB@ I,BJFI:I8Z/9/>:C=16ULF TDC8 S7F7Q!O_%$7CC2[ MKPMY\RVFGO%;B9+IYI)5=&/DOM3(#X MX.>0,^M;7@7QM9^+X62YMUM->LLQ75K(,/&>,E<\[20/RYH [.BBB@ I"0H) M/ H9@JEB< =2:\\\2MJOCU[?2?#NH0Q^'9MZZEJ-O(&D^4X,*CL3Z]Q[<$ Z M?5;B&ZDT*>WE26*2^#)(C!E8>5)R".M;M>>?"@0VWAZY\-W"JUWH-]- 0X!8 M NS(X^H8\_6O0Z "BBB@ K%\4D?V*/\ KZMO_1Z5ROQ$\5H_@?7_ .P-1W75 MA+%#>M:M^\@5F&X@^N,C/;GTKC-%\6/X:T:ZO-%T6[UGPA#=C[1?7EWYLV[Y M265",!5..W7G- 'N]%5[&[AU"PM[RV??!<1K+&WJK#(/Y&K% !116'XGN=2_ MX1W41H$D#:K'"3$C\X/TSU],]Z )M>FBE\.ZJ(W5RD$BMM(.T[16A:_ M\>D/_7-?Y5X!X/\ $VJ:7X:O;OP[X\O\ N'^54-=OYK31 M[Y[#9+J$5N\D,)/+,!QQ7@<'B35[33-+\0:-XNO-5UN[E*7VBW+AUSSD"/\ MA H ]Z\,X_X1K3_ /KBM:U8GA'7;/Q)X8LM4L8Q%#,G^J QY;#@K^!K;H * M**C>>))%C:1%=ONJ6 )^@H ?FL_1\?9YO^N[_P Z\CN?%7BGPOXUU[6FMKJ\ M\-)=)!@_3G\:]?T?4;#5M,@O]-DCEM;A=Z.G0Y]?>@"]1110 M 4F144]U;VP!GGCB#' ,CAU9,7_(V3_\ 7HO_ *%7 M ?$.\\3-XMT67PI++(8;:2X9 Q,$RC^'C@DBNM\%>,--\8Z>;RW00ZA$/+NK M=QB2)AV/?&: .IHHHH **9)(D*%Y'5$'5F. *\]\;:=K'B3Q=I>A+/J5KH,M MN\MQ<6#;"7!X#/V'M0!U6H$?\)1I'^Y-_(5MUYI\/M8CT[2M1M-=U%)$TF_: MSM[R[8;RIZ#<>_:O2E(8 @Y!Z$4 +112$@ DG H 6L?7,?:-'_Z_U_\ 0'KD M?BSJKP^&[$QWLT&ES7B17]S9R8=(SV!'3WKF= \;3^'-.TV1]!GF\)27/EVV MI7%UYTZL20'8'H.O3'% 'ME%-1UD174Y5AD'VIU !1TH-(?!-RQG^SSK=VYGP3)&P'/H2" ?QKU.@ HHHH *R_$1!\+ZN1S_H MF[J&!Y_'\0#Z"@_U$?^Z/Y5)6=H6J1ZWH5EJ<4311W,*RK&Q!*@C... M*T: "BBHS/$)1$9$$A&0F[G'TH ?D5E>&O\ D6]/_P"N*UY!H/C;Q#X1U&[U M#7H+J?PM?ZE-&)Y@S2VCAR!G/\)QT]CCT/MUE+:S64,EDT;6SH&B:+&TJ1P1 MCM0!/2%5)!(!(Y!(Z4M% !1110 4444 %%%% !1110 4444 %87B6^OUTZXM M="O+"+6 @D1+IN F<%L#GV';-:U[>6^GVX(8*ISR.O;N* )/&.OZCXQT<_V*_VD:5-MU;1 M9(=DEP%()8*?FV<'CKCK5SPWHD5YK%CXH\ W-O!I=ZPCU?29.(X_[V$[,/3\ MN#6;ITB>/_%%I?Z1;7WA_P 3Z:H749&AS 0#@HW.22,XR/8U[-8:99Z9%)'9 MVT4"R.99!$@73KFG:=AQ"_\ &8]RXXSV''K7L'@6 MPTO3_!]A'HPG^QR1^:K7 (D]6_#?ANR\,:.FFV>]TR7DDE.6E<]68^ MIK7 '0"@!:*** "F2RQP1/+*ZQQH-S.QP /4FG,P12S$!0,DGL*\D\5 M_$;0/%>DZIX7TF[F34;A&B@:6(I%.P/*JWOC':@"7Q]XPTCQ7X6O]'\-:S#= MZD&5FM8F(:= ?F1#C#9'IFN8BFT/Q)J_A@^#]%GL-9M)5%Z8K4PK#&!\PD( M!I))H_&$.@:)I7A:]TW7=,GC,\[VXBC@5?O$L.3G'3%>^1QJ@X50QZD#&: * M6FZ)IFD/0>]&GV>KV_BE_!]SXNNM7 MT_4[1I/M,4H\^V93SR,X!KT'PIX+T_PE%.;>:YN[JX(,UW=2;Y'QT!/H* (/ M!'@BR\(:;@$W.IS@-=7DO+R-Z9]!Z5U=%8WB7Q/IGA32S?ZI*RQEMB)&NYY& M/15'>*Z/"F3.1&?3(/>L3Q%=OXZN[/Q9X1@FNK_ $Q_(FTN^C^:,G[KA,D MC.:OV4OB#PCXUT*"7Q8VMPZK(T5U9RL&:%P,DJ 3@ \4 26J:=\4X5@OVGT' MQGI1PTD7R2H1W'0LOMVKM?!_@Q_#W^JS:KJMX1Y]W*@3*KPH &<8K=72 M-/75VU46<(OVC\HS[/G*^F:O4 %4M6U>QT/39M0U&Y2WM85RSNB2B[_LV^BV"Z3TV M@G=TX_\ KT 1_$6XNM6?0?%MK:7.L>'V7Y=-D1D"RG[CLN/F!..M;.F:[XV\ M.>+-'T[Q/+87MAK&Y(6MHA&;9PN=N,#('3G\ZY[4)O%_A>TT[Q'>>)0;V:>- M+G06*A45SPB*#P0*]!T'X<:7IFMKKLUYJ%_>?,\/VV?>("W7:,=>: -FR\): M/IWB.ZUVSMO(O;J,)-Y;%4?G.XJ.-WO_ /7K57*E?F&0.GW:YCQ-XMT[XEZ%<:5X9\VXOK.:.\:RN(S&+R)#RJ^H.0>:Y'6 MXKNPNI?&>BZ!-X:ALHHX[NRO%$0O=S;754'48QSQZ]10 [PK\1-0\%?V=HOV MBVU72[A8)8YIY2#8K)]Y'(!QCG'^0/;9/".BW'BBU\3"V\O4X8V7S8F*B0$8 M^<#[V!TS_08I^%/!?A_1] $%GIJ>3=,+B1;A0[%B=P!S_=[?2NJ P,4 +2$A M023@#J:"0 23@"N4T?QM:^)M9U33=)MI9K:R38=1X\AY>Z ]3CU&>_MD H>. M&F\8_#C4#X3U03.>@Z?I^F^';$ M\Z3+$?-E08#R,Y&22<\Y_/O-IWA;Q+\)+*W\0VTAOK)DSK6GQMG')_>1^N 1 M_P#JZ=M=>%-#^)"V&OMJ.I/ILT*XLEE,<,B@YPRXSUZ\T 6-+\.Q:GXGT_QW MIMY-9K?V*F[M-N1< J"A;T('\A[UVU,BBC@A2*)%2-%"JJC '0"GT %<+XA MURX\4'4O#'A'5HX-6MR@NKDHQ6*-CA@KC@2#T_KTN-XPL-9\577A.QBN;GR[ M=Q>WMLP"6I(P%+9^\>>G(./?'G&B^!_%.G-?>'GUPZ#I%C*SPZE C:A)(=R M;F)!.T<$?A0!K:)H5A\/?B3'H/EE]'U_3A$KW!W"6XCSN#9XRP)X]6 %7KCX M+VJW-U!IGB'4=.T.];==:7"MM8 MMTUR2-A%"#N96QQG' /?!YKQ?P[X=74=*E_LR^NM)^(FE2.UTDUPV;SYB>03 MR",#(X]>#4EZFI>&/&]QX=OM0318=6U"2[CUY8P9#&RG"!S]WG //&?0UL>' M?"EKXWU+5K/6[][R_P!&F2.'7=/DV/.C#.UF'!*]/;IF@#6TJSU#XB^%+*\T M?5AXRDX']&M=*L4*VUM&$3)R3ZD^Y M/--T'0;#PWI$&EZ9#Y5M"#@$Y+$\DD]R:TJ "L35/%F@Z5>IIU[K%E;7TPQ' M%+* V3TR.WXU1\5>/=)\)W%O:W4-Y=WEP"R6UE%YDFT=6(R,"O)_&_AS4],E MU2ZNTTUK#Q'>0".^O WGV1/.&&, #IU["@#1E^'7BB!M/UNWA2?Q/_:CS2W; MWK;/(Y*JP_NG X'K5_2+34_%T6I)9VND^&O$]A=^3?75O8I)YJD'[K'D9'UI MVDPZSK^I:GX'UCQ"]S#;P174&I:61$R $ (V/S_"O1/#'A:P\*::UG8F60R. M9)IYVW22N?XF/>@!WA7PY;>%/#UKI%J[2)""6D?J[$Y+'\:V:*.@H *\8\0? M#K7]2DUO5Y8OM.MM?QG2YA=LODP@C/'0#'X]:]@M[VUN]_V:YAF\MMK^6X;: M?0XZ&JVMZ:FL:->WTJ%H8)I3*8RY*J3V4'H/85D> _#NA:-: M7-SI&H2ZG+<2;)[V:;S7U>VZSI%GKVDW&FW\?F6TZE77H?J/>N0\$>" MO#FC:G<7=AJMQJU]:9MC)*?'&E+J% MM]J\.0V\AFB,Y11+_"2H.6-;WA7Q9;>+;*6[M;#4+2.-]H^VP^67[Y7DY%= M>E 'D?@7Q'I?A#3=4T[4+YEMK?5&M;&)B7?!/"J.I KOK;PCHMOXG?Q);6QA MOY8O+D,;%5<'NRC@GW-\!:!:_$/6-5DO8;W41+YT=KG/V4-W(]:])% ! M145S<0VEM)<7$BQPQJ6=V. H'4URGAWXE^'O$^L/IE@]RLX4O&9H2BS*/XD/ MJUBZM#H&K7UMI6J):W%TO^DPV\N"WRG[P'M0!PFD_"EY? M&^I:OK5QY^F&[-S9V0?*,Q_C<=,CTKU0 * .@% P!TI: "N7\>Z1J MNN>'AI^E2;&EGC%P/,\O=#GYQN'3BLN'XKZ _C>;PQ-YUO,C>6MQ,NU'D_N\ M\CV)ZUW?44 >$ZMH&L> 3XAN+#0+.X\)R>6)K.ZN6?+7]3_ .$GMBNA\5^#-$USQ%9S:SK5[&)\1QZ< M+G9%.5YQMZGU-=M##';PI#$@2-%"JH' H M:7=VT,IBEFB9$D'\)((!H XKQGXNL-0T+5]#\.ZW;/X@\DB*"&7]X2#\RJ>[ M8SP.:\EBDCLI-/U3P$NJ0:M9P--K-K/YGE_(,L)"W!)YZ?I71>*O"<7@OP=X M6:Y^QC4K;5HO,O85VY5FRV6/)Z=ZZHKI_P 66G2UNM8LM-LI3&T]NPCAO@?O M#U([4 :<&D6_C27PYXUT^YETZ\6,-(44$RQ,,F-OQ[__ %J[JJVGV%MIEA!8 MVD0BMX$$<:#H .E6: "N!IU#B0J=O&>#G%='7 MD5_\*9X]'E8:CIZ:D^L?;SJ4\7S1QY.%R>ISCC@4 <[?^%9?!^G>#];EBDMO M$DNJ1Q7LPN&L^'] L/# M6C0:7IL(CMX5Q[L>[$]R: )=(T>PT'3(=-TVW6WM(1A(UR<=^_6KU%% &)JO MBS1]&U?3]*NKDF^OY!'#!&I=N?XF Z+[G_&O&+?P];ZKXLU_1M=O;O3?&)NW MN=+U0SLHEB_@5><8]ASZ="*WO$W@[Q'8?$6;4M#D_P!'UI0D^H.-TFG*.7*D M_=!'3\NU9]CX:&N>-;GP=KNLOKMK#:"^LM3CD'VBU.X#:7&>NI[>U5?"OA+3O"-A+:V!FD::0RS3W#[Y)7QC+'\*WJ "BBB@ HHHH M **** "BBB@ HHHH *9+*D,322,$11DLQP *2>>*V@>>>5(HD&YW=@JJ/4D] M*\T^(/B%(KY-(\066?".J0!%U*W&K MZRO=&L-0?R[#5Y5S%*Z-QD8^Z2/7IZ5@_P#"%:MJOC"WMS<:W=ZI9W*-+JTZ M>1:PQ+R1"O<]ACBNE\,Z1?WEK<^ ?$^G-J6D+"9=.U>)04,1^[\W9AGC'/X< MUZCI.FQ:1I5MI\,DTD=O&(U>9R[D#U)H M*BJ20H!;DD#K3J** "BBFNZQH7 M=@JJ,DDX H 27_5/\^S@_-Z>]>76'BC5_ WB;^R?%=Z;W1K^4FQU9L?*Q/W' M(X _STK-^(GC"/6]#BN[&WU"?0K+4O(U,1 QB= #T8'E,\9S69X*TS3-5O&\ M.XM]1TW5(7NKF""Y::+31C]VJDYP^<9.@^/OA_:>,[-+VUF-IK%NNZUO M(6P3Z D=12_"_39M-\,-%>:(=,O?.87#%RYN6''F98D\^]=)X?T2'P]HEMI= MO/<3Q6Z[5>XDWN1]?Z5IT %%%% !16-XIUR7PYH%QJD6GSW_ ) !:&$C=M[G MZ"O./'WCNSU'0-"OK'5+RWT.\N"M]/8MMF3"Y\LDB>+-$N/$/AZYTZ MUU&>PFD7Y9H6P<^A]CWKQ>:_U'7;&U^'5_H,,&NV4J^3>-*L:*JG/F+GDDCL M.M=3\-=9OK'6%T*ZN;V]2]C:[A6>Z6.DSWTBR!_*:X\H^2K_W2_3/Z M4 6_&O@R'QG'I]O=S[;2WG\R:+'^M&,8SVKE-"MM>\&:]'X0OK>?5?#5]N2T MNE!+VXQRCD=L5ZF)$:,2*RE",A@>"/6L31/%%OK^I7L%A;326=J=GV[CRI'[ MJGE #?#O@GP]X4DGDT;3DMI)_P#6/N9V(],L3Q7045GZMK>FZ%;I<:I> MPVL3N(U:5L L>@H T*YWQ)X3A\1ZCHUY+=2P-IEP9T" '?D8PF]ATKK;:Z@O+:.YMI4EAD4,CHX- 'C&J>+%\ M(_%3Q*+6R>ZU&]A@2TM8U.)9".IQVKT#PQX&T+1YUUF/18+35[A-T["1I-C' ME@I8\<^E16CZ#??$6YFL]*-SJ,, 2YU)<&.$CI'D_P 6.N/QKLJ "BJ>J:K8 MZ+I\M_J-S';6L7+R2' %*\Y\9>(;3P9\5K;4IHI)6.CF*..-?F MGD+@*O'TKU?3-4LM9TZ&_P!/N8[BUF7V M1BTR $62'D,^> 2>@Z]: *WASPC8:I-;>+->\/6]MXBF'F./,=PA[':3@'&/ MI7:1, M_,.<\9^E8VL?$GPUHVEVFH/>-=0W@)@6S0RLX'4X'0#OFMCP_P"(]+\4:4FI M:3=+/;OQTPRGN&!Y!H \V^(6@Z+I-Q'J=QXONM'OX=-^SV20LJ-)L.>2!D@G M''%:_ACPI9>,=$T'Q'XKL&N-8B@&#([!2 YZ5U*@*H & .@H !@=*6@G )/05S%Y\0? M#5IHE '1W$,=S;RP3('BD4HZGHRD8 M(KQ&[^'5CHDMU9^*=>DM/!T$I_LQ%N!&QDD^8[L#G;S@FO4O"WC31?&-M+-I M-PS-"=LT,J%)(S[J?YU#XTU31-.TV-=7T^'4Y97VVE@T*RO/)V"J0?Q/:@#" M^$-U?WW@V:.^N);RTANY8+*YG!W3VXP%)SU'4?A7H,<:11K'&BHBC"JHP /0 M"F6J)':Q)' ($"@"( )[8''%2T %!&:P[GQAX?M$U1I=5MA_9?_ !^*&RT1 M[ CJ3SCCOQUJAX7^(GA[Q;=S6>GSRQWL0W&VN8S%(5]0#U'TH X+6?AO:Z1K M6HRWVK-8>!KAOMEU$LWEGS_NA,@9*Y.&M(\46VMZ#=23:UX5T^\1M M+N)9&!W%@J7P MXR/H%G)'I']D*Z;A8E%4PY[$+P#W_'UH M:=IMGI-A#8Z?;1V]K"NV.*,8"B MK5%94WB31K?4+FPFU*V2ZM8/M$T32 ,D?7U>O:-H6F>'M/6PTFRBM+522(XQU)[D MGDGW-4O"5Y;:AHPO+/1FTNVED8Q1M$L9D3L^T=,CUYK>H **S;G7M*L]6@TJ MYOX(KZX1GB@9L,RCJ?\ /H?2N;LOBOX2OM=&DQWSI*[F.*:6(K#*P.,*YX// MX4 XS_ "KDO#]IX;UCQ1I6DZ%? MW^K:3J=NYU>PO79Q$57(G6OH*:6.&!Y9G5(U!+LQP .^:Y[PEJ M.F:PE[>Z5HXM+3S=D5V(5C%V!U=<'/"6B>$[1[;1;%+9)#ND() M9G(Z9)))K;HHH P?%GBFW\*:4MW+;RW4TL@AM[:$9>:0]%%YBN6P\:DY;!'.=N>U=SJFAZ?K,EG)?0>:UG,+B [B-K@8!X M^M>,>/-)T)=?GL_#MKK#^,9;R.=9X_,VKDC=\W3:!^7K0!D: )]%\2Q7?@:X M@:6YNVM&T9Y2=\48PTDA)R"2">U>O^(++7/$5]'H@C:QT=X@][>1R?/)_P!, MH_3W)'2MC2O#>E:9.;^'3+.'49E'VBXBA56=L H'J36I6=K6B6'B"P^Q:E#Y MMOO5]NXCE3DTT^?0]>B@W1)>''#&+Z.+7K&>*S>V>1G;4I7YD9@Q^[^ KK/BCIOAB+4;M%M-6G\3WD*&S:W$C M!&4X4 C@>_6O0?#/A>TMK+3]2U'3;4Z^+=%GNS$IE+8YRW7/O0!7U63Q7J=C MI^FV]I'837<>;^\20.+8=U3N6/8]!6_H>AV'A[2XM/TZ+RX4Y)/+.W=F/ MM=/-IMC<7"7$]G;RSQ_)69?H2,BK0&* ,7PWX:YE;S+FZEY MDG<]68_T[5M444 9OB#1XO$&@WNDSR/''=1&,NG5<]Z\'U&R.D>)6TCQ+XMN M=/?2M/QI=W:QB#S!UP3SGMZ9KZ*JC?:-I>IO&^H:=:7;1G*-/ LA4^V1Q0!Q MWAC7/$]S\,;34&L3?:Q(-D0?Y-ZYPLC^V.3BMOPQX8.D&?4-0N#>:S>8:YN6 M'3T1/11Z5T:J$4*H 4# [4M !7FOQ7\4^*_"L%C>Z)!;#3Q(/M,\JE\'LK# MLI]17I50W5K;WUK);74*302*5>.1V^H6Z:FMFG_$NN8Y &O$Q\N]O+GD(W9:]$@@BMH$@@C6.)%"HBC 4#L!0!R MWAKPS=)J#>(O$$HN-;F3:%7_ %5HG_/.,?S/>NMHJMJ%H;[3[BT$\L!FC*>; M"VUTR.H/K0!SOCCQ-J7A6RMM1M=+^VV*RXOF4G?%'_>4#K6[I.K66MZ9!J&G M3I/;3+N1U/Z?6OGU-(\6>&_%[!GM;H'^%@Q(4GIC!KK_ M (=^"?'/A#Q5-]JN+!M#N SRQP.=F_L43 VGZ<4 =C\2M,T#4_"3IXBN9(+* M*5) T7WV8=%4=RA!',A]>W:NMH *XGQ;\1K;PUJ*Z7::7>ZOJ6 MSS9+>S7<8D]6/;Z5VU>1^+_!^OZ;K6L:[IGBNVT;2;]5:^GE4^;'MXPC 9^@ M!% 'J.G7OV^QAN&A>WDD0,T$A&^,D?=;'>L_Q;9:)?\ ARZB\1;?[,5=\Q:0 MH!CIR"#7CWA;3K"W^)6D)X+UB^U.-(F?6+MY2T3Y!QGMDGM_]>O3[[PU?:_X MG\[6I(7T*TVM:6*$D328_P!9+GKCH%Y'>@"YX+T[0M/\-VY\/6+6=C./-571 ME=L]VW)_#9\(^)=0USQ#+="6_NQ*QC$ (W;P>@Z\$G M^5 'T%J<%G=:5=P:AM^Q21,L^YMHV$?-D]AC-NGA MACMX4AAC6.)%"JB# 4#H * 'T444 %%%% !1110 4444 %%%% !1110!1UC2 M;/7-*N--U"$2VMPA1T/<5Y0_@GQK::=<>"HUM-1\-7##RK^YE_>6L>WN(S'(%8J<'W%>0'P/J"WR>!]8M[J_T?!FTK M6(Q^]LB/X6/3 ]/\@ V/"6C:YX*UQ_"5S8-JOAF]+O;7*J"+<=UDSQC^?;TK MT73-$TO18W33-/MK-7.6$$037&YR!U.*N4 M %%%% !6;KM]?:?I,]QIMA]OND *V_F!,_B:T6944LQ 4#))[5XEX\N=1UGQ M"VK>!_$"W+6L&R^M;.\ D95.<*N.?KS0!L>._&":GX0MKO2[R0Z>EXL.L&S< M^9 G\2Y'.,\9'45S%KH>D)XLMK+P5+:ZWHVIQ;]1TV:?>L:Y^^6/*M^M6=.C MTO7/$%KJO@B]@6_O4']KZ-=C]W*G1RPQ@-W]^HKUS1?"VA^'C*^DZ5:V3S?Z MPP( 6]L^GM0!%X=\'Z%X4BD31M.CM?-.78$LS>V3DX]JW:** "C/%!Z5XWH7 MQ2OK3Q)>6OB-2VB7-[)!9Z@$VJC XV-CM0!8\=^,?!OB&23P[J$-Z8UF\I=7 MCA'D6L_;Y\]1WQ7-P1ZK9Z'=?#?4- 74[NY#2Z??)(JQ2J>?,+-W'MS5[Q=X M2NK/4+32-.\/W6KZ'/%*\&V7*KG>"_"Y\+>'[?3Y;VYNY$7 M[T[!O+SU53CA: ,]/"6JR^!]*\/RZNT/E1K'>RQ EI4'55;MZ9KJ["PMM,L8 M;.SA6&WA4*B*, 59HH *\U^(7C;PG']H\.ZW87M_!@"ZEMH0Z6A/0LV>#]* MR+KXG:GH'Q"U6/48VN/#,N:;XTT5H9[2^T?1[G7=&U.Y M:[OH;>3=YTA&$SZ)0!B:7)=^#8+GPU=:7_PD&EZ_EM-O(G7$I(X5V;@8X[\5 MZ!X:\(Z[I?PWAT'^TELKXD[I4'F>2A.2JGU X!JS\._!K^%M!2.YN+AY)CYW MV65PT=JQ_ACXXZUVM &9H6AV7A[2HM/L(]D2:':6T;7\*("T(8_?!ZYH Z+Q[XU\/Z)"^DZK876J>?$6N+:UA$ MGEQ?WGR1M%>:Z)>0?#ZX?5-/M'UWPAK06.&1,&2!N@B?=P.N,&NE\:6,>I:7 M_P )-X9M;C5H-5DA&HQVTF6D@3HBCMD]:V?AMX.?28+O4YX+G3TOY6D31VD# M16ZY^7C'WL8H / /A36]#\'ZG;>;%I]U?3O/:QY\X6BMT!QP3WXXKJ?#/AJT M\-:>886::YE;S+FZDYDG<]68_P!*VZ* "N6\9^,=(\,6B0ZA;SWTUT&6.QMH MO,DE4#YCM_N@=_0UZ#\/=#O(+W7-=CM$TRRU=EEM+/<'V\, M>%8]"%Q=W-PU[J]VVZZO9!AG]%4?PJ.PKHJ*X+XJ:_K6A:3I?_"/2 :E:,$E>>V<>GUH Z7Q)XDT[PMI+:AJ+MY>X)''&NZ25ST55[DUX>6TZX\ M0/XU\&V<\=QIDYEU3P_;Q)XWE\I3K!:0+N=S^@ [DG@"L+XDZO?:'X#U&^TR?R;]3$D#;0?F:15Q@\=":YS1 M-9L_B7IDGAOQ3:R66M:?,DMS9JYC\PJE '&Z\FE_$/6IM1\,P M7.F>*;0)-+IVH1B+^T(UPRG&2">%Z]>/K6_HL]Q\1O&F@^)[#0VTM=(>6+4+ MB9U#N^W'E!1\QQD\D#J:R-+\':WXJ\3QOK&E7VD:C:7DUS=ZU%)M:7/$<QLYKNZ MF2&WA0O)(YP%41>3'J$9R"@(.2",X MS[^XK:\+^*_^$VTF3P1XVADL]4NK9'1U^3[9$0&#*>@; Y ]_0@85_X,UCQ% MXNNM'O-$NH$CO(?LNL+)A+6RB4A5C)_B.>>O/)Z4 3?\3;XB-I.E+X?_ +,U MOP_=1"^O7=46%5[(!\QW8! QTYQS7J.L>&'U[7K*?4+OS-(M!Y@T\)A99@> M&<_Q <87UK9T^Q%A910>=+.Z(JM/,09)2!C20L%"J6)/;%>.> _B7=:G%'HWC$-$NIK)]@U J$6=2S*5.. 0>!^ M'X@$?C#Q)X1^(%U%HX^V65WYC)IFNO%L@:5>JJ^.G]*R7@UGQ#X=7X;W M/AM5UW3"C17QD5(DB##]Z">3D<< YS4_B/P5J,NO'PQ#X?NKK2UM(K;2;PR9 MCM%W!I9&/]\D'TX &,&O9M T8:%I%O8_:[F\:%-GVBZ8-(P[ D#H.U &3K'A M6ZURSTS3KO4W&G0*HO8D7#794# +9X4D$D=ZZ>**.")(HD5(T4*J*,!0.@ I M]% !1110 4FT9SCGUI:* "BBB@ HHHH 0J"QK2MK=+2UBMX]VR) B[F).!ZD]:EHH **** "H;JUM[VV>WNH8YH9!AXY%# M*P]P:FHH HZ;H^FZ- 8--L;>TB)R4@C" G\*O444 %%%% #9(TFC:.1%=&&& M5AD$>A%4-,T'2=%,ATS3;6S,IRY@B5-Q]\5HT4 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-=UC1G=@JJ,EF. ! M7+^,?&UKX5AA@2%[W5KL[+2QBY>1O4^B^]<0WB7Q;JUYJ'@?Q'8V=KJ&I6#R M6_T_2N'B METC7CX>/@[1+K3_$UC,D=XD%JT:QJ.'\U@ #GGKS4.EQ>();^WT_^P+JU\1V M6RVLV2R5;:WC!^>4R$\L1WQ]*];N/ $+^,++Q-:7TME>HH6\6 #;=#'\0_K0 M!T5AH6E:9&](UC2;C3+N MP@:UG)9T" ?,?XAC^+WK6HH Q/"V@-X:T.'3&U"YOEB)V2W!RP7/"CV K;HH MH **** *5UI&G7EO?[WK63X1\)0^$+*XL;6]N9[1YC) M##,$M3U&;3KJX6QO&#K8D_NH&[E?K75444 %%%% $3VT$DZ3O#&TR A)"H M+*#U /:N6T_P!8Z1XRF\0:7:EHH Y+4? 5C=^,;+Q-9W4^GWT1_TDVV +IVQ#6E] ,2VY!_A(QQ[?U KH;:%H+ M6*%I9)FC0*9),;GP.IQW-344 %%%% "$ @@C(-8/B'P;HOB/03I-U9QQP*"8 M6A0*8&_O)CH<_G6_10!GZ)ITNDZ-:6$U[/>R01A&N)_OR$=S_G\ZT*** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ./\=> [ M3Q?:QSQR-9ZO:_-:7D?#(PZ ^HKB?A9(B^--6@\4?:7\8J-OFW'*M"/^>>!@ M#O\ Y->S5$+6W%R;D01>>5V&78-VWTSUQ0!)@4M%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 F4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D! end GRAPHIC 66 evax-20211231x20f059.jpg GRAPHIC begin 644 evax-20211231x20f059.jpg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end XML 67 R1.htm IDEA: XBRL DOCUMENT v3.22.1
    Document and Entity Information
    12 Months Ended
    Dec. 31, 2021
    shares
    Document Information [Line Items]  
    Document Type 20-F
    Document Registration Statement false
    Document Annual Report true
    Document Transition Report false
    Document Shell Company Report false
    Document Period End Date Dec. 31, 2021
    Entity File Number 001-39950
    Entity Registrant Name Evaxion Biotech A/S
    Entity Incorporation, State or Country Code G7
    Entity Address, Address Line One Dr. Neergaards Vej 5f
    Entity Address, City or Town Hoersholm
    Entity Address, Postal Zip Code DK-2970
    Entity Address, Country DK
    Title of 12(b) Security American Depositary Shares, each representingone ordinary share, nominal value DKK 1 per share
    Trading Symbol EVAX
    Security Exchange Name NASDAQ
    Entity Well-known Seasoned Issuer No
    Entity Voluntary Filers No
    Entity Current Reporting Status Yes
    Entity Interactive Data Current Yes
    Entity Filer Category Non-accelerated Filer
    Document Accounting Standard International Financial Reporting Standards
    Entity Emerging Growth Company true
    Entity Shell Company false
    Entity Common Stock, Shares Outstanding 23,203,808
    Entity Ex Transition Period false
    Entity Central Index Key 0001828253
    Current Fiscal Year End Date --12-31
    Document Fiscal Year Focus 2021
    Document Fiscal Period Focus FY
    Amendment Flag false
    Auditor Name EY Godkendt Revisionspartnerselskab
    Auditor Firm ID 1757
    Auditor Location Denmark
    Business contact  
    Document Information [Line Items]  
    Entity Address, Address Line One Dr. Neergaards
    Entity Address, City or Town Hoersholm
    Entity Address, Postal Zip Code DK-2970
    City Area Code 45
    Local Phone Number 53 53 18 50
    Contact Personnel Name Lars Staal Wegner
    Entity Address, Country DK

    XML 68 R2.htm IDEA: XBRL DOCUMENT v3.22.1
    Unaudited Condensed Consolidated Interim Statements of Comprehensive Loss - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Operating expenses:      
    Research and development $ 19,583 $ 10,902 $ 8,216
    General and administrative 6,251 5,666 2,647
    Total operating expenses 25,834 16,568 10,863
    Operating loss (25,834) (16,568) (10,863)
    Finance income 2,039 216 65
    Finance expenses (915) (223) (1,222)
    Net loss before tax (24,710) (16,575) (12,020)
    Income tax benefit 178 1,557 825
    Net loss for the year (24,532) (15,018) (11,195)
    Net loss attributable to shareholders of Evaxion Biotech A/S (24,532) (15,018) (11,195)
    Other comprehensive income that may be reclassified to profit or loss in subsequent periods: (net of tax)      
    Exchange differences on translation of foreign operations (83) (18)  
    Exchange rate adjustments of investments in subsidiaries 93    
    Tax on other comprehensive income, income/(expense) (5)    
    Other comprehensive income that will not be reclassified to profit or loss in subsequent periods: (net of tax)      
    Exchange differences on currency translation to presentation currency (1,547) 412 2
    Other comprehensive loss for the period, net of tax (1,542) 394 2
    Total comprehensive loss (26,074) (14,624) (11,193)
    Total comprehensive loss attributable to shareholders of Evaxion Biotech A/S $ (26,074) $ (14,624) $ (11,193)
    Basic earnings (loss) per share $ (1.26) $ (0.97) $ (0.81)
    Diluted earnings (loss) per share $ (1.12) $ (0.97) $ (0.81)
    XML 69 R3.htm IDEA: XBRL DOCUMENT v3.22.1
    Unaudited Condensed Consolidated Interim Statements of Financial Position
    $ in Thousands
    Dec. 31, 2021
    USD ($)
    Dec. 31, 2020
    USD ($)
    Non-current assets    
    Intangible assets $ 93 $ 100
    Deferred tax assets   262
    Property and equipment, net 5,174 221
    Government grants receivable   194
    Leasehold deposits 191 238
    Total non-current assets 5,458 1,015
    Current assets    
    Prepayments and other receivables 1,138 1,553
    Deferred offering costs   1,729
    Government grants receivable 563 418
    Tax receivables 838 1,416
    Cash and cash equivalents 32,166 5,834
    Total current assets 34,705 10,950
    TOTAL ASSETS 40,163 11,965
    EQUITY AND LIABILITIES    
    Share capital 3,755 2,648
    Other reserves 79,114 31,669
    Accumulated deficit (50,432) (27,279)
    Total equity 32,437 7,038
    Non-current liabilities    
    Lease liabilities, non-current 2,206  
    Loan from lessor, non-current 1,044  
    Provisions 153  
    Total non-current liabilities 3,403  
    Current liabilities    
    Lease liabilities 314 20
    Loan from lessor, current 126  
    Trade payables 2,848 3,673
    Other payables 1,035 1,234
    Total current liabilities 4,323 4,927
    Total liabilities 7,726 4,927
    TOTAL EQUITY AND LIABILITIES $ 40,163 $ 11,965
    XML 70 R4.htm IDEA: XBRL DOCUMENT v3.22.1
    Unaudited Condensed Consolidated Interim Statements of Changes in Equity
    kr in Thousands, $ in Thousands
    Share capital
    DKK (kr)
    Share capital
    USD ($)
    Share premium
    USD ($)
    Foreign currency translation reserve
    USD ($)
    Accumulated deficit
    USD ($)
    USD ($)
    Equity at Dec. 31, 2018 kr 12,917 $ 2,113 $ 4,106 $ (171) $ (6,979) $ (931)
    Net loss for the year         (11,195) (11,195)
    Other comprehensive income       2   2
    Share-based compensation         2,362 2,362
    Issuance of shares for cash   181 9,261     9,442
    Transaction costs     (13)     (13)
    Settlement of convertible debt instruments   187 9,508     9,695
    Equity at Dec. 31, 2019 15,184 2,481 22,862 (169) (15,812) 9,362
    Net loss for the year         (15,018) (15,018)
    Other comprehensive income       395   395
    Share-based compensation         3,551 3,551
    Issuance of shares for cash   167 8,853     9,020
    Transaction costs     (272)     (272)
    Equity at Dec. 31, 2020 16,198 2,648 31,443 226 (27,279) 7,038
    Net loss for the year         (24,532) (24,532)
    Other comprehensive income       (1,537)   (1,537)
    Tax effect on OCI items       (5)   (5)
    Share-based compensation         1,379 1,379
    Issuance of shares for cash   1,107 56,502     57,609
    Transaction costs     (7,515)     (7,515)
    Equity at Dec. 31, 2021 kr 23,204 $ 3,755 $ 80,430 $ (1,316) $ (50,432) $ 32,437
    XML 71 R5.htm IDEA: XBRL DOCUMENT v3.22.1
    Unaudited Condensed Consolidated Interim Statements of Cash Flows - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Operating activities:      
    Net loss for the year $ (24,532) $ (15,018) $ (11,195)
    Adjustments for non-cash items 541 1,583 2,945
    Interest received     9
    Interest paid (25) (30) (39)
    Income taxes received 846 812 688
    Cash flow from operating activities before changes in working capital (23,170) (12,653) (7,592)
    Cash flow from changes in working capital:      
    Changes in net working capital 1,237 215 573
    Net cash used in operating activities (21,933) (12,438) (7,019)
    Investing activities:      
    Investment in intangible assets (60) (35)  
    Purchase of property and equipment (1,300) (149) (61)
    Payment of non-current financial assets - leasehold deposits 30 (209) (7)
    Net (cash used in)/ provided by investing activities (1,330) (393) (68)
    Financing activities:      
    Proceeds from issuance of shares and exercise of warrants, less underwriter discounts 53,854 9,019 9,442
    Transaction costs related to issuance of shares (3,760) (128) (13)
    Proceeds from issuance of convertible debt instruments     152
    Repayment of loan from lessor (63)    
    Leasing installments (226) (74) (73)
    Net cash provided by financing activities 49,805 8,817 9,508
    Net (decrease)/increase in cash and cash equivalents 26,542 (4,014) 2,421
    Cash and cash equivalents at January 1 5,834 9,559 7,433
    Exchange rate adjustments on cash and cash equivalents (210) 288 (295)
    Cash and cash equivalents at December 31 32,166 5,834 $ 9,559
    Non-cash investing and financing activities      
    Capitalized intangible assets included in trade payables   $ 60  
    Acquisition of property and equipment included in trade payables $ 90    
    XML 72 R6.htm IDEA: XBRL DOCUMENT v3.22.1
    General Company Information
    12 Months Ended
    Dec. 31, 2021
    General Company Information  
    General Company Information

    Note 1. General Company Information

    Evaxion Biotech A/S (the “Company” or “Evaxion”) is an artificial intelligence (“AI”)-immunology platform company that uses its proprietary AI technology, engineering expertise and drug development know-how to simulate the human immune system and generate predictive models to identify and develop efficacious immunotherapies for patients in the global market. Unless the context otherwise requires, references to the “Company,” “we,” “us,” and “our”, refer to Evaxion Biotech A/S and its subsidiaries.

    Evaxion is a public limited liability company incorporated and domiciled in Denmark with its registered office located at Dr. Neergaards Vej 5f, DK-2970 Hoersholm, Denmark.

    On February 5, 2021, the Company completed an initial public offering (“IPO”), which resulted in the listing of American Depository Shares (“ADS”) representing the company’s ordinary shares, under the symbol “EVAX” in the United States on the NASDAQ Capital Market. Through the IPO, the Company sold 3,000,000 ADSs, each of which represents one ordinary share, at a price to the public of $10.00 per ADS. The Company received net proceeds of $25.3 million from the IPO, after deducting the underwriting discounts and commissions and offering expenses. Upon the completion of the IPO, authorized share capital consists of 3,000,000 shares of ordinary shares, par value DKK 1 per share.

    On November 9, 2021, the Company completed a follow-on public offering through which we issued and sold 3,942,856 ADSs, each of which represents one ordinary share, at a price to the public of $7.00 per ADS. The shares issued were inclusive of the 514,285 ADSs issued to the underwriters pursuant to the full exercise of their option to purchase additional shares on November 5, 2021. The Company received aggregate net proceeds of $24.9 million from the follow-on public offering, which includes the funds received for the additional shares issued to the underwriters, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. Upon the completion of the follow-on public offering, the Company’s registered, issued, and outstanding share capital was nominal DKK 23,141,524.

    At year end, due to warrant exercise, the outstanding share capital was nominal DKK 23,203,808.

    The consolidated financial statements of Evaxion Biotech and its subsidiaries (collectively, the “Group”) for the year ended December 31, 2021, were approved, and authorized for issuance, by the Board of Directors on March 31, 2022.

    Basis of Going Concern

    The Company’s Board of Directors has, at the time of approving the consolidated financial statements, a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. Based on the Company’s net proceeds secured through its recent IPO and follow-on public offering, together with access to its EIB loan, of which the Company has already received the proceeds from tranche no. 1 of €7 million on February 17, 2022, and the current cash on hand will allow the Company to meet its liabilities as they fall due for at least 12 months from the issuance of this Form 20-F. Thus, these consolidated financial statements are prepared on a going concern basis of accounting.

    Emerging Growth Company Status

    Evaxion is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”).

    The Company has elected to take advantage of specified reduced reporting and regulatory requirements in contrast to those otherwise applicable generally to public companies. This provision includes the exemption from the auditor attestation requirement in the assessment of the Company’s internal control over financial reporting pursuant to Section 404 the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act.

    Evaxion will remain an emerging growth company until the earliest of (i) the last day of the first fiscal year (a) following the fifth anniversary of the completion of the global offering, (b) in which its annual gross revenue totals at least $1.07 billion or (c) when the Company is deemed to be a large accelerated filer, which means the market value of the Company’s ordinary shares that is held by

    non-affiliates exceeds $700.0 million as of the prior June 30th and (ii) the date on which the Company has issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.

    COVID 19

    In December 2019, a novel strain of coronavirus (“COVID-19”) was reported in Wuhan, China and on March 11, 2020 the World Health Organization declared COVID-19 a pandemic. The COVID-19 pandemic has resulted in a widespread health crisis and numerous disease control measures being taken to limit its spread. As the pandemic unfolds throughout the world, the healthcare systems of the countries in which the Company is conducting its studies have experienced great disruption. Governments have instituted quarantining and mandated business and school closures. Travel has been severely restricted.

    The Company has closely been monitoring the impact of COVID-19. The Company’s top priority remained the health and safety of its staff and the patients in the studies. The Company maintains compliance with government and health authorities.

    The Company has worked closely with laboratories and investigators to ensure safe continuation and working requirements of our ongoing research activities and human clinical trials. The Company has not experienced a materially negative impact from COVID 19. As of December 31, 2021, the impact of the COVID-19 pandemic continues to unfold. As events continue to evolve and additional information becomes available, our estimates may change materially in the future.

    While business travel has been limited, the Company has remained active and effective in the process of raising capital with institutional investors by conducting key meetings on a virtual basis.

    XML 73 R7.htm IDEA: XBRL DOCUMENT v3.22.1
    Summary of Significant Accounting Policies
    12 Months Ended
    Dec. 31, 2021
    Summary of Significant Accounting Policies  
    Summary of Significant Accounting Policies

    Note 2. Summary of Significant Accounting Policies

    Basis of preparation

    The financial statements have been prepared in accordance with IFRS as issued by the IASB. The Company adopted IFRS in 2019 and applied it from the beginning of the period preceding adoption, starting on January 1, 2018.

    Management has assessed the impact of new or amended and revised accounting standards and interpretations (IFRSs) issued by the IASB and IFRSs endorsed by the European Union effective on or after January 1, 2021. It is assessed that application of amendments effective from January 1, 2021 has not had a material impact on the consolidated financial statements for 2021. Furthermore, Management does not anticipate any significant impact on future periods from the adoption of these amendments.

    The financial statements are presented in the Company’s presentation currency, U.S. dollar (“USD”) which is not the functional currency of the parent company. The Group’s financial statements are presented in USD as the result of the Company’s publicly listing the ADSs in the United States. The company’s functional currency is DKK for Denmark, AUD for Australia, and USD for the United States. The financial statements have been prepared on a going concern basis using a historical cost basis. All financial assets and liabilities are measured at amortized cost unless otherwise stated.

    Reclassifications of prior period presentation

    Certain items in prior year consolidated financial statements have been reclassified to conform to the current period’s presentation.

    Basis of consolidation

    The audited consolidated financial statements of the Company comprise the Statement of Financial Position as of December 31, 2021 and 2020, and the Statement of Comprehensive Loss for the twelve months ended December 31, 2021, 2020 and 2019. Subsidiaries are entities controlled by the Company. The Company controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and can affect those returns through its power over the entity. The financial statements of subsidiaries are included in the audited consolidated financial statements from the date that control commences until the date that control ceases. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Company. Control is reassessed whenever facts and circumstances indicate that there are changes of the control.

    All intra-Group assets and liabilities, equity, income, expenses, and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

    Retrospective effect of share split and bonus share issuance

    All share and per share data, including that related to warrants, in the consolidated financial statements give retroactive effect to a 2:1 share split and a bonus issue of shares in the ratio of 17:1 of the Company’s authorized, issued and outstanding ordinary shares, which was effective on January 4, 2021, with the corresponding impacts on both share capital and share premium also retroactively recognized.

    Currency translation of transactions and balances

    Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized as financial income or financial expenses in the statements of comprehensive loss. Non-monetary items in foreign currency which are measured at cost at the statements of financial position date are translated using the exchange rates at the date of the transaction.

    Translation of foreign operations

    Assets and liabilities in the Company’s functional currency, DKK and AUD, for Denmark and Australia, respectively, are translated to the Company’s presentation currency at the exchange rate applicable on December 31 for the respective year. Income and expenses in the Company’s functional currency are translated to USD at the average exchange rate which corresponds to an approximation of the exchange rates prevailing on each individual transaction date. Translation differences arising in the translation to presentation currency are recognized in other comprehensive income.

    Research and development expenses

    Research and development expenses are primarily internal and external costs incurred in the development of the Company’s product candidates, including personnel costs, share-based compensation, external research and development expenses, maintenance of the Company’s patents, overhead allocation and enhancements and maintenance of the Company’s technology platforms.

    The research activities are comprised of activities performed before filing an IND or equivalent and necessary pre-clinical activities for such product candidates. All research expenses are recognized in the period in which they are incurred and payments made prior to the receipt of goods or services to be used in research and development are deferred until the goods or services are received. The Company records accruals for estimated research and development costs, comprising payments for work performed by third-party contractors and others. Payments for these activities are based on the terms of the individual agreements, which may differ from the timing of the expense recognition of these costs, in which case, they are reflected in the financial statements as either prepaid- or accrued expenses.

    The development activities are comprised of the activities performed following the filing of an IND or equivalent clinical-enabling activities for such product candidates, including but not limited to, research and clinical development activities. In line with industry practice, internal and subcontracted development costs are expensed as incurred. Due to regulatory uncertainties and other uncertainties inherent in the development of new products, development expenses do not qualify for capitalization as intangible assets until marketing approval by a regulatory authority is obtained or considered highly probable. To date, the Company has not incurred any development costs which qualified for capitalization.

    Contract Research Organizations expenses and related prepayments and accruals

    Substantial portions of the Company’s clinical studies are performed by third-party laboratories, medical centers, contract research organizations and other vendors (collectively, the “CROs”). The CROs generally bill monthly or quarterly for services performed. For studies, the Company accrues expenses based upon estimated percentage of work completed.

    The Company’s estimates depend on the timeliness and accuracy of the data provided by the CROs regarding the status of each program and total program spending. The Company evaluates the estimates to determine if adjustments are necessary or appropriate based on information received.

    CROs invoice the Company upon the occurrence of predetermined contractual or activity-based milestones; however, the timing of these invoices and the Company’s related payments often do not correspond directly to the level of performance of contracted activities. To the extent payments are made by the Company in advance of the related activities performed by the CROs, they are included in prepayments to clinical research organizations and expensed when the activities performed by the CROs. To the extent the payments are made by the Company following the performance of the related activities, the expense is accrued for as a payable to clinical research organizations.

    Intellectual property

    The Company actively seeks to create, maintain and protect intellectual property and proprietary information and technology that is considered important to the Company’s business, which includes seeking and maintaining patents covering proprietary technology, product candidates, proprietary processes and any other inventions that are commercially and / or strategically important to the Company’s business development. These expenses are expensed as incurred and not capitalized as intangible assets until marketing approval by a regulatory authority is obtained or considered highly probable. The Company has not incurred any costs that qualify for capitalization.

    Income from government grants

    The Company receives grants for certain research and development activities. The grant income is recognized as a reduction of research and development expenses in the period in which the underlying expenditures were incurred and when there is reasonable assurance that the Company will comply with all conditions to receive the grant income. Government grants comprise direct grants and tax credits related to qualifying research and development costs in excess of the corporate tax rate. Tax credits in an amount up to the corporate tax rate are classified as income tax benefits.

    General and administrative expenses

    General and administrative expenses consist primarily of fees paid to external consultants and personnel costs, including share-based compensation for the Company’s executive, finance, corporate and business development functions. In addition, general and administrative expenses also include depreciation and other expenses for the Company’s corporate headquarters as well as other allocated overhead.

    Share-based payments

    The Company issues warrants as an incentive to employees and non-employees. The fair value of the warrants granted is recognized as an expense with a corresponding credit to accumulated deficit. The fair value is expensed over the requisite service period of the awards. The expense recognition is based on an estimate of the number of warrants expected to vest. The estimate is reassessed regularly, and on a cumulative basis, the expense is equal to the fair value of the number of warrants which actually vest.

    For employees and consultants providing services similar to employees of the Company, the fair value of the equity instruments is determined at the date of grant resulting in a fixed fair value at grant date that is not adjusted for future changes in the fair value of the equity awards that may occur over the service period. The grant date is defined as the date at which the parties agree to the contractual terms.

    For consultants providing other services that are not similar to employees of the Company, the transactions are measured at the fair value of the services received unless this is not reliably measurable. In such cases, the transactions are measured at fair value of the equity instruments granted at the dates when the services are provided.

    Modification of warrants which are beneficial are accounted for with their incremental value or over the shorter vesting period. Non-beneficial modifications such as an extension of the vesting period are not accounted for. Consequently, the original terms are deemed

    to continue to exist. The Company estimates the fair value of warrants using the underlying value of the Company's ordinary shares. Since the warrants granted before December 2020 are exercisable for nominal consideration, the warrants are valued using the fair value of the Company's ordinary shares on grant date less the exercise consideration. Warrants granted during 2021 are valued using a black-scholes share option pricing model. The assumptions used in calculating the fair value of share-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. The key assumption in this estimate is the fair value of the Company's ordinary share on the warrant grant date.

    Post-employment benefit costs

    The Company contributes to a defined contribution plan covering eligible employees. The contribution amount is based upon a fixed percentage of employee compensation and such contributions are expensed as incurred.

    Accounting for joint operations – Southern Denmark University

    The Company enters into agreements from time to time that may be subject to the requirements of IFRS 11, Joint Arrangements. The Company evaluates these agreements on execution and applies the requirements of the guidance. The collaboration agreement with Southern Denmark University (“SDU”) is considered a joint operation as defined in IFRS 11, with the principal place of business being Denmark. In September 2020, the Company terminated its existing agreement with SDU. For the years ended December 31, 2020, and 2019, the Company recorded $0.3 million and $0.3 million, respectively, in compensation cost for SDU employees which was reported in research and development costs in the statement of comprehensive loss.

    Accounting for joint operations - MSD International GmbH and MSD International Business GmbH

    The Company has entered into a collaboration agreement with MSD International GmbH and MSD International Business GmbH (jointly ‘MSD’). Under the arrangement, the Company will share its clinical trial in which the Company’s compound and MSD’s compound is dosed in combination.

    In determining the accounting treatment for these types of arrangements, the Company carefully evaluates the relationship between the two parties in order to determine whether the arrangement is, in substance, a collaboration arrangement between the two parties (to be accounted for in accordance with IFRS 11, Joint Arrangements), or rather, a vendor-customer contract (to be accounted for in accordance with IFRS 15, Revenue from Contracts with Customers).

    Management has determined that MSD does not meet the definition of a customer under IFRS 15. Consequently, the arrangement is classified as a collaboration arrangement and is accounted for as a joint operation in accordance with IFRS 11 resulting in the recognition of the Company’s own income and expense and assets and liabilities, respectively.

    Finance Income

    Finance income is comprised primarily of foreign currency gains.

    Finance Expense

    Finance expense is comprised primarily of changes in fair value of the Company’s convertible debt instruments and interest on the Company’s lease liability.

    Income tax

    The income tax for the period comprises current and deferred tax, including prior-year adjustments and changes in provisions for uncertain tax positions. Tax is recognized in the statement of comprehensive loss, except to the extent that it relates to items recognized in equity.

    Research and development tax credits are available to the Group under the tax laws of Denmark and Australia respectively, based on qualifying research and development spend as defined under those tax laws. Tax credits not exceeding the corporate tax rate are recognized as an income tax benefit. Tax credits in excess of the corporate tax rate are classified as government grants.

    Accruals for uncertain tax positions and/or valuation of government grant receivables require management to make judgments of potential exposures. Accruals for uncertain tax positions and/or valuation of government grant receivables are measured using either the most likely amount or the expected value amount, depending on which method the entity expects to better predict the resolution of the uncertainty. Tax benefits are not recognized unless the tax positions will probably be accepted by the tax authorities. This is based upon management’s interpretation of applicable laws and regulations and the expectation of how the tax authority will resolve the matter. Once considered probable of not being accepted, management reviews each material tax benefit and reflects the effect of the uncertainty in determining the related taxable amounts.

    Deferred taxes

    Deferred tax is measured according to the liability method on all temporary differences between the carrying amount and the tax base of assets and liabilities. Where the tax value can be determined according to alternative tax rules, deferred tax is measured on the basis of the planned use of the asset or the settlement of the obligation.

    Deferred tax assets are measured at the value at which they are expected to be utilized, either through elimination against tax on future earnings or through a set-off against deferred tax liabilities. Deferred tax assets are set off within the same legal tax entity and jurisdiction.

    Uncertainties exist with respect to the interpretation of complex tax regulations and the amount and timing of future taxable income. Given the complexity of existing contractual agreements, differences arising between the actual results and the assumptions made, or future changes to such assumptions could necessitate future adjustments to tax income and expenses already recorded. As at December 31, 2021 and 2020, the Company has not recognized any provisions for uncertain tax positions resulting in a risk that the deferred tax asset related to warrants is lower than disclosed.

    The Company recognizes deferred income tax assets if it is probable that sufficient taxable income will be available in the future against which the temporary differences and unused tax losses can be utilized. Management has considered future taxable income in assessing whether deferred income tax assets should be recognized and has concluded that the deferred income tax assets do not meet the criteria for recognition as assets in the statements of financial position.

    Tax receivables

    Current tax assets for the current and prior periods are measured at the amount expected to be recovered from the taxation authorities, using the tax rates and tax laws that have been enacted or substantively enacted by the end of the reporting period.

    Deferred offering costs

    Offering costs, consisting of legal, accounting, printer and filing fees directly attributable to the issuance of new shares relating to the Company’s initial public offering (“IPO”) in February 2021, were deferred and were offset against proceeds from the IPO upon the effectiveness of the offering. Deferred offering costs recorded as of December 31, 2020 were $1.7 million.

    Leases

    The Company assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

    The Company applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Company recognizes lease liabilities for future remaining lease payments and right-of-use assets representing the right to use the underlying assets.

    Leasehold improvements and Loan from lessor

    The Company’s lease contract comprises funding for the customization of the premises to the Company’s specific needs. The payment is determined based on the actual costs incurred for the customization, a repayment period of 8 years and an interest rate of 6% per annum.

    The Company has assessed whether this is a lease component, or a leasehold improvement funded by the lessor. We have considered the following factors:

    1.Which party designed the customization
    2.Which party had the right to direct changes to the work
    3.Who is taking on the economic risk of the cost price of the work

    A third party has designed the project according to the Company’s instructions, and the Company had the right to direct changes to the work during the construction period. Further, the Company has the full economic risk of the work due to 1:1 linkage between construction costs and payments to the lessor. Consequently, the Company has assessed that the customization is a leasehold improvement funded by the lessor and accordingly presented a leasehold improvement and a corresponding liability for the loan from the lessor.

    Right-of-use assets

    The Company recognizes a right-of-use asset at the lease commencement date (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost less any accumulated depreciation and impairment losses and adjusted for certain remeasurements of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, lease payments made at or before the commencement date less any lease incentives received, initial direct costs incurred, and restoration costs.

    Right-of-use assets are depreciated over the shorter of the lease term and the useful life of the right-of-use asset using the straight-line method. In addition, right-of-use assets are reduced by impairment losses, if any, and adjusted for certain remeasurements.

    The Company’s right-of-use assets are presented within property and equipment, net.

    Lease liabilities

    At the commencement date of the lease, the Company recognizes lease liabilities measured at the present value of the following payments, when applicable:

    fixed payments (including in-substance fixed payments), less any lease incentives receivable;
    variable lease payments (linked to an index or interest rate);
    expected payments under residual value guarantees;
    the exercise price of purchase options, where exercise is reasonably certain;
    lease payments in optional renewal periods, where exercise of extension options is reasonably certain;
    and penalty payments for the termination of a lease, if the lease term reflects the exercise of the respective termination option.

    The lease payments are discounted using the interest rate implicit in the lease if this rate can be readily determined. Otherwise, the Company’s incremental borrowing rate is used, being the rate that the Company would have to pay to borrow the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment with similar terms, security and conditions. Generally, the Company uses its incremental borrowing rate as the discount rate.

    Lease liabilities are subsequently measured at amortized cost using the effective interest method. In addition, the carrying amount of the lease liabilities are remeasured if there is a modification, a change in the lease term, or a change in the lease payments (e.g., changes to future payments resulting from a change in an index or rate used to determine such lease payments).

    Intangible assets

    The Company recognized intangible assets for licenses. Licenses are measured at cost less cumulative amortization and impairment. Cost is measured at fair value of the consideration transferred with addition of transactions costs. If additional consideration is transferred to the seller due to meeting certain milestones, these payments are added to the cost price once the conditions for making the payments are met.

    The capitalized assets are amortized over their useful lives, which are determined on the basis of the expected pattern of consumption of the expected future economic benefits embodied in the license or similar development agreement. Amortization commences only once the necessary regulatory and marketing approval has been received for the product candidates to which they relate. To date, the Company has not received any regulatory and marketing approval for any of its product candidates. Consequently, the Company did not recognize any amortization expense for its intangible assets.

    Property and equipment

    Property and equipment are stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. Depreciation is recognized on a straight-line basis over the estimated useful lives of the assets, as follows:

    Assets

        

    Useful life

    Properties

    Shorter of lease term and useful life of the asset

    Leasehold improvements

    11 years

    Other equipment

    5 – 10 years

    Impairment of non-financial assets

    Assets are tested for impairment annually, or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash-generating units). Non-financial assets other than goodwill that suffered impairment are reviewed for possible reversal of the impairment at the end of each reporting period. The Company has not recognized any impairment losses to date.

    Provisions

    Provisions are recognized when we have an existing legal or constructive obligation as a result of events occurring prior to or on the balance sheet date, and it is probable that the utilization of economic resources will be required to settle the obligation. Provisions are measured as the best estimate of the expense necessary to settle the obligation at the balance sheet date. Provisions that are estimated to mature after more than one year after the balance sheet date are measured at their present values, using a discount rate based on the Company’s risk adjusted incremental borrowing rate.

    Financial instruments

    A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. Financial instruments are classified at initial recognition, including on the basis of the purpose for which the instrument was acquired and managed. This classification determines the valuation of the instruments.

    (i) Non-derivative financial assets

    Non-derivative financial assets are recognized initially on the date they are originated. The Company derecognizes non-derivative financial assets when the contractual rights to cash flows expire or it transfers the right to receive cash flows in a transaction which transfers substantially all the risks and rewards of ownership of the asset. The Company’s financial assets are initially recognized at fair value and subsequently measured at amortized cost less accumulated impairment losses.

    The Company holds the following categories of non-derivative financial assets:

    Receivables

    Receivables (including lease deposits, receivables and receivables from unpaid capital) represent the Company’s right to an amount of consideration that is unconditional (i.e., only the passage of time is required before payment of the consideration is due). They are measured at amortized cost less impairment.

    Prepayments include expenditures related to future financial periods and are measured at amortized cost

    Cash and cash equivalents

    Cash is comprised of cash on hand and in bank deposit accounts. Cash equivalents are instruments with original maturities of 90 days or less. The Company does not have any cash equivalents for the years ended December 31, 2021 and 2020.

    (ii) Non-derivative financial liabilities

    Non-derivative financial liabilities comprise other payables which are measured initially at fair value and subsequently at amortized cost.

    Trade Payables

    Trade payables and accruals relate to the Group’s purchase of products and services from various vendors in the normal course of business.

    Other Payables

    Other payables are comprised of payables to clinical research organizations, employee liabilities and other liabilities. The contract liabilities consist of CROs and vendor accruals. Employee cost liabilities are comprised of provision for holiday allowance, provision for salaries and other employee related provisions. Other liabilities consist of commitments and liabilities related to government grants received in advance.

    Debt

    Debt is comprised of debt agreements that are carried at amortized cost using the effective interest method.

    (iii) Derivative financial liabilities

    Convertible debt instruments

    During 2018, the Company issued two convertible debt instruments which are determined to be financial instruments. As required by IAS 32 and IFRS 9, these instruments were separated into their components: debt, and embedded derivatives related to the conversion features, early settlement mechanism and change of control prepayment provision. The Company elected the fair value option and accounts for both the debt and the embedded derivatives as a single instrument that is measured at fair value. Details of the significant inputs and assumptions into the fair values of these instruments are provided in Note 20.

    Segment Information

    An operating segment is a part of the Company that conducts business activities from which it can generate revenue and incur costs, and for which independent financial information is available. Identification of segments is based on internal reporting to the chief operating decision maker (“CODM”). The CODM for the Company is the Chief Executive Officer. The Company does not divide its operations into different segments and the CODM operates and manages the Company’s entire operations as one segment, which is consistent with the Company’s internal organization and reporting system. The Company does not have any revenue and there are no material non-current assets attributable to countries other than Denmark.

    Shareholders’ Equity

    The share capital comprises the nominal amount of the company’s ordinary shares, each at a nominal value of DKK 1.

    Other Reserves includes the share premium comprising the amount received, attributable to shareholders’ equity, in excess of the nominal amount of the shares issued at the company’s capital increases, reduced by any expenses directly attributable to the capital increases as well as translation reserves. Translation reserves include exchange rate adjustments of equity and intragroup receivables forming part of the net investments in our group enterprises.

    Accumulated Deficit include the accumulated profit or loss as well as well as the reserve for share-based payment representing the corresponding entries to the share-based payment recognized in the profit or loss, arising from our warrant programs.

    Loss Per Share

    The calculation of basic loss per share is based on the Company’s net loss for the year attributable to shareholders of Evaxion Biotech A/S and on the weighted average number of ordinary shares outstanding during the year. The number of shares outstanding take in effect the 2 for 1 stock split and the 17 for 1 bonus share issuance on January 4, 2021. In calculating diluted loss per share, earnings and the average number of shares are adjusted for the dilutive effects of potential ordinary shares. Loss per share is not adjusted for any dilution that results in a loss per share that is lower than loss per ordinary share before dilution.

    Standards issued but not yet effective

    There were a number of standards and interpretations which were issued but were not yet effective at December 31, 2021 and have not been adopted for these financial statements:

    Amendment to IAS 37 Provisions, contingent liabilities and contingent assets, Onerous Contracts— Cost of Fulfilling a Contract (January 1, 2022)
    Amendments to IAS 16 Property, Plant and Equipment, proceeds before intended use (January 1, 2022)
    Annual Improvements 2018-2020 (January 1, 2022)
    Amendment to IAS 1 Presentation of Financial Statements: Disclosure of Accounting Policies (January 1, 2023)
    Amendment to IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors: Definition of Accounting Estimates (January 1, 2023)
    Amendments to IFRS 16 Leases: COVID-19-Related Rent Concessions beyond June 30, 2021 (April 1, 2021)

    The Company expects to adopt these standards, updates and interpretations when they become mandatory. These standards are not expected to have a significant impact on disclosures or amounts reported in the Company’s financial statements in the period of initial application and future reporting periods.

    XML 74 R8.htm IDEA: XBRL DOCUMENT v3.22.1
    First-Time Adoption of IFRS
    12 Months Ended
    Dec. 31, 2021
    First-Time Adoption of IFRS  
    First-Time Adoption of IFRS

    Note 3. First-Time Adoption of IFRS

    IFRS 1 – First-time adoption of IFRS

    Impact of initial application of IFRS 1 – first-time adoption of International Financial Reporting Standards

    The Company adopted IFRS as issued by IASB in the accompanying financial statements. The figures for 2019 in the statements of comprehensive loss have been prepared in accordance with IFRS as issued by the IASB.

    The disclosures required by IFRS 1, First-Time Adoption of IFRS, concerning the transition from Danish Financial Statement Act (“Local GAAP”) to IFRS were presented in the prior year financials. The financial statements for the year ended December 31, 2019 are the first the Company has prepared in accordance with IFRS. For periods up to and including the year ended December 31, 2018, the Company prepared its financial statements in accordance with the Danish Financial Statements Act. Accordingly, the Company has prepared financial statements that comply with IFRS applicable as at December 31, 2021, together with the comparative period data for the years ended December 31, 2020 and 2019.

    XML 75 R9.htm IDEA: XBRL DOCUMENT v3.22.1
    Significant Accounting Judgements, Estimates, and Assumptions
    12 Months Ended
    Dec. 31, 2021
    Significant Accounting Judgements, Estimates, and Assumptions  
    Significant Accounting Judgements, Estimates, and Assumptions

    Note 4. Significant Accounting Judgements, Estimates, and Assumptions

    The preparation of the consolidated financial statements in conformity with IFRS as issued by the IASB requires management to make judgements, estimates and assumptions that affect the application of policies and amounts reported in the financial statements and accompanying notes. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

    The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods.

    The critical accounting policies which involve significant estimates, assumptions or judgements, the actual outcome of which could have a material impact on the Company’s results and financial position outlined below, are as follows:

    Share-based compensation

    Management determines costs for share-based payments using market-based valuation techniques. The fair value of the share awards is determined at the date of grant using generally accepted valuation techniques or valuation based on the Company’s fundraising events. Assumptions are made and judgments are used in applying valuation techniques. Prior to the Company’s IPO completed in February 2021, these assumptions and judgments include estimating the fair value for the underlying Ordinary share on the warrant grant date, as well as the likelihood of liquidity events such as IPOs. Such judgments and assumptions are inherently uncertain. Changes in these assumptions affect the fair value estimates as well as the term applied to the expense recognition.

    Subsequent to the Company’s IPO completed in February 2021, determining the initial fair value and subsequent accounting for equity awards require significant judgment regarding expected life and volatility of an equity award; however, as a public listed company there is objective evidence of the fair value of an ordinary share on the date an equity award is granted. Refer to Note 8 for further detail surrounding share-based compensation.

    Leasehold Improvements and Loan from Lessor

    A significant judgment was made in respect of determining whether customization of leased premises forms part of the lease or is a leasehold improvement funded by the lessor. See the section “Leasehold improvements and Loan from lessor” in Note 2.

    There have been no other changes to the application of critical accounting judgments, or estimation uncertainties regarding accounting estimates.We refer to note 2 for a summary of significant accounting policies for further discussion.

    XML 76 R10.htm IDEA: XBRL DOCUMENT v3.22.1
    Financial Instruments and Risk Management
    12 Months Ended
    Dec. 31, 2021
    Financial Instruments and Risk Management  
    Financial Instruments and Risk Management

    Note 5. Financial Instruments and Risk Management

    Financial risk management and risk management framework

    In terms of financial risks, the Company has exposure to liquidity risk and market risk comprising foreign exchange risk. This note presents information about the Company’s exposure to each of the above risks together with the Company’s objectives, policies and processes for measuring and managing risks. The Company’s Board of Directors monitors each of these risks on a regular basis and implements policies as and when they are required. Details of the current risk management policies are provided below.

    Liquidity risk

    The exposure to liquidity risk primarily relates to the risk of failure to meet the Company’s obligations when they become due, which could happen if current assets are not enough to cover the amount of short-term liabilities. The Company has been dependent on its shareholders to fund its operations. The Company’s ability to continue as a going concern is dependent on its ability to raise financing to enable it to complete its product development and clinical trials. Management has determined that there is not substantial doubt about the Company’s ability to continue as a going concern for one year from the latest balance sheet date.

    As of December 31, 2021 and December 31, 2020, our available liquidity, comprised of cash and cash equivalents, was $32.2 million and $5.8 million, respectively and our total equity was $32.4 million and $7.0 million, respectively.

    On February 5, 2021, the Company completed our initial public offering through which we issued and sold 3,000,000 ADSs, each of which represents one ordinary share, at a price to the public of $10.00 per ADS. We received aggregate net proceeds of $25.3 million from the initial public offering, after deducting the underwriting discounts and commissions and offering expenses payable by us. Upon the completion of the initial public offering, our registered, issued, and outstanding share capital was nominal DKK 19,198,668 divided into 19,198,668 ordinary shares of DKK 1 each.

    On November 9, 2021, we completed a follow-on public offering through which we issued and sold 3,942,856 ADSs, each of which represents one ordinary share, at a price to the public of $7.00 per ADS. The shares issued were inclusive of the 514,285 ADSs issued to the underwriters pursuant to the full exercise of their option to purchase additional shares on November 5, 2021. We received aggregate net proceeds of $24.9 million from the follow-on public offering, which includes the funds received for the additional shares issued to the underwriters, after deducting the underwriting discounts and commissions and offering expenses payable by us. Upon the completion of the follow-on public offering, the Company’s registered, issued, and outstanding share capital was nominal DKK 23,141,524.

    At year end, due to warrant exercise, the outstanding share capital was nominal DKK 23,203,808.

    We expect that the net proceeds from our initial public offering, our cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements through at least 12 months subsequent to the issuance of this annual report.

    The Company’s approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to their reputation.

    The following are the contractual undiscounted outflows associated with the Company’s financial liabilities in the current and prior year:

        

    December 31, 2021

    (USD in thousands)

    Carrying

    Contractual 

     amount

    cash flows

    <1 year

    1 – 5 years

    >5 years

    Total

    Loan from lessor (1)

    $

    1,170

    $

    1,458

    $

    192

    $

    769

    $

    497

    $

    1,458

    Lease liabilities

     

    2,520

     

    3,698

     

    326

     

    1,223

     

    2,149

     

    3,698

    Trade payables

    2,848

     

    2,848

     

    2,848

     

     

     

    2,848

    Provisions

    153

    153

    153

    153

    Other payables

     

    46

    46

    46

    46

    Total

    $

    6,737

    $

    8,203

    $

    3,412

    $

    1,992

    $

    2,799

    $

    8,203

    (1)The loan amount as of December 31, 2021 is still subject to possible minor adjustment. Further information is provided in Note 17.

        

    December 31, 2020

    (USD in thousands)

    Carrying

    Contractual 

     amount

    cash flows

    <1 year

    1 – 5 years

    >5 years

    Total

    Lease liabilities

    $

    20

    $

    20

    $

    20

    $

    $

    $

    20

    Trade payables

    3,673

    3,673

    3,673

    3,673

    Other payables

     

    180

     

    180

     

    180

     

     

     

    180

    Total

    $

    3,873

    $

    3,873

    $

    3,873

    $

    $

    $

    3,873

    The financial liabilities include estimated or contractual interest rate payments.

    Market risk

    Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. The type of market risk that impacts the Company is currency risk. The Company does not currently have any loans or holdings that have variable interest rate. Accordingly, the Company is not exposed to material interest rate risk.

    Foreign currency risk

    Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The primary exposure derives from the Company’s operating expenses paid in foreign currencies, mainly USD and Australian dollars. This exposure is known as transaction exposure. Any reasonable or likely movements in foreign exchange rates would not have a material impact on the Company’s operating results. The Company’s policy for managing foreign currency risks is to convert cash received from financing activities to currencies consistent with the Company’s expected cash outflows.

    Credit risk

    Credit risk is the risk that a counterparty will not meet its obligations under a financial instrument, leading to a financial loss for the Company. The Company’s exposure to credit risk is limited to deposits with banks with high credit ratings. Accordingly, the Company does not have material credit risk and no provision for credit risk is recognized.

    Capital management

    The Company’s objectives when managing capital are to safeguard the Company’s ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders and to maintain an optimal capital structure to reduce the cost of capital.

    The Company raises capital from the issue of equity, grants or convertible loan notes. On a regular basis, management receives financial and operational performance reports that enable management to assess the adequacy of resources on hand and the Company’s liquidity position to determine future financing needs.

    Fair values

    Financial instruments measured at fair value in the statements of financial position are grouped into three levels of fair value hierarchy. This grouping is determined based on the lowest level of significant inputs used in fair value measurement, as follows:

    1.Level I – quoted prices in active markets for identical assets or liabilities.
    2.Level II – inputs other than quoted prices included within Level I that are observable for the instrument, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
    3.Level III – inputs for instrument that are not based on observable market data (unobservable inputs).

    There were no financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of December 31, 2021 and 2020.

    Convertible debt instruments

    The Company’s convertible debt instruments are Level III financial instruments and are carried at fair value through profit and loss. The convertible debt instruments were valued based on the present value of a probability weighting of the mutually exclusive settlement alternatives. Key inputs for this valuation were: (i) the exchange rate between USD and DKK, (ii) the discount rate on the issuance, (iii) the probability of a qualifying financing event and (iv) the Company’s share price. The most significant assumptions used in the valuation were the: Company’s share price, the probability of a qualifying financing event, the discount rate and the USD to DKK exchange rate. An increase or decrease in the key input ranging from 10 percent, depending on the input analyzed, would not result in a material change in the fair value of the convertible debt instruments. There were no transfers into or out of any classification of financial instruments in any period

    See Note 20 for the change in fair value of convertible debt during the year ended December 31, 2019.

    XML 77 R11.htm IDEA: XBRL DOCUMENT v3.22.1
    Operating Activities
    12 Months Ended
    Dec. 31, 2021
    Operating Activities  
    Operating Activities

    Note 6. Operating Activities

    Research and Development Expenses

        

    Years Ended December 31, 

        

    2021

        

    2020

        

    2019

    (USD in thousands)

    Employee salary and benefit expenses, excluding share-based compensation

    $

    (6,794)

    $

    (3,337)

    $

    (2,586)

    Share-based compensation expenses

     

    (1,051)

    (1,496)

    (1,021)

    Depreciation

     

    (273)

    (92)

    (65)

    External expenses

     

    (11,465)

    (5,977)

    (4,544)

    Total research and development expenses

    $

    (19,583)

    $

    (10,902)

    $

    (8,216)

    During the years ended December 31, 2021, 2020 and 2019, the Company recognized $0.3 million, $0.8 million and $0.5 million, respectively, related to government grants as a reduction of research and development expenses.

    General and Administrative Expenses

        

    Years Ended December 31, 

        

    2021

        

    2020

        

    2019

    (USD in thousands)

    Employee salary and benefit expenses, excluding share-based compensation

    $

    (1,824)

    $

    (1,098)

    $

    (517)

    Share-based compensation expenses

    (328)

    (1,912)

    (1,341)

    Professional and other fees

    (4,028)

    (2,644)

    (773)

    Depreciation

    (71)

    (12)

    (16)

    Total general and administrative expenses

    $

    (6,251)

    $

    (5,666)

    $

    (2,647)

    XML 78 R12.htm IDEA: XBRL DOCUMENT v3.22.1
    Employees and Employee-Related Costs
    12 Months Ended
    Dec. 31, 2021
    Employees and Employee-Related Costs  
    Employees and Employee-Related Costs

    Note 7. Employees and Employee-Related Costs

    The number of employees, including executive and non-executive directors, during the year was as follows:

        

    Years Ended December 31, 

        

    2021

        

    2020

        

    2019

    Average number of full-time employees

     

    53

    33

    25

    Number of employees at end of period:

     

      

    Denmark and United States

     

    61

    35

    31

    Total employees, at end of period

     

    61

    35

    31

    Employee Costs:

        

    Years Ended December 31, 

        

    2021

        

    2020

        

    2019

    (USD in thousands)

    Wages and salaries

    $

    6,909

    $

    4,016

    $

    2,819

    Cash bonus

    668

    Share-based compensation expenses

    1,379

    3,408

     

    2,362

    Defined contribution plans

    649

    206

     

    96

    Other social security expenses

    28

    17

     

    12

    Other staff expenses

    364

    196

     

    176

    Total

    $

    9,997

    $

    7,843

    $

    5,465

        

    Years Ended December 31,

        

    2021

        

    2020

        

    2019

    (USD in thousands)

    Total Employee costs classified as:

     

      

    Research and development expenses

    $

    7,845

    $

    4,833

    $

    3,607

    General and administrative expenses

    2,152

    3,010

     

    1,858

    Total

    $

    9,997

    $

    7,843

    $

    5,465

        

    Years Ended December 31, 

        

    2021

        

    2020

        

    2019

    (USD in thousands)

    Non-management employee benefit expenses classified as:

     

      

    Research and development expenses

    $

    6,414

    $

    4,009

    $

    2,590

    General and administrative expenses

    836

    611

     

    668

    Total

    $

    7,250

    $

    4,620

    $

    3,258

    Remuneration to the Board of Directors and Executive Management

        

    Year Ended December 31, 

    2021

    2020

    2019

    (USD in thousands)

    Remuneration to the Executive Management:

     

      

     

      

    Wages and salaries

    $

    1,833

    $

    1,298

    $

    900

    Share-based compensation expenses

    514

    1,566

     

    956

    Total

    2,347

    2,864

     

    1,856

    Remuneration to the Board of Directors:

     

      

    Wages and salaries

    313

    Share-based compensation expenses

    87

    359

     

    351

    Total

    400

    359

     

    351

    Remuneration to the Board of Directors and Executive Management classified as:

     

      

    Research and development expenses

    1,431

    824

     

    1,017

    General and administrative expenses

    1,316

    2,399

     

    1,190

    Total

    $

    2,747

    $

    3,223

    $

    2,207

    The Executive Management was comprised of four members in January 2019 and expanded again to five members in October 2019, of which one member resigned in 2020 and one other member resigned in 2021. It was expanded to 5 members again in 2021.

    XML 79 R13.htm IDEA: XBRL DOCUMENT v3.22.1
    Share-Based Payments
    12 Months Ended
    Dec. 31, 2021
    Share-Based Payments  
    Share-Based Payments

    Note 8. Share-Based Payments

    Warrant Program and Amendments

    The Company’s Articles of Association allow for the granting of equity compensation, in the form of equity settled warrants, to employees, consultants and Scientific Advisory Board members who provide services similar to employees, members of executive management, and the board of directors. The warrants granted in 2018 or before become exercisable upon an exit event, which triggers an immediate vesting, or at any time as determined by the board of directors in accordance with the terms of the plan. The warrants granted in 2021 vest gradually over 36 months after grant date or in the case of warrants to the Board of Directors vest immediately. The warrants granted in 2020 vest either gradually over 36 months or vest immediately. Vested warrants granted in 2020 are exercisable in certain exercise windows beginning in the second half of the year of 2021. Warrants granted up until 2019 expire on December 31, 2036. Warrants granted in 2021 and 2020 expire on December 31, 2032 and 2031, respectively. For the years ended December 31, 2021, 2020 and 2019, the number of warrants outstanding as a percentage of outstanding ordinary shares was 11.8%, 13.8% and 13.5%, respectively.

    In the second quarter of 2021, the Company granted 62,147 warrants to its Chief Medical Officer (“CMO”) which vest over 36 months.

    In 2019, the Company granted 150,660 warrants to its Chief Financial Officer (“CFO”) which were exercisable upon an exit event. In December 2020, the terms of the warrants issued to the Company’s CFO were amended to no longer comprise exercisability upon an exit event. Consequently, these warrants did not vest upon the IPO in February 2021 and will vest in accordance with the vesting schedule for warrants granted in 2020.

    On January 4, 2021, the Company’s board of directors and shareholders approved (i) a 2-for-1 stock split of its issued and outstanding ordinary shares and (ii) a bonus share issuance in the ratio of 17-for-1 of its issued and outstanding ordinary shares. The stock split also resulted in a reduction of the nominal value of the Company’s ordinary shares from DKK 2 to DKK 1. In accordance with the anti-dilution provisions of the warrant agreements, the number of warrants was increased by a ratio of 36 and the exercise price was decreased from DKK 2 to 1 DKK. Accordingly, information related to the Company’s warrants, have been retroactively adjusted to reflect the stock split and the bonus shares for all periods presented.

    The following schedule specifies the granted warrants:

    Weighted

    Weighted

     Average

     Average

    Remaining

    Number of

     Exercise

    Contractual

        

     warrants

        

    Price/Share

        

    Life (years)

    Warrants granted as at December 31, 2018

    1,674,324

    DKK 1

    18

    Warrants granted(1)

    257,832

    DKK 1

    17

    Warrants granted as at December 31, 2019

     

    1,932,156

     

    DKK 1

     

    17

    Warrants granted

    363,168

     

    DKK 1

     

    11

    Warrants forfeited

    (45,216)

    DKK 1

    16

    Warrants cancelled

    (22,032)

    DKK 1

    16

    Warrants granted as at December 31, 2020

    2,228,076

    DKK 1

    15

    Warrants granted during 2021(2)

    63,802

     

    DKK 1

     

    10

    Warrants granted December 2021

    523,599

    USD 5.38

    10

    Warrants exercised

    (62,284)

    (3)

    DKK 1

    Warrants forfeited

    (10,178)

    1

    Warrants cancelled

    (10,397)

    1

    Warrants granted as at December 31, 2021

    2,732,618

    DKK 7.53

    (4)

    13

    Warrants exercisable as at December 31, 2019

    Warrants exercisable as at December 31, 2020

    Warrants exercisable as at December 31, 2021

     

    2,072,122

     

     

    (1)The warrants are not incorporated in the articles of association. Rectification conducted in October 2020.

    (2)

    Of which 62,147 warrants were legally granted in June 2021 and the remaining 1,655 warrants were legally granted in December 2020.

    (3)

    The share price at the exercise date was USD 5.59.

    (4)

    December 31, 2021 USD-end rate used.

    During 2019 employees, external consultants, executive management and board members became contractually entitled to warrants that was rectified on December 17, 2020:

    In January 2019, 45,216 warrants granted to a member of executive management. They vest from December 2020 – December 2022. Fair value at grant date amounted to $0.3 million.
    In February 2019, 7,956 warrants granted to an employee. They vest from December 2020 – December 2022. Fair value at grant date amounted to $0.1 million.
    In September 2019, 54,000 warrants granted to an employee. The warrants vested immediately. Fair value at grant date amount to $0.5 million.
    In October 2019, 150,660 warrants granted to a member of executive management. The warrants vest annually over 3 years. Fair value at grant date amounted to $1.3 million.
    In December 2020, an aggregate of 126,972 warrants attributable to 2019 entitlements were granted to employees, members of our board of directors and consultants who provide similar services as employees. 63,612 warrants vested immediately and 63,360 warrants vest monthly over three years from January 2020 – December 2022. Fair value at grant date amounted to $1.2 million.
    In December 2020, an aggregate of 236,196 warrants attributable to 2020 entitlements were granted to employees, members of our board of directors and consultants who provide similar services as employees. Of the warrants granted, 120,888 warrants vested immediately and 115,308 warrants vest monthly over three years from January 2020 – December 2022. Fair value at grant date amounted to $2.3 million.
    In June 2021, 62,147 were granted to a member of Executive Management. Fair value at grant date amounted to $0.4 million.
    During 2021, an aggregate of 523,599 warrants attributable to 2021 entitlements were granted to employees, member of our board of directors and executive management. Of the warrants 22,916 were granted to our board of directors vested immediately. The warrants granted to employees and executive management vest over 36 months. Fair value at grant date amounted to $1.5 million.
    For the year ended December 31, 2019 the Company had 22,032 outstanding warrants to SDU employees and recognized an immaterial amount of expense for these warrants as research and development expenses in the statement of comprehensive loss. In September 2020, the Company terminated its existing agreement with SDU for business reasons. Under the terms of the SDU agreement, the Company did not incur a termination penalty and has no further obligations under this agreement.
    A member of the executive board terminated his employment contract as of April 30, 2020 and forfeited his right to 45,216 unvested warrants.
    A member of the executive board terminated his employment contract as of October, 2021 but no granted warrants remained unvested as of that date.

    Share-based compensation expenses included in the statements of comprehensive loss:

        

    Years Ended

    December 31, 

        

    2021

        

    2020

        

    2019

    (USD in thousands)

    Research and development expenses

    $

    1,051

    $

    1,496

    $

    1,021

    General and administrative expenses

    328

    1,912

     

    1,341

    Total

    $

    1,379

    $

    3,408

    $

    2,362

    In 2020 an amount of $0.1 million related to warrants issued as compensation for arranging investors to subscribe for shares has been recognized in equity as a share-based compensation expense related to the capital increase.

    Determination of Fair Value of Warrants

    The warrants issued under the share-based payment arrangement until December 2021 are exercisable for nominal consideration compared to the fair value of the shares resulting in virtually no time value. The Company values these warrants based on the intrinsic value of the shares measured as the difference between the fair value of the Company’s Ordinary shares and the warrant exercise price. Due to the highly specialized nature of services provided by consultants who provide services similar to those provided by employees of the Company, transactions with those consultants are measured at fair value of the equity instruments granted.

    Under the share-based payment arrangement, there is no protection against capital increases at a discount and dividend distribution. However, dividends are not likely to be distributed and there is generally no reason to raise new capital at below the current share price. On this basis, the Company has assessed that it is generally appropriate to assume that no such transactions will take place during the holding period. When issuing warrants in 2018, convertible bonds with a potential dilutive effect were outstanding, and fair value was adjusted to reflect this potential dilution.

    The stock split and bonus share issuance executed on January 4, 2021 resulted in a dilution of the warrant holders due to the increase of the exercise price compared to the pre stock split and bonus share issue. For warrants granted on December 17, 2020, the fair value was adjusted to reflect this dilution. For other grants, no such adjustment has been made.

    The fair values of the warrants are measured with reference to the share price of the underlying share. Up until December 2020, this share value was determined using the value established in different financing transactions with unrelated parties. In each of these transactions, the relative ownership of the Company was changed, and a share value was established using these fund-raising transactions. The fair values of warrants are estimated using a linear interpolation in USD of the share value on grant date based on the value established on capital event dates before and after the grant date.

    For warrants granted in December 2020, the Probability-Weighted Expected Return Method (“PWERM”) was applied, based on the weighted value of the share in a stay private scenario and an IPO scenario. 40% weight was put to the stay private scenario applying a share price equal to the share price of USD 8.89 at the November 2020 capital increase and 60% weight was put to the IPO scenario applying the mid-price of the indicative IPO price range of USD 11.00 available on the balance sheet. A 10% lack of marketability discount (DLOM) was applied to the IPO price.

    Warrants granted prior to December 2020 are exercisable only upon an exit event or upon the Board of Director’s decisions, which is a post vesting restriction. Since the warrants granted prior to 2020 do not expire until December 31, 2036, Management considers it highly unlikely that the warrants will not become exercisable and no downward adjustment to reflect the risk of the warrant not becoming exercisable is made to the fair value of the warrants.

    During 2020, the Company revised the estimated date of an IPO exit event to occur in February 2021. As of December 31, 2019, the estimated IPO exit event was December 2021. As a result of this change in estimate, the Company recognized an acceleration of expense of $0.8 million for the year ended December 31, 2020.

    Subsequent to the Company’s initial public offering completed in February 2021, determining the initial fair value and subsequent accounting for equity awards require significant judgment regarding expected life and volatility of an equity award; however, as a public listed company there is objective evidence of the fair value of an ordinary share on the date an equity award is granted. Due to the fact that as of 2021, warrants was granted at the share price on the date of grant, fair value comprises a time value which is significantly affected by the expected life and estimated volatility. The expected life of a warrant is based on the assumption that the holder will not exercise until after the equity award is fully vested. Actual exercise patterns may differ from the assumption used herein. The estimated volatility is based on peer group data and reflects the assumption that the historical volatility over a period similar to the life of the warrant is indicative of future trends, which may not necessarily be the actual outcome. The peer group consists of listed companies that management believes are similar to the Company in respect to industry and stage of development. Even with objective evidence of the fair value of an ordinary share, small changes in any other individual assumption or in combination with other assumptions could have resulted in significantly different valuations.

    The following assumptions have been applied for the warrants issued in December 2021:

    Expected term (in years)

        

    6.5

    Risk-free interest rate

     

    1.34

    Expected volatility

     

    85.0

    %

    Share price

    $

    4.20

    The exercise price of the warrants issued in June 2021 was DKK 1 and consequently, the warrants have virtually no time value. Therefore, fair value of the warrants has been determined as the intrinsic value based on a share price of $6.24.

    Amendments to Warrants

    As discussed above, the terms of the warrant granted to the company’s CFO were amended to no longer comprise an accelerated vesting upon an exit clause. This is considered a non-beneficial change, and consequently the accelerated vesting upon an exit event clause is deemed to continue to exist.

    For warrants to which the employees became entitled in 2019 but were not granted until December 2020, the Company recognized stock-based compensation expenses during the year ended December 31, 2019 and the interim period ended September 30, 2020, based on the terms expected to apply for these awards. Management expected the terms to be similar to the terms applicable to warrants granted up until 2018, including the accelerated vesting upon an exit clause. However, these warrants were granted subjected

    to a vesting schedule up to three years and did not allow for immediate vesting upon an exit event. Because the warrants were not granted until December 2020, the Company recognized the difference in expenses as a change in accounting estimate and not a modification of existing awards. As a result of this change in the accounting estimate, the share-based payment expense for 2020 was reduced by $0.4 million.

    The following schedule specifies the outstanding warrants as at December 31, 2021:

    Per

    warrant

    Average

    Remaining

    grant

    Number of

    exercise price

    term to

        

    date fair value

        

    warrants

        

    per warrant

        

    maturity

    Outstanding program

    (DKK)

    outstanding

    (DKK)

    (years)

    Grant (December 2016)

     

    20.91

     

    701,356

     

    1

     

    15

    Grant (September 2017)

     

    28.71

     

    617,184

     

    1

     

    15

    Grant (December 2017)

     

    28.71

     

    122,040

     

    1

     

    15

    Grant (during 2018)

     

    37.05

     

    174,564

     

    1

     

    15

    Grant (February 2019)

     

    42.57

     

    7,956

     

    1

     

    15

    Grant (September 2019)

     

    56.35

     

    54,000

     

    1

     

    15

    Grant (October 2019)

     

    56.97

     

    150,660

     

    1

     

    15

    Grant (December 2020)

     

    56.75

     

    317,457

     

    1

     

    9

    Grant (April 2021)

     

    45.31

     

    1,655

     

    1

     

    10

    Grant (June 2021)

     

    40.86

     

    62,147

     

    1

     

    10

    Grant (December 2021)

    19.22

    523,599

    USD 5.38

    10

    Granted at December 31, 2021

     

      

     

    2,732,618

     

      

     

      

    Warrants exercisable at December 31, 2021

     

    The following schedule specifies the outstanding warrants as at December 31, 2020:

    Per 

    warrant

    Average

    Remaining

    grant

    Number of

     exercise price

     term to 

    date fair value

     warrants 

    per warrant

    maturity

    Outstanding program

        

    (DKK)

        

    outstanding

        

    (DKK)

        

    (years)

    Grant (December 2016)

    20.91

    712,332

    1

    16

    Grant (April 2017)

    24.05

    13,896

    1

    16

    Grant (September 2017)

     

    28.71

     

    617,184

     

    1

     

    16

    Grant (December 2017)

     

    28.71

     

    127,044

     

    1

     

    16

    Grant (during 2018)

     

    37.05

     

    181,836

     

    1

     

    16

    Grant (February 2019)

     

    42.57

     

    7,956

     

    1

     

    16

    Grant (September 2019)

    56.35

    54,000

    1

    16

    Grant (October 2019)

    56.97

    150,660

    1

    16

    Grant (December 2020)

    56.75

    363,168

    1

    11

    Granted at December 31, 2020

    2,228,076

    1

    15

    Warrants exercisable at December 31, 2020

     

     

     

     

    The following schedule specifies the outstanding warrants as at December 31, 2019:

    Per 

    warrant

    Average

    Remaining

    grant

    Number of

     exercise price

     term to 

    date fair value

     warrants 

    per warrant

    maturity

    Outstanding program

        

    (DKK)

        

    outstanding

        

    (DKK)

        

    (years)

    Grant (December 2016)

    20.91

    712,332

    1

    17

    Grant (April 2017)

    24.05

    13,896

    1

    17

    Grant (September 2017)

    28.71

    617,184

    1

    17

    Grant (December 2017)

    28.71

    138,384

    1

    17

    Grant (during 2018)(1)**

    37.05

    192,528

    1

    17

    Grant (January 2019)(1)**

     

    37.05

     

    45,216

     

    1

     

    17

    Grant (February 2019)**

     

    42.57

     

    7,956

     

    1

     

    17

    Grant (September 2019)**

     

    56.35

     

    54,000

     

    1

     

    17

    Grant (October 2019)**

     

    56.97

     

    150,660

     

    1

     

    17

    Granted at December 31, 2019

     

     

    1,932,156

     

    1

     

    17

    Warrants exercisable at December 31, 2019

     

     

     

     

    (1)Awards valued on December 31, 2018 and January 1, 2019, respectively.

    **

    The warrants are not incorporated in the articles of association. Rectification was conducted in December 2020.

    The Board of Directors and Executive Management holding of share awards for the years ended December 31, 2019, 2020 and 2021 is shown below:

    Warrants held when

    Warrants held when

    becoming or leaving

    becoming or leaving

    December 31, 

    December 31, 

    as a member

    December 31, 

    as a member

    December 31, 

    Number of warrants held

        

    2018

        

    Granted

        

    2019

        

    of management

        

    Granted

        

    Forfeited

        

    2020

        

    of management

        

    Granted

        

    Exercised

        

    Forfeited

        

    2021

    Thomas William Wylonis(former)1

    342,612

    342,612

    (369,252)

    26,640

    369,252

    369,252

    Steven Projan

    23,436

    23,436

    18,612

    42,048

    4,583

    46,631

    Roberto Prego

     

    19,800

     

     

    19,800

     

     

    14,364

    34,164

    4,583

    38,747

    Joann Suzich(former)7

     

     

     

     

     

    10,260

    10,260

    10,260

    Marianne Søgaard2

    65,952

    28,368

    94,320

    9,167

    103,487

    Helen Boudreau (former)3

     

    5,436

    5,436

    (5,436)

    Kim Bjørnstrup (former)4

     

    (5,868)

    5,868

    Lars Holtug

    4,583

    4,583

    Board of Directors in total

     

    385,848

     

     

    385,848

     

    (309,168)

     

    109,548

    555,480

    22,916

    (5,436)

    572,960

    Lars Aage Staal Wegner

     

    844,416

     

     

    844,416

     

     

    7,668

    852,084

    64,167

    916,251

    Birgitte Rønø

    29,376

    45,000

    74,376

    Thomas Bogenrieder (former)5

     

    4,356

     

    45,216

     

    49,572

     

    (4,356)

     

    (45,216)

    4,356

    4,356

    Erik Heegaard

    97,564

    97,564

    Glenn S. Vraniak (former)6

     

    150,660

     

    150,660

     

     

    150,660

    150,660

    Executive Management in total

    848,772

     

    195,876

     

    1,044,648

     

    (4,356)

     

    7,668

    (45,216)

    1,007,100

    29,376

    206,731

    1,243,207

    (1)Board member until June 30, 2020, 252 warrants were granted for services provided after retirement from the Board of Director position.
    (2)As of November 25, 2020, 26,964 warrants were granted for services provided before taking on the Board of Directors position.
    (3)Board member from June 30, 2020 to May 25, 2021.
    (4)Board member from June 30, 2020 to November 4, 2020.
    (5)Part of Executive Management until March 31, 2020.
    (6)Mr. Vraniak resigned as the Chief Financial Officer of the Company effective November 1, 2021.
    (7)Board member until May 25, 2021.
    XML 80 R14.htm IDEA: XBRL DOCUMENT v3.22.1
    Financial Income and Expenses
    12 Months Ended
    Dec. 31, 2021
    Financial Income and Expenses  
    Financial Income and Expenses

    Note 9. Financial Income and Expenses

        

    Year Ended 

    December 31, 

        

    2021

        

    2020

        

    2019

    (USD in thousands)

    Financial income:

    Interest income, bank

    $

    $

    $

    8

    Interest income, other

     

    1

    Foreign exchange gains

    2,039

    216

     

    56

    Total financial income

    2,039

    216

     

    65

    Financial expenses:

    Interest expenses

    (5)

    (29)

     

    (36)

    Changes in fair value of convertible debt instruments

     

    (1,183)

    Interest expenses, lease liabilities

    (123)

     

    (3)

    Interest, loan from lessor

    (31)

    Foreign exchange losses

    (756)

    (194)

     

    Total financial expenses

    (915)

    (223)

     

    (1,222)

    Net financial items

    $

    1,124

    $

    (7)

    $

    (1,157)

    XML 81 R15.htm IDEA: XBRL DOCUMENT v3.22.1
    Income Taxes
    12 Months Ended
    Dec. 31, 2021
    Income Taxes  
    Income Taxes

    Note 10. Income Taxes

    (a)   Analysis of charge/(credit) for the year:

        

    Year Ended

    December 31, 

        

    2021

        

    2020

        

    2019

    (USD in thousands)

    Income tax expense/(benefit)

    $

    (178)

    $

    (1,557)

    $

    (825)

    Total income taxes for the year

    $

    (178)

    $

    (1,557)

    $

    (825)

    On December 31, 2021, the Company had tax loss carry-forwards in Denmark of $9.5 million (2020: $3.8 million in Denmark; 2019: $1.3 million in Denmark) for income tax purposes, all of which can be carried forward infinitely according to Danish Corporate Income Tax Act. As of December 31, 2021, the Company did not have any tax loss carry-forwards in any other tax jurisdictions.

    The benefit from income taxes for each year includes a tax credit for research and development expenditures at the applicable tax rate under the Danish Tax Assessment Act and Australian tax legislation, respectively.

    (b) Reconciliation of effective tax rate to Danish statutory tax rate

        

    Year Ended December 31, 

        

    2021

        

    2020

        

    2019

    Statutory corporate income tax rate in Denmark

     

    22

    %  

    22

    %  

    22

    %  

    Difference in corporate income tax rate in subsidiaries

    %

    Non-deductible income / (expenses)

     

    %  

    (1)

    %  

    (5)

    %  

    Non-taxable income / (expenses)

    %

    1

    %

    Additional tax deduction R&D expenses

    6

    %

    3

    %

    Tax credit research and development expenditures

     

    (4)

    %  

    9

    %  

    7

    %  

    Change in deferred tax asset not capitalized

     

    (23)

    %  

    (25)

    %  

    (17)

    %  

    Total effective tax rate

     

    1

    %  

    9

    %  

    7

    %  

    (c) Deferred tax in the statements of financial position

        

    Year Ended

    December 31, 

        

    2021

        

    2020

        

    2019

    (USD in thousands)

    Deferred Tax Positions:

     

    Warrants

    $

    2,118

    $

    4,289

    $

    3,034

    Loss carry forward

    9,530

    3,759

     

    1,270

    Research and development expenditures

    262

    Other items

    (98)

    (6)

    (34)

    Valuation allowance on deferred tax assets

    (11,550)

    (8,042)

     

    (4,270)

    Total capitalized

    $

    $

    262

    $

    Deferred tax attributable to research and development expenditures relates to development costs recognized as an expense in the consolidated financial statements in 2020 and are tax deductible in 2021.

    Under Danish tax legislation, the value of warrants to employees is income tax exempt subject to meeting certain conditions. The value of income tax exempt warrants is not tax deductible for the issuer. There is currently uncertainty in respect of the extent to which the conditions for being tax exempt are met and consequently the extent to which a tax deduction will be available for the company. Consequently, the deferred tax asset disclosed above is subject to uncertainty and there is a risk that the amount disclosed above is not tax deductible in full.

    XML 82 R16.htm IDEA: XBRL DOCUMENT v3.22.1
    Basic and Diluted Loss Per Share
    12 Months Ended
    Dec. 31, 2021
    Basic and Diluted Loss Per Share  
    Basic and Diluted Loss Per Share

    Note 11. Basic and Diluted Loss Per Share

    Basic loss per share is calculated by dividing the net loss attributable for the year to shareholders of Evaxion Biotech A/S by the weighted average number of ordinary shares outstanding during the year. As net losses from continuing operations were recorded in the years 2021, 2020 and 2019, the dilutive potential shares are anti-dilutive for the earnings per share calculation.

        

    Year Ended December 31, 

        

    2021

        

    2020

        

    2019

    (USD in thousands, except share amounts and per share amounts)

    Loss per share before and after dilution

     

      

     

      

    Net loss attributable to shareholders of Evaxion Biotech A/S

    $

    (24,532)

    $

    (15,018)

    $

    (11,195)

    Weighted-average number of ordinary shares outstanding

    19,493,143

    15,434,758

     

    13,892,314

    Loss per share before and after dilution

    $

    (1.26)

    $

    (0.97)

    $

    (0.81)

    The following potential shares are anti-dilutive and are therefore excluded from the weighted average number of shares for the purpose of diluted loss per share:

        

    December 31, 

        

    2021

        

    2020

        

    2019

    Warrants

     

    2,732,618

    2,228,076

    2,059,128

    XML 83 R17.htm IDEA: XBRL DOCUMENT v3.22.1
    Intangible assets
    12 Months Ended
    Dec. 31, 2021
    Intangible assets  
    Intangible assets

    Note 12. Intangible Assets

    In June 2020, the Company entered into a license agreement for the rights to certain intellectual properties. Upon execution of the license agreement, the Company was obligated to make a milestone payment of $35,000. The agreement remains in effect until the Company completes a Phase I/IIa clinical study, after that the Company has an option to extend the agreement for an additional 10-year term. Over the initial term of the agreement, the Company is obligated to make various additional milestone payments based on the progress of developed drug candidates. The Company determined that the milestone payments meet the definition of intangible assets and will be capitalized.

    During the twelve months ended December 31, 2020, the Company capitalized $35,000 as intangible assets for the acquisition of a non-exclusive technology license. Subject to meeting certain development milestones, additional consideration of up to $320,000 is to be transferred to the seller. Further, $250,000 is to be transferred to the seller upon each regulatory approval of an Evaxion product utilizing the in-licensed technology. As of December 31, 2020, the Company accrued for an additional $60,000 related to the license. The Company did not recognize any amortization expense for the years ended December 31, 2021 and 2020 as the asset has not been put in use. No intangible assets were recognized in earlier periods as the Company’s expenditures did not qualify for capitalization.

    During the twelve months ended December 31, 2020, the Company capitalized $60,000 as intangible assets for the acquisition of a non-exclusive technology license from SSI. Subject to successful commercialization of any Evaxion product utilizing the in-licensed technology, Evaxion is required to pay to the seller a royalty on net sales in the low teens. In the event any Evaxion product utilizing the in-licensed technology are commercialized by one of the Company’s partners, Evaxion is required to pay to the seller a percentage of any out-licensing revenue earned by the Company or its affiliates. If Evaxion enters into a sublicense agreement with a partner subsequent to the initiation of a Phase 2b clinical trial, Evaxion is required to pay to the seller a percentage of any sublicensing income in an amount in the lower double-digit range. If Evaxion enters into a sublicense agreement with a partner subsequent to the initiation of a Phase 3 trial, Evaxion is required to pay to the seller a percentage of any sublicensing income in the lower double-digit range. If Evaxion enters into a sublicense agreement with a partner without initiating a Phase 2b trial, Evaxion is required to pay to SSI a percentage of any sublicensing income in the mid double-digit range.

    The Company did not recognize any amortization expense for the years ended December 31, 2021, and 2020 as the asset has not been put in use.

        

    Intangible

        

        

    Assets

    Total

    (USD in thousands)

    Cost at December 31, 2020

    $

    100

    $

    100

    Additions during the year

     

     

    Exchange rate adjustments

     

    (7)

     

    (7)

    Cost at December 31, 2021

     

    93

     

    93

    Amortization at December 31, 2020

     

     

    Amortization for the year

     

     

    Exchange rate adjustment

     

     

    Amortization at December 31, 2021

     

     

    Carrying amount at December 31, 2021

    $

    93

    $

    93

    Intangible 

     

        

    Assets

        

    Total

    (USD in thousands)

    Cost at December 31, 2019

     

    $

     

    $

    Additions during the year

    95

    95

    Exchange rate adjustments

    5

    5

    Cost at December 31, 2020

    100

    100

    Amortization at December 31, 2019

    Amortization for the year

    Exchange rate adjustment

    Amortization at December 31, 2020

    Carrying amount at December 31, 2020

     

    $

    100

     

    $

    100

    XML 84 R18.htm IDEA: XBRL DOCUMENT v3.22.1
    Property, Plant and Equipment
    12 Months Ended
    Dec. 31, 2021
    Property, Plant and Equipment  
    Property, Plant and Equipment

    Note 13. Property and Equipment, Net

        

        

    Other

    Leasehold

    Property

        

    Equipment

        

    Improvements

        

    Total

    (USD in thousands)

    Cost at December 31, 2020

    $

    257

    $

    263

    $

    $

    520

    Additions during the year

     

    2,891

     

    1,025

     

    1,634

     

    5,550

    Disposals during the year

    (244)

    (244)

    Exchange rate adjustments

     

    (148)

     

    (63)

     

    (67)

     

    (278)

    Cost at December 31, 2021

     

    2,756

     

    1,225

     

    1,567

     

    5,548

    Depreciation at December 31, 2020

    $

    (237)

    $

    (62)

    $

    $

    (299)

    Depreciation for the year

     

    (179)

     

    (105)

     

    (59)

     

    (343)

    Depreciation reversed on disposals during the year

    244

    244

    Exchange rate adjustment

     

    17

     

    6

     

    1

     

    24

    Depreciation at December 31, 2021

     

    (155)

     

    (161)

     

    (58)

     

    (374)

    Carrying amount at December 31, 2021

    $

    2,601

    $

    1,064

    $

    1,509

    $

    5,174

    Carrying amount of right-of-use assets at December 31, 2021

    $

    2,601

    $

    $

    $

    2,601

    Other 

        

    Property

        

    Equipment

        

    Total

    (USD in thousands)

    Cost at December 31, 2019

    $

    179

    $

    93

    $

    272

    Additions during the year

     

    55

     

    149

     

    204

    Exchange rate adjustments

     

    23

     

    21

     

    44

    Cost at December 31, 2020

     

    257

     

    263

     

    520

    Depreciation at December 31, 2019

     

    (144)

     

    (27)

     

    (171)

    Depreciation for the year

     

    (71)

     

    (34)

     

    (105)

    Exchange rate adjustment

     

    (22)

     

    (1)

     

    (23)

    Depreciation at December 31, 2020

     

    (237)

     

    (62)

     

    (299)

    Carrying amount at December 31, 2020

    $

    20

    $

    201

    $

    221

    Carrying amount of right-of-use assets at December 31, 2020

    $

    20

    $

    $

    20

    Depreciation included in the statement of comprehensive loss:

        

    Year Ended

    December 31, 

        

    2021

        

    2020

        

    2019

    (USD in thousands)

    Research and development

    $

    270

    $

    90

    $

    64

    General and administrative

    73

    15

     

    16

    Total depreciation included in the statement of comprehensive loss

    $

    343

    $

    105

    $

    80

    Total accumulated depreciation of right-of-use assets at December 31, 

    $

    557

    $

    236

    $

    145

    XML 85 R19.htm IDEA: XBRL DOCUMENT v3.22.1
    Prepayments and other receivables
    12 Months Ended
    Dec. 31, 2021
    Prepayments and other receivables  
    Prepayments and other receivables

    Note 14. Prepayments and other receivables

        

    December 31, 

        

    2021

        

    2020

    (USD in thousands)

    VAT receivables

    $

    387

    $

    376

    Prepayments

     

    638

     

    1,175

    Other receivables

     

    113

     

    2

    Total prepayments and other receivables

    $

    1,138

    $

    1,553

    XML 86 R20.htm IDEA: XBRL DOCUMENT v3.22.1
    Other Payables
    12 Months Ended
    Dec. 31, 2021
    Other Payables  
    Other Payables

    Note 15. Other Payables

        

    December 31, 

        

    2021

        

    2020

    (USD in thousands)

    Employee cost liabilities

    $

    989

    $

    1,054

    Other liabilities

     

    46

     

    180

    Total other payables

    $

    1,035

    $

    1,234

    XML 87 R21.htm IDEA: XBRL DOCUMENT v3.22.1
    Cash and Cash Equivalents
    12 Months Ended
    Dec. 31, 2021
    Cash and Cash Equivalents  
    Cash and Cash Equivalents

    Note 16. Cash and Cash Equivalents

        

    December 31, 

        

    2021

        

    2020

    (USD in thousands)

    Cash and cash equivalents

    $

    32,166

    $

    5,834

    Total cash and cash equivalents

    $

    32,166

    $

    5,834

    Cash and cash equivalents consist mainly of cash on deposit with banks.

    Changes in Net Working Capital

        

    December 31, 

        

    2021

        

    2020

        

    2019

    (USD in thousands)

    Changes in receivables and tax receivables

    $

    1,863

    $

    (2,501)

    $

    (337)

    Changes in trade payables

    (647)

    1,798

     

    507

    Changes in other payables

    21

    918

     

    403

    Changes in net working capital

    $

    1,237

    $

    215

    $

    573

    Working capital is defined as current assets (excluding cash) less current liabilities (excluding convertible debt) and measures the net liquid assets the Company has available for the business.

    Adjustments for non-cash items

    Adjustments of non-cash items in the statements of comprehensive loss:

        

    Year Ended

    December 31, 

        

    2021

        

    2020

        

    2019

    (USD in thousands)

    Income taxes

    $

    (178)

    $

    (1,557)

    $

    (825)

    Tax credit schemes accounted for as grants

    (12)

    (510)

    Depreciation

    344

    105

     

    81

    Interest income

     

    (9)

    Interest expense

    159

    30

     

    39

    Share-based compensation expenses

    1,379

    3,408

     

    2,362

    Acquisition of property, plant and equipment

    (90)

    Change in fair value of convertible debt instruments

     

    1,183

    Other adjustments: Other adjustments, primarily exchange rate adjustments

    (1,061)

    107

     

    114

    Total adjustments for non-cash items

    $

    541

    $

    1,583

    $

    2,945

    Reconciliation of Liabilities from Financing Activities

    December 31, 

    Accumulated

    Exchange rate

    December 31, 

    (USD in thousands)

        

    2020

        

    Cash flows

        

     interest

        

    Additions

        

     adjustment

        

    2021

    Lease liabilities

    $

    20

    $

    (226)

    $

    123

    $

    2,731

    $

    (128)

    $

    2,520

    Loan from lessor

    31

    1,269

    (130)

    1,170

    Provisions

    161

    (8)

    153

    Total liabilities from financing activities

    $

    20

    $

    (226)

    $

    154

    $

    4,161

    $

    (266)

    $

    3,843

    December 31, 

    Accumulated

    Exchange rate

    December 31, 

    (USD in thousands)

        

    2019

        

    Cash flows

        

     interest

        

    Additions

        

     adjustment

        

    2020

    Lease liabilities

    $

    36

    $

    (74)

    $

    1

    $

    54

    $

    3

    $

    20

    Total liabilities from financing activities

    $

    36

    $

    (74)

    $

    1

    $

    54

    $

    3

    $

    20

    XML 88 R22.htm IDEA: XBRL DOCUMENT v3.22.1
    Leases
    12 Months Ended
    Dec. 31, 2021
    Leases  
    Leases

    Note 17. Leases

    As a result of the lease accounting of IFRS 16, the Company has capitalized the only right-of-use asset being the domicile lease. Upon implementation on January 1, 2018, the Company has recognized a liability to make lease payments (i.e. the lease liabilities) of $0.2 million and an asset representing the right to use the underlying asset during the lease term (i.e. the right-to-use asset) of $0.2 million. The liability was measured at the present value of the remaining lease payments, discounted using the lessee’s incremental borrowing rate as of the standard adoption date of January 1, 2018. The Company applied an incremental borrowing rate of 3.8%. For the years ended December 31, 2019,2020 and 2021, the expense related to variable lease payments not included in the lease liabilities was immaterial and was recognized in operating expense.

    In October 2020, the Company entered into a lease for approximately 1,356 square meters, which is allocated on 839 square meters of office space, and 518 square meters of laboratory space in Hørsholm, Denmark. The commencement date for the lease of the 839 square meters of office space was February 1, 2021 and the lease continues for a term of 10 years from that date. The commencement date for the additional laboratory space was August 13, 2021 and the lease continues for a term of 10 years with a subsequent 12-month cancellation notice period. The lease agreement contains an early termination provision which would trigger a termination fee of $2.7 million. The initial monthly payment is expected to be between $28,000 and $30,000, which consists of $12,000 for the office space, and is expected to be between $16,000 and $18,000 for the laboratory space. Through-out the term, the lease is subject to annual increases ranging from two to four percent on the annual lease payment amount.

    The Company had one operating lease in Copenhagen, Denmark as of December 31, 2020.

    We also occupied an office space in New York, New York, United States. The terms of the lease agreement included a 13 month occupancy period from January 2, 2020 through January 31, 2021. A termination notice was provided in November 2020 and the lease and occupancy terminated on January 31, 2021.

    For the years ended December 31, 2021, 2020 and 2019, the expense related to variable lease payments not included in the lease liabilities was immaterial and was recognized in operating expense.

    Set out below are the carrying amounts of the Company’s right-of-use assets and lease liabilities and the movements during the period:

        

    Right-of-Use Asset

        

    Lease liabilities

    (USD in thousands)

    At December 31, 2020

    $

    20

    $

    20

    Additions

     

    2,891

     

    2,731

    Depreciation

     

    (179)

     

    Interest Expense

     

     

    123

    Payments

     

     

    (226)

    Translation

     

    (131)

     

    (128)

    At December 31, 2021

    $

    2,601

    $

    2,520

        

    Right-of-Use Asset

        

    Lease liabilities

    (USD in thousands)

    At December 31, 2019

    $

    35

    $

    36

    Additions

     

    54

    54

    Depreciation

     

    (73)

    Interest Expense

     

    Payments

     

    4

    (74)

    Translation

     

    4

    At December 31, 2020

     

    $

    20

    $

    20

    The total cash outflow for leases was $0.2 million in 2021, and $0.2 million in 2020.

    Loan from Lessor

    In addition to the ordinary lease payments, the Company obtained financing from DTU Science Park A/S (“DTU”) for rebuilding the laboratory facility and engineering building to match the Company’s needs. The Company will repay the $1.3 million financing at a fixed interest rate of 6% over 8 years. If the lease is terminated due to default by the Company before the outstanding balance, including interest accrued, has been repaid, the remaining balance is due immediately. The finance liability is recorded at costs, which approximates fair value at the time of issuance. As of December 31, 2021, the Company is still in discussions with DTU on the actual costs incurred.

    As a result of the finance structure this amount is not included as Purchase of property and equipment within the consolidated statements of cash flows. The leasehold improvements recognized will be subject for adjustment when the actual costs incurred are made available from DTU.

    The following table sets forth the finance liability (in thousands):

        

    December 31,

    2021

    Loan from lessor

    $

    1,170

    Total Loan from lessor

     

    1,170

    Less: Loan from lessor, current portion

     

    (126)

    Total Loan from lessor, net of current portion

    $

    1,044

    XML 89 R23.htm IDEA: XBRL DOCUMENT v3.22.1
    Debt
    12 Months Ended
    Dec. 31, 2021
    Debt  
    Debt

    Note 18. Debt

    In August 2020, we executed a loan agreement, or the EIB Loan Agreement, with the European Investment Bank, or EIB, for a principal amount of €20.0 million, divided into three tranches of €7.0 million, €6.0 million and €7.0 million on the EIB Loan. Under the EIB Loan Agreement, the EIB Loan tranche balances are due six years from their respective disbursement dates. For all tranches, EIB is entitled to an aggregate of 1,047,744 cash settled warrants with an exercise price of 1 DKK per warrant. The 351,036 warrants attributable to the first tranche of €7.0 million were incorporated in the articles of association on December 17, 2020. As of December

    31, 2021, the Company initiated the draw down of the first tranche of the EIB Loan Agreement amounting to €7.0 million. The Company received the first tranche of €7.0 million on February 17, 2022.

    XML 90 R24.htm IDEA: XBRL DOCUMENT v3.22.1
    Capital Structure and Financial Matters
    12 Months Ended
    Dec. 31, 2021
    Capital Structure and Financial Matters  
    Capital Structure and Financial Matters

    Note 19. Capital Structure and Financial Matters

    Share Capital – Ordinary Shares

    Loss of subscribed share capital

    On December 31, 2018, the Company had lost more than 50% of its subscribed share capital. At the annual general meeting of the shareholders held on March 29, 2019, the Board of Directors gave, in accordance with section 119 of the Danish Companies Act, an account of the Company’s financial position. As part of the account, the Board of Directors stated that in its view, special actions were not required. The share capital of the Company was subsequently re-established through the conversion of the convertible debt instruments and issue of new shares during 2019.

    Capital transactions

    In September 2020, the Company issued 745,380 shares of ordinary shares to existing investors in the Company. The purchase price was $8.89 per share for aggregate proceeds of $6.6 million. The Company incurred immaterial issuance costs. The proceeds were received by the Company on September 17, 2020. On August 10, 2020, the Company’s articles of association were amended in connection with the execution of this transaction. The revised articles increased the authorized number of shares the Company can issue by: (i) the 745,380 shares issued in this transaction, as well as (ii) an additional 1,800,000 shares of Common ordinary share at a nominal price of DKK 1, to be issued any time prior to June 1, 2025. The amended articles also allow the Company to issue an additional 1,298,196 of compensatory ordinary share warrants to employees and consultants any time prior to June 1, 2025.

    In October 2020, we successfully completed part 2 of our “bridging round” of capital with outside investors in the amount of $2.4 million with a purchase price of $8.89 per share from the issuance of 269,136 of our ordinary shares and received the proceeds in November 2020. Transaction costs directly attributable to the third quarter of 2020 “bridging round” of capital with outside investors have a total amount of $144,022.

    In February 2021, we completed our IPO through which we issued and sold 3,000,000 American Depositary Shares, or ADSs, each of which represents one ordinary share, at a price to the public of $10.00 per ADS. We received aggregate net proceeds of $25.3 million from the IPO, after deducting the underwriting discounts and commissions and offering expenses. Upon the completion of the IPO, our registered, issued, and outstanding share capital was nominal DKK 19,198,668.

    In November 2021, we completed a follow-on public offering through which we issued and sold 3,942,856 ADSs, each of which represents one ordinary share, at a price to the public of $7.00 per ADS. The shares issued were inclusive of the 514,285 ADSs issued to the underwriters pursuant to the full exercise of their option to purchase additional shares on November 5, 2021. The Company received aggregate net proceeds of $24.9 million from the follow-on public offering, which includes the funds received for the additional shares issued to the underwriters, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. Upon the completion of the follow-on public offering, the Company’s registered, issued, and outstanding share capital was nominal DKK 23,141,524.

    At year end, due to warrant exercise, the outstanding share capital was nominal DKK 23,203,808.

    The following are changes in the Company’s share capital for the years ended December 31, 2019, 2020 and 2021:

    Number of

    Share Capital

        

     Ordinary Shares

        

     (DKK in thousands)

    Share capital, December 31, 2018

    12,917,016

    12,917

    Capital increase at July 17, 2019 (issuance of shares for cash)

     

    997,668

     

    998

    Capital increase at July 17, 2019 (conversion of Convertible Debt 1)

     

    302,976

     

    303

    Capital increase at July 17, 2019 (conversion of Convertible Debt 2)

    848,232

    848

    Capital increase at December 19, 2019 (issuance of shares for cash)

    118,260

    118

    Share capital, December 31, 2019

     

    15,184,152

     

    15,184

    Capital increase at September 17, 2020 (issuance of shares for cash)

     

    745,380

     

    745

    Capital increase at October 15, 2020 (issuance of shares for cash)

    269,136

    269

    Share capital, December 31, 2020

    16,198,668

    16,198

    Capital increase at February 9, 2021 (for initial public offering)

    3,000,000

    3,000

    Capital increase at November 9, 2021 (for follow-on offering)

     

    3,942,856

     

    3,943

    Capital increase November 2021 (exercised warrants)

    62,284

    63

    Share capital, December 31, 2021

     

    23,203,808

     

    23,204

    The Company’s share capital consists of the following ordinary shares:

        

    December 31, 

        

    2021

    2020

    (USD in thousands)

    Authorized, issued and fully paid

    23,203,808 (2020: 16,198,668) ordinary shares of DKK 1 each (2020: ordinary shares of DKK 1 each)

    $

    3,755

    $

    2,648

    $

    3,755

    $

    2,648

    The Company’s ordinary shares shall confer on the holders thereof the right to receive notice of, attend and vote at general meetings of the Company.

    Executive Management’s and Board of Director’s holding of shares

    At December 31, the board of directors and executive management held the following shareholdings in the Company:

    Number of ordinary shares owned

        

    2021

        

    2020

        

    2019

    Niels Iversen Møller

    4,292,604

    4,292,604

    4,292,604

    Andreas Holm Mattsson

     

    4,163,832

    4,163,832

    4,163,832

    Lars Aage Staal Wegner

     

    182,124

    182,124

    182,124

    Executive Management in total

     

    8,638,560

    8,638,560

    8,638,560

    Number of ordinary shares owned

        

    2021

        

    2020

        

    2019

    Roberto Prego

     

    310,248

    310,248

    310,248

    Thomas William Wylonis (former)

     

    485,676

    481,860

    Marianne Søgaard

    41,652

    41,652

    Steven Projan

     

    27,288

    27,288

    11,736

    Board of Directors in total

     

    379,188

    864,864

    803,844

    XML 91 R25.htm IDEA: XBRL DOCUMENT v3.22.1
    Convertible Debt Instruments
    12 Months Ended
    Dec. 31, 2021
    Debt  
    Convertible Debt Instruments

    Note 20. Convertible Debt Instruments

    During 2018, the Company issued two types of convertible debt instruments, (“Convertible Debt 1”) and one (“Convertible Debt 2”) for total proceeds of $8.0 million, of which $0.1 million was received from related parties, including members of the Board of Directors and Executive Management. The Company originally recorded both debt instruments at fair value as a financial liability and

    subsequently remeasured the instruments with the change being presented on the statement of comprehensive income for the reporting period. In July 2019, both instruments were converted into ordinary shares as a result of a qualified capital increase triggering a conversion based on the terms of the agreements.

    The following table summarizes the changes in the convertible debt instruments during the year ended December 31, 2019:

        

     Convertible loans

    (USD in thousands)

    Carrying amount at December 31, 2018

    $

    8,569

    Amount received in 2019

     

    152

    Fair value adjustment included in finance expenses

     

    1,183

    Currency adjustment

     

    (209)

    Converted to equity during 2019

     

    (9,695)

    Carrying amount at December 31, 2019

    $

    The main terms of Convertible Debt 1 were:

    Term: 12 months from issuance;
    Interest coupon 7.5 percent p.a. accruing over the term of the loan;
    Loan currencies: $0.9 million is USD denominated and $1.0 million is denominated in DKK (DKK 7.1 million);
    Lender conversion option if a capital increase in excess of DKK 9.8 million (or a qualified capital increase event) takes place before maturity. The conversion price is the share price obtained at the qualified capital increase event less a 20 percent discount;
    Repayment in cash of principal + accrued interest at a premium of 50 percent if all shares of the Company are sold; and
    Lender conversion option to a fixed number of shares if the loan has not been repaid or converted under the other settlement terms of the agreement.

    The main terms of Convertible Debt 2 were:

    Term: Expires on December 31, 2020;
    Interest coupon 7.5 percent p.a. accruing over the term of the loan;
    Loan currencies: $5.4 million is USD denominated and $0.7 million is denominated in DKK (DKK 5.0 million);
    Mandatory conversion if a capital increase in excess of $10.0 million (qualified capital increase) takes place before maturity. The conversion price is the share price obtained less a 5 percent discount if the capital increase take place in 2018, 10 percent if it takes place in 2019 and 20 percent if it takes place in 2020;
    Repayment in cash of principal + accrued interest at a premium of 50% if all shares of the Company are sold; and
    Mandatory conversion at maturity with a conversion price of $160.41. 10 days before conversion, USD denominated loans will convert into DKK whereas the conversion price remains denominated in USD.

    Convertible debt instruments were classified as financial liabilities until such time that the Company had an unconditional right to avoid settlement in cash and had no obligation to settle in a variable number of shares.

    For Convertible Debt 1, the Company did not have an unconditional right to avoid settlement in cash. In addition, Convertible Debt 2 comprised an obligation to settle in a variable number of shares at maturity. Therefore, both convertible debt instruments comprised a debt host instrument.

    Conversion features comprising a fixed number of the entity’s shares in exchange for a fixed principal in the entity’s functional currency were equity instruments and separated from the debt host contract as the residual between fair value of the contract and fair value of a similar debt instrument without the conversion feature. All other equity conversion features were embedded derivatives.

    Both convertible debt instruments included a conversion feature resulting in settlement in a variable number of shares. Consequently, none of the instruments comprised an equity component. They included the following non-closely related embedded derivatives:

    At maturity conversion options for Convertible Debt Instrument 1;
    At maturity conversion provisions for Convertible Debt Instrument 2;
    Early settlement mechanism on both issuances through delivery of a variable number of shares at a discounted price; and
    Change of control prepayment provision.
    XML 92 R26.htm IDEA: XBRL DOCUMENT v3.22.1
    Related Party Transactions
    12 Months Ended
    Dec. 31, 2021
    Related Party Transactions  
    Related Party Transactions

    Note 21. Related Party Transactions

        

    December 31, 

        

    2021

        

    2020

        

    2019

    (USD in thousands)

    The Company’s transactions with other related parties:

     

      

     

      

    Transactions with related parties (expenses):

     

      

     

      

    Accrued interest on convertible debt instruments issued to members of executive management and board of directors

    $

    $

    $

    (4)

    Balances with related parties at year-end (asset):

    Prepaid rent and deposit for a leased property from a related party

    $

    $

    7

    $

    Balances with related parties at year-end (liabilities):

     

      

    Convertible debt instruments issued to members of executive management and board of directors (nominal value plus accrued interest of 7.5%)

    $

    $

    $

    The Company’s related parties are comprised of significant shareholders of the Company, the executive management group, the board of directors and the close members of the family of these persons.

    The Company has not granted any loans, guarantees, or other commitments to or on behalf of any of the members in the board of directors or executive management. Other than the remuneration and other transactions relating to the board of directors or executive management and capital increases on the same terms as other investors, no other significant transactions have taken place with the board of directors or executive management for the years ended December 31, 2021, 2020 and 2019.

    XML 93 R27.htm IDEA: XBRL DOCUMENT v3.22.1
    Contractual Obligations
    12 Months Ended
    Dec. 31, 2021
    Contractual Obligations  
    Contractual Obligations

    Note 22. Contractual Obligations

    Litigations and investigations

    The Company is not involved in any pending litigations, claims and investigations that individually and in the aggregate that is expected to have a material impact on the financial position, operating profit or cash flow.

    The contractual obligations are similarly individually and, in the aggregate, not material to the future financial position, operating profit or cash flow.

    Contractual obligations

    At December 31, 2021, the Company had the following contractual commitments which fall due as follows:

        

    December 31, 2021

    (USD in thousands)

    Contractual

    cash flows

    <1 year

    1 – 2 years

    2 – 5 years

    >5 years

    Total

    Purchase obligations

    $

    72

    $

    72

    $

    $

    $

    $

    72

    Total

    $

    72

    $

    72

    $

    $

    $

    $

    72

    The Company has purchase obligations of $72 thousand due to CRO’s and a nominal amount due system provider as of December 31, 2021.

    At December 31, 2020, the Company had the following contractual commitments which fall due as follows:

        

    December 31, 2020

    (USD in thousands)

    Contractual

        

     cash flows

        

    <1 year

        

    1 – 2 years

        

    2 – 5 years

        

    >5 years

        

    Total

    Purchase obligations

    $

    712

    $

    712

    $

    $

    $

    $

    712

    Total

    $

    712

    $

    712

    $

    $

    $

    $

    712

    The Company has purchase obligations of $0.6 million due to CRO’s and $0.1 million due to university future partners as of December 31, 2020.

    XML 94 R28.htm IDEA: XBRL DOCUMENT v3.22.1
    Provisions
    12 Months Ended
    Dec. 31, 2021
    Provisions  
    Provisions

    Note 23. Provisions

    The Company is required to restore the lease premises of its office and laboratory space in Hørsholm, Denmark to its original condition at the end of the lease term. A provision is recognized for the present value using a discount rate based on the Company’s risk adjusted incremental borrowing rate of the estimated expenditure required to remove any leasehold improvements. These costs have been capitalized as part of the cost of leasehold improvements and are amortized over the lease term.

    Changes in the provision balance during the year ended December 31, 2021 are as follows:

        

    Provisions

    (USD in

    thousands)

    Carrying amount at January 1, 2021

    $

    Provision recognized

     

    161

    Additions

     

    Utilization of provision

     

    Change in the provision

     

    Currency adjustment

     

    (8)

    Carrying amount at December 31, 2021

    $

    153

    XML 95 R29.htm IDEA: XBRL DOCUMENT v3.22.1
    Fees to auditors
    12 Months Ended
    Dec. 31, 2021
    Fees to auditors  
    Fees to auditors

    Note 24. Fees to auditors

    The following table presents the fees to our independent registered public accounting firm, EY Godkendt Revisionspartnerselskab, recognized in general and administrative expenses in the Statement of Profit or Loss for the years ended December 31, 2021 and 2020. This note was prepared in accordance with the requirements of the Danish Financial Statements Act:

    December 31, 

    2021

    2020

     

    (USD in thousands)

    Audit fees

        

    $

    177

        

    $

    308

    Audit related fees

     

    108

     

    119

    Other fees

     

    328

     

    253

    Total fees

    $

    613

    $

    680

    Audit fees

    Audit fees consist of fees billed for professional services rendered by EY for the audit of our annual consolidated financial statements or services that are normally provided by the accountant in connection with statutory and regulatory filings or engagements for those fiscal years.

    Audit-Related fees

    Audit-related fees consist of assurance and related services performed by EY that are reasonably related to the performance of the audit or review of our consolidated financial statements and are not reported under “Audit-Related fees.”

    Other fees

    Other fees consist of services provided by EY for other permitted services, including fees for work performed by EY in connection with the initial public offering.

    XML 96 R30.htm IDEA: XBRL DOCUMENT v3.22.1
    Events After the Reporting Period
    12 Months Ended
    Dec. 31, 2021
    Events After the Reporting Period  
    Events After the Reporting Period

    Note 25. Events After the Reporting Period

    EIB Loan Drawdown

    As of December 31, 2021, the Company initiated the draw down of the first tranche of the EIB Loan Agreement amounting to €7.0 million. The Company received the first tranche of €7.0 million on February 17, 2022.

    Executive Management Agreements

    The Company entered into agreements to hire executives in its Chief Operating Officer and Chief Financial Officer roles subsequent to the date of this annual report. The Chief Operating Officer joined the Company on March 14, 2022 and the Chief Financial Officer is expected to join the Company in August 2022.

    Russia’s Invasion of Ukraine

    On February 24, 2022, Russia invaded Ukraine creating a global conflict. The resulting conflict and retaliatory measures by the global community have created global security concerns, including the possibility of expanded regional or global conflict, which have had, and are likely to continue to have, short-term and more likely longer-term adverse impacts on Ukraine and Europe and around the globe. Potential ramifications include disruption of the supply chain including research activities and complications with the conduct of ongoing and future clinical trials of our product candidates, including patient enrollment. The Company relies on global networks of contract research organizations and clinical trial sites to enroll patients, Delays in research activities or in the conduct of our clinical trials could increase associated costs and, depending upon the duration of any delays, require us to find alternative suppliers at additional expense. In addition, the conflict between Russia and the Ukraine has had significant ramifications on global financial markets, which may adversely impact our ability to raise capital on favorable terms or at all.

    XML 97 R31.htm IDEA: XBRL DOCUMENT v3.22.1
    Summary of Significant Accounting Policies (Policies)
    12 Months Ended
    Dec. 31, 2021
    Summary of Significant Accounting Policies  
    Basis of preparation

    Basis of preparation

    The financial statements have been prepared in accordance with IFRS as issued by the IASB. The Company adopted IFRS in 2019 and applied it from the beginning of the period preceding adoption, starting on January 1, 2018.

    Management has assessed the impact of new or amended and revised accounting standards and interpretations (IFRSs) issued by the IASB and IFRSs endorsed by the European Union effective on or after January 1, 2021. It is assessed that application of amendments effective from January 1, 2021 has not had a material impact on the consolidated financial statements for 2021. Furthermore, Management does not anticipate any significant impact on future periods from the adoption of these amendments.

    The financial statements are presented in the Company’s presentation currency, U.S. dollar (“USD”) which is not the functional currency of the parent company. The Group’s financial statements are presented in USD as the result of the Company’s publicly listing the ADSs in the United States. The company’s functional currency is DKK for Denmark, AUD for Australia, and USD for the United States. The financial statements have been prepared on a going concern basis using a historical cost basis. All financial assets and liabilities are measured at amortized cost unless otherwise stated.

    Reclassifications of prior period presentation

    Reclassifications of prior period presentation

    Certain items in prior year consolidated financial statements have been reclassified to conform to the current period’s presentation.

    Basis of consolidation

    Basis of consolidation

    The audited consolidated financial statements of the Company comprise the Statement of Financial Position as of December 31, 2021 and 2020, and the Statement of Comprehensive Loss for the twelve months ended December 31, 2021, 2020 and 2019. Subsidiaries are entities controlled by the Company. The Company controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and can affect those returns through its power over the entity. The financial statements of subsidiaries are included in the audited consolidated financial statements from the date that control commences until the date that control ceases. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Company. Control is reassessed whenever facts and circumstances indicate that there are changes of the control.

    All intra-Group assets and liabilities, equity, income, expenses, and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

    Retrospective effect of share split and bonus share issuance

    Retrospective effect of share split and bonus share issuance

    All share and per share data, including that related to warrants, in the consolidated financial statements give retroactive effect to a 2:1 share split and a bonus issue of shares in the ratio of 17:1 of the Company’s authorized, issued and outstanding ordinary shares, which was effective on January 4, 2021, with the corresponding impacts on both share capital and share premium also retroactively recognized.

    Currency translation of transactions and balances

    Currency translation of transactions and balances

    Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized as financial income or financial expenses in the statements of comprehensive loss. Non-monetary items in foreign currency which are measured at cost at the statements of financial position date are translated using the exchange rates at the date of the transaction.

    Translation of foreign operations

    Translation of foreign operations

    Assets and liabilities in the Company’s functional currency, DKK and AUD, for Denmark and Australia, respectively, are translated to the Company’s presentation currency at the exchange rate applicable on December 31 for the respective year. Income and expenses in the Company’s functional currency are translated to USD at the average exchange rate which corresponds to an approximation of the exchange rates prevailing on each individual transaction date. Translation differences arising in the translation to presentation currency are recognized in other comprehensive income.

    Research and development expenses

    Research and development expenses

    Research and development expenses are primarily internal and external costs incurred in the development of the Company’s product candidates, including personnel costs, share-based compensation, external research and development expenses, maintenance of the Company’s patents, overhead allocation and enhancements and maintenance of the Company’s technology platforms.

    The research activities are comprised of activities performed before filing an IND or equivalent and necessary pre-clinical activities for such product candidates. All research expenses are recognized in the period in which they are incurred and payments made prior to the receipt of goods or services to be used in research and development are deferred until the goods or services are received. The Company records accruals for estimated research and development costs, comprising payments for work performed by third-party contractors and others. Payments for these activities are based on the terms of the individual agreements, which may differ from the timing of the expense recognition of these costs, in which case, they are reflected in the financial statements as either prepaid- or accrued expenses.

    The development activities are comprised of the activities performed following the filing of an IND or equivalent clinical-enabling activities for such product candidates, including but not limited to, research and clinical development activities. In line with industry practice, internal and subcontracted development costs are expensed as incurred. Due to regulatory uncertainties and other uncertainties inherent in the development of new products, development expenses do not qualify for capitalization as intangible assets until marketing approval by a regulatory authority is obtained or considered highly probable. To date, the Company has not incurred any development costs which qualified for capitalization.

    Contract Research Organizations expenses and related prepayments and accruals

    Contract Research Organizations expenses and related prepayments and accruals

    Substantial portions of the Company’s clinical studies are performed by third-party laboratories, medical centers, contract research organizations and other vendors (collectively, the “CROs”). The CROs generally bill monthly or quarterly for services performed. For studies, the Company accrues expenses based upon estimated percentage of work completed.

    The Company’s estimates depend on the timeliness and accuracy of the data provided by the CROs regarding the status of each program and total program spending. The Company evaluates the estimates to determine if adjustments are necessary or appropriate based on information received.

    CROs invoice the Company upon the occurrence of predetermined contractual or activity-based milestones; however, the timing of these invoices and the Company’s related payments often do not correspond directly to the level of performance of contracted activities. To the extent payments are made by the Company in advance of the related activities performed by the CROs, they are included in prepayments to clinical research organizations and expensed when the activities performed by the CROs. To the extent the payments are made by the Company following the performance of the related activities, the expense is accrued for as a payable to clinical research organizations.

    Intellectual property

    Intellectual property

    The Company actively seeks to create, maintain and protect intellectual property and proprietary information and technology that is considered important to the Company’s business, which includes seeking and maintaining patents covering proprietary technology, product candidates, proprietary processes and any other inventions that are commercially and / or strategically important to the Company’s business development. These expenses are expensed as incurred and not capitalized as intangible assets until marketing approval by a regulatory authority is obtained or considered highly probable. The Company has not incurred any costs that qualify for capitalization.

    Income from government grants

    Income from government grants

    The Company receives grants for certain research and development activities. The grant income is recognized as a reduction of research and development expenses in the period in which the underlying expenditures were incurred and when there is reasonable assurance that the Company will comply with all conditions to receive the grant income. Government grants comprise direct grants and tax credits related to qualifying research and development costs in excess of the corporate tax rate. Tax credits in an amount up to the corporate tax rate are classified as income tax benefits.

    General and administrative expenses

    General and administrative expenses

    General and administrative expenses consist primarily of fees paid to external consultants and personnel costs, including share-based compensation for the Company’s executive, finance, corporate and business development functions. In addition, general and administrative expenses also include depreciation and other expenses for the Company’s corporate headquarters as well as other allocated overhead.

    Share-based payments

    Share-based payments

    The Company issues warrants as an incentive to employees and non-employees. The fair value of the warrants granted is recognized as an expense with a corresponding credit to accumulated deficit. The fair value is expensed over the requisite service period of the awards. The expense recognition is based on an estimate of the number of warrants expected to vest. The estimate is reassessed regularly, and on a cumulative basis, the expense is equal to the fair value of the number of warrants which actually vest.

    For employees and consultants providing services similar to employees of the Company, the fair value of the equity instruments is determined at the date of grant resulting in a fixed fair value at grant date that is not adjusted for future changes in the fair value of the equity awards that may occur over the service period. The grant date is defined as the date at which the parties agree to the contractual terms.

    For consultants providing other services that are not similar to employees of the Company, the transactions are measured at the fair value of the services received unless this is not reliably measurable. In such cases, the transactions are measured at fair value of the equity instruments granted at the dates when the services are provided.

    Modification of warrants which are beneficial are accounted for with their incremental value or over the shorter vesting period. Non-beneficial modifications such as an extension of the vesting period are not accounted for. Consequently, the original terms are deemed

    to continue to exist. The Company estimates the fair value of warrants using the underlying value of the Company's ordinary shares. Since the warrants granted before December 2020 are exercisable for nominal consideration, the warrants are valued using the fair value of the Company's ordinary shares on grant date less the exercise consideration. Warrants granted during 2021 are valued using a black-scholes share option pricing model. The assumptions used in calculating the fair value of share-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. The key assumption in this estimate is the fair value of the Company's ordinary share on the warrant grant date.

    Post-employment benefit costs

    Post-employment benefit costs

    The Company contributes to a defined contribution plan covering eligible employees. The contribution amount is based upon a fixed percentage of employee compensation and such contributions are expensed as incurred.

    Accounting for joint operations - Southern Denmark University

    Accounting for joint operations – Southern Denmark University

    The Company enters into agreements from time to time that may be subject to the requirements of IFRS 11, Joint Arrangements. The Company evaluates these agreements on execution and applies the requirements of the guidance. The collaboration agreement with Southern Denmark University (“SDU”) is considered a joint operation as defined in IFRS 11, with the principal place of business being Denmark. In September 2020, the Company terminated its existing agreement with SDU. For the years ended December 31, 2020, and 2019, the Company recorded $0.3 million and $0.3 million, respectively, in compensation cost for SDU employees which was reported in research and development costs in the statement of comprehensive loss.

    Accounting for joint operations - MSD International GmbH and MSD International Business GmbH

    The Company has entered into a collaboration agreement with MSD International GmbH and MSD International Business GmbH (jointly ‘MSD’). Under the arrangement, the Company will share its clinical trial in which the Company’s compound and MSD’s compound is dosed in combination.

    In determining the accounting treatment for these types of arrangements, the Company carefully evaluates the relationship between the two parties in order to determine whether the arrangement is, in substance, a collaboration arrangement between the two parties (to be accounted for in accordance with IFRS 11, Joint Arrangements), or rather, a vendor-customer contract (to be accounted for in accordance with IFRS 15, Revenue from Contracts with Customers).

    Management has determined that MSD does not meet the definition of a customer under IFRS 15. Consequently, the arrangement is classified as a collaboration arrangement and is accounted for as a joint operation in accordance with IFRS 11 resulting in the recognition of the Company’s own income and expense and assets and liabilities, respectively.

    Finance Income

    Finance Income

    Finance income is comprised primarily of foreign currency gains.

    Finance Expense

    Finance Expense

    Finance expense is comprised primarily of changes in fair value of the Company’s convertible debt instruments and interest on the Company’s lease liability.

    Income tax

    Income tax

    The income tax for the period comprises current and deferred tax, including prior-year adjustments and changes in provisions for uncertain tax positions. Tax is recognized in the statement of comprehensive loss, except to the extent that it relates to items recognized in equity.

    Research and development tax credits are available to the Group under the tax laws of Denmark and Australia respectively, based on qualifying research and development spend as defined under those tax laws. Tax credits not exceeding the corporate tax rate are recognized as an income tax benefit. Tax credits in excess of the corporate tax rate are classified as government grants.

    Accruals for uncertain tax positions and/or valuation of government grant receivables require management to make judgments of potential exposures. Accruals for uncertain tax positions and/or valuation of government grant receivables are measured using either the most likely amount or the expected value amount, depending on which method the entity expects to better predict the resolution of the uncertainty. Tax benefits are not recognized unless the tax positions will probably be accepted by the tax authorities. This is based upon management’s interpretation of applicable laws and regulations and the expectation of how the tax authority will resolve the matter. Once considered probable of not being accepted, management reviews each material tax benefit and reflects the effect of the uncertainty in determining the related taxable amounts.

    Deferred taxes

    Deferred taxes

    Deferred tax is measured according to the liability method on all temporary differences between the carrying amount and the tax base of assets and liabilities. Where the tax value can be determined according to alternative tax rules, deferred tax is measured on the basis of the planned use of the asset or the settlement of the obligation.

    Deferred tax assets are measured at the value at which they are expected to be utilized, either through elimination against tax on future earnings or through a set-off against deferred tax liabilities. Deferred tax assets are set off within the same legal tax entity and jurisdiction.

    Uncertainties exist with respect to the interpretation of complex tax regulations and the amount and timing of future taxable income. Given the complexity of existing contractual agreements, differences arising between the actual results and the assumptions made, or future changes to such assumptions could necessitate future adjustments to tax income and expenses already recorded. As at December 31, 2021 and 2020, the Company has not recognized any provisions for uncertain tax positions resulting in a risk that the deferred tax asset related to warrants is lower than disclosed.

    The Company recognizes deferred income tax assets if it is probable that sufficient taxable income will be available in the future against which the temporary differences and unused tax losses can be utilized. Management has considered future taxable income in assessing whether deferred income tax assets should be recognized and has concluded that the deferred income tax assets do not meet the criteria for recognition as assets in the statements of financial position.

    Tax receivables

    Tax receivables

    Current tax assets for the current and prior periods are measured at the amount expected to be recovered from the taxation authorities, using the tax rates and tax laws that have been enacted or substantively enacted by the end of the reporting period.

    Deferred offering costs

    Deferred offering costs

    Offering costs, consisting of legal, accounting, printer and filing fees directly attributable to the issuance of new shares relating to the Company’s initial public offering (“IPO”) in February 2021, were deferred and were offset against proceeds from the IPO upon the effectiveness of the offering. Deferred offering costs recorded as of December 31, 2020 were $1.7 million.

    Leases

    Leases

    The Company assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

    The Company applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Company recognizes lease liabilities for future remaining lease payments and right-of-use assets representing the right to use the underlying assets.

    Leasehold improvements and Loan from lessor

    The Company’s lease contract comprises funding for the customization of the premises to the Company’s specific needs. The payment is determined based on the actual costs incurred for the customization, a repayment period of 8 years and an interest rate of 6% per annum.

    The Company has assessed whether this is a lease component, or a leasehold improvement funded by the lessor. We have considered the following factors:

    1.Which party designed the customization
    2.Which party had the right to direct changes to the work
    3.Who is taking on the economic risk of the cost price of the work

    A third party has designed the project according to the Company’s instructions, and the Company had the right to direct changes to the work during the construction period. Further, the Company has the full economic risk of the work due to 1:1 linkage between construction costs and payments to the lessor. Consequently, the Company has assessed that the customization is a leasehold improvement funded by the lessor and accordingly presented a leasehold improvement and a corresponding liability for the loan from the lessor.

    Right-of-use assets

    The Company recognizes a right-of-use asset at the lease commencement date (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost less any accumulated depreciation and impairment losses and adjusted for certain remeasurements of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, lease payments made at or before the commencement date less any lease incentives received, initial direct costs incurred, and restoration costs.

    Right-of-use assets are depreciated over the shorter of the lease term and the useful life of the right-of-use asset using the straight-line method. In addition, right-of-use assets are reduced by impairment losses, if any, and adjusted for certain remeasurements.

    The Company’s right-of-use assets are presented within property and equipment, net.

    Lease liabilities

    At the commencement date of the lease, the Company recognizes lease liabilities measured at the present value of the following payments, when applicable:

    fixed payments (including in-substance fixed payments), less any lease incentives receivable;
    variable lease payments (linked to an index or interest rate);
    expected payments under residual value guarantees;
    the exercise price of purchase options, where exercise is reasonably certain;
    lease payments in optional renewal periods, where exercise of extension options is reasonably certain;
    and penalty payments for the termination of a lease, if the lease term reflects the exercise of the respective termination option.

    The lease payments are discounted using the interest rate implicit in the lease if this rate can be readily determined. Otherwise, the Company’s incremental borrowing rate is used, being the rate that the Company would have to pay to borrow the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment with similar terms, security and conditions. Generally, the Company uses its incremental borrowing rate as the discount rate.

    Lease liabilities are subsequently measured at amortized cost using the effective interest method. In addition, the carrying amount of the lease liabilities are remeasured if there is a modification, a change in the lease term, or a change in the lease payments (e.g., changes to future payments resulting from a change in an index or rate used to determine such lease payments).

    Intangible assets

    Intangible assets

    The Company recognized intangible assets for licenses. Licenses are measured at cost less cumulative amortization and impairment. Cost is measured at fair value of the consideration transferred with addition of transactions costs. If additional consideration is transferred to the seller due to meeting certain milestones, these payments are added to the cost price once the conditions for making the payments are met.

    The capitalized assets are amortized over their useful lives, which are determined on the basis of the expected pattern of consumption of the expected future economic benefits embodied in the license or similar development agreement. Amortization commences only once the necessary regulatory and marketing approval has been received for the product candidates to which they relate. To date, the Company has not received any regulatory and marketing approval for any of its product candidates. Consequently, the Company did not recognize any amortization expense for its intangible assets.

    Property and equipment

    Property and equipment

    Property and equipment are stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. Depreciation is recognized on a straight-line basis over the estimated useful lives of the assets, as follows:

    Assets

        

    Useful life

    Properties

    Shorter of lease term and useful life of the asset

    Leasehold improvements

    11 years

    Other equipment

    5 – 10 years

    Impairment of non-financial assets

    Impairment of non-financial assets

    Assets are tested for impairment annually, or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash-generating units). Non-financial assets other than goodwill that suffered impairment are reviewed for possible reversal of the impairment at the end of each reporting period. The Company has not recognized any impairment losses to date.

    Provisions

    Provisions

    Provisions are recognized when we have an existing legal or constructive obligation as a result of events occurring prior to or on the balance sheet date, and it is probable that the utilization of economic resources will be required to settle the obligation. Provisions are measured as the best estimate of the expense necessary to settle the obligation at the balance sheet date. Provisions that are estimated to mature after more than one year after the balance sheet date are measured at their present values, using a discount rate based on the Company’s risk adjusted incremental borrowing rate.

    Financial instruments

    Financial instruments

    A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. Financial instruments are classified at initial recognition, including on the basis of the purpose for which the instrument was acquired and managed. This classification determines the valuation of the instruments.

    (i) Non-derivative financial assets

    Non-derivative financial assets are recognized initially on the date they are originated. The Company derecognizes non-derivative financial assets when the contractual rights to cash flows expire or it transfers the right to receive cash flows in a transaction which transfers substantially all the risks and rewards of ownership of the asset. The Company’s financial assets are initially recognized at fair value and subsequently measured at amortized cost less accumulated impairment losses.

    The Company holds the following categories of non-derivative financial assets:

    Receivables

    Receivables (including lease deposits, receivables and receivables from unpaid capital) represent the Company’s right to an amount of consideration that is unconditional (i.e., only the passage of time is required before payment of the consideration is due). They are measured at amortized cost less impairment.

    Prepayments include expenditures related to future financial periods and are measured at amortized cost

    Cash and cash equivalents

    Cash is comprised of cash on hand and in bank deposit accounts. Cash equivalents are instruments with original maturities of 90 days or less. The Company does not have any cash equivalents for the years ended December 31, 2021 and 2020.

    (ii) Non-derivative financial liabilities

    Non-derivative financial liabilities comprise other payables which are measured initially at fair value and subsequently at amortized cost.

    Trade Payables

    Trade payables and accruals relate to the Group’s purchase of products and services from various vendors in the normal course of business.

    Other Payables

    Other payables are comprised of payables to clinical research organizations, employee liabilities and other liabilities. The contract liabilities consist of CROs and vendor accruals. Employee cost liabilities are comprised of provision for holiday allowance, provision for salaries and other employee related provisions. Other liabilities consist of commitments and liabilities related to government grants received in advance.

    Debt

    Debt is comprised of debt agreements that are carried at amortized cost using the effective interest method.

    (iii) Derivative financial liabilities

    Convertible debt instruments

    During 2018, the Company issued two convertible debt instruments which are determined to be financial instruments. As required by IAS 32 and IFRS 9, these instruments were separated into their components: debt, and embedded derivatives related to the conversion features, early settlement mechanism and change of control prepayment provision. The Company elected the fair value option and accounts for both the debt and the embedded derivatives as a single instrument that is measured at fair value. Details of the significant inputs and assumptions into the fair values of these instruments are provided in Note 20.

    Segment Information

    Segment Information

    An operating segment is a part of the Company that conducts business activities from which it can generate revenue and incur costs, and for which independent financial information is available. Identification of segments is based on internal reporting to the chief operating decision maker (“CODM”). The CODM for the Company is the Chief Executive Officer. The Company does not divide its operations into different segments and the CODM operates and manages the Company’s entire operations as one segment, which is consistent with the Company’s internal organization and reporting system. The Company does not have any revenue and there are no material non-current assets attributable to countries other than Denmark.

    Shareholders' Equity

    Shareholders’ Equity

    The share capital comprises the nominal amount of the company’s ordinary shares, each at a nominal value of DKK 1.

    Other Reserves includes the share premium comprising the amount received, attributable to shareholders’ equity, in excess of the nominal amount of the shares issued at the company’s capital increases, reduced by any expenses directly attributable to the capital increases as well as translation reserves. Translation reserves include exchange rate adjustments of equity and intragroup receivables forming part of the net investments in our group enterprises.

    Accumulated Deficit include the accumulated profit or loss as well as well as the reserve for share-based payment representing the corresponding entries to the share-based payment recognized in the profit or loss, arising from our warrant programs.

    Loss Per Share

    Loss Per Share

    The calculation of basic loss per share is based on the Company’s net loss for the year attributable to shareholders of Evaxion Biotech A/S and on the weighted average number of ordinary shares outstanding during the year. The number of shares outstanding take in effect the 2 for 1 stock split and the 17 for 1 bonus share issuance on January 4, 2021. In calculating diluted loss per share, earnings and the average number of shares are adjusted for the dilutive effects of potential ordinary shares. Loss per share is not adjusted for any dilution that results in a loss per share that is lower than loss per ordinary share before dilution.

    Standards issued but not yet effective

    Standards issued but not yet effective

    There were a number of standards and interpretations which were issued but were not yet effective at December 31, 2021 and have not been adopted for these financial statements:

    Amendment to IAS 37 Provisions, contingent liabilities and contingent assets, Onerous Contracts— Cost of Fulfilling a Contract (January 1, 2022)
    Amendments to IAS 16 Property, Plant and Equipment, proceeds before intended use (January 1, 2022)
    Annual Improvements 2018-2020 (January 1, 2022)
    Amendment to IAS 1 Presentation of Financial Statements: Disclosure of Accounting Policies (January 1, 2023)
    Amendment to IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors: Definition of Accounting Estimates (January 1, 2023)
    Amendments to IFRS 16 Leases: COVID-19-Related Rent Concessions beyond June 30, 2021 (April 1, 2021)

    The Company expects to adopt these standards, updates and interpretations when they become mandatory. These standards are not expected to have a significant impact on disclosures or amounts reported in the Company’s financial statements in the period of initial application and future reporting periods.

    XML 98 R32.htm IDEA: XBRL DOCUMENT v3.22.1
    Summary of Significant Accounting Policies (Tables)
    12 Months Ended
    Dec. 31, 2021
    Summary of Significant Accounting Policies  
    Summary of estimated useful lives of assets

    Assets

        

    Useful life

    Properties

    Shorter of lease term and useful life of the asset

    Leasehold improvements

    11 years

    Other equipment

    5 – 10 years

    XML 99 R33.htm IDEA: XBRL DOCUMENT v3.22.1
    Financial Instruments and Risk Management (Tables)
    12 Months Ended
    Dec. 31, 2021
    Financial Instruments and Risk Management  
    Schedule of contractual outflows of financial liabilities

        

    December 31, 2021

    (USD in thousands)

    Carrying

    Contractual 

     amount

    cash flows

    <1 year

    1 – 5 years

    >5 years

    Total

    Loan from lessor (1)

    $

    1,170

    $

    1,458

    $

    192

    $

    769

    $

    497

    $

    1,458

    Lease liabilities

     

    2,520

     

    3,698

     

    326

     

    1,223

     

    2,149

     

    3,698

    Trade payables

    2,848

     

    2,848

     

    2,848

     

     

     

    2,848

    Provisions

    153

    153

    153

    153

    Other payables

     

    46

    46

    46

    46

    Total

    $

    6,737

    $

    8,203

    $

    3,412

    $

    1,992

    $

    2,799

    $

    8,203

    (1)The loan amount as of December 31, 2021 is still subject to possible minor adjustment. Further information is provided in Note 17.

        

    December 31, 2020

    (USD in thousands)

    Carrying

    Contractual 

     amount

    cash flows

    <1 year

    1 – 5 years

    >5 years

    Total

    Lease liabilities

    $

    20

    $

    20

    $

    20

    $

    $

    $

    20

    Trade payables

    3,673

    3,673

    3,673

    3,673

    Other payables

     

    180

     

    180

     

    180

     

     

     

    180

    Total

    $

    3,873

    $

    3,873

    $

    3,873

    $

    $

    $

    3,873

    XML 100 R34.htm IDEA: XBRL DOCUMENT v3.22.1
    Operating Activities (Tables)
    12 Months Ended
    Dec. 31, 2021
    Operating Activities  
    Schedule of research and development expense components

        

    Years Ended December 31, 

        

    2021

        

    2020

        

    2019

    (USD in thousands)

    Employee salary and benefit expenses, excluding share-based compensation

    $

    (6,794)

    $

    (3,337)

    $

    (2,586)

    Share-based compensation expenses

     

    (1,051)

    (1,496)

    (1,021)

    Depreciation

     

    (273)

    (92)

    (65)

    External expenses

     

    (11,465)

    (5,977)

    (4,544)

    Total research and development expenses

    $

    (19,583)

    $

    (10,902)

    $

    (8,216)

    Schedule of general and administrative expense components

        

    Years Ended December 31, 

        

    2021

        

    2020

        

    2019

    (USD in thousands)

    Employee salary and benefit expenses, excluding share-based compensation

    $

    (1,824)

    $

    (1,098)

    $

    (517)

    Share-based compensation expenses

    (328)

    (1,912)

    (1,341)

    Professional and other fees

    (4,028)

    (2,644)

    (773)

    Depreciation

    (71)

    (12)

    (16)

    Total general and administrative expenses

    $

    (6,251)

    $

    (5,666)

    $

    (2,647)

    XML 101 R35.htm IDEA: XBRL DOCUMENT v3.22.1
    Employees and Employee-Related Costs (Tables)
    12 Months Ended
    Dec. 31, 2021
    Employees and Employee-Related Costs  
    Schedule of number of employees

        

    Years Ended December 31, 

        

    2021

        

    2020

        

    2019

    Average number of full-time employees

     

    53

    33

    25

    Number of employees at end of period:

     

      

    Denmark and United States

     

    61

    35

    31

    Total employees, at end of period

     

    61

    35

    31

    Schedule of employee costs

        

    Years Ended December 31, 

        

    2021

        

    2020

        

    2019

    (USD in thousands)

    Wages and salaries

    $

    6,909

    $

    4,016

    $

    2,819

    Cash bonus

    668

    Share-based compensation expenses

    1,379

    3,408

     

    2,362

    Defined contribution plans

    649

    206

     

    96

    Other social security expenses

    28

    17

     

    12

    Other staff expenses

    364

    196

     

    176

    Total

    $

    9,997

    $

    7,843

    $

    5,465

        

    Years Ended December 31,

        

    2021

        

    2020

        

    2019

    (USD in thousands)

    Total Employee costs classified as:

     

      

    Research and development expenses

    $

    7,845

    $

    4,833

    $

    3,607

    General and administrative expenses

    2,152

    3,010

     

    1,858

    Total

    $

    9,997

    $

    7,843

    $

    5,465

        

    Years Ended December 31, 

        

    2021

        

    2020

        

    2019

    (USD in thousands)

    Non-management employee benefit expenses classified as:

     

      

    Research and development expenses

    $

    6,414

    $

    4,009

    $

    2,590

    General and administrative expenses

    836

    611

     

    668

    Total

    $

    7,250

    $

    4,620

    $

    3,258

    Schedule of remuneration to the Board of Directors and Executive Management

        

    Year Ended December 31, 

    2021

    2020

    2019

    (USD in thousands)

    Remuneration to the Executive Management:

     

      

     

      

    Wages and salaries

    $

    1,833

    $

    1,298

    $

    900

    Share-based compensation expenses

    514

    1,566

     

    956

    Total

    2,347

    2,864

     

    1,856

    Remuneration to the Board of Directors:

     

      

    Wages and salaries

    313

    Share-based compensation expenses

    87

    359

     

    351

    Total

    400

    359

     

    351

    Remuneration to the Board of Directors and Executive Management classified as:

     

      

    Research and development expenses

    1,431

    824

     

    1,017

    General and administrative expenses

    1,316

    2,399

     

    1,190

    Total

    $

    2,747

    $

    3,223

    $

    2,207

    XML 102 R36.htm IDEA: XBRL DOCUMENT v3.22.1
    Share-Based Payments (Tables)
    12 Months Ended
    Dec. 31, 2021
    Share-Based Payments  
    Schedule of granted warrants

    Weighted

    Weighted

     Average

     Average

    Remaining

    Number of

     Exercise

    Contractual

        

     warrants

        

    Price/Share

        

    Life (years)

    Warrants granted as at December 31, 2018

    1,674,324

    DKK 1

    18

    Warrants granted(1)

    257,832

    DKK 1

    17

    Warrants granted as at December 31, 2019

     

    1,932,156

     

    DKK 1

     

    17

    Warrants granted

    363,168

     

    DKK 1

     

    11

    Warrants forfeited

    (45,216)

    DKK 1

    16

    Warrants cancelled

    (22,032)

    DKK 1

    16

    Warrants granted as at December 31, 2020

    2,228,076

    DKK 1

    15

    Warrants granted during 2021(2)

    63,802

     

    DKK 1

     

    10

    Warrants granted December 2021

    523,599

    USD 5.38

    10

    Warrants exercised

    (62,284)

    (3)

    DKK 1

    Warrants forfeited

    (10,178)

    1

    Warrants cancelled

    (10,397)

    1

    Warrants granted as at December 31, 2021

    2,732,618

    DKK 7.53

    (4)

    13

    Warrants exercisable as at December 31, 2019

    Warrants exercisable as at December 31, 2020

    Warrants exercisable as at December 31, 2021

     

    2,072,122

     

     

    (1)The warrants are not incorporated in the articles of association. Rectification conducted in October 2020.

    (2)

    Of which 62,147 warrants were legally granted in June 2021 and the remaining 1,655 warrants were legally granted in December 2020.

    (3)

    The share price at the exercise date was USD 5.59.

    (4)

    December 31, 2021 USD-end rate used.

    Schedule of share based compensation included in statements of comprehensive loss

        

    Years Ended

    December 31, 

        

    2021

        

    2020

        

    2019

    (USD in thousands)

    Research and development expenses

    $

    1,051

    $

    1,496

    $

    1,021

    General and administrative expenses

    328

    1,912

     

    1,341

    Total

    $

    1,379

    $

    3,408

    $

    2,362

    Schedule of assumptions have been applied for the warrants issued

    The following assumptions have been applied for the warrants issued in December 2021:

    Expected term (in years)

        

    6.5

    Risk-free interest rate

     

    1.34

    Expected volatility

     

    85.0

    %

    Share price

    $

    4.20

    Schedule of outstanding warrants by grant date

    The following schedule specifies the outstanding warrants as at December 31, 2021:

    Per

    warrant

    Average

    Remaining

    grant

    Number of

    exercise price

    term to

        

    date fair value

        

    warrants

        

    per warrant

        

    maturity

    Outstanding program

    (DKK)

    outstanding

    (DKK)

    (years)

    Grant (December 2016)

     

    20.91

     

    701,356

     

    1

     

    15

    Grant (September 2017)

     

    28.71

     

    617,184

     

    1

     

    15

    Grant (December 2017)

     

    28.71

     

    122,040

     

    1

     

    15

    Grant (during 2018)

     

    37.05

     

    174,564

     

    1

     

    15

    Grant (February 2019)

     

    42.57

     

    7,956

     

    1

     

    15

    Grant (September 2019)

     

    56.35

     

    54,000

     

    1

     

    15

    Grant (October 2019)

     

    56.97

     

    150,660

     

    1

     

    15

    Grant (December 2020)

     

    56.75

     

    317,457

     

    1

     

    9

    Grant (April 2021)

     

    45.31

     

    1,655

     

    1

     

    10

    Grant (June 2021)

     

    40.86

     

    62,147

     

    1

     

    10

    Grant (December 2021)

    19.22

    523,599

    USD 5.38

    10

    Granted at December 31, 2021

     

      

     

    2,732,618

     

      

     

      

    Warrants exercisable at December 31, 2021

     

    The following schedule specifies the outstanding warrants as at December 31, 2020:

    Per 

    warrant

    Average

    Remaining

    grant

    Number of

     exercise price

     term to 

    date fair value

     warrants 

    per warrant

    maturity

    Outstanding program

        

    (DKK)

        

    outstanding

        

    (DKK)

        

    (years)

    Grant (December 2016)

    20.91

    712,332

    1

    16

    Grant (April 2017)

    24.05

    13,896

    1

    16

    Grant (September 2017)

     

    28.71

     

    617,184

     

    1

     

    16

    Grant (December 2017)

     

    28.71

     

    127,044

     

    1

     

    16

    Grant (during 2018)

     

    37.05

     

    181,836

     

    1

     

    16

    Grant (February 2019)

     

    42.57

     

    7,956

     

    1

     

    16

    Grant (September 2019)

    56.35

    54,000

    1

    16

    Grant (October 2019)

    56.97

    150,660

    1

    16

    Grant (December 2020)

    56.75

    363,168

    1

    11

    Granted at December 31, 2020

    2,228,076

    1

    15

    Warrants exercisable at December 31, 2020

     

     

     

     

    The following schedule specifies the outstanding warrants as at December 31, 2019:

    Per 

    warrant

    Average

    Remaining

    grant

    Number of

     exercise price

     term to 

    date fair value

     warrants 

    per warrant

    maturity

    Outstanding program

        

    (DKK)

        

    outstanding

        

    (DKK)

        

    (years)

    Grant (December 2016)

    20.91

    712,332

    1

    17

    Grant (April 2017)

    24.05

    13,896

    1

    17

    Grant (September 2017)

    28.71

    617,184

    1

    17

    Grant (December 2017)

    28.71

    138,384

    1

    17

    Grant (during 2018)(1)**

    37.05

    192,528

    1

    17

    Grant (January 2019)(1)**

     

    37.05

     

    45,216

     

    1

     

    17

    Grant (February 2019)**

     

    42.57

     

    7,956

     

    1

     

    17

    Grant (September 2019)**

     

    56.35

     

    54,000

     

    1

     

    17

    Grant (October 2019)**

     

    56.97

     

    150,660

     

    1

     

    17

    Granted at December 31, 2019

     

     

    1,932,156

     

    1

     

    17

    Warrants exercisable at December 31, 2019

     

     

     

     

    (1)Awards valued on December 31, 2018 and January 1, 2019, respectively.

    **

    The warrants are not incorporated in the articles of association. Rectification was conducted in December 2020.

    Schedule of share based awards to Board of Directors and Executive Management

    The Board of Directors and Executive Management holding of share awards for the years ended December 31, 2019, 2020 and 2021 is shown below:

    Warrants held when

    Warrants held when

    becoming or leaving

    becoming or leaving

    December 31, 

    December 31, 

    as a member

    December 31, 

    as a member

    December 31, 

    Number of warrants held

        

    2018

        

    Granted

        

    2019

        

    of management

        

    Granted

        

    Forfeited

        

    2020

        

    of management

        

    Granted

        

    Exercised

        

    Forfeited

        

    2021

    Thomas William Wylonis(former)1

    342,612

    342,612

    (369,252)

    26,640

    369,252

    369,252

    Steven Projan

    23,436

    23,436

    18,612

    42,048

    4,583

    46,631

    Roberto Prego

     

    19,800

     

     

    19,800

     

     

    14,364

    34,164

    4,583

    38,747

    Joann Suzich(former)7

     

     

     

     

     

    10,260

    10,260

    10,260

    Marianne Søgaard2

    65,952

    28,368

    94,320

    9,167

    103,487

    Helen Boudreau (former)3

     

    5,436

    5,436

    (5,436)

    Kim Bjørnstrup (former)4

     

    (5,868)

    5,868

    Lars Holtug

    4,583

    4,583

    Board of Directors in total

     

    385,848

     

     

    385,848

     

    (309,168)

     

    109,548

    555,480

    22,916

    (5,436)

    572,960

    Lars Aage Staal Wegner

     

    844,416

     

     

    844,416

     

     

    7,668

    852,084

    64,167

    916,251

    Birgitte Rønø

    29,376

    45,000

    74,376

    Thomas Bogenrieder (former)5

     

    4,356

     

    45,216

     

    49,572

     

    (4,356)

     

    (45,216)

    4,356

    4,356

    Erik Heegaard

    97,564

    97,564

    Glenn S. Vraniak (former)6

     

    150,660

     

    150,660

     

     

    150,660

    150,660

    Executive Management in total

    848,772

     

    195,876

     

    1,044,648

     

    (4,356)

     

    7,668

    (45,216)

    1,007,100

    29,376

    206,731

    1,243,207

    (1)Board member until June 30, 2020, 252 warrants were granted for services provided after retirement from the Board of Director position.
    (2)As of November 25, 2020, 26,964 warrants were granted for services provided before taking on the Board of Directors position.
    (3)Board member from June 30, 2020 to May 25, 2021.
    (4)Board member from June 30, 2020 to November 4, 2020.
    (5)Part of Executive Management until March 31, 2020.
    (6)Mr. Vraniak resigned as the Chief Financial Officer of the Company effective November 1, 2021.
    (7)Board member until May 25, 2021.
    XML 103 R37.htm IDEA: XBRL DOCUMENT v3.22.1
    Financial Income and Expenses (Tables)
    12 Months Ended
    Dec. 31, 2021
    Financial Income and Expenses  
    Schedule of financial income and expenses

        

    Year Ended 

    December 31, 

        

    2021

        

    2020

        

    2019

    (USD in thousands)

    Financial income:

    Interest income, bank

    $

    $

    $

    8

    Interest income, other

     

    1

    Foreign exchange gains

    2,039

    216

     

    56

    Total financial income

    2,039

    216

     

    65

    Financial expenses:

    Interest expenses

    (5)

    (29)

     

    (36)

    Changes in fair value of convertible debt instruments

     

    (1,183)

    Interest expenses, lease liabilities

    (123)

     

    (3)

    Interest, loan from lessor

    (31)

    Foreign exchange losses

    (756)

    (194)

     

    Total financial expenses

    (915)

    (223)

     

    (1,222)

    Net financial items

    $

    1,124

    $

    (7)

    $

    (1,157)

    XML 104 R38.htm IDEA: XBRL DOCUMENT v3.22.1
    Income Taxes (Tables)
    12 Months Ended
    Dec. 31, 2021
    Income Taxes  
    Schedule of tax expense

        

    Year Ended

    December 31, 

        

    2021

        

    2020

        

    2019

    (USD in thousands)

    Income tax expense/(benefit)

    $

    (178)

    $

    (1,557)

    $

    (825)

    Total income taxes for the year

    $

    (178)

    $

    (1,557)

    $

    (825)

    Schedule of reconciliation of effective tax rate

        

    Year Ended December 31, 

        

    2021

        

    2020

        

    2019

    Statutory corporate income tax rate in Denmark

     

    22

    %  

    22

    %  

    22

    %  

    Difference in corporate income tax rate in subsidiaries

    %

    Non-deductible income / (expenses)

     

    %  

    (1)

    %  

    (5)

    %  

    Non-taxable income / (expenses)

    %

    1

    %

    Additional tax deduction R&D expenses

    6

    %

    3

    %

    Tax credit research and development expenditures

     

    (4)

    %  

    9

    %  

    7

    %  

    Change in deferred tax asset not capitalized

     

    (23)

    %  

    (25)

    %  

    (17)

    %  

    Total effective tax rate

     

    1

    %  

    9

    %  

    7

    %  

    Schedule of deferred tax in the statements of financial position

        

    Year Ended

    December 31, 

        

    2021

        

    2020

        

    2019

    (USD in thousands)

    Deferred Tax Positions:

     

    Warrants

    $

    2,118

    $

    4,289

    $

    3,034

    Loss carry forward

    9,530

    3,759

     

    1,270

    Research and development expenditures

    262

    Other items

    (98)

    (6)

    (34)

    Valuation allowance on deferred tax assets

    (11,550)

    (8,042)

     

    (4,270)

    Total capitalized

    $

    $

    262

    $

    XML 105 R39.htm IDEA: XBRL DOCUMENT v3.22.1
    Basic and Diluted Loss Per Share (Tables)
    12 Months Ended
    Dec. 31, 2021
    Basic and Diluted Loss Per Share  
    Schedule of basic and diluted loss per share

        

    Year Ended December 31, 

        

    2021

        

    2020

        

    2019

    (USD in thousands, except share amounts and per share amounts)

    Loss per share before and after dilution

     

      

     

      

    Net loss attributable to shareholders of Evaxion Biotech A/S

    $

    (24,532)

    $

    (15,018)

    $

    (11,195)

    Weighted-average number of ordinary shares outstanding

    19,493,143

    15,434,758

     

    13,892,314

    Loss per share before and after dilution

    $

    (1.26)

    $

    (0.97)

    $

    (0.81)

    Schedule of potential shares are anti-dilutive and excluded from the weighted average number of shares

        

    December 31, 

        

    2021

        

    2020

        

    2019

    Warrants

     

    2,732,618

    2,228,076

    2,059,128

    XML 106 R40.htm IDEA: XBRL DOCUMENT v3.22.1
    Intangible assets (Tables)
    12 Months Ended
    Dec. 31, 2021
    Intangible assets  
    Intangible assets TLG

        

    Intangible

        

        

    Assets

    Total

    (USD in thousands)

    Cost at December 31, 2020

    $

    100

    $

    100

    Additions during the year

     

     

    Exchange rate adjustments

     

    (7)

     

    (7)

    Cost at December 31, 2021

     

    93

     

    93

    Amortization at December 31, 2020

     

     

    Amortization for the year

     

     

    Exchange rate adjustment

     

     

    Amortization at December 31, 2021

     

     

    Carrying amount at December 31, 2021

    $

    93

    $

    93

    Intangible 

     

        

    Assets

        

    Total

    (USD in thousands)

    Cost at December 31, 2019

     

    $

     

    $

    Additions during the year

    95

    95

    Exchange rate adjustments

    5

    5

    Cost at December 31, 2020

    100

    100

    Amortization at December 31, 2019

    Amortization for the year

    Exchange rate adjustment

    Amortization at December 31, 2020

    Carrying amount at December 31, 2020

     

    $

    100

     

    $

    100

    XML 107 R41.htm IDEA: XBRL DOCUMENT v3.22.1
    Property, Plant and Equipment (Tables)
    12 Months Ended
    Dec. 31, 2021
    Property, Plant and Equipment  
    Schedule of property, plant and equipment

        

        

    Other

    Leasehold

    Property

        

    Equipment

        

    Improvements

        

    Total

    (USD in thousands)

    Cost at December 31, 2020

    $

    257

    $

    263

    $

    $

    520

    Additions during the year

     

    2,891

     

    1,025

     

    1,634

     

    5,550

    Disposals during the year

    (244)

    (244)

    Exchange rate adjustments

     

    (148)

     

    (63)

     

    (67)

     

    (278)

    Cost at December 31, 2021

     

    2,756

     

    1,225

     

    1,567

     

    5,548

    Depreciation at December 31, 2020

    $

    (237)

    $

    (62)

    $

    $

    (299)

    Depreciation for the year

     

    (179)

     

    (105)

     

    (59)

     

    (343)

    Depreciation reversed on disposals during the year

    244

    244

    Exchange rate adjustment

     

    17

     

    6

     

    1

     

    24

    Depreciation at December 31, 2021

     

    (155)

     

    (161)

     

    (58)

     

    (374)

    Carrying amount at December 31, 2021

    $

    2,601

    $

    1,064

    $

    1,509

    $

    5,174

    Carrying amount of right-of-use assets at December 31, 2021

    $

    2,601

    $

    $

    $

    2,601

    Other 

        

    Property

        

    Equipment

        

    Total

    (USD in thousands)

    Cost at December 31, 2019

    $

    179

    $

    93

    $

    272

    Additions during the year

     

    55

     

    149

     

    204

    Exchange rate adjustments

     

    23

     

    21

     

    44

    Cost at December 31, 2020

     

    257

     

    263

     

    520

    Depreciation at December 31, 2019

     

    (144)

     

    (27)

     

    (171)

    Depreciation for the year

     

    (71)

     

    (34)

     

    (105)

    Exchange rate adjustment

     

    (22)

     

    (1)

     

    (23)

    Depreciation at December 31, 2020

     

    (237)

     

    (62)

     

    (299)

    Carrying amount at December 31, 2020

    $

    20

    $

    201

    $

    221

    Carrying amount of right-of-use assets at December 31, 2020

    $

    20

    $

    $

    20

    Depreciation included in the statement of comprehensive loss:

        

    Year Ended

    December 31, 

        

    2021

        

    2020

        

    2019

    (USD in thousands)

    Research and development

    $

    270

    $

    90

    $

    64

    General and administrative

    73

    15

     

    16

    Total depreciation included in the statement of comprehensive loss

    $

    343

    $

    105

    $

    80

    Total accumulated depreciation of right-of-use assets at December 31, 

    $

    557

    $

    236

    $

    145

    XML 108 R42.htm IDEA: XBRL DOCUMENT v3.22.1
    Prepayments and other receivables (Tables)
    12 Months Ended
    Dec. 31, 2021
    Prepayments and other receivables  
    Prepayments and other receivables

        

    December 31, 

        

    2021

        

    2020

    (USD in thousands)

    VAT receivables

    $

    387

    $

    376

    Prepayments

     

    638

     

    1,175

    Other receivables

     

    113

     

    2

    Total prepayments and other receivables

    $

    1,138

    $

    1,553

    XML 109 R43.htm IDEA: XBRL DOCUMENT v3.22.1
    Other Payables (Tables)
    12 Months Ended
    Dec. 31, 2021
    Other Payables  
    Schedule of other payables

        

    December 31, 

        

    2021

        

    2020

    (USD in thousands)

    Employee cost liabilities

    $

    989

    $

    1,054

    Other liabilities

     

    46

     

    180

    Total other payables

    $

    1,035

    $

    1,234

    XML 110 R44.htm IDEA: XBRL DOCUMENT v3.22.1
    Cash and Cash Equivalents (Tables)
    12 Months Ended
    Dec. 31, 2021
    Cash and Cash Equivalents  
    Schedule of cash and cash equivalents

        

    December 31, 

        

    2021

        

    2020

    (USD in thousands)

    Cash and cash equivalents

    $

    32,166

    $

    5,834

    Total cash and cash equivalents

    $

    32,166

    $

    5,834

    Schedule of changes in net working capital

        

    December 31, 

        

    2021

        

    2020

        

    2019

    (USD in thousands)

    Changes in receivables and tax receivables

    $

    1,863

    $

    (2,501)

    $

    (337)

    Changes in trade payables

    (647)

    1,798

     

    507

    Changes in other payables

    21

    918

     

    403

    Changes in net working capital

    $

    1,237

    $

    215

    $

    573

    Schedule of adjustments for non-cash items

        

    Year Ended

    December 31, 

        

    2021

        

    2020

        

    2019

    (USD in thousands)

    Income taxes

    $

    (178)

    $

    (1,557)

    $

    (825)

    Tax credit schemes accounted for as grants

    (12)

    (510)

    Depreciation

    344

    105

     

    81

    Interest income

     

    (9)

    Interest expense

    159

    30

     

    39

    Share-based compensation expenses

    1,379

    3,408

     

    2,362

    Acquisition of property, plant and equipment

    (90)

    Change in fair value of convertible debt instruments

     

    1,183

    Other adjustments: Other adjustments, primarily exchange rate adjustments

    (1,061)

    107

     

    114

    Total adjustments for non-cash items

    $

    541

    $

    1,583

    $

    2,945

    Schedule of reconciliation of liabilities from financing activities

    December 31, 

    Accumulated

    Exchange rate

    December 31, 

    (USD in thousands)

        

    2020

        

    Cash flows

        

     interest

        

    Additions

        

     adjustment

        

    2021

    Lease liabilities

    $

    20

    $

    (226)

    $

    123

    $

    2,731

    $

    (128)

    $

    2,520

    Loan from lessor

    31

    1,269

    (130)

    1,170

    Provisions

    161

    (8)

    153

    Total liabilities from financing activities

    $

    20

    $

    (226)

    $

    154

    $

    4,161

    $

    (266)

    $

    3,843

    December 31, 

    Accumulated

    Exchange rate

    December 31, 

    (USD in thousands)

        

    2019

        

    Cash flows

        

     interest

        

    Additions

        

     adjustment

        

    2020

    Lease liabilities

    $

    36

    $

    (74)

    $

    1

    $

    54

    $

    3

    $

    20

    Total liabilities from financing activities

    $

    36

    $

    (74)

    $

    1

    $

    54

    $

    3

    $

    20

    XML 111 R45.htm IDEA: XBRL DOCUMENT v3.22.1
    Leases (Tables)
    12 Months Ended
    Dec. 31, 2021
    Leases  
    Schedule of carrying amounts of right-of-use assets and lease liabilities and the movements

        

    Right-of-Use Asset

        

    Lease liabilities

    (USD in thousands)

    At December 31, 2020

    $

    20

    $

    20

    Additions

     

    2,891

     

    2,731

    Depreciation

     

    (179)

     

    Interest Expense

     

     

    123

    Payments

     

     

    (226)

    Translation

     

    (131)

     

    (128)

    At December 31, 2021

    $

    2,601

    $

    2,520

        

    Right-of-Use Asset

        

    Lease liabilities

    (USD in thousands)

    At December 31, 2019

    $

    35

    $

    36

    Additions

     

    54

    54

    Depreciation

     

    (73)

    Interest Expense

     

    Payments

     

    4

    (74)

    Translation

     

    4

    At December 31, 2020

     

    $

    20

    $

    20

    Schedule of finance liability

        

    December 31,

    2021

    Loan from lessor

    $

    1,170

    Total Loan from lessor

     

    1,170

    Less: Loan from lessor, current portion

     

    (126)

    Total Loan from lessor, net of current portion

    $

    1,044

    XML 112 R46.htm IDEA: XBRL DOCUMENT v3.22.1
    Capital Structure and Financial Matters (Tables)
    12 Months Ended
    Dec. 31, 2021
    Capital Structure and Financial Matters  
    Schedule of changes in the share capital

    Number of

    Share Capital

        

     Ordinary Shares

        

     (DKK in thousands)

    Share capital, December 31, 2018

    12,917,016

    12,917

    Capital increase at July 17, 2019 (issuance of shares for cash)

     

    997,668

     

    998

    Capital increase at July 17, 2019 (conversion of Convertible Debt 1)

     

    302,976

     

    303

    Capital increase at July 17, 2019 (conversion of Convertible Debt 2)

    848,232

    848

    Capital increase at December 19, 2019 (issuance of shares for cash)

    118,260

    118

    Share capital, December 31, 2019

     

    15,184,152

     

    15,184

    Capital increase at September 17, 2020 (issuance of shares for cash)

     

    745,380

     

    745

    Capital increase at October 15, 2020 (issuance of shares for cash)

    269,136

    269

    Share capital, December 31, 2020

    16,198,668

    16,198

    Capital increase at February 9, 2021 (for initial public offering)

    3,000,000

    3,000

    Capital increase at November 9, 2021 (for follow-on offering)

     

    3,942,856

     

    3,943

    Capital increase November 2021 (exercised warrants)

    62,284

    63

    Share capital, December 31, 2021

     

    23,203,808

     

    23,204

        

    December 31, 

        

    2021

    2020

    (USD in thousands)

    Authorized, issued and fully paid

    23,203,808 (2020: 16,198,668) ordinary shares of DKK 1 each (2020: ordinary shares of DKK 1 each)

    $

    3,755

    $

    2,648

    $

    3,755

    $

    2,648

    Schedule of Executive Management's and Board of Director's holding of shares

    Number of ordinary shares owned

        

    2021

        

    2020

        

    2019

    Niels Iversen Møller

    4,292,604

    4,292,604

    4,292,604

    Andreas Holm Mattsson

     

    4,163,832

    4,163,832

    4,163,832

    Lars Aage Staal Wegner

     

    182,124

    182,124

    182,124

    Executive Management in total

     

    8,638,560

    8,638,560

    8,638,560

    Number of ordinary shares owned

        

    2021

        

    2020

        

    2019

    Roberto Prego

     

    310,248

    310,248

    310,248

    Thomas William Wylonis (former)

     

    485,676

    481,860

    Marianne Søgaard

    41,652

    41,652

    Steven Projan

     

    27,288

    27,288

    11,736

    Board of Directors in total

     

    379,188

    864,864

    803,844

    XML 113 R47.htm IDEA: XBRL DOCUMENT v3.22.1
    Convertible Debt Instruments (Tables)
    12 Months Ended
    Dec. 31, 2021
    Convertible debt instruments  
    Disclosure of detailed information about borrowings [line items]  
    Schedule of changes in the convertible debt instruments

        

     Convertible loans

    (USD in thousands)

    Carrying amount at December 31, 2018

    $

    8,569

    Amount received in 2019

     

    152

    Fair value adjustment included in finance expenses

     

    1,183

    Currency adjustment

     

    (209)

    Converted to equity during 2019

     

    (9,695)

    Carrying amount at December 31, 2019

    $

    XML 114 R48.htm IDEA: XBRL DOCUMENT v3.22.1
    Related Party Transactions (Tables)
    12 Months Ended
    Dec. 31, 2021
    Related Party Transactions  
    Schedule of transactions with related parties

        

    December 31, 

        

    2021

        

    2020

        

    2019

    (USD in thousands)

    The Company’s transactions with other related parties:

     

      

     

      

    Transactions with related parties (expenses):

     

      

     

      

    Accrued interest on convertible debt instruments issued to members of executive management and board of directors

    $

    $

    $

    (4)

    Balances with related parties at year-end (asset):

    Prepaid rent and deposit for a leased property from a related party

    $

    $

    7

    $

    Balances with related parties at year-end (liabilities):

     

      

    Convertible debt instruments issued to members of executive management and board of directors (nominal value plus accrued interest of 7.5%)

    $

    $

    $

    XML 115 R49.htm IDEA: XBRL DOCUMENT v3.22.1
    Contractual Obligations (Tables)
    12 Months Ended
    Dec. 31, 2021
    Contractual Obligations  
    Schedule of contractual commitments

        

    December 31, 2021

    (USD in thousands)

    Contractual

    cash flows

    <1 year

    1 – 2 years

    2 – 5 years

    >5 years

    Total

    Purchase obligations

    $

    72

    $

    72

    $

    $

    $

    $

    72

    Total

    $

    72

    $

    72

    $

    $

    $

    $

    72

        

    December 31, 2020

    (USD in thousands)

    Contractual

        

     cash flows

        

    <1 year

        

    1 – 2 years

        

    2 – 5 years

        

    >5 years

        

    Total

    Purchase obligations

    $

    712

    $

    712

    $

    $

    $

    $

    712

    Total

    $

    712

    $

    712

    $

    $

    $

    $

    712

    XML 116 R50.htm IDEA: XBRL DOCUMENT v3.22.1
    Provisions (Tables)
    12 Months Ended
    Dec. 31, 2021
    Provisions  
    Schedule of change in provisions.

        

    Provisions

    (USD in

    thousands)

    Carrying amount at January 1, 2021

    $

    Provision recognized

     

    161

    Additions

     

    Utilization of provision

     

    Change in the provision

     

    Currency adjustment

     

    (8)

    Carrying amount at December 31, 2021

    $

    153

    XML 117 R51.htm IDEA: XBRL DOCUMENT v3.22.1
    Fees to auditors (Tables)
    12 Months Ended
    Dec. 31, 2021
    Fees to auditors  
    Schedule of fees to independent registered public accounting firm

    December 31, 

    2021

    2020

     

    (USD in thousands)

    Audit fees

        

    $

    177

        

    $

    308

    Audit related fees

     

    108

     

    119

    Other fees

     

    328

     

    253

    Total fees

    $

    613

    $

    680

    XML 118 R52.htm IDEA: XBRL DOCUMENT v3.22.1
    General Company Information (Details)
    kr / shares in Units, $ / shares in Units, $ in Thousands, € in Millions
    1 Months Ended 12 Months Ended
    Nov. 09, 2021
    USD ($)
    $ / shares
    shares
    Nov. 05, 2021
    shares
    Feb. 05, 2021
    USD ($)
    $ / shares
    shares
    Nov. 30, 2021
    $ / shares
    Feb. 28, 2021
    USD ($)
    $ / shares
    shares
    Dec. 31, 2021
    USD ($)
    Feb. 17, 2022
    EUR (€)
    Feb. 14, 2022
    EUR (€)
    Dec. 31, 2021
    DKK (kr)
    Nov. 09, 2021
    DKK (kr)
    Feb. 28, 2021
    DKK (kr)
    Feb. 05, 2021
    kr / shares
    shares
    Dec. 31, 2020
    USD ($)
    General Company Information                          
    Share capital           $ 3,755     kr 23,203,808       $ 2,648
    Borrowings           1,170              
    ADS                          
    General Company Information                          
    Net proceeds $ 24,900                        
    Tranche 1                          
    General Company Information                          
    Borrowings | €             € 7.0            
    Tranche 1 | EIB Loan Agreement                          
    General Company Information                          
    Borrowings | €               € 7.0          
    IPO                          
    General Company Information                          
    Aggregate proceeds from IPO     $ 25,300                    
    Ordinary shares authorized on capital | shares     3,000,000                 3,000,000  
    Nominal value per share | kr / shares                       kr 1  
    IPO | ADS                          
    General Company Information                          
    Nominal value per share | $ / shares     $ 10.00                    
    Number of shares issued | shares     3,000,000   3,000,000                
    Share purchase price | $ / shares         $ 10.00                
    Net proceeds         $ 25,300                
    Share capital | kr                     kr 19,198,668    
    Follow-on public offering                          
    General Company Information                          
    Share capital | kr                   kr 23,141,524      
    Follow-on public offering | ADS                          
    General Company Information                          
    Number of shares issued | shares 3,942,856                        
    Share purchase price | $ / shares $ 7.00     $ 7.00                  
    Underwriters | ADS                          
    General Company Information                          
    Number of shares issued | shares   514,285                      
    Emerging Growth Company                          
    General Company Information                          
    Gross revenue total           1,070,000              
    Non-affiliates exceeds           700,000              
    Issued non-convertible debt securities           $ 1,000,000              
    XML 119 R53.htm IDEA: XBRL DOCUMENT v3.22.1
    Summary of Significant Accounting Policies - Retrospective effect of share split and bonus share issuance (Details)
    Jan. 04, 2021
    Summary of Significant Accounting Policies  
    Stock split on bonus issue of shares 2
    Bonus share issuance 17
    XML 120 R54.htm IDEA: XBRL DOCUMENT v3.22.1
    Summary of Significant Accounting Policies - Accounting for joint operation (Details) - USD ($)
    $ in Millions
    12 Months Ended
    Dec. 31, 2020
    Dec. 31, 2019
    Southern Denmark University collaboration agreement    
    Disclosure of joint operations [line items]    
    Compensation cost $ 0.3 $ 0.3
    XML 121 R55.htm IDEA: XBRL DOCUMENT v3.22.1
    Summary of Significant Accounting Policies - Deferred Offering Costs (Details)
    $ in Thousands
    Dec. 31, 2020
    USD ($)
    Summary of Significant Accounting Policies  
    Deferred offering costs $ 1,729
    XML 122 R56.htm IDEA: XBRL DOCUMENT v3.22.1
    Summary of Significant Accounting Policies - Leasehold improvements and Loan from lessor (Details)
    12 Months Ended
    Dec. 31, 2021
    Summary of Significant Accounting Policies  
    Repayment loan, term 8 years
    Loan, interest rate 6.00%
    Correlation between construction costs and payments to lessor 100.00%
    XML 123 R57.htm IDEA: XBRL DOCUMENT v3.22.1
    Summary of Significant Accounting Policies - Estimated useful lives of assets (Details)
    12 Months Ended
    Dec. 31, 2021
    Leasehold improvements  
    Disclosure of detailed information about property, plant and equipment [line items]  
    Useful lives 11 years
    Other equipment | Minimum  
    Disclosure of detailed information about property, plant and equipment [line items]  
    Useful lives 5 years
    Other equipment | Maximum  
    Disclosure of detailed information about property, plant and equipment [line items]  
    Useful lives 10 years
    XML 124 R58.htm IDEA: XBRL DOCUMENT v3.22.1
    Summary of Significant Accounting Policies - Impairment of non-financial assets (Details)
    12 Months Ended
    Dec. 31, 2021
    USD ($)
    Summary of Significant Accounting Policies  
    Impairment loss $ 0
    XML 125 R59.htm IDEA: XBRL DOCUMENT v3.22.1
    Summary of Significant Accounting Policies - Cash and cash equivalents (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Summary of Significant Accounting Policies    
    Cash equivalents $ 0 $ 0
    XML 126 R60.htm IDEA: XBRL DOCUMENT v3.22.1
    Summary of Significant Accounting Policies - Convertible debt instruments (Details)
    12 Months Ended
    Dec. 31, 2018
    instrument
    Summary of Significant Accounting Policies  
    Number of convertible debt instruments issued 2
    XML 127 R61.htm IDEA: XBRL DOCUMENT v3.22.1
    Summary of Significant Accounting Policies - Segment (Details)
    12 Months Ended
    Dec. 31, 2021
    segment
    Summary of Significant Accounting Policies  
    Number of operating business segments 1
    XML 128 R62.htm IDEA: XBRL DOCUMENT v3.22.1
    Summary of Significant Accounting Policies - Loss Per Share (Details)
    Jan. 04, 2021
    Summary of Significant Accounting Policies  
    Stock split on bonus issue of shares 2
    Bonus share issuance 17
    XML 129 R63.htm IDEA: XBRL DOCUMENT v3.22.1
    Financial Instruments and Risk Management - Liquidity risk (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    Financial Instruments and Risk Management        
    Cash and cash equivalents $ 32,166 $ 5,834 $ 9,559 $ 7,433
    Equity $ 32,437 $ 7,038 $ 9,362 $ (931)
    XML 130 R64.htm IDEA: XBRL DOCUMENT v3.22.1
    Financial Instruments and Risk Management - IPO (Details)
    kr / shares in Units, $ / shares in Units, $ in Thousands
    1 Months Ended
    Nov. 09, 2021
    USD ($)
    $ / shares
    shares
    Feb. 05, 2021
    USD ($)
    $ / shares
    shares
    Oct. 31, 2020
    USD ($)
    $ / shares
    shares
    Sep. 30, 2020
    USD ($)
    $ / shares
    shares
    Dec. 31, 2021
    DKK (kr)
    kr / shares
    shares
    Dec. 31, 2021
    USD ($)
    shares
    Nov. 09, 2021
    DKK (kr)
    kr / shares
    shares
    Feb. 05, 2021
    DKK (kr)
    kr / shares
    shares
    Dec. 31, 2020
    USD ($)
    shares
    Dec. 31, 2020
    kr / shares
    Aug. 10, 2020
    kr / shares
    Dec. 31, 2019
    USD ($)
    shares
    Dec. 31, 2018
    USD ($)
    shares
    Disclosure of non-adjusting events after reporting period [line items]                          
    Issued share capital (in DKK)         kr 23,203,808 $ 3,755     $ 2,648        
    Outstanding share capital (in DKK) | $           $ 32,437     $ 7,038     $ 9,362 $ (931)
    ADS                          
    Disclosure of non-adjusting events after reporting period [line items]                          
    Net proceeds | $ $ 24,900                        
    ADS | Initial Public Offering                          
    Disclosure of non-adjusting events after reporting period [line items]                          
    Number of shares issued 3,942,856 3,000,000                      
    Price per share | $ / shares $ 7.00 $ 10.00                      
    Net proceeds | $ $ 24,900 $ 25,300                      
    Number of shares issued (in shares)             514,285            
    Ordinary Shares, nominal value of DKK 1 per share                          
    Disclosure of non-adjusting events after reporting period [line items]                          
    Number of shares issued     269,136 745,380                  
    Price per share | $ / shares     $ 8.89 $ 8.89                  
    Net proceeds | $     $ 2,400 $ 6,600                  
    Number of shares issued (in shares)         23,203,808 23,203,808     16,198,668     15,184,152 12,917,016
    Nominal value per share | kr / shares         kr 1         kr 1 kr 1    
    Ordinary Shares, nominal value of DKK 1 per share | Initial Public Offering                          
    Disclosure of non-adjusting events after reporting period [line items]                          
    Registered share capital (in DKK) | kr             kr 23,141,524 kr 19,198,668          
    Issued share capital (in DKK) | kr             23,141,524 19,198,668          
    Outstanding share capital (in DKK) | kr             kr 23,141,524 kr 19,198,668          
    Shares registered (in shares)               19,198,668          
    Number of shares issued (in shares)               19,198,668          
    Shares outstanding (in shares)               19,198,668          
    Nominal value per share | kr / shares             kr 23,203,808 kr 1          
    XML 131 R65.htm IDEA: XBRL DOCUMENT v3.22.1
    Financial Instruments and Risk Management - Contractual undiscounted outflows (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Disclosure of maturity analysis for non-derivative financial liabilities [line items]    
    Carrying amount $ 6,737 $ 3,873
    Contractual cash flow 8,203 3,873
    Less than one year    
    Disclosure of maturity analysis for non-derivative financial liabilities [line items]    
    Contractual cash flow 3,412 3,873
    1-5 years    
    Disclosure of maturity analysis for non-derivative financial liabilities [line items]    
    Contractual cash flow 1,992  
    Greater than 5 years    
    Disclosure of maturity analysis for non-derivative financial liabilities [line items]    
    Contractual cash flow 2,799  
    Loan From Lessor    
    Disclosure of maturity analysis for non-derivative financial liabilities [line items]    
    Carrying amount 1,170  
    Contractual cash flow 1,458  
    Loan From Lessor | Less than one year    
    Disclosure of maturity analysis for non-derivative financial liabilities [line items]    
    Contractual cash flow 192  
    Loan From Lessor | 1-5 years    
    Disclosure of maturity analysis for non-derivative financial liabilities [line items]    
    Contractual cash flow 769  
    Loan From Lessor | Greater than 5 years    
    Disclosure of maturity analysis for non-derivative financial liabilities [line items]    
    Contractual cash flow 497  
    Lease liabilities    
    Disclosure of maturity analysis for non-derivative financial liabilities [line items]    
    Carrying amount 2,520 20
    Contractual cash flow 3,698 20
    Lease liabilities | Less than one year    
    Disclosure of maturity analysis for non-derivative financial liabilities [line items]    
    Contractual cash flow 326 20
    Lease liabilities | 1-5 years    
    Disclosure of maturity analysis for non-derivative financial liabilities [line items]    
    Contractual cash flow 1,223  
    Lease liabilities | Greater than 5 years    
    Disclosure of maturity analysis for non-derivative financial liabilities [line items]    
    Contractual cash flow 2,149  
    Trade payables    
    Disclosure of maturity analysis for non-derivative financial liabilities [line items]    
    Carrying amount 2,848 3,673
    Contractual cash flow 2,848 3,673
    Trade payables | Less than one year    
    Disclosure of maturity analysis for non-derivative financial liabilities [line items]    
    Contractual cash flow 2,848 3,673
    Provision    
    Disclosure of maturity analysis for non-derivative financial liabilities [line items]    
    Carrying amount 153  
    Contractual cash flow 153  
    Provision | Greater than 5 years    
    Disclosure of maturity analysis for non-derivative financial liabilities [line items]    
    Contractual cash flow 153  
    Other payables    
    Disclosure of maturity analysis for non-derivative financial liabilities [line items]    
    Carrying amount 46 180
    Contractual cash flow 46 180
    Other payables | Less than one year    
    Disclosure of maturity analysis for non-derivative financial liabilities [line items]    
    Contractual cash flow $ 46 $ 180
    XML 132 R66.htm IDEA: XBRL DOCUMENT v3.22.1
    Financial Instruments and Risk Management - Convertible debt instruments (Details)
    12 Months Ended
    Dec. 31, 2021
    USD ($)
    Financial Instruments and Risk Management  
    Transfers into Level 3 of fair value hierarchy, assets $ 0
    Transfers into Level 3 of fair value hierarchy, liabilities 0
    Transfers out of Level 1 into Level 2 of fair value hierarchy, assets held at end of reporting period 0
    Transfers out of Level 1 into Level 2 of fair value hierarchy, liabilities held at end of reporting period 0
    Transfers out of Level 2 into Level 1 of fair value hierarchy, assets held at end of reporting period 0
    Transfers out of Level 2 into Level 1 of fair value hierarchy, liabilities held at end of reporting period 0
    Transfers out of Level 3 of fair value hierarchy, assets 0
    Transfers out of Level 3 of fair value hierarchy, liabilities $ 0
    XML 133 R67.htm IDEA: XBRL DOCUMENT v3.22.1
    Operating Activities (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Disclosure of expenses by nature [line items]      
    Share-based compensation expenses $ (1,379) $ (3,408) $ (2,362)
    Recognized government grants as a reduction of research and development expenses 300 800 500
    Research and development      
    Disclosure of expenses by nature [line items]      
    Employee salary and benefit expenses, excluding share-based compensation (6,794) (3,337) (2,586)
    Share-based compensation expenses (1,051) (1,496) (1,021)
    Depreciation (273) (92) (65)
    External expenses (11,465) (5,977) (4,544)
    Total (19,583) (10,902) (8,216)
    General and administrative      
    Disclosure of expenses by nature [line items]      
    Employee salary and benefit expenses, excluding share-based compensation (1,824) (1,098) (517)
    Share-based compensation expenses (328) (1,912) (1,341)
    Professional fees (4,028) (2,644) (773)
    Depreciation (71) (12) (16)
    Total $ (6,251) $ (5,666) $ (2,647)
    XML 134 R68.htm IDEA: XBRL DOCUMENT v3.22.1
    Employees and Employee-Related Costs - Number of employees (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Number and average number of employees [abstract]      
    Average number of full-time employees 53 33 25
    Number of employees, including consultants, by country at end of period: 61 35 31
    Denmark and United States      
    Number and average number of employees [abstract]      
    Number of employees, including consultants, by country at end of period: 61 35 31
    XML 135 R69.htm IDEA: XBRL DOCUMENT v3.22.1
    Employees and Employee-Related Costs - Employee Costs (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Disclosure of expenses by nature [line items]      
    Wages and salaries $ 6,909 $ 4,016 $ 2,819
    Cash bonus 668    
    Share-based compensation expenses 1,379 3,408 2,362
    Defined contribution plans 649 206 96
    Other social security expenses 28 17 12
    Other staff expenses 364 196 176
    Total employee costs 9,997 7,843 5,465
    Non-management employee benefit expense 7,250 4,620 3,258
    Research and development      
    Disclosure of expenses by nature [line items]      
    Share-based compensation expenses 1,051 1,496 1,021
    Total employee costs 7,845 4,833 3,607
    Non-management employee benefit expense 6,414 4,009 2,590
    General and administrative      
    Disclosure of expenses by nature [line items]      
    Share-based compensation expenses 328 1,912 1,341
    Total employee costs 2,152 3,010 1,858
    Non-management employee benefit expense $ 836 $ 611 $ 668
    XML 136 R70.htm IDEA: XBRL DOCUMENT v3.22.1
    Employees and Employee-Related Costs - Board of Directors and Executive Management (Details)
    $ in Thousands
    1 Months Ended 12 Months Ended
    Oct. 31, 2019
    employee
    Jan. 31, 2019
    employee
    Dec. 31, 2021
    USD ($)
    employee
    Dec. 31, 2020
    USD ($)
    employee
    Dec. 31, 2019
    USD ($)
    Disclosure of transactions between related parties [line items]          
    Number of members of executive management | employee 5 4 5    
    Executive management which resigned | employee     1 1  
    Board of Directors and Executive Management          
    Disclosure of transactions between related parties [line items]          
    Total     $ 2,747 $ 3,223 $ 2,207
    Board of Directors and Executive Management | Research and development          
    Disclosure of transactions between related parties [line items]          
    Members of executive management     1,431 824 1,017
    Board of Directors and Executive Management | General and administrative          
    Disclosure of transactions between related parties [line items]          
    Members of executive management     1,316 2,399 1,190
    Executive Management          
    Disclosure of transactions between related parties [line items]          
    Wages and salaries     $ 1,833 $ 1,298 $ 900
    Share-based compensation expenses     514 1,566 956
    Total     2,347 2,864 1,856
    Board of Directors          
    Disclosure of transactions between related parties [line items]          
    Wages and salaries     313    
    Share-based compensation expenses     87 359 351
    Total     $ 400 $ 359 $ 351
    XML 137 R71.htm IDEA: XBRL DOCUMENT v3.22.1
    Share-Based Payments - Warrants (Details)
    1 Months Ended 3 Months Ended 12 Months Ended
    Jan. 04, 2021
    kr / shares
    Dec. 31, 2021
    kr / shares
    Jun. 30, 2021
    Dec. 31, 2020
    kr / shares
    Jun. 30, 2021
    Dec. 31, 2021
    kr / shares
    $ / shares
    Dec. 31, 2021
    kr / shares
    Dec. 31, 2020
    kr / shares
    Dec. 31, 2019
    kr / shares
    Aug. 10, 2020
    kr / shares
    Share-Based Payments                    
    Warrants as a percentage of outstanding shares           11.80% 11.80% 13.80% 13.50%  
    Warrants.                    
    Share-Based Payments                    
    Vesting period         36 months 36 months 36 months 36 months    
    Warrants granted   523,599 62,147 1,655 62,147 63,802 63,802 363,168 257,832  
    Warrants granted, price per share | (per share)           $ 5.38 kr 1 kr 1 kr 1  
    Warrants. | CFO                    
    Share-Based Payments                    
    Warrants granted                 150,660  
    Ordinary Shares, nominal value of DKK 1 per share                    
    Share-Based Payments                    
    Nominal value per share   kr 1   kr 1   $ 1 kr 1 kr 1   kr 1
    Ordinary Shares, nominal value of DKK 1 per share | Stock Split                    
    Share-Based Payments                    
    Share split ratio 2                  
    Bonus issue share ratio 17                  
    Nominal value per share prior to stock split kr 2                  
    Nominal value per share kr 1                  
    Ordinary Shares, nominal value of DKK 1 per share | Warrants. | Stock Split                    
    Share-Based Payments                    
    Increase in number of warrants, ratio 36                  
    Warrants granted exercise price, prior to stock split kr 2                  
    Warrants granted, price per share kr 1                  
    XML 138 R72.htm IDEA: XBRL DOCUMENT v3.22.1
    Share-Based Payments - Schedule of Warrants (Details)
    1 Months Ended 3 Months Ended 12 Months Ended
    Apr. 30, 2020
    Dec. 31, 2021
    kr / shares
    Jun. 30, 2021
    Dec. 31, 2020
    kr / shares
    Jun. 30, 2021
    Dec. 31, 2021
    kr / shares
    $ / shares
    Dec. 31, 2021
    kr / shares
    Dec. 31, 2020
    kr / shares
    Dec. 31, 2019
    kr / shares
    Dec. 31, 2018
    kr / shares
    Weighted Average Exercise Price/Share (DKK)                    
    Warrants cancelled, price per share             kr 1      
    Warrants exercisable, price per share   kr 1       kr 1 kr 1      
    Warrants.                    
    Number of warrants outstanding                    
    Warrants granted at beginning of period           2,228,076 2,228,076 1,932,156 1,674,324  
    Warrants granted   523,599 62,147 1,655 62,147 63,802 63,802 363,168 257,832  
    Warrants forfeited (45,216)         (10,178) (10,178) (45,216)    
    Exercised           (62,284) (62,284)      
    Warrants cancelled           (10,397) (10,397) (22,032)    
    Warrants granted at end of period   2,732,618   2,228,076   2,732,618 2,732,618 2,228,076 1,932,156 1,674,324
    Warrants exercisable   (2,072,122)       (2,072,122) (2,072,122)      
    Weighted Average Exercise Price/Share (DKK)                    
    Warrants granted at beginning of period, price per share             kr 1 kr 1 kr 1  
    Warrants granted, price per share | (per share)           kr 5.38 1 1 1  
    Warrants forfeited, price per share               1    
    Warrants cancelled, price per share               1    
    Warrants granted at end of period, price per share   kr 7.53   kr 1     7.53 kr 1 kr 1 kr 1
    Warrants exercisable, price per share   kr 1       kr 1 kr 1      
    Weighted Average Remaining Contractual Life (years)                    
    Warrants granted, remaining contractual life           10 years 10 years 15 years 17 years 18 years
    Warrants granted , remaining contractual life           13 years 13 years 11 years 17 years  
    Warrants forfeited , remaining contractual life           0 years 0 years 16 years    
    Warrants cancelled , remaining contractual life           0 years 0 years 16 years    
    Warrants exercisable, remaining contractual life           0 years 0 years 0 years 0 years  
    Other information                    
    Price per share | $ / shares           kr 5.59        
    XML 139 R73.htm IDEA: XBRL DOCUMENT v3.22.1
    Share-Based Payments - Warrants Rectified (Details)
    $ in Millions
    1 Months Ended 3 Months Ended 12 Months Ended
    Dec. 31, 2021
    USD ($)
    Oct. 31, 2021
    Jun. 30, 2021
    USD ($)
    Dec. 31, 2020
    USD ($)
    shares
    Oct. 31, 2019
    USD ($)
    shares
    Sep. 30, 2019
    USD ($)
    shares
    Feb. 28, 2019
    USD ($)
    shares
    Jan. 31, 2019
    USD ($)
    shares
    Jun. 30, 2021
    USD ($)
    Dec. 31, 2021
    USD ($)
    shares
    Dec. 31, 2020
    USD ($)
    Dec. 31, 2019
    Dec. 31, 2018
    Employees                          
    Share-Based Payments                          
    Warrants outstanding                       22,032 22,032
    Warrants.                          
    Share-Based Payments                          
    Number of share options granted in share-based payment arrangement 523,599   62,147 1,655         62,147 63,802 363,168 257,832  
    Warrants outstanding 2,732,618     2,228,076           2,732,618 2,228,076 1,932,156 1,674,324
    Warrants. | Employees                          
    Share-Based Payments                          
    Warrants granted with immediate vesting           54,000              
    Warrants Granted With Vesting Over The Next Three Years             7,956            
    Weighted average fair value at measurement date, share options granted | $           $ 0.5 $ 0.1            
    Warrants. | Executive Management                          
    Share-Based Payments                          
    Number of share options granted in share-based payment arrangement   0 62,147             523,599      
    Warrants granted with immediate vesting                   22,916      
    Warrants Granted With Vesting Over The Next Three Years         150,660     45,216          
    Weighted average fair value at measurement date, share options granted | $ $ 1.5   $ 0.4   $ 1.3     $ 0.3 $ 0.4 $ 1.5      
    Service period         3 years         36 months      
    2019 warrants entitlements                          
    Share-Based Payments                          
    Number of share options granted in share-based payment arrangement       126,972                  
    Warrants granted with immediate vesting       63,612                  
    Warrants Granted With Vesting Over The Next Three Years       63,360                  
    Weighted average fair value at measurement date, share options granted | $       $ 1.2             $ 1.2    
    Service period       3 years                  
    2020 warrants entitlements                          
    Share-Based Payments                          
    Number of share options granted in share-based payment arrangement       236,196                  
    Warrants granted with immediate vesting       120,888                  
    Warrants Granted With Vesting Over The Next Three Years       115,308                  
    Weighted average fair value at measurement date, share options granted | $       $ 2.3             $ 2.3    
    Service period       3 years                  
    XML 140 R74.htm IDEA: XBRL DOCUMENT v3.22.1
    Share-Based Payments - Compensation expense (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Share-Based Compensation      
    Share-based compensation expenses $ 1,379 $ 3,408 $ 2,362
    Warrants.      
    Share-Based Compensation      
    Compensation for arranging investors to subscribe for shares 100    
    Research and development      
    Share-Based Compensation      
    Share-based compensation expenses 1,051 1,496 1,021
    General and administrative      
    Share-Based Compensation      
    Share-based compensation expenses $ 328 $ 1,912 $ 1,341
    XML 141 R75.htm IDEA: XBRL DOCUMENT v3.22.1
    Share-Based Payments - Fair value of warrants (Details) - Warrants - USD ($)
    $ / shares in Units, $ in Millions
    1 Months Ended 12 Months Ended
    Dec. 31, 2020
    Dec. 31, 2021
    Dec. 31, 2020
    Share-Based Payments      
    Percentage of weightage for private scenario 40.00%    
    Share price for private scenarioe (USD per share)   $ 8.89  
    Percentage of weightage for IPO scenario 60.00%    
    Share price for IPO scenario (USD per share)   $ 11.00  
    Lack of marketability discount 10.00%    
    Acceleration of expense     $ 0.8
    XML 142 R76.htm IDEA: XBRL DOCUMENT v3.22.1
    Share-Based Payments - Assumptions of Warrants (Details) - Warrants.
    1 Months Ended 12 Months Ended
    Jun. 30, 2021
    $ / shares
    Jun. 30, 2021
    kr / shares
    Dec. 31, 2021
    Y
    $ / shares
    Disclosure of terms and conditions of share-based payment arrangement [line items]      
    Expected term (in years) | Y     6.5
    Risk-free interest rate     1.34%
    Expected volatility     85.00%
    Share price     $ 4.20
    Exercise price of the warrants issued | kr / shares   kr 1  
    Share price $ 6.24    
    XML 143 R77.htm IDEA: XBRL DOCUMENT v3.22.1
    Share-Based Payments - Amendments to Warrants (Details) - Warrants
    $ in Millions
    12 Months Ended
    Dec. 31, 2020
    USD ($)
    Share-Based Payments  
    Vesting period 3 years
    Reduction in share based compensation expense due to change in accounting estimate $ 0.4
    XML 144 R78.htm IDEA: XBRL DOCUMENT v3.22.1
    Share-Based Payments - Outstanding warrants (Details)
    12 Months Ended
    Dec. 31, 2021
    kr / shares
    Dec. 31, 2021
    $ / shares
    kr / shares
    Dec. 31, 2020
    kr / shares
    Dec. 31, 2019
    kr / shares
    Share-Based Payments        
    Warrants exercisable, price per share kr 1 kr 1    
    Warrants        
    Share-Based Payments        
    Number of warrants outstanding 2,732,618 2,732,618 2,228,076 1,932,156
    Average exercise price per warrant     kr 1 kr 1
    Remaining term to maturity     15 years 17 years
    Warrants | Grant December 2016        
    Share-Based Payments        
    Per warrant average grant date fair value kr 20.91   kr 20.91 kr 20.91
    Number of warrants outstanding 701,356 701,356 712,332 712,332
    Average exercise price per warrant kr 1   kr 1 kr 1
    Remaining term to maturity 15 years 15 years 16 years 17 years
    Warrants | Grant April 2017        
    Share-Based Payments        
    Per warrant average grant date fair value     kr 24.05 kr 24.05
    Number of warrants outstanding     13,896 13,896
    Average exercise price per warrant     kr 1 kr 1
    Remaining term to maturity     16 years 17 years
    Warrants | Grant September 2017        
    Share-Based Payments        
    Per warrant average grant date fair value kr 28.71   kr 28.71 kr 28.71
    Number of warrants outstanding 617,184 617,184 617,184 617,184
    Average exercise price per warrant kr 1   kr 1 kr 1
    Remaining term to maturity 15 years 15 years 16 years 17 years
    Warrants | Grant December 2017        
    Share-Based Payments        
    Per warrant average grant date fair value kr 28.71   kr 28.71 kr 28.71
    Number of warrants outstanding 122,040 122,040 127,044 138,384
    Average exercise price per warrant kr 1   kr 1 kr 1
    Remaining term to maturity 15 years 15 years 16 years 17 years
    Warrants | Granted during 2018        
    Share-Based Payments        
    Per warrant average grant date fair value kr 37.05   kr 37.05 kr 37.05
    Number of warrants outstanding 174,564 174,564 181,836 192,528
    Average exercise price per warrant kr 1   kr 1 kr 1
    Remaining term to maturity 15 years 15 years 16 years 17 years
    Warrants | Grant January 2019        
    Share-Based Payments        
    Per warrant average grant date fair value       kr 37.05
    Number of warrants outstanding       45,216
    Average exercise price per warrant       kr 1
    Remaining term to maturity       17 years
    Warrants | Grant February 2019        
    Share-Based Payments        
    Per warrant average grant date fair value kr 42.57   kr 42.57 kr 42.57
    Number of warrants outstanding 7,956 7,956 7,956 7,956
    Average exercise price per warrant kr 1   kr 1 kr 1
    Remaining term to maturity 15 years 15 years 16 years 17 years
    Warrants | Grant September 2019        
    Share-Based Payments        
    Per warrant average grant date fair value kr 56.35   kr 56.35 kr 56.35
    Number of warrants outstanding 54,000 54,000 54,000 54,000
    Average exercise price per warrant kr 1   kr 1 kr 1
    Remaining term to maturity 15 years 15 years 16 years 17 years
    Warrants | Grant October 2019        
    Share-Based Payments        
    Per warrant average grant date fair value kr 56.97   kr 56.97 kr 56.97
    Number of warrants outstanding 150,660 150,660 150,660 150,660
    Average exercise price per warrant kr 1   kr 1 kr 1
    Remaining term to maturity 15 years 15 years 16 years 17 years
    Warrants | Grant December 2020        
    Share-Based Payments        
    Per warrant average grant date fair value kr 56.75   kr 56.75  
    Number of warrants outstanding 317,457 317,457 363,168  
    Average exercise price per warrant kr 1   kr 1  
    Remaining term to maturity 9 years 9 years 11 years  
    Warrants | Grant April 2021        
    Share-Based Payments        
    Per warrant average grant date fair value kr 45.31      
    Number of warrants outstanding 1,655 1,655    
    Average exercise price per warrant kr 1      
    Remaining term to maturity 10 years 10 years    
    Warrants | Grant June 2021        
    Share-Based Payments        
    Per warrant average grant date fair value kr 40.86      
    Number of warrants outstanding 62,147 62,147    
    Average exercise price per warrant kr 1      
    Remaining term to maturity 10 years 10 years    
    Warrants | Grant December 2021        
    Share-Based Payments        
    Per warrant average grant date fair value kr 19.22      
    Number of warrants outstanding 523,599 523,599    
    Average exercise price per warrant | $ / shares   kr 5.38    
    Remaining term to maturity 10 years 10 years    
    XML 145 R79.htm IDEA: XBRL DOCUMENT v3.22.1
    Share-Based Payments - Key Management Holdings (Details)
    1 Months Ended 12 Months Ended
    Nov. 25, 2020
    Jun. 30, 2020
    Dec. 31, 2021
    shares
    Dec. 31, 2020
    shares
    Dec. 31, 2019
    Warrants          
    Share-Based Payments          
    Warrants granted at beginning of period     2,228,076 1,932,156  
    Warrants granted at end of period     2,732,618 2,228,076 1,932,156
    Board of Directors          
    Share-Based Payments          
    Warrants granted 26,964 252      
    Board of Directors | Warrants          
    Share-Based Payments          
    Warrants granted at beginning of period     555,480 385,848 385,848
    Warrants granted     22,916 109,548  
    Warrants held when becoming a member of management       (309,168)  
    Exercised     (5,436)    
    Warrants granted at end of period     572,960 555,480 385,848
    Thomas William Wylonis | Warrants          
    Share-Based Payments          
    Warrants granted at beginning of period     369,252 342,612 342,612
    Warrants granted       26,640  
    Warrants held when becoming a member of management       (369,252)  
    Warrants granted at end of period     369,252 369,252 342,612
    Steven Projan | Warrants          
    Share-Based Payments          
    Warrants granted at beginning of period     42,048 23,436 23,436
    Warrants granted     4,583 18,612  
    Warrants granted at end of period     46,631 42,048 23,436
    Roberto Prego | Warrants          
    Share-Based Payments          
    Warrants granted at beginning of period     34,164 19,800 19,800
    Warrants granted     4,583 14,364  
    Warrants granted at end of period     38,747 34,164 19,800
    Joann Suzich | Warrants          
    Share-Based Payments          
    Warrants granted at beginning of period     10,260    
    Warrants granted       10,260  
    Warrants granted at end of period     10,260 10,260  
    Marianne Sgaard | Warrants          
    Share-Based Payments          
    Warrants granted at beginning of period     94,320    
    Warrants granted     9,167 28,368  
    Warrants held when becoming a member of management       65,952  
    Warrants granted at end of period     103,487 94,320  
    Helen Boudreau | Warrants          
    Share-Based Payments          
    Warrants granted at beginning of period     5,436    
    Warrants granted       5,436  
    Exercised     (5,436)    
    Warrants granted at end of period       5,436  
    Kim Bjrnstrup (former | Warrants          
    Share-Based Payments          
    Warrants granted       5,868  
    Warrants held when becoming a member of management       (5,868)  
    Lars Holtug | Warrants          
    Share-Based Payments          
    Warrants granted     4,583    
    Warrants granted at end of period     4,583    
    Executive Management | Warrants          
    Share-Based Payments          
    Warrants granted at beginning of period     1,007,100 1,044,648 848,772
    Warrants granted     206,731 7,668 195,876
    Warrants held when becoming a member of management     29,376 (4,356)  
    Forfeited       (45,216)  
    Warrants granted at end of period     1,243,207 1,007,100 1,044,648
    Lars Aage Staal Wegner | Warrants          
    Share-Based Payments          
    Warrants granted at beginning of period     852,084 844,416 844,416
    Warrants granted     64,167 7,668  
    Warrants granted at end of period     916,251 852,084 844,416
    Birgitte Rn | Warrants          
    Share-Based Payments          
    Warrants granted     45,000    
    Warrants held when becoming a member of management     29,376    
    Warrants granted at end of period     74,376    
    Thomas Bogenrieder | Warrants          
    Share-Based Payments          
    Warrants granted at beginning of period     4,356 49,572 4,356
    Warrants granted         45,216
    Warrants held when becoming a member of management       (4,356)  
    Forfeited       (45,216)  
    Warrants granted at end of period     4,356 4,356 49,572
    Erik Heegaard | Warrants          
    Share-Based Payments          
    Warrants granted     97,564    
    Warrants granted at end of period     97,564    
    Glenn S. Vraniak | Warrants          
    Share-Based Payments          
    Warrants granted at beginning of period     150,660 150,660  
    Warrants granted         150,660
    Warrants granted at end of period     150,660 150,660 150,660
    XML 146 R80.htm IDEA: XBRL DOCUMENT v3.22.1
    Financial Income and Expenses (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Finance income:      
    Interest income, bank     $ 8
    Interest income, other     1
    Foreign exchange gains $ 2,039 $ 216 56
    Total financial income 2,039 216 65
    Finance expenses:      
    Interest expenses (5) (29) (36)
    Changes in fair value of convertible debt instruments     (1,183)
    Interest expenses, lease liabilities (123)   (3)
    Interest, loan from lessor (31)    
    Foreign exchange losses (756) (194)  
    Total financial expenses (915) (223) (1,222)
    Net financial items $ 1,124 $ (7) $ (1,157)
    XML 147 R81.htm IDEA: XBRL DOCUMENT v3.22.1
    Income Taxes - Analysis of charge(credit) (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Income Taxes      
    Income tax benefit $ (178) $ (1,557) $ (825)
    Total income taxes for the year (178) (1,557) (825)
    Operating tax loss carry-forwards $ 9,500 $ 3,800 $ 1,300
    XML 148 R82.htm IDEA: XBRL DOCUMENT v3.22.1
    Income Taxes - Reconciliation of effective tax rate (Details)
    12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Reconciliation of effective tax rate to Danish statutory tax rate      
    Statutory corporate income tax rate in Denmark 22.00% 22.00% 22.00%
    Non-deductible income / (expenses)   (1.00%) (5.00%)
    Non-taxable income / (expenses)   1.00%  
    Additional tax deduction R&D expenses 6.00% 3.00%  
    Tax credit research and development expenditures (4.00%) 9.00% 7.00%
    Change in deferred tax asset not capitalized (23.00%) (25.00%) (17.00%)
    Total effective tax rate 1.00% 9.00% 7.00%
    XML 149 R83.htm IDEA: XBRL DOCUMENT v3.22.1
    Income Taxes - Deferred tax (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Disclosure of temporary difference, unused tax losses and unused tax credits [line items]      
    Deferred tax position   $ 262  
    Gross | Warrants      
    Disclosure of temporary difference, unused tax losses and unused tax credits [line items]      
    Deferred tax position $ 2,118 4,289 $ 3,034
    Gross | Loss carry forward      
    Disclosure of temporary difference, unused tax losses and unused tax credits [line items]      
    Deferred tax position 9,530 3,759 1,270
    Gross | Research and development expenditures      
    Disclosure of temporary difference, unused tax losses and unused tax credits [line items]      
    Deferred tax position   262  
    Gross | Other items      
    Disclosure of temporary difference, unused tax losses and unused tax credits [line items]      
    Deferred tax position (98) (6) (34)
    Valuation allowance      
    Disclosure of temporary difference, unused tax losses and unused tax credits [line items]      
    Deferred tax position $ (11,550) $ (8,042) $ (4,270)
    XML 150 R84.htm IDEA: XBRL DOCUMENT v3.22.1
    Basic and Diluted Loss Per Share (Details) - USD ($)
    $ / shares in Units, $ in Thousands
    12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Basic and Diluted Loss Per Share      
    Net loss attributable to shareholders of Evaxion Biotech A/S $ (24,532) $ (15,018) $ (11,195)
    Weighted-average number of ordinary shares outstanding 19,493,143 15,434,758 13,892,314
    Loss per share before and after dilution $ (1.26) $ (0.97) $ (0.81)
    XML 151 R85.htm IDEA: XBRL DOCUMENT v3.22.1
    Basic and Diluted Loss Per Share - Anti-dilutive shares (Details) - shares
    12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Warrants.      
    Antidilutive Securities Excluded From Computation Of Earnings Per Share Line Items1 Line Items      
    Anti-dilutive shares 2,732,618 2,228,076 2,059,128
    XML 152 R86.htm IDEA: XBRL DOCUMENT v3.22.1
    Intangible assets - Paragraph (Details) - USD ($)
    1 Months Ended 12 Months Ended
    Jun. 30, 2020
    Dec. 31, 2020
    DisclosureOfIntangibleAssetsLineItems    
    Additional accrual related license agreement   $ 60,000
    Technology-based intangible assets [member]    
    DisclosureOfIntangibleAssetsLineItems    
    License agreement on milestone payment $ 35,000  
    Additional option to extend agreement term 10 years  
    Capitalized intangible assets   35,000
    Additional consideration   320,000
    Amount to be transferred upon each regulatory approval of a product   250,000
    Technology-based intangible assets [member] | SSI    
    DisclosureOfIntangibleAssetsLineItems    
    Capitalized intangible assets   $ 60,000
    XML 153 R87.htm IDEA: XBRL DOCUMENT v3.22.1
    Intangible assets - Table (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    DisclosureOfIntangibleAssetsLineItems    
    December 31, 2020 $ 100  
    December 31, 2021 93 $ 100
    Cost    
    DisclosureOfIntangibleAssetsLineItems    
    December 31, 2020 100  
    Additions during the year 95
    Exchange rate adjustments (7) 5
    December 31, 2021 93 100
    Accumulated depreciation and amortisation [member]    
    DisclosureOfIntangibleAssetsLineItems    
    December 31, 2020 0  
    Exchange rate adjustments  
    Amortization for the year  
    December 31, 2021   $ 0
    XML 154 R88.htm IDEA: XBRL DOCUMENT v3.22.1
    Property, Plant and Equipment (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Reconciliation of changes in property, plant and equipment [abstract]    
    Balance beginning of year $ 221  
    Balance end of year 5,174 $ 221
    Property    
    Reconciliation of changes in property, plant and equipment [abstract]    
    Balance beginning of year 20  
    Balance end of year 2,601 20
    Right-of-use assets    
    Reconciliation of changes in property, plant and equipment [abstract]    
    Balance beginning of year 20  
    Balance end of year 2,601 20
    Other equipment    
    Reconciliation of changes in property, plant and equipment [abstract]    
    Balance beginning of year 201  
    Balance end of year 1,064 201
    Leasehold improvements    
    Reconciliation of changes in property, plant and equipment [abstract]    
    Balance end of year 1,509  
    Cost    
    Reconciliation of changes in property, plant and equipment [abstract]    
    Balance beginning of year 520 272
    Additions during the year 5,550 204
    Disposals during the year (244)  
    Exchange rate adjustments (278) 44
    Balance end of year 5,548 520
    Cost | Property    
    Reconciliation of changes in property, plant and equipment [abstract]    
    Balance beginning of year 257 179
    Additions during the year 2,891 55
    Disposals during the year (244)  
    Exchange rate adjustments (148) 23
    Balance end of year 2,756 257
    Cost | Other equipment    
    Reconciliation of changes in property, plant and equipment [abstract]    
    Balance beginning of year 263 93
    Additions during the year 1,025 149
    Exchange rate adjustments (63) 21
    Balance end of year 1,225 263
    Cost | Leasehold improvements    
    Reconciliation of changes in property, plant and equipment [abstract]    
    Additions during the year 1,634  
    Exchange rate adjustments (67)  
    Balance end of year 1,567  
    Accumulated Depreciation    
    Reconciliation of changes in property, plant and equipment [abstract]    
    Balance beginning of year (299) (171)
    Depreciation for the year (343) (105)
    Depreciation reversed on disposals 244  
    Exchange rate adjustments 24 (23)
    Balance end of year (374) (299)
    Accumulated Depreciation | Property    
    Reconciliation of changes in property, plant and equipment [abstract]    
    Balance beginning of year (237) (144)
    Depreciation for the year (179) (71)
    Depreciation reversed on disposals 244  
    Exchange rate adjustments 17 (22)
    Balance end of year (155) (237)
    Accumulated Depreciation | Right-of-use assets    
    Reconciliation of changes in property, plant and equipment [abstract]    
    Balance beginning of year (236) (145)
    Balance end of year (557) (236)
    Accumulated Depreciation | Other equipment    
    Reconciliation of changes in property, plant and equipment [abstract]    
    Balance beginning of year (62) (27)
    Depreciation for the year (105) (34)
    Exchange rate adjustments 6 (1)
    Balance end of year (161) $ (62)
    Accumulated Depreciation | Leasehold improvements    
    Reconciliation of changes in property, plant and equipment [abstract]    
    Depreciation for the year (59)  
    Exchange rate adjustments 1  
    Balance end of year $ (58)  
    XML 155 R89.htm IDEA: XBRL DOCUMENT v3.22.1
    Property, Plant and Equipment - Depreciation (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Disclosure of detailed information about property, plant and equipment [line items]      
    Total property, plant and equipment $ (5,174) $ (221)  
    Accumulated Depreciation      
    Disclosure of detailed information about property, plant and equipment [line items]      
    Depreciation 343 105  
    Total property, plant and equipment 374 299 $ 171
    Cost      
    Disclosure of detailed information about property, plant and equipment [line items]      
    Total property, plant and equipment (5,548) (520) (272)
    Operating Expense      
    Disclosure of detailed information about property, plant and equipment [line items]      
    Depreciation 343 105 80
    Research and development      
    Disclosure of detailed information about property, plant and equipment [line items]      
    Depreciation 270 90 64
    General and administrative      
    Disclosure of detailed information about property, plant and equipment [line items]      
    Depreciation 73 15 16
    Property      
    Disclosure of detailed information about property, plant and equipment [line items]      
    Total property, plant and equipment (2,601) (20)  
    Property | Accumulated Depreciation      
    Disclosure of detailed information about property, plant and equipment [line items]      
    Depreciation 179 71  
    Total property, plant and equipment 155 237 144
    Property | Cost      
    Disclosure of detailed information about property, plant and equipment [line items]      
    Total property, plant and equipment (2,756) (257) (179)
    Right-of-use assets      
    Disclosure of detailed information about property, plant and equipment [line items]      
    Total property, plant and equipment (2,601) (20)  
    Right-of-use assets | Accumulated Depreciation      
    Disclosure of detailed information about property, plant and equipment [line items]      
    Total property, plant and equipment $ 557 $ 236 $ 145
    XML 156 R90.htm IDEA: XBRL DOCUMENT v3.22.1
    Prepayments and other receivables (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Prepayments and other receivables    
    VAT receivables $ 387 $ 376
    Prepayments 638 1,175
    Other receivables 113 2
    Total receivables $ 1,138 $ 1,553
    XML 157 R91.htm IDEA: XBRL DOCUMENT v3.22.1
    Other Payables (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Other Payables    
    Employee cost liabilities $ 989 $ 1,054
    Other liabilities 46 180
    Total other payables $ 1,035 $ 1,234
    XML 158 R92.htm IDEA: XBRL DOCUMENT v3.22.1
    Cash and Cash Equivalents (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Dec. 31, 2018
    Cash and Cash Equivalents        
    Cash and cash equivalents $ 32,166 $ 5,834    
    Total cash and cash equivalents $ 32,166 $ 5,834 $ 9,559 $ 7,433
    XML 159 R93.htm IDEA: XBRL DOCUMENT v3.22.1
    Cash and Cash Equivalents - Changes in Net Working Capital (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Cash flows from (used in) operating activities [abstract]      
    Changes in receivables and tax receivables $ 1,863 $ (2,501) $ (337)
    Changes in trade payables (647) 1,798 507
    Changes in other payables 21 918 403
    Changes in net working capital $ 1,237 $ 215 $ 573
    XML 160 R94.htm IDEA: XBRL DOCUMENT v3.22.1
    Cash and Cash Equivalents - Adjustments for non-cash items (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Adjustments to reconcile profit (loss) [abstract]      
    Income taxes $ (178) $ (1,557) $ (825)
    Tax credit schemes accounted for as grants (12) (510)  
    Depreciation and amortization 344 105 81
    Interest income     (9)
    Interest expense 159 30 39
    Share-based compensation expenses 1,379 3,408 2,362
    Acquisition of property, plant and equipment (90)    
    Change in fair value of convertible debt instruments     1,183
    Other adjustments, primarily exchange rate adjustments (1,061) 107 114
    Total adjustments for non-cash items $ 541 $ 1,583 $ 2,945
    XML 161 R95.htm IDEA: XBRL DOCUMENT v3.22.1
    Cash and Cash Equivalents - Reconciliation of Liabilities from Financing Activities (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Disclosure of reconciliation of liabilities arising from financing activities [line items]    
    Balance beginning of year $ 20 $ 36
    Cash flows (226) (74)
    Accumulated interest 154 1
    Additions 4,161 54
    Exchange rate adjustment (266) 3
    Balance end of year 3,843 20
    Lease liabilities    
    Disclosure of reconciliation of liabilities arising from financing activities [line items]    
    Balance beginning of year 20 36
    Cash flows (226) (74)
    Accumulated interest 123 1
    Additions 2,731 54
    Exchange rate adjustment (128) 3
    Balance end of year 2,520 $ 20
    Loan From Lessor    
    Disclosure of reconciliation of liabilities arising from financing activities [line items]    
    Cash flows  
    Accumulated interest 31  
    Additions 1,269  
    Exchange rate adjustment (130)  
    Balance end of year 1,170  
    Provision    
    Disclosure of reconciliation of liabilities arising from financing activities [line items]    
    Cash flows  
    Additions 161  
    Exchange rate adjustment (8)  
    Balance end of year $ 153  
    XML 162 R96.htm IDEA: XBRL DOCUMENT v3.22.1
    Leases (Details)
    1 Months Ended 12 Months Ended
    Oct. 31, 2020
    USD ($)
    Dec. 31, 2021
    USD ($)
    lease
    Dec. 31, 2020
    USD ($)
    Dec. 31, 2019
    USD ($)
    Jan. 01, 2018
    USD ($)
    Disclosure of quantitative information about right-of-use assets [line items]          
    Lease liabilities   $ 2,520,000 $ 20,000 $ 36,000  
    Right-to-use asset   $ 2,601,000 $ 20,000 $ 35,000  
    Repayment loan, term   8 years      
    Fixed interest rate          
    Disclosure of quantitative information about right-of-use assets [line items]          
    Repayment of lease liability $ 1,300,000        
    Borrowing Interest Rates 6        
    Repayment loan, term 8 years        
    Copenhagen, Denmark          
    Disclosure of quantitative information about right-of-use assets [line items]          
    Number of leases | lease   1      
    Hrsholm, Denmark          
    Disclosure of quantitative information about right-of-use assets [line items]          
    Lease space | m² 1,356        
    Lease term 10 years        
    Lease termination fee $ 2,700,000        
    Hrsholm, Denmark | Office space          
    Disclosure of quantitative information about right-of-use assets [line items]          
    Lease space | m² 839        
    Lease monthly payment $ 12,000        
    Hrsholm, Denmark | Laboratory space          
    Disclosure of quantitative information about right-of-use assets [line items]          
    Lease space | m² 518        
    Hrsholm, Denmark | Minimum          
    Disclosure of quantitative information about right-of-use assets [line items]          
    Lease monthly payment $ 28,000        
    Percentage of increase in annual lease payment 2.00%        
    Hrsholm, Denmark | Minimum | Laboratory space          
    Disclosure of quantitative information about right-of-use assets [line items]          
    Lease monthly payment $ 16,000        
    Hrsholm, Denmark | Maximum          
    Disclosure of quantitative information about right-of-use assets [line items]          
    Lease monthly payment $ 30,000        
    Percentage of increase in annual lease payment 4.00%        
    Hrsholm, Denmark | Maximum | Laboratory space          
    Disclosure of quantitative information about right-of-use assets [line items]          
    Lease monthly payment $ 18,000        
    New York, United States          
    Disclosure of quantitative information about right-of-use assets [line items]          
    Lease term 13 months        
    IFRS 16          
    Disclosure of quantitative information about right-of-use assets [line items]          
    Lease liabilities         $ 200,000
    Right-to-use asset         $ 200,000
    Incremental borrowing rate         3.80%
    XML 163 R97.htm IDEA: XBRL DOCUMENT v3.22.1
    Leases - Movements in Right-of-use Assets and Lease Liabilities (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Leases    
    Cash outflow for leases $ 200 $ 200
    Right-of-Use Asset    
    Balance beginning of year 20 35
    Additions 2,891 54
    Depreciation (179) (73)
    Payments   4
    Translation (131)  
    Balance end of year 2,601 20
    Lease liabilities    
    Balance beginning of year 20 36
    Additions 2,731 54
    Interest expense 123  
    Payments (226) (74)
    Translation (128) 4
    Balance end of year $ 2,520 $ 20
    XML 164 R98.htm IDEA: XBRL DOCUMENT v3.22.1
    Leases - Summary of finance liability (Details)
    $ in Thousands
    Dec. 31, 2021
    USD ($)
    Disclosure of financial liabilities [abstract]  
    Loan from lessor $ 1,170
    Total Loan from lessor 1,170
    Less: Loan from lessor, current portion (126)
    Total Loan from lessor, net of current portion $ 1,044
    XML 165 R99.htm IDEA: XBRL DOCUMENT v3.22.1
    Debt (Details)
    € in Millions
    1 Months Ended
    Aug. 31, 2020
    EUR (€)
    kr / shares
    shares
    Feb. 17, 2022
    EUR (€)
    Dec. 31, 2021
    EUR (€)
    Aug. 31, 2021
    loan
    Dec. 17, 2020
    EUR (€)
    Disclosure of detailed information about borrowings [line items]          
    Cash settled warrants | shares 1,047,744        
    EIB Loan Agreement          
    Disclosure of detailed information about borrowings [line items]          
    Principal amount € 20.0   € 7.0    
    Number of tranches | loan       3  
    Debt instrument term 6 years        
    Exercise price per warrant | kr / shares € 1        
    Warrants attributable to debt | shares 351,036        
    EIB Loan Agreement | Tranche 1          
    Disclosure of detailed information about borrowings [line items]          
    Principal amount € 7.0 € 7.0 € 7.0   € 7.0
    EIB Loan Agreement | Tranche 2          
    Disclosure of detailed information about borrowings [line items]          
    Principal amount 6.0        
    EIB Loan Agreement | Tranche 3          
    Disclosure of detailed information about borrowings [line items]          
    Principal amount € 7.0        
    XML 166 R100.htm IDEA: XBRL DOCUMENT v3.22.1
    Capital Structure and Financial Matters - Loss of subscribed share capital (Details)
    Dec. 31, 2018
    Capital Structure and Financial Matters  
    Minimum percentage of lost subscribed share capital 50.00%
    XML 167 R101.htm IDEA: XBRL DOCUMENT v3.22.1
    Capital Structure and Financial Matters - Capital transactions (Details)
    1 Months Ended 3 Months Ended 12 Months Ended
    Nov. 09, 2021
    USD ($)
    $ / shares
    shares
    Nov. 05, 2021
    shares
    Feb. 05, 2021
    $ / shares
    shares
    Aug. 10, 2020
    kr / shares
    shares
    Nov. 30, 2021
    USD ($)
    $ / shares
    shares
    Feb. 28, 2021
    USD ($)
    $ / shares
    shares
    Oct. 31, 2020
    USD ($)
    $ / shares
    shares
    Sep. 30, 2020
    USD ($)
    $ / shares
    shares
    Sep. 30, 2020
    USD ($)
    Dec. 31, 2021
    USD ($)
    Dec. 31, 2020
    USD ($)
    shares
    Dec. 31, 2019
    USD ($)
    shares
    Dec. 31, 2021
    DKK (kr)
    kr / shares
    shares
    Dec. 31, 2021
    USD ($)
    shares
    Nov. 30, 2021
    DKK (kr)
    shares
    Nov. 09, 2021
    DKK (kr)
    Feb. 28, 2021
    DKK (kr)
    Feb. 05, 2021
    kr / shares
    Dec. 31, 2020
    kr / shares
    Dec. 31, 2018
    USD ($)
    shares
    Disclosure of classes of share capital [line items]                                        
    Payments for share issue costs | $                   $ 3,760,000 $ 128,000 $ 13,000                
    Registered, issued, and outstanding share capital                     2,648,000   kr 23,203,808 $ 3,755,000            
    Share capital | $                     $ 7,038,000 $ 9,362,000   $ 32,437,000           $ (931,000)
    IPO                                        
    Disclosure of classes of share capital [line items]                                        
    Nominal value per share | kr / shares                                   kr 1    
    Follow-on public offering                                        
    Disclosure of classes of share capital [line items]                                        
    Registered, issued, and outstanding share capital | kr                               kr 23,141,524        
    Ordinary Shares, nominal value of DKK 1 per share                                        
    Disclosure of classes of share capital [line items]                                        
    Ordinary shares issued | shares             269,136 745,380                        
    Share purchase price | $ / shares             $ 8.89 $ 8.89                        
    Aggregate proceeds | $             $ 2,400,000 $ 6,600,000                        
    Increase in authorized number of shares | shares       745,380                                
    Additional increase in authorized number of shares | shares       1,800,000                                
    Nominal value per share | kr / shares       kr 1                 kr 1           kr 1  
    Additional number of ordinary share warrants allowed to issue | shares       1,298,196                                
    Payments for share issue costs | $                 $ 144,022                      
    Price per share | $ / shares             $ 8.89 $ 8.89                        
    Net proceeds from issuance of shares | $             $ 2,400,000 $ 6,600,000                        
    Share capital (in shares) | shares                     16,198,668 15,184,152 23,203,808 23,203,808           12,917,016
    ADS                                        
    Disclosure of classes of share capital [line items]                                        
    Aggregate proceeds | $ $ 24,900,000                                      
    Net proceeds from issuance of shares | $ $ 24,900,000                                      
    ADS | IPO                                        
    Disclosure of classes of share capital [line items]                                        
    Ordinary shares issued | shares     3,000,000     3,000,000                            
    Share purchase price | $ / shares           $ 10.00                            
    Aggregate proceeds | $           $ 25,300,000                            
    Nominal value per share | $ / shares     $ 10.00                                  
    Price per share | $ / shares           $ 10.00                            
    Net proceeds from issuance of shares | $           $ 25,300,000                            
    Registered, issued, and outstanding share capital | kr                                 kr 19,198,668      
    Share capital (in shares) | shares                             23,141,524          
    ADS | Follow-on public offering                                        
    Disclosure of classes of share capital [line items]                                        
    Ordinary shares issued | shares 3,942,856                                      
    Share purchase price | $ / shares $ 7.00       $ 7.00                              
    Price per share | $ / shares $ 7.00       $ 7.00                              
    Capital increase from offering (in shares) | shares   514,285     3,942,856                              
    Capital increase from offering | $         $ 24,900,000                              
    Share capital | kr                             kr 23,141,524          
    ADS | Underwriters                                        
    Disclosure of classes of share capital [line items]                                        
    Ordinary shares issued | shares   514,285                                    
    XML 168 R102.htm IDEA: XBRL DOCUMENT v3.22.1
    Capital Structure and Financial Matters - Changes in Share Capital (Details)
    $ in Thousands
    1 Months Ended 12 Months Ended
    Nov. 09, 2021
    DKK (kr)
    shares
    Feb. 09, 2021
    DKK (kr)
    shares
    Oct. 15, 2020
    DKK (kr)
    shares
    Sep. 17, 2020
    DKK (kr)
    shares
    Dec. 19, 2019
    DKK (kr)
    shares
    Jul. 17, 2019
    DKK (kr)
    shares
    Nov. 30, 2021
    DKK (kr)
    shares
    Dec. 31, 2021
    DKK (kr)
    shares
    Dec. 31, 2021
    USD ($)
    shares
    Dec. 31, 2020
    DKK (kr)
    shares
    Dec. 31, 2020
    USD ($)
    shares
    Dec. 31, 2019
    DKK (kr)
    shares
    Dec. 31, 2019
    USD ($)
    shares
    Capital Structure and Financial Matters                          
    Equity | $                 $ 7,038   $ 9,362   $ (931)
    Issuance of shares for cash | $                 57,609   9,020   9,442
    Settlement of convertible debt instruments | $                         9,695
    Equity | $                 32,437   7,038   9,362
    Share capital                          
    Capital Structure and Financial Matters                          
    Equity               kr 16,198,000 2,648 kr 15,184,000 2,481 kr 12,917,000 2,113
    Issuance of shares for cash kr 3,943,000 kr 3,000,000 kr 269,000 kr 745,000 kr 118,000 kr 998,000 kr 63,000   1,107   167   181
    Settlement of convertible debt instruments | $                         187
    Equity               kr 23,204,000 $ 3,755 kr 16,198,000 $ 2,648 kr 15,184,000 $ 2,481
    Share capital | Convertible Debt 1                          
    Capital Structure and Financial Matters                          
    Settlement of convertible debt instruments | kr           303,000              
    Share capital | Convertible Debt 2                          
    Capital Structure and Financial Matters                          
    Settlement of convertible debt instruments | kr           kr 848,000              
    Ordinary Shares, nominal value of DKK 1 per share                          
    Capital Structure and Financial Matters                          
    Share capital, shares, beginning of year | shares               16,198,668 16,198,668 15,184,152 15,184,152 12,917,016 12,917,016
    Issuance of shares for cash, shares | shares 3,942,856 3,000,000 269,136 745,380 118,260 997,668 62,284            
    Share capital, shares, end of the period | shares               23,203,808 23,203,808 16,198,668 16,198,668 15,184,152 15,184,152
    Ordinary Shares, nominal value of DKK 1 per share | Initial Public Offering                          
    Capital Structure and Financial Matters                          
    Equity | kr kr 23,141,524                        
    Ordinary Shares, nominal value of DKK 1 per share | Convertible Debt 1                          
    Capital Structure and Financial Matters                          
    Settlement of convertible debt instruments, shares | shares           302,976              
    Ordinary Shares, nominal value of DKK 1 per share | Convertible Debt 2                          
    Capital Structure and Financial Matters                          
    Settlement of convertible debt instruments, shares | shares           848,232              
    XML 169 R103.htm IDEA: XBRL DOCUMENT v3.22.1
    Capital Structure and Financial Matters - Share Capital (Details)
    kr / shares in Units, kr in Thousands, $ in Thousands
    Dec. 31, 2021
    DKK (kr)
    kr / shares
    shares
    Dec. 31, 2021
    USD ($)
    shares
    Dec. 31, 2020
    DKK (kr)
    kr / shares
    shares
    Dec. 31, 2020
    USD ($)
    shares
    Aug. 10, 2020
    kr / shares
    Dec. 31, 2019
    DKK (kr)
    shares
    Dec. 31, 2019
    USD ($)
    shares
    Dec. 31, 2018
    DKK (kr)
    shares
    Dec. 31, 2018
    USD ($)
    shares
    Disclosure of classes of share capital [line items]                  
    Share capital | $   $ 32,437   $ 7,038     $ 9,362   $ (931)
    Share capital                  
    Disclosure of classes of share capital [line items]                  
    Share capital kr 23,204 $ 3,755 kr 16,198 $ 2,648   kr 15,184 $ 2,481 kr 12,917 $ 2,113
    Ordinary Shares, nominal value of DKK 1 per share                  
    Disclosure of classes of share capital [line items]                  
    Allotted, called up and fully paid shares | shares 23,203,808 23,203,808 16,198,668 16,198,668   15,184,152 15,184,152 12,917,016 12,917,016
    Nominal value per share | kr / shares kr 1   kr 1   kr 1        
    XML 170 R104.htm IDEA: XBRL DOCUMENT v3.22.1
    Capital Structure and Financial Matters - Shareholdings by Directors and Executive Management (Details) - shares
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Executive Management      
    Disclosure of classes of share capital [line items]      
    Number of shares issued (in shares) 8,638,560 8,638,560 8,638,560
    Niels Iversen Mller      
    Disclosure of classes of share capital [line items]      
    Number of shares issued (in shares) 4,292,604 4,292,604 4,292,604
    Andreas Holm Mattsson      
    Disclosure of classes of share capital [line items]      
    Number of shares issued (in shares) 4,163,832 4,163,832 4,163,832
    Lars Aage Staal Wegner      
    Disclosure of classes of share capital [line items]      
    Number of shares issued (in shares) 182,124 182,124 182,124
    Board of Directors      
    Disclosure of classes of share capital [line items]      
    Number of shares issued (in shares) 379,188 864,864 803,844
    Roberto Prego      
    Disclosure of classes of share capital [line items]      
    Number of shares issued (in shares) 310,248 310,248 310,248
    Thomas William Wylonis      
    Disclosure of classes of share capital [line items]      
    Number of shares issued (in shares)   485,676 481,860
    Marianne Sgaard      
    Disclosure of classes of share capital [line items]      
    Number of shares issued (in shares) 41,652 41,652  
    Steven Projan      
    Disclosure of classes of share capital [line items]      
    Number of shares issued (in shares) 27,288 27,288 11,736
    XML 171 R105.htm IDEA: XBRL DOCUMENT v3.22.1
    Convertible Debt Instruments - Issuance (Details)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2019
    USD ($)
    Dec. 31, 2018
    USD ($)
    instrument
    Convertible Debt Instruments    
    Types of convertible debt instruments issued | instrument   2
    Proceeds from issuance of convertible debt instruments $ 152  
    Convertible debt instruments    
    Convertible Debt Instruments    
    Proceeds from issuance of convertible debt instruments   $ 8,000
    Convertible debt instruments | Board of Directors and Executive Management    
    Convertible Debt Instruments    
    Proceeds from issuance of convertible debt instruments   $ 100
    XML 172 R106.htm IDEA: XBRL DOCUMENT v3.22.1
    Convertible Debt Instruments - Summary of changes in the convertible debt instruments (Details)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2019
    USD ($)
    Borrowings [abstract]  
    Carrying amount at beginning of year $ 8,569
    Proceeds from issuance of convertible debt instruments 152
    Fair value adjustment included in finance expenses 1,183
    Currency adjustment (209)
    Converted to equity $ (9,695)
    Carrying amount at end of year  
    XML 173 R107.htm IDEA: XBRL DOCUMENT v3.22.1
    Convertible Debt Instruments - Terms of Convertible Debt (Details)
    $ / shares in Units, kr in Millions, $ in Millions
    12 Months Ended
    Dec. 31, 2018
    USD ($)
    $ / shares
    Dec. 31, 2021
    Dec. 31, 2018
    DKK (kr)
    Convertible Debt Instruments      
    Interest coupon   6.00%  
    Convertible debt instruments      
    Convertible Debt Instruments      
    Interest coupon   7.50%  
    Convertible Debt 1      
    Convertible Debt Instruments      
    Term 12 months    
    Interest coupon 7.50%   7.50%
    Capital increase threshold for loan conversion | kr     kr 9.8
    Discount on share price to be applied when calculating conversion price 20.00%   20.00%
    Premium to be applied in prepayment terms 50.00%    
    Convertible Debt 1 | USD      
    Convertible Debt Instruments      
    Loan $ 0.9    
    Convertible Debt 1 | DKK      
    Convertible Debt Instruments      
    Loan $ 1.0   kr 7.1
    Convertible Debt 2      
    Convertible Debt Instruments      
    Interest coupon 7.50%   7.50%
    Capital increase threshold for loan conversion $ 10.0    
    Premium to be applied in prepayment terms 50.00%    
    Mandatory conversion price at maturity | $ / shares $ 160.41    
    Period before conversion during which loans denominated in foreign currency will convert into functional currency loan 10 days    
    Convertible Debt 2 | Qualified capital increase occurs in year of loan issuance      
    Convertible Debt Instruments      
    Discount on share price to be applied when calculating conversion price 5.00%   5.00%
    Convertible Debt 2 | Qualified capital increase occurs in year following the loan issuance      
    Convertible Debt Instruments      
    Discount on share price to be applied when calculating conversion price 10.00%   10.00%
    Convertible Debt 2 | Qualified capital increase occurs in two years following the loan issuance      
    Convertible Debt Instruments      
    Discount on share price to be applied when calculating conversion price 20.00%   20.00%
    Convertible Debt 2 | USD      
    Convertible Debt Instruments      
    Loan $ 5.4    
    Convertible Debt 2 | DKK      
    Convertible Debt Instruments      
    Loan $ 0.7   kr 5.0
    XML 174 R108.htm IDEA: XBRL DOCUMENT v3.22.1
    Related Party Transactions (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Dec. 31, 2019
    Disclosure of transactions between related parties [line items]      
    Interest rate 6.00%    
    Convertible debt instruments      
    Disclosure of transactions between related parties [line items]      
    Accrued interest on convertible debt instruments issued to members of executive management and board of directors     $ (4)
    Prepaid rent and deposit for a leased property from a related party   $ 7  
    Interest rate 7.50%    
    XML 175 R109.htm IDEA: XBRL DOCUMENT v3.22.1
    Contractual Obligations - Contractual Commitments (Details) - USD ($)
    $ in Thousands
    Dec. 31, 2021
    Dec. 31, 2020
    Contractual obligations    
    Contractual commitments $ 72 $ 712
    Less than one year    
    Contractual obligations    
    Contractual commitments 72 712
    Purchase obligations    
    Contractual obligations    
    Contractual commitments 72 712
    Purchase obligations | Less than one year    
    Contractual obligations    
    Contractual commitments 72 712
    Purchase obligations | CRO's    
    Contractual obligations    
    Contractual commitments   600
    Purchase obligations | University future partners    
    Contractual obligations    
    Contractual commitments   $ 100
    Purchase obligations | System Provider    
    Contractual obligations    
    Contractual commitments $ 72,000  
    XML 176 R110.htm IDEA: XBRL DOCUMENT v3.22.1
    Provisions (Details)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2021
    USD ($)
    Provisions  
    Provision Recognized $ 161
    Currency adjustment (8)
    Carrying amount of ending balance $ 153
    XML 177 R111.htm IDEA: XBRL DOCUMENT v3.22.1
    Fees to auditors (Details) - USD ($)
    $ in Thousands
    12 Months Ended
    Dec. 31, 2021
    Dec. 31, 2020
    Fees to auditors    
    Audit fees $ 177 $ 308
    Audit related fees 108 119
    Other fees 328 253
    Total fees $ 613 $ 680
    XML 178 R112.htm IDEA: XBRL DOCUMENT v3.22.1
    Events After the Reporting Period (Details)
    $ in Thousands, € in Millions
    Feb. 17, 2022
    EUR (€)
    Feb. 14, 2022
    EUR (€)
    Dec. 31, 2021
    EUR (€)
    Dec. 31, 2021
    USD ($)
    Aug. 31, 2020
    EUR (€)
    Disclosure of non-adjusting events after reporting period [line items]          
    Borrowings | $       $ 1,170  
    Tranche 1          
    Disclosure of non-adjusting events after reporting period [line items]          
    Borrowings € 7.0        
    EIB Loan Agreement          
    Disclosure of non-adjusting events after reporting period [line items]          
    Principal amount     € 7.0   € 20.0
    EIB Loan Agreement | Tranche 1          
    Disclosure of non-adjusting events after reporting period [line items]          
    Borrowings   € 7.0      
    XML 179 evax-20211231x20f_htm.xml IDEA: XBRL DOCUMENT 0001828253 evax:WarrantsMember 2018-01-01 2018-12-31 0001828253 srt:ManagementMember evax:WarrantsMember 2021-12-31 0001828253 srt:ManagementMember evax:WarrantsMember 2021-06-30 0001828253 evax:WarrantsEntitlements2020Member 2020-12-31 0001828253 evax:WarrantsEntitlements2019Member 2020-12-31 0001828253 srt:ManagementMember evax:WarrantsMember 2019-10-31 0001828253 evax:EmployeesMember evax:WarrantsMember 2019-09-30 0001828253 evax:EmployeesMember evax:WarrantsMember 2019-02-28 0001828253 srt:ManagementMember evax:WarrantsMember 2019-01-31 0001828253 evax:IfrsWarrantMember 2019-01-01 2019-12-31 0001828253 ifrs-full:OtherPropertyPlantAndEquipmentMember ifrs-full:TopOfRangeMember 2021-01-01 2021-12-31 0001828253 ifrs-full:OtherPropertyPlantAndEquipmentMember ifrs-full:BottomOfRangeMember 2021-01-01 2021-12-31 0001828253 ifrs-full:LeaseholdImprovementsMember 2021-01-01 2021-12-31 0001828253 evax:IfrsEmergingGrowthCompanyMember 2021-01-01 2021-12-31 0001828253 ifrs-full:GrossCarryingAmountMember ifrs-full:OtherPropertyPlantAndEquipmentMember 2021-12-31 0001828253 ifrs-full:GrossCarryingAmountMember ifrs-full:LeaseholdImprovementsMember 2021-12-31 0001828253 ifrs-full:GrossCarryingAmountMember evax:AllPropertyExceptForOtherEquipmentMember 2021-12-31 0001828253 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember ifrs-full:RightofuseAssetsMember 2021-12-31 0001828253 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember ifrs-full:OtherPropertyPlantAndEquipmentMember 2021-12-31 0001828253 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember ifrs-full:LeaseholdImprovementsMember 2021-12-31 0001828253 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember evax:AllPropertyExceptForOtherEquipmentMember 2021-12-31 0001828253 ifrs-full:RightofuseAssetsMember 2021-12-31 0001828253 ifrs-full:OtherPropertyPlantAndEquipmentMember 2021-12-31 0001828253 ifrs-full:LeaseholdImprovementsMember 2021-12-31 0001828253 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2021-12-31 0001828253 evax:AllPropertyExceptForOtherEquipmentMember 2021-12-31 0001828253 ifrs-full:GrossCarryingAmountMember ifrs-full:OtherPropertyPlantAndEquipmentMember 2020-12-31 0001828253 ifrs-full:GrossCarryingAmountMember evax:AllPropertyExceptForOtherEquipmentMember 2020-12-31 0001828253 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember ifrs-full:RightofuseAssetsMember 2020-12-31 0001828253 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember ifrs-full:OtherPropertyPlantAndEquipmentMember 2020-12-31 0001828253 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember evax:AllPropertyExceptForOtherEquipmentMember 2020-12-31 0001828253 ifrs-full:RightofuseAssetsMember 2020-12-31 0001828253 ifrs-full:OtherPropertyPlantAndEquipmentMember 2020-12-31 0001828253 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2020-12-31 0001828253 evax:AllPropertyExceptForOtherEquipmentMember 2020-12-31 0001828253 ifrs-full:GrossCarryingAmountMember ifrs-full:OtherPropertyPlantAndEquipmentMember 2019-12-31 0001828253 ifrs-full:GrossCarryingAmountMember evax:AllPropertyExceptForOtherEquipmentMember 2019-12-31 0001828253 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember ifrs-full:RightofuseAssetsMember 2019-12-31 0001828253 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember ifrs-full:OtherPropertyPlantAndEquipmentMember 2019-12-31 0001828253 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember evax:AllPropertyExceptForOtherEquipmentMember 2019-12-31 0001828253 ifrs-full:GrossCarryingAmountMember 2019-12-31 0001828253 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2019-12-31 0001828253 evax:AmericanDepositarySharesMember 2021-11-09 2021-11-09 0001828253 evax:ConvertibleDebtsMember ifrs-full:KeyManagementPersonnelOfEntityOrParentMember 2018-01-01 2018-12-31 0001828253 evax:ConvertibleDebtsMember 2018-01-01 2018-12-31 0001828253 ifrs-full:OrdinarySharesMember 2020-07-01 2020-09-30 0001828253 evax:IfrsIpoMember evax:AmericanDepositarySharesMember 2021-02-05 0001828253 ifrs-full:OrdinarySharesMember 2020-08-10 0001828253 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2020-01-01 2020-12-31 0001828253 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2019-01-01 2019-12-31 0001828253 srt:ManagementMember 2021-12-31 0001828253 srt:DirectorMember 2021-12-31 0001828253 ifrs-full:OrdinarySharesMember 2021-12-31 0001828253 evax:StevenProjanMember 2021-12-31 0001828253 evax:RobertoPregoMember 2021-12-31 0001828253 evax:NielsIversenMllerMember 2021-12-31 0001828253 evax:MarianneSogaardMember 2021-12-31 0001828253 evax:LarsAageStaalWegnerMember 2021-12-31 0001828253 evax:AndreasHolmMattssonMember 2021-12-31 0001828253 evax:IfrsIpoMember evax:AmericanDepositarySharesMember 2021-11-30 0001828253 evax:AmericanDepositarySharesMember evax:InitialPublicOfferingMember 2021-11-09 0001828253 srt:ManagementMember 2020-12-31 0001828253 srt:DirectorMember 2020-12-31 0001828253 ifrs-full:OrdinarySharesMember 2020-12-31 0001828253 evax:ThomasWilliamWylonisMember 2020-12-31 0001828253 evax:StevenProjanMember 2020-12-31 0001828253 evax:RobertoPregoMember 2020-12-31 0001828253 evax:NielsIversenMllerMember 2020-12-31 0001828253 evax:MarianneSogaardMember 2020-12-31 0001828253 evax:LarsAageStaalWegnerMember 2020-12-31 0001828253 evax:AndreasHolmMattssonMember 2020-12-31 0001828253 srt:ManagementMember 2019-12-31 0001828253 srt:DirectorMember 2019-12-31 0001828253 ifrs-full:OrdinarySharesMember 2019-12-31 0001828253 evax:ThomasWilliamWylonisMember 2019-12-31 0001828253 evax:StevenProjanMember 2019-12-31 0001828253 evax:RobertoPregoMember 2019-12-31 0001828253 evax:NielsIversenMllerMember 2019-12-31 0001828253 evax:LarsAageStaalWegnerMember 2019-12-31 0001828253 evax:AndreasHolmMattssonMember 2019-12-31 0001828253 ifrs-full:OrdinarySharesMember 2018-12-31 0001828253 evax:IfrsIpoMember 2021-02-05 0001828253 evax:WarrantsMember 2021-12-01 2021-12-31 0001828253 srt:ManagementMember evax:WarrantsMember 2021-10-01 2021-10-31 0001828253 srt:ManagementMember evax:WarrantsMember 2021-06-01 2021-06-30 0001828253 evax:StevenProjanMember evax:IfrsWarrantMember 2021-01-01 2021-12-31 0001828253 evax:RobertoPregoMember evax:IfrsWarrantMember 2021-01-01 2021-12-31 0001828253 evax:MarianneSogaardMember evax:IfrsWarrantMember 2021-01-01 2021-12-31 0001828253 evax:LarsHoltugMember evax:IfrsWarrantMember 2021-01-01 2021-12-31 0001828253 evax:LarsAageStaalWegnerMember evax:IfrsWarrantMember 2021-01-01 2021-12-31 0001828253 evax:ErikHeegaardMember evax:IfrsWarrantMember 2021-01-01 2021-12-31 0001828253 evax:WarrantsMember 2020-12-01 2020-12-31 0001828253 srt:DirectorMember 2020-11-25 2020-11-25 0001828253 srt:DirectorMember 2020-06-01 2020-06-30 0001828253 evax:StevenProjanMember evax:IfrsWarrantMember 2020-01-01 2020-12-31 0001828253 evax:RobertoPregoMember evax:IfrsWarrantMember 2020-01-01 2020-12-31 0001828253 evax:LarsAageStaalWegnerMember evax:IfrsWarrantMember 2020-01-01 2020-12-31 0001828253 evax:JoannSuzichMember evax:IfrsWarrantMember 2020-01-01 2020-12-31 0001828253 evax:HelenBoudreauMember evax:IfrsWarrantMember 2020-01-01 2020-12-31 0001828253 srt:ManagementMember evax:IfrsWarrantMember 2019-01-01 2019-12-31 0001828253 srt:ChiefFinancialOfficerMember evax:WarrantsMember 2019-01-01 2019-12-31 0001828253 evax:ThomasBogenriederMember evax:IfrsWarrantMember 2019-01-01 2019-12-31 0001828253 evax:GlennS.VraniakMember evax:IfrsWarrantMember 2019-01-01 2019-12-31 0001828253 evax:WarrantsMember 2020-04-30 2020-04-30 0001828253 srt:DirectorMember evax:IfrsWarrantMember 2021-01-01 2021-12-31 0001828253 evax:HelenBoudreauMember evax:IfrsWarrantMember 2021-01-01 2021-12-31 0001828253 srt:ManagementMember evax:IfrsWarrantMember 2021-12-31 0001828253 srt:DirectorMember evax:IfrsWarrantMember 2021-12-31 0001828253 evax:ThomasWilliamWylonisMember evax:IfrsWarrantMember 2021-12-31 0001828253 evax:ThomasBogenriederMember evax:IfrsWarrantMember 2021-12-31 0001828253 evax:StevenProjanMember evax:IfrsWarrantMember 2021-12-31 0001828253 evax:RobertoPregoMember evax:IfrsWarrantMember 2021-12-31 0001828253 evax:MarianneSogaardMember evax:IfrsWarrantMember 2021-12-31 0001828253 evax:LarsHoltugMember evax:IfrsWarrantMember 2021-12-31 0001828253 evax:LarsAageStaalWegnerMember evax:IfrsWarrantMember 2021-12-31 0001828253 evax:JoannSuzichMember evax:IfrsWarrantMember 2021-12-31 0001828253 evax:GrantSeptember2019Member evax:IfrsWarrantMember 2021-12-31 0001828253 evax:GrantSeptember2017Member evax:IfrsWarrantMember 2021-12-31 0001828253 evax:GrantOctober2019Member evax:IfrsWarrantMember 2021-12-31 0001828253 evax:GrantJune2021Member evax:IfrsWarrantMember 2021-12-31 0001828253 evax:GrantFebruary2019Member evax:IfrsWarrantMember 2021-12-31 0001828253 evax:GrantedDuring2018Member evax:IfrsWarrantMember 2021-12-31 0001828253 evax:GrantDecember2021Member evax:IfrsWarrantMember 2021-12-31 0001828253 evax:GrantDecember2020Member evax:IfrsWarrantMember 2021-12-31 0001828253 evax:GrantDecember2017Member evax:IfrsWarrantMember 2021-12-31 0001828253 evax:GrantDecember2016Member evax:IfrsWarrantMember 2021-12-31 0001828253 evax:GrantApril2021Member evax:IfrsWarrantMember 2021-12-31 0001828253 evax:GlennS.VraniakMember evax:IfrsWarrantMember 2021-12-31 0001828253 evax:ErikHeegaardMember evax:IfrsWarrantMember 2021-12-31 0001828253 evax:BirgitteRnMember evax:IfrsWarrantMember 2021-12-31 0001828253 evax:WarrantsMember 2021-12-31 0001828253 evax:IfrsWarrantMember 2021-12-31 0001828253 srt:ManagementMember evax:IfrsWarrantMember 2020-12-31 0001828253 srt:DirectorMember evax:IfrsWarrantMember 2020-12-31 0001828253 evax:ThomasWilliamWylonisMember evax:IfrsWarrantMember 2020-12-31 0001828253 evax:ThomasBogenriederMember evax:IfrsWarrantMember 2020-12-31 0001828253 evax:StevenProjanMember evax:IfrsWarrantMember 2020-12-31 0001828253 evax:RobertoPregoMember evax:IfrsWarrantMember 2020-12-31 0001828253 evax:MarianneSogaardMember evax:IfrsWarrantMember 2020-12-31 0001828253 evax:LarsAageStaalWegnerMember evax:IfrsWarrantMember 2020-12-31 0001828253 evax:JoannSuzichMember evax:IfrsWarrantMember 2020-12-31 0001828253 evax:HelenBoudreauMember evax:IfrsWarrantMember 2020-12-31 0001828253 evax:GrantSeptember2019Member evax:IfrsWarrantMember 2020-12-31 0001828253 evax:GrantSeptember2017Member evax:IfrsWarrantMember 2020-12-31 0001828253 evax:GrantOctober2019Member evax:IfrsWarrantMember 2020-12-31 0001828253 evax:GrantFebruary2019Member evax:IfrsWarrantMember 2020-12-31 0001828253 evax:GrantedDuring2018Member evax:IfrsWarrantMember 2020-12-31 0001828253 evax:GrantDecember2020Member evax:IfrsWarrantMember 2020-12-31 0001828253 evax:GrantDecember2017Member evax:IfrsWarrantMember 2020-12-31 0001828253 evax:GrantDecember2016Member evax:IfrsWarrantMember 2020-12-31 0001828253 evax:GrantApril2017Member evax:IfrsWarrantMember 2020-12-31 0001828253 evax:GlennS.VraniakMember evax:IfrsWarrantMember 2020-12-31 0001828253 evax:WarrantsMember 2020-12-31 0001828253 evax:IfrsWarrantMember 2020-12-31 0001828253 srt:ManagementMember evax:IfrsWarrantMember 2019-12-31 0001828253 srt:DirectorMember evax:IfrsWarrantMember 2019-12-31 0001828253 evax:ThomasWilliamWylonisMember evax:IfrsWarrantMember 2019-12-31 0001828253 evax:ThomasBogenriederMember evax:IfrsWarrantMember 2019-12-31 0001828253 evax:StevenProjanMember evax:IfrsWarrantMember 2019-12-31 0001828253 evax:RobertoPregoMember evax:IfrsWarrantMember 2019-12-31 0001828253 evax:LarsAageStaalWegnerMember evax:IfrsWarrantMember 2019-12-31 0001828253 evax:GrantSeptember2019Member evax:IfrsWarrantMember 2019-12-31 0001828253 evax:GrantSeptember2017Member evax:IfrsWarrantMember 2019-12-31 0001828253 evax:GrantOctober2019Member evax:IfrsWarrantMember 2019-12-31 0001828253 evax:GrantJanuary2019Member evax:IfrsWarrantMember 2019-12-31 0001828253 evax:GrantFebruary2019Member evax:IfrsWarrantMember 2019-12-31 0001828253 evax:GrantedDuring2018Member evax:IfrsWarrantMember 2019-12-31 0001828253 evax:GrantDecember2017Member evax:IfrsWarrantMember 2019-12-31 0001828253 evax:GrantDecember2016Member evax:IfrsWarrantMember 2019-12-31 0001828253 evax:GrantApril2017Member evax:IfrsWarrantMember 2019-12-31 0001828253 evax:GlennS.VraniakMember evax:IfrsWarrantMember 2019-12-31 0001828253 evax:WarrantsMember 2019-12-31 0001828253 evax:IfrsWarrantMember 2019-12-31 0001828253 evax:EmployeesMember 2019-12-31 0001828253 srt:ManagementMember evax:IfrsWarrantMember 2018-12-31 0001828253 srt:DirectorMember evax:IfrsWarrantMember 2018-12-31 0001828253 evax:ThomasWilliamWylonisMember evax:IfrsWarrantMember 2018-12-31 0001828253 evax:ThomasBogenriederMember evax:IfrsWarrantMember 2018-12-31 0001828253 evax:StevenProjanMember evax:IfrsWarrantMember 2018-12-31 0001828253 evax:RobertoPregoMember evax:IfrsWarrantMember 2018-12-31 0001828253 evax:LarsAageStaalWegnerMember evax:IfrsWarrantMember 2018-12-31 0001828253 evax:WarrantsMember 2018-12-31 0001828253 evax:EmployeesMember 2018-12-31 0001828253 evax:ResearchAndDevelopmentExpensesMember ifrs-full:KeyManagementPersonnelOfEntityOrParentMember 2021-12-31 0001828253 evax:GeneralAndAdministrativeExpensesMember ifrs-full:KeyManagementPersonnelOfEntityOrParentMember 2021-12-31 0001828253 evax:ResearchAndDevelopmentExpensesMember ifrs-full:KeyManagementPersonnelOfEntityOrParentMember 2020-12-31 0001828253 evax:GeneralAndAdministrativeExpensesMember ifrs-full:KeyManagementPersonnelOfEntityOrParentMember 2020-12-31 0001828253 evax:ResearchAndDevelopmentExpensesMember ifrs-full:KeyManagementPersonnelOfEntityOrParentMember 2019-12-31 0001828253 evax:GeneralAndAdministrativeExpensesMember ifrs-full:KeyManagementPersonnelOfEntityOrParentMember 2019-12-31 0001828253 evax:EibLoanAgreementMember evax:TrancheOneMember 2022-02-17 0001828253 evax:EibLoanAgreementMember evax:TrancheOneMember 2021-12-31 0001828253 evax:EibLoanAgreementMember 2021-12-31 0001828253 evax:EibLoanAgreementMember evax:TrancheOneMember 2020-12-17 0001828253 evax:EibLoanAgreementMember evax:TrancheTwoMember 2020-08-31 0001828253 evax:EibLoanAgreementMember evax:TrancheThreeMember 2020-08-31 0001828253 evax:EibLoanAgreementMember evax:TrancheOneMember 2020-08-31 0001828253 evax:EibLoanAgreementMember 2020-08-31 0001828253 currency:USD evax:ConvertibleDebt2Member 2018-12-31 0001828253 currency:DKK evax:ConvertibleDebt2Member 2018-12-31 0001828253 currency:USD evax:ConvertibleDebt1Member 2018-12-31 0001828253 currency:DKK evax:ConvertibleDebt1Member 2018-12-31 0001828253 ifrs-full:LeaseLiabilitiesMember ifrs-full:NotLaterThanOneYearMember 2021-12-31 0001828253 ifrs-full:LeaseLiabilitiesMember ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember 2021-12-31 0001828253 ifrs-full:LeaseLiabilitiesMember ifrs-full:LaterThanFiveYearsMember 2021-12-31 0001828253 evax:TradePayablesMember ifrs-full:NotLaterThanOneYearMember 2021-12-31 0001828253 evax:ProvisionMember ifrs-full:LaterThanFiveYearsMember 2021-12-31 0001828253 evax:OtherPayablesMember ifrs-full:NotLaterThanOneYearMember 2021-12-31 0001828253 evax:LoanFromLessorMember ifrs-full:NotLaterThanOneYearMember 2021-12-31 0001828253 evax:LoanFromLessorMember ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember 2021-12-31 0001828253 evax:LoanFromLessorMember ifrs-full:LaterThanFiveYearsMember 2021-12-31 0001828253 ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember 2021-12-31 0001828253 ifrs-full:LaterThanFiveYearsMember 2021-12-31 0001828253 ifrs-full:LeaseLiabilitiesMember ifrs-full:NotLaterThanOneYearMember 2020-12-31 0001828253 evax:TradePayablesMember ifrs-full:NotLaterThanOneYearMember 2020-12-31 0001828253 evax:OtherPayablesMember ifrs-full:NotLaterThanOneYearMember 2020-12-31 0001828253 ifrs-full:LeaseLiabilitiesMember 2021-12-31 0001828253 evax:ProvisionMember 2021-12-31 0001828253 evax:LoanFromLessorMember 2021-12-31 0001828253 ifrs-full:LeaseLiabilitiesMember 2020-12-31 0001828253 ifrs-full:LeaseLiabilitiesMember 2019-12-31 0001828253 evax:Ifrs16Member 2018-01-01 0001828253 srt:ManagementMember 2021-01-01 2021-12-31 0001828253 srt:DirectorMember 2021-01-01 2021-12-31 0001828253 ifrs-full:KeyManagementPersonnelOfEntityOrParentMember 2021-01-01 2021-12-31 0001828253 srt:ManagementMember 2020-01-01 2020-12-31 0001828253 srt:DirectorMember 2020-01-01 2020-12-31 0001828253 ifrs-full:KeyManagementPersonnelOfEntityOrParentMember 2020-01-01 2020-12-31 0001828253 srt:ManagementMember 2019-01-01 2019-12-31 0001828253 srt:DirectorMember 2019-01-01 2019-12-31 0001828253 ifrs-full:KeyManagementPersonnelOfEntityOrParentMember 2019-01-01 2019-12-31 0001828253 ifrs-full:IssuedCapitalMember 2021-11-09 2021-11-09 0001828253 ifrs-full:IssuedCapitalMember 2021-11-01 2021-11-30 0001828253 ifrs-full:IssuedCapitalMember 2021-02-09 2021-02-09 0001828253 ifrs-full:SharePremiumMember 2021-01-01 2021-12-31 0001828253 ifrs-full:IssuedCapitalMember 2021-01-01 2021-12-31 0001828253 ifrs-full:IssuedCapitalMember 2020-10-15 2020-10-15 0001828253 ifrs-full:IssuedCapitalMember 2020-09-17 2020-09-17 0001828253 ifrs-full:SharePremiumMember 2020-01-01 2020-12-31 0001828253 ifrs-full:IssuedCapitalMember 2020-01-01 2020-12-31 0001828253 ifrs-full:IssuedCapitalMember 2019-12-19 2019-12-19 0001828253 ifrs-full:IssuedCapitalMember 2019-07-17 2019-07-17 0001828253 evax:FollowOnPublicOfferingMember 2021-11-09 0001828253 evax:IfrsIpoMember evax:AmericanDepositarySharesMember 2021-02-28 0001828253 ifrs-full:GrossCarryingAmountMember 2021-12-31 0001828253 ifrs-full:GrossCarryingAmountMember 2020-12-31 0001828253 ifrs-full:AccumulatedDepreciationAndAmortisationMember 2020-12-31 0001828253 ifrs-full:RetainedEarningsMember 2021-01-01 2021-12-31 0001828253 ifrs-full:RetainedEarningsMember 2020-01-01 2020-12-31 0001828253 ifrs-full:RetainedEarningsMember 2019-01-01 2019-12-31 0001828253 evax:ProvisionMember 2021-01-01 2021-12-31 0001828253 evax:ConvertibleDebt2Member ifrs-full:IssuedCapitalMember 2019-07-17 2019-07-17 0001828253 evax:ConvertibleDebt1Member ifrs-full:IssuedCapitalMember 2019-07-17 2019-07-17 0001828253 ifrs-full:SharePremiumMember 2019-01-01 2019-12-31 0001828253 ifrs-full:IssuedCapitalMember 2019-01-01 2019-12-31 0001828253 evax:FollowOnPublicOfferingMember evax:AmericanDepositarySharesMember 2021-11-09 2021-11-09 0001828253 evax:AmericanDepositarySharesMember evax:InitialPublicOfferingMember 2021-11-09 2021-11-09 0001828253 evax:UnderwritersMember evax:AmericanDepositarySharesMember 2021-11-05 2021-11-05 0001828253 evax:IfrsIpoMember evax:AmericanDepositarySharesMember 2021-02-05 2021-02-05 0001828253 evax:AmericanDepositarySharesMember evax:InitialPublicOfferingMember 2021-02-05 2021-02-05 0001828253 evax:IfrsIpoMember evax:AmericanDepositarySharesMember 2021-02-01 2021-02-28 0001828253 ifrs-full:OrdinarySharesMember 2020-10-01 2020-10-31 0001828253 ifrs-full:OrdinarySharesMember 2020-09-01 2020-09-30 0001828253 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2021-01-01 2021-12-31 0001828253 ifrs-full:LeaseLiabilitiesMember 2021-12-31 0001828253 evax:TradePayablesMember 2021-12-31 0001828253 evax:ProvisionMember 2021-12-31 0001828253 evax:OtherPayablesMember 2021-12-31 0001828253 evax:LoanFromLessorMember 2021-12-31 0001828253 ifrs-full:LeaseLiabilitiesMember 2020-12-31 0001828253 evax:TradePayablesMember 2020-12-31 0001828253 evax:OtherPayablesMember 2020-12-31 0001828253 ifrs-full:SharePremiumMember 2021-12-31 0001828253 ifrs-full:RetainedEarningsMember 2021-12-31 0001828253 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2021-12-31 0001828253 ifrs-full:IssuedCapitalMember 2021-12-31 0001828253 evax:FollowOnPublicOfferingMember evax:AmericanDepositarySharesMember 2021-11-30 0001828253 ifrs-full:SharePremiumMember 2020-12-31 0001828253 ifrs-full:RetainedEarningsMember 2020-12-31 0001828253 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2020-12-31 0001828253 ifrs-full:IssuedCapitalMember 2020-12-31 0001828253 ifrs-full:SharePremiumMember 2019-12-31 0001828253 ifrs-full:RetainedEarningsMember 2019-12-31 0001828253 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2019-12-31 0001828253 ifrs-full:IssuedCapitalMember 2019-12-31 0001828253 ifrs-full:SharePremiumMember 2018-12-31 0001828253 ifrs-full:RetainedEarningsMember 2018-12-31 0001828253 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2018-12-31 0001828253 ifrs-full:IssuedCapitalMember 2018-12-31 0001828253 evax:ConvertibleDebtsMember 2021-01-01 2021-12-31 0001828253 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember ifrs-full:OtherPropertyPlantAndEquipmentMember 2021-01-01 2021-12-31 0001828253 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember ifrs-full:LeaseholdImprovementsMember 2021-01-01 2021-12-31 0001828253 evax:ResearchAndDevelopmentExpensesMember 2021-01-01 2021-12-31 0001828253 evax:OperatingExpensesMember 2021-01-01 2021-12-31 0001828253 evax:GeneralAndAdministrativeExpensesMember 2021-01-01 2021-12-31 0001828253 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember ifrs-full:OtherPropertyPlantAndEquipmentMember 2020-01-01 2020-12-31 0001828253 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember evax:AllPropertyExceptForOtherEquipmentMember 2020-01-01 2020-12-31 0001828253 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2020-01-01 2020-12-31 0001828253 evax:ResearchAndDevelopmentExpensesMember 2020-01-01 2020-12-31 0001828253 evax:OperatingExpensesMember 2020-01-01 2020-12-31 0001828253 evax:GeneralAndAdministrativeExpensesMember 2020-01-01 2020-12-31 0001828253 evax:ResearchAndDevelopmentExpensesMember 2019-01-01 2019-12-31 0001828253 evax:OperatingExpensesMember 2019-01-01 2019-12-31 0001828253 evax:GeneralAndAdministrativeExpensesMember 2019-01-01 2019-12-31 0001828253 evax:IfrsGrossCarryingAmountMember ifrs-full:UnusedTaxLossesMember 2021-12-31 0001828253 evax:IfrsGrossCarryingAmountMember ifrs-full:OtherTemporaryDifferencesMember 2021-12-31 0001828253 evax:IfrsGrossCarryingAmountMember evax:IfrsWarrantMember 2021-12-31 0001828253 ifrs-full:AccumulatedImpairmentMember 2021-12-31 0001828253 evax:IfrsGrossCarryingAmountMember ifrs-full:UnusedTaxLossesMember 2020-12-31 0001828253 evax:IfrsGrossCarryingAmountMember ifrs-full:OtherTemporaryDifferencesMember 2020-12-31 0001828253 evax:IfrsGrossCarryingAmountMember evax:ResearchAndDevelopmentExpendituresMember 2020-12-31 0001828253 evax:IfrsGrossCarryingAmountMember evax:IfrsWarrantMember 2020-12-31 0001828253 ifrs-full:AccumulatedImpairmentMember 2020-12-31 0001828253 evax:IfrsGrossCarryingAmountMember ifrs-full:UnusedTaxLossesMember 2019-12-31 0001828253 evax:IfrsGrossCarryingAmountMember ifrs-full:OtherTemporaryDifferencesMember 2019-12-31 0001828253 evax:IfrsGrossCarryingAmountMember evax:IfrsWarrantMember 2019-12-31 0001828253 ifrs-full:AccumulatedImpairmentMember 2019-12-31 0001828253 evax:PurchaseObligationsMember ifrs-full:NotLaterThanOneYearMember 2021-12-31 0001828253 evax:PurchaseObligationsMember evax:SystemProviderMember 2021-12-31 0001828253 ifrs-full:NotLaterThanOneYearMember 2021-12-31 0001828253 evax:PurchaseObligationsMember 2021-12-31 0001828253 evax:PurchaseObligationsMember ifrs-full:NotLaterThanOneYearMember 2020-12-31 0001828253 evax:PurchaseObligationsMember evax:UniversityFuturePartnersMember 2020-12-31 0001828253 evax:PurchaseObligationsMember evax:ContractResearchOrganizationsMember 2020-12-31 0001828253 ifrs-full:NotLaterThanOneYearMember 2020-12-31 0001828253 evax:PurchaseObligationsMember 2020-12-31 0001828253 evax:ConvertibleDebtsMember 2021-12-31 0001828253 evax:TrancheOneMember 2022-02-17 0001828253 evax:EibLoanAgreementMember evax:TrancheOneMember 2022-02-14 0001828253 evax:ConvertibleDebtsMember 2020-12-31 0001828253 evax:IfrsEmergingGrowthCompanyMember 2021-12-31 0001828253 ifrs-full:AccumulatedDepreciationAndAmortisationMember 2021-01-01 2021-12-31 0001828253 ifrs-full:GrossCarryingAmountMember ifrs-full:OtherPropertyPlantAndEquipmentMember 2021-01-01 2021-12-31 0001828253 ifrs-full:GrossCarryingAmountMember ifrs-full:LeaseholdImprovementsMember 2021-01-01 2021-12-31 0001828253 ifrs-full:GrossCarryingAmountMember evax:AllPropertyExceptForOtherEquipmentMember 2021-01-01 2021-12-31 0001828253 ifrs-full:GrossCarryingAmountMember ifrs-full:OtherPropertyPlantAndEquipmentMember 2020-01-01 2020-12-31 0001828253 ifrs-full:GrossCarryingAmountMember evax:AllPropertyExceptForOtherEquipmentMember 2020-01-01 2020-12-31 0001828253 ifrs-full:GrossCarryingAmountMember 2021-01-01 2021-12-31 0001828253 evax:SSIMember ifrs-full:TechnologybasedIntangibleAssetsMember 2020-01-01 2020-12-31 0001828253 ifrs-full:TechnologybasedIntangibleAssetsMember 2020-01-01 2020-12-31 0001828253 ifrs-full:GrossCarryingAmountMember 2020-01-01 2020-12-31 0001828253 evax:GrantSeptember2019Member evax:IfrsWarrantMember 2021-01-01 2021-12-31 0001828253 evax:GrantSeptember2017Member evax:IfrsWarrantMember 2021-01-01 2021-12-31 0001828253 evax:GrantOctober2019Member evax:IfrsWarrantMember 2021-01-01 2021-12-31 0001828253 evax:GrantJune2021Member evax:IfrsWarrantMember 2021-01-01 2021-12-31 0001828253 evax:GrantFebruary2019Member evax:IfrsWarrantMember 2021-01-01 2021-12-31 0001828253 evax:GrantedDuring2018Member evax:IfrsWarrantMember 2021-01-01 2021-12-31 0001828253 evax:GrantDecember2021Member evax:IfrsWarrantMember 2021-01-01 2021-12-31 0001828253 evax:GrantDecember2020Member evax:IfrsWarrantMember 2021-01-01 2021-12-31 0001828253 evax:GrantDecember2017Member evax:IfrsWarrantMember 2021-01-01 2021-12-31 0001828253 evax:GrantDecember2016Member evax:IfrsWarrantMember 2021-01-01 2021-12-31 0001828253 evax:GrantApril2021Member evax:IfrsWarrantMember 2021-01-01 2021-12-31 0001828253 evax:GrantSeptember2019Member evax:IfrsWarrantMember 2020-01-01 2020-12-31 0001828253 evax:GrantSeptember2017Member evax:IfrsWarrantMember 2020-01-01 2020-12-31 0001828253 evax:GrantOctober2019Member evax:IfrsWarrantMember 2020-01-01 2020-12-31 0001828253 evax:GrantFebruary2019Member evax:IfrsWarrantMember 2020-01-01 2020-12-31 0001828253 evax:GrantedDuring2018Member evax:IfrsWarrantMember 2020-01-01 2020-12-31 0001828253 evax:GrantDecember2020Member evax:IfrsWarrantMember 2020-01-01 2020-12-31 0001828253 evax:GrantDecember2017Member evax:IfrsWarrantMember 2020-01-01 2020-12-31 0001828253 evax:GrantDecember2016Member evax:IfrsWarrantMember 2020-01-01 2020-12-31 0001828253 evax:GrantApril2017Member evax:IfrsWarrantMember 2020-01-01 2020-12-31 0001828253 evax:GrantSeptember2019Member evax:IfrsWarrantMember 2019-01-01 2019-12-31 0001828253 evax:GrantSeptember2017Member evax:IfrsWarrantMember 2019-01-01 2019-12-31 0001828253 evax:GrantOctober2019Member evax:IfrsWarrantMember 2019-01-01 2019-12-31 0001828253 evax:GrantJanuary2019Member evax:IfrsWarrantMember 2019-01-01 2019-12-31 0001828253 evax:GrantFebruary2019Member evax:IfrsWarrantMember 2019-01-01 2019-12-31 0001828253 evax:GrantedDuring2018Member evax:IfrsWarrantMember 2019-01-01 2019-12-31 0001828253 evax:GrantDecember2017Member evax:IfrsWarrantMember 2019-01-01 2019-12-31 0001828253 evax:GrantDecember2016Member evax:IfrsWarrantMember 2019-01-01 2019-12-31 0001828253 evax:GrantApril2017Member evax:IfrsWarrantMember 2019-01-01 2019-12-31 0001828253 evax:EmployeesMember evax:WarrantsMember 2019-02-01 2019-02-28 0001828253 srt:ManagementMember evax:WarrantsMember 2019-01-01 2019-01-31 0001828253 evax:EmployeesMember evax:WarrantsMember 2019-09-01 2019-09-30 0001828253 2018-01-01 2018-12-31 0001828253 2021-01-04 2021-01-04 0001828253 evax:WarrantsMember 2021-04-01 2021-06-30 0001828253 srt:ManagementMember evax:WarrantsMember 2021-01-01 2021-12-31 0001828253 evax:WarrantsEntitlements2020Member 2020-12-01 2020-12-31 0001828253 evax:WarrantsEntitlements2019Member 2020-12-01 2020-12-31 0001828253 srt:ManagementMember evax:WarrantsMember 2019-10-01 2019-10-31 0001828253 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember evax:AllPropertyExceptForOtherEquipmentMember 2021-01-01 2021-12-31 0001828253 ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember 2021-01-01 2021-12-31 0001828253 evax:WarrantsMember 2021-01-01 2021-12-31 0001828253 evax:WarrantsMember 2020-01-01 2020-12-31 0001828253 evax:WarrantsMember 2019-01-01 2019-12-31 0001828253 ifrs-full:OrdinarySharesMember evax:InitialPublicOfferingMember 2021-11-09 0001828253 ifrs-full:OrdinarySharesMember evax:InitialPublicOfferingMember 2021-02-05 0001828253 evax:ConvertibleDebt2Member 2018-01-01 2018-12-31 0001828253 ifrs-full:OrdinarySharesMember evax:StockSplitMember 2021-01-04 0001828253 srt:ManagementMember evax:IfrsWarrantMember 2021-01-01 2021-12-31 0001828253 evax:BirgitteRnMember evax:IfrsWarrantMember 2021-01-01 2021-12-31 0001828253 srt:ManagementMember evax:IfrsWarrantMember 2020-01-01 2020-12-31 0001828253 srt:DirectorMember evax:IfrsWarrantMember 2020-01-01 2020-12-31 0001828253 evax:ThomasWilliamWylonisMember evax:IfrsWarrantMember 2020-01-01 2020-12-31 0001828253 evax:ThomasBogenriederMember evax:IfrsWarrantMember 2020-01-01 2020-12-31 0001828253 evax:MarianneSogaardMember evax:IfrsWarrantMember 2020-01-01 2020-12-31 0001828253 evax:KimBjornstrupMember evax:IfrsWarrantMember 2020-01-01 2020-12-31 0001828253 2019-10-01 2019-10-31 0001828253 2019-01-01 2019-01-31 0001828253 evax:CopenhagenDenmarkMember 2021-12-31 0001828253 ifrs-full:CountryOfDomicileMember 2021-12-31 0001828253 ifrs-full:CountryOfDomicileMember 2020-12-31 0001828253 ifrs-full:CountryOfDomicileMember 2019-12-31 0001828253 2019-12-31 0001828253 2018-12-31 0001828253 evax:EibLoanAgreementMember 2021-08-31 0001828253 ifrs-full:TechnologybasedIntangibleAssetsMember 2020-12-31 0001828253 evax:HrsholmDenmarkMember 2020-10-01 2020-10-31 0001828253 country:US 2020-10-01 2020-10-31 0001828253 evax:HrsholmDenmarkMember evax:LaboratorySpaceMember 2020-10-31 0001828253 evax:HrsholmDenmarkMember 2020-10-31 0001828253 evax:HrsholmDenmarkMember evax:LaboratorySpaceMember ifrs-full:TopOfRangeMember 2020-10-31 0001828253 evax:HrsholmDenmarkMember evax:LaboratorySpaceMember ifrs-full:BottomOfRangeMember 2020-10-31 0001828253 evax:HrsholmDenmarkMember ifrs-full:TopOfRangeMember 2020-10-31 0001828253 evax:HrsholmDenmarkMember ifrs-full:BottomOfRangeMember 2020-10-31 0001828253 evax:HrsholmDenmarkMember evax:OfficeSpaceMember 2020-10-31 0001828253 evax:IfrsWarrantMember 2020-12-01 2020-12-31 0001828253 ifrs-full:OrdinarySharesMember 2020-08-10 2020-08-10 0001828253 evax:IfrsWarrantMember 2021-01-01 2021-12-31 0001828253 ifrs-full:LeaseLiabilitiesMember 2021-01-01 2021-12-31 0001828253 evax:LoanFromLessorMember 2021-01-01 2021-12-31 0001828253 ifrs-full:LeaseLiabilitiesMember 2020-01-01 2020-12-31 0001828253 ifrs-full:OrdinarySharesMember 2021-11-09 2021-11-09 0001828253 ifrs-full:OrdinarySharesMember 2021-11-01 2021-11-30 0001828253 ifrs-full:OrdinarySharesMember 2021-02-09 2021-02-09 0001828253 ifrs-full:OrdinarySharesMember 2020-10-15 2020-10-15 0001828253 ifrs-full:OrdinarySharesMember 2020-09-17 2020-09-17 0001828253 ifrs-full:OrdinarySharesMember 2019-12-19 2019-12-19 0001828253 ifrs-full:OrdinarySharesMember 2019-07-17 2019-07-17 0001828253 ifrs-full:OrdinarySharesMember evax:StockSplitMember evax:WarrantsMember 2021-01-04 2021-01-04 0001828253 evax:FollowOnPublicOfferingMember evax:AmericanDepositarySharesMember 2021-11-05 2021-11-05 0001828253 evax:FollowOnPublicOfferingMember evax:AmericanDepositarySharesMember 2021-11-01 2021-11-30 0001828253 evax:ConvertibleDebt2Member ifrs-full:OrdinarySharesMember 2019-07-17 2019-07-17 0001828253 evax:ConvertibleDebt1Member ifrs-full:OrdinarySharesMember 2019-07-17 2019-07-17 0001828253 evax:WarrantsMember 2021-06-01 2021-06-30 0001828253 evax:IfrsWarrantMember 2020-01-01 2020-12-31 0001828253 evax:EibLoanAgreementMember 2020-08-01 2020-08-31 0001828253 evax:ConvertibleDebtsMember 2019-12-31 0001828253 evax:ResearchAndDevelopmentExpensesMember 2021-01-01 2021-12-31 0001828253 evax:GeneralAndAdministrativeExpensesMember 2021-01-01 2021-12-31 0001828253 evax:ResearchAndDevelopmentExpensesMember 2020-01-01 2020-12-31 0001828253 evax:GeneralAndAdministrativeExpensesMember 2020-01-01 2020-12-31 0001828253 evax:ResearchAndDevelopmentExpensesMember 2019-01-01 2019-12-31 0001828253 evax:GeneralAndAdministrativeExpensesMember 2019-01-01 2019-12-31 0001828253 evax:QualifiedCapitalIncreaseOccursInYearOfLoanIssuanceMember evax:ConvertibleDebt2Member 2018-12-31 0001828253 evax:QualifiedCapitalIncreaseOccursInYearFollowingLoanIssuanceMember evax:ConvertibleDebt2Member 2018-12-31 0001828253 evax:QualifiedCapitalIncreaseOccursInTwoYearsFollowingLoanIssuanceMember evax:ConvertibleDebt2Member 2018-12-31 0001828253 evax:ConvertibleDebt1Member 2018-01-01 2018-12-31 0001828253 evax:SouthernDenmarkUniversityCollaborationAgreementMember 2020-01-01 2020-12-31 0001828253 evax:SouthernDenmarkUniversityCollaborationAgreementMember 2019-01-01 2019-12-31 0001828253 2020-08-01 2020-08-31 0001828253 evax:ConvertibleDebt2Member 2018-12-31 0001828253 evax:ConvertibleDebt1Member 2018-12-31 0001828253 2019-01-01 2019-12-31 0001828253 ifrs-full:FixedInterestRateMember 2020-10-01 2020-10-31 0001828253 ifrs-full:OrdinarySharesMember evax:StockSplitMember 2021-01-04 2021-01-04 0001828253 evax:WarrantsMember 2021-01-01 2021-12-31 0001828253 evax:WarrantsMember 2020-01-01 2020-12-31 0001828253 evax:WarrantsMember 2019-01-01 2019-12-31 0001828253 evax:IfrsIpoMember 2021-02-05 2021-02-05 0001828253 ifrs-full:TechnologybasedIntangibleAssetsMember 2020-06-01 2020-06-30 0001828253 2020-01-01 2020-12-31 0001828253 2020-12-31 0001828253 2021-12-31 0001828253 dei:BusinessContactMember 2021-01-01 2021-12-31 0001828253 2021-01-01 2021-12-31 evax:segment iso4217:DKK shares evax:instrument iso4217:EUR evax:Y shares iso4217:USD pure iso4217:DKK iso4217:USD shares utr:sqm evax:loan evax:employee evax:lease P0Y P0Y P0Y 0001828253 --12-31 2021 FY false -1.12 -0.97 -0.81 700000000 1.00 0 19198668 19198668 19198668 19198668 23141524 23141524 0 0 0 0 0 0 0 P0Y P0Y 23141524 20-F false true 2021-12-31 false false 001-39950 Evaxion Biotech A/S G7 Dr. Neergaards Vej 5f DK-2970 Hoersholm DK Lars Staal Wegner Dr. Neergaards DK-2970 Hoersholm DK 45 53 53 18 50 American Depositary Shares, each representingone ordinary share, nominal value DKK 1 per share EVAX NASDAQ NASDAQ 23203808 No No Yes Yes Non-accelerated Filer true false International Financial Reporting Standards false 1757 1757 EY Godkendt Revisionspartnerselskab Denmark 19583000 10902000 8216000 6251000 5666000 2647000 25834000 16568000 10863000 -25834000 -16568000 -10863000 2039000 216000 65000 915000 223000 1222000 -24710000 -16575000 -12020000 -178000 -1557000 -825000 -24532000 -15018000 -11195000 -24532000 -15018000 -11195000 -83000 -18000 93000 5000 -1547000 412000 2000 -1542000 394000 2000 -26074000 -14624000 -11193000 -26074000 -14624000 -11193000 -1.26 -0.97 -0.81 93000 100000 262000 5174000 221000 194000 191000 238000 5458000 1015000 1138000 1553000 1729000 563000 418000 838000 1416000 32166000 5834000 34705000 10950000 40163000 11965000 3755000 2648000 79114000 31669000 -50432000 -27279000 32437000 7038000 2206000 1044000 153000 3403000 314000 20000 126000 2848000 3673000 1035000 1234000 4323000 4927000 7726000 4927000 40163000 11965000 2113000 4106000 -171000 -6979000 -931000 -11195000 -11195000 2000 2000 2362000 2362000 181000 9261000 9442000 13000 13000 187000 9508000 9695000 2481000 22862000 -169000 -15812000 9362000 -15018000 -15018000 395000 395000 3551000 3551000 167000 8853000 9020000 272000 272000 2648000 31443000 226000 -27279000 7038000 -24532000 -24532000 -1537000 -1537000 5000 5000 1379000 1379000 1107000 56502000 57609000 7515000 7515000 3755000 80430000 -1316000 -50432000 32437000 -24532000 -15018000 -11195000 541000 1583000 2945000 9000 25000 30000 39000 846000 812000 688000 -23170000 -12653000 -7592000 1237000 215000 573000 -21933000 -12438000 -7019000 60000 35000 1300000 149000 61000 30000 -209000 -7000 -1330000 -393000 -68000 53854000 9019000 9442000 3760000 128000 13000 152000 63000 226000 74000 73000 49805000 8817000 9508000 26542000 -4014000 2421000 5834000 9559000 7433000 -210000 288000 -295000 32166000 5834000 9559000 60000 90000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 1. General Company Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Evaxion Biotech A/S (the “Company” or “Evaxion”) is an artificial intelligence (“AI”)-immunology platform company that uses its proprietary AI technology, engineering expertise and drug development know-how to simulate the human immune system and generate predictive models to identify and develop efficacious immunotherapies for patients in the global market. Unless the context otherwise requires, references to the “Company,” “we,” “us,” and “our”, refer to Evaxion Biotech A/S and its subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Evaxion is a public limited liability company incorporated and domiciled in Denmark with its registered office located at Dr. Neergaards Vej 5f, DK-2970 Hoersholm, Denmark.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On February 5, 2021, the Company completed an initial public offering (“IPO”), which resulted in the listing of American Depository Shares (“ADS”) representing the company’s ordinary shares, under the symbol “EVAX” in the United States on the NASDAQ Capital Market. Through the IPO, the Company sold 3,000,000 ADSs, each of which represents one ordinary share, at a price to the public of $10.00 per ADS. The Company received net proceeds of $25.3 million from the IPO, after deducting the underwriting discounts and commissions and offering expenses. Upon the completion of the IPO, authorized share capital consists of 3,000,000 shares of ordinary shares, par value DKK 1 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On November 9, 2021, the Company completed a follow-on public offering through which we issued and sold 3,942,856 ADSs, each of which represents one ordinary share, at a price to the public of $7.00 per ADS. The shares issued were inclusive of the 514,285 ADSs issued to the underwriters pursuant to the full exercise of their option to purchase additional shares on November 5, 2021. The Company received aggregate net proceeds of $24.9 million from the follow-on public offering, which includes the funds received for the additional shares issued to the underwriters, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. Upon the completion of the follow-on public offering, the Company’s registered, issued, and outstanding share capital was nominal DKK 23,141,524.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">At year end, due to warrant exercise, the outstanding share capital was nominal DKK 23,203,808.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements of Evaxion Biotech and its subsidiaries (collectively, the “Group”) for the year ended December 31, 2021, were approved, and authorized for issuance, by the Board of Directors on March 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Basis of Going Concern</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company’s Board of Directors has, at the time of approving the consolidated financial statements, a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. Based on the Company’s net proceeds secured through its recent IPO and follow-on public offering, together with access to its EIB loan, of which the Company has already received the proceeds from tranche no. 1 of €7 million on February 17, 2022, and the current cash on hand will allow the Company to meet its liabilities as they fall due for at least 12 months from the issuance of this Form 20-F. Thus, these consolidated financial statements are prepared on a going concern basis of accounting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Emerging Growth Company Status</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Evaxion is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has elected to take advantage of specified reduced reporting and regulatory requirements in contrast to those otherwise applicable generally to public companies. This provision includes the exemption from the auditor attestation requirement in the assessment of the Company’s internal control over financial reporting pursuant to Section 404 the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Evaxion will remain an emerging growth company until the earliest of (i) the last day of the first fiscal year (a) following the fifth anniversary of the completion of the global offering, (b) in which its annual gross revenue totals at least $1.07 billion or (c) when the Company is deemed to be a large accelerated filer, which means the market value of the Company’s ordinary shares that is held by </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">non-affiliates exceeds <span style="-sec-ix-hidden:Hidden_L_eDKu4tUUW4Iq-Rn3YdSQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$700.0</span></span> million as of the prior June 30th and (ii) the date on which the Company has issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">COVID 19</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In December 2019, a novel strain of coronavirus (“COVID-19”) was reported in Wuhan, China and on March 11, 2020 the World Health Organization declared COVID-19 a pandemic. The COVID-19 pandemic has resulted in a widespread health crisis and numerous disease control measures being taken to limit its spread. As the pandemic unfolds throughout the world, the healthcare systems of the countries in which the Company is conducting its studies have experienced great disruption. Governments have instituted quarantining and mandated business and school closures. Travel has been severely restricted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has closely been monitoring the impact of COVID-19. The Company’s top priority remained the health and safety of its staff and the patients in the studies. The Company maintains compliance with government and health authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has worked closely with laboratories and investigators to ensure safe continuation and working requirements of our ongoing research activities and human clinical trials. The Company has not experienced a materially negative impact from COVID 19. As of December 31, 2021, the impact of the COVID-19 pandemic continues to unfold. As events continue to evolve and additional information becomes available, our estimates may change materially in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">While business travel has been limited, the Company has remained active and effective in the process of raising capital with institutional investors by conducting key meetings on a virtual basis.</p> 3000000 10.00 25300000 3000000 1 3942856 7.00 514285 24900000 23141524 23203808 7000000 1070000000.00 1000000000.0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 2. Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Basis of preparation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The financial statements have been prepared in accordance with IFRS as issued by the IASB. The Company adopted IFRS in 2019 and applied it from the beginning of the period preceding adoption, starting on January 1, 2018.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Management has assessed the impact of new or amended and revised accounting standards and interpretations (IFRSs) issued by the IASB and IFRSs endorsed by the European Union effective on or after January 1, 2021. It is assessed that application of amendments effective from January 1, 2021 has not had a material impact on the consolidated financial statements for 2021. Furthermore, Management does not anticipate any significant impact on future periods from the adoption of these amendments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The financial statements are presented in the Company’s presentation currency, U.S. dollar (“USD”) which is not the functional currency of the parent company. The Group’s financial statements are presented in USD as the result of the Company’s publicly listing the ADSs in the United States. The company’s functional currency is DKK for Denmark, AUD for Australia, and USD for the United States. The financial statements have been prepared on a going concern basis using a historical cost basis. All financial assets and liabilities are measured at amortized cost unless otherwise stated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Reclassifications of prior period presentation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Certain items in prior year consolidated financial statements have been reclassified to conform to the current period’s presentation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Basis of consolidation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The audited consolidated financial statements of the Company comprise the Statement of Financial Position as of December 31, 2021 and 2020, and the Statement of Comprehensive Loss for the twelve months ended December 31, 2021, 2020 and 2019. Subsidiaries are entities controlled by the Company. The Company controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and can affect those returns through its power over the entity. The financial statements of subsidiaries are included in the audited consolidated financial statements from the date that control commences until the date that control ceases. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Company. Control is reassessed whenever facts and circumstances indicate that there are changes of the control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">All intra-Group assets and liabilities, equity, income, expenses, and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Retrospective effect of share split and bonus share issuance</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">All share and per share data, including that related to warrants, in the consolidated financial statements give retroactive effect to a 2:1 share split and a bonus issue of shares in the ratio of 17:1 of the Company’s authorized, issued and outstanding ordinary shares, which was effective on January 4, 2021, with the corresponding impacts on both share capital and share premium also retroactively recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Currency translation of transactions and balances</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized as financial income or financial expenses in the statements of comprehensive loss. Non-monetary items in foreign currency which are measured at cost at the statements of financial position date are translated using the exchange rates at the date of the transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Translation of foreign operations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Assets and liabilities in the Company’s functional currency, DKK and AUD, for Denmark and Australia, respectively, are translated to the Company’s presentation currency at the exchange rate applicable on December 31 for the respective year. Income and expenses in the Company’s functional currency are translated to USD at the average exchange rate which corresponds to an approximation of the exchange rates prevailing on each individual transaction date. Translation differences arising in the translation to presentation currency are recognized in other comprehensive income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and development expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses are primarily internal and external costs incurred in the development of the Company’s product candidates, including personnel costs, share-based compensation, external research and development expenses, maintenance of the Company’s patents, overhead allocation and enhancements and maintenance of the Company’s technology platforms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The research activities are comprised of activities performed before filing an IND or equivalent and necessary pre-clinical activities for such product candidates. All research expenses are recognized in the period in which they are incurred and payments made prior to the receipt of goods or services to be used in research and development are deferred until the goods or services are received. The Company records accruals for estimated research and development costs, comprising payments for work performed by third-party contractors and others. Payments for these activities are based on the terms of the individual agreements, which may differ from the timing of the expense recognition of these costs, in which case, they are reflected in the financial statements as either prepaid- or accrued expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The development activities are comprised of the activities performed following the filing of an IND or equivalent clinical-enabling activities for such product candidates, including but not limited to, research and clinical development activities. In line with industry practice, internal and subcontracted development costs are expensed as incurred. Due to regulatory uncertainties and other uncertainties inherent in the development of new products, development expenses do not qualify for capitalization as intangible assets until marketing approval by a regulatory authority is obtained or considered highly probable. To date, the Company has not incurred any development costs which qualified for capitalization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Contract Research Organizations expenses and related prepayments and accruals</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Substantial portions of the Company’s clinical studies are performed by third-party laboratories, medical centers, contract research organizations and other vendors (collectively, the “CROs”). The CROs generally bill monthly or quarterly for services performed. For studies, the Company accrues expenses based upon estimated percentage of work completed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company’s estimates depend on the timeliness and accuracy of the data provided by the CROs regarding the status of each program and total program spending. The Company evaluates the estimates to determine if adjustments are necessary or appropriate based on information received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">CROs invoice the Company upon the occurrence of predetermined contractual or activity-based milestones; however, the timing of these invoices and the Company’s related payments often do not correspond directly to the level of performance of contracted activities. To the extent payments are made by the Company in advance of the related activities performed by the CROs, they are included in prepayments to clinical research organizations and expensed when the activities performed by the CROs. To the extent the payments are made by the Company following the performance of the related activities, the expense is accrued for as a payable to clinical research organizations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Intellectual property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company actively seeks to create, maintain and protect intellectual property and proprietary information and technology that is considered important to the Company’s business, which includes seeking and maintaining patents covering proprietary technology, product candidates, proprietary processes and any other inventions that are commercially and / or strategically important to the Company’s business development. These expenses are expensed as incurred and not capitalized as intangible assets until marketing approval by a regulatory authority is obtained or considered highly probable. The Company has not incurred any costs that qualify for capitalization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Income from government grants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company receives grants for certain research and development activities. The grant income is recognized as a reduction of research and development expenses in the period in which the underlying expenditures were incurred and when there is reasonable assurance that the Company will comply with all conditions to receive the grant income. Government grants comprise direct grants and tax credits related to qualifying research and development costs in excess of the corporate tax rate. Tax credits in an amount up to the corporate tax rate are classified as income tax benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">General and administrative expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of fees paid to external consultants and personnel costs, including share-based compensation for the Company’s executive, finance, corporate and business development functions. In addition, general and administrative expenses also include depreciation and other expenses for the Company’s corporate headquarters as well as other allocated overhead.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Share-based payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company issues warrants as an incentive to employees and non-employees. The fair value of the warrants granted is recognized as an expense with a corresponding credit to accumulated deficit. The fair value is expensed over the requisite service period of the awards. The expense recognition is based on an estimate of the number of warrants expected to vest. The estimate is reassessed regularly, and on a cumulative basis, the expense is equal to the fair value of the number of warrants which actually vest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For employees and consultants providing services similar to employees of the Company, the fair value of the equity instruments is determined at the date of grant resulting in a fixed fair value at grant date that is not adjusted for future changes in the fair value of the equity awards that may occur over the service period. The grant date is defined as the date at which the parties agree to the contractual terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For consultants providing other services that are not similar to employees of the Company, the transactions are measured at the fair value of the services received unless this is not reliably measurable. In such cases, the transactions are measured at fair value of the equity instruments granted at the dates when the services are provided.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Modification of warrants which are beneficial are accounted for with their incremental value or over the shorter vesting period. Non-beneficial modifications such as an extension of the vesting period are not accounted for. Consequently, the original terms are deemed </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">to continue to exist. The Company estimates the fair value of warrants using the underlying value of the Company's ordinary shares. Since the warrants granted before December 2020 are exercisable for nominal consideration, the warrants are valued using the fair value of the Company's ordinary shares on grant date less the exercise consideration. Warrants granted during 2021 are valued using a black-scholes share option pricing model. The assumptions used in calculating the fair value of share-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. The key assumption in this estimate is the fair value of the Company's ordinary share on the warrant grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Post-employment benefit costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company contributes to a defined contribution plan covering eligible employees. The contribution amount is based upon a fixed percentage of employee compensation and such contributions are expensed as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Accounting for joint operations – Southern Denmark University</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company enters into agreements from time to time that may be subject to the requirements of IFRS 11, <i style="font-style:italic;">Joint Arrangements</i>. The Company evaluates these agreements on execution and applies the requirements of the guidance. The collaboration agreement with <i style="font-style:italic;">Southern Denmark University</i> (“SDU”) is considered a joint operation as defined in IFRS 11, with the principal place of business being Denmark. In September 2020, the Company terminated its existing agreement with SDU. For the years ended December 31, 2020, and 2019, the Company recorded $0.3 million and $0.3 million, respectively, in compensation cost for SDU employees which was reported in research and development costs in the statement of comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Accounting for joint operations - MSD International GmbH and MSD International Business GmbH</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has entered into a collaboration agreement with MSD International GmbH and MSD International Business GmbH (jointly ‘MSD’). Under the arrangement, the Company will share its clinical trial in which the Company’s compound and MSD’s compound is dosed in combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In determining the accounting treatment for these types of arrangements, the Company carefully evaluates the relationship between the two parties in order to determine whether the arrangement is, in substance, a collaboration arrangement between the two parties (to be accounted for in accordance with IFRS 11, Joint Arrangements), or rather, a vendor-customer contract (to be accounted for in accordance with IFRS 15, Revenue from Contracts with Customers).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Management has determined that MSD does not meet the definition of a customer under IFRS 15. Consequently, the arrangement is classified as a collaboration arrangement and is accounted for as a joint operation in accordance with IFRS 11 resulting in the recognition of the Company’s own income and expense and assets and liabilities, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Finance Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Finance income is comprised primarily of foreign currency gains.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Finance Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Finance expense is comprised primarily of changes in fair value of the Company’s convertible debt instruments and interest on the Company’s lease liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Income tax</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The income tax for the period comprises current and deferred tax, including prior-year adjustments and changes in provisions for uncertain tax positions. Tax is recognized in the statement of comprehensive loss, except to the extent that it relates to items recognized in equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development tax credits are available to the Group under the tax laws of Denmark and Australia respectively, based on qualifying research and development spend as defined under those tax laws. Tax credits not exceeding the corporate tax rate are recognized as an income tax benefit. Tax credits in excess of the corporate tax rate are classified as government grants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Accruals for uncertain tax positions and/or valuation of government grant receivables require management to make judgments of potential exposures. Accruals for uncertain tax positions and/or valuation of government grant receivables are measured using either the most likely amount or the expected value amount, depending on which method the entity expects to better predict the resolution of the uncertainty. Tax benefits are not recognized unless the tax positions will probably be accepted by the tax authorities. This is based upon management’s interpretation of applicable laws and regulations and the expectation of how the tax authority will resolve the matter. Once considered probable of not being accepted, management reviews each material tax benefit and reflects the effect of the uncertainty in determining the related taxable amounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Deferred taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Deferred tax is measured according to the liability method on all temporary differences between the carrying amount and the tax base of assets and liabilities. Where the tax value can be determined according to alternative tax rules, deferred tax is measured on the basis of the planned use of the asset or the settlement of the obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Deferred tax assets are measured at the value at which they are expected to be utilized, either through elimination against tax on future earnings or through a set-off against deferred tax liabilities. Deferred tax assets are set off within the same legal tax entity and jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Uncertainties exist with respect to the interpretation of complex tax regulations and the amount and timing of future taxable income. Given the complexity of existing contractual agreements, differences arising between the actual results and the assumptions made, or future changes to such assumptions could necessitate future adjustments to tax income and expenses already recorded. As at December 31, 2021 and 2020, the Company has not recognized any provisions for uncertain tax positions resulting in a risk that the deferred tax asset related to warrants is lower than disclosed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes deferred income tax assets if it is probable that sufficient taxable income will be available in the future against which the temporary differences and unused tax losses can be utilized. Management has considered future taxable income in assessing whether deferred income tax assets should be recognized and has concluded that the deferred income tax assets do not meet the criteria for recognition as assets in the statements of financial position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Tax receivables</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Current tax assets for the current and prior periods are measured at the amount expected to be recovered from the taxation authorities, using the tax rates and tax laws that have been enacted or substantively enacted by the end of the reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Deferred offering costs</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Offering costs, consisting of legal, accounting, printer and filing fees directly attributable to the issuance of new shares relating to the Company’s initial public offering (“IPO”) in February 2021, were deferred and were offset against proceeds from the IPO upon the effectiveness of the offering. Deferred offering costs recorded as of December 31, 2020 were $1.7 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Company recognizes lease liabilities for future remaining lease payments and right-of-use assets representing the right to use the underlying assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Leasehold improvements and Loan from lessor</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">The Company’s lease contract comprises funding for the customization of the premises to the Company’s specific needs. The payment is determined based on the actual costs incurred for the customization, a repayment period of </span><span style="font-style:normal;">8 years</span><span style="font-style:normal;"> and an interest rate of </span><span style="font-style:normal;">6%</span><span style="font-style:normal;"> per annum.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">The Company has assessed whether this is a lease component, or a leasehold improvement funded by the lessor. We have considered the following factors:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Which party designed the customization</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Which party had the right to direct changes to the work</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Who is taking on the economic risk of the cost price of the work</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">A third party has designed the project according to the Company’s instructions, and the Company had the right to direct changes to the work during the construction period. Further, the Company has the full economic risk of the work due to </span><span style="-sec-ix-hidden:Hidden_Qmw2ZQPaJ0meK1KHvTlnjQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1</span></span><span style="font-style:normal;">:1 linkage between construction costs and payments to the lessor. Consequently, the Company has assessed that the customization is a leasehold improvement funded by the lessor and accordingly presented a leasehold improvement and a corresponding liability for the loan from the lessor.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Right-of-use assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes a right-of-use asset at the lease commencement date (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost less any accumulated depreciation and impairment losses and adjusted for certain remeasurements of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, lease payments made at or before the commencement date less any lease incentives received, initial direct costs incurred, and restoration costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Right-of-use assets are depreciated over the shorter of the lease term and the useful life of the right-of-use asset using the straight-line method. In addition, right-of-use assets are reduced by impairment losses, if any, and adjusted for certain remeasurements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company’s right-of-use assets are presented within property and equipment, net.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Lease liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">At the commencement date of the lease, the Company recognizes lease liabilities measured at the present value of the following payments, when applicable:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fixed payments (including in-substance fixed payments), less any lease incentives receivable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">variable lease payments (linked to an index or interest rate);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expected payments under residual value guarantees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the exercise price of purchase options, where exercise is reasonably certain;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lease payments in optional renewal periods, where exercise of extension options is reasonably certain;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and penalty payments for the termination of a lease, if the lease term reflects the exercise of the respective termination option.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The lease payments are discounted using the interest rate implicit in the lease if this rate can be readily determined. Otherwise, the Company’s incremental borrowing rate is used, being the rate that the Company would have to pay to borrow the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment with similar terms, security and conditions. Generally, the Company uses its incremental borrowing rate as the discount rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Lease liabilities are subsequently measured at amortized cost using the effective interest method. In addition, the carrying amount of the lease liabilities are remeasured if there is a modification, a change in the lease term, or a change in the lease payments (e.g., changes to future payments resulting from a change in an index or rate used to determine such lease payments).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Intangible assets</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company recognized intangible assets for licenses. Licenses are measured at cost less cumulative amortization and impairment. Cost is measured at fair value of the consideration transferred with addition of transactions costs. If additional consideration is transferred to the seller due to meeting certain milestones, these payments are added to the cost price once the conditions for making the payments are met.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The capitalized assets are amortized over their useful lives, which are determined on the basis of the expected pattern of consumption of the expected future economic benefits embodied in the license or similar development agreement. Amortization commences only once the necessary regulatory and marketing approval has been received for the product candidates to which they relate. To date, the Company has not received any regulatory and marketing approval for any of its product candidates. Consequently, the Company did not recognize any amortization expense for its intangible assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Property and equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment are stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. Depreciation is recognized on a straight-line basis over the estimated useful lives of the assets, as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr><td style="vertical-align:bottom;width:39.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 2.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;width:2.06%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt 0pt 2.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;width:58.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 2.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Useful life</b></p></td><td style="vertical-align:bottom;width:0.08%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt 0pt 2.5pt 0pt;"/></tr><tr><td style="vertical-align:top;width:39.69%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:3.25pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Properties</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;border-top:1px solid #ffffff;margin:0pt;padding:3.25pt 0pt 1.5pt 0pt;"/><td style="vertical-align:top;width:58.15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:3.25pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shorter of lease term and useful life of the asset</p></td><td style="vertical-align:top;width:0.08%;background:#cceeff;border-top:1px solid #ffffff;margin:0pt;padding:3.25pt 0pt 1.5pt 0pt;"/></tr><tr><td style="vertical-align:top;width:39.69%;margin:0pt;padding:3.25pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:3.25pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:58.15%;margin:0pt;padding:3.25pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">11 years</p></td><td style="vertical-align:top;width:0.08%;margin:0pt;padding:3.25pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:39.69%;background:#cceeff;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other equipment</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"/><td style="vertical-align:top;width:58.15%;background:#cceeff;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5 – 10 years</p></td><td style="vertical-align:top;width:0.08%;background:#cceeff;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Impairment of non-financial assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Assets are tested for impairment annually, or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash-generating units). Non-financial assets other than goodwill that suffered impairment are reviewed for possible reversal of the impairment at the end of each reporting period. The Company has <span style="-sec-ix-hidden:Hidden_lNEhxHXjU0KCvv2MuKBLpw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not</span></span> recognized any impairment losses to date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Provisions</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Provisions are recognized when we have an existing legal or constructive obligation as a result of events occurring prior to or on the balance sheet date, and it is probable that the utilization of economic resources will be required to settle the obligation. Provisions are measured as the best estimate of the expense necessary to settle the obligation at the balance sheet date. Provisions that are estimated to mature after more than one year after the balance sheet date are measured at their present values, using a discount rate based on the Company’s risk adjusted incremental borrowing rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Financial instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. Financial instruments are classified at initial recognition, including on the basis of the purpose for which the instrument was acquired and managed. This classification determines the valuation of the instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">(i) Non-derivative financial assets</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Non-derivative financial assets are recognized initially on the date they are originated. The Company derecognizes non-derivative financial assets when the contractual rights to cash flows expire or it transfers the right to receive cash flows in a transaction which transfers substantially all the risks and rewards of ownership of the asset. The Company’s financial assets are initially recognized at fair value and subsequently measured at amortized cost less accumulated impairment losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company holds the following categories of non-derivative financial assets:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Receivables</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Receivables (including lease deposits, receivables and receivables from unpaid capital) represent the Company’s right to an amount of consideration that is unconditional (i.e., only the passage of time is required before payment of the consideration is due). They are measured at amortized cost less impairment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Prepayments include expenditures related to future financial periods and are measured at amortized cost</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Cash is comprised of cash on hand and in bank deposit accounts. Cash equivalents are instruments with original maturities of 90 days or less. The Company does not have any cash equivalents for the years ended December 31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">(ii) Non-derivative financial liabilities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Non-derivative financial liabilities comprise other payables which are measured initially at fair value and subsequently at amortized cost.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Trade Payables</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Trade payables and accruals relate to the Group’s purchase of products and services from various vendors in the normal course of business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Other Payables</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Other payables are comprised of payables to clinical research organizations, employee liabilities and other liabilities. The contract liabilities consist of CROs and vendor accruals. Employee cost liabilities are comprised of provision for holiday allowance, provision for salaries and other employee related provisions. Other liabilities consist of commitments and liabilities related to government grants received in advance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Debt</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Debt is comprised of debt agreements that are carried at amortized cost using the effective interest method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">(iii) Derivative financial liabilities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Convertible debt instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During 2018, the Company issued two convertible debt instruments which are determined to be financial instruments. As required by IAS 32 and IFRS 9, these instruments were separated into their components: debt, and embedded derivatives related to the conversion features, early settlement mechanism and change of control prepayment provision. The Company elected the fair value option and accounts for both the debt and the embedded derivatives as a single instrument that is measured at fair value. Details of the significant inputs and assumptions into the fair values of these instruments are provided in Note 20.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Segment Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">An operating segment is a part of the Company that conducts business activities from which it can generate revenue and incur costs, and for which independent financial information is available. Identification of segments is based on internal reporting to the chief operating decision maker (“CODM”). The CODM for the Company is the Chief Executive Officer. The Company does not divide its operations into different segments and the CODM operates and manages the Company’s entire operations as one segment, which is consistent with the Company’s internal organization and reporting system. The Company does not have any revenue and there are no material non-current assets attributable to countries other than Denmark.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Shareholders’ Equity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The share capital comprises the nominal amount of the company’s ordinary shares, each at a nominal value of DKK 1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Other Reserves includes the share premium comprising the amount received, attributable to shareholders’ equity, in excess of the nominal amount of the shares issued at the company’s capital increases, reduced by any expenses directly attributable to the capital increases as well as translation reserves. Translation reserves include exchange rate adjustments of equity and intragroup receivables forming part of the net investments in our group enterprises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Accumulated Deficit include the accumulated profit or loss as well as well as the reserve for share-based payment representing the corresponding entries to the share-based payment recognized in the profit or loss, arising from our warrant programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Loss Per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The calculation of basic loss per share is based on the Company’s net loss for the year attributable to shareholders of Evaxion Biotech A/S and on the weighted average number of ordinary shares outstanding during the year. The number of shares outstanding take in effect the 2 for 1 stock split and the 17 for 1 bonus share issuance on January 4, 2021. In calculating diluted loss per share, earnings and the average number of shares are adjusted for the dilutive effects of potential ordinary shares. Loss per share is not adjusted for any dilution that results in a loss per share that is lower than loss per ordinary share before dilution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Standards issued but not yet effective</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There were a number of standards and interpretations which were issued but were not yet effective at December 31, 2021 and have not been adopted for these financial statements:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amendment to IAS 37 Provisions, contingent liabilities and contingent assets, Onerous Contracts— Cost of Fulfilling a Contract (January 1, 2022)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amendments to IAS 16 Property, Plant and Equipment, proceeds before intended use (January 1, 2022)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Annual Improvements 2018-2020 (January 1, 2022)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amendment to IAS 1 Presentation of Financial Statements: Disclosure of Accounting Policies (January 1, 2023)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amendment to IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors: Definition of Accounting Estimates (January 1, 2023)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amendments to IFRS 16 Leases: COVID-19-Related Rent Concessions beyond June 30, 2021 (April 1, 2021)</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company expects to adopt these standards, updates and interpretations when they become mandatory. These standards are not expected to have a significant impact on disclosures or amounts reported in the Company’s financial statements in the period of initial application and future reporting periods.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Basis of preparation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The financial statements have been prepared in accordance with IFRS as issued by the IASB. The Company adopted IFRS in 2019 and applied it from the beginning of the period preceding adoption, starting on January 1, 2018.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Management has assessed the impact of new or amended and revised accounting standards and interpretations (IFRSs) issued by the IASB and IFRSs endorsed by the European Union effective on or after January 1, 2021. It is assessed that application of amendments effective from January 1, 2021 has not had a material impact on the consolidated financial statements for 2021. Furthermore, Management does not anticipate any significant impact on future periods from the adoption of these amendments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The financial statements are presented in the Company’s presentation currency, U.S. dollar (“USD”) which is not the functional currency of the parent company. The Group’s financial statements are presented in USD as the result of the Company’s publicly listing the ADSs in the United States. The company’s functional currency is DKK for Denmark, AUD for Australia, and USD for the United States. The financial statements have been prepared on a going concern basis using a historical cost basis. All financial assets and liabilities are measured at amortized cost unless otherwise stated.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Reclassifications of prior period presentation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Certain items in prior year consolidated financial statements have been reclassified to conform to the current period’s presentation.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Basis of consolidation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The audited consolidated financial statements of the Company comprise the Statement of Financial Position as of December 31, 2021 and 2020, and the Statement of Comprehensive Loss for the twelve months ended December 31, 2021, 2020 and 2019. Subsidiaries are entities controlled by the Company. The Company controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and can affect those returns through its power over the entity. The financial statements of subsidiaries are included in the audited consolidated financial statements from the date that control commences until the date that control ceases. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Company. Control is reassessed whenever facts and circumstances indicate that there are changes of the control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">All intra-Group assets and liabilities, equity, income, expenses, and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Retrospective effect of share split and bonus share issuance</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">All share and per share data, including that related to warrants, in the consolidated financial statements give retroactive effect to a 2:1 share split and a bonus issue of shares in the ratio of 17:1 of the Company’s authorized, issued and outstanding ordinary shares, which was effective on January 4, 2021, with the corresponding impacts on both share capital and share premium also retroactively recognized.</p> 2 17 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Currency translation of transactions and balances</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized as financial income or financial expenses in the statements of comprehensive loss. Non-monetary items in foreign currency which are measured at cost at the statements of financial position date are translated using the exchange rates at the date of the transaction.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Translation of foreign operations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Assets and liabilities in the Company’s functional currency, DKK and AUD, for Denmark and Australia, respectively, are translated to the Company’s presentation currency at the exchange rate applicable on December 31 for the respective year. Income and expenses in the Company’s functional currency are translated to USD at the average exchange rate which corresponds to an approximation of the exchange rates prevailing on each individual transaction date. Translation differences arising in the translation to presentation currency are recognized in other comprehensive income.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and development expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses are primarily internal and external costs incurred in the development of the Company’s product candidates, including personnel costs, share-based compensation, external research and development expenses, maintenance of the Company’s patents, overhead allocation and enhancements and maintenance of the Company’s technology platforms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The research activities are comprised of activities performed before filing an IND or equivalent and necessary pre-clinical activities for such product candidates. All research expenses are recognized in the period in which they are incurred and payments made prior to the receipt of goods or services to be used in research and development are deferred until the goods or services are received. The Company records accruals for estimated research and development costs, comprising payments for work performed by third-party contractors and others. Payments for these activities are based on the terms of the individual agreements, which may differ from the timing of the expense recognition of these costs, in which case, they are reflected in the financial statements as either prepaid- or accrued expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The development activities are comprised of the activities performed following the filing of an IND or equivalent clinical-enabling activities for such product candidates, including but not limited to, research and clinical development activities. In line with industry practice, internal and subcontracted development costs are expensed as incurred. Due to regulatory uncertainties and other uncertainties inherent in the development of new products, development expenses do not qualify for capitalization as intangible assets until marketing approval by a regulatory authority is obtained or considered highly probable. To date, the Company has not incurred any development costs which qualified for capitalization.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Contract Research Organizations expenses and related prepayments and accruals</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Substantial portions of the Company’s clinical studies are performed by third-party laboratories, medical centers, contract research organizations and other vendors (collectively, the “CROs”). The CROs generally bill monthly or quarterly for services performed. For studies, the Company accrues expenses based upon estimated percentage of work completed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company’s estimates depend on the timeliness and accuracy of the data provided by the CROs regarding the status of each program and total program spending. The Company evaluates the estimates to determine if adjustments are necessary or appropriate based on information received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">CROs invoice the Company upon the occurrence of predetermined contractual or activity-based milestones; however, the timing of these invoices and the Company’s related payments often do not correspond directly to the level of performance of contracted activities. To the extent payments are made by the Company in advance of the related activities performed by the CROs, they are included in prepayments to clinical research organizations and expensed when the activities performed by the CROs. To the extent the payments are made by the Company following the performance of the related activities, the expense is accrued for as a payable to clinical research organizations.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Intellectual property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company actively seeks to create, maintain and protect intellectual property and proprietary information and technology that is considered important to the Company’s business, which includes seeking and maintaining patents covering proprietary technology, product candidates, proprietary processes and any other inventions that are commercially and / or strategically important to the Company’s business development. These expenses are expensed as incurred and not capitalized as intangible assets until marketing approval by a regulatory authority is obtained or considered highly probable. The Company has not incurred any costs that qualify for capitalization.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Income from government grants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company receives grants for certain research and development activities. The grant income is recognized as a reduction of research and development expenses in the period in which the underlying expenditures were incurred and when there is reasonable assurance that the Company will comply with all conditions to receive the grant income. Government grants comprise direct grants and tax credits related to qualifying research and development costs in excess of the corporate tax rate. Tax credits in an amount up to the corporate tax rate are classified as income tax benefits.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">General and administrative expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of fees paid to external consultants and personnel costs, including share-based compensation for the Company’s executive, finance, corporate and business development functions. In addition, general and administrative expenses also include depreciation and other expenses for the Company’s corporate headquarters as well as other allocated overhead.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Share-based payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company issues warrants as an incentive to employees and non-employees. The fair value of the warrants granted is recognized as an expense with a corresponding credit to accumulated deficit. The fair value is expensed over the requisite service period of the awards. The expense recognition is based on an estimate of the number of warrants expected to vest. The estimate is reassessed regularly, and on a cumulative basis, the expense is equal to the fair value of the number of warrants which actually vest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For employees and consultants providing services similar to employees of the Company, the fair value of the equity instruments is determined at the date of grant resulting in a fixed fair value at grant date that is not adjusted for future changes in the fair value of the equity awards that may occur over the service period. The grant date is defined as the date at which the parties agree to the contractual terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For consultants providing other services that are not similar to employees of the Company, the transactions are measured at the fair value of the services received unless this is not reliably measurable. In such cases, the transactions are measured at fair value of the equity instruments granted at the dates when the services are provided.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Modification of warrants which are beneficial are accounted for with their incremental value or over the shorter vesting period. Non-beneficial modifications such as an extension of the vesting period are not accounted for. Consequently, the original terms are deemed </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">to continue to exist. The Company estimates the fair value of warrants using the underlying value of the Company's ordinary shares. Since the warrants granted before December 2020 are exercisable for nominal consideration, the warrants are valued using the fair value of the Company's ordinary shares on grant date less the exercise consideration. Warrants granted during 2021 are valued using a black-scholes share option pricing model. The assumptions used in calculating the fair value of share-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. The key assumption in this estimate is the fair value of the Company's ordinary share on the warrant grant date.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Post-employment benefit costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company contributes to a defined contribution plan covering eligible employees. The contribution amount is based upon a fixed percentage of employee compensation and such contributions are expensed as incurred.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Accounting for joint operations – Southern Denmark University</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company enters into agreements from time to time that may be subject to the requirements of IFRS 11, <i style="font-style:italic;">Joint Arrangements</i>. The Company evaluates these agreements on execution and applies the requirements of the guidance. The collaboration agreement with <i style="font-style:italic;">Southern Denmark University</i> (“SDU”) is considered a joint operation as defined in IFRS 11, with the principal place of business being Denmark. In September 2020, the Company terminated its existing agreement with SDU. For the years ended December 31, 2020, and 2019, the Company recorded $0.3 million and $0.3 million, respectively, in compensation cost for SDU employees which was reported in research and development costs in the statement of comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Accounting for joint operations - MSD International GmbH and MSD International Business GmbH</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has entered into a collaboration agreement with MSD International GmbH and MSD International Business GmbH (jointly ‘MSD’). Under the arrangement, the Company will share its clinical trial in which the Company’s compound and MSD’s compound is dosed in combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In determining the accounting treatment for these types of arrangements, the Company carefully evaluates the relationship between the two parties in order to determine whether the arrangement is, in substance, a collaboration arrangement between the two parties (to be accounted for in accordance with IFRS 11, Joint Arrangements), or rather, a vendor-customer contract (to be accounted for in accordance with IFRS 15, Revenue from Contracts with Customers).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Management has determined that MSD does not meet the definition of a customer under IFRS 15. Consequently, the arrangement is classified as a collaboration arrangement and is accounted for as a joint operation in accordance with IFRS 11 resulting in the recognition of the Company’s own income and expense and assets and liabilities, respectively.</p> 300000 300000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Finance Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Finance income is comprised primarily of foreign currency gains.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Finance Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Finance expense is comprised primarily of changes in fair value of the Company’s convertible debt instruments and interest on the Company’s lease liability.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Income tax</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The income tax for the period comprises current and deferred tax, including prior-year adjustments and changes in provisions for uncertain tax positions. Tax is recognized in the statement of comprehensive loss, except to the extent that it relates to items recognized in equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development tax credits are available to the Group under the tax laws of Denmark and Australia respectively, based on qualifying research and development spend as defined under those tax laws. Tax credits not exceeding the corporate tax rate are recognized as an income tax benefit. Tax credits in excess of the corporate tax rate are classified as government grants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Accruals for uncertain tax positions and/or valuation of government grant receivables require management to make judgments of potential exposures. Accruals for uncertain tax positions and/or valuation of government grant receivables are measured using either the most likely amount or the expected value amount, depending on which method the entity expects to better predict the resolution of the uncertainty. Tax benefits are not recognized unless the tax positions will probably be accepted by the tax authorities. This is based upon management’s interpretation of applicable laws and regulations and the expectation of how the tax authority will resolve the matter. Once considered probable of not being accepted, management reviews each material tax benefit and reflects the effect of the uncertainty in determining the related taxable amounts.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Deferred taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Deferred tax is measured according to the liability method on all temporary differences between the carrying amount and the tax base of assets and liabilities. Where the tax value can be determined according to alternative tax rules, deferred tax is measured on the basis of the planned use of the asset or the settlement of the obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Deferred tax assets are measured at the value at which they are expected to be utilized, either through elimination against tax on future earnings or through a set-off against deferred tax liabilities. Deferred tax assets are set off within the same legal tax entity and jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Uncertainties exist with respect to the interpretation of complex tax regulations and the amount and timing of future taxable income. Given the complexity of existing contractual agreements, differences arising between the actual results and the assumptions made, or future changes to such assumptions could necessitate future adjustments to tax income and expenses already recorded. As at December 31, 2021 and 2020, the Company has not recognized any provisions for uncertain tax positions resulting in a risk that the deferred tax asset related to warrants is lower than disclosed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes deferred income tax assets if it is probable that sufficient taxable income will be available in the future against which the temporary differences and unused tax losses can be utilized. Management has considered future taxable income in assessing whether deferred income tax assets should be recognized and has concluded that the deferred income tax assets do not meet the criteria for recognition as assets in the statements of financial position.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Tax receivables</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Current tax assets for the current and prior periods are measured at the amount expected to be recovered from the taxation authorities, using the tax rates and tax laws that have been enacted or substantively enacted by the end of the reporting period.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Deferred offering costs</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Offering costs, consisting of legal, accounting, printer and filing fees directly attributable to the issuance of new shares relating to the Company’s initial public offering (“IPO”) in February 2021, were deferred and were offset against proceeds from the IPO upon the effectiveness of the offering. Deferred offering costs recorded as of December 31, 2020 were $1.7 million.</p> 1700000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Company recognizes lease liabilities for future remaining lease payments and right-of-use assets representing the right to use the underlying assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Leasehold improvements and Loan from lessor</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">The Company’s lease contract comprises funding for the customization of the premises to the Company’s specific needs. The payment is determined based on the actual costs incurred for the customization, a repayment period of </span><span style="font-style:normal;">8 years</span><span style="font-style:normal;"> and an interest rate of </span><span style="font-style:normal;">6%</span><span style="font-style:normal;"> per annum.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">The Company has assessed whether this is a lease component, or a leasehold improvement funded by the lessor. We have considered the following factors:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Which party designed the customization</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Which party had the right to direct changes to the work</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Who is taking on the economic risk of the cost price of the work</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">A third party has designed the project according to the Company’s instructions, and the Company had the right to direct changes to the work during the construction period. Further, the Company has the full economic risk of the work due to </span><span style="-sec-ix-hidden:Hidden_Qmw2ZQPaJ0meK1KHvTlnjQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1</span></span><span style="font-style:normal;">:1 linkage between construction costs and payments to the lessor. Consequently, the Company has assessed that the customization is a leasehold improvement funded by the lessor and accordingly presented a leasehold improvement and a corresponding liability for the loan from the lessor.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Right-of-use assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes a right-of-use asset at the lease commencement date (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost less any accumulated depreciation and impairment losses and adjusted for certain remeasurements of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, lease payments made at or before the commencement date less any lease incentives received, initial direct costs incurred, and restoration costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Right-of-use assets are depreciated over the shorter of the lease term and the useful life of the right-of-use asset using the straight-line method. In addition, right-of-use assets are reduced by impairment losses, if any, and adjusted for certain remeasurements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company’s right-of-use assets are presented within property and equipment, net.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Lease liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">At the commencement date of the lease, the Company recognizes lease liabilities measured at the present value of the following payments, when applicable:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fixed payments (including in-substance fixed payments), less any lease incentives receivable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">variable lease payments (linked to an index or interest rate);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expected payments under residual value guarantees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the exercise price of purchase options, where exercise is reasonably certain;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lease payments in optional renewal periods, where exercise of extension options is reasonably certain;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and penalty payments for the termination of a lease, if the lease term reflects the exercise of the respective termination option.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The lease payments are discounted using the interest rate implicit in the lease if this rate can be readily determined. Otherwise, the Company’s incremental borrowing rate is used, being the rate that the Company would have to pay to borrow the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment with similar terms, security and conditions. Generally, the Company uses its incremental borrowing rate as the discount rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Lease liabilities are subsequently measured at amortized cost using the effective interest method. In addition, the carrying amount of the lease liabilities are remeasured if there is a modification, a change in the lease term, or a change in the lease payments (e.g., changes to future payments resulting from a change in an index or rate used to determine such lease payments).</p> P8Y 0.06 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Intangible assets</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company recognized intangible assets for licenses. Licenses are measured at cost less cumulative amortization and impairment. Cost is measured at fair value of the consideration transferred with addition of transactions costs. If additional consideration is transferred to the seller due to meeting certain milestones, these payments are added to the cost price once the conditions for making the payments are met.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The capitalized assets are amortized over their useful lives, which are determined on the basis of the expected pattern of consumption of the expected future economic benefits embodied in the license or similar development agreement. Amortization commences only once the necessary regulatory and marketing approval has been received for the product candidates to which they relate. To date, the Company has not received any regulatory and marketing approval for any of its product candidates. Consequently, the Company did not recognize any amortization expense for its intangible assets.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Property and equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment are stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. Depreciation is recognized on a straight-line basis over the estimated useful lives of the assets, as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr><td style="vertical-align:bottom;width:39.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 2.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;width:2.06%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt 0pt 2.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;width:58.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 2.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Useful life</b></p></td><td style="vertical-align:bottom;width:0.08%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt 0pt 2.5pt 0pt;"/></tr><tr><td style="vertical-align:top;width:39.69%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:3.25pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Properties</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;border-top:1px solid #ffffff;margin:0pt;padding:3.25pt 0pt 1.5pt 0pt;"/><td style="vertical-align:top;width:58.15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:3.25pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shorter of lease term and useful life of the asset</p></td><td style="vertical-align:top;width:0.08%;background:#cceeff;border-top:1px solid #ffffff;margin:0pt;padding:3.25pt 0pt 1.5pt 0pt;"/></tr><tr><td style="vertical-align:top;width:39.69%;margin:0pt;padding:3.25pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:3.25pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:58.15%;margin:0pt;padding:3.25pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">11 years</p></td><td style="vertical-align:top;width:0.08%;margin:0pt;padding:3.25pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:39.69%;background:#cceeff;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other equipment</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"/><td style="vertical-align:top;width:58.15%;background:#cceeff;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5 – 10 years</p></td><td style="vertical-align:top;width:0.08%;background:#cceeff;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"/></tr></table> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr><td style="vertical-align:bottom;width:39.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 2.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;width:2.06%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt 0pt 2.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;width:58.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 2.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Useful life</b></p></td><td style="vertical-align:bottom;width:0.08%;border-bottom:1px solid #ffffff;margin:0pt;padding:0pt 0pt 2.5pt 0pt;"/></tr><tr><td style="vertical-align:top;width:39.69%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:3.25pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Properties</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;border-top:1px solid #ffffff;margin:0pt;padding:3.25pt 0pt 1.5pt 0pt;"/><td style="vertical-align:top;width:58.15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:3.25pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shorter of lease term and useful life of the asset</p></td><td style="vertical-align:top;width:0.08%;background:#cceeff;border-top:1px solid #ffffff;margin:0pt;padding:3.25pt 0pt 1.5pt 0pt;"/></tr><tr><td style="vertical-align:top;width:39.69%;margin:0pt;padding:3.25pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:3.25pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:58.15%;margin:0pt;padding:3.25pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">11 years</p></td><td style="vertical-align:top;width:0.08%;margin:0pt;padding:3.25pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:39.69%;background:#cceeff;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other equipment</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"/><td style="vertical-align:top;width:58.15%;background:#cceeff;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5 – 10 years</p></td><td style="vertical-align:top;width:0.08%;background:#cceeff;margin:0pt;padding:3.5pt 0pt 1.5pt 0pt;"/></tr></table> P11Y P5Y P10Y <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Impairment of non-financial assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Assets are tested for impairment annually, or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash-generating units). Non-financial assets other than goodwill that suffered impairment are reviewed for possible reversal of the impairment at the end of each reporting period. The Company has <span style="-sec-ix-hidden:Hidden_lNEhxHXjU0KCvv2MuKBLpw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not</span></span> recognized any impairment losses to date.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Provisions</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Provisions are recognized when we have an existing legal or constructive obligation as a result of events occurring prior to or on the balance sheet date, and it is probable that the utilization of economic resources will be required to settle the obligation. Provisions are measured as the best estimate of the expense necessary to settle the obligation at the balance sheet date. Provisions that are estimated to mature after more than one year after the balance sheet date are measured at their present values, using a discount rate based on the Company’s risk adjusted incremental borrowing rate.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Financial instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. Financial instruments are classified at initial recognition, including on the basis of the purpose for which the instrument was acquired and managed. This classification determines the valuation of the instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">(i) Non-derivative financial assets</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Non-derivative financial assets are recognized initially on the date they are originated. The Company derecognizes non-derivative financial assets when the contractual rights to cash flows expire or it transfers the right to receive cash flows in a transaction which transfers substantially all the risks and rewards of ownership of the asset. The Company’s financial assets are initially recognized at fair value and subsequently measured at amortized cost less accumulated impairment losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company holds the following categories of non-derivative financial assets:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Receivables</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Receivables (including lease deposits, receivables and receivables from unpaid capital) represent the Company’s right to an amount of consideration that is unconditional (i.e., only the passage of time is required before payment of the consideration is due). They are measured at amortized cost less impairment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Prepayments include expenditures related to future financial periods and are measured at amortized cost</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Cash is comprised of cash on hand and in bank deposit accounts. Cash equivalents are instruments with original maturities of 90 days or less. The Company does not have any cash equivalents for the years ended December 31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">(ii) Non-derivative financial liabilities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Non-derivative financial liabilities comprise other payables which are measured initially at fair value and subsequently at amortized cost.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Trade Payables</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Trade payables and accruals relate to the Group’s purchase of products and services from various vendors in the normal course of business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Other Payables</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Other payables are comprised of payables to clinical research organizations, employee liabilities and other liabilities. The contract liabilities consist of CROs and vendor accruals. Employee cost liabilities are comprised of provision for holiday allowance, provision for salaries and other employee related provisions. Other liabilities consist of commitments and liabilities related to government grants received in advance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Debt</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Debt is comprised of debt agreements that are carried at amortized cost using the effective interest method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">(iii) Derivative financial liabilities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Convertible debt instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During 2018, the Company issued two convertible debt instruments which are determined to be financial instruments. As required by IAS 32 and IFRS 9, these instruments were separated into their components: debt, and embedded derivatives related to the conversion features, early settlement mechanism and change of control prepayment provision. The Company elected the fair value option and accounts for both the debt and the embedded derivatives as a single instrument that is measured at fair value. Details of the significant inputs and assumptions into the fair values of these instruments are provided in Note 20.</p> 0 0 2 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Segment Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">An operating segment is a part of the Company that conducts business activities from which it can generate revenue and incur costs, and for which independent financial information is available. Identification of segments is based on internal reporting to the chief operating decision maker (“CODM”). The CODM for the Company is the Chief Executive Officer. The Company does not divide its operations into different segments and the CODM operates and manages the Company’s entire operations as one segment, which is consistent with the Company’s internal organization and reporting system. The Company does not have any revenue and there are no material non-current assets attributable to countries other than Denmark.</p> 1 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Shareholders’ Equity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The share capital comprises the nominal amount of the company’s ordinary shares, each at a nominal value of DKK 1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Other Reserves includes the share premium comprising the amount received, attributable to shareholders’ equity, in excess of the nominal amount of the shares issued at the company’s capital increases, reduced by any expenses directly attributable to the capital increases as well as translation reserves. Translation reserves include exchange rate adjustments of equity and intragroup receivables forming part of the net investments in our group enterprises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Accumulated Deficit include the accumulated profit or loss as well as well as the reserve for share-based payment representing the corresponding entries to the share-based payment recognized in the profit or loss, arising from our warrant programs.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Loss Per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The calculation of basic loss per share is based on the Company’s net loss for the year attributable to shareholders of Evaxion Biotech A/S and on the weighted average number of ordinary shares outstanding during the year. The number of shares outstanding take in effect the 2 for 1 stock split and the 17 for 1 bonus share issuance on January 4, 2021. In calculating diluted loss per share, earnings and the average number of shares are adjusted for the dilutive effects of potential ordinary shares. Loss per share is not adjusted for any dilution that results in a loss per share that is lower than loss per ordinary share before dilution.</p> 2 17 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Standards issued but not yet effective</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There were a number of standards and interpretations which were issued but were not yet effective at December 31, 2021 and have not been adopted for these financial statements:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amendment to IAS 37 Provisions, contingent liabilities and contingent assets, Onerous Contracts— Cost of Fulfilling a Contract (January 1, 2022)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amendments to IAS 16 Property, Plant and Equipment, proceeds before intended use (January 1, 2022)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Annual Improvements 2018-2020 (January 1, 2022)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amendment to IAS 1 Presentation of Financial Statements: Disclosure of Accounting Policies (January 1, 2023)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amendment to IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors: Definition of Accounting Estimates (January 1, 2023)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amendments to IFRS 16 Leases: COVID-19-Related Rent Concessions beyond June 30, 2021 (April 1, 2021)</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company expects to adopt these standards, updates and interpretations when they become mandatory. These standards are not expected to have a significant impact on disclosures or amounts reported in the Company’s financial statements in the period of initial application and future reporting periods.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 3. First-Time Adoption of IFRS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">IFRS 1 – First-time adoption of IFRS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Impact of initial application of IFRS 1 – first-time adoption of International Financial Reporting Standards</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company adopted IFRS as issued by IASB in the accompanying financial statements. The figures for 2019 in the statements of comprehensive loss have been prepared in accordance with IFRS as issued by the IASB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The disclosures required by IFRS 1, <i style="font-style:italic;">First-Time Adoption of IFRS</i>, concerning the transition from Danish Financial Statement Act (“Local GAAP”) to IFRS were presented in the prior year financials. The financial statements for the year ended December 31, 2019 are the first the Company has prepared in accordance with IFRS. For periods up to and including the year ended December 31, 2018, the Company prepared its financial statements in accordance with the Danish Financial Statements Act. Accordingly, the Company has prepared financial statements that comply with IFRS applicable as at December 31, 2021, together with the comparative period data for the years ended December 31, 2020 and 2019.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 4. Significant Accounting Judgements, Estimates, and Assumptions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of the consolidated financial statements in conformity with IFRS as issued by the IASB requires management to make judgements, estimates and assumptions that affect the application of policies and amounts reported in the financial statements and accompanying notes. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The critical accounting policies which involve significant estimates, assumptions or judgements, the actual outcome of which could have a material impact on the Company’s results and financial position outlined below, are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Share-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Management determines costs for share-based payments using market-based valuation techniques. The fair value of the share awards is determined at the date of grant using generally accepted valuation techniques or valuation based on the Company’s fundraising events. Assumptions are made and judgments are used in applying valuation techniques. Prior to the Company’s IPO completed in February 2021, these assumptions and judgments include estimating the fair value for the underlying Ordinary share on the warrant grant date, as well as the likelihood of liquidity events such as IPOs. Such judgments and assumptions are inherently uncertain. Changes in these assumptions affect the fair value estimates as well as the term applied to the expense recognition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Subsequent to the Company’s IPO completed in February 2021, determining the initial fair value and subsequent accounting for equity awards require significant judgment regarding expected life and volatility of an equity award; however, as a public listed company there is objective evidence of the fair value of an ordinary share on the date an equity award is granted. Refer to Note 8 for further detail surrounding share-based compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Leasehold Improvements and Loan from Lessor</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A significant judgment was made in respect of determining whether customization of leased premises forms part of the lease or is a leasehold improvement funded by the lessor. See the section “Leasehold improvements and Loan from lessor” in Note 2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">There have been no other changes to the application of critical accounting judgments, or estimation uncertainties regarding accounting estimates.We refer to note 2 for a summary of significant accounting policies for further discussion.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 5. Financial Instruments and Risk Management</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Financial risk management and risk management framework</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In terms of financial risks, the Company has exposure to liquidity risk and market risk comprising foreign exchange risk. This note presents information about the Company’s exposure to each of the above risks together with the Company’s objectives, policies and processes for measuring and managing risks. The Company’s Board of Directors monitors each of these risks on a regular basis and implements policies as and when they are required. Details of the current risk management policies are provided below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Liquidity risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The exposure to liquidity risk primarily relates to the risk of failure to meet the Company’s obligations when they become due, which could happen if current assets are not enough to cover the amount of short-term liabilities. The Company has been dependent on its shareholders to fund its operations. The Company’s ability to continue as a going concern is dependent on its ability to raise financing to enable it to complete its product development and clinical trials. Management has determined that there is not substantial doubt about the Company’s ability to continue as a going concern for one year from the latest balance sheet date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021 and December 31, 2020, our available liquidity, comprised of cash and cash equivalents, was $32.2 million and $5.8 million, respectively and our total equity was $32.4 million and $7.0 million, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On February 5, 2021, the Company completed our initial public offering through which we issued and sold 3,000,000 ADSs, each of which represents one ordinary share, at a price to the public of $10.00 per ADS. We received aggregate net proceeds of $25.3 million from the initial public offering, after deducting the underwriting discounts and commissions and offering expenses payable by us. Upon the completion of the initial public offering, our registered, <span style="-sec-ix-hidden:Hidden_HeeOxZZaBEaX3B27hXg2_g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">issued</span></span><span style="white-space:pre-wrap;">, and </span><span style="-sec-ix-hidden:Hidden_k_GjSNGuzkyttH-pqp9QnA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">outstanding</span></span><span style="white-space:pre-wrap;"> share capital was nominal DKK 19,198,668 divided into 19,198,668 </span><span style="-sec-ix-hidden:Hidden_C0QNmzEmKUi9Mkm3vlYFfQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">ordinary</span></span><span style="white-space:pre-wrap;"> </span><span style="-sec-ix-hidden:Hidden_ebZ4-BSSPkeoCq_GKk1_Iw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">shares</span></span><span style="white-space:pre-wrap;"> of DKK 1 each.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On November 9, 2021, we completed a follow-on public offering through which we issued and sold 3,942,856 ADSs, each of which represents one ordinary share, at a price to the public of $7.00 per ADS. The shares issued were inclusive of the 514,285 ADSs issued to the underwriters pursuant to the full exercise of their option to purchase additional shares on November 5, 2021. We received aggregate net proceeds of $24.9 million from the follow-on public offering, which includes the funds received for the additional shares issued to the underwriters, after deducting the underwriting discounts and commissions and offering expenses payable by us. Upon the completion of the follow-on public offering, the Company’s registered, <span style="-sec-ix-hidden:Hidden__rJm0Z1sxkyJrgRcyLPnRA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">issued</span></span><span style="white-space:pre-wrap;">, and </span><span style="-sec-ix-hidden:Hidden_PwVJZlaxwki9DiuplL1z1Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">outstanding</span></span><span style="white-space:pre-wrap;"> share capital was nominal DKK 23,141,524.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">At year end, due to warrant exercise, the outstanding share capital was nominal DKK 23,203,808.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We expect that the net proceeds from our initial public offering, our cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements through at least 12 months subsequent to the issuance of this annual report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company’s approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to their reputation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following are the contractual undiscounted outflows associated with the Company’s financial liabilities in the current and prior year:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:58.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="17" style="vertical-align:bottom;width:58.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> <b style="font-weight:bold;">amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">cash flows</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&lt;1 year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1 – 5 years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&gt;5</b> <b style="font-weight:bold;">years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loan from lessor <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,170</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,458</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 192</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 769</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 497</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,458</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,520</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,698</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 326</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,223</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,149</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,698</p></td></tr><tr><td style="vertical-align:bottom;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,848</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,848</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,848</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,848</p></td></tr><tr><td style="vertical-align:bottom;width:40.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provisions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 153</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 153</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 153</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 153</p></td></tr><tr><td style="vertical-align:bottom;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">46</p></td></tr><tr><td style="vertical-align:bottom;width:40.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,737</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,412</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,992</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,799</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,203</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:6pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">The loan amount as of December 31, 2021 is still subject to possible minor adjustment. Further information is provided in Note 17.</span></td></tr></table><div style="margin-top:12pt;"/><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:58.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="17" style="vertical-align:bottom;width:58.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> <b style="font-weight:bold;">amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">cash flows</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&lt;1</b> <b style="font-weight:bold;">year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1 – 5</b> <b style="font-weight:bold;">years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&gt;5</b> <b style="font-weight:bold;">years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td></tr><tr><td style="vertical-align:bottom;width:40.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,673</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,673</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,673</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,673</p></td></tr><tr><td style="vertical-align:bottom;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 180</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 180</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 180</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 180</p></td></tr><tr><td style="vertical-align:bottom;width:40.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,873</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,873</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,873</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,873</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The financial liabilities include estimated or contractual interest rate payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Market risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. The type of market risk that impacts the Company is currency risk. The Company does not currently have any loans or holdings that have variable interest rate. Accordingly, the Company is not exposed to material interest rate risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Foreign currency risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The primary exposure derives from the Company’s operating expenses paid in foreign currencies, mainly USD and Australian dollars. This exposure is known as transaction exposure. Any reasonable or likely movements in foreign exchange rates would not have a material impact on the Company’s operating results. The Company’s policy for managing foreign currency risks is to convert cash received from financing activities to currencies consistent with the Company’s expected cash outflows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Credit risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Credit risk is the risk that a counterparty will not meet its obligations under a financial instrument, leading to a financial loss for the Company. The Company’s exposure to credit risk is limited to deposits with banks with high credit ratings. Accordingly, the Company does not have material credit risk and no provision for credit risk is recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Capital management</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company’s objectives when managing capital are to safeguard the Company’s ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders and to maintain an optimal capital structure to reduce the cost of capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company raises capital from the issue of equity, grants or convertible loan notes. On a regular basis, management receives financial and operational performance reports that enable management to assess the adequacy of resources on hand and the Company’s liquidity position to determine future financing needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair values</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Financial instruments measured at fair value in the statements of financial position are grouped into three levels of fair value hierarchy. This grouping is determined based on the lowest level of significant inputs used in fair value measurement, as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level I – quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level II – inputs other than quoted prices included within Level I that are observable for the instrument, either directly (i.e. as prices) or indirectly (i.e. derived from prices).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level III – inputs for instrument that are not based on observable market data (unobservable inputs).</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There were no financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of December 31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Convertible debt instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company’s convertible debt instruments are Level III financial instruments and are carried at fair value through profit and loss. The convertible debt instruments were valued based on the present value of a probability weighting of the mutually exclusive settlement alternatives. Key inputs for this valuation were: (i) the exchange rate between USD and DKK, (ii) the discount rate on the issuance, (iii) the probability of a qualifying financing event and (iv) the Company’s share price. The most significant assumptions used in the valuation were the: Company’s share price, the probability of a qualifying financing event, the discount rate and the USD to DKK exchange rate. An increase or decrease in the key input ranging from 10 percent, depending on the input analyzed, would not result in a material change in the fair value of the convertible debt instruments. <span style="-sec-ix-hidden:Hidden_CV7QFPcBFEudfD7-1oOjAA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">There</span></span> <span style="-sec-ix-hidden:Hidden_enoTWUZdGkOy1to47w0vZw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">were</span></span> no <span style="-sec-ix-hidden:Hidden_u7LPqlEnfUCJZ92UGzEKIQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">transfers</span></span> <span style="-sec-ix-hidden:Hidden_cYrz5eCiqkmXDOtfMcJizw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">into</span></span> or <span style="-sec-ix-hidden:Hidden_1vCKTDP0tE2Dt26azOuSfQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">out</span></span> of <span style="-sec-ix-hidden:Hidden_bmd-_ITrKUys5nc_2Fz-XA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any</span></span> <span style="-sec-ix-hidden:Hidden_iacy9_TzWkqq4jsVx9FRAQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">classification</span></span> of financial instruments in any period</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">See Note 20 for the change in fair value of convertible debt during the year ended December 31, 2019.</p> 32200000 5800000 32400000 7000000.0 3000000 10.00 25300000 19198668 19198668 1 3942856 7.00 514285 24900000 23141524 23203808 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:58.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="17" style="vertical-align:bottom;width:58.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> <b style="font-weight:bold;">amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">cash flows</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&lt;1 year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1 – 5 years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&gt;5</b> <b style="font-weight:bold;">years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loan from lessor <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,170</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,458</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 192</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 769</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 497</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,458</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,520</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,698</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 326</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,223</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,149</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,698</p></td></tr><tr><td style="vertical-align:bottom;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,848</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,848</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,848</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,848</p></td></tr><tr><td style="vertical-align:bottom;width:40.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provisions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 153</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 153</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 153</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 153</p></td></tr><tr><td style="vertical-align:bottom;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">46</p></td></tr><tr><td style="vertical-align:bottom;width:40.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,737</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,412</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,992</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,799</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,203</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:6pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">The loan amount as of December 31, 2021 is still subject to possible minor adjustment. Further information is provided in Note 17.</span></td></tr></table><div style="margin-top:12pt;"/><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:58.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="17" style="vertical-align:bottom;width:58.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> <b style="font-weight:bold;">amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">cash flows</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&lt;1</b> <b style="font-weight:bold;">year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1 – 5</b> <b style="font-weight:bold;">years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&gt;5</b> <b style="font-weight:bold;">years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td></tr><tr><td style="vertical-align:bottom;width:40.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,673</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,673</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,673</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,673</p></td></tr><tr><td style="vertical-align:bottom;width:40.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 180</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 180</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 180</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 180</p></td></tr><tr><td style="vertical-align:bottom;width:40.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,873</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,873</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,873</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,873</p></td></tr></table> 1170000 1458000 192000 769000 497000 1458000 2520000 3698000 326000 1223000 2149000 3698000 2848000 2848000 2848000 2848000 153000 153000 153000 153000 46000 46000 46000 46000 6737000 8203000 3412000 1992000 2799000 8203000 20000 20000 20000 20000 3673000 3673000 3673000 3673000 180000 180000 180000 180000 3873000 3873000 3873000 3873000 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 6. Operating Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:65.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;width:32.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Employee salary and benefit expenses, excluding share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,794)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,337)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,586)</p></td></tr><tr><td style="vertical-align:bottom;width:65.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,051)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,496)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,021)</p></td></tr><tr><td style="vertical-align:bottom;width:65.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (273)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (92)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (65)</p></td></tr><tr><td style="vertical-align:bottom;width:65.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">External expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,465)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,977)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,544)</p></td></tr><tr><td style="vertical-align:bottom;width:65.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,583)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,902)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,216)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the years ended December 31, 2021, 2020 and 2019, the Company recognized $0.3 million, $0.8 million and $0.5 million, respectively, related to government grants as a reduction of research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;width:32.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Employee salary and benefit expenses, excluding share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,824)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,098)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (517)</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Share-based compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (328)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,912)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,341)</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Professional and other fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,028)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,644)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (773)</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (71)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16)</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Total general and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,251)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,666)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,647)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:65.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;width:32.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Employee salary and benefit expenses, excluding share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,794)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,337)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,586)</p></td></tr><tr><td style="vertical-align:bottom;width:65.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,051)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,496)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,021)</p></td></tr><tr><td style="vertical-align:bottom;width:65.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (273)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (92)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (65)</p></td></tr><tr><td style="vertical-align:bottom;width:65.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">External expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,465)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,977)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,544)</p></td></tr><tr><td style="vertical-align:bottom;width:65.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,583)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,902)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,216)</p></td></tr></table> 6794000 3337000 2586000 1051000 1496000 1021000 273000 92000 65000 11465000 5977000 4544000 19583000 10902000 8216000 300000 800000 500000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;width:32.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Employee salary and benefit expenses, excluding share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,824)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,098)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (517)</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Share-based compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (328)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,912)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,341)</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Professional and other fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,028)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,644)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (773)</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (71)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16)</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Total general and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,251)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,666)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,647)</p></td></tr></table> 1824000 1098000 517000 328000 1912000 1341000 4028000 2644000 773000 71000 12000 16000 6251000 5666000 2647000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 7. Employees and Employee-Related Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The number of employees, including executive and non-executive directors, during the year was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Average number of full-time employees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Number of employees at end of period:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denmark and United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total employees, at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;">Employee Costs:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;width:32.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Wages and salaries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,909</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,819</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Cash bonus</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 668</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Share-based compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,379</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,408</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,362</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Defined contribution plans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 649</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 206</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 96</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other social security expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other staff expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 364</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 196</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 176</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,997</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,843</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,465</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended</b> <b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;width:32.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Total Employee costs classified as:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,833</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,607</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,152</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,010</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,858</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,997</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,843</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,465</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:66.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;width:31.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Non-management employee benefit expenses classified as:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,414</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,009</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,590</p></td></tr><tr><td style="vertical-align:bottom;width:66.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 836</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 611</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 668</p></td></tr><tr><td style="vertical-align:bottom;width:66.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,620</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,258</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;">Remuneration to the Board of Directors and Executive Management</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Remuneration to the Executive Management:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Wages and salaries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,833</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,298</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 900</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Share-based compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 514</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,566</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 956</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,347</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,864</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,856</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Remuneration to the Board of Directors:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Wages and salaries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 313</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Share-based compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 359</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 351</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 359</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 351</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Remuneration to the Board of Directors and Executive Management classified as:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,431</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 824</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,017</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,316</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,190</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,747</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,223</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,207</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Executive Management was comprised of four members in January 2019 and expanded again to five members in October 2019, of which one member resigned in 2020 and one other member resigned in 2021. It was expanded to 5 members again in 2021.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Average number of full-time employees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Number of employees at end of period:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denmark and United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total employees, at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31</p></td></tr></table> 53000 33000 25000 61000 35000 31000 61000 35000 31000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;width:32.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Wages and salaries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,909</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,819</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Cash bonus</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 668</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Share-based compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,379</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,408</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,362</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Defined contribution plans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 649</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 206</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 96</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other social security expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other staff expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 364</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 196</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 176</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,997</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,843</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,465</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended</b> <b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;width:32.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Total Employee costs classified as:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,833</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,607</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,152</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,010</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,858</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,997</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,843</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,465</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:66.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;width:31.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Non-management employee benefit expenses classified as:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,414</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,009</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,590</p></td></tr><tr><td style="vertical-align:bottom;width:66.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 836</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 611</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 668</p></td></tr><tr><td style="vertical-align:bottom;width:66.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,620</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,258</p></td></tr></table> 6909000 4016000 2819000 668000 1379000 3408000 2362000 649000 206000 96000 28000 17000 12000 364000 196000 176000 9997000 7843000 5465000 7845000 4833000 3607000 2152000 3010000 1858000 9997000 7843000 5465000 6414000 4009000 2590000 836000 611000 668000 7250000 4620000 3258000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Remuneration to the Executive Management:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Wages and salaries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,833</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,298</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 900</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Share-based compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 514</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,566</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 956</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,347</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,864</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,856</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Remuneration to the Board of Directors:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Wages and salaries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 313</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Share-based compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 359</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 351</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 359</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 351</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Remuneration to the Board of Directors and Executive Management classified as:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,431</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 824</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,017</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,316</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,190</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,747</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,223</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,207</p></td></tr></table> 1833000 1298000 900000 514000 1566000 956000 2347000 2864000 1856000 313000 87000 359000 351000 400000 359000 351000 1431000 824000 1017000 1316000 2399000 1190000 2747000 3223000 2207000 4 5 1 1 5 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 8. Share-Based Payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Warrant Program and Amendments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company’s Articles of Association allow for the granting of equity compensation, in the form of equity settled warrants, to employees, consultants and Scientific Advisory Board members who provide services similar to employees, members of executive management, and the board of directors. The warrants granted in 2018 or before become exercisable upon an exit event, which triggers an immediate vesting, or at any time as determined by the board of directors in accordance with the terms of the plan. The warrants granted in 2021 vest gradually over 36 months after grant date or in the case of warrants to the Board of Directors vest immediately. The warrants granted in 2020 vest either gradually over 36 months or vest immediately. Vested warrants granted in 2020 are exercisable in certain exercise windows beginning in the second half of the year of 2021. Warrants granted up until 2019 expire on December 31, 2036. Warrants granted in 2021 and 2020 expire on December 31, 2032 and 2031, respectively. For the years ended December 31, 2021, 2020 and 2019, the number of warrants outstanding as a percentage of outstanding ordinary shares was 11.8%, 13.8% and 13.5%, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the second quarter of 2021, the Company granted 62,147 warrants to its Chief Medical Officer (“CMO”) which vest over <span style="white-space:pre-wrap;">36 months</span><span style="white-space:pre-wrap;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In 2019, the Company granted 150,660 warrants to its Chief Financial Officer (“CFO”) which were exercisable upon an exit event. In December 2020, the terms of the warrants issued to the Company’s CFO were amended to no longer comprise exercisability upon an exit event. Consequently, these warrants did not vest upon the IPO in February 2021 and will vest in accordance with the vesting schedule for warrants granted in 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On January 4, 2021, the Company’s board of directors and shareholders approved (i) a 2-for-1 stock split of its issued and outstanding ordinary shares and (ii) a bonus share issuance in the ratio of 17-for-1 of its issued and outstanding ordinary shares. The stock split also resulted in a reduction of the nominal value of the Company’s ordinary shares from DKK 2 to DKK 1. In accordance with the anti-dilution provisions of the warrant agreements, the number of warrants was increased by a ratio of 36 and the exercise price was decreased from DKK 2 to 1 DKK. Accordingly, information related to the Company’s warrants, have been retroactively adjusted to reflect the stock split and the bonus shares for all periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following schedule specifies the granted warrants:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price/Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life (years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants granted as at December 31, 2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,674,324</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">DKK 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18</p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants granted<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 257,832</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">DKK 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17</p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants granted as at December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,932,156</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">DKK 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17</p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 363,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">DKK 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11</p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (45,216)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">DKK 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16</p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (22,032)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">DKK 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16</p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants granted as at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,228,076</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">DKK 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15</p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants granted during 2021<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 63,802</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">DKK 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10</p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants granted December 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 523,599</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">USD 5.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10</p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (62,284)</p></td><td style="vertical-align:top;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">(3)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">DKK 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,178)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,397)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants granted as at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,732,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">DKK 7.53</p></td><td style="vertical-align:top;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">(4)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13</p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants exercisable as at December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_RgYzXEqcz06ZnkMUZehCSA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> —</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants exercisable as at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_pBholIuj9UqD010IfuPNMA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> —</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants exercisable as at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,072,122</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup><span style="display:inline-block;width:28.42pt;"/>The warrants are not incorporated in the articles of association. Rectification conducted in October 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Of which 62,147 warrants were legally granted in June 2021 and the remaining 1,655 warrants were legally granted in December 2020.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The share price at the exercise date was USD 5.59.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">December 31, 2021 USD-end rate used.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During 2019 employees, external consultants, executive management and board members became contractually entitled to warrants that was rectified on December 17, 2020:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In January 2019, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">45,216</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> warrants granted to a member of executive management. They vest from December 2020 – December 2022. Fair value at grant date amounted to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.3</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In February 2019, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7,956</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> warrants granted to an employee. They vest from December 2020 – December 2022. Fair value at grant date amounted to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.1</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In September 2019, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">54,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> warrants granted to an employee. The warrants vested immediately. Fair value at grant date amount to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.5</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In October 2019, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">150,660</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> warrants granted to a member of executive management. The warrants vest annually over </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3 years</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Fair value at grant date amounted to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.3</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In December 2020, an aggregate of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">126,972</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> warrants attributable to 2019 entitlements were granted to employees, members of our board of directors and consultants who provide similar services as employees. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">63,612</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> warrants vested immediately and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">63,360</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> warrants vest monthly over </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three years</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> from January 2020 – December 2022. Fair value at grant date amounted to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.2</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In December 2020, an aggregate of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">236,196</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> warrants attributable to 2020 entitlements were granted to employees, members of our board of directors and consultants who provide similar services as employees. Of the warrants granted, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">120,888</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> warrants vested immediately and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">115,308</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> warrants vest monthly over </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three years</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> from January 2020 – December 2022. Fair value at grant date amounted to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$2.3</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In June 2021, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">62,147</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> were granted to a member of Executive Management. Fair value at grant date amounted to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.4</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">During 2021, an aggregate of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">523,599</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> warrants attributable to 2021 entitlements were granted to employees, member of our board of directors and executive management. Of the warrants </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">22,916</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> were granted to our board of directors vested immediately. The warrants granted to employees and executive management vest over </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">36 months</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Fair value at grant date amounted to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.5</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">For the year ended December 31, 2019 the Company had 22,032 outstanding warrants to SDU employees and recognized an immaterial amount of expense for these warrants as research and development expenses in the statement of comprehensive loss. In September 2020, the Company terminated its existing agreement with SDU for business reasons. Under the terms of the SDU agreement, the Company did not incur a termination penalty and has no further obligations under this agreement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A member of the executive board terminated his employment contract as of April 30, 2020 and forfeited his right to 45,216 unvested warrants.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A member of the executive board terminated his employment contract as of October, 2021 but no granted warrants remained unvested as of that date.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share-based compensation expenses included in the statements of comprehensive loss:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,496</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,021</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 328</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,912</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,341</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,379</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,408</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,362</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In 2020 an amount of $0.1 million related to warrants issued as compensation for arranging investors to subscribe for shares has been recognized in equity as a share-based compensation expense related to the capital increase.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Determination of Fair Value of Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The warrants issued under the share-based payment arrangement until December 2021 are exercisable for nominal consideration compared to the fair value of the shares resulting in virtually no time value. The Company values these warrants based on the intrinsic value of the shares measured as the difference between the fair value of the Company’s Ordinary shares and the warrant exercise price. Due to the highly specialized nature of services provided by consultants who provide services similar to those provided by employees of the Company, transactions with those consultants are measured at fair value of the equity instruments granted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the share-based payment arrangement, there is no protection against capital increases at a discount and dividend distribution. However, dividends are not likely to be distributed and there is generally no reason to raise new capital at below the current share price. On this basis, the Company has assessed that it is generally appropriate to assume that no such transactions will take place during the holding period. When issuing warrants in 2018, convertible bonds with a potential dilutive effect were outstanding, and fair value was adjusted to reflect this potential dilution.<span style="display:inline-block;width:11.61pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The stock split and bonus share issuance executed on January 4, 2021 resulted in a dilution of the warrant holders due to the increase of the exercise price compared to the pre stock split and bonus share issue. For warrants granted on December 17, 2020, the fair value was adjusted to reflect this dilution. For other grants, no such adjustment has been made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The fair values of the warrants are measured with reference to the share price of the underlying share. Up until December 2020, this share value was determined using the value established in different financing transactions with unrelated parties. In each of these transactions, the relative ownership of the Company was changed, and a share value was established using these fund-raising transactions. The fair values of warrants are estimated using a linear interpolation in USD of the share value on grant date based on the value established on capital event dates before and after the grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For warrants granted in December 2020, the Probability-Weighted Expected Return Method (“PWERM”) was applied, based on the weighted value of the share in a stay private scenario and an IPO scenario. 40% weight was put to the stay private scenario applying a share price equal to the share price of USD 8.89 at the November 2020 capital increase and 60% weight was put to the IPO scenario applying the mid-price of the indicative IPO price range of USD 11.00 available on the balance sheet. A 10% lack of marketability discount (DLOM) was applied to the IPO price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Warrants granted prior to December 2020 are exercisable only upon an exit event or upon the Board of Director’s decisions, which is a post vesting restriction. Since the warrants granted prior to 2020 do not expire until December 31, 2036, Management considers it highly unlikely that the warrants will not become exercisable and no downward adjustment to reflect the risk of the warrant not becoming exercisable is made to the fair value of the warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During 2020, the Company revised the estimated date of an IPO exit event to occur in February 2021. As of December 31, 2019, the estimated IPO exit event was December 2021. As a result of this change in estimate, the Company recognized an acceleration of expense of $0.8 million for the year ended December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Subsequent to the Company’s initial public offering completed in February 2021, determining the initial fair value and subsequent accounting for equity awards require significant judgment regarding expected life and volatility of an equity award; however, as a public listed company there is objective evidence of the fair value of an ordinary share on the date an equity award is granted. Due to the fact that as of 2021, warrants was granted at the share price on the date of grant, fair value comprises a time value which is significantly affected by the expected life and estimated volatility. The expected life of a warrant is based on the assumption that the holder will not exercise until after the equity award is fully vested. Actual exercise patterns may differ from the assumption used herein. The estimated volatility is based on peer group data and reflects the assumption that the historical volatility over a period similar to the life of the warrant is indicative of future trends, which may not necessarily be the actual outcome. The peer group consists of listed companies that management believes are similar to the Company in respect to industry and stage of development. Even with objective evidence of the fair value of an ordinary share, small changes in any other individual assumption or in combination with other assumptions could have resulted in significantly different valuations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following assumptions have been applied for the warrants issued in December 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 85.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The exercise price of the warrants issued in June 2021 was DKK 1 and consequently, the warrants have virtually no time value. Therefore, fair value of the warrants has been determined as the intrinsic value based on a share price of $6.24.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Amendments to Warrants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As discussed above, the terms of the warrant granted to the company’s CFO were amended to no longer comprise an accelerated vesting upon an exit clause. This is considered a non-beneficial change, and consequently the accelerated vesting upon an exit event clause is deemed to continue to exist.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">For warrants to which the employees became entitled in 2019 but were not granted until December 2020, the Company recognized stock-based compensation expenses during the year ended December 31, 2019 and the interim period ended September 30, 2020, based on the terms expected to apply for these awards. Management expected the terms to be similar to the terms applicable to warrants granted up until 2018, including the accelerated vesting upon an exit clause. However, these warrants were granted subjected </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">to a vesting schedule up to three years and did not allow for immediate vesting upon an exit event. Because the warrants were not granted until December 2020, the Company recognized the difference in expenses as a change in accounting estimate and not a modification of existing awards. As a result of this change in the accounting estimate, the share-based payment expense for 2020 was reduced by $0.4 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following schedule specifies the outstanding warrants as at December 31, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:99.98%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">warrant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercise price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">term to</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">date fair value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">per warrant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">maturity</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding program</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(DKK)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(DKK)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (December 2016)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 701,356</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 15</p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (September 2017)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 617,184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 15</p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (December 2017)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 122,040</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 15</p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (during 2018)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 37.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 174,564</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 15</p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (February 2019)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,956</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 15</p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (September 2019)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 15</p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (October 2019)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 150,660</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 15</p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (December 2020)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 317,457</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 9</p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (April 2021)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,655</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 10</p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (June 2021)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40.86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 62,147</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 10</p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (December 2021)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 523,599</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">USD 5.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 10</p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,732,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants exercisable at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following schedule specifies the outstanding warrants as at December 31, 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">warrant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> exercise price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> term to </b></p></td></tr><tr><td style="vertical-align:bottom;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">date fair value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> warrants </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">per warrant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">maturity</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding program</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(DKK)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(DKK)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (December 2016)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 712,332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">16</p></td></tr><tr><td style="vertical-align:bottom;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (April 2017)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,896</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">16</p></td></tr><tr><td style="vertical-align:bottom;width:44.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (September 2017)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 617,184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">16</p></td></tr><tr><td style="vertical-align:bottom;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (December 2017)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 127,044</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">16</p></td></tr><tr><td style="vertical-align:bottom;width:44.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (during 2018)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 37.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 181,836</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">16</p></td></tr><tr><td style="vertical-align:bottom;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (February 2019)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,956</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">16</p></td></tr><tr><td style="vertical-align:bottom;width:44.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (September 2019)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">16</p></td></tr><tr><td style="vertical-align:bottom;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (October 2019)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 150,660</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">16</p></td></tr><tr><td style="vertical-align:bottom;width:44.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (December 2020)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 363,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">11</p></td></tr><tr><td style="vertical-align:bottom;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,228,076</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">15</p></td></tr><tr><td style="vertical-align:bottom;width:44.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants exercisable at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';"> —</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following schedule specifies the outstanding warrants as at December 31, 2019:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">warrant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> exercise price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> term to </b></p></td></tr><tr><td style="vertical-align:bottom;width:53.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">date fair value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> warrants </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">per warrant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">maturity</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding program</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(DKK)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(DKK)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (December 2016)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 712,332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">17</p></td></tr><tr><td style="vertical-align:bottom;width:53.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (April 2017)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,896</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">17</p></td></tr><tr><td style="vertical-align:bottom;width:53.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (September 2017)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 617,184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">17</p></td></tr><tr><td style="vertical-align:bottom;width:53.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (December 2017)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 138,384</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">17</p></td></tr><tr><td style="vertical-align:bottom;width:53.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (during 2018)<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup>**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 37.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 192,528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">17</p></td></tr><tr><td style="vertical-align:bottom;width:53.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (January 2019)<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup>**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 37.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,216</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">17</p></td></tr><tr><td style="vertical-align:bottom;width:53.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (February 2019)**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,956</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">17</p></td></tr><tr><td style="vertical-align:bottom;width:53.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (September 2019)**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">17</p></td></tr><tr><td style="vertical-align:bottom;width:53.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (October 2019)**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 150,660</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">17</p></td></tr><tr><td style="vertical-align:bottom;width:53.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted at December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,932,156</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">17</p></td></tr><tr><td style="vertical-align:bottom;width:53.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants exercisable at December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Awards valued on December 31, 2018 and January 1, 2019, respectively.</span></td></tr></table><div style="margin-top:12pt;"/><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">**</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The warrants are not incorporated in the articles of association. Rectification was conducted in December 2020.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Board of Directors and Executive Management holding of share awards for the years ended December 31, 2019, 2020 and 2021 is shown below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants held when</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants held when</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">becoming or leaving</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">becoming or leaving</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">as a member</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">as a member</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Number of warrants held</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Granted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of management</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Granted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Forfeited</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of management</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Granted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercised</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Forfeited</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Thomas William Wylonis(former)<sup style="font-size:5.25pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">342,612</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">342,612</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (369,252)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,640</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 369,252</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 369,252</p></td></tr><tr><td style="vertical-align:bottom;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Steven Projan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">23,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,612</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,048</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,583</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,631</p></td></tr><tr><td style="vertical-align:bottom;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Roberto Prego</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,364</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,164</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,583</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,747</p></td></tr><tr><td style="vertical-align:bottom;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Joann Suzich(former)<sup style="font-size:5.25pt;line-height:100%;top:0pt;vertical-align:top;">7</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,260</p></td></tr><tr><td style="vertical-align:bottom;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Marianne Søgaard<sup style="font-size:5.25pt;line-height:100%;top:0pt;vertical-align:top;">2</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,952</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,368</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 94,320</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,167</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 103,487</p></td></tr><tr><td style="vertical-align:bottom;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Helen Boudreau (former)<sup style="font-size:5.25pt;line-height:100%;top:0pt;vertical-align:top;">3</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (5,436)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Kim Bjørnstrup (former)<sup style="font-size:5.25pt;line-height:100%;top:0pt;vertical-align:top;">4</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (5,868)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,868</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Lars Holtug</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 4,583</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 4,583</p></td></tr><tr><td style="vertical-align:bottom;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Board of Directors in total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 385,848</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 385,848</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (309,168)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 109,548</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 555,480</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,916</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (5,436)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 572,960</p></td></tr><tr><td style="vertical-align:bottom;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Lars Aage Staal Wegner</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 844,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 844,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,668</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 852,084</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 64,167</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 916,251</p></td></tr><tr><td style="vertical-align:bottom;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Birgitte Rønø</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,376</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 74,376</p></td></tr><tr><td style="vertical-align:bottom;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Thomas Bogenrieder (former)<sup style="font-size:5.25pt;line-height:100%;top:0pt;vertical-align:top;">5</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,356</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45,216</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 49,572</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (4,356)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (45,216)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,356</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,356</p></td></tr><tr><td style="vertical-align:bottom;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Erik Heegaard</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 97,564</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 97,564</p></td></tr><tr><td style="vertical-align:bottom;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Glenn S. Vraniak (former)<sup style="font-size:5.25pt;line-height:100%;top:0pt;vertical-align:top;">6</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 150,660</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 150,660</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 150,660</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 150,660</p></td></tr><tr><td style="vertical-align:bottom;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Executive Management in total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 848,772</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 195,876</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,044,648</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (4,356)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,668</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (45,216)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,007,100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,376</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 206,731</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,243,207</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Board member until June 30, 2020, </span><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">252</span><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> warrants were granted for services provided after retirement from the Board of Director position.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">As of November 25, 2020, </span><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">26,964</span><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> warrants were granted for services provided before taking on the Board of Directors position.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Board member from June 30, 2020 to May 25, 2021.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Board member from June 30, 2020 to November 4, 2020.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Part of Executive Management until March 31, 2020.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Mr. Vraniak resigned as the Chief Financial Officer of the Company effective November 1, 2021.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(7)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Board member until May 25, 2021.</span></td></tr></table> P36M P36M 0.118 0.138 0.135 62147 P36M 150660 2 17 2 1 36 2 1 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price/Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life (years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants granted as at December 31, 2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,674,324</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">DKK 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18</p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants granted<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 257,832</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">DKK 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17</p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants granted as at December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,932,156</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">DKK 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17</p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 363,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">DKK 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11</p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (45,216)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">DKK 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16</p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (22,032)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">DKK 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16</p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants granted as at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,228,076</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">DKK 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15</p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants granted during 2021<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 63,802</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">DKK 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10</p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants granted December 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 523,599</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">USD 5.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10</p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (62,284)</p></td><td style="vertical-align:top;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">(3)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">DKK 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,178)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,397)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants granted as at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,732,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">DKK 7.53</p></td><td style="vertical-align:top;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">(4)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13</p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants exercisable as at December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_RgYzXEqcz06ZnkMUZehCSA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> —</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants exercisable as at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_pBholIuj9UqD010IfuPNMA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> —</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:57.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants exercisable as at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,072,122</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup><span style="display:inline-block;width:28.42pt;"/>The warrants are not incorporated in the articles of association. Rectification conducted in October 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Of which 62,147 warrants were legally granted in June 2021 and the remaining 1,655 warrants were legally granted in December 2020.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The share price at the exercise date was USD 5.59.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">December 31, 2021 USD-end rate used.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p> 1674324 1 P18Y 257832 1 P17Y 1932156 1 P17Y 363168 1 P11Y 45216 1 P16Y 22032 1 P16Y 2228076 1 P15Y 63802 1 P10Y 523599 5.38 P10Y 62284 1 10178 1 10397 1 2732618 7.53 P13Y 2072122 62147 1655 5.59 45216 300000 7956 100000 54000 500000 150660 P3Y 1300000 126972 63612 63360 P3Y 1200000 236196 120888 115308 P3Y 2300000 62147 400000 523599 22916 P36M 1500000 22032 22032 45216 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,496</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,021</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 328</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,912</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,341</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,379</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,408</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,362</p></td></tr></table> 1051000 1496000 1021000 328000 1912000 1341000 1379000 3408000 2362000 100000 0.40 8.89 0.60 11.00 0.10 800000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following assumptions have been applied for the warrants issued in December 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 85.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 6.5 0.0134 0.850 4.20 1 6.24 P3Y 400000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following schedule specifies the outstanding warrants as at December 31, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:99.98%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">warrant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercise price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">term to</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">date fair value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">per warrant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">maturity</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding program</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(DKK)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(DKK)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (December 2016)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 701,356</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 15</p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (September 2017)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 617,184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 15</p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (December 2017)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 122,040</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 15</p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (during 2018)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 37.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 174,564</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 15</p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (February 2019)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,956</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 15</p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (September 2019)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 15</p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (October 2019)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 150,660</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 15</p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (December 2020)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 317,457</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 9</p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (April 2021)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,655</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 10</p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (June 2021)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40.86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 62,147</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 10</p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (December 2021)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 523,599</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">USD 5.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 10</p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,732,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants exercisable at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following schedule specifies the outstanding warrants as at December 31, 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">warrant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> exercise price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> term to </b></p></td></tr><tr><td style="vertical-align:bottom;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">date fair value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> warrants </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">per warrant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">maturity</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding program</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(DKK)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(DKK)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (December 2016)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 712,332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">16</p></td></tr><tr><td style="vertical-align:bottom;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (April 2017)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,896</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">16</p></td></tr><tr><td style="vertical-align:bottom;width:44.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (September 2017)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 617,184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">16</p></td></tr><tr><td style="vertical-align:bottom;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (December 2017)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 127,044</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">16</p></td></tr><tr><td style="vertical-align:bottom;width:44.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (during 2018)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 37.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 181,836</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">16</p></td></tr><tr><td style="vertical-align:bottom;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (February 2019)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,956</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">16</p></td></tr><tr><td style="vertical-align:bottom;width:44.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (September 2019)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">16</p></td></tr><tr><td style="vertical-align:bottom;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (October 2019)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 150,660</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">16</p></td></tr><tr><td style="vertical-align:bottom;width:44.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (December 2020)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 363,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">11</p></td></tr><tr><td style="vertical-align:bottom;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,228,076</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">15</p></td></tr><tr><td style="vertical-align:bottom;width:44.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants exercisable at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';"> —</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following schedule specifies the outstanding warrants as at December 31, 2019:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">warrant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> exercise price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> term to </b></p></td></tr><tr><td style="vertical-align:bottom;width:53.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">date fair value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> warrants </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">per warrant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">maturity</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding program</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(DKK)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(DKK)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (December 2016)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 712,332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">17</p></td></tr><tr><td style="vertical-align:bottom;width:53.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (April 2017)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,896</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">17</p></td></tr><tr><td style="vertical-align:bottom;width:53.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (September 2017)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 617,184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">17</p></td></tr><tr><td style="vertical-align:bottom;width:53.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (December 2017)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 138,384</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">17</p></td></tr><tr><td style="vertical-align:bottom;width:53.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (during 2018)<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup>**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 37.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 192,528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">17</p></td></tr><tr><td style="vertical-align:bottom;width:53.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (January 2019)<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup>**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 37.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,216</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">17</p></td></tr><tr><td style="vertical-align:bottom;width:53.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (February 2019)**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,956</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">17</p></td></tr><tr><td style="vertical-align:bottom;width:53.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (September 2019)**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">17</p></td></tr><tr><td style="vertical-align:bottom;width:53.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant (October 2019)**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 150,660</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">17</p></td></tr><tr><td style="vertical-align:bottom;width:53.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted at December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,932,156</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">17</p></td></tr><tr><td style="vertical-align:bottom;width:53.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants exercisable at December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Awards valued on December 31, 2018 and January 1, 2019, respectively.</span></td></tr></table><div style="margin-top:12pt;"/><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">**</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The warrants are not incorporated in the articles of association. Rectification was conducted in December 2020.</p></td></tr></table> 20.91 701356 1 P15Y 28.71 617184 1 P15Y 28.71 122040 1 P15Y 37.05 174564 1 P15Y 42.57 7956 1 P15Y 56.35 54000 1 P15Y 56.97 150660 1 P15Y 56.75 317457 1 P9Y 45.31 1655 1 P10Y 40.86 62147 1 P10Y 19.22 523599 5.38 P10Y 2732618 20.91 712332 1 P16Y 24.05 13896 1 P16Y 28.71 617184 1 P16Y 28.71 127044 1 P16Y 37.05 181836 1 P16Y 42.57 7956 1 P16Y 56.35 54000 1 P16Y 56.97 150660 1 P16Y 56.75 363168 1 P11Y 2228076 1 P15Y 20.91 712332 1 P17Y 24.05 13896 1 P17Y 28.71 617184 1 P17Y 28.71 138384 1 P17Y 37.05 192528 1 P17Y 37.05 45216 1 P17Y 42.57 7956 1 P17Y 56.35 54000 1 P17Y 56.97 150660 1 P17Y 1932156 1 P17Y <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Board of Directors and Executive Management holding of share awards for the years ended December 31, 2019, 2020 and 2021 is shown below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants held when</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants held when</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">becoming or leaving</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">becoming or leaving</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">as a member</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">as a member</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Number of warrants held</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Granted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of management</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Granted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Forfeited</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of management</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Granted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercised</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Forfeited</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Thomas William Wylonis(former)<sup style="font-size:5.25pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">342,612</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">342,612</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (369,252)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,640</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 369,252</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 369,252</p></td></tr><tr><td style="vertical-align:bottom;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Steven Projan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">23,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,612</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,048</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,583</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,631</p></td></tr><tr><td style="vertical-align:bottom;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Roberto Prego</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,364</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,164</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,583</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 38,747</p></td></tr><tr><td style="vertical-align:bottom;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Joann Suzich(former)<sup style="font-size:5.25pt;line-height:100%;top:0pt;vertical-align:top;">7</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,260</p></td></tr><tr><td style="vertical-align:bottom;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Marianne Søgaard<sup style="font-size:5.25pt;line-height:100%;top:0pt;vertical-align:top;">2</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,952</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,368</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 94,320</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,167</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 103,487</p></td></tr><tr><td style="vertical-align:bottom;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Helen Boudreau (former)<sup style="font-size:5.25pt;line-height:100%;top:0pt;vertical-align:top;">3</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,436</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (5,436)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Kim Bjørnstrup (former)<sup style="font-size:5.25pt;line-height:100%;top:0pt;vertical-align:top;">4</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (5,868)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,868</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Lars Holtug</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 4,583</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> 4,583</p></td></tr><tr><td style="vertical-align:bottom;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Board of Directors in total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 385,848</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 385,848</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (309,168)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 109,548</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 555,480</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,916</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (5,436)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 572,960</p></td></tr><tr><td style="vertical-align:bottom;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Lars Aage Staal Wegner</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 844,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 844,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,668</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 852,084</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 64,167</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 916,251</p></td></tr><tr><td style="vertical-align:bottom;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Birgitte Rønø</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,376</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 74,376</p></td></tr><tr><td style="vertical-align:bottom;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Thomas Bogenrieder (former)<sup style="font-size:5.25pt;line-height:100%;top:0pt;vertical-align:top;">5</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,356</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45,216</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 49,572</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (4,356)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (45,216)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,356</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,356</p></td></tr><tr><td style="vertical-align:bottom;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Erik Heegaard</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 97,564</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 97,564</p></td></tr><tr><td style="vertical-align:bottom;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Glenn S. Vraniak (former)<sup style="font-size:5.25pt;line-height:100%;top:0pt;vertical-align:top;">6</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 150,660</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 150,660</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 150,660</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 150,660</p></td></tr><tr><td style="vertical-align:bottom;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Executive Management in total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 848,772</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 195,876</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,044,648</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (4,356)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,668</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (45,216)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,007,100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,376</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 206,731</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,243,207</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Board member until June 30, 2020, </span><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">252</span><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> warrants were granted for services provided after retirement from the Board of Director position.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">As of November 25, 2020, </span><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">26,964</span><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> warrants were granted for services provided before taking on the Board of Directors position.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Board member from June 30, 2020 to May 25, 2021.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Board member from June 30, 2020 to November 4, 2020.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Part of Executive Management until March 31, 2020.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Mr. Vraniak resigned as the Chief Financial Officer of the Company effective November 1, 2021.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(7)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Board member until May 25, 2021.</span></td></tr></table> 342612 342612 -369252 26640 369252 369252 23436 23436 18612 42048 4583 46631 19800 19800 14364 34164 4583 38747 10260 10260 10260 65952 28368 94320 9167 103487 5436 5436 5436 -5868 5868 4583 4583 385848 385848 -309168 109548 555480 22916 5436 572960 844416 844416 7668 852084 64167 916251 29376 45000 74376 4356 45216 49572 -4356 45216 4356 4356 97564 97564 150660 150660 150660 150660 848772 195876 1044648 -4356 7668 45216 1007100 29376 206731 1243207 252 26964 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Note 9. Financial Income and Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended</b> </p></td></tr><tr><td style="vertical-align:bottom;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;width:30.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financial income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest income, bank</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8</p></td></tr><tr><td style="vertical-align:bottom;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest income, other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td></tr><tr><td style="vertical-align:bottom;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Foreign exchange gains</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,039</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 216</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56</p></td></tr><tr><td style="vertical-align:bottom;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total financial income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,039</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 216</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65</p></td></tr><tr><td style="vertical-align:bottom;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financial expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (29)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (36)</p></td></tr><tr><td style="vertical-align:bottom;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Changes in fair value of convertible debt instruments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,183)</p></td></tr><tr><td style="vertical-align:bottom;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest expenses, lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (123)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3)</p></td></tr><tr><td style="vertical-align:bottom;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest, loan from lessor</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (31)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Foreign exchange losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (756)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (194)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total financial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (915)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (223)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,222)</p></td></tr><tr><td style="vertical-align:bottom;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net financial items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,157)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended</b> </p></td></tr><tr><td style="vertical-align:bottom;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;width:30.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financial income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest income, bank</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8</p></td></tr><tr><td style="vertical-align:bottom;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest income, other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td></tr><tr><td style="vertical-align:bottom;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Foreign exchange gains</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,039</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 216</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56</p></td></tr><tr><td style="vertical-align:bottom;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total financial income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,039</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 216</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65</p></td></tr><tr><td style="vertical-align:bottom;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financial expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (29)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (36)</p></td></tr><tr><td style="vertical-align:bottom;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Changes in fair value of convertible debt instruments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,183)</p></td></tr><tr><td style="vertical-align:bottom;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest expenses, lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (123)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3)</p></td></tr><tr><td style="vertical-align:bottom;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest, loan from lessor</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (31)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Foreign exchange losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (756)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (194)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:66.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total financial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (915)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (223)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,222)</p></td></tr><tr><td style="vertical-align:bottom;width:66.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net financial items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,157)</p></td></tr></table> 8000 1000 2039000 216000 56000 2039000 216000 65000 5000 29000 36000 1183000 123000 3000 31000 756000 194000 915000 223000 1222000 1124000 -7000 -1157000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 10. Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><i style="font-style:italic;font-weight:normal;">(a)   Analysis of charge/(credit) for the year:</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:66.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax expense/(benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (178)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,557)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (825)</p></td></tr><tr><td style="vertical-align:bottom;width:66.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total income taxes for the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (178)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,557)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (825)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On December 31, 2021, the Company had tax loss carry-forwards in Denmark of $9.5 million (2020: $3.8 million in Denmark; 2019: $1.3 million in Denmark) for income tax purposes, all of which can be carried forward infinitely according to Danish Corporate Income Tax Act. As of December 31, 2021, the Company did not have any tax loss carry-forwards in any other tax jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The benefit from income taxes for each year includes a tax credit for research and development expenditures at the applicable tax rate under the Danish Tax Assessment Act and Australian tax legislation, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><i style="font-style:italic;font-weight:normal;">(b) Reconciliation of effective tax rate to Danish statutory tax rate</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Statutory corporate income tax rate in Denmark</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Difference in corporate income tax rate in subsidiaries </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Non-deductible income / (expenses)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Non-taxable income / (expenses)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Additional tax deduction R&amp;D expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Tax credit research and development expenditures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Change in deferred tax asset not capitalized</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (23)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (25)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (17)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total effective tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><i style="font-style:italic;font-weight:normal;">(c) Deferred tax in the statements of financial position</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;width:31.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred Tax Positions:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,118</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,289</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,034</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss carry forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,530</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,759</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,270</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenditures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 262</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (98)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (34)</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance on deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,550)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,042)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,270)</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total capitalized </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 262</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Deferred tax attributable to research and development expenditures relates to development costs recognized as an expense in the consolidated financial statements in 2020 and are tax deductible in 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Under Danish tax legislation, the value of warrants to employees is income tax exempt subject to meeting certain conditions. The value of income tax exempt warrants is not tax deductible for the issuer. There is currently uncertainty in respect of the extent to which the conditions for being tax exempt are met and consequently the extent to which a tax deduction will be available for the company. Consequently, the deferred tax asset disclosed above is subject to uncertainty and there is a risk that the amount disclosed above is not tax deductible in full.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:66.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax expense/(benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (178)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,557)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (825)</p></td></tr><tr><td style="vertical-align:bottom;width:66.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total income taxes for the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (178)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,557)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (825)</p></td></tr></table> -178000 -1557000 -825000 -178000 -1557000 -825000 9500000 3800000 1300000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Statutory corporate income tax rate in Denmark</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Difference in corporate income tax rate in subsidiaries </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Non-deductible income / (expenses)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Non-taxable income / (expenses)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Additional tax deduction R&amp;D expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Tax credit research and development expenditures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Change in deferred tax asset not capitalized</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (23)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (25)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (17)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td></tr><tr><td style="vertical-align:bottom;width:69.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total effective tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td></tr></table> 0.22 0.22 0.22 -0.01 -0.05 0.01 0.06 0.03 -0.04 0.09 0.07 -0.23 -0.25 -0.17 0.01 0.09 0.07 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;width:31.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred Tax Positions:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,118</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,289</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,034</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss carry forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,530</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,759</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,270</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenditures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 262</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (98)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (34)</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance on deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,550)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,042)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,270)</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total capitalized </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 262</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr></table> 2118000 4289000 3034000 9530000 3759000 1270000 262000 -98000 -6000 -34000 -11550000 -8042000 -4270000 262000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 11. Basic and Diluted Loss Per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic loss per share is calculated by dividing the net loss attributable for the year to shareholders of Evaxion Biotech A/S by the weighted average number of ordinary shares outstanding during the year. As net losses from continuing operations were recorded in the years 2021, 2020 and 2019, the dilutive potential shares are anti-dilutive for the earnings per share calculation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:44.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:53.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;width:44.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands, except share amounts and per share amounts)</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Loss per share before and after dilution</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:53.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to shareholders of Evaxion Biotech A/S</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (24,532)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (15,018)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,195)</p></td></tr><tr><td style="vertical-align:bottom;width:53.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average number of ordinary shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,493,143</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,434,758</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,892,314</p></td></tr><tr><td style="vertical-align:bottom;width:53.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Loss per share before and after dilution</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.26)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.97)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.81)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following potential shares are anti-dilutive and are therefore excluded from the weighted average number of shares for the purpose of diluted loss per share:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,732,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,228,076</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,059,128</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:44.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:53.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;width:44.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands, except share amounts and per share amounts)</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Loss per share before and after dilution</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:53.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to shareholders of Evaxion Biotech A/S</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (24,532)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (15,018)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,195)</p></td></tr><tr><td style="vertical-align:bottom;width:53.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average number of ordinary shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,493,143</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,434,758</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,892,314</p></td></tr><tr><td style="vertical-align:bottom;width:53.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Loss per share before and after dilution</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.26)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.97)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.81)</p></td></tr></table> -24532000 -15018000 -11195000 19493143 15434758 13892314 -1.26 -0.97 -0.81 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,732,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,228,076</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,059,128</p></td></tr></table> 2732618 2228076 2059128 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Note 12. Intangible Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In June 2020, the Company entered into a license agreement for the rights to certain intellectual properties. Upon execution of the license agreement, the Company was obligated to make a milestone payment of $35,000. The agreement remains in effect until the Company completes a Phase I/IIa clinical study, after that the Company has an option to extend the agreement for an additional 10-year term. Over the initial term of the agreement, the Company is obligated to make various additional milestone payments based on the progress of developed drug candidates. The Company determined that the milestone payments meet the definition of intangible assets and will be capitalized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">During the twelve months ended December 31, 2020, the Company capitalized $35,000 as intangible assets for the acquisition of a non-exclusive technology license. Subject to meeting certain development milestones, additional consideration of up to $320,000 is to be transferred to the seller. Further, $250,000 is to be transferred to the seller upon each regulatory approval of an Evaxion product utilizing the in-licensed technology. As of December 31, 2020, the Company accrued for an additional $60,000 related to the license. The Company did not recognize any amortization expense for the years ended December 31, 2021 and 2020 as the asset has not been put in use. No intangible assets were recognized in earlier periods as the Company’s expenditures did not qualify for capitalization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">During the twelve months ended December 31, 2020, the Company capitalized $60,000 as intangible assets for the acquisition of a non-exclusive technology license from SSI. Subject to successful commercialization of any Evaxion product utilizing the in-licensed technology, Evaxion is required to pay to the seller a royalty on net sales in the low teens. In the event any Evaxion product utilizing the in-licensed technology are commercialized by one of the Company’s partners, Evaxion is required to pay to the seller a percentage of any out-licensing revenue earned by the Company or its affiliates. If Evaxion enters into a sublicense agreement with a partner subsequent to the initiation of a Phase 2b clinical trial, Evaxion is required to pay to the seller a percentage of any sublicensing income in an amount in the lower double-digit range. If Evaxion enters into a sublicense agreement with a partner subsequent to the initiation of a Phase 3 trial, Evaxion is required to pay to the seller a percentage of any sublicensing income in the lower double-digit range. If Evaxion enters into a sublicense agreement with a partner without initiating a Phase 2b trial, Evaxion is required to pay to SSI a percentage of any sublicensing income in the mid double-digit range.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company did not recognize any amortization expense for the years ended December 31, 2021, and 2020 as the asset has not been put in use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intangible</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100</p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Additions during the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_2QMsWTTc6kuVuJhXsJJdRA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> —</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden___InvMwBlE-mZR_Af4c9nA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> —</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exchange rate adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7)</p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 93</p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization for the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_aCHGcn24xUGtW2OFMDRtvA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> —</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_qSIKlKoL9ECBbLaKVmLyiQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> —</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exchange rate adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_wAgzcqOSkkCUNwruV6gXvg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> —</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_maM3xDfYc0CgY0-8Xxqupw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> —</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Carrying amount at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 93</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intangible </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost at December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Additions during the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 95</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exchange rate adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization at December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization for the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exchange rate adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Carrying amount at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> 35000 P10Y 35000 320000 250000 60000 60000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intangible</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100</p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Additions during the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_2QMsWTTc6kuVuJhXsJJdRA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> —</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden___InvMwBlE-mZR_Af4c9nA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> —</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exchange rate adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7)</p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 93</p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization for the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_aCHGcn24xUGtW2OFMDRtvA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> —</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_qSIKlKoL9ECBbLaKVmLyiQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> —</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exchange rate adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_wAgzcqOSkkCUNwruV6gXvg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> —</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_maM3xDfYc0CgY0-8Xxqupw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> —</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Carrying amount at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 93</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intangible </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost at December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Additions during the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 95</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exchange rate adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization at December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization for the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exchange rate adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Carrying amount at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100</p></td></tr></table> 100000 100000 -7000 -7000 93000 93000 0 0 93000 93000 95000 95000 5000 5000 100000 100000 100000 100000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Note 13. Property and Equipment, Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leasehold</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Property</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equipment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Improvements</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 257</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 520</p></td></tr><tr><td style="vertical-align:bottom;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Additions during the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,891</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,634</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,550</p></td></tr><tr><td style="vertical-align:bottom;width:50.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Disposals during the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (244)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (244)</p></td></tr><tr><td style="vertical-align:bottom;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exchange rate adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (148)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (63)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (67)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (278)</p></td></tr><tr><td style="vertical-align:bottom;width:50.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,756</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,225</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,567</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,548</p></td></tr><tr><td style="vertical-align:bottom;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (237)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (62)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (299)</p></td></tr><tr><td style="vertical-align:bottom;width:50.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation for the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (179)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (105)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (59)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (343)</p></td></tr><tr><td style="vertical-align:bottom;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation reversed on disposals during the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 244</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 244</p></td></tr><tr><td style="vertical-align:bottom;width:50.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exchange rate adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24</p></td></tr><tr><td style="vertical-align:bottom;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (155)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (161)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (58)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (374)</p></td></tr><tr><td style="vertical-align:bottom;width:50.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Carrying amount at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,601</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,064</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,509</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,174</p></td></tr><tr><td style="vertical-align:bottom;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Carrying amount of right-of-use assets at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,601</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,601</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Property</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equipment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;width:35.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost at December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 272</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Additions during the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 149</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 204</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exchange rate adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 257</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 520</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation at December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (144)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (27)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (171)</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation for the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (71)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (34)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (105)</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exchange rate adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (22)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (23)</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (237)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (62)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (299)</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Carrying amount at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 201</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 221</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Carrying amount of right-of-use assets at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation included in the statement of comprehensive loss:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 270</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 64</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total depreciation included in the statement of comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 343</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total accumulated depreciation of right-of-use assets at December 31, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 557</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 236</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 145</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leasehold</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Property</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equipment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Improvements</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:47.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 257</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 520</p></td></tr><tr><td style="vertical-align:bottom;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Additions during the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,891</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,634</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,550</p></td></tr><tr><td style="vertical-align:bottom;width:50.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Disposals during the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (244)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (244)</p></td></tr><tr><td style="vertical-align:bottom;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exchange rate adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (148)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (63)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (67)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (278)</p></td></tr><tr><td style="vertical-align:bottom;width:50.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,756</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,225</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,567</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,548</p></td></tr><tr><td style="vertical-align:bottom;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (237)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (62)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (299)</p></td></tr><tr><td style="vertical-align:bottom;width:50.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation for the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (179)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (105)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (59)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (343)</p></td></tr><tr><td style="vertical-align:bottom;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation reversed on disposals during the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 244</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 244</p></td></tr><tr><td style="vertical-align:bottom;width:50.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exchange rate adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24</p></td></tr><tr><td style="vertical-align:bottom;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (155)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (161)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (58)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (374)</p></td></tr><tr><td style="vertical-align:bottom;width:50.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Carrying amount at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,601</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,064</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,509</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,174</p></td></tr><tr><td style="vertical-align:bottom;width:50.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Carrying amount of right-of-use assets at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,601</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,601</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Property</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equipment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;width:35.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost at December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 272</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Additions during the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 149</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 204</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exchange rate adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 257</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 520</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation at December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (144)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (27)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (171)</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation for the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (71)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (34)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (105)</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exchange rate adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (22)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (23)</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (237)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (62)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (299)</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Carrying amount at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 201</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 221</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Carrying amount of right-of-use assets at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation included in the statement of comprehensive loss:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 270</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 64</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total depreciation included in the statement of comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 343</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total accumulated depreciation of right-of-use assets at December 31, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 557</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 236</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 145</p></td></tr></table> 257000 263000 520000 2891000 1025000 1634000 5550000 244000 244000 -148000 -63000 -67000 -278000 2756000 1225000 1567000 5548000 -237000 -62000 -299000 179000 105000 59000 343000 244000 244000 17000 6000 1000 24000 -155000 -161000 -58000 -374000 2601000 1064000 1509000 5174000 2601000 2601000 179000 93000 272000 55000 149000 204000 23000 21000 44000 257000 263000 520000 -144000 -27000 -171000 71000 34000 105000 -22000 -1000 -23000 -237000 -62000 -299000 20000 201000 221000 20000 20000 270000 90000 64000 73000 15000 16000 343000 105000 80000 -557000 -236000 -145000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Note 14. Prepayments and other receivables</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">VAT receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 387</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 376</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Prepayments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 638</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,175</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 113</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total prepayments and other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,138</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,553</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">VAT receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 387</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 376</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Prepayments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 638</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,175</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 113</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total prepayments and other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,138</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,553</p></td></tr></table> 387000 376000 638000 1175000 113000 2000 1138000 1553000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Note 15. Other Payables</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;width:21.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee cost liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 989</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,054</p></td></tr><tr><td style="vertical-align:bottom;width:76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 180</p></td></tr><tr><td style="vertical-align:bottom;width:76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,035</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,234</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;width:21.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee cost liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 989</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,054</p></td></tr><tr><td style="vertical-align:bottom;width:76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 180</p></td></tr><tr><td style="vertical-align:bottom;width:76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,035</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,234</p></td></tr></table> 989000 1054000 46000 180000 1035000 1234000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Note 16. Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;width:21.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32,166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,834</p></td></tr><tr><td style="vertical-align:bottom;width:76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32,166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,834</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents consist mainly of cash on deposit with banks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;">Changes in Net Working Capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:66.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Changes in receivables and tax receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,863</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,501)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (337)</p></td></tr><tr><td style="vertical-align:bottom;width:66.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Changes in trade payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (647)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,798</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 507</p></td></tr><tr><td style="vertical-align:bottom;width:66.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Changes in other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 918</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 403</p></td></tr><tr><td style="vertical-align:bottom;width:66.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Changes in net working capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,237</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 215</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 573</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Working capital is defined as current assets (excluding cash) less current liabilities (excluding convertible debt) and measures the net liquid assets the Company has available for the business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Adjustments for non-cash items</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adjustments of non-cash items in the statements of comprehensive loss:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (178)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,557)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (825)</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax credit schemes accounted for as grants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (510)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9)</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 159</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share-based compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,379</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,408</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,362</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquisition of property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (90)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value of convertible debt instruments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,183</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other adjustments: Other adjustments, primarily exchange rate adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,061)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 107</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 114</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total adjustments for non-cash items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 541</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,583</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,945</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;">Reconciliation of Liabilities from Financing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exchange rate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:39.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash flows</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> <b style="font-weight:bold;">interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> <b style="font-weight:bold;">adjustment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (226)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,731</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (128)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,520</p></td></tr><tr><td style="vertical-align:bottom;width:39.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loan from lessor</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_eRFgqafrUE2QgGHRLhK93Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> —</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,269</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (130)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,170</p></td></tr><tr><td style="vertical-align:bottom;width:39.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provisions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_9aCDKcbkWEmVF1p5D86GTQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> —</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 161</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 153</p></td></tr><tr><td style="vertical-align:bottom;width:39.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total liabilities from financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (226)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 154</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,161</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (266)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,843</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exchange rate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:39.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cash flows</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> <b style="font-weight:bold;">interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> <b style="font-weight:bold;">adjustment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (74)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td></tr><tr><td style="vertical-align:bottom;width:39.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total liabilities from financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (74)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;width:21.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32,166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,834</p></td></tr><tr><td style="vertical-align:bottom;width:76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32,166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,834</p></td></tr></table> 32166000 5834000 32166000 5834000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:66.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Changes in receivables and tax receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,863</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,501)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (337)</p></td></tr><tr><td style="vertical-align:bottom;width:66.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Changes in trade payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (647)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,798</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 507</p></td></tr><tr><td style="vertical-align:bottom;width:66.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Changes in other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 918</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 403</p></td></tr><tr><td style="vertical-align:bottom;width:66.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Changes in net working capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,237</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 215</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 573</p></td></tr></table> -1863000 2501000 337000 647000 -1798000 -507000 -21000 -918000 -403000 1237000 215000 573000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (178)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,557)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (825)</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax credit schemes accounted for as grants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (510)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9)</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 159</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share-based compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,379</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,408</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,362</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquisition of property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (90)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value of convertible debt instruments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,183</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other adjustments: Other adjustments, primarily exchange rate adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,061)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 107</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 114</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total adjustments for non-cash items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 541</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,583</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,945</p></td></tr></table> -178000 -1557000 -825000 -12000 -510000 344000 105000 81000 9000 159000 30000 39000 1379000 3408000 2362000 -90000 1183000 -1061000 107000 114000 541000 1583000 2945000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exchange rate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:39.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash flows</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> <b style="font-weight:bold;">interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> <b style="font-weight:bold;">adjustment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (226)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,731</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (128)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,520</p></td></tr><tr><td style="vertical-align:bottom;width:39.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loan from lessor</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_eRFgqafrUE2QgGHRLhK93Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> —</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,269</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (130)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,170</p></td></tr><tr><td style="vertical-align:bottom;width:39.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provisions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_9aCDKcbkWEmVF1p5D86GTQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> —</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 161</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 153</p></td></tr><tr><td style="vertical-align:bottom;width:39.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total liabilities from financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (226)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 154</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,161</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (266)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,843</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exchange rate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:39.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cash flows</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> <b style="font-weight:bold;">interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> <b style="font-weight:bold;">adjustment</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (74)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td></tr><tr><td style="vertical-align:bottom;width:39.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total liabilities from financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (74)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td></tr></table> 20000 -226000 123000 2731000 -128000 2520000 31000 1269000 -130000 1170000 161000 -8000 153000 20000 -226000 154000 4161000 -266000 3843000 36000 -74000 1000 54000 3000 20000 36000 -74000 1000 54000 3000 20000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 17. Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As a result of the lease accounting of IFRS 16, the Company has capitalized the only right-of-use asset being the domicile lease. Upon implementation on January 1, 2018, the Company has recognized a liability to make lease payments (i.e. the lease liabilities) of $0.2 million and an asset representing the right to use the underlying asset during the lease term (i.e. the right-to-use asset) of $0.2 million. The liability was measured at the present value of the remaining lease payments, discounted using the lessee’s incremental borrowing rate as of the standard adoption date of January 1, 2018. The Company applied an incremental borrowing rate of 3.8%. For the years ended December 31, 2019,2020 and 2021, the expense related to variable lease payments not included in the lease liabilities was immaterial and was recognized in operating expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In October 2020, the Company entered into a lease for approximately 1,356 square meters, which is allocated on 839 square meters of office space, and 518 square meters of laboratory space in Hørsholm, Denmark. The commencement date for the lease of the 839 square meters of office space was February 1, 2021 and the lease continues for a term of <span style="white-space:pre-wrap;">10 years</span><span style="white-space:pre-wrap;"> from that date. The commencement date for the additional laboratory space was August 13, 2021 and the lease continues for a term of </span><span style="white-space:pre-wrap;">10 years</span><span style="white-space:pre-wrap;"> with a subsequent 12-month cancellation notice period. The lease agreement contains an early termination provision which would trigger a termination fee of $2.7 million. The initial monthly payment is expected to be between $28,000 and $30,000, which consists of $12,000 for the office space, and is expected to be between $16,000 and $18,000 for the laboratory space. Through-out the term, the lease is subject to annual increases ranging from two to four percent on the annual lease payment amount.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company had one operating lease in Copenhagen, Denmark as of December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We also occupied an office space in New York, New York, United States. The terms of the lease agreement included a 13 month occupancy period from January 2, 2020 through January 31, 2021. A termination notice was provided in November 2020 and the lease and occupancy terminated on January 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For the years ended December 31, 2021, 2020 and 2019, the expense related to variable lease payments not included in the lease liabilities was immaterial and was recognized in operating expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Set out below are the carrying amounts of the Company’s right-of-use assets and lease liabilities and the movements during the period:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Right-of-Use Asset</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Lease liabilities</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:68.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">At December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td></tr><tr><td style="vertical-align:bottom;width:68.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,891</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,731</p></td></tr><tr><td style="vertical-align:bottom;width:68.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (179)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:68.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest Expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 123</p></td></tr><tr><td style="vertical-align:bottom;width:68.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (226)</p></td></tr><tr><td style="vertical-align:bottom;width:68.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (131)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (128)</p></td></tr><tr><td style="vertical-align:bottom;width:68.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">At December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,601</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,520</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Right-of-Use Asset</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Lease liabilities</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:68.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;width:29.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36</p></td></tr><tr><td style="vertical-align:bottom;width:68.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 54</p></td></tr><tr><td style="vertical-align:bottom;width:68.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (73)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:68.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest Expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:68.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (74)</p></td></tr><tr><td style="vertical-align:bottom;width:68.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4</p></td></tr><tr><td style="vertical-align:bottom;width:68.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The total cash outflow for leases was $0.2 million in 2021, and $0.2 million in 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Loan from Lessor</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition to the ordinary lease payments, the Company obtained financing from DTU Science Park A/S (“DTU”) for rebuilding the laboratory facility and engineering building to match the Company’s needs. The Company will repay the $1.3 million financing at a fixed interest rate of 6% over <span style="white-space:pre-wrap;">8 years</span><span style="white-space:pre-wrap;">. If the lease is terminated due to default by the Company before the outstanding balance, including interest accrued, has been repaid, the remaining balance is due immediately. The finance liability is recorded at costs, which approximates fair value at the time of issuance. As of December 31, 2021, the Company is still in discussions with DTU on the actual costs incurred.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As a result of the finance structure this amount is not included as Purchase of property and equipment within the consolidated statements of cash flows. The leasehold improvements recognized will be subject for adjustment when the actual costs incurred are made available from DTU.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following table sets forth the finance liability (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:87.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:87.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:87.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:87.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loan from lessor</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,170</p></td></tr><tr><td style="vertical-align:bottom;width:87.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total Loan from lessor</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,170</p></td></tr><tr><td style="vertical-align:bottom;width:87.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Loan from lessor, current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (126)</p></td></tr><tr><td style="vertical-align:bottom;width:87.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total Loan from lessor, net of current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,044</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> 200000 200000 0.038 1356 839 518 839 P10Y P10Y 2700000 28000 30000 12000 16000 18000 0.02 0.04 1 P13M <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Right-of-Use Asset</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Lease liabilities</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:68.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">At December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td></tr><tr><td style="vertical-align:bottom;width:68.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,891</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,731</p></td></tr><tr><td style="vertical-align:bottom;width:68.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (179)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:68.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest Expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 123</p></td></tr><tr><td style="vertical-align:bottom;width:68.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (226)</p></td></tr><tr><td style="vertical-align:bottom;width:68.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (131)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (128)</p></td></tr><tr><td style="vertical-align:bottom;width:68.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">At December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,601</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,520</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Right-of-Use Asset</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Lease liabilities</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:68.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;width:29.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36</p></td></tr><tr><td style="vertical-align:bottom;width:68.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 54</p></td></tr><tr><td style="vertical-align:bottom;width:68.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (73)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:68.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest Expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:68.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (74)</p></td></tr><tr><td style="vertical-align:bottom;width:68.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4</p></td></tr><tr><td style="vertical-align:bottom;width:68.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td></tr></table> 20000 20000 2891000 2731000 179000 123000 226000 -131000 -128000 2601000 2520000 35000 36000 54000 54000 73000 4000 74000 4000 20000 20000 200000 200000 1300000 6 P8Y <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:87.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:87.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:87.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:87.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loan from lessor</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,170</p></td></tr><tr><td style="vertical-align:bottom;width:87.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total Loan from lessor</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,170</p></td></tr><tr><td style="vertical-align:bottom;width:87.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Loan from lessor, current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (126)</p></td></tr><tr><td style="vertical-align:bottom;width:87.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total Loan from lessor, net of current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,044</p></td></tr></table> 1170000 1170000 126000 1044000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 18. Debt</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;">In August 2020, we executed a loan agreement, or the EIB Loan Agreement, with the European Investment Bank, or EIB, for a principal amount of </span><span style="font-weight:normal;">€20.0 </span><span style="font-weight:normal;">million, divided into </span><span style="font-weight:normal;">three</span><span style="font-weight:normal;"> tranches of </span><span style="font-weight:normal;">€7.0 </span><span style="font-weight:normal;">million, </span><span style="font-weight:normal;">€6.0 </span><span style="font-weight:normal;">million and </span><span style="font-weight:normal;">€7.0 </span><span style="font-weight:normal;">million on the EIB Loan. Under the EIB Loan Agreement, the EIB Loan tranche balances are due </span><span style="font-weight:normal;">six years</span><span style="font-weight:normal;"> </span><span style="font-weight:normal;">from their respective disbursement dates. For all tranches, EIB is entitled to an aggregate of </span><span style="font-weight:normal;">1,047,744 </span><span style="font-weight:normal;">cash settled warrants with an exercise price of </span><span style="font-weight:normal;">1</span><span style="font-weight:normal;"> DKK per warrant. The </span><span style="font-weight:normal;">351,036 </span><span style="font-weight:normal;">warrants attributable to the first tranche of </span><span style="font-weight:normal;">€7.0 </span><span style="font-weight:normal;">million were incorporated in the articles of association on December 17, 2020. As of December </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">31, 2021, the Company initiated the draw down of the first tranche of the EIB Loan Agreement amounting to </span><span style="font-weight:normal;">€7.0 </span><span style="font-weight:normal;">million. The Company received the first tranche of </span><span style="font-weight:normal;">€7.0 </span><span style="font-weight:normal;">million on February 17, 2022.</span></p> 20000000.0 3 7000000.0 6000000.0 7000000.0 P6Y P6Y 1047744 1 351036 7000000.0 7000000.0 7000000.0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 19. Capital Structure and Financial Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Share Capital – Ordinary Shares</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Loss of subscribed share capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On December 31, 2018, the Company had lost more than 50% of its subscribed share capital. At the annual general meeting of the shareholders held on March 29, 2019, the Board of Directors gave, in accordance with section 119 of the Danish Companies Act, an account of the Company’s financial position. As part of the account, the Board of Directors stated that in its view, special actions were not required. The share capital of the Company was subsequently re-established through the conversion of the convertible debt instruments and issue of new shares during 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Capital transactions</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In September 2020, the Company issued 745,380 shares of ordinary shares to existing investors in the Company. The purchase price was $8.89 per share for aggregate proceeds of $6.6 million. The Company incurred immaterial issuance costs. The proceeds were received by the Company on September 17, 2020. On August 10, 2020, the Company’s articles of association were amended in connection with the execution of this transaction. The revised articles increased the authorized number of shares the Company can issue by: (i) the 745,380 shares issued in this transaction, as well as (ii) an additional 1,800,000 shares of Common ordinary share at a nominal price of DKK 1, to be issued any time prior to June 1, 2025. The amended articles also allow the Company to issue an additional 1,298,196 of compensatory ordinary share warrants to employees and consultants any time prior to June 1, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In October 2020, we successfully completed part 2 of our “bridging round” of capital with outside investors in the amount of $2.4 million with a purchase price of $8.89 per share from the issuance of 269,136 of our ordinary shares and received the proceeds in November 2020. Transaction costs directly attributable to the third quarter of 2020 “bridging round” of capital with outside investors have a total amount of $144,022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In February 2021, we completed our IPO through which we issued and sold 3,000,000 American Depositary Shares, or ADSs, each of which represents one ordinary share, at a price to the public of $10.00 per ADS. We received aggregate net proceeds of $25.3 million from the IPO, after deducting the underwriting discounts and commissions and offering expenses. Upon the completion of the IPO, our registered, issued, and outstanding share capital was nominal DKK 19,198,668.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In November 2021, we completed a follow-on public offering through which we issued and sold 3,942,856 ADSs, each of which represents one ordinary share, at a price to the public of $7.00 per ADS. The shares issued were inclusive of the 514,285 ADSs issued to the underwriters pursuant to the full exercise of their option to purchase additional shares on November 5, 2021. The Company received aggregate net proceeds of $24.9 million from the follow-on public offering, which includes the funds received for the additional shares issued to the underwriters, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. Upon the completion of the follow-on public offering, the Company’s registered, <span style="-sec-ix-hidden:Hidden_8gpgx84-bkK9sWPQPCK12w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">issued</span></span><span style="white-space:pre-wrap;">, and outstanding share capital was nominal DKK 23,141,524.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">At year end, due to warrant exercise, the outstanding share capital was nominal DKK 23,203,808.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following are changes in the Company’s share capital for the years ended December 31, 2019, 2020 and 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Share Capital</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> Ordinary Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (DKK in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share capital, December 31, 2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,917,016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,917</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">Capital increase at July 17, 2019 (issuance of shares for cash)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 997,668</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 998</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital increase at July 17, 2019 (conversion of Convertible Debt 1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 302,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 303</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital increase at July 17, 2019 (conversion of Convertible Debt 2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 848,232</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 848</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital increase at December 19, 2019 (issuance of shares for cash)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 118,260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 118</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share capital, December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,184,152</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,184</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital increase at September 17, 2020 (issuance of shares for cash)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 745,380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 745</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital increase at October 15, 2020 (issuance of shares for cash)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 269,136</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 269</p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share capital, December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,198,668</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,198</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital increase at February 9, 2021 (for initial public offering)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital increase at November 9, 2021 (for follow-on offering)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,942,856</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,943</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital increase November 2021 (exercised warrants)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 62,284</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 63</p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share capital, December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,203,808</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,204</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company’s share capital consists of the following ordinary shares:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:91.15%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:14.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:83.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:83.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:14.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">Authorized, issued and fully paid</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">23,203,808 (2020: 16,198,668) ordinary shares of DKK 1 each (2020: ordinary shares of DKK 1 each)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,755</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,648</p></td></tr><tr><td style="vertical-align:bottom;width:83.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,755</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,648</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company’s ordinary shares shall confer on the holders thereof the right to receive notice of, attend and vote at general meetings of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Executive Management’s and Board of Director’s holding of shares</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At December 31, the board of directors and executive management held the following shareholdings in the Company:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of ordinary shares owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Niels Iversen Møller</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,292,604</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,292,604</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,292,604</p></td></tr><tr><td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Andreas Holm Mattsson</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,163,832</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,163,832</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,163,832</p></td></tr><tr><td style="vertical-align:bottom;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lars Aage Staal Wegner</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 182,124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 182,124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 182,124</p></td></tr><tr><td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Executive Management in total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 8,638,560</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 8,638,560</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 8,638,560</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of ordinary shares owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Roberto Prego</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 310,248</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 310,248</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 310,248</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thomas William Wylonis (former)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 485,676</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 481,860</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Marianne Søgaard</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41,652</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41,652</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Steven Projan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,288</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,288</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,736</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Board of Directors in total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 379,188</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 864,864</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 803,844</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> 0.50 745380 8.89 6600000 745380 1800000 1 1298196 2400000 8.89 269136 144022 3000000 10.00 25300000 19198668 3942856 7.00 514285 24900000 23141524 23203808 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Share Capital</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> Ordinary Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (DKK in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share capital, December 31, 2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,917,016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,917</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">Capital increase at July 17, 2019 (issuance of shares for cash)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 997,668</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 998</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital increase at July 17, 2019 (conversion of Convertible Debt 1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 302,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 303</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital increase at July 17, 2019 (conversion of Convertible Debt 2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 848,232</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 848</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital increase at December 19, 2019 (issuance of shares for cash)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 118,260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 118</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share capital, December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,184,152</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,184</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital increase at September 17, 2020 (issuance of shares for cash)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 745,380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 745</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital increase at October 15, 2020 (issuance of shares for cash)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 269,136</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 269</p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share capital, December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,198,668</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,198</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital increase at February 9, 2021 (for initial public offering)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital increase at November 9, 2021 (for follow-on offering)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,942,856</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,943</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital increase November 2021 (exercised warrants)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 62,284</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 63</p></td></tr><tr><td style="vertical-align:bottom;width:66.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share capital, December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,203,808</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,204</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:91.15%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:14.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:83.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:83.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:14.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">Authorized, issued and fully paid</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:83.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">23,203,808 (2020: 16,198,668) ordinary shares of DKK 1 each (2020: ordinary shares of DKK 1 each)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,755</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,648</p></td></tr><tr><td style="vertical-align:bottom;width:83.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,755</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,648</p></td></tr></table> 12917016 12917000 997668 998000 302976 303000 848232 848000 118260 118000 15184152 15184000 745380 745000 269136 269000 16198668 16198000 3000000 3000000 3942856 3943000 62284 63000 23203808 23204000 23203808 16198668 1 1 3755000 2648000 3755000 2648000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of ordinary shares owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Niels Iversen Møller</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,292,604</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,292,604</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,292,604</p></td></tr><tr><td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Andreas Holm Mattsson</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,163,832</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,163,832</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,163,832</p></td></tr><tr><td style="vertical-align:bottom;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lars Aage Staal Wegner</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 182,124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 182,124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 182,124</p></td></tr><tr><td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Executive Management in total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 8,638,560</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 8,638,560</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 8,638,560</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of ordinary shares owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Roberto Prego</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 310,248</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 310,248</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 310,248</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thomas William Wylonis (former)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 485,676</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 481,860</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Marianne Søgaard</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41,652</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41,652</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Steven Projan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,288</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,288</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,736</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Board of Directors in total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 379,188</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 864,864</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 803,844</b></p></td></tr></table> 4292604 4292604 4292604 4163832 4163832 4163832 182124 182124 182124 8638560 8638560 8638560 310248 310248 310248 485676 481860 41652 41652 27288 27288 11736 379188 864864 803844 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 20. Convertible Debt Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">During 2018, the Company issued two types of convertible debt instruments, (“Convertible Debt 1”) and one (“Convertible Debt 2”) for total proceeds of $8.0 million, of which $0.1 million was received from related parties, including members of the Board of Directors and Executive Management. The Company originally recorded both debt instruments at fair value as a financial liability and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">subsequently remeasured the instruments with the change being presented on the statement of comprehensive income for the reporting period. In July 2019, both instruments were converted into ordinary shares as a result of a qualified capital increase triggering a conversion based on the terms of the agreements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following table summarizes the changes in the convertible debt instruments during the year ended December 31, 2019:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> Convertible loans</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Carrying amount at December 31, 2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,569</p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amount received in 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 152</p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fair value adjustment included in finance expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,183</p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Currency adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (209)</p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Converted to equity during 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,695)</p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Carrying amount at December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The main terms of Convertible Debt 1 were:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Term: </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">12 months</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> from issuance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Interest coupon </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.5</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> percent p.a. accruing over the term of the loan;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Loan currencies: </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.9</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million is USD denominated and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million is denominated in DKK (DKK </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.1</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Lender conversion option if a capital increase in excess of DKK </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9.8</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million (or a qualified capital increase event) takes place before maturity. The conversion price is the share price obtained at the qualified capital increase event less a </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">20</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> percent discount;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Repayment in cash of principal + accrued interest at a premium of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">50</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> percent if all shares of the Company are sold; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Lender conversion option to a fixed number of shares if the loan has not been repaid or converted under the other settlement terms of the agreement.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The main terms of Convertible Debt 2 were:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Term: Expires on December 31, 2020;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Interest coupon </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.5</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> percent p.a. accruing over the term of the loan;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Loan currencies: </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$5.4</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million is USD denominated and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.7</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million is denominated in DKK (DKK </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Mandatory conversion if a capital increase in excess of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$10.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million (qualified capital increase) takes place before maturity. The conversion price is the share price obtained less a </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> percent discount if the capital increase take place in 2018, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> percent if it takes place in 2019 and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">20</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> percent if it takes place in 2020;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Repayment in cash of principal + accrued interest at a premium of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">50%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> if all shares of the Company are sold; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Mandatory conversion at maturity with a conversion price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$160.41</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10 days</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> before conversion, USD denominated loans will convert into DKK whereas the conversion price remains denominated in USD.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Convertible debt instruments were classified as financial liabilities until such time that the Company had an unconditional right to avoid settlement in cash and had no obligation to settle in a variable number of shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For Convertible Debt 1, the Company did not have an unconditional right to avoid settlement in cash. In addition, Convertible Debt 2 comprised an obligation to settle in a variable number of shares at maturity. Therefore, both convertible debt instruments comprised a debt host instrument.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Conversion features comprising a fixed number of the entity’s shares in exchange for a fixed principal in the entity’s functional currency were equity instruments and separated from the debt host contract as the residual between fair value of the contract and fair value of a similar debt instrument without the conversion feature. All other equity conversion features were embedded derivatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Both convertible debt instruments included a conversion feature resulting in settlement in a variable number of shares. Consequently, none of the instruments comprised an equity component. They included the following non-closely related embedded derivatives:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">At maturity conversion options for Convertible Debt Instrument 1;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">At maturity conversion provisions for Convertible Debt Instrument 2;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Early settlement mechanism on both issuances through delivery of a variable number of shares at a discounted price; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.25pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Change of control prepayment provision.</span></td></tr></table> 2 8000000.0 100000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> Convertible loans</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Carrying amount at December 31, 2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,569</p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amount received in 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 152</p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fair value adjustment included in finance expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,183</p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Currency adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (209)</p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Converted to equity during 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,695)</p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Carrying amount at December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr></table> 8569000 152000 1183000 -209000 -9695000 P12M 0.075 900000 1000000.0 7100000 9800000 0.20 0.50 0.075 5400000 700000 5000000.0 10000000.0 0.05 0.10 0.20 0.50 160.41 P10D <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Note 21. Related Party Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">The Company’s transactions with other related parties:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Transactions with related parties (expenses):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued interest on convertible debt instruments issued to members of executive management and board of directors</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4)</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balances with related parties at year-end (asset):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid rent and deposit for a leased property from a related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balances with related parties at year-end (liabilities):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Convertible debt instruments issued to members of executive management and board of directors (nominal value plus accrued interest of 7.5%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company’s related parties are comprised of significant shareholders of the Company, the executive management group, the board of directors and the close members of the family of these persons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company has not granted any loans, guarantees, or other commitments to or on behalf of any of the members in the board of directors or executive management. Other than the remuneration and other transactions relating to the board of directors or executive management and capital increases on the same terms as other investors, no other significant transactions have taken place with the board of directors or executive management for the years ended December 31, 2021, 2020 and 2019.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;width:30.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">The Company’s transactions with other related parties:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Transactions with related parties (expenses):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued interest on convertible debt instruments issued to members of executive management and board of directors</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4)</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balances with related parties at year-end (asset):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid rent and deposit for a leased property from a related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balances with related parties at year-end (liabilities):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Convertible debt instruments issued to members of executive management and board of directors (nominal value plus accrued interest of 7.5%)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p> 4000 7000 0.075 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 22. Contractual Obligations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Litigations and investigations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is not involved in any pending litigations, claims and investigations that individually and in the aggregate that is expected to have a material impact on the financial position, operating profit or cash flow.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The contractual obligations are similarly individually and, in the aggregate, not material to the future financial position, operating profit or cash flow.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Contractual obligations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At December 31, 2021, the Company had the following contractual commitments which fall due as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:47.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">cash flows</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&lt;1</b> y<b style="font-weight:bold;">ear</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">1 – 2</b> <b style="font-weight:bold;">years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2 – 5</b> <b style="font-weight:bold;">years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&gt;5 years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Purchase obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 72</p></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 72</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has purchase obligations of $72 thousand due to CRO’s and a nominal amount due system provider as of December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At December 31, 2020, the Company had the following contractual commitments which fall due as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:47.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> <b style="font-weight:bold;">cash flows</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&lt;1</b> y<b style="font-weight:bold;">ear</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">1 – 2</b> <b style="font-weight:bold;">years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2 – 5</b> <b style="font-weight:bold;">years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&gt;5 years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Purchase obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 712</p></td></tr><tr><td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 712</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company has purchase obligations of $0.6 million due to CRO’s and $0.1 million due to university future partners as of December 31, 2020.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:47.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">cash flows</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&lt;1</b> y<b style="font-weight:bold;">ear</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">1 – 2</b> <b style="font-weight:bold;">years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2 – 5</b> <b style="font-weight:bold;">years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&gt;5 years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Purchase obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 72</p></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 72</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:47.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:47.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> <b style="font-weight:bold;">cash flows</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&lt;1</b> y<b style="font-weight:bold;">ear</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">1 – 2</b> <b style="font-weight:bold;">years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2 – 5</b> <b style="font-weight:bold;">years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&gt;5 years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Purchase obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 712</p></td></tr><tr><td style="vertical-align:bottom;width:50.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 712</p></td></tr></table> 72000 72000 72000 72000 72000 72000 72000000 712000 712000 712000 712000 712000 712000 600000 100000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 23. Provisions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is required to restore the lease premises of its office and laboratory space in Hørsholm, Denmark to its original condition at the end of the lease term. A provision is recognized for the present value using a discount rate based on the Company’s risk adjusted incremental borrowing rate of the estimated expenditure required to remove any leasehold improvements. These costs have been capitalized as part of the cost of leasehold improvements and are amortized over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Changes in the provision balance during the year ended December 31, 2021 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Provisions</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in </b></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Carrying amount at January 1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision recognized</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 161</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Utilization of provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in the provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Currency adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8)</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Carrying amount at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 153</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Provisions</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in </b></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Carrying amount at January 1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision recognized</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 161</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Utilization of provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in the provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Currency adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8)</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Carrying amount at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 153</p></td></tr></table> 161000 -8000 153000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 24. Fees to auditors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following table presents the fees to our independent registered public accounting firm, EY Godkendt Revisionspartnerselskab, recognized in general and administrative expenses in the Statement of Profit or Loss for the years ended December 31, 2021 and 2020. This note was prepared in accordance with the requirements of the Danish Financial Statements Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Audit fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 308</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Audit related fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 108</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 119</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 328</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 253</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 680</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Audit fees</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Audit fees consist of fees billed for professional services rendered by EY for the audit of our annual consolidated financial statements or services that are normally provided by the accountant in connection with statutory and regulatory filings or engagements for those fiscal years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Audit-Related fees</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Audit-related fees consist of assurance and related services performed by EY that are reasonably related to the performance of the audit or review of our consolidated financial statements and are not reported under “Audit-Related fees.”</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Other fees</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other fees consist of services provided by EY for other permitted services, including fees for work performed by EY in connection with the initial public offering.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(USD in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Audit fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 308</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Audit related fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 108</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 119</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 328</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 253</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 680</p></td></tr></table> 177000 308000 108000 119000 328000 253000 613000 680000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 25. Events After the Reporting Period</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">EIB Loan Drawdown</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">As of December 31, 2021, the Company initiated the draw down of the first tranche of the EIB Loan Agreement amounting to </span><span style="font-weight:normal;">€7.0</span><span style="font-weight:normal;"> million. The Company received the first tranche of </span><span style="font-weight:normal;">€7.0</span><span style="font-weight:normal;"> million on February 17, 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Executive Management Agreements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The Company entered into agreements to hire executives in its Chief Operating Officer and Chief Financial Officer roles subsequent to the date of this annual report. The Chief Operating Officer joined the Company on March 14, 2022 and the Chief Financial Officer is expected to join the Company in August 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Russia’s Invasion of Ukraine</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 4pt 0pt;"><span style="font-weight:normal;">On February 24, 2022, Russia invaded Ukraine creating a global conflict. The resulting conflict and retaliatory measures by the global community have created global security concerns, including the possibility of expanded regional or global conflict, which have had, and are likely to continue to have, short-term and more likely longer-term adverse impacts on Ukraine and Europe and around the globe. Potential ramifications include disruption of the supply chain including research activities and complications with the conduct of ongoing and future clinical trials of our product candidates, including patient enrollment. The Company relies on global networks of contract research organizations and clinical trial sites to enroll patients, Delays in research activities or in the conduct of our clinical trials could increase associated costs and, depending upon the duration of any delays, require us to find alternative suppliers at additional expense. In addition, the conflict between Russia and the Ukraine has had significant ramifications on global financial markets, which may adversely impact our ability to raise capital on favorable terms or at all. </span></p> 7000000.0 7000000.0 EXCEL 180 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

    &ULE97?;]HP$,?_%2OJ0RMM.+^@4(5(*S!M#Y-0:;=G MDQS$JF.GMB'=?S_;"1$,Z+(70.*AD.?7^$2T*YER9N;2G31.PTHQR6$JE= M61+Y^Q&8J*=>X!T6GNBVT'8!ITE%MK "_5(MI?%PIY+3$KBB@B,)FZGW)7A8 MQ#;>!?RD4*LC&]E*UD*\6N=[/O5\FQ PR+15(.:QAQDP9H5,&F^MIM<=:<%C M^Z#^U=5N:ED3!3/!?M%<%U-O[*$<-F3']).HOT%;S]#J98(I]XOJ)G9D3LQV M2HNRA8U?4MX\R7O;AR,@B*\ 80N$?8&H!:*^0-P"<5]@V *N=-S4[AHW)YJD MB10UDC;:J%G#==_1IE^4V^]DI:79I8;3Z8RH A&>(VW-W?H!E&.G@NQ4P91"=8F ZN#L_:TQ^:T\,II<\@&* H^H= / M@POXK#_N7\#GO?%@<@%?],?'IS@V7>]:'W:M#YU>]+^M_T [ZK0CIQW_2SNS M!ES3;MY9(S5R4O9>V:=1&(Q&"=X?OYKSJ.$XBKN@DS3C+LWXPS2?A2:LR;%O MLG&O9,^C3I)MOI;SH,EP.#D-6IP'W<=1]%?9^&@ [?7Z@\@MY0HQV!C,']R; MH97-E=4X6E1N)M="FPEW9F%N>9 VP.QOA- 'QXYY][^1_@%02P,$% @ M.()_5+?$I9[I @ 5P@ !D !X;"]W;W)K&UL MC59-3^,P$/TK5L0!I(5\M0F@MA)M6>T>6"%8EL-J#VXR;2P2.]@.A7^_8R<- M)6FK7AK;>6]FWHPST]%:R!>5 6CR7N1X&GA>Y!67AX;O 7\8;!66VMB ME"R$>#&;G^G8\4Q D$.BC06*CS>809X;0QC&:V/3:5T:XO9Z8_V[U8Y:%E3! M3.3/+-79V+ET2 I+6N7Z0:Q_0*-G:.PE(E?VEZP;K.>0I%):% T9(R@8KY_T MO0?C7@HK968+ 1. T.6IQ#+JW@SX_ MFNY?'5 3MN4*K;WP4+F6^*TJLI2B(*>5@A1S?D:P$4BJ37WLI\0TP\K]I0NE M)1[\.^![T/H>6-^#?;X_KX.$!/"B+'+)?QF% M(_=MNQ9]T'DP]/ROJ/D.5!C&+>B+N&$K;GBL.$Q8"J2D'WNUU*:&VP%$@[BC MI0_RXZO+CI0^:.CM41*U2J)CE0B=@3RH).KY#SK9GO4A5WY71A\S\,+=,N)6 M1GRL#([-9]TTGZ1N/KNTQ/T;%H3=JO1!@3_LJ.ECAG%7C;O5<@N0*SNZ%$E$ MQ77=G-K3=CK>V*'0.9_BU*R'W*>9>N3>4;EB7)$8_5&B](V M]H70.";L,L/)#]( \/U2"+W9& ?M?XG)?U!+ P04 " X@G]4=-0N:>X# M !4# &0 'AL+W=OB@9-NWM8[(&6QA:WDNB2]"/[ZW=(*;(MT=Y<8I*: MQ_<-AS.3R4'(GRH'T.18%I6:>KG6VX^^K](<2J8>Q!8J_+(6LF0:MW+CJZT$ MEEFELO##(!CX)>.5-YO8LR#[[Q3:[- M@3^;;-D&GD'_V#Y)W/FME8R74"DN*B)A/?4>Z<8!!! :DV)AC^[&$!16$L(8Y?C5&O]6D4S]>OUG^SY)',BBE8B.)/ MGNE\ZHT\DL&:[0K]31Q^AX908NREHE#V+SDTLH%'TIW2HFR4$4')J_J7'9M MG"G0P16%L%$(NPKQ%86H48C>JA W"K&-3$W%QF')-)M-I#@0::31FEG88%IM MI,\K<^_/6N)7CGIZMF J)ZS*B%U\^K7C>U9 I16Y)X_9/PB@M#O,,%*)ZCXU M8EQ#JE^3NW7ORCO"*?,_%3J%--?$U0C2._+2!,Z_AA%?@ MT)!\$97.%?E499!=&O"16TLP?"4X#V]:7$+Z0"+Z@81!2!V %F]7#QSJRS>K MT_$--E%[79&U%UVQ=WXE6N##2T65\@+(5HHUU^2N$ HOY"^V4EKBF_K[AL^X M]1E;G_$5GY^K5)1 -#N"\T9K[8'5-F5F/[NGP]'$WY]'V264),-+J:5#:A0F MK= %_*2%G]R$_YT=22HAP^C8J@D*BTTJ=I6&S*8U4V0C&4;41:ZVG5S@#CO< M'#()#=RH!RWJP4W42\ RGG)6%T=\GZP44O-_[8$+Z* '(HKC#M"^# V2SA7T M94;436784AG^3_YHD* TE@:32*Y'-.Q'<.QV.FJ=CM[F%([8(I7+ZWS4#TBF1(-3HPENDGI,L;DH;GF(M2E86Y#ZY0/9%OCX;(X#2FQ- M<7,VCL"1)%=>&3UK?_0FJD7.J@V8KK5F7!)L?CLP\+"N[A$>7V%MS6!EDA>!/>5YT#5JA3U<=P28X3&B]>,!O2&KUD&LZ% MG.$+'94L&-!.@CC$:- MTRXA&E_A>FIM-+I=J(5FQ3D-Q]#A9!;UND82]WCU MA6AR=C\-L;Y4.(Z[#<@_&[=*D!L[MBIB>TH]F+2G[6C\: ?"SOG?M+TQN,.-( 6LT&3P,,=:R'F'KC19;.]2MA,81T2YS'/M!&@'\OA9"OVZ, M@_8?B=E_4$L#!!0 ( #B"?U3208N3< 0 +D3 9 >&PO=V]R:W-H M965T*// 7\RV= V/H+YL[X6^ M\ZLH,4LADXQG2,!J[EWBBV4P, ZYQ5<&!UF[1J8K3YQ_-S=_Q'-O8!1! I$R M(:C^V\,2DL1$TCI^E$&]JDWC6+]^B7Z;=UYWYHE*6/+D&XO59NY-/!3#BNX2 M]< /OT/9H9&)%_%$YK_H4-H./!3MI.)IZ:P5I"PK_NESF8B: PY['$CI0)H. MPQZ'H'0(\HX6RO)N75-%%S/!#T@8:QW-7.2YR;UU;UAFAO%1"?V6:3^U6%*Y M032+47YQ\V/']C2!3$ETAAX@XEG$$D;SC/,5NF/T2=\K!A*M!$_1+@Y>GN X>< MH!J(((\7],5C,DJXW DPB1:MU">UU%/!I,EY/@2K:@BH'8*_3'C$%*3R;X>X M825NF(L;]HB[HHEN ] 3K%F6F;:THI] 1== %J'"/)2AR'YA$K2OI[9M$H25 MR9'"4:5PY%283]^5AE+GW"I\1[7VS@@)&Z(ZC,;#;E5AI2ITJKJ,HEVZ2ZB" M6,]_!0*DZM(7MIK&HV%#7H=-M[AQ)6[L%A?'S,RNSHR-6ZT-<8@;DMI&HYZ$ M32I-$Z>FF^=H0[,U(*%SAFC\CR:@7C0ZDS;I&-2P.:AMHZ!;X;12.#VI%$ S MTU$$TW:[DV'0$-C2N=7(-5EU4:L[C+J M$6CICMUX=[(*M\E-QD$35AU6?;3"EN_8#?BW\ JW"7Z&R:0ILVW50RQL08_= MI#^16;C-G@+PYZYC^Q ":G;;!?J5#2@58\[FO=TI6XZ7HO M^)Z9#W/7_+%,).$[+#L+0^*&X2MEYW3^#V5G$4C<"'3/_/8^MKX=/V[2 I*X M][)OFOCMS>K9I%M 8!$8N!%XXK0OH]27'#QJKHI^[1 D!;'.SX8DBO@N4\6I M0/6T.G^ZS$]=&L^O\,6R.$6R88I#K<]4Z/VE1 FL=,C!^5AG0Q3G1,6-XMO\ MJ.6)*\73_'(#- 9A#/3[%>?JY<8T4)W6+?X%4$L#!!0 ( #B"?U1'=@U> M9P4 #<= 9 >&PO=V]R:W-H965TU6NV%"0:L)C%CFU*D_?%K)VD,36)2 MJ1?6>IU.J3Y\EH21,BNWQ%4_W+G(N$ M*'TI%IY<"4IFF5$2>\CW0R\A+.V,AMEWMV(TY&L5LY3>"B#724+$=DQCOCGO MP,[+%W=LL53F"V\T7)$%O:?J874K])57JLQ80E/)> H$G9]W/L-/DZ!O#+(1 M?S*ZD3N?@0EEROFCN;B>G7=\XQ&-::2,!-'_GN@%C6.CI/WX68AVRCF-X>[G M%_5)%KP.9DHDO>#Q7VRFEN>=?@?,Z)RL8W7'-U]H$5#/Z$4\EME?L,G'GNG! MT5HJGA3&VH.$I?E_\EPD8L< X08#5!B@UP9A@P$N#/!K ]A@$!0&05N#7F'0 M:VL0%@9AEOL\65FF+XDBHZ'@&R#,:*UF/F3ERJQU@EEJ.NM>"?TKTW9J](WJ MLDCPX9(JPF+Y<>@IK6I^\Z)"89PKH 8%"&YXJI827*4S.JNQOSA@CQP"G@ZG MC F]Q#1&3L4?D>H"#$\ \I'_<'\)/OSZ,?G]%WC6_Z/./;?8)8U*,5B(Q29I M-5*7[:5>_*I1N6JM @?-*A.WRE>2=H&?J_1K5?92C\MVPIDL;G*.R2CF$6?6G?'ZZEA00*:F2X!^C")BBB?S7X4]0 M^A-D_@2N]@8Q(U,6,\6HK&N 7"+,) R)GT:HI\GL^T/O:;>Z->.JHZZJHW"X M.VHOCEX91\\91T;\4\5MJNH"Z54=#'U8#:1F7$T@U5&XUQA(6 82N@.A*[+5 M=R8%8D[2$Z"H2.I"<:OTP982(1T-Q# :E/X.66=?NQ'MK8EM'_$&E]!#[?F/QH6_O-K[3D3$7VH:E"W#]DO([ MG?*Z93DNI'H[7H0-\^_<[>![M-_X@,SA_H/(NH2<6A=FE[C4NSCMSB5-]?[N MT:5K20R/ \70LABZ8?Q]G4RI*%M0@O] TYWTHI#:+3YL*+YE*'1#](N02QXG MK=)L>0;#XTBS)1IT(RV_Y\D5B:C.8OW%EN8VA M?WAI6>I!-_:L)RS-RS"G==TVAE7@H3,'\) %'G(#[W7/Z8K\F,]95!3(M=NU M4$/P*%H06:8A-]-:MV"AL]N"?3QH2+I%'\(MID_,4T6\!07Q:Z?'U1L=:JZZ M)1URDZZFZM]T^O7N@HOMX<53>XA"Y=V;M*Q]6*M^#_8;$6_8A-_MJ M$G_#4I:L$U=T%FWH./9UR"(.M4%@L?DY%ELTXC>C\88\'UBAV!(1'P<1L24B;D/$-AD/JP_' 4_1)8H 9NWK7NET)G;X4V$SVP MF SU5]1-_7MD ,C@.(@05BT :(34\K!XPAS@OE M3,[.NTHW&J\G=_< ABXMR\'@.#@86 X&;3CH?A4[":H,1([GL,!",' SJM4+ MU$DATGIZ"[; #;9K0UVSD#5NI^4[L.K;QL(-MQCN]NMYZ^V< R54++(3.PDB MODY5?B14?EN>"G[.SL(\.SP_4KPA8L%2J>\->EA[[+P@QXR91;\ MU>)(#O (ZNGX(/3,KU%26@"3E#,D8+_T[O''#9X9!VOQ+X6SO!HC$\J.\U]F M\C5=>H%A!#DDRD 0_7B&#>2Y0=(\?E>@7KVG<;P>7] _V^!U,#LB8W+*U0]^_@)50+'!2W@N[2\Z5[:!AY*35+RHG#6#@K+R25ZJ1%PY MX,F 0U@YA&V'\8!#5#E$-M"2F0UK2Q19+00_(V&L-9H9V-Q8;QT-9>88'Y70 M;ZGV4ZMOH',@T0A]Y\^@CT=)1!FRISGB^]%) KJ7$O0R82FRUN@;)3N:4T6U MX_LM*$)S^4%#/#UNT?MW'] [ _$SXR>I?>3"5YJGVZTA?^\W46W#8W M#..:8>P,M;Y)3Y>;Y A[4H-.G&&O24Y8 F@'!\H890?$]^@5B.@+O(2*;X)J MQ=TUB>+^L*/71FG5V'.'IO$6KQV@:]?.:U[SF3EX/Y-4*3U]=SCO;#20!!XW@!<[M?@K" M9#Z8A9N3(+VW>BS&JA3'#8,P[^+$LH; M;7<4*FZ4#D?_7ZE66,Y:[;&))@.Q-S**W3KJ+-?*]X;5-.J<2==JJ&!Q(YXX M=O+ZRA0(D K!B^[;)/32BSL;XW"@)'&CL-@ML8ZB7..N7H["<-).2(_5="@C MC:YBM[#^K7J[LCG"X:Q-K6LU1*P15^Q6U[<6^*S['QMW+WF/5;O _:NFKP!Q ML+VP1 D_,55V1O5JW6_?VRZSM;XV?;AM)AN8LHG_3H2N6JF[BKV&#.ZF.F.B M[(O+B>)'VUKNN-*-JAUF^EL"A#'0[_>N*/!44" ".!0 &0 'AL+W=O$Z4,+:?V1Q!W%,2P-8X,-0M-N#V,/BG..166=)RE-^]_W)+M> MMB0E[,7627>_#TFG;(OZT50 ECW74IE)4%G;W(2A*2JHN;G"!A2ME*AK;BG4 MZ] T&OC*%]4R3*(H#6LN5)!G?FZN\PPW5@H%<\W,IJZY?IF"Q.TDB(.WB3NQ MKJR;"/.LX6M8@'UHYIJBL$=9B1J4$:B8AG(2?(QOIJG+]PG?!6S-SI@Y)TO$ M1Q=\64V"R D""85U")Q^3W +4CH@DO&[PPQZ2E>X.WY#_^2]DY 5*X[]LV^:FPX 5&V.Q[HI)02U4^^?/W3[L M%"3QD8*D*TB\[I;(JYQQR_-,XY9IETUH;N"M^FH2)Y0[E(75M"JHSN9?@2P9 M=LD6[:DP+%DI%%<%,"GX4DAA7]CY#"P7TERP,R84NZ]P8[A:F2RTI,$AA47' M-VWYDB-\,RBNV# >L"1*XH?%C)V?7?R-$I*#WD;2VT@\[/ 8K#"%1+/1\,> MX+*W(,CC3[XT5M,U^/4.X; G''K"T;%]0ZY8J;%F$HQ!?6@G6H34([CF>,KC M^#K*PJ<#O*.>=_0N[SU:LG4*>XLS/HE]W+./WW=-;#=[[ .ZJ%J#LJQ![7KM MD)SQGIS+.$D/RTE[.>E_;,: *7K,Z!J%CU0\M@F(HDN M2<4IL#]^24J6[$1B7/20BR1*,X]O9CB/XGC/Q;W<(BIXS-)<3KRM4KOWOB^3 M+6947O =YOK+FHN,*CT4&U_N!-*5=?F,KM9UX(P]6N*9%JN[X_@-6 ?4-7L)3::^P M+VT'?0^20BJ>5P<@B?.(2DPR&J'*)S'7J50^^) M ^FBU*\<^N?.,*@E8\#T(8ZW1S(,ME_76"6:Y65F?E=!? MF?93TSG&"M[.45&6RG?PYH]1-.C]!2R'&Y:FNO9R["L]C['VDPIS5F*&'9@$ M;GBNMA(6^0I7I_Z^YE>3# \D9Z$3\*K87$!$_H0P"(/%ESMX6_%\=R_ ![FE M F5Y;6%[[09?8GP!9&C!PQ/P%JRY&VN.24V4O(2U.#]HDG*:MT LSZ!3A18X MZ)P4):I73F3!HRYP)I.4RT(@\+5N9K."<*573BEW5C9BK6404R%HKB3\!YU+85;B]2V>$=V'*0EZ MPV&O-_8?6HCT:R)])Y'%QQE\TB6"JXU U,*K'-$-:M#!:R5X6%,8.N.Z%2Q/ MV(ZF0#->/(VJ3&F)<'F4TC"HLUDVS7.387N^1S6OD9/7WT46HS!I4;KF>K_HD<7H658>TYX<<;2K$R>?;H1>I4H+%A:)Q MBJ"X7L6Q_Y2K!XBK"HT@DE=31-)((G%K MXCDM6T&T-V2Y9[YL,G_99.DT.0VPD5KRJUI[5,C0E<-&>,FK*2]II)?\OO96 M$,?=TM4HC;02M[8Z\QNY0FOTDUR^5G[#1C-#MV:>D]_PN38^7;_^T;]WAF)C M3TD2$@-9_H;7;^N3V)4]?_B->7F,NZ%BH[<52'&M78.+H:ZK*$]&Y4#QG?V3 MC[G2YP+[N-6G213&0']??2'H=C:!*.%AH(=[1]5N1U+$X?KK2NK_^^*\4Q*5SNI2^V=K4S M.R.M70[./X46 -FST3:L>(O8W659D"T8$6:N TL[C?-&((7^F(7.@Z@3R.BL MR/./F1'*\JI,N;VO2M>C5A;VGH7>&.'_K$&[8<7G_)QX4,<68R*KRDX[?W%&432ZT,V*"<91Z:%?\\OULO8GTJ^*%@"!=K%IT^3=_)R$ $V3O]4-;8K?LM9#8WH-3ZX MX0N,?I:13SH=TI,-8VW.F>P#.C."28%1]O06S^,Y7 #F-U< Q0@HDNY3HZ1R M*U!4I7<#\[&:V.(B64UH$J=LO)1']+2K"(?51G0*A6:4ZR7V'IBP-;M75EBI M*+\3B. #^\"^N1"8:^CZ#D%Z=8":A5800(X4;[> 0NGPKLR0E$7^3(XJUB<5 MQ1456Y SMIB_9T4^O_T7GI&AR54QN2H2W^+_7+W2:3%U6J1.-UL M R_!(LUQ/"/M EX]J)>.Y_4FRWR6YV]>4IM=W'S\B';"'Y4-3$-#3/GLTY(S M?QK,4X"N2\-P<$BCE98M?\(F$\.CK(/INQHX-D(Z(PIC-F\K *X_R5_"@245- $XT"+!3@C@*T-0JH4$"[ M%G0*N%# NPI H^ 4"D[?&-Q"P>VK,"D4)GT5O$+!ZZO@%PK^;EIU00.[K)S= M6Z4J]FZUHG9!T*$EGRLTT@-HQ:))Y; M9V%,XB"4GU\2(2CCUD>KE!2,Q)QD=,BM=U,J2!CQ]P=C(;U),<=!8?DDMPPU MEJ^2IWW+]C]8T(;@[G9JO=M[OV>-+;XDC/+\?P?J:1]4)T?5@DS-(&?T7H'T M\.FS&>YXL]BW@)W!V8_L>;RS'C$B>VCFSGL$#;VAJ%_,J->!D+Z"//;^J!=F MU%NZKC(P /7K<-0.E&]FE"D-JHB!'N5[?Y32%VUGC6M%BS ?U1^J@%^VT 395@'3 W [K+ ',[@)EJ:>] ^GW C,C MW?5?7IZA=&,YFJKY!*OY!#-PI ,/>1 E/!U,R8,51(1SRM/+S((5%$/IKU3/ M"@5=\;\-5E%E%656L<;JC/R4AP;!+7EB*2R%G&^DO83+3W]9>UV\D&.Z&69Z MD'DZ0A/7EG\'XZ=ZY[?E /1:8I<=8J@NU8@,5Y%A8V0W=!%R.='I_$,>DGQ- M)[X\:W$A+\)XT4QM%W7E)IR:9]#%[0BN@C3S;:PI>XX[,.8XV6*<* MUC$&>]M8(]U5^^ZT;$]2%UOE:,OYR(4MN>NV'((835J"=VW!CSX"VJ#=*FC7 M&/3%[-K0 9,*9?*&?>=55CVC[U>)W.1*V"<2R69;T[+Y?EEFAKKU6BL-=&?1 MKSSQC9Z<)5&4;#_*(_]Z5M2__8,6-52&SE,Y/H):'*36*\0%Z MRY(H/@9F0JZBS1=W41:9=\..NXM_?8#<)L%<=,A-L".Y35,A1:N@#Z^N-RQ8 M$BXO6!BD/;IG:M$O!>:DYHVW[_EV[0_L!C!$I1F+8DM@ILOCQ8+1!1%I&$E MZ5PWWK\40'7"AMANS_>+#D'7;0HVG56D#"9F;H\#1M.4A[%%-F*9L/!?N5CB MS>I>-D.Y6+EI]7PN3/1>%8J[@9F\C^?S,+TK(+LD? T_O9:?P#-E45$[,'/[ M2Z?,YP*W>\P4IZ=G17XWBC0WR6J@0+MO[E62DP:U6%O"&$DWM20=;;(<(BEV MM:8R%(8;98"^!WQ7X[,:1M \C%ZTR?Y:@#:VQ1C;$&K'GSG!30 ]Q2 PN:!Y:LK;1J/M@A-2O06QX^D.)[9.;[X3O=:8%8 M[Q=D=Q#2>0_!IM=J+"#S6'C)7O>\P&P,*9TGM7M29F;OW2'GJ(/''61*A^)G M9.9G_=[)F)$I:M_BT69$<1XR<][ D7V.VK=/$S MOP8,HYD3W*;?EILFD::;M3O[9FHN?Z"O#M\9&95+MV]WG>+V'M4!:&HG5LIO5G NGFTC/<)G?S_@LKBL=FBM_]':&3)V<%2/];HEB1.7YF] M):7K+X:1ATNR"O+S=$T2]F2>9JN LLML8>3KC 2S0F@5&\@T'6,51$EOT"_N M/6:#?KJA<920QPSDF]4JR-XN29R^7O1@;W?C>[184G[#&/37P8(\$?IC_9BQ M*Z-BF44KDN11FH",S"]Z?\$O$XRX0('X)R*O^=YWP$V9INDSO[B=7?1,KA&) M24@Y1< ^7LB0Q#%G8GK\+$E[U9I<GW]/6&E ;9G"],X[SX#UY+K-D#X2:GZ:H49AJLHF3[&?PJ';$G@+P. M 50*(%T!7 I@70&K%+!T!>Q2P-85<$H!1U? +05<70&O%/!T!?Q2P&\+N%V! M,W>1,W77@%6PA6AWKK(+-]2.-]P%' H1[UQE%W)8Q-S8IF^1^Z. !H-^EKZ" MC.,9'_]2;*!"GJ5\E/"]_D0S]C1BC@@-HCC_!$[XP[^7Z29G)'G?H$Q! MOHP1ELI<;I5!'ES]BGGB\G(AFJR:S(]@&RD)OL6 MTG, [8+,?)?L2DWV1-:,S-4DNU:3C4C(R HSH?\NV5^J75ITYG"[H10;QJOXO"-O3;]:R==PNZPQ;.6\/3]!!_J>:;9R M],X7'(HPF;#3U+8'N0L%D>;(+&$C;D0U=@FTC8(,3R8$.S'M[,WZT) MTNG+%-3%OH4%;81VE'^Y-Z?#(I;)11JE MFD5MN!?4$0\J5%156$\-T#IR!8=U/X'ZK;^ MKKN1R@5U_X7NL=U=]V;H'=W=GK +/,OK=G?=S:&ZG7_+9LSF[&W[6T%^!I)T MQ6[$X"6(-T6_XD<2"-8DVW8NU3FB[H?(/++W45V2T3LE>3^ASLKV>P:F9!$E M290LN(UO),B8[[L/O4A2E7E5"\WU72(4;"J1?>Q*6[=NI'DBE_:PRU*Z.6E"[O2N M/*^[.5(?IW_'ZP?-<:AN]NC8)W%4-V^D;M[Z@X5.W?V*Q,,O-A&K5_+PX+K= M8_7Q]T/"HYK[<#T-8'CLWS#K/HC5??"#PX/%)L%F0%9@6^$Q]MXR\?? XR!C MHTX.8C)G@N:YRQBR[:O5[05-U\6+IVE*:;HJOBY),",9![#G\S2ENPO^+JMZ MP3WX'U!+ P04 " X@G]4:!@8L\(# !?#@ &@ 'AL+W=O* MYYA2K:3R^*\4-:J8FGAXO5>_S8M7Q3PC@>>,_DTBN9T:O@$BO$89E5_9;HG+ M@ERM%S(J\E^P*[&6 <),2!:79)5!3)+B'WTO%^* X 0=!+LDV V"/>X@."7! M&1IA5!)&0R.X)<%M$MP.@E<2O";![R",2\)X:$I^2?"'1@A*0C T@G)BV;G< MDF;1\MPO"R31;,+9#G"-5WKZ(C==SE'RO)U5VB>'(V1RF1B (UEX4R MXQB@) *W)$%)2-3\%R0EY@)\ *LM4G?W^/,%EHA0<0%>.#"!T#<%( EX2H@4 MEWI6#;YM62:4H)HXJXTGIE3)ZQ3,L$STIDC4[DAT@<,KX,!+8%LV7'S^#,Y? M^,5![.*W17=^@N[3:@'.SRXZM1;#M:Q3)$A)0) MO>W8&H04":%VD;K,(X"PW&S_:!X@$L?BWYZH3A75R:...J*N:N(_P%G;KBDD MO%Q"'[*O,\<>.>.)^7KHVV/4V'+\.FAY# HR6K9(C7Q8!]VW2-D!;'CQH44*0J?=0>-J[<>]:_\G MC]11R-^*TT\=8PE3Q[#J\2NB6>X"_7R!(,6\,$%/O_TJIO\;719448/>2J\I M9>JHCRY5 $IQ!+(T?Q589Y2^@121:'_(_^@^,6Z*&&[#BHYO-=PQ'PI<' -S M1WI>TY1#@72MUP!! U!( !H !X;"]W;W)KQW2 MA$\350()0>+<<^U[3GQL/%HI_=/,&;/HM1327/?FUBZ^!(')YZRDYDHMF(0G M4Z5+:N%6SP*ST(P6%:@4 0G#)"@IE[WQJ&I[T..16EK!)7O0R"S+DNJW6R;4 MZKJ'>^\-CWPVMZXA&(\6=,:>F/US\:#A+FBR%+QDTG ED6;3Z]X-_I*1U &J MB+\X6YF-:^1*F2CUT]U\+ZY[H1L1$RRW+@6%GQ=VQX1PF6 <_]5)>TV?#KAY M_9[]:U4\%#.AAMTI\(C^0[1Y$D;-6FC*FUT;)CL-/]X>HV;7F-O,3^6Y83IIAN#N#%+5J!/7-8MGP_IO4[:KY(Z7WH9 MITF4]A.0YV53V(YQV>FXK>KZ375]?W6<"8.^O\#KSR2Z%X)I#V=)DS6YH%*# MIM?!.90:[#$;DR%)PGA'J8YQV>FXK>K2IKK46]V-+&#-,^B;$F7E6,8HZ6%M MV.0=7E K'+:>')Y#K3KK%KT89D)$=N3J&IAU"-PN<6/9P=X2?Z>P;MR <+* M0X'#9S:3WOF%6X?%Y)*JM1:,H[.H%NUQC%."R>X^QW^UM% M=>'*:Q9^'VVMR^+^)>5J?1@G9Y$KV:,W&@QQFN[*M1^7)C%\=N4Z$!=&:7Q, MKM;QL=_R'Q649Q5ZT&RF?(RU+HO32RK5NC >GD6IX;Y2."3QGE+=XK+3<=L[ MPM;NB=_N_Y@K^"^'GKD0G);H^4THR7V3B[0V2_ %)2,;NUS_-O=CDMW56;?6 M&]C(#9(=*0[&X?38CH^T'D[\'GY/-:<2N'B:47 ['Q>M;Y+XDAJTQDI.[%\_ M-FWJK#MK?G]W#W$R;'O4K2T3ORT_6?8"V^T'K?ZEOCT<:8V0#"[)?VN7Q+\K M_2C_Z1ZQ9$#VUI=N8=F!,(P'4;(C4[!Q@N#.>V >S+@T2+ IX,*K 230ZR.4 M]8U5B^I08:*L565U.6>T8-H%P/.I4O;]QIU3- =9X_\!4$L#!!0 ( #B" M?U01C2?]NP( *\( : >&PO=V]R:W-H965T%,@MN'"W) F]0W2UG0L_<#B6C%3)).0.!^=@Y]\\2WQK8$[\IKF5O#,:5 M.>?W9G*9C1W/*,(24V4@B'ZM,,&R-$A:Q]\6U.DXC6%_O$'_:9W7SLR)Q(27 M?VBFBK$S)5:ZP55)0U;_+0 M!J)G$/@[#(+6('AA$.XR"%N#T#K:*+-N38DB<23X&H0YK=',P,;&6FMO*#-I MO%%"[U)MI^*$LQ4*1>G]'&;4HM O&'IEA%^K0$H0?"/4>^.,._MC" M'^^ OWU0]KCR0P/[:64ZH1B!O]@EVM-J!JJ@:4RE6 5!Y&[VJ)NT*D; M[%4W$SQ%S"3D@E=6A;U6;\C==KL:GF%/FC_8(6[8B1ON%9>\6\(S^),._N0S M$C_JX$=?$]ID]"JT(\_SML?VM%-W^N'8ZFLXX41D1NN4"EW9N9"@RPI;$^,=W8MI0GF*:57Q&QT%*AQ%Q#>D>F]XFF.S83Q9>VP=J,S$$W3]*_!]02P,$% @ .()_5&FD+D32 @ M,@< !H !X;"]W;W)K^;Z.,RR8OI%;%/0EE:I@AJ9JX^NM0I8X4)'[ M8:\W] O&A3>;N+6EFDUD:7(N<*E ET7!U&&.N=Q/O< [+3SS36;L@C^;;-D& M5VA>MDM%,[]F27B!0G,I0&$Z]>Z#NWED][L-WSGN=6,,-I*UE*]V\C69>CUK M"'.,C65@]-KA ^:Y)2(;;T=.KY:TP.;XQ/[H8J=8UDSC@\Q_\,1D4V_L08(I M*W/S+/=?\!C/P/+%,M?N"?OCWIX'<:F-+(Y@/")F5E%'WEA#.S!REVJ Q?YP@+7!OX M*K11)1V[T7 -JRI7(%.(,R8VJ($+,!E"W F%L@;P,L%&L9S?047=O^W3):: MB41/?$.>K;(?'_W-*W_A&7]!"$]2F$S#9Y%@\B^!3\'6$8>GB.=A)^,"XQOH M!Y\@[ 71RVH!EQ=7';3]^B#[CK9_AG8N%2&XV&CXR=9T%%1OOSIX;VO>6\=[ M>RY!3*D#T0(K9"D,, -KW' A[!JEY8!,M1UKQ3ITK/;/W,W&@V$T\74N'8,DRY<'[QG5J:QE9CPX_&@G&_W=FH=C;J3F&I%(KX MT/#5)CWZ('T=]LYD;%Q+C[NEJ[Q0_$8"OI7<'-JDQQ^*Y3H:1H-V[:C6COZW MN*:VFHQ[IA1I<:*KN!OJ=2FM/$"M37Y.P/4$L#!!0 ( M #B"?U3Y\MB=104 '$: : >&PO=V]R:W-H965T"_\TRG5^.9B.4T26IN/XF-K_1!M#$Z$L%5_8_ MVC1SPQ%**Z5%T0B#!04KZU_RHW%$1R".!@1P(X#W!*)D0"!N!.(] 8P'!))& M(+&>J:%8/RR()O,+*39(FMF@S5Q89UII@,]*$_?O6L)3!G)Z?BW*1RHUN^<4 M+>B]1E]*I64%D=4*_8S^I+)02"S1LWGO%U03QM4'] X%2.5$4H58B>Y*IM5' M]"#-X(9Q#M&%\;ON\"+08+HQ($@;,Z]J,_& F1%&-Z+4N4*_E!G-=A4$@+D% MCI^ 7V&OQ@5-QRB./B(<1K.[[POT_MT'AZ3'PNL7Z\-1C_CB"',67[^B]P_R M@P=FW,8WMGKC5\37HSYIU2=6?3*@_DNI*;A+HU14:U'VN/5VZT:_@;#SQNG'6&C)[L1LMSLBC]+Q5 M>GX*YT6AX[#0:[5AJ5Y.\8L!J1265'Q&=(@T>F,,KPYHZ EB31W'R^UBP X# M]H>?K)DF'%Z>%)H(19'. 5(N>(:@Q4! MY^?C6=C]@\1Z[+/5$5L4>VU=, 6>+C4"0RQIH[5D*9@LT#U%9+WFC&9HDU,P MF?"TXD2S6&5!T3;;F MW4+:%.]>?'[=DX-F.E:.7D[+-9] TD"U]2EWG!R=A)0CQ\J1GU5_AWSO]5\M M9NBES>]P?#Z0T8Y[HV/)%YP%O8 /B^/@Z"0DC!T)8S^;#CFK$9MV?.7>_:8U M"I_SQ=EX@"&P8V3LY\5GD+$/J"-)C$_B2<=LV$\3+Z@D!S0,5I+CY78Q.'[" M?@XYKI+T0DR>YTTXD!*.C["?C]Y$FP=T'Z1-[)@-3[VJ;DB9$2WD]EFY0D3# M]D]7DNDML(-WQW+5K'+6=>$T'"=#;Y8C1NPGQELJF>$N)-)MHF_5,J8J4 M^XW'KDV.U?%)6#UVK![[6?V$7=:!E2=#3=;Q(#%>S5T=<;83- O38% M7#F+)R=) 5>(8G\A.F4*^%<>WF2]0G 7O2MSL;]Z]*: ?_<2NW(2STX2.U<; MXO-7->2-V,[N93).^GN"Q%6*Q,^[O<[R[UX21\5)=))C3$>FB?_D8\A9C=C> M5N]L;P/3S)IU/;KGSZ!S1E]0N;+?.A2R;U=]7-_>;;^G?+9?$0(WO?X8D21,$:( E9?]^H!UJL[8G_O=!:%/8RIR2CTDR YTLA]-/ +-!^99K_ M!U!+ P04 " X@G]4A1EU_\," #*!P &@ 'AL+W=O&ULQ57;BMLP$/V5P6QA%[JQXUR[)('=A-)]*(2]M ^E#[(] M2<3*EBN-D^S?=^0X)J6."?2A+[8N8"MO1.68\L](F%<1=L_9M;E D)2A5?A@$0S\5,O-FDW)L:68379"2&2X- MV")-A7E_0*5W4Z_K'0>>Y'I#;L"?37*QQF>DUWQIN.?7+(E,,;-29V!P-?7N MNW>+L8LO [Y)W-F3-KA,(JW?7."NA5@-ZE@'X%Z)?.'%(I?5@($K.) MT3LP+IK97*,TLT1S^C)SV_Y,AFMV/$ 9A MMP$^OQP>-, 7%\.[G_Z$^^Q;;5Y8FQ>6?+US?-+&2MO"(.@5T*EY$=(.T=V, M@[\Y^RO1P@_' 9(PM3];%/1J!;U20?^,@L>,T* E,+Q*TW:TPX>=(/C0(J-? MR^BW\LQUMD5.,%+(ERXB/B663,'E@6P+_:"F'_PGGX>U@F%K@O=Q; JFET>_ MN63%+4F#M-;%DX84TPB-=/O7ZO>D2C_X2.FK6.:YUCO_MF+?#1YU!\S'W3PJG>^6^"K/F M7>3$5TP4=$9\+LWAY3AT2.=E+8TT<64NFQM^;-&X )Y?:4W'CBO/]?,]^PU0 M2P,$% @ .()_5*B%9]EX8%M8VT7_-ED1[>P!/VX6T@S\TN5-4N!*R8XDK"9>I_Q M;4A<@HOXQ>"@:F-D6UD)\60GW]93+[ 500*1MA+47/800I)8)5/'GT+4*[_3 M)M;'+^I?7/.FF155$(KD-UOK>.J-/;2&#F6MK3C6=3:0X(&FC MC9H=.#8NVW3#N+V-2RW-+C-Y>A8*KJ5AF=$$W:\2MJ66KD*?4'TG%&G*M+E[ M6J'+.6C*$G5E8AZ7F= $164%N5>J=QSROTSE*,*ZBEB MN=#0"=F'<3\;D8F_KU,Y$8*KF%<%]LL"^ZT%?@>ED(XI1X(#.@*5+5T/2M%! MQSR'I?*P*YZYT*"-YXF0)IZCLL!1:X&+3$:QL9DS^QZ7LN..B=Z4RC==$;WY M/]$3(4U$<5!95O!NIN@O>M=/%]<,$G>,&E<^@TE7L NE5MJG8AIQ5Y:%VSVK M 7?X'*>?"@(\)AH52G-PR"!GJ50>%VAVJ@]\C-Z44JIH]H MD^E, MI1J;E9:FN[ MF=^VS,^U^42+G3L:KH0V!TTWC,V[ $@;8/8W0NB7B3UMEF\7LW]02P,$% M @ .()_5'ZGW:DZ @ /04 !H !X;"]W;W)KXR/DT[()U4!:/1<,Z[F0:5UQRBJHB1J)!KC9*82L MB39366+52""Y2ZH9CL;C&->$\B!-W-I:IHEH-:,A,%Q M84/+2ML%G"8-*6$+^K%92S/# R6G-7!%!4<2BGEP']XM8AOO GY0Z-3)&-E* M=D(\V&0R2-O%T?*1_<;6;6G9$P5*P MGS37U3RX#5 .!6F9WHCN*_3US"PO$TRY7]3YV$DH3(N?;"SF7*Z))FDC1(6FC#@880>!->50I]Y M#OF_ &P<#C:CH\U%=)&X@FR$)N$'%(VC\'&[0M=7-Q>PDZ'ZB<-.WJW^ FPZ MP*8.-GT/AC:0B9+3E]>E^TH])784VS/[-(S#!._/2,\&Z=E%Z64K)?#L@$C^ MR]P9TS3ZG+*'S$Z4/]Z>%XX'X?BR,)'R0'F)2"U:KI$H$/#<+NP((SR#/3) M'(#TS>HG6C2N079"FW9SP\J\;R!M@-DOA-#'B1487LST#U!+ P04 " X M@G]4B;.1/6L" "T!@ &@ 'AL+W=O&UL MC95=;YLP%(;_BH5ZT4I;^4J@JPA2DZS:+JI5_=BN73@)5HV=V8=F^_>S#6$T M"5%OP#;G?<]S#N*0;:5ZU14 DC\U%WKF58B;:]_7104UU9=R \(\64E54S1; MM?;U1@$MG:CF?A0$B5]3)KP\:&W.WA@ MZPKM@9]G&[J&1\#GS;TR.[]W*5D-0C,IB(+5S+L)KQ>IC7N=^ZVDTM+U3#0O)? MK,1JYEUYI(05;3@^R.TWZ.J96K]"N-4YMJF+!O\1&5 M>7YVPY]%)QR44ER0./Y$HB,(C M0(N/RX,3.''?Q=CYQ1_LX@G+26\Y<9:3$VAIA^ 4L I0CD*UWI,AW"#Q"W7Y'U9H)33BLC&5PF9HV MJ79&MAN4&S=F7B2:H>66E?FM@+(!YOE*2MQM;(+^1Y7_ U!+ P04 " X M@G]4/A8S^N@" A"@ &@ 'AL+W=O&UL MQ59;;],P&/TK5IC0D$9S:7H;;:5>5C&)256WP0/BP4V^-F:.'6RG'1(_'MO) ML@K:D/&RE\1V?,YWOB_'E^&>BP>9 "CTF%(F1TZB5';INC)*(,6RQ3-@^LN& MBQ0KW15;5V8"<&Q!*74#S^NZ*2;,&0_MV%*,ASQ7E#!8"B3S-,7BYQ0HWX\< MWWD:6)%MHLR .QYF> NWH.ZSI= ]MV*)20I,$LZ0@,W(F?B7"S\P #OC,X&] M/&@CD\J:\P?3N8Y'CF<4 85(&0JL7SN8 :6&2>OX49(Z54P#/&P_L2]L\CJ9 M-98PX_0+B54RZ&#HEPJGI9@K2 E MK'CCQ[(0!X# /P$(2D#0%- N >VF@+ $A$T!G1+0:0KHEH"NK7U1+%OI.59X M/!1\CX29K=E,P_XNB]8%)LPXZU8)_95HG!I?[8 IB28;!0*I!- *,BX485NT M!$%XC,[GH#"A\ATZ0X2ANX3G$K-87J"W;_KM;OC!C-X02K51Y-!56I2A=J-2 MP+00$)P0L(!U"_F]"Q1X07!UOT+G)>V[(URS)EQA,ZYY/=<&/KX8*$06I_%8CI%T):5LAX0DA4RXT0O-+] N= M':MU@>]:O-DX=V/?[WE#=WP5X7KU8:[NIZB3QPS--D* 'WZJ)H<^A5I_W6+.:B$#&JS M6PK"(I)ABG#*\S]S*W:404U)BQ7^]XS@A'-][WD']UY8=[URFAC:/S@D_-?] M"_[S/N4'_V_J60FN<[5[<%B:R],-%EO")**PT1BOU=.K6Q3WD:*C>&;/SS57 M^C2VS43?X4"8"?K[AG/UU#%'&POWS//;Z^)H9! MJ5:>5T[G-"/E95Y0H9$TEQE1NBMG7EE(2I(2G#+N M=3N=T,L($^YH(!;9=:9*9YHOA!JZ46-RS.U],G3]\+7K&+IQGM"A>W_^\NLB M5UW5VUKF_N-JUGU? A>M927L'D%YV<%Z-8=2AG?J+1 0WP'[%?3OM MS^\_$-X6V4\<'92*/9G B.-#$K&=Y)U"!^Z8\+91#+P2DG&^,J8NV"8YCR7CM*[1XOQP5(^ M&M@W/=A8-4_&1"ZKV":"^9S4PW> =0\$,LX;@5W7&$:#@BA%I;C6G6IP97P" M.77[;E5HA3-)5GZWY[8.U4T'F>0RH;()X[MKTVC :0IR))O-X:[RP@-0J3S3 MC82162Y(I6'M43YENK&J53&(IJD%U4U#8SK O\EFN#=I M>\_B=0KVD*MW"ST=4?6A5NB-I"E;5OUEV@C V'V>!2L6FFY9ODA1W=*G6Y;1,<2JV^57<%6C?51XMA%]DY!9'@*(D^B)J-3$!D?O\C@ M!#36Q]9C%^D?I4BO/JYMG FW3H2-U8&3]]#]!*=\W@9U)@O&%1-U;\Z2A(HG M!T--K\A$_\C=XM?C$YJ2!5=W#3ATV_9'FK!%%C>C;B 1]:BV_0&FYX?-L5_' M8B*A2YJ,ZZZ<3:JFHQLZ:GV!PRYR75UV!/,QF!T!#(N#*][ (X[MJXW% 0]L%;#: M@?CV.%!3=I\@@%7%M&$[&$?B&$.@%NTU&H9(=D)XV=<'VR5!$,=V!#"[@B# M$-B-.((I T8$@35>2MGU->^\_OZ!=02P,$% @ .()_5)>*NQS M $P( L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/ M:(7->=I3W;+T]!;X"O M.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_ M'F9_42U(F^EJLR+W0N?I?C:_'B_ M>\IVLI%WLI3MP\FD?UR*"=O(2F[D-U&<3+P):];JZV]*RV^J:GFYR+4JRY.) MOW_CL]"MS)^\O.@@;_A=T[_2\KMK;D!.)K%G#KB4NFG[3_3'YX9Q)\R']\^V MK3J792OT&6_%!ZVVM:Q6W6',KYA9/Z./P^'O/HBO]?\)HUHN92[.5+[=B*K= MQU&+L@.LFK6LFPFK^$:<3 X?8;PJV/NJ-4%B%]7^4.:SW2\U7WU1[']U:W"M M&.K7TKRA+XH>G [RKXIO"]F*@KU352&J9O^H4:4L#)$%&0#(8$3(V\""G /( M^9B0=#F4K16.S0<,0*^;]IB[5@Q#[L!V>3:^[SYKNQ\9$CO&) M);-85]W';@#B=3B$[OE.]H- MOW>9D$E\8I68TRGS/EIGLMQVE]M'U33L2FC6G6\;$_G$)Q;*A1D:5ZON2QEO M&N%>>,@A/K%$3!)@>I;VX6=V5?+#4/;?K:R[_[,AD4=\8I%<:5%_;[ ]H&K7 MYOQJD0NYXW>EC8E,XA.KY++',EV+87):2(#,$1";XQUOUGW4^@?=N=WQ\JCO M"Y ^ F)]?!3<[>0"F(D06^),W-G7?8"L$!!;X1VOI4FIV<*,2_)VJ_=:>'2% MC8F\$!![P>07NR[-[WJW+GSV2,IF1)X(B#UQ&(Q<<=/9L1O-JX;W&7=Z5<\2=X2!0!O2BZ+STB0E8(B*UPWHTX6\7ZA%=IAPMI M("#6P/M=+ZK396ML8)3 KD6M=#]V-\,2.WF<(R_,B;T 1@+)%5YL16@8DE>V5C(KO,B>UBIY:#,42BF1.+!N:8[O6(O#,G]LZ3'',H MD"%23DBL')AL.A=CB)03$BL'IIO.^0Z1LEQ++99Y^#T4-R"8GE E,_]QI$>@GIDY9G4S\34QL3Z24DULOSV5]_XFU, M))J06#3/I("'B]/&1*()B47S(Q4<:C81,DQ$;)CCG' 0$+DE(G8+*'VR5V=V M.3Y";HFH:R4PZW+*R,@Q$;%C,&9D8R+'1,2.P9BQC0FK\M0)#<1,;$SDG&C, MXOQM:F,BYT3$SL&8F8V)G!-1%^D!YFU?\G[$1,Z)B)V#,7U[V0CR3SSBI-JM M;P_;8F2A>,1)M5O?GE2+D87B42?5'$QDH?@%B_=/,6U9QLA",;&%,*8MRQA9 M*":V$,:T91G#%6+$%AJ>23T3+9>E,]R,D81B8@GAJ52G!2$)Q<02PIA."T(2 MBJDK.Q#3;D$)DE!"+:&AB>DI^YMKD_@Z)=D$22BAEM PYL(XRF,Q.3( DEU*G0,&:79XJJX38FDE!"G0H-8YYSJ=G.6=*0( DE8]1V MINRT:;:;VET C"244*="SV":!X6[PC:!"Y6I4Z%AS,MM:Y"JPL9$%DJH4Z%A MS#_$ _O$*Z<)(0LE+[AB^4E)S^F04F2AE-A"3DG/7),5+Q\:V70Y1^ZNS$R1 MA5)B"QUA7HM"6;Z;(0BFQA9Y6=*=="8.O-*_73KTT119*7WIQL\'LI]WW M^9"-B2R4CKG4V>TWX:89\L7.J$@^M3&1A5+R(A JDMLM/4,6RJCWS1P5R0<2 M] SI)R/6#ZB2'[6=#.DG(];/\Y@FQ5@[F$@_V6AK#LP I/C'QD3ZR:@73 -, M,P"Q,9%^,F+]')9&#+49Y)N,V#??N:;LD]J)?0\D*W8M5^MVJI9V#YDAWV3$ MOGG$M&;;E_W873 SOK0QD6\R8M_TRS8&SS'3;:Q!H MZ(#"39H>N6D0:.2 PFV:'KEK$&CL@,(]F]Z8VW.<>KGOP7V;WH@;=$S_Y(#" MS9P>]:HW!.H,T7T/;N?TQESW=M0]P>V=WH@KWTR?[X#"+9[>2&O?NBEL\XX# M"C=Y>B^X^FW FCZ^30#U?0*>+H ;9,2W"Z"^7P#:(.6VB^--\26->SWF97VG6_>F/%811MSUXN2W+=^:UR^JCXL7AQD&'FQZ] M_0]02P,$% @ .()_5+/KGH D P PT$ !H !X;"]?1"_L-1T MLOLVR2 Y10]Z$O2/1,GXZH#@PY3K7/T:M^OY^;"?GIZ/T\7K;KN?KE=/\WS\ M,0S3YFG7'W M=AS_9^+AX>%Y,_X\;'[OQOW\C\'#G\/I97H:QWEU<;<^/8[S]6IXW7[>GH;W MBUV>)Z\N;N^O5Z?;>UL-2P?R$L@O'RA(H+!\H"B!XO*!D@1*RP?*$B@O'ZA( MH+)\H"J!ZO*!F@1JRP7O7V +V]ZNT!>OONQS9 ;Z]Z>X#>7O7V +V] MZNT!>GO5VP/T]JJW!^CM56\/T-NKWAZ@=U"] T#OH'H'@-Y!]0X O4.W60+0 M.ZC> :!W4+T#0.^@>@> WD'U#@"]@^H= 'H'U3L ](ZJ=P3H'57O"- [JMX1 MH'=4O2- []AM=@/TCJIW!.@=5>\(T#NJWA&@=U2](T#OJ'I'@-Y)]4X O9/J MG0!Z)]4[ ?1.JG<"Z)U4[P30.W5_5@+T3JIW NB=5.\$T#NIW@F@=U*]$T#O MK'IG@-Y9]'30!Z9]4[ _3.JG<& MZ)U5[PS0NZC>!:!W4;T+0.^B>A> WD7U+@"]B^I= 'H7U;L ]"ZJ=P'H7;K# M@@"]B^I= 'H7U;L ]*ZJ=P7H757O"M"[JMX5H'=5O2M [ZIZ5X#>5?6N +VK MZET!>E?5NP+TKMUA;X#>5?6N +V;ZMT >C?5NP'T;JIW ^C=5.\&T+NIW@V@ M=U.]&T#OIGHW@-Y-]6X O9OJW0!ZMZZL ]#;7%_7 ?AMKBOL.(#@YKK*C@,8 M;JXK[3B XN:ZVHX#.&ZN*^XX@.3FNNJ. UANKBOO.(#FYKKZC@-X;JXK\#B" MZ'T!D]' ["N8!-'[$N:WMC"G^6T[3I^)/M9=@._4>SY_=_Q\_OORXV;_;MZY M'K[&F&[^ E!+ P04 " X@G]4\W.3.W\" [/P $P %M#;VYT96YT M7U1Y<&5S72YX;6S-VT]OFS 8Q_&W$G&M K8!&Z:FEW;7K8>] 09.@\(_8;=+ MW_T;.ES\_6WY\FZU:'O!K>)=MY/GY+$U3O;5RX> M)SN$D>TX]Y4/?^>'9*KJ??5@$R6$3NIQ\';P:W^L$=U=#>.W: M<=A$L^U4]4M"'%8N<]RNG=Q5F! E[R8< M1_X<\++NZY.=Y[:QJ_MJ]E^J/LQ*#EWB_'-G77R^Q#L]CMMM6]MFK!_[L"1V MTVRKQNVL]7T7GXI>G4_V88?MZ5=>G+^4.1<89M[/X^3"B=F.;O\P.V_MCG/?+>;AD>5R^Q[^>\5O]#_:A('VD MD#XR2!\YI \-Z<- ^B@@?920/J2@-$(155)(E113)05525%54EB5%%&UL4$L! A0#% @ .()_ M5%)F%+U^!@ :AT !@ ("!#0@ 'AL+W=OC@4 /P5 8 M " @<$. !X;"]W;W)K&PO=V]R:W-H M965T&UL4$L! A0#% @ .()_5$878]DI!0 2A8 !@ M ("!"!H 'AL+W=O&PO=V]R:W-H965T&UL M4$L! A0#% @ .()_5$"E4"E,)P B( !@ ("!"3( M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ .()_ M5(-R&HL)#@ V"L !D ("!)&, 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ .()_5.9$Y9+J& ^%X M !D ("!H'H 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ .()_5*.RDB6K P W@D !D M ("!7YT 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ .()_5+&PO=V]R:W-H965T04 'X3 9 " @3ZQ M !X;"]W;W)K&UL4$L! A0#% @ .()_5#>J M!2J " 5Q< !D ("![K8 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ .()_5 B=XW&S!P "Q8 !D M ("!7\T 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ .()_5)DY0T1[ P $ @ !D ("! M6MT 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ .()_5+B>4\<_*0 UI !D ("!NNH 'AL+W=O&UL4$L! A0#% @ .()_5.=!+\A< M P 2 H !D ("!I1H! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ .()_5,C(MW@H P ?@D !D M ("!HRX! 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ .()_5#06(9'( @ [0D !D ("!S3D! M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M.()_5'=+!/U# @ 8 4 !D ("![4,! 'AL+W=O&UL4$L! A0#% @ .()_5$I_#Y/L! MD X !D ("! D\! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ .()_5-*Z@*:3 @ &PH !D M ("!9%H! 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ .()_5%5?^5&F!0 _AH !D ("!9&(! 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ .()_ M5,LMB''T 0 #00 !D ("!,6T! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ .()_5.K4V1D3 @ BP0 M !D ("!Q70! 'AL+W=OS0$" ":! &0 @($/=P$ M>&PO=V]R:W-H965T&UL4$L! A0#% @ .()_5 !N&=,, @ A@0 !D M ("!D7L! 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ .()_5 18+XN0!0 61L !D ("!IX(! 'AL+W=O M&PO=V]R:W-H965T"- M 0!X;"]W;W)K&UL4$L! A0#% @ .()_5'A; MY&Q*! H! !D ("!TI ! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ .()_5(TS!4U]! NA, !D M ("! 9T! 'AL+W=O&PO M=V]R:W-H965T 9 " @6VF 0!X;"]W;W)K&UL4$L! A0#% @ .()_5(8ELL;K!0 T1X !D ("! M)ZP! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ .()_5%:?4"H! P FP@ !D ("!K[@! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ .()_5"BR@JXT M" Y30 !D ("!YL8! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ .()_5'5_G M! P HPL !D M ("!_=4! 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ .()_5$ @A8]\ @ 2 8 !D ("!(^ ! M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M.()_5$]^;B;2!@ @RL !D ("!R.D! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ .()_5(T[&T&PO=V]R:W-H965TZ0( %<( 9 " @=G\ 0!X;"]W;W)K&UL4$L! A0#% @ .()_5'34+FGN P 5 P !D M ("!^?\! 'AL+W=O! ( >&PO=V]R:W-H M965T9P4 #<= 9 M " @<4( @!X;"]W;W)K&UL4$L! M A0#% @ .()_5-4C&AF# P J0P !D ("!8PX" 'AL M+W=ON*/!44" M ".!0 &0 @($=$@( >&PO=V]R:W-H965T&UL4$L! A0#% @ .()_ M5&[L=''J 0 *00 !H ("!EA@" 'AL+W=O&UL4$L! A0#% @ .()_5']".UIH!P ]B@ !H M ("!N!H" 'AL+W=O&UL4$L! A0# M% @ .()_5(N(1XSO!0 [!X !H ("!6"(" 'AL+W=O M&UL4$L! A0#% @ .()_5&@8&+/" P M7PX !H ("!?R@" 'AL+W=O&UL4$L! A0#% @ .()_5+S>MUP!! U!( !H ("! M>2P" 'AL+W=O&UL4$L! A0#% @ .()_ M5!&-)_V[ @ KP@ !H ("!LC " 'AL+W=O&UL4$L! A0#% @ .()_5&FD+D32 @ ,@< !H M ("!I3," 'AL+W=O&UL4$L! A0# M% @ .()_5/GRV)U%!0 <1H !H ("!KS8" 'AL+W=O M&UL4$L! A0#% @ .()_5(49=?_# @ MR@< !H ("!+#P" 'AL+W=O&UL4$L! A0#% @ .()_5*B%9&UL4$L! A0#% @ .()_ M5'ZGW:DZ @ /04 !H ("!2T(" 'AL+W=O&UL4$L! A0#% @ .()_5(FSD3UK @ M 8 !H M ("!O40" 'AL+W=O&UL4$L! A0# M% @ .()_5#X6,_KH @ (0H !H ("!8$<" 'AL+W=O M&UL4$L! A0#% @ .()_5*]'R5%; P M!A8 T ( !@$H" 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% @ .()_5+/KGH D P PT$ M !H ( !N%8" 'AL+U]R96QS+W=O ,(0 Q%P" end XML 181 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 182 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 183 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 465 412 1 false 111 0 false 14 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Unaudited Condensed Consolidated Interim Statements of Comprehensive Loss Sheet http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss Unaudited Condensed Consolidated Interim Statements of Comprehensive Loss Statements 2 false false R3.htm 00200 - Statement - Unaudited Condensed Consolidated Interim Statements of Financial Position Sheet http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition Unaudited Condensed Consolidated Interim Statements of Financial Position Statements 3 false false R4.htm 00300 - Statement - Unaudited Condensed Consolidated Interim Statements of Changes in Equity Sheet http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfChangesInEquity Unaudited Condensed Consolidated Interim Statements of Changes in Equity Statements 4 false false R5.htm 00400 - Statement - Unaudited Condensed Consolidated Interim Statements of Cash Flows Sheet http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows Unaudited Condensed Consolidated Interim Statements of Cash Flows Statements 5 false false R6.htm 10101 - Disclosure - General Company Information Sheet http://www.Evaxion.com/role/DisclosureGeneralCompanyInformation General Company Information Notes 6 false false R7.htm 10201 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 7 false false R8.htm 10301 - Disclosure - First-Time Adoption of IFRS Sheet http://www.Evaxion.com/role/DisclosureFirstTimeAdoptionOfIfrs First-Time Adoption of IFRS Notes 8 false false R9.htm 10401 - Disclosure - Significant Accounting Judgements, Estimates, and Assumptions Sheet http://www.Evaxion.com/role/DisclosureSignificantAccountingJudgementsEstimatesAndAssumptions Significant Accounting Judgements, Estimates, and Assumptions Notes 9 false false R10.htm 10501 - Disclosure - Financial Instruments and Risk Management Sheet http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagement Financial Instruments and Risk Management Notes 10 false false R11.htm 10601 - Disclosure - Operating Activities Sheet http://www.Evaxion.com/role/DisclosureOperatingActivities Operating Activities Notes 11 false false R12.htm 10701 - Disclosure - Employees and Employee-Related Costs Sheet http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCosts Employees and Employee-Related Costs Notes 12 false false R13.htm 10801 - Disclosure - Share-Based Payments Sheet http://www.Evaxion.com/role/DisclosureShareBasedPayments Share-Based Payments Notes 13 false false R14.htm 10901 - Disclosure - Financial Income and Expenses Sheet http://www.Evaxion.com/role/DisclosureFinancialIncomeAndExpenses Financial Income and Expenses Notes 14 false false R15.htm 11001 - Disclosure - Income Taxes Sheet http://www.Evaxion.com/role/DisclosureIncomeTaxes Income Taxes Notes 15 false false R16.htm 11101 - Disclosure - Basic and Diluted Loss Per Share Sheet http://www.Evaxion.com/role/DisclosureBasicAndDilutedLossPerShare Basic and Diluted Loss Per Share Notes 16 false false R17.htm 11201 - Disclosure - Intangible assets Sheet http://www.Evaxion.com/role/DisclosureIntangibleAssets Intangible assets Notes 17 false false R18.htm 11301 - Disclosure - Property, Plant and Equipment Sheet http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipment Property, Plant and Equipment Notes 18 false false R19.htm 11401 - Disclosure - Prepayments and other receivables Sheet http://www.Evaxion.com/role/DisclosurePrepaymentsAndOtherReceivables Prepayments and other receivables Notes 19 false false R20.htm 11501 - Disclosure - Other Payables Sheet http://www.Evaxion.com/role/DisclosureOtherPayables Other Payables Notes 20 false false R21.htm 11601 - Disclosure - Cash and Cash Equivalents Sheet http://www.Evaxion.com/role/DisclosureCashAndCashEquivalents Cash and Cash Equivalents Notes 21 false false R22.htm 11701 - Disclosure - Leases Sheet http://www.Evaxion.com/role/DisclosureLeases Leases Notes 22 false false R23.htm 11801 - Disclosure - Debt Sheet http://www.Evaxion.com/role/DisclosureDebt Debt Notes 23 false false R24.htm 11901 - Disclosure - Capital Structure and Financial Matters Sheet http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMatters Capital Structure and Financial Matters Notes 24 false false R25.htm 12001 - Disclosure - Convertible Debt Instruments Sheet http://www.Evaxion.com/role/DisclosureConvertibleDebtInstruments Convertible Debt Instruments Notes 25 false false R26.htm 12101 - Disclosure - Related Party Transactions Sheet http://www.Evaxion.com/role/DisclosureRelatedPartyTransactions Related Party Transactions Notes 26 false false R27.htm 12201 - Disclosure - Contractual Obligations Sheet http://www.Evaxion.com/role/DisclosureContractualObligations Contractual Obligations Notes 27 false false R28.htm 12301 - Disclosure - Provisions Sheet http://www.Evaxion.com/role/DisclosureProvisions Provisions Notes 28 false false R29.htm 12401 - Disclosure - Fees to auditors Sheet http://www.Evaxion.com/role/DisclosureFeesToAuditors Fees to auditors Notes 29 false false R30.htm 12501 - Disclosure - Events After the Reporting Period Sheet http://www.Evaxion.com/role/DisclosureEventsAfterReportingPeriod Events After the Reporting Period Notes 30 false false R31.htm 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPolicies 31 false false R32.htm 30203 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPolicies 32 false false R33.htm 30503 - Disclosure - Financial Instruments and Risk Management (Tables) Sheet http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementTables Financial Instruments and Risk Management (Tables) Tables http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagement 33 false false R34.htm 30603 - Disclosure - Operating Activities (Tables) Sheet http://www.Evaxion.com/role/DisclosureOperatingActivitiesTables Operating Activities (Tables) Tables http://www.Evaxion.com/role/DisclosureOperatingActivities 34 false false R35.htm 30703 - Disclosure - Employees and Employee-Related Costs (Tables) Sheet http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsTables Employees and Employee-Related Costs (Tables) Tables http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCosts 35 false false R36.htm 30803 - Disclosure - Share-Based Payments (Tables) Sheet http://www.Evaxion.com/role/DisclosureShareBasedPaymentsTables Share-Based Payments (Tables) Tables http://www.Evaxion.com/role/DisclosureShareBasedPayments 36 false false R37.htm 30903 - Disclosure - Financial Income and Expenses (Tables) Sheet http://www.Evaxion.com/role/DisclosureFinancialIncomeAndExpensesTables Financial Income and Expenses (Tables) Tables http://www.Evaxion.com/role/DisclosureFinancialIncomeAndExpenses 37 false false R38.htm 31003 - Disclosure - Income Taxes (Tables) Sheet http://www.Evaxion.com/role/DisclosureIncomeTaxesTables Income Taxes (Tables) Tables http://www.Evaxion.com/role/DisclosureIncomeTaxes 38 false false R39.htm 31103 - Disclosure - Basic and Diluted Loss Per Share (Tables) Sheet http://www.Evaxion.com/role/DisclosureBasicAndDilutedLossPerShareTables Basic and Diluted Loss Per Share (Tables) Tables http://www.Evaxion.com/role/DisclosureBasicAndDilutedLossPerShare 39 false false R40.htm 31203 - Disclosure - Intangible assets (Tables) Sheet http://www.Evaxion.com/role/DisclosureIntangibleAssetsTables Intangible assets (Tables) Tables http://www.Evaxion.com/role/DisclosureIntangibleAssets 40 false false R41.htm 31303 - Disclosure - Property, Plant and Equipment (Tables) Sheet http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentTables Property, Plant and Equipment (Tables) Tables http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipment 41 false false R42.htm 31403 - Disclosure - Prepayments and other receivables (Tables) Sheet http://www.Evaxion.com/role/DisclosurePrepaymentsAndOtherReceivablesTables Prepayments and other receivables (Tables) Tables http://www.Evaxion.com/role/DisclosurePrepaymentsAndOtherReceivables 42 false false R43.htm 31503 - Disclosure - Other Payables (Tables) Sheet http://www.Evaxion.com/role/DisclosureOtherPayablesTables Other Payables (Tables) Tables http://www.Evaxion.com/role/DisclosureOtherPayables 43 false false R44.htm 31603 - Disclosure - Cash and Cash Equivalents (Tables) Sheet http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsTables Cash and Cash Equivalents (Tables) Tables http://www.Evaxion.com/role/DisclosureCashAndCashEquivalents 44 false false R45.htm 31703 - Disclosure - Leases (Tables) Sheet http://www.Evaxion.com/role/DisclosureLeasesTables Leases (Tables) Tables http://www.Evaxion.com/role/DisclosureLeases 45 false false R46.htm 31903 - Disclosure - Capital Structure and Financial Matters (Tables) Sheet http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersTables Capital Structure and Financial Matters (Tables) Tables http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMatters 46 false false R47.htm 32003 - Disclosure - Convertible Debt Instruments (Tables) Sheet http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsTables Convertible Debt Instruments (Tables) Tables http://www.Evaxion.com/role/DisclosureConvertibleDebtInstruments 47 false false R48.htm 32103 - Disclosure - Related Party Transactions (Tables) Sheet http://www.Evaxion.com/role/DisclosureRelatedPartyTransactionsTables Related Party Transactions (Tables) Tables http://www.Evaxion.com/role/DisclosureRelatedPartyTransactions 48 false false R49.htm 32203 - Disclosure - Contractual Obligations (Tables) Sheet http://www.Evaxion.com/role/DisclosureContractualObligationsTables Contractual Obligations (Tables) Tables http://www.Evaxion.com/role/DisclosureContractualObligations 49 false false R50.htm 32303 - Disclosure - Provisions (Tables) Sheet http://www.Evaxion.com/role/DisclosureProvisionsTables Provisions (Tables) Tables http://www.Evaxion.com/role/DisclosureProvisions 50 false false R51.htm 32403 - Disclosure - Fees to auditors (Tables) Sheet http://www.Evaxion.com/role/DisclosureFeesToAuditorsTables Fees to auditors (Tables) Tables http://www.Evaxion.com/role/DisclosureFeesToAuditors 51 false false R52.htm 40101 - Disclosure - General Company Information (Details) Sheet http://www.Evaxion.com/role/DisclosureGeneralCompanyInformationDetails General Company Information (Details) Details http://www.Evaxion.com/role/DisclosureGeneralCompanyInformation 52 false false R53.htm 40201 - Disclosure - Summary of Significant Accounting Policies - Retrospective effect of share split and bonus share issuance (Details) Sheet http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRetrospectiveEffectOfShareSplitAndBonusShareIssuanceDetails Summary of Significant Accounting Policies - Retrospective effect of share split and bonus share issuance (Details) Details 53 false false R54.htm 40202 - Disclosure - Summary of Significant Accounting Policies - Accounting for joint operation (Details) Sheet http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountingForJointOperationDetails Summary of Significant Accounting Policies - Accounting for joint operation (Details) Details 54 false false R55.htm 40203 - Disclosure - Summary of Significant Accounting Policies - Deferred Offering Costs (Details) Sheet http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDeferredOfferingCostsDetails Summary of Significant Accounting Policies - Deferred Offering Costs (Details) Details 55 false false R56.htm 40204 - Disclosure - Summary of Significant Accounting Policies - Leasehold improvements and Loan from lessor (Details) Sheet http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeaseholdImprovementsAndLoanFromLessorDetails Summary of Significant Accounting Policies - Leasehold improvements and Loan from lessor (Details) Details 56 false false R57.htm 40205 - Disclosure - Summary of Significant Accounting Policies - Estimated useful lives of assets (Details) Sheet http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails Summary of Significant Accounting Policies - Estimated useful lives of assets (Details) Details 57 false false R58.htm 40206 - Disclosure - Summary of Significant Accounting Policies - Impairment of non-financial assets (Details) Sheet http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfNonFinancialAssetsDetails Summary of Significant Accounting Policies - Impairment of non-financial assets (Details) Details 58 false false R59.htm 40207 - Disclosure - Summary of Significant Accounting Policies - Cash and cash equivalents (Details) Sheet http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails Summary of Significant Accounting Policies - Cash and cash equivalents (Details) Details 59 false false R60.htm 40208 - Disclosure - Summary of Significant Accounting Policies - Convertible debt instruments (Details) Sheet http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConvertibleDebtInstrumentsDetails Summary of Significant Accounting Policies - Convertible debt instruments (Details) Details 60 false false R61.htm 40209 - Disclosure - Summary of Significant Accounting Policies - Segment (Details) Sheet http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentDetails Summary of Significant Accounting Policies - Segment (Details) Details http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables 61 false false R62.htm 40210 - Disclosure - Summary of Significant Accounting Policies - Loss Per Share (Details) Sheet http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLossPerShareDetails Summary of Significant Accounting Policies - Loss Per Share (Details) Details 62 false false R63.htm 40501 - Disclosure - Financial Instruments and Risk Management - Liquidity risk (Details) Sheet http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementLiquidityRiskDetails Financial Instruments and Risk Management - Liquidity risk (Details) Details 63 false false R64.htm 40502 - Disclosure - Financial Instruments and Risk Management - IPO (Details) Sheet http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementIpoDetails Financial Instruments and Risk Management - IPO (Details) Details http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementTables 64 false false R65.htm 40503 - Disclosure - Financial Instruments and Risk Management - Contractual undiscounted outflows (Details) Sheet http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementContractualUndiscountedOutflowsDetails Financial Instruments and Risk Management - Contractual undiscounted outflows (Details) Details 65 false false R66.htm 40504 - Disclosure - Financial Instruments and Risk Management - Convertible debt instruments (Details) Sheet http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementConvertibleDebtInstrumentsDetails Financial Instruments and Risk Management - Convertible debt instruments (Details) Details 66 false false R67.htm 40601 - Disclosure - Operating Activities (Details) Sheet http://www.Evaxion.com/role/DisclosureOperatingActivitiesDetails Operating Activities (Details) Details http://www.Evaxion.com/role/DisclosureOperatingActivitiesTables 67 false false R68.htm 40701 - Disclosure - Employees and Employee-Related Costs - Number of employees (Details) Sheet http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsNumberOfEmployeesDetails Employees and Employee-Related Costs - Number of employees (Details) Details 68 false false R69.htm 40702 - Disclosure - Employees and Employee-Related Costs - Employee Costs (Details) Sheet http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsEmployeeCostsDetails Employees and Employee-Related Costs - Employee Costs (Details) Details 69 false false R70.htm 40703 - Disclosure - Employees and Employee-Related Costs - Board of Directors and Executive Management (Details) Sheet http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsBoardOfDirectorsAndExecutiveManagementDetails Employees and Employee-Related Costs - Board of Directors and Executive Management (Details) Details 70 false false R71.htm 40801 - Disclosure - Share-Based Payments - Warrants (Details) Sheet http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsDetails Share-Based Payments - Warrants (Details) Details 71 false false R72.htm 40802 - Disclosure - Share-Based Payments - Schedule of Warrants (Details) Sheet http://www.Evaxion.com/role/DisclosureShareBasedPaymentsScheduleOfWarrantsDetails Share-Based Payments - Schedule of Warrants (Details) Details 72 false false R73.htm 40803 - Disclosure - Share-Based Payments - Warrants Rectified (Details) Sheet http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsRectifiedDetails Share-Based Payments - Warrants Rectified (Details) Details 73 false false R74.htm 40804 - Disclosure - Share-Based Payments - Compensation expense (Details) Sheet http://www.Evaxion.com/role/DisclosureShareBasedPaymentsCompensationExpenseDetails Share-Based Payments - Compensation expense (Details) Details 74 false false R75.htm 40805 - Disclosure - Share-Based Payments - Fair value of warrants (Details) Sheet http://www.Evaxion.com/role/DisclosureShareBasedPaymentsFairValueOfWarrantsDetails Share-Based Payments - Fair value of warrants (Details) Details 75 false false R76.htm 40806 - Disclosure - Share-Based Payments - Assumptions of Warrants (Details) Sheet http://www.Evaxion.com/role/DisclosureShareBasedPaymentsAssumptionsOfWarrantsDetails Share-Based Payments - Assumptions of Warrants (Details) Details 76 false false R77.htm 40807 - Disclosure - Share-Based Payments - Amendments to Warrants (Details) Sheet http://www.Evaxion.com/role/DisclosureShareBasedPaymentsAmendmentsToWarrantsDetails Share-Based Payments - Amendments to Warrants (Details) Details 77 false false R78.htm 40808 - Disclosure - Share-Based Payments - Outstanding warrants (Details) Sheet http://www.Evaxion.com/role/DisclosureShareBasedPaymentsOutstandingWarrantsDetails Share-Based Payments - Outstanding warrants (Details) Details 78 false false R79.htm 40809 - Disclosure - Share-Based Payments - Key Management Holdings (Details) Sheet http://www.Evaxion.com/role/DisclosureShareBasedPaymentsKeyManagementHoldingsDetails Share-Based Payments - Key Management Holdings (Details) Details 79 false false R80.htm 40901 - Disclosure - Financial Income and Expenses (Details) Sheet http://www.Evaxion.com/role/DisclosureFinancialIncomeAndExpensesDetails Financial Income and Expenses (Details) Details http://www.Evaxion.com/role/DisclosureFinancialIncomeAndExpensesTables 80 false false R81.htm 41001 - Disclosure - Income Taxes - Analysis of charge(credit) (Details) Sheet http://www.Evaxion.com/role/DisclosureIncomeTaxesAnalysisOfChargeCreditDetails Income Taxes - Analysis of charge(credit) (Details) Details 81 false false R82.htm 41002 - Disclosure - Income Taxes - Reconciliation of effective tax rate (Details) Sheet http://www.Evaxion.com/role/DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails Income Taxes - Reconciliation of effective tax rate (Details) Details 82 false false R83.htm 41003 - Disclosure - Income Taxes - Deferred tax (Details) Sheet http://www.Evaxion.com/role/DisclosureIncomeTaxesDeferredTaxDetails Income Taxes - Deferred tax (Details) Details 83 false false R84.htm 41101 - Disclosure - Basic and Diluted Loss Per Share (Details) Sheet http://www.Evaxion.com/role/DisclosureBasicAndDilutedLossPerShareDetails Basic and Diluted Loss Per Share (Details) Details http://www.Evaxion.com/role/DisclosureBasicAndDilutedLossPerShareTables 84 false false R85.htm 41102 - Disclosure - Basic and Diluted Loss Per Share - Anti-dilutive shares (Details) Sheet http://www.Evaxion.com/role/DisclosureBasicAndDilutedLossPerShareAntiDilutiveSharesDetails Basic and Diluted Loss Per Share - Anti-dilutive shares (Details) Details 85 false false R86.htm 41201 - Disclosure - Intangible assets - Paragraph (Details) Sheet http://www.Evaxion.com/role/DisclosureIntangibleAssetsParagraphDetails Intangible assets - Paragraph (Details) Details 86 false false R87.htm 41202 - Disclosure - Intangible assets - Table (Details) Sheet http://www.Evaxion.com/role/DisclosureIntangibleAssetsTableDetails Intangible assets - Table (Details) Details 87 false false R88.htm 41301 - Disclosure - Property, Plant and Equipment (Details) Sheet http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDetails Property, Plant and Equipment (Details) Details http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentTables 88 false false R89.htm 41302 - Disclosure - Property, Plant and Equipment - Depreciation (Details) Sheet http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDepreciationDetails Property, Plant and Equipment - Depreciation (Details) Details 89 false false R90.htm 41401 - Disclosure - Prepayments and other receivables (Details) Sheet http://www.Evaxion.com/role/DisclosurePrepaymentsAndOtherReceivablesDetails Prepayments and other receivables (Details) Details http://www.Evaxion.com/role/DisclosurePrepaymentsAndOtherReceivablesTables 90 false false R91.htm 41501 - Disclosure - Other Payables (Details) Sheet http://www.Evaxion.com/role/DisclosureOtherPayablesDetails Other Payables (Details) Details http://www.Evaxion.com/role/DisclosureOtherPayablesTables 91 false false R92.htm 41601 - Disclosure - Cash and Cash Equivalents (Details) Sheet http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsDetails Cash and Cash Equivalents (Details) Details http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsTables 92 false false R93.htm 41602 - Disclosure - Cash and Cash Equivalents - Changes in Net Working Capital (Details) Sheet http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsChangesInNetWorkingCapitalDetails Cash and Cash Equivalents - Changes in Net Working Capital (Details) Details 93 false false R94.htm 41603 - Disclosure - Cash and Cash Equivalents - Adjustments for non-cash items (Details) Sheet http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsAdjustmentsForNonCashItemsDetails Cash and Cash Equivalents - Adjustments for non-cash items (Details) Details 94 false false R95.htm 41604 - Disclosure - Cash and Cash Equivalents - Reconciliation of Liabilities from Financing Activities (Details) Sheet http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsReconciliationOfLiabilitiesFromFinancingActivitiesDetails Cash and Cash Equivalents - Reconciliation of Liabilities from Financing Activities (Details) Details 95 false false R96.htm 41701 - Disclosure - Leases (Details) Sheet http://www.Evaxion.com/role/DisclosureLeasesDetails Leases (Details) Details http://www.Evaxion.com/role/DisclosureLeasesTables 96 false false R97.htm 41702 - Disclosure - Leases - Movements in Right-of-use Assets and Lease Liabilities (Details) Sheet http://www.Evaxion.com/role/DisclosureLeasesMovementsInRightOfUseAssetsAndLeaseLiabilitiesDetails Leases - Movements in Right-of-use Assets and Lease Liabilities (Details) Details 97 false false R98.htm 41703 - Disclosure - Leases - Summary of finance liability (Details) Sheet http://www.Evaxion.com/role/DisclosureLeasesSummaryOfFinanceLiabilityDetails Leases - Summary of finance liability (Details) Details 98 false false R99.htm 41801 - Disclosure - Debt (Details) Sheet http://www.Evaxion.com/role/DisclosureDebtDetails Debt (Details) Details http://www.Evaxion.com/role/DisclosureDebt 99 false false R100.htm 41901 - Disclosure - Capital Structure and Financial Matters - Loss of subscribed share capital (Details) Sheet http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersLossOfSubscribedShareCapitalDetails Capital Structure and Financial Matters - Loss of subscribed share capital (Details) Details 100 false false R101.htm 41902 - Disclosure - Capital Structure and Financial Matters - Capital transactions (Details) Sheet http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersCapitalTransactionsDetails Capital Structure and Financial Matters - Capital transactions (Details) Details 101 false false R102.htm 41903 - Disclosure - Capital Structure and Financial Matters - Changes in Share Capital (Details) Sheet http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersChangesInShareCapitalDetails Capital Structure and Financial Matters - Changes in Share Capital (Details) Details 102 false false R103.htm 41904 - Disclosure - Capital Structure and Financial Matters - Share Capital (Details) Sheet http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersShareCapitalDetails Capital Structure and Financial Matters - Share Capital (Details) Details 103 false false R104.htm 41905 - Disclosure - Capital Structure and Financial Matters - Shareholdings by Directors and Executive Management (Details) Sheet http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersShareholdingsByDirectorsAndExecutiveManagementDetails Capital Structure and Financial Matters - Shareholdings by Directors and Executive Management (Details) Details 104 false false R105.htm 42001 - Disclosure - Convertible Debt Instruments - Issuance (Details) Sheet http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsIssuanceDetails Convertible Debt Instruments - Issuance (Details) Details 105 false false R106.htm 42002 - Disclosure - Convertible Debt Instruments - Summary of changes in the convertible debt instruments (Details) Sheet http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsSummaryOfChangesInConvertibleDebtInstrumentsDetails Convertible Debt Instruments - Summary of changes in the convertible debt instruments (Details) Details 106 false false R107.htm 42003 - Disclosure - Convertible Debt Instruments - Terms of Convertible Debt (Details) Sheet http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsTermsOfConvertibleDebtDetails Convertible Debt Instruments - Terms of Convertible Debt (Details) Details 107 false false R108.htm 42101 - Disclosure - Related Party Transactions (Details) Sheet http://www.Evaxion.com/role/DisclosureRelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://www.Evaxion.com/role/DisclosureRelatedPartyTransactionsTables 108 false false R109.htm 42201 - Disclosure - Contractual Obligations - Contractual Commitments (Details) Sheet http://www.Evaxion.com/role/DisclosureContractualObligationsContractualCommitmentsDetails Contractual Obligations - Contractual Commitments (Details) Details 109 false false R110.htm 42301 - Disclosure - Provisions (Details) Sheet http://www.Evaxion.com/role/DisclosureProvisionsDetails Provisions (Details) Details http://www.Evaxion.com/role/DisclosureProvisionsTables 110 false false R111.htm 42401 - Disclosure - Fees to auditors (Details) Sheet http://www.Evaxion.com/role/DisclosureFeesToAuditorsDetails Fees to auditors (Details) Details http://www.Evaxion.com/role/DisclosureFeesToAuditorsTables 111 false false R112.htm 42501 - Disclosure - Events After the Reporting Period (Details) Sheet http://www.Evaxion.com/role/DisclosureEventsAfterReportingPeriodDetails Events After the Reporting Period (Details) Details http://www.Evaxion.com/role/DisclosureEventsAfterReportingPeriod 112 false false All Reports Book All Reports evax-20211231x20f.htm evax-20211231.xsd evax-20211231_cal.xml evax-20211231_def.xml evax-20211231_lab.xml evax-20211231_pre.xml evax-20211231xex12d1.htm evax-20211231xex12d2.htm evax-20211231xex13d1.htm evax-20211231xex13d2.htm evax-20211231xex15d1.htm evax-20211231x20f005.jpg evax-20211231x20f006.jpg evax-20211231x20f007.jpg evax-20211231x20f008.jpg evax-20211231x20f009.jpg evax-20211231x20f010.jpg evax-20211231x20f011.jpg evax-20211231x20f012.jpg evax-20211231x20f013.jpg evax-20211231x20f014.jpg evax-20211231x20f015.jpg evax-20211231x20f016.jpg evax-20211231x20f017.jpg evax-20211231x20f018.jpg evax-20211231x20f019.jpg evax-20211231x20f020.jpg evax-20211231x20f021.jpg evax-20211231x20f022.jpg evax-20211231x20f023.jpg evax-20211231x20f024.jpg evax-20211231x20f025.jpg evax-20211231x20f026.jpg evax-20211231x20f027.jpg evax-20211231x20f028.jpg evax-20211231x20f029.jpg evax-20211231x20f030.jpg evax-20211231x20f031.jpg evax-20211231x20f032.jpg evax-20211231x20f033.jpg evax-20211231x20f034.jpg evax-20211231x20f035.jpg evax-20211231x20f036.jpg evax-20211231x20f037.jpg evax-20211231x20f038.jpg evax-20211231x20f039.jpg evax-20211231x20f040.jpg evax-20211231x20f041.jpg evax-20211231x20f042.jpg evax-20211231x20f043.jpg evax-20211231x20f044.jpg evax-20211231x20f045.jpg evax-20211231x20f046.jpg evax-20211231x20f047.jpg evax-20211231x20f048.jpg evax-20211231x20f049.jpg evax-20211231x20f050.jpg evax-20211231x20f051.jpg evax-20211231x20f052.jpg evax-20211231x20f053.jpg evax-20211231x20f054.jpg evax-20211231x20f055.jpg evax-20211231x20f056.jpg evax-20211231x20f057.jpg evax-20211231x20f058.jpg evax-20211231x20f059.jpg http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full http://xbrl.sec.gov/dei/2021q4 true true JSON 186 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "evax-20211231x20f.htm": { "axisCustom": 5, "axisStandard": 27, "contextCount": 465, "dts": { "calculationLink": { "local": [ "evax-20211231_cal.xml" ] }, "definitionLink": { "local": [ "evax-20211231_def.xml" ] }, "inline": { "local": [ "evax-20211231x20f.htm" ] }, "labelLink": { "local": [ "evax-20211231_lab.xml" ] }, "presentationLink": { "local": [ "evax-20211231_pre.xml" ] }, "schema": { "local": [ "evax-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 675, "entityCount": 1, "hidden": { "http://www.Evaxion.com/20211231": 6, "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full": 27, "http://xbrl.sec.gov/dei/2021q4": 5, "total": 38 }, "keyCustom": 123, "keyStandard": 289, "memberCustom": 71, "memberStandard": 31, "nsprefix": "evax", "nsuri": "http://www.Evaxion.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Financial Instruments and Risk Management", "role": "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagement", "shortName": "Financial Instruments and Risk Management", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R100": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2018_CJX0CgOhUUyMp_J5CWBiLg", "decimals": "2", "first": true, "lang": null, "name": "evax:MinimumPercentageOfLostSubscribedShareCapital", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_VXihgnh3Kk2QDRU39jja3A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41901 - Disclosure - Capital Structure and Financial Matters - Loss of subscribed share capital (Details)", "role": "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersLossOfSubscribedShareCapitalDetails", "shortName": "Capital Structure and Financial Matters - Loss of subscribed share capital (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2018_CJX0CgOhUUyMp_J5CWBiLg", "decimals": "2", "first": true, "lang": null, "name": "evax:MinimumPercentageOfLostSubscribedShareCapital", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_VXihgnh3Kk2QDRU39jja3A", "xsiNil": "false" } }, "R101": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:PaymentsForShareIssueCosts", "reportCount": 1, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41902 - Disclosure - Capital Structure and Financial Matters - Capital transactions (Details)", "role": "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersCapitalTransactionsDetails", "shortName": "Capital Structure and Financial Matters - Capital transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_8_10_2020_To_8_10_2020_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_Rn3l9iWMDE2vEORtbEHxow", "decimals": "INF", "lang": null, "name": "evax:NumberOfSharesAuthorisedIncrease", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_EyzmVIbeRk6F4XMicmIclw", "xsiNil": "false" } }, "R102": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2020_kliRcRutmUqg6D4sEtTi0g", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41903 - Disclosure - Capital Structure and Financial Matters - Changes in Share Capital (Details)", "role": "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersChangesInShareCapitalDetails", "shortName": "Capital Structure and Financial Matters - Changes in Share Capital (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_11_9_2021_To_11_9_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_sQg8FO29Skm0pJJ8Qf_EMg", "decimals": "-3", "lang": null, "name": "ifrs-full:IssueOfEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_DKK_PbpTCVT5nkiDmWhigE_P0g", "xsiNil": "false" } }, "R103": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2021_yLFUq--_mk2hzZFKxTtdnA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41904 - Disclosure - Capital Structure and Financial Matters - Share Capital (Details)", "role": "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersShareCapitalDetails", "shortName": "Capital Structure and Financial Matters - Share Capital (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R104": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "evax:DisclosureExecutiveManagementsAndBoardOfDirectorsHoldingOfSharesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_srt_ManagementMember_3Ciz6tqGEUiKlMFVAK3kBg", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_EyzmVIbeRk6F4XMicmIclw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41905 - Disclosure - Capital Structure and Financial Matters - Shareholdings by Directors and Executive Management (Details)", "role": "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersShareholdingsByDirectorsAndExecutiveManagementDetails", "shortName": "Capital Structure and Financial Matters - Shareholdings by Directors and Executive Management (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "evax:DisclosureExecutiveManagementsAndBoardOfDirectorsHoldingOfSharesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_srt_ManagementMember_3Ciz6tqGEUiKlMFVAK3kBg", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_EyzmVIbeRk6F4XMicmIclw", "xsiNil": "false" } }, "R105": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2018_To_12_31_2018_333avgk08ka0t0KGzEMnqg", "decimals": "INF", "first": true, "lang": null, "name": "evax:TypesOfConvertibleDebtInstrumentsIssued", "reportCount": 1, "unitRef": "Unit_Standard_instrument_iPnkdz7kdEO8pGg9vC8XGw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "42001 - Disclosure - Convertible Debt Instruments - Issuance (Details)", "role": "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsIssuanceDetails", "shortName": "Convertible Debt Instruments - Issuance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "evax:DisclosureOfBorrowingExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2018_To_12_31_2018_ifrs-full_BorrowingsByNameAxis_evax_ConvertibleDebtsMember_pOUCKgrdp0CPtMfpabBXqg", "decimals": "-5", "lang": null, "name": "ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" } }, "R106": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2018_CJX0CgOhUUyMp_J5CWBiLg", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ShorttermBorrowings", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "42002 - Disclosure - Convertible Debt Instruments - Summary of changes in the convertible debt instruments (Details)", "role": "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsSummaryOfChangesInConvertibleDebtInstrumentsDetails", "shortName": "Convertible Debt Instruments - Summary of changes in the convertible debt instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2018_CJX0CgOhUUyMp_J5CWBiLg", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ShorttermBorrowings", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" } }, "R107": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2021_yLFUq--_mk2hzZFKxTtdnA", "decimals": "2", "first": true, "lang": null, "name": "ifrs-full:BorrowingsInterestRate", "reportCount": 1, "unitRef": "Unit_Standard_pure_VXihgnh3Kk2QDRU39jja3A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "42003 - Disclosure - Convertible Debt Instruments - Terms of Convertible Debt (Details)", "role": "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsTermsOfConvertibleDebtDetails", "shortName": "Convertible Debt Instruments - Terms of Convertible Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2018_To_12_31_2018_ifrs-full_BorrowingsByNameAxis_evax_ConvertibleDebt1Member_UgvPZ_ZSF0y09rweZedIpQ", "decimals": null, "lang": "en-US", "name": "evax:DebtInstrumentTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R108": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2021_yLFUq--_mk2hzZFKxTtdnA", "decimals": "2", "first": true, "lang": null, "name": "ifrs-full:BorrowingsInterestRate", "reportCount": 1, "unitRef": "Unit_Standard_pure_VXihgnh3Kk2QDRU39jja3A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "42101 - Disclosure - Related Party Transactions (Details)", "role": "http://www.Evaxion.com/role/DisclosureRelatedPartyTransactionsDetails", "shortName": "Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2019_ifrs-full_BorrowingsByNameAxis_evax_ConvertibleDebtsMember_59M8rRhyQUaPGwWYeihDbw", "decimals": "-3", "lang": null, "name": "evax:ExpensesAccruedInterestRelatedPartyTransactions", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" } }, "R109": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfCommitmentsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2021_yLFUq--_mk2hzZFKxTtdnA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ContractualCapitalCommitments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "42201 - Disclosure - Contractual Obligations - Contractual Commitments (Details)", "role": "http://www.Evaxion.com/role/DisclosureContractualObligationsContractualCommitmentsDetails", "shortName": "Contractual Obligations - Contractual Commitments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfCommitmentsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2021_yLFUq--_mk2hzZFKxTtdnA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ContractualCapitalCommitments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - Operating Activities", "role": "http://www.Evaxion.com/role/DisclosureOperatingActivities", "shortName": "Operating Activities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R110": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "evax:ChangesInProvisionTableTextBlock", "ifrs-full:DisclosureOfProvisionsExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": "-3", "first": true, "lang": null, "name": "evax:ProvisionRecognized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "42301 - Disclosure - Provisions (Details)", "role": "http://www.Evaxion.com/role/DisclosureProvisionsDetails", "shortName": "Provisions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "evax:ChangesInProvisionTableTextBlock", "ifrs-full:DisclosureOfProvisionsExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": "-3", "first": true, "lang": null, "name": "evax:ProvisionRecognized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" } }, "R111": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "evax:ScheduleOfAuditorsRemunerationTableTextBlock", "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:AuditorsRemunerationForAuditServices", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "42401 - Disclosure - Fees to auditors (Details)", "role": "http://www.Evaxion.com/role/DisclosureFeesToAuditorsDetails", "shortName": "Fees to auditors (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "evax:ScheduleOfAuditorsRemunerationTableTextBlock", "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:AuditorsRemunerationForAuditServices", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" } }, "R112": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2021_yLFUq--_mk2hzZFKxTtdnA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Borrowings", "reportCount": 1, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "42501 - Disclosure - Events After the Reporting Period (Details)", "role": "http://www.Evaxion.com/role/DisclosureEventsAfterReportingPeriodDetails", "shortName": "Events After the Reporting Period (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Employees and Employee-Related Costs", "role": "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCosts", "shortName": "Employees and Employee-Related Costs", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - Share-Based Payments", "role": "http://www.Evaxion.com/role/DisclosureShareBasedPayments", "shortName": "Share-Based Payments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - Financial Income and Expenses", "role": "http://www.Evaxion.com/role/DisclosureFinancialIncomeAndExpenses", "shortName": "Financial Income and Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - Income Taxes", "role": "http://www.Evaxion.com/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11101 - Disclosure - Basic and Diluted Loss Per Share", "role": "http://www.Evaxion.com/role/DisclosureBasicAndDilutedLossPerShare", "shortName": "Basic and Diluted Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11201 - Disclosure - Intangible assets", "role": "http://www.Evaxion.com/role/DisclosureIntangibleAssets", "shortName": "Intangible assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11301 - Disclosure - Property, Plant and Equipment", "role": "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipment", "shortName": "Property, Plant and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "evax:ReceivablesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11401 - Disclosure - Prepayments and other receivables", "role": "http://www.Evaxion.com/role/DisclosurePrepaymentsAndOtherReceivables", "shortName": "Prepayments and other receivables", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "evax:ReceivablesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - Unaudited Condensed Consolidated Interim Statements of Comprehensive Loss", "role": "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss", "shortName": "Unaudited Condensed Consolidated Interim Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "evax:OtherPayablesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11501 - Disclosure - Other Payables", "role": "http://www.Evaxion.com/role/DisclosureOtherPayables", "shortName": "Other Payables", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "evax:OtherPayablesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11601 - Disclosure - Cash and Cash Equivalents", "role": "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalents", "shortName": "Cash and Cash Equivalents", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11701 - Disclosure - Leases", "role": "http://www.Evaxion.com/role/DisclosureLeases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBorrowingsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11801 - Disclosure - Debt", "role": "http://www.Evaxion.com/role/DisclosureDebt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBorrowingsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11901 - Disclosure - Capital Structure and Financial Matters", "role": "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMatters", "shortName": "Capital Structure and Financial Matters", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "evax:DisclosureOfBorrowingExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "12001 - Disclosure - Convertible Debt Instruments", "role": "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstruments", "shortName": "Convertible Debt Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "evax:DisclosureOfBorrowingExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "12101 - Disclosure - Related Party Transactions", "role": "http://www.Evaxion.com/role/DisclosureRelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "12201 - Disclosure - Contractual Obligations", "role": "http://www.Evaxion.com/role/DisclosureContractualObligations", "shortName": "Contractual Obligations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfProvisionsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "12301 - Disclosure - Provisions", "role": "http://www.Evaxion.com/role/DisclosureProvisions", "shortName": "Provisions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfProvisionsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "12401 - Disclosure - Fees to auditors", "role": "http://www.Evaxion.com/role/DisclosureFeesToAuditors", "shortName": "Fees to auditors", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2021_yLFUq--_mk2hzZFKxTtdnA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - Unaudited Condensed Consolidated Interim Statements of Financial Position", "role": "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition", "shortName": "Unaudited Condensed Consolidated Interim Statements of Financial Position", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2020_kliRcRutmUqg6D4sEtTi0g", "decimals": "-3", "lang": null, "name": "ifrs-full:DeferredTaxAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "12501 - Disclosure - Events After the Reporting Period", "role": "http://www.Evaxion.com/role/DisclosureEventsAfterReportingPeriod", "shortName": "Events After the Reporting Period", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDepreciationAndAmortisationExpenseExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30203 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDepreciationAndAmortisationExpenseExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - Financial Instruments and Risk Management (Tables)", "role": "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementTables", "shortName": "Financial Instruments and Risk Management (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30603 - Disclosure - Operating Activities (Tables)", "role": "http://www.Evaxion.com/role/DisclosureOperatingActivitiesTables", "shortName": "Operating Activities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfAdditionalInformationExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30703 - Disclosure - Employees and Employee-Related Costs (Tables)", "role": "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsTables", "shortName": "Employees and Employee-Related Costs (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfAdditionalInformationExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30803 - Disclosure - Share-Based Payments (Tables)", "role": "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsTables", "shortName": "Share-Based Payments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "evax:FinancialIncomeAndExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30903 - Disclosure - Financial Income and Expenses (Tables)", "role": "http://www.Evaxion.com/role/DisclosureFinancialIncomeAndExpensesTables", "shortName": "Financial Income and Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "evax:FinancialIncomeAndExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "evax:IfrsFinancialIncomeAndExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31003 - Disclosure - Income Taxes (Tables)", "role": "http://www.Evaxion.com/role/DisclosureIncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "evax:IfrsFinancialIncomeAndExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:EarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31103 - Disclosure - Basic and Diluted Loss Per Share (Tables)", "role": "http://www.Evaxion.com/role/DisclosureBasicAndDilutedLossPerShareTables", "shortName": "Basic and Diluted Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:EarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2018_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_ccTCpX48MU-VwugIjVZkJA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unitRef": "Unit_Standard_DKK_PbpTCVT5nkiDmWhigE_P0g", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - Unaudited Condensed Consolidated Interim Statements of Changes in Equity", "role": "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfChangesInEquity", "shortName": "Unaudited Condensed Consolidated Interim Statements of Changes in Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2018_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_ik_k1RROFEmSwuOPSDJ8dw", "decimals": "-3", "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31203 - Disclosure - Intangible assets (Tables)", "role": "http://www.Evaxion.com/role/DisclosureIntangibleAssetsTables", "shortName": "Intangible assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31303 - Disclosure - Property, Plant and Equipment (Tables)", "role": "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentTables", "shortName": "Property, Plant and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "evax:ReceivablesTextBlock", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "evax:DisclosureOfReceivablesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31403 - Disclosure - Prepayments and other receivables (Tables)", "role": "http://www.Evaxion.com/role/DisclosurePrepaymentsAndOtherReceivablesTables", "shortName": "Prepayments and other receivables (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "evax:ReceivablesTextBlock", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "evax:DisclosureOfReceivablesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "evax:OtherPayablesTextBlock", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "evax:DisclosureOfOtherPayablesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31503 - Disclosure - Other Payables (Tables)", "role": "http://www.Evaxion.com/role/DisclosureOtherPayablesTables", "shortName": "Other Payables (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "evax:OtherPayablesTextBlock", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "evax:DisclosureOfOtherPayablesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "evax:DisclosureOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31603 - Disclosure - Cash and Cash Equivalents (Tables)", "role": "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsTables", "shortName": "Cash and Cash Equivalents (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "evax:DisclosureOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31703 - Disclosure - Leases (Tables)", "role": "http://www.Evaxion.com/role/DisclosureLeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31903 - Disclosure - Capital Structure and Financial Matters (Tables)", "role": "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersTables", "shortName": "Capital Structure and Financial Matters (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_ifrs-full_BorrowingsByNameAxis_evax_ConvertibleDebtsMember_zGjMVWd-LUWI6T54hUmyiw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "32003 - Disclosure - Convertible Debt Instruments (Tables)", "role": "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsTables", "shortName": "Convertible Debt Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_ifrs-full_BorrowingsByNameAxis_evax_ConvertibleDebtsMember_zGjMVWd-LUWI6T54hUmyiw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "32103 - Disclosure - Related Party Transactions (Tables)", "role": "http://www.Evaxion.com/role/DisclosureRelatedPartyTransactionsTables", "shortName": "Related Party Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCommitmentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "32203 - Disclosure - Contractual Obligations (Tables)", "role": "http://www.Evaxion.com/role/DisclosureContractualObligationsTables", "shortName": "Contractual Obligations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCommitmentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - Unaudited Condensed Consolidated Interim Statements of Cash Flows", "role": "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows", "shortName": "Unaudited Condensed Consolidated Interim Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": "-3", "lang": null, "name": "ifrs-full:AdjustmentsForReconcileProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfProvisionsExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "evax:ChangesInProvisionTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "32303 - Disclosure - Provisions (Tables)", "role": "http://www.Evaxion.com/role/DisclosureProvisionsTables", "shortName": "Provisions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfProvisionsExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "evax:ChangesInProvisionTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "evax:ScheduleOfAuditorsRemunerationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "32403 - Disclosure - Fees to auditors (Tables)", "role": "http://www.Evaxion.com/role/DisclosureFeesToAuditorsTables", "shortName": "Fees to auditors (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "evax:ScheduleOfAuditorsRemunerationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2021_yLFUq--_mk2hzZFKxTtdnA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:IssuedCapital", "reportCount": 1, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40101 - Disclosure - General Company Information (Details)", "role": "http://www.Evaxion.com/role/DisclosureGeneralCompanyInformationDetails", "shortName": "General Company Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "evax:GeneralCompanyInformationTextBlock", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_2_5_2021_To_2_5_2021_evax_IfrsSubsidiarySaleOfStockAxis_evax_IfrsIpoMember_7UvUxy9HFUeq6WiNqgxQnA", "decimals": "-5", "lang": null, "name": "evax:AggregateAmountOnProceedsFromInitialPublicOffering", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "evax:RetrospectiveEffectOfShareSplitAndBonusShareIssuanceTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_4_2021_To_1_4_2021_Ejfr87jawUK982V9iejV8w", "decimals": "0", "first": true, "lang": null, "name": "evax:StockSplitOnBonusIssueOfShares", "reportCount": 1, "unitRef": "Unit_Standard_pure_VXihgnh3Kk2QDRU39jja3A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40201 - Disclosure - Summary of Significant Accounting Policies - Retrospective effect of share split and bonus share issuance (Details)", "role": "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRetrospectiveEffectOfShareSplitAndBonusShareIssuanceDetails", "shortName": "Summary of Significant Accounting Policies - Retrospective effect of share split and bonus share issuance (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R54": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DescriptionOfAccountingPolicyForInvestmentsInJointVentures", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_ifrs-full_JointOperationsAxis_evax_SouthernDenmarkUniversityCollaborationAgreementMember_hx25QOLCQkWQWTGDz-WQUg", "decimals": "-5", "first": true, "lang": null, "name": "evax:CompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40202 - Disclosure - Summary of Significant Accounting Policies - Accounting for joint operation (Details)", "role": "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountingForJointOperationDetails", "shortName": "Summary of Significant Accounting Policies - Accounting for joint operation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DescriptionOfAccountingPolicyForInvestmentsInJointVentures", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_ifrs-full_JointOperationsAxis_evax_SouthernDenmarkUniversityCollaborationAgreementMember_hx25QOLCQkWQWTGDz-WQUg", "decimals": "-5", "first": true, "lang": null, "name": "evax:CompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2020_kliRcRutmUqg6D4sEtTi0g", "decimals": "-3", "first": true, "lang": null, "name": "evax:DeferredOfferingCost", "reportCount": 1, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40203 - Disclosure - Summary of Significant Accounting Policies - Deferred Offering Costs (Details)", "role": "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDeferredOfferingCostsDetails", "shortName": "Summary of Significant Accounting Policies - Deferred Offering Costs (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R56": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "evax:RepaymentLoanTerm", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40204 - Disclosure - Summary of Significant Accounting Policies - Leasehold improvements and Loan from lessor (Details)", "role": "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeaseholdImprovementsAndLoanFromLessorDetails", "shortName": "Summary of Significant Accounting Policies - Leasehold improvements and Loan from lessor (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R57": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDepreciationAndAmortisationExpenseExplanatory", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember_zNP2xPM_Ck-gh_YTZ5dKGw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40205 - Disclosure - Summary of Significant Accounting Policies - Estimated useful lives of assets (Details)", "role": "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails", "shortName": "Summary of Significant Accounting Policies - Estimated useful lives of assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDepreciationAndAmortisationExpenseExplanatory", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_LeaseholdImprovementsMember_zNP2xPM_Ck-gh_YTZ5dKGw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R58": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "40206 - Disclosure - Summary of Significant Accounting Policies - Impairment of non-financial assets (Details)", "role": "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfNonFinancialAssetsDetails", "shortName": "Summary of Significant Accounting Policies - Impairment of non-financial assets (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R59": { "firstAnchor": { "ancestors": [ "ifrs-full:CashEquivalents", "p", "ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2021_yLFUq--_mk2hzZFKxTtdnA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CashEquivalents", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40207 - Disclosure - Summary of Significant Accounting Policies - Cash and cash equivalents (Details)", "role": "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails", "shortName": "Summary of Significant Accounting Policies - Cash and cash equivalents (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ifrs-full:CashEquivalents", "p", "ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2021_yLFUq--_mk2hzZFKxTtdnA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CashEquivalents", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "evax:GeneralCompanyInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - General Company Information", "role": "http://www.Evaxion.com/role/DisclosureGeneralCompanyInformation", "shortName": "General Company Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "evax:GeneralCompanyInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2018_To_12_31_2018_333avgk08ka0t0KGzEMnqg", "decimals": "INF", "first": true, "lang": null, "name": "evax:TypesOfConvertibleDebtInstrumentsIssued", "reportCount": 1, "unitRef": "Unit_Standard_instrument_iPnkdz7kdEO8pGg9vC8XGw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40208 - Disclosure - Summary of Significant Accounting Policies - Convertible debt instruments (Details)", "role": "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConvertibleDebtInstrumentsDetails", "shortName": "Summary of Significant Accounting Policies - Convertible debt instruments (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R61": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": "INF", "first": true, "lang": null, "name": "evax:NumberOfReportableSegments1", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_segment_UVyTC43Bw0Sn3xTB5cZTkQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40209 - Disclosure - Summary of Significant Accounting Policies - Segment (Details)", "role": "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentDetails", "shortName": "Summary of Significant Accounting Policies - Segment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": "INF", "first": true, "lang": null, "name": "evax:NumberOfReportableSegments1", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_segment_UVyTC43Bw0Sn3xTB5cZTkQ", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "evax:RetrospectiveEffectOfShareSplitAndBonusShareIssuanceTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_4_2021_To_1_4_2021_Ejfr87jawUK982V9iejV8w", "decimals": "0", "first": true, "lang": null, "name": "evax:StockSplitOnBonusIssueOfShares", "reportCount": 1, "unitRef": "Unit_Standard_pure_VXihgnh3Kk2QDRU39jja3A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40210 - Disclosure - Summary of Significant Accounting Policies - Loss Per Share (Details)", "role": "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLossPerShareDetails", "shortName": "Summary of Significant Accounting Policies - Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R63": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2021_yLFUq--_mk2hzZFKxTtdnA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - Financial Instruments and Risk Management - Liquidity risk (Details)", "role": "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementLiquidityRiskDetails", "shortName": "Financial Instruments and Risk Management - Liquidity risk (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R64": { "firstAnchor": { "ancestors": [ "p", "evax:GeneralCompanyInformationTextBlock", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2021_yLFUq--_mk2hzZFKxTtdnA", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:IssuedCapital", "reportCount": 1, "unitRef": "Unit_Standard_DKK_PbpTCVT5nkiDmWhigE_P0g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40502 - Disclosure - Financial Instruments and Risk Management - IPO (Details)", "role": "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementIpoDetails", "shortName": "Financial Instruments and Risk Management - IPO (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_11_9_2021_To_11_9_2021_ifrs-full_ClassesOfShareCapitalAxis_evax_AmericanDepositarySharesMember_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_evax_InitialPublicOfferingMember_e5ksG6B-7UCxuTsw-j_eDA", "decimals": "INF", "lang": null, "name": "ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_EyzmVIbeRk6F4XMicmIclw", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2021_yLFUq--_mk2hzZFKxTtdnA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:FinancialLiabilitiesAtAmortisedCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40503 - Disclosure - Financial Instruments and Risk Management - Contractual undiscounted outflows (Details)", "role": "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementContractualUndiscountedOutflowsDetails", "shortName": "Financial Instruments and Risk Management - Contractual undiscounted outflows (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2021_yLFUq--_mk2hzZFKxTtdnA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:FinancialLiabilitiesAtAmortisedCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40504 - Disclosure - Financial Instruments and Risk Management - Convertible debt instruments (Details)", "role": "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementConvertibleDebtInstrumentsDetails", "shortName": "Financial Instruments and Risk Management - Convertible debt instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees", "reportCount": 1, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - Operating Activities (Details)", "role": "http://www.Evaxion.com/role/DisclosureOperatingActivitiesDetails", "shortName": "Operating Activities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": "-5", "lang": null, "name": "ifrs-full:RevenueFromGovernmentGrants", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfAdditionalInformationExplanatory", "ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:AverageNumberOfEmployees", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - Employees and Employee-Related Costs - Number of employees (Details)", "role": "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsNumberOfEmployeesDetails", "shortName": "Employees and Employee-Related Costs - Number of employees (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfAdditionalInformationExplanatory", "ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:AverageNumberOfEmployees", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:WagesAndSalaries", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40702 - Disclosure - Employees and Employee-Related Costs - Employee Costs (Details)", "role": "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsEmployeeCostsDetails", "shortName": "Employees and Employee-Related Costs - Employee Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:WagesAndSalaries", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_10_1_2019_To_10_31_2019_79Iz3DQZaUeYP1ugU6NTnQ", "decimals": "INF", "first": true, "lang": null, "name": "evax:NumberOfMembersOfExecutiveManagement", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_employee_iv1QvrCrDESzxU8psZkO0A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40703 - Disclosure - Employees and Employee-Related Costs - Board of Directors and Executive Management (Details)", "role": "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsBoardOfDirectorsAndExecutiveManagementDetails", "shortName": "Employees and Employee-Related Costs - Board of Directors and Executive Management (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_10_1_2019_To_10_31_2019_79Iz3DQZaUeYP1ugU6NTnQ", "decimals": "INF", "first": true, "lang": null, "name": "evax:NumberOfMembersOfExecutiveManagement", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_employee_iv1QvrCrDESzxU8psZkO0A", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": "3", "first": true, "lang": null, "name": "evax:PercentageOfWarrantsToOutstandingShares", "reportCount": 1, "unitRef": "Unit_Standard_pure_VXihgnh3Kk2QDRU39jja3A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - Share-Based Payments - Warrants (Details)", "role": "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsDetails", "shortName": "Share-Based Payments - Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_jeDZ03hPJkuaC6GQXqz7Ww", "decimals": "3", "lang": null, "name": "evax:PercentageOfWarrantsToOutstandingShares", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_VXihgnh3Kk2QDRU39jja3A", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_DKK_shares_L3NWFdwt10ujDdW3RN0e1g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40802 - Disclosure - Share-Based Payments - Schedule of Warrants (Details)", "role": "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsScheduleOfWarrantsDetails", "shortName": "Share-Based Payments - Schedule of Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_DKK_shares_L3NWFdwt10ujDdW3RN0e1g", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "ifrs-full:NumberOfOutstandingShareOptions", "span", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2019_srt_TitleOfIndividualAxis_evax_EmployeesMember_flW5crsTBkOIFJUeIrhQBA", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfOutstandingShareOptions", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_VXihgnh3Kk2QDRU39jja3A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40803 - Disclosure - Share-Based Payments - Warrants Rectified (Details)", "role": "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsRectifiedDetails", "shortName": "Share-Based Payments - Warrants Rectified (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ifrs-full:NumberOfOutstandingShareOptions", "span", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2019_srt_TitleOfIndividualAxis_evax_EmployeesMember_flW5crsTBkOIFJUeIrhQBA", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfOutstandingShareOptions", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_VXihgnh3Kk2QDRU39jja3A", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees", "reportCount": 1, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40804 - Disclosure - Share-Based Payments - Compensation expense (Details)", "role": "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsCompensationExpenseDetails", "shortName": "Share-Based Payments - Compensation expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_evax_WarrantsMember_QDQDu8USFk2FRM_40Eb9Vw", "decimals": "-5", "lang": null, "name": "evax:ShareBasedCompensationExpenseForArrangingInvestorsToSubscribeForShares", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_12_1_2020_To_12_31_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_evax_IfrsWarrantMember_C9Nl20tzxEG76HBNdVQmRA", "decimals": "2", "first": true, "lang": null, "name": "evax:WeightageForPrivateScenarioSharePriceShareOptionsGranted", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_VXihgnh3Kk2QDRU39jja3A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40805 - Disclosure - Share-Based Payments - Fair value of warrants (Details)", "role": "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsFairValueOfWarrantsDetails", "shortName": "Share-Based Payments - Fair value of warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_12_1_2020_To_12_31_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_evax_IfrsWarrantMember_C9Nl20tzxEG76HBNdVQmRA", "decimals": "2", "first": true, "lang": null, "name": "evax:WeightageForPrivateScenarioSharePriceShareOptionsGranted", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_VXihgnh3Kk2QDRU39jja3A", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_evax_WarrantsMember_QDQDu8USFk2FRM_40Eb9Vw", "decimals": "1", "first": true, "lang": null, "name": "ifrs-full:DescriptionOfOptionLifeShareOptionsGranted", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_Y_BebnGvkArk-JDUm7665aGA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40806 - Disclosure - Share-Based Payments - Assumptions of Warrants (Details)", "role": "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsAssumptionsOfWarrantsDetails", "shortName": "Share-Based Payments - Assumptions of Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_evax_WarrantsMember_QDQDu8USFk2FRM_40Eb9Vw", "decimals": "1", "first": true, "lang": null, "name": "ifrs-full:DescriptionOfOptionLifeShareOptionsGranted", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_Y_BebnGvkArk-JDUm7665aGA", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_evax_IfrsWarrantMember_OrUtfAcUgkCiHmb58sj6iQ", "decimals": null, "first": true, "lang": "en-US", "name": "evax:ShareOptionsGrantedVestingPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40807 - Disclosure - Share-Based Payments - Amendments to Warrants (Details)", "role": "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsAmendmentsToWarrantsDetails", "shortName": "Share-Based Payments - Amendments to Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_evax_IfrsWarrantMember_OrUtfAcUgkCiHmb58sj6iQ", "decimals": null, "first": true, "lang": "en-US", "name": "evax:ShareOptionsGrantedVestingPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2021_yLFUq--_mk2hzZFKxTtdnA", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019", "reportCount": 1, "unitRef": "Unit_Divide_DKK_shares_L3NWFdwt10ujDdW3RN0e1g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40808 - Disclosure - Share-Based Payments - Outstanding warrants (Details)", "role": "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsOutstandingWarrantsDetails", "shortName": "Share-Based Payments - Outstanding warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "evax:ShareBasedCompensationAwardsOutstandingByGrantDateTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_evax_IfrsWarrantMember_OrUtfAcUgkCiHmb58sj6iQ", "decimals": "0", "lang": null, "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_DKK_shares_L3NWFdwt10ujDdW3RN0e1g", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "evax:ShareBasedCompensationAwardsOutstandingByGrantDateTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_evax_IfrsWarrantMember_jxlLoDdsMkWFGsfAjKzrqw", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfOutstandingShareOptions", "reportCount": 1, "unitRef": "Unit_Standard_pure_VXihgnh3Kk2QDRU39jja3A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40809 - Disclosure - Share-Based Payments - Key Management Holdings (Details)", "role": "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsKeyManagementHoldingsDetails", "shortName": "Share-Based Payments - Key Management Holdings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "evax:ShareBasedCompensationAwardsGrantedToKeyManagementPersonnelTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_11_25_2020_To_11_25_2020_ifrs-full_CategoriesOfRelatedPartiesAxis_srt_DirectorMember_VW0kX-O4f0Wnp5jPxJ4pIQ", "decimals": "INF", "lang": null, "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_VXihgnh3Kk2QDRU39jja3A", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFirstTimeAdoptionExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - First-Time Adoption of IFRS", "role": "http://www.Evaxion.com/role/DisclosureFirstTimeAdoptionOfIfrs", "shortName": "First-Time Adoption of IFRS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFirstTimeAdoptionExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "evax:FinancialIncomeAndExpenseTableTextBlock", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2019_To_12_31_2019_eQovIZT5G0Wz_OgpDcNYrQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:InterestIncomeOnCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - Financial Income and Expenses (Details)", "role": "http://www.Evaxion.com/role/DisclosureFinancialIncomeAndExpensesDetails", "shortName": "Financial Income and Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "evax:FinancialIncomeAndExpenseTableTextBlock", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2019_To_12_31_2019_eQovIZT5G0Wz_OgpDcNYrQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:InterestIncomeOnCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:IncomeTaxExpenseContinuingOperations", "reportCount": 1, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - Income Taxes - Analysis of charge(credit) (Details)", "role": "http://www.Evaxion.com/role/DisclosureIncomeTaxesAnalysisOfChargeCreditDetails", "shortName": "Income Taxes - Analysis of charge(credit) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2021_yLFUq--_mk2hzZFKxTtdnA", "decimals": "-5", "lang": null, "name": "ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "evax:IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": "2", "first": true, "lang": null, "name": "ifrs-full:ApplicableTaxRate", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_VXihgnh3Kk2QDRU39jja3A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41002 - Disclosure - Income Taxes - Reconciliation of effective tax rate (Details)", "role": "http://www.Evaxion.com/role/DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails", "shortName": "Income Taxes - Reconciliation of effective tax rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "evax:IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": "2", "first": true, "lang": null, "name": "ifrs-full:ApplicableTaxRate", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_VXihgnh3Kk2QDRU39jja3A", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2020_kliRcRutmUqg6D4sEtTi0g", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:DeferredTaxLiabilityAsset", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41003 - Disclosure - Income Taxes - Deferred tax (Details)", "role": "http://www.Evaxion.com/role/DisclosureIncomeTaxesDeferredTaxDetails", "shortName": "Income Taxes - Deferred tax (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2020_kliRcRutmUqg6D4sEtTi0g", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:DeferredTaxLiabilityAsset", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:EarningsPerShareExplanatory", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41101 - Disclosure - Basic and Diluted Loss Per Share (Details)", "role": "http://www.Evaxion.com/role/DisclosureBasicAndDilutedLossPerShareDetails", "shortName": "Basic and Diluted Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:EarningsPerShareExplanatory", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "evax:DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareTableTextBlock", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_evax_IfrsAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_evax_WarrantsMember_sPfAQETSNkGzjjJv0sFOUA", "decimals": "INF", "first": true, "lang": null, "name": "evax:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_EyzmVIbeRk6F4XMicmIclw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41102 - Disclosure - Basic and Diluted Loss Per Share - Anti-dilutive shares (Details)", "role": "http://www.Evaxion.com/role/DisclosureBasicAndDilutedLossPerShareAntiDilutiveSharesDetails", "shortName": "Basic and Diluted Loss Per Share - Anti-dilutive shares (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "evax:DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareTableTextBlock", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_evax_IfrsAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_evax_WarrantsMember_sPfAQETSNkGzjjJv0sFOUA", "decimals": "INF", "first": true, "lang": null, "name": "evax:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_EyzmVIbeRk6F4XMicmIclw", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2020_kliRcRutmUqg6D4sEtTi0g", "decimals": "0", "first": true, "lang": null, "name": "evax:AdditionalAccruedPaymentOnLicenseRelated", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41201 - Disclosure - Intangible assets - Paragraph (Details)", "role": "http://www.Evaxion.com/role/DisclosureIntangibleAssetsParagraphDetails", "shortName": "Intangible assets - Paragraph (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2020_kliRcRutmUqg6D4sEtTi0g", "decimals": "0", "first": true, "lang": null, "name": "evax:AdditionalAccruedPaymentOnLicenseRelated", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2020_kliRcRutmUqg6D4sEtTi0g", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41202 - Disclosure - Intangible assets - Table (Details)", "role": "http://www.Evaxion.com/role/DisclosureIntangibleAssetsTableDetails", "shortName": "Intangible assets - Table (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2020_To_12_31_2020_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_i1u-IEmx3kCumQucVTPj-Q", "decimals": "-3", "lang": null, "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2020_kliRcRutmUqg6D4sEtTi0g", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:PropertyPlantAndEquipment", "reportCount": 1, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41301 - Disclosure - Property, Plant and Equipment (Details)", "role": "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDetails", "shortName": "Property, Plant and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2021_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_OtherPropertyPlantAndEquipmentMember_2PEai1iY-064EWMiNDneIw", "decimals": "-3", "lang": null, "name": "ifrs-full:PropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2021_yLFUq--_mk2hzZFKxTtdnA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:PropertyPlantAndEquipment", "reportCount": 1, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41302 - Disclosure - Property, Plant and Equipment - Depreciation (Details)", "role": "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDepreciationDetails", "shortName": "Property, Plant and Equipment - Depreciation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_evax_OperatingExpensesMember_6A0MyGyNTUGXSHfdK4YrRA", "decimals": "-3", "lang": null, "name": "ifrs-full:DepreciationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Significant Accounting Judgements, Estimates, and Assumptions", "role": "http://www.Evaxion.com/role/DisclosureSignificantAccountingJudgementsEstimatesAndAssumptions", "shortName": "Significant Accounting Judgements, Estimates, and Assumptions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "evax:DisclosureOfReceivablesTableTextBlock", "evax:ReceivablesTextBlock", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2021_yLFUq--_mk2hzZFKxTtdnA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CurrentValueAddedTaxReceivables", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41401 - Disclosure - Prepayments and other receivables (Details)", "role": "http://www.Evaxion.com/role/DisclosurePrepaymentsAndOtherReceivablesDetails", "shortName": "Prepayments and other receivables (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "evax:DisclosureOfReceivablesTableTextBlock", "evax:ReceivablesTextBlock", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2021_yLFUq--_mk2hzZFKxTtdnA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CurrentValueAddedTaxReceivables", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "evax:DisclosureOfOtherPayablesTableTextBlock", "evax:OtherPayablesTextBlock", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2021_yLFUq--_mk2hzZFKxTtdnA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ShorttermEmployeeBenefitsAccruals", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41501 - Disclosure - Other Payables (Details)", "role": "http://www.Evaxion.com/role/DisclosureOtherPayablesDetails", "shortName": "Other Payables (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "evax:DisclosureOfOtherPayablesTableTextBlock", "evax:OtherPayablesTextBlock", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2021_yLFUq--_mk2hzZFKxTtdnA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ShorttermEmployeeBenefitsAccruals", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "evax:DisclosureOfCashAndCashEquivalentsTableTextBlock", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2021_yLFUq--_mk2hzZFKxTtdnA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:BalancesWithBanks", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41601 - Disclosure - Cash and Cash Equivalents (Details)", "role": "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsDetails", "shortName": "Cash and Cash Equivalents (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "evax:DisclosureOfCashAndCashEquivalentsTableTextBlock", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2021_yLFUq--_mk2hzZFKxTtdnA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:BalancesWithBanks", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "evax:DisclosureOfScheduleOfChangesInNetWorkingCapitalTableTextBlock", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41602 - Disclosure - Cash and Cash Equivalents - Changes in Net Working Capital (Details)", "role": "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsChangesInNetWorkingCapitalDetails", "shortName": "Cash and Cash Equivalents - Changes in Net Working Capital (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "evax:DisclosureOfScheduleOfChangesInNetWorkingCapitalTableTextBlock", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "evax:DisclosureOfAdjustmentsForNonCashItemsTableTextBlock", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:AdjustmentsForIncomeTaxExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41603 - Disclosure - Cash and Cash Equivalents - Adjustments for non-cash items (Details)", "role": "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsAdjustmentsForNonCashItemsDetails", "shortName": "Cash and Cash Equivalents - Adjustments for non-cash items (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "evax:DisclosureOfAdjustmentsForNonCashItemsTableTextBlock", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:AdjustmentsForIncomeTaxExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2020_kliRcRutmUqg6D4sEtTi0g", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities", "reportCount": 1, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41604 - Disclosure - Cash and Cash Equivalents - Reconciliation of Liabilities from Financing Activities (Details)", "role": "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsReconciliationOfLiabilitiesFromFinancingActivitiesDetails", "shortName": "Cash and Cash Equivalents - Reconciliation of Liabilities from Financing Activities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2019_Hxs2mtBNEkGv_dIdt23jvA", "decimals": "-3", "lang": null, "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" } }, "R96": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2021_yLFUq--_mk2hzZFKxTtdnA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:LeaseLiabilities", "reportCount": 1, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41701 - Disclosure - Leases (Details)", "role": "http://www.Evaxion.com/role/DisclosureLeasesDetails", "shortName": "Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_10_1_2020_To_10_31_2020_ifrs-full_TypesOfInterestRatesAxis_ifrs-full_FixedInterestRateMember_oS1S7hxtUk-Bz3Eb6Z9qsg", "decimals": "-5", "lang": null, "name": "evax:PaymentsforleaseliabilitiesAvailable", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" } }, "R97": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:CashOutflowForLeases", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41702 - Disclosure - Leases - Movements in Right-of-use Assets and Lease Liabilities (Details)", "role": "http://www.Evaxion.com/role/DisclosureLeasesMovementsInRightOfUseAssetsAndLeaseLiabilitiesDetails", "shortName": "Leases - Movements in Right-of-use Assets and Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_RFK0D7xw-kOO1vfWKrnwWQ", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:CashOutflowForLeases", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" } }, "R98": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2021_yLFUq--_mk2hzZFKxTtdnA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:FinancialLiabilitiesCarryingAmountImmediatelyAfterInitialApplicationOfIFRS9", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41703 - Disclosure - Leases - Summary of finance liability (Details)", "role": "http://www.Evaxion.com/role/DisclosureLeasesSummaryOfFinanceLiabilityDetails", "shortName": "Leases - Summary of finance liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "As_Of_12_31_2021_yLFUq--_mk2hzZFKxTtdnA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:FinancialLiabilitiesCarryingAmountImmediatelyAfterInitialApplicationOfIFRS9", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_uVbyuBRNoUmPwxs1C4R2pA", "xsiNil": "false" } }, "R99": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfBorrowingsExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_8_1_2020_To_8_31_2020_aVuQXOjjKkGrsrJ4WTFyJA", "decimals": "INF", "first": true, "lang": null, "name": "evax:CashSettledWarrant", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_EyzmVIbeRk6F4XMicmIclw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41801 - Disclosure - Debt (Details)", "role": "http://www.Evaxion.com/role/DisclosureDebtDetails", "shortName": "Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfBorrowingsExplanatory", "div", "div", "body", "html" ], "baseRef": "evax-20211231x20f.htm", "contextRef": "Duration_8_1_2020_To_8_31_2020_aVuQXOjjKkGrsrJ4WTFyJA", "decimals": "INF", "first": true, "lang": null, "name": "evax:CashSettledWarrant", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_EyzmVIbeRk6F4XMicmIclw", "xsiNil": "false" } } }, "segmentCount": 111, "tag": { "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "New York, United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesDetails" ], "xbrltype": "domainItemType" }, "currency_AllCurrenciesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "All Currencies [Domain]" } } }, "localname": "AllCurrenciesDomain", "nsuri": "http://xbrl.sec.gov/currency/2021", "presentation": [ "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsTermsOfConvertibleDebtDetails" ], "xbrltype": "domainItemType" }, "currency_DKK": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DKK" } } }, "localname": "DKK", "nsuri": "http://xbrl.sec.gov/currency/2021", "presentation": [ "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsTermsOfConvertibleDebtDetails" ], "xbrltype": "domainItemType" }, "currency_USD": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "USD" } } }, "localname": "USD", "nsuri": "http://xbrl.sec.gov/currency/2021", "presentation": [ "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsTermsOfConvertibleDebtDetails" ], "xbrltype": "domainItemType" }, "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.", "label": "Address Type [Domain]" } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r254", "r255", "r256" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r254", "r255", "r256" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r254", "r255", "r256" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_BusinessContactMember": { "auth_ref": [ "r255", "r256" ], "lang": { "en-us": { "role": { "documentation": "Business contact for the entity", "label": "Business contact" } } }, "localname": "BusinessContactMember", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_ContactPersonnelName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of contact personnel", "label": "Contact Personnel Name" } } }, "localname": "ContactPersonnelName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r254", "r255", "r256" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses, Address Type [Axis]" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.Evaxion.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "evax_AccountingJudgementsAndEstimatesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Significant Accounting Judgements, Estimates, and Assumptions" } } }, "localname": "AccountingJudgementsAndEstimatesAbstract", "nsuri": "http://www.Evaxion.com/20211231", "xbrltype": "stringItemType" }, "evax_AcquisitionOfPropertyAndEquipmentIncludedInTradePayables": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash acquisition of property and equipment included in trade payables.", "label": "Acquisition Of Property And Equipment Included In Trade Payables", "terseLabel": "Acquisition of property and equipment included in trade payables" } } }, "localname": "AcquisitionOfPropertyAndEquipmentIncludedInTradePayables", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "evax_AcquisitionOfPropertyPlantAndEquipment": { "auth_ref": [], "calculation": { "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsAdjustmentsForNonCashItemsDetails": { "order": 9.0, "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of acquisition of property, plant and equipment.", "label": "Acquisition Of Property Plant And Equipment", "terseLabel": "Acquisition of property, plant and equipment" } } }, "localname": "AcquisitionOfPropertyPlantAndEquipment", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsAdjustmentsForNonCashItemsDetails" ], "xbrltype": "monetaryItemType" }, "evax_AdditionalAccruedPaymentOnLicenseRelated": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Additional amount accrued related to license agreement.", "label": "Additional Accrued Payment on License related", "terseLabel": "Additional accrual related license agreement" } } }, "localname": "AdditionalAccruedPaymentOnLicenseRelated", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureIntangibleAssetsParagraphDetails" ], "xbrltype": "monetaryItemType" }, "evax_AdditionalLeaseLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of addition for lease liabilities during the period.", "label": "Additional Lease Liabilities", "terseLabel": "Additions" } } }, "localname": "AdditionalLeaseLiabilities", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesMovementsInRightOfUseAssetsAndLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "evax_AdditionalOptionToExtendAgreementTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The additional extension period of license agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Additional Option to Extend Agreement Term", "terseLabel": "Additional option to extend agreement term" } } }, "localname": "AdditionalOptionToExtendAgreementTerm", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureIntangibleAssetsParagraphDetails" ], "xbrltype": "durationItemType" }, "evax_AdjustmentsForTaxCreditSchemesAccountedForAsGrants": { "auth_ref": [], "calculation": { "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsAdjustmentsForNonCashItemsDetails": { "order": 4.0, "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for tax credit schemes accounted for as grants to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments For Tax credit schemes Accounted for as Grants", "terseLabel": "Tax credit schemes accounted for as grants" } } }, "localname": "AdjustmentsForTaxCreditSchemesAccountedForAsGrants", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsAdjustmentsForNonCashItemsDetails" ], "xbrltype": "monetaryItemType" }, "evax_AggregateAmountOnProceedsFromInitialPublicOffering": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount represents the aggregate amount on proceeds from initial public offering.", "label": "Aggregate Amount on Proceeds from Initial Public Offering", "verboseLabel": "Aggregate proceeds from IPO" } } }, "localname": "AggregateAmountOnProceedsFromInitialPublicOffering", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureGeneralCompanyInformationDetails" ], "xbrltype": "monetaryItemType" }, "evax_AllPropertyExceptForOtherEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents all property except for other equipment.", "label": "Property" } } }, "localname": "AllPropertyExceptForOtherEquipmentMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDepreciationDetails", "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "evax_AmericanDepositarySharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for American Depositary Shares.", "label": "ADS" } } }, "localname": "AmericanDepositarySharesMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersCapitalTransactionsDetails", "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementIpoDetails", "http://www.Evaxion.com/role/DisclosureGeneralCompanyInformationDetails" ], "xbrltype": "domainItemType" }, "evax_AndreasHolmMattssonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Andreas Holm Mattsson", "label": "Andreas Holm Mattsson" } } }, "localname": "AndreasHolmMattssonMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersShareholdingsByDirectorsAndExecutiveManagementDetails" ], "xbrltype": "domainItemType" }, "evax_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share Amount1", "terseLabel": "Anti-dilutive shares" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureBasicAndDilutedLossPerShareAntiDilutiveSharesDetails" ], "xbrltype": "sharesItemType" }, "evax_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems1LineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Line Items1 Line Items" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems1LineItems", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureBasicAndDilutedLossPerShareAntiDilutiveSharesDetails" ], "xbrltype": "stringItemType" }, "evax_AuditorSRemunerationForAuditRelatedServices": { "auth_ref": [], "calculation": { "http://www.Evaxion.com/role/DisclosureFeesToAuditorsDetails": { "order": 1.0, "parentTag": "ifrs-full_AuditorsRemuneration", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of fees paid or payable to the entity's auditors for auditing related services.", "label": "Auditor's remuneration for audit related services", "terseLabel": "Audit related fees" } } }, "localname": "AuditorSRemunerationForAuditRelatedServices", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureFeesToAuditorsDetails" ], "xbrltype": "monetaryItemType" }, "evax_BirgitteRnMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Birgitte Rn.", "label": "Birgitte Rn" } } }, "localname": "BirgitteRnMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsKeyManagementHoldingsDetails" ], "xbrltype": "domainItemType" }, "evax_BonusSharesRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the issue of bonus shares.", "label": "Bonus Shares, Ratio", "verboseLabel": "Bonus issue share ratio" } } }, "localname": "BonusSharesRatio", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsDetails" ], "xbrltype": "pureItemType" }, "evax_BorrowingInterestRates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rate of interest for Borrowings", "label": "Borrowing Interest Rates" } } }, "localname": "BorrowingInterestRates", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesDetails" ], "xbrltype": "pureItemType" }, "evax_BorrowingsConvertedToEquity": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents converted to equity in borrowings.", "label": "Borrowings Converted To Equity", "terseLabel": "Converted to equity" } } }, "localname": "BorrowingsConvertedToEquity", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsSummaryOfChangesInConvertibleDebtInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "evax_BorrowingsCurrencyAdjustment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents currency adjustment in borrowings.", "label": "Borrowings Currency Adjustment", "terseLabel": "Currency adjustment" } } }, "localname": "BorrowingsCurrencyAdjustment", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsSummaryOfChangesInConvertibleDebtInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "evax_BorrowingsFairValueAdjustmentIncludedInFinanceExpenses": { "auth_ref": [], "calculation": { "http://www.Evaxion.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "order": 1.0, "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents fair value adjustment included in finance expenses in borrowings.", "label": "Borrowings Fair Value Adjustment Included In Finance Expenses", "negatedTerseLabel": "Changes in fair value of convertible debt instruments", "terseLabel": "Fair value adjustment included in finance expenses" } } }, "localname": "BorrowingsFairValueAdjustmentIncludedInFinanceExpenses", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsSummaryOfChangesInConvertibleDebtInstrumentsDetails", "http://www.Evaxion.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "evax_CapitalIncreaseThresholdForLoanConversion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Capital increase threshold for loan conversion.", "label": "Capital Increase Threshold For Loan Conversion", "terseLabel": "Capital increase threshold for loan conversion" } } }, "localname": "CapitalIncreaseThresholdForLoanConversion", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsTermsOfConvertibleDebtDetails" ], "xbrltype": "monetaryItemType" }, "evax_CapitalizedIntangibleAssetsIncludedInTradePayables": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash capitalized intangible assets included in trade payables.", "label": "Capitalized Intangible Assets Included In Trade Payables", "terseLabel": "Capitalized intangible assets included in trade payables" } } }, "localname": "CapitalizedIntangibleAssetsIncludedInTradePayables", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "evax_CashBonus": { "auth_ref": [], "calculation": { "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsEmployeeCostsDetails": { "order": 6.0, "parentTag": "evax_EmployeeBenefitsAndShareBasedCompensations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense from cash bonus.", "label": "Cash Bonus", "terseLabel": "Cash bonus" } } }, "localname": "CashBonus", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsEmployeeCostsDetails" ], "xbrltype": "monetaryItemType" }, "evax_CashFlowsFromChangesInWorkingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Cash flows from changes in working capital [abstract]", "terseLabel": "Cash flow from changes in working capital:" } } }, "localname": "CashFlowsFromChangesInWorkingCapitalAbstract", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "evax_CashSettledWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash Settled Warrants.", "label": "Cash Settled Warrant", "terseLabel": "Cash settled warrants" } } }, "localname": "CashSettledWarrant", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureDebtDetails" ], "xbrltype": "sharesItemType" }, "evax_ChangesInProvisionTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of provision.", "label": "Changes In Provision Table Text Block", "terseLabel": "Schedule of change in provisions." } } }, "localname": "ChangesInProvisionTableTextBlock", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureProvisionsTables" ], "xbrltype": "textBlockItemType" }, "evax_CommitmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of commitment.", "label": "Commitments [Axis]" } } }, "localname": "CommitmentsAxis", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureContractualObligationsContractualCommitmentsDetails" ], "xbrltype": "stringItemType" }, "evax_CommitmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Future obligation.", "label": "Commitments [Domain]" } } }, "localname": "CommitmentsDomain", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureContractualObligationsContractualCommitmentsDetails" ], "xbrltype": "domainItemType" }, "evax_CompensationExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Compensation expense paid to joint operation", "label": "Compensation expense", "terseLabel": "Compensation cost" } } }, "localname": "CompensationExpense", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountingForJointOperationDetails" ], "xbrltype": "monetaryItemType" }, "evax_ContractResearchOrganizationsExpensesAndRelatedPrepaymentsAndAccruals": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract Research Organizations expenses and related prepayments and accruals", "label": "Contract Research Organizations expenses and related prepayments and accruals", "terseLabel": "Contract Research Organizations expenses and related prepayments and accruals" } } }, "localname": "ContractResearchOrganizationsExpensesAndRelatedPrepaymentsAndAccruals", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "evax_ContractResearchOrganizationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents third-party laboratories, medical centers, contract research organizations and other vendors.", "label": "CRO's" } } }, "localname": "ContractResearchOrganizationsMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureContractualObligationsContractualCommitmentsDetails" ], "xbrltype": "domainItemType" }, "evax_ContractualObligations.Table": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to contractual obligations.", "label": "Contractual Obligations. [Table]" } } }, "localname": "ContractualObligations.Table", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureContractualObligationsContractualCommitmentsDetails" ], "xbrltype": "stringItemType" }, "evax_ContractualObligationsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.", "label": "Contractual obligations [Line Items]", "terseLabel": "Contractual obligations" } } }, "localname": "ContractualObligationsLineItems", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureContractualObligationsContractualCommitmentsDetails" ], "xbrltype": "stringItemType" }, "evax_ConvertibleDebt1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Convertible Debt 1.", "label": "Convertible Debt 1" } } }, "localname": "ConvertibleDebt1Member", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersChangesInShareCapitalDetails", "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsTermsOfConvertibleDebtDetails" ], "xbrltype": "domainItemType" }, "evax_ConvertibleDebt2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Convertible Debt 2.", "label": "Convertible Debt 2" } } }, "localname": "ConvertibleDebt2Member", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersChangesInShareCapitalDetails", "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsTermsOfConvertibleDebtDetails" ], "xbrltype": "domainItemType" }, "evax_ConvertibleDebtsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents convertible debt instruments.", "label": "Convertible debt instruments" } } }, "localname": "ConvertibleDebtsMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsIssuanceDetails", "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsTables", "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsTermsOfConvertibleDebtDetails", "http://www.Evaxion.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "evax_CopenhagenDenmarkMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Copenhagen, Denmark.", "label": "Copenhagen, Denmark" } } }, "localname": "CopenhagenDenmarkMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesDetails" ], "xbrltype": "domainItemType" }, "evax_CorrelationBetweenConstructionCostsAndPaymentsToLessor": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The correlation between construction costs and payments to the lessor for leasehold improvements, which is used to show the economic risk of the work due.", "label": "Correlation between construction costs and payments to lessor" } } }, "localname": "CorrelationBetweenConstructionCostsAndPaymentsToLessor", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeaseholdImprovementsAndLoanFromLessorDetails" ], "xbrltype": "percentItemType" }, "evax_DebtInstrumentTerm1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument Term1", "terseLabel": "Term" } } }, "localname": "DebtInstrumentTerm1", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsTermsOfConvertibleDebtDetails" ], "xbrltype": "durationItemType" }, "evax_DeferredOfferingCost": { "auth_ref": [], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of deferred offering costs.", "label": "Deferred Offering Cost", "terseLabel": "Deferred offering costs" } } }, "localname": "DeferredOfferingCost", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDeferredOfferingCostsDetails", "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "evax_DeferredOfferingCostsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for the deferred offering costs.", "label": "Deferred Offering Costs [text block]", "terseLabel": "Deferred offering costs" } } }, "localname": "DeferredOfferingCostsTextBlock", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "evax_DeprecatedBasicAndDilutedEarningsLossPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic and diluted earnings (loss) per share", "verboseLabel": "Loss per share before and after dilution" } } }, "localname": "DeprecatedBasicAndDilutedEarningsLossPerShare", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureBasicAndDilutedLossPerShareDetails" ], "xbrltype": "perShareItemType" }, "evax_DisclosureExecutiveManagementsAndBoardOfDirectorsHoldingOfSharesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Executive Management's and Board of Director's holding of shares.", "label": "Disclosure Executive Management's And Board Of Director's Holding Of Shares [Table Text Block]", "terseLabel": "Schedule of Executive Management's and Board of Director's holding of shares" } } }, "localname": "DisclosureExecutiveManagementsAndBoardOfDirectorsHoldingOfSharesTableTextBlock", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersTables" ], "xbrltype": "textBlockItemType" }, "evax_DisclosureNumberOfWarrantAwardsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Disclosure Number of Warrant Awards [Abstract]", "terseLabel": "Number of warrants outstanding" } } }, "localname": "DisclosureNumberOfWarrantAwardsAbstract", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsScheduleOfWarrantsDetails" ], "xbrltype": "stringItemType" }, "evax_DisclosureOfAdjustmentsForNonCashItemsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of adjustments for non-cash items.", "label": "Disclosure Of Adjustments For Non-cash Items [Table Text Block]", "terseLabel": "Schedule of adjustments for non-cash items" } } }, "localname": "DisclosureOfAdjustmentsForNonCashItemsTableTextBlock", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsTables" ], "xbrltype": "textBlockItemType" }, "evax_DisclosureOfBorrowingExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Disclosure Of Borrowings Explanatory.", "label": "Disclosure Of Borrowing Explanatory", "terseLabel": "Convertible Debt Instruments" } } }, "localname": "DisclosureOfBorrowingExplanatory", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstruments" ], "xbrltype": "textBlockItemType" }, "evax_DisclosureOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of cash and cash equivalents.", "label": "Disclosure Of Cash And Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of cash and cash equivalents" } } }, "localname": "DisclosureOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsTables" ], "xbrltype": "textBlockItemType" }, "evax_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatoryTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed Information about intangible assets explanatory.", "label": "Disclosure Of Detailed Information About Intangible Assets Explanatory table" } } }, "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatoryTable", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureIntangibleAssetsTableDetails" ], "xbrltype": "stringItemType" }, "evax_DisclosureOfExpensesByNatureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of expenses by nature", "label": "Disclosure of expenses by nature [line items]", "terseLabel": "Share-Based Compensation" } } }, "localname": "DisclosureOfExpensesByNatureLineItems", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsEmployeeCostsDetails", "http://www.Evaxion.com/role/DisclosureOperatingActivitiesDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "evax_DisclosureOfExpensesByNatureTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information about expenses by nature.", "label": "Disclosure of expenses by nature [table]" } } }, "localname": "DisclosureOfExpensesByNatureTable", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsEmployeeCostsDetails", "http://www.Evaxion.com/role/DisclosureOperatingActivitiesDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "evax_DisclosureOfGeneralCompanyInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of General Company Information [line items]", "label": "Disclosure of General Company Information [line items]", "terseLabel": "General Company Information" } } }, "localname": "DisclosureOfGeneralCompanyInformationLineItems", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureGeneralCompanyInformationDetails" ], "xbrltype": "stringItemType" }, "evax_DisclosureOfGeneralCompanyInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of General Company Information [Table]", "label": "Disclosure of General Company Information [Table]" } } }, "localname": "DisclosureOfGeneralCompanyInformationTable", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureGeneralCompanyInformationDetails" ], "xbrltype": "stringItemType" }, "evax_DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of instruments (including contingently issuable shares) that could potentially dilute basic earnings per share in the future, but were not included in the calculation of diluted earnings per share because they are antidilutive for the period(s) presented.", "label": "Disclosure Of Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of potential shares are anti-dilutive and excluded from the weighted average number of shares" } } }, "localname": "DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareTableTextBlock", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureBasicAndDilutedLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "evax_DisclosureOfOtherPayablesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of other payables.", "label": "Disclosure Of Other Payables [Table Text Block]", "terseLabel": "Schedule of other payables" } } }, "localname": "DisclosureOfOtherPayablesTableTextBlock", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureOtherPayablesTables" ], "xbrltype": "textBlockItemType" }, "evax_DisclosureOfReceivablesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of receivables.", "label": "Disclosure Of Receivables [Table Text Block]", "verboseLabel": "Prepayments and other receivables" } } }, "localname": "DisclosureOfReceivablesTableTextBlock", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosurePrepaymentsAndOtherReceivablesTables" ], "xbrltype": "textBlockItemType" }, "evax_DisclosureOfScheduleOfChangesInNetWorkingCapitalTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of changes in net working capital.", "label": "Disclosure Of Schedule Of Changes In Net Working Capital [Table Text Block]", "terseLabel": "Schedule of changes in net working capital" } } }, "localname": "DisclosureOfScheduleOfChangesInNetWorkingCapitalTableTextBlock", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsTables" ], "xbrltype": "textBlockItemType" }, "evax_DisclosureRemainingContractualLifeWarrantAwardsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Disclosure Remaining Contractual Life Warrant Awards [Abstract]", "terseLabel": "Weighted Average Remaining Contractual Life (years)" } } }, "localname": "DisclosureRemainingContractualLifeWarrantAwardsAbstract", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsScheduleOfWarrantsDetails" ], "xbrltype": "stringItemType" }, "evax_DisclosureShareBasedCompensationGeneralDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Disclosure Share-Based Compensation General Disclosure [Abstract]", "terseLabel": "Other information" } } }, "localname": "DisclosureShareBasedCompensationGeneralDisclosureAbstract", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsScheduleOfWarrantsDetails" ], "xbrltype": "stringItemType" }, "evax_DisclosureWeightedAverageExercisePriceWarrantAwardsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Disclosure Weighted Average Exercise Price Warrant Awards [Abstract]", "terseLabel": "Weighted Average Exercise Price/Share (DKK)" } } }, "localname": "DisclosureWeightedAverageExercisePriceWarrantAwardsAbstract", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsScheduleOfWarrantsDetails" ], "xbrltype": "stringItemType" }, "evax_DiscountOnSharePriceToBeAppliedWhenCalculatingConversionPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Discount on share price to be applied when calculating conversion price.", "label": "Discount On Share Price To Be Applied When Calculating Conversion Price", "terseLabel": "Discount on share price to be applied when calculating conversion price" } } }, "localname": "DiscountOnSharePriceToBeAppliedWhenCalculatingConversionPrice", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsTermsOfConvertibleDebtDetails" ], "xbrltype": "percentItemType" }, "evax_DocumentAndEntityInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document and Entity Information" } } }, "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.Evaxion.com/20211231", "xbrltype": "stringItemType" }, "evax_EibLoanAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for EIB loan agreement.", "label": "EIB Loan Agreement" } } }, "localname": "EibLoanAgreementMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureDebtDetails", "http://www.Evaxion.com/role/DisclosureEventsAfterReportingPeriodDetails", "http://www.Evaxion.com/role/DisclosureGeneralCompanyInformationDetails" ], "xbrltype": "domainItemType" }, "evax_EmployeeBenefitsAndShareBasedCompensations": { "auth_ref": [], "calculation": { "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsEmployeeCostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total employee related costs, including share-based compensation expense.", "label": "Employee Benefits and Share-based Compensations", "totalLabel": "Total employee costs" } } }, "localname": "EmployeeBenefitsAndShareBasedCompensations", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsEmployeeCostsDetails" ], "xbrltype": "monetaryItemType" }, "evax_EmployeesAndConsultantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employees and consultants.", "label": "Employees and consultants" } } }, "localname": "EmployeesAndConsultantsMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsRectifiedDetails" ], "xbrltype": "domainItemType" }, "evax_EmployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employees.", "label": "Employees" } } }, "localname": "EmployeesMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsRectifiedDetails" ], "xbrltype": "domainItemType" }, "evax_ErikHeegaardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Erik Heegaard.", "label": "Erik Heegaard" } } }, "localname": "ErikHeegaardMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsKeyManagementHoldingsDetails" ], "xbrltype": "domainItemType" }, "evax_ExpensesAccruedInterestRelatedPartyTransactions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents transactions with related parties expenses relating to accrued interest.", "label": "Expenses Accrued Interest Related Party Transactions", "negatedLabel": "Accrued interest on convertible debt instruments issued to members of executive management and board of directors" } } }, "localname": "ExpensesAccruedInterestRelatedPartyTransactions", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "evax_ExpensesByFunctionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Expenses by function [abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "ExpensesByFunctionAbstract", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "evax_ExpensesByFunctionAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total of all expenses by function.", "label": "Expenses by function [axis]" } } }, "localname": "ExpensesByFunctionAxis", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsBoardOfDirectorsAndExecutiveManagementDetails", "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsEmployeeCostsDetails", "http://www.Evaxion.com/role/DisclosureOperatingActivitiesDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "evax_ExpensesByFunctionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expenses by function.", "label": "Expenses by function [member]" } } }, "localname": "ExpensesByFunctionMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsBoardOfDirectorsAndExecutiveManagementDetails", "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsEmployeeCostsDetails", "http://www.Evaxion.com/role/DisclosureOperatingActivitiesDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "evax_FinanceExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Finance expense [abstract]", "terseLabel": "Finance expenses:" } } }, "localname": "FinanceExpenseAbstract", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "xbrltype": "stringItemType" }, "evax_FinanceIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Finance income [abstract]", "terseLabel": "Finance income:" } } }, "localname": "FinanceIncomeAbstract", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "xbrltype": "stringItemType" }, "evax_FinanceIncomeCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Financial Income and Expenses" } } }, "localname": "FinanceIncomeCostAbstract", "nsuri": "http://www.Evaxion.com/20211231", "xbrltype": "stringItemType" }, "evax_FinancialIncomeAndExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of components of finance income and finance cost.", "label": "Financial income and expense [table text block]", "terseLabel": "Schedule of financial income and expenses" } } }, "localname": "FinancialIncomeAndExpenseTableTextBlock", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialIncomeAndExpensesTables" ], "xbrltype": "textBlockItemType" }, "evax_FollowOnPublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for follow-on public offering.", "label": "Follow-on public offering" } } }, "localname": "FollowOnPublicOfferingMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersCapitalTransactionsDetails", "http://www.Evaxion.com/role/DisclosureGeneralCompanyInformationDetails" ], "xbrltype": "domainItemType" }, "evax_GeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpensesMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsBoardOfDirectorsAndExecutiveManagementDetails", "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsEmployeeCostsDetails", "http://www.Evaxion.com/role/DisclosureOperatingActivitiesDetails", "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDepreciationDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "evax_GeneralCompanyInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "General Company Information" } } }, "localname": "GeneralCompanyInformationAbstract", "nsuri": "http://www.Evaxion.com/20211231", "xbrltype": "stringItemType" }, "evax_GeneralCompanyInformationTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of general company information.", "label": "General Company Information [Text Block]", "terseLabel": "General Company Information" } } }, "localname": "GeneralCompanyInformationTextBlock", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureGeneralCompanyInformation" ], "xbrltype": "textBlockItemType" }, "evax_GlennS.VraniakMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Glenn S. Vraniak.", "label": "Glenn S. Vraniak" } } }, "localname": "GlennS.VraniakMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsKeyManagementHoldingsDetails" ], "xbrltype": "domainItemType" }, "evax_GovernmentGrantsReceivableCurrent": { "auth_ref": [], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of government grants receivable current.", "label": "Government Grants Receivable Current", "terseLabel": "Government grants receivable" } } }, "localname": "GovernmentGrantsReceivableCurrent", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "evax_GovernmentGrantsReceivablesNoncurrent": { "auth_ref": [], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 4.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of non-current government grants receivables.", "label": "Government Grants Receivables, NonCurrent", "terseLabel": "Government grants receivable" } } }, "localname": "GovernmentGrantsReceivablesNoncurrent", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "evax_GrantApril2017Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Award granted April 2017.", "label": "Grant April 2017" } } }, "localname": "GrantApril2017Member", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsOutstandingWarrantsDetails" ], "xbrltype": "domainItemType" }, "evax_GrantApril2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Award granted April 2021.", "label": "Grant April 2021" } } }, "localname": "GrantApril2021Member", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsOutstandingWarrantsDetails" ], "xbrltype": "domainItemType" }, "evax_GrantDecember2016Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Award granted December 2016.", "label": "Grant December 2016" } } }, "localname": "GrantDecember2016Member", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsOutstandingWarrantsDetails" ], "xbrltype": "domainItemType" }, "evax_GrantDecember2017Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Award granted December 2017.", "label": "Grant December 2017" } } }, "localname": "GrantDecember2017Member", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsOutstandingWarrantsDetails" ], "xbrltype": "domainItemType" }, "evax_GrantDecember2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Award granted December 2020.", "label": "Grant December 2020" } } }, "localname": "GrantDecember2020Member", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsOutstandingWarrantsDetails" ], "xbrltype": "domainItemType" }, "evax_GrantDecember2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Award granted December 2021.", "label": "Grant December 2021" } } }, "localname": "GrantDecember2021Member", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsOutstandingWarrantsDetails" ], "xbrltype": "domainItemType" }, "evax_GrantFebruary2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Award granted February 2019.", "label": "Grant February 2019" } } }, "localname": "GrantFebruary2019Member", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsOutstandingWarrantsDetails" ], "xbrltype": "domainItemType" }, "evax_GrantJanuary2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Award granted January 2019.", "label": "Grant January 2019" } } }, "localname": "GrantJanuary2019Member", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsOutstandingWarrantsDetails" ], "xbrltype": "domainItemType" }, "evax_GrantJune2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Award granted June 2021.", "label": "Grant June 2021" } } }, "localname": "GrantJune2021Member", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsOutstandingWarrantsDetails" ], "xbrltype": "domainItemType" }, "evax_GrantOctober2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Award granted October 2019.", "label": "Grant October 2019" } } }, "localname": "GrantOctober2019Member", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsOutstandingWarrantsDetails" ], "xbrltype": "domainItemType" }, "evax_GrantSeptember2017Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Award granted September 2017.", "label": "Grant September 2017" } } }, "localname": "GrantSeptember2017Member", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsOutstandingWarrantsDetails" ], "xbrltype": "domainItemType" }, "evax_GrantSeptember2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Award granted September 2019.", "label": "Grant September 2019" } } }, "localname": "GrantSeptember2019Member", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsOutstandingWarrantsDetails" ], "xbrltype": "domainItemType" }, "evax_GrantedDuring2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Award granted during 2018.", "label": "Granted during 2018" } } }, "localname": "GrantedDuring2018Member", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsOutstandingWarrantsDetails" ], "xbrltype": "domainItemType" }, "evax_HelenBoudreauMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Helen Boudreau.", "label": "Helen Boudreau" } } }, "localname": "HelenBoudreauMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsKeyManagementHoldingsDetails" ], "xbrltype": "domainItemType" }, "evax_HrsholmDenmarkMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Hrsholm, Denmark.", "label": "Hrsholm, Denmark" } } }, "localname": "HrsholmDenmarkMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesDetails" ], "xbrltype": "domainItemType" }, "evax_Ifrs16Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents IFRS 16.", "label": "IFRS 16" } } }, "localname": "Ifrs16Member", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesDetails" ], "xbrltype": "domainItemType" }, "evax_IfrsAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Ifrs Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]" } } }, "localname": "IfrsAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureBasicAndDilutedLossPerShareAntiDilutiveSharesDetails" ], "xbrltype": "stringItemType" }, "evax_IfrsAntidilutiveSecuritiesNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Ifrs Antidilutive Securities, Name [Domain]" } } }, "localname": "IfrsAntidilutiveSecuritiesNameDomain", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureBasicAndDilutedLossPerShareAntiDilutiveSharesDetails" ], "xbrltype": "domainItemType" }, "evax_IfrsAwardDateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Ifrs Award Date [Axis]" } } }, "localname": "IfrsAwardDateAxis", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsOutstandingWarrantsDetails" ], "xbrltype": "stringItemType" }, "evax_IfrsAwardDateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted.", "label": "Ifrs Award Date [Domain]" } } }, "localname": "IfrsAwardDateDomain", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsOutstandingWarrantsDetails" ], "xbrltype": "domainItemType" }, "evax_IfrsDebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Ifrs Debt Instrument, Term", "terseLabel": "Payment period", "verboseLabel": "Debt instrument term" } } }, "localname": "IfrsDebtInstrumentTerm", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureDebtDetails", "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails" ], "xbrltype": "durationItemType" }, "evax_IfrsEmergingGrowthCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Emerging Growth Company.", "label": "Emerging Growth Company" } } }, "localname": "IfrsEmergingGrowthCompanyMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureGeneralCompanyInformationDetails" ], "xbrltype": "domainItemType" }, "evax_IfrsFinancialIncomeAndExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of components of finance income and finance cost.", "label": "Ifrs Financial Income And Expense [table text block]", "terseLabel": "Schedule of tax expense" } } }, "localname": "IfrsFinancialIncomeAndExpenseTableTextBlock", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "evax_IfrsGrossCarryingAmountMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "It represents information pertaining to gross carrying amount.", "label": "Gross" } } }, "localname": "IfrsGrossCarryingAmountMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureIncomeTaxesDeferredTaxDetails" ], "xbrltype": "domainItemType" }, "evax_IfrsIncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Income Taxes" } } }, "localname": "IfrsIncomeTaxDisclosureAbstract", "nsuri": "http://www.Evaxion.com/20211231", "xbrltype": "stringItemType" }, "evax_IfrsIpoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The member represents first sale of stock by a private company to the public.", "label": "IPO" } } }, "localname": "IfrsIpoMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersCapitalTransactionsDetails", "http://www.Evaxion.com/role/DisclosureGeneralCompanyInformationDetails" ], "xbrltype": "domainItemType" }, "evax_IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage amounts of the reported amount of income tax expense to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Ifrs Schedule Of Effective Income Tax Rate Reconciliation [Table Text Block]", "verboseLabel": "Schedule of reconciliation of effective tax rate" } } }, "localname": "IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "evax_IfrsShareBasedPaymentArrangementAcceleratedCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.", "label": "Ifrs Share-based Payment Arrangement, Accelerated Cost", "terseLabel": "Acceleration of expense" } } }, "localname": "IfrsShareBasedPaymentArrangementAcceleratedCost", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsFairValueOfWarrantsDetails" ], "xbrltype": "monetaryItemType" }, "evax_IfrsSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "IFRS Share Price", "terseLabel": "Share price" } } }, "localname": "IfrsSharePrice", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsAssumptionsOfWarrantsDetails" ], "xbrltype": "perShareItemType" }, "evax_IfrsSubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity stock.", "label": "IFRS Subsidiary Sale of Stock Axis" } } }, "localname": "IfrsSubsidiarySaleOfStockAxis", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersCapitalTransactionsDetails", "http://www.Evaxion.com/role/DisclosureGeneralCompanyInformationDetails" ], "xbrltype": "stringItemType" }, "evax_IfrsWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant to purchase shares at a specified price.", "label": "Warrants" } } }, "localname": "IfrsWarrantMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureIncomeTaxesDeferredTaxDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsAmendmentsToWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsFairValueOfWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsKeyManagementHoldingsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsOutstandingWarrantsDetails" ], "xbrltype": "domainItemType" }, "evax_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in shares resulting from the conversion of convertible instruments.", "label": "Increase (Decrease) Through Conversion Of Convertible Instruments Shares", "terseLabel": "Settlement of convertible debt instruments, shares" } } }, "localname": "IncreaseDecreaseThroughConversionOfConvertibleInstrumentsShares", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersChangesInShareCapitalDetails" ], "xbrltype": "sharesItemType" }, "evax_IncreaseInCapitalForInitialPublicOffering": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The amount of increase in capital for initial public offering.", "label": "Increase in Capital for Initial Public Offering", "terseLabel": "Capital increase at February 9, 2021 for initial public offering, shares", "verboseLabel": "Capital increase from offering (in shares)" } } }, "localname": "IncreaseInCapitalForInitialPublicOffering", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersCapitalTransactionsDetails", "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersChangesInShareCapitalDetails" ], "xbrltype": "sharesItemType" }, "evax_IncreaseInNumberOfWarrantsRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rati f increase in number f warrants.", "label": "Increase In Number Of Warrants, Ratio", "terseLabel": "Increase in number of warrants, ratio" } } }, "localname": "IncreaseInNumberOfWarrantsRatio", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsDetails" ], "xbrltype": "pureItemType" }, "evax_IncreaseInSharesThroughIssuanceOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The increase in shares resulting from the issuance of shares.", "label": "Increase In Shares Through Issuance Of Shares", "terseLabel": "Issuance of shares for cash, shares" } } }, "localname": "IncreaseInSharesThroughIssuanceOfShares", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersChangesInShareCapitalDetails" ], "xbrltype": "sharesItemType" }, "evax_IncreaseThroughAccumulatedInterestLiabilitiesArisingFromFinancingActivities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase in liabilities arising from financing activities resulting from new leases.", "label": "Increase Through Accumulated Interest Liabilities Arising From Financing Activities", "terseLabel": "Accumulated interest" } } }, "localname": "IncreaseThroughAccumulatedInterestLiabilitiesArisingFromFinancingActivities", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsReconciliationOfLiabilitiesFromFinancingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "evax_InitialPublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for initial public offering of the entity's shares of stocks.", "label": "Initial Public Offering" } } }, "localname": "InitialPublicOfferingMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersChangesInShareCapitalDetails", "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementIpoDetails" ], "xbrltype": "domainItemType" }, "evax_InitialPublicOfferingScenarioSharePriceShareOptionsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The share price to go public in initial public offering scenario assumed in calculating fair value.", "label": "Initial Public Offering Scenario, Share Price, Share Options Granted", "terseLabel": "Share price for IPO scenario (USD per share)" } } }, "localname": "InitialPublicOfferingScenarioSharePriceShareOptionsGranted", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsFairValueOfWarrantsDetails" ], "xbrltype": "perShareItemType" }, "evax_IntangibleAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible assets Description", "label": "Intangible assets Text Block", "terseLabel": "Intangible assets" } } }, "localname": "IntangibleAssetsTextBlock", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "evax_IssuanceOfAdditionalOrdinaryShareWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The additional number of additional ordinary share warrants authorized for issuance.", "label": "Issuance OF Additional Ordinary Share warrants", "verboseLabel": "Additional number of ordinary share warrants allowed to issue" } } }, "localname": "IssuanceOfAdditionalOrdinaryShareWarrants", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersCapitalTransactionsDetails" ], "xbrltype": "sharesItemType" }, "evax_JoannSuzichMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Joann Suzich.", "label": "Joann Suzich" } } }, "localname": "JoannSuzichMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsKeyManagementHoldingsDetails" ], "xbrltype": "domainItemType" }, "evax_KimBjornstrupMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Kim Bjrnstrup (former).", "label": "Kim Bjrnstrup (former" } } }, "localname": "KimBjornstrupMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsKeyManagementHoldingsDetails" ], "xbrltype": "domainItemType" }, "evax_LaboratorySpaceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for laboratory space.", "label": "Laboratory space" } } }, "localname": "LaboratorySpaceMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesDetails" ], "xbrltype": "domainItemType" }, "evax_LackOfMarketabilityDiscountShareOptionsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The lack of marketability discount of warrants granted.", "label": "Lack Of Marketability Discount, Share Options Granted", "terseLabel": "Lack of marketability discount" } } }, "localname": "LackOfMarketabilityDiscountShareOptionsGranted", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsFairValueOfWarrantsDetails" ], "xbrltype": "percentItemType" }, "evax_LarsAageStaalWegnerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lars Aage Staal Wegner.", "label": "Lars Aage Staal Wegner" } } }, "localname": "LarsAageStaalWegnerMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersShareholdingsByDirectorsAndExecutiveManagementDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsKeyManagementHoldingsDetails" ], "xbrltype": "domainItemType" }, "evax_LarsHoltugMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Lars Holtug (Member).", "label": "Lars Holtug" } } }, "localname": "LarsHoltugMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsKeyManagementHoldingsDetails" ], "xbrltype": "domainItemType" }, "evax_LeaseLiabilitiesIncreaseDecreaseFromTranslation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in the translation that relates to lease liabilities.", "label": "Lease Liabilities Increase (Decrease) From Translation", "terseLabel": "Translation" } } }, "localname": "LeaseLiabilitiesIncreaseDecreaseFromTranslation", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesMovementsInRightOfUseAssetsAndLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "evax_LeaseMonthlyPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of lease payment.", "label": "Lease Monthly Payment", "terseLabel": "Lease monthly payment" } } }, "localname": "LeaseMonthlyPayment", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "evax_LeaseSpace": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area space for leases.", "label": "Lease Space", "terseLabel": "Lease space" } } }, "localname": "LeaseSpace", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesDetails" ], "xbrltype": "areaItemType" }, "evax_LeaseTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term of lease.", "label": "Lease Term", "terseLabel": "Lease term" } } }, "localname": "LeaseTerm", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesDetails" ], "xbrltype": "durationItemType" }, "evax_LeaseTerminationFee": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of lease termination fee.", "label": "Lease termination Fee", "terseLabel": "Lease termination fee" } } }, "localname": "LeaseTerminationFee", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "evax_LicenseAgreementMilestonePaymentAdditionalPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The maximum amount of additional consideration payable subject to meeting certain development milestones in license agreement.", "label": "License Agreement Milestone Payment, Additional Payment", "terseLabel": "Additional consideration" } } }, "localname": "LicenseAgreementMilestonePaymentAdditionalPayment", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureIntangibleAssetsParagraphDetails" ], "xbrltype": "monetaryItemType" }, "evax_LicenseAgreementOnMilestonePayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of milestone payment upon execution of license agreement.", "label": "License Agreement on Milestone Payment", "terseLabel": "License agreement on milestone payment" } } }, "localname": "LicenseAgreementOnMilestonePayment", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureIntangibleAssetsParagraphDetails" ], "xbrltype": "monetaryItemType" }, "evax_LicenseAgreementPaymentApprovalOfProduct": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of consideration payable upon each regulatory approval of a product utilizing the in-licensed technology.", "label": "License Agreement Payment, Approval of Product", "terseLabel": "Amount to be transferred upon each regulatory approval of a product" } } }, "localname": "LicenseAgreementPaymentApprovalOfProduct", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureIntangibleAssetsParagraphDetails" ], "xbrltype": "monetaryItemType" }, "evax_LoanAgreementNumberOfTranches": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of tranches of the releases of the total loan principal amount per agreement.", "label": "Loan Agreement, Number of Tranches", "terseLabel": "Number of tranches" } } }, "localname": "LoanAgreementNumberOfTranches", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureDebtDetails" ], "xbrltype": "integerItemType" }, "evax_LoanFromLessorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for loan from lessor.", "label": "Loan From Lessor" } } }, "localname": "LoanFromLessorMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsReconciliationOfLiabilitiesFromFinancingActivitiesDetails", "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementContractualUndiscountedOutflowsDetails" ], "xbrltype": "domainItemType" }, "evax_MandatoryConversionPriceAtMaturity": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mandatory conversion price at maturity.", "label": "Mandatory Conversion Price At Maturity", "terseLabel": "Mandatory conversion price at maturity" } } }, "localname": "MandatoryConversionPriceAtMaturity", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsTermsOfConvertibleDebtDetails" ], "xbrltype": "perShareItemType" }, "evax_MarianneSogaardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Marianne Sgaard.", "label": "Marianne Sgaard" } } }, "localname": "MarianneSogaardMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersShareholdingsByDirectorsAndExecutiveManagementDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsKeyManagementHoldingsDetails" ], "xbrltype": "domainItemType" }, "evax_MinimumPercentageOfLostSubscribedShareCapital": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum percentage of lost subscribed share capital", "label": "Minimum Percentage Of Lost Subscribed Share Capital", "terseLabel": "Minimum percentage of lost subscribed share capital" } } }, "localname": "MinimumPercentageOfLostSubscribedShareCapital", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersLossOfSubscribedShareCapitalDetails" ], "xbrltype": "percentItemType" }, "evax_NielsIversenMllerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Niels Iversen Mller", "label": "Niels Iversen Mller" } } }, "localname": "NielsIversenMllerMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersShareholdingsByDirectorsAndExecutiveManagementDetails" ], "xbrltype": "domainItemType" }, "evax_NonCashInvestingAndFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Non-Cash Investing And Financing Activities [Abstract]", "terseLabel": "Non-cash investing and financing activities" } } }, "localname": "NonCashInvestingAndFinancingActivitiesAbstract", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "evax_NonManagementEmployeeBenefitsExpenseIncludingShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-management employee related costs, including share-based compensation expense.", "label": "Non management employee benefits expense including share-based compensation", "terseLabel": "Non-management employee benefit expense" } } }, "localname": "NonManagementEmployeeBenefitsExpenseIncludingShareBasedCompensation", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsEmployeeCostsDetails" ], "xbrltype": "monetaryItemType" }, "evax_NumberExecutiveManagementMemberResigned": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of members of executive management who resigned during the period.", "label": "Number Executive Management Member Resigned", "terseLabel": "Executive management which resigned" } } }, "localname": "NumberExecutiveManagementMemberResigned", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsBoardOfDirectorsAndExecutiveManagementDetails" ], "xbrltype": "integerItemType" }, "evax_NumberOfEmployeesAndConsultants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of employees and consultants.", "label": "Number of employees and consultants", "terseLabel": "Number of employees, including consultants, by country at end of period:" } } }, "localname": "NumberOfEmployeesAndConsultants", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsNumberOfEmployeesDetails" ], "xbrltype": "decimalItemType" }, "evax_NumberOfLeases": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents number of leases.", "label": "Number Of Leases", "terseLabel": "Number of leases" } } }, "localname": "NumberOfLeases", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesDetails" ], "xbrltype": "integerItemType" }, "evax_NumberOfMembersOfExecutiveManagement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of members of the executive management.", "label": "Number of Members Of Executive Management", "terseLabel": "Number of members of executive management" } } }, "localname": "NumberOfMembersOfExecutiveManagement", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsBoardOfDirectorsAndExecutiveManagementDetails" ], "xbrltype": "integerItemType" }, "evax_NumberOfReportableSegments1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity.", "label": "Number Of Reportable Segments1", "terseLabel": "Number of operating business segments" } } }, "localname": "NumberOfReportableSegments1", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSegmentDetails" ], "xbrltype": "integerItemType" }, "evax_NumberOfShareOptionsHeld": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of share options held.", "label": "Number OF Share Options Held", "terseLabel": "Warrants held when becoming a member of management" } } }, "localname": "NumberOfShareOptionsHeld", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsKeyManagementHoldingsDetails" ], "xbrltype": "sharesItemType" }, "evax_NumberOfSharesAuthorisedAdditionalIncrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The additional increase in number of shares authorized.", "label": "Number of Shares Authorised Additional Increase", "terseLabel": "Additional increase in authorized number of shares" } } }, "localname": "NumberOfSharesAuthorisedAdditionalIncrease", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersCapitalTransactionsDetails" ], "xbrltype": "sharesItemType" }, "evax_NumberOfSharesAuthorisedIncrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The increase in number of shares authorized.", "label": "Number of Shares Authorised Increase", "terseLabel": "Increase in authorized number of shares" } } }, "localname": "NumberOfSharesAuthorisedIncrease", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersCapitalTransactionsDetails" ], "xbrltype": "sharesItemType" }, "evax_OfficeSpaceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for office space.", "label": "Office space" } } }, "localname": "OfficeSpaceMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesDetails" ], "xbrltype": "domainItemType" }, "evax_OperatingExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing operating expense.", "label": "Operating Expense" } } }, "localname": "OperatingExpensesMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDepreciationDetails" ], "xbrltype": "domainItemType" }, "evax_OperatingLeaseInterestExpenseExcludingVariableLeaseCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The interest expense for operating leases, excluding expenses related to variable lease payments.", "label": "Operating Lease, Interest Expense, Excluding Variable Lease Costs", "terseLabel": "Interest expense" } } }, "localname": "OperatingLeaseInterestExpenseExcludingVariableLeaseCosts", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesMovementsInRightOfUseAssetsAndLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "evax_OtherPayablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Other Payables" } } }, "localname": "OtherPayablesAbstract", "nsuri": "http://www.Evaxion.com/20211231", "xbrltype": "stringItemType" }, "evax_OtherPayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other payables.", "label": "Other payables" } } }, "localname": "OtherPayablesMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementContractualUndiscountedOutflowsDetails" ], "xbrltype": "domainItemType" }, "evax_OtherPayablesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of other payables.", "label": "Other Payables [Text Block]", "terseLabel": "Other Payables" } } }, "localname": "OtherPayablesTextBlock", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureOtherPayables" ], "xbrltype": "textBlockItemType" }, "evax_ParValuePerSharePriorToStockSplit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The nominal value per share prior to stock split.", "label": "Par Value Per Share, Prior to Stock Split", "terseLabel": "Nominal value per share prior to stock split" } } }, "localname": "ParValuePerSharePriorToStockSplit", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsDetails" ], "xbrltype": "perShareItemType" }, "evax_PaymentsForLeaseLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of payment for lease liabilities during the period.", "label": "Payments for Lease Liabilities", "negatedLabel": "Payments" } } }, "localname": "PaymentsForLeaseLiabilities", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesMovementsInRightOfUseAssetsAndLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "evax_PaymentsforleaseliabilitiesAvailable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For Lease Liabilities (available)", "label": "Payments For Lease Liabilities (available)", "terseLabel": "Repayment of lease liability" } } }, "localname": "PaymentsforleaseliabilitiesAvailable", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "evax_PercentageOfIncreaseInAnnualLeasePayment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of increase in annual lease payment.", "label": "Percentage OF Increase In Annual Lease Payment", "terseLabel": "Percentage of increase in annual lease payment" } } }, "localname": "PercentageOfIncreaseInAnnualLeasePayment", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesDetails" ], "xbrltype": "percentItemType" }, "evax_PercentageOfWarrantsToOutstandingShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of warrants outstanding expressed as a percentage of the total outstanding shares.", "label": "Percentage of warrants to outstanding shares", "terseLabel": "Warrants as a percentage of outstanding shares" } } }, "localname": "PercentageOfWarrantsToOutstandingShares", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsDetails" ], "xbrltype": "percentItemType" }, "evax_PeriodBeforeConversionDuringWhichLoansDenominatedInForeignCurrencyWillConvertIntoFunctionalCurrencyLoan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period before conversion during which loans denominated in foreign currency will convert into functional currency loan", "label": "Period Before Conversion During Which Loans Denominated In Foreign Currency Will Convert Into Functional Currency Loan", "terseLabel": "Period before conversion during which loans denominated in foreign currency will convert into functional currency loan" } } }, "localname": "PeriodBeforeConversionDuringWhichLoansDenominatedInForeignCurrencyWillConvertIntoFunctionalCurrencyLoan", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsTermsOfConvertibleDebtDetails" ], "xbrltype": "durationItemType" }, "evax_PremiumToBeAppliedInPrepaymentTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Premium to be applied in prepayment terms.", "label": "Premium To Be Applied In Prepayment Terms", "terseLabel": "Premium to be applied in prepayment terms" } } }, "localname": "PremiumToBeAppliedInPrepaymentTerms", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsTermsOfConvertibleDebtDetails" ], "xbrltype": "percentItemType" }, "evax_PrivateScenarioSharePriceShareOptionsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The share price to the stay private scenario assumed in calculating fair value.", "label": "Private Scenario, Share Price, Share Options Granted", "terseLabel": "Share price for private scenarioe (USD per share)" } } }, "localname": "PrivateScenarioSharePriceShareOptionsGranted", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsFairValueOfWarrantsDetails" ], "xbrltype": "perShareItemType" }, "evax_ProvisionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represent the information about provisions.", "label": "Provision" } } }, "localname": "ProvisionMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsReconciliationOfLiabilitiesFromFinancingActivitiesDetails", "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementContractualUndiscountedOutflowsDetails" ], "xbrltype": "domainItemType" }, "evax_ProvisionRecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Provision recognized.", "label": "Provision Recognized" } } }, "localname": "ProvisionRecognized", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "evax_PurchaseObligationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents purchase obligations", "label": "Purchase obligations" } } }, "localname": "PurchaseObligationsMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureContractualObligationsContractualCommitmentsDetails" ], "xbrltype": "domainItemType" }, "evax_QualifiedCapitalIncreaseOccursInTwoYearsFollowingLoanIssuanceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Qualified capital increase occurs in two years following the loan issuance.", "label": "Qualified capital increase occurs in two years following the loan issuance" } } }, "localname": "QualifiedCapitalIncreaseOccursInTwoYearsFollowingLoanIssuanceMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsTermsOfConvertibleDebtDetails" ], "xbrltype": "domainItemType" }, "evax_QualifiedCapitalIncreaseOccursInYearFollowingLoanIssuanceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Qualified capital increase occurs in year following the loan issuance.", "label": "Qualified capital increase occurs in year following the loan issuance" } } }, "localname": "QualifiedCapitalIncreaseOccursInYearFollowingLoanIssuanceMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsTermsOfConvertibleDebtDetails" ], "xbrltype": "domainItemType" }, "evax_QualifiedCapitalIncreaseOccursInYearOfLoanIssuanceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Qualified capital increase occurs in year of loan issuance.", "label": "Qualified capital increase occurs in year of loan issuance" } } }, "localname": "QualifiedCapitalIncreaseOccursInYearOfLoanIssuanceMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsTermsOfConvertibleDebtDetails" ], "xbrltype": "domainItemType" }, "evax_ReceiptPaymentOfNonCurrentFinancialAssets": { "auth_ref": [], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow (outflow) for non current financial assets for leasehold deposits.", "label": "Receipt (Payment) of Non Current Financial Assets", "terseLabel": "Payment of non-current financial assets - leasehold deposits" } } }, "localname": "ReceiptPaymentOfNonCurrentFinancialAssets", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "evax_ReceivablesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of receivables.", "label": "Receivables [Text Block]", "verboseLabel": "Prepayments and other receivables" } } }, "localname": "ReceivablesTextBlock", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosurePrepaymentsAndOtherReceivables" ], "xbrltype": "textBlockItemType" }, "evax_ReductionInShareBasedCompensationExpenseChangeInEstimate": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of share based compensation expense due to change in accounting estimate.", "label": "Reduction In Share Based Compensation Expense, Change in Estimate", "terseLabel": "Reduction in share based compensation expense due to change in accounting estimate" } } }, "localname": "ReductionInShareBasedCompensationExpenseChangeInEstimate", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsAmendmentsToWarrantsDetails" ], "xbrltype": "monetaryItemType" }, "evax_RegisteredCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The nominal value of registered capital.", "label": "Registered Capital", "terseLabel": "Registered share capital (in DKK)" } } }, "localname": "RegisteredCapital", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementIpoDetails" ], "xbrltype": "monetaryItemType" }, "evax_RemainingContractualLifeOfExercisableShareOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Remaining contractual life of exercisable share options", "label": "Remaining contractual life of exercisable share options", "terseLabel": "Warrants exercisable, remaining contractual life", "verboseLabel": "Warrants exercisable, remaining term to maturity" } } }, "localname": "RemainingContractualLifeOfExercisableShareOptions", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsOutstandingWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsScheduleOfWarrantsDetails" ], "xbrltype": "durationItemType" }, "evax_RepaymentLoanTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Repayment loan term.", "label": "Repayment Loan Term", "terseLabel": "Repayment loan, term" } } }, "localname": "RepaymentLoanTerm", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesDetails", "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeaseholdImprovementsAndLoanFromLessorDetails" ], "xbrltype": "durationItemType" }, "evax_ResearchAndDevelopmentExpendituresMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for research and development expenditures that have been incurred and are carried forward for use against future taxable profit.", "label": "Research and development expenditures" } } }, "localname": "ResearchAndDevelopmentExpendituresMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureIncomeTaxesDeferredTaxDetails" ], "xbrltype": "domainItemType" }, "evax_ResearchAndDevelopmentExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpensesMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsBoardOfDirectorsAndExecutiveManagementDetails", "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsEmployeeCostsDetails", "http://www.Evaxion.com/role/DisclosureOperatingActivitiesDetails", "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDepreciationDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "evax_RetrospectiveEffectOfShareSplitAndBonusShareIssuanceTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for the retrospective effect of share split and bonus share issuance.", "label": "Retrospective Effect of Share Split and Bonus Share Issuance [text block]", "terseLabel": "Retrospective effect of share split and bonus share issuance" } } }, "localname": "RetrospectiveEffectOfShareSplitAndBonusShareIssuanceTextBlock", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "evax_ReversalOfDepreciationPropertyPlantAndEquipment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of depreciation reversed on property, plant and equipment due to disposals made during the period.", "label": "Reversal of Depreciation, Property Plant And Equipment", "terseLabel": "Depreciation reversed on disposals" } } }, "localname": "ReversalOfDepreciationPropertyPlantAndEquipment", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "evax_RightOfUseAssetsIncreaseDecreaseFromTranslation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in the translation that relates to right-of-use assets.", "label": "Right-of-use Assets Increase (Decrease) From Translation", "terseLabel": "Translation" } } }, "localname": "RightOfUseAssetsIncreaseDecreaseFromTranslation", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesMovementsInRightOfUseAssetsAndLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "evax_RightOfUseAssetsPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of Right of use assets payments.", "label": "Right of Use Assets Payments", "terseLabel": "Payments" } } }, "localname": "RightOfUseAssetsPayments", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesMovementsInRightOfUseAssetsAndLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "evax_RobertoPregoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Roberto Prego.", "label": "Roberto Prego" } } }, "localname": "RobertoPregoMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersShareholdingsByDirectorsAndExecutiveManagementDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsKeyManagementHoldingsDetails" ], "xbrltype": "domainItemType" }, "evax_SSIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for SSI.", "label": "SSI" } } }, "localname": "SSIMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureIntangibleAssetsParagraphDetails" ], "xbrltype": "domainItemType" }, "evax_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable1Table": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share Table1 [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable1Table", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureBasicAndDilutedLossPerShareAntiDilutiveSharesDetails" ], "xbrltype": "stringItemType" }, "evax_ScheduleOfAuditorsRemunerationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of compensation to the entity's auditors.", "label": "Schedule of auditors' remuneration [table text block]", "terseLabel": "Schedule of fees to independent registered public accounting firm" } } }, "localname": "ScheduleOfAuditorsRemunerationTableTextBlock", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureFeesToAuditorsTables" ], "xbrltype": "textBlockItemType" }, "evax_ShareBasedCompensationAwardsGrantedToKeyManagementPersonnelTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of share based compensation awards granted to key management personnel.", "label": "Share based compensation awards granted to key management personnel [table text block]", "terseLabel": "Schedule of share based awards to Board of Directors and Executive Management" } } }, "localname": "ShareBasedCompensationAwardsGrantedToKeyManagementPersonnelTableTextBlock", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsTables" ], "xbrltype": "textBlockItemType" }, "evax_ShareBasedCompensationAwardsOutstandingByGrantDateTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of share based compensation awards outstanding by grant date.", "label": "Share based compensation awards outstanding by grant date [table text block]", "terseLabel": "Schedule of outstanding warrants by grant date" } } }, "localname": "ShareBasedCompensationAwardsOutstandingByGrantDateTableTextBlock", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsTables" ], "xbrltype": "textBlockItemType" }, "evax_ShareBasedCompensationExpenseByFunctionTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of share based compensation expense by function.", "label": "Share based compensation expense by function [table text block]", "terseLabel": "Schedule of share based compensation included in statements of comprehensive loss" } } }, "localname": "ShareBasedCompensationExpenseByFunctionTableTextBlock", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsTables" ], "xbrltype": "textBlockItemType" }, "evax_ShareBasedCompensationExpenseForArrangingInvestorsToSubscribeForShares": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of warrants issued as compensation for arranging investors to subscribe for shares.", "label": "Share Based Compensation Expense For Arranging Investors To Subscribe For Shares", "terseLabel": "Compensation for arranging investors to subscribe for shares" } } }, "localname": "ShareBasedCompensationExpenseForArrangingInvestorsToSubscribeForShares", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "evax_ShareBasedCompensationVestingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time over which share based compensation vests.", "label": "Service period", "terseLabel": "Service period" } } }, "localname": "ShareBasedCompensationVestingPeriod", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsRectifiedDetails" ], "xbrltype": "durationItemType" }, "evax_ShareOptionsGrantedVestingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vesting period of share options granted.", "label": "Share options Granted, Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareOptionsGrantedVestingPeriod", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsAmendmentsToWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsDetails" ], "xbrltype": "durationItemType" }, "evax_ShareSplitConversionRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Share Split, Conversion Ratio", "verboseLabel": "Share split ratio" } } }, "localname": "ShareSplitConversionRatio", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsDetails" ], "xbrltype": "pureItemType" }, "evax_ShareholdersEquityTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for shareholders' equity.", "label": "Shareholders Equity [Text Block]", "terseLabel": "Shareholders' Equity" } } }, "localname": "ShareholdersEquityTextBlock", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "evax_SouthernDenmarkUniversityCollaborationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the joint operation, collaboration agreement with Southern Denmark University.", "label": "Southern Denmark University collaboration agreement" } } }, "localname": "SouthernDenmarkUniversityCollaborationAgreementMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountingForJointOperationDetails" ], "xbrltype": "domainItemType" }, "evax_StevenProjanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Steven Projan.", "label": "Steven Projan" } } }, "localname": "StevenProjanMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersShareholdingsByDirectorsAndExecutiveManagementDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsKeyManagementHoldingsDetails" ], "xbrltype": "domainItemType" }, "evax_StockSplitFromOrdinaryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock split ratio of issued and outstanding ordinary shares.", "label": "Stock Split from Ordinary Shares", "terseLabel": "Bonus share issuance" } } }, "localname": "StockSplitFromOrdinaryShares", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLossPerShareDetails", "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRetrospectiveEffectOfShareSplitAndBonusShareIssuanceDetails" ], "xbrltype": "pureItemType" }, "evax_StockSplitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for stock split.", "label": "Stock Split" } } }, "localname": "StockSplitMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureGeneralCompanyInformationDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsDetails" ], "xbrltype": "domainItemType" }, "evax_StockSplitOnBonusIssueOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion on bonus issue of shares.", "label": "Stock Split on Bonus Issue of Shares", "terseLabel": "Stock split on bonus issue of shares" } } }, "localname": "StockSplitOnBonusIssueOfShares", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLossPerShareDetails", "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRetrospectiveEffectOfShareSplitAndBonusShareIssuanceDetails" ], "xbrltype": "pureItemType" }, "evax_SummaryOfSignificantAccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Summary of Significant Accounting Policies" } } }, "localname": "SummaryOfSignificantAccountingPoliciesAbstract", "nsuri": "http://www.Evaxion.com/20211231", "xbrltype": "stringItemType" }, "evax_SystemProviderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for system provider.", "label": "System Provider" } } }, "localname": "SystemProviderMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureContractualObligationsContractualCommitmentsDetails" ], "xbrltype": "domainItemType" }, "evax_TaxRateEffectOfChangeInDeferredTax": { "auth_ref": [], "calculation": { "http://www.Evaxion.com/role/DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails": { "order": 6.0, "parentTag": "ifrs-full_AverageEffectiveTaxRate", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from the change in deferred tax asset not capitalized.", "label": "Tax rate effect of change in deferred tax", "terseLabel": "Change in deferred tax asset not capitalized" } } }, "localname": "TaxRateEffectOfChangeInDeferredTax", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails" ], "xbrltype": "percentItemType" }, "evax_TaxRateEffectOfResearchAndDevelopmentExpenses": { "auth_ref": [], "calculation": { "http://www.Evaxion.com/role/DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails": { "order": 4.0, "parentTag": "ifrs-full_AverageEffectiveTaxRate", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from additional tax deduction for research and development expenses.", "label": "Tax rate effect of research and development expenses", "terseLabel": "Additional tax deduction R&D expenses" } } }, "localname": "TaxRateEffectOfResearchAndDevelopmentExpenses", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails" ], "xbrltype": "percentItemType" }, "evax_TaxRateEffectOfResearchAndDevelopmentTaxCredit": { "auth_ref": [], "calculation": { "http://www.Evaxion.com/role/DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails": { "order": 5.0, "parentTag": "ifrs-full_AverageEffectiveTaxRate", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from research and development tax credits.", "label": "Tax rate effect of research and development tax credit", "terseLabel": "Tax credit research and development expenditures" } } }, "localname": "TaxRateEffectOfResearchAndDevelopmentTaxCredit", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails" ], "xbrltype": "percentItemType" }, "evax_TaxReceivablesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for tax receivables.", "label": "Tax Receivables [Text Block]", "terseLabel": "Tax receivables" } } }, "localname": "TaxReceivablesTextBlock", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "evax_ThomasBogenriederMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Thomas Bogenrieder.", "label": "Thomas Bogenrieder" } } }, "localname": "ThomasBogenriederMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsKeyManagementHoldingsDetails" ], "xbrltype": "domainItemType" }, "evax_ThomasWilliamWylonisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Thomas William Wylonis.", "label": "Thomas William Wylonis" } } }, "localname": "ThomasWilliamWylonisMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersShareholdingsByDirectorsAndExecutiveManagementDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsKeyManagementHoldingsDetails" ], "xbrltype": "domainItemType" }, "evax_TradePayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trade payables.", "label": "Trade payables" } } }, "localname": "TradePayablesMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementContractualUndiscountedOutflowsDetails" ], "xbrltype": "domainItemType" }, "evax_TrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for tranche one.", "label": "Tranche 1" } } }, "localname": "TrancheOneMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureDebtDetails", "http://www.Evaxion.com/role/DisclosureEventsAfterReportingPeriodDetails", "http://www.Evaxion.com/role/DisclosureGeneralCompanyInformationDetails" ], "xbrltype": "domainItemType" }, "evax_TrancheThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for tranche three.", "label": "Tranche 3" } } }, "localname": "TrancheThreeMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureDebtDetails" ], "xbrltype": "domainItemType" }, "evax_TrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for tranche two.", "label": "Tranche 2" } } }, "localname": "TrancheTwoMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureDebtDetails" ], "xbrltype": "domainItemType" }, "evax_TranslationOfForeignOperationsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for translation of foreign operations.", "label": "Translation Of Foreign Operations [Text block]", "terseLabel": "Translation of foreign operations" } } }, "localname": "TranslationOfForeignOperationsTextBlock", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "evax_TypesOfConvertibleDebtInstrumentsIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents types of convertible debt instruments issued during period.", "label": "Types Of Convertible Debt Instruments Issued", "terseLabel": "Types of convertible debt instruments issued", "verboseLabel": "Number of convertible debt instruments issued" } } }, "localname": "TypesOfConvertibleDebtInstrumentsIssued", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsIssuanceDetails", "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConvertibleDebtInstrumentsDetails" ], "xbrltype": "integerItemType" }, "evax_UnderwritersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for underwriters.", "label": "Underwriters" } } }, "localname": "UnderwritersMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersCapitalTransactionsDetails", "http://www.Evaxion.com/role/DisclosureGeneralCompanyInformationDetails" ], "xbrltype": "domainItemType" }, "evax_UniversityFuturePartnersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents university future partners.", "label": "University future partners" } } }, "localname": "UniversityFuturePartnersMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureContractualObligationsContractualCommitmentsDetails" ], "xbrltype": "domainItemType" }, "evax_WarrantsAttributableToDebtInstrumentAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amount of warrants attributable to debt instrument amount.", "label": "Warrants Attributable To Debt Instrument Amount", "terseLabel": "Warrants attributable to debt" } } }, "localname": "WarrantsAttributableToDebtInstrumentAmount", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureDebtDetails" ], "xbrltype": "sharesItemType" }, "evax_WarrantsEntitlements2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for 2019 warrants entitlements.", "label": "2019 warrants entitlements" } } }, "localname": "WarrantsEntitlements2019Member", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsRectifiedDetails" ], "xbrltype": "domainItemType" }, "evax_WarrantsEntitlements2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for 2020 warrants entitlements.", "label": "2020 warrants entitlements" } } }, "localname": "WarrantsEntitlements2020Member", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsRectifiedDetails" ], "xbrltype": "domainItemType" }, "evax_WarrantsGrantedWithImmediateVesting": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants granted with immediate vesting.", "label": "Warrants granted with immediate vesting" } } }, "localname": "WarrantsGrantedWithImmediateVesting", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsRectifiedDetails" ], "xbrltype": "sharesItemType" }, "evax_WarrantsGrantedWithVestingOverNextThreeYears": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants granted during the period with vesting over next 3 years.", "label": "Warrants Granted With Vesting Over The Next Three Years" } } }, "localname": "WarrantsGrantedWithVestingOverNextThreeYears", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsRectifiedDetails" ], "xbrltype": "sharesItemType" }, "evax_WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents warrants.", "label": "Warrants." } } }, "localname": "WarrantsMember", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureBasicAndDilutedLossPerShareAntiDilutiveSharesDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsAssumptionsOfWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsCompensationExpenseDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsScheduleOfWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsRectifiedDetails" ], "xbrltype": "domainItemType" }, "evax_WeightageForIpoScenarioSharePriceShareOptionsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of weightage put to the IPO scenario applying the midprice of the indicative IPO price range.", "label": "Weightage For IPO Scenario, Share Price, Share Options Granted", "terseLabel": "Percentage of weightage for IPO scenario" } } }, "localname": "WeightageForIpoScenarioSharePriceShareOptionsGranted", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsFairValueOfWarrantsDetails" ], "xbrltype": "percentItemType" }, "evax_WeightageForPrivateScenarioSharePriceShareOptionsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of weightage put to the stay private scenario applying a share price equal to the share price.", "label": "Weightage For Private Scenario, Share Price, Share Options Granted", "terseLabel": "Percentage of weightage for private scenario" } } }, "localname": "WeightageForPrivateScenarioSharePriceShareOptionsGranted", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsFairValueOfWarrantsDetails" ], "xbrltype": "percentItemType" }, "evax_WeightedAverageExercisePriceOfShareOptionsGrantedInShareBasedPaymentArrangementPriorToStockSplit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement, prior to stock split.", "label": "Weighted average exercise price of share options granted in share-based payment arrangement, prior to stock split", "terseLabel": "Warrants granted exercise price, prior to stock split" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInShareBasedPaymentArrangementPriorToStockSplit", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsDetails" ], "xbrltype": "perShareItemType" }, "evax_WeightedAverageGrantDateFairValueOfShareOptionsGrantedInShareBasedPaymentArrangementPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The per share weighted average grant date fair value of share options granted in share-based payment arrangement during the period.", "label": "Weighted Average Grant Date Fair Value Of Share Options Granted In Share-based Payment Arrangement, Per Share", "terseLabel": "Per warrant average grant date fair value" } } }, "localname": "WeightedAverageGrantDateFairValueOfShareOptionsGrantedInShareBasedPaymentArrangementPerShare", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsOutstandingWarrantsDetails" ], "xbrltype": "perShareItemType" }, "evax_WeightedAverageRemainingContractualLifeOfShareOptionsCancelledDuringPeriod.": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average remaining contractual life of share options cancelled during the period.", "label": "Weighted Average Remaining Contractual Life Of Share Options Cancelled During Period.", "terseLabel": "Warrants cancelled , remaining contractual life" } } }, "localname": "WeightedAverageRemainingContractualLifeOfShareOptionsCancelledDuringPeriod.", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsScheduleOfWarrantsDetails" ], "xbrltype": "durationItemType" }, "evax_WeightedAverageRemainingContractualLifeOfShareOptionsForfeitedDuringPeriod.": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average remaining contractual life of share options forfeited during the period.", "label": "Weighted Average Remaining Contractual Life Of Share Options Forfeited During Period.", "terseLabel": "Warrants forfeited , remaining contractual life" } } }, "localname": "WeightedAverageRemainingContractualLifeOfShareOptionsForfeitedDuringPeriod.", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsScheduleOfWarrantsDetails" ], "xbrltype": "durationItemType" }, "evax_WeightedAverageRemainingContractualLifeOfShareOptionsGrantedDuringPeriod.": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average remaining contractual life of share options granted during the period.", "label": "Weighted average remaining contractual life of share options granted during the period.", "terseLabel": "Warrants granted , remaining contractual life" } } }, "localname": "WeightedAverageRemainingContractualLifeOfShareOptionsGrantedDuringPeriod.", "nsuri": "http://www.Evaxion.com/20211231", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsScheduleOfWarrantsDetails" ], "xbrltype": "durationItemType" }, "ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember": { "auth_ref": [ "r64", "r72", "r105", "r115", "r118" ], "lang": { "en": { "role": { "documentation": "This member stands for accumulated depreciation, amortisation and impairment. [Refer: Impairment loss; Depreciation and amortisation expense]" } }, "en-us": { "role": { "label": "Accumulated Depreciation" } } }, "localname": "AccumulatedDepreciationAmortisationAndImpairmentMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDepreciationDetails", "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AccumulatedDepreciationAndAmortisationMember": { "auth_ref": [ "r64", "r72", "r105", "r115", "r118" ], "lang": { "en": { "role": { "documentation": "This member stands for accumulated depreciation and amortisation. [Refer: Depreciation and amortisation expense]" } }, "en-us": { "role": { "label": "Accumulated depreciation and amortisation [member]" } } }, "localname": "AccumulatedDepreciationAndAmortisationMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureIntangibleAssetsTableDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AccumulatedImpairmentMember": { "auth_ref": [ "r64", "r105", "r115", "r118", "r202", "r207", "r211", "r245", "r248" ], "lang": { "en": { "role": { "documentation": "This member stands for accumulated impairment. [Refer: Impairment loss]" } }, "en-us": { "role": { "label": "Valuation allowance" } } }, "localname": "AccumulatedImpairmentMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureIncomeTaxesDeferredTaxDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r106" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Additions other than through business combinations, intangible assets other than goodwill", "terseLabel": "Additions during the year", "verboseLabel": "Capitalized intangible assets" } } }, "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureIntangibleAssetsParagraphDetails", "http://www.Evaxion.com/role/DisclosureIntangibleAssetsTableDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": { "auth_ref": [ "r65" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]" } }, "en-us": { "role": { "label": "Additions other than through business combinations, property, plant and equipment", "terseLabel": "Additions during the year" } } }, "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdditionsToRightofuseAssets": { "auth_ref": [ "r180" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]" } }, "en-us": { "role": { "label": "Additions to right-of-use assets", "terseLabel": "Additions" } } }, "localname": "AdditionsToRightofuseAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesMovementsInRightOfUseAssetsAndLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": { "auth_ref": [ "r130" ], "calculation": { "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsChangesInNetWorkingCapitalDetails": { "order": 1.0, "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for decrease (increase) in trade and other receivables", "negatedTerseLabel": "Changes in receivables and tax receivables" } } }, "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsChangesInNetWorkingCapitalDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDepreciationExpense": { "auth_ref": [ "r130" ], "calculation": { "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsAdjustmentsForNonCashItemsDetails": { "order": 1.0, "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for depreciation expense", "terseLabel": "Depreciation and amortization" } } }, "localname": "AdjustmentsForDepreciationExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsAdjustmentsForNonCashItemsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForFairValueGainsLosses": { "auth_ref": [ "r129" ], "calculation": { "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsAdjustmentsForNonCashItemsDetails": { "order": 2.0, "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for fair value losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for fair value losses (gains)", "verboseLabel": "Change in fair value of convertible debt instruments" } } }, "localname": "AdjustmentsForFairValueGainsLosses", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsAdjustmentsForNonCashItemsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncomeTaxExpense": { "auth_ref": [ "r134" ], "calculation": { "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsAdjustmentsForNonCashItemsDetails": { "order": 3.0, "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for income tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for income tax expense", "verboseLabel": "Income taxes" } } }, "localname": "AdjustmentsForIncomeTaxExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsAdjustmentsForNonCashItemsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables": { "auth_ref": [ "r128" ], "calculation": { "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsChangesInNetWorkingCapitalDetails": { "order": 2.0, "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for increase (decrease) in other operating payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for increase (decrease) in other operating payables", "negatedTerseLabel": "Changes in other payables" } } }, "localname": "AdjustmentsForIncreaseDecreaseInOtherOperatingPayables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsChangesInNetWorkingCapitalDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": { "auth_ref": [ "r128" ], "calculation": { "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsChangesInNetWorkingCapitalDetails": { "order": 3.0, "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for increase (decrease) in trade accounts payable", "negatedTerseLabel": "Changes in trade payables" } } }, "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsChangesInNetWorkingCapitalDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForInterestExpense": { "auth_ref": [ "r130" ], "calculation": { "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsAdjustmentsForNonCashItemsDetails": { "order": 5.0, "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for interest expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Interest expense; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for interest expense", "verboseLabel": "Interest expense" } } }, "localname": "AdjustmentsForInterestExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsAdjustmentsForNonCashItemsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForInterestIncome": { "auth_ref": [ "r130" ], "calculation": { "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsAdjustmentsForNonCashItemsDetails": { "order": 6.0, "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Adjustments for interest income expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Interest income; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for interest income", "negatedTerseLabel": "Interest income" } } }, "localname": "AdjustmentsForInterestIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsAdjustmentsForNonCashItemsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForProvisions": { "auth_ref": [ "r129" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Provisions; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for provisions", "terseLabel": "Currency adjustment" } } }, "localname": "AdjustmentsForProvisions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureProvisionsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForReconcileProfitLoss": { "auth_ref": [ "r130" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments to reconcile profit (loss)", "terseLabel": "Adjustments for non-cash items" } } }, "localname": "AdjustmentsForReconcileProfitLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile profit (loss) [abstract]" } } }, "localname": "AdjustmentsForReconcileProfitLossAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsAdjustmentsForNonCashItemsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_AdjustmentsForSharebasedPayments": { "auth_ref": [ "r129" ], "calculation": { "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsAdjustmentsForNonCashItemsDetails": { "order": 7.0, "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for share-based payments", "verboseLabel": "Share-based compensation expenses" } } }, "localname": "AdjustmentsForSharebasedPayments", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsAdjustmentsForNonCashItemsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital": { "auth_ref": [ "r130" ], "calculation": { "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsAdjustmentsForNonCashItemsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments, other than changes in working capital, to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments to reconcile profit (loss) other than changes in working capital", "totalLabel": "Total adjustments for non-cash items" } } }, "localname": "AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsAdjustmentsForNonCashItemsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AggregatedTimeBandsMember": { "auth_ref": [ "r26", "r75", "r173", "r183", "r184", "r204", "r219", "r221", "r238", "r239", "r241", "r242" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } }, "en-us": { "role": { "label": "Aggregated time bands [member]" } } }, "localname": "AggregatedTimeBandsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureContractualObligationsContractualCommitmentsDetails", "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementContractualUndiscountedOutflowsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r107" ], "lang": { "en": { "role": { "documentation": "The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Amortisation, intangible assets other than goodwill", "terseLabel": "Amortization for the year" } } }, "localname": "AmortisationIntangibleAssetsOtherThanGoodwill", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureIntangibleAssetsTableDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount": { "auth_ref": [ "r103", "r104" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount by which a cash-generating unit's (group of units') recoverable amount exceeds its carrying amount. [Refer: Carrying amount [member]; Cash-generating units [member]]" } }, "en-us": { "role": { "label": "Amount by which unit's recoverable amount exceeds its carrying amount", "terseLabel": "Non-affiliates exceeds" } } }, "localname": "AmountByWhichUnitsRecoverableAmountExceedsItsCarryingAmount", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureGeneralCompanyInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AmountsReceivableRelatedPartyTransactions": { "auth_ref": [ "r87", "r91" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amounts receivable resulting from related party transactions. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Amounts receivable, related party transactions", "verboseLabel": "Prepaid rent and deposit for a leased property from a related party" } } }, "localname": "AmountsReceivableRelatedPartyTransactions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ApplicableTaxRate": { "auth_ref": [ "r57" ], "calculation": { "http://www.Evaxion.com/role/DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails": { "order": 1.0, "parentTag": "ifrs-full_AverageEffectiveTaxRate", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The applicable income tax rate." } }, "en-us": { "role": { "label": "Applicable tax rate", "terseLabel": "Statutory corporate income tax rate in Denmark" } } }, "localname": "ApplicableTaxRate", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_Assets": { "auth_ref": [ "r23", "r164", "r165", "r168", "r227", "r230" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": { "auth_ref": [ "r3", "r11" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Attribution of expenses by nature to their function [axis]" } } }, "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDepreciationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_AuditorsRemuneration": { "auth_ref": [ "r11" ], "calculation": { "http://www.Evaxion.com/role/DisclosureFeesToAuditorsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of fees paid or payable to the entity's auditors." } }, "en-us": { "role": { "label": "Auditor's remuneration", "totalLabel": "Total fees" } } }, "localname": "AuditorsRemuneration", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureFeesToAuditorsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AuditorsRemunerationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fees to auditors" } } }, "localname": "AuditorsRemunerationAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_AuditorsRemunerationForAuditServices": { "auth_ref": [ "r11" ], "calculation": { "http://www.Evaxion.com/role/DisclosureFeesToAuditorsDetails": { "order": 2.0, "parentTag": "ifrs-full_AuditorsRemuneration", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of fees paid or payable to the entity's auditors for auditing services." } }, "en-us": { "role": { "label": "Auditor's remuneration for audit services", "terseLabel": "Audit fees" } } }, "localname": "AuditorsRemunerationForAuditServices", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureFeesToAuditorsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AuditorsRemunerationForOtherServices": { "auth_ref": [ "r11" ], "calculation": { "http://www.Evaxion.com/role/DisclosureFeesToAuditorsDetails": { "order": 3.0, "parentTag": "ifrs-full_AuditorsRemuneration", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of fees paid or payable to the entity's auditors for services that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Auditor's remuneration for other services", "terseLabel": "Other fees" } } }, "localname": "AuditorsRemunerationForOtherServices", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureFeesToAuditorsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AverageEffectiveTaxRate": { "auth_ref": [ "r57" ], "calculation": { "http://www.Evaxion.com/role/DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en": { "role": { "documentation": "The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]" } }, "en-us": { "role": { "label": "Average effective tax rate", "totalLabel": "Total effective tax rate" } } }, "localname": "AverageEffectiveTaxRate", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_AverageNumberOfEmployees": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The average number of personnel employed by the entity during a period." } }, "en-us": { "role": { "label": "Average number of employees", "terseLabel": "Average number of full-time employees" } } }, "localname": "AverageNumberOfEmployees", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsNumberOfEmployeesDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_BalancesWithBanks": { "auth_ref": [ "r140" ], "calculation": { "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsDetails": { "order": 1.0, "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash balances held at banks." } }, "en-us": { "role": { "label": "Balances with banks", "terseLabel": "Cash and cash equivalents" } } }, "localname": "BalancesWithBanks", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_BasicEarningsLossPerShare": { "auth_ref": [ "r95", "r96" ], "lang": { "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } }, "en-us": { "role": { "label": "Basic earnings (loss) per share" } } }, "localname": "BasicEarningsLossPerShare", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "ifrs-full_Borrowings": { "auth_ref": [ "r23" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of outstanding funds that the entity is obligated to repay." } }, "en-us": { "role": { "label": "Borrowings", "totalLabel": "Total Loan from lessor", "verboseLabel": "Borrowings" } } }, "localname": "Borrowings", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureEventsAfterReportingPeriodDetails", "http://www.Evaxion.com/role/DisclosureGeneralCompanyInformationDetails", "http://www.Evaxion.com/role/DisclosureLeasesSummaryOfFinanceLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_BorrowingsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Borrowings [abstract]" } } }, "localname": "BorrowingsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsSummaryOfChangesInConvertibleDebtInstrumentsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_BorrowingsByNameAxis": { "auth_ref": [ "r216" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Borrowings by name [axis]" } } }, "localname": "BorrowingsByNameAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersChangesInShareCapitalDetails", "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsIssuanceDetails", "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsTables", "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsTermsOfConvertibleDebtDetails", "http://www.Evaxion.com/role/DisclosureDebtDetails", "http://www.Evaxion.com/role/DisclosureEventsAfterReportingPeriodDetails", "http://www.Evaxion.com/role/DisclosureGeneralCompanyInformationDetails", "http://www.Evaxion.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_BorrowingsByNameMember": { "auth_ref": [ "r216" ], "lang": { "en": { "role": { "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Borrowings by name [member]" } } }, "localname": "BorrowingsByNameMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersChangesInShareCapitalDetails", "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsIssuanceDetails", "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsTables", "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsTermsOfConvertibleDebtDetails", "http://www.Evaxion.com/role/DisclosureDebtDetails", "http://www.Evaxion.com/role/DisclosureEventsAfterReportingPeriodDetails", "http://www.Evaxion.com/role/DisclosureGeneralCompanyInformationDetails", "http://www.Evaxion.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_BorrowingsInterestRate": { "auth_ref": [ "r216" ], "lang": { "en": { "role": { "documentation": "The interest rate on borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Borrowings, interest rate", "positiveLabel": "Loan, interest rate", "terseLabel": "Interest rate", "verboseLabel": "Interest coupon" } } }, "localname": "BorrowingsInterestRate", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsTermsOfConvertibleDebtDetails", "http://www.Evaxion.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeaseholdImprovementsAndLoanFromLessorDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_BottomOfRangeMember": { "auth_ref": [ "r170", "r171", "r172", "r198", "r216", "r241" ], "lang": { "en": { "role": { "documentation": "This member stands for the bottom of a range." } }, "en-us": { "role": { "label": "Minimum" } } }, "localname": "BottomOfRangeMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesDetails", "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": { "auth_ref": [ "r64", "r69", "r105", "r109", "r114", "r115", "r116", "r117", "r118", "r202", "r207", "r208", "r245", "r249" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]" } } }, "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureIncomeTaxesDeferredTaxDetails", "http://www.Evaxion.com/role/DisclosureIntangibleAssetsTableDetails", "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDepreciationDetails", "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CarryingAmountMember": { "auth_ref": [ "r69", "r109", "r114", "r116", "r117", "r202", "r207", "r208", "r245", "r247" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]" } }, "en-us": { "role": { "label": "Carrying amount [member]" } } }, "localname": "CarryingAmountMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureIncomeTaxesDeferredTaxDetails", "http://www.Evaxion.com/role/DisclosureIntangibleAssetsTableDetails", "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDepreciationDetails", "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CashAndCashEquivalents": { "auth_ref": [ "r19", "r140", "r160" ], "calculation": { "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 5.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } }, "en-us": { "role": { "label": "Cash and cash equivalent", "periodEndLabel": "Cash and cash equivalents at December 31", "periodStartLabel": "Cash and cash equivalents at January 1", "terseLabel": "Cash and cash equivalents", "totalLabel": "Total cash and cash equivalents" } } }, "localname": "CashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsDetails", "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementLiquidityRiskDetails", "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows", "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_CashEquivalents": { "auth_ref": [ "r140" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value." } }, "en-us": { "role": { "label": "Cash equivalents", "terseLabel": "Cash equivalents" } } }, "localname": "CashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "auth_ref": [ "r119", "r141" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 3.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity." } }, "en-us": { "role": { "label": "Cash flows from (used in) financing activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "CashFlowsFromUsedInFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities [abstract]", "terseLabel": "Financing activities:" } } }, "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "auth_ref": [ "r119", "r141" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents." } }, "en-us": { "role": { "label": "Cash flows from (used in) investing activities", "totalLabel": "Net (cash used in)/ provided by investing activities" } } }, "localname": "CashFlowsFromUsedInInvestingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities [abstract]", "terseLabel": "Investing activities:" } } }, "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "auth_ref": [ "r119", "r141" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Cash flows from (used in) operating activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "CashFlowsFromUsedInOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities [abstract]", "terseLabel": "Operating activities:" } } }, "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsChangesInNetWorkingCapitalDetails", "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": { "auth_ref": [ "r130", "r142" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital." } }, "en-us": { "role": { "label": "Cash flows from (used in) operations before changes in working capital", "totalLabel": "Cash flow from operating activities before changes in working capital" } } }, "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashOutflowForLeases": { "auth_ref": [ "r179" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for leases." } }, "en-us": { "role": { "label": "Cash outflow for leases" } } }, "localname": "CashOutflowForLeases", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesMovementsInRightOfUseAssetsAndLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "auth_ref": [ "r90" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Categories of related parties [axis]" } } }, "localname": "CategoriesOfRelatedPartiesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersShareholdingsByDirectorsAndExecutiveManagementDetails", "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsIssuanceDetails", "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsBoardOfDirectorsAndExecutiveManagementDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsKeyManagementHoldingsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ChangesInEquity": { "auth_ref": [ "r8" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity. [Refer: Equity]" } }, "en-us": { "role": { "label": "Increase (decrease) in equity", "terseLabel": "Capital increase at February 9, 2021 for initial public offering", "verboseLabel": "Capital increase from offering" } } }, "localname": "ChangesInEquity", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersCapitalTransactionsDetails", "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersChangesInShareCapitalDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ChangesInEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unaudited Condensed Consolidated Interim Statements of Changes in Equity" } } }, "localname": "ChangesInEquityAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfEmployeeBenefitsExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employees and Employee-Related Costs" } } }, "localname": "ClassesOfEmployeeBenefitsExpenseAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": { "auth_ref": [ "r110" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of intangible assets other than goodwill [axis]" } } }, "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureIntangibleAssetsParagraphDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfLiabilitiesAxis": { "auth_ref": [ "r169" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of liabilities [axis]" } } }, "localname": "ClassesOfLiabilitiesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementContractualUndiscountedOutflowsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "auth_ref": [ "r70" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of property, plant and equipment [axis]" } } }, "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesDetails", "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDepreciationDetails", "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDetails", "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfShareCapitalAxis": { "auth_ref": [ "r37" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of share capital [axis]" } } }, "localname": "ClassesOfShareCapitalAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersCapitalTransactionsDetails", "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersChangesInShareCapitalDetails", "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersShareCapitalDetails", "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementIpoDetails", "http://www.Evaxion.com/role/DisclosureGeneralCompanyInformationDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfShareCapitalMember": { "auth_ref": [ "r37" ], "lang": { "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } }, "en-us": { "role": { "label": "Share capital [member]" } } }, "localname": "ClassesOfShareCapitalMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersCapitalTransactionsDetails", "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersChangesInShareCapitalDetails", "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersShareCapitalDetails", "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementIpoDetails", "http://www.Evaxion.com/role/DisclosureGeneralCompanyInformationDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ComponentsOfEquityAxis": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Components of equity [axis]" } } }, "localname": "ComponentsOfEquityAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersChangesInShareCapitalDetails", "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersShareCapitalDetails", "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfChangesInEquity" ], "xbrltype": "stringItemType" }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]", "terseLabel": "Other comprehensive income that may be reclassified to profit or loss in subsequent periods: (net of tax)" } } }, "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract]", "terseLabel": "Other comprehensive income that will not be reclassified to profit or loss in subsequent periods: (net of tax)" } } }, "localname": "ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "ifrs-full_ComprehensiveIncome": { "auth_ref": [ "r4", "r41", "r148", "r150", "r152", "r157" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } }, "en-us": { "role": { "label": "Comprehensive income", "totalLabel": "Total comprehensive loss" } } }, "localname": "ComprehensiveIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": { "auth_ref": [ "r4", "r43" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]" } }, "en-us": { "role": { "label": "Comprehensive income, attributable to owners of parent", "totalLabel": "Total comprehensive loss attributable to shareholders of Evaxion Biotech A/S" } } }, "localname": "ComprehensiveIncomeAttributableToOwnersOfParent", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ContractualCapitalCommitments": { "auth_ref": [ "r11" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of capital commitments for which the entity has entered into a contract. [Refer: Capital commitments]" } }, "en-us": { "role": { "label": "Contractual capital commitments", "terseLabel": "Contractual commitments" } } }, "localname": "ContractualCapitalCommitments", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureContractualObligationsContractualCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CounterpartiesAxis": { "auth_ref": [ "r222" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Counterparties [axis]" } } }, "localname": "CounterpartiesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureContractualObligationsContractualCommitmentsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CounterpartiesMember": { "auth_ref": [ "r222" ], "lang": { "en": { "role": { "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used." } }, "en-us": { "role": { "label": "Counterparties [member]" } } }, "localname": "CounterpartiesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureContractualObligationsContractualCommitmentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CountryOfDomicileMember": { "auth_ref": [ "r234", "r235" ], "lang": { "en": { "role": { "documentation": "This member stands for the country in which the entity is registered and where it has its legal address or registered office." } }, "en-us": { "role": { "label": "Denmark and United States" } } }, "localname": "CountryOfDomicileMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsNumberOfEmployeesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CurrentAssets": { "auth_ref": [ "r27", "r152", "r153" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } }, "en-us": { "role": { "label": "Current assets", "totalLabel": "Total current assets" } } }, "localname": "CurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets [abstract]", "terseLabel": "Current assets" } } }, "localname": "CurrentAssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentLeaseLiabilities": { "auth_ref": [ "r176" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Current lease liabilities", "terseLabel": "Lease liabilities" } } }, "localname": "CurrentLeaseLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLiabilities": { "auth_ref": [ "r28", "r152", "r155" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } }, "en-us": { "role": { "label": "Current liabilities", "totalLabel": "Total current liabilities" } } }, "localname": "CurrentLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities [abstract]", "terseLabel": "Current liabilities" } } }, "localname": "CurrentLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentPortionOfLongtermBorrowings": { "auth_ref": [ "r23" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The current portion of non-current borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Current portion of non-current borrowings", "negatedLabel": "Less: Loan from lessor, current portion", "terseLabel": "Loan from lessor, current" } } }, "localname": "CurrentPortionOfLongtermBorrowings", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesSummaryOfFinanceLiabilityDetails", "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentPrepaidExpenses": { "auth_ref": [ "r11" ], "calculation": { "http://www.Evaxion.com/role/DisclosurePrepaymentsAndOtherReceivablesDetails": { "order": 1.0, "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised." } }, "en-us": { "role": { "label": "Current prepaid expenses", "terseLabel": "Prepayments" } } }, "localname": "CurrentPrepaidExpenses", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosurePrepaymentsAndOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets": { "auth_ref": [ "r23" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current prepayments and other current assets. [Refer: Other current assets; Current prepayments]" } }, "en-us": { "role": { "label": "Current prepayments and other current assets", "terseLabel": "Prepayments and other receivables" } } }, "localname": "CurrentPrepaymentsAndOtherCurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentTaxAssetsCurrent": { "auth_ref": [ "r21" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 4.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The current amount of current tax assets. [Refer: Current tax assets]" } }, "en-us": { "role": { "label": "Current tax assets, current", "terseLabel": "Tax receivables" } } }, "localname": "CurrentTaxAssetsCurrent", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentValueAddedTaxReceivables": { "auth_ref": [ "r31" ], "calculation": { "http://www.Evaxion.com/role/DisclosurePrepaymentsAndOtherReceivablesDetails": { "order": 2.0, "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current value added tax receivables. [Refer: Value added tax receivables]" } }, "en-us": { "role": { "label": "Current value added tax receivables", "terseLabel": "VAT receivables" } } }, "localname": "CurrentValueAddedTaxReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosurePrepaymentsAndOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DebtSecurities": { "auth_ref": [ "r23" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of instruments issued by the entity that represent indebtedness." } }, "en-us": { "role": { "label": "Debt instruments issued", "terseLabel": "Issued non-convertible debt securities" } } }, "localname": "DebtSecurities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureGeneralCompanyInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DeferredTaxAssets": { "auth_ref": [ "r22", "r24", "r59" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } }, "en-us": { "role": { "label": "Deferred tax assets", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredTaxAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DeferredTaxLiabilityAsset": { "auth_ref": [ "r59" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]" } }, "en-us": { "role": { "label": "Deferred tax liability (asset)", "terseLabel": "Deferred tax position" } } }, "localname": "DeferredTaxLiabilityAsset", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureIncomeTaxesDeferredTaxDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DepreciationExpense": { "auth_ref": [ "r11" ], "calculation": { "http://www.Evaxion.com/role/DisclosureOperatingActivitiesDetails": { "order": 1.0, "parentTag": "ifrs-full_ExpenseByNature", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives." } }, "en-us": { "role": { "label": "Depreciation expense", "negatedLabel": "Depreciation" } } }, "localname": "DepreciationExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureOperatingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DepreciationPropertyPlantAndEquipment": { "auth_ref": [ "r67", "r71" ], "lang": { "en": { "role": { "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]" } }, "en-us": { "role": { "label": "Depreciation, property, plant and equipment", "negatedTerseLabel": "Depreciation for the year", "verboseLabel": "Depreciation" } } }, "localname": "DepreciationPropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDepreciationDetails", "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DepreciationRightofuseAssets": { "auth_ref": [ "r177" ], "lang": { "en": { "role": { "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]" } }, "en-us": { "role": { "label": "Depreciation, right-of-use assets", "negatedLabel": "Depreciation" } } }, "localname": "DepreciationRightofuseAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesMovementsInRightOfUseAssetsAndLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for deferred income tax. [Refer: Deferred tax expense (income)]" } }, "en-us": { "role": { "label": "Description of accounting policy for deferred income tax [text block]", "terseLabel": "Deferred taxes" } } }, "localname": "DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for earnings per share." } }, "en-us": { "role": { "label": "Description of accounting policy for earnings per share [text block]", "terseLabel": "Loss Per Share" } } }, "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment." } }, "en-us": { "role": { "label": "Description of accounting policy for employee benefits [text block]", "terseLabel": "Post-employment benefit costs" } } }, "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForExpensesExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for expenses." } }, "en-us": { "role": { "label": "Description of accounting policy for expenses [text block]", "terseLabel": "General and administrative expenses" } } }, "localname": "DescriptionOfAccountingPolicyForExpensesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForFinanceCostsExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for finance costs. [Refer: Finance costs]" } }, "en-us": { "role": { "label": "Description of accounting policy for finance costs [text block]", "terseLabel": "Finance Expense" } } }, "localname": "DescriptionOfAccountingPolicyForFinanceCostsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for finance income and costs. [Refer: Finance income (cost)]" } }, "en-us": { "role": { "label": "Description of accounting policy for finance income and costs [text block]", "terseLabel": "Finance Income" } } }, "localname": "DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for financial instruments. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Description of accounting policy for financial instruments [text block]", "terseLabel": "Financial instruments" } } }, "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForFunctionalCurrencyExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for the currency of the primary economic environment in which the entity operates." } }, "en-us": { "role": { "label": "Description of accounting policy for functional currency [text block]", "verboseLabel": "Currency translation of transactions and balances" } } }, "localname": "DescriptionOfAccountingPolicyForFunctionalCurrencyExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants": { "auth_ref": [ "r80" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for government grants, including the methods of presentation adopted in the financial statements. [Refer: Government [member]; Government grants]" } }, "en-us": { "role": { "label": "Description of accounting policy for government grants [text block]", "terseLabel": "Income from government grants" } } }, "localname": "DescriptionOfAccountingPolicyForGovernmentGrants", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for the impairment of non-financial assets. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Description of accounting policy for impairment of non-financial assets [text block]", "terseLabel": "Impairment of non-financial assets" } } }, "localname": "DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for income tax." } }, "en-us": { "role": { "label": "Description of accounting policy for income tax [text block]", "terseLabel": "Income tax" } } }, "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Description of accounting policy for intangible assets other than goodwill [text block]", "terseLabel": "Intellectual property" } } }, "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForInvestmentsInJointVentures": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for investments in joint ventures. [Refer: Joint ventures [member]]" } }, "en-us": { "role": { "label": "Description of accounting policy for investments in joint ventures [text block]", "terseLabel": "Accounting for joint operations - Southern Denmark University" } } }, "localname": "DescriptionOfAccountingPolicyForInvestmentsInJointVentures", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time." } }, "en-us": { "role": { "label": "Description of accounting policy for leases [text block]", "terseLabel": "Leases" } } }, "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Description of accounting policy for property, plant and equipment [text block]", "terseLabel": "Property and equipment" } } }, "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for provisions. [Refer: Provisions]" } }, "en-us": { "role": { "label": "Description of accounting policy for provisions [text block]", "terseLabel": "Provisions" } } }, "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]" } }, "en-us": { "role": { "label": "Description of accounting policy for research and development expense [text block]", "terseLabel": "Research and development expenses" } } }, "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for segment reporting." } }, "en-us": { "role": { "label": "Description of accounting policy for segment reporting [text block]", "terseLabel": "Segment Information" } } }, "localname": "DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]" } }, "en-us": { "role": { "label": "Description of accounting policy for share-based payment transactions [text block]", "terseLabel": "Share-based payments" } } }, "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations": { "auth_ref": [ "r145" ], "lang": { "en": { "role": { "documentation": "The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have." } }, "en-us": { "role": { "label": "Disclosure of expected impact of initial application of new standards or interpretations [text block]", "terseLabel": "Standards issued but not yet effective" } } }, "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "First-Time Adoption of IFRS" } } }, "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": { "auth_ref": [ "r200" ], "lang": { "en": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time." } }, "en-us": { "role": { "label": "Expected volatility, share options granted", "terseLabel": "Expected volatility" } } }, "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsAssumptionsOfWarrantsDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_DescriptionOfNatureAmountAndCorrectionOfAccountingErrorsInPriorPeriodsEstimate": { "auth_ref": [ "r146" ], "lang": { "en": { "role": { "documentation": "The description of the nature of accounting errors in prior periods." } }, "en-us": { "role": { "label": "Description of nature of accounting errors in prior periods [text block]", "terseLabel": "Reclassifications of prior period presentation" } } }, "localname": "DescriptionOfNatureAmountAndCorrectionOfAccountingErrorsInPriorPeriodsEstimate", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": { "auth_ref": [ "r200" ], "lang": { "en": { "role": { "documentation": "The option life of share options granted." } }, "en-us": { "role": { "label": "Option life, share options granted", "terseLabel": "Expected term (in years)" } } }, "localname": "DescriptionOfOptionLifeShareOptionsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsAssumptionsOfWarrantsDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "auth_ref": [ "r200" ], "lang": { "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } }, "en-us": { "role": { "label": "Risk free interest rate, share options granted", "terseLabel": "Risk-free interest rate" } } }, "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsAssumptionsOfWarrantsDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_DilutedEarningsLossPerShare": { "auth_ref": [ "r95", "r96" ], "lang": { "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } }, "en-us": { "role": { "label": "Diluted earnings (loss) per share" } } }, "localname": "DilutedEarningsLossPerShare", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]" } }, "en-us": { "role": { "label": "Disclosure of accounting judgements and estimates [text block]", "terseLabel": "Significant Accounting Judgements, Estimates, and Assumptions" } } }, "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureSignificantAccountingJudgementsEstimatesAndAssumptions" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfAdditionalInformationExplanatory": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The disclosure of additional information that is not presented elsewhere in the financial statements, but that is relevant to an understanding of them." } }, "en-us": { "role": { "label": "Disclosure of additional information [text block]", "terseLabel": "Schedule of number of employees" } } }, "localname": "DisclosureOfAdditionalInformationExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfAuditorsRemunerationExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of compensation to the entity's auditors." } }, "en-us": { "role": { "label": "Disclosure of auditors' remuneration [text block]", "terseLabel": "Fees to auditors" } } }, "localname": "DisclosureOfAuditorsRemunerationExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureFeesToAuditors" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfBasisOfConsolidationExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of the basis used for consolidation." } }, "en-us": { "role": { "label": "Disclosure of basis of consolidation [text block]", "terseLabel": "Basis of consolidation" } } }, "localname": "DisclosureOfBasisOfConsolidationExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of the basis used for the preparation of the financial statements." } }, "en-us": { "role": { "label": "Disclosure of basis of preparation of financial statements [text block]", "terseLabel": "Basis of preparation" } } }, "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfBorrowingsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Disclosure of borrowings [text block]", "verboseLabel": "Debt" } } }, "localname": "DisclosureOfBorrowingsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureDebt" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Disclosure of cash and cash equivalents [text block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "DisclosureOfCashAndCashEquivalentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalents" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Capital Structure and Financial Matters" } } }, "localname": "DisclosureOfClassesOfShareCapitalAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": { "auth_ref": [ "r37" ], "lang": { "en": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]" } }, "en-us": { "role": { "label": "Disclosure of classes of share capital [text block]", "terseLabel": "Schedule of changes in the share capital" } } }, "localname": "DisclosureOfClassesOfShareCapitalExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of classes of share capital [line items]", "terseLabel": "Capital Structure and Financial Matters" } } }, "localname": "DisclosureOfClassesOfShareCapitalLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersCapitalTransactionsDetails", "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersChangesInShareCapitalDetails", "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersShareCapitalDetails", "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersShareholdingsByDirectorsAndExecutiveManagementDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalTable": { "auth_ref": [ "r37" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to classes of share capital." } }, "en-us": { "role": { "label": "Disclosure of classes of share capital [table]" } } }, "localname": "DisclosureOfClassesOfShareCapitalTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersCapitalTransactionsDetails", "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersChangesInShareCapitalDetails", "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersShareCapitalDetails", "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersShareholdingsByDirectorsAndExecutiveManagementDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]" } }, "en-us": { "role": { "label": "Disclosure of commitments and contingent liabilities [text block]", "terseLabel": "Contractual Obligations" } } }, "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureContractualObligations" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfCommitmentsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of commitments." } }, "en-us": { "role": { "label": "Disclosure of commitments [text block]", "terseLabel": "Schedule of contractual commitments" } } }, "localname": "DisclosureOfCommitmentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureContractualObligationsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfContingentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Contractual Obligations" } } }, "localname": "DisclosureOfContingentLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDepreciationAndAmortisationExpenseExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of depreciation and amortisation expense. [Refer: Depreciation and amortisation expense]" } }, "en-us": { "role": { "label": "Disclosure of depreciation and amortisation expense [text block]", "terseLabel": "Summary of estimated useful lives of assets" } } }, "localname": "DisclosureOfDepreciationAndAmortisationExpenseExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt" } } }, "localname": "DisclosureOfDetailedInformationAboutBorrowingsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory": { "auth_ref": [ "r216" ], "lang": { "en": { "role": { "documentation": "The disclosure of detailed information about borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [text block]", "terseLabel": "Schedule of changes in the convertible debt instruments" } } }, "localname": "DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [line items]", "terseLabel": "Convertible Debt Instruments" } } }, "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsIssuanceDetails", "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsTables", "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsTermsOfConvertibleDebtDetails", "http://www.Evaxion.com/role/DisclosureDebtDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": { "auth_ref": [ "r216" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of borrowings." } }, "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [table]" } } }, "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsIssuanceDetails", "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsTables", "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsTermsOfConvertibleDebtDetails", "http://www.Evaxion.com/role/DisclosureDebtDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": { "auth_ref": [ "r206", "r209", "r216" ], "lang": { "en": { "role": { "documentation": "The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [text block]", "terseLabel": "Financial Instruments and Risk Management" } } }, "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagement" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": { "auth_ref": [ "r110" ], "lang": { "en": { "role": { "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [text block]", "terseLabel": "Intangible assets TLG" } } }, "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": { "auth_ref": [ "r70" ], "lang": { "en": { "role": { "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [text block]", "terseLabel": "Schedule of property, plant and equipment" } } }, "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEarningsPerShareExplanatory": { "auth_ref": [ "r99" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for earnings per share." } }, "en-us": { "role": { "label": "Disclosure of earnings per share [text block]", "terseLabel": "Basic and Diluted Loss Per Share" } } }, "localname": "DisclosureOfEarningsPerShareExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureBasicAndDilutedLossPerShare" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": { "auth_ref": [ "r79" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for employee benefits." } }, "en-us": { "role": { "label": "Disclosure of employee benefits [text block]", "terseLabel": "Schedule of employee costs" } } }, "localname": "DisclosureOfEmployeeBenefitsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": { "auth_ref": [ "r54" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for events after the reporting period." } }, "en-us": { "role": { "label": "Disclosure of events after reporting period [text block]", "terseLabel": "Events After the Reporting Period" } } }, "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureEventsAfterReportingPeriod" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfExpensesByNatureExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of expenses by nature. [Refer: Expenses, by nature]" } }, "en-us": { "role": { "label": "Disclosure of expenses by nature [text block]", "terseLabel": "Operating Activities" } } }, "localname": "DisclosureOfExpensesByNatureExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureOperatingActivities" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of finance income (cost). [Refer: Finance income (cost)]" } }, "en-us": { "role": { "label": "Disclosure of finance income (cost) [text block]", "terseLabel": "Financial Income and Expenses" } } }, "localname": "DisclosureOfFinanceIncomeExpenseExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialIncomeAndExpenses" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Instruments and Risk Management" } } }, "localname": "DisclosureOfFinancialInstrumentsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of financial liabilities [abstract]" } } }, "localname": "DisclosureOfFinancialLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory": { "auth_ref": [ "r216" ], "lang": { "en": { "role": { "documentation": "The disclosure of financial liabilities. [Refer: Financial liabilities]" } }, "en-us": { "role": { "label": "Disclosure of financial liabilities [text block]", "terseLabel": "Schedule of finance liability" } } }, "localname": "DisclosureOfFinancialLiabilitiesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFirstTimeAdoptionExplanatory": { "auth_ref": [ "r151" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for the entity's first-time adoption of International Financial Reporting Standards." } }, "en-us": { "role": { "label": "Disclosure of first-time adoption [text block]", "terseLabel": "First-Time Adoption of IFRS" } } }, "localname": "DisclosureOfFirstTimeAdoptionExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureFirstTimeAdoptionOfIfrs" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of general and administrative expenses. [Refer: Administrative expenses]" } }, "en-us": { "role": { "label": "Disclosure of general and administrative expense [text block]", "terseLabel": "Schedule of general and administrative expense components" } } }, "localname": "DisclosureOfGeneralAndAdministrativeExpenseExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureOperatingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfGeographicalAreasLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of geographical areas [line items]" } } }, "localname": "DisclosureOfGeographicalAreasLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsNumberOfEmployeesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfGeographicalAreasTable": { "auth_ref": [ "r236" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to geographical areas." } }, "en-us": { "role": { "label": "Disclosure of geographical areas [table]" } } }, "localname": "DisclosureOfGeographicalAreasTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsNumberOfEmployeesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "auth_ref": [ "r61" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for income taxes." } }, "en-us": { "role": { "label": "Disclosure of income tax [text block]", "terseLabel": "Income Taxes" } } }, "localname": "DisclosureOfIncomeTaxExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": { "auth_ref": [ "r201" ], "lang": { "en": { "role": { "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options." } }, "en-us": { "role": { "label": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]", "verboseLabel": "Schedule of assumptions have been applied for the warrants issued" } } }, "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of information about employees." } }, "en-us": { "role": { "label": "Disclosure of information about employees [text block]", "terseLabel": "Employees and Employee-Related Costs" } } }, "localname": "DisclosureOfInformationAboutEmployeesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCosts" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Disclosure of information about key management personnel [text block]", "terseLabel": "Schedule of remuneration to the Board of Directors and Executive Management" } } }, "localname": "DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIntangibleAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible assets" } } }, "localname": "DisclosureOfIntangibleAssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": { "auth_ref": [ "r113" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for intangible assets." } }, "en-us": { "role": { "label": "Disclosure of intangible assets [text block]", "terseLabel": "Intangible assets" } } }, "localname": "DisclosureOfIntangibleAssetsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "DisclosureOfIntangibleAssetsLineItems" } } }, "localname": "DisclosureOfIntangibleAssetsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureIntangibleAssetsParagraphDetails", "http://www.Evaxion.com/role/DisclosureIntangibleAssetsTableDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfIntangibleAssetsTable": { "auth_ref": [ "r110" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of intangible assets." } }, "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [table]" } } }, "localname": "DisclosureOfIntangibleAssetsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureIntangibleAssetsParagraphDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfJointOperationsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of joint operations [line items]" } } }, "localname": "DisclosureOfJointOperationsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountingForJointOperationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfJointOperationsTable": { "auth_ref": [ "r163" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to joint operations." } }, "en-us": { "role": { "label": "Disclosure of joint operations [table]" } } }, "localname": "DisclosureOfJointOperationsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountingForJointOperationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfLeasesExplanatory": { "auth_ref": [ "r186", "r187" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for leases." } }, "en-us": { "role": { "label": "Disclosure of leases [text block]", "terseLabel": "Leases" } } }, "localname": "DisclosureOfLeasesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeases" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of maturity analysis for non-derivative financial liabilities [line items]" } } }, "localname": "DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementContractualUndiscountedOutflowsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable": { "auth_ref": [ "r212" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the maturity analysis for non-derivative financial liabilities." } }, "en-us": { "role": { "label": "Disclosure of maturity analysis for non-derivative financial liabilities [table]" } } }, "localname": "DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementContractualUndiscountedOutflowsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Events After the Reporting Period" } } }, "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [line items]" } } }, "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureEventsAfterReportingPeriodDetails", "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementIpoDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": { "auth_ref": [ "r53" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period." } }, "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [table]" } } }, "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureEventsAfterReportingPeriodDetails", "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementIpoDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": { "auth_ref": [ "r196" ], "lang": { "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Disclosure of number and weighted average exercise prices of share options [text block]", "terseLabel": "Schedule of granted warrants" } } }, "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": { "auth_ref": [ "r73" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for property, plant and equipment." } }, "en-us": { "role": { "label": "Disclosure of property, plant and equipment [text block]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipment" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [line items]" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDepreciationDetails", "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDetails", "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r70" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of property, plant and equipment." } }, "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [table]" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDepreciationDetails", "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDetails", "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfProvisionsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of provisions. [Refer: Provisions]" } }, "en-us": { "role": { "label": "Disclosure of provisions [text block]", "terseLabel": "Provisions" } } }, "localname": "DisclosureOfProvisionsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureProvisions" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of quantitative information about right-of-use assets [abstract]", "terseLabel": "Right-of-Use Asset" } } }, "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesMovementsInRightOfUseAssetsAndLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": { "auth_ref": [ "r182" ], "lang": { "en": { "role": { "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]" } }, "en-us": { "role": { "label": "Disclosure of quantitative information about right-of-use assets [text block]", "terseLabel": "Schedule of carrying amounts of right-of-use assets and lease liabilities and the movements" } } }, "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of quantitative information about right-of-use assets [line items]" } } }, "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable": { "auth_ref": [ "r182" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to right-of-use assets." } }, "en-us": { "role": { "label": "Disclosure of quantitative information about right-of-use assets [table]" } } }, "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory": { "auth_ref": [ "r139" ], "lang": { "en": { "role": { "documentation": "The disclosure of the reconciliation of liabilities arising from financing activities. [Refer: Liabilities arising from financing activities]" } }, "en-us": { "role": { "label": "Disclosure of reconciliation of liabilities arising from financing activities [text block]", "terseLabel": "Schedule of reconciliation of liabilities from financing activities" } } }, "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of reconciliation of liabilities arising from financing activities [line items]" } } }, "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsReconciliationOfLiabilitiesFromFinancingActivitiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable": { "auth_ref": [ "r139" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the reconciliation of liabilities arising from financing activities." } }, "en-us": { "role": { "label": "Disclosure of reconciliation of liabilities arising from financing activities [table]" } } }, "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsReconciliationOfLiabilitiesFromFinancingActivitiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "auth_ref": [ "r92" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for related parties." } }, "en-us": { "role": { "label": "Disclosure of related party [text block]", "terseLabel": "Related Party Transactions" } } }, "localname": "DisclosureOfRelatedPartyExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of research and development expense. [Refer: Research and development expense]" } }, "en-us": { "role": { "label": "Disclosure of research and development expense [text block]", "terseLabel": "Schedule of research and development expense components" } } }, "localname": "DisclosureOfResearchAndDevelopmentExpenseExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureOperatingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "auth_ref": [ "r38" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } }, "en-us": { "role": { "label": "Disclosure of share capital, reserves and other equity interest [text block]", "terseLabel": "Capital Structure and Financial Matters" } } }, "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMatters" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": { "auth_ref": [ "r188" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for share-based payment arrangements." } }, "en-us": { "role": { "label": "Disclosure of share-based payment arrangements [text block]", "terseLabel": "Share-Based Payments" } } }, "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPayments" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": { "auth_ref": [ "r13" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for significant accounting policies applied by the entity." } }, "en-us": { "role": { "label": "Disclosure of significant accounting policies [text block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory": { "auth_ref": [ "r60" ], "lang": { "en": { "role": { "documentation": "The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]" } }, "en-us": { "role": { "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [text block]", "verboseLabel": "Schedule of deferred tax in the statements of financial position" } } }, "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]" } } }, "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureIncomeTaxesDeferredTaxDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": { "auth_ref": [ "r60" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits." } }, "en-us": { "role": { "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]" } } }, "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureIncomeTaxesDeferredTaxDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payments" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]", "verboseLabel": "Share-Based Payments" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsAmendmentsToWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsAssumptionsOfWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsFairValueOfWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsKeyManagementHoldingsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsOutstandingWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsScheduleOfWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsRectifiedDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "auth_ref": [ "r199" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } }, "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [table]" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsAmendmentsToWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsAssumptionsOfWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsFairValueOfWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsKeyManagementHoldingsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsOutstandingWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsScheduleOfWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsRectifiedDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": { "auth_ref": [ "r88" ], "lang": { "en": { "role": { "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Disclosure of transactions between related parties [text block]", "terseLabel": "Schedule of transactions with related parties" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureRelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of transactions between related parties [line items]" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsBoardOfDirectorsAndExecutiveManagementDetails", "http://www.Evaxion.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": { "auth_ref": [ "r90" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to transactions between related parties." } }, "en-us": { "role": { "label": "Disclosure of transactions between related parties [table]" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsBoardOfDirectorsAndExecutiveManagementDetails", "http://www.Evaxion.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisposalsPropertyPlantAndEquipment": { "auth_ref": [ "r66" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Disposals, property, plant and equipment", "negatedLabel": "Disposals during the year" } } }, "localname": "DisposalsPropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic and Diluted Loss Per Share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_EarningsPerShareExplanatory": { "auth_ref": [ "r95" ], "lang": { "en": { "role": { "documentation": "The disclosure of earnings per share." } }, "en-us": { "role": { "label": "Earnings per share [text block]", "terseLabel": "Schedule of basic and diluted loss per share" } } }, "localname": "EarningsPerShareExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureBasicAndDilutedLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "auth_ref": [ "r131", "r132" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Effect of exchange rate changes on cash and cash equivalents", "terseLabel": "Exchange rate adjustments on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EmployeeBenefitsExpense": { "auth_ref": [ "r1", "r3", "r51" ], "calculation": { "http://www.Evaxion.com/role/DisclosureOperatingActivitiesDetails": { "order": 2.0, "parentTag": "ifrs-full_ExpenseByNature", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment." } }, "en-us": { "role": { "label": "Employee benefits expense", "negatedTerseLabel": "Employee salary and benefit expenses, excluding share-based compensation" } } }, "localname": "EmployeeBenefitsExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureOperatingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EntitysTotalForJointOperationsMember": { "auth_ref": [ "r163" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Joint operations' axis if no other member is used." } }, "en-us": { "role": { "label": "Entity's total for joint operations [member]" } } }, "localname": "EntitysTotalForJointOperationsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountingForJointOperationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_EntitysTotalForRelatedPartiesMember": { "auth_ref": [ "r90" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } }, "en-us": { "role": { "label": "Entity's total for related parties [member]" } } }, "localname": "EntitysTotalForRelatedPartiesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersShareholdingsByDirectorsAndExecutiveManagementDetails", "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsIssuanceDetails", "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsBoardOfDirectorsAndExecutiveManagementDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsKeyManagementHoldingsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Equity": { "auth_ref": [ "r23", "r32", "r147", "r149", "r164", "r165", "r168" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } }, "en-us": { "role": { "label": "Equity", "periodEndLabel": "Equity", "periodStartLabel": "Equity", "terseLabel": "Outstanding share capital (in DKK)", "totalLabel": "Total equity", "verboseLabel": "Share capital" } } }, "localname": "Equity", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersCapitalTransactionsDetails", "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersChangesInShareCapitalDetails", "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersShareCapitalDetails", "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementIpoDetails", "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementLiquidityRiskDetails", "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfChangesInEquity", "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAndLiabilities": { "auth_ref": [ "r23" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } }, "en-us": { "role": { "label": "Equity and liabilities", "totalLabel": "TOTAL EQUITY AND LIABILITIES" } } }, "localname": "EquityAndLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity and liabilities [abstract]", "terseLabel": "EQUITY AND LIABILITIES" } } }, "localname": "EquityAndLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_EquityMember": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } }, "en-us": { "role": { "label": "Equity [member]" } } }, "localname": "EquityMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersChangesInShareCapitalDetails", "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersShareCapitalDetails", "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_ExercisePriceShareOptionsGranted2019": { "auth_ref": [ "r200" ], "lang": { "en": { "role": { "documentation": "The exercise price of share options granted." } }, "en-us": { "role": { "label": "Exercise price, share options granted", "terseLabel": "Exercise price per warrant", "verboseLabel": "Exercise price of the warrants issued" } } }, "localname": "ExercisePriceShareOptionsGranted2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureDebtDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsAssumptionsOfWarrantsDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_ExpenseByNature": { "auth_ref": [ "r51" ], "calculation": { "http://www.Evaxion.com/role/DisclosureOperatingActivitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenses aggregated according to their nature (for example, depreciation, purchases of materials, transport costs, employee benefits and advertising costs), and not reallocated among functions within the entity." } }, "en-us": { "role": { "label": "Expenses, by nature", "negatedTotalLabel": "Total" } } }, "localname": "ExpenseByNature", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureOperatingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ExpenseByNatureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Activities" } } }, "localname": "ExpenseByNatureAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": { "auth_ref": [ "r11" ], "calculation": { "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsEmployeeCostsDetails": { "order": 1.0, "parentTag": "evax_EmployeeBenefitsAndShareBasedCompensations", "weight": 1.0 }, "http://www.Evaxion.com/role/DisclosureOperatingActivitiesDetails": { "order": 3.0, "parentTag": "ifrs-full_ExpenseByNature", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]" } }, "en-us": { "role": { "label": "Expense from share-based payment transactions with employees", "negatedLabel": "Share-based compensation expenses", "terseLabel": "Share-based compensation expenses" } } }, "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsEmployeeCostsDetails", "http://www.Evaxion.com/role/DisclosureOperatingActivitiesDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinanceCosts": { "auth_ref": [ "r45" ], "calculation": { "http://www.Evaxion.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "order": 1.0, "parentTag": "ifrs-full_FinanceIncomeCost", "weight": -1.0 }, "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of costs associated with financing activities of the entity." } }, "en-us": { "role": { "label": "Finance costs", "negatedTerseLabel": "Finance expenses", "negatedTotalLabel": "Total financial expenses" } } }, "localname": "FinanceCosts", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialIncomeAndExpensesDetails", "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinanceIncome": { "auth_ref": [ "r47" ], "calculation": { "http://www.Evaxion.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "order": 2.0, "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0 }, "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income associated with interest and other financing activities of the entity." } }, "en-us": { "role": { "label": "Finance income", "terseLabel": "Finance income", "totalLabel": "Total financial income" } } }, "localname": "FinanceIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialIncomeAndExpensesDetails", "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinanceIncomeCost": { "auth_ref": [ "r47" ], "calculation": { "http://www.Evaxion.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income or cost associated with interest and other financing activities of the entity." } }, "en-us": { "role": { "label": "Finance income (cost)", "totalLabel": "Net financial items" } } }, "localname": "FinanceIncomeCost", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialLiabilities": { "auth_ref": [ "r205" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]" } }, "en-us": { "role": { "label": "Financial liabilities", "totalLabel": "Total Loan from lessor, net of current portion" } } }, "localname": "FinancialLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesSummaryOfFinanceLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialLiabilitiesAtAmortisedCost": { "auth_ref": [ "r217", "r246" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of financial liabilities at amortised cost. The amortised cost is the amount at which financial liabilities are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount. [Refer: Financial liabilities]" } }, "en-us": { "role": { "label": "Financial liabilities at amortised cost", "verboseLabel": "Carrying amount" } } }, "localname": "FinancialLiabilitiesAtAmortisedCost", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementContractualUndiscountedOutflowsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialLiabilitiesCarryingAmountImmediatelyAfterInitialApplicationOfIFRS9": { "auth_ref": [ "r215" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The carrying amount of financial liabilities immediately after the initial application of IFRS 9. [Refer: Financial liabilities]" } }, "en-us": { "role": { "label": "Financial liabilities, carrying amount immediately after initial application of IFRS 9", "terseLabel": "Loan from lessor" } } }, "localname": "FinancialLiabilitiesCarryingAmountImmediatelyAfterInitialApplicationOfIFRS9", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesSummaryOfFinanceLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FixedInterestRateMember": { "auth_ref": [ "r213" ], "lang": { "en": { "role": { "documentation": "This member stands for a fixed interest rate. [Refer: Interest rate risk [member]]" } }, "en-us": { "role": { "label": "Fixed interest rate" } } }, "localname": "FixedInterestRateMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_GeneralAndAdministrativeExpense": { "auth_ref": [ "r11" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense relating to general and administrative activities of the entity." } }, "en-us": { "role": { "label": "General and administrative expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GeographicalAreasAxis": { "auth_ref": [ "r74", "r174", "r236", "r243" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Geographical areas [axis]" } } }, "localname": "GeographicalAreasAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsNumberOfEmployeesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_GeographicalAreasMember": { "auth_ref": [ "r74", "r174", "r236", "r243" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used." } }, "en-us": { "role": { "label": "Geographical areas [member]" } } }, "localname": "GeographicalAreasMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsNumberOfEmployeesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_GrossCarryingAmountMember": { "auth_ref": [ "r64", "r105", "r115", "r118", "r202", "r208", "r210", "r211", "r245", "r249" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]" } }, "en-us": { "role": { "label": "Cost" } } }, "localname": "GrossCarryingAmountMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureIntangibleAssetsTableDetails", "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDepreciationDetails", "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ImpairmentLoss": { "auth_ref": [ "r101", "r102" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount recognised as a reduction of the carrying amount of an asset or cash-generating unit to its recoverable amount. [Refer: Carrying amount [member]]" } }, "en-us": { "role": { "label": "Impairment loss", "terseLabel": "Impairment loss" } } }, "localname": "ImpairmentLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfNonFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "auth_ref": [ "r46", "r55", "r56", "r57", "r93", "r162", "r226" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]" } }, "en-us": { "role": { "label": "Tax expense (income)", "negatedLabel": "Income tax benefit", "terseLabel": "Income tax benefit", "verboseLabel": "Total income taxes for the year" } } }, "localname": "IncomeTaxExpenseContinuingOperations", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureIncomeTaxesAnalysisOfChargeCreditDetails", "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss": { "auth_ref": [ "r50" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "order": 4.0, "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of income tax relating to amounts recognised in other comprehensive income that will be reclassified to profit or loss. [Refer: Income tax relating to components of other comprehensive income]" } }, "en-us": { "role": { "label": "Income tax relating to components of other comprehensive income that will be reclassified to profit or loss", "negatedLabel": "Tax on other comprehensive income, income/(expense)", "negatedTerseLabel": "Tax effect on OCI items" } } }, "localname": "IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfChangesInEquity", "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": { "auth_ref": [ "r120", "r134" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 5.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]" } }, "en-us": { "role": { "label": "Income taxes paid (refund), classified as operating activities", "terseLabel": "Income taxes received" } } }, "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": { "auth_ref": [ "r140" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } }, "en-us": { "role": { "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes", "totalLabel": "Net (decrease)/increase in cash and cash equivalents" } } }, "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]" } }, "en-us": { "role": { "label": "Increase (decrease) in number of ordinary shares issued", "terseLabel": "Ordinary shares issued", "verboseLabel": "Number of shares issued" } } }, "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssued", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersCapitalTransactionsDetails", "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementIpoDetails", "http://www.Evaxion.com/role/DisclosureGeneralCompanyInformationDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_IncreaseDecreaseInWorkingCapital": { "auth_ref": [ "r130" ], "calculation": { "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsChangesInNetWorkingCapitalDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in working capital." } }, "en-us": { "role": { "label": "Increase (decrease) in working capital", "terseLabel": "Changes in net working capital", "totalLabel": "Changes in net working capital" } } }, "localname": "IncreaseDecreaseInWorkingCapital", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsChangesInNetWorkingCapitalDetails", "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments": { "auth_ref": [ "r8" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the conversion of convertible instruments." } }, "en-us": { "role": { "label": "Increase (decrease) through conversion of convertible instruments, equity", "terseLabel": "Settlement of convertible debt instruments", "verboseLabel": "Settlement of convertible debt instruments" } } }, "localname": "IncreaseDecreaseThroughConversionOfConvertibleInstruments", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersChangesInShareCapitalDetails", "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities": { "auth_ref": [ "r136" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from the effect of changes in foreign exchange rates. [Refer: Liabilities arising from financing activities]" } }, "en-us": { "role": { "label": "Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities", "verboseLabel": "Exchange rate adjustment" } } }, "localname": "IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsReconciliationOfLiabilitiesFromFinancingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities": { "auth_ref": [ "r135" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows. [Refer: Cash flows from (used in) financing activities; Liabilities arising from financing activities]" } }, "en-us": { "role": { "label": "Increase (decrease) through financing cash flows, liabilities arising from financing activities", "verboseLabel": "Cash flows" } } }, "localname": "IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsReconciliationOfLiabilitiesFromFinancingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r108" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Increase (decrease) through net exchange differences, intangible assets other than goodwill", "terseLabel": "Exchange rate adjustments" } } }, "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureIntangibleAssetsTableDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment": { "auth_ref": [ "r68" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Increase (decrease) through net exchange differences, property, plant and equipment", "terseLabel": "Exchange rate adjustments" } } }, "localname": "IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "auth_ref": [ "r7" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } }, "en-us": { "role": { "label": "Increase (decrease) through share-based payment transactions, equity", "verboseLabel": "Share-based compensation" } } }, "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities": { "auth_ref": [ "r137", "r142" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]" } }, "en-us": { "role": { "label": "Increase through new leases, liabilities arising from financing activities", "verboseLabel": "Additions" } } }, "localname": "IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsReconciliationOfLiabilitiesFromFinancingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InitiallyAppliedIFRSsAxis": { "auth_ref": [ "r144" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Initially applied IFRSs [axis]" } } }, "localname": "InitiallyAppliedIFRSsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_InitiallyAppliedIFRSsMember": { "auth_ref": [ "r144" ], "lang": { "en": { "role": { "documentation": "This member stands for IFRSs that have been initially applied by the entity. It also represents the standard value for the 'Initially applied IFRSs' axis if no other member is used. [Refer: IFRSs [member]]" } }, "en-us": { "role": { "label": "Initially applied IFRSs [member]" } } }, "localname": "InitiallyAppliedIFRSsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r17", "r109" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } }, "en-us": { "role": { "label": "Intangible assets other than goodwill", "periodEndLabel": "December 31, 2021", "periodStartLabel": "December 31, 2020", "terseLabel": "Intangible assets" } } }, "localname": "IntangibleAssetsOtherThanGoodwill", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureIntangibleAssetsTableDetails", "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": { "auth_ref": [ "r100", "r110", "r182" ], "lang": { "en": { "role": { "documentation": "This member stands for intangible assets other than goodwill. It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Cost at December 31, 2019" } } }, "localname": "IntangibleAssetsOtherThanGoodwillMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureIntangibleAssetsParagraphDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_InterestExpense": { "auth_ref": [ "r161", "r225", "r232" ], "calculation": { "http://www.Evaxion.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "order": 2.0, "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense arising from interest." } }, "en-us": { "role": { "label": "Interest expense", "negatedTerseLabel": "Interest expenses" } } }, "localname": "InterestExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestExpenseOnBorrowings": { "auth_ref": [ "r11" ], "calculation": { "http://www.Evaxion.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "order": 3.0, "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]" } }, "en-us": { "role": { "label": "Interest expense on borrowings", "negatedTerseLabel": "Interest, loan from lessor" } } }, "localname": "InterestExpenseOnBorrowings", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestExpenseOnLeaseLiabilities": { "auth_ref": [ "r178" ], "calculation": { "http://www.Evaxion.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "order": 4.0, "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Interest expense on lease liabilities", "negatedTerseLabel": "Interest expenses, lease liabilities" } } }, "localname": "InterestExpenseOnLeaseLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestIncomeOnCashAndCashEquivalents": { "auth_ref": [ "r11" ], "calculation": { "http://www.Evaxion.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "order": 1.0, "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of interest income on cash and cash equivalents. [Refer: Interest income; Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Interest income on cash and cash equivalents", "terseLabel": "Interest income, bank" } } }, "localname": "InterestIncomeOnCashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestIncomeOnOtherFinancialAssets": { "auth_ref": [ "r11" ], "calculation": { "http://www.Evaxion.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "order": 2.0, "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of interest income on other financial assets. [Refer: Interest income; Other financial assets]" } }, "en-us": { "role": { "label": "Interest income on other financial assets", "terseLabel": "Interest income, other" } } }, "localname": "InterestIncomeOnOtherFinancialAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestPaidClassifiedAsOperatingActivities": { "auth_ref": [ "r133" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for interest paid, classified as operating activities." } }, "en-us": { "role": { "label": "Interest paid, classified as operating activities", "negatedTerseLabel": "Interest paid" } } }, "localname": "InterestPaidClassifiedAsOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestRateTypesMember": { "auth_ref": [ "r213" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of interest rates. It also represents the standard value for the 'Types of interest rates' axis if no other member is used. [Refer: Interest rate risk [member]]" } }, "en-us": { "role": { "label": "Interest rate types [member]" } } }, "localname": "InterestRateTypesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_InterestReceivedClassifiedAsOperatingActivities": { "auth_ref": [ "r133" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from interest received, classified as operating activities." } }, "en-us": { "role": { "label": "Interest received, classified as operating activities", "terseLabel": "Interest received" } } }, "localname": "InterestReceivedClassifiedAsOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssueOfEquity": { "auth_ref": [ "r7" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } }, "en-us": { "role": { "label": "Issue of equity", "terseLabel": "Issuance of shares for cash" } } }, "localname": "IssueOfEquity", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersChangesInShareCapitalDetails", "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapital": { "auth_ref": [ "r32" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The nominal value of capital issued." } }, "en-us": { "role": { "label": "Issued capital", "positiveLabel": "Registered, issued, and outstanding share capital", "terseLabel": "Share capital", "verboseLabel": "Issued share capital (in DKK)" } } }, "localname": "IssuedCapital", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersCapitalTransactionsDetails", "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementIpoDetails", "http://www.Evaxion.com/role/DisclosureGeneralCompanyInformationDetails", "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapitalMember": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } }, "en-us": { "role": { "label": "Share capital" } } }, "localname": "IssuedCapitalMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersChangesInShareCapitalDetails", "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersShareCapitalDetails", "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_JointOperationsAxis": { "auth_ref": [ "r163" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Joint operations [axis]" } } }, "localname": "JointOperationsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountingForJointOperationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_KeyManagementPersonnelCompensation": { "auth_ref": [ "r86" ], "calculation": { "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsBoardOfDirectorsAndExecutiveManagementDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key management personnel compensation", "totalLabel": "Total" } } }, "localname": "KeyManagementPersonnelCompensation", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsBoardOfDirectorsAndExecutiveManagementDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "auth_ref": [ "r85" ], "calculation": { "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsBoardOfDirectorsAndExecutiveManagementDetails": { "order": 1.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key management personnel compensation, share-based payment", "terseLabel": "Share-based compensation expenses" } } }, "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsBoardOfDirectorsAndExecutiveManagementDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": { "auth_ref": [ "r84" ], "calculation": { "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsBoardOfDirectorsAndExecutiveManagementDetails": { "order": 2.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key management personnel compensation, short-term employee benefits", "terseLabel": "Wages and salaries" } } }, "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsBoardOfDirectorsAndExecutiveManagementDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelOfEntityOrParentMember": { "auth_ref": [ "r89" ], "lang": { "en": { "role": { "documentation": "This member stands for those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including any director (whether executive or otherwise) of that entity." } }, "en-us": { "role": { "label": "Board of Directors and Executive Management" } } }, "localname": "KeyManagementPersonnelOfEntityOrParentMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsIssuanceDetails", "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsBoardOfDirectorsAndExecutiveManagementDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LaterThanFiveYearsMember": { "auth_ref": [ "r183", "r184", "r219", "r220", "r223", "r242" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of later than five years." } }, "en-us": { "role": { "label": "Greater than 5 years" } } }, "localname": "LaterThanFiveYearsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementContractualUndiscountedOutflowsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember": { "auth_ref": [ "r218", "r223" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than five years." } }, "en-us": { "role": { "label": "1-5 years" } } }, "localname": "LaterThanOneYearAndNotLaterThanFiveYearsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementContractualUndiscountedOutflowsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LeaseLiabilities": { "auth_ref": [ "r176" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } }, "en-us": { "role": { "label": "Lease liabilities.", "periodEndLabel": "Balance end of year", "periodStartLabel": "Balance beginning of year", "verboseLabel": "Lease liabilities" } } }, "localname": "LeaseLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesDetails", "http://www.Evaxion.com/role/DisclosureLeasesMovementsInRightOfUseAssetsAndLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease liabilities [abstract]", "terseLabel": "Lease liabilities" } } }, "localname": "LeaseLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesMovementsInRightOfUseAssetsAndLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_LeaseLiabilitiesMember": { "auth_ref": [ "r138", "r143" ], "lang": { "en": { "role": { "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Lease liabilities" } } }, "localname": "LeaseLiabilitiesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsReconciliationOfLiabilitiesFromFinancingActivitiesDetails", "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementContractualUndiscountedOutflowsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LeaseholdImprovementsMember": { "auth_ref": [ "r62" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing improvements to assets held under a lease agreement." } }, "en-us": { "role": { "label": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDetails", "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Liabilities": { "auth_ref": [ "r23", "r164", "r165", "r168", "r227", "r231" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LiabilitiesArisingFromFinancingActivities": { "auth_ref": [ "r139" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]" } }, "en-us": { "role": { "label": "Liabilities arising from financing activities", "periodEndLabel": "Balance end of year", "periodStartLabel": "Balance beginning of year" } } }, "localname": "LiabilitiesArisingFromFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsReconciliationOfLiabilitiesFromFinancingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis": { "auth_ref": [ "r139" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Liabilities arising from financing activities [axis]" } } }, "localname": "LiabilitiesArisingFromFinancingActivitiesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsReconciliationOfLiabilitiesFromFinancingActivitiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember": { "auth_ref": [ "r139" ], "lang": { "en": { "role": { "documentation": "This member stands for liabilities arising from financing activities. It also represents the standard value for the 'Liabilities arising from financing activities' axis if no other member is used. [Refer: Liabilities arising from financing activities]" } }, "en-us": { "role": { "label": "Liabilities arising from financing activities [member]" } } }, "localname": "LiabilitiesArisingFromFinancingActivitiesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsReconciliationOfLiabilitiesFromFinancingActivitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LiabilitiesMember": { "auth_ref": [ "r169" ], "lang": { "en": { "role": { "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]" } }, "en-us": { "role": { "label": "Liabilities [member]" } } }, "localname": "LiabilitiesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementContractualUndiscountedOutflowsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LineItemsByFunctionMember": { "auth_ref": [ "r3", "r11" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value of the \u2018Attribution of expenses by nature to their function' axis if no other member is used." } }, "en-us": { "role": { "label": "Line items by function [member]" } } }, "localname": "LineItemsByFunctionMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDepreciationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LongtermBorrowings": { "auth_ref": [ "r23" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The non-current portion of non-current borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Non-current portion of non-current borrowings", "terseLabel": "Loan from lessor, non-current" } } }, "localname": "LongtermBorrowings", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LongtermDeposits": { "auth_ref": [ "r23" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 5.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of long-term deposits held by the entity." } }, "en-us": { "role": { "label": "Long-term deposits", "terseLabel": "Leasehold deposits" } } }, "localname": "LongtermDeposits", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Major components of tax expense (income) [abstract]" } } }, "localname": "MajorComponentsOfTaxExpenseIncomeAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities": { "auth_ref": [ "r212" ], "lang": { "en": { "role": { "documentation": "The disclosure of a maturity analysis for non-derivative financial liabilities (including issued financial guarantee contracts) that shows the remaining contractual maturities. [Refer: Derivative financial liabilities]" } }, "en-us": { "role": { "label": "Disclosure of maturity analysis for non-derivative financial liabilities [text block]", "terseLabel": "Schedule of contractual outflows of financial liabilities" } } }, "localname": "MaturityAnalysisForNonderivativeFinancialLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_MaturityAxis": { "auth_ref": [ "r26", "r75", "r173", "r183", "r184", "r204", "r214", "r219", "r238", "r239", "r241", "r242" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Maturity [axis]" } } }, "localname": "MaturityAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureContractualObligationsContractualCommitmentsDetails", "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementContractualUndiscountedOutflowsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_NetForeignExchangeGain": { "auth_ref": [ "r14", "r82" ], "calculation": { "http://www.Evaxion.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "order": 3.0, "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The net gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } }, "en-us": { "role": { "label": "Net foreign exchange gain", "terseLabel": "Foreign exchange gains" } } }, "localname": "NetForeignExchangeGain", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NetForeignExchangeLoss": { "auth_ref": [ "r14", "r82" ], "calculation": { "http://www.Evaxion.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "order": 5.0, "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The net loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } }, "en-us": { "role": { "label": "Net foreign exchange loss", "negatedTerseLabel": "Foreign exchange losses" } } }, "localname": "NetForeignExchangeLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "auth_ref": [ "r53" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Non-adjusting events after reporting period [axis]" } } }, "localname": "NonadjustingEventsAfterReportingPeriodAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersChangesInShareCapitalDetails", "http://www.Evaxion.com/role/DisclosureEventsAfterReportingPeriodDetails", "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementIpoDetails", "http://www.Evaxion.com/role/DisclosureGeneralCompanyInformationDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_NonadjustingEventsMember": { "auth_ref": [ "r53" ], "lang": { "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } }, "en-us": { "role": { "label": "Non-adjusting events after reporting period [member]" } } }, "localname": "NonadjustingEventsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersChangesInShareCapitalDetails", "http://www.Evaxion.com/role/DisclosureEventsAfterReportingPeriodDetails", "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementIpoDetails", "http://www.Evaxion.com/role/DisclosureGeneralCompanyInformationDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_NoncurrentAssets": { "auth_ref": [ "r27", "r152", "r154" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } }, "en-us": { "role": { "label": "Non-current assets", "totalLabel": "Total non-current assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current assets [abstract]", "terseLabel": "Non-current assets" } } }, "localname": "NoncurrentAssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentLeaseLiabilities": { "auth_ref": [ "r176" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Non-current lease liabilities", "terseLabel": "Lease liabilities, non-current" } } }, "localname": "NoncurrentLeaseLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLiabilities": { "auth_ref": [ "r28", "r152", "r156" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } }, "en-us": { "role": { "label": "Non-current liabilities", "totalLabel": "Total non-current liabilities" } } }, "localname": "NoncurrentLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current liabilities [abstract]", "terseLabel": "Non-current liabilities" } } }, "localname": "NoncurrentLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentProvisions": { "auth_ref": [ "r20" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]" } }, "en-us": { "role": { "label": "Non-current provisions", "periodEndLabel": "Carrying amount of ending balance", "periodStartLabel": "Carrying amount of Begging balance", "terseLabel": "Provisions" } } }, "localname": "NoncurrentProvisions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureProvisionsDetails", "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NonderivativeFinancialLiabilitiesUndiscountedCashFlows": { "auth_ref": [ "r212" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of contractual undiscounted cash flows in relation to non-derivative financial liabilities." } }, "en-us": { "role": { "label": "Non-derivative financial liabilities, undiscounted cash flows", "terseLabel": "Contractual cash flow" } } }, "localname": "NonderivativeFinancialLiabilitiesUndiscountedCashFlows", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementContractualUndiscountedOutflowsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NotLaterThanOneYearMember": { "auth_ref": [ "r25", "r183", "r184", "r219", "r223", "r242" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } }, "en-us": { "role": { "label": "Less than one year" } } }, "localname": "NotLaterThanOneYearMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureContractualObligationsContractualCommitmentsDetails", "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementContractualUndiscountedOutflowsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_NotionalAmount": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument." } }, "en-us": { "role": { "label": "Notional amount", "terseLabel": "Principal amount", "verboseLabel": "Loan" } } }, "localname": "NotionalAmount", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsTermsOfConvertibleDebtDetails", "http://www.Evaxion.com/role/DisclosureDebtDetails", "http://www.Evaxion.com/role/DisclosureEventsAfterReportingPeriodDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NumberAndAverageNumberOfEmployeesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number and average number of employees [abstract]" } } }, "localname": "NumberAndAverageNumberOfEmployeesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsNumberOfEmployeesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_NumberOfEmployees": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The number of personnel employed by the entity at a date." } }, "en-us": { "role": { "label": "Number of employees", "terseLabel": "Members of executive management" } } }, "localname": "NumberOfEmployees", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsBoardOfDirectorsAndExecutiveManagementDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfOutstandingShareOptions": { "auth_ref": [ "r189", "r194", "r198" ], "lang": { "en": { "role": { "documentation": "The number of share options outstanding in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of share options outstanding in share-based payment arrangement", "periodEndLabel": "Warrants granted at end of period", "periodStartLabel": "Warrants granted at beginning of period", "terseLabel": "Warrants outstanding", "verboseLabel": "Number of warrants outstanding" } } }, "localname": "NumberOfOutstandingShareOptions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsKeyManagementHoldingsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsOutstandingWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsScheduleOfWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsRectifiedDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": { "auth_ref": [ "r195" ], "lang": { "en": { "role": { "documentation": "The number of share options exercisable in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of share options exercisable in share-based payment arrangement", "negatedLabel": "Warrants exercisable", "terseLabel": "Warrants exercisable" } } }, "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsOutstandingWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsScheduleOfWarrantsDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": { "auth_ref": [ "r192" ], "lang": { "en": { "role": { "documentation": "The number of share options exercised in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of share options exercised in share-based payment arrangement", "negatedLabel": "Exercised" } } }, "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsKeyManagementHoldingsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsScheduleOfWarrantsDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement": { "auth_ref": [ "r193" ], "lang": { "en": { "role": { "documentation": "The number of share options expired in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number Of Share Options Expired In Sharebased Payment Arrangement", "negatedLabel": "Warrants cancelled" } } }, "localname": "NumberOfShareOptionsExpiredInSharebasedPaymentArrangement", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsScheduleOfWarrantsDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": { "auth_ref": [ "r191" ], "lang": { "en": { "role": { "documentation": "The number of share options forfeited in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number Of Share Options Forfeited In Sharebased Payment Arrangement", "negatedLabel": "Warrants forfeited", "negatedTerseLabel": "Forfeited" } } }, "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsKeyManagementHoldingsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsScheduleOfWarrantsDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": { "auth_ref": [ "r190" ], "lang": { "en": { "role": { "documentation": "The number of share options granted in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of share options granted in share-based payment arrangement", "terseLabel": "Warrants granted" } } }, "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsKeyManagementHoldingsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsScheduleOfWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsRectifiedDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfSharesAuthorised": { "auth_ref": [ "r34" ], "lang": { "en": { "role": { "documentation": "The number of shares authorised." } }, "en-us": { "role": { "label": "Number of shares authorised", "terseLabel": "Ordinary shares authorized on capital", "verboseLabel": "Shares registered (in shares)" } } }, "localname": "NumberOfSharesAuthorised", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementIpoDetails", "http://www.Evaxion.com/role/DisclosureGeneralCompanyInformationDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_NumberOfSharesIssued": { "auth_ref": [ "r8" ], "lang": { "en": { "role": { "documentation": "The number of shares issued by the entity." } }, "en-us": { "role": { "label": "Number of shares issued (in shares)", "periodEndLabel": "Share capital, shares, end of the period", "periodStartLabel": "Share capital, shares, beginning of year", "positiveLabel": "Share capital (in shares)", "terseLabel": "Allotted, called up and fully paid shares" } } }, "localname": "NumberOfSharesIssued", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersCapitalTransactionsDetails", "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersChangesInShareCapitalDetails", "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersShareCapitalDetails", "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersShareholdingsByDirectorsAndExecutiveManagementDetails", "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementIpoDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_NumberOfSharesOutstanding": { "auth_ref": [ "r36" ], "lang": { "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } }, "en-us": { "role": { "label": "Number of shares outstanding", "terseLabel": "Shares outstanding (in shares)" } } }, "localname": "NumberOfSharesOutstanding", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementIpoDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_OperatingExpense": { "auth_ref": [ "r47" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of all operating expenses." } }, "en-us": { "role": { "label": "Operating expense", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OrdinarySharesMember": { "auth_ref": [ "r37", "r95" ], "lang": { "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used." } }, "en-us": { "role": { "label": "Ordinary Shares, nominal value of DKK 1 per share" } } }, "localname": "OrdinarySharesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersCapitalTransactionsDetails", "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersChangesInShareCapitalDetails", "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersShareCapitalDetails", "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementIpoDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_OtherAdjustmentsForNoncashItems": { "auth_ref": [ "r129" ], "calculation": { "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsAdjustmentsForNonCashItemsDetails": { "order": 8.0, "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for non-cash items to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Other adjustments for non-cash items", "verboseLabel": "Other adjustments, primarily exchange rate adjustments" } } }, "localname": "OtherAdjustmentsForNoncashItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCashAndCashEquivalentsAdjustmentsForNonCashItemsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncome": { "auth_ref": [ "r6", "r40", "r48", "r159" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]" } }, "en-us": { "role": { "label": "Other comprehensive income", "totalLabel": "Other comprehensive loss for the period, net of tax" } } }, "localname": "OtherComprehensiveIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncomeBeforeTax": { "auth_ref": [ "r49" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income, before tax. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Other comprehensive income, before tax", "terseLabel": "Other comprehensive income" } } }, "localname": "OtherComprehensiveIncomeBeforeTax", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxChangeInValueOfForeignCurrencyBasisSpreads": { "auth_ref": [ "r29", "r48" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "order": 3.0, "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to change in value of foreign currency basis spreads. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Other comprehensive income, net of tax, change in value of foreign currency basis spreads", "terseLabel": "Exchange rate adjustments of investments in subsidiaries" } } }, "localname": "OtherComprehensiveIncomeNetOfTaxChangeInValueOfForeignCurrencyBasisSpreads", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "auth_ref": [ "r29", "r48" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Other comprehensive income, net of tax, exchange differences on translation", "verboseLabel": "Exchange differences on translation of foreign operations" } } }, "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations": { "auth_ref": [ "r48" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, related to exchange differences on translation of the financial statements of a parent company or a stand-alone entity to a different presentation currency. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Other Comprehensive Income Net Of Tax Exchange Difference On Currency Translation", "terseLabel": "Exchange differences on currency translation to presentation currency" } } }, "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCurrentLiabilities": { "auth_ref": [ "r23" ], "calculation": { "http://www.Evaxion.com/role/DisclosureOtherPayablesDetails": { "order": 1.0, "parentTag": "ifrs-full_OtherCurrentPayables", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]" } }, "en-us": { "role": { "label": "Other current liabilities", "terseLabel": "Other liabilities" } } }, "localname": "OtherCurrentLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureOtherPayablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCurrentPayables": { "auth_ref": [ "r23" ], "calculation": { "http://www.Evaxion.com/role/DisclosureOtherPayablesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 4.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other current payables", "terseLabel": "Other payables", "totalLabel": "Total other payables" } } }, "localname": "OtherCurrentPayables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureOtherPayablesDetails", "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCurrentReceivables": { "auth_ref": [ "r31" ], "calculation": { "http://www.Evaxion.com/role/DisclosurePrepaymentsAndOtherReceivablesDetails": { "order": 3.0, "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current other receivables. [Refer: Other receivables]" } }, "en-us": { "role": { "label": "Other current receivables", "terseLabel": "Other receivables" } } }, "localname": "OtherCurrentReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosurePrepaymentsAndOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherEmployeeExpense": { "auth_ref": [ "r76" ], "calculation": { "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsEmployeeCostsDetails": { "order": 2.0, "parentTag": "evax_EmployeeBenefitsAndShareBasedCompensations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of employee expenses that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other employee expense", "terseLabel": "Other staff expenses" } } }, "localname": "OtherEmployeeExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsEmployeeCostsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherExpenseByNature": { "auth_ref": [ "r1", "r51" ], "calculation": { "http://www.Evaxion.com/role/DisclosureOperatingActivitiesDetails": { "order": 4.0, "parentTag": "ifrs-full_ExpenseByNature", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'nature of expense' form for its analysis of expenses. [Refer: Expenses, by nature]" } }, "en-us": { "role": { "label": "Other expenses, by nature", "negatedTerseLabel": "External expenses" } } }, "localname": "OtherExpenseByNature", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureOperatingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherPropertyPlantAndEquipmentMember": { "auth_ref": [ "r62" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing property, plant and equipment that the entity does not separately disclose in the same statement or note. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Other equipment" } } }, "localname": "OtherPropertyPlantAndEquipmentMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDetails", "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_OtherReserves": { "auth_ref": [ "r32" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]" } }, "en-us": { "role": { "label": "Other reserves", "terseLabel": "Other reserves" } } }, "localname": "OtherReserves", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherTemporaryDifferencesMember": { "auth_ref": [ "r60" ], "lang": { "en": { "role": { "documentation": "This member stands for temporary differences that the entity does not separately disclose in the same statement or note. [Refer: Temporary differences [member]]" } }, "en-us": { "role": { "label": "Other items" } } }, "localname": "OtherTemporaryDifferencesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureIncomeTaxesDeferredTaxDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ParValuePerShare": { "auth_ref": [ "r35" ], "lang": { "en": { "role": { "documentation": "The nominal value per share." } }, "en-us": { "role": { "label": "Par value per share", "verboseLabel": "Nominal value per share" } } }, "localname": "ParValuePerShare", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersCapitalTransactionsDetails", "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersShareCapitalDetails", "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementIpoDetails", "http://www.Evaxion.com/role/DisclosureGeneralCompanyInformationDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_PaymentsForShareIssueCosts": { "auth_ref": [ "r126" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for share issue costs." } }, "en-us": { "role": { "label": "Payments for share issue costs", "negatedTerseLabel": "Transaction costs related to issuance of shares" } } }, "localname": "PaymentsForShareIssueCosts", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersCapitalTransactionsDetails", "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "auth_ref": [ "r125" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 5.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Payments of lease liabilities, classified as financing activities", "negatedTerseLabel": "Leasing installments" } } }, "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans": { "auth_ref": [ "r77" ], "calculation": { "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsEmployeeCostsDetails": { "order": 3.0, "parentTag": "evax_EmployeeBenefitsAndShareBasedCompensations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of post-employment benefit expense relating to defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods." } }, "en-us": { "role": { "label": "Post-employment benefit expense, defined contribution plans", "terseLabel": "Defined contribution plans" } } }, "localname": "PostemploymentBenefitExpenseDefinedContributionPlans", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsEmployeeCostsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PresentationOfLeasesForLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases" } } }, "localname": "PresentationOfLeasesForLesseeAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": { "auth_ref": [ "r123" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Proceeds from borrowings, classified as financing activities", "verboseLabel": "Proceeds from issuance of convertible debt instruments" } } }, "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsIssuanceDetails", "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsSummaryOfChangesInConvertibleDebtInstrumentsDetails", "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromIssueOfOrdinaryShares": { "auth_ref": [ "r126" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]" } }, "en-us": { "role": { "label": "Proceeds from issue of ordinary shares", "positiveLabel": "Net proceeds from issuance of shares", "terseLabel": "Net proceeds", "verboseLabel": "Aggregate proceeds" } } }, "localname": "ProceedsFromIssueOfOrdinaryShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersCapitalTransactionsDetails", "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementIpoDetails", "http://www.Evaxion.com/role/DisclosureGeneralCompanyInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromIssuingShares": { "auth_ref": [ "r122" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from issuing shares." } }, "en-us": { "role": { "label": "Proceeds from issuing shares", "terseLabel": "Proceeds from issuance of shares and exercise of warrants, less underwriter discounts" } } }, "localname": "ProceedsFromIssuingShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfessionalFeesExpense": { "auth_ref": [ "r11" ], "calculation": { "http://www.Evaxion.com/role/DisclosureOperatingActivitiesDetails": { "order": 5.0, "parentTag": "ifrs-full_ExpenseByNature", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of fees paid or payable for professional services." } }, "en-us": { "role": { "label": "Professional fees expense", "negatedLabel": "Professional fees" } } }, "localname": "ProfessionalFeesExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureOperatingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLoss": { "auth_ref": [ "r5", "r39", "r127", "r148", "r150", "r152", "r227", "r229", "r240", "r244" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 }, "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Profit (loss)", "totalLabel": "Net loss for the year", "verboseLabel": "Net loss for the year" } } }, "localname": "ProfitLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows", "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfChangesInEquity", "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity": { "auth_ref": [ "r97" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) attributable to ordinary equity holders of the parent entity. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss), attributable to ordinary equity holders of parent entity", "terseLabel": "Net loss attributable to shareholders of Evaxion Biotech A/S" } } }, "localname": "ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureBasicAndDilutedLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossAttributableToOwnersOfParent": { "auth_ref": [ "r42" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss), attributable to owners of parent", "terseLabel": "Net loss attributable to shareholders of Evaxion Biotech A/S" } } }, "localname": "ProfitLossAttributableToOwnersOfParent", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossBeforeTax": { "auth_ref": [ "r1", "r2", "r203", "r227", "r229" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss) before tax", "totalLabel": "Net loss before tax" } } }, "localname": "ProfitLossBeforeTax", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossFromOperatingActivities": { "auth_ref": [ "r47", "r94" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "order": 3.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss) from operating activities", "terseLabel": "Operating loss" } } }, "localname": "ProfitLossFromOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PropertyPlantAndEquipment": { "auth_ref": [ "r16", "r69" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period." } }, "en-us": { "role": { "label": "Property, plant and equipments", "negatedLabel": "Total property, plant and equipment", "periodEndLabel": "Balance end of year", "periodStartLabel": "Balance beginning of year", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDepreciationDetails", "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDetails", "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PropertyPlantAndEquipmentMember": { "auth_ref": [ "r70", "r100", "r182" ], "lang": { "en": { "role": { "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Property, plant and equipment [member]" } } }, "localname": "PropertyPlantAndEquipmentMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesDetails", "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDepreciationDetails", "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDetails", "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ProvisionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Provisions" } } }, "localname": "ProvisionsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": { "auth_ref": [ "r121" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Purchase of intangible assets, classified as investing activities", "negatedLabel": "Investment in intangible assets" } } }, "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "auth_ref": [ "r121" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Purchase of property, plant and equipment, classified as investing activities", "negatedTerseLabel": "Purchase of property and equipment" } } }, "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RangeAxis": { "auth_ref": [ "r170", "r171", "r172", "r198", "r216", "r241" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Range [axis]" } } }, "localname": "RangeAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesDetails", "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_RangesMember": { "auth_ref": [ "r170", "r171", "r172", "r198", "r216", "r241" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } }, "en-us": { "role": { "label": "Ranges [member]" } } }, "localname": "RangesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesDetails", "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ReclassifiedItemsAxis": { "auth_ref": [ "r15" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Reclassified items [axis]" } } }, "localname": "ReclassifiedItemsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureDebtDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ReclassifiedItemsMember": { "auth_ref": [ "r15" ], "lang": { "en": { "role": { "documentation": "This member stands for items that have been reclassified when the entity changes their presentation or classification in its financial statements. It also represents the standard value for the 'Reclassified items' axis if no other member is used." } }, "en-us": { "role": { "label": "Reclassified items [member]" } } }, "localname": "ReclassifiedItemsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureDebtDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reconciliation of average effective tax rate and applicable tax rate [abstract]", "terseLabel": "Reconciliation of effective tax rate to Danish statutory tax rate" } } }, "localname": "ReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reconciliation of changes in property, plant and equipment [abstract]" } } }, "localname": "ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": { "auth_ref": [ "r124" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Repayments of borrowings, classified as financing activities", "negatedLabel": "Repayment of loan from lessor" } } }, "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ResearchAndDevelopmentExpense": { "auth_ref": [ "r112" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } }, "en-us": { "role": { "label": "Research and development expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": { "auth_ref": [ "r10", "r83" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Foreign currency translation reserve" } } }, "localname": "ReserveOfExchangeDifferencesOnTranslationMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_RetainedEarnings": { "auth_ref": [ "r32", "r52" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Retained earnings", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarnings", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RetainedEarningsMember": { "auth_ref": [ "r9", "r10" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_Revenue": { "auth_ref": [ "r1", "r2", "r44", "r152", "r158", "r203", "r224", "r228", "r233", "r234", "r237" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims." } }, "en-us": { "role": { "label": "Revenue", "terseLabel": "Gross revenue total" } } }, "localname": "Revenue", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureGeneralCompanyInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RevenueFromGovernmentGrants": { "auth_ref": [ "r81" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income recognised in relation to government grants. [Refer: Government grants]" } }, "en-us": { "role": { "label": "Income from government grants", "terseLabel": "Recognized government grants as a reduction of research and development expenses" } } }, "localname": "RevenueFromGovernmentGrants", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureOperatingActivitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RightofuseAssets": { "auth_ref": [ "r181" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } }, "en-us": { "role": { "label": "Right-of-use assets.", "periodEndLabel": "Balance end of year", "periodStartLabel": "Balance beginning of year", "verboseLabel": "Right-to-use asset" } } }, "localname": "RightofuseAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesDetails", "http://www.Evaxion.com/role/DisclosureLeasesMovementsInRightOfUseAssetsAndLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RightofuseAssetsMember": { "auth_ref": [ "r175" ], "lang": { "en": { "role": { "documentation": "This member stands for right-of-use assets. [Refer: Right-of-use assets]" } }, "en-us": { "role": { "label": "Right-of-use assets" } } }, "localname": "RightofuseAssetsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDepreciationDetails", "http://www.Evaxion.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ShareIssueRelatedCost": { "auth_ref": [ "r8" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cost related to the issuance of shares." } }, "en-us": { "role": { "label": "Share issue related cost", "negatedLabel": "Transaction costs" } } }, "localname": "ShareIssueRelatedCost", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SharePremiumMember": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } }, "en-us": { "role": { "label": "Share premium" } } }, "localname": "SharePremiumMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_SharebasedPaymentArrangementsMember": { "auth_ref": [ "r199" ], "lang": { "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } }, "en-us": { "role": { "label": "Share-based payment arrangements [member]" } } }, "localname": "SharebasedPaymentArrangementsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsAmendmentsToWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsAssumptionsOfWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsCompensationExpenseDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsFairValueOfWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsKeyManagementHoldingsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsOutstandingWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsScheduleOfWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsRectifiedDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ShorttermBorrowings": { "auth_ref": [ "r23" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Current borrowings", "periodEndLabel": "Carrying amount at end of year", "periodStartLabel": "Carrying amount at beginning of year" } } }, "localname": "ShorttermBorrowings", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsSummaryOfChangesInConvertibleDebtInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ShorttermEmployeeBenefitsAccruals": { "auth_ref": [ "r33" ], "calculation": { "http://www.Evaxion.com/role/DisclosureOtherPayablesDetails": { "order": 2.0, "parentTag": "ifrs-full_OtherCurrentPayables", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]" } }, "en-us": { "role": { "label": "Short-term employee benefits accruals", "terseLabel": "Employee cost liabilities" } } }, "localname": "ShorttermEmployeeBenefitsAccruals", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureOtherPayablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SocialSecurityContributions": { "auth_ref": [ "r78" ], "calculation": { "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsEmployeeCostsDetails": { "order": 4.0, "parentTag": "evax_EmployeeBenefitsAndShareBasedCompensations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "A class of employee benefits expense that represents social security contributions. [Refer: Employee benefits expense]" } }, "en-us": { "role": { "label": "Social security contributions", "terseLabel": "Other social security expenses" } } }, "localname": "SocialSecurityContributions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsEmployeeCostsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unaudited Condensed Consolidated Interim Statements of Cash Flows" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Statement of changes in equity [line items]" } } }, "localname": "StatementOfChangesInEquityLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfChangesInEquity" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityTable": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } }, "en-us": { "role": { "label": "Statement of changes in equity [table]" } } }, "localname": "StatementOfChangesInEquityTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfChangesInEquity" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unaudited Condensed Consolidated Interim Statements of Comprehensive Loss" } } }, "localname": "StatementOfComprehensiveIncomeAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unaudited Condensed Consolidated Interim Statements of Financial Position" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss": { "auth_ref": [ "r57" ], "calculation": { "http://www.Evaxion.com/role/DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails": { "order": 2.0, "parentTag": "ifrs-full_AverageEffectiveTaxRate", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from the expenses not deductible in determining taxable profit. [Refer: Average effective tax rate; Applicable tax rate]" } }, "en-us": { "role": { "label": "Tax rate effect of expense not deductible in determining taxable profit (tax loss)", "terseLabel": "Non-deductible income / (expenses)" } } }, "localname": "TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_TaxRateEffectOfRevenuesExemptFromTaxation": { "auth_ref": [ "r57" ], "calculation": { "http://www.Evaxion.com/role/DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails": { "order": 3.0, "parentTag": "ifrs-full_AverageEffectiveTaxRate", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from revenue that is exempt from taxation. [Refer: Average effective tax rate; Applicable tax rate]" } }, "en-us": { "role": { "label": "Tax rate effect of revenues exempt from taxation", "terseLabel": "Non-taxable income / (expenses)" } } }, "localname": "TaxRateEffectOfRevenuesExemptFromTaxation", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_TechnologybasedIntangibleAssetsMember": { "auth_ref": [ "r111" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of intangible assets representing assets based on technology. Such assets may include patented and unpatented technology, databases as well as trade secrets. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Technology-based intangible assets [member]" } } }, "localname": "TechnologybasedIntangibleAssetsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureIntangibleAssetsParagraphDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": { "auth_ref": [ "r60" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Temporary difference, unused tax losses and unused tax credits [axis]" } } }, "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureIncomeTaxesDeferredTaxDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember": { "auth_ref": [ "r60" ], "lang": { "en": { "role": { "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } }, "en-us": { "role": { "label": "Temporary difference, unused tax losses and unused tax credits [member]" } } }, "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureIncomeTaxesDeferredTaxDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TopOfRangeMember": { "auth_ref": [ "r170", "r171", "r172", "r198", "r216", "r241" ], "lang": { "en": { "role": { "documentation": "This member stands for top of a range." } }, "en-us": { "role": { "label": "Maximum" } } }, "localname": "TopOfRangeMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesDetails", "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": { "auth_ref": [ "r30", "r33" ], "calculation": { "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]" } }, "en-us": { "role": { "label": "Current trade payables", "terseLabel": "Trade payables" } } }, "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/StatementUnauditedCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeAndOtherCurrentReceivables": { "auth_ref": [ "r18", "r31" ], "calculation": { "http://www.Evaxion.com/role/DisclosurePrepaymentsAndOtherReceivablesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]" } }, "en-us": { "role": { "label": "Trade and other current receivables", "totalLabel": "Total receivables" } } }, "localname": "TradeAndOtherCurrentReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosurePrepaymentsAndOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeAndOtherCurrentReceivablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepayments and other receivables" } } }, "localname": "TradeAndOtherCurrentReceivablesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets": { "auth_ref": [ "r167" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of transfers of assets into Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]" } }, "en-us": { "role": { "label": "Transfers into Level 3 of fair value hierarchy, assets" } } }, "localname": "TransfersIntoLevel3OfFairValueHierarchyAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementConvertibleDebtInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities": { "auth_ref": [ "r167" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of transfers of liabilities into Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]" } }, "en-us": { "role": { "label": "Transfers into Level 3 of fair value hierarchy, liabilities" } } }, "localname": "TransfersIntoLevel3OfFairValueHierarchyLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementConvertibleDebtInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets": { "auth_ref": [ "r166" ], "lang": { "en": { "role": { "documentation": "The amount of transfers out of Level 1 and into Level 2 of the fair value hierarchy of assets held at the end of the reporting period. [Refer: Level 1 of fair value hierarchy [member]; Level 2 of fair value hierarchy [member]]" } }, "en-us": { "role": { "label": "Transfers out of Level 1 into Level 2 of fair value hierarchy, assets held at end of reporting period" } } }, "localname": "TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementConvertibleDebtInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities": { "auth_ref": [ "r166" ], "lang": { "en": { "role": { "documentation": "The amount of transfers out of Level 1 and into Level 2 of the fair value hierarchy of liabilities held at the end of the reporting period. [Refer: Level 1 of fair value hierarchy [member]; Level 2 of fair value hierarchy [member]]" } }, "en-us": { "role": { "label": "Transfers out of Level 1 into Level 2 of fair value hierarchy, liabilities held at end of reporting period" } } }, "localname": "TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementConvertibleDebtInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets": { "auth_ref": [ "r166" ], "lang": { "en": { "role": { "documentation": "The amount of transfers out of Level 2 and into Level 1 of the fair value hierarchy of assets held at the end of the reporting period. [Refer: Level 1 of fair value hierarchy [member]; Level 2 of fair value hierarchy [member]]" } }, "en-us": { "role": { "label": "Transfers out of Level 2 into Level 1 of fair value hierarchy, assets held at end of reporting period" } } }, "localname": "TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementConvertibleDebtInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities": { "auth_ref": [ "r166" ], "lang": { "en": { "role": { "documentation": "The amount of transfers out of Level 2 and into Level 1 of the fair value hierarchy of liabilities held at the end of the reporting period. [Refer: Level 1 of fair value hierarchy [member]; Level 2 of fair value hierarchy [member]]" } }, "en-us": { "role": { "label": "Transfers out of Level 2 into Level 1 of fair value hierarchy, liabilities held at end of reporting period" } } }, "localname": "TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementConvertibleDebtInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets": { "auth_ref": [ "r167" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of transfers of assets out of Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]" } }, "en-us": { "role": { "label": "Transfers out of Level 3 of fair value hierarchy, assets" } } }, "localname": "TransfersOutOfLevel3OfFairValueHierarchyAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementConvertibleDebtInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities": { "auth_ref": [ "r167" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of transfers of liabilities out of Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]" } }, "en-us": { "role": { "label": "Transfers out of Level 3 of fair value hierarchy, liabilities" } } }, "localname": "TransfersOutOfLevel3OfFairValueHierarchyLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementConvertibleDebtInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TypesOfInterestRatesAxis": { "auth_ref": [ "r213" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types of interest rates [axis]" } } }, "localname": "TypesOfInterestRatesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "auth_ref": [ "r199" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types of share-based payment arrangements [axis]" } } }, "localname": "TypesOfSharebasedPaymentArrangementsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsAmendmentsToWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsAssumptionsOfWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsCompensationExpenseDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsFairValueOfWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsKeyManagementHoldingsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsOutstandingWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsScheduleOfWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsRectifiedDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised": { "auth_ref": [ "r58" ], "lang": { "en": { "role": { "documentation": "The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]" } }, "en-us": { "role": { "label": "Unused tax losses for which no deferred tax asset recognised", "terseLabel": "Operating tax loss carry-forwards" } } }, "localname": "UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureIncomeTaxesAnalysisOfChargeCreditDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_UnusedTaxLossesMember": { "auth_ref": [ "r60" ], "lang": { "en": { "role": { "documentation": "This member stands for tax losses that have been incurred and are carried forward for use against future taxable profit." } }, "en-us": { "role": { "label": "Loss carry forward" } } }, "localname": "UnusedTaxLossesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureIncomeTaxesDeferredTaxDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment": { "auth_ref": [ "r63" ], "lang": { "en": { "role": { "documentation": "The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Useful life measured as period of time, property, plant and equipment", "terseLabel": "Useful lives" } } }, "localname": "UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfAssetsDetails" ], "xbrltype": "durationItemType" }, "ifrs-full_WagesAndSalaries": { "auth_ref": [ "r78" ], "calculation": { "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsEmployeeCostsDetails": { "order": 5.0, "parentTag": "evax_EmployeeBenefitsAndShareBasedCompensations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]" } }, "en-us": { "role": { "label": "Wages and salaries", "terseLabel": "Wages and salaries" } } }, "localname": "WagesAndSalaries", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsEmployeeCostsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": { "auth_ref": [ "r195" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement", "terseLabel": "Warrants exercisable, price per share" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsOutstandingWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsScheduleOfWarrantsDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019": { "auth_ref": [ "r193" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average exercise price of share options expired in share-based payment arrangement", "terseLabel": "Warrants cancelled, price per share" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsScheduleOfWarrantsDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": { "auth_ref": [ "r191" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average exercise price of share options forfeited in share-based payment arrangement", "terseLabel": "Warrants forfeited, price per share" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsScheduleOfWarrantsDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": { "auth_ref": [ "r190" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average exercise price of share options granted in share-based payment arrangement", "terseLabel": "Warrants granted, price per share", "verboseLabel": "Average exercise price per warrant" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsOutstandingWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsScheduleOfWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": { "auth_ref": [ "r189", "r194" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement", "periodEndLabel": "Warrants granted at end of period, price per share", "periodStartLabel": "Warrants granted at beginning of period, price per share" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsScheduleOfWarrantsDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted": { "auth_ref": [ "r201" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average fair value at measurement date, share options granted" } } }, "localname": "WeightedAverageFairValueAtMeasurementDateShareOptionsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsRectifiedDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16": { "auth_ref": [ "r185" ], "lang": { "en": { "role": { "documentation": "The weighted average lessee's incremental borrowing rate applied to lease liabilities recognised in the statement of financial position at the date of initial application of IFRS 16. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment." } }, "en-us": { "role": { "label": "Weighted average lessee's incremental borrowing rate applied to lease liabilities recognised at date of initial application of IFRS 16", "terseLabel": "Incremental borrowing rate" } } }, "localname": "WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": { "auth_ref": [ "r198" ], "lang": { "en": { "role": { "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average remaining contractual life of outstanding share options", "terseLabel": "Warrants granted, remaining contractual life", "verboseLabel": "Remaining term to maturity" } } }, "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsOutstandingWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsScheduleOfWarrantsDetails" ], "xbrltype": "durationItemType" }, "ifrs-full_WeightedAverageSharePrice2019": { "auth_ref": [ "r197" ], "lang": { "en": { "role": { "documentation": "The weighted average share price. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average share price", "terseLabel": "Share purchase price", "verboseLabel": "Price per share" } } }, "localname": "WeightedAverageSharePrice2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersCapitalTransactionsDetails", "http://www.Evaxion.com/role/DisclosureFinancialInstrumentsAndRiskManagementIpoDetails", "http://www.Evaxion.com/role/DisclosureGeneralCompanyInformationDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsScheduleOfWarrantsDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019": { "auth_ref": [ "r200" ], "lang": { "en": { "role": { "documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average share price, share options granted", "verboseLabel": "Share price" } } }, "localname": "WeightedAverageSharePriceShareOptionsGranted2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsAssumptionsOfWarrantsDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageShares": { "auth_ref": [ "r98" ], "lang": { "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } }, "en-us": { "role": { "label": "Weighted average number of ordinary shares outstanding", "terseLabel": "Weighted-average number of ordinary shares outstanding" } } }, "localname": "WeightedAverageShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.Evaxion.com/role/DisclosureBasicAndDilutedLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "srt_ChiefFinancialOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CFO" } } }, "localname": "ChiefFinancialOfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.Evaxion.com/role/DisclosureIntangibleAssetsParagraphDetails" ], "xbrltype": "stringItemType" }, "srt_CurrencyAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Currency [Axis]" } } }, "localname": "CurrencyAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsTermsOfConvertibleDebtDetails" ], "xbrltype": "stringItemType" }, "srt_DirectorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Board of Directors" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersShareholdingsByDirectorsAndExecutiveManagementDetails", "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsBoardOfDirectorsAndExecutiveManagementDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsKeyManagementHoldingsDetails" ], "xbrltype": "domainItemType" }, "srt_ManagementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Executive Management" } } }, "localname": "ManagementMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersShareholdingsByDirectorsAndExecutiveManagementDetails", "http://www.Evaxion.com/role/DisclosureEmployeesAndEmployeeRelatedCostsBoardOfDirectorsAndExecutiveManagementDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsKeyManagementHoldingsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsRectifiedDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.Evaxion.com/role/DisclosureIntangibleAssetsParagraphDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.Evaxion.com/role/DisclosureCapitalStructureAndFinancialMattersCapitalTransactionsDetails", "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsTermsOfConvertibleDebtDetails", "http://www.Evaxion.com/role/DisclosureGeneralCompanyInformationDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.Evaxion.com/role/DisclosureLeasesDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.Evaxion.com/role/DisclosureConvertibleDebtInstrumentsTermsOfConvertibleDebtDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsRectifiedDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsDetails", "http://www.Evaxion.com/role/DisclosureShareBasedPaymentsWarrantsRectifiedDetails" ], "xbrltype": "domainItemType" } }, "unitCount": 14 } }, "std_ref": { "r0": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "10", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2021-03-24" }, "r1": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "102", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_102&doctype=Standard", "URIDate": "2021-03-24" }, "r10": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "108", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_108&doctype=Standard", "URIDate": "2021-03-24" }, "r100": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "36", "Paragraph": "127", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_127&doctype=Standard", "URIDate": "2021-03-24" }, "r101": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "36", "Paragraph": "130", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_130_b&doctype=Standard", "URIDate": "2021-03-24" }, "r102": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "36", "Paragraph": "130", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_130_d_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r103": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "36", "Paragraph": "134", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_134_f_i&doctype=Standard", "URIDate": "2021-03-24" }, "r104": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "36", "Paragraph": "135", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_135_e_i&doctype=Standard", "URIDate": "2021-03-24" }, "r105": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2021-03-24" }, "r106": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e_i&doctype=Standard", "URIDate": "2021-03-24" }, "r107": { "Clause": "vi", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e_vi&doctype=Standard", "URIDate": "2021-03-24" }, "r108": { "Clause": "vii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e_vii&doctype=Standard", "URIDate": "2021-03-24" }, "r109": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2021-03-24" }, "r11": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "112", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2021-03-24" }, "r110": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118&doctype=Standard", "URIDate": "2021-03-24" }, "r111": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "119", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_119&doctype=Standard", "URIDate": "2021-03-24" }, "r112": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "126", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_126&doctype=Standard", "URIDate": "2021-03-24" }, "r113": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI", "URIDate": "2021-03-24" }, "r114": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "40", "Paragraph": "76", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_76&doctype=Standard", "URIDate": "2021-03-24" }, "r115": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "40", "Paragraph": "79", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2021-03-24" }, "r116": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "40", "Paragraph": "79", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2021-03-24" }, "r117": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "41", "Paragraph": "50", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=41&code=ifrs-tx-2021-en-r&anchor=para_50&doctype=Standard", "URIDate": "2021-03-24" }, "r118": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "41", "Paragraph": "54", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=41&code=ifrs-tx-2021-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2021-03-24" }, "r119": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "10", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_10&doctype=Standard", "URIDate": "2021-03-24" }, "r12": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "117", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117_b&doctype=Standard", "URIDate": "2021-03-24" }, "r120": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "14", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_14_f&doctype=Standard", "URIDate": "2021-03-24" }, "r121": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "16", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2021-03-24" }, "r122": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2021-03-24" }, "r123": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_c&doctype=Standard", "URIDate": "2021-03-24" }, "r124": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_d&doctype=Standard", "URIDate": "2021-03-24" }, "r125": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2021-03-24" }, "r126": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17&doctype=Standard", "URIDate": "2021-03-24" }, "r127": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "18", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2021-03-24" }, "r128": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2021-03-24" }, "r129": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2021-03-24" }, "r13": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "117", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117&doctype=Standard", "URIDate": "2021-03-24" }, "r130": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20&doctype=Standard", "URIDate": "2021-03-24" }, "r131": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "25", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_25&doctype=Standard", "URIDate": "2021-03-24" }, "r132": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "28", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_28&doctype=Standard", "URIDate": "2021-03-24" }, "r133": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "31", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_31&doctype=Standard", "URIDate": "2021-03-24" }, "r134": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "35", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35&doctype=Standard", "URIDate": "2021-03-24" }, "r135": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "44B", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_44B_a&doctype=Standard", "URIDate": "2021-03-24" }, "r136": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "44B", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_44B_c&doctype=Standard", "URIDate": "2021-03-24" }, "r137": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "44B", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_44B&doctype=Standard", "URIDate": "2021-03-24" }, "r138": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "44C", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_44C&doctype=Standard", "URIDate": "2021-03-24" }, "r139": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "44D", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_44D&doctype=Standard", "URIDate": "2021-03-24" }, "r14": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "35", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_35&doctype=Standard", "URIDate": "2021-03-24" }, "r140": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "45", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard", "URIDate": "2021-03-24" }, "r141": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "50", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2021-03-24" }, "r142": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A__IAS07_IE_A_TI", "URIDate": "2021-03-24" }, "r143": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Section": "C Reconciliation of liabilities arising from financing activities", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C__IAS07_IE_C_TI", "URIDate": "2021-03-24" }, "r144": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "8", "Paragraph": "28", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28&doctype=Standard", "URIDate": "2021-03-24" }, "r145": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "8", "Paragraph": "30", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=8&code=ifrs-tx-2021-en-r&anchor=para_30_b&doctype=Standard", "URIDate": "2021-03-24" }, "r146": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "8", "Paragraph": "49", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=8&code=ifrs-tx-2021-en-r&anchor=para_49_a&doctype=Standard", "URIDate": "2021-03-24" }, "r147": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2021-03-24" }, "r148": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2021-03-24" }, "r149": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2021-03-24" }, "r15": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "41", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_41&doctype=Standard", "URIDate": "2021-03-24" }, "r150": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r151": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Section": "Presentation and disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS01_g20-33_TI", "URIDate": "2021-03-24" }, "r152": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B10", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r153": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r154": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r155": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r156": { "Clause": "iv", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r157": { "Clause": "ix", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r158": { "Clause": "v", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r159": { "Clause": "viii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r16": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_a&doctype=Standard", "URIDate": "2021-03-24" }, "r160": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r161": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r162": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r163": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B4", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B4_c&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r164": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2021-03-24" }, "r165": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2021-03-24" }, "r166": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_c&doctype=Standard", "URIDate": "2021-03-24" }, "r167": { "Clause": "iv", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_e_iv&doctype=Standard", "URIDate": "2021-03-24" }, "r168": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2021-03-24" }, "r169": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93&doctype=Standard", "URIDate": "2021-03-24" }, "r17": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_c&doctype=Standard", "URIDate": "2021-03-24" }, "r170": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "B6", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r171": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "IE63", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2021-03-24" }, "r172": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "14", "Paragraph": "33", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2021-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2021-03-24" }, "r173": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "120", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2021-03-24" }, "r174": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "B89", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r175": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "33", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_33&doctype=Standard", "URIDate": "2021-03-24" }, "r176": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "47", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2021-03-24" }, "r177": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_a&doctype=Standard", "URIDate": "2021-03-24" }, "r178": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_b&doctype=Standard", "URIDate": "2021-03-24" }, "r179": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_g&doctype=Standard", "URIDate": "2021-03-24" }, "r18": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "h", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_h&doctype=Standard", "URIDate": "2021-03-24" }, "r180": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "h", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_h&doctype=Standard", "URIDate": "2021-03-24" }, "r181": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "j", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2021-03-24" }, "r182": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53&doctype=Standard", "URIDate": "2021-03-24" }, "r183": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "94", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_94&doctype=Standard", "URIDate": "2021-03-24" }, "r184": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "97", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_97&doctype=Standard", "URIDate": "2021-03-24" }, "r185": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "C12", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_C12_a&doctype=Appendix&subtype=C", "URIDate": "2021-03-24" }, "r186": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI", "URIDate": "2021-03-24" }, "r187": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Section": "Presentation", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI", "URIDate": "2021-03-24" }, "r188": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "44", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_44&doctype=Standard", "URIDate": "2021-03-24" }, "r189": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_i&doctype=Standard", "URIDate": "2021-03-24" }, "r19": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "i", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2021-03-24" }, "r190": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r191": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r192": { "Clause": "iv", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_iv&doctype=Standard", "URIDate": "2021-03-24" }, "r193": { "Clause": "v", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_v&doctype=Standard", "URIDate": "2021-03-24" }, "r194": { "Clause": "vi", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_vi&doctype=Standard", "URIDate": "2021-03-24" }, "r195": { "Clause": "vii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_vii&doctype=Standard", "URIDate": "2021-03-24" }, "r196": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b&doctype=Standard", "URIDate": "2021-03-24" }, "r197": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_c&doctype=Standard", "URIDate": "2021-03-24" }, "r198": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2021-03-24" }, "r199": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard", "URIDate": "2021-03-24" }, "r2": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "103", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_103&doctype=Standard", "URIDate": "2021-03-24" }, "r20": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "l", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_l&doctype=Standard", "URIDate": "2021-03-24" }, "r200": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2021-03-24" }, "r201": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2021-03-24" }, "r202": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "3", "Paragraph": "B67", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r203": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "5", "Paragraph": "33", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2021-03-24" }, "r204": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "23B", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2021-03-24" }, "r205": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "25", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_25&doctype=Standard", "URIDate": "2021-03-24" }, "r206": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "31", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_31&doctype=Standard", "URIDate": "2021-03-24" }, "r207": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35H", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2021-03-24" }, "r208": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35I", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2021-03-24" }, "r209": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35K", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2021-03-24" }, "r21": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "n", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_n&doctype=Standard", "URIDate": "2021-03-24" }, "r210": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35M", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2021-03-24" }, "r211": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35N", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2021-03-24" }, "r212": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "39", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_39_a&doctype=Standard", "URIDate": "2021-03-24" }, "r213": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "39", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_39&doctype=Standard", "URIDate": "2021-03-24" }, "r214": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "42E", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2021-03-24" }, "r215": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "42I", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_42I_b&doctype=Standard", "URIDate": "2021-03-24" }, "r216": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "7", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard", "URIDate": "2021-03-24" }, "r217": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "8", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_8_g&doctype=Standard", "URIDate": "2021-03-24" }, "r218": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "B11", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B11_d&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r219": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "B11", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r22": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "o", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_o&doctype=Standard", "URIDate": "2021-03-24" }, "r220": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "B35", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r221": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "B35", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r222": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "B52", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B52&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r223": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "IG31A", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2021-03-24" }, "r224": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2021-03-24" }, "r225": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_d&doctype=Standard", "URIDate": "2021-03-24" }, "r226": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "h", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2021-03-24" }, "r227": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23&doctype=Standard", "URIDate": "2021-03-24" }, "r228": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2021-03-24" }, "r229": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2021-03-24" }, "r23": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "55", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_55&doctype=Standard", "URIDate": "2021-03-24" }, "r230": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2021-03-24" }, "r231": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2021-03-24" }, "r232": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2021-03-24" }, "r233": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "32", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_32&doctype=Standard", "URIDate": "2021-03-24" }, "r234": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "33", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2021-03-24" }, "r235": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "33", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2021-03-24" }, "r236": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "33", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_33&doctype=Standard", "URIDate": "2021-03-24" }, "r237": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "34", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard", "URIDate": "2021-03-24" }, "r238": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "109", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_109&doctype=Standard", "URIDate": "2021-03-24" }, "r239": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "109A", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2021-03-24" }, "r24": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "56", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_56&doctype=Standard", "URIDate": "2021-03-24" }, "r240": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "113", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2021-03-24" }, "r241": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "120", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_120&doctype=Standard", "URIDate": "2021-03-24" }, "r242": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "132", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2021-03-24" }, "r243": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "96", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_96_b&doctype=Standard", "URIDate": "2021-03-24" }, "r244": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39L", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39L_e&doctype=Standard", "URIDate": "2021-03-24" }, "r245": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "37", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b", "URIDate": "2021-03-24" }, "r246": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "8", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_f&doctype=Standard&book=b", "URIDate": "2021-03-24" }, "r247": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG29", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29_a&doctype=Implementation%20Guidance&book=b", "URIDate": "2021-03-24" }, "r248": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG29", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29_b&doctype=Implementation%20Guidance&book=b", "URIDate": "2021-03-24" }, "r249": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG29", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29&doctype=Implementation%20Guidance&book=b", "URIDate": "2021-03-24" }, "r25": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "61", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_61_a&doctype=Standard", "URIDate": "2021-03-24" }, "r250": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r251": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r252": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r253": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r254": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r255": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r256": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r257": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r258": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r259": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r26": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "61", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_61&doctype=Standard", "URIDate": "2021-03-24" }, "r260": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r27": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "66", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard", "URIDate": "2021-03-24" }, "r28": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "69", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_69&doctype=Standard", "URIDate": "2021-03-24" }, "r29": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "7", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard", "URIDate": "2021-03-24" }, "r3": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "104", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_104&doctype=Standard", "URIDate": "2021-03-24" }, "r30": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "70", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_70&doctype=Standard", "URIDate": "2021-03-24" }, "r31": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2021-03-24" }, "r32": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2021-03-24" }, "r33": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78&doctype=Standard", "URIDate": "2021-03-24" }, "r34": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_i&doctype=Standard", "URIDate": "2021-03-24" }, "r35": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r36": { "Clause": "iv", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2021-03-24" }, "r37": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2021-03-24" }, "r38": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79&doctype=Standard", "URIDate": "2021-03-24" }, "r39": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2021-03-24" }, "r4": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_a&doctype=Standard", "URIDate": "2021-03-24" }, "r40": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_b&doctype=Standard", "URIDate": "2021-03-24" }, "r41": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_c&doctype=Standard", "URIDate": "2021-03-24" }, "r42": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81B", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81B_a_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r43": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81B", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81B_b_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r44": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_a&doctype=Standard", "URIDate": "2021-03-24" }, "r45": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_b&doctype=Standard", "URIDate": "2021-03-24" }, "r46": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_d&doctype=Standard", "URIDate": "2021-03-24" }, "r47": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "85", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_85&doctype=Standard", "URIDate": "2021-03-24" }, "r48": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "91", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_91_a&doctype=Standard", "URIDate": "2021-03-24" }, "r49": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "91", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_91_b&doctype=Standard", "URIDate": "2021-03-24" }, "r5": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_i&doctype=Standard", "URIDate": "2021-03-24" }, "r50": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "91", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_91&doctype=Standard", "URIDate": "2021-03-24" }, "r51": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "99", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_99&doctype=Standard", "URIDate": "2021-03-24" }, "r52": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "IG6", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2021-03-24" }, "r53": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "10", "Paragraph": "21", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&anchor=para_21&doctype=Standard", "URIDate": "2021-03-24" }, "r54": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "10", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI", "URIDate": "2021-03-24" }, "r55": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "79", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_79&doctype=Standard", "URIDate": "2021-03-24" }, "r56": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2021-03-24" }, "r57": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r58": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_e&doctype=Standard", "URIDate": "2021-03-24" }, "r59": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2021-03-24" }, "r6": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r60": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_g&doctype=Standard", "URIDate": "2021-03-24" }, "r61": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI", "URIDate": "2021-03-24" }, "r62": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "37", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_37&doctype=Standard", "URIDate": "2021-03-24" }, "r63": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_c&doctype=Standard", "URIDate": "2021-03-24" }, "r64": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2021-03-24" }, "r65": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_i&doctype=Standard", "URIDate": "2021-03-24" }, "r66": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r67": { "Clause": "vii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_vii&doctype=Standard", "URIDate": "2021-03-24" }, "r68": { "Clause": "viii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_viii&doctype=Standard", "URIDate": "2021-03-24" }, "r69": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2021-03-24" }, "r7": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r70": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73&doctype=Standard", "URIDate": "2021-03-24" }, "r71": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "75", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_75_a&doctype=Standard", "URIDate": "2021-03-24" }, "r72": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "75", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_75_b&doctype=Standard", "URIDate": "2021-03-24" }, "r73": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI", "URIDate": "2021-03-24" }, "r74": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "138", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2021-03-24" }, "r75": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "147", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2021-03-24" }, "r76": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "5", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_5&doctype=Standard", "URIDate": "2021-03-24" }, "r77": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "53", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_53&doctype=Standard", "URIDate": "2021-03-24" }, "r78": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "9", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_9&doctype=Standard", "URIDate": "2021-03-24" }, "r79": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Section": "Scope", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS19_g2-7_TI", "URIDate": "2021-03-24" }, "r8": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2021-03-24" }, "r80": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "20", "Paragraph": "39", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=20&code=ifrs-tx-2021-en-r&anchor=para_39_a&doctype=Standard", "URIDate": "2021-03-24" }, "r81": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "20", "Paragraph": "39", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=20&code=ifrs-tx-2021-en-r&anchor=para_39_b&doctype=Standard", "URIDate": "2021-03-24" }, "r82": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "21", "Paragraph": "52", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2021-03-24" }, "r83": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "21", "Paragraph": "52", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&anchor=para_52_b&doctype=Standard", "URIDate": "2021-03-24" }, "r84": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2021-03-24" }, "r85": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2021-03-24" }, "r86": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "17", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17&doctype=Standard", "URIDate": "2021-03-24" }, "r87": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "18", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2021-03-24" }, "r88": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "18", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_18&doctype=Standard", "URIDate": "2021-03-24" }, "r89": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "19", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_19_f&doctype=Standard", "URIDate": "2021-03-24" }, "r9": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106&doctype=Standard", "URIDate": "2021-03-24" }, "r90": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "19", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_19&doctype=Standard", "URIDate": "2021-03-24" }, "r91": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "20", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_20&doctype=Standard", "URIDate": "2021-03-24" }, "r92": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Section": "Disclosures", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI", "URIDate": "2021-03-24" }, "r93": { "Clause": "viii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2021-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2021-03-24" }, "r94": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "32", "Paragraph": "IE33", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=32&code=ifrs-tx-2021-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2021-03-24" }, "r95": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Paragraph": "66", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard", "URIDate": "2021-03-24" }, "r96": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Paragraph": "67", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_67&doctype=Standard", "URIDate": "2021-03-24" }, "r97": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Paragraph": "70", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_70_a&doctype=Standard", "URIDate": "2021-03-24" }, "r98": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Paragraph": "70", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2021-03-24" }, "r99": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI", "URIDate": "2021-03-24" } }, "version": "2.1" } ZIP 187 0001104659-22-041054-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-041054-xbrl.zip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�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�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ʾ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

    S,=LH9&&\Y*CO6^^ M\.QUG*-"0S_C?+TWJ%F[>'>NS\A$]]]D4E]; M:+,U&..F,C(E]:2*+/B/]XT@_CZ.SM&#?-"5$60]X.2Z\WC_@W9FYJUWABL" M;TCYT:6O1)L8+H0BACPE\1*%_8P FRB)G!@BH+I(H8PW1S?@LO3$LB7LB _U M7M9IC-0Q3?]RN3NXRRPG*I9OCNA-G0DSUNJ MTV[T+O+.O=M*T]R1W75/$&3V+'G&V-#*CYUY7&,%=$T?3UB2%PDP_E,L/CXG40*A-0>(AV/(*4LSIA]3Z-O[$5U\ M(>+_O>)9O=^= **(YTQ%6*_-QN;$ MK2V-2*+9^N'3$!6A1-O]"4IHL!PTL!QLZ6G45PDN00@NI?EF"JH9U'XNKHK: M)L@%5WC&O8N$U9HD_VVF3!#/.X>]"WQ_G4 MYUG;.44D'($@ZO.YC:F05+&40WW"S2CDA6V&U=Z1W3A./10[M2%H9W@*_;+E M..Z.9VQ$,^)5MC7RDV59[*[) :K;9,-.(YK,,#DE; MS%J33N%R\PWXN:/Q(C3IP'N.^0G: 74'O[9Y<(T\02\;W!6X?S$P^9:QOU2E MI"P/-@JW\ZG$_^V)8)3>WX4RXR:<09KZ+@GK;:J:1O80\9-M8956Q8F*AC96 M5)0UM4-LH8T>$]RG03/1:"[^-69^/UG033E^9I&AA.^Q";-7[6]Z=9' EJSD M_'\"C^$/C/'%\\P,X_ >*3FE-8?O=[%A-!W8/X ;8("1P M"2?B^M%:_:'=3)OO\&!0\-!+T5:% ,32 ;U\EB1WZ5D\(>".LQLT5ITV=_,RLE]R]*-&$(H M+5NCG7-MJ=B'< 2\_"F5+QGKML[[M -PX/; <# MS"XRMZ$N3^!3LZ*'6^40VPVGHK>0+HR]J=LDE[B_>_>S^P\,\(B<5DYV$053 MTQ9!+,.Z-PDA*=D%A)ATV'M:Y&BU*XNW([R=TOC#JZM_3*3QM562\QJ,LX_- MGU? YQ3B#S @A$KD\M*(7Z7EA_Q]X6=$/UOMCQ>BJT4XV\\T'. .<0H8$*/? M#8FB.:_YUB2^FQ&6_7.!GX=K>=0TC2]F2-,D6").IG:VTHWH;GF8**XC+-2H MI-QM=TJ)#J>BIITN:NK;QH)A/O0'N\+RNGVL6>_(E/[Q@15:)OG?]Z(WDC$' M_O_4RHY(OI*XU::YWVJ2ZSR@ZA\ONCYJM_RH*9_T,#M@F6C$>.>G<##Q]E:# M',];!>&&[>.V1O;8]TW02C0%(0RH/M>8TUVA8?K, , E6M_>7JY^C)<(V7$) M0/(0X@MY_3U(MC^5SODY=5&%EE\>4M,[4>+L'2[YE\_CKJLRL+X+&ELR,G,N<4?!4@4KR-&>%&E_T1$AHY MEII6)+(@%5S3-!EP.S*NG'-7@=<,\0BT=[BF3]6-,E(IYZNT_JP[">E_+_?S MTXJSG^W<#2;(:BD[XL17V@6A*=?\+2X*\B?H\(%3DOXBJ 2_K"11'G4H8 D: M)Q-T1FQYX1%3E2N+#E&R;7T#7%8@[U"$EAT_N&?>6OMZ;6![%9.+N1&JR*.] M)Q2XCZLS$ M>RFHC/ \U97GX1&]MI^W7D=N;(;-4,WO?K8BP0@+;;#BJ>0E9S,9GSS1C6"@ M2_3[;9T4F#1=Y]X5C)J/\FB_OP3>_2JHT[WD$-*5&;:MY$6I9H:'6%DL3T_F M" ,L_#J5=[6G"'@TI%'+.($#)"J"LK7#VZ6OGPS[33I)2+4Z%5?\3RQ/JKLJ60/(YE?>U<@D2NUP,&;+[6V.%G$N M-*)286FMU4J(-:S,SZ^\%I$K5 U9)$AX(45;(F$0R @P&H M<-P->;$-_V=*B>GGRQ:?2&>60[J5O<9-@/6!HOE%[C@,- M_CU*O^VS& IB$:3#5X M7K?[?UEX+>;Q$KS4R)@7&/)OY*ON0TL6PY811&B6\HXK[H8\KN4?4H^C643$ M<+G#Z#1G+>R"+*Y?,[RJVN_!@U[X"EF>AFYSOFP !FLL5 U^?+' MC;+-[$EJ!E*5UM%(OI5@'A/9EE%*'N--GU1256R<% VB9(TZF(7G4)7&0__/ M1 =3U3$)=SN2-/%GLP!0:;&VL ORQ>M6WF_K?*G%R5=YITYO28.:RTJHMEMI M19D*G;A,MN@[Q2\89APXMF% =G1XKKB,@_Y13J13]\*L@_WKU; [LRZD;@V$ MFTK=O=CQ:=UU&D8S]F69+SF6 2R1D/U^F0O,J&P9$I';+\\9*[)O>I9I.8C> MO/TI.+Q7RE(TO:BT[.[:I/=<.3=9GR5842U'I[_*/O]%*%FD/.Y.OE*OM-0Z MI:TQ7=]PJ!5EI>(U"1\YL;)*7RV^LD1'2PI:%,O^NH\91Q+K]Z$T3E0Q80NY MB2YK75Y7[D^1C*5$JM*T7'DIGU'S$^5_X@$-FN*G&<;GWUO\];F4HX%<<6&N$\WK]XGLQF'H?UYH%[6] M=)9T#"D&[,^H$[E0.!A)$^*J9)4'&Z>FW[^.)E9^5TPU^79651K ^R\8OM[+ MJ.B[444O(1((V;;3R26H>!C[FUX$BPA)9T6,A]XJS25H]@.A_^C( MIW2X>/)?XA)=DJQJ5NV(HL,:MO%\FG/J6-I (;85X:0"'>:]0-_ M]P6]-?Q)-7:Y=^GWS5G$K?."D>WW&K/@23Z4?4>!FU,]&795AYVFI-I#)7#) MP>ONI6FVO8PQPM/A0 JRZRL-I^;GW&@/A$I7JB N(?4WD8*;GH72GJL*=37# MQIY4\[(A/Q9D;66=88!I2\J<8:R\AC.A.(0,LS?WJ$JU41I/(_K?_D@LF%(F MKZNK=+MQGBL,,&\3IB3$TVJ>6)SKW.S9?2(V9WD.$S$45O"UG"X5PI)(MVN/ M,%6\R'ML:WZ4TD7@*=-%EY+ CXU] /5%Y MAE8&NFQUU3H6YSD\#4)MFB7R1\6WPJH@+;-)C6C%],+FI<@B^>PSF4[E[IJ[ MDL3^L5[]/9R6'1GQN>))#[']ZU(VM@_"A0-/G\=B>6[FE MJ^.;M+TC<:*LZ#?TM%J#\]@&_6PL*(/F],GPXP?(RPENP!BRL3B9V451HW?@ M7JIX P[;/4$6I35K\)=I _N$L"I.B8?/G=I]%&]FGG1S^\H.QP89WNB2F>0[ MS2EW^@8[67A8N\^G\M7W.<HC1/>41^(E>U6J!H7XE55/ M>U8%RLR;8M?FMS>@EKMRWD]G"Z>H%3%UGN-F\>[BLQ1;48K9#>\]JD943A/$ MV]8W5U20(O_33$19J@<.2-_6UR]/,B,A@>3.[!GD(H'FY+4[LO,NU#:(NX8, MB:+"!]6XYBKX&UN[]R_67EVKHU'.N!0P03X$!=S?@P2BX MSY&5_^&;N%,TCONG9AC07?["HX.8TDOH0J<;Y'A_2(CX+"L%G2$XT[?$7@L! M,EB/.(L7XS;%"^7_P^^3'=C8@]_72_'),A+QR4X'L*IJT'RNR63;,9V?)GNW M[ @_(B(^M5$7'(RNIA[%-*AWT8O-:&6EQRZ)Y6 MV1)YQ.7.!]V18;YH_JQ%%GQ=E"U#KWF!]]#9],UBRHZJN_4UO_YO^I^'3SIB MW7I7OY0QH%']1EC7ZUB&!RH'!/,"[ 2:EM^C(>XWXT[753?V'5(6EY(^UF"L MP]O&M\-B%0'!,, WT@F,^X&O0DBS^?&S+OW0$\@&!@A-<^WJZ:14MWIHSFY, MVU$<^6;XU@YV-%3Y'S&>R9>XHA&?\'R?/J:T35[SB>E$C!WXCFF2X8_WBPV% MND/_\?@'Q_DL5N(HH!-X1"O9^^PE=E.I+FM0]&A\,'WN>O' MI=.2N>0'WH"#64QE&E[,L.-;/'X&$-#L3[NLU\]U.;R(RA+=#OVUD6YP.KO30OOBJ=_Z8JQU%]W!!HKVY>=+$#EW[$QY MG_S*O2XC2-;I]).C[:.8;A7&>CB[T:P4?/$5?6-0L:-7Q'JN__'V?EC^<.., M&].$Z6BXN'KV=&U5MQ6_X"-#F,1=VO$309NM46 65C"%QVW(" PH2B6BA![@ M_WPR@Z2$;>I<:TQ5$"Q/<-U7D'_OXML69)B=K]%(KWOG0?U(NL>=0*M-GN3A9F>I:L)JM:WOP85>09/%A>?#1?[F)W.\T9 M$T').8B)Z#-?5ZS$TL!2/\TF;H5!?G';2?!"J4Y:D#VKM5L\V(VT$D_7WMH$ M ZKF?P\]7Z59+/10OEK!,0NZ7,R^WW;V?"+E#?-X%+>.E:]?<#2]QAFL?JK5 M\=^]QU2?Y3'"LA:C;;"MI'DA;=%LJI?Q4C^0W/'G?3/\R'NB+?4U/KSPR?_P M"?IDFP;U@;Q0PNM]HNKR^175K)4P:J="* "8/V395G2$G1*X2*]^"[PY?9CG MDA?E8\R*#)UV;-"3XO>0&#J.3"OX7X6JKY28)=%^4??2I# L:OH0Z9I9[Q%E MN;3"@#_DJ1#*^73PXT)3TRGK#\<[[:2'K:I)4(#5@]:/[:0M1SSHX.7S1FV; M52*+A]W[@&L 7MDD\*;2-CL,!F#8:]T4VAN@,=*TI&-2]\K'M-Q[B5R3L\AN M6#X%/\G" !.^%\VC0I9T!OCE>\)\!47;%965S[M7X@F$ '0SX]#=@9Q)/%IC-G,\UY^[QF('& M;;XD>Y3PW9_9AZ5M!^G@\/MY3LPWLW[VHK;:%4PC^,/0>@+&#C98Z%V_I_6!<$O9Y\S6::;8;U^G"66K%?2I6 MNJM$KE?>\!(;;KS%!GV>GU_8;"[W?FE$D@K_F=_SS)J5IX<$?JGX")^!,$-; MNQ=>./LZ=>R#I?>VP+@5>TZ\CCEZEK=VAKXOBVN]CVVE G%"FB[?\_>0-+F3DL"9N37'LSYTVO&LAF&WJN&[UO35F7:5I,,I")X&[Q ME2+\OESS-NE.1GB6'XSMIDC8%&K/C"!L^-U"@Z.AR&Q7GEPB"0:0BY9/'9-J M7XBEY]D0\&G',*;=- TTHI!+[#S+W96K*7]4$=R[H*@'A5ZSS">2W_&?(LTF M]LN._ !^(D2?JF875UK\\969"T+^/*,F3ZBH7VC)2KQS.1?[A,XX0EOLT#C- MW\^&H32-V=B0QMO\YGO\$)6W;\R].GC3U,I?(EGK/HJ@WW0NZE0#AV#H MSIU3L"C5,VQLN D:Y_:F,5VQ*"1MU^QR%@0OPP_/@#8DH-XN.+2I3X%Q8;@? M83Y+<*Q,D/?GIP%N0J*D%@@:*O@P^^5)>JIKVKB% YM?"?%#0(LY*1"_X9N3 M"M]X38ESN$9+**MLC?FGX'('AWXFNWA305'V+-!#76"&_2^]BPR72Q@#0JBA M#]QL,?UFY3(__9P^-L/E0R?Y]UBH$Z>D\0#MD)?):+$_FS<3U P"3VJ= MTQV$MT'&;GX8PN%OQ-,YH%H-8CP,M=O)!^)(1H[]Y:IQG8Z<,&#(Y9EEHO>M M6H].R='/+^(D9R\8;XTB'KZ0DS#U_-4IY@L6RH'QS6*Y>9$LXSRHC$7MX=N6 M#O!!2H#F-'1FFR(D[$7$9E=S1J,H_=5FD+;30Q:X4N]_>*H;*@< M#-BD-:K_+K4]/+*>X12]76US[O\*/"S>#[[%==PU]/C:P>:R>:K=K^V!V\=\ MY#&X1TTD*"T:Z_/,DJ>N^BVB<8*4:F6 +V5:KLGCA=/*08V?98\AE[:9]V\, M9*@#-;$_I4N& 74=FCSNS&.Z\_SPD-7A8Z>SECZJ/SP#?/-L\%/DF?O^BEY%I6 M6J6=Y0U?ZJY"(Z?EL>%6- 8] *']DO(NZAK(5^5-2JX:Q\MHSDD@NC$$WT<:7'3%/=2<3 A>2#=_/6E\%A - MN=9CG/HD1]T781;??LJ6E'#EO9 _1)%/> (#F(\J3KV>O^U&Q[362+(DO9PQ MS3R)SS=6VC[*&G7-[%OSE-HQZ-!:('U/K( [X1+'UFHDYU"9\D==/TS+'//@ MUVIS32 V&R>6$/:^FD& E#I_'-U( &\Z/B6)HKUT3KQ\G9M:=WJ3?H<;>!\D M7NF2C0;>^7%@=',&OJ:OBKW;2QL7V_-;3TS2F=BRR-O]LM0<*B+M5KJ^NFAS M;C?3$87"C]DD,$:JO7. ^9T[>[ ][:H:^XB"-XZV9D:6PA M+IN&6@X21*^Y/0_FI)($X>)Y.!(Q/?;JU!!'&^?\G)#4IIU_I':3Y6*HIMK],.8E@=D$44GBXZ#+^CL'G%V1@292M;ED!)0=7;*-B\NO MIB@]H*7&CHZO+%#*?D>VY%]'JIW7")0VW)S4,;5Q8X-BII0@4$E9ZB?B"^=T M88TLYSKB<4*U;P6@46DM:Z>6W9XO+4,V%IWGL:XQJ/1!2T=G9SHY7@6M$3N, M)V]8^7;ND%^#B/';BX[$&#LN,@N\0QINYZWHKVAB7V'#[1;UFH\3I; -V:FL MI!IS[T' T5E**LWA=/$?K;%LG[1WM&DA9[&4T4RX9 M@T:/QGK"[QR4MPU0+B@C705X%=._[R1.3\L7.S9)J._@/M4.40LX3R7%"OR\ MJ9:8>M/5,L7&,)M,<*G3GYC'#H\[;/032QQUO)BWD81C2AH__E^.XNO=1!$4 MY^F##-_]9O!\K>XD0!8\# +%8XHE%TKS+"VBLX!?0;WG5C=G:-_M,^PYRE!T M?#F]3ZOVVE!"O3V:UVYB(H,+#"$+27H;/KB= 2D#@8[3#JV*)]@WS; [J'-$ M>S^Z#OOVQX\BT_D.$1]X43)?S$0V%ED)?8YYTY_FE]=[ATBL@Z-H)D!,!^'R MO*LD87(1V\!75'Z>3)F\"7PQNL-D>9;=U+9)/A)1>W.BH)M/E""K]1$&A!^) M4^I)&.:EDT6PVM+9$1.98Z^HEP#5P',.63:VU6$L4G[V;QCP,'=^<[4^M"<. M2;6VS4(*_1^BB;BG\E#]"A3:V:DAGK_3Q%7.6SB6L/S2RXBHZ0 M?9&R.1,A=#"Z];D $'X@S;Q>Q0.'?*%$76'H[\3*NA2@C.1U:%1GJ+VQQU,U MD Y1G]5I0+,KWF]QY#CH[@>SSC491^J&H[Z2%RU+SN'G;KP*PHNI*3W)ZHZ[ MA ]@#\ #7@$;J'K_ZQP'JE[860II]?TF%=O+X<9?S_*"[YYV4"J=9@=7B8=?+/H_Y%5PC>%?WDNK6 M^V*M/XP+!@.,%*:>DKNP(H33Q_[!&0N-ZA%QA>J^>B@J7 M_&P8PF7%U88X16#2!"NJX?A+\F)#O,Q8L/(1!6ARQKT2%KOZ*W%ZD[?,'QF9**"8,6"BI M\B?R+-:..O%>B&,_<[VC'0^A[ODB.&2T+^]\9Q1NX]K]#\ZT^E?.#/>' 5IT M?LN>_RC:<'RI>;81MK45Q[1*N75/L&]NBC$-Y736KZ'8F4MG)%E;Q\&:;N6@ M?7WB#0/"-G7E5YM435M(80#1\:3M0V5C43;ZK19ZS_J(4^U[L<^W2<+^MZ]6 MS/?:C\).4A8SO+!-P3=]QL_[1/>=GMMI--.KP9V\2^@<'QF+PRXI$D&4N&?7Y!:RP';!U;T16:?09T/D5COT_&?MAU@K^%5/&#"P'K9T%W%3SJ8L$RJ/NS)) L3GT9%7ZX ORX5,W+8/N91:MYID]SD;Y;J+&8V(Q>O>6:!FUBY/]P(KT)/B7E8SL5J?L M9AJP)^*YQI=,,-$[KZ6NMR)Q*%(OW_3>;.A7(NCCTP+NIA_'5NI7U_?3#:MH M\IPL]2DIQKK?L^2IP^[Q3VI6I+ZTYR:3@>M<(E,:-%DK370NRZ,FHA:TII=_ MYUC%X)6H+OPF"^($QY8_"4UU44-53UVC8OCZ'O%6B.D],K@'"UR:0;.N ]ZG MO*NT:N.C94(I G@^2FSF!.2JOT7<+X@MOI0(IU4X/JU49B@)@\%G.3 @T..) M^V/DV(_W=VI>,YAM0"_#8_Y#ENW;F" F=DM"#U05CH?O<9"X<\K;N$-MJ__- MFFNS ;+L8UHM&.#Y.5L:T'[$R'YZ^"OB_0>U M+0TH(V# CC#'8]13":X0!G__?'.Z6_5?2;'@X0!T&7#2+EV,LB/L43TS(N-!KD/I2N[<$0!< )^IW@/"K,&8S M>2M!H8V,4S3&ZB"MWMK#B$^I(T.N*VNKC1+[(-LN>DV?X^$=Y@_9B[B+*O9 MBL)_UQ&%M'7N1NGK9T4*)'050_TSK>"]JNU/%^D2,?;S.%C!<+^E M;T>RGS6C^[V'WX&YLZ>+@Y9(+6B(YKAG8XN/?&8;X-1_=\& ;+FN4,>7P:13 M;::Q%(XXG57])^9=/#@MT7=KLMBI;X?!09J,X$^--C_H5,="WDB[B7XWUY2R M%RW^_7EWTBU(9OL%?K4[=3J 0U5%WU#6M:!(\]OF5"BQ>Z:DE_-_7+QOT!TN(F;.YF.>+:Y+0SEP M)GIDRJ";,;Y>C8$G$*]9W-W0%*CE1N9\)QILP#7C&5*[?J*)4[C-LSN0^Q-_.' M7 9(,=S @X.\.P;GD%BG22.'*TR))$YOZH#K7M85JH1?G@JCFF(:6 MSE.6*U2VY&7+P:@PP&@T,*2#PXUYS:"4:(\H#H*I_C+US'SS;S#4YAKUV7 5 M6V8;4>9)]5W9S\#Q-PPY^+T< [JG)F%J\[XL)8 M+9<FV-EB9.#N\,!^ ;*[11E/65\/*J?O=+ MO&<'88^]=X[[&S(>0B.'+8Z8.U=O&J,_68S](CK-*CY@^3;[I"XZ;%41&$H[ M>'47!U5YM59=W5,4C.>9LO\8 .DV@E31'!W9_@K-\D(;7IUP-%%UEF=(]$[2 M=EUEWM=(MV,)[[DO$"5\4FZ$IVIH2+O=- [D%_:7\$X[;\AD)F=>-O6=;N:2 M7XV#:J2Y_W LTK__4J7S?">J,S?Z#T[XKU'F1[Z4I0&C$#/C,R.BRQK'A?D:D1\?BSV]DL+6BW:D0/YW&4D- M5B_:29*^F2X&I;PLC5BG4#)OC1=1R)5GT6.? MB918)M).C!<\'O.SL::]$.'PY9I7?S)4KE.\,O>9O,>7<3HAVJY*5@?!UYEK?Q6.@ M#JGPI_G2;Y$>?CNQB#^/)E]GUP@%Y=#D)_5^HH_ZH!4Z*JAFZ_-(5+$SJYHV MRG1[;]PJ8-PB@K!6G9+9>W+(VTT"M1W@CF%0GZ*X%3BOI(GES\@Q$=CZ@'FV M3R36Z.](?C O!(HXR9_6VYOH&T^I=J1;[C\8*&F;9D"F\2]+H8O@Y1\B)?:Y^:X'AH56B-,]:1.SFF@Z%0&0..,:=U M01$GK1,Q9B.;:@N,L*_[65LG'Z:&;F>-4NA1QXBBL9,>M+3:NICFJM6UZJ>T MQH_8Z+<&5,]-3:M.&1E@H>\\GWA!'I]X!TUIZXY0EVV9*J['65&VQ^CY8?A)Q\N-RCB6I:DM MP&#I%\H++Q6EU.*+V\XG(LA@.V',Z9GCB5E]7=TL1W6:=JL,*SW ? JB)2)F MF.\,_!RSR#P<$GD&<#)0="N,Y\D?\'A%3RNRCLVTB[3V$0CRS,HD]-*DF/U4 MX5)R38!:GU=7??;ZZKYG^5,U121[M$V8G'WBHX%^/X*'RR_*P7HTLKW43=TW M+&SWC)GO)9Z&CGRT=='?+O?7OHL,SX?3,$;U^\\K%23W'(!'> GG'-Z%QC@C+4 M&;($]NK.GH0WR)DEBPR7#ILF2DIBC%,,BXPI/0'RDO1"H*+DY$DI=U=ZA"KF7>59GXJ:%/O+10T^'[46/L0CZ#\+!CPB#J^KS>;D(=-%G/@Z6[G-Q7+)2B> MZ2*.V6&T$97Y3EA4JN_66W3B^^"214(:_6>EKSA#NV_DR2 V,_8N="PD6:S3 M]CM0[/P)]T,_-UN,ZB2W1+FU U+0\TRL;=K\R6#JMOZSL')=)!L[FYDR)X;99.TG>3US ^7")1RCY]W;9GT.?88G<9D>SC!!$2Q@P M9\CP1.,MO4S:*?NAT>>P(')K<[)I_@)OXYX:MZFD=6G+1DA0-MWI(I=K,TK;3BQ4O9>_K=$.713!SF M>.&P@N&ZCNP:L6GXZ>'61'2@HT\^I+L=G0P.FO2@[5-@1:(55,^>:I[2:UJD M]#5S669J]A8!;ZZV?O+Z,;=8GY5^2^M;V?[^CPFC4H&29,5R#)K![QZZYZ=T ML=L'?YU4[!JVHR,9;1ZCP3.SPO _K951PQ&NZ0?'-YP2O@\@UYLG3/$/\'HT70.NC*R/M M\R/A&Q!:8WMU$%V7)TVS-+8I.M[&!NOS4 X54%;3/5!;PJ['WB?97LI3! %>" ['D M&55IEZ:UBIR\2"9 $\M_&=SB@E0K(+Z6! ,JQ-5/WU]USL;86BWV]->_CC@1 MU;_7;#&5H];)-RS)!U00#OY)30VOY'_F(.7%_]UT1!^U?ZD9 R2H@K@P5!]9 MY[\V)G&DSBZWWH,W&/Y&"W\E(IR2&Y$48@N&/<.=!1'H8!5S7ZL'G0N9=E9E MM*I0!QY315I3R+[H]!=ABI^9:?9H -N4IMC/S"IVB>NKM+B37V8OM9^,'@YI M^:]X@+HC@HNFGR]VV5?CU*W='[-C9,S:.V" @5(#"(K=Y?Z0M1ZVK[4=*:!M M9U72%=[;T/,TK0D ^LN&-._T>4O5-SK:EH#NU MHSFQH> %% B%TQ(1MTK10XIF= G7_-'>SKDRYC="]\*;M%V-K91S$"2,=.5F M>T"[BA$9_LJTPID\IL+T9K*CFW\SO):CH/F!V+44?)M38W MZK.T'[=.[>BPJ7#;?7 P2P1]>3N;I R9&VO.(IDISFQ6F&1T?[D@PX5N\ZQ: M]J6TK=0HT]VY+V"5#];K*>YV#0WN,DQN^!MHT"75L^3,7WR*(#M%?/BJ8D G MYIJ@=-E@V^R$D?7UM=P1<\9?\;>CE;0B6\+V,U!*Q F]AC0H*3@V)-2OM>QN M[=4DV?""^LH0^CK'MSL!Y;?YV([$^UXJKUR@G^MO,EEZ+MY?KMEP53A'6%J; M9F %!KVU"W!Z*76"SA6"5GCYNS>Y)NM(3T=VB)YZ^/R-NNL=Q&Y/5\SP#GTM M-J&F\J^+T5"H^+%/1]8"<)R&#%B<%H)UO&4B-H5/Y4.R]H,VPFZ3Y:1DL#;,IH.7TTB=Y/VU3J_Y" M6U:9/RBP;,TW/_?GW^UE%[+!&3R4Q<@S$J*?;/;YV9 M7$AF5KW5O/:11?\=%GX&CXX+F1W<8<97P))'8*BP3VVNN1\3C^[5L,TV8F]J844]B!%+/Y0[O79!)$9,Z=@"0[\;U-6_4<^"F M.,VM5'FY!!IK_UJNCL<8/4O6'Z?UVB1C^=L2\\[]*=H&Z_AI[L&W#O MAPZ!<-SV>5OS/+D6I"_0ES*D$6VM\9,KF(OOK +@Q^1W8X$),L:"62P;M[\! MS^?_5]MSBQ1QE' ':$)EU2HPOWC/'.2@8V*NIHM8$58W74ZY]_Z& 1Q8L?@+ MLX$!?;446_D7_$$-$_@&2P9&BEYX38%?E>SY4V29J2V =BEJTQZ6"Y[,:& M:EUK'I]]$9[FC>UTN9RHD'3(?!FR#:5]WO^,<%GN[9!@6<@:NDI<]&U/=]?T M4LY/-X[A<-*]F,EP-4AK"G=1=ZC8^O969?]7$&^,RP)@6O%W,U73JP\FH<'2 M+3.6"5NZ ZRN1?R)YHJ%IGJ\$%Q]X+FF^L_YMW*[ M-Z]LK5FFQ0GSUBEAU?%Y"\K3/C%P\V9 2TWZG8^9\;[;(YQ>\'C$.T;;*\K?G M.8""T%'P2+G03':3$H]N86J(>\CSH[!PU?K:J^@05.512=&C=/ 8C1__YO?04?KV62

    L%"Q4JB?<"1#OV&Z^S5H\GR]X(LN?+]4-@0!@-Y*(-:Z6C M=H5H?$&"+UGBQ_!Q?,[\*IZ6?7,YD:HT7L _IZ'Q_]\&^_,_ %!+ P04 M" X@G]4,6&*-(@] 04 & &5V87@M,C R,3$R,S%X,C!F,#$S+FIP M9^VZ!5A<3;H@?'!W=P*-! L67$.P$$(@N =W=P*-!$C0 &"!">XNP=W">XN MP=VA>TGF?M\D<^_,_6?WW]VY]]G#4TW7Z:I7JUZK@DY!EP#L9U*R4@ ,+ # MW/\!T%E D!&1$1"1$!&0D)"04%&1G!K$Q M4-.PT)*3,_(^9&'GX.;FIF+@%^;C%&+CXN;\ 00&!04%'0V=& .#F/,!^0/. M?_J!?@5PD($\V" X&!H %@<&#@<&V@Y0W=.) //S ?[M@8&%@T= 1$)&046[ M'U")#<#"P,'!PL,A(,##W__J=?\[ (^#@/N 0QP13_$U$HT]/J=O9!HR[9/2 M%@*E;X<@+@,'/Q140B)B$E(Z>@;&ATSCD[.+JYN[A_S8@,.C=^^"HZ(\QL7&?XA/2,S*SOF3GY.:5 ME5=45E77U-:UMK5W='9U]_2.C(Z-3TQ.3<\LKZRNK6]L?M_:/CH^.3T[O[B\ MNO[!%PP !_/'\Q_RA7//%RP\/!P\T@^^8&!=?PS @4=XP(&(*ZZ(]-H>CX;3 M%QG_261::0L*+9?2(8&!PS=40A#W,MW1#]9^;$'C1RW$/QO4(_5K#FRT:LL-]ZQ#\B ]^AJT2[]+=ITNW_3O4QT?0B!GJLFB M8]4W;=???LA$[_^VX&=N!4<+*Y%M7\?)15F^-W[_H,%::$$"2SL_A];&0<36 M=BCWB,BGPC("FX4G0:7?YPI\/II_/%+;6*3R:R3#"$2^%HY$]IOJTR;]*FWK:=B3=-L\@ M=4/N,A/0VA#W3;.'9;N3LTAT O%X7(K]Q?! %_]* )-MJD8R^!^(Q&,_90F, M95;-6WU!*!":8LAK+XT !6)55WM#JY-\OJ!>&^%$"9P6@5MCP3:'@_4YZFX> ML\I-1$?(KQ/&Y*IXYB,#X."RG\/L2:Y./>9[]/>U8SEIXTUZ:;*CV/R9K8@F M@"UJ;E:C7.[N:_?WV:87GUZV^78Z M[CI*E&@D&_\CF85!@38P^M:HG"WK?C9+Y/3\ E'8Z@PN"C)S6*/,:C$\598L M5NL HIS]O6J@0"3_NPY2V.,GQ=AO:F02W7N^4E%_W4G@3YMB&6+ZNQNX47/R MJRYAY1&H:KUX4T=@OX.-<.7I\3H1VM=E\>42A9SNI1-=^Q5/&18A62]+:U-G MUU#50H$L:*6?UB\!H!.AS%,:S?V !F*X,I]3^V?T=.W-]MI^FVM3 MI"-.9>;M?CW.E# *$=6' D4AM]_O;4K-P3_:HIX(73Z[6BT3UV9553J:$XQL M^_3ARC<2MH8;&8]>XE @@PPC!HW[*(;'I]>@P-\C?;)@2P3^L)V2!B@\FV/? MYB6UE'#8"G(.R%1=]GK75815:0)N)?NRK;BE6-BXET>?Z.HR48^W]XIXG5KZ M0TAM4^HA'X'0\"ZA:1(4^'O,ZWY*1ANIE*E0%^G+TWN:#$"QZB_ M)8,"5%8&A1IO&$?V$WJRK%\@VT:B>QOY]_OV1BD./W5P&Y05]Q/\-H#98N*N M\ \LR8Y MH^0J'NNCAPZT81J597=_7;JG;-%.WF $WU\4K-W9%@['QG[0$),D#+S-CIF'2#^F,5#&S(*_9Z>7%43%!CQ=,TL/WJ%F3 \&?K3O4& 9 M?0R\C!G1GFPD:N(.>\4OHO^D RXRHK[&( 4*(*LS[>I(><,9I:_K(61_4K)V D^IK+8T'(_;4;SF MO3UU6!PZ##RN0'"QY>%-^P4K$Q0PEB>*@QN(5_:9E7H6:KIQGETFM&^[U! QTLN:@NKW"@-#T"?.B QA[7#+N?TDO"%BD>X;Q=@#]9'B\+A*ED>4FSU$Y#*H>4S1U3EH%[6#"K"?-Z>X M^=UO:5>8S>B2O7 A?&DA Y$SB#"OQHY&_4\[#-7,D=J10N2KR[V$,X^MB@OE M$B,:;-2K=JTAE)\.MIE#\L*NW]UK+!65,=WG9]O56QY,GW%2(YR<4"-ZE/TE MZQR?C?Y8BYB6N2(R.;Y(H)ZL^%U=9E^FUFS%Q(0J3]7Y\2QH3MM=I^=KYRXF M_ZT%W< P3JP0T8K#.J)_CBVJ>L2#,@#DX>%_UJ$^G B3S !%VBZ"M*]Z"4R,<#MI;4:@AR0VF2>N%=V& 1,E:V5CEW;N>+ M%_.9/OS D0IX&>V(]U,W-X5X_ O,*>+P>&+:(DGKYM!3LC#7&YN=5HCS;8'F MNN9W;E ,=5G&@Y8A6GXX N^;E>*9O0HS/&FW2?EZOTU6)Y1/DO7K?*$PG]L^ ML'.,?M/U\I> :X/ 3SR>6J]AE[\!6\XVBWXR]VPQ9XU)%0I]=PXP?PX>: M*Q>'KTFF3:*,!4UTLRUO)N-(F?M 'IDS8659&U\#%0-5KS!W782\M17=SS'0 MM:B"FNC&'AE6A\C'X(IUF,;(1 !X/< JM7UR+4$\0V!EM]5&?;1L@Y89"NZS MUX)J2$@IAI,C]9ZB(837=C1#;;FXM4^.,K=SD*6D9N#UUZOQ8D&;DUDFU>UH MKY<7=VNX9T/ 3 N6ZJC:4E^['C#@XA&^X+JE$;PX3 MD7\U2;4Q(IR%E3M?QH9[JV@-TA?WK#;,! >+I:=10\O2T4^<^"*?$ K@*3%F MC@:&4W^##)%CMZ#GC4B6ANPOTK ;R/+W7KOBZ[Y."[%?2JR742DRX>AVFAQ# MUY6(E2\NR=!_DRT\"!QH1+J9:B=O>ZI7)'8E(ZK$/GX7^Z2-"7GO \HUZE:E MZ'LDQ9K:F(K)_NOG=>;F;!*\0_10@/V##]XL@'ZVFJ5@>/3"4LZ2$3.&C.!= MA]>CQ)-Y7ZK8H)@'SXJ+ELP77.ZW?,TMP8I[IE/$DV:3)RJE*%_YD(J'(XHD M29'>GE%XOBHO5R%\[[KQ;I\-O\"H,RO)E*)4JZXZ(G/"ZK20;4S.B.5 R:V8 M+5MUV@=VW3!,#&W2QVW7HK-\=5;FUA$SX\M,YHQ7$FX'OF)IF,ZZ*B=?=W=? MK5"XCU/ZR2XI\8D;G'KU<"6KDBTK8>?!;B"E7.]-JS$B/\GKLX+592R9X5OQJMDO+B9/;H6O'.M[51VD;>SY*LD-&N&O9#0;MMH^*P M6DH*O@\N<%DP8B82$LA7Y1OP*EO)YGJ-8F+>JTVW^M5T8CH., ^5F+W>7H"9 M=.J+>UJ>L,VX*AUEELZGTTWN)W";>K+U:N@0_R*X#YV7Z00VOOR&1X+FO&S?K>=, 4Q3<$72+\YZ+U/4JL>+"T6ZJ78G7%YJ M=(Z@<[U]B88SR_!8T<'VY7![=L09*^004M&;\# SF(&C>RM6>\^ :R+G*;?R MHE7=?8@7WWQ0+CW+UKRY87NS.PS_3[V&%7>VMU"?'6*A"R3N7'<0/GJB/40H M5+OV'!9QDI9DYVKDKFP'XFT"!9H&J/Z<+D8Z0?[T(\+O&@2\0>)JAI.1NO8L%=6]I7OG54A?FN +-A,\]C89D."["V$+U(>^' UU MH&A'#KK;H29O*'#1U'3VS:R)=/*-@B%;FK'=B:RUW8< =S*'N)[YY&!$%(;' M?9,JRRGD.FYZT@VEE97A4G7Q()>/ZR3 @PRCKGYB,W*DB.=S_-S MUV*UXTMN:V4W1HH-D37@F-NRN62W[@/MTRZMJG?S_1??0%&?^@MV>64^=0\Y M\%VKF33C['FW8<0$)HK$OI9]4.54)Z4^\41VX3E=2>;F.O4'_IZ-,A'JR_!9 MW?'4\*]=YX)F/:RX99G1W:Z]2^Q(".'\%$!NQ.,S"?Z IH97)%JY+2$TG"!1 M>H_5D8_;1%DD&.LMJH/K)UI(PHY#'H62.F^=%]%%U]+-]B=[O' ,0E%'V! LTF$:7SX*&*Q8O[78?_'X+GAOG?#9U+(/A8O(D M_3N2HOP)WLW.U;?_JOU77=>Q4, -K!G2KW!0O*F RQ"U*'"WO+@C.4PJ0HF\ M0#_RUO<96;<$XE;8*G^Q\KC)X9?Z(@N/Q^OUVO*FC\>'9EY7!X]EVF<8(!CW M>+O/M3;H_80C_2EE46\P79;7,XRR/NM2L*6N,B"@1R[?TK-F0M:&-L5A5K89 MD=Z '1&&1"A*G%SEG5,.]PTSF=3(K,S\BJ!.WLE[G6A,H:]=I5VCH1?%I+_0 MG-6W020L-=I&2=$0WF,39=(P9C3FR%>#2G,LR^2R&N5&$:1GD;#95N>2YN7U M:'K]W@U4[-!7EVJTFXCUG"3Y1E>'(Q4_7J_)SM_O[N M['9[_ZT+%$!/6!!V?)6PO"H9\JPFTL@M5B<4>.!7C2ZM[5I4?R/7.@,%@H[N MD@;0M@E=RCGS-"N./[1\88I'97?TG4.?#/L)Z?M//!,V#^OG3$O5;X6&T7D5 MY[M8TA^RH;^:58@'X3Q7?M"#4I-SDXJW2)LE=Y_U804,DV16Q6<*HDYUL?C9 MX["@AY&0^:Z.%7O'K/[*9JW>"<)MA/PA)-*>)V05@Z=WG(UE]1%!4I0D<4PF M[B.RNDT33)@N^H:1Q)],9OS4HVI!W3MG_$4.T:;FSW\!EI]*H1NTA%;/*MKJ M3=M0'T-SO%X),Y#IREI1CO@R7&S-3L&F"US>FQH8PQO>$9KC,5:>BBX?).YY*LN/9='L[M8.QJ.M9_2LE0I<8>( MG()PHFM]K(QR*) WD]P6?RZJB)_$2#\RQ]PLT77#:L/6?.[2!^HPXDSD#TWO M?XL X\.-W9P1DW)I8%A"L9JW?HRQE)H$[O""&DOU>HD_8;O9^P*\&R0&X*2 M3K9TK7]A5EZZ'F;\UD,QGPFHG)E)]2-[NW"=5(-1)\:>I9X[ M0PQ;T!@N;]JU_ AC_IGF?B^S<>R*N5AI!?]FBX MW@'"D'ITZP)J\O7&J%MY^(@EQJ2HY?Q&0=LF0 F0.PYR.G81#%S>2(QPFY8( M:#L\'7D/GS,00XU3&<>B0'WVW;[#WOL7=OOBG> M M3M)H!\_\FB=ALFRKU0X4_("<@_[<'*0^AM&.62 0J7D6LR),=@-^&O?BQ"#B M3:1L_.N3EU<.+)^,NKL%[:2D-8%B6Z_7=!=3^Z>!)9]F*UM#/@:A!W_E0" ) M(HL3/4!-?R.7SMI8$)'U/,(3WG&Z=>([Y:8[P(1^MQP#(M=G9_"QBUM N_&. MMC8^#Q&D#S9EF?&*BXI R]4PG&U8M1/U%,+.)E>9?]6FD&O!L8BV"C_QKGEZ MF?;*.D54$" M %>[+VS1%)]OKEEXJGIH_B)RR(QMN2:*N%4FR$8,B(4G! (5!SW&JKTI/\@: MVG_1Y5;CB9+IG0RCZS9VGNEU%5G^)M/2U3>:4)SE9G+R;(S[BG8LU5-+\%&9 MN[S9FQZ8&8V0]^PHQD/SW^T/Q,B:]Z&P" 8*#Y' M$[TZ]8??>?HC3/2M'[7=")$(^( =2*/ M 2+1 P5T"Z% &BJ0^ <\?"^_(8@7]7V(8%"@*$8 ^1.@]!0+%-@\]F7[G&,F4-A_/A'9;D/]>JI]?14,D"*' 6:LN%-BCH^8/,VT_%Z O14QQ3N7@ZLTG MC\R3/8Y#J#=2R[)3HD&S$F+EI;8T1Z=;,2/LA[OET6$Z/WF60]<4'!ZO'2N]?*I88] M/:!D65!TM/*5=6I,QPU"RNVU^'T,V:$RMFO5&>,F60"'+2JB3M7JE?\L;QM\ MC-H !8JP%N^BE3A46X<,H$"Z^"C$/>(PZZ\S7S3;>W^L^)_7U>_CL5EC\MB- MJP)D]FEA@Y/_4A3^SQHS60=+6]MH3G>X+$VP R8'FDS^PR&K!X;)X^7J3:") MW5,M MZJ 7N,%@YN?5ADV@_B2Z%*-C-EIH\1!EC#;7;T*JM+CMB2;!]8R^UQ ME7IDG&/R.&'^/5?3A!,WY&7% 4>[R/UK,<].Q8;![WJ[;(KLW-$L9T MEZ!]LJ6\R .-RIIX[KY1PB-L?2*RT@\"8SANF\]+ZY-GA)F.^=>2XE^M@[KM ML+P;4%/,*3=$M3)N.Y4A;&,$22U%TH[97:3/;&ADTI/-4:,.VRF><>A]V%UN MLN/ZX' E]*I(6WM&:T;OT6=[/KEN2#_*:$]M./LGVEPIQQ-3.EY,OD*)(RYY M),3> ]%#JJ-LJO>D;F%&/$2^Q!\* UIH20[V106$,SU#=CZ*?AJL.2*L_C++ MPK3PV%B]SRH.I,_;=X++L[1IUL4^Y1:A6'OCU?8L:JX-O(H*IP UW\MO%Q'!5U",VOE EJB=5>3<;"GB M>7VLU.M2]B#66?*SC!GI&B^;B!,27E+=8E/'(AVS(Z1HV7ATS-%NXR1I8Q1L M*SCT@GE9F\RC9 OD!IV<::Y[3IX,O.=#\VG)V]IDJFH1'-"TMM[C[RFF09(QZ#S%YL1IW M*SQE+K *OT$,>:6;QS,;\2SBE K7Y]=#F_5CB"QHQ3$O))EKQ;SZ)H&SS>A$ M]Q4O^NG_2?8 @L/=LF2&*RT><48Q!&7(W(/WUMWYN9;UUNS\\A]*NVT MVRYK27O1PW+NH:OC>BC0!>Z,N-1(,+V]TH$"J\VKTA41=M?K6!N"%LSOH4! M_!?P4,PB1!#"#6[M'Q7=[#V A10@/1^D01-,H(Y9A6U%?Y3=L-G@E? OU%, M]1M^<\KELUZJ?IU7 MO7ON=N48)7YV_G-Q.02=4-P1M$.!W_CXEQ'DF/H]"$CV?80]"04DZ72+8!=7 MZ#]C#,Q]&?S^/A,SU7H)7F4SQ:+\7T:E.=^AP#%ZQ-TF%!@><( "OZ+/5[]] M.EIH34A47@F-U#T?534<'"+ MEGK73Z7H^YP7S9*:M;=W'O\FP:4V+5?%6?0*01<\B70 Z2F8?F.\7 -RBM,L M5PI5?!_M(ZWKX2(:H]<4RU^A%9\6JZ"*:9;WMD<$I3JAU4+,#3%/B4K*YKR*-RB-)6IFEQ VG# L= M!;PCK!:-HJ4G]C;#C,+?E/)2&F1Z:\R\&41B&(,+?PCSC2<[.Z,[PLNJD S! MF3.'J8L/*1FEY3:W='O&JHS%?ILP?+>#0-485+*+Z'$L*M#3>#C>F>'I*#R8 M1J+!&8E0_2 C-"/M^4'+\M0FL%DDUJ%$:A4!IBL<>L==NV$9(; R7=AMC@+7 MA][D2B9&3-RRM"HTC*0G21/*2&XGJ#0,(XG_\B]-K:FI:I2%[5$Q'8Z65N=( MWP/X !42A@B+C?3+STL]A28U\MY37$FHC= =&N,+TVCO# M+DJ2P[OKJ>VZ@<+*'IA0*UDFK"=32&87?+EJG914EGTWDN/ZYJ45<%+%2J('!>P78*T^!>,) M4;&4=2:,<#T%F7.@?WKI4^Y838X@&@,X?U2E]U_%PG*+7XN0&M>OCWJ\<%2D M,N[E\@&3GWRUT?H7OGYIVJ;MEEHAA6P#UDNQ)GBX3\W4?2NNU4R5*W5>8- J M6/8%1'X0L@\(<^@?7,:'V>]_*.O(3#*1O4>]=)TL;_"8F>P1G5-^M=?N*GL5 M04F]NOT8P9W%]9P.77LT?8QWYIS0%$^_JY\XR94/O&$X)O,W:^<<&[:F/A8B MPN@K>OTX5")&3!1X7#Z0Z=VRY(EG#5_,]S;(9[Z#CU00FL14(F8=]:Q%55_R M %#N!#XP964'6SUB8U%BW']*M.05M97>_@HW\#G<&$6> K43;2%E7S]8<61N MT?>K!:[V?(4Q]YT""IQDZ=XL0C!.?93[G-=0DT5YUHG%T8)7B))93'PLK45;<;>@ZHSKP1HK6'G)^O%:0 MH)M>8J/PP'L0[ #__*WO,$6'UJ*MIJ5"#B,:16!66#A%6"VB-$=>?HI=7_UL MSD:C3;!PRBI\U#$9%M:Z!2N^/'[N\C< M>Y,E< "YY;U4:_@F^ZU9B2'NH6"M-Y(_V,@"?(IY;\.:,2#XOW8(#KB5SM%J MJ:;M(88MS66/1:^1[JW78B 40!7]K7>1P'B.5@,V[KJ*0(1TCT&![Q3WOL6; M[);QMQ[S@EG&%-OR71S5AA#9#>TK*)#JO'AW:7N8\6NGV#T]0K\^Z%P;_.G0 M=C=, >([";Y8;FZ-^.5[XT:PL-_^_P)A#YNG-5S[_IMW+J=[?Z M+R/U_"P+MOJHUJV@G("(TV+// '16W_:G]=J3KFD2W3:;MA$^]VRSZ7N21?; M:;XY7%R6_K6C>R))V>**M5L#!3B68Y,IQXO9,JK#6YK_:OMRFAB7EV!&43/W<>FX91*Y M+NS8WIER<]7$GO5M.D2EICQR6:>WMQ_GRY4L.A^QWD=['8*J&,*@)2BPVVWD M3EM9;M;6C%"2G2R@.JYR+X0UO'LVM:F@@#CW7.(<;BEHN]B81M!*-=2OJZ1+ MRTFN7,*45?9?:>6H Y!F\ M87)(F'0$+VO#GM=+-$#MD(PMH=0@H\SE;12I&>FN)W@=U57F+1H&LP3B))ZPD,O)?<&"K";O)"%?-_T MCQIMD26W=Y\L8V9=;C0*4'X4WU#2U3=*3!5H;MV 8FI!3W/L3FJ=&)I7)/+" M'QU3FD6&?\U_["62I$GI[(RD!9O0*"R+9'Q9NV]HBF.P_XVM_,,&G33M#\2P MXK3 :H2]Q@0E7M5H<<%ZM0OV[%71?ZV+U8;LEECFX^E*R8.*8K1X@R 7/, MJV64E_+-.$A_$A/"V>8?TA!#P%<4(_;F*JT=:\ I4I]N-ZZM*4E@S("'[>\6 M([^9_.CFORQ5[+KD*==C8_M8WH.93$[&FL0@S#I#5;7D;JLQREIYJF#PZ3RQO^ 7UVTS7)ER)GNK M;C"-IN<53_/HX+;Y-)!]I+%7)JN])-'UA!HEK&.2'*96H4F*2^D^@7EE*?0] M-H2YW2:@>4:7\#C3>E9#T6?-/W*K9=-?C.Q4[9'QRGJDYL8=[N"PI"L?9I$1 MSM?O]37$HN /_#V *?Q$R&7@#*N(8*VU;;JY\;%!M:<+GLPE"&@64RA!XFM) MQ?!@3FXX2H[^4JLCL<>34N,^.>@;YY!I(@W7]"2?ZJMO%)/"I1SW"0XSP5;* M('9A\732\W[EF@H668 M_,; FB?.&+FMYIQ7WC0#CARV]Y/GB>I>TA9 0C!C*NR/5GJKF%'5F"J?S1 E MUX<>8()D"!]#GMME@!_16<5,U8';1^C+^'Y!E$?]M3OVJ.H+1\T!1\DR;$+=GRY0 M5WA>@AN FPJ86;WO:N:L 0OQ#J#Z\J@G"+<%VSLTUK2N(/T VN_2;X(UB0*= MA=DN%(A<":M=8@EW$$JO8C($V8^M.WE+NP?=7OF.A[R>V18H; XZNY'7E+NQ MG!Q=5/:3"]QX"+OQ- +^-K*I%2ECE;A8JMHU:H8AAD>F&^W1A2QY,!#UAR#_ MLY:3DRI<'UF>X?\$F'[;XX9&/_&@^;QB!Y!@7L7.^D, M!;[)JN4 Z<&,?[;?_)A:7G@$%*#N_G%W] Y]^"^@LQEN UFAP,["SRJF=IX# MN-M@$=)XG\*IY1?>XJ1.'KN^]R35**AKS M!=&6G/(9<]7HJ5;]F-B>K&1%+ZYSZQK3Z+C_CG+P)A4C&K@C=L&Q3HPDM= MT9.?S&CB<^Y3LX<&L%PM?L#G4>B5PC]1&&V0?3QP6557>5R.G+@F[4)6%4D" M>)VAH[G Q(TM_2"!7TC7L,&-HF#EM0.-^EKTAOU&'?N@F!(AY]HU._$@BJ%; MU?=XM>[J]Q-P[&&SFP#(MMM$L3O:5M$ON\@.$+AF(I.%C)HB=')L=!:'NW4/ MV6%M20(JDRR[9QB8YX,0,,V(6; >6$ZI10V6RB]8)& MP$O?&OW#[:]43Q"E#7MR&Y[&.;AYW+%()&;@X,#?S#;FIT3+CA<]=HZ2:Y1_ M$*<22:>^KT%@+13(!""M(XHULU_5=MJ+D?)08I2.-O5&ZNA4$(Z B]+[)^/CGI4?"J\*R!R<\A==9:\N,'+%#8M$UJ:"BEA?X"J$Q':K@C=V!# M@"[4)VXFQ)E-CD/(^WM7#[^^8-(PXJT(QLA*793:HI C+'UUCE0UGX0*I6YK-6[0$0\Z-[386*AR9/AX6SI M:UT@#W_MO%Z44-;'=H;(=UX0K"7*=56S&!U6^[T"9D+4M\ H>N^1J]W%X."H MCBP^V\C^#+]J:,Y723C D.+8T62QM62V3"KN FP8O+FGJ&G 'MG34-N"4F\C MNRIDM!IJB*9<-FE5W#2$,)A%_X$N6'8= S22U+E<6OHVT?5=#[+;$)R-)&ME M;"EE?)Z.SE#NPG-Z/V;;!'6P@Z&/D!_(;M;W!(5D/H;:T#X58^N6(5M;ZQV= M^PR'M:-UV!)%>9T@^>H!;(C_[$+<#<.-M'R5Z*PK$5X+?\+"';Q@I(\1+6HB MJH^I5#LH?!2NJH7] ME#3J>V]F"Z6F$2K2Z:NKHQRJ*2WUZS)";^O9R1Y>E(+*\'9K&,Z&SS M'G//SBC!,^G,(/J4OJ;TWL%%=/&?)5?]?!#XNFYL,!MC?;SP?-TXEC7(!K^( MI^R#.,:@%R)'<.'266/XP@;S4.4S["^S]=&<%9M4',?KH"]8%]ZOD@74Y,3( MZR^)%,S9R/:X\N8$99G>+?<).@PT]\UQRO(AD3!4$XPI2@+X_]8(XHJV/4P^ MZ[]2$?T^2=W>^[)$7YK:=T\SINV-_'VR(Q]WYRIZC9*;6&$3:D] (?#"TLD\ M@O+2#=VK2.'F^#[TOF58H(0"*;6B!WW@ /?.:+JWJ@Z2SAQJ=89D!NPM1.2X M#NR\V'-P%TQWS5-QDHWAM$1S[R'2UGOOIGCV[2\2J2*\F0F4I!/)K4WJP'I< MY35'Q8%L2^QSST>>MN.&H>DO^7%UY>2"ET4.+V[O>NX3!*U;YL&!IEB=-/,T M<>ZRW1CUE(^@0W)^+^XW0>L]1TD+H,O=A^0;%(]$@(+"&7/_)R.ZECER9C-6LE8?8$$+EPP. M^^%]:_"/[6_N3Q(]24PQ0W3XCWVGVBS7J?=?^"0BV9<<2PS!Q5 M[!AYM%=I+U80\ZY-Z'5I^.?KL<,P0JW 18(ZJ3+&KD]MC&(L#@J&6P.4([I/ MU&>&"L!X#5#@[4W;XLD%P]W5?7X'P3O @_-I5RL-[@@TS,.C26O MY^;+&KSBUC:&YG\%^1=]7O5"7>B@B5IO"S20_MB5C[=UH/M*DG)&_"Y+JPS2 M9%KRZP91_1)=;#XSTVUE Q_(=?(00>:B94^72&L!IWR99@(]1?A[H0H'4A.H_R^?WYD$>X'I5QR- MSXEZ8A0WHM3QS/.@'1< M0'2$'SO:;A8#=67:500)?X8.;N6;TE(^$IMI9+I[E5' V)U)7QCKYJ31\ MX -9('PUN"-1J]$/,C.R/#*>O*GVRBP%2M&2 MI^ Q5T)$\;KLA2MPOQ_.)F8@ZX]$?!) (I-:3,H195\E=QYPEIJ!7>_GB!6* MG>$T@_M4?\2MFM"?OM(A7P2+TM# \XP9 73Q(()<_Z&H-+C5-IL^@Z*@JNR) MNDRGM-O7)SG$^V1E7#6 9_3IT$M%LKR'0T(1K?ELB2;5\@[4KYBIGR=]P#?T MP0+LL"C]?/@9CBICY@BWZ!.B^^RI7T896@1^E#[!^RHH(WIGI?KNR"NT_GUY M='<8?/GS_D2:4"O!Q.A0)'3IE_C1L\)4T\O\=_UO0KV^C8XD"F8(=WF? E7E=U]&2&ZK0P;$;LA?Q]'RB9PJ5_R[^C?<$VH7NSP2 M'P2?M=4L@5]B]C]:P;S#SHN24!E!1@])X')329O62-_,8&;868\^PWY! M>_+45952CF 0!>:C*1+5I[.\G?Q+E4*18=;"=FM;BG;]&?W^\-F7J5W]/+@(M+72)QXHK^I0K;G@^.T6 .&/JHL"GYFI6B3H?*>:884*-D83&KIL# M;0XJ!05G52O>FB-G/W^[:>[HLZ(0%\ $&VI*PMH#(!@I@#R)SB12MW">7FB^ MH?MB$-F%$9=(^P&-G.DA X#KMJ>R=_"&R]G>$E]5D: !F'UN)1-L]>60H'>/ MP49!MVMXJ?G;V=.:4=N"_< T5U-0MO%I"+93)$]D'=]E"ZKW%E_W@(FY+L%8 M0=$I?!2S6,+SUZ1'-I\3%-?+8K _HM::[$0].<2B#Z%>BS#,A72/BGZG,+_? MV40_RIQ_[3#MX6L@@3SQF\NXAZZ1-,&+ 3\KA[]TZB4)Q7LH.Q[MAG%!?"=2 M+I;!/^J/?WXO^B;YP4&Z5.Z&]OF/NF7VW:7>CR+F7SOY%8I&Y)&[2O_M2,BE M8'X!F7UZ@U"T6,XQNU;$5>.I.O[7_/4GRD?G4O$_*J4*-X?-/\JF?^VHF:5W M\]-.9=U%?@$/"XQ";A]=*O[R766&L0Q3YOPAV,@\Y12SXMZUH/TX!_AKA\ E MF,4_2CA8;YK4] ZN4/2@%0H$4/W:T4G_J7O"OF>C"1>*B*UC ?%/_%$/A2J$ M[-7 O_(F1W4)!>X-W$X=%/B>F3_V?T$;3+'16>9#V;3" ?D40ST!"D=4%C._ M)? _8)8T_\J>NM_$POBSV19\IA*K_9O*;X8H=H^5A:K M2G,#J7>TH\?+FFK?=49,7FLE^Y36\HPCW($<"5N*@F2MA43.8\0P?S0P'T5H MZBH)1:-[*H8&*VM63?B*G%NR6_EZ=S<:O1N?L/2K5VJB[BN&QN[.-N>>'77Q MI#+KO;M +(7()4"1',J?+;GR4--8NDSIBVD0^S,C%D6'?G^SN=3;S*/ U61. MF$;)U]J7$;MU2><'9MX#\)%=+%>V<=YS5/750,V@.KG12GRV6Q[:[#=K$+-U M'4&-6M1+F+!N'"CP-=Q==\[T@$U, )4YA9*>U>&H,)6IO$ LWML$42V"J=Z= MNG-7RDTQZ0R6[DCK6='P%"$L%XW?KMQKVC?6RH87QKI=21%/Q 0TF9BU NHK M I=%UG**&OQ;2+;YN%_"5_R2S/R]1A"]HO6^L((?'9=;@:5D-EYYJ;/L662Y M_Y1/^^9,93Y>^W75YZRM^L>"[J;5=?TLD3X.R)O\--$NX]$/&=G,K8SD/XMV M"#1$;;OVF1M^D7R#*SL?J=YP\_ZEN[94@Z>*#F]'PGE:(10PV"T-7S86W*>D MY'%_W;4_8K*9Y 596G+*%STL.96HTRO1H_@JI=?S0IH/?O]"R',,^W*SS05> M&C':WN85-8O+MR^+NG#VK_9HY[IVG,"?TNQ7]PR8\Y'3Y3GU]H@S(W'$L4R> M?I."K[4CAAR&Y\82K^;&ZA&XA2C4C)LV$09;+U*U^Q"@"\?. M_Y6XN\40G?0@D'J<[8"^9&S?AEXZ;&*%^)VR"<*D&2UU# EK]+%O,M.I+O=A MNUU>6WI_Y), ?+H"<46M'&(;F-.#G_EA- MTKLN#?(L/]3OEA>T7*:_'5R-W_<5!A&H>_Y&,CDA9NH+]TG M+;-%WH>=!=^BYOI6(WAAW$YJF(A2$.B^M]#%KUDZ;\\-R2@4"/[+_:V@$]JR])K%2PT/WML;/2BP M>&\U5W+NS49&_P*OAOH$ (=<.@@,@D%+C8$[W, M^W$EY0=]@DS,87\+Y6^0_+@)HY5VV[V;4\3[-U#^94G-^^6@M;;Y]U%YI9=! MF9_E;;R'/$N>&':V#SI@733^.77_^_\9+K.ECQ@DW0F>\^:@ .52-92;& GW MC$;L.(G&4P3@=V>%NT6I?];EA8GYN(:SHY O@/HWQ>&\L(A;\#;X;!Y\JJ2R M_=L-3*9?:\/CVQD94*";4_0B!0I(<,-X_,P]9*' @Q#P]3)#\454X3B_Z!J' M+130/;Z^]TZ,L.OXBF((/T\3"?XX37QL\>/^Z5_3%< F2TBUCG6]HYW&S*#: M-8J&D^))E%J*8M=CG[J%..'I*"@@+9/E3X0F% D+=_N=G LFM$ =W3XRO+7: M67:U+3 MD<=\5K-M528\" 1[J:H>%-05-451:J2]JJ-;!<#N1=?*CK9O*T8 MZYN+E!L>W:J$CTKO$GC"" L>SVL3NX+(W-&E+]8+)][ S_,+6D?4M M;CU#W'L:)=@E6 ''SQE%'B\1F2UTR9H81\P)R^:UGSTICB-QH5=@J5*@/DFV MWWV!H>TEW>;JZ,L:JL0=G#=$ETK;1P<;)7.3[6!XK;^J_%U3@F. U/./[='@(XF?.F!NUH M\7J#:EIO\59T*=E4TL,8WQ.+'=(+@0++4 #^1(!YE#%CRCWH7.T""F!=,L1_ MNT=*V=8O6M;$[Y^B[F#@JT05 V MG/(*]G."-3XM 9RRQ7*_$)$ 0?]VX.1%+.W)1?CA )ORJ%E!M>87J/)"%?WX_#+Y,?AUQGD6(U6UC=IR73"1["..2#=1S O]]Z,=M.? M0&I$(7Z6'U)]Q.&-*%.'D6PK=5G#TV+BX'$^2-**X]6XO"<)%#%(3<:4WF9^ MG^XC,,T=@F*SMY\\+;3C^.E=-ZI]Z)+]*-PA@Y@VAK>@B/3?42A MT_\#4$L#!!0 ( #B"?U12O(L>"3T &M% 8 979A>"TR,#(Q,3(S M,7@R,&8P,30N:G!GO;IE6%S;LBX\\>"N01)H7(*[)00/[M9 T,;="18@(3@! M$CP$#2Z-6W!W=W=W"WU9:^UU[E[[G'//WOL[SS?[J1_SF;/'J!JCZJVW:@[8 M-&P9P)&3DI4"X. ! .[Q!\#F G@"3(R"C+2$Q04%%34)V@8!)@8Z.@8I'CX MV 049%24%&3DY,] ;/3/J%EHR,D9^!A9V#FXN;FIZ 5$^#F%V;BX.7\;! X5 M%14#'8,$$Y.$\SGY<\Y_^8*U +A/X$C@Q1'@J %X7#@$7#A8.T#UJ"<2W.\7 M\+<+#AX!$0D9Y0DJ&OKC"U < !X. 0$>$0$)"1'Q\:GOXW, $1<)[SG'2V1\ M%6,4:D<"SH"8;T]H7I7])%0=.09QO74*1$4C(B8A):.EHV=@9.+FX>7C%Q"4 M>"TI)2TC*Z>FKJ&II:VC:V)J9FYA";%R=G%U<_?P] IZ'QP2^N%C6&SG)Z=7UQ>7=_<_F87'( ]^?U7]J%^V@7/"(B B+*;W;!P;O_]@(N M(M)S#F2\ERHHQH[XU)P!3PA>Q7PK^XE*PZ5Z3/C6:02-",2]0GORFVF_6_;/ M&1;X;UGV'X;]7[MF 0P$N,?-0\ %Q(!=T>>[?+I1'TQ+R\:)INXHQQ>JS% W MY7\^$5A?@WK1AT(]+A;@^U2CLDZ0C;<72-XADG66'R/'LKTHAGH83[ ='I*9 ML(Q@1U.&(2O!EUR;M#4?1^@NZ'2YF$-CW1*>])KTH%P[ITD"=B.2!(#*?RUP MGU8-)#1'SS<;QEA9[8@(/.GQN]70OHNQH= 7J1X??7S!@PQ5T'TJKV/_[6S_ M>\!,7P;IVQD2DNZB5/-1^5]8#X,433:7IU+)D<@Z,J3W>U_LL:TU+=JTW!@A MK(/)5I-CTBS!6IO*?/ H_-3^/-DG):'+U2$6S4_IL=ZV*\KO"^D!&,>02]$7 MPZ[,9;:0O"Y0!&G\.TTT=8P4#A+^0R$MD4P/,?72=)G8Y;GJ&=;#M<\%5(W, M9HY=^FS\&5Q82\5..9/_[(2PJB0+O+"MRKJ>L.N&K*GA/A?-*2UP6:Q^+6_8 M7!WX]*+T/>369S*A,KVNTY5>J;V3#>!, [(MB+GE;^C M./F>QTS.*#=Z@;S'K*^F2]*UI>.T8VRCFZN3,X=$ MO)HOGRE[(@;$'#*C#:U<]%K5M0XY!"DFD*Z-3>C1X?,M\6>)XD]=/#&._,7R M[ XYE2>[>F8^7225-W#>IZ#3<8@;;DS'(U$%>"@(B,[Z$T/O7:^7&ZHKB!03;_5Y MG;EC<=YZ#.>W($0[JRYZ\*FG]1E^Q&RZNT/7\W"" 1UD*Q5=\/Z"_#YF&4JV MG@Y)89Z:R6_Z>_O\EUS\I04.PC=+(+J#Z45SE;>^+?&X5?Q,&C&-:-%/[JTC MIGRP\W83M<8D0!R'@6/=2!_F3_!D^,D1TC#MKI4DZ\>POKGZ8JCH@^5(?BB> MD<,%U";GWZ(!.PR98UT)JQH?0CWT?LA%6X=N2^D2VPJL@S"'0>0N?G?E) *S5/ M,*3Q$%6V@98,U#\5R2VP&!;-.&3@2=FIPI'QK"I.]HXAV MN:3MG;/:C,T3!JN12@/&*$ZEDGHBLJT3-26?]#-> 0\(H MUDJCH*"X'.]*Z-[JOFRC+P_2\Y3_HJ4((*BJ" K]LI9S5 M^0O92K?S$I&Y),IS.Y=6>>>MRB+OJ$C)&MI[F8HRC+XA8G7VMK<669=E<9!G MP PA1;@H)KGV;ML[);05?&VBZ5SR$BNVIKZVNB;$:)OSAYK3 M1?>V4BZAR-+[DHWR"5+NZX'YV56#UW>)CN\Y4[:$'9Z& 0>@J7,/>\I!!<41 M-N5@R_ ,=GI_CCUEZ]E;RT_69'KR[M[N](FVMKA +0)H_1B@4/#T7[EMDKL:%3^>V?S=#@;H3 Y>C>!2B5,9Y4EE0ZJM&Q?$6YW M# KT0%1&LHXBES?)!NN#M]W=KC0KI/'GZC%$SX*98(#+^* M8HT&A+!-ZG&^#2\JJ^DQZ%,#S8X7+.N>; M5=NITZ\J R6L[CG+"Y+?!'Q>QW ;6C$@?N]#BQ+"O \8R$?R$M/51WIP3*S,HYKF]%K#S;$> M53:[]=7%")CSIGZZP'0Z>)35-J,V7:TR$CWJ@I/[!Y'2MR/MV:&(Y5&VHV5> M>_[*JK U+QG D68?\!/QMQ-.D.,8O42$P1)^2(O' OC3+V;*U5/#[6K\OST!JJW?8:7=:4R7?ZZM5 M\B$GNE*QI3OMH*=)H0'YF\;Q]) M; Y[T%,SG,>543)5]%FH$ 8]XG+:H>@0#FLJ2H/\]$_H+*^J[;GX0NW\! XS?PX 152T5_>9/,& - M!K3"@$L2I5^$M*Y_]P>-ASG;2QA0ZMEW6<(\>%J_/\CGR]7!FKW1^*M\?K:W MO+7#WW5;!D0UCBN./Z(BX8S9]76]-];3SL0W5TC;%64Q.P,^+'P(;YZV-N;U M8/8$5X^*OZ((LO26ZJ,M$M;N2!?E^G-RY8]3NTY]VR+D 0A4)/]E(>R;]Q$; MMCNTVZP+V_2K!'WIC\7MRURGT29M9X*S4=: M2':L.Z=P+)^FN8B"8QJWAF&8'W95'E53_;;83G2)5(G@2?5]O%CHTL7LX]I* MH@'GN@R9_FC_+RE,"DZIMK5,Y.!I_;7=YL0TX'0))O VQ*$07T#^("28A^*F M9'(ST2&9Z_8Z)4Y3^G%MU8G^0W]TL&Y6>?L4>V$,_5?J1" 3!GA$M@4-017 M9KX9F$+M39P-OLAGZF6-8QET.#H#\_5+#%C>/@U8P($XQ&)LM84!_7ZPN^LVLOSW92.X%)BCL"<#Y1)>ZWL XZ9 M>\J+C>=7]K;6N5+482N9LV'4/IOLH@;3>[&.2;49UWY@):)I^;SM(JSLR^L2 MNJ:09\_E'2$;E2^[E-(C@B+/X18]_L&-P)Z%D+J+G-J5?-<7.-F_:B<^/Y$, MDPS:Z FJP0>'BB-9[&H25T>10B?,R]&P-B*Y;9>NAGF^2=*5?%.)^U0GO*5T MK/61]=[0.4^VJ%S\KGF4(,03;AL-M](O1F6GR8>$%5E9>)N PKD3WZC M*_(D=TN6T=RNTE$PPP3*[SZ$&I,H'"H9;")!PYX)'D1+G M%//-+@T>#%.WB@>6%@8=TZV TZ5],3QT.-;&G(RZ,$E?>PC'? X(0F-*PN86 M&"A>2X^"\&R-N+"R49$WHO@ ZGG^W$E>5YH\AE\4C(!TAAZ_,)5BD?*V44'' M0((9697SB0"BZC R55"1>?EQ9*JM(T9I'[DIMS-YW:F'R5[8_#\)@\Q"*E5A M\LE2MC>>5;P4(5*3_,MWFA%JC3# T.11J.YHE)&@<.H,V\A(K'_#+P/%!U9F M^?IQ>HRW5<$Y#D&@8%+^^X*TXY+(PGNMO,59/5T%G&KE'>;R\EY.C0\_^=O@ M14YB-(7ML;+Y0D$&K*EF6!C9%I%4"\N'?8+E:U-AZTUX=;*L-R&6:;@85@%L MQG%HI&7^,=\02NAIB@"OX-^2G.=41/-Z_KTH#"B>\KMET,J<2O68>Y!+;SNZ M/7"' 9G!@!?KGPGQGQ(MH3R/L]8ZC3,=\-XD^WQ^6Z=IC\3#I. [;K@1%14] M [W%.=J.PI,AQ"!&T!M2;:] P?'*?QY]U9W:36GPZDSN&G?E&+F3*LCZ=_PRA2SEYY8[HJ/V#;ZR6Z5H&13&K=E)A$16WL-\UEW M6;R00Z]/DR_S.%/V97[N3@#FKU]%&3[ON?KSZRD'GSL_[_+?C++D0S:=]GA@2G(C1 M%$%I2L(N8C$9:*+$9;5C/JPY.@:Q=L^KU>/XE]=RR1W'PJ;R*"\GA<2J1/J9 MK2O%TDSA>-/NZDP6@QNAUAZ'1)OXB%E/UO$PBV5;?FX[>2DCGO^SZ4/QZI=O MU"\?O_T(+:;4H]L[JMMK&#!#YL_V9\I,7%6B?\#UU3H@&G+&GJ%=0K3 I#X0 M4/95%[N*R-24'(2^J%8F ^2 M,__2:LH0,DY=%2)(:1,/:DM\@5B"9)WPBD;$KJ*TOP*=9@-:ME(/: M>K7HW;M"P,,BF' N7*)Y+^1F9CB.[,)*SOI G<^')%CM)W! M9Y!=Y,=GXBR2$L!K[0]%8TN,30\C9Q-J3CX(59O*%.,$I/2A/[L?T'W,W P9 M:%Z5[F,08L>=V"R^ ?PG(,?HDDC4$J&Q"WDQ!.M$07!)?I\[><(.\TO,3W*: M4N8]U S'M23DO];B.KR"/;$C[2+CU^8^?2PI/EBKA;Z78N7)L_DXJR<47VO7 M0)67@:U5 8565./.S'4A@A)0R1!)A>,"U,9,!#YBBZ"H)9TVXW@DMM?Q?E]S MNGTOO9_D@J\#D O*"$JU>+H"EC^50*84E!23-''Y/Q M[BB?5A(B=2G^GS=?MA"B.31=L(GWZA(_G-_U?;I2$3GG?9&#I)RFIXOZYDOG M_N&60"=_!M92!PPX@0$K?G<8] ]AL75A9[^L=9J;)QMX,(="2_9IR,ICN(]P M57UJ^6_T4]*SO9 0M5#H:L8A>QVCF=4[+'4[>G]&G6,N<8\SG%EI2=,5F<] MK+,?(M]9",4TLM>NUNFIU\HXNK(XR:8W?*PTV8E3&]%@K,4G84CS7ETZJ)YP MA;#87PBY0JLJK$VKJ)Z[QR=(A%,LL?$?3)9=4$%GK2?WO'U=$BZK^:+;W-W? M3H4:RV@SMFRE3MO;:!6I*.ML:8T-YY;R^UF5:JZT4/#?_;L];=MW?L8DBR%)5/6:0]T[3DL$C3,[.^3 /':.#TR G+ MK;I:;J+00'/!#LK\/!:^ES#J'BF26;#\LU9=<5^@PEY9>>TL5_A:BNHH7$"8 M[K#_XQ#P"?D@=FWH_*0JV/?+33Z!BF>L'04:]I&S#ACMA.NZHBW:RDE;R?PH M6O/U<[VT/"65H[VD_!,RZSY[-)Z!M)PDCQ 7SVSK]&>5/H$_KOE!,=-;)$?Z M1ZWRG^:&JGIO&]P31B3)5:6JZ926-C[)X/SX\CF0O>9 G#)=DG"@.JJ!.]%] MM;6&PU5:1I<\[2?X[+$R5-'GW0K*Y+E%B-Y]C['>CQB [%.T*"'N/[M3Y)GPU)LQ) M1730S;C!X^@2WEH2A=KYRW1CQYN(J8H&O]-$G!Z>$R/43 '09,&XN=J\>/:[U8A0&/ MBW/<_"L$_Q'V9 W^]2+A[X57&K=S<(' O"([(GJ:^.[(N;8IFZQ(Z6YFS=]W MJ0D&O!Q^YSIXG=LQ:QZ4OS-9G0:)KOD:QO8JA]3)#U^[ELV"OGSL]J$^^=7G MK<.7!A4%F3':@LAJ\<;1OI*L-F]_F\"Q&7?UC-N7]7N#O'7>A9Y;%;:-!9[\ M&9*!?_@%?0F;I]9V>8&B,68%V_W5U:HS107H>4?4#B5VVZA8J&L!*5OA^#JB.*5CK!?H!<%3ASQ% MNM8>NK*',EA5!PGA3/Z 6H(P5B78@E>RQD:/ M;L.(U[93/V]^9DA<4"MO1)R<(M=_,5W';\=):#2D]B?%W MW.B$/-(DO/,&T!81:FP929[Y?" ;@/EODNV5J MLW"*T9MDT<.7")%>DQ&Y[;C.JR0V6"E(R?.T<6#:%@=Q/)%@4,=ZF*<7QTR&RYXF;KHPUJELZ?)5Q\* 0$, SI\=14Z7 MH2C2Z!&8$3Y?AY;H;E,2QM?FU]7SWZ10!]8GQ.= M3'ZR]'QYG4HIVTD,\T71(8]0-\L%[# M^9HOCHC/O$:+O89TRI,[^)2S:BTB:-0BT1EMPA^XQ_6F%;)KAQ]]/N0/OP5S M0Y/$"/0'\GHL\J _0%-\S"L77W1>:>\O=KY, 92 8R[P'!BW1.Z%L!G(@>KZ MC=[ :3&KC::>^VL,F4@(_I4BP;IQ[;XEP@+U\\Q7A22$B+C#X^Y5!^XFCC;E ME:PL"B0Q@M]H2"G7BN32'=\9-/@N*5FY DZ)[]#-CR>3,W=F.P;3*>)KJUZ0 M6ZY:]MK8]K:1BKS4['8OT&9J4JXEK^;<&;J?Q&$"5-%]HGH(KM<_E$?FW%L1#1 MMB+/H5;TN8+Z5%GS1E%5J6Q;, 3DUL=QUNSQPT&:E'20>=CGC9$AVF[GI@#( M7Z=O$^0QKV7<3;K&L^F'N1:J>?)FRF&W;NV14+P>6P3E"S\K#S;",7:WHTGS M&D8I_0TZ_Y$\>+'^:Q"KQ4%97;)D:(6[4V?P:6YF'EIUY.7$YQ#- MZYCP#06;C&_U;=;W,GU.FE9D/'1>LCYQ_P7/G7Z/[?? )UE<4D17#3'^ 9ET MR!Z5Z:%M[)-Y^88<1]EK2D);-_$^8I;XEW,M#!A6S3(_^*UZ=O2*"MLZGOJP M/B:V\K0VJ=54&IK0RMW7+;N8140J@HU0.^ 6_^AK>+89-2<1XXSK"PJ.$ PG M+LC9O$(NT"_1;H+(:*>()0 ,HU3D]P8%6V9/]JGF6QFDDUA!-_*M MTH*/J[9X"K8NIN,'*PU/F6J?-AV*6MC2<# B=^]W[7A0QOJXT9D%6?6 M^A'#@"X8$ P#]MG3;YGD=O]YOOM7"5LU1L1^_LS(/6LVK)Y,RTU*M#8?FFD^ M;]\0TS0 H2HLFF@*$Q!MF?A%]29*9NQMI11;VV:LQ*2T< 65DS55VXF?U1)O M+74<&@+F![N=]#3# LJT%J\I!1T5A6+W\>W"&^)R [X+&!!P,_](&*V3SW5,)8Q_LI X.Y7C%:1!(N.'V"?X7T)AP\%KKE]\'O_T7+QX" M*%PT_G(+N&AT[5PFW7KDKZ=FW_%>LO0OT= ;H6P8!!,ZIK/>=W\62#I%:QUO M7K<;;MY+'7H(C*__JV]F5+@]EKOP#7Z=5]&09APV\YHFCH]%1AHRT!&C-J2F MT[5-%&'\(_!/,'WA==I8!]TF\X'NG>*''MK"R:I9TMIN65)WECLL5(!2D RX MS!M\*[$OM%G>H);;5+#B*]""TN[:+,;S_D.\E"EG[.^IA-I]A:J/^_: )=( IZ+)2L]+D7.;5HO M2O:(>V?+2^+<.1M,.'H&X2,EO6C_,[G^MS@'$H4N F\ZHT[VQ^^:#B-56.(\ M@[L< YZLZ:&VQ73.@C=7<4*F7=A ^&WURPL>^\X'&B6L;6R&UPFKSAO2^**" MD7I3\ 4^HLEW$J\3M;[J';C'4?%\<0Q>>04#RE$N"IEX!+S%&O:SY=1W?AD7 M\8*;C[&*&6*?Q#)$@RR_::@; 8)HO@2:6R0:S#-VJVE(P=]0F?=OAF/YZ86I MK.K5C_RFIA^99==#]SB+7MR0^V%91;):_W06(M^Y4W0ZVE-6"0B3\-5?G=JMYM']M84S>8+V[C. M7;:_EK7E+G"@JST5_- 6.5UBLO._&4_J/3F13\ Z^B!+/BY*?RWF MU1>X5H+F91302OF- \PS-I_^2ZK>.KU/+LVE'O2J1*9M;)ZD!0Z.LHU?T2!5 M"=M!"I,V4&/Z&5H6D[O>-I2]\Q^"?TD%(\)"R!]&&YP:RF4X:D/819A$Y!^D M#M ?:N7[:2X^C15):(Y-%,'3DCA_/N5Q)31 Z>(E_<$*^_B5?MEPE12>^#K M&,2/QB2,> C#?0M#U7)[MD7?J\3SD!W#U\B]X*:]-85/\[.X#092C*57)PU# M[ZGZQEM#VS2K-(D3B4V7#&71/1.)J01VABW\18+M9CIC=%IC,C,1231($*+D M;#?R&_P[MGIP;$(XUD F).MD>H]UZ'LIBU@;%PA'M @_//0]#9*IL6!LD+>'K&JX2#CE%A%J45!!VM5^9X+/DONR1GXU'*# M-9IY^ORK;<8A$WM3&YI@@,JRQZ2/8WH^;GXRIM)@/7S#DUDRR6KZ;E#JN&OQU-8)L<4XFH75!G!X3^G"6LAPSC0:<__A?Z:1N^3 _ M-+>+71(GP@#QR#JFO][["R)'4,1_)8A?QQ/T91Q_Y#C&5H:G?):&%X-;,."E MW$(AZ]][M_C3/^.2\-/JW"=Y0]1=YR4K8C+?'^)O$GF[\)[! )-?WX=]K:V2 M01 F@AC"X0M-4F1_84IK& #UH)M=I<)KLS>]FB+FT)W?Y2+6GF0IJG\3^OP1 MV"$BBLB.6@TB18O@ZR'%Y /BRZM3%)O.1>LJOYQE8V+IU)QBS4R%:ZJ.% M1;8AA36Q3]N8\3=Z BHS'ERW"?_3IXQ_X?N)IB:TJ#BA["4&JVN>/E[59<]$ ME)MHF%"2:FQ8/1..LT\9L/SN-':OE2L56N= M%_:([HFQY3=QLJW/YMEC\LD9+HXFJUQ\X>4]39LGZ(AUPV' 'A45$U;W]_(H MI4ZHW7[""3SW:.?WO/" -.>= _U#K.JNS'T7P9BL6DA]4\E]0ZA.^_!L9^2/ M8I1^N"$>$4YNCDZ">@&J]@4%T3H:0H)8@63;A6!"S/$A>[O3++!YBW;$]#): M$6]>U63W6>?KT1,"W-3^K;G[$_4X+VJ]JHW:0VIH0$Z:9"0/*4MG>;L[V0@F M>^QB6]Z'XS._QNVF!26O!$Q1O:^31VJS@PT=\"E98!APP->\H>NJI3+GJ-/G M&])%)DF69947QDXH!1!*J-15AVWVF*:!C$5725N>V=A92T7_B(O-^"7Y4OR) MT9-G0=W4"7\P2X3$DX&)C;1X,UIH1,=%;5.$O6W10?L ")%WI?)BRU9RV1!_ MT?KV;5L^I"ZX^)N=OWYC1W7\4U$E])YUQPZ^5>D9_#;< <\"3'8)=X(8Q>&& M/%/2V>*"'I2; 'T8T/I)B('-WC14,_!P6:\#OL@+T5 M<'[[_TNX_=[C_'_1.7^^?^R@_G_/#]_3/&R-(;GQU!^1=1;\$785@/@>AA]J M>V2VT,P%!3];BOKPP@B&-FQ[W7Y*1N*(:IFQ%ZYP,$#DE:>*WY)2^ ,P7MOA MRAU!VJ=>^5"7BB0ITD]4]I6-3B;:U<(&K% MRC]W[EI"-O(ESZB\GY@AYZ7$"S&)EOL?Y#D/A%>)^SM=:XD+)??8_:L^QFOC MU1-OHV0:$M1G[MK(OXC[-BH5N7MA15;A)-=_G#U2KE$VKWN7.Z(U(IVMX)JQ M'Q4WTL]NY@S5O4E7B(9!WF]2E?R;)_ MAPQ0Z>Z$/_7:=I2#L/(((;FZ8H23*KW"DE2MF62Q7>KC^DA[0"Y>_^Y5/N3V MU;R.^-44YP+OR&-]K0$BP[C MV"O*$Q8X$B#D*&:'\)<%E.2E2>@$-4U/2\A]KVS[\Z>]WQ'FN]M-L7/+<[TF MP>D0!P4*.BM6!2^_ESKCKMGN!_CO&6OO&O)1)18W;1Y#)8_E[S=WK8G6JDON MN%^\SPQ#*]%QMD_D'&RJ0F.:8-8]M-"UIKV$X6.1YY%TN_NT47'TET**EI[M MRC0KQ=?/K;X.A(I*PE-9LN1.Q3.X!EXK(9*\_,_?QQ'(O+^8S3#W!_U6[/VC M]Y_K_F.$9&!+_I=5XE?02$<4QX3S&#UI[FB=W4^CS#!&?RVA%<.+AT>\+VUH MOD5T'?GKO0O\MF0=>NFDXK/[\KML@M\L3 E @.>@.-@ *KTY0.;Z*CI6;@H MY/1-/:]GLEAS=?@PRO/5$BK+1+Y99IV&*50+'S8S8]PW0&&]N!&J&*\O?W&+ MQU+;QLL[9R>NATRE![H?'DUC,K7C+OAY8,CE:=$V4_4;!,4O A'.4YM,?FB[ M_H )86JN>W&H? )5+'/\4G'S,6G X]S5H3!@ZQH&+'T4NTX:F'P'VJXS:+"W MHVV,F7N*BV;D%=NB9:8.9:57FEC6YD&7*3;1G"=ZF4)E!?JA)]6TG"LL&.O\ MJ;KD'M%D]OI,O!8:9N)R\I6 0RJXQ] .F>GE6A16(@,/]A>,F/6>&!@0.7FN MW(7(2""33P;\^,$.4 0["QJ7^GW0'3_>G52;%RG$:4QQ0F"11#PX#[1TB[.Z&' ?C2]W2+5# @?0T& MO /!@%7KC)SZ+)7*6,Y,!I;^+@!N/JE J>ZN>?GKFBAC-A*5G45: M$-*-4!\TLM=*RAZ3$O_(_&Z"KDG#R(=BMFFF0'(\9.]X##&R'1K<+^.=.#G( M"XT<E3^4Y%\C$,8UJ']2K)1U9)KDDP8$Q(Q\Q^"KZ, M9^< .L!S8';">C'?'J+]T$_SP:06P'APW=.3SLCR&'W-L%V8^Z.TFP?<_=YA28*V,X-S@!'*YJ#TU&M9<^B>]0CK*Z*Q M71!N=!$ZXS/OM_7KKR/@J7_D;?]@1W*ZNDI2M3[VB#2P:F6F$&7 M\7PN[>M33PK/@K#WA-_QF>*9-!)Y9 V^-A]#N37OS]=J+X<%'HDZ>JMJER#\B&5)OR/>YDUH]-@P\;9\*YVM=!B%=N M!_:%QL0E,P>Y&B@B>LP#UO3APB3K(H<5SAZ/.#0Y:_M]^QL'.$!YP>"EF37K MQ/A(FSU>8JPL"5,>A2Q]MEK>?NRP7%+C3._+$^:?EH715D9,%(5EL_*GZ1+O ME\>;C\OO:1\)+]_C1LHV7X?9Q3MG7YL__.+!M/H)FK2?/1WE>J9IZBH)((RO MNUT4UU6PK#^ZB-FU_$.@/0SPC_,[(?!K[3M._(6X! /@Z![=F+DPTU^ [CIY MA4!UX$=Y'BEHMA^@NNI /^%K9?F6J/$VRQ07PH'HMT18MHIS=JMZDAP^D?6K'WK]JX_;A:RJ/>=4.LA/G?O[F8O?I>Q>K8@OU(?+]T<6-81U MF" \!?GMJ_#T-S%ZA$H:HP<\16Q;"DU1_54UKV(90.3>N,-7&5A2+SX2"2K& M<2\R>^P?/FM.^!E1Z"1/'NG/JP5$L[<5.2PR7']=49#O:L*>8+7?\%80U NI M\ROOY45^\P+)R?.\Q'"$&YT"18G7+5.'< .2%;LJ 8J56=#Y,=4OI)S'I6!LODZ*7%LS#'HW1#]]M)&V!\%]/5F>Y[:/RAPP MX$4<1W5_IG2WKO(?_TYK^R2;,_2\]'K0AB:UX26!*>\;9$3C,S^7-;%4U:;K M'MEPDE.4DY0FDN-C;4LV/6OEO]2/M9%(+Z3T]E6T MU>;WDTP10\60)0E6VW?M7ZN?"ZG[N3OY6T.O]6PW?#B'39(P8UF;2 W8I?N] M@@S\XHC_4'Q_HZ^O_^=J?MV/W K-QH-?D&M*L^\^YL?K9/K*>[>?I/.[XK]( M6],@#*$P9;ETR37# /22%K]SHF08 .3\AL)-IV]A0!H$!OB$"7]YS%Y)?DO4 MT+#RLCY5.34GN:EM1R)#_ :AU:?0\A$>D:NG\O&Q*.'1',.EP"_F]*DF^IWC MI3YC^@\VQNSLB.CR.4:.@V"QSP^$NP]O#,\&Q(YBI/^FJ*95L@;Y3>4^EGQ< M0E?DS+W*<1T-IG2[8[?L4PPW+_/-A$)%)T<5;YI> M[(XEK&3S^F1=G6)J!$:DRF[R6Z;2 9NHB'>(+8,%O'Y[O?8/=/5'="]N-M.O MNK_W?'KPS/UURJB6F5_+?46>LQZ[[R!V7'>/\AA'D.9CM,>7R\ZI/J5AE"5K M6T],@#@J>6Q6[1'T/3 M7\WOA#O]N-X'J9YJ=G3=[8Y\Z5[!_>&-W^]KHT\49]6V9O$AV]KIN2WG-//G M&]FA9Y2?@?2_JE!^].Z%!Y,]+D0+DM]O7"W;'G$I4,-"3-6V;SW>\.>61?W- MI@PLE =B0__'(IZ5[P'N-W08GVPF:<#U=,#V[TH95K1#7"!-M]['S,6^*P\1?:;'(RJRT9_'WG3W+ MMB@Q0X0[W6B9^0+/C-)U_W8B6PO.+&>7TT=%0=)%@*7(=K4V#&+PG;V;XG-A MS,%-=1D5[Z&_EM_?&@M!:P9,1_K'FF79T]%LQ;9@_G('5)H<;XO<-;UQ913" MXS6E"1ONNXMQ5HNJ@$T)6XJE!(N6" E[QI]/ ^:6"&='_AC&(1WO_-.O5W.* MM6,VQ8_#](\$H'5>Z] PN3-'/Q'&".H"6V; "_??FS*U,+N8/O7F]D:,&U?9L@M#AJY7U=C:^3CLNZ MF;2>99@_/5P4",.?*R7->I(A T,)99HN<86"LU-([Y-&"$Z31H\:=4K*X:Q, MC_!)%T_U;ZLAL-:(*BRQ?"#7MY]NE=X=4Y3)&MY7&7P4U'/4X>*BC))@_4 Q M::@W:E>Y('IM)6L+03/P'$G6GJ#B+,R3\L(/MZ GV0'G_NV,7[='8 KJ>4S.:J=FFW(4 M5&ZTSAT(<$0[N3NG:.7_T=V VP$;KC0BVVJU)Q76+073CMF"JKSEM=7ZM!&1 MKJ+GGCH+5=.' QS@;Y* LR'V>5\15!*=,[J8^4)XKM1?N<0:\.26W?0WQH M?KXI8&#H::U@0S")_)J!K9$9H\X4K.*/#&3_D9#R=W6+T[_K^I:H-@2.+CD8 MG\U)"@\WG.E+H$ML,=6Q1%3W,WDR80)"X!,,,A<^(DUWWJ%BGHH^R-M# MOMX658G"PDFMRD> \C)?U/IS+[3K :(2M%1+::-^;6'G*!I3E;M%\8 /?UL/%B M[\Y;S*G'^9VS9^0QM/"$%:-XW7QBF9TC_4+\,9D[DZ3R$M-,!G(53'O9C,;5 MNCVN?$?=R8TN!8H"\J:_S+[TME-YE6#/XX#@.W^V5%WD>?E]60QG=S9XL,3= M,P=][ZN1=""M/:M1N!C:?E8HR\U"9!#%'E%7"U_" ^WQ9O2J=!44BEG0&UU: MG=X;W5@7(N9Q:">=.8Q2K+EQ5YNG(,U RG1W:)^]1OLY[.H/1PEF,O=#G MY#5%G^O#,W'12#BZME^GB'1+4_B&C9:SUX%VYW/+$$JTM!QP\;UPY^VP0:K< MT'Y'%6K#Q;3>F)MC4MA8.YG&9;:?L:TG02(16H3#MQKQMF=;.S=:*88^K!,O MFL;<].2KZI)<8UCW9U9#@#)/[\\' JSWXL5/2*Z*TUO3Q1II&BD2O56+-6PZMJ8VK#-V<%EIVJ7F$_5[D/L#@B>&RS-;YRNU.DO@@I%ITTC(3N= M5^!?(##76'AVH9(F/9JP^#"XW^03QV!PAZ"\N]V7^<'^ MER*H+48,"'D/LZ--O6S-E?L/@X9]>#=[I=57SBD6LQ5B*URCS2O/!>EOI6-I3+YDBL,)9;))P?1. M[$#RIZX8?/,GKSXV5J?<-[_@::4*\?HVXBI"/S#*^X:>?8E$>[Y[5 X$+[6/ MS.Z8?1@M*Q'P$J@NT9\ MZ%WM^B_F@?TF8JNJQ!@P*7BXE_=DMKU!,>%HEW,ZP%2^?6B7O5<)I[W=G:?(? M_'V9VOM?S^A]:\ M*A>2:K\X0JR2%:"[Z:.Q]M0/\U<:8I7WW%R"6>0B*0$?>MHC[?%HO1!+U3@9 M^K@V>G[#4L2#RNJ*(AEWH-*V)6V9' +Z@EU/NI/BE=99)LRUT@.MCWBEX*RP M8.*RP].NY>$[)9?A.7F:OTEGF,,5T"D)J!\?!=%.\I >OJ"-/1*O@9?B&MI, MKD7F[:X1RHRF^/F!7P2%?.I')A-U9CA3.-PV8\+E\>Q&< MI#(_D?V%^[K@]PR/LR,N#F,0!0OQDY,IA X4:(:(EM*1V-V1;*?UH[6"#/A" MA)_^"K^\2@K)=2PPE,!.Q!SH#0#)2?=_)2^/Z\9,43LW1-#>KKZ\8O3-,Z!- M$M3^Z=:00N=7J%?KSG<#1F M(;YR1+^3&C]0^FIY [>V$/1Y'@Y)%I&#(K],VKWD^INK"+,"*NU5XKM)8G>A M SO_IR9U.@1.([%\K[V7(SU+#$8/[&S.IY\W-%CW91LNSG,BL;6O'PMBO]P1 MQ]FN(TK/T.5I2K5)V#YHG"#]L!#N&.L@4B#W;YUM^?>DV+NC8M>M"E6DZ+U7 M0EI]HG+9DS?EK6V(7=,Q/;->D8*/I-1)%//XGBSR&^U&P6+QU]SNLITIM MT.5^;C\TFK^OO<@_*SS2_P3\%8-#KS6ZC4R:X$\/F7ZDLZ)_5M=_+V4^\BO; M]Q+&Y-:.M-D'E9FK@[NBNJ324EVO!)X%C>,_@1; !5 M<@ & &5V87@M,C R,3$R,S%X,C!F,#$U+FIP9^R[!51K+$$;]S=">X0(&G ^#A$!#@ M$1&0D! 1GUH]G]H!B#A(+UZ]%7V&J_0%F7CY^L0_B$I)2TC(JGU35U#4T@0:&1L8FIB S M>P=')V<75S?_KP&!0<$AH;%QW^(3$K__ &=F9>?DYN47%%965=?4UM4W-/[L M[.KNZ>WK'QB?F)R:GIF=FU]=6]_8W-K>V=T[/3N_N+RZOKF]^TTO. "W+]? M_U0OG">]X!$1$1"1?],+#M[YMPXXB$BOWCY[(:J$_,46EXK=%P7O?4Q&10?J M:P[E$WQ]NS$T FK.59K3WU3[7;._IIC?_Y9F_Z'8W_2:!V @P#TY#P$'( )H M._5>HZW(W6\[B=J943",D2BSY?00J,+PP?[\C-]M)M'[)V@M[8ZH1N$!U?JT MY#C<^TREANUN&QL:AO]3O4 &1Q%(&A>W97S\0-O* -DA'V" =H38 2D56N M4X5'#& >%+'N9AH?/X_9'=?)"@;X:?ZWX;*@N'IX,,!H=Z'WBJQWQ!:M@[%\_ M_!<-+DY:<4#X+SW\NQ-2,+S83\4DWPI33;$7Q4!CE[*6LIX<,?$W1V@^AP$* MZV$ &^^WBO]'1$QJ^Z_B1$/5"Q-;O;'V7JXUWI.3:"2)K*D2^EEI$'^4=7#Y MOWS0$)_ZN2CI @8ADW$CV-Y(M^/W0$>_3^S+O&5[O)"5=(Y?\21#9 MI\7U@CX/?;Z;I(+?OK^ TV9Q%B&\O?E1X-U "/5A"BR32&QOP0(]?*3/#!V- MS@RE!Y09G @6K2KXN[6%7MP86 *E/[Y7UUD"!J*)P,5ZWI21EDYTZ(H($U4T MCW-A"CD*$5S3:AE;X%-_CC\<(7574]7?)$/SETYPP#3I@@&>UVAX,.3OL\N9 M>%+&&L?C?9\2ME./Q";C5Y-2:=:##(A &Z )* M!AYES90I!G'(8]#W(D8C"\;$M8_4F-"(5)9 C7(;J_)//?."+F !!?AY6Y9 M5T9((22;VQ#^N)Q!7^$DW.$8/)2V @U##F?S@!1]&V6Q(+B,T6,W3'CI[.;Q M]>ZJE*T;*A35+4P^RHQ9W&^?1S;QZP EOM9'"B&/JE$V+?RD?^V+&_A#6:[< M9^:C0Z-H*P\.L@%),J)PDGBT$-"60/<1;>)*&?+-Q/M$E9,+8$1R@K-2KZVU M+;TU.WLGK^!*/+7_'N/E<5 K^8U ;P*_06Z)?;[@:#-C)7STVR]UMNM\@H], M+RA"2 B#+J(.VM!VG-6FSQ>RKY47?A'/B<&KNET1;>?8+[&S,TW MD^O%]N-UX3:*:#MQR7!8:\W*=;-Q5-S,L06UK;ZJCR@I:ZMK#I;Y2$W^[N,% MTPSOD.ORUPN)4\+0BR%Z!L-4QW/;^;>#%'TD.QZ.ZT+(/0Q7DZ-'EHZY*!$V M,R^SYELDEO=#\TY@@.YI88S)HTNF,%2KHU0$_-H>@(0"=?(C8+W6+#V'Q$E6 MB3LY"G2*&',SWMF=BJ7 7Y[BMJ%7T]_ +\1F.)2G>((>XN1Y&]W@']O_(WVH"]W M:L$P0%3U(/HFMH6LS&EJ5(4LDG"7KXY"))3V)DWA-.^ MD]]OS^C==^ PHOUS@>2H3?!/V^NCJ3%;K\-26?O59:S9&UU(#SDGSPP/>&') MK./S![,D7PNH]N5QZ-$#Q4H8!>8^X370XHU>B#=,9B27QR]X%<>#J[9-\GBSN&'O?I9&_B0Z3'G]Z&(P0)"10& M57[/D3$NYHR7"1UEQM 6W&:$YX #[$5]T65GY5[(I:5]1KHNF\@ M;VDDG")] OLNBLYO7K8#)4.JCU'-V/L2P4OL2D6;Y$QJ8GAQ=W0@ M3X9R%H, 3SB9S"I[8S&Z+VJ\D57B41%>+P^ZY"&4E,66GS!^_ ]O-\. M[S';4N&;R>G#_I9[&\T1'7=?/X* J\PV=O;>R\ MOD3))Y]WN^8XMHJ<5IS6EEC:)+P?GI]F8R0:M+(PH8Y[9(HM8:!-CZ.U.K-$ MPE,"OL!3$@?\1NZ2!]

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

    UPH^=V; M)_S<)S1*@GL[I=<"MMT0@QTE^>E_EQA&@4&M;E MJZ5AE<376$LFNB&]W$Y7_R@FR^VM@F0$[I;'(*Z;(>6YRX]$W3)[PO5H;-DP MT @1"K18TX"[I6OC5T==/1][JD;*'Y+Q!#\Z@R/W-Y*2>\E%@?4V>6.SUY2V MKN&U,UU?Z3LX:4RCM,%JAIB1*NZC,:%1%ZR-8M"U?&GM^\8OE*CW6<"BR4*- M?TYDP)B'2"JPDW>MG8/%?X!?P-W:$S1QN5/>=9A[Q?+(HWK!DUJ%>Y:(Y W7XF/QQ62LGR?J<4[^9PT=U+%T\U] M.Y_$:AGO680->!NFR^#PT6+7$^(:@GWB*9Q6.+F1L9TE*+KDXRU,B@W7U_=0 M)K]HM5&"H< ESA+0B%MV\K3[0?#E$] &_>_A4BS&%9B,$5Z):OR --)"1 YK[*'X+ M?.VXJ>X'G8G;K%U<7XQK2F^UWU#5GMS>>^T5JU=&4!!C/67^KH5P/NHE6[YN MQZ^OJQF]*/3#L#*R!OT#:++M9O&KK/#G'1263I(MOMUIT]/!K7Q>3E%6'_:: M9R7\&8M$UI'Z>DU]I?XJ: 2F.]@_3\[2 PMU/1!>?BDUADPW\W!]4,)C,+KK MB4LVY_;@6H\71!$M#FEJ:FAMBC\XL$C:?-VX[3Q,Y17!. UQ*>EW\0+ #%$C M3#K[69:9ZK&=M5T")PI):KIDXFY$+,L0EW(?NEQM:]+G%F]22H\Y)B=/<]&S MX.27JV*]C$X3EC6);B9N)@P;OV.M%[BBE;_U)G%1IAE1(%!B0 _0?W]&9/M> M&'[;E9&VQ,"#3*ZYW=/6HNFYA/J/S#<6[EJ;MC() V)&C.(K?+#\\0N'V-<( MI+&'%J(L'45'&X:'HXNU>?LRFCM!B?>]-#+]0O3K:2Z';_V>J4[-)J4^2OPG MQFSPA(O[99HJLKDVL>SQJX-36L!!/DHQD?]XAQJ[HY:07T0UFG, MD#GE2$G"X6[66)T7UT_-7P54A]#WA3J!!0SG"J=,HFCU*[.SM].8.@:%Q$M- MK3V'/*K[*IH&;H'X&6(6ZOJ/(\,-S$)C/&/'7P@>GKN),9Y&Y^<=S#E9U3]V MY]R/KVU1M.P0Z:R*S J@3Z3;&=Q_FR(#>+[W8SR-JNW26;)*)IKE41HFO)CY M+,VL7QBK^L8PQ K5.).B/4K!:-.!3'=^L>^68"YAC/\DE5\JNE+VAP& A)6, M\% 98WT.BP<9F2?$:(5CJX< Y_J@@BO M%R=7)S%*'^DI/1:=+*W)&3>75U 2E*4T37$^V^7F9)G\GHGSM.XT)NKY%?Y@ MSL ^G=Q.URP/4M2E:9?P=CVR]%G@,V-O M,;#>!N/W#R=U:T0[F++#)7XMDOYL_PN+IK:PNG,Z'$ MOEW1:^L@"*%%((P<"M7#0P(4""_:E?4IN8D.OW7^XT;.'_W\L:"X#*X) R50 M5PG8X '8@@+M5:#3-W]TG3.W+49<-*G^J-/_EV( MY"<%X?G>_=-Q)!@";/&[.T8H0"CW9_\9MJQ/OXPO3%_HU9V@N' B!36 PNNHQ;5\:RU DW MV$_5T5VA3=1&C'Z'@Q(HG[M=PD?DG)T=_A0#_:]OY/Y>ZSD%W8=[Q3PX0;+K M#O%_.QL/>8@07)0 ZFUTVF["^Q M*/=LRJ0PB5A"@75>\7L9JO] 1^;_FC%>E1EU&.#((_SHT#?>4%@4BH(;MD-DN-(L,18?;TB6#D7>XZ)10$<#E^S77RYB&9?"E;K5.L1+;@U(]3BJ(6 MN/C&[TS97UDT^%]! 8S7?>WGI.+76#A0 %?N#Z41J&NC_FG7L(59N&5PBT5U MCQP*!3YDA[/Z__>0_XI#F,DV!2+X^,/[?FIPZRJS.@YD6'RP5^NFHW%BRHZ@ M%H#(P9C S.2YJ<&?M=V=45-VVY2E2%3E(CB))B9)!DH @B$0E@V1)DG,2 M$ 1$,I)SSB"A ,E),A(D2%51Y)Q!,E+-=V]_K_WNZ+[]WGVC__2XN\;^<6J? ML?::>\ZUSMRH'Z@%@.B9O*(\ $(# -#M#T#! 5D @H4%QL*$@,%@;&P(#AXI M/AXN+AX5R1U"4CIJ!GHZ:EK:N\S<;'?O<3+1TMX7?L#YD%= 0("!351"A$^< MFU^ [X\@(&QL;#QF*"_#>!_#A :.@8F%AB"C8-[^P*4"$ #H:.C8:!C8F)@W*[ZW:X#&,28 M)(R\TEAWU$W ]YQ(^0)CX_8!<0 M%!(6$7TD^T1._JF"XK,7+S6UM'5T]GD'!;\/"0W[ M$!X7_RDA,2DY)34W+[^@L*BXI+2FM@Y:W]#XI:FKN^=K;U__P.#$]\FIZ9D? ML[#%I>65U;7UCG9^<7EW_@ @'HH#_'_Q87\2TN- P,= SP'[A M:!Y_O$",@_&"Z=G^/\^=0D(/?TG:95["\8A M.$@(VGYKEY,H4A0"V^O:D..""^F)I+#=C7%49/<[A-7[FBQFZ.M.LS56AY.' M*Q/LJV"NP9[$)73V2F[ 1Z<#!'\N$I3'"8:&.W!CF(,A)H,KYN9>7E2TT7K- MOZ+=4(#TKM)1* J(G'X:*B[A;[W$$?GZ7 YD]PC9>3?RC/QHZ X3K9GH&T(3 M0SO ' 68S?F/^6A9D0]*KD089J 5E$O MOT,B:W\OL,>CD(']9)(Y#E%>+0SX3>'Q[VMS MBS,L:?D$![[K,%(_>HEL&*SMS65$ 2!CU7K/;(+>M?'RX7O+/=[!K[V>\*[( M'8M^ U^VFVG4)SUJ8O(,52.X@!4-#)E52JK8AM936.VAM<*&E] MP9+MP_,PD@I!YSQ&;H\?/D7#50/:< M[6OLN.+!OL':["6&$,L"U MM0L]U\6_LHL85(JR?RL"7]6!9OW_X,A#XSKWEB-7_]\)ZY%;:"I\K9D0; T+B5_\J(^O?(;HFL!'6L>O<'_%6A[H MBI'" ;*NZ+=O@F!)JX0H@*94+_QK?KYJL6?NZ9R%$^UK60AR/3=Z[LBO+*_2 MJ/>2Y>:+9:&?2QFQW\%(V3+S;&?^I2P\#Z"*8_X"05Y@99C%1J M;DAXCUXBU5RIP8-ABP+,>0L+3KV8)Y;Q;EQXHR[N\8+!5\%"RWO92U"!2'3M MNN]N/]9@95XX+!59F8:F3@1]8M'*(Z.+F84!=/1E^8/W>,\GW.\\ZJ,B)/PV MS)?]=C\]P&D[/-.GC,;V8YI7BZ%KO/Z;XSPN@I6YKA4OOROOTTIG>-=;QH9Q M7V%3N[S8NK1F_0_T2B-?>YSX^(J&NE8BLR]3$_>[FJ;+BFUFO!.SP):NB!/>5G:!U<9H^CS45#^ M.9V"X>G]9=SWB9CNL4K=1\%4#@M;>7%B'I7N?1UZ]3FE'4BV%&ZNJ!1\Z$!# M#$\6IXM ]D/X]X0!R@%P=1GY6\AD(A>-TID=:)=H3#!'%/:Q MXZQ(QWXJ,/M];T?0-K'^\^'[D9XM;-[>L3B@U_/HRORM*52J>J]]0Z+DK1H* M.&P:/4C\X%&@6J'DA\%^II=^IK43W1BV N]<#CK"BRYPG00-;5&0>[^\448! M'RLK\H]2[6H$[EZ8E?F7;8AE3LZT?(Z4E?JX]]@JSF)(]I@IG9&A>9TM<%MU M2H F0[9WFF(40\,Z=G-&* F4%;_V200>)4^TGGD29+M@)\^#G2&L!O=SHCU\ MBE%MD&P>CB3Q#7W:1\+MLCF0C7\E'*KVY8A+7+GX>2]F(]Y'8HW@! P&'G " MTT%IJ,YXSXMGOG8/H^B09DFAV'7OWV3Q5-]E>#X='2*@U"K9.[&LG<(V+5?< MT)@J21SPVJ07&!T9Z!@8<:KQY._A6.AW:2&,JXJ=?]8B=6D><.#,8(BJ*:?D4(4<^RUM6/IZKLX M4RIVD+UX6\<[ORAO33K+QS-N(^[(O76E&EN1-_8[PR2&#$C.,DI0&'WI;)\I M>[ D9 ;IQTJ35H*?4#$W0&!/5GFO/HZ8),>YT9WV>)(;R_D^>F'7/(98Q>W4Z4Z01;F\P!H\GC[<-L;(6+W9]G8JW M".V [P6U]2'S>-C:']+C&VC]RQ>N&/2 [S=]32@@^[3@0A8%]&X5YI%8"[5; M3XJK^MAA+62:%Q()TP.C28@968/]R+JT.=OND"'5*.'T.?VA#PQ6<-HRQG5P MS?)A-H1^JTML@(NAEP)7W.1CF3B3_13"V=V8J"5VDL!&I,J.S<<$_ 'Z('') MB(5>(*+8U]*6@>?=4_'34O),JBG..K\7Y["OMU^^H\AIN"RU# ZCP M$V$*$E+L7Q:C<9"Z3T*UFAH_P0S%?G 84'@NL9>2:P'8D$X@_3 P%:AUXZI( MV)I%G-=OB27"PU)RYHYIN>6_\7E2;4/U$ !0+1-G=E9J7(D6[N MFQYQ&(O,A8Z[*;/U-,VMD-?/U,,JABE J_&VLM6:N@J=WX16G1#3!-$+=FZF M8V:-F702/\/LXT??M_0E%-H'%9+RM+E$N(X [D2Z@A/\G4OZFYKF5@.RV*!/ M"U6(+=O=CKNC$H)+XZ^@M8N[9+L:U++ZLC>&;(KT4<,?[M2C.)3 MX8]294-'C&$.V6+S<.5^J3\DN_[\+' Y5CR.2O5N4&V!;/&3II>\0SY+AC*4 MJPF,\A9AJXC%I\1GXIH.1%;",ZF54:=A<=9:F\PO9CG7\,CA-7(GN00O[+(S+%-@UDO MLN/2O@%PCN6$Q@_=U>A5P .(SZ6I+4=;0_:4I M;7_%&]"HP2(DX/)N:=J6I+3_W>/E]RI):-8-&?X05MSR, MPM$L*]FL74U5 (1CX_T"P8R[K#@<150\3RAVLR[&>^Q^LJNU0(285[(@#*]< M:?HHMJ057+,<=$WW ;BT3%V#&D&VF[IM'04+,NKT6C,*JEW3.!Q6$[EEEM/M M+_SZ;-)4#E0J*,*@-"656A#NQ%7=A?C8UJG87,IA\_>_UMF<@#&PK!^)=>*0 MB\^2SP_&USATPW=)O$%'+P2Z'W.\ *W>MGVB=Y]QDHY_V!)2844+?-K]Q<,\T:Q27UU>/[ $MCT^,R MRCEBTYPOT872#._-ORXJF]V0Z-ON?M??'(SM3ZQ^M0+OK]S9CB-8\>N@-0N, M"M"2J IHD<7*<@#-WNDKD'O]"KF.H9"$_T"\DLI17GJ[/YM0YB_=:>.OOXE%P6-5JN!Q>5 A).:$,1$7.PG.F&Y;9[I9']\B_UB_1 M.E/IO2.]Q$&+H[2=ZQ,U19*F!%$J MJWE'-MK+GU@!8D8[/E67A#9&GZ2N[4M'T>#)/6VL;2\XN^:D)M/[O7![_#PK MA?JZZ#G"V.!X+_1^Y8JR5BO-J&W97==WF]T-O>CU/A&?*A8G*X49"+@?=,4T MA&%>*30\QTO\^E MPMEK?Z8"<#?ZH]3H_EYJ#'\O._^_E1W_.4T/1Z$>O. B M61]1]_RCX^!W&*83%:Q_61=7-GSCQ@TN=:1'3 O>QEB1R? M9(GLSEA83-&+R3"O/)G!XXU/Z-)3 M:3W>(YBCV!8_=ZIER@2,IH9^6&!P0S-,K%$#LML8V/D/.U3<9[(R5H!I M)WPR[C]'(-PK-.@,EGQG 4NWCCU(7(\!!J6/ &H#YQ=61B MP_Y^K=;"Y&'XFB+9X![(Q&-Y*WO*_URQKNIB5_@&70D%](QAM9+%H@!LH004 M(%&( CJL_<]3I199)]K7Z^;/\7E0P)W'U#^UGEXSP[2O3]-N;U(%*&#)ZK:# MICU# 9G?_1<$VJ^5 =MQ78:#>&NC8YC#-582"OB0=T-BQW'CA+U_C;/;()N$?[]-9R MD?2-%M5UU>VM"@6.'@=C_)_LG2-H[=8Q#CLV=6'"T6Y^3/+A#V(%"?DX4G(3 MG[K'"B&]C%HD)CGLE]-YEE]%WJ(GB(QPB*>:0P'T<6XG5W5_;+-QY.W?EY]U MB\WK[,.U5\EH[M8T=OV@0DXSKPTQ__WTKGZ*@CCS\HUP,_PE-ELJR73]K:?!(?*PRA\T[2SKYB3& %.IYO;+FV>%L#=5JRP MEQW &*7.2P)*1U<3C6>&V&M]*41_]%)./_*!!@)K?FKR+Y1X&@OPKO_P>1 M_%4@V?C>'$S_(!+_+N4"_U'K]@-JHQO6 ,&-?Z?Q[S3^G<;_FS3T'%7IAK$% MGB0C+!0U""1#8Q^3N%;JMCSUGE%^7=U1*UD)\W5XIZDFN[;'))Z.QOO533#9 M5ZKP89808D0*9G 1F25,B21P+J)UBKJ/SO'D\#DL?QJ?DU?.P:FP%1ZCR+ZU ME>_?/,#4RC4:5FG4X^XNA$\#0^A[=:DR(E:>$;V3II$G?('0ZGDD^!XZ2?%0 MO]RY$SR[Q*Z 2R\- S]WE&)7:KVCVM:J/Q2F9 "YSEZ2-XIWWVTA[GTL !J* MIC822I& P>%[=H)0".E>5\"5N[!XNO&*6?J,O2A:#;S;6TD?T?$F?O"+85RQ M*=\7KCJ7C@$V=/3423E(>)"(>F!\*J!W/S< YW;RB\L5J^:?>ZA-QG#'Q3>UWY8KE7B6G_J8JALQQ;W]>U+;BITO%,4H,.;V2@X9N/MJU>9 M)O&^TP1O0T.Y"*-DB[T%R?"=[&&B\E;TI"(^Z'(P*+O4^#G(I&1%UF]]8?,+DJDT^-/V?9[PBAWKL2>0[J= M8MJN(WRFY]8^FKP=%YRDMPX7_H#MOFCH_GG[VU,R+57:: MH;"(QT(^&*;WT7 =R&4]7!-C=.8DQE\P1N/P4MX71E.!_%K8W$ F:,WW$0FE MX,]-?1KG;1!^<>^A _O=*V'+=HE0<>H?T=V7;Y2M-M'!M?V!PY6ZH%YMT8%7 M8' 4IKPX;QYD.4*GL =!YB'T<)BR9#T! 8)_AP6P3;A)E\D*#-AQJO?Q=U'+ M2#I':89U;B;LZY&]^M8[K_H^!QH]%)EO#1F0XB<9]CIASNHM5P/)D?Y]ZE+W M%G@4*CGOT$T0&JYJ!RG. M7[9J?=Y^KI ;HLM5&*YK&6!JAF%>>9 6AE[U[/OGUFBU6J7D$.+C*.D-OY+H M@MF6X^*<5:?CVC6,2]GV);"+ M<\/SU'+#[P-_S/(,2XTO$R,MV]2M95))/!A-\5VQ.RK@9;VI5WN#R$MBLN&W MIE@$6 HKM$%?V7RLGDRFVU&4I-R6&IKT VACN"*W*:"\POK8M. S^%50526' MK$I[M$:=?G(@I"*2(HP!V9]&%T3#?7VL04E" ML!=4*)FO=2 *7$[[G[)FG#K4_DKV$F4;0L#EO2,LBQJ>C:F1R00&8 &D'">L MJ<5M0ERDZL\G[^>& W].CLA#HPCN.GP?U>IP&O=WBYJ9NMA=Y DOUN_>[#J. MA(AB!I#-:FD5+8YP:&?M4B1:,]_H?!P>P"BVZZ ?1@N<[0L'2J05+'[V7CFKCWG4 [(5Y1_] MK\7TK3B:Z7"U/B'IOW/;_3RW;#BF4'6+@W-WY!5WV$,&M@=.!*X,"55J)^EO M<(T;5*B>O_](A@=/YE8=Q%X)# ?&_U3;'[/2^#QN R&1"^]JP"_-D+RGD] 1 M.H*<(W"*#40V<+LI2WZ3IILZ*2>0EQGB*V&:P9AF5,6)Y_>WT=M/W-ZUN$$( M.0167&"+>!*S.QO]P'I;BU_U\)@]VS_W&RZH.F0L_T@ M1O>'#K2\_DSHQOFY;-OR&@831\?VY!GIQO)!L##YG:\>A?*G[%KS=EWXV97? M,[V6IS/<;ZA;)LDOE4WG[,EYV%RU%_G2&LQ K8^S\>;/E>U5TB1@LSTN11DR ME;_\[>6\-?0&H^A\#"O2I8UM9D] <8@B$\WN[9]^ONK4TII\P1S\WJOE$IG4RIP*16:U4 F0;&9GB?9 M.,+T?&%61X,QBIA;G8PO4_@^/I);JWL2E!X8\S9THEPX@M.X/E5Q\PC M9B^.]_+?^ >S>!U])H6)/.77]$/C;H;.KH:*6P![UQ_#6'N4551D=_3/;;RJ M4K:R9 M!>T)8GMW]!745O60);/(MSYQ#)'$FZ(;#I2B\SF[_%HQZ?5Q+Q\H;V%P-#^& MX@HC+[#*72@/D%H':^4IDS52.2=O5>C M)7^"6N4L_1TVYG]2?+XU!)]0 +54PT^'2]P?_@O/_",!J_%_G0!SF\N,WA3! M9B_VTXEX*I.X(4:&NWTYXB]_#UB&M)%D:(\D\=/J+U6HX>:>- F]>V M!I=A MS5_>VV,\)*MHAK9.[]?U%(T0/[# HW!2GR^PUC7L\[-)(K8<\F].=[G0DC4X M?X-0%9GB'%^G3+)8*K;G34>?H=NRE5#J/B7R$KHL>,>ZU.-70J HRE95P?(V MO_-E>VMU[3^#K5Z2]Z^?BF!\V9:+M8,#SZ$Q00^.!&4.],_> F!PA9UJPV)Z@*=,^+<7[$H*=R.O:A1.2J.?2:6>AT M_]1V^&.^^EHYNPZ''5?#3'8%#OM$;, M4]S[-0ZU/2@Q%IN66Y4L2SS?=C&1M948EPX;H( "QB'ZHK]CUSBK%[(JW_\M MY:>_DU@J*/!/5K/QJ3G$?J=Y_%=[GO_8JVX4@/;BV@I=OG2+SU#6A+/>B;DV M-U$'$4-#5TKX6S %V&GXX,NM4_$()^?;LTIMJI;GN?.XOL1#I.<.FC&DR 73 MX,O=2]KP\9JI"BCNAYP@+ZNWAQ9]*,"H]37'N2'7;K:ARHC6CWALBG J_IF, MVF]T+$R@O1-Q:5?$;F\)?&HSTI+GZV= )5 MNB,2T4,(FZ%19383R=^_58"8<_6=KWIO8LMR/H6P4ZQL-Y*(;G[#MPN*35V7 M6DJ\HOB! NIV;D:^,5U9==!G^11!K;F;TM92GKTQ'V M?\*63:3R_X7,\&]_P?77@KC]7-6V_U84#+\=98" ;>:,&Y=]GT;-1]4@51_; M#R2<"(4E>6>5A1SYAT3D S\K?E?%R[U]7PDO-SLWU@IS;B[9"Q+<@E^S;C 5 M_G=.VX])3QA($;-(G;"*>W$3^YJ&HA;6$(7MN=H MU)0@3]2]QLKM;VQSWJ ? Q!TJDX13DP^*U\.%]M"^$BI7LWF!.?TRJO2V'L1 M6"+BF:I&+S3@#+AZ6Y$EK$569W*&9*MMA*ME]6N:F&UJ"N!HZ<=T+/^F^IT@349:'!CG!4$,3X%5P/F2B3[' BM^I1P''73Q7"^IR (-% MP^U]C]A_'BVZ!HX"1B'M^X%RI(!?XOR-IQP*\,61'') >+W4$ ;YJT#/-7W MOUBD^'5P_XJK_?K@X\WYK1<#S]JA@/5@H[..O']'_G?D_U\CL_W'WR6:,I53 M &@,-!%^'QTU^S\ 4$L#!!0 ( #B"?U2-#0Y'(3@ & Y 8 979A M>"TR,#(Q,3(S,7@R,&8P-# N:G!GG;EU5%Q!^^?9A. 0 @&"DP#!W9T0@@[Y_E5UZM;G M/G*>JOLT^[0*>*DLKR0/0'L& *#]>P!/"P!9 #8F)A8F!C86%A8.#C8N/@D! M/AX>/@7Q*T(2&DHZ6AI*:NHWC%S,;^@Y&*BI6819.7AX!00$Z)A%)47X)+CX M!?C^LP@:#@X./AX^.0$!.=];ZK=\_Y_MJ1- A(U&!UA$1Z,'/"-"0R=">^H! MT/W;)P;:?S/ _VEHS]"?8V!B8>/@XOV; 'L)>(:&CO[L.3H&QO/G_T8#_HT# MGA-A$+_EE<%\I6F&1>]"PO;X4/-'U*MR5-&?G/78!QGE[>,;\CTT M+#PB,BHQ*3DE->WGK_2\_(+"HN*2TK+:.BBLOJ&QJ;FKNZ>WKW]@<&@*/CV# M0,[.S:^M;VQN;>_L[NVCSOZ>7UQ>7=_<_H<+#8".]C_L?\E%](_KV?/GZ,^Q M_L.%]LSK/Q.(GF.\Y<4DEM'$,G-Y1<_W#9OD0T)NS1\H_Z#]-[+_=V#!_[_(_B^P_^*:!^"CH_US'CH10!IP=3N(O+B6D+2E&1UM MZZF1B*8UU9BU$C'>C"M8AY7_N/X1M)ZJ0V,+7HI;"PY<^XK&Y6.%[.!;3#J! MMGZ>VV#QA%PW/(KKYF6W16[;'%.!H/&ZU5/;A#1;AZH<+M44&FTR5T\ = T[ MT+N&J8L,3B$_H[RKJEH*':S4T;W,4W X(D.[[74@>UUME.+A<2H8'"^^\U(V MQ0,G3M9_I\IWMQ4H6-3RVT!_+B7U2M,RL3>E*2(^8W1@ER0HE#IJU_AX9!'N M,7#!^>%RBMTH^8[JYV;*M#WG+K9$)C7<8]27$XG'-<'EW"L'_>% MXH%^X*N.)B<")3-K!\?FT>]][ -821@T^2Z/?J5YL6\@W[^XE2TM/@+\+WA[6F-OF;)MRX.-V+2 F MW)%/6(_FM-I^G,+>B3ONK1]U8@L-*ME)6!",7E>(N^N7>@VK^Y*XC_#A8IYU M-8]VE'+ZE,UK )\U?M.,8DI$WZ=T+'39EB]^E'K#^;DM@,I\4VS3/9;<6<%]&IH5D_+$VWE+!N M]*ALRP21W8>VL8\)Y2!UTA*K^2 ?=N* ZB9!BZXCJ?#U@R/*8P252-7&Z]0$ M!:$+C/<*@%5?="6X8:RZ14$K4JI_G49:"6Q N* SI$;N@"&OV&^(&'5I9Z\+ MUT"%ASE86Q.)-BX3#9%185%0KSUO<5>?K+/#K\YTJT,R.\\I0 M.KZNZR+4$.P=>>2(:TQ&)#/-_ MIZ\AO1,L$YX3&/@^R&K+Z*^AG0(R5P1;; MY/P[U&'&Q;)8@4CK)P:]V/\7F1/,.4/QR@:; MVNQ*FR,F5-\85U,&[_D5:MNS9.>-0.&EDR#_^M1FQXZUY*GBE"3-L(\M,N(B MZ=+<4F:#JSO7X1#3N7D.6JQJ)/'^P1'*+BJ2W5@436KBQZ9'>8VCT#NJ9UI M?RJ1./D[AU9S=YO,RAW-1)%#>84-I:Y1IBO*K)/<::NZ)P#TSX0M0BS@G$=P"7(XV9/8 MUXG6>@\9US3*.A@JJJU5#\NFO>/(H-W>'AC:8V7D%6&TS/3: PJ%VY(E;(RJ MJT$3-6TN-8U]M)3'85<\C(Z,9RPI JDA,0N^6:$DF@:4&)\[X!P> A_;H5%K M&ENZ.HMHY1YCUWTH^_,#71^G7+W64(EA(8W.5 #F^&G2GUZ1HN5@S_JBK-3H MHCVX $*71X:="^$]\4RAR,X*?D1KL 6VB4G#9DBI/]OG_ZI>S-1T]P2@+$S- M+YGC2@AR8)"4P74BTG(6G.2\C0#U"\,9CO$BL?"B-$I*LI [9(.]0?CZXI!KRB_ M;/+OF1GZ>2ZT@/'#L$082&ZLJ">%?D^>'X"1;<%#V,<%8S Y/'/L"I89(CT&]Q&;,%36N,K]O2+*GF HGLSIC#ZD?1I'.VH9?I8="5:-8$#ETU> M[^J03<;-A+U1%:&$XL45!3_!3#Z@0FQB[58:;3C,S1<9775X'M84HI0N.G7& M[FF@7/MCRT?KQ0N93BF858!<3J^A@#93(9BC>NS D4:BN'-3"F>0VN) /=4H M.EV&%=0PNU@GF,V]-HX1:H?)BL46FBLWV_!E65_69,U2!3CH+V/96%\ M>R\+>QE0I,JL$3?I&%M0EZQ%_-X9$VUP<"/>$/8$P"E@Q:R [Z7]&"^29TI= MNCRV&1@P&Q.G/;]A"DGG0 "QE(S\HCW@#A^%L?@5M@@J WIYO+WDC02@E%\: MYB:O*@+U.YU,JMKTI!A"J\XS7CF(B!5P$%<#)$--3_H_W:X7 MP*8..S7HD2E;LL(6Q^R3M_&)5MU&8WVAZ?%.2DRB4>V@D2GF:>GXR2^63N [-APNH9@#QE&NX M'-SOO%5*Y5F^^AO9Y] M1!VD<[1L[J"5K:7 [TM;UOL;4> MM0OL, FDW @6O^D16= )@WS/:]]/Q=3<#CG_\^.)I46+7["NG"7B#)Q#&EI-:M^,Z912JPBM7<"*W: M1X(VV74P/IUE/^E339RXS=04J8IV,P8V+\4?"A,UG (@VQ\GRS8C$;GI$/ P MU-%L5]U%/Z0/X6)@5P>:6S)4*<+@__,&HWK%/?@%MK1APCV0M"VFX75ZP#0Q MQ^0?$A-VBJ5.MIZ\'^OO5_A MK/APE&;[DWM$H2B '7.GGPRAZQO3(/1:22H3!1EMG#>0?4#\2^7L&<.[WMOO M7NF?G6V\$@J7AC]^7-/)^D!&%>C(?S*KO97QPB:_-J]I\-XXP4YK5JX8J"[8 M&+'XG?UG:W<_Q;!%$S7N[CXEV#5)W;32J2_=,;=L3_=R/J!YY, +_ZCY_5I57:.@AT5,FC*"S@#U;K9:G5NC5O$-K>]F;2GU;<#)5%ZX/,(\ MHROQ"6!=^CC\;:.1S@94^ S?]WQ\ ]C'TJL'#4(NJM-+H/PE*ZM"'>REZS:$ MB?97[,TN0_M3&?^*W?Z-:@A:6]+6ZD"]YV'DV4^-Q"?^)=--GS! _57I@;VQ MEPE#VJ9[+C^B'GZO(-22:_?:UZ%5<]9H\'D"I-.*L83J6Q^/XFJ@AV:K:*7P MU[&D2_+'NKCK_TIW)?NSX27&IHIU9' MQ+%&B<6&SN[Y90/F?CL#&TG',S*870#R8L]QV7Q\X]E&+X9EV4!,6.@R\9'@@G,TT<2$/)Q8Y M,O_Y*<=6ZW,C .T@)A"&T(P*G*QQ91@G#+]8N9;[4O,X'G]$6!Y0S3W_&DWB M#[,)B%?/24*Z=%]L)<(2[!ZVH 5/G6?]]#O%F5"'IG:ET'/:/.<_!&1P%11U M7YG7<>G,'[BTXCOA'+:^_+51=$>67XNN)Y)'W<[%L'@^.M!I7J,&_] MI#KO79F^ /!$C3S+97RUGX#/NK>V?A"!=YJ:T(3LNXOQ> M%(+E+F#("AA$VYZDK*@[,+A3-:\3%09L=1F'>,SFD[3E_]L#P3F-G3JA=]G( M;%^=G1>QDJ/$!<,+P.9E'[^!83(_Z"!1CJ#@ UA23,2#RH ;'],_YBNY)G4I\VXFMO48$UWII47\I_1"W85(>'M?8*P?6>&:N%^;U&!> MG$K0X@(O7@,ZFAN0YS/0:.R T>R;U')>^:"I M^2$O5(,'0 [0+OM\5+WHU-0+W#,3779B M!!<[88)X?NJ$"_K+P)_)98MAC.R8PT)B+E\E#[1!U3-<'=47>"H"B>M]&Z.) M,]MX/S1*T9HMK9K]-56RPNE%5)UD$3 ',Z[5Q MO_$MTH_#E8TUE0:A"W<:SO6'\A;Y7=KG4&LA1EUSTE,:/^ZK=S+O 3W'[N M#*I=G;XM[@U@@BL*DU6K /U2E'"J+X@J^ZJ'&8?^\RKBMIS>98&Z#@1S5E^.+97B*G$"ZIX- M2QN45'#-+%-_*M"@6V_+.3H3F32>[&B?,DZ;O"7/'\UDM21-.@$?8D,%"4=NIN2!1Z<^]+9U? M/OCY3P"(<5SIFJID.[61=WHO+2MBCM9[^AXR%U]33*GA.+I@]'Q+Y*CT:&A_ M@TV&]C>\?*=-W 3U^GNQ'+%B36U%,,6@98+B ,._94"]:])DAM=Y/<,OSXX9 MUFV4MM1++DATN\;2MY>\Z%/I!>G8)R_%V%A&24?<,4@TW_^O]?UOU&@[$MHF ML'[VN,Q$US7&?Z.MU/8C,UEGSNKQ<>%3;>K9F648=II;"RV@BL\I IG-@B*M MC\Y-LG 03Q:N93+XNAE*$VON_PG%?AVO53<%;5*98V>UHL;R%-F9U9.KVB7+ M)IUH%76Q :A*/3*GR@PZW/..>LA'Q6BGGEC0V12>MA%9@"8YSN/)KD$[MNFB M7Q+G/7-V^,B,@]U6!-H9I]P/N&FO?7TX'"?-9*Q1Q*[6)Y+%8J+=J!%N&#YB_P#>BT_]V MQI[YUQS +AI<_:.W>$0DT20)=X!/@&X*JDUXUE+%,UO^PA! V=)85,DM]=ZP:E4W7K+%R!2^#6K9(6E2QI(?8)R:'1( M64K^V):]MFV[*@]XSU4=KIVE_;D!.]D4VC,BQ*-N MD!%-(MW)BU'MB.X^'AVS.OY,@R);/]+IA'== MOBX%EP K#=>:/V:'S(R;J?&Z>KZW\-[HKS4<<\\BZEY\F+-6SS![W+VJDIP\ M=U#O>2W,]XP$&0S1_+L$@=SS_N /L?$ M;J)ITMY?G?@ZOJMAV+8TX;%>ZGEV*3TR5X6(4A/Z>F2M/.QRZF'CAE;]"_.\ M8_8\HP^3ZLH;D/>!8=W^U4YWP[QVBZJ3V'W)T8B]*(;2GD$V=5-&=Q#Q;[%$ M[$VCU"AG,8+[0&-DT?5)5\*-:KF^/&G:@SMX(OX$#>A:A:/,4P+UXQ]/)2MD MW)_TA4Q"7!IZZ?P',3V=5:R<9-2^I&".\A< M-CW=@]P],Q1O1=7T&4&09N+5G=@0< &Z$%0K==R2$G_>ZZ?0U8(1OW9.A:2S MLZ4)+V&F&] +!PK,/[:(&_9&.E7BQ)*X&+X-9TIHX)IPUK#)#N DF?;BQ6)G*FC:U6_W@9<$--63I3 M#(I2G5?@9!-DT7%:_OY-:L%V5C#JJM,7:YT<,IW&M.ZZDB M5W%CX>V[%B8N66>D(?%#7!1W.1&#Q2);D!?8>5RNAU0C"6UM&+[+H;_UO;U4 M56BDB*CMI*P>F:4*;A%\I6J)K1Y)"H8AJ7?4_3%:\&Y:=,HO41R\[6_EJ%\M MYD"<M8[?K]>I6BC*%7&^]'LH^ MA>QG?YXE#8M2$XX@SE>X2!=\J#W>[$3KS3-_*0A9EXY(NZT1KX"FW+VK)\34 MOAH_+_)V_#PC8;1.2#P<7V<8E&LD[! YG' ]K>3EM.H4YAAV_'IZA("!8,-M M[$%-JOB\4LR$QE;,NOOD6L%]7 P\9\8NL294XK45+^F;OA5#79EX)IZAXII= MC-,RF8>H1+O3+?41.&ATVWKQ^K0R?HU-[,!K=FR\+CBPI3PU3;NQ WYHD4T2 MR?E;/R_6C^4X8#\V/.;"Y,6RZD,\QUL3M*O>#I&K(U#!GLK^<8ZN]_E^7Q%_ MMCC#GIF<#V8XJM2@QW FPMB4XFA,81VV;^A8_J7"H' IM$L=_=Q2<'VZ4"R( M6+)Q5,7\B$33(/E_Y+->6TM4WQBX-(.H*W3V#O>O"9X-(EOTM#[?IX28JXH; M9+,E^W_3&D'YB]ED>UC.06U'F@%;-+=Y\6S7H9)%=3Y.57M_\H39 MMQ9[[B7XN4NJS$YI&]O?G89"I[Y._3YCPFJB#LQKPG-M]*=#5K*:^XE&(W*%]']+2Z'[Z9V_5K@R7]@\ MZ:F$E_F0E6$K>S0;]2=DK2&*._].H*804BZTK9>VQ8Q$+ZWRZF6:U*B!??8! M%05I%8Z.0$5RL.^%X/[\?,N*?]9#3_EY/5P'=2;Q&+TL!/@OF MFC?G@N>DI&W4G_;8%2Q$IV*6YOX>9YRF]31'AWC6&)3NPT6MQBLQI'MHL>#^ M')>G5(-<)XLG]E_+HL^K JMPKW_\;8BK)-*)%G IP_?8:-@ _C2$E^M.^3JZ M6KP=E#L[[MOU]/3BART7BX2H0;M'&=REHB3!1='*3:@-]!/^]/M)-=^E_KTTQ(*](-;CV?B6BLMX4MMJC:@ZWP-Y+'EE#\=@"W<9LH%B@X-+?[R'SM;H90Q!S2DII\UNZ)/JGO>Q=UC$"^O_:R0B+K))=+W:Z* MDG:R/<\U9P/8F34G82;$>PV^XY%<:EDV/Y)LBPM^?I9,EUV\TW7?7UCR+7ZP M<="2.JB/.>=D_MR $!AP@E@2D)0GC,LNTKGH'?0]DAVLF,[0*?P:##O8#I?N MVJC: 0WJK[/5O[#\YR-S.Y+OW[)]M9 Y_JJH3^G J#U=-;FEJ:TY MW[R@R/)BU>GTJ'TYI1*YP5]/ .)6@Z(56V$0'4S*?^HE8X+Z, 66=&25X-1Q M%=1)9!:D2I@.2+*P\&2O.ZWJ]H/H,K9.ST$@&2DQ=%GAYY4,?92"X^&M*P9,IY_=F0EZ)F M3>MM>DNI=_[GFOV?[F]#;?TE45QIC*C=](NLNOS[^BNN MD#=/ (_XBRJEMFNOM85U94,H?E 4&7U1)7W,%]NN\2:-[G51[5"5;),*[\N_ M>J?:-EXU.%RS9;"!W:$7/K2PI7O&"2YH[+/U?12^*VB 1C/\+6#C+T25>ZTC M'#J<;]-)3MIMV$KI7%#Q:T6>E Q&,PO5E'.E0?NO M<]%_%\@)I=+5()9583B6&8?T+ _7?_S+;1SO DJ0H2@O%E935OPEIV20(_ $ MZ'(J,U%P,JLT5OU^39SM,EY.\ERK !:M[OD[Y>3 B MRE>#7H#50%?*H042:>HI\>OLZ6W7PFMSR=%*7!!U>ZFU6Z0)K'M\0Y=7HY0F M:^2$6BJNT-M@(4&$Q:V >(]@39)I(K!L&_8W'V:3V& M-AV-BF_YGQDT6U=7Y2:D)).^"1;IY1B]0X'D#:RJG48\2#1!MGL1:FB,J^:M M>?W=Y1M/ *+]^7RL6+(\*5?5P?OYCT,)K2>F9:;N5XP937O+ZXX[2/U%I&/ M_OM.27JLNE7GM'G[3BUQF]/N\O;L.1/YL>*;VQC$9C8!8OW-WC+/]$O/5V4# MK*_4KD-MN\#IP/VX;(^:#T$O[?*UE)84'5G+!?S/]B<')AO9Z:F))DI)SPF[ M5D@[(MR98"W.2(2^@N22N/!YE3BJ(\1?Y3(ZUO.O:NW'3OX,9L97#T?%Z>%K M@HNIRY+!),Q?>K@JQ4U=V6OK8NV,ES1'U212. ((__6KJ9[_V].>)?B1OOKT M*+*I+;"5$3PL>DE: >Z4L"XU/E@6:8;ID4>ITY-RAI+O^^P!R>VD$)Y.'\U MY<5XD%%5IW7,P@IT$H)+%;=[[$!SR5&WFYUF=LBT8&PN5U?X>_0 M]TG@YID8I#[6T*MG94$O8/"@KH'3K%K[AA:^T VR"?Z@M\"3EZ59_4GD'+R'V"QTGG;MG1@%'D1EK1ZKQ\PY_ M>%[?]2I@J#="^J[CG1@<:B=@Y1571EKY%Y7TMRK#TG1[CRR/7*%?A " MDEF-%?XSWQ#^.UHG45Q5B\QF)&^UYV0<"^(74F+)YDL48B*%IT*(ZR_?!+\8 M9K&>VG'[QN@S7^%*'D!(.A-^E<]R/U)F(,CDR]D1O!V^,^'_)8C\,)YM),7B M<.4E] EPX96N6Q "+;%P&G$Q]BQE_@;)$9/,6LVH,UR44)8V[ DQ01X6NF'6 M^&SQWF@I"1_1:1MUX^FZ=&S'&?[<%UBJNJ+]%K#A8*'4\,,[J:N7,V)VRFBL MEAV]7W;49>6%^_6Q1)"+3['\H"V)JP"]R=KX$A;I^*)4;OD2]Z]WO=,CSI@J M;H?LLZTX:V&GB%A&)+;A95#6A 4;UD=2#S-\2::,JU\D[,.OM/8,&/#D4%=1 M'C\K"T)4)P=ATV/9$S['C#^"A?G0D>B<\>_M'A,V8@TW^@ROPCV,'*3&5/D6 M%Q7>6$NY;KRM]D.+>0 GG#X!P@6/R(P>%!Y?1A8AU]EOKSV M/RUL[#?6?0+TQ&/8W?9'NL=JRU!99@O#8PTU5V>T M-\Z2!Z_^M-,BH0<.VG]N8^L+7WRMX[=-CQ%FI2ZE/3Q\9^0\;A&W(_+[14Z/ M%&MS+4HH;0W"A,TX?;*1Z,2WF4#-^UN4\842HRGN %S"H]([7AD:0*58;]0! M-38R$>RI,*M/?)OIG\\HY"U9UIZ[AG>$WF=(&.$^<'+AYR?"5-\49_3M71_= M._W7#,[/-RC6:][^"YBU)P#&<+'MK4#:Z_290Z1A9$-S+.6\,,.5W8A+:YPP M_K=Q&, 7ZYN_-G.,!#<9Y%U)??( 2L)N(;,M[.C./LCS_%F:MO;[G1J!]TE4M'K\J1PCOD( /8VM)+-':C M0J<@S@(Q LC;.KD2TVCBF5-\)GB)Q2IZ4AHMQOQ_1_7 !XQ!&PE3'#07W6=:O/T M\ E@W7:Z6]UPDXZ M?% XJC[:X^7DT9>&UJ31^*M/>]4\W:Y8('%=A_CO_B:V>=YZ"D$O1!^[$>TS M GMNM'-P%_%DLG'9,9?YKY*KR#'?VWF;#F+NH'H.C*7B;$N;./DM1QDZY5O^ MDDV]=QO2:'/>E:3)PG,G&\8*/!3/?7F.V?,)=;23MN=^(HJVH;MZDZNG).GN M7HC4YL\:C4^ U&^RZ+MNRX5I?>VX<.<$T%SJV+,%A=8GP$9>JTH/+2[B7F2K MJF*X"Y+@\G(Q_%Z:(S%[?[Z>VJA60^!=W#/Z8443 M]W(%H?LR&"TI=@EP#&[AUKR, M4\\3X<=B5OT@::!T0:5B]#WN0Z]2=S+%FZ!8W_ P]R? LWT>^=/E=],]KFF$ ML&]/ ,^FC!.LX0T'&4^ZN> M8@UXA"&U:BL@H\.;7Q1P*,4KG?AWC3CYNGH59H_,(CQ9?@?"G/6&;TTB_94* MNW<,3)8+B+*5,. 7 U4:I]R]#)"5_D(P43_-R,^7X^1= P'8A^#@2C(78V33 M FY-!V>%;RQ),FS(\?]^,_5?(C4\>T1T]1\_ ;(\=#L(6V79D!D-P'&B4?1C)7LIB&^0L+,^#7N&$KZZX4J7O?? M?2<7ZG9-JDDTD><7XS#?UUU+,D[WI ZA).7NI)$_GZC80_694?(&]4P3.^UY1T))/679?52<85.]O ML4Z*KC %5ZQGB,Y I3',85V4OCE]D953?YVCE:/[DZ9G2:F>5&JXLU>PRM\- M4K\ IE(EQOR7:VD$VT-8=_G?U,+7>B%PG'O9LN7]O];B7WX4R#X"1 KFE9$- M15L+)0]B\P+*_1^[&4)D9;YZGA M1D9"[UJ@P,.F':ZV(,J)ZQ6[OFZEEC$RT2S"Z3CV;Z>O(PG#[C5)_DK?4F\, M-FIY \Z=.I'Y:KCZ8/WMI*U2MP6MC2XI4=C<8[C??APO?4[N)N5X4B?R5H// MV\BHJ8XAP<'5?T!]9Z#\JOW5:7_D!.A# LXM9"DY@T:]4N\6X0WW!Z]5JV4% MD+79B)YQJPV^/\<7D8YUM:T-8G(RKRRO/$B=ET1DK0=@;$;9&$K#9@-1. RE MH+RR^U?F C1JM,YI)MFZ#9R/;VVS3:$(R+% =.K08?.GM[?"']@ZNH9?.>3O MZ\G2 I?.XREH<$.^@A4*69D@-4)72>)#+'E-JL\KI=>Y0XUZVNDL[#OV+L-' M&T3[ O10E7TQ5F5\+G:*JD"#;-(\?_T9Z)*H^_#"Y_0SH3.$7SA[M?M-/XAU MF6$&UC*PKA)/S/CH-#+QKPIRV+2'-B[*J&G@ G MA <@&3H6_$/&E_FI]&W&'"PS_BA=L-M(OTZI/'5Y:7F^=^!?_>8[P61[ M_8 =QRA)I2J3T_'O]OZBM-?(T1:7N\&,&T(9$);U>@>1+?$ 1Q47)]&"BWQX MR,4 Y*<4RW6WB%%*&FW]ZF34)4PG;RI21-FY(+DH(^&<#=4KUNZ5M)X3T]L' ME[!3'(@_7'S4*?_M;X#"3Z\0FO\*2WQM"KFKK6B_^"/!J2@W>"XI,JWEJ= T M:7 +*BI8ZC*=R:CFA && M$%!OOK]&) +87$I1!5L )TTX;W)I^D7G"*J[P]PGPU?>SK:LX=_29R;;V M%/#H0ER+CW#15#P$.%$I+1]+L-:4@A#YO5E'C9^>H8U"))EBAZ;O]=LT![I7 MUVX6^K08>T>YENM.SXP5_& 9J&+[=XHI!SH:*:[7RTYLN.&VY%YG@!(\E\CL M ^8LH[&7>VYG*H!,\X>L6Q>K5>\LIFPJ MB-C?;P7S&GB% J,-H^V"1$LB/ ME@65<4IRO7-1V *PKNN, 4R9&)0,7@%]/7UTRX$D7KR0\*SN"/.:%@(U/M<*#[SI.]E?3L)]D4@ M(Z#>]]PEPV6<>4O>@4>=[76L"7AT-W;MV1?1%AX/">OFM"^G9)W_O#\9O]8K M7P :@LDX/",9G+449P--$:(!'A3*W'Y933!6D2X@1[QTQS7X2\#+C@GN#[UL M)XH%-\GQ%L:2J9$5)HM UFGQP2[V=1GG3Q7_2XGH'#\.G]Q)-G4VJ][P0"F M-\E_+T4)3W,NU>UF4'KA5LVIG$&R9F0U]JVDTIP] 9-M >4KQ=&E6. ER0PI MQZ)GR4M'%KWN%TG:"-.IWR*-Z;(O.3NUQ+;;@KIS"#@$2K4.-%Q\7%N_*@P4 M[RVWGJQ59MYV] BW)>#BZ29Z@7[SBO3OF+S7ZC.W,TF1"NE>W9-=KL]C"R5' MCS)DJ1(YP67)^_K?! FR<"J9&P9[D"=2O :SGNC:Y#M\G#FW3HKEUKUV@ P' M6>.GW3+>JU#[-[^8N_6=63BAW+O-/(UL7:E&2TR@Z1W/K5)RQQ<%Q,L:+^>N MQI(]S/4VS&U9)$[0-$DKQUB4 ID:C&ZRR%FU\IG'LEJ;R;V6Q;Y!Q[FZ<$R? M.VBMXA/:Y1=_HOU3F2[-[0D,<\OT@JCDA%V.?(^^J2_+9-7\G-L06;'18'97 MP<9S.4;@(UB*Z#BAO00IE*H5T:5.5Q55[E )CEQ=J4G,X8HGOI8@[&JF(D2W M$SZB:N>$N"2.N>K[X>['97SA*B?[9>% XCEAKO3K=>DAOV'STD(WOJ=NR /3 MZJ&&=*A?^I2(]]*8XYY-VB\=7OB5F9)KPXV7Z!)6MZ[T_ FCXI>&^IM/L>,_ MGP"K['X];KU.!3=&:%YO/D8?Z$&.CLZS!!1^E!)O912INQDT6Q*4+0M!G+$C M@E-1#68'UXC3\-JH[X&LCLYJ^:72MLS'_2B>H\5^">*P/J0N8R!LYJ Y<2]= M<'3968?GUR-JSSAFH.97GG96Q>= S'Q47QD7Q_F#%-/XSSR#%]Y[7]G9! -2 M1%=RX6Q2RS#!R1KW!!M(^ AW\V?G,Z1I_"5KK.#!?DB=X"A[!* M3BXJ\;IOC>JS@LI,X^OX(L8;1:4+?<.TKE0'MKY$WT1E4G/CE#I>W V/L ?> MQ2T[FZPHHKD9!0A]A_,[F\L%R/&ZR , M2-7,X7:WEJSVKC0S_L48V< X*6HBV_^!=?!.5+[YH.F[^;Z\>^'D[A?OVDG. M5J +VZHX20I6Z0FPH%K)IF9_WOQ83P/>TT9MD2AY$(FTKX(1R''-I:J1XE#S MH+>YIZ:GV[XJFX,BR9RNUEG<*([E_71M2]6TU!6094&('57PG9C+4F'9[GU< MG/[Y"?'N^//=.B.U%B"A1E N:5=_Y*+H$1J/SO8%WLY<,<\!M[^0$5$]9 MYP*=W#1G=>WPV!WI"%]^)44Q\=5K)W3T+46EV >9HPO2)?'V4? M[)VND&"^#CQES+K;*Q7A"?_#O^XQ$L\0-"RC!_4&7:X##9UE5YJP6M2> 0&PKF3DXK065K&GW%X1-T+,O]+[@OD0R$%HL)7D@8?K\KDEP0(MGZN;PNQW*MNJ/)0\"N0E-AA:L;/+4=1SZFHU4]"N.$I>?XQ#CL\5U M%9?IL^G.V%EH4VFIGNW&/(@KUL-#!$RAD*L"QR(H2UYSHI(!=6Q#^;_J_#/X M7Y?S[/\A-M$B?7I;.O'/EJO64:H+NNBGK%7XKOB*4=T3,3,NI8:P\ 6M#Q,6 MXLFO;G4B"@WR#%Z+ZUM:FDYI1<\EKR-VQW*ZTP6[3](^U5M=S/)K=>?9_A#: M/728:?N VR$G;JP$JYZ(^HT!0)O5&*C@Z23:E;>=(>TY<$ ?68OZ/8C+%\1& MD]C(7J\7P/1G-A46GG-I.VE;_\.%IM4TJ$6[7\+U>;=I\S&NM\CMYV1V25G@ M=]S?I@ ,GXZ8S93G-QB#(^\2[J6GBJ! MN'CFR!_H,.>0]"37*EK-/;'#P;F@G2V7HP>%PX_AB%6M8%$A5P437Z20T)'U MI7P$.6_L]^T,J2RPZ^Z97*I,J*FBR/E I4)XXJ2D /RD"7ZT?@$VN0935&>4 M9VQ"6WY-]-M7= DMM(T_W]3YV-;\TV A+:%;A8V_'(,/8V_\9L^H=N_RKSWG M:][8LB'%-[Z6&K<>!:F#CA/%L^;'%\_^Z484G ):I3NY,D.&O5YSGSO., M=8-4@LN];\\\:7]=",P5I*_#$S';]^_[%B\)#JP65VXE !)GJ$\#P5[9BAG&= M=:(QK&A=-F'QLQ-CG?[*"6F@\]KL(#C[G'M^XL)SJU/J#1Y-@JAS!=@957>XIEE'TW5EH\,:)9O4(?B M.DT"=[:Y<EM7EL%:9+)J8#5Q^$2!5OL7]GOX[85 M\Y.(^3Q%C^7 >V.)^A_VV)4+,6GZ<&ZGA'[9[$:9B[S_L!;!(.DSJA_&&"88 M)X ;Q0/89;=S+Z0 'EFPI3"P+)2^(]$$8K[]G_XU8CW-_1]02P,$% @ M.()_5/]!%(#)#@ ]Q !@ !E=F%X+3(P,C$Q,C,Q>#(P9C T,2YJ<&?= M5G=44]O2/R%T0:3WCM)10PA%,!1I(B"]21,$ >G]>C&(@EX40I&@@(2FB(@4 M:5($I2,( <$ 0NA->@TE.2_>]=[WO&]]WUKO>W^^.6O6.F?/K)GY[?GMV0?$ M@Y/ JEI:.EH:>CHZ.@8&>D8F#F>G$"29>-G86 M#D$^82%!/@$!$0D%21$Q.7$! 2EE:;ESY^%PN+"DJH8*3%U!$0[[&03"P,# M=(*)AYF9!R8J( K[?PO8#+#2 S<@G%"(&$#%"H&R0L!60)A2)PWD3P'^+A J M*#4-+1T] ^,)BD/5*8 * H5244-I:*BI*=8HBAV@9J5A$SVO17[_0922EI&;@20EE%54WGDJZ>OH'A M90M+*VL;6SM[-_<;'IXWO;R#0T+#PB,B?[MW/S;NP<,_XE-2GZ1ATI\^R\C+ M+WCQLO!5T>N*=Y55U36U[^L^M;2VM7=T=G4/#'X=&OZ&'QF=FIZ9G9M?6%Q: MWMS:WMG=VR<>'/[$!0&@D'_(_XJ+E8*+BIH:2DWW$Q>$*ORG RLUC>AY6C8M M,SK70'8QV%UZ#NWDW/*/#.**YANIY BOYWDC]%%NTL$02A>MAT"L8#K7L[)(WA&N MB1,<<1RVTPG:>5+-5]4@F@*EB=DX!TWN=3:[ZI=YSJK5N4(.I)7-Q],-,_;9 M-&7$Z S!0<3]9'OJFR_D^4RN^;-61\R\52F]U3BXLLMS2;FZ['OKRT"'>SP@K#9?X(]]+$:LQ1KK% M?T\<&] D?7'(XF-=XUSZ(_BX.9GY,N"1REPL.;UO,551EJ^1C)B0-GL*].^FUU5@7=:&J9]F] M]UO:JODD[,MPJ^X5F*6U;E&86AD$$J#9? ']NS5M_0RSGL9%VK)OZD)VF25-AW)M0_EE;]<.UBE6GG8Q5C=MB,0LI>C_WSY@]QPB9)G?:K9U@Z^+5<,=SVU2^&U MK3&_ZY?I[YSJ3%:=#<9OM*8/!N8W^MSW@QQ&.WSF&JYHLY6K@(!MBGO4FF[8 M]DTUX[99Y6"OZI1KVD"B=:R1E."YJ'K+1_E+Q46"AK=\8S?YC9L?^XO_&(Y6 M'VRY([F)J J\ONV8]L \#H6 ];.\2SHYR(;.2FNG#_!1;#$?A]\!PCOO;+Q7G*%^T,Z_Z*7S'0&C!Q> M&-=+'R*H:)I3C\;5COKILHBWVR9.?]U-@$W;7768&/_,M)?2(%,NAH%^!@XR MTZ$7ZK:=8J=&"FIQ>2F.3LQVGQ%^D[J6J*<;@$3@X$91/BZD-I17B:?RR+(Q MR76-2T3P0V&)755E3<5=EZH8%=%KR0*7.?4BU1F!C'BI'*K_-GT]06AQ28;G M=F&TV&04#-WZ[Z1YOPO-Y,_$ES 7/>JM>6^X*2URCG=&_(SVKWL MK09I-_@93T$6+N;$,!L)Y=]0I$G<&A^YZ\)UU1!:]/:WA1;N\/U4)\=>W_DO MC W>!3G.J=#LII"%'[K[]_F6)[94YN+8 \/V(;ASEG"'\P>[>SDGHY>MM5E4 M'#5Q65,831U6?'!7CC=&,LQOTEIW8GE 2DK#H$]0-S@I0L\4X;7&=$8_WO+J MEP%?#ZNK(R*_A7& P JSI2P3GJV(([#Z9-@9F*I%C(%DN :=P%7:D>&=]/3\Z.UXAO*KD01N+2C+_RYU'(K?[QR>&AC;SOU 5\C7_*V-EY M]Y@>32]KK2Z!'3&,/\/X-2V:-W$]NGX]UIH,D1\#""H=.0MOC8'0)%/F'FW; MTX9N&KP\YY /BV3B,EV&8(.W?697LEY]L5T3W6IL=R!!H0Z&_S/,!NO#H.WMC[W.'1L9I> M@R"X$6JZ&,/]VH.3R;U!PAM]=6=)M%7"1W/(3]$7D$2[#R= (#>^;QLY9:ET MEIL8WAJ$7SKT*.7\6A+X?CH6SY;K4&JB&#\/ E/8$.=#9F_D?CZJW3"1]X5LK1H-J\/ AKLY$/.A6L[[VVNE^Y98?=/@T!3'QF.NF$' M D'.1\<@,&/=T D""WDH@C8:ACQ8Q.[WYTUUUW.B*MZ P/NS)#)J,_](IN\H M!00("R# 5_6/L!R1R2#0=PD$/L1RG[3"%Y/2/$E=J/5M$$@0'K%&?4\G@P"2 M.%3Z]Z#Y/6CR;Y*D':G:H+<=[)MBXR$@0#W^?=1075$N.7KIPNSO!/M-EM5> M9W+,-Q @LE$JF]L5?AXV188^.E6BJ',4; ," M.54@0*9N(N)([XLIW;$' 1"@(],+B5^J[K\7-E$VMX;/WPQ'(345"2B)LGH/J=K2CW MUA*R/>?(M_"8])'2"YOCF[^\^YC>,*H0'QU:ZV6F=W0BII5X#E59W[=[1D6J MT]KVAVI$R1:3V]#D&+X:,A.E2WPSQTI1'MD*83Z?0YW+6&N[]IC8&&;H/SWUX,EES M9;MYOU#^0_; -=&A7?B1>HPJ4\;C>.53] !F(4;ZL*#.+U^PTO>5[=.9Y^[) M3J$M4M2LWR;>M^'<$D82:UP#BA6?Z-717[E!I3#3UP-TF/@\-QP+MB0$OR3W M5FZW"H^.HK/T+J%&@_S$E^KAA#+\$T_R:!.^D(DPBHZ.8ABW]7]AGS2\5+24 M_&E0[M/L-:AZA&8]1*/V1_;SU[45<3VVOEBC;/?LQT.#%T*Y*S^,B?L0+$3L&ZH3"<'7&+%L[KF3:\E=BF/MH6P*3%QW#!1.V[84!NNQLC# M29+QNI[!/H#0Z72$YRN^7.=GNZ$@2JX.N']/8HP@Z%!FP>OJ:X-<@$)LYV73(0SFMBF0.U*?> M#6<2DS7J&0@PSB!_G2A_&4SUS(E;@QT?N)H(>XY^PXY/QRNS%;/"]N V9_-_ MYQVH=%-]9-68^F7L^7*6V\5[$_%0G8'%O'AJSLQB0[=J'O]5YE8%0[HNF$S2 MA>B3:L-IKD2L3;I19:R\>ZS"0I"X(I4-XPG$G1Q?H14I*A;9%N0.$QH$ K^ M/_*[-_I(4''*4>$"@6D?-10K8<)4/>-:!2PJF[W3NWBEGU>\&,S5:%I^%6NK9_Q+LYE:#(@AH4H;9 M!DT3,2-[WZ&V8D@AQT?7)Z)D)ED"%BO7LU*KNJA"DGE-;+27GS')NJ\]D/0C M]D*/JY9&4,N6:CY&(V;%P.%3.BN#:UF S^ZM @+"4[M%ZJ5,E-D"0QY# M_,EG+]Z2B0YBV61/OKM;HCSD9OJ.O-KWW&\0[9(C$!7Y9Y'=7!<% M&FOC<2$J+]CDH^V+F9;VE\ILU*#^!:ZE@R(;<, M(!HG,>2<>R"4]*$#URU 8#QD\EOI7:Q_YTS\7.)KP]OHDJC>H#4'D MIU*<)@>RK!)]2&-+R:V&BI76-JW0X?+IFK*J."W<3*PE MNI7QO2[ 8?:+MK#Q6IOGU,5PEG?2E6Y1?AHX5RK'--2[?45L&UK2VR-GL MT)REWLB]?/_M@^RP\=6R+A+IV5@]06C'3).E ;?B/[_M)RI_9NCJU(C!Z%@Z MCX;6+-_=!@T7C#)B;U/.(U3TV;:DM7P_UMQT1I<#8F&ZT9C2)E%#,X<)5^AY MNY0/.7P: "R' & &5V87@M,C R,3$R M,S%X,C!F,#0R+FIP9]V8950@C00)$-S= B&XNQ,"(<&: MAD:"!G<)G4"PQC70>'!H"$%"< N> $/NNW?NFGFSUGLS'V?7^M>7?>JL^IVS M3^W_JMNYV^_ /34E524 Q, ,.XNX!8-* !XN+@@7!P\$ B$CX]'0$1!3$1( M2$1#1DY*P4#+Q,A 2T__@)6?XP$S+PL]/:<8%Z^ H(B("!.'A+2XD!2_L(C0 MWTDP\/'QB0B)J(F)J84>TC\4^K^.VTX C ?, 9=8&,P )A@#"XQQVPLPW;TG M#L8_ OAG8&!B8>/@@O#P"0CO!M3? S QL+ PL;%P<+"Q[[*A=WD &XQ#]E!0 M#I=<]P6(V8M"Z'52 1Z+?$T7I=[70U9A:^\(? *J^]0TM&SL')Q1D9%Q\1"DU/> MI::E9V1F%185EY26E5=4UGZNJV]H;$(V=_?T]GWI'T -3DQ.3<_,SLTOK*RN MK?_8^+FYM7UT_.OD].S\XO+J+Q<&@(7QK_@_WH+]H_R/Y[ M8!'_3V3_$^S?7 L $1;&W>9A@0%9( $KE"K6!Q%DG!07^J(WJW+;HUF\]X+[ M 0=Q5U\H]@<:!9*WML8RN3B'S1:AQ8YIN0&9&^L(I3\_Q:45+EU\[CG+TDICB6>?]B.,;(C6 M>3<\DXC-6SE*.JR$O[.7=8)T>Y ;R)',YF3%5N@M(:]$(HL%M3VC:C2&S IW M)FLZ]^7[TW]1Z6(Y%,\G(?"@V?%<>+Y]"VSB]FM-476;R\/8TC<,'(CSWB7/ M$[[I,X+WTFZD5P969^U:4DP]J&^(0]F#:8 NPI9\T'Y"61-BU8/0T6>[QR!= MHS%DO.O/1)N)K[4DF;17EE]_5)UY51SJYV1^D(<->!%I::<[*:M!$GSTA%[_ M(L6@*44C6O\3#VOP+F1+N*AKH^BA%1K+LZ<4GZ5-5N4('L/?L<+4UD*%.V;0 MECQ2 (60O%=?.2>'KVQ!=]U:A0OGT3W8M+[X],)Q[ZA19*_C+Z72^GWT^O.W M='I1\>Y M0VYV!=BT)5C$$:^>@UW %W"=J1=3;AMU\!Z7,'I,R/%\N^L]_%,&KVRO XO] MBI5K'C-!2)$=_1[54W=O&KEM#&QZ)K4$#R+'=#)%UF:[%BFCC6F28;<8&,65 M52XGUON)EYH(5-!*\=1,E[&9*OL\08.U88PX#4=*LG-IWIJT@]G-0&T]Q.C< M[.UY^*+D_:<)H$X,;S'!@8.Y69N0E38FW;KZ^M;)E31">>)F,/P1%A:V[QH4 MZH&_*;SU=>N@Q/PZF4-(F1:Q! M.94G*/LLG$71382KB4C0B,HX6 M3,8W967A]IE]O9.@+&I/2K]--K=)'N1?2Q%3;X.YP'"\N)/D%\-0_W M=3%:W897\B6X+4+(K!8A5>).3?HQ&)@HA'("_U\)::'05RO=@]Z<.5H,Z9O4!^A:HK..S=LN7AQH2EJ:AQ+9,)S#=O@S\T6IT0)W82^F \A(0K4*'&4 M3#C)>BY0722.\N$H@&UID?UPT9NF[&V,$7V/:ITZWN6[!:+((E3Q3FW&F5[D M5?,V?T$8GXN5?Y#MP+-ZU<:3L\;%85-@Y7S)4$TYMFG)(G;.9-41Z7;0G681 M+3A<5"$?9B@%#][D*132,XX=TTA^"^-:Z6 M-+ ?6@EK9ZZ!JWV>,AY-H^M_^MH&EF;O_H8!#MHR;%5U"*M EZ,_42+9BB(Z#]56+G0(%U%81,YY'*[:'I_V[XPE;H/:>2C21/? M9T&WR74]6'\#@R6TSD#*5C+Y]K*N)M2KY:_YK9J\O!XL<3_MC9D-+SH09#PM ML:NTV#9[9\TGM+HP*F+#VY@4Y/XX#=M&>^KV,_N47 MK%B7;_1Y8W:0IJ;!MO30=;\E2;\CW()0MV*ZLO>JQS9^U(LK[[E-[LEQ*\^6 MNC!.RB.;\]$OF^%NDH_*D,W!0B90^7IM:DL2J82A;#:/*6 M?O6NW=J#"QGP.@?YD['I(V2JFF_O8;NJR&>V@6GF8P\6=*WXGUZ"UY^37A_O M7DN,F#5\_=@?,[78X^E ^S9%M-N<'3T&P(B6?HSACS^,<7XXHY[9F\9,J,Q0F5 MF%$.H"$64'8$(#-M8S#.6OM9=OXLUHW.*8[ARPSX$L8*V[,?^\;3:GMUFD]R MQ*IZWUNR-G?;FRN 5/<9/"IM+O"CT6_VK+-[UVG+YQH%0CXWGVG#MEJ0?TP7-IJEA 3] L)06Z89//G:%*O[CZGNZUDNBR3#6VW\4NRUSU71KT_* M22)VL./X4[WM\Q0C[JYSBPH63?EM;DG^L'8AAB:OP#_.GX(?Q$)S@AC7P5"D^ ^9O.+-7>4C7FWP M3GZFDNBA'U'9O\&R[.[BC;P%[J/6GY.CP6DP;?) M/4/8M'M"^V:J"V:5M%>7=T%IQ@M6%^PN1W%\^H!6-^6-C]RM-!1567^1.]+: M3%JA-+9B/N&]GFP.9J,K/=\ZI_755;0RU===9OC4'+ZZ.OWV2&";X)0I9N"/ M2^O-9-SOTB;IIRUFH;D/,_.=[< EN6N;A_/OPZ6FS? M^S,TI:L8D&NEJT@!_%,8N5>,Z>R%S6_F.MVG&_'5?K7DRSY_55]PES7PZ:(< M?D1T5%PCOC"PD]@S#DV& F5E6T:2!NYID*^=B "9KT-,/E/3@YSYF-#_307- M]5%G,^8N,;V)@R4,VO+$FHI #ERF>=*/C^A2KTOZ- N^M-C=LOBH&"HQ<$HS M5J_C%J!A:D3N7QH@KB*?)PBO76-ODV\M6]-\-Z/CV,Y;R[0E:3BQS]),GG0% M"^NL@@9RJBX]9GPK>*PV80SY4/=XR6MVSU/5H13W>G40,B1^L[^\HK\LE;7C M)\V,-IC4A WJR1"Y,1'3D38;CT-3-#KB#":J1?%(K)&1;,^+ !>Q+V8MCC(D MTWXB#U1Q6JA1N_V1URH(J*^-EE3Y1E5,CBJ7FQM<9E)*?G:AO:P$O?!LF[@4 M]6,HP(G*\+>#NT_VNI5#076QV*^&H5 ZW8!;H/33I9I,28WVA5@A?^IW.I=& M[,5M#?=2^VUOSX[\L37+-R92E)!]7]Z7$],L6>.M$GSU$]MF[_O9ONO5*#() M=I(^(Y^&RR^G^M;I6NB\M4):>TU5<"=O).HJ4C[%H=!]\E_+F##,;Y7/H5\R M(:[4);;$;&ZAA_]'G6FN4N@\RCVC#P@PT&F/9";.J$;@I_$[F5@@S^[N=H)/>E<)]C904D9WP(L]D4WQV&;F(T]$X8. M@\."E!;B/BP**Y &/BDNNX+M6FJ/U:2U2&HR&N'4R^8 J1##Y]"K'XBV[RWQ M',JI"/?BIB>#Y9UN1B@)%E BSV.56R!Q/^<6>,YED%YPE??3(DPO6A0Q^ARA MG7:F7!6H=M:]UG.6UB ,^DT/[F&.Y*F/2.@UVO/,(Y'<[CA0_!,?X-=G1D#N MI>S&A>Q2C:30-:7]!SQE2OF.=ME2C+%Z1S/<_CQKB3)5.F: ]6B.ML:E$FW) MJV?>\-O)BISU#_:#;)M]Y9'2Y2(#=S-3SSCR$X@B^X#G(-U4UE?^9 8EM6X.LBZPM]-/5#D] MRR?T-1!:,N]^DA98Q-=)\MV^Q-Z0QAK80N7C%!:&9# ;.;''4P:R91 9FK=9 M+J"()AJO!")_.DU%0*O@KU3'J$_R"4\,3>KI) HC#)!Q;MU1SKA?+SMN34AD^3FX1.,-\_0 M6RK"(K4>[A)[^&RAOK]7FTP58=;E$G9FKF/=F#*LF2=#LO8M7)KJ[\EN3>E[ M?@QQECW@N GGF;FK"L-_5T6+@&SO)7W&\LJ?P2S9/]&^!U>7:L5MI+_[+Z>7 MF&X4F@.N7Y;H649?K_W9F7C>^RKZ;NOY9RL6_XCO5-X";?>/19>,"0_7$%4W M)\\'9OTLM7@N:J6?B1W^+?M1=PI=1<#NVY+%_*+&S(+K.>PH(M>\$+&2BV\M M>&G,]NCMZ<,2MB(%^N&%0*@% C.3]KO*H/ >#KY69 G%-3[GHOYXW?>O8)XA>%=;@XCS;I,J:9A40&>R/#XBO'&($XZRBK M^Z\'4%BG)9_&$;O%L:<,3+_EF6J'R+H)Q-YM.+C#O**,+$.L6P8YL2(;#JM1 MDQOJ:/'2IILOYB9QGT)K[17JR+=2:0Y%1R20D''PV! MYHH$KO-TX^^E+A AJJG[K3RUZP-\=4!YWQS%XK&%S!V/V;KG^LAZ5VD>VNMI MS6#_$ A:C,Z^@N[NZKO.LLY5M\*^M\8UDC,4;:SEN0>M(E:A &?A?X@G;D)V MO3HP_::5]Q8X"][C&3M ?&P5/2(TG"[^^NC U:.:;RW!7-1X =7R($*.01$( MQJ$8L/WU0A52>Z"#-B\?L]'^3\4VU*KN<%VT&M?_Z1TW/UE HFU0N UA0B#U M6)M']$Q"2+7-KK]C\[ ME&-AH<<[T7](&MP:SN 0!TY L'-$Q\>5R9\;XZN^' -UVWZR M__[H]%Q@RM:,59AIW7575ST-C.,ZFP?@BW6F[A;H2K6>*/M/D.^8?(17:0H! M9^%GR-TM_+^E7RTCI%I'''T6:K,FC6+^9PNVI!3:+#A*#B^S,26_&Q<:TY3= M JCG,QV[Y&ZW0$$;X ]^FBB?I%1@HTA0^1BCD^**,Q^;%5!]@(%B;RVQ;TL. M0;HR1Z@K(Y-5BC/GS0SM1[T20,B/VAUO%YUF=4!XMI'C$N+H1"67P5V/C[8U M;]%;+45/\9$EA!WT9$5-:Q'!L^Q\FTFIEE$_W\ZX:??R>,\<8&YM;G%:2R1U M=C(6T?_<,C$R\T+&+JQNV(>K/X@07_R""1+G2_C@4G4H&%(A*JU@TYNP!<1> M6 V0J#(=\I*^,&G^ENY7NB,[WS!+D)9N:3?8#/_V%$DCAZ[R#"$8]7S5)Z)N MN9,)!G>QN\MG0@J2+KHVR% M_!KRC*%28=&R9HF@$\=*LORP7PX;[3)44N4(YQD*JS-$^!%.-31ET>Q;&N;< M>[GU584&1K,;^<)3'K,6$X=7!^/8H:-B-)CD5C9YR%B#O/ MNT?\3*2=]5/SUU.>N); "<=ZFO0AG)I:O2:)TV?\WC*I8BD%A50(7 .C]$;: M'$2*] 3**;A/8[\IZ0D=U*N+E0C+LC*?.Q(+\,0)LO6\\^=IC5^V^(L;4D:H M]J@5;2($\-;]Q$>"C7)"J4K*ND)P7U8D2JY[2\=;4E:)3OE66T_?K;K2G7O4 MP;4O^6CJ9!:59^=K2[:,5%$K-0##6T/\L(Y*4I[5QEEH,F3>3(UGHM#'W'#] MN=,_53R]"Z)?JJM,\-9D]-#/*M+KW.4I9+-^'G[P*72>/?.V7#3-."66)^R0 M%.H!4\6P.N7E7VL"_F9I%2XE<^I!GKW]9%%6V378KQ-E2O/ASVMRC:'S"P$) M.[O),5$O&[]XA[;M1#5_GO8+9!5TG!W'.[&M8PR.?,29B@\XC#,Z3VP:"^P( MX8FDQX1U*S"LY(#E6V5,:09VHD:5VX" ..9-,&@] "!SKQOJ=WPF4Q(11EZ MH=]/^K3._]C&]B-WI.M)URBQ[5B1)GM-,=GW;N^5@'&"I-<3AI'1LA>V7PFKT(%$_>!8 M-L/E$]1&6JC\X,(J3]#^=ZA3 G/\.D;>)JG9:OX$OV]&2<*:8M-4VIHV]!OX MG7],N96-MR=P^7I@[9C22)O$^1,-G[O1\9.8(U*B2*:=(H/ X'O5F5!D1 M/ X*%M64^D8H&.KJGO#DK5K+J.11]G3 ;-UF/9TYOCN8WQT603U$U-#S9OD8 MP3\X83[@1TCGQG8SOK";''<+I#N_S:"RGA]PY:+N%RW-DMX-CG^[,=)N7O7= MUJ*XE\U:]^KD[Q^E2CZU+T$;$73H(+8WU\ZL^75ANKF<#5,?/-B3ZOD,^UBM ;_OKG[O \Y%X'H6W PXJ/;8>_3FO7JY.[9;S; > M[D(HB21M4',CP:X## ]MD]/SPUU<)CKI: M2YIR9KNX^>Z];AD2$ES*.U\TJUD\ .?J-5SAL#$0"[NBFG"6( U!>_6[WZZ[6?4)R:>.R+ MS!=.\J_5M5I)(=?CA@TD]I$TJTW/\=#.9WGD]0/U;?)TOSMV=[S9HYBX_#U> M$K>W!8T$BWIEA?U)O7:YZ8(L7]&-@QS^GD^Q..8L#X)MPG*N5ML_>(&[X)_59V72L)S@F2CA^ISOG,USN.'IU4L5.RBG[U*Y<' M?I\A,]YP:D<*<[P]-827N[+6<@#MOQ*MW2KY)CO7699>RPY"!9F[WZU=Q_-I M\,N;'VS1+W\"89%R*\I+JRY%6+BQ>Y0EW-Z$[I>DLW0=!%+.'VTJ3;=5Z;0X M8 L9B?&_7_,68Z$/;,]6JS*;:4EN5L8T^:ML*X=GSCEW[\DL/QJR]L3?2471 M'%BF%SNMJ4WPN2JD'[,0F-P"X/TPR5\\F8A2D[V/?%0+^#]4OGU78[#6ZV%K MDY:E/4V:2 ,[SNG)?U6DG''^:RDIK*&<0!_U7]?2=]<(E.XZ,0V]H#RU(NT# M>_XN8QH;%,?BY-&=A89!MPW?"7WJPK8%J\0D%19R&NA@5L( :1Q)*""H^,]' M_]'(UT1N@4N>J]GK"+>.$S'$:-.([(W:3?TM8/7>XYIX$^MS(903HQ:9P.$I M9*C:7QW$%K_Q7L:A*7?Z8'_LO:!U2QS3RA])FX4V4-^LOMF%^X]\__C%8B7% M;>@P1=[ [ ->/IS&^5;Z8\- M;%R2#6ZP,?IG2HXJ,_CKT)>!]7'#"T1R;DK+6%!N:K%UV/G1%OK#@B86FXS42Y$"8TGA81K> M.N> A8*K5P22@;1-!LJ)2=>B\JB:K1X)4R6JU)TZQT7"+^1+F%IHISL;M^!< M+T?:W]\""&%%2K*W=DF&W<([JX)KL$)(306@FL#":Z-NTMP"QX\N$.0;AP" M! \N3;! X^Z-P^1]Y_^_F8,YF)E=ZSZJ6K7JJOVL7?=^GA>>UP OE(%*0 2 M,@" ]'< GI< <@!,='0,=#1,# P,+"Q,;%P2/%P<'%Q*(F("$EHJ>CI:*AH: M!A8>=@8F+F8:&H[7+[GX^(6$A.C9Q:1$!21Y!(4$_MD$"0L+"Q<'EP(/CT* MD891X/\YGG\ "#$!HX!R%"0F #(A$@HATO-/ /W?0:DZ=L@B:N89B89.14U!2L;*Q<[Q\)20L\EI43%SNG3Q005%)64M; M1U=/W\#0W,+2RMK&UL[-W$1D5'1,_F_X__(1?B7"QD5%045XQ\N)&2O?Q80HJ(Q\J,3R6I@F+H0 M,PF$8)*\32JH[\%B%M0\)35SG<(F8Q%:9SW[!^U?LO\[L-#_+[+_@/TOKD4 M+@K2W^2A$ )D -<7TRV== ?JW=VMS0%RZF@\CF8$6^QI$&^-G( U19F0VLG+ M:GL9@H7%<;90^Q2H9[YI3IJ B*OB@QJI4G$FMT01SOMYQ^UFB,KH,%F Y+)( ML7.1<]R:A7GP;U1SB(S"G)/'$8%6V-$!N'Q)S")7&ZQCVBF N8NT&+0BW.ZR M/B:R=5)LLT)W4]!BX8ISN"N=/YX=L+[$_7;;=MLOW&?]A2)S:KD%!L,+Z;*+ M2M=HR08!23$X 61O^H J?#GI+27X:1QXPCWK_\M9\().H9ZNJ5GPS\K^7?/" ME<&GA-5ISE@/CA*!GL1?F,,8-B>@^47YFM(2J0=INS'Q5XKM3T!L/OS5S$'? M.H_U=NJE]NSHO,W'$AVV>*M7#:\N-3$W>5?%[A9&:]$3CCP0D)F=U! M;@LZ5"&"@8JX27]QHGZI?US]@0G@=<0J/W+'H69%YA5]M1@KC[L9'N=)]W1Y M6[1@U'"L<\9Z6%$ 6ET89=MP<=0:=?")&2_"6 C3/O:W ',[LJ2HX;!6)Q>? M90?S?W]YZWW;0)T@X18S'ROW_:DO4AF85L.T:"9MR]6NR!F!8-"Q?: O-N(] M8<=EO!^6\. =L]7ILLLJO;OGC;[NWO?,Z$6C);&T&;YM< M,9LW>;^M6<_.N]K#8%G 6"_;SL'%;\%M(QB+2FHY?(. U^XGK]F*:,_<7S?7PSGQQ2I^X6TTOW-)@E=W2 M !,P&/_U$@7EO/!RT);T\AE TE^^_PPP2YA[@/J8&\B.XUIC. \"UC;RYHAO M>G'\;AV.:[)>%K7:2#\I8'7JYSA3,Q#XSD*F'2X/6JU#MN/>;_UBT]HZ<2SF M?:.JX+<^QJN>![?/!D\;<=DSHS,S4KL^-66P(N@[S?,S?OK&N4ZP>!:_=^3: M$+D8P0:RTAPQ6$NWCJG@=WJ5V8NG>O$-2Y4M%42ZI-*S#%4%%]'$#U[59-?A M[5TGKZCPYG9M%7EQ,E(;RK3H3<8H20J;LN=VUF)E>1_3W):QSE"K[5'V7,XLCQZH*J3R"+9?@'_X[OHE=7=6\J>WM_ MT<3J(PV+G4<&=N=J6Z3O9K(A1!7.=.OI$J6&NZ"V^F$=606M^;I8 HT#'BS>)[T M"P21V"%$^GZU1GBF+TX'\0')AXF@,"F7D%GB&Y@+ D>R_IZ+TC]=6O^V$29C MJ&%I)QAK ]0S?5S8"I#.FW4;_/YW\\^\5Q:GG5M]$U:\A+_!6[8D!<8_>."B M>.-2@C%#,U=^58]N:M:SVS'LD%8\DOK*K>DW(DF32?OB&ZOM&K:.W%WC#%&R M<3ZFZ,L!XIK4G)KU%=!(AR!G'W.LR\OBXG:4V&.?E:[N"M N='M\?W%5U-VZ M\WR>M,X;=@(M31I)(M_!SBB)7*;!NP0UKT6[0C62]YW+0/?R1PE%+BXX MPDV+,2PCP0]1W;PH=;)7Y1-13G5FF!Z"1/(!UO=KY<7%LO0-S M^H1@3&860HH-*5OT?"LFF_Z2EOA@M'=RJ/B9%&43=#TC]SD6634K744>>+ES M'9JJU7T.YU&IZ< HFGRMD_?Y/^^J/7775N2WA:YU>W6TT97,'8"8YL&8X_;- M9"(AS0'I>$O-UJ.4$W7SC1 "/(./(\E;WSXE4F.F>;9UO;9X ?2FN2HNH2L7 M^^B:4,/=WUD6V05C$1B_/JVN'L) .U!T^=UYV.QFT1&R!@9EK610H9/U,A$@CG(O@-:E^[K!WSA M&0*0:FD]M_#(?O&FT,6I,BSG\V&:Z;8!4EIS76W=^VJ*9-F#!/'9C,725A?K MFJI]#1 D-TXSM?G-A^NW(+Q=S#68@P/76$NSR'\E8W]'@-UG2O%9CR>Z2^]";-("Z.8OW')C*@A\;9 MS3A +V%@GETA89'$G5HGG0\[47;W5;^<[:&F*AJ)AJ*I/(DZTK\B[?5_U,E-!C8Y^&QD 20 )"WG]5:^#3L4WD#@WWY07T?_Q9#U]?]\\HR\Y MKFM$<%+W\2D?Y>;X>&"=M.8J5RCQJS41T"7I!-*M/,\7&H@HU72S7YGTS#Y[ M+=N=:98Z9O7+&??@_,F\1*'B0>=T*WSG-X//%59(#UG2,>7=]0/G\):62Q7( M9M[0'&?4)H]SK/CA^//6CT,^I.LQ=VGJ[DC5J2M:Z8%IPJH_XG*V?&HYF=): M$X5Q68=Y9,F13?&/^*)FE95Y(R60WWF1IAN/XO>J >\6]M4-&%AK6: 2 %H? MTKI2[T2%>>^9*TQVESD4T\@'U NC[1)38NGPM2K!IWBJZNNOSX \_@W ,Z#C M&3 $$X;'\^#I7IBDL)SUEM,R&C,@N*^?3;2@K MFZC,*G,WA#WA:O1 E%L(3!%6M>]H'KO=\PZ%Z_?1+I[%GLB33NN<)#.UK)=3 MU)44G6=/4J313G&N\PH5]#.1T;1@MM,[-^C1QA\20VB!?04Q!8N0NA%FG(6' M9J?L'8S>ME(QCR'2T+8+%H :$MUBMA2UD76U%&NOZCN^\=.$NA4LHQ-/Z5AD M.7".],N-O:[@P$1PK0NTTID&VBEX)>ZXRLO=8( M[_@/@_G^H?Y3L#8=?O(T+QU&*S81DK-.=B%A7A 7+.CTOH]@/0AWT,D98XG= M2=S?TWPJ",DD8(,7W2[+I-XER!HL-9\KD6'J=#T'.F%$R:$#!NR6Z0KF*G[T ML'AU69PF5M(X>^!^CV@\131O2(0_ Y2ZAR&Z^TST7)PW*?D#'1L_\UB? ='" MB>'NA=-?+8A6C :39XQ26L('C?@/CE3@:F0'73P1>/@SP.3%>1'C],DBP=P. MP =Q[.,.M-,[&=PE:'-UH?2WI S%NUB/ ;6Y^C\0Y3B;6MN3J4#@M=NTA)?D M^<2[U@PMR!2$U52RL=J-Y_#[LJMK@+,])&Q])^**EW3,TM::R;;-P<_1\N)K MIK7CV[ EF\W[K"T'X4R+,Q4[C8*L8R7:H\*GAYI> IA,N*_\5G4;0<1AAV#9 M+Y#^'$UUBM>HF]#@7IX,]A*Y6!E%&5AF??P]KMG&2Q#P5X (_+H/X0MM+%X= M?1UY6')>".E,[ MSFEPE"_W&DUT";,XPKU]ZJJ'>#S2_K"6:^)C=UR7PM!1#C)]4^?YDBU^ZCU]ZN\D;%#OUR26<94@2^RE*A>97J,TR0:\H!_]1F> MWI$-)X^WR'O8I;(C7UM9P+^JH=*LXM&V-&RR5!A$]1$T*7CF7DH#]]5Y@OW?>PIB%29]E.B*VIYK# MKZ]Z[O1*N*1$DK7V"G:XC/6A6ZH+QW0D9R2"]EDHV7BN)'RKAK_X6!C<:*H> MLCK\?B T5[T/E&.$;Y,W%5=[?(0G^^%CO@?&HL\XN M"X@ZV1NO-;GU\N)9IUYHF:L82A)VGF?8P8&!T.EID?C @@2GR[LF%V*YX_^=)0Q#A80%%1_HT ?[*FN@-KP]J)A//GEP(RK5O+I&'1 ME4%_W?'\,YR^I/V[Q"AAG&;[C+'.W+9WO\Q#?/V0!U-N]$KWJ2S3JQSF88AZ MH]Z@4/FA:LQ FAOEU8_\[OI8!Y%M(WQ?*LE'/D>_#Y(?&CZ@8J[9J 1GMU7ID]X M_H/@I&S"22-?=LQS9JN,WE9TJ=DMIKI$UV0$__&/W+0D-?R(VF0&?%1=>^&! M^ZI!EF'Q 8 UZ'+,65%',=S]POCKRLC&SRQK_],_WJ%=U QW[37.M&\Z;OB[R.AN6]W<*8'[-_+QHP M="9=\QB]7O4H%S_USM/B&4"X%EC:$H2_2Y6>428)U;VCZZ8=)GH_?O,E99@Z M0:\V@!,$'QE9!;2?]TA8QC7/>#T#*NN;,CNPJ@P7QTBGIH5%XN642.(=?MWT M#)XVB]5FV59Z&1M\KMZIDQ/LO^-.*"H5.<%>V?4Z(QH5(H/K6USI\B.N!TGR M6 M^J@;!TEL!BMT %GIF9BFV!ABSM_XK_NE6SY\*8SA /RWRGG-DNVIHPK!#9(. ME0%8--J7ZACC=#1=8>_F-V.>%GF/%#?/"U[70'$\CT^6DQ;TBH'ST*P8%=S( M?FGV-#GF31^1$;^S\X'NBIH38F\OO%([U8[_8[3_Y(F3BO<>V,Y\! MF$^U>^O=A&-,%M7) Z62?A8TPKY*U2HS03_6,GBHQ ^]Q#O/;5^_)M=+9FN% MBWY)GR!K\Y8"T*+X!A%6?L2DTH%!.'JD0: JF=*CY2!!HX#Q0O!ERV%)&QZ) M1=QE6[R\^Y=!T0L"Z!?GII;D:?/X^,M&27KGM<@X;7V#EZV0- ME[P'1Y4\;3R)AHG&_C\-$@6=0$M]6*]O\"R2#6M4?Y.'E13@>LR;2XLU+Y%Q:!27\$)NZ$R8B.MT>B0XGMC\Z0DZ9-UL MJ4&8NAC47V+S4\.6S=J",/T%J8 %="658S37A+13\O2OXA_A:EI&)0DE\,1P M/7OKBC[$&.W2UL)OC>//CS-/PW6&IW\?-:$)HH7'*M46(H[UR=.S?"!ME:2\ M[W+[?5VE<$%X$>5'4.T6/9%WW1/AD9IJPSU2;MW//-!C 9,.1WN4V8IH->(F M;--HGPSF*SS6A/!UW4<68WT_$C\P-^CL+?T,,&R%YV-U_S4S/"='9#UPF(OQ M\YZ@>/1M*:5Y=FC8N!PB> ?#=._\'"3%#UH\[LAZM3"(\&II[\H! M+?V((W=;JQ^E P"(LWKG_0F\JNS-#:D&DRI RT $,1=+K')%R7% M5?7&Z?(SP%Q_MT]3SMR):=QHB4!293N3=NKBW%&27M8P"Q;& .O0*]N_'ECU M ZEX11ZFR+5(P[',W)90XGPGT<#4<+;L"I$"UB$RW?0! C8#:C93+C_8UH#L MH*.]Q4WS&SSD9X ]B%CRK0VBRXMQ&&_PC7,0L]'1,Z#OH#U72Z,#,M\UDM&L M/FZJ*(I#8XE,PR?:,T&QZ:O#21\^LQ O.#*O0S?PYQ!N>)$V=B:O$@B M&&KM8;SP [4"T3-HN*/6&RW3B)>!Z 6+>W1&G#2Z05_Z__CC5R&IT_I$8ZQ4 MK5HY6,.EIVFL)OH, "Y7LD4!#T)70D,)YH.9SH)BMMINU,#5/=0@6E6F$?1A M>9=DP4N*:EKZ]BXEACE=@2?U5^S:.9GIW^4\Q6BL?CCGI>Q+=UIQHZ'&-5EG' M\P/;C[8U^;MI719R/B66V-7F%HX4U#Q1K[0E?1FO+V<^\]WI4'*RMZRT>4N M@T>V0#7S6O< M#Z1N2[8.)8#X$'V(1)=:8 A;2C(4O/DH'V6M?H9?\;H\6X-9)A3>)N6F& F: M9O^>'_[%$M3&MTEX*;P-%2_9^7QBU33'M?:U@L4G^H+>PQ'>^--LYP._BN7L M$EY8O#5;\Z%3D)DWYW%I!O>];Q)+JXRFB]% VOJ>/_>&WJP#%1P'+[MK[.7M M=\5;$$:9D5=MB:1:A0DHFM2LH9DSOSV2/E^M1JUT]V*?)_D[IX.^8/OCGL39 MU56M-_Q Z;Q_]7ZO;-_AM&FMM;3F8O9P=M,J_8NO)LQTX#^^[5^IKRR7Y!;# M! *&OK0' ,8 A?JC3/K%TX\!7<=@USN_SPWXYKPT)C;-Q^B3KN@$)O8?9")@Y&3T]M/" M]IPW0R-KX)6C/!=C42=3EI(CKD=\[+0#B?*W![,_3L$CFYW1FVOAU?]OO&%:8)U8213U:-Z445UM%PE;0"3^YKG##?9/MK&W)$&;8R[V3ES\+7&4HP*;<@S/&.'*ZT M(H?#,0E%VFN-I!RLT0W Z#?D(#(,J%''K8_Y].89$+S=+O7J[!G0N!8+G.$_ M!UPHB@"I*:2/Q@Q3W@.UI"%!.QP[H]Q;/[LC@P9: F("+X/PR/_,7C+'Y>AQ M5<.RVD7;Z:.H^D/4CJ@]6B-%N9O-/7:2>NJ4&[HBGN;80QKB%ZXP)N]A4N7[ M"/8/R:LCOR:($[E$HS!3\\3SNL,E>GO2M_?T'G7[V1^/%D(\BH;M>%!&" MY7B2+D[(G M ,5AQJB^TA7>T[O7KKM90UMK%K\[G@'-E.N#+0\'66<'^@4 MVNJ@U77/B=Z1\'V FER#-/,TF;?B^49[2)]RB?>P":4:K?S[5PKV*Y0]YY/9 S#8V+K$HX31-&SP.]>CBV#FC\II0H8E[]W0$9\]L/%7>TR[F("_-(CHJ3UE;:>AIT%D*X0JZB<8-^**XSZ6H&- M7BI$FO/YKG@]QT-J:O"?/$R9$M>YTA/OJB>12P4=2J"ALNYC@(&U[FQ)^U<@ MH@:,UW:L;2:@1/MC;_"B\CJ0$WIZG(L \36+ASU,?Y=AFM:2K96?8>@+SWW!^FQ:6 BDFJ]BW M]@^%(+[CZHN>-.5]#M3IQA2GCY#%E)YC&%+GSZ3_-GB[9T!5\NW[O52+1):$ M?WN03S1+5EU@CD_M2?OM)9L.LZ%11X6"A6?2^\8W*8PCXA$8"S#B&G_%YID3 M54A\00>V\X738O =_LZ!YDV[%IBZUW->0_KW,:'9D&3EQK;,S%FEN$QD#=.I M=(GG-ZG^L>H6,S%YP!KV0:[NSN'&X@[Y=Q7\ Y4IZB?ZLP!H,T-S,AFTE?E5 M24/=I?#X@^YL+M=ATT\SU$/++_CKO@2_GM(R7*SNG!!614[G"FZX;@,;A<-- M1#(3%=5_:.V*]&>Y>) ;TJ!+3 B"ENW6><:FO0FWD5R]PV7+5K^>+..^W0RJ M\=QG ".G1,Y ZU];%0+ >/0.*WX_*MM6\P2U#C:(.4PY:F!>GMO]IF%E^I_O"/VPE:+ISKH MW2K[T(Y^1CO9"T1BAPD(Y$]JDR]R965$$X0[[! 4]?!U9"H\M.]4&]SEA"P) M[R4!ZX'UWWJ9PG5H :2I?.XYV=^+@ (I8,+?!J ]1-*2X<_ZGV%("K?;U1KR M7B5@_+]MQ1OV;!-T4U72GT1S$;B1Y,R"'&;*](TY/E[8TDSP!*.^[&C MDIKKKTP&'5KPJ.XF!IN:@B2& 5$CM[@[J,RK8Z&O&8>^N0GH1+8O".1-DQX. MD#=49FN*Z5LR#8P_NC/[\FL-!(W;JZC.\C+..K&W3!]#EQV8A]\NAX3!2$G, M637/#;O/.8E%1\ABI[BE+^@LB/VY9PP2[R*B^#&^$30]I8TJ;=I1A<]G@VDR M8HE%YN,%#!3.7(S?^_)&06C1FH2;8WJ'M[\,2^ZX-5F. LK% ]G:$O&]3?KZ M=",XU4VLGP$@B<>=9P#2D8X6WE&6DXJ'I.TT(IX&/Z/RSY[>,0+Z?H_%3 S\ MCHOL+3J*.8V(J#2DKF37\.HI6SI;R&7O3G*:_,50^V:\TOCLA&P>T%?O&SP= M&D$[J, VQJR\U)XJ5,,THP YYV9>Q%H^'N1E]JT_MGLDT7NKQ,D,TO_;0W_Z MCVU0]]4E7ZI55\%M6,^3VU0&;*+W:)UHB,=09U"(.3A.&8!KY*@5L?D51U\Z M^]69O)RV@Q-#;; 5/<'&?1B>+A..:=*+M(.'90O3A0W/ "@.4L/9:IP# #&+\59-OV"O2Q6AN!%O^%:+:*M$ MS4@0;S75S!Y)TSW$\+^9)[ F+X-NE_H^Y:D"VXZO;L$J,EGU8 -T@3[FK#HG M_(UM8#]IPN*>P7NKV2W]JL!32V>!#U)2][-J=<,LKTY!_OU%]V,]NJ('!W(_ MM8YY+!RG]'>TTG%B@Z>4&(D57B0Z]QX;G=J W0EL\UH*%%>.@->Q@7[Y7D7 M+?55X5LX:&B 1F9 Q8F4\9FRBQ]N\]62Y-(->IZ%U MN+Y09\NS[=YFK^+^>62;_F614_ZV0\Z3#K.MYZ8B^A6^]D--?(FO^4R)<6%R M"7[/$>MRV6,V(.47]?"?;3!WC[_'W9R?,9,PE'!Y6V%!JPY G"?%J1DCE6"B?VX%>>4&OP IVOV+3+G/]/27N*9@3,N[*T?P] MX?MELAP#-V5T*!3EY:$=R11W$>/G ME&3:CZSWY3\>.95C/J12=X8.]5/I3"#B4IHJR91D?,+Z!N/ G 11BD&95&\OR&S)Y"ZN+"E(/YS(>WZA]L%? MF6#GD<7_\Y.@# *>>E?^5GD>7UL!>>@+L*'K%CEX+,[B;DI3P[#$-/_Y]_\ M4$L#!!0 ( #B"?U2CV$\_66D *%R 8 979A>"TR,#(Q,3(S,7@R M,&8P-#0N:G!GM+MU6!W/LBX\N+N[!W<)+DFP$#2XAD#PA2^"!;0^]W[/_7H][Q^]>J:G:[JKZJWNFI?YES4 \Z.4K!0 M!0T 4*\_X&41> \@PL,CP,,A(B @("$A(J/BHJ&BH* 28>-@X)(14Y"3$9.2 M4M*RT5-2L]"0DC*\963AX.3AX:&@%Q#AYQ)FX^;A^JL3*"0D)%045$(T-$(N M*E(JKO_K\M(!8"%"'4+5P$!1 ]!84#!84"_= ,7K..&@_E: OQ47$'S_05)*6D;VXV=5 M-74-32UM(^-O)J9FYA8.CF G9Q=7-S__@,"@X)#0V+CXA,2D'\DI6=DYN7GY M!85%5=4UM77U#8U-G5W=/;U]_0.#DU/3,[-S\PN0]8W-K>V=W;W]@_.+RZOK MF]N[^S]_R04%P$#]H_RW_%XA35M-UA&F>1 +%$/WHJ72)CTB/E>DF561 M"OY'B[$N&TS1]G6&MBE;^M:JF%)K6K1F=\8.C]O^WR-F%J)84[5>6+]++"B7 M2=R=?)FUU+3QENQU8.V7"QUMD.;-!&>S"\Q[UN76TK]E =3JRA&#P-HX_#75 MZ%2X:9VY628&Q_EH]KG4ZL>0&A&^;AE3*,C \"3H^*+)&Z%PIVD,0]>ESM#F MJ=DHKS,0\YNEZT+&=P22CYOEK8Z.2@B\&^[M1\<&$FWILC25H1MJ#3$23,U9 M7YHK%_FW;LO4%]7F-N46CJSIY,1-VX-E;5I&\]:*RD<&"_7%2:]X]Z_\?:9] MKC,QF/RTST7*,CQ -GFI"\S-.74=E28-CI259%@<2^Y.>?53P/!(M*?SQU5#/0$HK44=[6"/[)FWQ= QSU* MP[2+*+[7VR4Z3H$7^NJ-'\J%H,TM#H>KG (P9(7^&[*I0_^C\HHS3YV'=Z?= MY)PN)>##W;I&0]A9C1V&X[9/X64GKKL^^HUKBYN%+D*RS9:K=2V) VV;YB3S MJ#A^JY2S:J==>O@/RFVMEJ4J!&T.=-VV^CQFNX1;&!;[-2-\4])3H*L'P@]\ M=7O8/&0!@$Y6* .0%>I[< 'II> [V6"@&5V^X%?.^)0"I(>.O #^89(O0&9M MTM,+8'">\Y_JF6B"S-S/V*P$S[ZS!K=/7KU1=S(U!G]0M+Q6KU\ 8F JJUIL MG7K":X_UVPO@-?=H]E_OY]:-"M%X?TZ+'_,VI"=IX03?<[;^8^[Y(WUZPDB^ MOR/NX@N MWW>\F!GF&[(V"/'B.PR!;@2E%ZNK#-RXA_[-$>W;MQ8=2X67-,(9C[<8PTH_F!# M=TGTMAC_=\>FCQX8L-.G%N7'?'WQIF&?3N^?AU(?3+UL@"QG,LR33WG.2-PX9.]9MJ0IT4WTQ[R/(.6,+4GS^,G MYS-?Q#K+,;ST3;GB-U(_ CUIZ%7T01=31Y21.)B&*E#$09S*<"9=K]_B76LX<%..D00//>!':]9*NKK,4Y1WYM. M9#R/V'N@GVT>4[D*$+O3>%2'@5,S,V%P>&\C7O M8;P20LJ"2X9VX,:H3EAS\E']!S"!.VO[MYAZ^&!#!V^GRP%2AQ'-LY[1T@+Y MHA%/L$O]6VUC&UQY](Y\Q^)&*7[#B_-3_0!)P.4I(\1#$H2>!E?:<]3Y:C$^ MI,]_\PF.O5N("^I8DMDR0BC5;YQ[E,WW3/LVPT;;S&I&[5,R3C>6 F7;S3XH M02=-&8[>..*68#KT:S_NP+Q0[AO*RAN^06D!,HQIX[6;3 R!J5H;+(NW@E8I M =>=O_&N&S.&O'TC!]>S;:(],H\)=XFV9GO;-^1-^E3:*VLO6\[!1/5J=2RH M\-B:NX2]YU&ZYWK7N%!;33-](3F5*9!764-$!W;I.B$!L7SN3B9J$+$6SL-1 MYNDC75E#ZT/FCZ7$,32H^)N%9$5N?]FC?\!X$C$S]ITX8FZ5FRT#U)5&F(Z' M_#GN#2JY)2(;8?*D%M6]QR^400*HRD!&;UFT.>HRV7-V':XQZM( M4W VH[]KI,-@!D^JW;@20MF$KFC2YL_XL[.6:9[FQ2D4A6H]S7=Y;[!DAMH3 M-ZD<(BVKJALC;P91&JJWQXC[DPGY#6,>]Z MC*-[^%;Y>#SS[4]TU_Y,[64B MMHT@/)Y'/=_C>J9@W&]2/%TP:3- LU=+O #"1B] FR2%J=^S2]\+X!&:& J$ M'8U[C1&^ * $(ELK-Y]B&E/?A1/L&#%1Q0+L8K7 MQV9&%KX /B!Q8@P;_-X%5)W*7E5PB1=J5TE;8E]W8AVCYTX;7,'@T=C0W4S4 MT>MX]FB*O-9TE/^C%V#B/T9D]F\C*CG]'Z[D&\>4\.7">(#.(#7'M22U* B% M+BKH@!E7_VR&J.I3:.$=,ZU7CY9JT98"VKY785&Z9I-%,CA.;OUTW-EP0;4"]L]L7O+&$[/Z+%O-D&F\O$W#:2Q793]>7:74 M,R6)G^;;=C257=G)(ZH9AU,OIF0BA]>7*YN?RT",I0S-4M45Q0]Z4/16Z M*4R?IV5.SG,NGY E"$"A6_=QH[:Q>.>Q2)Z\S4AGTJ:&A7EHN*&$MG'-0NA%>AG_( MZ'"R :0%MBP^9@4'N8<9@Y-SFZ8@CE*QJRRY.*0(:VX:%GS_5\/5A4;!2$UG6UU:G&;+=" MJ?FD0805R[>;=_J3="Y769SW:9@K^N.?%*0"1W*\"^ MI66@C08.Y'GI(M_[QVB^ %4.EQ[]" M(HX./IGAK@ET;%9DHD%>*2WR*XAH*SM_Y<9@XGAK>>^D=:%W$U\JAJE'N#EJ MELZZVL#&"BNQ5B0CDLA^12F _0(U]LZR]JRULOJL+LG*X[''*O3[1!2WSZ,F MK>DY#W!Z)^7(7BW2?B,2%'T1DBY6738;[?B5?,K3SF\RF4E&VX1J4NK#0"T ]FO " MZ-N^:@WTSPV#>SRPUY^+GR^ .,\I^@O07YWK-9MS=) MS)6(T!S5N2A$9UE.&DO'LXC0?\7^*5:G]MV[XV528TRWM91C5I:2:S$4Z7Q= M:=+$24@)SHF MZSW95<*VB7P#L=4RCIQCM%%-_QU)ZC:;ITE@#P36.^0M\ MF2Z^'<3VKL2M<7AI_VLY,J/>[XPM4V79C?7,)EDRHU+O1"6=$H;,OK!'/:H" M@*N3+L8M>5/*OS#K_XQWMDA7)0^L%E-*3;$K4'8[DEU!]8[(MNA(E*AK?MJ\ M849V:*4W[2+=A;BZU1.K=8<7OP802UN9(L/+EC&O MMT=<91#\+F)+VRWNP0](U^6"$'3!T^W M^HKB9]3QJU;LR2>>(416O-,\5&I=8^9H[BM6+,NDB M J>S2\/:[!6UDZ@^ U!S")$8LTVKR$.X*SB3N3[*7RV-F6CD0^&%V!1$DWD[ M'Q5KILMJ2?C% V\$8&I+X]6KA#L X5XZ8R5IA;;:11<0Z*0%+Y\NNV=+UJ28 M1((H0IPY*D&19E\<^VV8L'"%G)"E.C1#+F;S_6& PX2BB-NS&O-=D%2D>P&% M:HT6B.;2&G.P,41$9]Q>3/#BP290E+9V*A:+-[SM70U6%\OPX.\LEQ3=A,&, M5,PT?N%+]8SUQ IRS5AWOE!@4F=P>+&,+%R^2B(2U_6#:7IV*'!:^W,(]/ZW M=MIRZOF8#:O_<&SO8D)@[YZDUMGI8YB@QI-KUZMG0]XT/0.-Y/O8C.P4NH-L MJ9H;W-U)8BM\M[<6P^WA[2#-[!A>_TFU!&QP/23&A:D*YS4MIC[%K63$#479 MJHV^Y3SB5GVF=;E^A,E96)'.;;UO_#G8X5GD1[2U=N&.W'>7M*&(;+9".TXY M]R@,%BHD\<"!0Q@@\7[UK Y^=37/]'<.W2MT$U;'C[P%I3F52P@_N.-7&C:C M,=Z/,L!43IT\K^;KZ+LJ$F1@#VPW=+%)V7KV6HRH3VTT^,G7!I[8B&Y3JR7J M&KE[\"=/UBWCC#[/=8[[4)SM#/GL+--#;5&#>X M@%C6EH5%53M9R+]_=4B?[P$/K"MB](% UDV\P8$0 T'<"P*L]MN@]CNU9A"- M0E5[8UM=97W@R=Z.:RP'L6+AJ3AINS\8XUB,R"5O]\C9*5F'M7$.??6-^WS60T;XER3@GT M(3?EU&>22:$M.ANMZ@8$.A]Y/L3KTI6$TD@GH6P'*@\!/_B%38G*=A4G M;3RD"R1*[P)A4#'K'M 81S_0UU3=<+FAAUWOU/&4WZ-8>EU?9/QA9(!1D,+L M',8*ENQ7):(G\R[Q0A^AH=N0,P5;:^]HJ8Z0CZNEQD1UUAF'R^%(R0%=1)]] M1?T=2VS0Q56$^BS#"G_HR6%>YIEV%D=SQNV+DS@J2P*XKW"][4$1*/\Z.3FE MX"FU;^Q 5M1%/\H!-=P_M(WJ3.NWW^/DQB,/'_8-14OZZP R8VV$'PL_A2/6 M-'IRF4%?TTEQYO*^!K'N1'-[2I46#_9'$T($6RQ?J97&V[)LR3;!Q)!O'I,2 M5.EXT:UM'M4QCP*[%-I ZZNO@3<(\=I2FWD!#@=MGH"IEO]+A\>THK6@6+5Q M,DF4LLHE-?F!+#KR,.;W'PWZ-<40;>[),MW_)6+/-[,+4E<:=.@P9DIIN-3\0H'QIZN4< M-Y%_A.7_ E4-;A1WUS>4T:&:/M/C*"K:3(G)!6RY5B::"QR+MJ[%-6AY:3]> MEQ#B7T[AX@4(38F,O]#1$IE_&UU<&<(&RN8\@3$WY!"FL#@"E9U^DNP8DGL$9-OT''#47'V=36ZEZ7$CBUUQ-C,?.$OB3*.0I@KR'60^IG> MI6[+DKG/99L=[:F.Q_RA0ZA)I@WM@UWNIOU2D2W1D;$^U)6OFT9K)QW/:A -UBRO_R,%D[2S0\NMJ2? +E'J#MARYD?. M-(X3)QVMW$![^^'\0YR^'J7Q5 U M]*7F_L)2XI<7 ,?)7.; #=UOMB$-YO=^N8>: 8GN@$C3<.#%Y$S0L-+W8Z*0 M_9A+T'&,?I^5LKW(/PT5]YAYZ2JECXNEBEK%5MXN\@&0#VY'P&& M?K+*<5GES\WSP8JG .OD@B]W6,3]UU^!\!,+!3 *YK$K2&^BUVE4ACT!(M[A M.V:#ZEG#=AU#RF]-L2JD1MM.=!;+R]U-U],IH/CP1.6T^B2&[^>GV!0&GQ?S MM0V0Y[4UM?5S2UMLRQ=-#.*=-"@Q.M06Z,HV)WNO<965*/^RTB//3(K$\ED] MNRBRJ2-5Y\;)^AQXS@Q8T-U\KL<=95U=.RM3G6ZNX1\2)[0+R54:Q'^YP]]7 M7N\T*H8_RLH[ZUG=UT68=B0HS4'* M/S[V_*1UIH^[YH':A=GH_55 ,I%?ZJ]CZN0W"A?L0\GUN(9U6:GK;MK&Y'R7 M5DR0J%I7K6D-(PTB@6>W/OBJ-TEZD3\RRK\_VXI]V97"EED5ULHV:\@2QO)S M \&AH(-^"9W!"]VL2E=O](]>MIPK18+M#E4RSOB#K1B5."FX+X*^Z8SWKF7R MM(Q-&Z79.;US)AU:J<6].B.>U)1THUGLGWQO$:0GH2YMK51AQIR$5(OZ?L*X6BT.D: A<=2FB>YREB'W @2KB@BV9 U1 MOW&-= _>C)Z4I]F:=/HHY>I(B&D$L7)/1_7W_WJX>%VI?WH^?_R@^ORG3UA$IL2H'B_RF%\JCC#GNP(7Z M^E?@TFB E.G'MR3?;)__P28,UR HG+A5$N&US3N3/+V%D5@LFO3DA#(SPY@/J90O\!=LT]FJSZ8LZ\[ORM6; M\)."/_$Y+-VK?^F%=X8*CTM][)Z3!^,5N^C+6)7BGPQ#CD,A*^*^FC=G11WG M,1T"9!2^GH>F;8B#?P?:@2@X6CT@V'D\T@IFV0![NI@ZUUYU&A1M/EL3=;K,GC?T'"LE$%PY[VGO+7WQ[WXP%I0D5VU_@\Z43O4TASO.4+O4(Y+YY!XQ32[ MX70YWN=3*%B6+18K*2Z[ 4KP1BO!^XG2*[(W9*+SU4S?TJ6W<^WM1_L::>/$ M"3,@!):;E8A3&4.8KD+>5E:K:4^45HY,8:B;,[5 M9J<)GX$>LQ? S%(P"I_8#?+!3=%S.DJ92NCCAFBRY9K0@(-FW@(@V%4H7 M/[D, _,P)2\M=_ LYQ+I6X,P1XB:DO\M+?B(.4<175( HVA9L:!!8)%Q$?,/ MY>;EB/0O\QNGE-ZZV9O*=ZMFDH,,I*YF=E<#;U+L9*^-Y&G4432O'N#JJWSP MOGZ2)K?%F'X!M+-_210LL@X:Z$A@QKJ^^8S;\WR)XW<1F5P:RH3TCY!5>*IG M3I^DZ3Q4YX"GZ8GY(Z$U%:=8F=&9-&Y8*) M835FG\FG-F:(T"[$?=#P6*6N,B]G#K/NET65#GVR(%$2)_OM#U.?$S-H#.Q7^U-<_ +,Q:_^ M@O1E@/KXN%=3&JV,%V>6-V9U0/@'-GA9CAJL!(EZ5Q7?3K,,[%)B* M#PN?HIZCL.XCN1]%.^N-5_'P7O/#W7?K;J6X[8RW_0[R?" M]85>BVO8>MI,M]L7)RN-)\ _BV]LLSX6%A_F8D.HQ,2U",D\'72)*V3&6%%3<^;WVH30*[>2"._U9QU#$L^ MUB?0\JC5/(GW"V^_=1%CW&DJ/T;3>?96? UCE.=$-C!PAHR*]K'TS?.(A"_6 MY0=)?4L:^?>'D.?2Y'%/V<5> MXT@OP!F3H 71,GU]Z4D1!K;A#0F MXZVQZ@2D M3@/7QN$-_&O.\US&>O@Z#PZVX*I%OTWG20M(;]+7.B4,FG'1MHF ML,^G.1$!._X7GJ6N&,R[QT,"EY#M'E:8*FEI3K':$'^E]IR?2?2F^E%M,XV[ MDQW: E/_XU2A,?Z$:YJ(E$L)"/_V6/#G8?VXK%?)X$_6DF,OET0LBK75V_<9 M&U8/CKC3.F3)<4]^KC:;(D*?9Z[Z>OKV8B 4TJ:<6(-= M3ZW)^R358M7N39KM?F2^*W'+9-0L3&# M)797\-%AJI_IHB5Q^M5^,-#ZZ\9=D1U$)I?6-M5$BK#LUZV8J?]>LH?J_MG>VLNI9Q(( MIC^KC;IIL8#$:9=#<+Q1?[HBD'I:^I\_IYFDI,W^ MB_UP0=, C<'XRR6: >7BWKUZ5,[X4F7@;%$7>XSXIRPVGFFD4QR:BV:W1SWA MO?A%\,"8LG[KJSH-IV.UUYSAW4+ P1N+>GT MLR] #75#/(GC)='YP)##K4/,1=3'QDWV$&U%WUI/;H5VWQTM]LCW[S*#YX3L M[5UW*\HRE&=JCJGA,E3:ZFM"?E"W7,#"18DCG8H3,.2H:R@-2JAP(0K JHS_ MM64)I[/X,\QLIO0HI_FKK?I;-4JWQVX-SI(%Q1(+8L_I9\)D".13I?G&@"XI M1NO8B-^=AI$6)+ YSUR#[V:NWJZ+]W>WQ?+#=XH(_I7GO9D_:'73-CL-,ML3 M993AZ<;F1E1>P$*IX"M/^K=]%*DO15K! /B--WZHL4H?ETW(S-R,@OG5OVO< M5S])7*C?>H\\A44!^T!-/77B"\HD:\I;6DN M+NR0"%_5=]!,:CY1%C82Z9G]!ZIIKI-:MZ;'A_JDSRWR4LLL-5M:Z2C95%\/ M<;/HES(]VCD)#WL V74]OB'9\_Q0D..#)@C4N5 1B8O M %FJ779I'V MWJ,6*;QCAK8[;?A:^^;<)!FI[\][KV:DYYI[K>^CGA$0YG@O MBOVP&++:+7]23#PIC(T9I/-'M%L60J\YG>"I/RD>L1BF;'U&DG;T?8&2PW*Y MF=?N&ZM_D&>$QO -#O#'+$T+]SD4Z5&VN%O\YH@ 4]QI0B9[Z[Y?Y E#=]F] MB6YPF1PU&AJ2G8CJ"ADJ8@EV4R-XW2CF&XHD^N]P NOKE,*'YJO7TBU*4BBZ M]-1':A8E&UH:Q?@=[!AB[*8#A3$&4Y05]3[>V*3,"B*VT2U;F,7LI9,U3;/) M= 4OWIHMWXIRB G.5_OU:B=2J#1536:)&-88"$J\ ##6"&MHIN9MW&=!@5?S M/#JN\C5.EMN(3M56?;KINR('4QX*9QU$@OX?D7HU8\:V9=OZD_##E[W6E^KG M*L-_ 2@?J?X+,@0GS,I']&SP#=2O/?(#RFJO9W_ MOL)9/T(S?-/G]7&QG+/]_#9(1[?6='8B-.JZ4EM&7:S/_%!'["SU3J9"2UA) M*TK(?BCF"D6%'K?I9[Y*._$+,"\<9D!CFKR3K'!D2M@K>ON]-N?6Z?SI?M.@ M&/GR\V8&HE?G)ZQR-O)%&VX>!:4VNSDRSI4FPD?G-9?Y(HLZ">\!:+ZQBVQQ M"Q031U.56AKD[:<8%'7R*!9EBY3P:/-=CTF$>RP)<5PVC*?+E/?G.)T2W_4L M5D7:7CDOC-0L\ZE M?KTIM"FH;;V4*JS;H!+F5T&$Y,<+VZO.V7QE"PB'OGK'Y@O%'I/VL_EXC+_X MKY,,O(B-M*]Z*%US!#?G.7'%TJ26;YQ.G%7A*N?Q!S*1/.1> .JR\A= _[/7 M'GS:^NI_F#F\OK'-M^UGGMNM*VFN;W[Q:*CG'^''RN$(SU5TQ-\-L> _171J6,0 M^PD;Z_,(^X\H)**M+[X8I*%VY\?>L"_ -\N_=<&<=M;>*T>!)?<]XI?%^%.B M?)&A3W[_[BF(@G'S5R;&A\KJ,,6*^BIOCL 5WI"WI&E%'%Q>R)6ZY8_TB117 M*'->9QKL=\JO!'<[Z FZ=O41;^@9%VI&^5_;55Y)L:OAZ[MH=7X!X.Q?@ ! MSGD3Q5V10&+]IC8A)\GF5%I^ M6W=I%=-QHDR"XH;L_&O&H?YTR>:"4D2W.GMHRX>FR,J<,1N^^J]A;W[CF$\Q M.CVL,L#L\"/X[6M#1AS'RY8QE!J:ZFO$;[G[D.-JB @9Z*=2?F!*27^\*">S M_*-?;VA6;E3@!<9O#/4\$HMBX\-=!WH]\\1KH?^RJB>$3Y\0AM)*^< MV,-S^Z9FTEMY'FP:E[*>"1\2;%@6ZQP24_KKJ@/QJNI3&<1:'(;< MKZZ+"\L7[RUWS.T0^D;J"'"Z')!'8 M90!,3/@CG>'3V MQYMR*)^WTMC5!Z/NG2MB/^Q.Q'^9]/JW22S]QR3*CLZD)4]/:/[Q"CZN)20V M.^8E]*U;KH8(@\;)_1UW2W$1Y__R<27R;SO=%.**ERV )B8/AV M$/,#ANSM5NKV,M'?OYMQ'"HGL52_N8V@]6?J0Q%7P^V[&*J,0KO$&Q4D/M12 M8F0I]A9ACAU_Q'L3LV%>^[8-1X>QP5(3UEU;3*2K;6=LI'_31\_!FL%IC8]_ M[-.X4'74F=I-DJMK&5U.U0#M7.!9SNP(%N(:4TSS*4S%I9YS N'ND&*_!N\Z M.]J!&UEOMD/1 =^?@)$C7^D&3609NU1&NF (/ !#^&CIKE*II_BIL=+U6P@; MM5GR.J@L,QP;PT@\TJO#WCS.Y;LFST-\2^3DA8N^(?D,>TLES#1:AVD;LT8W M ;ZV5]!IF?66C@L^/AK#IP3:+U_090<(\3+63I$P$"&K.G17=QI['4\@"(AC; M&L+,O\2"'"4K$]=-')@'/6H6B/&MCB4'(-D5(^\WV='$0GERL1-_J4^A<5JW?,I*2$N]XJ!7MU<<- M9,L62,.-9FQ;)/&'5T2^TBC*S5\B0?J6V>,UO1..)&2<9>1;D,Y*HM0O;?#< MFL^49VZ6<[/%EDS5ILAK[+N6P7-+V598)UBNLZZ7CC M].-690';$#U]?=W:X0MI\NXE-54XW514AE.M/WW^UR0_2ZT/96>2%!NF,WWA MHB7C,-_U!/\FC9X?LP!6)GGER!SDPI2KAB38Q%=^:F+*4/J-^R(^,B=F=)-3 M-$S3GZM8R#YE9/:(Y Y@Q1(M#MG$W^Y'"L;IT0?QY$\XHLCSO;?^A%+]1,X5 M+.6)1"^:DZX@[Z#=WA5<&^:IS\A+E/GP;:'97QS07!S \NYX6N-0M*Z!FI<& M6[Y)3;I7K3/S7UPR0I2R]^0OHV;'=?G.:OJ,;7:RG;[XV5_K-RI?R:A'$NCB MBT/]#NE&LPBSXO/HA-75_1O+J.J.2IY8L >J\1Q&T2,[Z-WH+,\TE>RO]./Z M%A+?G-.6!"(2/9>N[_%0RZLK"^8ICG.W5=)H)8QMLH2V<'9N&L%7)&A.\"POH>97_#FOZBW"4J815:?[SY3ED]3=M>CS_>I,M;VMK6U;HGCNF@NO"QJ9-U!]X"!_N>C?$6E3)%B4&@(U&&Y0[ M=?F/]V"=OJBCCA#6G"H'XH%4S E,9UHKT2OY#L,>P.U#10]70")/C$0_>F;X MU-Z_[901TDC"PBIAZ*+7)I=:IH@&D#4?U&-U5+7UUS-:NZ<"M@@.XVJ+:>]F M1]TUK=^HQAXH,N&)]U SW59RT;2S_%ZH244@='%MGR M"6+BQ:>*S7J+X+Q_7;41Q)!.:/I .BI:6Z0OLM;M$6;W6%YC#'_EG6FMD$[0 MG)T$P2>3CC"$V;&I,M"%& 60,@RL.>$5BY]T PP= -2\RH0D]+\DI#"486R0 M-8T4W=F=E(!11CCI,HZ5%VC#7:.0HH/$W+R%!IE[CW@QR.;;(G(WE>N#+'*J MEG1"\/F7VF9-*1_[^4QIC<:O\UYYBW^ $#S$)!N+\I M8[22B$^C@A8?:YJT$HRY:!0&@_0HT4V'(N35TNZEON?",MY M;J@VS/Q4K=>)H&2BK8 B3##^HN,-6(%H*+$Q/O:-UV80F4/4:OTK+::&.^&T MWE0-J%_.*S963IDLX;S&:>YX>%LW*1G=='S5 ZS#W;DMY=8W#$5:VXZ.M*C> MF(QCRJE35M=>%"M#EE:T;0&FZ;#-Z7H"2I!F@DLL*$)C@'W8X7K'6\0B=%U8 MHO N<:H':U'KJ082YC)2X3OP+7)'M^Z<.=7U"]"*>.!V549\L-DGN)-(HE37 M;FX4N(>6>(S#7-LX> 8O[@$G?+DTCM"DK _>>'M.5E>:UQ:#UUEM?O[ADH7< M-%';K,N8G(O ;G>RFD+G_(J[!TJNWF7+[+B_4J7>7T'U?B1J.8H%&K'7(<," MN YE'@*UO-^X"U5T)B_8$9KON6[:SS96)K#]\$D@&C3O,%;FKLXYXV$#J^%\ M:%Y$=[UERW9=TZ]2S [W,=5T"P&F88#,# :R5XX?>M@[Y$"WH7- (!CTXS+G MLPX6J7NI!HF[YW&73<%M*<6Q#9ENYZ&YR%W]A\98DL*:&5E31FRN8BI"W7XM M:1B:RTP,S:QB\ZHQT21SWD&KAEA<-I)R_%&7&:JY!'>KK;7CAL8>RMZ\35P;SED)H=,9: MYXYA=\TA""/X)R0(X:;YJN=LE>SAO,SN9 P"==Y]=FC=V!1\2@O0:HK-+$!: M6>/RW&2S#?(>VB]SK,6QK63GZGO;K1[XS=@8Z^W/BZN3WLQWTITQ>_@AO+,+ MU^IA@[%;:2/;?@E1WZ%LLV'LMC::+/Y^C-!H0.R2I8>."*I98,W02![OLK$E ML0IKAL4G913V5H0-K=Z(PM79X^L//:^=KJ+5;5BT:5F38P>+NS_C[:9(!7B6 MND"8;3 A!O)52ZW=L8JWI!<=7!ZE,!E-03ND5T29Z%44&.9M'"FLEH(1)5P? MHYP-!7&Q1PB6K=XR2&S:QS2@7R\6!0 , 'IG/"KJWP^^OUD*'K=%!I>2UFNH M^'ZMJ8?*C6=G436MV"G77UDTG[5?7AZ._HU]XNS@#>=*UIW4QGK./^-HB83; M[Y$7N&.".1KS%EH7;;R)$_VK,'^?&V >]8R3IGTU;_&V'?+'Z1=<]Z=J83C0 MCTUXOG4]*/ HEZW@3JNE?!5(M)/9M#%Q.TX@1>E7:EQJ6B;&Y,\\S=:T'"^+ M'WKZ1RB\$Q'*N6(2XPX=QQK_8Q8,5)54;.]$_Z^)W^KJ1+#DF5.@X_4:'\KZ M0'[#<$.:B'=%4>(('V-#@:C^L#&<>_-=N'E:R%O0J%V&HD7L_SZOYK^@Q !S M3\7B?'',U)4N,=^D5TXG8$!)$4[/C0OK-T4"2%F<]#:@A<]1R'SEN'2KM:$A M=GT8RRJ2^FZP%UWFS92>[E@J:$>P5N2QU+0 M9ZN(@%!P52@LN4$W@3W+4/H\Y>S,&$C8,A-L#=%)LB8(X!_[K&L:)"QDM[&0 M-0N.#]43WF)5O2F,J MOZ+=A[XNV6F Y(KF#X6;G_1$Z96E#=L;5Y,O63K)ML8_S3J3*#VZ45$?U"/^ MAT2;_P?0(-IY;-J.[$"!H_YD7^ 0<;\6#Y:",?9+Q2CS M%.6?9)CEGU#&A5-3]@:.X!##<"V)&525\%11 00+\'\YR?C_ WB#!^G44V = M3P?INH846:H*MDG-&)KHAR2L .$*YJDE-1'+'HS"TMFT;&V1*SAC7_,O#5B? MNE$YZ\>P<>G3I8519\4"'JF,-GBF>)\4973D?I2F0W;P?4I79&,E0KZK((Y. M>JUI9B)YL*\=*^C(LO V.]5,:M%X578Y.@TP/,PK#]*@6H?'OC4EU<@! 5 M:ES%Q^?_1GDB?1N(1%G,F>U/4DR*V6*3*+YY:@MY+ :-"N[2FH;[B)-=XWH' M G[1KKFO-G)G]_PVX+BV_<@5;)9X.8(94UO'$I1%T#N^TCT[$IAK7I@S9DX% M#C3Q&7C7 .:GB>:^WA?'W\OFE5.=.7+4D6R:IL?LG*25"*;?^8HG39X3"C1+ M2=]"B\6!#/,F+H5L:&1H!8 M%3N8 ?PAA807;D8MX:? 8@T'T2@ZXMJ?V8BYL!HY5F@T:_=A\\MH;..(G &! MH\STOHM,M$%FG*YGU@EAE6J^"!=K=18"&\9QA]0O%41[;NK+ *[Z]^PR<\BG MV8I5W6#C9A--"17G!)61<2<@)>G3]#%O!-^J4L4/>4M;GXUHZ+>,IWXC__B< MZY]0O+2JM0!Z4)O&M'YHL_)QN!J113W7_4#GJYK(/1'C!W,7"L0VMA/<)5^A M:'ZIJ74O5;AT@W1FVJLY<^X2=>R:"8C .29\5IX\JK7\5M]>+[NAH87[]JPJ M-1#6'E$T'FJ7'.?,H_Y6L:AV<'%>-\$5?\");@W!K< MD/2_)&3]SSFYS"3=H@R3CYPVI)#X*H9H [?O, >25G/QC[*)!XEPH,S7&\NAQKK7;I31+,M;./M#F/;9 M=?#*1:B&3(8O$0TXD0JT[&B[4!M]WBCF*3S,@'J1&+L"W MOE6:L@);?K8L6/CM;"WS1F 3O9'LS/S&R:G)L\2ISNE<9[&7(^:#CYIT!2[4 M3K2N)7%9$'FD,)Y(]L+>Y>(0V#$4678;I.H=?K(DK<_?8ZQCKD\Y9^7!_(T@ MB.TH=[PD%T>^@#KKTPZV+R_1$+R(FYW^E"3@2M!E@ZJ/$K;'Z_GF45,N][>Y MV$U1Q,K774>[+R] (7"NG^UN#1_E8&-#^ (H[05G/\4">/:AP%8+2OX!L5<7 M*U.GF?:<4FA_W@ \LAC_V+Z^.;K?AMB=9#GK$8^\TZ+N U-9+IAW8L&Q4TE7 MJKG-A#F5@R92:*Y%69R<*O_.P8 Q]^T\+XPE>3:85FD$Z;T-B4X"HYPRD,U1T],>3& M6=KZJ@^07LJ%F:B(5_\)&J1V/AQG?9=#%\TG 7,R HZ3OM\U!]3 M@3"*D,B:H1P>>FVQQF$XR ]8J/_G22&$68])8%[D^BQ*D'W[NY^N2B$L8?Q MY2=5S\M=&\,XF(3(.>0NNB96Y^P-$!>R9 -\",Q'+IG(Z:1GS]6YAY#6DU^E M ^X@,*795[-I+^3P5'1.7PY^$;=9EE4<\M5>N2S9?/%Q63NZ*EF\>5<8)OPA M!D(ENW#K_A/F\<,8Q4'CO'6W/,1ALF 5W,H\)Q4^%Q!"'S# MRD6# S>DVLKFJ?RV>K.3#Y$K&BLJ')RIX6KM:"YQ!C/?J4OK"JU86',F\(]9 ML>V88B=116TYYOEI(/5&=Y[K>\S%@NU>1\0*22Q.?U%S3Q9^7^P2UR.'$'I2TAMG"N*!7E#J.!E/_/H>YB)6 MQ(WXD#@_"2K*>+$*:S@^$2?_\3IZA*7E)=;Y;36Q1[UD[K9L5>E#0MU])?$"_,@RY_J*@M]$5SY MFG6-30V!:/Q6:-%[LN8N&R%IT@FJ0=I0_B_,)6J(OU2!S"]0$&_A/NV*V:#N5B&9 MH)ZF;KZ4< *"3\%&3Q/O.(HOGE;%+P#"4O,K9I*T[V,Z,:0KD ]GW;^#H0Q(JH2N\#2Z]7&FA!584VZ/ ML10MAK\TU"9G);Q%Y4 5PII60B J]M#U9'K4EOO%-69C@SLW+M+/1>5P2X., M:(\@(HWW3@S?DG7#9<*FC+;.!EO>FDJ):QP%=$A(83#;-'=GM)X%>OQ1=AQ+ MJ (OYYX?KA#LS!"'L+.;>ET:)5:SH[I+HL^G1AFE'*.W[*!-X.-H@W%@ ,'/.[%, M"#HZYYWIDMOJ23WZ=$54EOBOWPI=O@"AQ%9-G69U^/6([,:-3KX05:=(E0+- M:M 6J%=B/T[?1]XR16,8S&9&00Z+B1PU[\<\+OJR)!^-9BO;LQU/X(!?J M^;K)TT[)EHRTNHLE5%+D?1XA3[8YR5H_28XT 0+,'P9N,>G?K5(OTRU*]-'/ MCKCE>=QX4V2%K!/\/1J72.B?8:$>&6"BSTZC>'72WNV7@R!_D+ZX_P!9L5[R M0)F:U9%_MP8$-EN=B#%"0-?WY8:1HW\FW?DD4YC[/>I( M?LXGJ9EA-#\LSK MG36 M\:K.R>()LKNUXPFJ1+IX&T/XCJ(JA)'W_D=J"RVP(V?I:AH=0RJC%WP%\Z8Q M"LWE5OY0D>:=N904Q[KQ;)G]BSN^0L;W[>C]N0 M._(MQ<>+=O]3IZ;ILS$0+ .(:#IX_=U:/R+GO6G\T%N#&S.8JCN?3;@SKR"( MRP?%@E$B5NJ$NL(ON2'TXU 9WQ'%W)^YAN7GMWC S"4&Y^+$*L5\-;F. MTX,9@*XP_LL)(XF?WIR&?Q0-4++J&C.C^Q!$L^\V#3GO-8ES7T,[F>,/*(H>V+DOAJ.OZ4K)?5 MY%Y/#J'\8B_+#^,MB#QXIO'GKTR3>6NO)S@&F**_O<*J,@^Y+(CN@(U=X:(T MCREZP/WG.?BL%\"_ONL%N,*O?0':]F L0GO^]9_76O,_M>MK9?ERTT[2FK4D M.GB+$=M2>5/Z8KQCCCDG._7W4,X:R3D0K'D#L;*^V($L(-"DM)MNB*%I:DF8 MPY=:4?GR1D#%T9L1DHXC2$A^_6L?O M!2 DS'?T"1JN'ZRBN<,WO'G^6\(:/\LSAF(.&6YJJR5KJ3Y0A"L*^S$KGO-- MPXS&VV&@K*S%;R.P-&_))7;N8_M$B8F[2:#,B0W=O.A713'&I_[%(($#2UMK3$=N%_]?:547&LR]I-T*"!X!X\P=V#) 0+$MP]08;!G< "6X! B0$ M"TY@<-<08 8)KL'=(0RNPR7[WGU/SC[[W&^=/]^/^C']KC7=J_NM>IZGNJJZ MDUAGZ_'38-D"VJ_.FCIT;ZKEQE\_-/=)"K>)"=9AZU='9Y9Y$I@HTG7"4,L& ME!C*W !QVYVM/Z<@&RE;H*1!R(H/PO'R)..")4 LY5>8Z$9^#4^7C[\!7KSR MM%[:',5-70"<@ UV@PB@^_9.^\\C(8+<5[@)?\P_^,S'23LLP:]1$2%Y65BV7B!0WLX"5]//)RG=E3KW@C^=&B;/=?A3) M$:LK_)9-0%'6J:@>=?O4J#R)=G+0T;;\B(J1-K2PE',?&#WR/4N"MT_Y;E9Z M.Y]O,49,./:] =@OQ=8'9E?.U=; V[68(J>=WJ'M1' 3 M3<_U/4J-:'[GM['E/\D)5F\ 6H_CT]-, MU?^[M$M\UT^U=-@GG][78E+OE2 M;XH.@2*XKT/6;X!!C0"Q+[_2_F6PX(AG$?JU0AA\?FK-XG87!#U)$8!*T8;4 M(Z'2S*M"FTRTJ98W!]G_;B'O_,5YEBGGZZ_8(7!Z'^O]+SXU66[34J(61%T* M.!1^C:W4E-\C34?7FD*F)%DP;,WXB_PJHS\'92QL)TB?&Y<.;A04<#+5)^%- MJ#,165V%LR!B2]#5I(/^6@#=5 D39EF&"7LT5+4PA:J&3#VP$0@C+ZJ\!19M M41BQ&<(DWPBCF;8P[ZSV16O"TU'W(IQ+DJI CGS4KNTU]H?FT1UOFGS4,7X& M.I3^E*#(5RXLSOIIR>X]=.X@;4%<@0C20E6W:9@KE/?:<@ZQ\3J^D"(9B@(S[ ;K MAMRFZZV3?-FLO#LL=%ZNGE#G^8?&25.;Q"US&KM#E3@-QKW?82;U#,-^6'F& M*5):X>C0^_C55MJ$>S?FW((UEOKF6& M0$OFY.O,MD-K?Q!^ XQ%\0#+/R\C@.FL[*!G*6AQ65X?0Y0>\[7 J;7>_YX, M0\&;5DARK5*BE*$B1K.Z'R-2RG^F?4]Y^P?N?1EG@0=[EF)B!@S=C>^HB0S1 MTJ4HCV@\=G>J?,,M*YL:+1HE&IDQ3+QZ5F+20-_]"?4$6^H+$M:#0^[?PYAE M--&[WXK_PY]_NLAG$--QN7%7"2YKZP958E>NQM^DT.)VKE:<;.Q"S5/3#' V M>G 66>)7SFU1'P1R)WQR(AAZ1^,DFO?]_4."#Y8TO";0PDU*CTI[SF-Q*M^N M)QAW)"?II4?P S6.M MA86X#%B#BK#"2)47+8T0;&Z8U67GW;-[I)+][#C_Y'*9^%_^II@?^]3#R51N MM?_3>^H8)YEB_=T:KW1V7\M52^5$]=C%ZR5=.:.CLI[7YD3A,<]9S'<" G0/ M&5*XQ#;F.G[;Z,0T+A4GM"V93_07SY8@_Y+*R>MRJ,K3@WWF%]5;W,, =/R6! +ZO0U@>: M5&E5Z\%_UYRI1+H-S1U->XJR)NJ/6U@A('4\U7H-:44&));J4Y)=[)HB6^=O M &DE8.*O%*GF<^6ET/9WO_"5EENU22XJH1OS6CC"$Z'U,&]+)Y#3?IC".>>< MSB:,A$,8G_#W-MYR)5/JQV%@6+GYX MM$3#52("C<9JBD,CJL+W"!)>46BE=:HMN?[L!-RT_LB7GK%?.X9#=H2ED$&) M8[KL"Z7'+N+BD*FV=A@KT!G=L<$QS"T M\.VA)?+3Y@T 0-FIXGS-P1[$F>G,[QYN"0/.%T.W>$-+1G?UBR0L=K@O&U=LID2;_@$;$M-8%]>HU>43/%* MLG\([N@#W9_0#57?AS9G3557C2NO=I-7^;K!5(=1\1?N.*G>+8E9?CK"M9IN M&,EFY1M(GOC1&\*QRG\D$0$L-HDO]VGL(5=+H=&S334_7=&;WZ+GO>78)851 MG#>@IHN/Y[_YV5K5I+_4F%$Q:[ 7/^JM^V+'.:PQ8I/#39+[>5-C8WE9T-S2 M;NT DPW*NXN,[^-"O^]Y 931H=]>)&@;*ZO6C%6=%SN,O":*XL'$W,(S*#:\ MIA&:,18J+.C@Z9>=)9%;+MMA,[!'3R-[6C$H@'AI$57NP*5E==CV9-7KY .I\M3MCH$K-["1/5L1#0.=9,+)1]P8H/;U% M=Z+J;4;9&\#X5UWUY0VP<5>:\N@O>7U7NGM"&9@F&&/9PZ/O9YW9*SY3A;SX MZ&]&E2K.>6@@I(L-'SD',D]>LM,??W"_-8K(JBG MX$/7!&DR?^:MHIP-GM[K:M=\9:;&!S&36=VN#S#M'!T(9=I8!W5)N",E%$'0 M N0$F>=@V&=2IUV;DGM3 M$\@!5RWV\1;GO%]=8&+SGPJU8&:,P7K" E6&E$"PG7U_*G'KV0GPI]ZS90CO7\!K *M?GPKM7- M'2[XHKCIV52'3XP M-MAT'Z>U0,O=?DZ!9-"9,=A[@: !\.O71Q7[&J";P"& MDX\W@$D<9./.^T_M.49^]6;WO1T[T!)A(EO\BI\A7:SX+^V'+L\ M%M\_J5RB K&Y14L;/.KJ=?Y(P1G3;FZ M*.G!F#E=9-<9>]=7MP>H#Z<"Q.;O;GKZ"(<4'UUNOJW\1DY$7:>NEZ@.3PB0 M[CZ"?EF[NK.FAK99XOAX7%\_*D.X-UF*M>_P=:MGNE=)? #V:A7=.6V3(?(X M'QE>DE ,VV-T"6#6KA/[W\G+]G6UBTH>O!S0BK@)\F%\"EAJN^ MB,>>G21?MU\5YEN[84HM&/,*#& ;H,>ESK#5@6@53_,(\S%NWDLPG$Y'SQP3@C&1(T[']OJ;K@5+/DJ MMUX$BEVG>8!W*P%B)I!^MZ( )?D&""]NIC*MB0'K"DT%SKY>CWR(_UAKN]/= M_JX&2AO#:-KT MJ&%@?^_+\G9&<8W4UOB@IZ\+%5,25(!HOQ5C6--PY_PI.QR.H:?G&,95H6IS4D(TA>RB_F\FU(AY]J)@-JB*'EVC::JOEI]#@*/AE^[ M.JYJ:OT#$;7"6<\7ST,L)8A):TRKE?X=LE?]NX>Z_*&KV@1;6U?Y@O*:? M(/]3/K_TC;GK))&R4(]U(%T>\+QB'P3UMK#4?)G8Y_L4E],6R.%HZ\C!5XGZ MYG*<@C&/8%&:JA77'KJPGTKF44NV2].OEN#NNLYA7]P6!0Y,9&65/,#3W6^- M/.8T[#B8,O'[M..:V_LUKI" ($$J,51TW=,DJ/8U"77YV1,U_?3%#'/1.BW= M-LO M\S2,!Z4S8A4+TT9,C+7:*X99:^>PSHC"NR:!;4EE(M!3/8(?G:P=M*O=XMW&FBVC$=FZ5*@$0I^2X"K6A/,&\!^Y 9X.8FK^ M1FDP7LZ'N151Y5?7-6FE 1R!>HD#C"(D.A 2F[PY=>X0);KS5\@,I83;1Q47 M:G(;*=_=(E1NX?&UDB3CD\:6.)IQILO"T82O2+?AQ@I4LO86UJ&E_;F/5',! MO6!RQE[_1OEJT),E,*7W4I#X"I]2VST2\_I8F:YMK2:\PKS\1679N 8J=]+= MQGIU#/EJ/03W13,W\IO.+?LBP1/8@8U%-_SAY=E_>CE(1V7B*IK2\=K7""*R MB37&Q,9T1!*^>!FV4C<:)/3\5BXAKIC8D(EUWL7&& +ZQQI?4 QAT4YB;-HB M5]V9N;W6?KTI$UJ72QE7& 55)>>H]C1'>^R(H/L MC,61,DD9QYU21X0RS+^K-E&IL-97MZ%&/?*-&_FL-+W0\".1Y.]4^&MH /Y= MEOK8X-- 0=L=B[HQVF_*WEP<*78);J2,4H)AT6XI M3;Q]^>OI8O8TOBV=;2EU M<8+;1<.A_CV=GQQG6?O@DJX1)P;/L8!13KQ!EJAM@AX][@>[5>;7MJG'% M!YE4]GMJ\UMBJ"F;2%K!:R&F,2E6=Y)_85+&R0J:4\<4MP8!>S-K=G'B1O.@Y_E!M,Z4,YZG<4LI] MLG:HY[<6KO%J=C^-_BV-YUP)W@&\?A4.3.Z,(E?;DY\/7[\_//%N?';]<3K] M;, .\"/6D1PO]!?TMN?@>)#1$\SLF;0 /XT$ &Q(HS3)E?9+LQ;*,19?0S/D MD_A=RG618RC(EYTMH@\/VB DXA8M<]7I!"%B''-LHG/B-B^OB.!O]6YZ->/D M;V1/L6WXF))R+#;4'KJ[:^^PJ(#4[T2TOQF@8U4JT>YUGE9. S_QOHTPPG3' M?:V)+T8$V1L_73:*3ROLKM8JS)"O':)BSB*[X+."/H=("0>I[4^01W'$5[_F MEHPG_P^X5Q4)M[<><-I"CC?)D 'L2@'TS3= +$[LQ73,[8^+ZM_!(W/&880%#ZO(*G^%O]X$7-MLQN^*4TIA0MU!$MP4KO,_9C5 MQS 'G_AZOLWOGQY+C"6W#Q"W:#18:Z&K@Z#:6NE#,P^Z"#/-R!VD1&8/7\_[ MIGO_>F7P)PNX_F<6T/JO+ "5ZE>\B/S?> $5K]+G6)-7[WD1B&9%R\[_3ZN? M#9+I$+OK >\ M^EUTC];UR.3!H_[?@DQF?-]OO(ZD=,^\JCP%%-Y!&"S5Q(%!8&\==:&; !<7K]V4-23)V%X(@!FRE#B@FI+;7I*Z)$\N-7C97ZLV!DF_U0WUUT,/E M>8$6I=*+G"VEY2FH*4Z1,1>GTD 'F?"+C^;3'2K4$<./TF6/VB3Q '?!:/"M M+@OY_&O^#V1#0Z?/TA#2M5@ F4BENR!^CY*&P%2M&+VB\ZEU/9=%Y\L.1<5% M.;X8'P^WM,W=)!W7<7$,$C@G+V.N[(<8="*D @5:"?4E0+BDIWBL*:\(4>M. M9[=3Q^8)SC2?[U^G5:D;=DS<^VQ:98_2[S,V/U.-?+*A;'U[>I-;&69R<@/T M*PTWW7HG5>S%VGQ/I?T-L (:@VS/S9]W&^C^@^5@Y?]B.55_LIQ<_99?Q,;Z M3V)CH(6"_O/*RP@RP8)\5F1C>L!MF_%'5'C4][>'V5!E_R69NKR,-MR6;;N3 MC)#-L!&'IK\*F[G'QZ-%Y!$7+T9YY+/69)HS;6IH:"=,.0:+NT[I8VL(*'A$ M#J9/PGR3GK:!,H<6K]]$D:\LN#XU._;I>Z\0BF5P+Z Z!%-8)XE<="3;\JF- M8*EN!CF6]R=S.\1])L#\7_[2D('?C=M 4C2]56$7ERC2]"YHV,5G 25N)-\N M%DD(QE+S%!G>?5MK7RK^MNU=$08:DIX."C@C:1 GN>X0EZG@^OJ:I-D]LZ!O M,TV#P6E9D^U2PM*N<)\$9035E%>&:6MR^\59T#'T.Y/MCN(/VI&XZ93=_U;L M#?^MV#=KU9ALWSS8'EA2A&(#JS? HG H,H#V-D*V@2;PS!'6'<-G<,VRY+:) M@TE9JNX8'(_[^:?*ZU%T(W/-(1' ?BO%ZV=G@2R)A,-7_ 4;TR]IP1WO'+N8 MT%_$!<;+N1F8=D!(.80VOWAAZMFBF:DPW;M>AZL32*MXT#+X\>O41;8+)SN" M75V(UJBY)-JH0AXH+J1CR!M13\A)TRHNE(8_?M32.CK2T4(Q2C0G=-U65>:B MOKXGY(.8:Y0Z4UF\9:288:W[!L>C+Z2I.9,C.BAK"ETN,,,D&I.CX-&2E<'2 M^<9D&U/QON-CCBXL?>%S;FZ(%J?&2%RB,%49,> 4VSK 8I!Q=')[2)Z(^B7M MRDJGI7PIHY8Y+%0:@6'>%&$]FU]VKK4R89AM&[?1P)G^D3B6R:.<0^GG6 !Y M=]$8@RCD]PN6A9 6I\RF36W0TA]DA6@YGB4+N73RWBZG[&YDXILB[WM!-E"6 MZ*Y(FY]@=K!3Y7TT&ZK>?$Y$GGLWOWQRX8[6Y8&4V(:[L4G[TW+0K-(F)W0T MF.M\RP? 9+I^5/+&W!9,L[J;.%07JEDG_/D ^ZHG>Q5NSW:U@7I? Q%D;.OI M@=B@?7#('#SDFL^S4G@GPWI99+$BB'50XDD]H[;(2$8!R<20-#DE)&)IE#N[ MVIC.(* [8\Y(GX\!D:YW!+WXA^?@^\(:Y/KK%^LY=A:)9KS+N\DO%=_@%F,] M^,I$&'54S!V*I)R0D/(6LR-LTGG%P!![^6)/2Q3<$XQ09\$>LQ M5OR\==="H1%DBX9&37.I.N,O4C2JCOG>"T<-@:NC>QL]BZX_X?A] (_1Q]4J M/>A8U2J3:-4<3!U?^[@X3[FI\MILW$W#D2M]2^5$PVD'H']]+4(R.R1-;7P2 MNQQYJ>G(59Z%QE&:6)$@JH,K%3NJR[RL%CI_3T*E:#,Y/>X#-]M._:% V/XE$D4O$Q?8 #J.8W$V;$D<]) MN&^Q;1D<7/#T93R[+OJLN1%=\PAF/A2\@41#O I?!$$(#$$IF@;2BV,Y52[G M!*V79S#0E_WT^OSM\829Z2DJFB=>E,&IA14VN5_I1+:\4#'K.MT$4+JO8^$9 M1V2#K?L8:DBN(I;HY;>CKYHI8>%KO91/VW?X++'U8I=O )L)D!S@9' \$5/% MB7&JY:?V)!%LP4=,ZG)G6C4L"N_]AV][L,>0DV@5YM"8U?!EL*5L^YW\:PS5&V!?;+L@$U]H M0 G1E_B>- Y$21&#-2[(^9+%"0/#'V*7Y=CD(J'30':2%-I<'+W^Z424-V!1 M:!G2 JH>+5T>$=B.["9XO["VZ]QMQP'0\G0_EB MFY@;K!U[I*G-Z[L$-V^UG%K($7Q8 M0(3#*FB*+*I&KI'_ 7/X;-)YA6M"O+)V'WFJLYTY!(%4U6- MMFB=%05;/GF?\A+=O1]GKL]!O16&:]H*[P/Z.P(PF0 ^>=9 $Q!&QI>SY8ZL MS?3=*F_5\\=#;R]9\&7A;QI$$U97G&283HA1\#,'_)E14E*>S9H7!E^IK.PPUD6M MI>8L9]+7B@=1Y$@T-5M4Q%73-Z>8#P83#ZVPBB<7/6D_2JBCU>IZG.CL.KL+ M.'VKFSG@4>=S$GU\O#)1"ED&6SS!3W!<^9@R96,UH_ C8W:66V^:PFO%:"%N M0K#)'1.!C(^TE-"A+*8:/GS6>KWB$ H4=XFVD3]J'V^(Q?/RH2.P53>\B]?9 MTU'>Z\[*36^T<'\T,!5W_4X I\V4^=!1UT[?[NS:]R50O7"7O)DJIFJB_Z]D M8FY=""IYBE94UY+ S%<'RT$"376[E.J82(O3AN@>PVGYZ&$A)ZE'!_/W9K;2 M&7TOH>(ZD*I-LIH)(8^:KH0G LPAWJ87H9-_':>MY7QN=B.23%<7\9UO7#8_+3VS*H_F2.'GB/H5U^OA\#U%Z0!E3Z@+^<>G?3#+\T[2- M?XVNM'_9W))F5AOU,JTUN?XD$V.K=CO/-IG,BE' 1HFQ3HVW_%N0;\+74N;1 MZF97..5[=0/]F30A*T*UO#WI(1%[,2."IK>OBZG=OL)9D@W&'![3@S3/_(JA MV4ESMD13HKU!6)=(NQ,\\IZZ#3V4 37%_8F0A4&!LQ?SN\)+)!&@'\043#A# MRI;,\C*IJ2C21#8FU%6#.J\B#".+/G;Q&\\^/L\!S&7L<0-$2,I_N83D4BMA MR9O%PBIQ.I]7-\D3^.-'R<]J(^"*#=7&#KI/<(79 M8,+HY=4?G#[5 _&B)*J29,J(I6CM[-&JZ?A6JU%SWG-3VQ=!0PKD][[2"A.\ MI@2^WUY?J7MOE[N*QM+:TZ61AZ%_MEPQM>8244:3XTF>C?;2KJTAUR@T- M9=^U$04K+!M_R70#L-UXX(YH3M\"&:)E&=@6IG:>(TDH[P+J=:>ZIH+Y\X(9M6+, M3FM4DVJ2PP8'+%TR5^6?%\6XQM\U $81JY%V2.:1J9[QG^H?[?6GJ#QY)1N2 MT%DC9&7#A9VK,CZ@&@N'7$DY95B.5_]@3C86RGJ(JMP@H@C;C1#1<.*/6?JT MX(AGY 61K5'N[=UTF)L33*'8BQKJ6'"ME,0 _9O!9G]:N?L\X>3&B>''.=]P MJTL)TI-)6ZMDBJG,C"9,B?&8SR2C%WX=.KH,4YOOPO+8J!D]F-4,#LFK<'8A M'44DR%!GLP,,Y(\X_&E;JQ>719&>6\P#SET4>+\:HSS:-1 F17C].60:M3:T M4UM+7J$_UFMG,[BM\4B^E;61KU-(%HT)S/+U*E08BF.18A''$Q.YJ&DHKF2X M:DP;RH.P8G@D]709,>E'IUK*H6?C!^/#C2>3I2IQP5 MT>%,MH'RH%N?+M,D+*@^97R$YTONBZ =PJ& RN(U-@V!2M =#="')<+F@222 MCS),W"5#J2@) >B@7WGC*-E"I@"@FR6IO$DS6ZW4RW]9K:8)I&_5I@O3+G,M MA[M)8AT)H*Q=S(>9_(3-.Y8WI%_ .,N"@R:KQC-7Z!Y2K;J_CVYQP#*1\_2G MW&\.2>,=;RT'5_49;-$D$QK4LV5[[%CNK>.NUT+>8'W]G1$UW5M+.B3$LQZT6GZ MQ=U+69OB#V$7#7/3MCOCM_Q?SW[/@0+JL*0AX]P4BHGF7SWD52F-P-WU MM28I']_A-NVO\N9"X[?UI/EHVF1VP-NUV24X:6/ )":8C?[T4NO2JC&>M_KE M)QO<2Q_/G6 M4KQFX7I!7O6:_Z>8HM_G:X+KJ^;DC(4XNO<8$! M9.,!_$>&Z BU:/3T4JZBASR\A[EW*$:=3"@2Z+8..ABC:!708D#38[)LVN2 M&78TIUF,-ZN"I7X.(!$H;0U_GIY/P@D03[A'4\P&904IWP\ ]FS'Y/6'H<=] MM-O/&_BPN"QYZZ-[R@:X]LLP-(LGO=3N#BLI;]IIB8T) M37SS(WS/[Q0/=X0()+^25;"\S%*I0P\UV/Q_CHO^'X,C",+L7TOEJ;B[NZ-Q M9*+SWZ_B=PI&Q!/74G0"-K-S!I.&@GVKWX7VN>>2K+&RM]1(5@W2\[DC)%SS M^G*4S$C2_*#O/K$_)YTT J,0J&K9=75ONQE!C\2 M^D'6DTXCG^D5<8*F]7V<34(7^^X0$&R00TO%_Q; M;3 5]DU-3'H"2IDS(D\[?';MG+KPJGCH/VF64E#0YN@ 1)E.,M%+/#O2N MMP1_10UGI! O<[T8=XA=C%;N,'C?D)3K>D?Z5.=4]03!GCOR#"5&CZE_10? MT$QU05D+H-@_5&G*T&P>VQ$D-E1T4&Q(89,)U5IFT,+\D&H-0H')DVRAR$8! MP,EG[1>R7X)?#*($*O\?D/UWIB,57KVZOQ9WLE8+"AK.80O\AM<_2?5AORAA M=! CK>^[1U+%S'>%"&:NE8<6P,J^J."*+F75K=[096Y) U=@:2_&K, JI7=: M>>Y;)E"'*4Q-/FIG3&G--['[69KW.=?(SF5NQOB#(*?0'M'0-+#PKJ_1WE?] MJCCS)YW!T2<_L9[^M:6EJ6&L5W7T?4S.P7R$@^4T-G=B0Z_$K1>W'Z#7?MAY MAM/W("[1E_[5NMF.N$[GOWY\X/\TH]:H*].7BWX2X=(I:]KG9CKJG7>GC# 6 MRU/C-O5I61'/A4\',MN]_7)AR>'@QSF1;P^Q]PX\W]3?[5D,:UM!U? R9D:8 M1'KG>:4,XVD,CXV3EZQ6>W7VDZV)&UG=\YKA31]%>;-(A]T:EAGZHD68M!RV M0W&GNFE?-1^$]0GI)798MB^N6_0$5V<_AP<6!WN#'9:)3AN _UZ.2 9;CB@X MFOA1P0[F+[3_3WI%LR)Z$"SYGMEG/@=(6&=IB7FLF\?V6&QI(6HA:D(,&TH+ MPP1&\$O<($*.4W[.Y@9^^V>)+1O6;5/XO!E&NNAY6P;P<#KM_99*\T)92%58 M71(O,2('%S5,O_)K&VQ!S'?\M9 U;)R3FI:A,>A2(ZI"G("/JCJ6KN5 :C4 MER>?/JWIT 2:;]MM!>4/F[MPBS(V>K3++U9@# N@'[P2S??RH,@>67[G_9UB M3M_@F0CYBR2F!7Q@AUWG/^R(+95$2'7PYZM8"D9#5QHL[.[BC>WPW&5P[Y:7 M>5/'8^^Q3D[<,!&9,]HD(QQ:U7LN<)[YT?PP*TQ1_+O3)"'/#:!!EN0:.$D9 MVCY'/L;MX%X@V+IS?@2657!8RE#]$.P]%,A5U#\[K96N1K\,!1[/?SNA%6YL MG6 :=2"=VI,+[:X)AEYU9<.[>9R3P.T_S2PS!3?>_R=N]3_F#0GG<"^]=S9P M*7; :JB Y:M'V,,11XU1IQ@ZFR)$O^/ .R):JIX5P-LDM=A(1]#.*$,-]G9Z M8CR+]4VP/? TC!KW^.LRT\5XWW^Z[]>CFN2Y0]T*LICI' #-#3T0WP=OF<32<][Z[F(H9KD@L'H:54ZXT-,/$\_$PD8/0H<1%$- M85L(?A N*T\9+$<#H/[G>YH-]>;'?P%02P,$% @ .()_5/&AGZ,",0 MQ#@ !@ !E=F%X+3(P,C$Q,C,Q>#(P9C T-2YJ<&>]>F58'%NV=N$.01IW M" [!79/@@<8U0 )!.SB$Q@D)$-P22"!8",&=QMTEN#=NP5V#?IUSSYD[<^ZY M@H2%A86+@TN.AT?.ST#-P/]O7W?- "$FDAA2 M-@H2(X!,B(1"B'37#M AYHF&]-L%_'XA(:.@HJ%C8&)AXR#^ +L'(".AH""C MHJ"AH:(B1GT1XP J(1H1 Y\<.K'F&%I96UC:^?J MYO[* ^KI]>9M4'#(N]"PN/CW'Q(2/WY*^I+Y->M;=DYN7EEY!:RRJKJFMK6M MO:.SJ[NG=V1T;'QBQ&:4M6$P" M6@<@#$Z@;!7*E;R^+1J+Y;Y@^W?(-Q"#<9%A2(GW0'N*=ZSDB M-=ZN(!\F.D8>'(HYB"@P1C2:8 \1! ( 3[%R>J0Y:8 /?]FNB12&@\T\Y_U-NBJU@C MQ894OB4L7)#O[.F(98NJPOQ!G\<3F]_K2C?I9Y?NJ#T,Y^;YBW$?$6<<59>S M^+Z\KD_WJ]W;VZTYS.6;:6?UAX5S+"J"F?H'"1^6'$FA#^V931^?4WX*,SF/ZZ;PR19E^!B5 MKI^K3[R2]I-"DO .>.YZ!WQYD8X/#V-+1_Y7K!0&)K6A9/NX9=20516W29VQ M2J'@I!(H\0+9+["BV)%^=,>ZH<8E1HY*F0F-%1M=N7EU\P> MMLU:\>E';95JI/AB51K70VKE(Y=W=6%72< ECQB1P832M DYNIYVC-R&O*LT MYT'_6;%_UM:E= 8HJO#;)U0M-8)/5%_#81\2F8;N^>:#VTB'#"_TE2IA*47< MRV5!3)_>Y\8^Q.7#B(T=X-0+$+VA:DD4EXZT_A*IS#(:H8^BJ1]"X,Y<<_^- M]2I0NI(ZGK:T$.)1ZU"X@M MG4#LXG6&S:5OZANIA \6]KR3+T,^X=4R67S?C.$; MYY1WP%LMB-GI[AV V>.!EP67 MIYGMY+V/54U4P$A/O"":3J [;!VU_6AT/6RWF"D.+F*< %"\UCR.$2>>/,P? M3UZ:?FE],)'(DT@1U;++"'G!1&7!(1S=!\KZK82IP>V#/]%MS,YHR^Z X0\S M^L2' K=R260W(05-)Y:OQ@!->9(_&Q+:VJR><+$SSZOBYV-I*H7?[(:V[&Z- MRL3=]4Y.\T5>Q9K.2!(C:S:(AQ5_V]2P#;O5M+*^^MZ5EF6TNN8QVW]\G/_2 M[$L8!][?ZBSHF2NE*F1$P;2<0/<0*U9 MQ1TTX7< L0S."LJMR;<[8#F_5FW>:)^^$7W'K1\0#V-C16'- D#M%^NW"F!4 M_ZFG=\#&)\[O[+9!O(NHFU-]$=6S M#KW/1B;USB8\HCPD2]5=4AT0:..$]SXZY%5"2<5HOX6@#2=@]H.B1TH%B MA,7PRWL7M[=CA?7/9FX"B==\,E<'?=RNV5"&[1?#)N8YH4P&2Z'("F&\(-EF ME(-<#BK1K,!>3.N4(I8H(<5/[]EC UK,,5!8/^O\%EBD]NLG=T",51 "\[8? MW% @\ER&6&:5(L-_RJOO#E#XR[ZEXT'< 7&\WW[$Y:R0E3*3CM( *,L_OP-: M+9<&+W%F_!=TPE? >"6]V\(14H]6-=!W06#P.)>[@9$Q3LX>DQ[\>XBH] >7 MWWOJ+RM((]X.72K&,]OF?SC*_=7X&B8ZZQH@,!,GEH[O"K[(7>I7[#BRT5B0 MU?EJ/N_4=3Y2?L\"A9KP]<])5U/..P#+-#-[NW:@VH?O6^&/9$?LK54[CKXU ME\U50.PEWX#WHGZY'/^L<1>_]1)+)R0*4K4 MP;Y3<]M&XF.W7(D=C7BT]&4C]HN4N4?PWJ55\WGM@T=L*Q3%RJ4C;G,/^F\' M1W?M)2?F6*>7#,[3M%_W%.G_ Z[(TL#^54K@N8I(Y[?2TFH$5YQ:PGZ/@IG M,=V61&BX#1$&@_W1ZI"&.A$<2[%R _BJ0N?]F)BLPV;1W:2#NCN OK](K6] M_]N&N..[H%DO:)@V:S(SSW3S@$[[=W1#%WG >QR$EU$CK$'5$>D0 5G'#&6C MHQ.>/8Y8!Y%FY6U>2F74CNT7[NRVX/R852%T\<)- JKD%7$/GS;'MW"HDH11 MT)#SETAA,A7RFL*35\QYS$7,901;ZAVQ/CO,3%*L"")U^_S[28:PYQ -^0CR'5R9-H(/UA!JF\8R_=TC#MJN I.77E87/U M,RY(1&\ZYWV5D2NW4PY7Q2V[7L.@L.1/]A4KZ-8)#(D:F#)L>\H 02'@:7\> M5.0CDV4,@0\&2O+=Q)L_+C."JXK &1XVQ[5?EQ%.8C!%<J/<>FQS*1,J4N4O%SBKR1H1;.@0_(UNC:%Z1@DQGR$=AKFA_T,4F MR$$.H/LUPZ?@*/_5%P>*-T&#MZ%Q=7;+/O\AG*05;?E/-=*-N8,??+^Z7Q&_ M,R!BK^5\J9]DNM'(W7 P5Q51#+NB"N]3]=\5Y6(>U6@C)?/K\&_$%YU+A6W, MWT]H)<#9*MN*K4CR,E*:Q*SI4ZS80Z']4O]EO?D25-6V4?]X'O/#U^GUP>RB M0G:^&1[EV' Z0V=!F5EZ/-W5A'K(CVOX(SE-NCJ-N+J4PE&T262&7"A6\_YNZ_ MY#KE='7TMT4;0PVT2.7= @]%:&"D^$A.6(SX42O$1DLOP<]\>5J,B6;;X_@T MR25C(_Q0];D7D^=,9<(2R\J7?<'JS:Z9W1'3E<+@@_XID=V!5^M% @-L M*+WU9NXK[/%R)AZJ(]P%394[@Y]LW8ZD]P5>!Z:;-]A5IX6F'>$.->U(6=X! MF9R5?\W[_CXKQ^L,3/$1',%H=)OU-L(.F/O%(_XP!,1M:$*3VSS@DB,5JNZT MPXP1[Y_)Z77YW,.#Z.F'"O8U6+2=OR(5V7_NSA'-L2;P_EESU%LGYS<[:H!S M;?#KE3N R+8_'>+A12W^M$YK:V_XA< @.7U,GI\N*W7J['(#B- B4E,!) MX MZX>V+?N3V%S".B-SH>:3.WNQ) MB.%PL5M?@GO@'EE0+S4O+J^3KVL@XOT$SLA=U,]SN8,3+-4 MK_ :>TY8@!CL3=T M24NE\S6219PL^8_Z8],Q]TV'TSN@]")3O;RTZF:ZJAJ)AX%!SDH1U8+^NN[- MBS25$T[]8VX&GYHYRL_5;6[[^[)$8V15E7#[B/.J>"[A(88X0^I%CM=Q=EY9 M^;;"XGN)TLFYLJSEGY&87\16(V.NNHYA XO7K"O]C[0.,=Y]F_1I$%&$509N M38@%Z(61S87$G/8!^ 1/QDP9#JU#KN66F]#EOD)(/3 MIH?\R#?\: ^ESDJMZ?;VZ V8*EV^ET8OKWW>(GA;MU0]VDE4Z05,/A0C(S:!0H;ROO$$+H&[ZM<"R&"56!S*\2PV, M#-LD'TKU1-MLHUQC;P,M\A8Q"1U YH-1P0)!1G1;K1UY*G?E<&24LN5/10P/ MLV.Z0 Y8XK1TYC7'GB[G;)%X1U^NU)TV@DC_O40 MW:&M-,.1%?LR.SV;J0%*=XR?8Y7PR,B5]["&JI3F'H,L/7JO XB,VL%-8<.W MF3YCVQ]6L]^'T;LJE?(6+& 5APUITX49(:_2I'VJ6]?/8T\[GC/'EXDSSBB7 M?_D2QDY"HBD/@+Y?RXWO"](A;5U^2V,+VYNG'Z[1:*9I=I-T$QK5=J_/ L5R.Z=C/4LB9+[F5C= 7BN^K$>*,!6^M75K!SQU4 1>OW/O=D?[GTG MKYX%]U<$75HU:!J(!VMAQ\8H>AVPC;8;?2NK=0SAEF0OP)PM[%\U8LRJP!C] MSHKKFRBT[\S)I518Y:2!/_PZS0[P_16G/\FXW?S0P\'KB%1,!!+4(.0/OP:& M_?^:E!8]RYP&IRAV%BXH._ROT"LYLLAH>B)6N#]JRH/N_Y$%Y*F\<1$FW,K@74 [[)I(.T*CNOO:PS,QS$BOIU$>]6 MCPM)Y'P)V:1\)I'FAP9XSV6-Z5=JF+35]:8*Q8JP:\."%>16:;UTQHW5(SJ^ M&2E,6NU\9?NVNB+P7'&PB_KTVJX?^!6A/R?TTS\)P?^Q NAT[V16CG^!9ABB M+=1PNI19&R5+ 0F>MH4IDS@K0[X%%4%2>^_T]:+O\=.IG;$!K X0^:H\]YR.(-<0SQ M&IM\5>CN4$+ #WK?^=0!A2J$L3:O]Y ER''9D<#49E*KCX3,AG">RP&%_C!& MT0XX@D (WIS%< G/E9:EY@GU6_\B3\:>UB3Z7N&AO%D6R;I,.W M%]?;HZO(-4R/WQ$6"W388ZAHJ M2RN#B4JQLG".%#)%!UE1:$^0K)\([WZ=3E9]557)RQ!&&OT\4CB"W6R)_ID% MS/66^Y V]]N6EWIH.AP.SMM2T'L$W2E5I(8D6,WT; $=;F?''>Z.H'8BKIC> MU\-CJ_RQ,?(N\]Q#0M[]%HJ3)^CEX@F??F3'0PTM$L1(D/G38Q202)!<6U/O M^Q-!-86LROGFV./$"F/+0RW,"]*O8KLF2MQDR"]BZPTM,B_"E4K+*2,+JC2R MZK\?S7#0QEM'N8XY)]4LI1%LWY(-%U1LT(%KT!Q8&V//.)<[MPR* M@F*7"+ NBKKT&Y/;2S<\AK?LMGU?17,^%8\-BI1#TN,;1:%+ 6RNE5/9!>>P MM'0L;AHL6TMDCD;JDH[2*"[HVFAIP^4:1]P@$-7BW3K!8PL,B2>?HV!;_V.? M!"EDF>#B&D$I&)LN>51F"V3N^7?]^-5.0(AJ<-%; T!!B_L_08729?X;G87P MU@./Z[")-$.9$PN$8GX^B,B]CNB;-PB5.+12V-N6=JL83G>%@;B=T25+]1Y1 MOK^!;- *9Z36:"OE^TN.FC$BKJZUKH;F[EE=\/RS&GH/>KU=$J1CLM!B=S4' M?LE'WJ[V0N^9-_E,#"5=M[%'D/,9V6>BWR.+'^'Y\KTT*7S.K\#D$F:(I5BX7H[VF1]R33>RP6"J,@PQF M.UN]/=ZN>F$ L?NRE"#3R[,9M9+JQOH/YI55D5D)"AMYZ,KY(%6#6E4:VJ,M M566'"3;#_GK-?4\GZ0W3U9-T7#.\BWVE0ZGM:2-%;T>7DO"W44=S7_A;U5%# M4_/W=23_O@8_]%_PFSQJ3RK*]L\QWC8"O^,IQ!4^5LXFJ2H)$'[LG+@TD\$< MY8\=;S@L5/@ H,^ MX/S,R&XE':"]591U!]#G#UXNW@&76.FX.?7&$$EV07&'DD.EC-A$<#PN 7T4 MQ^-#M5!F9;0=7 ).J3H%OVJIO,&0IE6CD:;M ;H;0$<\X35IIAOK<9(P/3I@ M+>2TUM10FJ(H1.?JBGF1@'X805R4D@^Z'7 "2N-9S]^YH(M[3W1=W[^'B/8# MPSN@Q2=M2?.C3S&Y<1O63)5*K$;J0OT377LZ\-CB>'L\9Q[NSXC^F#M@I5^T M17#N#$NM(PLR6SO/_EJGW-:K&WB1MO-3IA6VL_>EJ:RJOLI\:)"RCX()-1\W MBD =CWORVDOM#G@Z\U//'Y&-J]K#3=N=!#> GE5PX>\MC )^TW"S$.+.Z>+)^7[[^D=?MH]L)9CM>3HG+.OCJ+YDN'*E MZ"KWX<_#3MQ=O!+?N1L[@J13LA_9YW(\C%-^\6ZX_][+ZTZM5\]6 IR@Z7A- M!!W>&"&"W3!&O".C]BKRS1]H5$U/)R*M-HTBUZZ>+XCP^EHXNZ_94+Z?]$53;IG2U] 2 M3!8^6$F5=<-Q> M6_DV"=0N,QT[T_V";&377Q#1;68M'%=,O[YCDI?=MIR!YP0RX*NI1"R:>+#'6#JA!A&KL@7:5LXXK8U.UTG MN W@D&C"VTRL KM*>J#K7W4XK,G]Y 38D,D08=@BN$+_Q22TJC@_.N)>/#-[ M^YR^;J;$ZM)^2G)%X@Y0:7)B!_WU?2V*_-]Y#AKWLQD\THMY$ZG"G-?7TRN^D43/UM[@ MO\5W-9/TS5::A)DG/8@\Q6-2#PKLS[6K;3FVHIE@*\.7FHK.\IX,W_M:>F % M<\=\Q"6LK91JCO[T+?,+6LPSH76C!V'7-,Y%1M,+:=B%R39#LST2BMAI%0EM M&5(8U+M;;"CC@EFA@N',@9M%2\;0UJ<">_Q%PR&L-4R?K\9K@\<+YPO^)'ZL:2';S]$: N=-3?:>,;ODO*NF$-U2 M%G)M;2(1I+L'?36I65<3 JY.Y+Q?41Q7A(]/X-PI#WB0Z-$?AH1\#! R=@&K MJ]E'_5?^_F,UI9 ^9MNB,'B6C_O&H)'^#HCNQ[EMY;P#OJP6]@+Y-Y^>WP'2 MP@OGF_ZMT3LS!#^/*N^ )M5;D%T8$$4%M1\KX.TBBH\C?/CFIY[D'7 D:7 ' M3$G[W^"+SQ8@./LJM!11]CX(2*9V0ZKYV]9?(_=HLMY!989YK9<=NDWKS8=U MWE!/#+2NN=-K3KL\.X_MK,U14UA#1VN[B."KX4_,3))+BJPTT)-T A(Z?!C( M965IC"&*OZW]:'7E&]CK7%3G*V&NR5Z 8G*9$R0CLO]E0,/P;_5@H@XW[N?9@J,'62:P/+;-/+Y'Q"OR MX)# X?3''7!0)*D8X5O7ZG^AWG4KM.E1[$KS?M\:6\TEYXFFQ([^2R><9RO2 ML!^F;(<.I3E/;2_=OWH%A_L9MI_9"_*J2KH[]8HUK6B M;_/;9LN?OS?^N5$@2'.17I]*N-[8Z2>'HN)CT&8HJ40/DZXF)350@*'E+PX< M[\.)#:O*1RN2L=R\O;M2YA]7?Q;9JUQA4(GMZ1XL*6Q"V2JUNT4_\.UH3"9- MH=S"(XO%E.#/9>.J6<>('_#L=Z=,;%O W^;EHLQJZ-]1F?G \^"^4_:8974Q MUD6Y;QY4L6/"2SCX/,GODRVNBQ$CF,&0/!"+0JI,'V5A(D#070;_6MD_HM@3 MV4Y:LW$!#U[GFV)_[H2U&5 /VIX,NQ2NL:=J.UBP>47F$:)=59LZ+\82I*74TL@ MQ7E*8L_\'QVQB@WY6Y:7X!59-7M]$6"F9?:G=78SU'PPXY_2E\U;/ZF]?3T M0QG&>22EO$G#><,U7K2#J]FW^)'H Y2Z4=\$RA4:L:$,N-$AFYH:S9IL%WM: MYH7Z#S]@K->O#Y/*#+TOKQOCT(/=*XL!VG#*5$2U.:(PT4%WX35X/1EMY/OK M^:Z-DF-%%=%(VUY!\>]K H?A(C0Z*\5+$P'B'/\H[CX,0KT,)9F6,ZTA/+FY MT[-07R&*PN^1SDSJU.PO<+U*I#!(4ID/I7X4YU^X["VTW+(1;E;]^/'LTA.U M.*'OZ+BG#QLX#>-$B.*@=PLG+!?E=P!:]AT0EGE+RN0_E+P\>$V:AHB*^/3^ MSJY5&%5X-6."]KL19>3R&R3)29'EZ%!:\@._#+2H4I_AV>\99XI48O*L5,DT M&&:]]3C+/*'+3630'_N&90<#C=PF%@:H9Q&%B%:]B)\FK*9W&!TL:;DLI8+W M4(W,H+[FB(CBZ:8C 28O5I_PLGDNXT3O_-FZ=D4@?!4%M^Q[3ADR M/Z_R^AO-;=/[PSY2%C1[A;G&<.->9ZHZW^.(ZW07Z$EQG*1^:E916<(_UZ40;)+R9F0>:,9[- ZTH_\0J&WE\JP,-W6 M./*1Z@O,W>-[1<9X"Q'8)W3 M>$X+!)9-<6X#5Z9(9H2:S52@"-?@=0BT7CF M^C,,.+W,S_7OYCB^K9:Y#82\__-ZYSR0]&<^TVY-Q3NTVF2RI!@%:_%MR]+H M_QTOU_O@>?9AI::@PIM3V8=FN9R9]+!SQFU$05=6=!U>Y-_:[GA)[(,@X(&C M=T"'!@9$W@E\J Z7V-@Q:YUG-:[1Z*'& /^<5D!Z)N)&09=B\.<9I..W;M]* M(D"QR/XZ7Z:-[HA]8^%T!0.!T,G)RS@]J.\DJ9:_E\7(+!OY2L/T%0Z_P_V" MLJ?5%O=!G^QW,T-[-]LC\@*N:H&5BQ?-,+K[8DR+5UCL ?W'D MY.;AH(&:^-[$3O8E->E."<^0GV_1=X_/1W(T:!XZ&JBD>DZ;9QK3,YQ<]]*5 MQC^68HOCIJHI6^,0\K#91V1W4[+1D090]=ZB=?4&FDTKW5EY9O M\4PW7BOA^FD5)>R;[!W#B['(F7SPDK16NFIQ.P7[@?BVYE!VFF:4F&>-4UYS M#2M251R_#4K-G\#]:)#$%#K8KI?DP[YHN"A<^Y;L;64FUBR3?8?7J32L#D': MS1"D?2-USG]Q !O8S2=HNP,.?Q;[3SU&W,W9)KLE:B+W'Y:J1>BLSR!%]8EK M"POI#(8#O+Z;HM4!8"R=2J'CJ?]*4R'P*BFH,5?PW4LA&^#":QO0S.7)+2!MBCYSU 0_B?)U&RMQO91@6W(3AF(1[*CO9$;91W@&VS M4QZOC)R>_Q+GH?\-\4SQ-46++!7M+PFC-_B;A)DK%A]V+R;?%']"JK9(%8KK MW?@\5U8@@?5R(N3ZOM\#!#GS=K\#WHBRH5BWTQW^1#!&>?^3IQ]J3#URMOWX M&I/!,5#T->D^%U;Z+0V:9DX>F^[@'\_LO6:#HCC?30:..1Q;&*.P!I3LU6?"\*O$NN[]1#0R E#WB!_K$_ M%#A>J%R;W0&/S[;O '0G72RA)O+&.G2$"L?$ZR8T[D$?W&7C5^7_C!"\B*!X MW?]5&OK+"";X7S.(OR4:_%L\29!F-#4,U80ZWA,_G:&RG><=D7W*%_ENS454 M])1$ _7D#^&%-U= -A%O9/*X;.9[L!C3\YA>!4PA(1*D0:ACB]&#(,LD>V'V M[R-?VE]4IV191OIML9L[90[I/_K;]HZ.>,J[\405$4W?A@R!<-\%L0AJAZYO MT'3<:,H-$6FF(8O2BCBV5>,ZSY[W,<)=C*74^-6@8?WPS5N>L1/.?L6. WFI MP4"'?5.)CVO5Q]:P&.DV_B+^'"4Z%C"J6[%%9778'ISS([4D?[K;\VL5!;ET M3'=NGC:#,F\IE0&J.NNU+Y]0V*6K!;?QI =5RZ(&6BS8\/T-FZA2+^:$# MJ3 K?OZYL=7HOFG0__QL;[7M1SJKR1JRS;NO/2Q!V4\[HJ+X&WQC7ST%0J6'7+DX3DI9)D865ZY>1G+@H.[ M3MLF%0(J_Z^0_3+4 'XH:-"N]K$T2^V0D(3J102E^U(M'CD15YL%"PK*ZS[W M]2QN! [35Z7IE)#&4\W84*I"+9'D-S&?%CQ=.VP6I;:J+V^!=ZR'T"F-"28G MVVL_.<1MG[6I9(?ML#!QF6NU[SZ]U[SHL<>&,KOQMS-<)=?*R_T/6H=E)W\L M*SO@8*97!F7%MD:48DL@]0@BE7-XQHI;4[V/F%!\6T&\%(T]95/HQ*.61\+_ M=J:."_SDL_MIL:@O\U8<:Y1;&LGF@DV\EB=#4UVJ?)B$>;+>=&8WQ=R8D_>D M[Z+9/1-H6JNP5^$J89MDW7C]%Q7I"8@] M=_L>4S#S Z;4L/07:;T!3(V-L-&7W^H;JJ/FX: YYK+*<'J/+*&G]Y?>JU&N/S-''VJG3OTP"GW4>B@ +I"*N#2IS*5UK)=QIJS@ M=*+Z1/)J0,)]<0CM 0X4G[-'H;38]FAJZ^'V]VI892W+P)&N#'=7@NAZ$8'? M^*:@!0KR'RM=/4@(22KL"M5NO;P_:^3PU3YHU8/LU>U+?4PL/,K%",(6UI$ M<;;]ET)SXJ=<^Z1*'[["$@R2]T27@GT5(,V% MA58GWY;B%\-\( $^FVP%>Y471VV_,,3R\"^T)Q? MF0D 8TL 6*PPU>5"CUO"8ERS;3IKR!L([2'1'4#8C2(=8,U\1E%\_W:R[O!5 M:9;)- 7]X1-SJU%WFUU33BJ8NBFNV&S/F\@+ZB0@9C ?6C:CF&R0\F!7B$5_ M5"B%!;EL4\3_N+]YW4H!2_KSE9=9\#6[[==WIU1U>")7?DIG<_-PXW?7$WN* MWYP$MNP<\:$N@X]%]$O@][/FOVA!NAEB*CAY%CZF2^*[#H@5PG^/4KZI*C]\ MEOMCZ+X>BTUF; G.L]U!)ZQT;&F&0[SLX)W=(D[U!5375CE+3 4=O!J 3AVV<,$QTT&&W*4[[MXOHS.Z7F[($/OR ML0>=* ;:ZV;:QFH2I/@E,+;)PC:\X4?-4KBOQ).&, 'I9,%09^HJ._7-6(6' M$VHW?ME0BH[(QB'%!X#M8=)4Q MIXM5^J21X="AW+MP^Z"K2'YIVLVFJN7;0AL52_H;YAJ+<0, ,/U4F(8.I5.O M+JD:*^):$=?=T5R0RS1I9C;&":9PI7#0!9_;(--A7M#V:42K3T2EPJ6B5NO4 M[AE_67;'()+\7![Q.4>TBUK_V_#O<&!-HB<2*OD(LK0KTQ^+UC%64#ICR)37 MX[33\C"'=2PBM35 C ;2J0D)T:PL&S-^2CTA"3FDD]4K6'>YA+[Q.ZL6OH+;+]&ELK-K[\ MW1'!O[ ?/F;%6ZF44:-:5:-!>_%4=+N$M$\.%:>'O>Z)L<)K12R"=2R/A5=1 M+JWA]3B:ON K:PW5I=RV0Y##XR0O>#FLL)T:R/NZ>W1 ]6K/ZRH,\']G5>L/ M@MMY695+=1;[T.ZKU@2]@/)8V"(KVE;M!>GB#H#%A+:3,(*YW:Z^3?#8OX?H M\]W>7)]_8ASDBG6XRDUMQ@_\=K ?S"4I7.7_3#'HP?WCU2K\)YIB="()3:U8 M/RHW?H<"2&T'E=(.B(34BA5 F@\0:Z*Z:'R L7$(7J78YUDCG8@EAE'J;39< M4#Y++,:;9=N>O5(X#B2XY84I=:4$5F\\1: BQ8"FDF7Q-V#AN MC>O\T]5D3PQ+!OQ!W?5F3XH-Q:/%E."0-+H(&@3;[L.Y$='6M3K*G%Y7CBS8 M22'Y<#6U!1EBBF0(90P%,01/LQ!DFU&@7'_D]:D%MNN*?F6 M#SOKG69\5_J^+(770FB%/SZ5XZ[WQL[$VB=S3ZB6SHM ;V=3UV5PZ/ 4Y%)J MK DNK@&KY3.9,I4OY2E<_?FXNXVA\F!J\"'D00VH2E4?."\ M!PJ:E]B0>3.P'=!]:G?F9V46 MI9_-],ZSUH)(I0C^B&YPT3@!?\X&&RLD5[7,47@-9YK,6'I_CA&V::ZG%&MR M7JU!<1C9-4F35QF;'B1#!C4WK+=F M@@9.^&JKC%<:3RW,*-[&?E7!XD!?6&)>]Z@2VGZO@8X10Z>H#]H^ MTZXTF,]<2U5*DR:W72:4YVT)QWV/ZESV*7W,]-)7>K]78';R61[H84XS"J"! M//S?FT""Y)*JZ2:;9 )@7 ^LJN^O>\M2TP\G4[O>&%5H8*1<0%HIW]9&9NTU MD4W#?$&W_?B9%O3R8X65!\Q@N4ZY/='B1[HZ&GF 9C/P#-OHGS7A[+RLZUHU MN*VK/-[5X]9YY407SI5 Q2Q T;7(]E7PJ57C:]-.0JE>]+[';XDHWKM&X7FR MP)8YBT%V7K[C-^-GKS-,\HLB_7$2_D*535CF>759<.G_*PF M^&="+X)EIXERUJT6279W_+&!MI"E'X7^N9NW#(UEH_033+58N3-\"Q"_,&@U MMO1.2J?W:8=7Q[]X?.IW0Q9 T_HNJ\&OO,'Y/K'KE0KI.=#LZ"4JFK6ZI-%0L*WTU$H^)G<%<^9 MQM"E3;8'F=[$#H*RE_SQ6M*-P;R!F ^*P_J]$CK>HMM7FX>!>[%^5&W\4W[U M%X9"IG>0$%1D5TF9FI7]R-G#?"8]M@MM0*U,)RT7!:\5IBS5?^\A_G?3_P]02P,$% @ .()_5#2Y<12S,P MT38 !@ !E=F%X+3(P,C$Q,C,Q>#(P9C T-BYJ<&>MN75<'-&Z)=H$:1+< MW2$0W%U#\! L:"/!M7&78$&#:X('MV[ M[M_ZIVIWU5Z[/EO??II[6@5@*\HJR (07@ ",\_P-,"0!J BH("1$%&!0*! M+U^BOD+'QT!'0T,GP<7#PJ<@I:*D("4GIZ9G9Z2F9:4C)V<2>,/*R<7+RTO% M*"0FR"W*SL/+_? % M#@(B#L)3+X#J>9W("/\V /\8""\0D9!1@*@O7Z$]3ZC#!KQ 0$1\@82(C(R$ M]'S7[_D^ D'&9>&2PH%3\T82.N$SQT8_P.5[FU5%X'ZQ D]CXEST,M7A$3$ M)*0,KQF9WC#S\O$+" H)2[^3D9635U#4^*BII:VCJV=J9FYA:65MX^+JYN[A MZ>4=_"4D-"P\(C(A,2DY)?7;][3')J>F96=CZ=GYQ>75] M+Y"0$)& ?WDAO/#X.P$'"9F&"P572@UH[(1'RQV(BO\V_D=5UTLZ'O43 A/G MB5>$]+QK#*=_J?T;L_\]8D'_5\S^7V+_G1<<@(Z(\/SQ$'$ $H#K6Z;< "&J M\"SZYA-8&&2KVH%]^^R*A3?IK3F7 R,KMM\Z0)!BE"6Q]O1S2['.[UNQPL8B MM8Z9U[4)5R $\MF) 5.'W$L#PB[Z:-&O(9J198T/CEX"3 MX3#F#5%'/]O,)T"(K7W]*PV==@,SH_H?#V5?SM%_M6#]C&YQ/VW 1QB9]_S9 M^TAMP"%;-_VI:OJM$=_6W@)+!$;+@6JQ)T($TF/RHJ=1'^+'&S_3=64I7\A5 MN]M 2DBE-DVX6H(7$&!1G7]C:DF97MA59 .[$JAGX7YH%HNF[S;][A'$Z>Q% M[@1O'B%3J!MWM15C[E-[,0KY)S8^6/FQG)D1C#2@=#+K[);H5NLZ_T/=_7L"E[T3*+2+XNG,1&?!DAXLO2%$.@KV94Y6)JE$RL+2L4JGQ)"FX)X$]YU_='\ MB2RT.SI[7]9W:#G!SA!P ]T^:3HYS ,%G;TP?UAE<+],/=KH*/*N3WM7;>.A M381JQ]-Z( ?>7[R7 M2D'-O_9.Z!XR]:F!B#2+N!(%2BXF<(F(@JG:_#0R^;F(O MT;+F<[#>MTP?ED,/()86N,N#)E^0Z0E?Z>Q,A?!IZ)V^SL[Y:8LQUY1@F[G- M!($L6WYJ7'0,B$.1$[_<%J.9)U<>&'B?Y'$[[DP$B2DI);;61 MVWSQN)J8A!^9.JDT18,/;&S6EBZ_/@&"4QW<&[!*%(I4&M[46Q*#OQ3_WG)/ M$%-VT7ML33N<% ]Q<7-!\N8B4K$AQP[U].TL>O1&6NK\$S8;(.8>>1Z+V![V M!'BY74451FET,%$$PL[O2"%O;6(BJ^?*\!CSA>6-(\C@J_ZO "0X)7O0#I4X M,*Y]!!M G(QP.F8\31_[R52V9^#/3Y!E#*]48S:K4A7 S"N^G2'S<^]?WY8G M?/OJA4=E=YSPZ@Q30S6M)@UAHD_:1[?"\O"#86BY-@G@8DPQ#[IG*C/.A_&^ M\ E0#6I=X(GN^QC'K,1Q2!F4TOC J H[X#OD'P"UU;J Y(_V3_$%U61OXH(\MX1LQZ:XBQTD0Z08D;F?,(:SIET M+0.3]NK"@6=?$A3.,S)::AK$OYOJ>L=&V;G>M91QV7JX>*&?@AA:4=&4Z0:V M 4W4G]@5& $F$$^?7JU'VM##M?KF>A^E8#"OMCS.K&1.?( *%>=V -\)-R:0 M@@F.*4CN>E60&X"N%BB##_A&PHCX.@AA#^%V5W_G'A>_<6;EZ^XY1&7 [J:L3\G 6K59 #XZOR'T94!DB;ALO!*3^"I.]F@ M?6XU+QI$]FH"RE%0;\[^NPS]?2/S07Z"SH[@B.TX"D>XJ$;AC;W@Y_FK",ML M6C20CIZN^8!!:8?:4"?T,T=$)?WWZ7NN=0/VN>R;/TU30U%86G,*5,G29<\[ MUM!/OR$VT^W)H#S[9O\2[8$8G)7@J8U90NB"=Z?%-(& M4Q5N\2_*'V6&A3P0,P!>UX+7.9A!R^MD+590\*8N33)B_YXSB?P@;7X^@.FY MM#AX8P7(C61"C+R)?BSKH;KBA/OS0V<;*\)7]EJYG@"F&$7G-H=6".UZB'%? M,W8$C_<_YDP<0([,&F.H,L]0&:DMHE"6\#5-2!>B5E MUA,VMS+;Z4*T+,6&A'3%Z*B#]WM;W-9Y#2';:3(Q3-,U+>3(B D*%_EJ0[NW MP/#V%0?_TA7K*7WK66?07+BIF[;'*_2$S9T;?+#A=]%ITH&P5F7_=<^Z=]ER MC?7U[_C=&VS9Y\P'1E[CKZ73KV8%%PGQ->5YUKR#[7CR+DRP%@N9"ASEVIJ5CR/3)CB_Z$.B4CJ+=9%TU@(WHQ>#?"[* M'JG'&3LFRB&U0^NA.RJ-H>MSBR\&^WFZVX6Z2$@(.F0 7BE5^7O-#+U9]-,< M.43'_N2G0PZ6])622"BO%? I[E W/#=Q!5_4MU.P7=0+]^?Y+L"? .I>&W&2 MXV'*X3FE K^(MJ@M$U!\8);/]J;VSR @Z,H -=7KP.U\@[1H%*ZI\=0G)$GT M*!X>\^RNB1Q!;].7L*59A!AT2D8_>FM!S#QM'R5['MO9)2Y<9ML ZC,0\#'O MT$93J% <':>V?H"D(!^H1ROEJIVR\DX4IV\;U']HS-DH]N;QB? Q-CSC+6*/R\J'GSU_7_O0&P V^)TS!(] M$#^S&&O\^78MO%!1?PXC.QC5Z@CF[0)H"FI^(A#*2O=*H;VJ22O^L\9P($Q, M^$+,MO&T=?;J$766H7EJ0:U!29M;CX7@7%;8S!E80E$VYHNW]I)55*G(AF4- M V68X2=:NH&A;B:"QO7'!#*H!"G@BO0?CBWXSY9K^\]V'YN5 MD1)R%GY5KL_Q0Z3Y#L95:$TI'MO;<"Y>0 KB D,>^66[! Z*<+NYM)ZP@ M>;I]?.;7V*O?%8DO":;-O:"??.A(PS=TPAT?ANS.Q*J42G^:HB1Z\1=M^072 M6#2>:[_9"CPW\R ^U'Y#03">5VQ.AX039_OZ2+?+4UNG\E0[0D/OSBV2^%"/ M0D0YTM4Z@9!93P$@R@7/YCB):F:'UZ&9 MC;LM1*N VFMAGT)Q"M^E.I!81:G%J4GUA)KR6KS!C#>O^Y54DX(##?Z-[X[%)X(P/]/8)$.^C_ 2HT.FX M0- '1K;*G )53T:NKQB_6$RE_WRV2B< MOU+9E[MG7D(QS93=UYT^GS:T<:Z4"*!6!:KX0*V%G6L,]U*TNKS_3)6:GO/M MM!/?M*WN+X%T8Y3E#A1AE';J2X&DBBV:GS6RFO17SX,--+-[LE'F.*U$^0J/ M*$CED<+.[=)^K#D@>=HJSES.'USXF,5#6UNKCUZUX%3F;"(DJ%!-!K _ ;J' M3K0?,$B-'I'8Y)Q.);KXK\Y^^2H5"48K@6,^_9JC %"HU+E2S9-:/B!")(Z[ MGX4-MQ]0OBE(_O44Z_(;_+R2$"]@D+ JD./D9W^:]E=7VZ2I^ZV462_TJE\Y MV/3NYJ)X'M))UEH*#CN+2MN<)GWU@\--]%>(!+.J0)$- M'^LZ*N >W#S>HJ.IUBV(> OUR ]!K(4*XIB%<;*IYQ%NQVYV8\AK38L.4GN< MPD6-Z7ZYD.4R=5KQ_&U"+OSQ%@8(RZP8N' G%,O5Y6-+F^-DG*\D,%K?N+&; M35]2F##-Q=8L[L7R2D:9$0 SS!RM$"MG^-+9Z&32-1N3^&H56HD?35][JC;N MZ<0!2V@;R:C"X+. ;YYVT?\ MJ5;I0CWK\[J^42SC77UP6/?/)2KE6C\1$%N9K@WW M\L)/=U+YRK6D'_I!W) A8 */))($3MV(X<+[ZDG7!S&^DI1#Z.S68@_5_((I M\@"C4[^8",Q\[1AWP?8S9O4I?A\;==K*:.HO1T)6OX.J U11&'TVAIL8_]3[ MQDF^=-=9\.P6NV5C QOY:2L&_=E,\^)T@A36VV_'NM1-53Y*7@WT00?)]ZMF821H,BH+?[_L1]>IRSK-0AV M"HG.+*D=:2BT^O"NN%8*A3BC&%G#N3W)UR'3 BEQ1O,JEB[$"<"'L)P!N M?) $\U#M93AE]XG@6$J.$3A^I6+MG+>'CB9 MT=6J\IDW?"75M2ZQ_3)L[;?)2U,8@;Y MGP"N3E/++?#!$]A]8-@_LJTW(.CZ491=8C_1GTZSEN,/4>W*[5^5)4E@\:^O MXR/\^*N!=(4%[OWWC2[OG@"U>1";H8F.C2> WG.<77DHH #8JLG@(_QS5A_Z M^U;M?X3U.H#)3-[9CZ MXWUGT7B,XFF_-Z8_9;]U8UU@;5.66"Q57!Y-J7J&5S+J!&L#>/?AJTDB/X-< MN]?ATI#X"5 5.O6GSKVNS_<_]DML_VW.?XWH%NN%Z+D-,1X=N.8VQ*784-KK MBHIY5HJ,6+.'BZD]Y#'SS]^ZJ'2QR[9PC*'WM#N$1%I^38J>'--GQ@%C M";3DZ=US<-['_M-SXKX!HZX>$U.8=,IS4F:!E@6ST3@-5W =238RX.QME"IB M<6XD0 Y=+0B;C!R7)UA7V/![LOJJ/Z,W@7GK*5P%:MQ<&SG;U'JS9[I52@YKF\HXT2Y[3:/$!7T2V=G6VAS MM@!?%44EXL!(_60TSYPBS;#VI!K-\ELOP]A)*GG%;&M%CR&%/[KGQEO0"BI\ M-]O:BRYHC:_$XE4WM_L745Q9;UB.Y[*RB;*H-=PC]$.=K7M4*HT;@HTIN2F0 M9"R?Y?Z_]-E_\M\=0Y89]E4#E7>3V?85D#TT2SLYG;@ND@2C7*@_+LMX8?*G M( 6#&1S\&IX,)H E_:UVZ#U-:F\[W4UPB6>V7@,/B*]E@& *.J.NZTA+&2)G M]-YE!. C&UN@]]M;K##5+)T-8J*31]GI)KY3_S5#-^RC(F^29(@Q+[?H8IVRB*:('4@LDH5E@MB]^6BS*KV:]]6 M_V&/7SA!W/6P#0(Z74!;!E()HS'JLP6"BTY9&Q"BG.B9U45-4^(;/^2E[8AB MK1KA63W2QJK[?+M0)D;,Q$1K8D_:I"R_YV"4X"@ >!?\_^)Q6EA?6^6SB,>S M3M[97/NSNV., -X:N4 (X18U$VUE@N2=\7Z+JM[0V]#*Q;EO\U[Y0 MCM!078_ZV>:-KT7"K[6#B&<%31JCZ62(7^42=P(TC5!NG(TP?U>3-2&/5GEO M[SVN9E\F"JABF1LUBX7H3M+.F$Q7%+16!S%!\W&/E#*W'",;^R>R6S+&49;^ MB[42+[-VM$_>ORE9V8V/X,@)S ]!MY#\)0(V5%G3^4Q^\Q4,U9^;&\K=3TE- M+!J%$:+'LR /_8DE7MTX@500*Y>";B2T4F6TP IL&9WXY@VFQ12C/('[AK9K M&+)]]\9Y?6O*/H8SON,[NK%JUJ2"4\8]_"_IR;+(7O4&M_G7W3M&[(-8;_/(<]23>/S1P#RE?\ R6JIXY%$#S:?Q22E6Z4RR^NJF=H>=)U M' M][8H,R:(WB[%O71@RW(A_[0H?J)6Z5*[2BET:% 1>L^&F;PJPH&^;[ M->^G4W7"G' M^_CAOB:7L&;G>ISEKZ@L$;5TDPBO\Q3%*%3-D_6I;FP16*,P[F,& ML[6V18[.X$^I8M4ZR8D1'/_$'!@ 7)/$>\Z+@'\%#;-XFNC\Y!D<+]8!P&?> M/;MX.5XP>3$TBE,S5.J>Z86@_2%4"96=-JE"C2QT8$M#BRH$#%Z=%.A!4JM1 M$30)1Z!^?[,+2D((V1"Y&^'H2FN[RA;E-.BR.Y-A[06K PT]QXK:6<9$\=9% M#*1[O7T53FF? !]35'7FE K#OQ09TQ.B]0M?'AH\ 6)R@G8ZX;\$-%@YQ6J MR3^XOU"V !DI9W:67YV&+%U'\AYRJQ OK(2ABX\\A#"T#+_(WA#%''@"P"0I M^_XW>Z/_DZZJ3A;+*3DET?CK:3-IWGD<$*AB.6.^H#HK_2%Y=0],BF?YV ML/Y'(% DXV2&O\JCS^HNUMUO-LP3"AJ])2D )(3/\_W0@;\+;X /6:IBK%(G M/@'>;U#],@GDCZ]13GD7^CI!]E4D=^\5 1$<+;/RA[VN$N6+RLOC/Q]==-,; M#46*&,C9U3 !=!5B\H6ISOJ9;9-AH8S1%S6XE>R)BK_$$.5_=?P@J-/Y3-00 M(\97I'8WQ!!/O%,M/RPA!4K:LKUK01;_K#G6],LSNQ=7&ZLLRQKQBPE$M&/ MZ70(^LQP(I8=Z:N0;V3CM+ XIRO#+58^^.'*KT7^%BR1J3OEB[BF3*4:^010 M&;>#0-?H!UBM0_6CR#\C3:>XNOY_2).&_F4V'EDB,Y8GVX%.]*1B+<278"VZ MH(&V5L86JG7[[@!N7W//;!S"G7>U'BH8\T./Z<5].'%CPF>5/0$NP=?I10X5 MFB<[[Z9$Q=;0?# X]3]1<;L(5U /GZRP:B4INX M[1NM !(I44P?#36P?JI@D<6E +.090R!R>&UK#QYANMOH4)PY@KK&C8G-=,0 M'7GPS:U&;D,,]@^B9#)IR@_"&XQIO&@-E9-3BHI?<'),\JLVHQRU*1_K@G-V M(RA_^+?==SDPQ@>UVM"6=H?)';1H+? M+"S,132=@O(D/(0*"R>M<9BYDI(*RF1GD%;-)M3T^Y"N)N6\JS76-] MI].^MY-\W%9!L7S-=DBB_/TG8ZG.&CWUH2>/]3.^9_ MT?;Z3]V;LI)E:&:A_G)3%$,KF([$R"0 18$12.ZC91E^;Y!W8\CTN.(XXB* MK=M9J+ C'AZ<>+E[K%^W'+V^0@D?;FZ!AN3)Y[-_)]OV"=P5#3XJ.2H;*\E! M;Y$@VZ,BH%0FZ@F_!4?&/Q24L'YW#4]X(?LJB*+2ZT!L?XHWFG9 :A)R,<*_ MQ'9(;5!"^@3@V5-1]X%QG=QU\C\BAUXQ$1(*O"G.. W .O^[>N:Z MRX?Z=#M[]DVN7E3D(,+-!X3".1NMM'P4'Z'W\:%PG3P.B7#\5P]HKA]5G-!M M=+=D$#S(LX)AN_+VILL?@2;D--U9+TGNVW;GP[B/E&6TO);6)1K-U2L2#HB( M+V]O841K7C2I.F[UK1JONR6MEZ6BS@- P)A+12+EQ6'-)#TM^QV?CY=")@;B MJPJ\$>'7>&B'CF*Q#A!%MK.N+%TR]%\HCIR> Q0R_"!]/5[W7*;\^2I2^>L M,=1!>A^+HKES3@L)61H"+!-4C2>44 ^:!LM/1NZLL? M]?06;KZ^FC"E1I_=>;7*CU6"F$!BQ-GO:];@U^-K/MJ+?=+OA?Z8,;\DO]6: M$-R7E=J5XZF+O'+N4\G)TT9(-5=M9T.&9U(9(]+WK)1':C7;)]G6[:; H^.R@6!OO56 M"1(/Q\?K6T:57RIQ$.UFT59-0OGD3:L:JU/03-I->%;S/L7'QP?Y:!5]$15R M*?05G*I%VRT(V@*C.[>UIAORVR76A;WEB;I315;Y)X]["3 [0?;"BK['(LRF M#) +;Y63R(: )#]/E/ <++5LZ\<0FP;#FZW;2?OH$%HW]C=6GJ] M+!00IK:L)-'F;GD10>F^:P(UJHN/"66B+LI;P#V+R!Q_GW^[7PH799BW0BL-/B*TUS,\> MKN/AC]-*9M9G<WNB/[A*!M=D$Q9U:&PL#]I9EOE(R$IZE$#0J4R3(/Z>/ MCP\4W))4"X2W*$F$>8MGDR@I'!N3O0TF*XV/60W9/YXM8+IF/CO0EB 0%6 D M9"FU86R8NYC/EHA098D??Z2^61@0;NN/-BY8^*T6-^G7;F9-21S8SY^%'D8' M!1JRC$]U1R8,/P$6TN;/R<6G/-VA*)QYY%@VYRLH-X1O?)76!1EF'.*L82SV MI'!I/'G%\L!O=V;HWN?:J!K638HKM(S")5"=E6V/SY0G65_7FM)V*94.]?R6 MW7^X/MJ=Q8D;9Z]1'42]6FQL_@97G!T72AQ>#NE'8&P0&R@PY@A](YM[IC->'C[P\1>F(P*X8^_Q+B&+ Z?!MM,CQSL@;ET,?*N=VLYCWF/5')Z?& M1Z-L^E\J&-RFB;])TK,2$,#5+^Q[T_J324;?8Y5\\ZKT$:>EIFTB977,?HUB M29=QJ&]JTYK>YUW@%9Y<^5HC7==JP; MHT*;+(+*&8L9-\_7TV!"!<+)_2&#&$0[:DSO\WWE9IO,I,SC.0+^O7/!B^6= MPH45:U;?,I\6?C/IL_Q2Q>)[[U?F[1UY2XML;?4EUKR_7GZ,,3=QY/:DG!D M^5*,'V3[0:O6B8E+#";VD#]@J77NZF1QGQ T?+DG*]D7UFI;1X4>FF"0".R0 M5Y*O8O97^699*BI31H/7(2AG1R(@L!;<>E/PG=S0ZZI:H_!F]JHR\6Q29:20 MJ[>CWW$S-NJ=;F9TQ$GFORC@]68QRE*30PM[;K4,8T\BRCF."M-[A;^HM;]3 M+AK^E!2ULV.<\2#F!:$[T#?WN_77HOV0FZ!@/7T0^]6URO^*DX/4F#')'2XO M:;"&*:>OM'UKUTX%>NN_S&Y&X8MP]N]W!1X8CL5+:W26# MSQ(G:+ZSXV$]V=C';BVZ^I[>>UYT?@7E\[HH/KB]GV!R_B7[CDO$Y:Y8M0.U M.#Q+^:;TSEQ#ZTT8P#61W=GJ@K$(/AV#%6IK#S;[+Z8W84)\R#MY EC4?XL;PC;1K,N M+*B*)LGR"G3[O(9 ID"^NEUSC^.P_O*> WCE]YAJDY[N=8943?F-K2Y@5,QK M5XM/)63(IT@9Z?/K4Z0$SC]:5W^*PC-VMJ5G\\?;2:'?\QGR;Z]*Z1=U0S*' M0D6S91[K5#/$DC,3.VP3V3_[$3CN1WHY0OP$;D&1 M"!+14SV,DR+Y3U(S=9-8#Q+^EV5))[">:,:/L_=RUGS;/TBM&W*77P=]BAI6 M,]H6W#DV/2F+EC^K?59&-_1UXN96%1V/" EUS 3>+_U),C-:KK> M(M$&W6V(I!-*THYIA M]WBR>^Y&_O>('EVD^=XQF=Q='J8NZ.I-2W9'\I;NOMC#G$*KU]#"UNLURE2P M]=K^0F.PUY3A"%J5T!^3^'A_J>R2BK<%:C(*9W:"0H)0O[]YEI4I-Q+P%^OW MENLM8LR/:"CC%K/V;#^$\R,HQRZL\@3//YO^1,Q &$-I_HGVFT],&/XX<[VP MV%OS;KFTA^[B6><-],#O;E)VM,QR>R%9(9&G&\D*K,4^//$1HW,3VA M/3W-VE=4H1G;V5AXO%]N":M9F MZ R:O47WX[$'QS3*PF1+Z;D1H?4RQXRO,2(T&%Q\\WDH1QTK!BF&V C*GX!A@09S$4UJU/TH< M>',-K6ZM>"2 A1_<^^3O$]XN:O/O^[EXN+&F#%,(Y!BT.?]1Q?9W18^\5 38 M)=!SB59S?I1A_>4-$$[;\*5;3_=S^9AY<"_@9@[VS;91EOS"XHR"3P1WCI)$ M0MD,- ?EB[/Z>OQ$.BN6PU1!+^0@'B%!;0"RV[\>_5\)W?KTUP)"=7U%A=! MBP["Z;C\0OJ^C8BBYZ- ?(2]F_G[ C==:M/3;Z4O0=]YB5P/Q=4%U-F&60,YS;.S) M!$&259^-M./?B$DSK>#\A9OJGFYE/(.E%:X8<\3-$$5"LJ'5!*#*!YN0V%C7 M?3\3"E*8;&.PG-)4?M?G="3:-;G;RH!-#F(@\2 $"]=*("TVTI?-WQK? @VM MR:+9I.L#*6W.1M,H2W)PESBULB'%&PBD_RM6.!F(Z-%S<=BYFX.#9*GQ9P/@\LA-T'I);M[,'?_ M9[L<(>DH2_=7I=P*OY&]!K[PKA!AD>C;4C*.'][?A;B"^MHQV4SV MJN2(R5]XUSM[P_*QB;$EJ4^DAZ9)T2]BFVP%_2\KF[?G0QA_!KJC9&B M&<>)CR*G_#-89DA\6IB]WB:G6S<5#V?C-O\R*K_ 1;U942]%+M"X0>=^ M)!R?'/$,C$A\G#$.=//WLRW44?'SX>ZQ?4'"$-_,'%/8^$W4+]=&&#V+1?CC M"$/!_NZLXJ#H'X/(8K0,NZ7X.&^$$8^8K[3);NA%Q734L)2E&T3-UI//$%.^ MMM94C'6BF4\-7HZI. Y 4\Z[EE0Z>(#(&*:MRWX]KHI+@?YNC=R;B-QO92@# MIW05F.T;X]/PJS;CM;;7!DKJ2?DO0Q ^UHA01N8X*QSJ/P%ZQK!6K/B]?[34 M?/T0>G9:5#]%D_I+Z1TS"@*YLY0@.3I,TP\(9RV,UM0=YGQ_987<7=9ZC5"7"6/%)VHR0Y1>Z(%)6P+=?K8U7[ M0';M'/M=L4I=.BR$_< M$S.H] Y]@7E[I%C!=KQ+RA-08XPS.GN<-R9:G$M7)8CBTP@2X?=2;KGI\G:\ M2B-Z1[O?Z%6Q(W_(*GC8$RV(*3L[WA\\R- M^F-_I/#G&P$U HP O=9BGO!F\>L.T=N7HC]BXXEWD)O( E:Q MO+>/?#G600XU*]:&E-5!"A="O-:NEVT(8)0S=IBL-+97Z8 M:JW?U347ZX1 :>7@ X9+%O-I>3M9UKNODAW3- WU AX>.&#YM7!R)R&*D1[=!7ZFI5EV(C58*/ZFHP#*5#*Z! M)*P;T?7/&O%J9C @?N4D![AT,_(D9W_0LB:PFEM_TG'A4M;=7AKJ0+ZDW255$_VZ+E MFY:NV=MR1P6S<_T_$4[18=?ZEJ)N?9^DRGK6%K)Q=6^\;T"[%<5ZH+D_.'X_ MM#S>_R27C&O:$,W,&0=63!BJ%7H^ ;3K)P[Y,@W7J#[4S["[WEV=Q?&/-T6, M3DK2M&O4KFZ7VAARG"9GAH1,PYS>%:G<^4TN=.$G2#<-&7'S?_*M_$9BZ)(& MN&)F^7LH#[T8>P':U]/\Q34DFK)@D2*:HT#BK)@5#-QC26\_+6PK6-G3$[@J M*)@ _10TG4E#_EBO>][B'5P;'R-TQ"-)"9'QXGL"?/55LQ5[C+8NAJ^H6/N@ MOSWCC6#X3LD]0DI'$4T;/W@AQJ.9JC]=]Z#4":-:B,5[J-]#BY[-Y=J6#1-) M=$+:V%K=8*2;#!"+C#SOP!LJECG5>,>Y%XHJF^G"]"6'6?%P@,M(EL'<4ZJHU]@_8) 9 MJ*C$0Z6.3L71O'^@UR;EYB-QB49_\Q4$[.1$"3'/]PN6:9A65 (XN9[)ZC]L M=+_@/QU5!GCW$>QD49QBA;XT#]]OFW14SLPC-C0V.MF_BYYF="$$LC%W^9YR>O)82 MXC5/@#P9@ ^G*[LJ=RHB@\L@_M[9&)%GY)TT[%[;I0A2KJW5[)8HQR.)AGL. MIHEU"G(44;?)XCBE#/:#6+OL$<)PY?@BI7T8&F7JB)!"+50=-9WZ_;QRL#[F MMA:>]^M=998LWOCL[9K'XG(D:U#HA8-K&Q<&'-+3IE3P]OB]H8'& MK]N,BP?XBYPL/9SPI;AQQ8:C1PFZ^IUF \20FEE*"55'KJ5$LPN$6]U7>J=L MQ&E/'BN*#=ZJS^[H:G[7V,*1(X;+4S@"[>O2BV]:>DE30BKFE4J'Q^LC^5!W M^(?0XO1?X+/@%@][+IV_ ES3T!(Q42@A).2GNLF#;W&8L[+&67>+EE_ N!8X^T)OQ>&0.YGKPEI19X -<6 ]W=Z M IJ"@_VRG(Y6B+-,4*5NTL(RI_*;KPHS'+@GNPTXY1KA[\R3Q_E1R9T,P/_E M :G:=*T!AZX.3&,*XJ#%K8@6KB69?]DO1T">13E1,-F?6@0SRZM/3:T](,6@:*K"N$?WHY@.V##P69)1FI.);(8YSTFL/":L%: M\D:JD^5'60CA:5::PUA2\5/P2*87'1&^(L (7MRQB MP3Z=L!XX7]N76>Q=+;7Y426E%YT_R+,V35&>_R1Q(\M+=5!QT''@0U6)LG+E M3^-N?]DO?#>U>;(=P99A%H.!KXITG?8ANU@?I&^H M"UI4MKE;3=#IX07OY5^45MX823;$;X;)3&UXL.NF+"&(]),U.'4]![)J7C\N MQ?@B>'3]$\!<_UVK]!- ]-9OQ3[9<*-'F .A_3'FC+5JM:O'4Z')[FB#0"\ MG[?/,&9XEJ7)?J,^@IU!4Y?A(T(&AZ2*.M &XO/#6CAYD\@#;EXP\HMJKR"% MP.+#/2Y3;@!PO#:"SWS&Z'TM6$J6<+.[4.H)\*+?>MP*;EX;IX"2;8O7U3%L M%B$5Z_7S<"-ZH *"K_IB\3?TX[7AOATL2C4J3(,:=J_X M4XE]G?K78+,_ZD_: RW)!L"Y^&/3?),9\)48&?WS.Y+,]V MD<[T(X4+/;R2"3-84)UKD$34)XWM7BA73Q>-Q>_UL(@:];=WE4P&JYO\7-/> M$S( _=#1V>5UGW#P>HQM$*DU#L :E1@YUA>3V?N_'YMC/EKS_37/3/?S#[/^G7V>9^UUGGW/FL?] 1Z#B#14%%7 M 4 8 "ZN@#T)* $X&!C0["Q<" 0""XN#AX!!2$!/CX!+1DY,04C'3,3(QT# M PL['Q<+*P\; P.WV'4> 4$H%,K,)2$C+B3-)PP5^ED$A(N+2X!/0$-(2"-T MC>&:T+\\T!\ 4AP0#T@ #&(%,$A!8%(0N@-@ON*)!?IM +\/$ 88$PL;@H.+ MAW\U 4D"8(# 8 Q,,!86)N;5W8"K^P F*1;9-4$%;'*]!Q!65PJAX/AL'#;% MJE9*_<%==F$KMQ!GE[>/[./1I6/BSYQ&1"8DODY)37KU&Y.3FY1<4%A67 MO'U7C:RIK:MO:&OOZ.SZV/VI9VAX9'1L?.(K:GYA<6EY975M?6-O_^#PZ/CD M]/O93UT@ SZ8_R'NDBO=&%@8H(Q(3]U@3"\?TX@Q<2Z)HA-IJ '>>!*SBH4 MC$.A&)]=U8K+)JR_2VGE-HA'Q0Z=Y]C[*>TW9?^GE@4D ..#GCS@G"XZ[06>#+/'X/<32"!03".*+S#KIX^4Q)^DCB&YW9,21U M(2;*=FM"TBV,P^SQ+QI1M[Y\<5/G%M)V\8SG:% M)?.,!BU"J3HJ#B,X YN8 C1C2/R\DH_7DYB8G1P*_<%CJ<0EXFW5) M"0D2,6NV:Y4,F+[(@$\<7$LVM_YB/YWHO5@K%_W0\9(EUF /$EYNI#T*_RIB M_CW%T)G"CJ1'W+I5]B5H1D^9 O@+W&:D1IVK?_!U#6N_,K/82-DSYABTF)'W M7_X@31XD?\(:)(FXV2=23K7ZP4OP])GVN"<+ MC&,Z9$5SB:.HVW0GS,^AJ'_5F>R-_%Z:C3$9$033MIGLRM6!.Q*ZWE[PTD4=/J166*A*?ZT M0,[V@>XNQ<&GJ1[Q0Y'/G_:$.W770TPN%/(X\WB5/SL,. A_6[?DV< M;3W#'CP5/?UVFK?4_!8?K3>/^C/QF)**)6F4/FL%U6CSO3%*-2W!@3_XN M:UDI^Q6#W\,GR%SF3GZ2VE;U)E/ES&/$K"_@J_IYLHZX,:/I; !2/6A)6>9O M-9II,LI;YER]+2LC@M&50N5^^R0A^("@$$=(0'C[U,D!#5 BRW6T:YJ>:0X\ M(%/!5_4MYVB*7 SO$5HB"(TZHLDB-DPP7K 8DLPY_,R YR-!RWBSE6=%COP) M?[IPQR[J4^%7AUYV+R_O&0^L3_=2'R]RK5X(W"PX90STNF0<.UPO3%X@%--+ MP+=F<[HF>.*^?@D%;:@8CRE'=8>H+%V7SFQ+ZRM160'+",%68 &BQ*3^PGO. MT4>TG($DK4^TJ!4-"0']5W=;Y_P[GE@F92]LTC@=RH%.:YPED-'Z^P,6&L." M!!B@ME7\]*Q=R0'(X!T]98#B"I01"^E,YY:#?-#/,HHWH?71\^DSL[TC5/GS MJ]0TD$U^[VG%G=@\(!"?4G4)$*] 1 *] U S9Z(UTT+3CX[U96)BD@SC(630%:FA'<[B$'7="<0R(D>7 +P"SL9,H=-]7 M90D!83XVI"P,VLX=X75",MH9C7:F1O#>?Y\&=15?F[A+_\J+-TT7#/>G]A0M MMO-;(":9AMVTNK0I(U-B$,P+#6;#9)8BJP:=11+ MKNPI-;416/X)NNJ.CKJ('<2[M4K%HZI>V>'QUHHBVJ M?G%:CEFZW'%9]Y&+P=VR7!EP\98CR(TUJ1N%ZI X(J G]J4>-?D:6G?NB]*X M!':;I;= %M)1[E$;P>^+H.RS+EG6X7U(.#3Q#N^X[K/+4@>'1]:BR;J2WPT[*;BY<>;V,KN:R2*!_H'#3QX!K/BT2/IR M1;5:VY7U4+7O[/NJ!:Z'E-D_F\RN6QF(%5Z39=?JW3\S=<9,G5A MWBZXTXDC\157P.)X!OOM''C4">+G@KH$+,2(<"'[TS$CH/?*%+J@ MGS"?C0QUIXJ?B$&@V\>8,&!LEU(>I_S/PO +9PV!4 M]#7$.700@:EOV43B2(6QOZ5FK8Y5^%#?RFR_AY)D%6E?3RZG M_LIT7\)6ZU/UG(WWDUOQ=_S]"&N/^UZ[EZZGH)*CXC3>*H$Z7#4TMN/W>XCI M@R %[F:R!"_48G72J^%4JUK!4X(FP\X(UY.4E4=7(H<&E=UEV<:0-)[--^4' M6_I2QC=Y^EU=PH9PP+>]1'K;<'$.FI%#QQG:-0*(R8 MB9!Q&B#C $.,YX3.NKN9]SH#RI#&-RX0O1]!V(@,39\C3A27-41P_[=^*-A14CFZ34(R@D2D*8L='RL$WJXR6CE M+'K&W1WW/?4XNJ/$Z9*W1'$5]5;D/;%]@V7C?&HI(6?7V/R1.?3-AZ(.&AMV M,FS?"E3]>PHTT*W3A@:.J9C/6!V!=>[?N^$GRA">44:QOHSI#19R,Z^M=+>/ M'CT<17!G843^\R 6.T_';]2.9JHB='I^$ M4VF_AXI&_ASW0N/#(2&B>V89-,-P'JO&#-X[&[4I0M@-37:*)B'S*N3+NA!Y M;O#C/YC\*G3]YB\K)XLHX5]0]2N(E#K?MHM6%JZWMR4C?GR)5^[_$VW%>A:PBQU(Q+LM-C+ M2"F:GC&>7A<5V_;#:PBHZ#KF9J2(?_F Y=I('/%MG)(G^,/E.QG;GHRR9XSZ M;1?F&B?C+Z!O>ZQ0;\E>6332A 'W'S_4A?@J4\96G,9,*L+4")L[E[<7WYJ9 MFG$[L*.$/B8 @"=[\%"0*'=9+[X%<@_KA?DD3Q54OYJ\57([@9;Z&QO1Q\(1 M$L<"Y,(K:.II]1H/OR>OBMJ76=NW\E_B5^FGJD *T@09KIV LY'8G]*)6;*1 MRG$7?:*S2'T2F,;.HB+CBQ1=^_^HP_R=J+ \R$KM06^N@W\76)_0]M*V /XGI1Y:@?=.OH> M39Y/3-[]$.+YG'6%MIY>ETG2LV+E'V\(_RKF^?R]X$?/!H\"B3:TD;9V A-- MW?,/0;0N.#8W%+BJ%AK@^,:U8[P6VV7.Y6S/PW"][0?(/^Z&@]G6S5=C>!93 MC8;M1JL;IPT48JY3:?JIH;03$QHM%BU-O,+!%;CKAM)8]L>?2V20T2N9.9\E MD6'Y*TI9*+&XO(1(L[C"J3G;(*F_ALF5"P,T<$T.'PU,& >N193F53AWRNV3 M[[[_$?;L\CDB2%*#^\_1\U^!./-SU'%V/HBPI?A'$O&$7;UZ6[%P7ZI7&SX& MM@(7XVWQ;V9/&,9F34:/^CF7^:HG?:UB9NQWC;R3"2)I K88W/O98T9?+Z;? M6J=.]O8>$YA=BR7O=,?Z,L .X[R3&PN-[FTG>$SW=;>@V+ED;9,W&5$CJN'U MH>H3?B[QW?U70<*H(#'[G-*965.'FG+W $_"\H8?Z[9QK+$=>_)4W$7;.RR- MM9HO''(1M-A+":($93(*#'1<=>%CD(P%^_DP;%-UFAM%)USY@/HOR#^[N+^SO:%NM MFH:K>7[-"]O)N:;(;BLWC=DJ#>]S]Y>P6<#9OAP:)S$WK4^8V1@S8'A312-E_#@& M9\T>C/\ARPS&Q#^\/<(;5E-Z_M222FB/K:%H2XS,=0?V^O1UY3HJ;NS0;+/R MW:1#C9!XV.@SU Y"R!H<O+*SAH.[51O9G7-;%"%ZQ9BEA(P,$W1 ?GSL$VX4AOJX7%" MA-6Y)-\13U;_18S,)K*F M-F9HC-X^F+3C!1V&FPLVUGV?_\D$?FU1[4*$MRL#,1K=>S0_!=\N&U)-OH5) M35 \)AW6[20<.;"[O!);W%]\;_VSM'="3ZD?90_4K6LCZ\9;L6EZ%Q5QB5[W M0)(C^FEBHS>C'JE/S2;@G ?9Y]?2FNMNF*2NZI;D$;DGW,9VU,%'G4;*46WT M>EY%=3Z.Y[,EQDV/[GP\KZ*=40&.,%<] >_#/T[SOYPQC'YI]?]>0_L6=EJU MD?](7T4##HRR<^:8=ZX?RZ5\X:\[FJYUDNCS,U*8YW[26PI[8S&M[EL2\<"O M-#E*):9 FDPJ^KU&^A]+R4$:S6G&'&[B=5>EK)5JO(<-W' M96/&CEY][OYB!O+]'/^[YNB+,OZN"BDESP4MO69'2C3^M1+^!9 M_;\BV&7V:XO0H.W(K$[3[L;Z@46O%],1)U%PW^T%' ;#PC"/=,N>;X8CGJ4O M<)T\::WC\"E=Z<*B6,ZG#B+[]YA?0-6WCWBQS_K-;[+*5/<[%V@M8MY/NI_' MU SS;D=,9[R[_Z23\%!OG[/9)7MD_[SSC>L;2E-$W MMD+_HK28-_-A1=4V7N3T'2?_!(E%RO%QB05>[,L#PV&19J:%&5Y-'3(5LF7C M3J@^J-[,F0WK3HA4)% YUZNXHQGMI])T,V"Q>GP!>%9 MC-2%39SMK6_(TGYRQP8/$J570ZC[$?2@CY]CTQ)CB-P_8*1H[^Z\RU\[>UES M9:TBEJMLS=N*[PA>F-5'*=11OU*D"0S06_QU*FU5JI)E&JQ^J-HMU==##$^6P&E*:-- M>@4PIFN[HTG9#0>YH]YBJ0X\L&""K(LO6]$GS)&$;?33VHPMP\%Q5NO,LMN9CFM-Y%@?+]@,$6$SA;Y% MYALD']UO3HG?B.K&O7,7N!%U2/E>IHE:%TI-\A%Z6V"P.SOI69V(DNKN9P1;8RWC3DB>RQBJM1EAY'Z^J)4_5I,2 .-U ^PW1KQG8P/#FWCU Z" M]\1Z/_;1,*?V3F?Z'V[K;<[P[UH6[YZM:KS)0"WOP+61!4EXEQ>:M3@91C/Z M] R+4;8-VFRM#1IFZPWAQ7G&VA6=<)*,O2Q#KY?Z8+7OL'$>S7 M!4U5.I>XPX.&%-OVK780/VC58BJO_Z3_WLP)1VPMK5P)B_>'1NL M0-+:Q3\4$OR"91Y,%W41+,]XA&)3%[0O^5ZS8MM@ #Q/=.(6I9_-+5# M;Q)ES#%(AD]AA.^2WG1L2&LE&1]3S2*3,B^;ZU?LQQXFT MDU((JH!LX4T9)O+@^N.*R#HT0*[@^V#A!WF'RU=S2Y29@JN#)^-;YR0J[7QS M?D-:+0;W/GNP3CO=(6I$;,"RE;$EM]!"I'S$M>KA%'"_1T?*Q)@TTQ55M&') M,L:UQS'V8GY3\[K-FQK-%\7\[#86_>GQ%8,C85>MVCTWR@@^5]*HW2..X!K\ M9@DWT#5Y\$:9R>?IC5OYX2Y$("OA#R MH4"P].@]VPW!B_L8TS0 T9SO=6,F\WG<;Q0B&L%GP"FV28^A=/U,@&VW[!M% MVL83ZM5+J]^6C,XN7ZQGMH]H6]?WN\Z K]U="9Q]*0GSDZZM)Y1AE3Z![3., M8TT2Q68H,Q,U3RUUE_[J^^U\;NH?N2A LX,FF;OQ:X&'M,/O=Z_+=<6>JAW* MG1&LSYY29"[*TWD8VEVP/V;^@>WQ[0)/9R_WDDR&^#)4TOL2B^MT #N=\C4: MP&5ZA@84TJ70 $;BA3T:>!JKA :R^M+10+#Z)114J&P;V*::C08&[&ZC@0]Y M:(!.;IYU VL"1>B@3G]P&C X?^$ ]M?. 3^]RD\K6(?:-+GMI_6>)LQMZOL M2Y")*[)Y_;(S;Y.*31-"JNY.3CNGLS/G7QG3$6^9_O]D.R]Y^J*@*ZOJ,&.GO]G"MZ^1.[9RMC:>ZI9HLS'8Q:TK?O%9R4SU+NR-FU<;EU MS9C//5;/,K%HUL? L.9<--\WU^+#;?_&""O/_@KWX8,2:SHZ M_X*5_K,QGQ7$13V72'@SU&!0GO;>;I0]\R%X6&Z73&XW]Y(T&GP9]-CN$D/U MDK)4&; );!/,"AP@UKKBH88&VF)/5:#$9Z#US%-^( M1^\DU$XP--_0?@"8/B" V+^M1!'8)ORSBO;O52HF9E&.7GHSQE.JKG#N'G7Z MAW15OS I*R=N1=@DW'O1RZSE+G(XK'P9$_W\Z]O<0@:OBI)(H.?*-&OY*].8 MKNP,BD<#8**$!): "G*Q@-R,L(HP$0&QK DYNG&9!;@Q0$SK$'SIM6ZV(;7;!)0GX MA[,7F+$7W%=4['ZCDOH[%<>_V/KO=*YL3?]IAO/?V/HG0_Y$XH[ILT@>:#^9 M0P-C]TMS1YQM@N! +[QCZPS8#S/_YJ[2"6VO5&*,"5(8XXK 5#TK"(=FTTJ$&EM,?K1^X^G)S&*7Q2!TP,OZ(+UX>P2=TIY0TOMZ-B%BDI&'LY5X_JZ/AHV0TL/GJ=I[J MY5X_2[D!^CHQ*S0._"7)_L&"=X:*K*#9.NE9;8%W?C[7O7X:>K[GZ;>+4):2/J] M?]L9"./HPMU/L.$/'H]:C2SDBH".CI9[G%:P(M01RNX4);J0\"!!%KQ#ZJT;9SY[346(OA:SKK4(8Z>HX96T:EU4?;I&(% 7T/^ M_CL=ZF2HV#7E@'677[!= 5JA'\C!5+E.R<_CE5GA#2$F"/JH2JE;32&" M?4(2#"N--_Z'*<^]\3_Y 3GG:99,<=* I,0*W6Y@<<+].29X-D^DL>@$O6 D7" MOE1VEUL:=<^^('REXP^)7G]D2K_IQ4AMQ$3NP]&"4+^G1K70FBQ3RI] <7'Z M22IXP[77\Z4N!*$P%ZW?-M:_E3#U260EZLRS?=JCZ$#_%'T3M("<_7Z+KO#4JJ(\6L3',$Y8@&,>OJZ+I]/E<8Y0=(-$QMO M?')U4@T'8K)=DJD?L-Z*L"6%5FW9:FU-/18=[GJ"U-':?5);X//X7*ENJ&70 MNZA)7\$_X9JF"+W+T\0Z7V,IK]",B4JS_>$O9(_N"1!F5_7)"*_?SB*6J]HM MWVYYEJ^2#,,Z?-SFXB 6URM"V!_^;*8<: M-[,I\]=L^%+P>TEJ[$D!A1S/#)<\*^]?4>SAQS=WI-MY7:19Z/B(M2FB CN+ M-TDQSVW[1M5]!N'@Q W!H>I#0C']87^M:V_?--0.$=22F7-LM!F*6AG36!#M MT\:X3(.V/U1L1 +HK_\&4$L#!!0 ( #B"?U1.^@&VLTX +=0 8 M979A>"TR,#(Q,3(S,7@R,&8P-#@N:G!GG+=E5!S \Z8[Z&"!X.X:+#@,#@D> MW)T@00=WEP !!@\0!G>'X!Z"#QX[6WWJ2W>?/O5T M]ZEZZW7A=1WP5E%601: @ @ (/P;@-GH& 1?,?.Q$(2\]#HI6N["34FSQAXS5U#T3&(B$E(R1B9F%G>L?+Q M"P@*@80_?)21E9-74-34TM;1U=,WL+"T^F)M8VOGYN[AZ>7MXQOV-3PB\EM4 M=%+R]Y34M!_IT/R"PJ+BDM*R\KKZAL:FYI;6MI[>OOZ!0=C0\-3TS.S<_,(B M?&-S:WMG=^_O_L'YQ>75];7=Z/2\&F>$YJZ3&$0,?!N,Y_]! M^^]D___ 0O^OR/Y?L/_B@@.PD!#^/1X2+D "+GUAO/">$.:O>^ZE.N..+QX?P"Y0-"S2DSLQ6)Z$$?_!Z"7\G+J/K+BQ MJ#O/>(*_K>8T]2Q"" FG!2E)@54K+OVJAO%7Q*7F/.?5,^?BKBHH6L:)1*1G M&_5>[C8(V_Y/P2;2W*'( "1P.7 WD9_'XS[ M=2FN>39[4C">.?2Y,D8-XSEU_W/(RSGV1_ MDD%YX7C"," QXL3$BI-"(B4E'214)-CM7$'W8)T.O"GY\UUW M NHT8(J_W];^/OK-5Z)$$71ZM$]Q0O2.JYW!CIG)8[ZH\>=^'V>G< GP.Z;' M=ABJ)9FM %4'EN;3'5(6-]4Z;R0R[>3DJ>*!WLP[YMX;$G$ ME-FZ,25NZ$T]/%E9MHGV$PEOU>,>WLIU*9X_#A7-<&:HS]:0:[2YA8F>^.<& MM>6ZO@)D #H-?X=]KT"'YI]5E1T5D+^U=7#2:.,C.9DSN_\"1;D'#W]NL7O77NE+D,7^E]?X']Q-OR^0*:&L^/$5&V?8@E7DIFD MP!8*'#=EII6$# 7C#'==(+!?C-;IZ*B1A*DN>\_F'D9+&J%%X0:[V@_+3IG[ M%^F^89%Z*3SU6_!!7:A6CMJ[EH:COA*BZO3 : =7AMK*Q+8VKN&ZS% QJ=*] M]J8F%N:6:+H]NU-G06J'F>_*,J3_6[;\G_Z.5]X@F!(Z,<!B=[T?]$4_ M$6]-B)U0==6*GE9!Z'C ;@/;OAXTHV[K)6Q*HB]75;4S7LJQNLDRFF#47B>K MBO#]F :X'Y8>F._,DXO:FX?;2;L2-&D\I',D,>9WU MJGLC2HQ[KB4>$L@PW:CLBL-TSK$ECX57WIUNC;R3&"J(/_A)1]@&.M#L1U@GPU%<^$T9UK$I*!7, M,(*-(T1SO357]T(H;E?7;M@9$^.:DMK?!5S8G\<_@ ;$Y=>:FDHUS6WR+,3R MIDD+F??+34^U';9]YJ"V\-S4U86"3P2$7\A#PY%H MK+.S@V>D]PNO X(TH+<>GG(RU)&<3QI?9BHYBVVKMVUQ'3.%MYCM8"X-W$AQ M"ENYA%YJ+5,GM)UI_0;\TR;LF"@-<]$&7(@NH20H9O(2@MJ(C24_YXIFJ:;E M$VRA[LTH%K&WW!"ZT$>!Y''\DTS/ZXK;;-RZ4"$&,N/$:9Z?A!RLHP>RDYSK MSO+' \)S*5S#A2#"^>(,DH$N]F3?'X$$7=GO,?E3*EWL=(@RBG)BQS-:EW9P M0UV%&-8MLQM'#;Q77WITZU*G1):T<3 K^QHB!,STO;+3Z:N%)@B7O=VDA!VS MQ8^MJMMNN/[SYK3VF+,/_AV9_&"Q>8FM]CB@F_)PW>6+6E-[QC;:YYW..,] M M5$$M-SYCJ3, :"L!!]-F0-I0:3QA-2D=S)^+[HI)=W_A2=+AYF;^M"5L=KD, MF4"._^%^.F"__Q[++@<.M3M%\I?2MM0,H5O_'.ERJC^CHK['5SAC!7-25[Z/ M?/QP782%/OCAKSU2H<'_R$:X/UB3Y &N"L_3N6.RO]>)#C.&2UXT># MLW0,SLDFQ E2=Y%[OOOSY/B);4%7ADSWMJBV/ZI/R"]A&2UZ%36$'K@[_9'H&(%IFD((8LW<)=%]26<]OI8.^O1 MS(PJ2U+\%;!J]_?[N*)[3<5+5\UA[B4->DAPY,_ALE? 8O8/2U:![9#GM18) MVHD]==[,Y.3L/=&7@+*,3J$''4XY+=NDDT$9I+_!0<*F?*\ [U? FM(+(7;@ M=\N92YY[7,[C%4FG\K(7K9V$+1MFZA4@_OV%>!1(2JHZIAY]4 UR]IEM 4\=:2@ MOHUT*JVBYR6=YJ?W2.(EIQ-U%< *:Z5)1DW)U8EY'(JT-MMGFPIU*(: MX)WVENP?#_D.P5(C'ZCV_DK)^ J]:^#I3V:(IU.57[_S?\KH=1Z_T"5-?C2K MTG]5J5).)YJ&YE2?'-R^HN603 "/#1);O^_]V9>>^A4%NEXPDL D \2; M] @PQ/R'[.(5\,9?>M;AZ6.;8WWYTIJ),&] -,!9XAL2/84U$()C,55R%[D5 M^[Y/6.:[\)M[GZ0M_\4W;[7@KM7ZWN.^V"[+&#NF>H_:.Q%%J&D[1H8!YXA9 M16XA2=R)%TF\[1ANX_;RQGRMCMFGM1/:G09^5!4U_E*-T>_K]B,]^N:.7OQ" M\2B>RA6ZAY8E!\NN:C*NNXCM32U;IIT:F5LZ\%,%T5L9]F%?MO*V'"6H4F;U MC=;D\KJ^09_%EQPMY1HOI=[3\\1OP+!Z@S&2@WUUR?/WN0[F?;,K*N KHNA< M4H3M )--N7M-YMS'ODF,A*PMA8.L'P9*!AF40>'N,55D:(VQ5N;M+7KIM.$K MS:S)E^_<4I913]-*28O'. M]S%Y%^03H8$@@D\#073NHTJOLC9<'-(T_I2GK*52&'?/O\_^Q%]\ +?GT^FU M&EDZD6B/MT5E^1ZPE7D^2,(?2S/#7],@!RX?Y85>3,1$+IA&CK?K7R=-P&]:,=B-:@P8#2IJK7 UP8JW/QJZF M]U.)0AB4PRVQ](*ED)N.KI$@ZP\:-0;JD7ST7KL6 M,JK]+8IQ]LWIVF^%HZ;&@2YN>@AJLY5PK*]@Q;GC6W=&;'.D<*QF2T4W>QW% MWB'QZPW(E'$/RGL1C"H0OT&B)G0XAL'E>%KF/ZVD$CG31ASMKHHGPP"5+4!9 MB(T6DMW&/7ZV-_^E,BD:4/@WN3@'7-!8U9)LORSE[)5*;YN0>%L[#B3<]\V) MOC:FTLM+UDB CZ$W$R>!!N'H]X'JXZL\AB&02ZAB[.SFL,>R<1'^HMOX._N] MG3E_O8?8V(D<]F:%=PO:& 'YR$X9GJZ3"7+2:,[VR^[&4HT<3/!-M0KGR0KE MMX?DN)FXV:S,RH,:^[.:?_[D1[/QJN5'V_(!"C>A!C_&U--RT3$U,6>4&3]. M/?Y!]LUG'$_Q0:HO'\(L8W'N#8.)-UZJ?ML-L.YV1)H@8UQ\&[433R$P&T/M MH_=N0M3M;GXJ2^A]"ZHE,PB()S@+BG#*.\ZK: M.=WX-4-YNL8RZ8#)>R,K6W?X^17 A13*FR1U34K5]J"]FN93-1) <;'4SP=F MS,J'P1P->*02U@EE83"3%67]YOGCZBDEH6-'L(61251N J_"6Q'5X8):Y..' M;!=#65S%H1^*;JZ=<1+*9_UST&1[@P;#JXM"Q284!K,6V, J,1:0YCQ>Q0XS M(^.'N_;\U;'GT6C]$0_1(M,N" 0]D!VE45L.@W]F]%LJ--FG5Z5ZMJ? M$_B'2\@2CD 9,N[*-B&J32$]HT39IW,A^D7D&Q8M(V;'=UM$_Z+:04H$"HP> M1X[AK*RDP_K61D&FF?01S+LMU]6 [<<0CL[?*/$FK;!JZ(CV68]XR0S-E$<$@;DB#<#ZP21(' MU!'-]B8,87>3#Q7JR$\,E?"@ 4V8W.\1VC58,:.TK>VJUMNO!BAG'-K;6#+= MP&V+X4K*8%*U<55S!=@M3< [8HUZXW=@E)6>"J7.@E8J\\P 8<]!"O/:?+#T M=J74 ML7^I9&O.#)=>AE<0K:;?.W?^%AMDFVL3.-_IU>NU]@\]C>LC5N(_-=#O8W),=D]A*A>Q_D9SG^ M^8.;>=^2L+WZ##6\I;Y<+M"E8#W.>W+OB]]FD@Q)P-)R*'CKH!F1S9"EP-6=5DUGXJNV@VA3C=$-3$C/:3S0T+^Y_HI3(5!J- M82\D[ETWIVYU:(;_B+*JR%EU9+6M\.Q+;,D$7>FW907^5H1B-2$,'$9YFH8;/C .>W0SL[0B_C0NSP[7PN#-?^-^'^^,'E-RU/1K/ M9!8_U_:3976GR")1';CJO8C.YZ'J;'N\ BSG\+/2V#V%;:?;]U*WFGB>!Y[( MH=)KEY/R#I,FUA;K-V1G2R?,ZEP.IEF+%+6'\H*L(4W M!K=M$*XG[N;[)KU5>^9]*XYMM1R:/SRY-F.(9TW\Y&\A00I6S#EI]-8=X+"Q MR^9LG,0,RK-U(<](P$&!C4N<9N+-)2?6KFUY9X MKMV5M?@>_X(<:'&$HIVJV=+\@[29Z%*$Z.]4 %"&4/24GGMUR8K=BUJ!Q&KB M"84KOU3^?IL3H1OSKT1($*>RET)A93P3U,U_ZH [@Q*!A 2I+>P54$^UF\]Q MY[G5_#,O_E? ,H/3*P&)475D#_.2HDLI7'3WIAJ),_89S>; M/BGLB!<4F<"V95-_"B(I\'T]B>N!M+D^B2%R8MSLJJH"I0%6II MVK15=1[I:.ZG)1J/\A+@( &#;G5)Q=X@F,<*"6[$7]YKC&$U30\AGW=HRO:; M"!KQ),Z\]26SXN93B?UC%N2.-/T\?>2G_6.;Y#Z&<) A8+.@Z_%O$+=6R).L ML)_VM\7F-X5.L.Y7@#T%=9^+@:R]R.\%QSY,I[61/$,4BH&')8SFUX M .99;W_59A?ZP/S[+-G1;YSUL]^HV5X!OR,/WO@?(N@@?""41?C@I6UQ05TN M0?W!.*TWUJ-!XIL 9&^D<4[WZ++$*D/H%?!G8[_H% ]02&_ M)D.'2*XHH)\B7XB#W'[G8JF^]>[Z>#:57+82V^U%L%J U(P,>6G<766]JR@P M7I2L4VY:-?3T<;^#N;'^I&&C",9V=AG:K;AK6OLTQSQ[ ETL2B'M2R P/M%N M6A?!.A:BQXR3#9A(5Z9\JH,O+E&^_Z2:2I*X8IDA$B?FLP>%+Z<&?'I_S-E& M=$7>#E9\'&^=VC,4&H=IK#?4UEO$;B=4Q+4..N@$3W4U=2B!T@P;(OK8Y AT M+B+UQ(W66;,*SV1!6U4\@[W[-UWU8^4K![I#M&_P%U/"?[HT&M\S9/.@BO4; MA.ZB$58.9($ML.25,J)Z>? D14*#T?:R55>H4A3V3_$9*W9 *_:&$<:2E3KU MJ\MFPN,6&*3R*)[!Z.K'@_R=ZW[/7P+TCZRF.1P=TO_QG+?^\4-W>/W^WXVX_G65D?=] /63C5C6Y_-> LRHO0)3(@#)O0P M*X'KG:-[]@J(LGA#,>5CR!A;:#Y"_Q;GIQ5-W.^X9];,"9\M9?7&]F,JR5I6 MV4]U)%634O=*(I:95S0Z+A7"M6J>ME7S][X>.%]R[[N0=#7:9-9JECL[FY>T M\^.$T+Y7_\8?706L/O[(Q$*4%*O@[2=:)9[B(V>C%-Z!'W<4)T9;C\F2IV?0 M(]VY-#R$3>7/5%99*7 Z/DG960&)1BN^-M&DOON)'[NX%?]ICLPVT=XWK'5F M9CLDD51"164RIPBDH2+M4RRQH-M1 M/26]<_6BNKS^-S4,EP-JJ!I"RKV>W&&PZRI*=V.9P-?+&B"R/YBK8;_M9+$I3?*"H*"T@X:1"WS'F7S?812M[> M.G8U>!,4D>E/Y2%Y)!:YC=")JE$2EZIBY+&PU8&A43>?,[QCJ.T>D07>JH.U M@E%/ 0;1X'&QOI,VN8 VCS]XL6H[#<]US0VFWLD9=_ULR69Q(IVSB<;TH0 < M/TEXKU\+D5) KYW"'JYG)R Z WJ%C>B6M858DJL5+?4YSH, [,P'W53O/2E3 M3.^$&)'8$>&&7)3'X.1!)))!QY7#Z2=>KS<1824*%#>;WN#1'EM';E'T2Q$7 MR!:R5_=0/FYR!_E"ZSCK+-[R VKTGGL7T?ZMKW'#*5_L.GRQLCIV%;D87.C\\/BI7>31AHW\SU84D\J(R7Q.-+P512ZTA!4I#$;V@< M])?,T8F1#0V@5C&\W_I!]*T62%6 C#_1Z1[+\<6>"%RV/V&7AF?8_E;'YN7B MK5MB]K6:9Y+EF D'!5:RH;V!M'YC[ [DIHZ-)-_()QVFI1FRBRCKB],^\$+A&]]:8[-BY.) MXJ U'Z 9W/TNB.2R#**L0^_WR>XDW!Q#3V'X@GN*K:*OYIQ;^ACL2>$L-%AA"S.G[4LIPR]*MH:]U@Q#K M8#LY$D1N0/[HO>.)E>^!A2J$Y(D^Q%RRI\SVE^FX;/KNDZFWY[)WV",K>A6G M!6Y%,VS=<3T8D[)2JT:J/;&?9^JF1]^JH\50A-"3CE^O)UTZ:SF-P@+SQ%?' MLV#3^(/*)'N#1Y:E.DD&E4DWMM0]8'TO2>%:5%?\H>]2_'XT2>(6,AZ4SD^0 MNS^LD5+]Z/GWG=\A[.CD28KPIHCZQC$=O(LN'[%IKRHL:QZH Q.:$..>K_(P MP3N7[5H7D^%;6LAMP3.H%VOL_QVUG>Q"F_(-= @)"& ;JKQF"-WGU.!)ZNGY MZ/".-@1&OP.,ZPJW-[J;>[AY$!ER3/\2ZYFK)YT/28X-/MY.S@:-&6;)\0=% MEJ8(%17OS022GC=FM] W9PO6SI"F^T$?T*(!)O)5C^^3?(P)1[T#\Z3&HI:KLZ8/ 58/!=7D1PW:?T%O(T"7ET MD=T6M>JB( ,D;FO'9G]R4%.B^HUQK[CY= #/+JF8F%@ZU1\/VDNR@CV%8CP( M#GCE++Z@SYTD1FS7)3NI#QGA[)GR]E*M\*S2/JEMG2>I=0W9EV U.FP,*BVK MG\"L&%L2GOH >RN_O)ZY6#-J'561+P*B7@$(.H[DHYR]=R,YC_LW\7^T%; 5 MQ MSYI'NM4[M2/:%*O@+SHZYHHZ&T<^$G*I^CO M33///AZ\O#9NN@=5@"D,ST;E""A8E MN:?6WCR\N:@YFCI>YV(@Q"3@#51:XEL4%_H3@#K<%9X2OO(*^"?CD*2L[/G[ M0D\64J(PWZ(>)<>%K;:-1.K<'7_)#1W)$]_83[=3%)WOAW;%#^1Y@3_O[U)F1RQ EE4T<<,NG/3=S:)6NK*+=BTN"W1J\OMAH?D.VL90]=C>R>%( M!WSQ98!@2ZPS2YR1D=#OX9"_ F"/FSB/:,K_[H*LN^KT?Y_ S5A6GRM2"51S MR08VNSS,\-,( :DBJ2/IRG 9\WSQ&&A5,9F' [YF!L8A5!#SR#O$CEH[G'5X MR5*MT;O"T(>A*IH1/O3 1MS'M31E077J&WTY;5[,_YU&B]= MQ0$RA0<*%3:IPM] AA7N:2@_QR2^705+*(JJW<*B^W,>G,8!/ M3=11-4W7[)_$$@+>\N">V8*6)<:-/A MHP5YL5L"!O?O=;.<#]FS^ZN,1@N#KJVZ$5*C%FZ$HF^!;OLF3NZ6];-KNAW3 M%MQ1V?!WEEFX9K(#Y1<7 M G75>J'+U[=_V4P5YJR@^^(K8,+9E)[::+&06IXFP+TF1S)A(;CFFHC9"@7S[Q[N_Q=%I[[!RW M9+_";70]TQ)'ZNS-/M$24U"G:&6MJ I1Q[J] N!D'6Y ^:L1$!(J'F^>F5R> MI[D$QL&33 G\ ]:?U4^?SG[3M(S"%-O.\KQ + 5>Y'4N^KZ-QA'['L>5!#XA>,>B-EG!_^N3XC M8 W0X?V#BY=R@_$'^9:NCEGE&:LL9&427)BV6PNJ&2+$[*TPM$"\OK@Z9&?( M#7\YH'2$W"=9!%(&]"%'E]B4L5@8*5E=_8!*JS=_VK:(B,N;:FZBLCS+E#\E M[>*JW E<5@>[:V[V0J/.&S%SEHBL8:KTAL)OY0T5.)_X44); M[I'HCRUF+L@IK$GXI^#C#YZU',V11]99@C31IJPDL]Y#C-'N&ZW'8QXO3"M5 M2W #$_UE!;.D\-03^ G?:+A+NR.V%O[#G%MXH'>YBU';I?A*Y7M[E,JG0A.+D6>!/)WJU"6?&1 QTW!%9 M0X;P[^X?;IU[2[=$=; A8X6,-VG(PO[$G],I'9%V+8> 0$\2,^O$.-\YW*3Q MFVURPNA5QS2B5\"7+V8?*+X/=5.B(5]7Y9%,IPD;=+[(NII,G3M]:)K7> 6H M_03SZAIJ/6K&UP]^IIH=%M#7R]R0'"#98HA;GI?(MQ6 RQ;\>K!LE1)J#O.K MIK5(OGRWSN68"_']4E([]Z0>5!CTI5+ 8?L4']07>1LP.!1\6?! M=L[\8O=4.HNI(47#:*23B8>3,(-YIWO7'(19.K1.U M<^^I]^X5>6]&[4LKNS>;Y5:KJ3$,XY#PLA#*Q,GN#%_P%)@G.6LX"F1%NK[! MNGW>#0BMGZF(6PRXZ+ISL [JM3;'C?? O=^^'$S0#,>5B+1E5E!@O5#&^LF% M!9+O4^$EF/199Z@E$"4I,,"PY(20XNVT*7.XW5/FWU44WXG(U4[G-=D+I2?Z ML+5@_5/(Z[[8/=%_6:K]FCQ8"C]>FWSH5WFV:\AZAU5!>ZBU8]?(H?[]4O)M M^ZRGKWM$16TNBG4Q47%M,;XDSDHV6]_UX[/3QW/*WKL@[4M<3\P,Y1;RM#@U M".'GE0![.*_)YW/\'E7&\WGW,KJX&Y:^" E^M>!6QM"MW:=GNR1EHVK4RH[-[OS6%5+65O"CFGZC]]RS1 +8G\,4@H!5_-3]PSBCOD?\PCZ%+^@ M73!8UN-)4>Q,E] ON%<[@F621W->X!4&6&4H"4):^!E-LO3J6! MV(MG^R#UZ>*.J?Q?[4W0N:,!S[ZFT5#9-R-;)-M4\B>L5TF^J+6V1MV)HX[F MJ<,,SDN&OG7K#QZ;J>2)UCX4:V9?.SAK&F\)&2@NT+6QPJ4^6![JE'YMDJO"(233 M%R':SDBLJ=W%R:*@F[%'A Y6X,B;V((=T_W$1C4\8.$>ZI%*HC :%W.))5LRI'=>7$24A#B$]XK[ ' /!.E'Q0B17J8>6>I+,36%FT[L.5*KU+ M'!ON04>G2$-4+J=4<\0BH* X/XVN*K]S7?OT,^)Z VKH@SUUSGU/_B<"\")4 M?:CT9XZ%D]/I"+S9E&*>:A@!3@29R:.APUO$5$'+WMT5<*WW_+M+L"M(!ZI2 M:I+HD&,+2=1#<*&E.PR8;5^R4-*EF;'4\K=)+M9:F1GIV$:\W,Z&@^^Q3(?% MJOV29!V'G?K0N+ISPP\]]]$X+HD=NGIB:/]5?S1148ZM88\>DNE^#(6?U82! MG4[,X^;@;"&LD2&]2.S,MK*K()(A=FPNE_GH,76OF=EYG4G"#J3B9<-N-MOY MW0LG 0E6..-*@^/.S1[R=C#Z_E!-R:;/)WD3.I)2&&Q]GGL#)_)!, Q?@&[7 M=CC!"BKM>R%O$L8,;^M<.X)&*? E_36BF09?X_N<5VL7IN/4\_J"<_ M3]_/D&&-6M^1!*(FW!O?XOR>276EP% ^[S,5^OQGU\HWUS, /([FLZ"VWZ\ Q?LYGC>=%3<7ZQ+?(27W M\R;D97L6+T,Y3[A![<0OHW9ECQ57IHNQ>7- !Q)X+9\OD6A MG SAWQ?LL]WX,AMAK69/3_QE8Y-E.9:6;,M4^0(,^7#-"&?T]>O-.L=!15TA M3,S%AA7%N9'"RK(0ZF%L+FR7,:V9JV,1Y29C5FH<93\16]RU M+%E0SJB.);8IM=NPT3K$\U!)5DQ=/.7HTBGV/LQ#C&Q$H2G)CX/?,?5!:5YAU^)M MPG#,,)]%8@..BIN2Y$Q-Q9/^N4!ST5C)*B8UG491DZ34O1[7GE;%KF>CS# M":1CG^PZ);1=+>%UA9K6#^6,)XIQ\\A?Z(FR>D2P[MB^_X MBBULGC54VZ,5-1,05"2G\9[BP?)%N@R7(T;GJ_(KP/]?"S1?Q?9YI^X5,,W["LB5='N 'A2U[FT*!$;^?&*>=:@2 MI]+K%;O"E6?\\=U6.N>7GZ[M0"9]_$;_E&IT_.X"=%Y>C:B:%\4-)T4!.-4TM:S?S3=G>$?*!1>,'@AEGL%?"L=FWT%!(A3]QR^ FISL=;P^![B(VO M8UE'" 7,HW%Z8>\H]E+Y83:F\,\HJ7GTJL5U/HG+$VYMNDL-<6'D*F['4^VM MCIS;L04!_/IZ9O$--1)%/KP"H/^ M@1NGLA3YINF?'R<7EE8-V#K'DXQ'_Q7;6.8_SMY )"?*;^,NF@;ZW;:%=(L3 MCA>2#&W-*"9\1LD)@V44"5*'<2DY!7:5%27ZJXL3 I_A!]9?N6G>^L\R,U-D MWJS/B3UA1=$+WL2.]*)V;P^^O=@"H7TMH!PDW*]V/%QU< @9=^_^-H;4#!1!!7 MJO2?"JO00F[9]"UF5)6["JA.4M,<\3LP/?_RDL6PCZQDX1[2[5=7R8D=;0Z^ M&,L,O'X_%P^&SP712NJ9@H"4E7O+$(,$&^>[+^-*50:;-V.[-$L=GK#1)"3( MCE&P0+W+,ME?=:]6O*3&^ ]3-6#'&B4'F['*>YIOXYCO-/:P]+ $A8J\$.YFLQ!1D5D9QV9E+[%W.>% M<6$L"TJ*.V26$5:!SP6&P?Q6'74\GZK]>TH^J\EBNLQ^6_B<)AVW]%CG2BR"T)!\=! M*2;$/6E\S]LPA,;4+1C'X$^7TAOU-=.X.2E[7+VO&I]%>Q#,%9B1D&S6W: 5 M99UQ*06&,3(ZJ3?_JJ-KCY7_3U:Y%0Q4H4'_W=JOS"0&CB]^E*)#71YZTXUL MP,AM89TT!DS:!4/SD$94DNT+'QKJ*G.[(0I\<@_S M"W*OL4"V M4^9WXEM%H*Z?@TR%DKV[Y$]$]/<)2QF42H ^BSR@6,4L6_+Y MV.&^I[/QDJ'/+9Y$ZOEV["16*GUB*&J@XVP14W(]3WE&[.0ZM _W0^F/JN&? M-$'EU.^NEM:*A2\SYPTW6G?.M(M6Q@M\Y[P$U>EES#4Y1\8I(/X0X H(F*/8 M:\OY^=PC?*RROR;;>U>G!7#LZ1#;2U628])Y.'.]O^(O#@W?K2(L=#%_)UHA M/<1[2A/P5,\IB(6?\YV*U5A0PY$GVN4PZ(+) V3>.)NMY8&YV-$X/656*A\A MM!B3.O$PU_WX\BS&5E=W=M(!Y_B:%N2DYX@G)3Q$ZH'ZZ6DOJ2\Q?F,SG:BU MV"8;.U5,7)VI BRN/!H<.]IW;:) 'FA$Q<,[UV:(YWBUT!3SN'[>Y C.?UXB MI*8+'V(.EC23ZC5O[&T6N$_6>:FV-C JT[M0>!(LS1^B6X+A"77,K5V53)L'$O4<#4WM M'67C;K^I.]0R+7ZN9T(M;-H"&LX'*:^F%6_?[\:P,U0;[FA_^3 GL M.UI J*YY\ J0+M"_:/44/90Z>RD2]1% M+MLR05'#7QY:_W&X MH"V = (NQ9$65N,^*&'#6Y8*Q-)6Y$3ST!F0[QX"TI.^ZNZFW6U0 UMP&#=,"ZS.5N<(7T@D3E^/?E!7UR!;A$BEN<\F[ MM9/2;(D"$2=.IQCB%D]R%R4^V;V7!6Y4.<.UPJC'%BNE"ZNO@-M9$>R (&'I M@KL?:H@D@ZX2^ J-(IG/*)QJOCDE!*Z^LA)D@()*O>*B?-,%E DX>/N;]>SW MZ'N-&9%]6U+@F*H HAB)NV/J%^5'MUG)I<@.^[N MO4#@RT?3GC:NDZEFMWARHOU+SLCWSLB0)5\0N$L.8?X:M:QKU%68*DCBI=-& MF60<%C_2,Q 0/X'[8J]5"(#$$4#BS52O^"LG)V0-"&/UX]4[(T1L-MO3\>8T M^5MT!E-H!_0#<) N2DDH+N>[YC+T**.R4+,V)0B6ES\4+QP29YSL+22B ]XP MQ$Z8I%LD7U?I3OE_2MW?& G"-5S6KQNO ;^9!D/ZBE9(%2.0PN($DHT"LOH$ M;F\NE=]F"VWK>G?TA/\&T3MO!\@IGN+T^0F=.EB'&&HZ#WGXL8.=0^6C MV>U^NY:K'#4I]#-O:UQRFXN_F^%3)E915O%QX+(\+U;)W+6BZK]:1V0 B>"87?12* *K;@0-HZP_UY,HC& M 5EQCI,'!>^R$,O$.S5,A+!PXUZD3&C0$[MD4Y*RM3E[H_7T5BW>TGH/$>@# M+<:B* V+U(0=_QNTPK-_^DB[$>1X?2@/'FMLAG,6MKI1CO+@+*^',\0G0T(@ MVDL"Y^&SI5!JLJ5*7A.QRC<<2RPM&0AQ/9J_-N8IIBWN(LT=^>W3C W& ]3! M4'WV:GQW5[EV9^G[/G!B^#&LW'ZS$U%)ONH:$VS^=^D 7-IW+"JUPUXJ ',Y MZ-1RYVM\@^77]=8["8UITO%:I#_B+;BPT6M#^DSS+W=T3:EWC/XLF+YQAE^I MHL(;QD91DX!&@OR0(#0TICO+3\H/-KE4RS$?\Q(9/>A$,%71Z8= >8L2T M< %M<8O@5-:$O +BRDIIY=R^DEL&$B]F?@YB&*IBHQ0Z;!M(*9#$?G^BE8G3 MCO&4^PI8HUTZK_YZ;[[8,R\F0\V[W(%I7V9+!9SB2,6TIK;&6S?B Z?=MY++ M3XP9[JEU2*6['^:=$B0J/$M5K'ZR*4\4F%4CU(*888?FNW]>XM_+'F81K\& MC%'.2%S/3;X"?B!KF<(?_"-M.AM7_HX3O,A6U^,>L**[T/0&;TU&V""$:B5\ M$="A*I5ZT1HP%]DL5RK>OQ#8K6M>.:@-E_A1BIV!&$J7M$N[3SD2_R>)!?'< M;:%F_Q,CC-YI$T7-7BE\4TQQ/6C^8^P_(<_7 XUVSYY3O=VP?);B@[;5(XWX MN_EX/XS>W, =,@H^(%P^K=<7*PRW_=R;H?)UE2,8=[2_G9]'E;=%D.6T; )W)0PPA+ M04?;%"/>BLP.6HY&+Y]J"_? \A;@^OI!*R;?IGYEHLQ )HBQT(Q/LYO=B<2B M)P\%=6XK[V:W]$"1KVF(+>?V!R3S):N\*:O*I(+][.Y+ MCV7:NZ_-">QA+3U-.#O]8 \_?&O[(U_MB,:")?@@NOU?Y6*= W1SZ7G:B.W8 MUK\^ "K>H3U"NP<_3%6LHLJ+%;'*N:WA%8=FC.I%>E?4PR5*H70&R,?A-)Z/Q#1ON;I#?HN!]@U3LVGK9CLD*#!MO?$68\)VZ>7[L)JP M45T[*!X>Y\[+VJQ%R\ ,%MZ1S)ON@Z5(DLEPL;3] C2G&CHXDM)K'WC@9,F/-?BXQO-%O6-%/ %F1(25!4 M $GDS"E(FV+ZU=7Q:,D=@B5-RKM-!%K&?,O#A2H!+Z^[TS29X40B-]?65L<< MAXQE![O-/.@JE]@VG596??>M^NXRB!ZIFDH>.XH.[E&NBE-1N#H>\X#OQM^( M+'+ 29B4_)QX2/;81V@30Y-^8T4@6_KN@;8(O8KA8;Y=?R+?#1S30Z8ZZ*ML M<9>0)PL[K%MTVW&'*Z6KG7/97+HG?@54X)B<_:JG.'3QL$QM.@*9'4A3A$0N MW1KN&H4=FJ0QY5#,I;HL2@:.%:%5$QDZZ^ACD[L'1*#1)__!G\H ;[PG.VBK M%$SHZ4&%-+P+HF_1R]RS!>XP2NV)AU6S0#N^?V:TZ@HZG%'+F&VL^9 X^4)Q MF&2T)&5=W.O'G>P^!2#%XY+74,+F'=J'U>0_,6Z@-;@K2]_P@4WD>X8/9&>W M2$@ UI0J;!]Z?0E_A117=;#D2P-_C&12. /_X!P>&IH7:^Q3QGY^4\31$\U2 M.2;[L]1(.TQ=*!=#@T,SQ5Y69K/\GV1-9[TNU^"P56Q4U-X-?L=5.J:RF<<' M&"XJUV^\AB3D1H[2;_,47P.7O:AFO:%XVT1IY,(+.]53WSN8N(?ZSL$;F"K5J6) M^L,LY/?Q]"[CAC, WWF]U/.>JNV!\CZ/P:!#$RL/?\:NSL\S$1QJJ$^>\*0)5QU39LJ;1G-?X>? 8G?2.* :W M ]N!6[:1UA!<*>P.S-)943K.67<$GGZ<=J(VU>K5T+[,D2YZS:HJ>$\KBE MD*/'1%V;7%\!K!MI.>I_M!3=/#0,/;R6M@VBU3IK+D"+C0H>[Y+>K9(@[A0+ MW-"2)''UUZ]1N,2U$!:+2C$U@1OR[EDI%I;.#"R5VF'; M#J=#0C3FG8/=1&<*&QELE;U\265N//T-E(,2+$>@?K= RC.L/W?Q&K/7F#4\ M(VK&O2K=&.'?F(6$1.-5_.8+EGIJ/]8.A.!Z8Z "2C/GW[/REP#')CB+4JCV M[K7"K(N##,P9%=]Z[1WJ9<2N @$:.Q-2T8'<4]& +P-B!M]E\[-D #0 =X(& M=4D4']V!+IPA\63;34/^5X#"U!I>XBJ=[\N;^-_0:X/HW57R=EMP-;T^;0J& M/$3(BAZ9N@?JZ?5QF%5Q])[5*FIK-?TMCZ.1!R[^TU;0G]EWZLV9I6LMH9W- M6XE7GV'5:7W9%#G=JXQI'U.Z)K,@#PX7 7/ V,H M'O#-6#GYQ&T#6URVV%D MI\Z0.=X7^,TUX9J'T"4]K+Y($/@<9#H78<%RI$"R?DO_)",KR[I4[ /T//W! M$]_Y\N<58.-%B&#RHWN"GA*GY16 T:,N0BN2==)8:;AT%]3;9JFK&\4.]\CS MMM#[-?Z[=:5C*_ (QU1QZ3PPV:_*^YOM"11"IM66-B9ZL?2<;D[*F,""+:[F MDFPBJTO)'::\4' GMZ._L/3CYF-'7=NY5^1U%=E#?^7)>XEZIZVF>#L?L_H> M4F.IQTCD$$B-P4ZEIMJY=42CMT7_336_H8_B#I$J#5NUG.IW"FO"GK*:XN)J22^%8C9]G^KY4S#H6[?/OX; MRTU#UADWV1G;R!8IPA@UR9YE!F/?,H@BLF09"IE"8ZW(/K8Q*&,+6;*E;#48 M2W>H$%FS9'_\_R_^Q[/9[7>1[G];W>?/UV&Y@X9W4( M"&P]3Q3?!O[TG)X&6DN ]6A]H:#^@:EA+:)J:>\@(?]A/?NTWU\4L07$//D0 MV$6%!;:JZEPBXDRBS98V1T M6,G?%_SK_N9^_^(UZ.8YD/798H3!C@SLT-MG\*?$6N#J M?L_&46M59_57[=#RCX#JXV02-HPB$_9-FX$\OX1V/^]M6"8%Z"XGC; IKUIH MG&?DGHJT G@X+YMH1>4> V@U?)CH0"J[IJ<(#=3QFZS'LVCI8.!_1YZ*2I&X M7EYL.JW5U<:BTQQY?OY(8JAU1L3'U[:_I36;CC%96*!_CJ-_: U,PA.VG 2* M28K)?V[[FTL8"R>X:G*P,'G*))EJS#43CK8O5?'8X286WT-;FECI-?)=(BLV M^<[@,FV.GY%02\N41TF/RM)\!=0ZC&PPDP-&Y*WVW?QS%>1!8[5HY/SZLA%? M%L6[IAQYBRWAH9YC?Y[NXZB1>%/U_1NO!Z'C7G(D+#5F(?3EKBG/JG>1=Y[G M$ZM-^^SI]%ZM7_T]D+LU]/?, X4^-]9W;PG!IDL'VCY>=\_T3>"XD: M?];M9_Y:/=QNQD;LT]=0H<]LST8*$A4C5_DOPHAX35\F?_OY^,U]06N%@,P. M!L/R!$ALIMA-MXTM_HLK*HZ9I>-FN-$3E4;J 1HQ'C=<'3B 9!FMU!@;MY++ M]I4U]WRD\_D2U)Y,VDTN@M@5Y+L_=O/SBB."XWJ9&[7"1@//I$M99F5%6-0> M.44KFAYDO$QV"59X_>X6\_?7AN@)-WC#!DT'\! 0K"%FS^>&C[PW8S?3*NZ; MM'J5L2O4#TDQE'3WV%6AK5KV(@Q'1E>U+H37]'@H/,7/?S!POW:?)]*M.>4M M2RDC#*]Y9CY<7"3=]]*4]X4_9OM$)$,+V>/G8&(L C*/OVK?PU"_#_+742+W M"SQ(/TV*?FLNA,2M""R;9*M/>L18OU/6&!@96&W,_C:OK=)OV3A\*\C$0*L7 M%H?A;OF6TJ2J5VX#-&I(X9D45=L&*3AL2/')O\?'R[>HAJU=Z)R)/R\LM2!8 M5/U4.Z+8Y].FW*3=NB"R=@%"#OW)65]H/QX(V35M2F'3 M DLS2,)R9Y@A)TO]?*SFDR'F8"@&O61M@_;BPZN2L(7PT6RRE0<6&/#OU^VH MO%;KD($7D\BR@!83=4\79$)<\8!\S/IN/7'F5[7;$+'VL%0:@1B %4%SXGT5_"CG M(;4^Y*;KB4$E%^ ;W"^RLC1+ M&L$0/C]"M@?Y"VSH[(I; \%)^>UM\+LS=4-(_AXAXE:E;21DTM:I8L(R+TX7 MX]X08,8$\7#9L8T(96DHD35/-PUJH1Q*RN[CNC_2?K5(OK7&7@EP]!D+F/R MU:Y;&TS(.#?5F^=YR?!P^ <-O*T$V%R^4ZP]VQ[*Q-N8^JXA(.##G09/(O%^ M]U6)MPD=ME,X3,!:0+2#\!^:: M_:>7S 06E-Q4N*>ZC2:FW*1ECH%9,SU$F_6 -2:X3O/QWE6RGQMM1AR6F*0S M5+B2?FLUNJ_>ORO"PSXW*9RE)&3,C$U188L5N:\]D61]F+'E=*L30RV_B) $ M;T+1<^&39^\U#JPMTPZRZ%$+/,FF<>4&HNRF*KE/J]L&]]U^VWTA^2UIWB#- M?#;87.5"?K-7[K!/_W*ZCR.KM1DQ(:J\:N6.CS?EUQ!M$NR>1="CFB2.@5>A ME4URY,Y?2G"SC*BQK12B:SH180FU94>VG%X MN>0WP<_Z**SD\.@86+(*>%[^ '3G4VZ>](OZ;)$W\0?,IEP:TW%[?T9]D^N6 MY'\;CM]VE619$W ST MKM6]#;7+"Y(M62B<"ZL5XIR+[+7R,N@)U/Y41HD!QSKBW.Q61\\7/W5,;YG^XNE+E\J[LK.]*K8*>L"JJ M=M]W5^/*@QNR$78RJZ+6?BS>.U'QQ\#IY7!)@=:6H.;1.='F!JV'OT8L$>0@ MG;<$-+Q47J%'GQ->]=PNRFEL*\ I7H0QN7W"TB@0X^#Z\X_&3(W)+ZZYR*D= MK3UK'&W/!_RU97Q1RL-=[RVA2HQ\%LXB9"%@BD3#H'>1:'<(R*#+V@4SA0Z& M@.P_>>O)Q>$E&N+D&T38'H[:9+L0NY'0OJ4CECH:-4%!;9=OX,8$6;YX@\!? M!^H5"]!WC(>.#A-(TM0K#:C% <.QCF7/_,M%[V&97/!E#\>G\,CK9E+(!0Z5 MG"TA$9&:M0V#.Y(]IVLTF$U'%!KRG_DJY MUV5!/RRPG$:@OCARN"1@Q,ER#Q>J2)DUL8#=BQM&I;=D@00:T*H%[(KF=*%M M+3>MI,Y1P86[>Z2Z_/(7?\R&/$S(P$G?]E#8(? -S'+R]\PXUOM,'TJ/?[>H M&;SYXZ6O3%JS2F6 7MERKOU7(0R6:=X&K:'AV M] A4G:T':W&X>*VI*-05_>V0WKVB&OU%.+(VMC1$IM-RRN@P5[RUOC;E&O0M MZV_+..=30IXQ/@O/* JK"J2ZQAB-O'3#=X*EXM%+1*N?6DHEMHYL3]]\-%P9 M%TJMD?@#X(+DZ#-6^MN2-1K5EWU;+;)OI&?,/Z>'J#HV?J*B7S40YHXZ+*1R MO R29.F:ZTG$F@_) MMD$#5-":25B%&$A:4-BK3C>2K6&,"@:"N5%4"D<:FYO]R].#= RZ- M!?(E1@PLJ"_@Y!Y=@0 I3. V19] UK("9;\S3R=7">N]TX76#=<5R^D: JX4 MXP3#,@R/)B"91.D1AOF/]'[-8TZ$T[R631+A'10 3C$F=TE0=/[>KN,$U:T7 MO";K?^1L:Y**@M67#Q0U+!=+2G5FFST[G5B"(L2,E.)*'*YV)WQP\ MO35]Z/.YM/QQML,P;XD V4!4TKZZ+GM\$?.);B\C@OIFW->ZDB,9C/YN>MPO/!TTU!TL%%W/G]"'5B-[EWSE\+ES9/"_O\:HA\IDL/*+FOR/6U*+6 MSR_Q''#2Q"]6KP?VY:1T1!5:(F:,?M\_BOMV#+2Y'0-=Z/T0@68I)YE?QP ^ MU 8IUQ:42C2>P8/W2L M"UR-?B-0YY%R=&\9V6,.:X(<@4&'7IIK=N(5POI-AU&]Z[)S\8-<$PF*?N[3 M*/?$QJ/*@/DUAJ8JSG#I=8[7Y1.-#KS&,O[UR&?N>\E.=V'[UO5>(L+#F_S- M+?(F=51[YZ>%H.21U[G=U"6YL30J5EAM[:D_ N=N MI8BX/]FK"4+TU>$*JC5C[J,@(%YP;)>-B[ER'MA/<\26K^IB^2L%P)SH74-H MDACQQ *E'842)1ZE].M,-D5=B)/77I E+BF@0%=. K"7(;&@!(HP+F*,@_L>2W7,@#?ZAE[+&V M]3Z9R[SUD>#D">HS^)])^'-_*7E'%U#TD_)PI8QJG1&RW$*;Y&)1;R8UD(,D M6:7' H;6U-<])13DK59T;?&?@VA(UJ-H@0'L?S.(_Q-,XK,VE!TI"FUN]S90F*I8+G?/ 1TZULDDE=+F[0TQ(N1FY&:]V M'"C?:Y$Z3?UYG0%$P/Z="]+_,ZDG.OL407T8I120 ,E$ !@ !E=F%X M+3(P,C$Q,C,Q>#(P9C T.2YJ<&>LNP547(#@&MS=7=?Z5_8Y=^_L<\_YQ[OWO#AJX!$V'#PV'+0+ MH(!])R+<'Q?PSPON$3P"(A(R"BK:8UB'FB? (SAX^$<(\(B(" BPMYZP]P " M-B(.%;L8$JZ2 3*U+1Z'3W06"LW+BG9\Y=%C6DY#.U]4-(*GA$3$=,_H&9XS MV3TY/3N_N+RZOKG])1<< _W7]>_E0L;)M:PP<%[V5T5D4[*@VG\C&^H=TH&@$MUPK= MR2_1_I#L_TPPW_^59'\*]I= M4?OY5V(U"16Q>7"D7"J"!JIA!6SUSD >V:W6JE0?D[EJM[K2IHJ(^AQ"G-^FN M[)6N:'"HWKRNF:D7O<(G;R,#/4P=\Q=O;L-J+^UUB_Q];TYIR)V<8ONW''30 M'830[>#F:R*2*FFM+,W(SFKD+!-Z=3#/H<#^ -;-22T4:).%X'>:B1"?R'FQ MC%\(VZU8J\TBJ]#/RJ(W*Y42"&<^(M)).(J^%D<.O/_(^N%J-Y:EV5F9DZ+& M.JK @7$X(SX OG2T!X4/.1,9_)!L 5$>):N=L =D;^/OZDVJ]Z%D'"*6%_/ M*45<:M)JPZKF8J)"S;,(V$56D;Y3^Z1'FP'V+/.#VV7S6KL"DJ@8-28:=%7GG[1$+5U^U=O+!P0%M M>,E"C/2H-(UY.X(ZVVH&IDN&QD0-X8&-IL-=J%,$^^67H"??=HW8?:["_+6] M7.#)>_-EJ?)<7FG"15;-W&@,N3T3&$%*I3@YHKCSNU%['Y^;6N+)?'G,_I0M M,1IN+6*S>AD*1+I @7F*_H822]F&J6:Z53*.<=-9UA2-M<6/#92.F1@;X^=; MBGVF%OVN"*]R*,82[S@Z(1Y6;4=C4,#_8^1RN+.L[RD&EGH*%T_8"!9G?^0! M%A-74K@DW@=*5I$=_KU!Y4"9D[XI-<+2(Q[MN:[%]X,K&L$B3MO?%9UCDWKV M-SYBT>EC%H33)7&4BI1?J?-IZE3EMA6\"X;K&S; MJZ.\FV(:&MLY*^S??!M6%Z,SO(7?/&,D3NH/WP]WHUJ[QD\/F'@+_DWG\+[O M._1%":G51GR*(C)2YN,#E;@^#/O?F[K:.MBPH9<7S5. > $[EZ?755%L(]MSV*% ME#@V,34-JJU:NOS$TH'W!ZW\/688;"GN?'T/IUZ\[O35W4X[S)[#WL3J]]1)+T;AP(K^">. MW>LJ^GI]'-I+$B+M7M_D@TD3]4!./!P8:9CC%Y3D_O_1DK;TC\.O[^Y>=-U6 MC\T343BQ"54T9Z$REB/L8YP1#B./5]2F$YZ$+(5^G68EZEHT6:K)8%A=QSXU M(O%(Z[0I%88#R ;,$T@4;C'J%&[6VU9D%>ZC*,C?4 MDL1RQ=RK#F=VGN]M_".!M2@I->3H66^>A%XYVC#MG/:I'/X*%QZW0UO&_R=E0N;%*X<$M@4UVKH=G M2BI@@B3>/Z^8,:_LJ90R-]ON9!P@CI*J**428E^=F"#8NS-<]WD1U66#&DEA M3F_]PXA^3:=TSZL0+CI5I^5$2=/ ??N D5DGZJ67 M,X)<^)\L]6/*X>W/\L MNI;M5C?9[5]2J>>)T:J68:[;MT-'?,VQEL 1!3'Q.B*?^+5,?T[PM28@*2)H M*B%DZ&-F3V9%C\O%:OVSXZOPYKG:2,5T/BW"KA>>=33O3NLDVH@T7U1BO[EYR>MIN;'_A@\OD ^\?5().DU\"&/Q'9*V_CB$+/?/B1WW!.Z7>% MKV_A?'428WEKM9E=**@=?V9M&.#Q19#+?VW6Z]0@ZODNC]/1DB(B!I$J5Y>J M8B&Y*$ (V%B$::OXN! M@QPE3B1!#QX)=M^OB.NL1.T'6YN1G2*_PLDA=RF M4W?244Y,,O!J>Y7#J5N2;5@WJM)6P'R]E%&F,78]--&132-OGRZ2GGA]-G+U MQ!W@/CP2ZL-OCTZ>_6EH%1P9%XANUR)&N!,"_!UM_^:3>"I&FZV<;1".=P7" ML!\BWH9;FS+NL1U)ZO#(*,N]E[GQ5DJU3VNH!N%VKPB_[,%XN:D][E2I]7W: MU#;2 J?TGBS7;_T1)A9R#>!HI[$3;77&8H5KCZ@[FM\G#%SE08'?9@(E=BR^ M:&I)ERT1TPF=.:1<8-U69,+)?1OFFPU?:SNDP'4@V)G._F16HD!_?A@;)V?G M\C27+!Z(_4CDL*H0E?[8:1]ND24B:8S+TM),E[WAE67\L%S(WW5;VH-FC4F7 M@\&J%%V.)]M['S.R/QS MJ=2DSAOO+E7;4XRFJDB]<[CQWS7/,U".(ZEUP'P3<5YE0&?MJ^V.GJ?-2AE9 MBP_N;I4X!]'[8)I6HT FS&X3?N:L!#U4(>P]'YLWQ\,A64W31\^:5=L:*]PM MM;_6465,BZRKW#3-Z\ MT7]??<9S^'.CU'8O\O59"ZC#BZVJ-4#Z<+.V)N;DD"Z8S:,/[IF(L1-A+&-Q MLU_8R2Z#12,HO/J!XWGS7,,SFOT#NNHREI[!_?:D,LHU"H>#(3YX+KC=MM] M@A&#G"M$L#H<']LZIR/_&YF@.O_*('W7"TMVBZ>)=>&FC*^)9W>W7"68GL:A MG6.B)-HBM[GM.+3=>$*!LCQ('!S>Y;%":62U.%Y(;4XDNUCOX)$:3J=\-'RO MN5F_&T]LF:.O0@K.(+!8LD#U!RG1HE#SC__J4,D!_E4""#Q.;NO&U%AU0+*]S/ M6/]U=+5]J-GZ!-%@=CD)L>3%_=U/LS Y]XH0'5J1,^(85!>UD8E>EP+5[[T$]%+!( M2IUQM2U6EU/2-T#4=GJSZHK5A]R*A!%J@V*)O:W&7NY8'ZAC);:J?3D_RLF+ M\4S$!,Z'?\]/E*S92CD4NI$^>"85TVS5RS]HM>L&#F/E#L>9G=W<(&8106JL MU^Q_^4SSZ0]FH.M3OFU=1.8#()CQ.^SC:NT\?^&_7*GYYH7_$_8AV]YE,..J MT?%2.%6LS.E%4V3,] -5^M:/[CYFC7*:3?%XP"B\V8B_T+2#G#%!UK+&,>)4 M\&WP>OKYCTV)L^!W&RXD:=)D;:^!W@3B(ZO0PH7&]%B!E]?'L)GTBJ= M+3VB@\[( /^@Y::D4 VCO9^AP.TAZ%Q+210U!_Q="#RM"3XW4MW-_OT&8(HY ML0ER)$-6'4GW0C$HH9RB:UG"C373K.,C=2N42L(GU;%J^DA?+@':'FO^]Z6,J$N03 M?(;"@;X^&AK26]7)W):+ZH1I12DA''0A.X;W()\O4V.+/3]92@PB"!4-C,)? M^BSE A_5%T$3'TQ&WD7,CAW*WO&5TIYV^>2R4-,P&R$CHVMO0G:*^R"4EE"WFN,C&1:+L/LA)93RIRU<<^I>U^'#3^N*MDLTZ/(_#8\%YA M\FM=B@O7P#/]&E=VO^QVDQM MBR?47=+Q5-@2);T*%%(HW)W=OW1N_.!TV?W,1?=Q KG.HAX)#>FQI*"ZM@0> MH*JK !'CS;AHAP+GN&J%I3 $H?P\? N+3VY1,U$S_PQ3"LW!IW=00%_A@7'^ MGW&-JCP;1!^\MP,%<@']+R$,P+]I<"2'&;EO?^>1^%:M.[>J\O00T4O]BW;0 M.;8HZ5;(LXG5\@FD6-YH>Y:+G&>B.?%29I-!W_CXA-W1I\1=SO1\N"X3I?P> M6.9[_'ZP4!UVQBU0- &W=:L0[B'N6JC1 MZYPSFYO[(YJ)RT1^NQ+5=L*(LG/X;NWD_5'$19/@0/W'=1O MTPPY9'VN/L[5GY^ONY'AP4;1CW#2+&\>LQJP]T5_?6G!K//#I1<_F(Z%%R1<>EJ+<^^^$X]-GKN M2QO6ORG#4\I; 1"(Y/G<*")_WFT5/$'GU)^=^ZDE09?C8QR='?^)H;(G=][H ML+&)8RT*[^* R4-\LOFNRXIU=I&A#+$M@Y/_">L628XJ27D[7L&RQ]JN)_4O M SBI;3&W%;I*V+,E2ZW3-P]9I->-RCEAX*.AZ^ W\/M^D)YRBQSF&*[0%9J[ MM(.MQ5"G:?RPLH@J\?$M17.#80L?H^N!;@L>W";VO?0TJQ7K^^K1E:B.TW)3 M&44A^B;A _NE^2,3)ED.^E>"3BZDJ0!I!\3E+&"X]CO(D*JO,5,:I] M*8DR?'KQNLS5R#)_CKMFH]F^HPLGAG4ER@YK@A@XBX<9:7RB=;3I\XAN5K@0 MPP$:CH!^[+3OJ P?^2@?F(PD3@(*W%>U/:DA/2C.GEED*Y@_7=(2A=8LGF3Z MVL?81O>XD[B[6+&LU=4&4P6PU]"$ORR,%$64%<5SB+Q!9GMPB(4"XA8:H'5V M=YA^K4*!GP5<_^%%_J,#/"51Q'_7%&%^?.,*TIIQJWJ;!8..@:,'3]!Y)CS$ M: W2 KYT:WL+VA0![4U# =.BXY=6SV3<8& M?F2]9K1K-F*Z^!+"Q4^?T0@]IPH1HW6?%B1U,-AV!:4!KG;WTE.9T4*#S+33 MKZ03Z@2OH$!1G9,)S]DVTBEB4$<5P3\(6UE_)[:JDE94" !.RU?N)P/ MXBA[1SWX5) HLL!B5-E3VE[$UT]_]%#[ W%)7/AV50%HJ!H.P9@TY*:EVOT9 MQ6Y_ADF1T].4S4\KY^%:#DK#L336XM?DH'C,V&TTLUOBD+/AQ_<*=1/T\H*Z MP1_8-/PUP1MQ@2=W>>=79>+%LY9V1Q^_A#P'PJ\4Q@K-0:?(L#4K184"F2&U M2PX/C%]AJDKISG:[G'&+DHGT$PI\EU*"=0B&=4!K>?L!"JS3Y$.!Z5>P@!U1 MW'%5%Z=_X^"P1IO/1*&%Y >.DB/_=DVI^24G:5 MC!]UIW%%T@P^\TM#V;6&'B8L+$J4A0+?XJ$ ,6C%P 4$"=!E@P*/U._-X'/_ MT0?K7_L(0@*L_M['Z], H> ?3L>ZC!_M06%B3\Q^>9SZN5I( \& -/W2U#&?6 M158L4;TEQ/Q=^"A:!]R'*D0RZ8N2PK.V\.+LE=P99CC>)^]PIZ]"WS >=KC1 MC$3[?:G?[N3:#?D9?V#X_EV_XCN_*)<"_CJMNIW3TWH^Y-EH<*.5-J)3W\//,Z-DR"(?M>LT$;+6U="9OR.1UT MS).Z:Y4*7L$""*V+X2(LY+2S $!7OC%M:8[2>[06NW;%<,@3ZD,IZ8D?Z_0L MM7X\_"%^8VNRQ]Z< M/EINL*B[]\$1ME*2W*[3/:Z#K4$Q18#8MONX]BYZ 7W/ %\%PC10O(6Q1K!3IO+9SV:%*=@ M)])M03%VVW0HTJKB.JE.K7Q^\.G/U20? DA9>E+!N^M$([O1H-RE-J<7&0MW MG3,A)X/Z"A..)!W!ELP\/^20T; 25)(V]-RO"M6OL,V)N;OKWQ/[CZ@(,/K2 M?'A7SK_&G9V-WTB?5K5 U< 5U;[AB55?R&'5U2&Z*%/1&]_5PE#U50@^Y9I$EH+_OK MSY_DD#]$5(>O)<5?WEAEB')8#F5-T"3W+W^RCE!/$&F=E%**+AE.>AO]5.BK M:TDZ>5K098S@C0CSCE)3@3G')R1R??&;J=R,B(,CMMDIO@U6?W&/U$>24F"% M+7V^)?I[N:WT+J&HBGXXZ8V7.Z:P6*F>AG:$-U/!AK''"[WR"L: MA4K.+'WI4 #=5R.^UU;1 GR*V@S;/)AQ9Z;(#R*\!@4^@AD+_L3 (I[2F)_MM!^(B+G?O^='P)Y0M?K3!BC91B6, M7(JT];%MR'249 M&?J:*L86&7$JPG\(I'<4?2Z(5--Q,PS5YK=._;0BM6@THI;JI*:8VA1(XZMS MDE*B4?!=U*\XY!.,F7,O+91G3Q,_^#K?C(" M(8_OT/PACI*T3M'H*5R0DB,U()N4FG,ZJ;=/H%2\K M&4TWRJS'@U[RZ(G8=Q#,;PQ#7@I$/C@H/ #JP^2LAD(&Q7"]MQ_:AEH#JV#F M%Y$-!71A%%H4_RPRE'8XO*9BQYT-\LDBNSZWX@T7UE6 A;"X5 BD;_0):N)F MV-VM%SPTF$^=@9:O'9D!/*)="VP@[K$JBY?KQT; MM7BE'BG<: N8N'UF:<&FOW"@@J5U3:@:LIT]H' 8XLC7LQREY$/ZY.UH?Q/: M?NBO9[]>%O#476F?9EL:"6I3O.97?[=I[ 4;5&DC[TI"&DX8#B0FAO@&A6:7 M84/7+SDMK[W[\8G^ZV^]AUM08%1>7U6]?PE9THMI1_]BR.8!;_)"WG[ _HO@ M?^1UA2R8+E_'9R2H&R)HJ M8@]B[BJ;8'+[5O4>WKJ!7F6@3 06WF.L@8[,,ZZ?+-W+6^$_MC"9+\N:XCT@ MLJH^./YQ5]%C/4T$!5HM>[B/GNRF/YNDF^#6KDLWI?6GW0\#.ZIG/FKZ>HVU MQJTL=6GYA-/GHQWX9/9,.^A934/"["I]B$MJ3G1])PUF9L@4VN.59V]TW_1^ MH\#A!L$O82?;<-4AR!B/O8/_&95Z /JA#MO\3DDM\$B5+13PL80"7=,1+J8= MMWFA-3Y?S5\4#58W-:726@A6'&PSU?S]LY\SZ"N^41O9:_L7V;4[P63GGC;: M@6]:QW/'<>QK6.F2!&SV28!W%%IG;=>*BYR0RV389,A0(+C$!M/CT>22UJ?K M$'?5<=S->)99/X7@:INE]U=+$9I9.1C2@@7'/U];^^#&PR^+KSRP3\\ MP--ED&'U[3]"R%++WD;'UJSE03EY M3\5HXG 8-6605CE+7%YPC37A.@F-2P60#"Q5S5LV?J+=L@@FH;\HD4UCZ*0) MJM&5GW3#=5A:4SW'F\"/C+5"BP%/<;G2GW!O*YO=-HS,?UZ@\K[I>_)^F,*9 M-F3)B"FY#8,+A>W^#<;]E;,LFE!^S#PGJZHW28#KGM[)6+-@^VUMEE&99N[# M1DG-EX3Y#0(AOYGR/II6#'>"^"+MW6-9NJ8BE!SV"I4HZ4.LK.*O-:Q8+Q_P ME!0U8/08[O4X1,0&"NS!=F347((@X^0,#+/P7DCH:P:X7U%,Y.T>&R3,8L7K MN7F@NBP31W)P#@;5N5)?Z=[?T+B4;;6UU@&$Q75RQNF1SY[J/MDQWW^'IEX; M&+.DN["XNV1:\TGH$1O///ZW&%#CR:UI&S=%$#$+5N<1@IV/*Z.K(@[8E50J M%?= @P#",U7#3S#4PS'-_-&7,'#34Z2F! J@O(JE^JP^D9SCM$1#O?Y\GS?V M@5UW_G[GU,)^=B[UU=/I4RTA"HNDK2GQWCJM<-Z^IXFTVK+H@C[?;Z=-G5=T M,>>;)2_6HIX8J\?#L[5B,N(??^"HF+-W4%[Q4J:61'"B#-C1<'^>8D\3-U:M M:6.3Z:/9F[+A]:90L.*REWMIC[CX5GBP-"-/M',_R'^@#-&V(T,G0J$AGXL" M2R12>.-')6W5A]-LY=RW$2VWIH"7H].T]"0W!E% 3G3+/1%V8[T!-6Y:CM^$ MTV7)\_8>'NW*][0_;1T]>71#/N4[(CS*0U$X-IUX*["P"C81+"K:IS*^$8 ? M/_NJ98[;]W4@3W?N3?#S?FD5:GY@I2VKV JYDWB>][0%"B1>FHN+,RN+R(7N MUE\!8:LU=@E3\Y\2-AYP^H6U!#7AD/>ME4;R;T9.L\N,,CIJF$TLR_"+.\B^ ME^)PIJ-%0(%T2P$HH#)^SVN<8I4LU2C$_A[!Y_Y5QA'%FTG]CD6GHE6^A,E' MW=CH8^0AK?$8N8<7C L*^5Q0X/HD\&%4I@ 6)#">0>I!$%_S#TC,AD3#_?PY MOP =_T] ;[\,OR77/O;K$3%&72FZ$7'0G7K36WC!#B&3JO5D&O_S>#G^M"3G M3%O61KBJ4@&7J6OGR@\SZ=YRY^CQ@*M(S/L)*@TV\I?CK_*H].&I&RL _AV+C$[C:A/L5S3W*LN[G_AU(["9^0W[6722.+F%3\,T+? M-5^0?T5[F>#T:I*T47WMS&MOS@#""P1'H5'>]YEC;#L"!X.#]^%T714,G8AH M>.12],??N><1(DZ[,/P078@0"GK+2EP.4V.[/8I# -'VY%:#,#?UPFV+2O.I M'EX3Z0F,P6F:&GE>SP[I(15?U'W7$L6@M]Y(4X0B%XE42#(H.S";%1BK(ZR+ M?!A5^S0TO#RYQFA);$1.'?U>Z:(_XP%!O5 ]\IX6X3I/B^;PA@:D"^/5C9=H M&QE=%K7P8\W.*Z PH= ^(6Y/^L/UZ-F^I(>IOF>@WOQ[J5SWIQ8WE-^/%XB, MG&1PE+_ONBICBI%?C =\+914\I(2=JWGJ_94^3W1NJF -P %\*^"GH[=ZC^@ M3(^*X-6W-9;S$N=0D^S@/$M&-CGMW=B+6&#:+,.7B0SRHB%// -OFS2LEC"1 M]"WRLFC.5YM38KYL'?E&7I/#2<)XP#PSX'6652R(&L=MVZBM#B]/J)JA*MJ/YPZ?BSXT/PABV'%U6/,65E63E4_')A%SX:D;1>**"5VS_,-4P[3.N=+N?_*E D+\:\#A>>-$SU M58Q'(0K]X]23&2-""A7E:@ZB]^]X$E2\/[Y>#SMVI3V+E7N%)"G?>>W$^Y@7 MHT>8OT#EX(G7Z8M3]F"[IYLWKT_9SY&Y?$D^89'K*HTGQK MCZ/98C>-G5ZV/7QX8'C4=N\>?+DU8)49MA9V#I'\TH!.JSBD$32-D#ZS6B+Q MW,RO56_NL#\P%;L?"F2\+K)#B3,FW4?8]!:D\,LX53UON]W@A81:W'YI5;_F MAP)T^K!0N%0%O%U;5LB4HEWELN^2$ AC-=>2K<\L"::5C>1:6AP3A:D]5O1O M*6QRW1X:ALI\;FB3(/(7TEE3CIM;KH MUO-HC':9!TEW'UV7$-D83CU)/ L19R1G6%!LFT8E@1?6'Z(9I I/&^N-"+"X M*O2T89GC7#NQ:%9?@ZHQ#IJ?;:AC?A_T125SN2AT6^HZ<.Z:G6A$[OQ,]?'D MA"=G%XWM0ZD+_$/V='EAY+%V5^.^H3Z.RZRK"9\1,5+\V[OWWFLS:M&13$U. M=$W[;E.A*PHZ<$2>&_Q_@CQ5RNO:YJ?GX#579.@@*G.C^@%MBO)[LX'J=-!=U6/R1-< MR&LD&%?6A<6BHEH['=VOW[!5# ?%AJGH#F=A3\G;DA%R<']5]?E.XZRDQ;T) M1F6]8"IA4;O ^KD2U&O.1*X+;R<2XH)\?*"7K/%&*,:6YU/#ER0E"7PZ1%>V M>VHMU:/@&IGW%8TF[@G/7D6=VI]S[ZF>7@4=7'2=U+8Q8UL^(FB*Z[I<-)D_ M7,O[8%+]M?1[\H$:%,"J5B-D\LI>U(?4Z(2N' :2(%%8TB_:0&I6;7=%JN<\P2H?H8#9"45P=M<0($;CM>\Y/EX B<^C;8IVN11F MZFK#E)W_V1J[*21/J3DE-32:T2S<.&WSA?FQF=IC7+/HBF"E1',J&;B@JSU] MX=*2TOX#XKUTVJ2;"-QWB7$_XX4%#I=#+LK\=]P2M")GA[[T&XN3[,)]"N,Y MFU[\FJ.E59G%L)^PY2F!I_;,1P)/$9%)X?JF#::\L,A0(A=/"]P[" 4>G"EN M61@R$<9 Z^2@O>*V6_:B 8@@J8NKS(Y>UE]Y''6,$W$Y73TF6:G>.&,,*BA@ M3 X6R0CG*VJBXC5VF0JV>>IW3WV;UH4D._>E =ZW8>-)>F?#?5'Z"=W$+>2S M9:%KV;=3:P-TIU[*]2F5.]P=Q[[H/J2F,;#7.FZURV43D^ F3?O 5C MXV_5R;XN]6T*QR4^FWW<\S9=OJG6VXY/Y&)26<8]U(@O[T1XD"0O4'-LU5PC M[>63"HK$Y/%4=I&BD3N5ZFW$'ZB9"W) \H!F_U,6O/J=].\+)TLI(:.'7/*: M/S];33;GRM $Z-MN2YV5#BB,.-S)&$]1FV)_3S\X+#$)H:F9&.7MV\>, MLLYTBZ*N?!24R]."Q?.+@PX)4TX!]=A]B/5A MO#@?0&LJPL/!-0;A/+<+V497F4I$\/,7A;5>2-*&2@46[.+V5+UQHX@3(U6;FZ6,?HX<0UD_?I[XBZ%+=N M4@X\>+-*4RYK%?M_JF..'70*NM^IT;K-"^@@K5XI^UZ.KHY-K/Z4\.6UN^Z-?0>$K^O MI7_?"@6FQZ' ZUC9RKKQZB)M0>D$!JI@)6PW %'JSTBBA''"D7H-/[0U.L_"K.&.>8/T%HG4JQ D<%XX/,V55#.(CQ09:AHW"UCEU ML3S.(/EX.ZG?CJY[-EDH3QG&1B.!!*N?.8(I_N?\[0S6/6[V97PX;1*Q7=?; MRWRJY(/-)2*20/*>,@S-FP7BY\1HM8A$-SJ]BU$,SB_A&U,Q5DW-1D0&HF# 6&S[*- MD<''UMT!:06[UFTG)R_"9"LUHRGG4&'15^D6)A$[=-2ERL)^K?SZH],E:W>KL4 M<, S+VT>T*>G","GV!/@O2_@[4>MKT\^6UT'KG*\ :T:\$("+*A.\%E"3H;Z M,0G#+MKW5!XG0.Z\'!/H*!8ITH3DVF"_K=]9L,R'V%76\]%0!:TF6>MGI#7L M#9K>K-UUGN5PEET%;DEZBS-^B/(9.67@?"WS3!-5^,W:('-$L4#DT)?O%Q1I M@OY))[3>3VAMT]O8!0EP"$MM28QH1JH[(#!5 M!O2(\@T)F$0GU3'+\/72<\U'*MV,_NK%ZOOC4 03W*<^!HO;XI9N68IV0V[T ME[?NXSW9( T*4.#+;&M^J;GUX%K%,L\B?FQW!AZWMAHZ(N&GPZO.E+"E^P.\)0TB1%=U7M8G"!&7UWH)0RY M,:PZ^K^M?>#OX9S!3;U[?E&F6D8YIG*G?QDSQ?ILW=R)RA"Y@A%FB:8V0Z4D M2^4Y;A2?FIGR7$!B@;+C:X1*R>]I-I/OJL#IR/@-$B[#04<7;!37G7K'M9]7 M^;EJ_5=4&AY#\%!U(M!T:_?;M8E#*Z3;@TYPK[VHM$VFI6 MHC<6;RQF@#;MF^#K@&W!BSP/K6.-R?.,:YESC\[2G7<*I"/'8U_.(NT$(@=: M7!<3W[MZKC99L7:JU81R/]C>*US_-2VM:W*0 KC.\C!8WB/3.4JY2>4:X[2_<%O5.^ M;_6-3<_4#YWR52E$D70-&_?^_#FWH!;OSC\C_Q O?;CH&F="9JS:/T#MM,CX.*\=+=Y;%KV*?FS*:'S!1M; M6^H8VG:E,,]YQT-,BVSKG._G3&J&]*'B()+LS'^ M&&W"[#[!S_UV=/1?X:U5^;9ECM0)\YKH^LZ%X0XI9=3H4[BC>U0? ]K;C((R M!))110%]R)1;E.?%%/N6WTSJ+,UH.?MC/*O;!I\0WMB&K1O!D]K/I2X<7R8X MY.=^>DW$DXDB0 4<]E8(K6;E&AX.%C)\R3'X'] (^!XS!'9>P;0.5B37 PC( MWV:'XA2+XF)*_X%PTM!=HU04)_.#6TB^;(),R.O=WI[IRVD"K4[=N7:V#/QQ M:JN6!O32+E?T#4Y=#K/1/6/'B=F+"Y?;ZFI%8.SX#H=+.Y#(S M'.:]+\>_M_NP[X2TNK3T56U[K)BO3-WA5S>F%5LY(ACH]A^JPQ_&*"@+@]), M+1+5GYX42EER*:W[V[ A1L(HG[Y\WTH+JTIBK7A$JL-7< =3CO7P3QHHT&JQ MX,D<%2>8P39WS:G:]*JAL0$R'!Z![_2^85OAJZ6SY''13B);@:Q=G9Y64C8F M3_@#ZE966=929XKQ)]A@T1%I^8F=;L8G*.NU+_UJ&<(U>K7A_3P5'E6/TM8E M:*>]7*&]B= A30 V2'8%U+E7!8.YB7*>6R4E;BC$(N.?[[HH2(GY5X5A79GG M=0BP[YE2/)R]*EK0I'R[?^CAC^]S%V[^;&W)YG5;[HSNUS932,0*@=C08LV% MS3W5+-O]C104\)@(7I&GYE73EF[7$YO3M#?3#4WAHY&I0WBWC__L]_QM$4HH M,8*2MX"JYV\Y7D4.,]#:(N@*^;0PY2\LKT.^=^^%+$-456!14.+2[2UX1_3I M]I<08+F5\IKJHD97_S6%+774%PLZ"7ZD;M=+I#.,)W@_J7:M+S[]8= M"4']K9&EVMTB\&,>"LDY*E8>2 2[V'U0P 7\].RJA$HE45(NV_X[75V$M:[K M!9D%MF%6@YWZ>%:)I_8*% BMKEL >(_S%MQ-!K /\S*V=.ZK+'G"*S<[C UF M99U4M)]+1)N$@@U"A74BY<87EJLCF=6X(>"UMT89&HU6"5.X@N3L9$T5)8.\ M*ULA%P6JAUD$MF"O;6_U;;^,#?$4,1/#K_F8RGRT)H8$>/#,ZW=H%S:!$)18 M&7JMR0DRY?<=DN"-!06;J\B=\:D:(;9E,J9.6AT&7N?KS4V#[U# 8QU=E5: M6I$FNZT5[AO"4-R/_2\5,FIS_UI$@P?,@6Y0=D$7HZ!S.#V257!@],)UE6IC M[)L)PF&'TT/Y;FW;(4E$]_B_E<:-]N;D3P=CZXCE^PW>VT=:3Q=BP\FGUQQ3,]DL6'0=LMZB*YH M"EYYYZ68> <+NU>;>NJ.=SUW:A\D&&>O72'[3:V^Z;[\9EXX+G:K5,P\=:>2 M"V3TM!2]^/3WSP^0(1Z.;'?W2RMZ%2L_F<=E9=W-D;[/>.?Y]0TK]-0^1S_! MNE9I1+Z_WM6_NFGKB/,@&P%M]2I#@;9!"/[!A")RDHO@2FDT;/-QM7<3$NH* MN!B7N2ICLNVB1R+=SF\9((( M+8EI;OK*WZ>_L!.]H Q;&Z=I>4M>B\MR+S%Q[YS;8^,A2!:RH[9=9D^?8%+? M\V85U_ME&(5*AL490:!>V^0%X;M*/ZWF%NF+0=#;TB"X1\S&08 M\7"G][ZWSW-9$YK!DZTR'(\;J&M37J0FV.F^P M>N4T4IQ,LN G_1(* /T1,)J()J\MR5'VR4-X%4._FZ?UQ8EUFGF>!4&M_OL0 M0A0V)HH6YD\?^6@1#V+UPID+$!28BW&XE'_T9L+'F%^LM^$W6]+U"&&L5%K7 ME$A\XKR1$GE-7JA@**4O,606TE3^N7S89_?J:+7M"3XUB[B2B.8%4$7Q@*Y> M.@6+]7B1873#*/NE."'N527KL*7;XAI'_FQTOUFJ0%MWD:6YR/&9 MQS=1H4MNI5??SPE5?OC$\LWG&#L5L7=%]P05 F+^:[F&,RZ1K]*DXHM^@LJ3 M5,^*S?UB\V?!2QM0@%B>?>%I86[9O<BGX=]S[[QW&OQ:3JWQ*W7'!<_[UB1OO? M9'(S'Y__LT[B7QN-Y_AY88K"O<]^VYXO>)NZI&X!]+H@!S8G^0"DGA[BRP!7 M^Q=U+U,E^HO9!$,^1@0%*2$P( M8!I/;K]1ZN6;\5=Q$-P?%41VL!62 9WSY/I!Q)^V70RQ/:3$_H?GWJRC__S+ M#1'&:PFF/8Q5"L1=>JE)&=;1YTQX@:TH=PV'+\3.\5/36:[;OY3]/+JGP_PZ M\"T=?^CH;J7B%NW2C?'F;E?A^6K5\$EHSVLKM?ZESEH[CS)6)SX*G<1[[]+A M;_H87&T(DE=PLU>J28:6/Z6$+M $L2:NN.=&9?IJC 7_X(F_!/Y=-]O>Q7K")/.>45MN:$R@_$9WV.,"?WY4GJ<65^;0 MA5D?Q4,M'%*ET)L?!P7\110^+;(P\O3E55S%1>[H'4GHUT2+#-$'SGD\.]') M'YG7-:\]638N:DJXV&>:O.=>&=!'WWEN].&(WCGZM@+B6VM6$+?!TO,EH5T" M[VW20<@5+L.7+)AW'SDJX4=]C62?\BHH]X M_T6Y&>?^1?V]27X[76>\4/I[ZOTW$V5LV;CXFF%MVM(0L(@]N?$Q^XP[^?TJ M%,#DV#_-"W%',Q2Z=&:BM6)^BLVC&J T HO. MU!W8#N!*MGR0;[AD]/9H;!RNP:]#UBQ51] -PB)X&AG& M-^2U_F8JWL_^74G.1W!O,_@0:T/U+[\#Y_4KK(0U-(&> J30[(5==?Y3JVR. M%V1O!. .%2C"/0;*+*Z2/!KD=^F;?+J3=\G-&C+O!E(,M"A:NJG2+9AC.UBI*/4<&.@__\5IWB M!(Y;VPHD-5Y#U]C@+@\QR091F^O'!"G0O;6-G0T\A7OVKQ_GT5C0H,8Z*$$Q\^*CP@*,+__01* MKY#G-^#ZA^]0=62ZYFKAV(1L5& T6]%DO.-4*XJ[CHL!=2[H2*4&3:2"'01B M;U7%]&0XC \(AA%/*(*.[I4*A2_N/_F"[3&]I-7+X6_2+Y*9<3K>RJ-')Y#$ M2?O;"4N:6W65.*+XB=A&>S23DOUEBI"3%MV\OCU:=5I,E'%PT)XQHZ^U'1:B&^XO$#:C#F_N.*7$*:D M^5]+].N?*/C!>SD9MR3*,/=*%;ITN_44,BCS[Q^+/C7[9YEC2;Z^^%?S:=YI MEEH2EUDID6\FK<8G],%L]RJ%P@?GX57T?7X@6J89N+U=]^D6#VD9BI7#2P0L7O7'AO6N27P.YEUU*.1"GO%&M2(^PZR133UT@CL\CC@]?4J^N/ M35*FU"^5?\XM#6#D?+1>I0P!-J1^L#>TS(5-876NQ]^#LU&JZM]HK-UEO0&_ MGG4JDJD-RW)SQ)$:@[$<5_JF/=1$;>7D"!G[L/BE @ MZ1IF0_H/Z64C?^B'M#00\Q%9V=PBO;12)EN?5O.,>%$TZ6+6]B62Q]5:&^'\ M=9%Z/(Z:+NM3)AL4/HP(WKH"4&:I0Q335ET5>5E!2XWE &U_GNGZ;_WTNC,W58/N BJOF8SZI[*M@H][>YP% M)*MLLG5_#']=:$L(V1*1"\PB]TY'N1ITG_1(SLN)L7 R1WFF5A]&269?;]A: M5D?\AI-UPWC/E1SPLSC6'G'GYS=9[ SO:';%O M]H=4Y#7VP^0WF$?+$Y#NJB3Z,WHK+OFX:#F^%U]W65[E1JW@N5UUW073O@Y92/2#?VK[B9MJESFEF_9+S+$+M_?I+A]\%A M+:1^C1"D^ET5.X]I@2RN^,@RAC(8[/3 $-TR7;>U*(W\ M^.1N\P>S9\X!%'CTJ(6#WRB%.X9>/3Q -6X=>Q?#OGIJLR"O_/;_EZX'R/_W MPQ"UY7]3"<_PZ.$7]N'W7A>MF@8(T;4R#:S8NK6PL-C2)E_MMP7CK\)8\,]5 M>7)YG59$30_$A%>SO M#$+WT%RAP+1(5-IUANAEO< NZ=.9*[Q@)'4>5G99?C<=H9"OMT"?:.MJRPAV MW# $45NTF*M9VV[,A#A,D%V);/BZ6+^368ZG"^Y1EI[A*+] <"Q@6F/#=.G5 M/TY=- G/'WB$F^#3ZI*Q&QC9]6ZZQD5];3/9O7*N*R'O3=+)99+=<>RAR"FD M36LE_EFM0-RX<$1(F1'8O$"+;B%\@I?GD*.R8R4.0EVL]C[H7RONBZS^6U4^ M8/7;L_B0N!?:B:X8/E04OREY'A%Y'RS^[A"\N M->J&L!WW!E;?E%SL;7NG< 2,>KD:*[\0%1OVRH-?;.;L!I$*290#W'L&+>U-9AG:LN?+[Z>LMYL/NY,@"^EBMGMB%Y/XOVTY\M4UG MS\9F94K@29$I6L+MOSF280I&8)5P4ZL,4%2$5(D;[9K1^^WL7 M]G5(NI7D[28GZ54=1]9N&=,3,/JT6_'8)*EUB(VDVU&G MZU0J?61N]ERTG$ M[2ML*=LZ!^R(7.?(U>]$PL*WTVW:.NVNUHD$XU);%#M%-9&1+\U&'6T4'U@O MM5U21F;Z7>Y4Z]FPKYBN$B_*=,BT*6/X?** MP^+I[M4[6W.;NSZ%":RFZ]5F6=B"-XL7']6-CCJ$BO>L"VX90*XD[I$\=]=0 MI1-I(QU.;$(]N%<.1#0<][953<(*:BB$8IX34E)NG>SH\QI.'0_PQ(P-FA$> MJ/]CW8D.YC^"7Z_E)LALNGZ-WH@?TI,AK&*_H#TUQUY\CA#=1%,FJ2Q&$53: MR)M;,:S*^#G-PU:6"2&"UPFRZVM9?FV_:H/F8MK%T5KCIGP1.Q#R7OY8/*/Y M,=;JLOV(VT49_6>EUOJP7NZ#'T%N1?U=%)W<6M4%2D-"343C7S./&J[(2A9J M+BIU9A7PCOGZ97 #U,B[WDZ>6/NLIMEW7(EXA>J@R\%L M)]V1''0H\[Q;3JYQ06$E#I;,XM+;\95D%9UL1@2]Z>BPV3 M0 @=*J\*A169#Z[NI]K,A-+]JP0X()BO#PBI-)9X^I\49-V>=DJT]!R]=CNE MS^[H(OK]KQGBTKHVWN_-D9TW$4FK\->_!ZMZ(\7P@/B!E7(KP_?0=O$5P9I[ MRV3H=-.YJX=F5]UO?51; O&IR_[.^$1LV5M;GF24C3JS6?R852UV#@6;\ .7 M]*O'E^C>\-HJM&]4\ULJ^X;$U< 9!N%]J;OITX?.?D> M2M+^1O7"B3DU;F5]62DMP2<8=%WAA7S@'@#,)P9FYE,@909\DMUZ5O7T'D!9 M5#6RW.G6I^05-$N O33:.?MH+N#)H8R)VVB'Q9LM>94<$^G=D>,U19%!2O#D MH1VPB%3L/Q*=YVK7#,IQ_B2,E:UH%_%6'.QLB9%C::7\@<4ZN5_P=&2<(2$! M,:#+"M?PW*IXM9H5DK1-PR/6,D2HVJ $R+#8$2.LU/OY#A\Q\V%\ 1WHWH/X MV;?FUWL+2XXKP<-25A@=_#$I^I\H!7 H8>F W9W.INE@(,5Y@S(DTP8(NT!4 M,4M*IOD)MW^T;I[JZ7>N!\+7)G=E5,88B&Y=_;$ZM&JP=33_*:S>@VVF4/EB M7&N+M)XN@Q^(V&!@3#@/*:%JKT64&_*RU\ MM@F.@1/7Z=UY(#=.^(S"<:<&&):5?9O$+M^%X=@E?G[CDT$@2XL,)DPE;!YR MMP.J3"D$"OX:$@2'C,4C8LJ*@\W'':PXQA]8(MJ?8XPN^ M:*KKOJ;^\TTSHJL52N MW?#L@@UV$3F^&VM L=]Z:Y)B&QW!M5SNYE0JA%(DE)V*[8)@@1XP'BUPN$M_ M >P67D^[,>=MJM0A*;,NZ)!YK@K0DI5)723^T,D<^(/O&MD+ER9UK_W21..2 M?$GRC&U !RH1,URGO0HQ-%:K(>U^R#\N *ZT *5D4LKWHZ<:,[(6A2RD<8&' MR]/UER,,<.KCWSD?_!(!XWY3-.//\"C'P]FO_+B$_5 E<>%Z6#@DWW MA6I'@K/VTU&#*U#LN=Y*H+>S$\-:_.&LH//W$[EA::(G.ZC,^!"!11UF9H<( M'G?+5X9[#L\EG:S%1Q5RA\2>9QI88/#UPQ$P"OUT#T%Q3@# M4M6BM^11TTCX%./6'D##]0E.;50O *U^)?=;U*7A,(+P,=:VN$]*UU.NU1NZ M7369&D*3RWA7&NW_S PJ#D^W/(TN%RG^U-RK5, S<57&S.IG_F'E5JWXEF)?YTEV 8H8KBE#Q9GZ2 MQJVX'9/"HVU[ !H/)+ 24M6DYAJM+DJ+UR03#9C//ZQZ;J4CN!G4^=2/;5(8 M::#^AF%J-=1_0V;>U7\T1XYPW)1&.SN9_X;[ST]QVYY>'@2ZLW:A-7\P857] M[Y:U1]/A1;IH.+,-5 MQNE.7AHU^%A5DME/#E5\_FX( ,V/VHJV2&^XE_VE/.H2.'2>418A+RYYW\F] M;V9R0C)'V96QQKM 7\)MXC(\ARBOID?JCH1J+FDZIO^@U!'KS'.80L:I'QL< M[*PU99GKD/&.E#_%!/9L'[10BBC?W,\I^-K7AJ[Z.CZVQ*^81Q@=HQMM M7B?T?2]&HHINV2:WM^INV"AGO870P+_)DFAM,C\=;I2,2:!YQ_ U!+ M P04 " X@G]4",ZQY QS !\?@ & &5V87@M,C R,3$R,S%X,C!F M,#4P+FIP9[R[!5A)3\#V@?\/__OA M !$6B@+J"S24AP J$0H:$0JB'6! RGD/Y8\+ M^.M"045#OX>!B86-V#CD%)14U"RL;.P"8N\ M?"4E+2,K)Z^B^EY-74-3R]#HD[&)J9FYG;V#HY.SBZO/-U\__X# H*CHF-BX M^.\)B>D9F5D_LW-R\\K**RJKJFMJZWZUM7=T=G7W](Z.C4],3DW/S*ZLKJUO M;&YM[^R>G)Z=7UQ>0:]O?NN% J"A_.OZ?]2+"*D7*CHZ&CKF;[U04)U^$Q"A MWWO AT$LJ83YT8;D(;\7%NF+R+325FRF)\K'9 :V(SCDS (K+">_5?M#L_]O MBGG_CS3[6['_T&L6P$5#04X>&A$ LX427E;O+-5N=E3U!P&2QX!+Z)$F M:%8= 9PA "<$ %Z"61265E4U0"?^I"\-E* * (8 % M!+!TA0"H0176"& +?@1' ,W0J0(M&/]Q03R+%OSF(TM.4] S9MQ5;$JL0=0H M^97 ?5L1-2,]C..#CMCY+W<-B]JF)WH5IV_S,:Z49]C,YK[BDUZL&]G(B."K MN4S]MZ-D6# 0P$"?5N^87E;7-][/>2E@(9"-8WS_-A?-$LB@-<*]I1ZOAFJO M].4;^0*1S15J9YAISZD+DN+C:?TH9/'NOJ4 $'_AC" 0PJ[[U7XTQN75,[IN+ MCJ')'#;928E^629#W9YF;%W13;"(GEZ\-IGL=%S_ZW)J9%KLYAN_E,GE3K:+ M9)A&QL?-/%B#Q"B^<*?I5H!M>7?S/ZTSV/]><':)6$RQ4R)9065[*, M/]%DT%"$@"GT8OX:Y&]+(8#_W53%T!^9.T]%>O7-.+CE7&P%.1_-E.T*TP/XDH:9T\/ MCSA&8'XW_F"LV&9I70N>_$@A.*S*]6 MJ[WWR_ K:?M!?HM/HR_02#7P!X-.YYK#X#3!P18\TLL(8$I0\B:QHPZ* %K) M4^B%+Q*W8.00+K*1@QCUH6H&>O<7UX1FKO8OJPX.P=\+>IH$H+TZ^S5EP7=] M'VRNHQ5C_?DE8M.;M'ZL%H<:H]-9CL%KVZ@1P'ZEO&( /6^,^R+3.&B9WQ+^ M(DSZD>$>)]J-UE=%$)C9*2;?Y1N! MNK "S/&I3IX\7:'%\4<$DXZ@R72+39#K[LN+B$3/@>"DVU=#A'N/ MP4.F2-.GZ9/]R!(W9H.CFTF,,,#.[][0#_B+2$S-F[9E*]CC%PXW#CMF0&"VQ#<3K%-45T>K\F=HKOM]7X$F'F M4N,F^O4>CV]>M]V,[$_;0ZZ_>[$@!5ZH M Y]D=7?U>_A*N4=2A(FI$\R?D&=*E,?!'6P9 E.>?-UPN(U# $5!H; .VA#A M\+SMXH0'T+8U#<_+#/3FB]$)4"I9AO7)4 ?1C\?1OO&485CZ?$#J^70_K2RUU#^V@8AVWI GV]E,L=I-,: M8X&0N:&FD@WN-E?"\'W WI%>X'@P-[QTKXJ89,1]N?":EIJ[R\XQ2,K! 3>$ M2O$%OA0/(PY[^E>*-&$$72;C\K2:(?X+5/##F?-'?K7[,C% M>3'(< >HZQ% (4P_R(YY56)N/8Y@\'FDM]M$SJ5B]2("&#J8NH-;G^2P%[_M M7J[G]FBZ@H.MP$=GX%"VN2/0UN46[?D+T" +_,T V?(Q>Z#U@ZQ9DS["HOJZ31*3Y\M>.:J0%>ES;&T MVB\1A;.J0 :RV4MXQ&)788C5+(098997:F"_'F;Q#\E-_["5SE^V.J\O]A<1 MX'!>VNG-^5%]O5C\8VCSH%9N2J MU^JN8\R6 Z0;VD7/T.C,JO2(1RPS4GYMSAX<'$:-D)\-AE\5'$HX0Z]5R5OI M3A3FVE+=J%(L?C._^YOY'U8I_LU<.68N3?@7%PL%H, 7M?>9L"UJJ$C[Z3@6: %4C5'01F>U6JE-1Z[ M30 !F.H@%]?/4$T)@[#PL"77IO!Q.!N4?DBMH;+V>*Q'[$F#+6AZ1?0['_IZ M4E)B+@*X;]BB?\XEAP"^OD-N0I>\[,B%[GJ(>" IK7_K3L2X2W"(]?+%=?ZV M(E2;'A4!I+U' ,?X#">9","W=!ET0\: ( 5Y"QX3G7KI)@,I1BSFQ8Q^G2TPZ$A]F.&XJH$( ;P(_$UE!EJQ=&:#^Z(A11P>.7#WB>X_1F'$ M?'#LD5C-ZVZYBO>JMGZ2)::!X/,,SA.:")TO(E4CT>-KA6[(D9OO@8!3\:^[8Y Y[Z1J56F^L6]A]"+MDW$J@;]OZ<]%KH<<2T 79:^TIS""5W/FJ M)/LS^S=I2?.498^-F*R.])+4Z\"_YH^M[[ SX+"72$O=MVM% .>LO'?7_C". M6T7&]3,Q M_^H8 MF7#X5!_&#O2N(TK^C=$ M:T@?^P#973QCGS;%Q.?H-VU3$_2#W7%?&]*%;#?W3R6!?RT>5]]AG8"7'B. M$\'M1?23IM#5!?&,L31RE;DOEVQ ^B57&,Z=B)H#\WK5(\XN7=5*7:VNEV/& MXX)<,=65 9^2$_-LSB)%4S%]JD4\R;1D[=EV@=U"S/2>[0\&VSK M-054RXF3JPIN 2DG"(3S"&'K67[FCW&H/8NUB#VGRAOG%09 MGJ"\%7^VISE(IW$T>.2:T[E>;="GFW.;I[BC]*-:'#7(.V@LEJ2_!_<4L@;+ MS9J_<(3M5+S7Q%F9*G30PQNQ%)1J2G03;(RB\&;VG7T>P&R &[X1NHY[;RWM MRQO;2K"\CWK]3B[FE'0%9- M"HVS^VA :@11($UI:&:2Z\W8)M3"PN@1WF*N8ZYYN,"HC"F.P ?YYR%Q&PC MX0QM3&*BMR?;.=D2%OCYP@O],T6?4;PYE0BN_;URZ&:ZJ9@D:](4'GW.)=_& M[,M-RGCGCXXWK15F:BL^%%PUWD^2L]'8)@LA>-"HT;8[JDSG*/:CK.J*I/+G--9QASX9 MA"W>3Y:&1XJ_C)4.2Q[/#JXD2>4OR!:R/HCD>4*I.Y*K;N#LWM-"2]=T0VUN^/U\@XN._)I%T4<"B3ZE]O^9-4RD\<14[3F/= MX-2] !/4=1I"7T,JEP7M,Q"=V_MLS6)ZN?GBM(>!F?^B>_?)3I>\X"&UX]/P MMCTYM5$%7?E+V>(M69Y,"[Z TVGC'WBG^/4V29-N4.D1]_=V/Z7 =C9FUL96 M"VG5"\(M5*$JC.0]%YW"!3G<[C+<2FWWBHI&%HAS J(,E+]% 4<5Z[?4JA4G M/!WK%".M!7(.[(9X+9JX821^LPMO11C^&%< 9IF^ Z?7Y7I=J7S%05IL9SMR MP%^=V L*.'ZZ1DEY5:1<'"JD7L]VAW-C2!T%=CPHM6FXPZ 4@MT7W_77RBKE M?M M"AG6JHSX[QWH>KA?'.O_4G?U#S \(YKY8BH:)4LLS)J8=[97-E4=&19_T.&TJ]UT<+^#'L.W%YD6& M9%=UV*-B//!P'.B4 JJ$=(C9;:!S5L](L*^CQR<$P-%WX0#K^O&'9XMV10#N MG@X[X.,Z=UZD2S=#>C0#I$?3A^I*D"/AY!D2Q(G O@R:X%X&=?U^EY\72,2# MB\LU.E]WT0GOZ"%]T_V,7Y!SMNJ[$S)>V*-P;"26I"* JT-._7_U\?M3LFQH MUY8>TMG>A_P"G;,WW]WXQ<,IA+Z!ME6BX; VF4G]4_^)J3-ZB\MK>-LE;P5# MN(5+4Z%:&NF"^#9JIV[:SK#]-WPQ[!$(##U?:(#M%_$Z2CFM@ M]Y&&7>B"H[Y$ !U*%]FPM-_V3WK5MY[=+[%]).7J[:Y]K/"PY/BN!=V(H$P* M+J!Z]Q$Y3=FEND/4)S*PT-FI._ 0 LC ^Z0&SS=V8 B(K^*4%1*IB%AW7."@ MNC,37,+MRYBM/%W0[C,?S7FESJHJ@SL23PD0YREB7D]1#7\8T4TN_LH6MK$V M?LA$%*"F;)G9\]I[FC',\_TS)I_IQ$*G9;>;@9&IOCQBZF MGCF, 5^PWO>A\.>0?.J&B$#*AL\SLZ&^+6P6=DDV/;1*7TJ[1W1C)%"3SZL- MQ6QWW2X]XJAD#C7R",N,/(Z2C-"@QV9QBQAG^\QQ=&]'+]?(& M9IR%&U=,E4D"W,KV?A+[M:0*Y*W(1;;FCGPUCJ^51_ >VIX_#&)]> MB+H,7@!%,FPI[#6TC63CVLZLA^I\X@O!\Q42!JUDW8]^!$P/=.(0VIU&C]L/ MO"%H2S;?E2.?=*,)&)&>28],H+L2V<>TQN0KZ6E9MAO@2D4:0XJTA7,S-F_) M-#&).BQ95-+A_B=:IPMT)\R://MWF!.>Z"<=\:$"X2+B)4N_@+JJ(79P@[CJ M)%DTK]('^JD[J,R9GQZ^% ^B:^%A+FE^B;,/,0%D]( M@GNDAPO:%W5AQPN M*YUE.@G\$<#'1$62G<>KL](#^[+/0L-A%6C#5^=B5]D4PV_H):5(WT>1?L.@ M9"0Z4I!"?6!A.O1<9GC<>.RV^#JH4DK]R?V'D941]K-@:C-O)1CFJ=6\] ]K>C5Y@ML6777Y%TGA9;]8@_O['96@5RU^7'M.>>+L4>0;1 M'A;@/!6QL XD;A6HYLT6B&?=U#3DL9\C%Z:CBXQGX*,!U+I;Q)^1[@W1[@RM MM)F89.N\%(IG*>!KG#$*8@TD+(>ERG;AA7T7[%MVQ7F3?S=RK5RW3VX<<&)( M@ ,A )NT7KZTW+B&G(X-GKD//7$4<9R[F?Q&+^*-]VA*D?I36QNZY$LYM]HV MS- 6E>J UO!#VKNU ;MZDMO\:Z524$USK,2G:>[!9@5H2%KAA_&'-;+*NYI9 M41Q>C\(&5Q3[ZK^8M'R8IK/I4+,.(#^3+AG(G/].SEKU+G[#B# V *79>JE? M7L$)/43]<4X6"GLM4PJ'(]L5Q6GZR3YULOA4^[/*^U<-#:/&9X\>/-8)X TQ M5WUF?PI7*5G'3;$;>CUF+<'X,E=G7D=O1\4EWA$NU5W=Q%>$QO4@Q%)46*F^ MR&5'9[$#O@W+:3EGB.7J*C&W/W&7K%(@L9IE#OL4D-4MY!+F>!KU6#YVY7FH M-K EMEGC(-U"HP$GRY(2Y/KLE9^P2D7PROQ+%3*#P6)04<_)2/;GY+PO?=CB MP;%GZI-/=I#14V1R*+ MSZ]!28;!%:X$0Y4&.R+O-VOSYLSBB%RJU0DJ*4HNV(91>@0O3+Z)<9FLX*'2 M/1W' #>+3;?&O9P(/T4KR8TN&:W-S]ZYK%.#W/.-X<*KP")^-I6*"G%PN!=; M4*VNPOSX5=9ZY"!JSJY<+MVD@(DC3AZ_9AA _[/)"II]0@=3<9Z5CN70)<>\ M3K*YS*8;ND4K.9H:C7FXWL7!GA[>#@FXHG_2]-3Q\_%VA(1A>%JR_TGS.5U3 M9:OR:HBZEAP74T)]?2E[5@?ESP>__Z:BI\>3&GPE#M)1"@+D.6RDV5'^4_.( M_]TK\&'XAA0WTQ4R(:H#Q9*Q)&H-G,^:A LJ[-EZFPI2+=PO>BXZ;4(F?]1. M43V"M9G(T_39+C0'LS\R8.H81\3#0L\M7X$W<"I>J(7&]$*X+^K'+U@_&MF1 MCT^X^>[GACS6/A.? M864IVV*#F)_#Y;?WQ3YE5IPL#'C0%6X;/^GGMMMZ06]9BI=_FB1@(F:_UT'H MG-V63L5$T6=MNATH7C9]: 9Q?[-I0MFB^JGU?-M.UH0K&YIW.75KJ!HU2Y-; MC,NQV8=3P2=2XG#M^H5D@ZYJ_!UT2L-K,V; ^D$"DS1_.^4G%)RUN[2:LZ/1 M^JX3B-_ K%]#Z"J]=LVM:*S+B]ZTLQ*2B@J39]O/: U*SI<(3?FQ8-= MT._<%D.IZ6 J"T?;/LN-Z9GF>X9^,RH]O1>OZ?GQ%;5V'YZDA.(A@'A+^[C+ M2-_;)UDI8E6&CQUO:V^+&9:?[6BI3=V +L7J&OPP1TC,AS!GU(6( PVN6W?Q MA]L^MC*2A-".H@VMGU3E,Y>45<9PT?:(V;19Y7A+&5M.7YD8>#B?YU71,S>/ MG5]S'X362IM\BES%8Y9J(2AM]O\"4!_R-ABF_?".%,.-+E'H(1Z/%/!4SR(H.%71YS3W8?(::[K9:?IK-2/-76 MX8.#WBD^*5&L'^9#TX'N_@MA347^7:G>FU?PC+(O(W:=&=0QQJZA? MRMF^>-P1&&JHOL.[BD,I9%K/VV%K,N95?&@ #]?<]*T"8V8Z)@ M% =I1@:N'Z8WGGO/\5R7K;.HYFF1[@_9N@^/2(KC7+$QQYIS;G!N;#D,4T@3 MV=1#Q_E%DOPP(R0+$DO-YJ^=5GF]C8Z-&Y3)C$;5(I]@GKH#Y3$VTS=$ M^S),>^H4MEJE;X/8\PB5I$B!_ZU@23&GLA4)9V7J[-/4K25J >SI01BD2E+ MOQ>]C&.W%@0PIP6YA*>1V]\*W?UZO&KF#TY' * LO&EBT:-O<'1ZZE%PI2#6 MUXGB=\24=N@>+SP45:#X$]OGZ@DP]9/KXPNOD8H>F[P%ML%=E^J0*P3@? F[ MXQ)(2@ZVE**M[C@*\#O8/.X,%SHD/6A*)E@"G?4S2"Z=7A33SBD?9%@Z=')R M=F]&U]>2SSX=KS>=4WW(4V&9ZSA2]?7AG/1LO"6-*>K_H&&=ZS8 2PP] ;% MD=WU@P^#..4I.AA.A2ST+Y"JP4,$8[7IV4(@Y'LZX5 $ $$ +P5C-R!*FNQE MUQ&]''#-"U(7DW&E[K8$W'0(LETFSD.*-D0XHOW(/N>[+84/E[H M&Z8#SM.E$$]L^,PHN'K_XUJATW4_0%U]1.XCS48NW]B>,WXHUQ\ZJO M++WG2SN,]/[-:0..F1CH1!&N/AH6Y&89,AV:W=WI]<6!<.SH7TT/W((U-,R$ M0O0PT +F3PWA1FX>7+Z%[MU_'#G_>_'"JIT6DZ@8Z?P_!ZITO._ M-]L?A:,[G"GO8?D30E*4'K94TG8+9^VV>$_.$[RJ:+-8?KK1GK"'(1Z;H+'Y MH)L^^3$> &4 M9P?CMQ#S@\/#Y=**Q-W=]T%8[QK"NGR5QB>5G8P#-=I.LH,.&AZL7/-NH"KX M7?.DL=T9)3>CC$_UQ5_%BR3#KJ;*$HI,;$^%#Q7/+XM\.A] MIK'",JMO4UTH"'999^3:?':WJ MWT*;UZ3_4=?1FWTZTK=)NRAC5K]B#;N%QL/AO-"1?]2G**I"*VRO_?_?AD+N M1=JFCP/KYM!@.)%?U!*<*.>"]+40Y'(3/;ISH08&EF^?4[',L!0HD/O+%*_O MV_ >JMR-2"D0PS= "Z2J,4_:ETZ?6H N[D!P/XM'=8$"W1?%@5.N]F64JQ#E M)%%4%!RJ[Z>N7T0N"\W$&#(%1MJ(:M3&7_Z@4EY6(/WX45/(Q)2?BUCF..(> M;<_]V'*O]+I&F38U%?-9RY28TY9J)[N9)[H2,+&WI#TMM(1V8>,=QRIB7_KH MRXU'=',MR$_G/;*Q=$OX3C^@7=4E"D?8EL>GU]>'^Y4WG#;Z96!7"K&RO^YN M#<+$TD@R?!#^-A/5O$$/IX+:/IYAUF:A'O42KM5@NK,A.R-,AVO M7VQ@/HG7L@ M!S]*]!A&F!%MP=IV40Q4K%WSD<,/=A8_$ALG*AE#:PKC9??K M-:_N>@ M'RU#QX_[MN)>$!(JC:/*B,OT/V[S&?CPGLWCVX0WF4!=?S8:&!\%%_$_DIY;K*=/B.OI%Z$,SR^.>D M?_MEZ;'-O64T.!1\%P,G2Z;2G(E5%E(7^Y">,NX'>JF87D>KPK]II*=YF3F[ M&"M()C% D!SQX49)9<1K1V$F/,D[Z(?I.>D/BM'X8HE*4@!3+V'>R&E>^])0J[%MCE.$VSXT/U&E;/<:$X5*/O M]GN 1:?*%21',777XV1'+W"MF33;UUV4I9=,J-QS=X+ "=1QC@;IFVPRCTS1 MI)>C2Y$QZ.^WU4B1$TRFU%_\I!K_ B\]-#T+"7,[? ]GV6DY5C=K+7SHS"L%3[,T_ M5%6AFN^@X5((X!OF+_USWFGP4J3.55@#S0A/'_I$MJY^A/MG3=R,EAP]HP*#BE8U!*_A M@0O:JUF6!DU:,:K0^'DB-3%TT*K/"&AOPF((=F]UP79OE6XPU@W,,Y%4_(6, MI?6TEUAZ;,XK1-5MH"JEPS3JF3ZMLX@^YI[!5+]9P98*2T6_,%,=Q.9."CEQ M/C"*E?PC3#,*=2V6F/(^\U#F<$*60-IHS6::PA&8Z,]YHK,NIPH&XY>0=:Z2 M8R%80!W;G4L7+"^+=3F!+TC9U 3&*$&, -)/I7<.U1.V<)7@_\XTGC+-_Y7ET*NX7$36(EX.E@@8T M.GT@5V_ B=G3($-^AO,I7X?RM[C"X$1>!;KL]F8TT\D4W)JF4?MZ"^U@=3G- MM#=9T<\^WFP=%X&7$8#_>:B5N.&MRMOJ>CX!/PT,&^\RKZG>$,KP= M:7AO;?ESILWLOA973*"C]]P/R+#Z_0KU+'=3JI/8ZCL77KC?Q):VA2L8AS^^ MO?NO%67>P]/>7*MX)47&K7"+S*CME925,*J=Q/W#!$7K-5^K$^X^$;-JE%PT MC>_0VB_5E9Z24OY"].MY'A.-X\%K@@58!J6.T?N>H]0Q"99%O?E\RH_CV<;3 M:0F>QBA?Q669&7[5:?/2;,?5N4?HZ)NKCT:)]617;SIB\#.@?&7X$O[]B?U6 M(2O,RS6IT:^QT)R>:[1HXZ6;BR6CZ4>L4C^QJ+< %5M45Z'P13-)\V4(V%2W MM(4>_.C991O]<',]XT<)=>"@=7WJI:O8T&%3B9LG-P=>Y(OJ/Z2IDHU]97@E M+V_H!$1&>#I>;=9W07TR:,:CAQKLWR6P4K0]TU0'/]+F:L1BWMI8HR2++8+V M*4R(B>=I9.BXE'=3LVC(0FC=A]3*XQ]G/;:$XEZYMXIBC*QR'HR:Q[% 3_I5K04*O^U\Z)*=Q=# M6C[+NN9'AJ%&]'I/?0F]:X>8KJS RWH7S'"QDL*A'NM8OT)*+&,@RUIF/MDNCHQ"?S*F![$#_RQ9 M:I\^]'9HRC[P:D6W?Q@5!-SXK P%RP2[\]&./88/5[4+*>RV?%F2IKVSTV7- MS=8VO]$=3';\<7!HR%=S*0YOW-O4]U_DM,:&YMW/I0VF"7GIV%A%T@9N402] MGAH/ZMVEDOW$Q.@3(66K&LY=(?+QD9&[5^$.!35&M4N6+L'BG*S*L]LVJ(8; MD8\JUYS$,V>3_NJJ$Y8&L(!&=5W+;B8LQ-,_O%T]<.HU2W_11Q:3#^E!G(%_ M1]NB2C+F@#E>:=[6,\H!D<2OW.8HW<"'F[$ZER%BOV2" 5+C#?M$>]9/Z>U)4S$D M9U5\MO8.M6Y1LND/GH,,HM1+M.*IQB_-Y&*O[1?H["W,^!S<0A(-K M+C)T9QM\72FE[Q5/$$A'T,X [-+SCN\?%AP>?)!]P%?RPU&.)^4QUX"8RO&9 MTG%* MW%QD;F2 ][ +=H>13V$--L8W"'GFC)3. /TTT'[V0MP0?TJI?UKXDJK&\NM$[# 5QW==#%Z!X",,YBJ"#83_;O MC(3@:"* J5T$L(VGJ^@%/98(1 !ZD0B K(X GIOOBI$@@(?2 MP7\]C(<)*$,3-M5!& ZU15L)#CQBV"PF@/\RL6*6,511"M*V1,%=41]H&*=! M52WF,FM')&:RI]NP1%GA;!+%.E;<$SJ#C2+B$WZDSI&V>XR4AZJP4L%Y/8QC M^D"3K\: 6+AKM.*MHWN[($T^_9I.O+] \WXSC7-FWJIHN;4MY)AQI?EDV1P! M!%8J[H?O!WO/&7J\>,9\/KL2?QT!QIDC2HWIJ[#F)*UVQ_>Y$/3K&Y^R:Y/@ M#X%VSL$;XI'IL_G90.4V J#T<_]HB=1' 0F<@BZ'LWO9QQDI8)*_\O+_@!-F MA=O,WW B:ZP8V+S^>1*\=P.^PYW4M==C+I,^>5LR-_=C)APN8?%D'_ON\HY= M&_OP77KQG1>H:2F+X8/B4?7.:QS2]PB@A.UJ[CSC3QI47S+PG[5;5+!'LSR0 M)J7_9TVB!;)D/?J574D=_D^)+#% M!]RU03V66ERG?#S^T,@*"E(#8T/CYE1#%](9ZFO>#E'M73O0KZ9GND2^P650?!#W:T!B)30XU ME][="AE1=#8*/WJ -IF@R_;L[R.DV2 ">< <8'J7S82&.9G\YC76E#675Y## M/PZ/GJ,G 7*7J:B-&V?JRI,2_YD/K^+%8P^;\3NY'I@%]6A9:>&SA?E2 M%P>\T*0I)WQBRG?UI?M 3W&BPYT>F- B7BOI&L/XFA0!H.*3@5'TLD^L=4\% M]CR(*=KCV0:2"*XW"8 [Q=-BQCDIRAD=!_JJWVLNVI+&PO"A>(5E[M.1JJ], M?[:8HOY'@Q[D^(/ANTG07HS^0/Z X]1/E\P0"^'V?QPG#K7&7S3_YP3 W M:W+G)@3WU;/L\% [EN+ D(WLWM:4+++NN$*\,<1(,I!NHFRR MKLW$($H^LM4J>S/RUS?,^<0PBZ?UL7UNM)B=,OI0Z0)#MDV+DN*&WKO3]C:CYW]W_O-=BKR]_8_)L:/$MZ5*4%C2':M]L$0H\@(O[%7 MW'@KE\,5].C49#!^&CY2CP"*3L';TG4,_DQPK@-N!%#)!@\VOT&?U2:)MB8' MSY.U6=@P@\EA DRA[SQ2]$@-R]_G-?1.LD4-KL+TAF /2LF>?72APAQ>R2\X MOLP4#"?0, ?6AW#*P8TA0GN)&YX\(5 1T TL_%I0\CA8^1:9*MI?"EO(E67< M^:][IN7QW-;'@SV[V$[<33HFERXVFV](U%&J&N^O[FYU5/UUCU95QP%C[P23 M_#E9CV;3%?AX#Z/_/&38 2V0*K,;%],20X>4PC;!#S&:8^38=3NDS[KI!CZ_ M609S\,H/V3%'DA*]8 H!#5#:ZEAM"P'RAX<63&IU%KQ4NT)?I[]EN(,OW1A'M\;%MBE@-.<7MSG M>O-T?4%P?%0;C3/@A-NRLAX2LTX(%K&&/73-Q>V[E'YM+$3!^6K-:FT#LMJ" MGF3?(4<0N @FW(F?(B\I4"M/< _^U/5]WW8+_51C[4:)+>C( ,_RDH;=_:MA MM2)/N;%CC&6"N"R;:/F0@%MKFF"75Z5];2S/-PH^[D5EV3*OYLW[]70Q3P!% MPS?ZF+HLF>4#=E;RZ^F2G,W?Q:HL6[;0/\F"PK/$H& M&_#5TY8,NIX^;\F+6^1NK*S0_N0W\LV4B&HXJN'9D ZM/Q/$7/SXZL55&X6K M58+XPEKG4Q=/#=^V_$.# GX10JF/4S*YSI#W)\P$GRZ??7]*&4 VTP1WB^[< M[$KM1JU=(_5^&I&!+CT]$$;6B'VQ/,%U05(M6:$<\?[]-&%AD/[LV%)ISE)>^5^]\":,R3,9@2 MY,T(H+@/?(>A]=H4/ ,310"2;Q01 ( $R3"E2S ^ AA644$FY.@(8"VV,DO+ MU(F:/L'"@_#VS9S\W,J;LJ]A)[')DDB?I6$UBJ]/>G) MOG8:T,LYZTEOPF YTI+XH469FN%%>Z8?<V!L&#Z>^^VRI3/4J<,Q_NUT5T M85QQF2Z?[.TE%S2N^4V-JE-D697+VC?H%(TQ,5*=#< -7R%:1YZBG60NDY5;X)'YQ0XF>6-AI,F:#E M_2P[:MW,KT9)Z]SRL!7 M7&Z^(7,3*\LD;"@KT1A1>$+_%5^N@ '=%#)-3UQ:_JF]/^7STE$UV^FR)UGT MB:BF"-A?ZMN;P.(?'[N4*#>:4V$647JP?7M>1[8HJ+]:M-Y4T07%( MXP0?& M_DSI6LWX=UAC4_3X;]"7> _&LPU'CWB":9Q"TSC::/, MY((4L<]IS3X*-LLKV-S3K!@+,;I'P="5LI8RGO(CE H!S+K&WZ%;@X\?((#. M'RQWYR,5MDNZLB&/>\_X,'>QBR!P(CPVN#\=%PPN /[U !E.#:]E@2&=V8E, MY<(!1T>KH89A-SM$TF1JC@#!!SQ^B_S\V#D;!QO^&SFNQW=O'/2/ \Q Y\]V M]+=.,O[!RNZ5L&;703X'&$S,*>/A&)"!DR\*8)8,V". _Z)#N[#F -AL5_^< MJ!&Y._T1 '5H,2^]44+1(;4JI29N@:9,Z:"4 ^B_&HY[4,NBKSYF1GRA/3?I M($KM(T2'Y(VW6[!!Y^*JJ0(N":FOW46' _B_EK9G0&#J$?VJF?&7Q]0RW#8[ MT4H'A5_0HIJ9/$? M""/;7)?)>JCFDE]Z'(\WC/&]\BJ:%<]V57_&0(MJ9U-CK&W'#IGL_.CA:A,[%% MOI&L=:I;S;I#_2Q='%[>=QV4J!G/#*;3',==Y>87:WK(L%G8;0%K8'/3*:S] MP-G3,I@!;0N3BLGZ\Q;FDZX"9X,WKUA^:506?*)G(P1>?^N+&JAFQNU*\A;Y M8L&ZU')Z_UO8E7)5.)"0$?)$S.+,5[@3BX=J9[:( 7UNR)!63?EH_*=-A4"V MD5D,+0PBM,A6G*VE=V2SJZK=R C-?Y>X< XE.QC6[A/3/FA?8CT+K5G'[.K% M4 34"A+C_7C.8TR9QS[5!E*EJ9AC#AIZXI#M-&3C#LQE&1'<:\P<#7UQ0ZKX M4)-G @TSJ4 *BNY>L_:@5.>[,#"A*9%>+Y.A;4&-+JT>M/7&FR/&(QW$&,@< MT? F]H'S<[1U7%R?+GG&"0&"5C@ MO&),H._'-ULW:U:WFF.7W,[#" ?/;AEH M<4.>>+6 %-L3U[CT M>A?=(+B[]ZW1RQ\W5+,8O%C'*[LDG7]_B-T8\&%84#N?K-&[4XXG*:*,0\\F MZ21IS6=(OOS3BKC:B?)+Z_4.5K%:VA ^4<6BYVUH*;'9G_)VD7#[R=(B]>U8 M>U&T D]%K3T_Q6DGZ-N5N%G4[LUZ/)%\W?WV4FF#,(&J>//&>F M)VFD/-[ C9T$/C"I--*/FS,*,TO!P#:*]"I-Y+:U[+3'*TDXW<5!,>WNQ?#(5%AN& M+RWE4&;AND=*M(U'S(P S*;C1I=[GSH4PS"1?B@XP\0/ 6QM:2'=DC,8 M6B= ";:8!@]7_T0 2T@%H1N64+"<-5G6N1H][=AX&YKGJ6@@6J;OVWX,6RQF M5X/2?^-5:(FF.P(3=K"S^>10<)2RL/RYE8)J>PF<(Q:D:(EBG=OWAF1NB)G? MC/9?-0.@NG2B DB )#(%!RM#0%T3.BH\Q*=*P M:"!K5L<<[W*CM[!?*>_HN>(]C:1(2&]Y7C'Q\OY@QFI3Z%W6"F:]5/\D/BM] M/0$NZ!$8YUC^IG-W5K1/KO"G[LCK4)KP=])X[L4YTST_S9W4B!% 055L.LBK MTTS)5<.!O)I+28JL-.)W OC.E9I=' _@)U?S?BHUFR6)-JRR$U'BS/1)-Z\7 MBS[F!OCC#39DX7C>[\:G/+!GYU_KD26WZL^?'B^E@M[:S'5 MH)B' R='4^/:65SJWBOAM"NMXZ+45K%HJ/G4RZ2L2X$S?6A\* MW9V;EIGRYHR?/"J(OOZUH?6:,VJ$ Y>T% BQZZO>>JM/9L'!'OMH@I;6NY2] MB]-F++NWP57I#F)YUXD FD(99BZ7YJUOMT=ZO??UH?(.EM&,<4!4VIOT!2!4 M?O_!LVO^!EHU(4GMO^G^[BFJ@>O*97@K,7>+S% ]J$'E!\TU2U MD@Y&4?B3(/9/@F2.V5>3=#/)#>NJ-C&;+OQG#B#W/[X)?&Y^M^4U=_M6VP/TSEL6 M#D,U>!7UZJE?M%<(QF?#0O4*"G+R_LNR/ES6%]CJ\(>^BLT+S)Z"(N:SWVRX MS<#\Z65ERR'>-5W/!B7>KZ5U"23&GM/[:BMB+.EISPZ0#912T,@R\/'EAO?W M?;#ILLJNLJ!Y5Q;]9MR*.\MY8<7#=^USOIN/[A,+U^BG9^[7\Y01.4^\ON)C M>6$B_ZX>[U$ MCW*-+76H"4_J\K[^(>1V>XPH4MN3J-X2U'Y9G8-B89_XCL"CE \>,_3;HM5W MYQ8R+TNK=54>O'4/1 !"&"(+?.2>OZ&>G!7=(_]T8IPD//D*XEV(W4_F/9H M4]L:BG-PP%$:L$K$T,S"YH4;"ESN9_2\^T;XN$/\^0^?DGXA4F? M9Y'34BC%Q?6@+5?ED$_N^3W,M'2?%@&@6[_?6VB6PM;':Q;RVK<_0GK]0YFW M3);$5QSV5-LO&(J5 *GJR*&/6S=1%5C[[!N2&,R)-[ MAA9E@7-D9"GG(#:W&I=5NW]>885A$D'0 RYT&9R=G*JDF+CHJY\45K@!(_%=F0>7QB.-Z<&W^VE(]S*I[ZR&;OQT*BB8&NB4 MGJ=_T8^:"QB*OG5='C,Z#OFFG=5PF^1WIKOVB:JGB\Y?\BAI;$NR=U =F6MD M!KV$61%7EI9*5GRO$#73 $:K/1>N7_*%D@UBFX8AUA.&

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ʆ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�G4/,*[;UZF5A#ETI=G MDI,I;K@4*;:/@.(6$RC0*_E-5I]8 M-^B WW"L%W#"VZN*W\GC(8=/?+_B5] MVJ.)259S'1''.RL2^-M;OAYB,_+WHF3Z(T?E3T%#XHM.#/ULRJ0]P,F6 ME6;52JJ8Y.H_C!&' ;V0R+'W;(+QM=O=9ILFF9+O\\0HKA4]LS M=S\).JXTI<$=KATK[] MFA6*_9\CTH9;8W"UD-WITB9'^ =-NA_S=E/MLQI!"HGR-D:OPR( D"$3GD/F M=WCCLL"RZ^V_$T&G5$X MU_BM=:@NC+$Q.U_FGEFFII]Q^FST=\O^@SWG-I+W:6G8#PA@EY MG/2W(FG\/@OC$'1C C(IW+ M=T6I\I^7(K'E[M'8ZF HMM-C0QP4<9J\6#^;AQHR8>.%?97#86GF"=D5$QG: M"N(L(1WB';M6>W=*?3##=EYJGC'\AO'BNYCC8#%W6/1 %F[R!6]A7(":/'-( M3TZXJ"RIU[S41(^O8V)G?BU;UMXLRA5K?:K&*0KLP#0/X]E=2@HY_1(:EU%S$X?=>6SHLH$VOZQD,OWQ&1549K)K532 M5*U4++=#6+*^8/7@OLQA="IDM+ERG>GB3=#5#9]64G80"5%<8R4R,'"#^*FI MH^[SD]A3$'TP-3O1^I559<&Y>EJS0'_,;1?WYG)[[94?G;3K4K9EE2'-MR J MA*J[R037M%'6YFGF.B'EH\5:+E0S=2..-[H6DL";K]LH6:,2/)D]\&?@#,UD MHY-^CHRC"'^'XR9+CEEM"MIFNU4*HYO$X4J>:_TURM"4E5&2 ZJCKW>\9U+B MN&Y&5#-)'7R ^:9OSS$LD]G)ID%?L&;,&*H^;80U<8(.T)XF%X<2,T96^*\/ MK^SWCHTV5!L%CK36^!A#$HN MY!I0(^\]&O3@G&67TO%52$+).@[Y\&FS5\2-WP)M,"2S7.FNI(M>IL)I)KR& MBM+ ?"NNCA')6"2M?--TCRY+&;*DSY_M:O0\0T_?3*V9-L'D,9R#?^.@6P>$ M[+YL*DZ/J)'/7G;B;B]P45C/MA$?JZSKM%'B3Z6Y+O?==F7#H#;51,? 1$W M"<3 KDH$('IU\%D6,5<*\HE@3)2?OZ7^/]5=9U13V[H-':E2I0DJ(")%5"(* MA"K-("!(;WI BC%&>NA->HU(5SI2 P(!)#3I('("!!.!$$A JI1(B]3'N>>, M<>^/.][?-]Z/^7.-M=>WYMK?-_>>>W\5IP"UF/&6UAOQ)]P=>-VTB]LE-8MW M/V1<^?CE\SS+4B2&I"&RU/=0W!$+E#S;7W!;A1LNTZ-@6-9573DP\11P?:%- MW9W4[M0G9)%6Z#B[.F54]G+)\F.[KP>7^:#GJSM-&W.[*[B.B!PK4OB/[&_B M)N &$8#*8LOFN>?*+A\SF]$6R7)RJC,(^UB+F[Y,EG:>EJ"S0#22,.?<\GA0 M@5#^/KDWVFBMRLYO#)#H:P5L8OSP#[/=.:8SPS"YB?'!R\U-KY\MINX\ MLLNEOCD%D,5>^ZBP2TN. :T^V 9FU=AR"J5E=(DLO0RT]*IT"PAID'R7.>J/ M=%7X%+8A#@D/@Q_@$^';!J.9CGF8GB9T#[7?=G#)>G[[3HW^S+;W%-./-0U! M(4"^#D76,H3Q4WAI2RM$=RS/U*]/H,?@LM2E-^?6'3K)K')>O99CRQ%WZL:( ME_:;$4/;0Z< P^*=?0EO9)),3X!%]KW.&,.&F$?9>E/R5Z+,W]<-#5X<>6'" M8*]BW#A>?;FN/OQ24Y16B9L"H++C,K[Z"%B$J73D_U5$QQ(I^Q/.PE0!K+"> MPL4]);-RUCTW^=UT^&UO0SS]GDA* (#\4]4C>)Y=W7IL7?'W#BC@FM+]S!@1 M)9J&^%\[C5"ZWAL>I(1E,K[:-7YD/4_7=Z(TQ-F%+61S3J::6OR!^H><[CH_ MUB*_=S^UL 'B(4[_[*X)\US@;JWF%B9J7:X:=0Q^A(4:=E'[;=&_8 M!],.L/SF3'$HNJ"%KM$MRB39 M_0F\=P2N7$4[)E9;6_0+)# / @"5Q'; ?>OZJ$ !FR,[U1/?D\$H M8+_8DMXVG%OA_\8/9)VRLV[[^)&&8,>E,3*%,3*P!",^<'%"]];*-R]BF]BC M>F6].%M]RHV$E][[XZBC,S56%ZO:A:??SB-FUQ95)NV=%=TPX54AG])I7<\D M5=;+9NN(/H '40"O:NRUU8\U@? $5^O?N2^V0&SI'CSYOD!N.KI)BBP1W&77 MFB-"E+(@N1D705P@W@!+W4HNK7(:C<]TC7( OL5.OB,S8+1TL>;SR,\JT',!9Q906:U*VAW'7-K7JX=;N>D?ARYR@^N'9XQ/;?\ANQE*WT 7W5NU B=V59: M66R-<\07:5.-L>"]IV./_:0DGEAJ%UE/6BWC? ]\.B?7N26Y[C^N,!]XY3_R M9!K^QYHI11&-B4VF M>REQ]2 #A*E\!=\)JXLF%0;Z2VB,T+^&)2+V;2^NJ?K4F^B,(_^[// M?IL_M4!@9? 2/@5N:_2QF9I>(A6QF[!NI!B7;]7J#[[_FTEP_4U@Z.X:=K,- M&%Q+S?\35Q*U(_,0Z?[':X1BUBG 6CY@OL!!+P#0,M>NHH4]4GH9!/H#YWL[ M!6@^ECX-FO:3.(84EIBST)8#.,),1YEDYCE%IN"&T]-R[_\LKB L]#@];RUY M=M'J@.7;UDG]U&(*+%CN[1[WU]:DQG[57E'RIQ01JI)#9N\(.9]S;0]M>YPX M;6_@W<*ERP&^W#5@#*L%+N&F7N;E26U-;J7$^;![]=Z:.0?;Z*UV.D^K!&,J M6.N2^FW"-&KSCM_/QIP@%#U;9\ C>YCK]EUO).V[$W#D2'W\2-J]N'TV2E8- M U%-9*M&HJ$EB1&$])WU$7 M-=24G\^R.B_P"-GM7XB]V1Z_,/)RYS3Q$NZVD3 M+-^J1P1!W,OLX->!J(D@X*N>+YTMF?L9=4N2OKL2OI\'?HD.ZP!-M[PQ>Q?E5V^Y9/@PW#"/816F&\ GASKJ?D.UVD/ +=C:1WE$ M\FV1<*N*KGV^!:;/!Q&S4N&["8%5QV*,4!FKQ)"]P122$Y8.>Q3&GG+.;6HI MHG%@*WTD\GF'8+O\'OYZ08+'C#-&X"2X76;,>X0'/.;DC54\A "],L[?Y_'8 M[U,'-Z09CZ]#KZ(S5O6='KO_Z%^ZY'.WZNV_(F/QLC4XN&SE-L&]20R&UF"9 M_AU^FYHSYO+8]*N&R2V#=0?)^>'W>M84UN=$)@HMH;%:^ ;RQ28 D6[TJBHY MI&V4<2#YZ$E._FNYFIW6(8Z\S 2.CR\(OU.E*/)Z=S&"%W6\^-&BJ7FR3?5; MCYO0Q*2*OLY'6)?\@/Z6PQ\IUV>1UMCB\5W,>9O5#N;V<-BF22AD&>^T[UFF M)WLS;.;X('YWY$+WE%A,8FW)BD63L=)!#RW =EHM;X+F0DR06"'<5)I'%UO< MN&UD'RX[LIZ6EO)\YJ\FVAA>T?3Y@ M],FO&W XVU"2P6Z92O:9K.?U4^>=Y M)Z=&@!5E-C%(F"PHL;51R+Z2Y/(KTS*9:\$&,[V$>33+-](E6N5:.!.D-*'( M,+&QH0TNFY6(KWM0EJ_0X"=*^+9Y ?Y@%6."&E?; %S;S>?$LD M6P(4MCYJ60:_T;W4311KQOYH;VE%7-@TZFIKVS6_2W*C ZE*5@[/! MQ\4]Z)FH]2,!VE5;-^W20A#K';CZ@T$T]7W%LMCY1JM=@:GYGIM_-BUZ)X86 M=:@@)@(6<^P12SV6 M-HY'$D(.G1E8V!6?WI)DOLE/ O.=?,NB0EO)K:5'2C&:)^.V,F2C%1/_O <\ M;RJ#->:$&K8VNVI)4 ;QED^?_*^J^4T^>S4V57<-)-J8^LEN("+,>Y08.M@,4P MY1NB5'S/@<2-DM6F"S9E^5R0!(C5_3P[1V(0 F69LYR9&J3V*=C,&!7LURTT M:D5"*#B'HYGS_>AJ%""EE-+$@(PS!7).*1KZ$N@&M+XLE.@[_JPD7/E*\B0( MXDIJCLPWB-@TRV-]#[KQPYU'SYU.YV7+;_@ L?\:8(LS"MC.V77POCF7/]\G M6 4#$0TBN2%'15X9A]RM*>M1$T)MX?*>1N5 LFV_MJ#3LJ6\OIW==1],%X6Q M_&ASG;\HWL,?QU$( ^W@-3-4A-W:AB1-U)R:#PM\1KP<4B.Y7H;6LJOAM+[>EA]?"J8E6O^\TU%)/$2G=E_>3D MG)C16YHA]\PF->Z.4\#K^>XM<#G5Y=68_??\71R;OH331PQI,>V=)>Q(40$#B1_DS_2F/(AQD!>14B,6_=/ M\EX37C!57I*BU)H#:,+'P^YMLL$M0,QV]@0"<*/6=[JFUEG =<=QVS!T6\#$9V!I5C1/@%O0=A>">ENUCS$FHS932^G!?$S&6,GIB M3K1:S3A+WOJP^^RHPNT^ (QZA0CCAA,=12;=1SZX6UJH&0WXS'I= MW;"K3$MT$E3-64-ULB2$][V[&IBSC.!79([G M>_P$H/#7GU *JR'\RAQI'A6K9M7\J?)+7@< E3=PVH\=$JO[4V)AN\+KMT*O M'AL:T$&9%MWY/"('M"#OQH"YZG$!SGG"E(?5&3:X_%M@+Y<:IVV6=]$./XR# M G97-$1>MN4X]H*>0_5Z%.Q6\J11YQ31OH4""8=:P![I?GVIJ#5\"A*VW$ ( MTJ5\B"0'LK.C&L=%K1I9X]YKMZX/O.4-&A!4357.&1P_NHBD5O52.NI*'=V% MDDH7\$H!$Z90=Z]>CYZ!&0#-+" 0WZK#K=7Z2(-^8+K>CLR\U1K$/B[Q@>#5UM4^E3RA.A5H1DH-W:QE4UKCB5 MS3CH+ R4ZWJRT'+HB]_%='Y"UK)2:T]XH%>-Z>%3@K*[X"IG;Y_?:I-<-)'2 MR\)TJ:!C9@'+$S:).=>Q4B M]1U(6\CO(_OE\7R8YER(6"Q]B )%ZG7()7N=XI0F:_O?B3DN:,J+\%*'RMIW MZ5+)^>/U#NRNO6H7':/WU83-\=[=27P4A*E$K,+QLE0:8@"P!%2//>(K'ZX5 M8],F'58AY:!7FL9A;-G)8WZ,&;KJLQ)B1@"!KEJ74<6GA>[\>^J0EC8W,]U P&6R'G9^HEF%NSTL)7C6W^F>&Z<)5MX+1K M,SKZ7F'JTWF$M@SGJ^?/K]$FYQ:OH!49V>_T$\>O>)HR=].&LK3_4Z=-BAL4 MNRWH>#^-MA"D#^!ZK#C"9#!F&&.(A;[X6B;_),[LK)QQ&_O?&SS\-P!GG'3] MGE062V;-T=AU)@9!(22KI^&7 V=L?OY$U25D(MJ-BP[QYXF2E)=(_W*X6*_O M'5]T=.F37]8C;@N5KXQP"\>W-834[E%NP8OOH\?;!,DR@HT2F/=NB:P$O2/] MQ,!C]0(3M8;#Z M(>TJOM?75JYZ4C8=BIQG6GH[:"RK%Q0L@]M0I6&E=@_WXC+')QV*HMJL -/> M-X^T#T:9=,ZX8//L*]["!EK:.#)P&\QV/7&)$#[B-O:/ES*M$@[3QRGF)MW: MZ&9L?)?AS7:QU]G.2CN@$7;;7G"(6@SBE MSP7!L8^H2L3 MZY1Q2U/Z2K0@DWCDL@9PF%K\.<-!?,+[V%0F&S5C^L7*#%8"S@K@#1Y#Z[195%"(Q0W^5?&M!8F MB=/G<9FC;."7FB?<-P>:=VG1PFXVK%:%[L[9Q1H?#&ZV;"F_\P,"_R;\:UIF M\4LXSM@@X2)JBJ;RPV_O/#X79-GPLCR!;5Y5%CGQZ?R7 /%&&R6Y/P7^W*_7 M%-#]E+\YJ.=U$JH\6O3OL_Q_B?DCGSD5XPM3 ZJ>P+Q:R+:-@UZ/.$?803PY MA%\_8?ZA#2=O<.G1'\6P7(\O*/$3_[DG'*> !7S#8RT_@;Q]M'^D[ M:[C;!S (!_]W_?;_ 32GD_\#4$L#!!0 ( #B"?U1D709*2%$ /YG 8 M 979A>"TR,#(Q,3(S,7@R,&8P-3DN:G!G[+P%5%Q=MBZZT<()[JY!@[LE MP4.08,$3( 0J. E.(0$"P0DDP0GNP=T=@KN[!W>>^ M=\<=9]=88^RY]UYSS;EDSODM*?@T?!FXIZ*@K @(0, $N('P.> 1P &.CH( M'0T#! )A8F)@X1#CXF!CXU 0$N$3TU#2T=)04E/3,_.PT3-R,5%3LXO1$0_K+!?S/"PD9!14-'82!B86-^*#R'H",A(*"C(J" MAH:*BGCKC7@/H!*@$3+PR:$3:;X ,3H2\_M%IV,P/2QM)=$:.6(6>.GDCXE% M2D9.0OK/#WQR>G9^<7EU??-++R0 !>G?KO]0 M+P*$7LBHJ"BHH%]Z(2&[_OJ !6-@0^=4$X3],*1B)'?#X/X871Z:2LFDX#6 M$O ->P($VJY74&[P=.'!Y]QH.O!]JESFC&8,#AS>3&\1(P7 ,S4(LBV1 M P>6SC-@1#(X<͓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end

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ᑓ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